PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cuenda, A; Cohen, P				Cuenda, A; Cohen, P			Stress-activated protein kinase-2 p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; P70 S6 KINASE; CELLULAR STRESSES; MAMMALIAN TARGET; SAP KINASES; KB CELLS; MAP; PHOSPHORYLATION; SPECIFICITY; MECHANISMS	The differentiation of C2C12 myoblasts to myotubes was found to be accompanied by a strong activation of p70 S6 kinase and the mitogen-activated protein kinase (MAPK) family member SAPK2/p38, without significant activation of p42 MAPK and only slight activation of SAPK1/JNK and protein kinase B alpha. Consistent with these findings, SE 203580 (a specific inhibitor of SAPK2/p38) or rapamycin (which blocks the activation of p70 S6 kinase) prevented the formation of multinucleated myotubes, as well as the expression of muscle-specific proteins that included SAPK3 (another MAPK family member). PD 098059 (which prevents the activation of p42 MAPK) had no effect on myotube formation. Surprisingly, the slow activation of p70 S6 kinase during differentiation was not only prevented by rapamycin but also by SE 203580, and the activation of MAPKAP kinase-2 (an in vivo substrate of SAPK2/p38) was not only prevented by SE 203580 but also by rapamycin. In contrast, the acute activation of p70 S6 kinase in C2C12 myoblasts induced by phorbol esters was unaffected by SE 203580 and the acute activation of MAPKAP kinase-g induced by anisomycin was unaffected by rapamycin, These results show for the first time that SAPK2/p38 plays an essential role in C2C12 cell differentiation.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Dundee	Cuenda, A (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, MSI-WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEHNER C, 1996, P NATL ACAD SCI USA, V93, P4355; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STOKOE D, 1993, BIOCHEM J, V296, P842; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794	36	271	279	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4341	4346		10.1074/jbc.274.7.4341	http://dx.doi.org/10.1074/jbc.274.7.4341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933636	hybrid			2022-12-25	WOS:000078575500060
J	Fletcher, AI; Shuang, RQ; Giovannucci, DR; Zhang, L; Bittner, MA; Stuenkel, EL				Fletcher, AI; Shuang, RQ; Giovannucci, DR; Zhang, L; Bittner, MA; Stuenkel, EL			Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CDC2-LIKE KINASE; DIRECTED PROTEIN-KINASE; UNC-18 GENE ENCODES; RAT-BRAIN; SYNAPTIC TRANSMISSION; CDK5 ACTIVATOR; SEC1 HOMOLOG; YEAST; SYNTAXIN; SECRETION	Munc18a, a mammalian neuronal homologue of Saccharomyces cerevisiae Sec1p protein, is essential for secretion, likely as a result of its high affinity interaction with the target SNARE protein syntaxin 1a (where SNARE is derived from SNAP receptor (the soluble N-ethylmaleimide-sensitive fusion protein)). However, this interaction inhibits vesicle SNARE interactions with syntaxin that are required for secretory vesicles to achieve competency for membrane fusion, As such, regulation of the interaction between Munc18a and syntaxin la may provide an important mechanism controlling secretory responsiveness. Cyclin-dependent kinase 5 (Cdk5), a member of the Cdc2 family of cell division kinases, co-purifies with Munc18a from rat brain, interacts directly with Munc18a in vitro, and utilizes Munc18a as a substrate for phosphorylation, We have now demonstrated that Cdk5 is capable of phosphorylating Munc18a in vitro within a preformed Munc18a syntaxin la heterodimer complex and that this results in the disassembly of the complex, Using site-directed mutagenesis, the Cdk5 phosphorylation site on Munc18a was identified as Thr(574). Stimulation of secretion from neuroendocrine cells produced a corresponding rapid translocation of cytosolic Cdk5 to a particulate fraction and an increase of Cdk5 kinase activity. Inhibition of Cdk5 with olomoucine decreased evoked norepinephrine secretion from chromaffin cells, an effect not observed with the inactive analogue iso-olomoucine, The effects of olomoucine were independent of calcium influx as evidenced by secretary inhibition in permeabilized chromaffin cells and in cells under whole-cell voltage clamp. Furthermore, transfection and expression in chromaffin cells of a neural specific Cdk5 activator, p25, led to a strong increase in nicotinic agonist-induced secretory responses. Our data suggest a model whereby Cdk5 acts to regulate Munc18a interaction with syntaxin la and thereby modulates the level of vesicle SNARE interaction with syntaxin 1a and secretory responsiveness.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Stuenkel, EL (corresponding author), Univ Michigan, Dept Physiol, 7804 Med Sci 2 Bldg, Ann Arbor, MI 48109 USA.	esterm@umich.edu	Giovannucci, David R/A-5657-2018	Stuenkel, Edward/0000-0001-8225-5725	NIDDK NIH HHS [DK50127] Funding Source: Medline; NINDS NIH HHS [NS36227] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036227] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; COWLES CR, 1994, J CELL SCI, V107, P3449; Dresbach T, 1998, J NEUROSCI, V18, P2923; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Graham ME, 1997, J NEUROCHEM, V69, P2369; Green SL, 1997, NEUROCHEM INT, V31, P617, DOI 10.1016/S0197-0186(97)00012-0; Guidato S, 1998, J NEUROCHEM, V70, P335; Halachmi N, 1996, J NEUROCHEM, V66, P889; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERRINGTON J, 1994, PULSE CONTROL VERSIO; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; QI Z, 1995, MOL CELL BIOCHEM, V149, P35, DOI 10.1007/BF01076561; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SUDHOF TC, 1993, CELL, V75, P1; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127	54	165	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4027	4035		10.1074/jbc.274.7.4027	http://dx.doi.org/10.1074/jbc.274.7.4027			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933594	hybrid			2022-12-25	WOS:000078575500018
J	Tlapak-Simmons, VL; Baggenstoss, BA; Clyne, T; Weigel, PH				Tlapak-Simmons, VL; Baggenstoss, BA; Clyne, T; Weigel, PH			Purification and lipid dependence of the recombinant hyaluronan syntheses from Streptococcus pyogenes and Streptococcus equisimilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; OLIGODENDROGLIOMA CELLS; BINDING-PROTEINS; ACID CAPSULE; SYNTHASE; GENE; IDENTIFICATION; SOLUBILIZATION; EXPRESSION; SYNTHETASE	The two hyaluronan synthases (HASs) from Streptococcus pyogenes (spHAS) and Streptococcus equisimilis (seHAS) were expressed in Escherichia coli as recombinant proteins containing His(6) tails. Both enzymes were expressed as major membrane proteins, accounting for similar to 5-8% of the total membrane protein. Using nickel chelate affinity chromatography, the HASs were purified to homogeneity from n-dodecyl beta-D-maltoside extracts, High levels of HAS activity could be achieved only if the purified enzymes were supplemented with either bovine or E. coli cardiolipin (CL), although bovine CL gave consistently greater activity. Mass spectroscopic analysis revealed that the fatty acid compositions of these two CL preparations did not overlap. The two HAS enzymes showed similar but distinct activation profiles with the 10 other lipids tested. For example, phosphatidic acid and phosphatidylethanolamine stimulated seHAS, but not spHAS, Phosphatidylserine stimulated both enzymes. spHAS appears to be more CL-specific than seHAS, although both purified enzymes still contain endogenous CL that can not easily be removed. Both seHAS and spHAS were inhibited by phosphatidylcholine, sphingomyelin, and sulfatides and were not substantially stimulated by cerebrosides, phosphatidylglycerol, or phosphatidylinositol. With both HASs, CL increased the K-m for UDP-GlcUA, but decreased the K-m for UDP-GlcNAc and gave an overall stimulation of V-max, A kinetic characterization of the two membrane-bound and purified HASs is presented in the accompanying paper (Tlapak-Simmons, V. L., Baggenstoss, B. A. Kumari, K., Heldermon, C., and Weigel, P. H. (1999) J. Biol. Chem, 274, 4246-4253), Both purified HASs became inactive after storage for similar to 5 days at 4 degrees C, Both purified enzymes also lost activity over 4-5 days when stored at -80 degrees C in the presence of CL, but reached a level of activity that then slowly decreased over a period of months. Although the purified enzymes stored in the absence of CL at -80 degrees C were much less active, the enzymes retained this same low level of activity for at least 5 weeks. When both spHAS and seHAS were stored without CL at -80 degrees C, even after 2 months, they could be stimulated by the addition of bovine CL to similar to 60% of the initial activity of the freshly purified enzyme.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.		Clyne, Bill/V-7473-2019		NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 1983, J SURG RES, V35, P410, DOI 10.1016/0022-4804(83)90030-6; BALAZS EA, 1993, J RHEUMATOL, V20, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EVERED D, 1989, CIBA F SYMP, V143, P1; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; GRESSNER AM, 1995, DIGESTION, V56, P335, DOI 10.1159/000201257; HELDERMON C, 1996, MOL BIOL CELL, V7, P55; ILLUM L, 1994, J CONTROL RELEASE, V29, P133, DOI 10.1016/0168-3659(94)90129-5; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; JUBBELL JA, 1996, J CONTROL RELEASE, V39, P305; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KUJAWA MJ, 1983, DEV BIOL, V99, P277, DOI 10.1016/0012-1606(83)90277-4; KUJAWA MJ, 1986, DEV BIOL, V114, P504, DOI 10.1016/0012-1606(86)90214-9; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; Meyer K, 1934, J BIOL CHEM, V107, P629; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; NG KF, 1989, J BIOL CHEM, V264, P11776; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; Schmidt KH, 1996, MED MICROBIOL IMMUN, V184, P169, DOI 10.1007/PL00008248; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; TLAPAKSIMMONS VL, 1997, GLYCOBIOLOGY, V7, P1032; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305, DOI [10.1007/978-1-4615-3770-0_10, DOI 10.1007/978-1-4615-3770-0_10]; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; TURLEY EA, 1985, J CELL SCI, V78, P133; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	50	74	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4239	4245		10.1074/jbc.274.7.4239	http://dx.doi.org/10.1074/jbc.274.7.4239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933623	hybrid			2022-12-25	WOS:000078575500047
J	Lee, MG; Wigley, WC; Zeng, WZ; Noel, LE; Marino, CR; Thomas, PJ; Muallem, S				Lee, MG; Wigley, WC; Zeng, WZ; Noel, LE; Marino, CR; Thomas, PJ; Muallem, S			Regulation of Cl-/HCO3- exchange by cystic fibrosis transmembrane conductance regulator expressed in NIH 3T3 and HEK 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICARBONATE SECRETION; SULFONYLUREA RECEPTOR; MEMBRANE LOCALIZATION; SODIUM-CHANNELS; CFTR; TRANSPORTERS; BINDING; CL; K+; PATHWAY	A central function of cystic fibrosis transmembrane conductance regulator (CFTR)-expressing tissues is the secretion of fluid containing 100-140 mM HCO3-. High levels of HCO3- maintain secreted proteins such as mucins (all tissues) and digestive enzymes (pancreas) in a soluble and/or inactive state. HCO3- secretion is impaired in CF in all CFTR-expressing, HCO3--secreting tissues examined. The mechanism responsible for this critical problem in CF is unknown, Since a major component of HCO3- secretion in CFTR-expressing cells is mediated by the action of a Cl-/HCO3- exchanger (AE), in the present work we examined the regulation of AE activity by CFTR. In NIH 3T3 cells stably transfected with wild type CFTR and in HEK 293 cells expressing WT and several mutant CFTR, activation of CFTR by cAMP stimulated AE activity. Pharmacological and mutagenesis studies indicated that expression of CFTR in the plasma membrane, but not the Cl- conductive function of CFTR was required for activation of AE. Furthermore, mutations in NBD2 altered regulation of AE activity by CFTR independent of their effect on Cl- channel activity. At very high expression levels CFTR modified the sensitivity of AE to 4,4'-diisothiocyanatostilbene-2,2'-disulfonate, The novel finding of regulation of Cl-/HCO3- exchange by CFTR reported here may have important physiological implications and explain, at least in part, the impaired HCO3- secretion in CF.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Tennessee, Dept Physiol & Med, Memphis, TN 38163 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tennessee System; University of Tennessee Health Science Center	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Thomas, Philip J/F-7115-2012; Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK49835, DK38938] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK038938, R01DK049835] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARGENT BE, 1994, PHYSL GASTROINTESTIN, P1478; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; Cook D. I., 1994, P1061; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Gray MA, 1995, BIOSCIENCE REP, V15, P531, DOI 10.1007/BF01204355; Greger R, 1996, J MOL MED-JMM, V74, P527; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HADORN B, 1968, CAN MED ASSOC J, V98, P377; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hogan DL, 1997, GASTROENTEROLOGY, V113, P533, DOI 10.1053/gast.1997.v113.pm9247473; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Ismailov II, 1996, J BIOL CHEM, V271, P4725; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; MUALLEM S, 1992, J BIOL CHEM, V267, P17658; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1989, ANN NY ACAD SCI, V574, P438; SATO K, 1990, J LAB CLIN MED, V115, P504; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; Sheppard DN, 1996, MOL MED TODAY, V2, P290, DOI 10.1016/1357-4310(96)10028-9; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Warth R, 1996, PFLUG ARCH EUR J PHY, V432, P81, DOI 10.1007/s004240050108; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wigley WC, 1998, BIOCHEMISTRY-US, V37, P844, DOI 10.1021/bi972293n; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	38	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3414	3421		10.1074/jbc.274.6.3414	http://dx.doi.org/10.1074/jbc.274.6.3414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920885	hybrid			2022-12-25	WOS:000078428200025
J	Pierik, AJ; Roseboom, W; Happe, RP; Bagley, KA; Albracht, SPJ				Pierik, AJ; Roseboom, W; Happe, RP; Bagley, KA; Albracht, SPJ			Carbon monoxide and cyanide as intrinsic ligands to iron in the active site of [NiFe]-hydrogenases - NiFe(CN)(2)CO, biology's way to activate H-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; CHROMATIUM-VINOSUM; MOLECULAR-BIOLOGY; NIFE HYDROGENASE; SULFUR CLUSTERS; FE-HYDROGENASE; NICKEL; DEHYDROGENASE; THIOCYANATE; COMPLEXES	Infrared-spectroscopic studies on the [NiFe]-hydrogenase of Chromatium vinosum enriched in N-15 Or C-13, as well as chemical analyses, show that this enzyme contains three non-exchangeable, intrinsic, diatomic molecules as ligands to the active site, one carbon monoxide molecule and two cyanide groups. The results form an explanation for the three non-protein ligands to iron detected in the crystal structure of the Desulfovibrio gigas hydrogenase (Volbeda, A., Garcin, E., Piras, C., De Lacey, A. I., Fernandez, V. M., Hatchikian, E. C., Frey, M., and Fontecilla-Camps, J. C. (1996) J. Am. Chem. Sec. 118, 12989-12996) and for the low spin character of the lone ferrous iron ion observed with Mossbauer spectroscopy (Surerus, K. K., Chen, M., Van der Zwaan, W., Rusnak, F. M., Kolk, M., Duin, E. C., Albracht, S. P. J., and Munck, E. (1994) Biochemistry 33, 4980-4993). The results do not support the notion, based upon studies of Desulfovibrio vulgaris [NiFe]-hydrogenase (Higuchi, Y., Yagi, T., and Noritake, Y. (1997) Structure 5, 1671-1680), that SO is a ligand to the active site. The occurrence of both cyanide and carbon monoxide as intrinsic constituents of a prosthetic group is unprecedented in biology.	Univ Amsterdam, EC Slater Inst Biochem Res, NL-1018 TV Amsterdam, Netherlands; SUNY Coll Buffalo, Dept Chem, Buffalo, NY 14222 USA	University of Amsterdam; State University of New York (SUNY) System; Buffalo State College	Albracht, SPJ (corresponding author), Univ Amsterdam, EC Slater Inst Biochem Res, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.		Pierik, Antonio J/G-1108-2010	Pierik, Antonio J/0000-0002-1509-6370; Roseboom, Winfried/0000-0002-4034-8330				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; BAGLEY KA, 1995, BIOCHEMISTRY-US, V34, P5527, DOI 10.1021/bi00016a026; BAGLEY KA, 1994, BIOCHEMISTRY-US, V33, P9229, DOI 10.1021/bi00197a026; BONAM D, 1984, J BACTERIOL, V159, P693, DOI 10.1128/JB.159.2.693-699.1984; BOXER GE, 1952, ARCH BIOCHEM BIOPHYS, V39, P292, DOI 10.1016/0003-9861(52)90338-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COREMANS JMCC, 1992, BIOCHIM BIOPHYS ACTA, V1119, P157, DOI 10.1016/0167-4838(92)90386-R; Cotton F. A., 1988, ADV INORG CHEM, P1021; Darensbourg DJ, 1997, J AM CHEM SOC, V119, P7903, DOI 10.1021/ja971559a; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; EPSTEIN J, 1947, ANAL CHEM, V19, P272, DOI 10.1021/ac60004a018; Frey M, 1998, STRUCT BOND, V90, P97; FRIEDRICH B, 1993, ANNU REV MICROBIOL, V47, P351, DOI 10.1146/annurev.mi.47.100193.002031; HAGEN WR, 1986, FEBS LETT, V203, P59, DOI 10.1016/0014-5793(86)81436-3; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; Hartmann GC, 1996, ARCH MICROBIOL, V165, P187, DOI 10.1007/s002030050314; Higuchi Y, 1997, STRUCTURE, V5, P1671, DOI 10.1016/S0969-2126(97)00313-4; Hsu HF, 1997, J AM CHEM SOC, V119, P8371, DOI 10.1021/ja971139l; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEEUSSEN JCL, 1989, ANALYST, V114, P959, DOI 10.1039/an9891400959; MITCHELL CA, 1930, ALLENS COMMERCIAL OR, V8, P492; NAGASHIMA S, 1978, ANAL CHIM ACTA, V99, P197, DOI 10.1016/S0003-2670(01)84514-1; NAKAMOTO K, 1997, INFRARED RAMAN SPECT, P95; PIERIK AJ, 1992, EUR J BIOCHEM, V209, P63, DOI 10.1111/j.1432-1033.1992.tb17261.x; Rey L, 1996, MOL GEN GENET, V252, P237; SHRIVER DF, 1966, J AM CHEM SOC, V88, P1672, DOI 10.1021/ja00960a018; STREKAS T, 1980, BIOCHIM BIOPHYS ACTA, V616, P1, DOI 10.1016/0005-2744(80)90257-0; SURERUS KK, 1994, BIOCHEMISTRY-US, V33, P4980, DOI 10.1021/bi00182a029; TANAKA A, 1992, ANAL CHIM ACTA, V261, P281, DOI 10.1016/0003-2670(92)80203-J; VanderSpek TM, 1996, EUR J BIOCHEM, V237, P629; VIGNAIS PM, 1994, ARCH MICROBIOL, V161, P1; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; ZIRNGIBL C, 1992, EUR J BIOCHEM, V208, P511, DOI 10.1111/j.1432-1033.1992.tb17215.x	36	203	210	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3331	3337		10.1074/jbc.274.6.3331	http://dx.doi.org/10.1074/jbc.274.6.3331			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920874	hybrid			2022-12-25	WOS:000078428200014
J	Zocchi, E; Usai, C; Guida, L; Franco, L; Bruzzone, S; Passalacqua, M; De Flora, A				Zocchi, E; Usai, C; Guida, L; Franco, L; Bruzzone, S; Passalacqua, M; De Flora, A			Ligand-induced internalization of CD38 results in intracellular Ca2+ mobilization: role of NAD(+) transport across cell membranes	FASEB JOURNAL			English	Article						pyridine nucleotides; cyclic ADP-ribose; intracellular calcium homeostasis; NAD(+) transporter	CYCLIC-ADP-RIBOSE; SEA-URCHIN EGGS; ANTIGEN CD38; SURFACE; PROTEIN; NAD+; GLYCOHYDROLASE; IDENTIFICATION; GLYCOPROTEIN; ERYTHROCYTES	CD38, a transmembrane glycoprotein widely expressed in vertebrate cells, is a bifunctional ectoenzyme catalyzing the synthesis and hydrolysis of cyclic ADP-ribose (cADPR). cADPR is a universal second messenger that releases calcium from intracellular stores. Since cADPR is generated by CD38 at the outer surface of many cells, where it acts intracellularly, increasing attention is paid to addressing this topological paradox. Recently, we demonstrated that CD38 is a catalytically active, unidirectional transmembrane transporter of cADPR, which then reaches its receptor-operated intracellular calcium stores. Moreover, CD38 was reported to undergo a selective and extensive internalization through non clathrin-coated endocytotic vesicles upon incubating CD38(+) cells with either NAD(+) or thiol compounds: these endocytotic vesicles can convert cytosolic NAD into cADPR despite an asymmetric unfavorable orientation that makes the active site of CD38 intravesicular. Here we demonstrate that the cADPR-generating activity of the endocytotic vesicles results in remarkable and sustained increases of intracellular free calcium concentration in different cells exposed to either NAD(+), or GSH, or N-acetylcysteine. This effect of CD38-internalizing Ligands on intracellular calcium levels was found to involve a two-step mechanism: 1) influx of cytosolic NAD(+) into the endocytotic vesicles, mediated by a hitherto unrecognized dinucleotide transport system that is saturable, bidirectional, inhibitable by 8-N-3-NAD(+), and characterized by poor dinucleotide specificity, low affinity, and high efficiency; 2) intravesicular CD38-catalyzed conversion of NAD+ to cADPR, followed by out-pumping of the cyclic nucleotide into the cytosol and subsequent release of calcium from thapsigargin-sensitive stores. This unknown intracellular trafficking of NAD(+) and cADPR based on two distinctive and specific transmembrane carriers for either nucleotide can affect the intracellular calcium homeostasis in CD38(+) cells.	Univ Genoa, Inst Biochem, I-16132 Genoa, Italy; CNR, Inst Cybernet & Biophys, I-16149 Genoa, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR)	De Flora, A (corresponding author), Univ Genoa, Inst Biochem, Viale Benedetto XV-1, I-16132 Genoa, Italy.	toninodf@unige.it	Passalacqua, Mario/W-1973-2019; Bruzzone, Santina/A-4264-2015	Passalacqua, Mario/0000-0003-2779-6259; Bruzzone, Santina/0000-0003-2034-3716; Usai, Cesare/0000-0001-8863-7759				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Beutler E., 1984, GLUTATHIONE RED CELL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 1998, FEBS LETT, V433, P275, DOI 10.1016/S0014-5793(98)00929-6; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Franco L, 1998, FASEB J, V12, P1507; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KONTANI K, 1993, J BIOL CHEM, V268, P16895; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1991, J BIOL CHEM, V266, P2276; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LUND AK, 1995, J TRAUMA, V38, P469, DOI 10.1097/00005373-199504000-00001; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Meldolesi J, 1998, NATURE, V392, P863, DOI 10.1038/31804; NEUBURGER M, 1983, BIOCHEM J, V216, P443, DOI 10.1042/bj2160443; Rustin P, 1996, J BIOL CHEM, V271, P14785, DOI 10.1074/jbc.271.25.14785; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	43	85	95	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					273	283		10.1096/fasebj.13.2.273	http://dx.doi.org/10.1096/fasebj.13.2.273			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973315				2022-12-25	WOS:000078615200007
J	Fritsche, E; Humm, A; Huber, R				Fritsche, E; Humm, A; Huber, R			The ligand-induced structural changes of human L-arginine : glycine amidinotransferase - A mutational and crystallographic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY L-ARGININE; GYRATE ATROPHY; GROWTH-HORMONE; CREATINE; RAT; BIOSYNTHESIS; CLONING; MUSCLE; RETINA; HYPERORNITHINEMIA	Human L-arginine:glycine amidinotransferase (AT) shows large structural changes of the 300-flap and of helix H9 upon binding of L-arginine and L-ornithine, described as a closed and an open conformation (Humm, A, Fritsche, E., Steinbacher, S., and Huber, R. (1997) EMBO J. 16, 3373-3385), To elucidate the structural basis of these induced-fit movements, the x-ray structures of AT in complex with the amidino acceptor glycine and its analogs gamma-aminobutyric acid and delta-aminovaleric acid, as well as in complex with the amidino donor analogs L-alanine, L-alpha-aminobutyric acid, and L-norvaline, have been solved at 2.6-, 2.5-, 2.37-, 2.3-, 2.5-, and 2.4-Angstrom resolutions, respectively. The latter three compounds were found to stabilize the open conformer. The glycine analogs bind in a distinct manner and do not induce the transition to the open state. The complex with glycine revealed a third binding mode, reflecting the rather broad substrate specificity of AT. These findings identified a role for the cu-amino group of the ligand in stabilizing the open conformer. The kinetic, structural, and thermodynamic properties of the mutants AT Delta M302 and AT Delta 11 (lacks 11 residues of H9) confirmed the key role of Asn(300) and suggest that in mammalian amidinotransferases, the role of helix H9 is in accelerating amidino transfer by an induced-fit mechanism. Helix H9 does not add to the stability of the protein.	Max Planck Inst Biochem, Abt Strukturforsch, Dept Struct Res, D-82152 Martinsried, Germany	Max Planck Society	Fritsche, E (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Dept Struct Res, Klopferspitz 18a, D-82152 Martinsried, Germany.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1992, XPLOR VERSION 3 1; CONCONI F, 1964, J BIOL CHEM, V240, P2461; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fritsche E, 1997, EUR J BIOCHEM, V247, P483, DOI 10.1111/j.1432-1033.1997.00483.x; FRITSCHE E, 1999, IN PRESS BIOCHEMISTR; GRAZI E, 1968, J BIOL CHEM, V243, P538; GRAZI E, 1964, J BIOL CHEM, V240, P2465; GROSS MD, 1986, ARCH BIOCHEM BIOPHYS, V251, P747, DOI 10.1016/0003-9861(86)90385-1; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; GUTHMILLER P, 1994, J BIOL CHEM, V269, P17556; Humm A, 1997, BIOCHEM J, V322, P771, DOI 10.1042/bj3220771; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LASKOWSKI RA, 1992, PROCHECK VERSION 3 3; LESLIE A, 1994, MOSFLM USER GUIDE MO; LOIKE JD, 1988, P NATL ACAD SCI USA, V85, P807, DOI 10.1073/pnas.85.3.807; MAKHATADZE GI, 1990, J MOL BIOL, V213, P375, DOI 10.1016/S0022-2836(05)80197-4; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGUIRE DM, 1980, J BIOL CHEM, V255, P1152; MCGUIRE DM, 1984, J BIOL CHEM, V259, P2034; OHNUKI T, 1985, J BACTERIOL, V164, P85, DOI 10.1128/JB.164.1.85-94.1985; Piepersberg W., 1997, BIOTECHNOLOGY ANTIBI, P81; RATNER S, 1956, ARCH BIOCHEM BIOPHYS, V63, P296, DOI 10.1016/0003-9861(56)90045-5; RONCA G, 1966, J BIOL CHEM, V241, P2589; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIH VE, 1978, AM J HUM GENET, V30, P174; SIPILA I, 1979, NEUROLOGY, V29, P996, DOI 10.1212/WNL.29.7.996; SIPILA I, 1980, BIOCHIM BIOPHYS ACTA, V613, P79, DOI 10.1016/0005-2744(80)90194-1; TAKEDA M, 1992, EUR J CLIN CHEM CLIN, V30, P325; TORMANEN CD, 1985, BIOSCIENCE REP, V5, P309, DOI 10.1007/BF01116902; VANPILSUM JF, 1968, ARCH BIOCHEM BIOPHYS, V124, P372, DOI 10.1016/0003-9861(68)90340-8; VANPILSUM JF, 1972, BIOCHEM J, V126, P325, DOI 10.1042/bj1260325; VANPILSUM JF, 1970, ANAL BIOCHEM, V35, P277, DOI 10.1016/0003-2697(70)90035-7; Walker J.B., 1973, ENZYMES, P497; WALKER JB, 1961, J BIOL CHEM, V236, P493; WALKER JB, 1958, J BIOL CHEM, V231, P1; WALKER JB, 1976, BIOCHEMISTRY-US, V15, P2519, DOI 10.1021/bi00657a004; WALKER JB, 1979, ADV ENZYMOL, V50, P172; WALKER JB, 1975, METHDOS ENZYMOL, V43, P41; WALKER MS, 1962, J BIOL CHEM, V237, P473; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3026	3032		10.1074/jbc.274.5.3026	http://dx.doi.org/10.1074/jbc.274.5.3026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915841	hybrid			2022-12-25	WOS:000078319500059
J	Mahata, SK; Mahata, M; Parmer, RJ; O'Connor, DT				Mahata, SK; Mahata, M; Parmer, RJ; O'Connor, DT			Desensitization of catecholamine release - The novel catecholamine release-inhibitory peptide catestatin (chromogranin A(344-364)) acts at the receptor to prevent nicotinic cholinergic tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; SUBUNIT; PHEOCHROMOCYTOMA; SECRETION; CELLS; PC12; TRANSITIONS; SENSITIVITY; EXPRESSION; ANTAGONIST	Nicotinic cholinergic receptors undergo desensitization upon repeated or prolonged exposure to agonist, We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment, catestatin (chromogranin A(344-364)), on agonist-induced desensitization of catecholamine release from pheochromocytoma cells. In a dose-dependent fashion, the nicotinic antagonist catestatin blocked agonist desensitization of both catecholamine release (IC50 similar to 0.24 mu M) and Na-22(+) uptake (IC50 similar to 0.31 mu M), the initial step in nicotinic cationic signal transduction; both secretion inhibition and blockade of desensitization were noncompetitive with agonist, Desensitizing effects of the nicotinic agonists nicotine and epibatidine were blocked. This antagonist action was specific to desensitization by nicotinic agonists, since catestatin did not block desensitization of catecholamine release induced by agents which bypass the nicotinic receptor. Hill plots with slopes near unity suggested noncooperativity for catestatin effects on both nicotinic responses (secretory antagonism and blockade of desensitization). Human, bovine, and rat catestatins (as well as substance P) had similar potencies. IC50 values for secretion inhibition and blockade of desensitization paralleled each other (r = 0.76, n = 10 antagonists, p = 0.01) for several noncompetitive nicotinic antagonists. Peptide nicotinic antagonists (catestatins, substance P) were far more potent inhibitors of both secretion (p = 0.019) and desensitization (p = 0.005) than nonpeptide antagonists (trimethaphan, hexamethonium, procaine, phencyclidine, cocaine, or clonidine), and the peptides displayed enhanced selectivity to block desensitization versus secretion (p = 0.003). We conclude that catestatin is a highly potent, dose-dependent, noncompetitive, noncooperative, specific inhibitor of nicotinic desensitization, an effect which may have implications for control of catecholamine release.	Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Ctr Mol Genet, San Diego, CA 92161 USA; San Diego Vet Adm Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Mahata, SK (corresponding author), Univ Calif San Diego, Dept Med, 9111H,3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Mahata, Sushil/AAF-8781-2021		NHLBI NIH HHS [HL55583] Funding Source: Medline; NIDA NIH HHS [DA11311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011311, R29DA011311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Baenziger JE, 1997, BIOCHEMISTRY-US, V36, P3617, DOI 10.1021/bi962845m; Blumenthal EM, 1997, J NEUROSCI, V17, P6094; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BOYD ND, 1987, J PHYSIOL-LONDON, V389, P45, DOI 10.1113/jphysiol.1987.sp016646; BROWN RD, 1983, MOL PHARMACOL, V23, P8; CONLEY EC, 1996, ION CHANNEL FACTS BO, V1; CONLEY EC, 1996, ION CHANNEL FACTS BO, V1, P36; Fenster CP, 1997, J NEUROSCI, V17, P5747; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROSS A, 1991, PFLUG ARCH EUR J PHY, V419, P545, DOI 10.1007/BF00370805; HSIAO RJ, 1991, MEDICINE, V70, P33, DOI 10.1097/00005792-199101000-00003; HSIAO RJ, 1990, KIDNEY INT, V37, P955, DOI 10.1038/ki.1990.71; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; LINDSTROM J, 1995, ANN NY ACAD SCI, V757, P100, DOI 10.1111/j.1749-6632.1995.tb17467.x; LIVETT BG, 1991, ANN NY ACAD SCI, V632, P249, DOI 10.1111/j.1749-6632.1991.tb33113.x; LIVETT BG, 1993, J ANAT, V183, P277; LIVETT BG, 1993, TRENDS PHARMACOL SCI, V14, P345, DOI 10.1016/0165-6147(93)90090-7; LUKAS RJ, 1989, J PHARMACOL EXP THER, V251, P175; LUKAS RJ, 1992, INT REV NEUROBIOL, V34, P25, DOI 10.1016/S0074-7742(08)60097-5; Mahata S K, 1998, Adv Pharmacol, V42, P260; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OCHOA ELM, 1989, CELL MOL NEUROBIOL, V9, P141, DOI 10.1007/BF00713026; OCONNOR DT, 1989, CLIN CHEM, V35, P1631; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Rogers S W, 1991, Protein Expr Purif, V2, P108, DOI 10.1016/1046-5928(91)90058-Q; ROWELL PP, 1994, J NEUROCHEM, V63, P561; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SIMASKO SM, 1986, MOL PHARMACOL, V30, P6; Tsigelny I, 1998, REGUL PEPTIDES, V77, P43, DOI 10.1016/S0167-0115(98)00040-8; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VIBAT CRT, 1995, CELL MOL NEUROBIOL, V15, P411, DOI 10.1007/BF02071877; WEILAND G, 1977, J BIOL CHEM, V252, P7648; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITING P, 1991, MOL PHARMACOL, V40, P463; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; ZHOU XF, 1991, J PHYSIOL-LONDON, V433, P393, DOI 10.1113/jphysiol.1991.sp018433	39	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2920	2928		10.1074/jbc.274.5.2920	http://dx.doi.org/10.1074/jbc.274.5.2920			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915830	hybrid			2022-12-25	WOS:000078319500048
J	Zhou, C; Horstman, D; Carpenter, G; Roberts, MF				Zhou, C; Horstman, D; Carpenter, G; Roberts, MF			Action of phosphatidylinositol-specific phospholipase C gamma 1 on soluble and micellar substrates - Separating effects on catalysis from modulation of the surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; X-DOMAIN; Y-DOMAIN; PHOSPHORYLATION; ACTIVATION; MECHANISM; PURIFICATION; ASSOCIATION; EXPRESSION; PROTEINS	(T)he kinetics of PI-PLC gamma 1 toward a water-soluble substrate (inositol 1,2-cyclic phosphate, cIP) and phosphatidylinositol (PI) in detergent mixed micelles were monitored by P-31 NMR spectroscopy. That cIP is also a substrate (K-m = similar to 15 mM) implies a two-step mechanism (intramolecular phosphotransferase reaction to form cIP followed by cyclic phosphodiesterase activity to form inositol-1-phosphate (I-1-P)), PI is cleaved by PI-PLC gamma 1 to form cIP and I-I-P with the enzyme specific activity and ratio of products (cIP/I-1-P) regulated by assay temperature, pH, Ca2+, and other amphiphilic additives, Cleavage of both cIP and PI by the enzyme is optimal at pH 5, The effect of Ca2+ on PI-PLC gamma 1 activity is unique compared with other isozymes enzymes: Ca2+ is necessary for the activity and low Ca2+ activates the enzyme; however, high Ca2+ inhibits PI-PLC gamma 1 hydrolysis of phosphoinositides (but not cIP) with the extent of inhibition dependent on pH, substrate identity (cIP or PI), substrate presentation (e.g. detergent matrix), and substrate surface concentration. This inhibition of PI-PLC gamma 1 by high Ca2+ is proposed to derive from the divalent metal ion-inducing clustering of the PI and reducing its accessibility to the enzyme, Amphiphilic additives such as phosphatidic acid, fatty acid, and sodium dodecylsulfate enhance PI cleavage in micelles at pH 7.5 but not at pH 5.0; they have no effect on cIP hydrolysis at either pH value. These different kinetic patterns are used to propose a model for regulation of the enzyme. A key hypothesis is that there is a pH-dependent conformational change in the enzyme that controls accessibility of the active site to both water-soluble cIP and interfacially organized PI. The low activity enzyme at pH 7.5 can be activated by PA (or phosphorylation by tyrosine kinase), However, this activation requires lipophilic substrate (PI) present because cIP hydrolysis is not enhanced in the presence of PA.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Boston College; Vanderbilt University	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu			NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026762] Funding Source: NIH RePORTER; NCI NIH HHS [CA75195] Funding Source: Medline; NIGMS NIH HHS [GM 26762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; EMORI Y, 1989, J BIOL CHEM, V264, P21885; Essen LO, 1997, BIOCHEMISTRY-US, V36, P1704, DOI 10.1021/bi962512p; FERNALD AW, 1994, BIOCHEM J, V302, P503, DOI 10.1042/bj3020503; GARIGAPATI VR, 1995, J COLLOID INTERF SCI, V169, P486, DOI 10.1006/jcis.1995.1059; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Grobler JA, 1996, PROTEIN SCI, V5, P680; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; Horstman DA, 1996, P NATL ACAD SCI USA, V93, P7518, DOI 10.1073/pnas.93.15.7518; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MINTA A, 1989, J BIOL CHEM, V264, P8171; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Roberts M. F., 1998, PHOSPHOINOSITIDES CH, V718, P137; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P8514, DOI 10.1021/bi970560j; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P356, DOI 10.1021/bi960602o; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P11223, DOI 10.1021/bi971039s; Zhou C, 1997, BIOCHEMISTRY-US, V36, P347, DOI 10.1021/bi960601w	32	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2786	2793		10.1074/jbc.274.5.2786	http://dx.doi.org/10.1074/jbc.274.5.2786			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915811	hybrid			2022-12-25	WOS:000078319500029
J	Ljungman, M; Zhang, FF; Chen, F; Rainbow, AJ; McKay, BC				Ljungman, M; Zhang, FF; Chen, F; Rainbow, AJ; McKay, BC			Inhibition of RNA polymerase II as a trigger for the p53 response	ONCOGENE			English	Article						transcription; p53; p21(WAF1); apoptosis	WILD-TYPE P53; DNA-DAMAGING AGENTS; TRANSCRIPTIONALLY ACTIVE P53; CYCLE CHECKPOINT PATHWAY; SUPPRESSOR PROTEIN P53; CELL-CYCLE; IN-VIVO; TUMOR-SUPPRESSOR; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION	The mechanisms by which the p53 response is triggered following exposure to DNA-damaging agents have not yet been clearly elucidated. We and others have previously suggested that blockage of RNA polymerase II may be the trigger for induction of the p53 response following exposure to ultraviolet light. Here we report on the correlation between inhibition of mRNA synthesis and the induction of p53, p21(WAF1) and apoptosis in diploid human fibroblasts treated with either UV light, cisplatin or the RNA synthesis inhibitors actinomycin D, DRB, H7 and alpha-amanitin. Exposure to ionizing radiation or the proteasome inhibitor LLnL, however, induced p53 and p21(WAF1) without affecting mRNA synthesis. Importantly, induction of p53 by the RNA synthesis or proteasome inhibitors did not correlate with the induction of DNA strand breaks. Furthermore, cisplatin-induced accumulation of active p53 in repair-deficient XP-A cells occurred despite the lack of DNA strand break induction. Our results suggest that the induction of the p53 response by certain toxic agents is not triggered by DNA strand breaks but rather, may be linked to inhibition of mRNA synthesis either directly by the poisoning of RNA polymerase II or indirectly by the induction of elongation-blocking DNA lesions.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Michigan System; University of Michigan; McMaster University	Ljungman, M (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AHNSTROM G, 1981, MEASUREMENT STRAND B, P403; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Chung DH, 1998, RADIAT RES, V149, P187, DOI 10.2307/3579929; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDA Y, 1993, BIOCHEMISTRY-US, V32, P8582, DOI 10.1021/bi00084a027; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EGYHAZI E, 1976, NATURE, V262, P319, DOI 10.1038/262319a0; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GIARDINA C, 1993, J BIOL CHEM, V268, P23806; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JARVIS WD, 1994, CANCER RES, V54, P1707; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KUWANO M, 1973, EXP CELL RES, V82, P454, DOI 10.1016/0014-4827(73)90365-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu M, 1998, CANCER RES, V58, P1723; Ljungman M, 1996, BBA-GENE STRUCT EXPR, V1307, P171, DOI 10.1016/0167-4781(96)00037-1; Ljungman M, 1996, ONCOGENE, V13, P823; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; Loignon M, 1997, CANCER RES, V57, P3390; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCHNIK AN, 1988, NUCLEIC ACIDS RES, V16, P5175, DOI 10.1093/nar/16.11.5175; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Ohnishi T, 1998, ONCOGENE, V16, P1507, DOI 10.1038/sj.onc.1201663; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Plaumann B, 1996, ONCOGENE, V13, P1605; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; RODI CP, 1989, J CELL PHYSIOL, V141, P346, DOI 10.1002/jcp.1041410216; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SELBY CP, 1990, J BIOL CHEM, V265, P21330; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SMITH ML, 1995, ONCOGENE, V10, P1053; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	91	243	243	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					583	592		10.1038/sj.onc.1202356	http://dx.doi.org/10.1038/sj.onc.1202356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989808				2022-12-25	WOS:000078394400003
J	Lu, WG; Mayer, BJ				Lu, WG; Mayer, BJ			Mechanism of activation of Pak1 kinase by membrane localization	ONCOGENE			English	Article						Pak kinase; Nck; SH2/SH3 adaptors; Cdc42; Rac; signal transduction	P21-ACTIVATED PROTEIN-KINASES; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; ADAPTER PROTEIN; BINDING-PROTEIN; CELL-CYCLE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; FOCAL COMPLEXES	Pak kinases are a family of serine/threonine protein kinases homologous to Ste20p of yeast. Paks can be activated in vivo and in vitro by binding to GTP-bound Cdc42 and Rad, members of the Rho family of small GTPases implicated in regulating the organization of the actin cytoskeleton. We have previously reported that the SH2/SH3-containing adaptor protein Nck binds Pak kinase through its second SH3 domain. Pak1 can be targeted to the membrane by Nck in response to tyrosine phosphorylation, and membrane association of Pak1 is sufficient to increase its specific activity. The mechanism whereby Pak is activated by membrane localization, however, is unknown, We show here that expression of three proteins that inhibit Rho-family GTPases by different mechanisms (RhoGDI, Bcr and D57Y Cdc42) all block the activation of Pak by a membrane-targeted Nck SH3 domain, demonstrating that the in vivo activation of Pak1 induced by membrane localization is dependent on Rho-family GTPases. This implies that Pak activity can be regulated in cells both by the level of GTP loading of various Rho-family GTPases and the local concentration of Pak relative to these GTPases. Our data also suggest the existence of Rho-family GTPases in addition to Cdc42 and Rad that can activate Pak on membranes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, 320 Longwood Ave, Boston, MA 02115 USA.							BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cullen BR, 1996, CURR BIOL, V6, P1557, DOI 10.1016/S0960-9822(02)70770-7; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Harden N, 1996, MOL CELL BIOL, V16, P1896; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HU G, 1995, MOL CELL BIOL, V15, P1169; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	66	69	69	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					797	806		10.1038/sj.onc.1202361	http://dx.doi.org/10.1038/sj.onc.1202361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989831				2022-12-25	WOS:000078394400026
J	Cheshire, JL; Williams, BRG; Baldwin, AS				Cheshire, JL; Williams, BRG; Baldwin, AS			Involvement of double-stranded RNA-activated protein kinase in the synergistic activation of nuclear factor-kappa B by tumor necrosis factor-alpha and gamma-interferon in preneuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT EIF-2-ALPHA KINASE; IFN-GAMMA; ADHESION MOLECULE-1; GENE-EXPRESSION; 3T3-F442A CELLS; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; BETA DEGRADATION; PKR; INDUCTION	Tumor necrosis factor-alpha (TNF-alpha) and gamma-interferon (IFN-gamma) cooperate during a variety of biological responses and ultimately synergistically enhance the expression of genes involved in immune and inflammatory responses. Recently, we demonstrated that IFN-gamma can significantly potentiate TNF-alpha-induced nuclear factor (NF)-kappa B nuclear translocation in neuronal derived and endothelial cell lines. The mechanism by which these two cytokines exert their synergistic effect on NF-kappa B involves the de novo degradation of the NF-kappa B inhibitor, I kappa B beta. The double-stranded RNA-dependent kinase PKR is IFN-inducible and has been implicated in the activation of NF-kappa B; therefore, we examined the possibility that PKR may play a role in the synergistic activation of NF-kappa B during TNF-alpha/IFN-gamma cotreatment. The PKR inhibitor 2-aminopurine (2-AP) inhibited TNF-alpha/IFN-gamma-induced NF-kappa B nuclear translocation in neuronal derived cells but not in endothelial cells. The induced degradation of I kappa B beta, which is normally observed upon TNF-alpha/IFN-gamma cotreatment, was blocked completely by 2-AP in neuronal derived cells. Also, 2-AP treatment or overexpression of a catalytically inactive PKR inhibited the TNF-alpha/IFN-gamma-induced synergistic activation of kappa B-dependent gene expression. Our results suggest that the signal generated by IFN-gamma during TNF-alpha/IFN-gamma cotreatment may require PKR to elicit enhanced NF-kappa B activity, and this signal may affect the stability of the I kappa B beta protein.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Cleveland Clinic Foundation	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NIAID NIH HHS [AI34039, AI35098] Funding Source: Medline; NIA NIH HHS [1 F32 AG05745] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039, R37AI035098, R01AI035098, R21AI034039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F32AG005745] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLANCHET O, 1991, INT J CANCER, P138; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOUKAS J, 1990, J IMMUNOL, V145, P1727; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KALVAKOLANU DVR, 1991, J BIOL CHEM, V266, P873; KRAKAUER T, 1993, J IMMUNOL, V150, P1205; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; Petryshyn R, 1996, ARCH BIOCHEM BIOPHYS, V326, P290, DOI 10.1006/abbi.1996.0078; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; SANCEAU J, 1992, J IMMUNOL, V149, P1671; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; Weil R, 1997, J BIOL CHEM, V272, P9942; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	66	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4801	4806		10.1074/jbc.274.8.4801	http://dx.doi.org/10.1074/jbc.274.8.4801			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988719	Green Published, hybrid			2022-12-25	WOS:000078698200044
J	Miyagi, T; Wada, T; Iwamatsu, A; Hata, K; Yoshikawa, Y; Tokuyama, S; Sawada, M				Miyagi, T; Wada, T; Iwamatsu, A; Hata, K; Yoshikawa, Y; Tokuyama, S; Sawada, M			Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; CYTOSOLIC SIALIDASE; GROWTH-CONTROL; GM3 GANGLIOSIDE; MESSENGER-RNA; GENE-TRANSFER; RAT-LIVER; DIFFERENTIATION; FIBROBLASTS; ACID	Gangliosides are plasma membrane components thought to play important roles in cell surface interactions, cell differentiation, and transmembrane signaling. A mammalian sialidase located in plasma membranes is unique in specifically hydrolyzing gangliosides, suggesting crucial roles in regulation of cell surface functions. Here we describe the cloning and expression of a cDNA for the ganglioside sialidase, isolated from a bovine brain cDNA library based on the amino acid sequence of the purified enzyme from bovine brain. This cDNA encodes a 428-amino acid protein containing a putative transmembrane domain and the three Asp boxes characteristic of sialidases and sharing 19-38% sequence identity with other sialidases, Northern blot and polymerase chain reaction analyses revealed a general distribution of the gene in mammalian species, including man, and the mouse. In COS-7 cells transiently expressing the sialidase, the activity was found to be 40-fold that of the control level with ganglioside substrates in the presence of Triton X-100, and the hydrolysis was almost specific to gangliosides other than GM1 and GM2, both alpha 2-->3 and alpha 2-->8 sialyl linkages being susceptible. The major subcellular localization of the expressed sialidase was assessed to be plasma membrane by Percoll density gradient centrifugation of cell homogenates and by immunofluorescence staining of the transfected COS-7 cells. Analysis of the membrane topology by protease protection assay suggested that this sialidase has a type I membrane orientation with its amino terminus facing to the extracytoplasmic side and lacking a signal sequence.	Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 236, Japan	Kirin Brewery Company Limited	Miyagi, T (corresponding author), Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan.	tmiyagi@mcc.pref.miyagi.jp						Akita H, 1997, HISTOCHEM CELL BIOL, V107, P495, DOI 10.1007/s004180050137; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Carrillo MB, 1997, GLYCOBIOLOGY, V7, P975; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; Hata K, 1998, J BIOCHEM-TOKYO, V123, P899; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOYER LL, 1992, MOL MICROBIOL, V6, P873, DOI 10.1111/j.1365-2958.1992.tb01538.x; Igdoura SA, 1998, HUM MOL GENET, V7, P115, DOI 10.1093/hmg/7.1.115; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; Kopitz J, 1997, EUR J BIOCHEM, V248, P527, DOI 10.1111/j.1432-1033.1997.00527.x; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LIESER M, 1989, BIOCHEM J, V260, P69, DOI 10.1042/bj2600069; MACALA LJ, 1995, GLYCOBIOLOGY, V5, P67, DOI 10.1093/glycob/5.1.67; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; MIYAGI T, 1984, EUR J BIOCHEM, V141, P75, DOI 10.1111/j.1432-1033.1984.tb08159.x; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; MIYAGI T, 1990, JPN J CANCER RES, V81, P1286, DOI 10.1111/j.1349-7006.1990.tb02692.x; OHMAN R, 1971, J NEUROCHEM, V18, P79, DOI 10.1111/j.1471-4159.1971.tb00168.x; OHMAN R, 1971, J NEUROCHEM, V18, P89, DOI 10.1111/j.1471-4159.1971.tb00169.x; Palestini P, 1998, BIOCHEMISTRY-US, V37, P3143, DOI 10.1021/bi971838a; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROGGENTIN P, 1993, MOL MICROBIOL, V9, P915, DOI 10.1111/j.1365-2958.1993.tb01221.x; ROGGENTIN P, 1988, FEBS LETT, V238, P31, DOI 10.1016/0014-5793(88)80219-9; ROST B, 1995, PROTEIN SCI, V4, P521; Sato K, 1996, BIOCHEM BIOPH RES CO, V221, P826, DOI 10.1006/bbrc.1996.0681; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHENGRUND CL, 1973, J BIOL CHEM, V248, P4424; Tatewaki K, 1997, EXP CELL RES, V233, P145, DOI 10.1006/excr.1997.3563; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; USUKI S, 1988, J BIOL CHEM, V263, P10595; USUKI S, 1988, J BIOL CHEM, V263, P6847; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; YOGEESWARAN G, 1975, BIOCHEMISTRY-US, V14, P2151, DOI 10.1021/bi00681a017; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341; [No title captured]	47	152	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5004	5011		10.1074/jbc.274.8.5004	http://dx.doi.org/10.1074/jbc.274.8.5004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988745	hybrid			2022-12-25	WOS:000078698200070
J	Schwientek, T; Nomoto, M; Levery, SB; Merkx, G; van Kessel, AG; Bennett, EP; Hollingsworth, MA; Clausen, H				Schwientek, T; Nomoto, M; Levery, SB; Merkx, G; van Kessel, AG; Bennett, EP; Hollingsworth, MA; Clausen, H			Control of O-glycan branch formation - Molecular cloning of human cDNA encoding a novel beta 1,6-N-acetylglucosaminyltransferase forming core 2 and core 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; HUMAN COLONIC MUCIN; OLIGOSACCHARIDE STRUCTURES; CORRELATION SPECTROSCOPY; LINKED OLIGOSACCHARIDES; GENE FAMILY; UDP-GLCNAC; CELL-LINES; EXPRESSION	A novel human UDP-GlcNAc: Gal/GlcNAc beta 1-3GalNAc alpha beta 1,6GlcNAc-transferase, designated C2/4GnT, was identified by BLAST analysis of expressed sequence tags. The sequence of C2/4GnT encoded a putative type II transmembrane protein with significant sequence similarity to human C2GnT and IGnT, Expression of the secreted form of C2/4GnT in insect cells showed that the gene product had UDP-N-acetyl-alpha-D-glucosamine: acceptor beta 1,6-N-acetylglucosaminyltransferase (beta 1,6GlcNAc-transferase) activity. Analysis of substrate specificity revealed that the enzyme catalyzed O-glycan branch formation of the core 2 and core 4 type. NMR analyses of the product formed with core 3-para-nitrophenyl confirmed the product core 4-para-nitrophenyl, The coding region of C2/4GnT was contained in a single exon and located to chromosome 15q21.3. Northern analysis revealed a restricted expression pattern of C2/4GnT mainly in colon, kidney, pancreas, and small intestine. No expression of C2/4GnT was detected in brain, heart, liver, ovary, placenta, spleen, thymus, and peripheral blood leukocytes, The expression of core 2 O-glycans has been correlated with cell differentiation processes and cancer. The results confirm the predicted existence of a beta 1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation. The redundancy in beta 1,6Glc-NAc-transferases capable of forming core 2 O-glycans is important for understanding the mechanisms leading to specific changes in core 2 branching during cell development and malignant transformation.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	University of Copenhagen; University of Nebraska System; University of Nebraska Medical Center; University System of Georgia; University of Georgia; Radboud University Nijmegen	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.		Bennett, Eric/AAG-6120-2020; van Kessel, Ad Geurts/A-2810-2010; clausen, henrik/AAD-8016-2021	Bennett, Eric/0000-0002-4976-0647; 	NCI NIH HHS [1 RO1 CA66234, 1RO1 CA66234] Funding Source: Medline; NCRR NIH HHS [5 P41 RR05351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1988, J MAGN RESON, V78, P186, DOI 10.1016/0022-2364(88)90172-2; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, GLYCOBIOLOGY, V8, P547, DOI 10.1093/glycob/8.6.547; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BREG J, 1988, EUR J BIOCHEM, V171, P643, DOI 10.1111/j.1432-1033.1988.tb13835.x; Brockhausen I, 1997, BIOCHEM SOC T, V25, P871, DOI 10.1042/bst0250871; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; Bush CA, 1988, B MAGN RESON, V10, P73; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; Fukuda M, 1996, CANCER RES, V56, P2237; HANISCH FG, 1993, EUR J BIOCHEM, V217, P645, DOI 10.1111/j.1432-1033.1993.tb18288.x; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HOUNSELL EF, 1989, EUR J BIOCHEM, V186, P597, DOI 10.1111/j.1432-1033.1989.tb15250.x; Karlsson NG, 1997, J BIOL CHEM, V272, P27025, DOI 10.1074/jbc.272.43.27025; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUHNS W, 1993, GLYCOCONJUGATE J, V10, P381, DOI 10.1007/BF00731043; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leppanen A, 1998, J BIOL CHEM, V273, P17399, DOI 10.1074/jbc.273.28.17399; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Natunen J, 1997, GLYCOBIOLOGY, V7, P711, DOI 10.1093/glycob/7.5.711; Olavesen MG, 1997, GENOMICS, V46, P303, DOI 10.1006/geno.1997.5032; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PILLER F, 1988, J BIOL CHEM, V263, P15146; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; POLLEXKRUGER A, 1993, GLYCOCONJUGATE J, V10, P365, DOI 10.1007/BF00731042; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SAITOH O, 1991, BLOOD, V77, P1491; SANGADALA S, 1991, MOL CELL BIOCHEM, V101, P125; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SCHACHTER H, 1971, J BIOL CHEM, V246, P5321; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SEKINE M, 1994, J BIOL CHEM, V269, P31143; Sekine M, 1997, J BIOL CHEM, V272, P27246, DOI 10.1074/jbc.272.43.27246; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Sutherlin ME, 1997, CANCER RES, V57, P4744; Toki D, 1997, BIOCHEM J, V325, P63, DOI 10.1042/bj3250063; VanderElst IE, 1998, GLYCOBIOLOGY, V8, P731, DOI 10.1093/glycob/8.7.731; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; Yoshida Y, 1996, GLYCOBIOLOGY, V6, P573, DOI 10.1093/glycob/6.6.573; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	65	84	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4504	4512		10.1074/jbc.274.8.4504	http://dx.doi.org/10.1074/jbc.274.8.4504			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988682	hybrid			2022-12-25	WOS:000078698200007
J	Volkman, BF; Anderson, ME; Clark, KD; Hayakawa, Y; Strand, MR; Markley, JL				Volkman, BF; Anderson, ME; Clark, KD; Hayakawa, Y; Strand, MR; Markley, JL			Structure of the insect cytokine peptide plasmatocyte-spreading peptide 1 from Pseudoplusia includens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEINS; PROGRAM; SPECTROSCOPY; THROMBIN	The structure of the recently identified plasmatocyte spreading peptide from the moth Pseudoplusia includens (PSP1) has been determined by NMR spectroscopy. This novel insect cytokine consists of 23 amino acid residues and a single disulfide bond. Torsion angle dynamics calculations utilizing a total of 337 distance constraints yielded an ensemble of 30 structures with an average backbone root mean square deviation for residues 7-22 of 0.18 Angstrom from the mean structure. The structure consists of a disordered N-terminal region and a well defined core that is stabilized by numerous hydrophobic interactions and a short beta-hairpin. Structural comparisons confirm that PSP1 adopts an epidermal growth factor (EGF)-like fold with close similarity to the C-terminal subdomain of EGF-like module 5 of human thrombomodulin. The combination of the three-dimensional structure of PSP1 and the extensive literature on EGF-receptor interactions should accelerate the process of identifying the specific residues responsible for receptor binding activity of this family of immunoregulatory peptides.	Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA; Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Hokkaido University	Volkman, BF (corresponding author), Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil Madison, 433 Babcock Dr, Madison, WI 53706 USA.	volkman@nmrfam.wisc.edu	Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020; Clark, Kevin/GQA-9811-2022	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; 	NCRR NIH HHS [RR02781, RR02301] Funding Source: Medline; NIAID NIH HHS [AI32917] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032917] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Bartels C, 1996, J BIOMOL NMR, V7, P207, DOI 10.1007/BF00202037; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1991, J MAGN RESON, V91, P174, DOI 10.1016/0022-2364(91)90422-P; Benitez BAS, 1997, J MOL BIOL, V273, P913, DOI 10.1006/jmbi.1997.1356; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; Hrabal R, 1996, PROTEIN SCI, V5, P195; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; Wuthrich K, 1986, NMR PROTEINS NUCL AC	20	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4493	4496		10.1074/jbc.274.8.4493	http://dx.doi.org/10.1074/jbc.274.8.4493			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988679	hybrid			2022-12-25	WOS:000078698200004
J	Gary, R; Kim, K; Cornelius, HL; Park, MS; Matsumoto, Y				Gary, R; Kim, K; Cornelius, HL; Park, MS; Matsumoto, Y			Proliferating cell nuclear antigen facilitates excision in long-patch base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; STRUCTURE-SPECIFIC ENDONUCLEASE; DEOXYRIBOSE PHOSPHATE RESIDUES; HUMAN APURINIC ENDONUCLEASE; HUMAN FLAP ENDONUCLEASE-1; MISMATCH REPAIR; HUMAN FEN-1; PCNA; REPLICATION; BINDING	There are two distinct pathways for the removal of modified DNA bases through base excision repair (BER) in vertebrates, Following 5' incision by AP endonuclease, the pathways diverge as two different excision mechanisms are possible, In short-patch repair, DNA polymerase beta accounts for both excision activity and single nucleotide repair synthesis. In long-patch repair, the damage-containing strand is excised by the structure-specific endonuclease FEN-1 and approximately 2-8 nucleotides are incorporated by proliferating cell nuclear antigen (PCNA)-dependent synthesis. PCNA is an accessory factor of DNA polymerases delta and epsilon that is required for DNA replication and repair. PCNA binds to FEN-1 and stimulates its nuclease activity, but the physiological significance of this interaction is unknown. The importance of the PCNA-FEN-1 interaction in BER was investigated, In a reconstituted BER assay system containing FEN-1, omission of PCNA caused the accumulation of pre-excision reaction intermediates which could be converted to completely repaired product by addition of PCNA. When dNTPs were omitted from the reaction to suppress repair synthesis, PCNA was required for the formation of excised reaction intermediates. In contrast, a PCNA mutant that could not bind to FEN-1 was unable to stimulate excision, To further study this effect, a mutant of FEN-T was identified that retained full nuclease activity but was specifically defective in binding to PCNA. The mutant FEN-1 exhibited one-tenth the specific activity of wild type FEN-1 in the reconstituted BER assay, and this repair defect was due to a kinetic block at the excision step as evidenced by the accumulation of pre-excision intermediates when dNTPs were omitted, These results indicate that PCNA facilitates excision during long-patch BER through its interaction with FEN-1.	Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA; Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Fox Chase Cancer Center	Gary, R (corresponding author), Univ Calif Los Alamos Natl Lab, Div Life Sci, M888, Los Alamos, NM 87545 USA.		Park, Min Sung/HCH-2207-2022; Gary, Ronald K/A-8650-2008	Gary, Ronald K/0000-0001-5079-1953; Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL CANCER INSTITUTE [R29CA063154, R29CA071630, R01CA063154] Funding Source: NIH RePORTER; NCI NIH HHS [CA71630, CA63154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henderson DS, 1998, MUTAGENESIS, V13, P57; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P172; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713	45	141	143	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4354	4363		10.1074/jbc.274.7.4354	http://dx.doi.org/10.1074/jbc.274.7.4354			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933638	hybrid			2022-12-25	WOS:000078575500062
J	Kishi, A; Kato, M; Shimizu, T; Kato, K; Matsumoto, K; Yoshida, S; Shiosaka, S; Hakoshima, T				Kishi, A; Kato, M; Shimizu, T; Kato, K; Matsumoto, K; Yoshida, S; Shiosaka, S; Hakoshima, T			Crystal structure of neuropsin, a hippocampal protease involved in kindling epileptogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SERINE-PROTEASE; X-RAY; CRYSTALLOGRAPHIC REFINEMENT; NEURITE OUTGROWTH; NERVOUS-SYSTEM; MOUSE-BRAIN; TRYPSIN; EXPRESSION; CRYSTALLIZATION	Neuropsin is a novel serine protease, the expression of which is highly localized in the limbic areas of the mouse brain and which is suggested to be involved in kindling epileptogenesis and hippocampal plasticity, The 2.1-Angstrom resolution crystal structure of neuropsin provides the first three-dimensional view of one of the serine proteases highly expressed in the nervous system, and reveals a serine protease fold that exhibits chimeric features between trypsin and nerve growth factor-gamma (NGF gamma), a member of the kallikrein family. Neuropsin possesses an N-glycosylated "kallikrein loop" but forms six disulfide bonds corresponding to those of trypsin, The ordered kallikrein loop projects proline toward the active site tee restrict smaller residues or proline at the P2 position of substrates. Loop F, which participates in forming the S3/S4 sites, is similar to trypsin rather than NGF gamma. The unique conformations of loops G and H form an S1 pocket specific for both arginine and lysine, These characteristic loop structures forming the substrate-binding site suggest the novel substrate specificity of neuropsin and give a clue to the design of its specific inhibitors.	Nara Inst Sci & Technol, Dept Mol Biol, Nara 6300101, Japan; Nara Inst Sci & Technol, Dept Cell Biol, Nara 6300101, Japan	Nara Institute of Science & Technology; Nara Institute of Science & Technology	Hakoshima, T (corresponding author), Nara Inst Sci & Technol, Dept Mol Biol, 8916-5 Takayama, Nara 6300101, Japan.	hakosima@bs.aist-nara.ac.jp	Shiosaka, Sadao/B-1142-2008					Akita H, 1997, BRAIN RES, V769, P86, DOI 10.1016/S0006-8993(97)00674-4; Bax B, 1997, STRUCTURE, V5, P1275, DOI 10.1016/S0969-2126(97)00280-3; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHEN ZL, 1995, J NEUROSCI, V15, P5088; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; FRIEDRICH A, 1996, TRENDS GLYCOSCI GLYC, V40, P101; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kishi T, 1997, J STRUCT BIOL, V118, P248, DOI 10.1006/jsbi.1997.3862; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okabe A, 1996, BRAIN RES, V728, P116, DOI 10.1016/S0006-8993(96)00473-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Shimizu C, 1998, J BIOL CHEM, V273, P11189, DOI 10.1074/jbc.273.18.11189; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; Timm DE, 1997, PROTEIN SCI, V6, P1418, DOI 10.1002/pro.5560060706; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X	29	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4220	4224		10.1074/jbc.274.7.4220	http://dx.doi.org/10.1074/jbc.274.7.4220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933620	hybrid			2022-12-25	WOS:000078575500044
J	Coy, DL; Wagenbach, M; Howard, J				Coy, DL; Wagenbach, M; Howard, J			Kinesin takes one 8-nm step for each ATP that it hydrolyzes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA KINESIN; MOLECULAR MOTORS; SLIDING DISTANCE; MICROTUBULES; FORCE; MOVEMENT; MUSCLE; ACTIN; TRANSPORT; MECHANISM	Conventional kinesin is a motor protein that moves stepwise along microtubules carrying membrane-bound organelles toward the periphery of cells. The steps are of amplitude 8.1 nm, the distance between adjacent tubulin binding sites, and are powered by the hydrolysis of ATP, We have asked: how many steps does kinesin take for each molecule of ATP that it hydrolyzes? To answer this question, the motility and ATP hydrolysis of recombinant, heterotetrameric and homodimeric conventional Drosophila kinesins adsorbed to 200-nm-diameter casein-coated silica beads were assayed under identical, single-molecule conditions. Division of the speed by the maximum microtubule-activated ATPase rate gave a stoichiometry of 1.08 +/- 0.09 steps for each ATP hydrolyzed at 1 mM ATP, Therefore, under low loads in which the drag force much less than 1 pN, coupling between the chemical and mechanical cycles of kinesin is tight, consistent with conventional power stroke models. Our results rule out models that require two or more ATPs/step, such as some thermal ratchet models, or that propose multiple steps powered by single ATPs.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Howard, J (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	johoward@u.washington.edu	Howard, Jonathon/J-7492-2016; Howard, Jonathon/D-4229-2011	Howard, Jonathon/0000-0003-0086-1196; Howard, Jonathon/0000-0003-0086-1196	NIAMS NIH HHS [AR40593] Funding Source: Medline; NIGMS NIH HHS [GM08268] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR040593, R01AR040593] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Astumian RD, 1996, BIOPHYS J, V70, P637, DOI 10.1016/S0006-3495(96)79605-4; BERG H, 1983, RANDOM WALKS BIOL, P56; BLOCK SM, 1990, NATURE, V348, P284; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; Coy David L., 1994, Current Opinion in Neurobiology, V4, P662, DOI 10.1016/0959-4388(94)90007-8; EISENBERG E, 1978, PROG BIOPHYS MOL BIO, V33, P55; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HOWARD J, 1993, METHOD CELL BIOL, V39, P138; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	34	291	296	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3667	3671		10.1074/jbc.274.6.3667	http://dx.doi.org/10.1074/jbc.274.6.3667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920916	hybrid			2022-12-25	WOS:000078428200056
J	Ricci, MS; Toscano, DG; Mattingly, CJ; Toscano, WA				Ricci, MS; Toscano, DG; Mattingly, CJ; Toscano, WA			Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; XENOBIOTIC RESPONSIVE ELEMENT; ARYL-HYDROCARBON HYDROXYLASE; O-DEETHYLASE ACTIVITY; AH RECEPTOR; FUNCTIONAL-ANALYSIS; GENE-EXPRESSION; MESSENGER-RNA; INVITRO TRANSCRIPTION; REGULATORY ELEMENTS	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exerts its toxic action via the aryl hydrocarbon (Ah) receptor, which induces a battery of xenobiotic-metabolizing enzymes, including the cytochrome P450 isozyme, CYP1A1, TCDD-induced 7-ethoxycoumarin-O-deethylase activity was reduced 75% in cultured human endometrial ECC-1 cells exposed to various concentrations of 17 beta-estradiol for up to 72 h, with a half-maximal effective concentration (EC50) of 0.9 nM. Reduced enzyme activity was correlated with decreased CYP1A1 mRNA levels, and transcription. Exposure to TCDD plus 17 beta-estradiol also reduced CYP1A1 activity in MCF-7 breast cancer cells but not in Hep-3B human liver cells or HuE primary human keratinocytes, suggesting that the effect was specific to estrogen-regulated cells. Estrogen receptor antagonists 4-hydroxytamoxifen and 7 alpha-[9-(4,4,5,5,5-pentafluoro-pentylsulfinyl)nonyl]estra-1,3,5(10)-triene3,17 beta-diol restored TCDD-induced CYP1A1 transcription, steady-state mRNA levels, and enzymatic activity in ECC-1 cells. Gel mobility shift assay showed that 17 beta-estradiol had little effect on Ah receptor binding to its DNA-responsive element. 17 beta-Estradiol did not alter the induction of another Ah receptor-regulated gene, CYP1B1, suggesting that altered Ah receptor binding to DNA does not mediate reduced CYP1A1 transcription, Transfecting ECC-1 cells with a general transcription factor involved in CYP1A1 induction, nuclear factor-1, reversed 17 beta-estradiol antagonism of dioxin induced-CYP1A1, The data suggest that 17 beta-estradiol reduced CYP1A1 expression at the transcriptional level by squelching available nuclear factor-1, a transcription factor that interacts with both Ah and estrogen receptors.	Tulane Univ, Sch Publ Hlth & Trop Med SL29, Dept Environm Hlth Sci, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med SL29, Ctr Bioenvironm Res, New Orleans, LA 70112 USA	Tulane University; Tulane University	Toscano, WA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med SL29, Dept Environm Hlth Sci, 1430 Tulane Ave, New Orleans, LA 70112 USA.	wtoscan@tmc.tulane.edu		Mattingly, Carolyn/0000-0002-2146-9436				ASTROFF B, 1988, TOXICOL APPL PHARM, V95, P435, DOI 10.1016/0041-008X(88)90361-4; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BOIS FY, 1994, ENVIRON HEALTH PERSP, V102, P476, DOI 10.2307/3432044; BOULET AP, 1987, IN VITRO CELL DEV B, V23, P93; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P7878, DOI 10.1073/pnas.87.20.7878; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DENISON MS, 1988, J BIOL CHEM, V263, P17221; Devito Michael J., 1994, P139; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLO MA, 1986, TOXICOL LETT, V32, P123, DOI 10.1016/0378-4274(86)90058-5; GASIEWICZ TA, 1991, BIOCHEMISTRY-US, V30, P2909, DOI 10.1021/bi00225a026; GREENLEE WF, 1978, J PHARMACOL EXP THER, V205, P596; HARRIS M, 1990, CANCER RES, V50, P3579; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HIRSCH V, 1986, P NATL ACAD SCI USA, V83, P9754, DOI 10.1073/pnas.83.24.9754; Hoivik D, 1997, J BIOL CHEM, V272, P30270, DOI 10.1074/jbc.272.48.30270; HORWITZ KB, 1975, STEROIDS, V26, P785, DOI 10.1016/0039-128X(75)90110-5; HUDSON LG, 1983, BIOCHEM BIOPH RES CO, V115, P611, DOI 10.1016/S0006-291X(83)80188-0; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; KONINCKX PR, 1994, HUM REPROD, V9, P1001, DOI 10.1093/oxfordjournals.humrep.a138623; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; KUBOTA M, 1991, J BIOCHEM-TOKYO, V110, P232, DOI 10.1093/oxfordjournals.jbchem.a123562; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lavin AL, 1998, ARCH BIOCHEM BIOPHYS, V352, P9, DOI 10.1006/abbi.1998.0587; Li Jonathan J., 1995, P397; LIEHR JG, 1995, P NATL ACAD SCI USA, V92, P9220, DOI 10.1073/pnas.92.20.9220; Liehr JG, 1996, P NATL ACAD SCI USA, V93, P3294, DOI 10.1073/pnas.93.8.3294; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MARTUCCI CP, 1993, PHARMACOL THERAPEUT, V57, P237, DOI 10.1016/0163-7258(93)90057-K; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; Miller CA, 1997, J BIOL CHEM, V272, P32824, DOI 10.1074/jbc.272.52.32824; MOORE M, 1993, J STEROID BIOCHEM, V44, P251, DOI 10.1016/0960-0760(93)90085-B; MOORE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P483, DOI 10.1006/abbi.1993.1451; NEBERT DW, 1970, INT J CANCER, V6, P470, DOI 10.1002/ijc.2910060318; OLIVE DL, 1993, NEW ENGL J MED, V328, P1759, DOI 10.1056/NEJM199306173282407; OMALLEY B, 1993, STEROID HORMONE ACTI, P44; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; Pink JJ, 1996, CANCER RES, V56, P2321; POLAND A, 1976, J BIOL CHEM, V251, P4936; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; Prough RA, 1996, FASEB J, V10, P1369, DOI 10.1096/fasebj.10.12.8903507; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; RICCI MS, 1999, IN PRESS IN VITRO CE; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; RODRIGUES AD, 1991, METHOD ENZYMOL, V206, P423; Safe S, 1995, TOXICOL LETT, V82-3, P731, DOI 10.1016/0378-4274(95)03591-5; SAFE S, 1991, PHARMACOL TOXICOL, V69, P400, DOI 10.1111/j.1600-0773.1991.tb01321.x; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATYASWAROOP PG, 1983, SCIENCE, V219, P58, DOI 10.1126/science.6849115; SATYASWAROOP PG, 1986, PROGR CANC RES THERA, P430; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WAKELING AE, 1991, CANCER RES, V51, P3867; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; WHITLOCK JP, 1994, TRENDS ENDOCRIN MET, V5, P183, DOI 10.1016/1043-2760(94)90075-2; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; Wo YYP, 1997, J BIOL CHEM, V272, P26702, DOI 10.1074/jbc.272.42.26702; ZACHAREWSKI T, 1998, REPROD DEV TOXICOLOG, P431	79	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3430	3438		10.1074/jbc.274.6.3430	http://dx.doi.org/10.1074/jbc.274.6.3430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920887	hybrid			2022-12-25	WOS:000078428200027
J	Swanson, KD; Taylor, LK; Haung, L; Burlingame, AL; Landreth, GE				Swanson, KD; Taylor, LK; Haung, L; Burlingame, AL; Landreth, GE			Transcription factor phosphorylation by pp90(rsk2) - Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; COFFIN-LOWRY SYNDROME; RIBOSOMAL S6 KINASE; DNA-BINDING DOMAIN; C-FOS; PHORBOL ESTER; MAP KINASES; INHIBITOR; POTENT	The in vitro phosphorylation of transcription factors by growth factor-activated protein kinases has resulted in the discovery of a number of activities whose identities and relationships to one another are unclear. Fos kinase is a growth factor-stimulated serine/threonine protein kinase that phosphorylates c-Fos at serine 362 within the carboxyl-terminal regulatory domain. Fos kinase activation is dependent on p21(ras) and mitogen-activated protein kinase/ERK kinase kinase (MEK) activity and is independent of phosphatidylinositol 3-kinase activity. We have purified Fos kinase by affinity chromatography using the Sepharose-linked protein kinase inhibitor, bisindolylmaleimide (BIM), Fos kinase has an apparent molecular mass of 88 kDa, and mass spectrophotometric analysis of the isolated protein showed that it produced tryptic fragments identical to those predicted for pp90(rsk2), Fos kinase isolated from nerve growth factor-stimulated PC12 cells is indistinguishable from NGFI-B kinase I, based on their chromatographic behavior, substrate specificities, and relative sensitivity to BIM, Furthermore, we have distinguished Fos kinase from calcium/cAMP response element-binding protein (CREB) kinase, Therefore, Fos kinase and NGFI-B kinase I and pp90(rsk2) represent the same protein kinase species, Moreover, we report that pp90(rsk2) exists within nerve growth factor-stimulated PC12 cells as two chromatographically and immunologically distinct species, Finally, we demonstrate that CREB kinase is distinct from pp90(rsk2).	Case Western Reserve Univ, Sch Med, Alzheimers Res Lab, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Alzheimers Res Lab, Dept Neurol, Cleveland, OH 44106 USA; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Case Western Reserve University; Case Western Reserve University; University of California System; University of California San Francisco	Landreth, GE (corresponding author), Case Western Reserve Univ, Sch Med E504, Alzheimers Lab, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NIA NIH HHS [AG-00105] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; CURRAN T, 1984, CELL, V36, P259; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Grammer TC, 1996, J BIOL CHEM, V271, P23650, DOI 10.1074/jbc.271.39.23650; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIRATA Y, 1995, J NEUROCHEM, V65, P1780; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Pende M, 1997, J NEUROSCI, V17, P1291; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	39	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3385	3395		10.1074/jbc.274.6.3385	http://dx.doi.org/10.1074/jbc.274.6.3385			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920881	hybrid			2022-12-25	WOS:000078428200021
J	Firsov, D; Robert-Nicoud, M; Gruender, S; Schild, L; Rossier, BC				Firsov, D; Robert-Nicoud, M; Gruender, S; Schild, L; Rossier, BC			Mutational analysis of cysteine-rich domains of the epithelium sodium channel (ENaC) - Identification of cysteines essential for channel expression at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; ALPHA-SUBUNIT; BETA-SUBUNIT; NA+ CHANNEL; ALDOSTERONE	One of the characteristic features of the structure of the epithelial sodium channel family (ENaC) is the presence of two highly conserved cysteine-rich domains (CRD1 and CRD2) in the large extracellular loops of the proteins. We have studied the role of CRDs in the functional expression of rat alpha beta gamma ENaC subunits by systematically mutating cysteine residues (singly or in combinations) into either serine or alanine, In the Xenopus oocyte expression system, mutations of two cysteines in CRD1 of alpha, beta, or gamma ENaC subunits led to a temperature-dependent inactivation of the channel. In CRD1, one of the cysteines of the rat alpha ENaC subunit (Cys(158)) is homologous to Cys(133) Of the corresponding human subunit causing, when mutated to tyrosine (C133Y), pseudohypoaldosteronism type 1, a severe salt-loosing syndrome in neonates. In CRD2, mutation of two cysteines in alpha and beta but not in the gamma subunit also produced a temperature-dependent inactivation of the channel. The main features of the mutant cysteine channels are: (i) a decrease in cell surface expression of channel molecules that parallels the decrease in channel activity and (ii) a normal assembly or rate of degradation as assessed by nondenaturing co-immunoprecipitation of [S-35]methionine-labeled channel protein. These data indicate that the two cysteines in CRD1 and CRD2 are not a prerequisite for subunit assembly and/or intrinsic channel activity. We propose that they play an essential role in the efficient transport of assembled channels to the plasma membrane.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Rossier, BC (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Bernard.Rossier@ipharm.unil.ch	Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883				Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Beggah AT, 1997, J BIOL CHEM, V272, P10318; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GEERING K, 1982, J BIOL CHEM, V257, P338; GEERING K, 1985, J BIOL CHEM, V260, P5154; Green WN, 1997, J BIOL CHEM, V272, P20945, DOI 10.1074/jbc.272.33.20945; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Grunder S, 1997, J AM SOC NEPHROL, V8, pA0161; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; May A, 1997, J AM SOC NEPHROL, V8, P1813; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329	31	67	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2743	2749		10.1074/jbc.274.5.2743	http://dx.doi.org/10.1074/jbc.274.5.2743			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915805	hybrid			2022-12-25	WOS:000078319500023
J	Matsui, T; Ozaki, S; Liong, E; Phillips, GN; Watanabe, Y				Matsui, T; Ozaki, S; Liong, E; Phillips, GN; Watanabe, Y			Effects of the location of distal histidine in the reaction of myoglobin with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; CYTOCHROME-C PEROXIDASE; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; HORSERADISH-PEROXIDASE; HEME IRON; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; ACTIVE-SITE; COMPOUND-I	To clarify how the location of distal histidine affects the activation process of H2O2 by heme proteins, we have characterized reactions with H2O2 for the L29H/H64L and F43H/H64L mutants of sperm whale myoglobin (Mb), designed to locate the histidine farther from the heme iron. Whereas the L29H/H64L double substitution retarded the reaction with H2O2, an 11-fold rate increase versus wild-type Mb was observed for the F43H/H64L mutant. The V-max values for 1-electron oxidations by the myoglobins correlate well with the varied reactivities with H2O2. The functions of the distal histidine as a general acid-base catalyst were examined based on the reactions with cumene hydroperoxide and cyanide, and only the histidine in F43H/H64L Mb was suggested to facilitate heterolysis of the peroxide bond. The x-ray crystal structures of the mutants confirmed that the distal histidines in F43H/H64L Mb and peroxidase are similar in distance from the heme iron, whereas the distal histidine in L29H/H64L Mb is located too far to enhance heterolysis. Our results indicate that the proper positioning of the distal histidine is essential for the activation of H2O2 by heme enzymes.	Inst Mol Sci, Okazaki, Aichi 444, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 444, Japan; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Graduate University for Advanced Studies - Japan; Rice University	Watanabe, Y (corresponding author), Inst Mol Sci, Okazaki, Aichi 444, Japan.	yoshi@ims.ac.jp	Matsui, Toshitaka/B-1570-2008	Matsui, Toshitaka/0000-0003-3865-8468	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40252] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ALLENTOFF AJ, 1992, J AM CHEM SOC, V114, P9744, DOI 10.1021/ja00051a003; BRANCACCIO A, 1994, J BIOL CHEM, V269, P13843; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARVER TE, 1990, J BIOL CHEM, V265, P20007; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; EVERSE J, 1994, METHOD ENZYMOL, V231, P547; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; KING NK, 1963, J BIOL CHEM, V238, P1520; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; MEEHAN EJ, 1961, J AM CHEM SOC, V83, P2232, DOI 10.1021/ja01471a004; Mukai M, 1997, J AM CHEM SOC, V119, P1758, DOI 10.1021/ja962551o; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 1996, J AM CHEM SOC, V118, P9784, DOI 10.1021/ja961223l; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RAMETTE RW, 1965, J AM CHEM SOC, V87, P5001, DOI 10.1021/ja00950a005; RAO SI, 1993, J BIOL CHEM, V268, P803; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; YONETANI T, 1967, J BIOL CHEM, V242, P1974	43	174	178	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2838	2844		10.1074/jbc.274.5.2838	http://dx.doi.org/10.1074/jbc.274.5.2838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915818	hybrid			2022-12-25	WOS:000078319500036
J	Miele, C; Caruso, M; Calleja, V; Auricchio, R; Oriente, F; Formisano, P; Condorelli, G; Cafieri, A; Sawka-Verhelle, D; Van Obberghen, E; Beguinot, F				Miele, C; Caruso, M; Calleja, V; Auricchio, R; Oriente, F; Formisano, P; Condorelli, G; Cafieri, A; Sawka-Verhelle, D; Van Obberghen, E; Beguinot, F			Differential role of insulin receptor substrate (IRS)-1 and IRS-2 in L6 skeletal muscle cells expressing the Arg(1152)-> Gln insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; MICE; SHC; PHOSPHORYLATION; ASSOCIATION; INHIBITOR	In L6 muscle cells expressing the Arg(1152) --> Gln insulin receptor (Mut), basal tyrosine phosphorylation of insulin receptor substrate (IRS)-1 was increased by 35% compared with wild-type cells (WT), Upon exposure to insulin, IRS-1 phosphorylation increased by 12-fold in both the Mut and WT cells. IRS-2 was constitutively phosphorylated in Mut cells and not further phosphorylated by insulin. The maximal phosphorylation of IRS-S in basal Mut cells was paralleled by a 4-fold increased binding of the kinase regulatory loop binding domain of IRS-S to the Arg(1152) --> Gln receptor. Grb2 and phosphatidylinositol 3-kinase association to IRS-1 and IRS-2 reflected the phosphorylation levels of the two IRSs, Mitogen-activated protein kinase activation and [H-3]thymidine incorporation closely correlated with IRS-1 phosphorylation in Mut and WT cells, while glycogen synthesis and synthase activity correlated with IRS-S phosphorylation, The Arg(1152) Gln mutant did not signal Shc phosphorylation or Shc-Grb2 association in intact L6 cells, while binding Shc in a yeast two-hybrid system and phosphorylating Shc in vitro. Thus, IRS-2 appears to mediate insulin regulation of glucose storage in Mut cells, while insulin-stimulated mitogenesis correlates with the activation of the IRS-1/mitogen-activated protein kinase pathway in these cells. IRS-1 and She-mediated mitogenesis may be redundant in muscle cells.	Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples, Ctr Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; INSERM, U145, F-06107 Nice, France	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Beguinot, F (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; ORIENTE, Francesco/J-6652-2018	Condorelli, Gerolama/0000-0003-0177-8829; ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; Denton R.M., 1997, INT TXB DIABETES MEL, P469; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HARADA S, 1995, J BIOL CHEM, V270, P26632, DOI 10.1074/jbc.270.44.26632; HARPER JW, 1993, CELL, V75, P805; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KAHN CR, 1997, INT TXB DIABETES MEL, P437; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MATSUOKA K, 1993, EMBO J, V12, P3467; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; Miller J.H., 1972, EXPT MOL GENETICS; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OKADA T, 1994, J BIOL CHEM, V269, P3568; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TOBE K, 1993, J BIOL CHEM, V268, P11167; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; WHITE MF, 1994, J BIOL CHEM, V268, P1; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	49	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3094	3102		10.1074/jbc.274.5.3094	http://dx.doi.org/10.1074/jbc.274.5.3094			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915848	hybrid			2022-12-25	WOS:000078319500066
J	Salvucci, M; Lemoine, A; Saffroy, R; Azoulay, D; Lepere, B; Gaillard, S; Bismuth, H; Reynes, R; Debuire, B				Salvucci, M; Lemoine, A; Saffroy, R; Azoulay, D; Lepere, B; Gaillard, S; Bismuth, H; Reynes, R; Debuire, B			Microsatellite instability in European hepatocellular carcinoma	ONCOGENE			English	Article						transforming growth factor (TGF beta) type II; receptor (RII) gene; cirrhosis; clinicopathological characteristics; recurrent disease; prognostic factor	II RECEPTOR GENE; GENOMIC INSTABILITY; COLORECTAL-CANCER; LIVER-TRANSPLANTATION; ULCERATIVE-COLITIS; MUTATION COMMON; BREAST-CANCER; HEPATITIS; REPEATS; ADENOCARCINOMA	Genetic instability has been detected in many types of cancers but poorly investigated in hepatocellular carcinoma (HCC). We have studied the incidence of microsatellite instability (MI) at eight highly polymorphic microsatellite markers and the poly A tract BAT26 and tested for mutations at two sites of repetitive sequence (poly-A nucleotides 709-718 and GT repeat-nucleotides 1931-1936) in the Transforming Growth Factor beta (TGF beta) type II receptor (RII) gene, in a group of 46 European HCCs and the surrounding nontumour tissue. This analysis showed that 63% of HCCs exhibit MI in at least one chromosome locus and 41% in two or more loci. No mutations of the TGF beta RII gene were found in the MI positive tumours. No correlation was found with clinicopathological characteristics of the tumours such as cirrhosis, etiology, number of nodules, Edmondson's grade and vascular invasion. However, in patients who had a rearranged D16S402 microsatellite in their tumour, the recurrent disease and the number of nodules were significantly higher than in the others (P<0.005 and P<0.02, respectively). We propose to consider D16S402 rearrangement in HCC as a prognostic factor to identify patients presenting a higher risk of recurrence.	Hop Paul Brousse, Dept Biochem, F-94804 Villejuif, France; Hop Paul Brousse, Hepatobiliary Surg & Liver Transplant Res Unit, F-94804 Villejuif, France; Hop Paul Brousse, Dept Pathol, F-94804 Villejuif, France; Fac Med Paris Sud, CEA, CNRS, UMR 217, Fontenay Aux Roses, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Debuire, B (corresponding author), Hop Paul Brousse, Dept Biochem, 14 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.		Azoulay, Daniel/Q-7887-2018	SAFFROY, RAPHAEL/0000-0002-9878-3669				Abe T, 1996, EUR J SURG ONCOL, V22, P474, DOI 10.1016/S0748-7983(96)92824-3; AKASHI Y, 1991, HEPATOLOGY, V14, P262, DOI 10.1016/0270-9139(91)91413-U; ARZIMANOGLOU IA, 1996, CARCINOGENESIS, V47, P1799; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Boige V, 1997, CANCER RES, V57, P1986; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; BRENTNALL TA, 1995, CANCER RES, V55, P4264; Brentnall TA, 1996, CANCER RES, V56, P1237; Chung YJ, 1996, CANCER RES, V56, P4662; DeMarchis L, 1997, CLIN CANCER RES, V3, P241; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HANN HJ, 1993, CANCER RES, V53, P5087; HOANG JM, 1996, CANCER RES, V53, P300; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kaneko H, 1996, LEUKEMIA, V10, P1696; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; Lemoine A, 1997, ANN SURG, V226, P43, DOI 10.1097/00000658-199707000-00006; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOTHE RA, 1993, CANCER RES, V53, P5849; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; PARSONS R, 1995, CANCER RES, V55, P5548; Paulson TG, 1996, CANCER RES, V56, P4021; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; RHYU MG, 1994, ONCOGENE, V9, P29; Salvucci M, 1996, ONCOGENE, V13, P2681; SAMUEL D, 1995, HEPATOLOGY, V21, P333, DOI 10.1016/0270-9139(95)90089-6; SHRIDHAR V, 1994, CANCER RES, V54, P2084; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Takenoshita S, 1997, CARCINOGENESIS, V18, P1427, DOI 10.1093/carcin/18.7.1427; TAMURA G, 1995, CANCER RES, V55, P1933; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Togo G, 1996, CANCER RES, V56, P5620; UCHIDA T, 1994, CANCER RES, V54, P3682; Vincent F, 1996, BIOCHEM BIOPH RES CO, V223, P561, DOI 10.1006/bbrc.1996.0934; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Zhu JG, 1996, ONCOGENE, V12, P1417	46	66	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					181	187		10.1038/sj.onc.1202279	http://dx.doi.org/10.1038/sj.onc.1202279			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926933				2022-12-25	WOS:000078166000020
J	Adderley, SR; Fitzgerald, DJ				Adderley, SR; Fitzgerald, DJ			Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FREE-RADICALS; REPERFUSION INJURY; INDUCED APOPTOSIS; CARDIAC MYOCYTES; RAT-HEART; EXPRESSION; STRESS; CELLS; SUPEROXIDE	Oxidative stress causes cardiac damage following ischemia/reperfusion and in response to anthracyclines. Extracellular signal-regulated kinases (ERK) 1/2 are activated by oxidative stress in cardiac myocytes and protect cardiac myocytes from apoptosis. Prostaglandins (PG) also protect cells from injury in a number of tissues, including the cardiomyocyte, Cyclooxygenase (COX) the rate-limiting enzyme in PG biosynthesis has two isoforms, the constitutive COX-1 and an inducible COX-2. Here, we examined the effects of two oxidative stresses, hydrogen peroxide (H2O2) and the anthracycline doxorubicin on the activity of ERK1/2 and the expression of COX isoforms and PG formation in neonatal rat primary cardiomyocytes. These cells expressed COX-1 at rest and both COX isoforms on treatment with phorbol 12-myristate 13-acetate. Exposure to 50 mu M H2O2 for 10 min or doxorubicin at 10 and 100 mu g/ml caused expression of COX-2 that was prevented by free radical scavengers. COX-2 induction was associated with activation of ERK1/2 and the specific ERK-inhibitor PD098059 abolished COX-2 expression. Treatment of cells with decoy oligonucleotides corresponding to COX-2 promoter elements implicated the AP-1 and NF kappa B-2 but not the NF-kappa B-1 in the transcription of COX-2. Induction of COX-2 mRNA and protein was accompanied by increased prostacyclin formation, which was abolished by the selective COX-2 inhibitor, NS-398, and PD098059. H2O2 and doxorubicin enhanced the release of lactate dehydrogenase and free radical scavengers prevented this. NS-398 enhanced the release of lactate dehydrogenase in response to H2O2 and doxorubicin, whereas the injury was prevented by iloprost, a stable prostacyclin analogue. In cardiomyocytes cell injury by H2O2 and doxorubicin is limited by an increase in prostacyclin formation that reflects induction of COX-2 mediated by ERK1/2 activation.	Royal Coll Surgeons Ireland, Ctr Cardiovasc Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin	Fitzgerald, DJ (corresponding author), Royal Coll Surgeons Ireland, Ctr Cardiovasc Sci, 123 St Stephens Green, Dublin 2, Ireland.	dfitzgerald@rcsi.ie						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BAKER CW, 1994, J BIOL CHEM, V269, P3985; BALINT GA, 1994, EXP TOXICOL PATHOL, V46, P37, DOI 10.1016/S0940-2993(11)80011-4; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Boveris A, 1977, Adv Exp Med Biol, V78, P67; BRISTOW MR, 1983, J CARDIOVASC PHARM, V5, P913, DOI 10.1097/00005344-198311000-00002; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; CHURCH DJ, 1994, BIOCHEM J, V303, P217, DOI 10.1042/bj3030217; COWAN DB, 1993, J BIOL CHEM, V268, P26904; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEMPLE B, 1996, ANNU REV GENET, V25, P315; DOROSHOW JH, 1983, CANCER RES, V43, P4543; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; Feng LL, 1997, ADV EXP MED BIOL, V407, P281; Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67; Goppelt-Struebe M, 1998, J CELL PHYSIOL, V175, P341, DOI 10.1002/(SICI)1097-4652(199806)175:3<341::AID-JCP12>3.0.CO;2-8; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HEARSE DJ, 1975, J MOL CELL CARDIOL, V7, P315, DOI 10.1016/0022-2828(75)90121-2; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hoshida S, 1996, J MOL CELL CARDIOL, V28, P1845, DOI 10.1006/jmcc.1996.0177; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; JADINE L, 1996, AM J PHYSIOL, V271, P12197; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kostic MM, 1997, J MOL CELL CARDIOL, V29, P3135, DOI 10.1006/jmcc.1997.0544; Ledwith BJ, 1997, J BIOL CHEM, V272, P3707, DOI 10.1074/jbc.272.6.3707; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Morecki S, 1998, INT J CANCER, V75, P894, DOI 10.1002/(SICI)1097-0215(19980316)75:6<894::AID-IJC12>3.0.CO;2-3; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pang LH, 1998, AM J PHYSIOL-LUNG C, V275, pL322, DOI 10.1152/ajplung.1998.275.2.L322; PENG M, 1995, CELL MOL BIOL RES, V41, P189; Reiser COA, 1998, BIOCHEM J, V330, P1107; SARVAZYAN NA, 1995, LIFE SCI, V57, P1003, DOI 10.1016/0024-3205(95)02036-I; SATO A, 1995, EMBO J, V12, P2005; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SIGNAL PK, 1998, NEW ENGL J MED, V339, P900; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Soler HM, 1997, J SURG RES, V67, P46, DOI 10.1006/jsre.1996.4917; Song W, 1996, BRIT J PHARMACOL, V118, P2157, DOI 10.1111/j.1476-5381.1996.tb15657.x; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VonKnethen A, 1997, FASEB J, V11, P887; WERNS SW, 1986, CIRCULATION, V74, P1, DOI 10.1161/01.CIR.74.1.1; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamazaki T, 1997, CIRCULATION, V95, P1260; YANHNA H, 1997, ARTERIOSCL THROM VAS, V17, P2808; Zerrouk A, 1998, J CARDIOVASC PHARM, V31, P525, DOI 10.1097/00005344-199804000-00009; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353	59	325	341	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5038	5046		10.1074/jbc.274.8.5038	http://dx.doi.org/10.1074/jbc.274.8.5038			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988750	hybrid			2022-12-25	WOS:000078698200075
J	Henstra, SA; Tuinhof, M; Duurkens, RH; Robillard, GT				Henstra, SA; Tuinhof, M; Duurkens, RH; Robillard, GT			The Bacillus stearothermophilus mannitol regulator, MtlR, of the phosphotransferase system - A DNA-binding protein, regulated by HPr and IICBmtl-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; SUBTILIS LEVANASE OPERON; GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; CATABOLITE REPRESSION; NUCLEOTIDE-SEQUENCE; LACTOCOCCUS-LACTIS; TRANSCRIPTIONAL ANTITERMINATORS; STREPTOCOCCUS-MUTANS; RNA-POLYMERASE	D-Mannitol is taken up by Bacillus stearothermophilus and phosphorylated via a phosphoenolpyruvate-dependent phosphotransferase system (PTS). The genes involved in the mannitol uptake were recently cloned and sequenced. One of the genes codes for a putative transcriptional regulator, MtlR. The presence of a DNA binding helix-turn-helix motif and two antiterminator-like PTS regulation domains, suggest that MtlR is a DNA-binding protein, the activity of which can be regulated by phosphorylation by components of the PTS. To demonstrate DNA binding of MtIR to a region upstream of the mannitol promoter, by DNA footprinting, MtlR was overproduced and purified. EI, HPr, IIA(mtl), and IICBmtl of B. stearothermophilus were purified and used to demonstrate that MtlR can be phosphorylated and regulated by HPr and IICBmtl, in vitro. Phosphorylation of MtlR by HPr increases the affinity of MtlR for its binding site, whereas phosphorylation by IICBmtl results in a reduction of this affinity. The differential effect of phosphorylation, by two different proteins, on the DNA binding properties of a bacterial transcriptional regulator has not, to our knowledge, been described before. Regulation of MtlR by two components of the PTS is an example of an elegant control system sensing both the presence of mannitol and the need to utilize this substrate.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Arnaud M, 1996, J BIOL CHEM, V271, P18966, DOI 10.1074/jbc.271.31.18966; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARDOWSKI J, 1994, J BACTERIOL, V176, P5681, DOI 10.1128/JB.176.18.5681-5685.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HANSEN PV, 1985, NUCLEIC ACIDS RES, V13, P5927; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; Henstra SA, 1996, J BACTERIOL, V178, P5586, DOI 10.1128/jb.178.19.5586-5591.1996; HONEYMAN AL, 1992, INFECT IMMUN, V60, P3369, DOI 10.1128/IAI.60.8.3369-3375.1992; HUECK CJ, 1994, RES MICROBIOL, V145, P503, DOI 10.1016/0923-2508(94)90028-0; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; Idelson M, 1998, J BACTERIOL, V180, P660, DOI 10.1128/JB.180.3.660-666.1998; KRISHNAN BR, 1991, NUCLEIC ACIDS RES, V19, P1153, DOI 10.1093/nar/19.5.1153; Kruger S, 1996, J BACTERIOL, V178, P2637; Lai Xiaokuang, 1995, Microbiology (Reading), V141, P1443, DOI 10.1099/13500872-141-6-1443; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; LU Z, 1989, NUCLEIC ACIDS RES, V17, P4883, DOI 10.1093/nar/17.12.4883; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; MARTINVERSTRAETE I, 1995, J BACTERIOL, V177, P6919, DOI 10.1128/jb.177.23.6919-6927.1995; NOVOTNY MJ, 1984, J BACTERIOL, V159, P986, DOI 10.1128/JB.159.3.986-990.1984; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REESE MG, 1996, P PAC S BIOC 1996; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1996, TRANSPORT PROCESSES, P549; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; ROSEY EL, 1992, J BACTERIOL, V174, P6159, DOI 10.1128/JB.174.19.6159-6170.1992; Sambrook J., 2002, MOL CLONING LAB MANU; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STULKE J, 1995, J BACTERIOL, V177, P6928; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; Stulke J, 1997, MOL MICROBIOL, V25, P65, DOI 10.1046/j.1365-2958.1997.4351797.x; Tobisch S, 1997, J BACTERIOL, V179, P496, DOI 10.1128/jb.179.2.496-506.1997; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; VANROOIJEN RJ, 1990, J BIOL CHEM, V265, P18499; VANROOIJEN RJ, 1992, J BACTERIOL, V174, P2273, DOI 10.1128/JB.174.7.2273-2280.1992; YAMADA M, 1988, J MOL BIOL, V203, P569, DOI 10.1016/0022-2836(88)90193-3; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUKOWSKI MM, 1990, GENE, V90, P153, DOI 10.1016/0378-1119(90)90453-X	49	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4754	4763		10.1074/jbc.274.8.4754	http://dx.doi.org/10.1074/jbc.274.8.4754			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988713	Green Published, hybrid			2022-12-25	WOS:000078698200038
J	Meivar-Levy, I; Futerman, AH				Meivar-Levy, I; Futerman, AH			Up-regulation of neutral glycosphingolipid synthesis upon long term inhibition of ceramide synthesis by fumonisin B-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGANINE N-ACYLTRANSFERASE; BURKITTS-LYMPHOMA CELLS; RAT-LIVER; GOLGI-APPARATUS; SHIGA TOXIN; EXPRESSION; DIFFERENTIATION; SPHINGOLIPIDS; GANGLIOSIDES; APOPTOSIS	In a previous study we observed that long term (5 days) incubation with fumonisin B-1 (FB1), an inhibitor of acylation of sphingoid long chain bases to (dihydro)ceramide, resulted in morphological and biochemical changes in 3T3 fibroblasts (Meivar-Levy, I., Sabanay, Il,, Bershadsky, A. D,, and Futerman, A. H. (1997) J, Biol, Chem, 272, 1558-1564). Among these were changes in the profile of synthesis of sphingolipids (SLs) and glycosphingolipids (GSLs), Whereas [H-3]globotriaosylceramide ([H-3]Gb(3)) comprised 1.9% of the total [H-3]SLs and [H-3]GSLs synthesized in control cells, it comprised 16.5% in FB1-treated cells. We now demonstrate by in vitro analysis that inhibition of ceramide synthesis by FB1 for 5 days results in up-regulation of the activities of three enzymes in the pathway of Gb(3) synthesis, namely glucosylceramide, lactosylceramide, and Gb(3) synthases; up-regulation is due to an increase in V-max, with no change in K-m values toward lipid substrates, Moreover, molecular analysis (reverse transcriptase-polymerase chain reaction) of glucosylceramide synthase indicated that this enzyme is up regulated at the transcriptional level. No changes in either the V-max or K-m values of sphingomyelin or of GM(3) synthase were detected after FB1 treatment. Analysis of SL and GSL synthesis in cultured cells using [4,5-H-3]sphinganine as a metabolic precursor demonstrated that at low substrate concentrations, Gb(3) synthesis is favored over GM(3) synthesis and glucosylceramide synthesis is favored over sphingomyelin synthesis, whereas the opposite is true at high substrate concentrations. These data demonstrate that GSL synthesis and in particular Gb(3) synthesis are tightly regulated in fibroblasts, presumably so as to maintain constant levels of Gb(3) on the cell surface.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmfuter@weizmann.weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUHOURS JF, 1976, BIOCHIM BIOPHYS ACTA, V441, P123, DOI 10.1016/0005-2760(76)90287-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; FUTERMAN AH, 1992, METHOD ENZYMOL, V209, P437; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HAKOMORI S, 1984, TRENDS BIOCHEM SCI, V9, P453, DOI 10.1016/0968-0004(84)90156-7; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; LANNERT H, 1994, FEBS LETT, V342, P91, DOI 10.1016/0014-5793(94)80591-1; LEDEEN RW, 1992, TRENDS GLYCOSCI GLYC, V4, P174; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MANGENEY M, 1993, CANCER RES, V53, P5314; MeivarLevy I, 1997, J BIOL CHEM, V272, P1558, DOI 10.1074/jbc.272.3.1558; MEIVARLEVY I, 1994, BIOCHEM J, V303, P377, DOI 10.1042/bj3030377; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; NAIKI M, 1974, BIOCHEM BIOPH RES CO, V60, P1105, DOI 10.1016/0006-291X(74)90426-4; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Sando GN, 1996, J BIOL CHEM, V271, P22044, DOI 10.1074/jbc.271.36.22044; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; STULTS CLM, 1995, GLYCOCONJUGATE J, V12, P680, DOI 10.1007/BF00731265; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Taga S, 1997, BLOOD, V90, P2757, DOI 10.1182/blood.V90.7.2757.2757_2757_2767; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; WIELS J, 1984, J BIOL CHEM, V259, P4783; YAMASHIRO S, 1993, CANCER RES, V53, P5395	42	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4607	4612		10.1074/jbc.274.8.4607	http://dx.doi.org/10.1074/jbc.274.8.4607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988695	hybrid			2022-12-25	WOS:000078698200020
J	Walker, JB; Nesheim, ME				Walker, JB; Nesheim, ME			The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED FIBRIN; A-ALPHA-CHAIN; CROSSLINKED FIBRIN; SUBUNIT STRUCTURE; FACTOR-XIII; GEL ELECTROPHORESIS; ELECTRON-MICROSCOPY; FRAGMENT-D; PURIFICATION; COMPLEXES	We used a perfused clot system to study the degradation of cross-linked fibrin, Multiangle laser light scattering showed that plasmin-mediated cleavage caused the release of noncovalently associated fibrin degradation products (FDPs) with a weight-averaged molar mass (M-w) of similar to 6 x 10(6) g/mol. The M-w of FDPs is dependent on ionic strength, and the M-w observed at 0.15 M NaCl resulted from the self-association of FDPs having M, of similar to 3.8 x 10(6) g/mol. Complete solubilization required the cleavage of similar to 25% of fragment D/fragment E connections, with 48% alpha-, 62% beta-, and 42% gamma-chains cleaved. These results showed that D-E cleavage cannot be explained by a random mechanism, implying cooperativity. Gel filtration and multiangle laser light scattering showed that FDPs range from 2.5 x 10(5) to 1 x 10(7) g/mol. In addition to fragment E, FDPs are composed of fragments ranging from 2 x 10(5) Da (D-dimer, or DD) to at least 2.3 x 10(6) Da (DX8D). FDP mass distribution is consistent with a model whereby FDPs bind to fibrin with affinities proportional to fragment mass. Root mean square radius analysis showed that small FDPs approximate rigid rods, but this relationship breaks down as FDPs size increases, suggesting that large FDPs possess significant flexibility.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NHLBI NIH HHS [HL 46703-6] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU I, 1992, BIOCHIM BIOPHYS ACTA, V1119, P268, DOI 10.1016/0167-4838(92)90213-W; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARADET TC, 1995, BIOPHYS J, V68, P1551, DOI 10.1016/S0006-3495(95)80327-9; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CARR ME, 1980, MACROMOLECULES, V13, P1473, DOI 10.1021/ma60078a022; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHASE T, 1970, METHOD ENZYMOL, V19, P20; COLLEN D, 1975, J BIOL CHEM, V250, P5808; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FERGUSON EW, 1975, J BIOL CHEM, V250, P7210; FRANCIS CW, 1987, J CLIN INVEST, V80, P1459, DOI 10.1172/JCI113226; FRANCIS CW, 1986, ANNU REV MED, V37, P187; FRANCIS CW, 1982, SEMIN THROMB HEMOST, V8, P25, DOI 10.1055/s-2007-1005040; FRANCIS CW, 1980, BLOOD, V56, P456; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1983, THROMB RES, P27; HOLM B, 1985, THROMB RES, V37, P165, DOI 10.1016/0049-3848(85)90043-X; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; LIU CY, 1986, THROMB HAEMOSTASIS, V56, P100; LORAND L, 1981, METHOD ENZYMOL, V80, P333; Lundblad R L, 1976, Methods Enzymol, V45, P156; Marder V J, 1967, Trans Assoc Am Physicians, V80, P156; MARDER VJ, 1983, ANN NY ACAD SCI, V408, P397, DOI 10.1111/j.1749-6632.1983.tb23260.x; MIHALYI E, 1983, ANN NY ACAD SCI, V408, P60, DOI 10.1111/j.1749-6632.1983.tb23234.x; MONTEJO JM, 1992, BIOCHEMISTRY-US, V31, P7580, DOI 10.1021/bi00148a020; MOSESSON MW, 1973, J BIOL CHEM, V248, P7913; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; Pfitzner SA, 1997, THROMB HAEMOSTASIS, V78, P1069; PIZZO SV, 1972, J BIOL CHEM, V247, P636; PIZZO SV, 1973, J BIOL CHEM, V248, P4584; PIZZO SV, 1973, J BIOL CHEM, V248, P4574; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; Rudchenko S, 1996, J BIOL CHEM, V271, P2523, DOI 10.1074/jbc.271.5.2523; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; Tanford C., 1961, PHYS CHEM MACROMOLEC; Toyosawa M, 1997, ELECTROPHORESIS, V18, P118, DOI 10.1002/elps.1150180122; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1993, J BIOL CHEM, V268, P26618; WEISEL JW, 1987, P NATL ACAD SCI USA, V84, P8991, DOI 10.1073/pnas.84.24.8991; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3; ZHANG JZ, 1994, J BIOL CHEM, V269, P652	52	97	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5201	5212		10.1074/jbc.274.8.5201	http://dx.doi.org/10.1074/jbc.274.8.5201			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988770	hybrid			2022-12-25	WOS:000078698200095
J	Warner, DR; Romanowski, R; Yu, SH; Weinstein, LS				Warner, DR; Romanowski, R; Yu, SH; Weinstein, LS			Mutagenesis of the conserved residue Glu(259) of G(s)alpha demonstrates the importance of interactions between switches 2 and 3 for activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; GS-ALPHA; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; HEREDITARY OSTEODYSTROPHY; ESCHERICHIA-COLI; GTP HYDROLYSIS; G(S-ALPHA); RECEPTOR; MUTATION	We previously reported that substitution of Arg(258) within the switch 3 region of G(s)alpha impaired activation and increased basal GDP release due to loss of an interaction between the helical and GTPase domains (Warner, D. R., Weng, G., Yu, S., Matalon, R., and Weinstein, L. S. (1998) J Biol. Chem. 273, 23976-23983). The adjacent residue (Glu(259)) is strictly conserved in G protein alpha-subunits and is predicted to be important in activation. To determine the importance of Glu(259), this residue was mutated to Ala (G(s)alpha-E259A), Gln (G(s)alpha-E259Q), Asp (G(s)alpha-E259D), or Val (G(s)alpha-E259V), and the properties of in vitro translation products were examined. The G(s)alpha-E259V was studied because this mutation was identified in a patient with Albright hereditary osteodystrophy. 549 eye reconstitution assays demonstrated that G(s)alpha-E259D stimulated adenylyl cyclase normally in the presence of GTP gamma S but was less efficient with isoproterenol or AlF4-. The other mutants had more severely impaired effector activation, particularly in response to AlF4-. In trypsin protection assays, GTP gamma S was a more effective activator than AlF4- for all mutants, with G(s)alpha-E259D being the least severely impaired. For G(s)alpha-E259D, the AlF4--induced activation defect was more pronounced at low Mg2+ concentrations. G(s)alpha-E259D and G(s)alpha-E259A purified from Escherichia coli had normal rates of GDP release (as assessed by the rate GrT gamma S binding). However, for both mutants, the ability of AlF4- to decrease the rate of GTP gamma S binding was impaired, suggesting that they bound AlF4- more poorly. GrTP gamma S bound to purified G(s)alpha-E259D irreversibly in the presence of 1 mM free Mg2+, but dissociated readily at micromolar concentrations. Sucrose density gradient analysis of in, vitro translates demonstrated that all mutants except G(s)alpha-E259V bind to beta gamma at 0 degrees C and were stable at higher temperatures. In the active conformation Glu(259) interacts with conserved residues in the switch 2 region that are important in maintaining both the active state and AlF4- in the guanine nucleotide binding pocket. Although both G(s)alpha Arg(258) and Glu(259) are critical for activation, the mechanisms by which these residues affect G(s)alpha. protein activation are distinct.	NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Warner, DR (corresponding author), NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bldg 49,Rm 2A28, Bethesda, MD 20892 USA.	dwarner@helix.nih.gov	Weinstein, Lee S/I-5575-2015	Weinstein, Lee/0000-0002-1899-5152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043302, ZIADK043302] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed SF, 1998, CLIN ENDOCRINOL, V49, P525, DOI 10.1046/j.1365-2265.1998.00572.x; Basi NS, 1997, ANAL BIOCHEM, V251, P103, DOI 10.1006/abio.1997.2255; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CARTY DJ, 1994, METHOD ENZYMOL, V237, P38; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LAMBRIGHT DG, 1996, NATURE, V379, P297; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE E, 1992, J BIOL CHEM, V267, P1212; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P276; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Warner DR, 1997, MOL ENDOCRINOL, V11, P1718, DOI 10.1210/me.11.11.1718; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4977	4984		10.1074/jbc.274.8.4977	http://dx.doi.org/10.1074/jbc.274.8.4977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988742	hybrid			2022-12-25	WOS:000078698200067
J	Schmidt, A; Grimm, R; Schmidt, J; Scheel, D; Strack, D; Rosahl, S				Schmidt, A; Grimm, R; Schmidt, J; Scheel, D; Strack, D; Rosahl, S			Cloning and expression of a potato cDNA encoding hydroxycinnamoyl-CoA : Tyramine N-(hydroxycinnamoyl)transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION-CULTURES; SOLANUM-TUBEROSUM L; PHENYLALANINE AMMONIA-LYASE; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; PHYTOPHTHORA-INFESTANS; NICOTIANA-TABACUM; PURIFICATION; COENZYME; LEAVES; ACCUMULATION	Hydroxycinnamoyl-CoA:tyramine N-(hydroxycinnamoyl)transferase (THT; EC 2.3.1.110) catalyzes the transfer of hydroxycinnamic acids from the respective CoA esters to tyramine and other amines in the formation of N-(hydroxycinnamoyl)amines. Expression of THT is induced by Phytophthora infestans, the causative agent of late blight disease in potato. The amino acid sequences of nine endopeptidase LysC-liberated peptides from purified potato THT were determined. Using degenerate primers, a THT-specific fragment was obtained by reverse transcription-polymerase chain reaction, and THT cDNA clones were isolated from a library constructed from RNA of elicitor-treated potato cells. The open reading frame encoding a protein of 248 amino acids was expressed in Escherichia coli, Recombinant THT exhibited a broad substrate specificity, similar to that of native potato THT, accepting cinnamoyl-, 4-coumaroyl-, caffeoyl-, feruloyl- and sinapoyl-CoA as acyl donors and tyramine, octopamine, and noradrenalin as accepters tested. Elicitor-induced THT transcript accumulation in cultured potato cells peaked 5 h after initiation of treatment, whereas enzyme activity was highest from 5 to 30 h after elicitation, In soil-grown potato plants, THT mRNA was most abundant in roots. Genomic Southern analyses indicate that, in potato, THT is encoded by a multigene family.	Inst Biochem Pflanzen, Abt Sekundarstoffwechsel, D-06120 Halle, Germany; Inst Biochem Pflanzen, Abt Nat Stoff Chem, D-06120 Halle, Germany; Inst Biochem Pflanzen, Abt Stress & Entwicklungsbiol, D-06120 Halle, Germany; Hewlett Packard GMBH, Waldbronn Analyt Div, D-76337 Waldbronn, Germany	Leibniz Institut fur Pflanzenbiochemie; Leibniz Institut fur Pflanzenbiochemie; Leibniz Institut fur Pflanzenbiochemie; Hewlett-Packard	Strack, D (corresponding author), Inst Biochem Pflanzen, Abt Sekundarstoffwechsel, Weinberg 3, D-06120 Halle, Germany.	dstrack@ipb.uni-halle.de						BECKERANDRE M, 1991, J BIOL CHEM, V266, P8551; BEIMEN A, 1992, BOT ACTA, V105, P152, DOI 10.1111/j.1438-8677.1992.tb00281.x; Clarke D. D., 1982, ACTIVE DEFENSE MECH, P321; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DUNSMUIR P, 1988, PLANT MOL BIOL MAN C, V1, P1; Eckerskorn C, 1996, ELECTROPHORESIS, V17, P899, DOI 10.1002/elps.1150170511; FRITZEMEIER KH, 1987, PLANT PHYSIOL, V85, P34, DOI 10.1104/pp.85.1.34; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; Fry WE, 1997, PLANT DIS, V81, P1349, DOI 10.1094/PDIS.1997.81.12.1349; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; GRANDMAISON J, 1993, MYCORRHIZA, V3, P155, DOI 10.1007/BF00203609; GROSS GG, 1966, Z NATURFORSCH PT B, VB 21, P683; Hohlfeld H, 1996, PLANTA, V199, P166, DOI 10.1007/BF00196893; HOHLFELD H, 1995, PLANT PHYSIOL, V107, P545, DOI 10.1104/pp.107.2.545; HRAZDINA G, 1976, ARCH BIOCHEM BIOPHYS, V175, P392, DOI 10.1016/0003-9861(76)90526-9; JOOS HJ, 1992, EUR J BIOCHEM, V204, P621, DOI 10.1111/j.1432-1033.1992.tb16675.x; Keller H, 1996, PHYTOCHEMISTRY, V42, P389, DOI 10.1016/0031-9422(95)00866-7; KUC J, 1985, ARCH BIOCHEM BIOPHYS, V236, P455; KUC J, 1982, PHYTOALEXINS, P81; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MATERN U, 1995, CAN J BOT, V73, pS511, DOI 10.1139/b95-290; Miersch O, 1998, PHYTOCHEMISTRY, V47, P327, DOI 10.1016/S0031-9422(97)00617-1; Negrel J, 1996, PHYTOCHEMISTRY, V43, P1195, DOI 10.1016/S0031-9422(96)00500-6; NEGREL J, 1993, J PLANT PHYSIOL, V142, P518, DOI 10.1016/S0176-1617(11)80392-5; Negrel J, 1997, EUR J BIOCHEM, V247, P1127, DOI 10.1111/j.1432-1033.1997.01127.x; Negrel J, 1995, PHYSIOL PLANTARUM, V95, P569, DOI 10.1111/j.1399-3054.1995.tb05524.x; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P2797, DOI 10.1016/0031-9422(84)83018-6; NICHOLSON RL, 1992, ANNU REV PHYTOPATHOL, V30, P369, DOI 10.1146/annurev.py.30.090192.002101; Pearce G, 1998, PHYTOCHEMISTRY, V47, P659, DOI 10.1016/S0031-9422(97)00620-1; ROHWER F, 1987, PLANTA, V170, P556, DOI 10.1007/BF00402991; Schmidt A, 1998, PLANTA, V205, P51, DOI 10.1007/s004250050295; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STRACK D, 1987, J PLANT PHYSIOL, V131, P61, DOI 10.1016/S0176-1617(87)80268-7; VILLEGAS M, 1990, PHYSIOL PLANTARUM, V78, P414, DOI 10.1111/j.1399-3054.1990.tb09057.x	36	88	93	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4273	4280		10.1074/jbc.274.7.4273	http://dx.doi.org/10.1074/jbc.274.7.4273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933628	hybrid			2022-12-25	WOS:000078575500052
J	Iyer, RR; Wells, RD				Iyer, RR; Wells, RD			Expansion and deletion of triplet repeat sequences in Escherichia coli occur on the leading strand of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; FRAGILE-X-SYNDROME; CENTER-DOT-CAG; HEREDITARY-DISEASE GENES; SYNTHESIS IN-VITRO; TRINUCLEOTIDE REPEATS; HAIRPIN STRUCTURES; CTG; INSTABILITY; FORM	Expansions and deletions of triplet repeat sequences that cause human hereditary neurological diseases were previously suggested to be mediated by the formation of DNA hairpins on the lagging strand during replication. The replication properties of CTG.CAG, CGG.CCG, and TTC.GAA repeats were studied in Escherichia coli using an in vivo phagemid system as a model for continuous leading strand synthesis. The repeats were substantially deleted when the CTG, CGG, and GAA repeats were the templates for rolling circle replication from the fl phage origin, The deletions may be mediated by hairpins formed by these repeat tracts. The distributions of the deletion products of the CTG.CAG and CGG.CCG tracts indicated that hairpins of discrete sizes mediate deletions during complementary strand synthesis. Deletions during rolling circle synthesis are caused by larger hairpins of specific sizes. Thus, most deletion products were of defined lengths, suggesting a preference for specific hairpin intermediates. Small expansions of the CTG.CAG and CGG.CCG repeats were also observed, presumably due to the formation of CTG and CGG hairpins on the nascent complementary strand. Since rolling circle replication has been established in vitro as a model for leading strand synthesis, we conclude that triplet repeat instability can also occur on the leading strand of DNA replication.	Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol,Dept Biochem & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Ctr Genome Res, Inst Biosci & Technol,Dept Biochem & Biophys, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	RWELLS@IBT.TAMU.EDU			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BAAS PD, 1988, CURR TOP MICROBIOL, V136, P31; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P467; BAUMEL I, 1984, EUR J BIOCHEM, V138, P247, DOI 10.1111/j.1432-1033.1984.tb07908.x; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Darlow JM, 1998, J MOL BIOL, V275, P3, DOI 10.1006/jmbi.1997.1453; Denhardt D.T., 1978, SINGLE STRANDED DNA; ENEA V, 1975, J MOL BIOL, V96, P495, DOI 10.1016/0022-2836(75)90175-8; Fischbeck KH, 1997, J INHERIT METAB DIS, V20, P152, DOI 10.1023/A:1005344403603; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; Gao XL, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P623; GAO XL, 1995, J AM CHEM SOC, V117, P8883, DOI 10.1021/ja00139a035; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; HIASA H, 1998, GENETIC INSTABILITIE, P732; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; Hoogeveen AT, 1997, J INHERIT METAB DIS, V20, P139, DOI 10.1023/A:1005392319533; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Khan SA, 1997, MICROBIOL MOL BIOL R, V61, P442, DOI 10.1128/.61.4.442-455.1997; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P784, DOI 10.1093/nar/24.4.784; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; MOK M, 1987, J BIOL CHEM, V262, P16644; MOK M, 1987, J BIOL CHEM, V262, P2304; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; PIECZENIK G, 1975, NATURE, V253, P131, DOI 10.1038/253131a0; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; Strong PN, 1997, J INHERIT METAB DIS, V20, P159, DOI 10.1023/A:1005396420442; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; Zheng MX, 1996, J MOL BIOL, V264, P323, DOI 10.1006/jmbi.1996.0643	72	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3865	3877		10.1074/jbc.274.6.3865	http://dx.doi.org/10.1074/jbc.274.6.3865			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920942	hybrid			2022-12-25	WOS:000078428200082
J	Scheidegger, KJ; Du, J; Delafontaine, P				Scheidegger, KJ; Du, J; Delafontaine, P			Distinct and common pathways in the regulation of insulin-like growth factor-1 receptor gene expression by angiotensin II and basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RAT CARDIAC FIBROBLASTS; PROTEIN-TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; LOW-DENSITY-LIPOPROTEIN; KINASE-C ACTIVATION; KAPPA-B-ALPHA; IGF-I; 3T3 CELLS; DIFFERENTIAL ACTIVATION	Angiotensin II (Ang II) and basic fibroblast growth factor (bFGF) are important modulators of cell growth under physiological and pathophysiological conditions. We and others have previously shown that these growth factors increase insulin-like growth factor-1 receptor (IGF-1R) number and mRNA in vascular smooth muscle cells and that this effect is transcriptionally regulated. To study the mechanisms and the signaling pathways involved, IGF-1R promoter reporter constructs were transiently transfected in CHO-AT, cells that overexpress angiotensin AT(1) receptors. Our findings indicate that Ang II and bFGF significantly increased IGF-1R promoter activity up to 7- and 3-fold, respectively. The effect induced by Ang II was mediated via a tyrosine kinase-dependent mechanism, since tyrphostin A25 largely inhibited the Ang II-induced increase in promoter activity. In addition, co-transfection of dominant negative Ras, Raf, and MEK1 or pretreatment with the MEK inhibitor PD 98059 dose-dependently decreased both the Ang II- and bFGF-induced increase in IGF-1R transcription and protein expression, suggesting that the Ras-Raf-mitogen-activated protein kinase kinase pathway is required for both growth factors. Reactive oxygen species have been shown to act as second messengers in Ang II-induced signaling, and activation of the transcription factor NF-kappa B is redox-sensitive. While co-transfection of dominant negative I kappa B alpha mutant completely inhibited the Ang II-induced increase in transcription, it had no effect on the bFGF signaling. In contrast, co-transfection studies indicated that the transcription factors STAT1, STAT3, and c-Jun and the Janus kinase 2 kinase are required in the signaling pathway of bFGF, whereas only dominant c-Jun inhibited the Ang II-induced effect. In summary, these data demonstrate that Ang II and bFGF increase IGF-1R gene transcription via distinct as well as shared pathways and have important implications for understanding growth-stimulatory effects of these growth factors on vascular cells.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland; Emory Univ, Dept Med, Atlanta, GA 30322 USA	University of Geneva; Emory University	Delafontaine, P (corresponding author), Univ Hosp Geneva, Div Cardiol, Rue Micheli Crest 24, CH-1211 Geneva 14, Switzerland.	Patrice.Delafontaine@hcuge.ch		Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL047035, R01HL045317] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45317, HL 47035] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1980, P NATL ACAD SCI-BIOL, V77, P6644, DOI 10.1073/pnas.77.11.6644; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELAFONTAINE P, 1995, J BIOL CHEM, V270, P14383, DOI 10.1074/jbc.270.24.14383; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; Delafontaine P, 1996, J CLIN INVEST, V97, P139, DOI 10.1172/JCI118381; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Du J, 1996, ENDOCRINOLOGY, V137, P1378, DOI 10.1210/en.137.4.1378; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1995, CARDIOVASC RES, V30, P511, DOI 10.1016/0008-6363(95)00088-7; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; ROSENTHAL SM, 1991, MOL ENDOCRINOL, V5, P678, DOI 10.1210/mend-5-5-678; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; SA G, 1994, J BIOL CHEM, V269, P3219; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHORB W, 1995, J MOL CELL CARDIOL, V27, P1151, DOI 10.1016/0022-2828(95)90051-9; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; VILLASCHI S, 1993, AM J PATHOL, V143, P181; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1990, BIOCHEM BIOPH RES CO, V169, P1021, DOI 10.1016/0006-291X(90)91996-6; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	85	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3522	3530		10.1074/jbc.274.6.3522	http://dx.doi.org/10.1074/jbc.274.6.3522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920898	hybrid			2022-12-25	WOS:000078428200038
J	Greenberg, RA; O'Hagan, RC; Deng, HY; Xiao, QR; Hann, SR; Adams, RR; Lichtsteiner, S; Chin, L; Morin, GB; DePinho, RA				Greenberg, RA; O'Hagan, RC; Deng, HY; Xiao, QR; Hann, SR; Adams, RR; Lichtsteiner, S; Chin, L; Morin, GB; DePinho, RA			Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation	ONCOGENE			English	Article						Myc; telomerase; TERT; transformation	CATALYTIC SUBUNIT GENE; ORNITHINE DECARBOXYLASE; IMMORTAL CELLS; TUMOR-CELLS; EXPRESSION; SENESCENCE; PROTEIN; DIFFERENTIATION; FIBROBLASTS; ACTIVATION	The telomerase reverse transcriptase component (TERT) is not expressed in most primary somatic human cells and tissues, but is upregulated in the majority of immortalized cell lines and tumors. Here, we identify the c-Myc transcription factor as a direct mediator of telomerase activation in primary human fibroblasts through its ability to specifically induce TERT gene expression. Through the use of a hormone inducible form of c-Myc (c-MSc-ER), we demonstrate that MSc-induced activation of the hTERT promoter requires an evolutionarily conserved E-box and that c-Myc-ER-induced accumulation of hTERT mRNA takes place in the absence of de novo protein synthesis. These findings demonstrate that the TERT gene is a direct transcriptional target of c-Myc, Since telomerase activation frequently correlates with immortalization and telomerase functions to stabilize telomers in cycling cells, we tested whether Myc-induced activation of TERT gene expression represents an important mechanism through which c-Myc acts to immortalize cells. Employing the rat embryo fibroblast cooperation assay, we show that TERT is unable to substitute for c-Myc in the transformation of primary rodent fibroblasts, suggesting that the transforming activities of Myc extend beyond its ability to activate TERT gene expression and hence telomerase activity.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Med Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Geron Corp, Menlo Park, CA 94025 USA	Harvard University; Dana-Farber Cancer Institute; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Vanderbilt University; Geron Corporation	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374; DePinho, Ronald/0000-0002-5625-577X	NEI NIH HHS [R01EY09300] Funding Source: Medline; NICHD NIH HHS [R01HD28317] Funding Source: Medline; NIGMS NIH HHS [5T32GM07491] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISHOP JM, 1991, COLD SH Q B, V56, P99; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446	39	342	375	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1219	1226		10.1038/sj.onc.1202669	http://dx.doi.org/10.1038/sj.onc.1202669			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022128				2022-12-25	WOS:000078510700011
J	Sengupta, S; Tripathi, J; Tandon, R; Raje, M; Roy, RP; Basu, SK; Mukhopadhyay, A				Sengupta, S; Tripathi, J; Tandon, R; Raje, M; Roy, RP; Basu, SK; Mukhopadhyay, A			Hemoglobin endocytosis in Leishmania is mediated through a 46-kDa protein located in the flagellar pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MEXICANA-AMAZONENSIS; TRYPANOSOMA-BRUCEI; BINDING PROTEIN; RECEPTOR; HEME; IDENTIFICATION; TRANSFERRIN; ACQUISITION; PARASITES	Four lines of evidence indicate that a specific high affinity binding site on the surface of Leishmania donovani promastigotes mediates rapid internalization and degradation of hemoglobin. 1) Binding and uptake of I-125-hemoglobin by Leishmania followed saturation kinetics and were competed by unlabeled hemoglobin but not by globin or hemin or other heme- or iron-containing proteins. 2) Immunogold labeling studies revealed that, at 4 degrees C, hemoglobin binding was localized in the flagellar pocket of the promastigotes. Indirect immuno-fluorescence assays showed that, at 37 degrees C, the bound hemoglobin in such cells entered an endocytic compartment within 2 min and dispersed throughout the cell body by 15 min. 3) After incubation with hemoglobin-gold conjugates at 25 degrees C or 37 degrees C, the particles accumulated in discrete intracellular vesicles. 4) A single biotinylated protein of 46-kDa was revealed when solubilized membranes from surface biotinylated intact Leishmania adsorbed by hemoglobin-agarose beads were subjected to SDS-polyacrylamide gel electrophoresis and Western blotting with avidin-horseradish peroxidase, Considered together, these data indicate that this 46-kDa protein on the cell surface of L, donovani promastigotes mediates the binding of hemoglobin and its rapid internalization through a vesicular pathway characteristic of receptor-mediated endocytosis.	Natl Inst Immunol, New Delhi 110067, India; Inst Microbial Technol, Sector 39A, Chandigarh 160014, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Basu, SK (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	sandip@nii.res.in	Mukhopadhyay, Asok/C-4051-2009					Bastin P, 1996, MOL BIOCHEM PARASIT, V76, P43, DOI 10.1016/0166-6851(95)02537-5; BASU SK, 1984, J BIOSCIENCES, V6, P535, DOI 10.1007/BF02703904; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Bezkorovainy A, 1987, IRON INFECTION, P27; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; BUSSON S, 1989, BIOL CELL, V67, P37, DOI 10.1111/j.1768-322X.1989.tb03008.x; CHANG CS, 1985, MOL BIOCHEM PARASIT, V16, P267, DOI 10.1016/0166-6851(85)90069-6; CHANG KP, 1983, INT REV CYTOL, P267; CHANG KP, 1974, SCIENCE, V183, P531, DOI 10.1126/science.183.4124.531; CHANG KP, 1975, P NATL ACAD SCI USA, V72, P2979, DOI 10.1073/pnas.72.8.2979; CHAUDHURI G, 1982, INDIAN J MED RES, V76, P157; Chen CJ, 1996, INFECT IMMUN, V64, P5008, DOI 10.1128/IAI.64.12.5008-5014.1996; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; DEMEY J, 1986, IMMUNOCYTOCHEMISTRY, P115; Fujimura S, 1996, INFECT IMMUN, V64, P2339, DOI 10.1128/IAI.64.6.2339-2342.1996; GALBRAITH RA, 1988, MOL BIOCHEM PARASIT, V29, P47, DOI 10.1016/0166-6851(88)90118-1; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; LWOFF M, 1965, BIOCH PHYSL PROTOZOA, P131; MARSDEN PD, 1984, REV INFECT DIS, V6, P736; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Osborn M, 1994, CELL BIOL LAB HDB, V2, P347; OUAISSI MA, 1986, MOL BIOCHEM PARASIT, V19, P201, DOI 10.1016/0166-6851(86)90002-2; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; OVERKAMP D, 1988, J IMMUNOASSAY, V9, P51, DOI 10.1080/01971528808053210; Rosenthal PJ, 1996, MOL BIOCHEM PARASIT, V83, P131, DOI 10.1016/S0166-6851(96)02763-6; Roy J.C., 1932, IND J MED RES, V20, P367; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; Tanaka WTH, 1997, BIOCHEM BIOPH RES CO, V232, P350, DOI 10.1006/bbrc.1997.6247; VOYIATZAKI CS, 1992, J BIOL CHEM, V267, P9112; WILEMAN T, 1985, BIOCHEM J, V232, P1; ZURZOLO C, 1994, CELL BIOL LAB HDB, V3, P185	35	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2758	2765		10.1074/jbc.274.5.2758	http://dx.doi.org/10.1074/jbc.274.5.2758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915807	hybrid			2022-12-25	WOS:000078319500025
J	Hamik, A; Setiadi, H; Bu, GJ; McEver, RP; Morrissey, JH				Hamik, A; Setiadi, H; Bu, GJ; McEver, RP; Morrissey, JH			Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SEPTIC SHOCK; FACTOR-XA; CELL-SURFACE; FACTOR-VIIA; COAGULATION INHIBITOR; BLOOD-COAGULATION; INTRAVASCULAR COAGULATION; PLASMINOGEN-ACTIVATOR; MONOCLONAL-ANTIBODY; UROKINASE RECEPTOR	Inflammatory mediators like bacterial lipopolysaccharide induce monocytes to express tissue factor (TF), the cell-surface protein that triggers the blood clotting cascade in hemostasis and thrombotic disease. The physiologic ligand for TF is the serine protease, factor VIIa (FVIIa), and the resulting bimolecular enzyme, TF/FVIIa, can be reversibly inhibited by tissue factor pathway inhibitor (TFPI), Culturing monocytic cells in the presence of both FVIIa and TFPI caused down-regulation of TF expression via reducing its half-life. To exert this effect, FVIIa had to be competent to bind both TF and TFPI, and TFPI had to contain the C-terminal domain required for binding to other cell-surface receptors, including the low density lipoprotein receptor-related protein (LRP), TF down-regulation by FVIIa plus TFPI was abrogated by the 39-kDa receptor-associated protein, which blocks binding of all known ligands to LRP, Furthermore, treatment with FVIIa plus TFPI caused monocyte TF to colocalize with alpha-adaptin, a component of clathrin-coated pits. Thus, in addition to reversibly inhibiting TF/FVIIa catalytic activity, TFPI also mediates the permanent down-regulation of cell-surface TF in monocytic cells via LRP-dependent internalization and degradation. This represents an unusual mechanism for receptor internalization, requiring ligand-dependent bridging of one cell-surface receptor (TF) to a second cell-surface receptor (LRP), the latter being capable of clathrin-mediated internalization.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL); Washington University (WUSTL)	Morrissey, JH (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	morrissey@scientist.com	Morrissey, James H/H-4933-2011; Setiadi, Hendra/ACQ-9386-2022; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; Setiadi, Hendra/0000-0002-0570-1354	NHLBI NIH HHS [P50 HL54502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; BROZE GJ, 1987, BLOOD, V69, P150; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; CARR C, 1994, CIRC SHOCK, V44, P126; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; CZEKAY RP, 1995, J CELL SCI, V108, P1433; DAY KC, 1990, BLOOD, V76, P1538; DRAKE TA, 1993, AM J PATHOL, V142, P1458; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GIRARD TJ, 1993, METHOD ENZYMOL, V222, P195; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; Girard TJ, 1997, NEW THERAPEUTIC AGEN, P225; Goretzki L, 1997, J CELL SCI, V110, P1395; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HELINSKI EH, 1988, J LEUKOCYTE BIOL, V44, P111, DOI 10.1002/jlb.44.2.111; Ho GY, 1996, J BIOL CHEM, V271, P9497, DOI 10.1074/jbc.271.16.9497; Jesty J, 1976, Methods Enzymol, V45, P95; KAZAMA Y, 1993, BLOOD, V81, P676; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MCGEE MP, 1994, J EXP MED, V179, P1847, DOI 10.1084/jem.179.6.1847; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; Mulder AB, 1996, BLOOD, V88, P1306, DOI 10.1182/blood.V88.4.1306.bloodjournal8841306; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NERI SG, 1990, LANCET, V336, P1444; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NIEMETZ J, 1971, NATURE-NEW BIOL, V232, P247, DOI 10.1038/newbio232247a0; NOVOTNY WF, 1988, BLOOD, V72, P2020; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OKAJIMA K, 1991, AM J HEMATOL, V36, P265, DOI 10.1002/ajh.2830360408; OSTERUD B, 1995, THROMB HAEMOSTASIS, V73, P873; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; RIVERS RPA, 1975, BRIT J HAEMATOL, V30, P311, DOI 10.1111/j.1365-2141.1975.tb00547.x; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SCHWARTZ BS, 1982, J EXP MED, V155, P1464, DOI 10.1084/jem.155.5.1464; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Solberg S, 1990, Blood Coagul Fibrinolysis, V1, P595; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Tenno T, 1997, THROMB RES, V88, P215, DOI 10.1016/S0049-3848(97)00232-6; TIPPING PG, 1989, ATHEROSCLEROSIS, V79, P237, DOI 10.1016/0021-9150(89)90129-9; Wang PY, 1996, J INFLAMM, V47, P126; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	70	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4962	4969		10.1074/jbc.274.8.4962	http://dx.doi.org/10.1074/jbc.274.8.4962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988740	hybrid			2022-12-25	WOS:000078698200065
J	Koppelman, SJ; Bruijnzeel-Koomen, CAFM; Hessing, M; de Jongh, HHJ				Koppelman, SJ; Bruijnzeel-Koomen, CAFM; Hessing, M; de Jongh, HHJ			Heat-induced conformational changes of Ara h 1, a major peanut allergen, do not affect its allergenic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOPIC-DERMATITIS; IGE-BINDING; THERMAL-DENATURATION; SECONDARY STRUCTURE; PROTEIN STRUCTURE; DOUBLE-BLIND; HYPERSENSITIVITY; CHALLENGE; IDENTIFICATION; STABILIZATION	Ara h 1, a major peanut allergen was isolated, and its structure on secondary, tertiary, and quaternary level at ambient temperature was investigated using spectroscopic and biochemical techniques. Ara h 1 appeared to be a highly structured protein on a secondary level, possesses a clear tertiary fold, and is present as a trimeric complex. Heat treatment of purified Ara h 1 results in an endothermic, irreversible transition between 80 and 90 degrees C, leading to an increase in beta-structures and a concomitant aggregation of the protein. Ara h 1 from peanuts that were heat-treated prior to the purification procedure exhibited a similar denatured state with an increased secondary folding and a decreased solubility, The effect of heat treatment on the in vitro allergenic properties of Ara h 1 was investigated by means of a fluid-phase IgE binding assay using serum from patients with a clinically proven peanut allergy. Ara h 1 purified from peanuts heated at different temperatures exhibited IgE binding properties similar to those found for native Ara h 1, indicating that the allergenicity of Ara h 1 is heat-stable. We conclude that the allergenicity of Ara h 1 is unaffected by heating, although native Ara h 1 undergoes a significant heat-induced denaturation on a molecular level, indicating that the recognition of conformational epitopes of Ara h 1 by IgE either is not a dominant mechanism or is restricted to parts of the protein that are not sensitive to heat denaturation.	TNO, Nutr & Food Res Inst, Dept Prot Technol, NL-3700 AJ Zeist, Netherlands; Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Wageningen Univ Agr, TNO, Ctr Prot Technol, NL-6700 EV Wageningen, Netherlands	Netherlands Organization Applied Science Research; Utrecht University; Netherlands Organization Applied Science Research; Wageningen University & Research	Koppelman, SJ (corresponding author), TNO, Nutr & Food Res Inst, Dept Prot Technol, POB 360, NL-3700 AJ Zeist, Netherlands.	koppelman@voeding.tno.nl						BARNETT D, 1986, BIOCHIM BIOPHYS ACTA, V882, P97, DOI 10.1016/0304-4165(86)90060-7; BERKHOUT TA, 1987, BIOCHIM BIOPHYS ACTA, V897, P1, DOI 10.1016/0005-2736(87)90308-7; BURKS AW, 1995, INT ARCH ALLERGY IMM, V107, P248, DOI 10.1159/000236993; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P889, DOI 10.1016/0091-6749(92)90461-A; Buschmann L, 1996, MONOGR ALLERGY, V32, P92; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; deJongh HHJ, 1996, ANAL BIOCHEM, V242, P95, DOI 10.1006/abio.1996.0434; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hourihane JO, 1997, BRIT MED J, V314, P1084, DOI 10.1136/bmj.314.7087.1084; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; KALNIN NN, 1990, BIOPOLYMERS, V30, P1273, DOI 10.1002/bip.360301311; KOPPELMAN SJ, 1996, WORLD INGREDIENTS, V12, P35; LAPANJE S, 1989, BIOPHYS CHEM, V34, P155, DOI 10.1016/0301-4622(89)80053-5; LAWRENCE MC, 1990, EMBO J, V9, P9, DOI 10.1002/j.1460-2075.1990.tb08074.x; LAWRENCE MC, 1994, J MOL BIOL, V238, P748, DOI 10.1006/jmbi.1994.1333; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; Phillips R. D., 1981, ACS Symposium Series, V147, P275; Pots AM, 1998, EUR J BIOCHEM, V252, P66, DOI 10.1046/j.1432-1327.1998.2520066.x; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI [10.1146/annurev.nu.16.070196.001113, 10.1146/annurev.nutr.16.1.161]; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Smith J., 1997, International Food Ingredients, P13; Stanley JS, 1996, ADV EXP MED BIOL, V409, P213; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207, DOI 10.1016/S0091-6749(98)70410-5; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VUILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303, DOI 10.1021/bi00090a005; Yeung JM, 1996, J AOAC INT, V79, P1411	38	144	157	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4770	4777		10.1074/jbc.274.8.4770	http://dx.doi.org/10.1074/jbc.274.8.4770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988715	Green Published, hybrid			2022-12-25	WOS:000078698200040
J	Till, JH; Chan, PM; Miller, WT				Till, JH; Chan, PM; Miller, WT			Engineering the substrate specificity of the Abl tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE; CRYSTAL-STRUCTURE; PROTEIN-KINASES; MUTATION; BINDING; DOMAIN; PHOSPHORYLATION; PEPTIDES; LEUKEMIA; ONCOGENE	c-Abl is a non-receptor tyrosine kinase that is involved in a variety of signaling pathways. Activated forms of c-Abl are associated with some forms of human leukemia. Presently, no high resolution structure of the tyrosine kinase domain of Abl is available. We have developed a structural homology model of the catalytic domain of Abl based on the crystal structure of the insulin receptor tyrosine kinase, Using this model as a guide, we selected residues near the active site predicted to play a role in peptide/protein substrate recognition. We expressed and purified 15 mutant forms of Abl with single amino acid substitutions at these positions and tested their peptide substrate specificity. We report here the identification of seven residues involved in recognition of the P-1, P+1, and P+3 positions of bound peptide substrate. Mutations in these residues cause distinct changes in substrate specificity. The results suggest features of Abl substrate recognition that may be relevant to related tyrosine kinases.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA58530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen PB, 1996, J BIOL CHEM, V271, P19585, DOI 10.1074/jbc.271.32.19585; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; Moro Marina, 1997, Leukemia (Basingstoke), V11, P313; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SURLES MC, 1994, PROTEIN SCI, V3, P198; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4471, DOI 10.1021/bi00388a043; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILL JH, 1994, J BIOL CHEM, V269, P7423; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; XU W, 1997, NATURE, V385, P596; Zhou Songyang, 1995, Nature (London), V373, P536	34	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4995	5003		10.1074/jbc.274.8.4995	http://dx.doi.org/10.1074/jbc.274.8.4995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988744	hybrid			2022-12-25	WOS:000078698200069
J	van Leeuwen, JEM; Paik, PK; Samelson, LE				van Leeuwen, JEM; Paik, PK; Samelson, LE			Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol S-kinase association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED CBL; OF-FUNCTION MUTATION; PROTOONCOGENE C-CBL; EGF RECEPTOR; V-CBL; BCR-ABL; CELLS; CRKL; C3G; TRANSFORMATION	The Cbl proto-oncogene product is a complex adapter protein that functions as a negative regulator of protein tyrosine kinases. It is rapidly tyrosine-phosphorylated and associates with Crk(L) and p85 phosphatidylinositol 3-kinase (PI3K) upon engagement of numerous receptors linked to tyrosine kinases. Elucidation of the mechanism(s) underlying Cbl deregulation is therefore of considerable interest. The 70Z Cbl oncoprotein shows increased baseline tyrosine phosphorylation in fibroblasts and enhances nuclear factor of activated T cells (NFAT) activity in Jurkat T cells. Its transforming ability has been proposed to relate to its increased phosphotyrosine content. We demonstrate that 70Z Cbl shows increased basal and activation-induced tyrosine phosphorylation and association with Crk(L) and p85 PI3K in Jurkat T cells. 70Z Cbl, however, retains the ability to enhance NFAT and activating protein 1 (AP1) activity in the absence of Crk(L)/p85 PI3K association. In contrast, the G306E mutation, which inactivates the phosphotyrosine binding domain of CM, blocks NFAT/AP1 activation by 70Z Cbl. We conclude that 70Z Cbl-induced NFAT/AP1 activation requires the phosphotyrosine binding domain but not Crk(L)/p85 PI3K association. We hypothesize that 70Z Cbl acts as a dominant negative by blocking the negative regulatory function of the Cbl phosphotyrosine binding domain on protein-tyrosine kinases.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	van Leeuwen, JEM (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	vanleeuj@box-v.nih.gov	van Leeuwen, Jeroen/G-3555-2010		NATIONAL CANCER INSTITUTE [Z01BC010304, ZIABC010304] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; KEANE MM, 1995, ONCOGENE, V10, P2367; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhao QH, 1996, MOL CELL BIOL, V16, P6765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5153	5162		10.1074/jbc.274.8.5153	http://dx.doi.org/10.1074/jbc.274.8.5153			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988765	hybrid			2022-12-25	WOS:000078698200090
J	Goudet, G; Delhalle, S; Biemar, F; Martial, JA; Peers, B				Goudet, G; Delhalle, S; Biemar, F; Martial, JA; Peers, B			Functional and cooperative interactions between the homeodomain PDX1, Pbx, and Prep1 factors on the somatostatin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; HUMAN PROTOONCOGENE PBX1; DNA-BINDING SPECIFICITY; CAMP RESPONSE ELEMENT; HOMEOBOX GENES; HOX PROTEINS; TRANSCRIPTIONAL ACTIVATOR; FACTOR STF-1; EXTRADENTICLE; EXPRESSION	Expression of the somatostatin gene in endocrine pancreatic cells is controlled by several regulatory cis-elements located in the promoter region. Among these, the adjacent UE-A and TSEI elements, located from -113 to -85 relative to the transcription initiation site, function in combination and act as a pancreas-specific mini-enhancer. The TSEI element is recognized by the pancreatic homeodomain factor PDX1. In the present study, we show that the UE-A element binds a heterodimeric complex composed of a Pbx factor and the Prep1 protein, both belonging to the atypical three-amino acid loop extension homeodomain family. Recombinant Pbx1 and Prep1 proteins bind cooperatively to the UE-A site, whereas neither protein can bind this site alone. Transient transfection experiments reveal that both Pbx1 and Prep1 are required to generate a strong transcriptional activation from the UE-A element when this element is inserted close to the TATA box. In contrast, in the context of the intact somatostatin promoter or mini-enhancer, Pbx1 and Prep1 alone have no effect, but they produce a drastic activation when the pancreatic homeodomain factor PDX1 is also coexpressed. Thus, the activity of the somatostatin mini-enhancer is mediated by a cooperative interaction between the Pbx-Prep1 heterodimeric complex and the pancreatic factor PDX1.	Univ Liege, Inst Chim, Lab Biol Mol & Genie Genet, B-4000 Sart Tilman, Belgium	University of Liege	Peers, B (corresponding author), Univ Liege, Inst Chim, Lab Biol Mol & Genie Genet, Batiment B6, B-4000 Sart Tilman, Belgium.							Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chen HM, 1997, GENOMICS, V41, P193, DOI 10.1006/geno.1997.4632; DeCesare D, 1996, ONCOGENE, V13, P2551; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kurant E, 1998, DEVELOPMENT, V125, P1037; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Montminy M R, 1990, Recent Prog Horm Res, V46, P219; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; SUN B, 1995, EMBO J, V14, P520, DOI 10.1002/j.1460-2075.1995.tb07028.x; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6	44	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4067	4073		10.1074/jbc.274.7.4067	http://dx.doi.org/10.1074/jbc.274.7.4067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933599	hybrid			2022-12-25	WOS:000078575500023
J	Bevans, CG; Harris, AL				Bevans, CG; Harris, AL			Direct high affinity modulation of connexin channel activity by cyclic nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTION MEMBRANE CHANNELS; MAJOR COAT PROTEIN; NICOTINIC ACETYLCHOLINE-RECEPTOR; CGMP-BINDING-SITES; GAP-JUNCTIONS; ASPARTIC-ACID; ION CHANNELS; CAMP; COMMUNICATION; DICTYOSTELIUM	Connexin channels mediate molecular communication between cells. However, positive identification of biological ligands that directly and noncovalently modulate their activity has been elusive. This study demonstrates a high affinity inhibition of connexin channels by the purine cyclic monophosphates cAMP and cGMP, Purified homomeric connexin-32 and heteromeric connexin-32/connexin-26 channels were inhibited by exposure to nanomolar levels of the nucleotides prior to incorporation into membranes. Access to the site of action, or affinity for the nucleotides, was greatly reduced following incorporation of the connexin channels into membranes, where inhibition required millimolar concentrations of the nucleotides, The high affinity inhibition did not occur with similar concentrations of AMP, ADP, ATP, cTMP, or cCMP. This is the first report of a direct ligand effect on connexin channel function, The high affinity and specificity of the inhibition suggest a biological role in control of connexin channels and also may lead to the application of affinity reagents to study of connexin channel structure-function.	Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA	Johns Hopkins University	Harris, AL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.		Bevans, Carville/C-6651-2009	Bevans, Carville/0000-0001-7389-2124; Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bastiaanse EML, 1997, CARDIOVASC RES, V33, P272, DOI 10.1016/S0008-6363(96)00193-9; Bevans C. G., 1996, Molecular Biology of the Cell, V7, p281A; Bevans C. G., 1996, Biophysical Journal, V70, pA32; Bevans C. G., 1997, Biophysical Journal, V72, pA272; Bevans C. G., 1995, Molecular Biology of the Cell, V6, p190A; Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CAVALIERI SJ, 1976, J MOL BIOL, V102, P713, DOI 10.1016/0022-2836(76)90287-4; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P118; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARRIS AL, 1981, J GEN PHYSIOL, V77, P95, DOI 10.1085/jgp.77.1.95; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HARRIS AL, 1997, GAP JUNCTIONS, P60; HARRIS AL, 1994, BIOMEMBRANE ELECTROC, P197; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; Kalman L, 1997, BIOCHEMISTRY-US, V36, P4489, DOI 10.1021/bi961860o; Kim JY, 1997, J BIOL CHEM, V272, P2060; KIM JY, 1994, J BIOL CHEM, V269, P28724; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KURAOKA A, 1993, J HISTOCHEM CYTOCHEM, V41, P971, DOI 10.1177/41.7.8390496; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; LEHNINGER AL, 1974, P NATL ACAD SCI USA, V71, P1520, DOI 10.1073/pnas.71.4.1520; Lo CW, 1996, J BIOENERG BIOMEMBR, V28, P379, DOI 10.1007/BF02110114; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MAKINO S, 1975, J BIOL CHEM, V250, P4327; MATTHEWS BW, 1982, LIPID PROTEIN INTERA, P1; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORENO AP, 1992, BIOPHYS J, V62, P51, DOI 10.1016/S0006-3495(92)81775-7; MORENO AP, 1991, BIOPHYS J, V59, P920, DOI 10.1016/S0006-3495(91)82305-0; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; Nicholson BJ, 1998, GAP JUNCTIONS, P3; NORTH RA, 1994, LIGAND VOLTAGE GATED; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PERACCHIA C, 1995, HDB MEMBRANE CHANNEL, P361; PICCOLINO M, 1984, J NEUROSCI, V4, P2477; PITTS JD, 1977, EXP CELL RES, V104, P153, DOI 10.1016/0014-4827(77)90078-7; PRASAD K, 1994, J BIOL CHEM, V269, P6931; REYNOLDS JA, 1982, LIPID PROTEIN INTERA, P193; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; RISEK B, 1995, J CELL SCI, V108, P1017; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SOSINSKY G, 1995, P NATL ACAD SCI USA, V92, P9210, DOI 10.1073/pnas.92.20.9210; Spray David C., 1994, P195; SPRAY DC, 1979, SCIENCE, V204, P432, DOI 10.1126/science.312530; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Spruijt RB, 1996, BIOCHEMISTRY-US, V35, P10383, DOI 10.1021/bi960410t; Stopar D, 1997, BIOCHEMISTRY-US, V36, P12268, DOI 10.1021/bi970747a; Stopar D, 1996, BIOCHEMISTRY-US, V35, P15467, DOI 10.1021/bi961770j; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; TAKENSKWAK BR, 1992, PFLUG ARCH EUR J PHY, V422, P198, DOI 10.1007/BF00370421; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; TSIEN RW, 1976, J PHYSIOL-LONDON, V260, P117, DOI 10.1113/jphysiol.1976.sp011507; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144; VANHAASTERT PJM, 1983, J BIOL CHEM, V258, P9636; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WIERENGA RK, 1992, FEBS LETT, V307, P34, DOI 10.1016/0014-5793(92)80897-P; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G; Zanello LP, 1996, BIOPHYS J, V70, P2155, DOI 10.1016/S0006-3495(96)79781-3; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	74	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3720	3725		10.1074/jbc.274.6.3720	http://dx.doi.org/10.1074/jbc.274.6.3720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920924	hybrid			2022-12-25	WOS:000078428200064
J	Kekuda, R; Wang, HP; Huang, W; Pajor, AM; Leibach, FH; Devoe, LD; Prasad, PD; Ganapathy, V				Kekuda, R; Wang, HP; Huang, W; Pajor, AM; Leibach, FH; Devoe, LD; Prasad, PD; Ganapathy, V			Primary structure and functional characteristics of a mammalian sodium-coupled high affinity dicarboxylate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; BRUSH-BORDER MEMBRANES; EXPRESSION CLONING; UPHILL TRANSPORT; SEQUENCE; IDENTIFICATION; COTRANSPORTER; SPECIFICITY; SUCCINATE; GRADIENT	We have cloned a Na+-dependent, high affinity dicarboxylate transporter (NaDC3) from rat placenta. NaDC3 exhibits 48% identity in amino acid sequence with rat NaDC1, a Na+-dependent, low affinity dicarboxylate transporter. NaDC3-specific mRNA is detectable in kidney, brain, liver, and placenta. When expressed in mammalian cells, NaDC3 mediates Na+-dependent transport of succinate with a K-t of 2 mu M. The transport function of NaDC3 shows a sigmoidal relationship with regard to Na+ concentration, with a Hill coefficient of 2.7. NaDC3 accepts a number of dicarboxylates including dimethylsuccinate as substrates and excludes monocarboxylates. Li+ inhibits NaDC3 in the presence of Na+. Transport of succinate by NaDC3 is markedly influenced by pH, the transport function gradually decreasing when pH is acidified from 8.0 to 5.5. In contrast, the influence of pH on NaDC3-mediated transport of citrate is biphasic in which a pH change from 8.0 to 6.5 stimulates the transport and any further acidification inhibits the transport. In addition, the potency of citrate to compete with NaDC3-mediated transport of succinate increases 25-fold when pH is changed from 7.5 to 5.5. These data show that NaDC3 interacts preferentially with the divalent anionic species of citrate. This represents the first report on the cloning and functional characterization of a mammalian Na+-dependent, high affinity dicarboxylate transporter.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Texas System; University of Texas Medical Branch Galveston	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	vganapat@mai.mcg.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 33347] Funding Source: Medline; NIDA NIH HHS [DA 10045] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bai LQ, 1997, AM J PHYSIOL-GASTR L, V273, pG267, DOI 10.1152/ajpgi.1997.273.2.G267; BALKOVETZ DF, 1988, J BIOL CHEM, V263, P13823; Benson DA, 1996, NUCLEIC ACIDS RES, V24, P1, DOI 10.1093/nar/24.1.1; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BROWNE JL, 1978, PROC R SOC SER B-BIO, V200, P117, DOI 10.1098/rspb.1978.0010; BURCKHARDT G, 1984, PFLUG ARCH EUR J PHY, V401, P254, DOI 10.1007/BF00582592; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; GANAPATHY V, 1988, BIOCHEM J, V249, P179, DOI 10.1042/bj2490179; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Khatri IA, 1996, BBA-GENE STRUCT EXPR, V1309, P58, DOI 10.1016/S0167-4781(96)00138-8; KIPPEN I, 1979, P NATL ACAD SCI USA, V76, P3397, DOI 10.1073/pnas.76.7.3397; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MOSELEY RH, 1992, AM J PHYSIOL, V263, pG871, DOI 10.1152/ajpgi.1992.263.6.G871; Pajor AM, 1998, J BIOL CHEM, V273, P18923, DOI 10.1074/jbc.273.30.18923; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PAJOR AM, 1996, AM J PHYSIOL, V270, pF462; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; PRASAD PD, 1998, TROPHOBLAST RES, V11, P243; Sekine T, 1998, AM J PHYSIOL-RENAL, V275, pF298, DOI 10.1152/ajprenal.1998.275.2.F298; SMITH CH, 1992, ANNU REV NUTR, V12, P183, DOI 10.1146/annurev.nu.12.070192.001151; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VOGELI G, 1987, METHOD ENZYMOL, V152, P407; WOLFFRAM S, 1992, COMP BIOCHEM PHYS A, V101, P759, DOI 10.1016/0300-9629(92)90355-T; WRIGHT EM, 1993, SOC GEN PHY, V48, P229; WRIGHT SH, 1981, BIOCHIM BIOPHYS ACTA, V640, P767, DOI 10.1016/0005-2736(81)90107-3; WRIGHT SH, 1980, J MEMBRANE BIOL, V57, P73, DOI 10.1007/BF01868987; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF432, DOI 10.1152/ajprenal.1987.253.3.F432; ZIMMERLI B, 1992, PFLUG ARCH EUR J PHY, V421, P329, DOI 10.1007/BF00374220	31	91	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3422	3429		10.1074/jbc.274.6.3422	http://dx.doi.org/10.1074/jbc.274.6.3422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920886	hybrid			2022-12-25	WOS:000078428200026
J	Lin, D; Gish, GD; Songyang, Z; Pawson, T				Lin, D; Gish, GD; Songyang, Z; Pawson, T			The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; DENSITY PROTEIN PSD-95; EPH-FAMILY; TRANSMEMBRANE LIGANDS; MOLECULAR-CLONING; COMMISSURAL AXONS; K+ CHANNELS; IN-VITRO; NUK; PHOSPHATASE	Ephrin B proteins function as ligands for B class Eph receptor tyrosine kinases and are postulated to possess an intrinsic signaling function. The sequence at the carboxyl terminus of B-type ephrins contains a putative PDZ binding site, providing a possible mechanism through which transmembrane ephrins might interact with cytoplasmic proteins. To test this notion, a day 10.5 mouse embryonic expression library was screened with a biotinylated peptide corresponding to the carboxyl terminus of ephrin B3. Three of the positive cDNAs encoded polypeptides with multiple PDZ domains, representing fragments of the molecule GRIP, the protein syntenin, and PHIP, a novel PDZ domain-containing protein related to Caenorhabditis elegans PAR-3. In addition, the binding specificities of PDZ domains previously predicted by an oriented library approach (Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997) Science 275, 73-77) identified the tyrosine phosphatase FAP-1 as a potential binding partner for B ephrins. In vitro studies demonstrated that the fifth PDZ domain of FAP-I and full-length syntenin bound ephrin B1 via the carboxyl-terminal motif. Lastly, syntenin and ephrin B1 could be co-immunoprecipitated from transfected COS-1 cells, suggesting that PDZ domain binding of B ephrins can occur in cells. These results indicate that the carboxyl-terminal motif of B ephrins provides a binding site for specific PDZ domain-containing proteins, which might localize the transmembrane ligands for interactions with Eph receptors or participate in signaling within ephrin B-expressing cells.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Massachusetts Institute of Technology (MIT)	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					[Anonymous], 1997, Cell, V90, P403; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SHAO HN, 1994, J BIOL CHEM, V269, P26606; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6	55	211	216	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3726	3733		10.1074/jbc.274.6.3726	http://dx.doi.org/10.1074/jbc.274.6.3726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920925	hybrid			2022-12-25	WOS:000078428200065
J	Skourides, PA; Perera, SA; Ren, RB				Skourides, PA; Perera, SA; Ren, RB			Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins	ONCOGENE			English	Article						chronic myelogenous leukemia; Bcr-Abl; phosphorylation; Grb2; Shc; Cbl	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; TRANSGENIC MICE; SIGNAL-TRANSDUCTION; INTEGRIN FUNCTION; ADAPTER PROTEIN; LYMPHOID-CELLS; V-ABL; ONCOGENE	Bcr-Abl plays a critical role in the pathogenesis of Philadelphia chromosome-positive leukemia. Although a large number of substrates and interacting proteins of Bcr-Abl have been identified, it remains unclear whether Bcr-Abl assembles multi-protein complexes and if it does where these complexes are within cells. We have investigated the localization of Bcr-Abl in 32D myeloid cells attached to the extracellular matrix. We have found that Bcr-Abl displays a polarized distribution, colocalizing with a subset of filamentous actin at trailing portions of migrating 32D cells, and localizes on the cortical F-actin and on vesicle-like structures in resting 32D cells. Deletion of the actin binding domain of Bcr-Abl (Bcr-Abl-AD) dramatically enhances the localization of Bcr-Abl on the vesicle-like structures. These distinct localization patterns of Bcr-Abl and Bcr-Abl-AD enabled us to examine the localization of Bcr-Abl substrate and interacting proteins in relation to Bcr-Abl. We found that a subset of biochemically defined target proteins of Bcr-Abl redistributed and co-localized with Bcr-Abl on F-actin and on vesicle-like structures. The co-localization of signaling proteins with Bcr-Abl at its sites of localization supports the idea that Bcr-Abl forms a multi-protein signaling complex, while the polarized distribution and vesicle-like localization of Bcr-Abl may play a role in leukemogenesis.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, MS 029, Waltham, MA 02254 USA.			Skourides, Paris/0000-0003-3502-5729	NCI NIH HHS [CA68008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Cortes JE, 1996, AM J MED, V100, P555, DOI 10.1016/S0002-9343(96)00061-7; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Enright H, 1996, Curr Opin Hematol, V3, P303; Goldman J M, 1997, Curr Opin Hematol, V4, P277; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HAWLEY RG, 1994, GENE THER, V1, P136; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PULL L, 1994, EMBO J, V13, P764; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; ZHANG X, 1998, IN PRESS BLOOD	60	29	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1165	1176		10.1038/sj.onc.1202407	http://dx.doi.org/10.1038/sj.onc.1202407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022122				2022-12-25	WOS:000078510700005
J	Khare, S; Kumar, U; Sasi, R; Puebla, L; Calderon, L; Lemstrom, K; Hayry, P; Patel, YC				Khare, S; Kumar, U; Sasi, R; Puebla, L; Calderon, L; Lemstrom, K; Hayry, P; Patel, YC			Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty	FASEB JOURNAL			English	Article						receptor subtypes; smooth muscle cell; SST; leukocyte; MAPK; macrophage	SMOOTH-MUSCLE CELLS; 5'-FLANKING PROMOTER REGION; RIBONUCLEIC-ACID EXPRESSION; GROWTH-FACTOR-I; ARTERIAL INJURY; CORONARY ANGIOPLASTY; SEQUENCE-ANALYSIS; BALLOON INJURY; CELLULAR PROLIFERATION; POTENTIAL TREATMENT	Treatment of restenosis after angioplasty with octapeptide somatostatin (SST) analogs has met with variable success. These analogs bind with high affinity to only two SST receptor (SSTR) subtypes (2 and 5), display moderate affinity for SSTR3, and low affinity for SSTR1 and 4. To optimize the vasculoprotective effect of SST, we have investigated the pattern of expression of all five SSTRs in rat thoracic aorta in the resting state and at 15 min, 3, 7, and 14 days after balloon endothelial denudation. SSTR1-5 were analyzed as mRNA by semiquantitative reverse transcriptase-polymerase chain reaction and as protein by immunocytochemistry. All five SSTRs were expressed in rat aorta both as mRNA and protein and displayed a time-dependent, subtype-selective response to endothelial denudation. mRNA for SSTR1 and 2 increased acutely (SSTR1 > SSTR2) on days 3 and 7, coincident with smooth muscle cell (SMC) proliferation, and declined to basal levels by day 14. SSTR3 and 4 displayed a different pattern with a delayed, more gradual increase in mRNA beginning at days 3-7 and continued to increase thereafter. SSTR5 mRNA was constitutively expressed at a low level and showed no change during the 2 wk postinjury period. By immunohistochemistry, SSTR1-5 antigens were localized predominantly in SMC that were present in the media or had migrated into the intima; antigen expression correlated with receptor mRNA expression. Notably, only SSTR1,3,4 were expressed in the intima: SSTR1 and 4 during the proliferative burst and SSTR3 and 4 after proliferation, when SMC migration into the intima continues. These results demonstrate dynamic changes in SSTR1-5 expression after vascular trauma localized to areas of vascular SMC migration and replication. In view of their early and prominent induction, SSTR1 may be the optimal subtype to target for inhibition of myointimal proliferation, and SSTR3 and 4 for migration and remodeling.	McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada; Univ Helsinki, Haartman Inst, Transplantat Lab, FIN-00014 Helsinki, Finland	McGill University; Royal Victoria Hospital; University of Helsinki	Patel, YC (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs, Room M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	patel@rvhmed.lan.megill.ea	Lemström, Karl B/J-8885-2016	Lemström, Karl B/0000-0001-6920-4093				Aguila MC, 1996, ENDOCRINOLOGY, V137, P1585, DOI 10.1210/en.137.5.1585; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BRUNO JF, 1994, BIOCHEM BIOPH RES CO, V202, P1738, DOI 10.1006/bbrc.1994.2136; Chen JC, 1997, J INVEST SURG, V10, P17, DOI 10.3109/08941939709032120; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DIESMARQUES ML, 1995, ENDOCRINOL METAB, V136, P3444; EMANUELSSON H, 1995, CIRCULATION, V91, P1689, DOI 10.1161/01.CIR.91.6.1689; ERIKSEN UH, 1995, AM HEART J, V130, P1, DOI 10.1016/0002-8703(95)90227-9; FOEGH ML, 1994, J VASC SURG, V19, P1084, DOI 10.1016/S0741-5214(94)70221-7; Foegh ML, 1997, TRANSPLANT P, V29, P2605, DOI 10.1016/S0041-1345(97)00526-5; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GOLDBERG ID, 1979, SCIENCE, V205, P920, DOI 10.1126/science.472713; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; Greenwood MT, 1997, MOL PHARMACOL, V52, P807, DOI 10.1124/mol.52.5.807; GREENWOOD MT, 1994, BIOCHEM BIOPH RES CO, V205, P1883, DOI 10.1006/bbrc.1994.2890; GREENWOOD MT, 1995, GENE, V159, P291, DOI 10.1016/0378-1119(95)00059-F; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; HAYRY P, 1995, FASEB J, V9, P1336; HAYRY P, 1993, IMMUNOL REV, V134, P33, DOI 10.1111/j.1600-065X.1993.tb00639.x; HAYRY P, 1993, FASEB J, V7, P1055, DOI 10.1096/fasebj.7.11.8370476; HOLMES D, 1988, J AM COLL CARDIOL, V22, P1149; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; HONG MK, 1993, CIRCULATION, V88, P638, DOI 10.1161/01.CIR.88.2.638; James RA, 1997, ENDOCRINOLOGY, V138, P719, DOI 10.1210/en.138.2.719; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; KUMAR U, 1997, ENDOCRINOLOGY, V138, P4474; Lemstrom KB, 1997, CIRCULATION, V96, P1240, DOI 10.1161/01.CIR.96.4.1240; LESZCZYNSKI D, 1993, REGUL PEPTIDES, V43, P131, DOI 10.1016/0167-0115(93)90147-Z; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; PATEL YC, 1993, BIOCHEM BIOPH RES CO, V192, P288, DOI 10.1006/bbrc.1993.1412; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; PATEL YC, 1994, J BIOL CHEM, V269, P1506; PATEL YC, 1999, HDB PHYSL; Pscherer A, 1996, EMBO J, V15, P6680, DOI 10.1002/j.1460-2075.1996.tb01058.x; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REUBI JC, 1994, INT J CANCER, V56, P681, DOI 10.1002/ijc.2910560513; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sirois MG, 1997, CIRCULATION, V95, P669, DOI 10.1161/01.CIR.95.3.669; VIDAL C, 1994, MOL PHARMACOL, V46, P97; vonEssen R, 1997, CIRCULATION, V96, P1482, DOI 10.1161/01.CIR.96.5.1482; WAHREN J, 1976, LANCET, V2, P1213; WALTERNG EA, 1991, J SURG RES, V50, P245; Weckbecker G, 1997, TRANSPLANT P, V29, P2599, DOI 10.1016/S0041-1345(97)00523-X; WRIGHTON CJ, 1996, J EXP MED, V183, P1; XU Y, 1995, ENDOCRINOLOGY, V136, P5070, DOI 10.1210/en.136.11.5070; Xu Y, 1996, ENDOCRINOLOGY, V137, P5634, DOI 10.1210/en.137.12.5634; XU Y, 1995, BIOCHEM BIOPH RES CO, V206, P935, DOI 10.1006/bbrc.1995.1132; YURNI K, 1997, LAB INVEST, V76, P329	53	34	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					387	394		10.1096/fasebj.13.2.387	http://dx.doi.org/10.1096/fasebj.13.2.387			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973327				2022-12-25	WOS:000078615200019
J	Qiu, GF; Ahmed, M; Sells, SF; Mohiuddin, M; Weinstein, MH; Rangnekar, VM				Qiu, GF; Ahmed, M; Sells, SF; Mohiuddin, M; Weinstein, MH; Rangnekar, VM			Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4	ONCOGENE			English	Article						Par-4; Bcl-2; apoptosis; prostate	PROTEIN-KINASE-C; CELL-DEATH; APOPTOSIS; CANCER; ISOFORMS; FAMILY	Par-4 is a widely expressed protein that sensitizes both prostatic and non-prostatic cells to apoptosis, Constitutive- or regulated- overexpression of Par-4 caused a reduction in the levels of the anti-apoptotic protein Bcl-2, Replenishment of Bcl-2 levels abrogated susceptibility to Par-4-dependent apoptosis, suggesting that Par-4-mediated apoptosis requires downmodulation of Bcl-2 levels. The inverse correlation between Par-4 and Bcl-2 expression was recapitulated in human prostate tumors, Par-4 but not Bcl-2 was detected in the secretory epithelium of benign prostatic tumors and in primary and metastatic prostate cancers that are apt to undergo apoptosis, Moreover, xenografts of human, androgen-dependent CWR22 tumors showed Par-4 but not Bcl-2 expression. By contrast, androgen-independent CWR22R tumors derived from the CWR22 xenografts showed mutually exclusive expression patterns of Par-4 and Bcl-2, These findings suggest a mechanism by which Par-4 may sensitize prostate tumor cells to apoptosis.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA.				NATIONAL CANCER INSTITUTE [R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [CA60872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIHARA M, 1995, CANCER-AM CANCER SOC, V75, P522, DOI 10.1002/1097-0142(19950115)75:2<522::AID-CNCR2820750215>3.0.CO;2-W; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Berges RR, 1995, CLIN CANCER RES, V1, P473; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Bromberg Jacqueline, 1993, Current Opinion in Oncology, V5, P546, DOI 10.1097/00001622-199305000-00017; CARTER HB, 1990, PROSTATE, V16, P39; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Krajewska M, 1996, AM J PATHOL, V148, P1567; MCCOLLOUGH DL, 1988, DIAGNOSIS MANAGEMENT, P405; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NAGABHUSHAN M, 1996, CANCER RES, V56, P6049; RAFFO A, 1990, CANCER RES, V55, P4438; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; StClair EG, 1997, J BIOL CHEM, V272, P29347; Tu HC, 1996, INT J CANCER, V69, P357, DOI 10.1002/(SICI)1097-0215(19961021)69:5<357::AID-IJC1>3.0.CO;2-4; WHEELER TM, 1994, J CELL BIOCHEM, P202; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	30	72	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					623	631		10.1038/sj.onc.1202344	http://dx.doi.org/10.1038/sj.onc.1202344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989812				2022-12-25	WOS:000078394400007
J	Scotlandi, K; Manara, MC; Serra, M; Benini, S; Maurici, D; Caputo, A; De Giovanni, C; Lollini, PL; Nanni, P; Picci, P; Campanacci, M; Baldini, N				Scotlandi, K; Manara, MC; Serra, M; Benini, S; Maurici, D; Caputo, A; De Giovanni, C; Lollini, PL; Nanni, P; Picci, P; Campanacci, M; Baldini, N			The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells	ONCOGENE			English	Article						MDR1 gene; tumorigenicity; metastasis; osteosarcoma; P-glycoprotein	MULTIDRUG-RESISTANCE; TUMOR PROGRESSION; COMPLEMENTARY-DNA; MDR PROTEIN; GENE; ESTABLISHMENT; AMPLIFICATION; BEHAVIOR; GROWTH; LINES	The relationship between P-glycoprotein expression and malignancy is controversial. We have recently found that, in osteosarcoma, multidrug resistance (MDR) is associated with a less aggressive behavior, both in vitro and in clinical settings. In this study, we evaluated whether P-glycoprotein overexpression has a cause-effect relationship with the reduced metastatic potential of MDR cells, or rather reflects a more complex phenotype, MDR1 gene-transfected osteosarcoma cell clones, showing different levels of P-glycoprotein expression, were analysed for their in vitro characteristics and their tumorigenic and metastatic ability in athymic mice. Apart from the different levels of P-glycoprotein, no significant change in the expression of surface antigens or in the differentiative features were observed in the MDR1 gene transfectants compared to the parental cell lines or control clones, obtained by transfection with neo gene alone. In contrast to controls, however, MDR1 transfectants showed a significantly lower ability to grow in semi-solid medium and were completely unable to grow and give lung metastases in athymic mice. These findings indicate that P-glycoprotein overexpression is causally associated with a low malignant potential of osteosarcoma cells, and open new insights on the role and functions of P-glycoprotein activity.	Istituti Ortopedici Rizzoli, Lab Ricerca Oncol, I-40136 Bologna, Italy; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; Univ Bologna, Ist Cancerol, I-40126 Bologna, Italy	University of Ferrara; University of Bologna	Baldini, N (corresponding author), Istituti Ortopedici Rizzoli, Lab Ricerca Oncol, I-40136 Bologna, Italy.		Caputo, Antonella/ABE-7851-2020; Serra, Massimo/J-4878-2016; De Giovanni, Carla/B-1312-2009; Baldini, Nicola/J-4806-2016; Lollini, Pier Luigi/A-7644-2008; Scotlandi, Katia/J-9009-2016; Manara, Maria Cristina/K-3366-2018; Picci, Piero/J-5979-2016; BENINI, STEFANIA/D-1804-2019	Caputo, Antonella/0000-0002-1241-0299; Serra, Massimo/0000-0003-0742-1177; Baldini, Nicola/0000-0003-2228-3833; Lollini, Pier Luigi/0000-0003-1702-4108; Scotlandi, Katia/0000-0001-6114-9499; Manara, Maria Cristina/0000-0001-5686-720X; DE GIOVANNI, CARLA/0000-0003-4388-4988; Nanni, Patrizia/0000-0001-5319-0803; Picci, Piero/0000-0002-8519-4101; BENINI, STEFANIA/0000-0003-0958-9088				Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; BASHIR I, 1994, INT J CANCER, V57, P719, DOI 10.1002/ijc.2910570519; BENARD J, 1989, INT J CANCER, V43, P471, DOI 10.1002/ijc.2910430322; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; BIEDLER JL, 1975, J NATL CANCER I, V55, P671, DOI 10.1093/jnci/55.3.671; BRADLEY G, 1992, CANCER RES, V52, P5154; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chan HSL, 1997, J NATL CANCER I, V89, P1706, DOI 10.1093/jnci/89.22.1706; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HABU S, 1981, J IMMUNOL, V127, P34; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hoffman MM, 1996, J GEN PHYSIOL, V108, P295, DOI 10.1085/jgp.108.4.295; Kerbel R. S., 1993, P583; LINCKE CR, 1990, CANCER RES, V50, P1779; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; PINEDO HM, 1995, NEW ENGL J MED, V333, P1417, DOI 10.1056/NEJM199511233332111; RIORDAN JR, 1989, SCIENCE, V245, P1066; RODAN SB, 1987, CANCER RES, V47, P4961; Roepe PD, 1996, J BIOENERG BIOMEMBR, V28, P541, DOI 10.1007/BF02110444; Scotlandi K, 1996, CANCER RES, V56, P2434; SERRA M, 1993, ANTICANCER RES, V13, P323; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004	31	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					739	746		10.1038/sj.onc.1202330	http://dx.doi.org/10.1038/sj.onc.1202330			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989824				2022-12-25	WOS:000078394400019
J	Nishida, K; Kaziro, Y; Satoh, T				Nishida, K; Kaziro, Y; Satoh, T			Anti-apoptotic function of Rac in hematopoietic cells	ONCOGENE			English	Article						Akt; apoptosis; p38 mitogen-activated protein kinase; phosphatidylinositol 3-kinase; Rac	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; COLONY-STIMULATING FACTOR; SIGNALING PATHWAY; JUN KINASE; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; SELECTIVE ACTIVATION; CYTOKINE DEPRIVATION	The small GTP-binding protein Rac plays a pivotal role in the regulation of diverse physiological events including reorganization of the actin cytoskeleton, cell cycle progression, and transformation. Here we show an anti-apoptotic effect of Rac in interleukin-3-dependent murine hematopoietic BaF3 cells. Activated Rac(G12V), when ectopically expressed in BaF3 cells, rendered the cells resistant to apoptosis upon interleukin-3 deprivation, while activated mutants of Rho and Cdc42 displayed no significant anti-apoptotic effect. In contrast to activated Ras, which also supports cell survival in the absence of interleukin-3, Rac required fetal bovine serum for the prevention of cell death. The involvement of phosphatidylinositol 3-kinase downstream of Rac was demonstrated by the inhibition of Rac-induced cell survival by wortmannin and LY294002 and the presence of phosphatidylinositol kinase activity in the Rac immunoprecipitate, Furthermore, the serine/threonine kinase Akt was stimulated by activated Rac and fetal bovine serum in a synergistic manner. Rac-induced Akt activation was mediated by phosphorylation of threonine-308 and serine-473, In addition to the phosphatidylinositol 3-kinase/Akt pathway, the p38 mitogen-activated protein kinase pathway was crucial for Rac-dependent survival, whereas p38 mitogen-activated protein kinase was not implicated in Ras-induced anti-apoptotic signaling. These findings provide evidence for the involvement of Rac in survival signaling of hematopoietic cells.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Satoh, T (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Satoh, Takaya/K-2628-2014	Nishida, Kazuhiko/0000-0001-8825-8441				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu R, 1997, BIOCHEM BIOPH RES CO, V234, P611, DOI 10.1006/bbrc.1997.6643; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Tago K, 1998, J BIOCHEM-TOKYO, V123, P659; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	74	81	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					407	415		10.1038/sj.onc.1202301	http://dx.doi.org/10.1038/sj.onc.1202301			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927197				2022-12-25	WOS:000078166500013
J	Voorhoeve, PM; Hijmans, EM; Bernards, R				Voorhoeve, PM; Hijmans, EM; Bernards, R			Functional interaction between a novel protein phosphatase 2A regulatory subunit, PR59, and the retinoblastoma-related p107 protein	ONCOGENE			English	Article						cell cycle; p107; protein phosphatase 2A; retinoblastoma protein	SERINE THREONINE PHOSPHATASES; CYCLIN-DEPENDENT KINASES; DNA-BINDING ACTIVITY; CELL-PROLIFERATION; CATALYTIC SUBUNIT; GENE FAMILY; IN-VIVO; E2F; COMPLEXES; CDK2	The proteins of the retinoblastoma family are potent inhibitors of cell cycle progression. It is well documented that their growth-inhibitory activity can be abolished by phosphorylation on serine and threonine residues by cyclin dependent kinases, In contrast, very little is known about the dephosphorylation of retinoblastoma-family proteins. We report here the isolation, by virtue of its ability to associate,vith p107, of a novel Protein Phosphatase 2A (PP2A) regulatory subunit, named PR59, PR59 shares sequence homology with a known regulatory subunit of PP2A, PR72, but differs from PR72 in its expression pattern and its functional properties. We show that PR59 co-immunoprecipitates with the PP2A catalytic subunit, indicating that PR59 is a genuine component of PP2A hole-enzymes. In vivo, PR59 associates specifically with p107, but not with pRb, Elevated expression of PR59 results in dephosphorylation of p107, but not of pRb, and inhibits cell proliferation by causing cells to accumulate in G1, These data support a model in which the distinct PP2A regulatory subunits act to target the PP2A catalytic subunit to specific substrates and suggest a role for PP2A in regulation of p107.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bernards R, 1997, BBA-REV CANCER, V1333, pM33, DOI 10.1016/S0304-419X(97)00027-9; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAVRE B, 1994, J BIOL CHEM, V269, P16331; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RADULESCU RT, 1995, MED HYPOTHESES, V44, P28, DOI 10.1016/0306-9877(95)90297-X; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Tung HYL, 1997, FEBS LETT, V401, P197, DOI 10.1016/S0014-5793(96)01470-6; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Virshup DM, 1993, ADV PROTEIN PHOSPHAT, V7, P271; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	57	87	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					515	524		10.1038/sj.onc.1202316	http://dx.doi.org/10.1038/sj.onc.1202316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927208	Green Published			2022-12-25	WOS:000078166500024
J	Zhan, QM; Kontny, U; Iglesias, M; Alamo, I; Yu, K; Hollander, MC; Woodworth, CD; Fornace, AJ				Zhan, QM; Kontny, U; Iglesias, M; Alamo, I; Yu, K; Hollander, MC; Woodworth, CD; Fornace, AJ			Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress	ONCOGENE			English	Article						BCL-2; GADD45; p21(CIPI/WAF1); p53; apoptosis; ionizing radiation; methylmethane sulfonate; UV radiation	PROGRAMMED CELL-DEATH; DNA-DAMAGING AGENTS; NUCLEAR ANTIGEN; GENE-EXPRESSION; P53; PROTEIN; APOPTOSIS; INDUCTION; GROWTH; GADD45	In the cellular response to genotoxic stress, cell cycle checkpoint and apoptosis are considered to be two of the major biological events in maintaining genomic stability. The tumor suppressor p53 has been shown to play critical roles in these stress-induced cellular responses at least in part through the activation of its down-stream genes, such as p21(ClPl/WAFl), GADD45 and BAX. In addition, p53 has been found to down-regulate the expression of BCL-2, which is able to block apoptosis induced by both p53-dependent and independent signaling events. In this report,,ve have found that increased expression of Bcl-2 protein in the human Burkitt's lymphoma WMN cell line suppressed apoptosis induced by different DNA-damaging agents. The induction of p53-regulated genes including GADDIS, p21(ClPl/WAFl) and BAX by genotoxic stress was substantially reduced in cells expressing high levels of Bcl-2 protein. Furthermore, Bcl-2 protein was shown to specifically suppress the p53-mediated transactivation of p21(ClPl/WAFl) and PG13-CAT, which is a typical p53-binding-site reporter construct, Similarly, the inhibitory effect of Bcl-2 protein was seen in a GADD45 promoter reporter construct after treatment with methylmethane sulfonate or UV-radiation, These results indicate that in addition to its apoptosis-suppressing activity, Bcl-2 protein is able to inhibit transactivation of p53-regulated genes, which function in multiple important cellular responses to genotoxic stress, including the control of cell cycle checkpoints, cell growth suppression and DNA repair.	NCI, Biol Chem Lab, Bethesda, MD 20892 USA; NCI, Div Basic Sci, Biol Lab, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, Div Clin Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), NCI, Biol Chem Lab, Room 5CO9,Bldg 37, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HALDAR S, 1994, CANCER RES, V54, P2095; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAROCCA RV, 1990, J STEROID BIOCHEM, V37, P893, DOI 10.1016/0960-0760(90)90439-R; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1995, CELL, V80, P293; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1991, CANCER RES, V51, P6550; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1992, CELL, V70, P526; WOODWORTH CD, 1992, ONCOGENE, V7, P619; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937	46	45	56	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					297	304		10.1038/sj.onc.1202310	http://dx.doi.org/10.1038/sj.onc.1202310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927186				2022-12-25	WOS:000078166500002
J	Chen, ZH; Seimiya, H; Naito, M; Mashima, T; Kizaki, A; Dan, S; Imaizumi, M; Ichijo, H; Miyazono, K; Tsuruo, T				Chen, ZH; Seimiya, H; Naito, M; Mashima, T; Kizaki, A; Dan, S; Imaizumi, M; Ichijo, H; Miyazono, K; Tsuruo, T			ASK1 mediates apoptotic cell death induced by genotoxic stress	ONCOGENE			English	Article						ASK1; apoptosis; kinase cascades; genotoxic stress	ACTIVATED PROTEIN-KINASE; CHEMOTHERAPY-INDUCED APOPTOSIS; CERAMIDE-INDUCED APOPTOSIS; LEUKEMIA U937 CELLS; C-JUN; JNK ACTIVATION; POLY(ADP-RIBOSE) POLYMERASE; SIGNALING PATHWAY; GAMMA-RADIATION; TNF RECEPTOR-1	Genotoxic stress-induced apoptosis is mediated by caspase family proteases as triggered by other stimuli. In this study, we found that the DNA-damaging agent cisplatin (cDDP) activated MAP kinase kinase kinase ASK1 and subsequent downstream subgroups of MAP kinase kinase, SEK1 (or MKK4) and MKK3/MKK6, which in turn activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and p38 MAP kinase prior to caspase family protease activation and the onset of apoptosis in human ovarian carcinoma (OVCAR-3) and human kidney (293T) cells. As reported previously, benzyloxy carbonyl-Asp-CH2OC(O)-2, 6-dichlorobenzene (Z-Asp), a preferential inhibitor of caspase family proteases, blocked the apoptosis of OVCAR-3 cells induced by the genotoxic stress cDDP. Z-Asp, however, did not inhibit ASK1 activation and the subsequent kinase cascades. Overexpression of kinase-negative ASK1 (K709R), which inhibited ASK1 activation and the downstream MKK3-p38 and MKK4-JNK1 pathways, also suppressed the caspase protease activation and apoptosis induced by cDDP. These results indicate that the ASK1 pathway is involved in genotoxic stress-induced apoptosis and mediates apoptosis at a step upstream of caspase protease activation.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan.			Ichijo, Hidenori/0000-0002-5005-6438; Seimiya, Hiroyuki/0000-0003-3314-9736				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MEYN RE, 1994, CANCER CHEMOTH PHARM, V33, P410, DOI 10.1007/BF00686270; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Teng DHF, 1997, CANCER RES, V57, P4177; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	49	157	162	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					173	180		10.1038/sj.onc.1202276	http://dx.doi.org/10.1038/sj.onc.1202276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926932				2022-12-25	WOS:000078166000019
J	Bernish, B; van de Rijn, I				Bernish, B; van de Rijn, I			Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GRAM-POSITIVE BACTERIA; MOLECULAR CHARACTERIZATION; M-PROTEIN; SIGNAL-TRANSDUCTION; RNA-POLYMERASE; CLONED GENES; EXPRESSION; CAPSULE; VIRULENCE	Hyaluronic acid production by group A streptococci is regulated by transcriptional control. In this study, transposon mutagenesis of an unencapsulated strain yielded an encapsulated mutant. Two genes homologous to sensors and response regulators of bacterial two-component systems were identified downstream of the transposon insertion. Inactivation of the putative sensor gene, csrS, in three different unencapsulated strains yielded encapsulated mutant strains. Electrophoretic mobility shift assays determined factor(s) in a cytoplasmic extract of an unencapsulated group A streptococcal strain was binding to a double-stranded DNA fragment derived from the has operon promoter. In contrast, similarly prepared cytoplasmic extracts from a csrS deletion mutant did not shift the fragment. The putative response regulator, CsrR, was partially purified and was shown to bind the has operon promoter fragment, The affinity and specificity of CsrR for the fragment were increased significantly after incubation with acetyl phosphate. DNase I footprinting determined that the acetyl phosphate-treated CsrR was binding to key sequences in the promoter and the coding region of hasA. Therefore, a two-component system is repressing the production of hyaluronic acid in group A streptococci using a phosphorylation-dependent binding interaction between the response regulator CsrR and the promoter region of the has operon.	Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University	van de Rijn, I (corresponding author), Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ivr@fubmc.edu	Bernish, Brian/J-9447-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037320] Funding Source: NIH RePORTER; NCI NIH HHS [CA12107] Funding Source: Medline; NIAID NIH HHS [AI37320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti S, 1998, MOL MICROBIOL, V28, P343, DOI 10.1046/j.1365-2958.1998.00800.x; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; CHODOSH LA, 1995, CURRENT PROTOCOLS MO, P1; Cleary PP, 1998, MOL MICROBIOL, V28, P157, DOI 10.1046/j.1365-2958.1998.00786.x; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; CRATER DL, 1995, J BIOL CHEM, V270, P28676, DOI 10.1074/jbc.270.48.28676; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; DUNNY GM, 1991, APPL ENVIRON MICROB, V57, P1194, DOI 10.1128/AEM.57.4.1194-1201.1991; GAWRONBURKE C, 1984, J BACTERIOL, V159, P214, DOI 10.1128/JB.159.1.214-221.1984; HEATH A, 1997, 97 GEN M AM SOC MICR, V36, pB45; Husmann LK, 1997, INFECT IMMUN, V65, P1422, DOI 10.1128/IAI.65.4.1422-1430.1997; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; McCleary WR, 1996, MOL MICROBIOL, V20, P1155, DOI 10.1111/j.1365-2958.1996.tb02636.x; Moore DD, 1995, GLOB MOB SURV; Moses AE, 1997, INFECT IMMUN, V65, P64, DOI 10.1128/IAI.65.1.64-71.1997; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PEREZCASAL J, 1992, RES MICROBIOL, V143, P549, DOI 10.1016/0923-2508(92)90112-2; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; Podbielski A, 1996, GENE, V177, P137, DOI 10.1016/0378-1119(96)84178-3; PODBIELSKI A, 1995, INFECT IMMUN, V63, P9, DOI 10.1128/IAI.63.1.9-20.1995; RICCI ML, 1994, FEMS MICROBIOL LETT, V119, P47; Schmidt KH, 1996, MED MICROBIOL IMMUN, V184, P169, DOI 10.1007/PL00008248; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; SCOPES RK, 1994, PROTEIN PURIFICATION, P347; SIMPSON WJ, 1990, J BACTERIOL, V172, P696, DOI 10.1128/jb.172.2.696-700.1990; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VANDERIJN I, 1979, INFECT IMMUN, V26, P883, DOI 10.1128/IAI.26.3.883-891.1979; WESSELS MR, 1994, P NATL ACAD SCI USA, V91, P12238, DOI 10.1073/pnas.91.25.12238; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4786	4793		10.1074/jbc.274.8.4786	http://dx.doi.org/10.1074/jbc.274.8.4786			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988717	hybrid			2022-12-25	WOS:000078698200042
J	Negrutskii, BS; Shalak, VF; Kerjan, P; El'skaya, AV; Mirande, M				Negrutskii, BS; Shalak, VF; Kerjan, P; El'skaya, AV; Mirande, M			Functional interaction of mammalian valyl-tRNA synthetase with elongation factor EF-1 alpha in the complex with EF-1H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; PROTEIN-SYNTHESIS; FACTOR-I; RABBIT LIVER; FACTOR 1-ALPHA; PHOSPHORYLATION; CELLS; FACTOR-1-BETA; PURIFICATION	In mammalian cells valyl-tRNA synthetase (ValRS) forms a high M-r complex with the four subunits of elongation factor EF-1H. The beta, gamma, and delta subunits, that contribute the guanine nucleotide exchange activity of EF-1H, are tightly associated with the NH2-terminal polypeptide extension of valyl-tRNA synthetase, In this study, we have examined the possibility that the functioning of the companion enzyme EF-1 alpha could regulate valyl-tRNA synthetase activity. We show here that the addition of EF-1 alpha and GTP in excess in the aminoacylation mixture is accompanied by a 2-fold stimulation of valyl-tRNA(Val) synthesis catalyzed by the vall-tRNA synthetase component of the ValRS EF-1H complex. This effect is not observed in the presence of EF-1 alpha and GDP or EF-Tu GTP and requires association of valyl-tRNA synthetase within the ValRS EF-1H complex. Since valyl-tRNA synthetase and elongation factor EF-1 alpha catalyze two consecutive steps of the in vivo tRNA cycle, aminoacylation and formation of the ternary complex EF-1 alpha.GTP.Val-tRNA(Val) that serves as a vector of tRNA from the synthetase to the ribosome, the data suggest a coordinate regulation of these two successive reactions. The EF-1 alpha.GTP-dependent stimulation of valyl-tRNA synthetase activity provides further evidence for tRNA channeling during protein synthesis in mammalian cells.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Natl Acad Sci Ukraine, Inst Mol Biol & Genet, UA-232143 Kiev, Ukraine	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU	Mirande, M (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	marc.mirande@lebs.cnrs-gif.fr	Shalak, Vyacheslav F/D-3707-2015; Negrutskii, Boris/G-6439-2016	Shalak, Vyacheslav F/0000-0001-6114-6482; Negrutskii, Boris/0000-0001-5974-1629; El'skaya, Anna/0000-0002-7327-4075				ARAI KI, 1974, J BIOCHEM-TOKYO, V76, P293, DOI 10.1093/oxfordjournals.jbchem.a130571; BARBARESE E, 1995, J CELL SCI, V108, P2781; BEC G, 1994, J BIOL CHEM, V269, P2086; BEC G, 1989, J BIOL CHEM, V264, P21131; BEC G, 1989, J BIOL CHEM, V264, P21138; CRECHET JB, 1986, EUR J BIOCHEM, V161, P655, DOI 10.1111/j.1432-1033.1986.tb10490.x; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; Kawaguchi Y, 1998, J VIROL, V72, P1731, DOI 10.1128/JVI.72.3.1731-1736.1998; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Minella O, 1996, EUR J BIOCHEM, V237, P685, DOI 10.1111/j.1432-1033.1996.0685p.x; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1985, EXP CELL RES, V156, P91, DOI 10.1016/0014-4827(85)90264-2; MOTORIN YA, 1991, EUR J BIOCHEM, V201, P325, DOI 10.1111/j.1432-1033.1991.tb16289.x; Negrutskii BS, 1996, FEBS LETT, V382, P18, DOI 10.1016/0014-5793(96)00128-7; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; PALEN E, 1994, BIOCHEMISTRY-US, V33, P8515, DOI 10.1021/bi00194a016; Petrushenko ZM, 1997, FEBS LETT, V407, P13, DOI 10.1016/S0014-5793(97)00242-1; REED VS, 1994, J BIOL CHEM, V269, P32932; Sanders J, 1996, J CELL SCI, V109, P1113; Sheu GT, 1997, J BIOL CHEM, V272, P33290, DOI 10.1074/jbc.272.52.33290; SLOBIN LI, 1981, BIOCHEM BIOPH RES CO, V101, P1388, DOI 10.1016/0006-291X(81)91601-6; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	31	72	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4545	4550		10.1074/jbc.274.8.4545	http://dx.doi.org/10.1074/jbc.274.8.4545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988688	hybrid			2022-12-25	WOS:000078698200013
J	Paka, L; Kako, Y; Obunike, JC; Pillarisetti, S				Paka, L; Kako, Y; Obunike, JC; Pillarisetti, S			Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains - A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; DEACETYLASE N-SULFOTRANSFERASE; FIBROBLAST GROWTH-FACTOR; CORONARY HEART-DISEASE; SUBENDOTHELIAL MATRIX; CELL-PROLIFERATION; MOLECULAR-CLONING; HUMAN AORTA; PROTEOGLYCAN; ATHEROSCLEROSIS	Reduced heparin and heparan sulfate (HS) proteoglycans (PG) have been observed in both inflammation and atherosclerosis. Methods to increase endogenous heparin and heparan sulfate are not known. We found that incubation of endothelial cells with 500-1,000 mu g/ml high density lipoprotein (HDL) increased (SO4)-S-35 incorporation into PG by 1.5-2.5-fold. A major portion of this increase was in HS and was the result of increased synthesis. Total PG core proteins were not altered by HDL; however, the ratio of (SO4)-S-35 to [H-3]glucosamine was increased by HDL, suggesting increased sulfation of glycosaminoglycans. In addition, HDL increased the amount of highly sulfated heparin-like HS in the subendothelial matrix, HS from HDL-treated cells bound 40 +/- 5% more I-125-antithrombin III (requires 3-O sulfated HS) and 49 +/- 3% fewer monocytes. Moreover, the HS isolated from HDL-treated cells inhibited smooth muscle cell proliferation (by 83 +/- 5%) better than control HS (56 +/- 6%) and heparin (42 +/- 6%). HDL isolated from apolipoprotein E (apoE)-null mice did not stimulate HS production unless apoE was added. ApoE also stimulated HS production in the absence of HDL. ApoE did not increase (SO4)-S-35 incorporation in macrophages and fibroblasts, suggesting that this is an endothelial cell-specific process. Receptor-associated protein inhibited apoE-mediated stimulation of HS only at higher (20 mu g/ml) doses, suggesting the involvement of a receptor-associated protein-sensitive pathway in mediating apoE actions. In summary, our data identify a novel mechanism by which apoE and apoE-containing HDL can be antiatherogenic. Identification of specific apoE peptides that stimulate endothelial heparin/HS production may have important therapeutic applications.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Div Prevent Med, New York, NY 10032 USA	Columbia University; Columbia University	Pillarisetti, S (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, BB 901,630 W 168th St, New York, NY 10032 USA.	heparin@email.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095, R37HL045095] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45095] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Alston WK, 1997, J CELL PHYSIOL, V173, P102, DOI 10.1002/(SICI)1097-4652(199710)173:1<102::AID-JCP12>3.3.CO;2-5; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DESILVA HV, 1994, J LIPID RES, V35, P1297; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ENGELBERG H, 1991, SEMIN THROMB HEMOST, V17, P5; Engelberg H, 1997, SEMIN THROMB HEMOST, V23, P159, DOI 10.1055/s-2007-996085; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; GALLIS ZS, 1994, J CLIN INVEST, V94, P2493; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; GURETZKI HJ, 1994, ATHEROSCLEROSIS, V107, P15, DOI 10.1016/0021-9150(94)90137-6; HOFF HF, 1986, ATHEROSCLEROSIS, V61, P231, DOI 10.1016/0021-9150(86)90143-7; HOLLMANN J, 1989, ARTERIOSCLEROSIS, V9, P154, DOI 10.1161/01.ATV.9.2.154; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kruse R, 1996, BASIC RES CARDIOL, V91, P344; LANIR N, 1988, J IMMUNOL, V140, P2340; LIDER O, 1990, EUR J IMMUNOL, V20, P493, DOI 10.1002/eji.1830200306; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P3; MURATA K, 1989, ATHEROSCLEROSIS, V78, P69, DOI 10.1016/0021-9150(89)90160-3; MURATA K, 1985, STROKE, V16, P687, DOI 10.1161/01.STR.16.4.687; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Patsch W, 1995, Adv Pharmacol, V32, P375, DOI 10.1016/S1054-3589(08)61018-2; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Pillarisetti S, 1997, J CLIN INVEST, V100, P867, DOI 10.1172/JCI119602; Pillarisetti S, 1995, J BIOL CHEM, V270, P29760; PILLARISETTI S, 1992, J BIOL CHEM, V267, P16517; PINHAL MAS, 1995, THROMB HAEMOSTASIS, V74, P1169; PYE DA, 1995, BBA-MOL CELL RES, V1266, P235, DOI 10.1016/0167-4889(95)00012-H; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; RAMASAMY S, 1995, J CELL PHYSIOL, V162, P119, DOI 10.1002/jcp.1041620114; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; RICHARDSON M, 1982, ARTERIOSCLEROSIS, V2, P369, DOI 10.1161/01.ATV.2.5.369; Riddell DR, 1997, J BIOL CHEM, V272, P89; ROSENBERG RD, 1989, AM J MED, V87, pS2, DOI 10.1016/0002-9343(89)80523-6; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SRINIVASAN SR, 1991, ADV EXP MED BIOL, V285, P373; STINS MF, 1993, J LIPID RES, V34, P1853; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 1995, THROMB HAEMOSTASIS, V74, P534; VOLKER W, 1990, EUR HEART J, V11, P29, DOI 10.1093/eurheartj/11.suppl_E.29; WAGNER WD, 1985, ANN NY ACAD SCI, V454, P52, DOI 10.1111/j.1749-6632.1985.tb11844.x; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WIGHT TN, 1985, FED PROC, V44, P381; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1020; WILLIAMS DL, 1985, ANN NY ACAD SCI, V454, P222, DOI 10.1111/j.1749-6632.1985.tb11861.x; WILSON HM, 1993, CLIN CHIM ACTA, V220, P175, DOI 10.1016/0009-8981(93)90046-7	63	39	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4816	4823		10.1074/jbc.274.8.4816	http://dx.doi.org/10.1074/jbc.274.8.4816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988721	hybrid			2022-12-25	WOS:000078698200046
J	Velasco, G; Pendas, AM; Fueyo, A; Knauper, V; Murphy, G; Lopez-Otin, C				Velasco, G; Pendas, AM; Fueyo, A; Knauper, V; Murphy, G; Lopez-Otin, C			Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; HUMAN STROMELYSIN-3; IV COLLAGENASE; CLEAVAGE SITES; GENE FAMILY; SUBSTRATE-SPECIFICITY; CHROMOSOMAL LOCATION; BREAST CARCINOMAS	A cDNA encoding a new human matrix metalloproteinase (MMP), tentatively called MMP-23, has been cloned from an ovary cDNA Library. This protein exhibits sequence similarity with MMPs, but displays a different domain structure. Thus, MMP-23 lacks a recognizable signal sequence and has a short prodomain, although it contains a single cysteine residue that can be part of the cysteine-switch mechanism operating for maintaining enzyme latency. The C-terminal domain is considerably shortened and shows no sequence similarity to hemopexin, whereas all human MMPs, with the exception of matrilysin, contain four hemopexin-like repeats. Furthermore, MMP-23 is devoid of structural features distinctive of the diverse MMP subclasses, including the specific residues located close to the zinc-binding site in collagenases, the transmembrane domain of membrane-type MMPs, or the fibronectin-like domain of gelatinases. Fluorescent in situ hybridization experiments showed that the human MMP-23 gene maps to 1p36, a location which differs from all MMP genes mapped to date. Recombinant MMP-23 produced in Escherichia coli exhibits low, but significant proteolytic activity against a synthetic substrate commonly used for assaying MMPs. Northern blot analysis demonstrated that MMP-23 is predominantly expressed in ovary, testis, and prostate, suggesting that this new MMP may play a specialized role in reproductive processes.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oviedo; University of East Anglia	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	clo@dwarf1.quimica.uniovi.es	Pendas, Alberto M/L-1017-2014; Velasco, Gloria/AAS-5842-2021; López-Otín, Carlos/AAB-2106-2020; Fueyo, Antonio/ABH-3243-2020	Velasco, Gloria/0000-0001-8032-5056; López-Otín, Carlos/0000-0001-6964-1904; Fueyo, Antonio/0000-0002-7121-9398; Knauper, Vera/0000-0002-3965-9924; Pendas, Alberto M/0000-0001-9264-3721				Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Couet J, 1996, J BIOL CHEM, V271, P4545; DEVEREUX J, NUCLEIC ACIDS RES, V12, P387; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Gururajan R, 1998, GENOMICS, V52, P101, DOI 10.1006/geno.1998.5401; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; Hulboy DL, 1997, MOL HUM REPROD, V3, P27, DOI 10.1093/molehr/3.1.27; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KINOSHITA T, 1992, P NATL ACAD SCI USA, V89, P4693, DOI 10.1073/pnas.89.10.4693; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LEVY A, 1992, GENOMICS, V13, P881, DOI 10.1016/0888-7543(92)90175-R; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Maniatis T., 1982, MOL CLONING LAB MANU; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MAST AE, 1991, J BIOL CHEM, V266, P15810; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mattei MG, 1997, GENOMICS, V40, P168, DOI 10.1006/geno.1996.4559; MIGNON C, 1995, GENOMICS, V28, P360, DOI 10.1006/geno.1995.1159; MITCHELL TI, 1993, BIOCHIM BIOPHYS ACTA, V1156, P245, DOI 10.1016/0304-4165(93)90038-A; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pak JH, 1997, FEBS LETT, V404, P283, DOI 10.1016/S0014-5793(97)00141-5; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; PENDAS AM, 1994, CYTOGENET CELL GENET, V66, P263, DOI 10.1159/000133708; PENDAS AM, 1994, CYTOGENET CELL GENET, V67, P31, DOI 10.1159/000133792; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; Pendas AM, 1996, GENOMICS, V37, P266, DOI 10.1006/geno.1996.0557; Puente XS, 1996, CANCER RES, V56, P944; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STJEAN PL, 1995, ANN HUM GENET, V59, P17; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yang MZ, 1998, J BIOL CHEM, V273, P17893, DOI 10.1074/jbc.273.28.17893; Yang MZ, 1997, J BIOL CHEM, V272, P13527, DOI 10.1074/jbc.272.21.13527	61	164	177	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4570	4576		10.1074/jbc.274.8.4570	http://dx.doi.org/10.1074/jbc.274.8.4570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988691	hybrid			2022-12-25	WOS:000078698200016
J	Zong, H; Raman, N; Mickelson-Young, LA; Atkinson, SJ; Quilliam, LA				Zong, H; Raman, N; Mickelson-Young, LA; Atkinson, SJ; Quilliam, LA			Loop 6 of RhoA confers specificity for effector binding, stress fiber formation, and cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ACTIN POLYMERIZATION; INDEPENDENT PATHWAYS; POTENTIAL EFFECTOR; CYCLE PROGRESSION; CRYSTAL-STRUCTURE; RAC REGULATION; INSERT REGION; ACTIVATION; GTPASES	Rho family GTPases regulate multiple cellular processes, including cytoskeletal organization, gene expression, and transformation. These effects are achieved through the interaction of GTP-bound proteins with various downstream targets. A series of RhoA/Rad and Rho/Ras chimeras was generated to map the domain(s) of RhoA involved in its association with two classes of effector kinase, represented by PRK2 and ROCK-I, Although the switch 1 domain was required for effector binding, the N terminus of Rho (residues 1-75) was interchangeable with that of Rac, This suggested that the region of Rho that confers effector binding specificity lay further C-terminal, Subsequent studies indicated that the "insert domain" (residues 123-137), a region unique to Rho family GTPases, is not the specificity determinant. However, a determinant for effector binding was identified between Rho residues 75-92, Rac to Rho point mutations (V85D or A88D) within loop 6 of Rac promoted its association with PRK2 and ROCK, whereas the reciprocal Rho(D87V/D90A) double mutant significantly reduced effector binding capacity. In vivo studies showed that microinjection of Rac(Q6IL/V85D/ A88D) but not Rac(Q6IL)) induced stress fiber formation in LLC-PK epithelial cells, suggesting that loop 6 residues conferred the ability of Rac to activate ROCK. On the other hand, the reciprocal Rho (Q6IL/D87V/D90A) mutant was defective in its ability to transform NM 3T3 cells. These data suggest that although Rho effecters can utilize a Rho or Rac switch I domain to sense the GTP-bound state of Rho, unique residues within loop 6 are essential for determining both effector binding specificity and cellular function.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Div Nephrol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS 4053, Indianapolis, IN 46202 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019					Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JOHN J, 1993, J BIOL CHEM, V268, P923; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leung T, 1996, MOL CELL BIOL, V16, P5313; LI L, 1997, J BIOL CHEM, V272, P32830; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MOODIE SA, 1995, ONCOGENE, V11, P447; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SELF AJ, 1993, ONCOGENE, V8, P655; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WITTINGHOFER A, 1993, CIBA F SYMP, V176, P6; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; XU XM, 1994, J BIOL CHEM, V269, P23569; Yu WP, 1997, J BIOL CHEM, V272, P10030	51	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4551	4560		10.1074/jbc.274.8.4551	http://dx.doi.org/10.1074/jbc.274.8.4551			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988689	hybrid			2022-12-25	WOS:000078698200014
J	Alzuherri, HM; White, RJ				Alzuherri, HM; White, RJ			Regulation of RNA polymerase I transcription in response to F9 embryonal carcinoma stem cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; RIBOSOMAL-RNA; FACTOR UBF; SPECIES-SPECIFICITY; TBP; INDUCTION; SUBUNITS; COMPLEX; GENES; SL1	Dramatic changes in the patterns of transcription are a common feature of early development, We have used F9 embryonal carcinoma cells as a model system to study gene regulation during an early stage of murine embryogenesis, We find that transcription by RNA polymerase I decreases when F9 cells differentiate into parietal endoderm, The reduced rate of transcription is associated with a down-regulation of several components of the Glass I transcription apparatus. The most substantial change involves the essential factor SL1, which is a multisubunit complex that contains the TATA-binding protein and three TATA-binding protein-associated factors (TAFs), The abundance of two of these TAFs, TAAF(I)48 and TAF(I)95, decreases during F9 cell differentiation. Developmental regulation of a specific class of genes may therefore be achieved through changes in the availability of TAFs.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Alzuherri, HM (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland.							Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; CAIRNS C, 1995, NUCLEIC ACIDS RES, V23, P4583, DOI 10.1093/nar/23.22.4583; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAREY MF, 1986, MOL CELL BIOL, V6, P3068, DOI 10.1128/MCB.6.9.3068; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KUHN A, 1992, P NATL ACAD SCI USA, V89, P7340, DOI 10.1073/pnas.89.16.7340; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; PAULE MR, 1998, TRANSCRIPTION RIBOSO, pR1; Reeder R. H., 1995, NUCL ACIDS MOL BIOL, V9, P251; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SEGALL J, 1980, J BIOL CHEM, V255, P1986; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VASSEUR M, 1985, EMBO J, V4, P1749, DOI 10.1002/j.1460-2075.1985.tb03846.x; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	29	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4328	4334		10.1074/jbc.274.7.4328	http://dx.doi.org/10.1074/jbc.274.7.4328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933634	hybrid			2022-12-25	WOS:000078575500058
J	Haggie, PM; Brindle, KM				Haggie, PM; Brindle, KM			Mitochondrial citrate synthase is immobilized in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID CYCLE ENZYMES; P-31 NMR VISIBILITY; SACCHAROMYCES-CEREVISIAE; TCA CYCLE; MALATE-DEHYDROGENASE; FUSION PROTEIN; YEAST; ORGANIZATION; TRANSFORMATION; METABOLITES	The enzymes of the tricarboxylic acid cycle in the mitochondrial matrix are proposed to form a multienzyme complex, in which there is channeling of substrates between enzyme active sites. However no direct evidence has been obtained in vivo for the involvement of these enzymes in such a complex. We have labeled the tricarboxylic acid cycle enzyme, citrate synthase 1, in the yeast Saccharomyces cerevisiae, by biosynthetic incorporation of Fi-fluorotryptophan. Comparison of the F-19 NMR resonance intensities from the labeled enzyme in the intact cell and in cell-free lysates indicated that the enzyme is motionally restricted in vivo, consistent with its participation in a multienzyme complex.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Brindle, KM (corresponding author), Univ Cambridge, Dept Biochem, Old Addenbrookes Site,80 Tennis Court Rd, Cambridge CB2 1GA, England.							ARAGON JJ, 1991, FASEB J, V5, P2945, DOI 10.1096/fasebj.5.14.1752361; BARNES SJ, 1986, FEBS LETT, V201, P267, DOI 10.1016/0014-5793(86)80621-4; Braden M, 1976, Front Oral Physiol, V2, P1; BRINDLE K, 1989, FEBS LETT, V255, P121, DOI 10.1016/0014-5793(89)81073-7; Cantor C.R., 1980, BIOPHYS CHEM; COUSENS DJ, 1990, NUCLEIC ACIDS RES, V18, P1308, DOI 10.1093/nar/18.5.1308; Elcock AH, 1996, BIOCHEMISTRY-US, V35, P12652, DOI 10.1021/bi9614747; FREIFELDER D, 1982, PHYSICAL BIOCH; FUSHIMI K, 1991, J CELL BIOL, V112, P719, DOI 10.1083/jcb.112.4.719; GANCEDO JM, 1973, BIOCHIMIE, V55, P205, DOI 10.1016/S0300-9084(73)80393-1; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; Hubbard SJ, 1993, NACCESS COMPUTER PRO; HUTSON SM, 1989, BIOCHEMISTRY-US, V28, P4325, DOI 10.1021/bi00436a030; HUTSON SM, 1992, BIOCHEMISTRY-US, V31, P1322, DOI 10.1021/bi00120a007; JEFFREY FM, 1989, BIOCHEMISTRY-US, V28, P5323, DOI 10.1021/bi00439a003; Jia YK, 1997, MOL MICROBIOL, V24, P53, DOI 10.1046/j.1365-2958.1997.3011669.x; JONES EW, 1991, J BIOL CHEM, V266, P7963; KISPAL G, 1989, J BIOL CHEM, V264, P11204; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11684, DOI 10.1021/bi00205a003; LINDBLADH C, 1994, BIOCHEMISTRY-US, V33, P11692, DOI 10.1021/bi00205a004; LopezBeltran EA, 1996, J BIOL CHEM, V271, P10648, DOI 10.1074/jbc.271.18.10648; MASSON S, 1992, BIOCHEMISTRY-US, V31, P7488, DOI 10.1021/bi00148a008; McAlisterHenn L, 1997, PROG NUCLEIC ACID RE, V57, P317, DOI 10.1016/S0079-6603(08)60285-8; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; Mitchell CG, 1996, BIOCHEM J, V313, P769, DOI 10.1042/bj3130769; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCALETTAR BA, 1991, P NATL ACAD SCI USA, V88, P8057, DOI 10.1073/pnas.88.18.8057; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; SRERE PA, 1993, BIOL CHEM H-S, V374, P833; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRERE PA, 1995, ADV MOL CEL, V11, P125; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; SUISSA M, 1984, EMBO J, V3, P1781; SUMEGI B, 1990, BIOCHEMISTRY-US, V29, P9106, DOI 10.1021/bi00491a002; SUMEGI B, 1993, BIOCHEMISTRY-US, V32, P12725, DOI 10.1021/bi00210a022; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Velot C, 1997, BIOCHEMISTRY-US, V36, P14271, DOI 10.1021/bi972011j; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WESTERHOFF HV, 1992, CURR TOP CELL REGUL, V33, P361; Williams SP, 1997, BIOPHYS J, V72, P490, DOI 10.1016/S0006-3495(97)78690-9; WILLIAMS SP, 1993, BIOCHEMISTRY-US, V32, P4895, DOI 10.1021/bi00069a026	46	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3941	3945		10.1074/jbc.274.7.3941	http://dx.doi.org/10.1074/jbc.274.7.3941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933583	hybrid			2022-12-25	WOS:000078575500007
J	Kwong, PD; Wyatt, R; Desjardins, E; Robinson, J; Culp, JS; Hellmig, BD; Sweet, RW; Sodroski, J; Hendrickson, WA				Kwong, PD; Wyatt, R; Desjardins, E; Robinson, J; Culp, JS; Hellmig, BD; Sweet, RW; Sodroski, J; Hendrickson, WA			Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN CRYSTALLIZATION; HUMAN CD4; VARIABLE REGIONS; ATOMIC-STRUCTURE; BINDING; RECEPTOR; RETROVIRUS; INFECTION; ANTIBODY	The extensive glycosylation and conformational mobility of gp120, the envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1), pose formidable barriers for crystallization. To surmount these difficulties, we used probability analysis to determine the most effective crystallization approach and derive equations which show that a strategy, which we term variational crystallization, substantially enhances the overall probability of crystallization for gp120, Variational crystallization focuses on protein modification as opposed to crystallization screening. Multiple variants of gp120 were analyzed with an iterative cycle involving a limited set of crystallization conditions and biochemical feedback on protease sensitivity, glycosylation status, and monoclonal antibody binding. Sources of likely conformational heterogeneity such as N-linked carbohydrates, flexible or mobile N and C termini, and variable internal loops were reduced or eliminated, and ligands such as CD4 and antigen-binding fragments (Fabs) of monoclonal antibodies were used to restrict conformational mobility as well as to alter the crystallization surface. Through successive cycles of manipulation involving 18 different variants, we succeeded in growing six different types of gp120 crystals. One of these, a ternary complex composed of gp120, its receptor CD4, and the Fab of the human neutralizing monoclonal antibody 17b, diffracts to a minimum Bragg spacing of at least 2.2 Angstrom and is suitable for structural analysis.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Dana Farber Canc Inst, Div Human Retrovirol, Boston, MA 02115 USA; Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Tulane University; GlaxoSmithKline	Kwong, PD (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Binley JM, 1998, AIDS RES HUM RETROV, V14, P191, DOI 10.1089/aid.1998.14.191; BRAND CM, 1972, NATURE, V87, P713; CARTER CW, 1979, J BIOL CHEM, V254, P2219; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; CHEN SX, 1992, P NATL ACAD SCI USA, V89, P5872, DOI 10.1073/pnas.89.13.5872; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUCRUIX A, CRYSTALLIZATION NUCL; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JARVEST RL, 1993, BIOORG MED CHEM LETT, V3, P2851, DOI 10.1016/S0960-894X(01)80778-2; JORDAN SR, 1985, SCIENCE, V230, P1383; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KELDERS HA, 1987, PROTEIN ENG, V1, P301, DOI 10.1093/protein/1.4.301; KENDREW JC, 1956, P ROY SOC          A, V238, P305; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kovari LC, 1995, STRUCTURE, V3, P1291, DOI 10.1016/S0969-2126(01)00266-0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; KWONG PD, 1999, IN PRESS J APPL CRYS; LANGEDIJK JPM, 1992, ARCH VIROL, V126, P129, DOI 10.1007/BF01309690; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUSTBADER JW, 1989, BIOCHEMISTRY-US, V28, P9239, DOI 10.1021/bi00450a001; LUSTY CJ, 1999, IN PRESS J APPL CRYS; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MORRIS DW, 1989, BIOTECHNIQUES, V7, P522; MYERS G, 1996, HUMAN RETROVIRUSES A; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STURA EA, 1992, J CRYST GROWTH, V122, P273, DOI 10.1016/0022-0248(92)90256-I; TEETER MM, 1979, J MOL BIOL, V127, P219, DOI 10.1016/0022-2836(79)90242-0; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; THALI M, 1991, J VIROL, V65, P6188, DOI 10.1128/JVI.65.11.6188-6193.1991; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WUKOVITZ SW, 1995, NAT STRUCT BIOL, V2, P1062, DOI 10.1038/nsb1295-1062; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150	63	101	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4115	4123		10.1074/jbc.274.7.4115	http://dx.doi.org/10.1074/jbc.274.7.4115			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933605	hybrid			2022-12-25	WOS:000078575500029
J	Ritz-Laser, B; Estreicher, A; Klages, N; Saule, S; Philippe, J				Ritz-Laser, B; Estreicher, A; Klages, N; Saule, S; Philippe, J			Pax-6 and Cdx-2/3 interact to activate glucagon gene expression on the G(1) control element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEIN CDX-2/3; CELL-SPECIFIC EXPRESSION; HOMEOBOX-CONTAINING GENE; PROMOTER ELEMENT; DNA-BINDING; INSULIN GENE; TRANSCRIPTION; IDENTIFICATION; SEQUENCES; CLONING	The promoter element G(1), critical for alpha-cell-specific expression of the glucagon gene, contains two AT-rich sequences important for transcriptional activity. Pax-6, a paired homeodomain protein previously shown to be required for normal alpha-cell development and to interact with the enhancer element G(3) of the glucagon gene, binds as a monomer to the distal AT-rich site of G(1), However, although the paired domain of Pax-6 is sufficient for interaction with the G(3) element, the paired domain and the homeodomain are required for high affinity binding to G(1), In addition to monomer formation, Pax-6 interacts with Cdx-2/3, a caudal-related homeodomain protein binding to the proximal AT-rich site, to form a heterodimer on G(1), Both proteins are capable of directly interacting in the absence of DNA. In BHK-21 cells, Pax-6 activates glucagon gene transcription both through G(1) and G(3), and heterodimerization with Cdx-2/3 on G(1) leads to more than additive transcriptional activation, In glucagon-producing cells, both G(3) and G(1) are critical for basal transcription, and the Pax-6 and Cdx-2/3 binding sites are required for activation. We conclude that Pax-6 is not only critical for cu-cell development but also for glucagon gene transcription by its independent interaction with the two DNA control elements, G(1) and G(3).	Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland; Inst Pasteur, CNRS EP56, Lab Differentiat Cellulaire & Mol, F-59019 Lille, France	University of Geneva; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Ritz-Laser, B (corresponding author), Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland.			Estreicher, Anne/0000-0001-6828-2508				Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Heller RS, 1998, GASTROENTEROLOGY, V115, P381, DOI 10.1016/S0016-5085(98)70204-5; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; Jin TR, 1996, MOL CELL BIOL, V16, P19; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1991, DNA CELL BIOL, V10, P119, DOI 10.1089/dna.1991.10.119; PHILIPPE J, 1991, ENDOCR REV, V12, P252, DOI 10.1210/edrv-12-3-252; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584	29	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4124	4132		10.1074/jbc.274.7.4124	http://dx.doi.org/10.1074/jbc.274.7.4124			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933606	hybrid			2022-12-25	WOS:000078575500030
J	Scholz, A; Truss, M; Beato, M				Scholz, A; Truss, M; Beato, M			Hormone-dependent recruitment of NF-Y to the uteroglobin gene enhancer associated with chromatin remodeling in rabbit endometrial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR VIRUS PROMOTER; LIGATION MEDIATED PCR; BINDING FACTOR CBF; TRANSCRIPTIONAL ACTIVATION; MMTV PROMOTER; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; DNA-BINDING; FUNCTIONAL DOMAINS	Expression of the rabbit uteroglobin gene is hormonally induced in cells of the endometrial epithelium during the preimplantation phase of pregnancy. Here we show that progesterone activation of the gene is mediated by two clusters of hormone responsive elements located between 2.4 and 2.7 kilobase pairs upstream of the transcriptional start site. Between these two clusters, genomic footprinting studies in the intact endometrial epithelium reveal the hormone-inducible occupancy of several cis-acting elements. One of the protected elements shows sequence homology to the consensus binding site of the transcription factor NF-Y, which binds to the element in gel shift experiments. This uteroglobin Y box is essential for enhancer activity in transient transfection experiments with endometrial and non-endometrial cell lines, in accordance with the ubiquitous expression of NF-Y. To understand why binding of this ubiquitous factor to the uteroglobin Y box in endometrium depends on hormone induction, we examined the chromatin structure of the relevant gene region. In the uninduced state, the enhancer region appears to be organized into positioned nucleosomes. Upon hormone induction, this nucleosomal pattern is lost and the enhancer region becomes hypersensitive to nucleases, suggesting that a hormone-induced change in the local chromatin structure unmasks previously unaccessible binding sites for transcription factors. Our results emphasize the limitations of using transient transfection assays for the functional analysis of cis-acting elements and underline the need for including the native chromatin organization in this kind of studies.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg	Beato, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	beato@imt.uni-marburg.de	Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BEATO M, 1976, EUR J BIOCHEM, V64, P15, DOI 10.1111/j.1432-1033.1976.tb10270.x; BEATO M, 1983, REGULATION GENE EXPR, P151; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BEIER HM, 1975, CELL TISSUE RES, V165, P1; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BLENDY JA, 1995, RECENT PROG HORM RES, V50, P97; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BONDY KL, 1993, NUCLEIC ACIDS RES, V21, P5277, DOI 10.1093/nar/21.22.5277; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; CARTWRIGHT IL, 1983, P NATL ACAD SCI-BIOL, V80, P3213, DOI 10.1073/pnas.80.11.3213; CATO ACB, 1984, EMBO J, V3, P2771, DOI 10.1002/j.1460-2075.1984.tb02208.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Eisfeld K, 1997, NUCLEIC ACIDS RES, V25, P3733, DOI 10.1093/nar/25.18.3733; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HEINS B, 1981, MOL CELL ENDOCRINOL, V21, P139, DOI 10.1016/0303-7207(81)90051-4; HELFTENBEIN G, 1993, ONCOGENE, V8, P2075; HELFTENBEIN G, 1991, ANN NY ACAD SCI, V622, P69; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAY E, 1972, BIOCHIM BIOPHYS ACTA, V271, P436, DOI 10.1016/0005-2795(72)90219-X; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENNE C, 1982, P NATL ACAD SCI-BIOL, V79, P4853, DOI 10.1073/pnas.79.16.4853; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUKHERJEE AB, 1993, MOL CELL ENDOCRINOL, V94, pR15, DOI 10.1016/0303-7207(93)90176-K; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; NEULEN J, 1982, MOL CELL ENDOCRINOL, V25, P183, DOI 10.1016/0303-7207(82)90051-X; NISHIDA M, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P1103; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOSKE IG, 1976, BIOL REPROD, V15, P704, DOI 10.1095/biolreprod15.5.704; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RAJKUMAR K, 1983, ENDOCRINOLOGY, V112, P1490, DOI 10.1210/endo-112-4-1490; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVOURET JF, 1980, J BIOL CHEM, V255, P4131; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; SEYFRED MA, 1990, MOL ENDOCRINOL, V4, P1226, DOI 10.1210/mend-4-8-1226; SHEN XZ, 1983, ENDOCRINOLOGY, V112, P871, DOI 10.1210/endo-112-3-871; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; Spangenberg C, 1998, J MOL BIOL, V278, P725, DOI 10.1006/jmbi.1998.1718; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P1632, DOI 10.1210/endo-119-4-1632; WHITSON GL, 1974, SCIENCE, V183, P668, DOI 10.1126/science.183.4125.668; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	86	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4017	4026		10.1074/jbc.274.7.4017	http://dx.doi.org/10.1074/jbc.274.7.4017			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933593	hybrid			2022-12-25	WOS:000078575500017
J	Tanaka, K; Horiguchi, K; Yoshida, T; Takeda, M; Fujisawa, H; Takeuchi, K; Umeda, M; Kato, S; Ihara, S; Nagata, S; Fukui, Y				Tanaka, K; Horiguchi, K; Yoshida, T; Takeda, M; Fujisawa, H; Takeuchi, K; Umeda, M; Kato, S; Ihara, S; Nagata, S; Fukui, Y			Evidence that a phosphatidylinositol 3,4,5-trisphosphate-binding protein can function in nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE THYMUS; KINASE-B; 3-KINASE; CELLS; ACTIVATION; ALPHA; PURIFICATION; RECEPTOR; SYSTEM; BRAIN	PIP3BP is a phosphatidylinositol 3,4,5-trisphosphate-binding protein (PIP3BP) abundant in brain, containing a zinc: finger motif and two pleckstrin homology (PH) domains. Staining of rat brain cells with anti-PIP3BP antibody and determination of localization of PIP3BP fused to the green fluorescent protein (GFP-PIP3BP) revealed that PIP3BP was targeted to the nucleus. Targeting was dependent on a putative nuclear localization signal in PIP3BP. Generation of PIP3 in the nucleus was detected in H2O2-treated 293T cells, nerve growth factor (NGF)-treated PC12 cells, and platelet-derived growth factor (PDGF)-treated NIH 3T3 cells. Translocation of phosphatidylinositol 3-kinase (PI 3-kinase) to the nucleus and enhanced activity of PI 3-kinase in the nucleus fraction were observed after H2O2 treatment of 293T cells, suggesting that PI 3-kinase can be activated in the nucleus as well as in the membrane after appropriate stimulation of the cells, Go-expression of the constitutively active PI 3-kinase with PIP3BP resulted in exportation of the protein from the nucleus to the cytoplasm, suggesting that PIP3BP can function as a PIP3-binding protein in the intact cells. These results imply that there may be an unknown function of PI 3-kinase in the nucleus.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, Tokyo 1130032, Japan; Inst Environm Toxicol, Div Toxicol, Mitsukaido, Ibaraki 3030043, Japan; Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Fukui, Y (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ayfukui@hongo.ecc.u-tokyo.ac.jp	Yoshida, Toshinori/B-7255-2015; Fukui, Yasuhisa/E-8806-2010; Nagata, Satoshi/B-5781-2008	Nagata, Satoshi/0000-0001-9156-5215; Yamada, Kaori/0000-0003-4075-9866				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; FUKUI Y, 1991, ONCOGENE, V6, P407; Fukui Y, 1998, J BIOCHEM-TOKYO, V124, P1; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kabuyama Y, 1996, EUR J BIOCHEM, V238, P350, DOI 10.1111/j.1432-1033.1996.0350z.x; Kita Y, 1998, J CELL SCI, V111, P907; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NAGATA S, 1991, HYBRIDOMA, V10, P317, DOI 10.1089/hyb.1991.10.317; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; Shirai T, 1998, BBA-MOL CELL RES, V1402, P292, DOI 10.1016/S0167-4889(98)00014-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Yoshida T, 1998, TOXICOL PATHOL, V26, P411, DOI 10.1177/019262339802600316	30	115	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3919	3922		10.1074/jbc.274.7.3919	http://dx.doi.org/10.1074/jbc.274.7.3919			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933577	hybrid			2022-12-25	WOS:000078575500001
J	Tlapak-Simmons, VL; Baggenstoss, BA; Kumari, K; Heldermon, C; Weigel, PH				Tlapak-Simmons, VL; Baggenstoss, BA; Kumari, K; Heldermon, C; Weigel, PH			Kinetic characterization of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; OLIGODENDROGLIOMA CELLS; BINDING-PROTEINS; ACID SYNTHASE; DG42 GENE; XENOPUS; IDENTIFICATION; SOLUBILIZATION; EXPRESSION; SYNTHETASE	The two hyaluronan synthases (HASs) from Streptococcus pyogenes (spHAS) and Streptococcus equisimilis (seHAS) were expressed in Escherichia colt as recombinant proteins containing His(6) tails, The accompanying paper has described the purification and lipid dependence of both HASs, their preference for cardiolipin, and their stability during storage (Tlapak-Simmons, V. L., Baggenstoss, B. A. Clyne, T., and Weigel, P. H. (1999) J. Biol. Chem. 274, 4239-4245). Kinetic characterization of the enzymes in isolated membranes gave K-m values for UDP-GlcUA of 40 +/- 4 mu M for spHAS and 51 +/- 5 mu M for seHAS, In both cases, the V-max profiles at various concentrations of UDP-GlcNAc were hyperbolic, with no evidence of cooperativity. In contrast, membrane-bound spHAS, but not seHAS, showed sigmoidal behavior as the UDP-GlcNAc concentration was increased, with a Hill number of similar to 2, indicating significant cooperativity, The Hill number for UDP-GlcNAc utilization by seHAS was I, confirming the lack of cooperativity for UDP-GlcNAc in this enzyme. The K-m values for UDP-GlcNAc were 60 +/- 7 mu M for seHAS and 149 +/- 3 mu M for spHAS in the isolated membranes. The kinetic characteristics of the two affinity-purified HAS enzymes were assessed in the presence of cardiolipin after 8-9 days of storage at -80 degrees C without cardiolipin. With increasing storage time, the enzymes showed a gradual increase in their K-m values for both substrates and a decrease in V-max. Even in the presence of cardiolipin, the detergent-solubilized; purified HASs had substantially higher K-m values for both substrates than the membrane-bound enzymes, The KUDP-GlcUA for purified spHAS and seHAS increased 2-4-fold. The KUDP-GlcNAc for spHAS and seHAS increased 4- and 5-fold, respectively. Despite the higher K-m values, the V-max values for the purified HASs were only similar to 50% lower than those for the membrane-bound enzymes. Significantly, purified spHAS displayed the same cooperative interaction with UDP-GlcNAc (n(H) similar to 2), whereas purified seHAS showed no cooperativity.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu		Heldermon, Coy/0000-0002-2148-2868	NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 1983, J SURG RES, V35, P410, DOI 10.1016/0022-4804(83)90030-6; Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; BALAZS EA, 1993, J RHEUMATOL, V20, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cartee RT, 1998, GLYCOBIOLOGY, V8, P1123; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DeAngelis PL, 1995, DEV BIOL STAND, V85, P225; EVERED D, 1989, CIBA F SYMP, V143, P1; FEINBERG RN, 1983, SCIENCE, V220, P1177, DOI 10.1126/science.6857242; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; GRESSNER AM, 1995, DIGESTION, V56, P335, DOI 10.1159/000201257; Harwood C., 1990, MOL BIOL METHODS BAC, P1; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAURENT TC, 1987, ACTA OTO-LARYNGOL, P7; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; Meyer K, 1934, J BIOL CHEM, V107, P629; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; NG KF, 1989, J BIOL CHEM, V264, P11776; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SEMINO AM, 1996, P NATL ACAD SCI USA, V93, P47; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; TlapakSimmons VL, 1997, GLYCOBIOLOGY, V7, P71; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; TURLEY EA, 1985, J CELL SCI, V78, P133; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	51	56	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4246	4253		10.1074/jbc.274.7.4246	http://dx.doi.org/10.1074/jbc.274.7.4246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933624	hybrid			2022-12-25	WOS:000078575500048
J	Chen, YR; Gunther, MR; Mason, RP				Chen, YR; Gunther, MR; Mason, RP			An electron spin resonance spin-trapping investigation of the free radicals formed by the reaction of mitochondrial cytochrome c oxidase with H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBATE-INDUCED PEROXIDATION; RAT-LIVER MITOCHONDRIA; BOVINE SERUM-ALBUMIN; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; ESCHERICHIA-COLI; NITRIC-OXIDE; FATTY-ACIDS; OXYGEN; PROTEIN	The reaction of purified bovine mitochondrial cytochrome c oxidase (CcO) and hydrogen peroxide was studied using the ESR spin-trapping technique. A protein-centered radical adduct was trapped by 5,5-dimethyl-1-pyrroline N-oxide and was assigned to a thiyl radical adduct based on its hyperfine coupling constants of a(N) = 14.7 G and a(beta)(H) = 15.7 G. The ESR spectra obtained using the nitroso spin traps 3,5-dibromo-4-nitrosobenzenesulfonic acid (DBNBS) and 2-methyl-2-nitrosopropane (MNP) indicated that both DBNBS/.CcO and MNP/.CcO radical adducts are immobilized nitroxides formed by the trapping of protein-derived radicals. Alkylation of the free thiols on the enzyme with N-ethylmaleimide (NEM) prevented 5,5 dimethyl-1-pyrroline N-oxide adduct formation and changed the spectra of the MNP and DBNBS radical adducts, Nonspecific protease treatment of MNP-d(9)/(NEM)-N-.-CcO converted its spectrum from that of an immobilized nitroxide to an isotropic three-line spectrum characteristic of rapid molecular motion, Super-hyperfine couplings were detected in this spectrum and assigned to the MNP/.tyrosyl adduct(s), The inhibition of either CcO or NEM-CcO with potassium cyanide prevented detectable MNP adduct formation, indicating heme involvement in the reaction. The results indicate that one or more cysteine residues are the preferred reductant of the presumed ferryl porphyrin cation radical residue intermediate. When the cysteine residues are blocked with NEM, one or more tyrosine residues become the preferred reductant, forming the tyrosyl radical.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chen, YR (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	chen6@niehs.nih.gov	Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; Brigellius R., 1985, OXIDATIVE STRESS, P243; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; Deterding LJ, 1998, J BIOL CHEM, V273, P12863, DOI 10.1074/jbc.273.21.12863; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; GRACEFFA P, 1983, ARCH BIOCHEM BIOPHYS, V225, P802, DOI 10.1016/0003-9861(83)90092-9; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HE DY, 1994, J BIOL CHEM, V269, P2292; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KALYANARAMAN B, 1979, TETRAHEDRON LETT, P4809; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KAUR H, 1981, J CHEM SOC CHEM COMM, P142, DOI 10.1039/c39810000142; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; Konstantinov AA, 1998, BBA-BIOENERGETICS, V1363, P11, DOI 10.1016/S0005-2728(97)00087-X; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P8580, DOI 10.1021/bi952096t; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Prutz W A, 1986, Free Radic Res Commun, V2, P69, DOI 10.3109/10715768609088056; PRUTZ WA, 1990, NATO ADV SCI I A-LIF, V197, P389; PRUTZ WA, 1987, RADIAT RES, V2, P134; REINHECKEL T, 1995, BBA-BIOMEMBRANES, V1239, P45, DOI 10.1016/0005-2736(95)00142-P; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; SCHONEICH C, 1989, BIOCHEM BIOPH RES CO, V161, P113, DOI 10.1016/0006-291X(89)91568-4; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L; THOMAS JW, 1994, BIOCHEMISTRY-US, V33, P13013, DOI 10.1021/bi00248a010; TRUMPER L, 1988, BIOMED BIOCHIM ACTA, V47, P933; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; Verkhovsky MI, 1996, P NATL ACAD SCI USA, V93, P12235, DOI 10.1073/pnas.93.22.12235; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WISWEDEL I, 1988, BIOCHIM BIOPHYS ACTA, V934, P80, DOI 10.1016/0005-2728(88)90122-3; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; YU CA, 1975, J BIOL CHEM, V250, P1383; Zaslavsky D, 1998, BIOCHEMISTRY-US, V37, P3062, DOI 10.1021/bi971877m; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	53	69	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3308	3314		10.1074/jbc.274.6.3308	http://dx.doi.org/10.1074/jbc.274.6.3308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920871	hybrid			2022-12-25	WOS:000078428200011
J	Garton, AJ; Tonks, NK				Garton, AJ; Tonks, NK			Regulation of fibroblast motility by the protein tyrosine phosphatase PTP-PEST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; SWISS 3T3 CELLS; PHOSPHOTYROSINE-CONTAINING PROTEINS; V-CRK ONCOGENE; GROWTH-FACTOR; SUBSTRATE P130(CAS); SH3 DOMAINS; SRC KINASE; C-SRC	The protein tyrosine phosphatase PTP-PEST is a cytosolic enzyme that displays a remarkable degree of selectivity for tyrosine-phosphorylated p130(Cas) as a substrate, both in vitro and in intact cells, We have investigated the physiological role of PTP-PEST using Rat1 fibroblast-derived stable cell lines that we have engineered to overexpress PTP-PEST. These cell lines exhibit normal levels of tyrosine phosphorylation of the majority of proteins but have significantly lower levels of tyrosine phosphorylation of p130(Cas) than control cells. Initial cellular events occurring following integrin-mediated attachment to fibronectin (cell attachment and spreading) are essentially unchanged in cells overexpressing PTP-PEST; similarly, the extent and time course of mitogen-activated protein kinase activation in response to integrin engagement is unchanged. In contrast, the reduced phosphorylation state of p130(Cas) is associated with a considerably reduced rate of cell migration and a failure of cells overexpressing PTP-PEST to accomplish the normally observed redistribution of p130(Cas) to the leading edge of migrating cells. Furthermore, cells overexpressing PTP-PEST demonstrate significantly reduced levels of association of p130(Cas) with the Crk adaptor protein. Our results suggest that one physiological role of PTP-PEST is to dephosphorylate p130(Cas), thereby controlling tyrosine phosphorylation dependent signaling events downstream of p130(Cas) and regulating cell migration.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tonks@cshl.org			NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; FINCHAM VJ, EMBO J, V1781, P98; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HABIB T, 1994, J BIOL CHEM, V269, P25243; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; ILLC D, 1995, NATURE, V377, P539; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nievers MG, 1997, J CELL SCI, V110, P389; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; RANKIN S, 1994, J BIOL CHEM, V269, P704; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YANG Q, 1993, J BIOL CHEM, V268, P6622; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	66	115	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3811	3818		10.1074/jbc.274.6.3811	http://dx.doi.org/10.1074/jbc.274.6.3811			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920935	hybrid			2022-12-25	WOS:000078428200075
J	Hong, H; Darimont, BD; Ma, H; Yang, L; Yamamoto, KR; Stallcup, MR				Hong, H; Darimont, BD; Ma, H; Yang, L; Yamamoto, KR; Stallcup, MR			An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; RETINOIC ACID; ACTIVATION; SUPERFAMILY; PROTEIN; SRC-1	Transcriptional coactivators of the p160 family (SRC-1, GRIP1, and p/CIP) associate with DNA-bound nuclear receptors (NRs) and help the NRs to recruit an active transcription initiation complex to the promoters of target genes. Previous studies have demonstrated the importance of the NR interaction domain (NID) of p160 proteins containing three NR box motifs (LXXLL) for the interaction with the hormone-binding domains of NRs, Here we report that, in addition to NID, another region of coactivator GRIP1 (amino acids 1011-1121), called the auxiliary NID (NIDaux), is required in vitro and in vivo for efficient interaction with a subset of NRs, including the glucocorticoid receptor (GR), androgen receptor, and retinoic acid receptor cu, A second group of NRs, which includes the progesterone receptor, retinoid X receptor alpha, thyroid hormone receptor beta 1, and vitamin D receptor, required only NID for efficient interaction. For binding to GR, the MD and NIDaux of GRIP1 must act in cis, but deletion of up to 144 amino acids between the two regions did not reduce binding efficiency. Amino acids 1011-1121 of GRIP1 also contain a p300 interaction domain, but mutational analysis indicated that the p300 interaction function within this region is separable from the ability to contribute to GR hormone-binding domain binding. SRC-1 lacks an NIDaux activity equivalent to that in GRIP1.	Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of Southern California; University of California System; University of California San Francisco	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R37CA020535, R01CA020535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NCI NIH HHS [CA20535] Funding Source: Medline; NIDDK NIH HHS [DK43093] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN DG, 1994, MOL ENDOCRINOL, V8, P422, DOI 10.1210/me.8.4.422; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	48	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3496	3502		10.1074/jbc.274.6.3496	http://dx.doi.org/10.1074/jbc.274.6.3496			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920895	hybrid			2022-12-25	WOS:000078428200035
J	Murakami, A; Kimura, K; Nakano, A				Murakami, A; Kimura, K; Nakano, A			The inactive form of a yeast casein kinase I suppresses the secretory defect of the sec12 mutant - Implication of negative regulation by the Hrr25 kinase in the vesicle budding from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MEMBRANE GLYCOPROTEIN; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; STATIONARY-PHASE; GOLGI-APPARATUS; MAP KINASE; TRANSPORT; GENE	Sec12p is the guanine nucleotide exchange factor of Sari GTPase and functions at the very upstream in the vesicle budding reactions from the endoplasmic reticulum (ER). We previously identified three yeast loci, RST1, RST2, and RST3, whose mutations suppressed the temperature-sensitive growth of the sec12-4 mutant (Nakano, A. (1996) J. Biochem. (Tokyo) 120, 642-646). In the present study, we cloned the wild-type RST2 gene by complementation of the cold-sensitive phenotype of the rst2-1 mutant. RST2 turned out to be identical to HRR25, a gene encoding a dual-specificity casein kinase I in yeast. The rst2-1 mutation, which is now renamed hrr25-2, was due to the T176I amino acid replacement in the kinase domain. This mutation remedied not only the temperature-sensitive growth but also the defect of ER-to-Golgi protein transport of sec12. Immunoprecipitation of the hemagglutinin-tagged Hrr25-2 protein and a subsequent protein kinase assay showed that the kinase activity of the mutant protein was markedly reduced. The overproduction of another kinase-minus mutant of Hrr25p (Hrr25p K38A) slightly suppressed the growth defect of sec12-4 as well. These observations suggest that the reduction of the kinase activity in the mutant protein is important for the suppression of sec12. We propose that Hrr25p negatively regulates the vesicle budding from the ER.	RIKEN, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan; Natl Food Res Inst, Genet Engn Lab, Tsukuba, Ibaraki 305, Japan	RIKEN; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Nakano, A (corresponding author), RIKEN, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan.	nakano@postman.riken.go.jp	Nakano, Akihiko/A-6420-2016; Nakano, Akihiko/G-4942-2014; Kimura, Keitarou/B-1589-2010; Nakano, Akihiko/C-6185-2009	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X; Kimura, Keitarou/0000-0003-4641-4041; Murakami-Sekimata, Akiko/0000-0002-9417-2377				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Nakano A, 1996, J BIOCHEM-TOKYO, V120, P642; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWELS J, 1991, P NATL ACAD SCI USA, V88, P9548; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VANCURA A, 1994, J BIOL CHEM, V269, P19271; Wang XM, 1996, MOL CELL BIOL, V16, P5375; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	34	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3804	3810		10.1074/jbc.274.6.3804	http://dx.doi.org/10.1074/jbc.274.6.3804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920934	hybrid			2022-12-25	WOS:000078428200074
J	Shahrestanifar, M; Fan, XM; Manning, DR				Shahrestanifar, M; Fan, XM; Manning, DR			Lysophosphatidic acid activates NF-kappa B in fibroblasts - A requirement for multiple inputs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; RIBOSOMAL S6 KINASE; SWISS 3T3 CELLS; GROWTH-FACTOR; SIGNALING PATHWAYS; MOLECULAR-CLONING; RAT-1 FIBROBLASTS; GENE-EXPRESSION; COUPLED PATHWAY	Lysophosphatidic acid (LPA) is a growth factor that exerts a number of well characterized biological actions on fibroblasts and other cells. In the present study, we investigated the possibility that LPA activates the transcription factor NF-kappa B. NF-kappa B is a target of cytokines, but its activation by other classes of agonists has raised considerable interest in the control of processes such as inflammation and wound healing through varied mechanisms. We find that LPA causes a marked activation of NF-kappa B in Swiss 3T3 fibroblasts as determined by the degradation of I kappa B-alpha in the cytosol and the emergence of kappa B binding activity in nuclear extracts. The EC50 for activation of NF-kappa B is 1-5 mu M, a range similar to that reported for reinitiation of DNA synthesis and activation of the serum response element. Activation of NF-kappa B is attenuated by pertussis toxin and inhibitors of protein kinase C, and it is completely blocked by the Ca2+ chelator BAPTA-AM, The combination of phorbol ester and thapsigargin promotes an activation comparable with that of LPA Activation by LPA is additionally inhibited by tyrphostin A25 but not genistein or AG1478, indicating a selective utilization of protein-tyrosine kinases, and by certain antioxidants, implying a role for reactive oxygen species. The activation is also inhibited by tricyclodecan-9-yl-xanthogenate (D609), implying a requirement for hydrolysis of phosphatidylcholine. The data demonstrate the utilization of multiple pathways in the activation of NF-kappa B by LPA, not inconsistent with the relevance of several families of GTP-binding regulatory proteins.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	manning@pharm.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1990, J BIOL CHEM, V265, P12232; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MARI B, 1994, J BIOL CHEM, V269, P8517; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NOBES CD, 1995, J CELL SCI, V108, P225; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; PERKINS LM, 1994, NUCLEIC ACIDS RES, V22, P450, DOI 10.1093/nar/22.3.450; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHUTZE S, 1992, CELL, V71, P765; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3828	3833		10.1074/jbc.274.6.3828	http://dx.doi.org/10.1074/jbc.274.6.3828			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920937	hybrid			2022-12-25	WOS:000078428200077
J	Werten, S; Wechselberger, R; Boelens, R; van der Vliet, PC; Kaptein, R				Werten, S; Wechselberger, R; Boelens, R; van der Vliet, PC; Kaptein, R			Identification of the single-stranded DNA binding surface of the transcriptional coactivator PC4 by NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSED-FIELD GRADIENTS; RELAXATION; DOMAIN; SPECTROSCOPY; SENSITIVITY; ACTIVATION; HOMOLOGY	The C-terminal domain of the eukaryotic transcriptional cofactor PC4 (PC4(CTD)) is known to bind with nanomolar affinity to single-stranded (ss)DNA. Here, NMR is used to study DNA binding by this domain in more detail. Amide resonance shifts that were observed in a (HN)-H-1-N-15-HSQC-monitored titration of N-15-labeled protein with the oligonucleotide dT(18) indicate that binding of the nucleic acid occurs by means of two anti-parallel channels that were previously identified in the PC4(CTD) crystal structure. The beta-sheets and loops that make up these channels exhibit above average flexibility in the absence of ssDNA, which is reflected in higher values of T-1 rho, reduced heteronuclear nuclear Overhauser effects and faster deuterium exchange rates for the amides in this region. Upon ssDNA binding, this excess flexibility is significantly reduced. The binding of ssDNA by symmetry-related channels reported here provides a structural rationale for the preference of PC4(CTD) for juxtaposed single-stranded regions (e.g. in heteroduplexes) observed in earlier work.	Univ Utrecht, Bijvoet Centrum Biomol Onderzoek, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Lab Fysiol Chem, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University	Kaptein, R (corresponding author), Univ Utrecht, Bijvoet Centrum Biomol Onderzoek, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Werten, Sebastiaan/AAU-9011-2021; Boelens, Rolf/B-4702-2009	Werten, Sebastiaan/0000-0003-2244-9688; Boelens, Rolf/0000-0002-6939-8913				BALLARD DW, 1988, J BIOL CHEM, V263, P8450; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CAVANAGH J, 1991, J MAGN RESON, V91, P429, DOI 10.1016/0022-2364(91)90209-C; Cavanagh J., 1996, PROTEIN NMR SPECTROS; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Pan ZQ, 1996, J BIOL CHEM, V271, P22111, DOI 10.1074/jbc.271.36.22111; PENG JW, 1994, METHOD ENZYMOL, V239, P563; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Suck D, 1997, NAT STRUCT BIOL, V4, P161, DOI 10.1038/nsb0397-161; Vis H, 1998, J BIOMOL NMR, V11, P265, DOI 10.1023/A:1008208615714; VIS H, 1995, Q MAGN RES BIOL MED, V2, P107; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492	28	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3693	3699		10.1074/jbc.274.6.3693	http://dx.doi.org/10.1074/jbc.274.6.3693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920920	hybrid			2022-12-25	WOS:000078428200060
J	Yamaguchi, K; Yamaguchi, F; Miyamoto, O; Sugimoto, K; Konishi, R; Hatase, O; Tokuda, M				Yamaguchi, K; Yamaguchi, F; Miyamoto, O; Sugimoto, K; Konishi, R; Hatase, O; Tokuda, M			Calbrain, a novel two EF-hand calcium-binding protein that suppresses Ca2+/calmodulin-dependent protein kinase II activity in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; CALMODULIN-BINDING; RAT-BRAIN; AUTOPHOSPHORYLATION; RELEASE; CELLS; PHOSPHORYLATION; EVOLUTIONARY; ACTIVATION; EXPRESSION	A cDNA clone that encodes a novel Ca2+-binding protein was isolated from a human brain cDNA library. The gene for this clone, termed calbrain, encodes a 70-amino acid polypeptide with a predicted molecular mass of 8.06 kDa, The analysis of deduced amino acid sequence revealed that calbrain contains two putative EF-hand motifs that show significantly high homology to those of the calmodulin (CaM) family rather than two EF-hand protein families. By Northern hybridization analysis, an approximate 1.5-kilobase pair transcript of calbrain was detected exclusively in the brain, and in situ hybridization study revealed its abundant expression in the hippocampus, habenular area in the epithalamus, and in the cerebellum. A recombinant calbrain protein showed a Ca2+ binding capacity, suggesting the functional potency as a regulator of Ca2+-mediated cellular processes. Ca2+/calmodulin-dependent kinase II, the most abundant protein kinase in the hippocampus and strongly implicated in the basic neuronal functions, was used to evaluate the physiological roles of calbrain, Studies in vitro revealed that calbrain competitively inhibited CaM binding to Ca2+/calmodulin-dependent kinase II (K-i = 129 nM) and reduced its kinase activity and autophosphorylation.	Kagawa Med Univ, Fac Med, Dept Physiol, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Fac Med, Dept Biol, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Fac Med, Dept Pharmacobioinformat, Miki, Kagawa 7610793, Japan	Kagawa University; Kagawa University; Kagawa University	Tokuda, M (corresponding author), Kagawa Med Univ, Fac Med, Dept Physiol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	tokuda@kms.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDRESSEN C, 1993, CELL TISSUE RES, V271, P181, DOI 10.1007/BF00318606; BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BRAUN K, 1990, PROG HISTOCHEM CYTOC, V21, pU1; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1980, BIOCHEM J, V258, P313; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DELORENZO RJ, 1981, CELL CALCIUM, V2, P365, DOI 10.1016/0143-4160(81)90026-9; DELORENZO RJ, 1979, P NATL ACAD SCI USA, V76, P1838, DOI 10.1073/pnas.76.4.1838; DESILVA JJR, 1991, BIOL CHEM ELEMENTS, P269; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FISCHER R, 1988, J BIOL CHEM, V263, P17055; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; GOODMAN M, 1979, J MOL EVOL, V13, P331, DOI 10.1007/BF01731373; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GuptaRoy B, 1996, J BIOL CHEM, V271, P19846, DOI 10.1074/jbc.271.33.19846; HAGIWARA T, 1991, J BIOL CHEM, V266, P16401; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HUNTER T, 1991, METHOD ENZYMOL, P274; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOSAKA T, 1993, EXP BRAIN RES, V93, P483; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; OCHIISHI T, 1993, BRAIN RES, V610, P97, DOI 10.1016/0006-8993(93)91222-E; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PARMENTIER M, 1987, EUR J BIOCHEM, V170, P207, DOI 10.1111/j.1432-1033.1987.tb13688.x; PERRET C, 1988, J MOL EVOL, V27, P351, DOI 10.1007/BF02101198; RASMUSSEN H, 1977, PHYSIOL REV, V57, P421, DOI 10.1152/physrev.1977.57.3.421; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; RUBIN RP, 1970, PHARMACOL REV, V22, P389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Segel I.H., 1975, ENZYME KINETICS; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; Siesjo B K, 1986, Adv Neurol, V44, P813; VANAMAN TC, 1980, CALCIUM CELL FUNCTIO, V1, P41; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1991, BRAIN RES, V541, P198, DOI 10.1016/0006-8993(91)91019-W; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108; Yoshimura Y, 1997, J BIOL CHEM, V272, P26354, DOI 10.1074/jbc.272.42.26354	60	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3610	3616		10.1074/jbc.274.6.3610	http://dx.doi.org/10.1074/jbc.274.6.3610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920909	hybrid			2022-12-25	WOS:000078428200049
J	Webb, SJ; Nicholson, D; Bubb, VJ; Wyllie, AH				Webb, SJ; Nicholson, D; Bubb, VJ; Wyllie, AH			Caspase-mediated cleavage of APC results in an aminoterminal fragment with an intact armadillo repeat domain	FASEB JOURNAL			English	Article						apoptosis; adenomatous polyposis coli; PARP; protein kinase; beta-catenin	APOPTOSIS IN-VITRO; BETA-CATENIN; POLY(ADP-RIBOSE) POLYMERASE; PROTEOLYTIC CLEAVAGE; PROTEIN; EXPRESSION; HOMOLOG; FAMILY; GENE	During the effector phase of apoptosis, caspase activation appears to be responsible for the distinctive structural changes of apoptosis and perhaps for some of the changes in function of the doomed cells. There is therefore interest in identifying caspase substrates and the details of the cleavage events. Here we define precisely the event responsible for generation of a stable 90 kDa fragment from the oncosuppressor protein adenomatous polyposis coli (APC), Using synthetic radiolabeled APC peptides as substrate, we demonstrate cleavage by cytosolic extracts from preapoptotic cells. This cleavage was reproduced by recombinant caspase-3 and blocked by a tetrapeptide inhibitor Ac-DEVD-CHO, which is specific for caspase-3 family members. Inhibitors specific for caspase-1 and -8 however, were less effective in blocking APC cleavage. Mutation of a candidate DNID caspase-3 target site completely abolished cleavage, This cleavage may be of biological importance since the 90 kDa fragment consists of a sequence that is highly conserved in the human, rat, mouse, Xenopus, and Drosophila APC, although wide sequence divergence is observed in Drosophila immediately carboxy-terminal to the DNID site. Furthermore, cleavage at this site separates two significant functional domains: an aminoterminal armadillo repeat and an adjacent series of beta-catenin binding sites. Further circumstantial evidence for the significance of APC-related pathways in apoptosis is provided by the observation that apoptosis also induces cleavage of beta-catenin itself, a protein known to accumulate in cells depleted in functional APC and that appears to link cell-cell signaling to changes in transcription and cell movement.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Merck Frosst Canada Inc, Pointe Claire, PQ H9R 4P8, Canada; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Edinburgh; Merck & Company; University of Cambridge	Webb, SJ (corresponding author), Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.	sjwebb01@homer.louisville.edu						Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Midgley CA, 1997, J PATHOL, V181, P426; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907	19	28	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					339	346		10.1096/fasebj.13.2.339	http://dx.doi.org/10.1096/fasebj.13.2.339			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973322				2022-12-25	WOS:000078615200014
J	Borland, G; Murphy, G; Ager, A				Borland, G; Murphy, G; Ager, A			Issue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE; TISSUE INHIBITOR; CELL-SURFACE; CHEMOTACTIC FACTORS; TERMINAL DOMAIN; MEL-14 ANTIGEN; IN-VITRO; IDENTIFICATION; DISINTEGRIN	Although the enzyme or enzymes mediating shedding of L-selectin have not yet been identified, this activity can be blocked by synthetic hydroxamic acid-based inhibitors of metalloproteinases such as Ro 31-9790, However, the endogenous matrix metalloproteinase inhibitor tissue inhibitor of metalloproteinases (TIMP)-1 does not block L-selectin shedding. Here, we report that TIMP-3, but not TIMP-2, inhibits L-selectin shedding from mouse and human lymphocytes, Jurkat T cells, and human monocytes, TIMP-3 has an IC50 of 0.3-0.4 mu M on these cell types compared with 0.7-4.8 mu M for Ro 31-9790, A metalloproteinase (tumor necrosis factor-alpha (TNF-alpha)converting enzyme; ADAM17) has recently been identified which cleaves the pro-form of TNF-alpha to produce soluble cytokine, We compared inhibition of L-selectin shedding by TIMPs and Ro 31-9790 with inhibition of TNF-alpha shedding from human monocytes, TIMP-3 inhibited TNF-alpha shedding (IC50 of 0.1 mu M), as did Ro 31-9790 (IC50 of 0.4 mu M). TIMP-2 had a partial effect, and TIMP-1 did not inhibit. This study confirms that L-selectin sheddase is a metalloproteinase, but not a matrix metalloproteinase, and investigates the relationship between shedding of L-selectin and TNF-alpha.	Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	MRC National Institute for Medical Research; University of East Anglia	Ager, A (corresponding author), Natl Inst Med Res, Div Cellular Immunol, Mill Hill,The Ridgeway, London NW7 1AA, England.			Ager, Ann/0000-0002-5763-8908				Ager A, 1997, BIOCHEM SOC T, V25, P421, DOI 10.1042/bst0250421; Allport JR, 1997, J IMMUNOL, V158, P4365; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bennett TA, 1996, J IMMUNOL, V156, P3093; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BORLAND G, 1999, IN PRESS METALLOPROT; BUHRER C, 1992, SCAND J IMMUNOL, V35, P107, DOI 10.1111/j.1365-3083.1992.tb02839.x; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; Parvathy S, 1997, BIOCHEM J, V327, P37, DOI 10.1042/bj3270037; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Solomon KA, 1997, J IMMUNOL, V159, P4524; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275	37	108	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2810	2815		10.1074/jbc.274.5.2810	http://dx.doi.org/10.1074/jbc.274.5.2810			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915814	hybrid			2022-12-25	WOS:000078319500032
J	Ellinghaus, P; Wolfrum, C; Assmann, G; Spener, F; Seedorf, U				Ellinghaus, P; Wolfrum, C; Assmann, G; Spener, F; Seedorf, U			Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPAR alpha) in sterol carrier protein 2- sterol carrier protein x-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; BINDING-PROTEIN; RAT-LIVER; HYPOLIPIDEMIC AGENTS; GENE-EXPRESSION; BETA-OXIDATION; LIGAND; EICOSANOIDS; PATHWAY; THIOLASE	We showed recently that a targeted null mutation in the murine sterol carrier protein 2-/sterol carrier protein x-gene (Scp2) leads to defective peroxisomal catabolism of 3,7,11,15-tetramethylhexadecanoic acid (phytanic acid), peroxisome proliferation, hypolipidemia, and enhanced hepatic expression of several genes that have been demonstrated to be transcriptionally regulated by the peroxisome proliferator-activated receptor alpha (PPAR alpha), As a broad range of fatty acids activates PPAR alpha in vitro, we examined whether the latter effects could be because of phytanic acid-induced activation of this transcription factor. Dietary phytol supplementation was used to modulate the concentration of phytanic acid in C57B1/6 and Scp2 (-/-) mice. We found that the serum concentrations of phytanic acid correlated well with the expression of genes encoding peroxisomal beta-oxidation enzymes and liver fatty acid-binding protein, who have all been demonstrated to contain functionally active peroxisome proliferator response elements in their promoter regions. In accordance with these findings, a stimulating effect on acyl-CoA oxidase gene expression was also observed after incubation of the rat hepatoma cell line MH1C1 with phytanic acid. Moreover, reporter gene studies revealed that phytanic acid induces the expression of a peroxisome proliferator response element-driven chloramphenicol transferase reporter gene comparable with strong peroxisome proliferators, In addition, the ability of phytanic acid to act as an inductor of PPAR alpha-dependent gene expression corresponded with high affinity binding of this dietary branched chain fatty acid to recombinant PPAR alpha, We conclude that phytanic acid can be considered as a bona fide physiological ligand of murine PPAR alpha.	Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ Munster, Inst Biochem, D-48149 Munster, Germany; Univ Munster, Inst Klin Chem & Lab Med, Zent Lab, D-48149 Munster, Germany	University of Munster; University of Munster; University of Munster	Seedorf, U (corresponding author), Univ Munster, Inst Arterioskleroseforsch, Domagkstr 3, D-48149 Munster, Germany.	seedorfu@uni-muenster.de		Wolfrum, Christian/0000-0002-3862-6805				Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; BROCARD C, 1993, BIOL CELL, V77, P37, DOI 10.1016/S0248-4900(05)80172-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DWIVEDI RS, 1989, TOXICOL PATHOL, V17, P16, DOI 10.1177/01926233890171P103; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Keller H, 1997, BIOL CHEM, V378, P651, DOI 10.1515/bchm.1997.378.7.651; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kitahara K, 1996, J Exp Ther Oncol, V1, P7; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; SCHLENIUS AK, 1995, BIOCHIM BIOPHYS ACTA, V1258, P257; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SEEDORF U, 1991, J BIOL CHEM, V266, P630; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SHA RS, 1993, J BIOL CHEM, V268, P7885; SINGH H, 1994, J BIOL CHEM, V269, P9514; Steinberg D., 1995, METABOLIC MOL BASES, P2351; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Verhoeven NM, 1998, J LIPID RES, V39, P66; Wanders RJA, 1997, BIOCHEM BIOPH RES CO, V236, P565, DOI 10.1006/bbrc.1997.7007; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353	40	142	148	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2766	2772		10.1074/jbc.274.5.2766	http://dx.doi.org/10.1074/jbc.274.5.2766			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915808	hybrid			2022-12-25	WOS:000078319500026
J	Mains, RE; Alam, MR; Johnson, RC; Darlington, DN; Back, N; Hand, TA; Eipper, BA				Mains, RE; Alam, MR; Johnson, RC; Darlington, DN; Back, N; Hand, TA; Eipper, BA			Kalirin, a multifunctional PAM COOH-terminal domain interactor protein, affects cytoskeletal organization and ACTH secretion from AtT-20 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PEPTIDE-PROCESSING ENZYME; PLECKSTRIN HOMOLOGY DOMAIN; ROUTING DETERMINANTS; SIGNALING MOLECULES; CYTOSOLIC DOMAIN; MESSENGER-RNA; TUMOR-CELLS; EXPRESSION; MEMBRANE	The production and regulated secretion of bioactive peptides require a series of lumenal enzymes to convert inactive precursors into bioactive peptides plus several cytosolic proteins to govern granule formation, maturation, translocation, and exocytosis. Peptidylglycine alpha-amidating monooxygenase (PAM), an enzyme essential for biosynthesis of many peptides, is an integral membrane protein with trafficking information in both its lumenal and cytosolic domains. Kalirin, a PAM cytosolic domain interactor protein with spectrin-like repeats and GDP/GTP exchange factor activity for Rad, is expressed with PAM in neurons but is not expressed in the anterior pituitary or AtT-20 corticotrope cells. Expression of Kalirin alters the cytoskeletal organization of Chinese hamster ovary and AtT-20 cells expressing membrane PAM. Expression of membrane PARI also alters cytoskeletal organization, demonstrating the presence of endogenous proteins that can mediate this effect. Significant amounts of both PAM and Kalirin fractionate with cytoskeletal elements. Since cytoskeletal organization is critical for exocytosis, constitutive-like and regulated secretions were evaluated. Whereas the constitutive-like secretion of adrenocorticotropic hormone (ACTH) is increased by expression of membrane PAM, regulated secretion is eliminated. Expression of Kalirin in AtT-20 cells expressing membrane PAM restores stimulated secretion of ACTH. Thus, Kalirin or its homologue may be essential for regulated secretion, and the PAM-Kalirin interaction may coordinate intragranular with cytosolic events.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Helsinki, Dept Anat, Inst Biomed, Helsinki 00014, Finland	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Helsinki	Eipper, BA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	beipper@jhmi.edu	Darlington, Daniel/CAG-1917-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032948, R01DK032948, R37DK032948] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; ALAM MR, SOC NEUR ABST; ARVAN P, 1991, J BIOL CHEM, V266, P14171; BACK N, 1995, NEUROSCI RES, V22, P267, DOI 10.1016/0168-0102(95)00903-7; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRION C, 1992, J BIOL CHEM, V267, P1477; Calakos N, 1996, PHYSIOL REV, V76, P1; Carbajal ME, 1997, ENDOCRINOLOGY, V138, P5374, DOI 10.1210/en.138.12.5374; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; CUTTITTA F, 1993, ANAT REC, V236, P87, DOI 10.1002/ar.1092360112; Darlington DN, 1997, J HISTOCHEM CYTOCHEM, V45, P1265, DOI 10.1177/002215549704500910; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DEBOLD AJ, 1973, CARDIOVASC RES, V7, P351; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; GEE P, 1993, BRAIN RES, V617, P238, DOI 10.1016/0006-8993(93)91091-6; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; Klumperman J, 1996, J NEUROSCI, V16, P7930; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MAINS RE, 1984, ENDOCRINOLOGY, V115, P1683, DOI 10.1210/endo-115-5-1683; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MAINS RE, 1991, MOL ENDOCRINOL, V5, P187, DOI 10.1210/mend-5-2-187; MARTINEZ A, 1993, J HISTOCHEM CYTOCHEM, V41, P375, DOI 10.1177/41.3.8094086; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NAIK DV, 1973, Z ZELLFORSCH MIK ANA, V142, P305, DOI 10.1007/BF00307355; NER A, 1998, NATURE, V391, P195; Oldham CD, 1997, AM J PHYSIOL-CELL PH, V273, pC1908, DOI 10.1152/ajpcell.1997.273.6.C1908; Paquet L, 1996, MOL CELL ENDOCRINOL, V120, P161, DOI 10.1016/0303-7207(96)03834-8; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHAFER MKH, 1992, J NEUROSCI, V12, P222; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; STEEL JH, 1994, CELL TISSUE RES, V276, P197, DOI 10.1007/BF00354800; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YUN HY, 1995, J BIOL CHEM, V270, P30075; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	74	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2929	2937		10.1074/jbc.274.5.2929	http://dx.doi.org/10.1074/jbc.274.5.2929			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915831	hybrid			2022-12-25	WOS:000078319500049
J	Park, PW; Broekelmann, TJ; Mecham, BR; Mecham, RP				Park, PW; Broekelmann, TJ; Mecham, BR; Mecham, RP			Characterization of the elastin binding domain in the cell-surface 25-kDa elastin-binding protein of Staphylococcus aureus (EbpS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; INTEGRIN ALPHA-4-BETA-1; STREPTOCOCCUS-PYOGENES; FIBRONECTIN RECEPTOR; COLLAGEN-BINDING; HEPARAN-SULFATE; IIICS REGION; ADHESIN; DEGRADATION; SEQUENCE	Our previous studies have established that a cell-surface 25-kDa elastin-binding protein of Staphylococcus aureus (EbpS) mediates binding of this pathogen to the extracellular matrix protein elastin. Results from binding assays examining the activity of various EbpS fragments suggested that the elastin recognition domain is contained within the first 59 amino acids. In this report, we have used functional analyses with synthetic peptides and recombinant truncated forms of EbpS to localize the elastin binding domain to a 21-amino acid region contained within residues 14-34 of EbpS. Further evidence for the importance of this domain was obtained by demonstrating that the inhibitory activity of anti-EbpS antibodies on staphylococcal elastin binding was neutralized when these antibodies were pre-absorbed with a truncated recombinant EbpS construct containing residues 1-34. Overlapping synthetic peptides corresponding to EbpS residues 14-36 were then generated and tested for elastin binding activity to define further the elastin binding domain, and results from these studies showed that sequences spanning amino acids Gln(14)-Asp(23), Asp(17)-Asp(23), and Thr(18)-Glu(34) inhibit binding of Staphylococcus aureus to elastin. Our analyses indicate that the hexameric sequence Thr(18)-Asn-Ser-His-Gln-Asp(23) is the minimal sequence common to all active synthetic peptides, proteolytic fragments, and recombinant constructs of EbpS. Furthermore, substitution of Asp(23) with Asn abrogated the blocking activity of the synthetic peptides, demonstrating the requirement for a charged amino acid at this location. The composite data indicate that staphylococcal elastin binding is mediated by a discrete domain defined by short peptide sequences in the amino-terminal extracellular region of EbpS.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.			Park, Pyong Woo/0000-0002-7979-4979	NHLBI NIH HHS [HL41926, HL53325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053325, R01HL053325, R01HL041926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BADDOUR LM, 1994, INFECT IMMUN, V62, P2143, DOI 10.1128/IAI.62.6.2143-2148.1994; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; FLETCHER TS, 1987, BIOCHEMISTRY-US, V26, P7256, DOI 10.1021/bi00397a010; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HOLDERBAUM D, 1986, INFECT IMMUN, V54, P359, DOI 10.1128/IAI.54.2.359-364.1986; HOOK M, 1990, CELL DIFFER DEV, V32, P433, DOI 10.1016/0922-3371(90)90060-A; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0; LIANG OD, 1992, INFECT IMMUN, V60, P899, DOI 10.1128/IAI.60.3.899-906.1992; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; Park PW, 1996, J INVEST DERMATOL, V106, P1075, DOI 10.1111/1523-1747.ep12339292; PARK PW, 1991, J BIOL CHEM, V266, P23399; PARK PW, 1995, INT J BIOCHEM CELL B, V27, P139, DOI 10.1016/1357-2725(94)00086-Q; Park PW, 1996, J BIOL CHEM, V271, P15803, DOI 10.1074/jbc.271.26.15803; PARK PW, 1993, INTERACTIONS ELASTIN; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RAJA RH, 1990, INFECT IMMUN, V58, P2593, DOI 10.1128/IAI.58.8.2593-2598.1990; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SJOBRING U, 1992, INFECT IMMUN, V60, P3601; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986; STEFFENSEN B, 1995, J BIOL CHEM, V270, P1155; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x	39	19	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2845	2850		10.1074/jbc.274.5.2845	http://dx.doi.org/10.1074/jbc.274.5.2845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915819	Green Submitted, hybrid			2022-12-25	WOS:000078319500037
J	Hartmann, BL; Geley, S; Loffler, M; Hattmannstorfer, R; Strasser-Wozak, EMC; Auer, B; Kofler, R				Hartmann, BL; Geley, S; Loffler, M; Hattmannstorfer, R; Strasser-Wozak, EMC; Auer, B; Kofler, R			Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis	ONCOGENE			English	Article						glucocorticoid; apoptosis; bcl-2; leukemia; tetracycline-regulated gene expression	POLY(ADP-RIBOSE) POLYMERASE CLEAVAGE; FAMILY PROTEASE INHIBITORS; CERAMIDE-INDUCED APOPTOSIS; LINE CCRF-CEM; CELL-DEATH; CYTOCHROME-C; REGULATED APOPTOSIS; THYMOCYTE APOPTOSIS; REPRESSIVE FUNCTION; DNA FRAGMENTATION	Due to their growth arrest- and apoptosis-inducing ability, glucocorticoids (GC) are widely used in the therapy of various lymphoid malignancies. Cell death is associated with activation of members of the interleukin-1 beta-converting enzyme (ICE) protease/caspase family and, is presumably prevented by the anti-apoptotic protein Bcl-2. To further address the role of Bcl-2 in CC-mediated cytotoxicity, we generated subclones of the GC-sensitive human T-cell acute lymphoblastic leukemia line CCRF-CEM, in which transgenic Bcl-2 expression is regulated by tetracycline. Up to about 48 h, exogenous Bcl-2 almost completely protected these cells from apoptosis, digestion of poly-ADP ribose polymerase (PARP) and generation of Asp-Glu-Val-Asp cleaving (DEVDase) activity. However, when the cells were cultured for another 24 h in the continuous presence of GC, they underwent massive apoptosis that was associated with DEVDase activity and PARP cleavage. Bcl-2 did not markedly affect GC-mediated growth arrest, thereby separating the anti-proliferative from the apoptosis-inducing effect of GC. Moreover, Bcl-2 did not prevent the dramatic reduction in the levels of several mRNAs observed during GC treatment, including the transgenic Bcl-2 mRNA. Thus, Bcl-2 can be placed upstream of effector caspase activation, but downstream of other GC-regulated events, such as growth arrest and the potentially critical repression of steady state levels of multiple mRNA.	Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria.							ADELMAN NE, 1983, J EXP MED, V158, P1350, DOI 10.1084/jem.158.4.1350; ALNEMRI ES, 1992, CANCER RES, V52, P491; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Benson RSP, 1998, CELL DEATH DIFFER, V5, P432, DOI 10.1038/sj.cdd.4400366; Boulakia CA, 1996, ONCOGENE, V12, P529; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Decaudin D, 1997, CANCER RES, V57, P62; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANSSTORMS RB, 1995, J STEROID BIOCHEM, V53, P1, DOI 10.1016/0960-0760(95)00034-W; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Ibrado AM, 1996, CANCER RES, V56, P4743; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Melkova Z, 1997, FEBS LETT, V403, P273, DOI 10.1016/S0014-5793(97)00065-3; MEMON SA, 1995, J IMMUNOL, V155, P4644; Messmer UK, 1996, FEBS LETT, V384, P162; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1993, BLOOD, V81, P151; Miyashita T, 1997, BIOCHEM BIOPH RES CO, V233, P781, DOI 10.1006/bbrc.1997.6559; MIYASHITA T, 1992, CANCER RES, V52, P5407; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; Moreno MB, 1996, J IMMUNOL, V157, P3845; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; POWERS JH, 1993, CANCER RES, V53, P4059; Robertson NM, 1997, CANCER RES, V57, P43; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; Shimizu S, 1996, ONCOGENE, V12, P2251; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THULASI R, 1993, J BIOL CHEM, V268, P18306; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; Urashima M, 1997, BLOOD, V90, P279; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	77	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					713	719		10.1038/sj.onc.1202339	http://dx.doi.org/10.1038/sj.onc.1202339			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989821				2022-12-25	WOS:000078394400016
J	Martincic, D; Koury, MJ; Gale, K; Whitlock, JA				Martincic, D; Koury, MJ; Gale, K; Whitlock, JA			Detection of mutations by automated fluorescence/RNA-based dideoxy fingerprinting (ARddF)	ONCOGENE			English	Article						dideoxyfingerprinting (ddF); mutation detection; p53 gene; automated sequencing	SEVERE COMBINED IMMUNODEFICIENCY; P53 GENE; DNA; DDF; POLYMORPHISMS; SEQUENCE	Dideoxy fingerprinting (ddF) is a hybrid technique which combines aspects of single strand conformational polymorphism (SSCP) and dideoxy sequencing to detect the presence of single base changes in a defined fragment of nucleic acid, ddF is no more technically demanding than SSCP, yet it is more sensitive in detecting point mutations. We describe here the adaptation of conventional ddF to an automated sequencing system using fluorescent Cy5 labeled primers. We show that automated RNA-based ddF (ARddF) has several advantages over conventional radioisotope-based ddF, including: (1) analysis of larger nucleic acid fragments (up to 10(3) bp), due to the ability to continuously analyse and compile sequencing information; (2) greater reliability for distinguishing mutant sequences from wild type sequences (particularly when the mutation leads to gain or loss of a dideoxy termination segment); (3) the use of fluorescent labeled primers, making ARddF less hazardous than methods requiring radionucleotides, The use of ARddF in conjunction with new methods for isolating RNA from nine small number of cells facilitates mutational analysis of small tissue biopsies and other limited samples, and will allow more widespread application of mutational screening in the setting of clinical diagnostic laboratories.	Vanderbilt Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Internal Med, Div Hematol, Nashville, TN 37232 USA; Vet Adm Med Ctr, Nashville, TN 37232 USA; Amersham Pharm Biotech, Piscataway, NJ 08854 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Martincic, D (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37232 USA.			Whitlock, James/0000-0002-7887-0634	NCI NIH HHS [1P30CA68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; Chen HL, 1997, MOL MED TODAY, V3, P160, DOI 10.1016/S1357-4310(97)01003-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID YB, 1988, ONCOGENE, V3, P179; Durocher F, 1996, J MED GENET, V33, P814, DOI 10.1136/jmg.33.10.814; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; Koury MJ, 1997, BLOOD, V90, P4054, DOI 10.1182/blood.V90.10.4054; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LIU Q, 1992, HUM MOL GENET, V5, P107; Martincic D, 1996, ONCOGENE, V13, P2039; MARTINCIC D, 1998, IN PRESS BLOOD; Miyata I, 1997, ENDOCR J, V44, P149, DOI 10.1507/endocrj.44.149; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Olsen LS, 1996, PHARMACOL TOXICOL, V78, P364, DOI 10.1111/j.1600-0773.1996.tb00220.x; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; *PHARM BIOT, 1996, ALF EXPR DNA SEQ US; Puck JM, 1997, BLOOD, V89, P1968; Puck JM, 1997, HUM GENET, V99, P628, DOI 10.1007/s004390050418; QUIANG L, 1995, AM J MED GENET, V60, P165; QUIANG L, 1994, PCR METH APPL, V4, P97; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Scriver C.R., 1995, METABOLIC MOL BASES, P1; Sobell JL, 1997, AM J MED GENET, V74, P44, DOI 10.1002/(SICI)1096-8628(19970221)74:1<44::AID-AJMG10>3.0.CO;2-R; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; ZAHURAK M, 1996, J NATL CANCER I, V88, P1580; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155	31	6	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					617	621		10.1038/sj.onc.1202295	http://dx.doi.org/10.1038/sj.onc.1202295			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989811				2022-12-25	WOS:000078394400006
J	Porte, D; Tuckermann, J; Becker, M; Baumann, B; Teurich, S; Higgins, T; Owen, MJ; Schorpp-Kistner, M; Angel, P				Porte, D; Tuckermann, J; Becker, M; Baumann, B; Teurich, S; Higgins, T; Owen, MJ; Schorpp-Kistner, M; Angel, P			Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone	ONCOGENE			English	Article						AP-1; collagenase; parathyroid hormone; osteoblast; Cbfa; bone development; Runt	ACUTE MYELOID-LEUKEMIA; HUMAN MATRIX METALLOPROTEINASE; RAT OSTEOBLASTIC CELLS; C-FOS GENE; TARGETED DISRUPTION; POLYOMAVIRUS ENHANCER; MOLECULAR-CLONING; PROMOTER ACTIVITY; OSTEOCALCIN GENE; MESSENGER-RNA	PTH is a major regulator of calcium homeostasis by mobilizing calcium through bone resorption, We show that the expression of collagenase-3 (MMP-13), a member of the family of matrix metalloproteinases, required for the cleavage of collagens in the bone, is increased upon PTH injection in mice. A cis-acting element in the collagenase-3 promoter was identified which, together with AP-1, is required for induction by PTH, This element contains CCACA motifs which are required for binding of the 65 kDa osteoblast-specific splice variant of Cbfa1. Introduction of mutations in this binding site that interfere with protein interaction also eliminates PTH inducibilty and transactivation by Cbfa/Runt proteins, While DNA binding activity of AP-1 is increased upon PTH treatment, high basal level of Cbfa/ Runt binding activity is detectable in untreated cells which is not further increased by PTH, suggesting that AP-1 and Cbfa1 contribute to transcriptional activation through different mechanisms, In agreement with the critical role of both proteins defined in tissue culture cells, expression of collagenase-3 is reduced in mice lacking c-fos and is completely absent in cbfa1(-/-)embryos. These data provide the first evidence for a critical role of Cbfa1, a major regulator of bone de development, in PTH-dependent processes such as bone resorption.	Deutsch Krebsforschungszentrum, Abt Signaltransdukt & Wachstumskontrolle, D-69120 Heidelberg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Imperial Canc Res Fund, Lincolns Inn Fields, London WC2A 3PX, England	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Cancer Research UK	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Abt Signaltransdukt & Wachstumskontrolle, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo-124-3-1107; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAE SC, 1993, ONCOGENE, V8, P809; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Evans DB, 1996, J BONE MINER RES, V11, P1066; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GACK S, 1994, J BIOL CHEM, V269, P10363; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg Henry M., 1996, P68; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTOT V, 1995, J CELL SCI, V108, P529; MINDEN A, 1997, BIOCHIM BIOPHYS ACTA, V1333, pF85; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Pollock JH, 1996, J BONE MINER RES, V11, P754; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; SATAKE M, 1988, ONCOGENE, V3, P69; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996	54	131	133	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					667	678		10.1038/sj.onc.1202333	http://dx.doi.org/10.1038/sj.onc.1202333			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989817				2022-12-25	WOS:000078394400012
J	Ye, DW; Mendelsohn, J; Fan, Z				Ye, DW; Mendelsohn, J; Fan, Z			Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225	ONCOGENE			English	Article						EGF receptor; HER2; mAb; p27(Kip1); CDK; cell cycle	MONOCLONAL-ANTIBODY; BREAST-CANCER; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; OVARIAN-CANCER; G(1) ARREST; NEU; HETERODIMERIZATION; P27(KIP1)	Overexpression of epidermal growth factor (EGF) receptor and HER2 (p185(neu)) may both contribute to the growth of human cancers. A humanized anti-HER2 monoclonal antibody (mAb) 4D5 and a human-mouse chimeric anti-EGF receptor mAb C225 are currently being investigated in clinical trials for their anti-tumor activities. In the present study, we have examined the effect of concurrent treatment of OVCA 420 human ovarian cancer cells with mAb C225 and mAb 4D5, Exposure of OVCA420 cells to saturating concentrations of C225 (20 nM) for 7 days resulted in 40-50% growth inhibition, and exposure to 20 nM mAb 4D5 also resulted in 30-40% growth inhibition. The growth inhibition of OVCA420 cells by mAb C225 or 4D5 was associated with an increased G1 cell population; an increased level of a cyclin-dependent kinase (CDK) inhibitor p27(Kip1) with increased association of p27(Kip1) with CDK2, CDK4 and CDK6; and decreased activities of these CDKs, Combination treatment with concurrent exposure to mAbs C225 and 4D5 resulted in additive anti-proliferative effects on these cells, which was accompanied by enhanced G1 cell distribution, a greater increase in the levels of p27(Kip1) and a greater decrease in the activities of CDK kinases, The anti-proliferative effects and related changes in cell cycle regulators induced by mAb 4D5, mAb C225 or the combination of the two mAbs could be reversed by concurrent exposure to exogenous EGF, Our data suggest the potential fruitful cooperation of anti-EGF receptor mAb and anti-HER2 mAb in the treatment of human cancers stimulated by EGF receptor and HER2 signals.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA68425, CA42060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042060, R01CA042060, P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BOS M, 1996, P AN M AM SOC CLIN, V15, P443; Chou J. L., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P10; COBLEIGH MA, 1998, P AN M AM SOC CLIN, V17, pA97; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FALCEY J, 1997, P AN M AM SOC CLIN, V16, pA383; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; FAN Z, 1993, J BIOL CHEM, V268, P21073; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PEGRAM M, 1995, P AN M AM SOC CLIN, V14, P106; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; Peng D, 1996, CANCER RES, V56, P3666; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHOTT S, 1990, STAT HLTH PROFESSION, P151; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Wu XP, 1996, ONCOGENE, V12, P1397	39	123	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					731	738		10.1038/sj.onc.1202319	http://dx.doi.org/10.1038/sj.onc.1202319			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989823				2022-12-25	WOS:000078394400018
J	Biswas, T; Ramana, CV; Srinivasan, G; Boldogh, I; Hazra, TK; Chen, ZP; Tano, K; Thompson, EB; Mitra, S				Biswas, T; Ramana, CV; Srinivasan, G; Boldogh, I; Hazra, TK; Chen, ZP; Tano, K; Thompson, EB; Mitra, S			Activation of human O-6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone	ONCOGENE			English	Article						CNU; DNA damage; DNA repair; glucocorticoid; gene regulation	O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; NUCLEAR RECEPTORS; MAMMALIAN-CELLS; CROSS-LINKING; TUMOR CELLS; CPG ISLAND; DNA	O-6-methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, removes the mutagenic DNA adduct O-6-alkylguanine, which is synthesized both endogenously and after exposure to alkylnitrosamines and alkylating antitumor drugs such as 2-chloroethyl-N-nitrosourea (CNU), The MGMT gene is highly regulated in mammalian cells and its overexpression, observed in many types of tumor cells, is often associated with cellular resistance to CNU, Dexamethasone, a synthetic glucocorticoid hormone, was found to increase MGMT expression in HeLa S3 cells, concomitant with their increased resistance to CNU, Two putative glucocorticoid responsive elements (GREs) were identified in the human MGMT (hMGMT) promoter. Transient expression of the luciferase reporter gene driven by an hMGMT promoter fragment containing these GREs was activated by dexamethasone. DNase I footprinting assays demonstrated the binding of glucocorticoid receptor to these sequences. In vitro transcription experiment showed that these DNA sequences are functional in glucocorticoid receptor signal-mediated activation of transcription. These results suggest glucocorticoid-mediated induction of the MGMT gene contributes to high level expression of MGMT.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Kyoto Univ, Reactor Inst, Osaka 59004, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Kyoto University	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.			chilakamarti, ramana/0000-0002-5153-8252	NATIONAL CANCER INSTITUTE [R01CA031721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31721] Funding Source: Medline; NIEHS NIH HHS [ES 07572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRENT TP, 1985, P NATL ACAD SCI USA, V82, P2985, DOI 10.1073/pnas.82.9.2985; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMBROSIO SM, 1987, CANCER RES, V47, P51; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Heiss JD, 1996, J CLIN INVEST, V98, P1400, DOI 10.1172/JCI118927; Izumi T, 1996, BIOCHEMISTRY-US, V35, P14679, DOI 10.1021/bi961995u; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kokkinakis DM, 1997, CANCER RES, V57, P5360; LEBLANC B, 1994, DNA PROTEIN INTERACT, P1; Levin Victor A., 1997, P2022; Liu LL, 1996, CANCER RES, V56, P1880; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; McEwan IJ, 1995, MUTAT RES-FUND MOL M, V333, P15, DOI 10.1016/0027-5107(95)00126-3; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MYRNES B, 1984, CARCINOGENESIS, V5, P1061, DOI 10.1093/carcin/5.8.1061; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; PEGG AE, 1995, BIOCHEM PHARMACOL, V50, P1141, DOI 10.1016/0006-2952(95)00249-Y; PEGG AE, 1990, CANCER RES, V50, P6119; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; ROBINS P, 1983, NUCLEIC ACIDS RES, V11, P7743, DOI 10.1093/nar/11.22.7743; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAGHER D, 1989, CANCER RES, V49, P5339; SALMON SE, 1989, CANC PRINCIPLES PRAC, P2344; SCHOLD SC, 1989, J NEUROSURG, V70, P573, DOI 10.3171/jns.1989.70.4.0573; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Singer B., 1983, MOL BIOL MUTAGENS CA; SNOW ET, 1984, J BIOL CHEM, V259, P8095; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WASHINGTON WJ, 1989, MECH AGEING DEV, V48, P43, DOI 10.1016/0047-6374(89)90024-9; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; YAROSH DB, 1984, MUTAT RES, V131, P27, DOI 10.1016/0167-8817(84)90044-0; YUNG W K A, 1990, Current Opinion in Oncology, V2, P673	46	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					525	532		10.1038/sj.onc.1202320	http://dx.doi.org/10.1038/sj.onc.1202320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927209				2022-12-25	WOS:000078166500025
J	Grand, RJA; Turnell, AS; Mason, GGF; Wang, WL; Milner, AE; Mymryk, JS; Rookes, SM; Rivett, AJ; Gallimore, PH				Grand, RJA; Turnell, AS; Mason, GGF; Wang, WL; Milner, AE; Mymryk, JS; Rookes, SM; Rivett, AJ; Gallimore, PH			Adenovirus early region 1A protein binds to mammalian SUG1-a regulatory component of the proteasome	ONCOGENE			English	Article						adenovirus; adenovirus 12; E1A; SUG1; proteasome; Trip 1	WILD-TYPE P53; E1A PROTEIN; TRANSCRIPTIONAL MEDIATOR; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; 26-S PROTEASOME; DNA-SYNTHESIS; ACTIVATION; APOPTOSIS; SUBUNIT	Adenovirus early region 1A (Ad E1A) is a multifunctional protein which is essential for adenovirus-mediated transformation and oncogenesis, Whilst E1A is generally considered to exert its influence on recipient cells through regulation of transcription it also increases the le, el of cellular p53 by increasing the protein half-life. With this in, view, we have investigated the relationship of Ad E1A to the proteasome, which is normally responsible for degradation of p53, Here we have shown that both Ad5 and Ad12 EIA 12S and 13S proteins can be co-immunoprecipitated with proteasomes and that the larger Ad12 E1A protein binds strongly to at least three components of the 26S but not 20S proteasome, One of these interacting species has been identified as mammalian SUG1, a proteasome regulatory component which also plays a role in the cell as a mediator of transcription, In vitro assays have demonstrated a direct interaction between Ad12 E1A 13S protein and mouse SUG1, Following infection of human cells with Ad5 wt and Ad5 mutants with lesions in the E1A gene it has been shown that human SUG1 can be co-immunoprecipitated with full-length E1A and with E1A carrying a deletion in conserved region 1 which is the region considered to be responsible for increased expression of p53, We have concluded therefore that Ad E1A binds strongly to SUG1 but that this interaction is not responsible for inhibition of proteasome activity, This is consistent with the observation that purified Ad12 E1A inhibits the activity of the purified 20S but not 26S proteasomes, We have also demonstrated that SUG1 can be co-immunoprecipitated with SV40 T and therefore,ve suggest that this may represent a common interaction of transforming proteins of DNA tumour viruses.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada	University of Birmingham; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; University of Bristol; Western University (University of Western Ontario)	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BOULLATA IJ, 1991, MUSLIM WORLD, V81, P299; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P330, DOI 10.1006/viro.1998.9102; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KRISTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785, DOI 10.1006/bbrc.1994.2876; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARUYAMA K, 1987, ONCOGENE, V1, P361; MASON GGF, 1998, IN PRESS FEBS LETT; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MYMRYK JS, 1993, J GEN VIROL, V74, P2131, DOI 10.1099/0022-1317-74-10-2131; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Seeger M, 1997, J BIOL CHEM, V272, P8145, DOI 10.1074/jbc.272.13.8145; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VOMBAUR E, 1995, EMBO J, V15, P110; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					449	458		10.1038/sj.onc.1202304	http://dx.doi.org/10.1038/sj.onc.1202304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927201				2022-12-25	WOS:000078166500017
J	Chen, P; Gatei, M; O'Connell, MJ; Khanna, KK; Bugg, SJ; Hogg, A; Scott, SP; Hobson, K; Lavin, MF				Chen, P; Gatei, M; O'Connell, MJ; Khanna, KK; Bugg, SJ; Hogg, A; Scott, SP; Hobson, K; Lavin, MF			Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells	ONCOGENE			English	Article						ataxia-telangiectasia; chk1; radiosensitivity; G2/M checkpoint; cell cycle	DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; WEE1 KINASE; P53 PROTEIN; ATM; GENE; PATHWAY; PHOSPHORYLATION	Cells from patients with the human genetic disorder ataxia-telangiectasia (A-T) are defective in the activation of cell cycle checkpoints in response to ionizing radiation damage. In order to understand the role of ATM in checkpoint control we investigated whether Schizosaccaromyces pombe chk1, a protein kinase implicated in controlling the G2 DNA damage checkpoint, might alter the radiosensitive phenotype in A-T cells. The fission yeast chk1 gene was cloned into an EBV-based vector under the control of a metallothionein promoter and transfected into A-T lymphoblastoid cells, Induction of chk1 enhanced the survival of an A-T cell line in response to radiation exposure as determined by cell viability and reduction of radiation-induced chromosome aberrations. This can be accounted for at least in part by the restoration of the G2 checkpoint to chk1 expressing cells. There was no evidence that chk1 expression corrected either the G1/S checkpoint or radioresistant DNA synthesis in S phase in these cells. These results suggest that chk1 when overexpressed acts downstream from ATM to restore the G2 checkpoint in these cells and correct the radiosensitive phenotype, These data allow us to dissociate individual checkpoint events and relate them to the radiosensitive phenotype in A-T cells.	Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Peter MacCallum Res Inst, E Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Peter Maccallum Cancer Center; University of Melbourne; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Hobson, Keith/Q-9306-2019; Lavin, Martin F/F-5961-2014; Khanna, Kum Kum/I-1747-2013	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BADIE C, 1995, CANCER RES, V55, P1232; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BATES PR, 1985, INT J RADIAT BIOL, V47, P713, DOI 10.1080/09553008514550951; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KONIG K, 1980, RADIAT ENVIRON BIOPH, V18, P257, DOI 10.1007/BF01324268; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEEPER DB, 1972, RADIAT RES, V50, P410; LEHMANN AR, 1986, INT J RADIAT BIOL, V49, P639; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; Westphal CH, 1997, CURR BIOL, V7, pR789, DOI 10.1016/S0960-9822(06)00406-4; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	58	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					249	256		10.1038/sj.onc.1202257	http://dx.doi.org/10.1038/sj.onc.1202257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926940				2022-12-25	WOS:000078166000027
J	Krynska, B; Otte, J; Franks, R; Khalili, K; Croul, S				Krynska, B; Otte, J; Franks, R; Khalili, K; Croul, S			Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals	ONCOGENE			English	Article						human virus; brain tumors; transgenic mice	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; JC VIRUS-DNA; HUMAN NEUROTROPIC POLYOMAVIRUS; HUMAN PAPOVAVIRUS JC; TRANSGENIC MICE; EARLY PROTEIN; BK-VIRUS; TISSUE; URINE; EXPRESSION	JCV is a papovavirus which is widespread in the human population. The prototype Mad-1 variant of JCV induces a fatal demyelinating disease of the central nervous system (CNS) called Progressive Multifocal Leukoencephalopathy (PML) in immunosuppressed individuals. The unique tropism of JCV (Mad-l) to the CNS is attributed to the tissue-specific regulation of the viral early promoter which is responsible for the production of the viral regulatory protein, T-antigen, The archetype form of this virus, JCV(CY), which has been repeatedly isolated from the urine of PML and non-PML individuals, is distinct from JCV(Mad-1) in the structural organization of the regulatory sequence. To characterize the tissue specific expression of JCV(CY) and to investigate its potential in inducing disease, transgenic mice containing the early region of JCV(CY) were generated. Some of these mice between 9-13 months of age exhibited signs of illness as manifested by paralysis of rear limbs, hunched posture, and poor grooming. Neuropathological examination indicated no sign of hypomyelination of the brain, but surprisingly, revealed the presence of primitive tumors originating from the cerebellum and the surrounding brain stem. The tumor masses also infiltrated the surrounding tissue. Results from RNA and protein studies revealed a high level of T-antigen mRNA expression in hindbrains of clinically normal and affected transgenic mice. However, higher levels of T-antigen RNA and protein were detected in brains of the animals exhibiting severe illness. The close resemblance of JCV(CY) induced tumor in transgenic mice to the human medulloblastoma/primitive neuroectodermal tumor (PNETs) in location, histologic appearance, and expression of marker proteins strongly suggests the utility of this novel animal model for the study of human brain tumors.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Univ Illinois, Coll Med, Dept Genet, Chicago, IL 60612 USA; Allegheny Univ Hlth Sci, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Drexel University	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Broad & Vine,MS 406, Philadelphia, PA 19102 USA.			Croul, Sidney/0000-0002-2224-5485				ARTHUR RR, 1989, PROG MED VIROL, V36, P42; ARTHUR RR, 1989, J CLIN MICROBIOL, V27, P1174, DOI 10.1128/JCM.27.6.1174-1179.1989; ASTROM KE, 1958, BRAIN, V81, P93, DOI 10.1093/brain/81.1.93; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; COLEMAN DV, 1980, J INFECT DIS, V142, P1, DOI 10.1093/infdis/142.1.1; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; EGAN JD, 1980, TRANSPLANTATION, V29, P84, DOI 10.1097/00007890-198001000-00021; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Franks RR, 1996, ONCOGENE, V12, P2573; FRIDQUE RJ, 1992, MOL NEUROVIROLOGY, P25; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; GARDNER SD, 1984, J CLIN PATHOL, V37, P578, DOI 10.1136/jcp.37.5.578; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HO K, 1980, ACTA NEUROPATHOL, V52, P81, DOI 10.1007/BF00687233; ISHAQ M, 1994, P NATL ACAD SCI USA, V91, P8283, DOI 10.1073/pnas.91.17.8283; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LIBERSKI PP, 1982, NEUROPATOL POL, V20, P3; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; Matsushima T, 1997, NEUROLOGY, V48, P279, DOI 10.1212/WNL.48.1.279; MYERS C, 1989, J VIROL, V63, P4445, DOI 10.1128/JVI.63.10.4445-4449.1989; OHASHI T, 1978, J NEUROPATH EXP NEUR, V37, P667, DOI 10.1097/00005072-197809000-00301; PADGETT BL, 1971, LANCET, V1, P1257; RAJ GV, 1995, INT J ONCOL, V7, P801; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RHEIN GMZ, 1965, SCIENCE, V148, P1477, DOI 10.1126/science.148.3676.1477; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SURI C, 1993, J NEUROSCI, V13, P1280; TORNATORE C, 1992, ANN NEUROL, V31, P454, DOI 10.1002/ana.410310426; Vago L, 1996, J ACQ IMMUN DEF SYND, V12, P139, DOI 10.1097/00042560-199606010-00006; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEINER LP, 1972, NEW ENGL J MED, V286, P385, DOI 10.1056/NEJM197202242860801; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; YOGO Y, 1991, J VIROL, V65, P2422, DOI 10.1128/JVI.65.5.2422-2428.1991; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205; ZURHEIN GM, 1987, CANC CAMPAIGN EXPT N, V10, P19; ZURHEIN GM, 1975, P 7 INT C NEUR, V1, P479	43	85	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					39	46		10.1038/sj.onc.1202278	http://dx.doi.org/10.1038/sj.onc.1202278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926918	Bronze			2022-12-25	WOS:000078166000005
J	Lorentz, O; Cadoret, A; Duluc, I; Capeau, J; Gespach, C; Cherqui, G; Freund, JN				Lorentz, O; Cadoret, A; Duluc, I; Capeau, J; Gespach, C; Cherqui, G; Freund, JN			Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras	ONCOGENE			English	Article						caco-2; HT-29 cells; protein kinase c; MEK1-MAP kinase; AP-1; Jun/Fos	MIDDLE-T-ONCOGENES; PASSAGE RODENT CELLS; KINASE-C-ALPHA; EPITHELIAL-CELLS; CACO-2 CELLS; COLORECTAL CARCINOGENESIS; MALIGNANT TRANSFORMATION; INTESTINAL EPITHELIUM; NEGATIVE REGULATION; PROTEIN EXPRESSION	Constitutive activation of the ras proto-oncogene is a frequent and early event in colon cancers, but the downstream nuclear targets are not fully understood. The Cdx-1 and Cdx-2 homeobox genes play crucial roles in intestinal cell proliferation and differentiation, In addition, Cdx-2 is a colonic tumour-suppressor gene, whereas Cdx-1 has oncogenic potential. Here, we show that constitutive activation of ras alters Cdx-1 and Cdx-2 expression in human colonic Caco-2 and HT-29 cells that harbour a normal ras proto-oncogene. Oncogenic ras downregulates Cdx-2 through activation of the PKC pathway and a decline in activity of the Cdx-2 promoter AP-1 site, This decline results from a PKC-dependent decrease in the relative expression of c-Jun, an activator of Cdx-2 transcription, compared to c-Fos, an inhibitor of Cdx-2. Unlike Cdx-2, Cdx-1 is upregulated by oncogenic ras and this effect is mediated by activation of the MEK1 pathway. These results indicate that oncogenic ras activation has opposite effects on Cdx-1 and Cdx-2 expression through distinct signalling pathways and they provide the first evidence for a functional link between ras activation and the downregulation of the Cdx-2 tumour-suppressor gene in colon cancer cells.	INSERM, U381, F-67200 Strasbourg, France; INSERM, U402, F-75571 Paris, France; INSERM, U482, F-75571 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Freund, JN (corresponding author), INSERM, U381, 3 Ave Moliere, F-67200 Strasbourg, France.		Duluc, Isabelle/O-1972-2017; Cadoret, Axelle/L-2529-2017; Freund, Jean-Noel/R-4383-2016; DULUC, Isabelle/AAA-7062-2022	Duluc, Isabelle/0000-0001-8396-6385; Cadoret, Axelle/0000-0002-4283-6864; Freund, Jean-Noel/0000-0002-0971-3774; DULUC, Isabelle/0000-0001-8396-6385				BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CHANTRET I, 1994, J CELL SCI, V107, P213; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; DAVIDSON LA, 1995, J NUTR, V125, P49; DELAGE S, 1993, CANCER RES, V53, P2762; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; FOSTER E, 1994, BIOTECHNIQUES, V16, P18; FREUND JN, 1992, FEBS LETT, V314, P163, DOI 10.1016/0014-5793(92)80965-J; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HU YL, 1993, J BIOL CHEM, V268, P27214; Ilyas M, 1996, HISTOPATHOLOGY, V28, P389, DOI 10.1046/j.1365-2559.1996.339381.x; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Peddanna N, 1995, ANTICANCER RES, V15, P2055; PINTO M, 1983, BIOL CELL, V47, P323; PINTO M, 1982, BIOL CELL, V44, P193; ROUSSET M, 1980, JNCI-J NATL CANCER I, V65, P885; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SPANDIDOS DA, 1986, J GEN VIROL, V67, P793, DOI 10.1099/0022-1317-67-4-793; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STOPERA SA, 1992, CARCINOGENESIS, V13, P573, DOI 10.1093/carcin/13.4.573; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Velazquez OC, 1996, JPEN-PARENTER ENTER, V20, P243, DOI 10.1177/0148607196020004243; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364	39	76	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					87	92		10.1038/sj.onc.1202280	http://dx.doi.org/10.1038/sj.onc.1202280			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926923				2022-12-25	WOS:000078166000010
J	Nevels, M; Spruss, T; Wolf, H; Dobner, T				Nevels, M; Spruss, T; Wolf, H; Dobner, T			The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53	ONCOGENE			English	Article						DNA tumor virus; viral oncogene	TRANSCRIPTIONAL ACTIVATION; 55-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; INFECTED-CELLS; E1B PROTEINS; 5 DNA; APOPTOSIS; GENE; BINDING; ANTIGEN	The adenovirus type 5 (Ad5) E4orf6 protein promotes focus formation of primary baby rat kidney (BRK) cells in cooperation with Ad5 E1 proteins. This activity is most likely related to the ability of the E4orf6 protein to bind to p53 and modulate its tumor suppressor functions. In this study we report that transformed BRK cells that stably express E40rf6 in addition to E1A and E1B (ABS cells) displayed multiple additional properties commonly associated with a high grade of oncogenic transformation compared to cells expressing only E1A and E1B (AB cells). These properties included morphological alterations, markedly enhanced growth rates and growth to much higher saturation densities. Following injection into nude mice ABS-derived tumors exhibited accelerated growth and, based on histopathological criteria, proofed to be much more malignant compared to tumors generated by AB cells. Interestingly, these highly transformed properties of ABS cells correlated with a dramatic reduction of p53 steady-state levels which inversely correlated with E40rf6 expression. From these results we conclude that expression of the Ad5 E40rf6 protein (i) confers additional transformed in vitro properties to primary rat cells expressing the Ad5 Fl proteins, and (ii) increases the tumorigenic and malignant potential of these cells in vivo. Our data suggest that the Ad5 E40rf6 protein enhances the intrinsic ability of E1-transformed rat cells to grow in a neoplastic state by completely inactivating p53 tumor suppressor function in combination with the E1A and E1B proteins.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany	University of Regensburg	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany.		Nevels, Michael M/J-4783-2014	Nevels, Michael M/0000-0002-7115-407X				BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Logan J, 1984, CANCER CELL, V2, P527; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SHIROKI K, 1981, J VIROL, V38, P1048, DOI 10.1128/JVI.38.3.1048-1054.1981; Spruss T, 1996, CONTR ONCOL, V51, P12; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TOOZE J, 1981, COLD SPRING HARBOR, P943; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	55	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					9	17		10.1038/sj.onc.1202284	http://dx.doi.org/10.1038/sj.onc.1202284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926915				2022-12-25	WOS:000078166000002
J	de Cock, H; Brandenburg, K; Wiese, A; Holst, O; Seydel, U				de Cock, H; Brandenburg, K; Wiese, A; Holst, O; Seydel, U			Non-lamellar structure and negative charges of lipopolysaccharides required for efficient folding of outer membrane protein PhoE of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE LIPID-A; CHEMICAL-STRUCTURE; INVITRO TRIMERIZATION; SALMONELLA-MINNESOTA; MOLECULAR-BASIS; OMPF; TRANSLOCATION; INSERTION; SYSTEMS; PORIN	Lipopolysaccharides (LPS) are amphiphilic molecules in the outer leaflet of the bacterial outer membrane. Recently, an early role for LPS in the folding of outer membrane porin PhoE was demonstrated in vitro, In order to elucidate the molecular mechanism of LPS-protein interactions, folding of PhoE protein was studied with a large set of well characterized LPS chemotypes. We demonstrate that negative charges in the inner core region contribute to the high efficiency of folding of PhoE protein. In addition, the supramolecular structure of the LPS aggregate seems to be important. LPS with a lipid A part that prefers a lamellar or a direct micellar structure and a high state of order of its acyl chains is much less efficient to support folding as compared with LPS with lipid A that prefers a non-lamellar structure and a low acyl chain order. These in vitro data indicate that extensive interactions between the core and lipid A region of LPS with the protein are required to support protein folding. The LPS-PhoE binding might be promoted by the presence of hydroxy fatty acids in the lipid A moiety of LPS.	Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Res Ctr Borstel, Dept Immunochem, D-23845 Borstel, Germany; Res Ctr Borstel, Dept Biochem Microbiol, D-23845 Borstel, Germany	Utrecht University; Forschungszentrum Borstel; Forschungszentrum Borstel	de Cock, H (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	J.J.P.A.deCock@Bio.UU.NL	de Cock, Hans/B-7790-2011	de Cock, Hans/0000-0002-8420-6764				AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCQUETPAGES C, 1981, EUR J BIOCHEM, V118, P105, DOI 10.1111/j.1432-1033.1981.tb05491.x; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOLLA JM, 1988, EMBO J, V7, P3595, DOI 10.1002/j.1460-2075.1988.tb03237.x; Brandenburg K, 1997, BBA-BIOMEMBRANES, V1329, P183, DOI 10.1016/S0005-2736(97)00109-0; BRANDENBURG K, 1992, J STRUCT BIOL, V108, P93, DOI 10.1016/1047-8477(92)90010-8; BRANDENBURG K, 1984, BIOCHIM BIOPHYS ACTA, V775, P225, DOI 10.1016/0005-2736(84)90174-3; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; BRANDENBURG K, 1995, BACTERIAL ENDOTOXINS, P167; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; deCock H, 1996, J BIOL CHEM, V271, P12885, DOI 10.1074/jbc.271.22.12885; DECOCK H, 1990, BIOCHIMIE, V72, P177, DOI 10.1016/0300-9084(90)90143-5; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EISELE JL, 1990, J BIOL CHEM, V265, P10217; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HOLST O, 1993, EUR J BIOCHEM, V214, P695, DOI 10.1111/j.1432-1033.1993.tb17970.x; HOLST O, 1998, ENDOTOXINS HLTH DIS; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; KAWAHARA K, 1991, FEBS LETT, V292, P107, DOI 10.1016/0014-5793(91)80845-T; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; KOPLOW J, 1974, J BACTERIOL, V117, P527, DOI 10.1128/JB.117.2.527-543.1974; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; Lasch P, 1998, BIOPHYS J, V75, P840, DOI 10.1016/S0006-3495(98)77573-3; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; LUZZATI V, 1993, J MOL BIOL, V229, P540, DOI 10.1006/jmbi.1993.1053; MAYER H, 1990, ADV EXP MED BIOL, V256, P45; MULLERLOENNIES S, 1994, EUR J BIOCHEM, V224, P751, DOI 10.1111/j.1432-1033.1994.t01-1-00751.x; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PAGES C, 1982, EUR J BIOCHEM, V122, P381, DOI 10.1111/j.1432-1033.1982.tb05892.x; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; REINHART RA, 1988, ARCH INTERN MED, V148, P2415, DOI 10.1001/archinte.148.11.2415; RIED G, 1990, J BACTERIOL, V172, P6048, DOI 10.1128/jb.172.10.6048-6053.1990; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; SEYDEL U, 1993, J STRUCT BIOL, V110, P232, DOI 10.1006/jsbi.1993.1026; SEYDEL U, 1998, ENDOTOXIN HLTH DIS; SEYDEL U, 1992, BACTERIAL ENDOTOXIC, V1, P225; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; TOMMASSEN J, 1981, J BACTERIOL, V147, P118, DOI 10.1128/JB.147.1.118-123.1981; WEISS MS, 1991, SCIENCE, V254, P1727; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILKINSON BJ, 1986, FEMS MICROBIOL LETT, V37, P63, DOI 10.1111/j.1574-6968.1986.tb01767.x	55	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5114	5119		10.1074/jbc.274.8.5114	http://dx.doi.org/10.1074/jbc.274.8.5114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988760	hybrid			2022-12-25	WOS:000078698200085
J	Dirnbach, E; Steel, DG; Gafni, A				Dirnbach, E; Steel, DG; Gafni, A			Proline isomerization is unlikely to be the cause of slow annealing and reactivation during the folding of alkaline phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BETA-LACTOGLOBULIN; ESCHERICHIA-COLI; RIBONUCLEASE-A; PHOSPHOGLYCERATE KINASE; PROLYL ISOMERASE; CYCLOSPORINE-A; PROTEIN; CYCLOPHILIN; MECHANISM; CATALYSIS	The in vitro folding of Escherichia coli alkaline phosphatase (AP) from the guanidine hydrochloride (GdnHCl) denatured state is characterized by a significant slow phase in the post activational recovery of native protein lability (probed by the susceptibility to GdnHCl denaturation and occurring on the time scale of days) as well as a slow phase in the recovery of activity ton the time scale of minutes). Slow folding events have often been attributed to cis-trans isomerizations of X-Pro peptide bonds, a plausible explanation for AP, which contains 21 prolines per subunit, To investigate the role of proline isomerization in the two measures of refolding mentioned above, we have performed "double-jump" GdnHCl denaturation/renaturation experiments, with a third jump, where the rate of unfolding of refolded protein upon exposure to denaturant was added to assess the rate of change of lability, Our measurements of the time evolution of both the lability and the reactivation of refolded AP as a function of denaturation time show that proline isomerization is unlikely to be the cause of either of these slow events in the refolding of AP. The conclusions are further confirmed by the absence of proline isomerization effects when AP is refolded in the presence of human and periplasmic E, coli peptidyl-prolyl isomerase.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Gafni, A (corresponding author), Univ Michigan, Div Biophys Res, Rm 913,N Ingalls Bldg, Ann Arbor, MI 48109 USA.	arigafni@umich.edu			NIA NIH HHS [T32AG00114, AG09761] Funding Source: Medline; NIGMS NIH HHS [5T32GM08270-66] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114, R01AG009761] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; CHLEBOWSKI JF, 1977, J BIOL CHEM, V252, P7042; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; COOK KH, 1979, P NATL ACAD SCI USA, V76, P6157, DOI 10.1073/pnas.76.12.6157; CREIGHTON TE, 1980, J MOL BIOL, V137, P431, DOI 10.1016/0022-2836(80)90167-9; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GETTINS P, 1983, J BIOL CHEM, V258, P396; HATTORI M, 1993, J BIOL CHEM, V268, P22414; HIREMATH LS, 1982, J GERONTOL, V37, P680, DOI 10.1093/geronj/37.6.680; KEIFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053; KIM EE, 1990, CLIN CHIM ACTA, V186, P175, DOI 10.1016/0009-8981(90)90035-Q; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEVITT M, 1981, J MOL BIOL, V145, P251, DOI 10.1016/0022-2836(81)90342-9; LIN LN, 1983, BIOCHEMISTRY-US, V22, P564, DOI 10.1021/bi00272a007; LIN LN, 1983, BIOCHEMISTRY-US, V22, P559, DOI 10.1021/bi00272a006; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MALAMY MH, 1964, BIOCHEMISTRY-US, V3, P1893, DOI 10.1021/bi00900a018; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Reimer U, 1997, BIOCHEMISTRY-US, V36, P13802, DOI 10.1021/bi9713916; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P3552, DOI 10.1021/bi00863a029; ROTHSTEIN M, 1985, REV BIOL RES AGING, V2, P421; Schmid F X, 1986, Methods Enzymol, V131, P70; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; STRAMBINI GB, 1985, CHEM PHYS LETT, V115, P196, DOI 10.1016/0009-2614(85)80678-3; SUBRAMANIAM V, 1995, BIOCHEMISTRY-US, V34, P1133, DOI 10.1021/bi00004a005; Subramaniam V, 1996, PROTEIN SCI, V5, P2089, DOI 10.1002/pro.5560051015; Veeraraghavan S, 1997, BIOCHEMISTRY-US, V36, P15134, DOI 10.1021/bi971357r; YUH KCM, 1987, P NATL ACAD SCI USA, V84, P7458, DOI 10.1073/pnas.84.21.7458; ZUNIGA A, 1988, BIOCHIM BIOPHYS ACTA, V955, P50, DOI 10.1016/0167-4838(88)90178-1	39	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4532	4536		10.1074/jbc.274.8.4532	http://dx.doi.org/10.1074/jbc.274.8.4532			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988686	hybrid			2022-12-25	WOS:000078698200011
J	Kim, M; Thum, KE; Morishige, DT; Mullet, JE				Kim, M; Thum, KE; Morishige, DT; Mullet, JE			Detailed architecture of the barley chloroplast psbD-psbC blue light-responsive promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSTARD SINAPIS-ALBA; POLYMERASE-ALPHA-SUBUNIT; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; LEAF DEVELOPMENT; PROTEIN-KINASE; SIGMA-FACTORS	The photosystem II reaction center chlorophyll protein D2, is encoded by the chloroplast gene psbD. PsbD is transcribed from at least three different promoters, one which is activated by high fluence blue light. Sequences within 130 base pairs (bp) of the psbD blue light-responsive promoter (BLRP) are highly conserved in higher plants. In this study, the structure of the psbD BLRP was analyzed in detail using deletion and site-directed mutagenesis and in vitro transcription. Deletion analysis showed that a 53-bp DNA region of the psbD BLRP, from -57 to -5, was sufficient for transcription in vitro. Mutation of a putative prokaryotic -10 element (TATTCT) located from -7 to -12 inhibited transcription from the psbD BLRP. In contrast, mutation of a putative prokaryotic -35 element, had no influence on transcription. Mutation of a TATATA sequence located between the barley psbA -10 and -35 elements significantly reduced transcription from this promoter. However, site-directed mutation of sequences located between -35 and -10 had no effect on transcription from the psbD BLRP. Transcription from the psbD BLRP was previously shown to require a 22-bp sequence, termed the AAG-box, located between -36 and -57. The AAG-box specifically binds the protein complex AGF. Site-directed mutagenesis identified two different sequence motifs in the AAG-box that are important for transcription in vitro. Based on these results, we propose that positive factors bind to the AAG-box and interact with the chloroplast-encoded RNA polymerase to promote transcription from the psbD BLRP. Transcription from the psbD BLRP is thus similar to type II bacterial promoters that use activating proteins to stimulate transcription. Transcription of the psbD BLRP was similar to 6.5-fold greater in plastid extracts from illuminated versus dark-grown plants. This suggests that light-induced activation of this promoter in vivo involves factors interacting with the 53-bp psbD BLRP in vitro.	Texas A&M Univ, Crop Biotechnol Ctr, Dept Biochem & Biophys, College Stn, TX 77843 USA; Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Chem, Div Appl Biol & Chem, Suwon 441744, South Korea	Texas A&M University System; Texas A&M University College Station; Seoul National University (SNU)	Mullet, JE (corresponding author), Texas A&M Univ, Crop Biotechnol Ctr, Dept Biochem & Biophys, College Stn, TX 77843 USA.				NIGMS NIH HHS [GM 37987] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1995, EMBO J, V14, P3721, DOI 10.1002/j.1460-2075.1995.tb00042.x; Baginsky S, 1997, PLANT MOL BIOL, V34, P181, DOI 10.1023/A:1005802909902; BAUMGARTNER BJ, 1993, PLANT PHYSIOL, V101, P781, DOI 10.1104/pp.101.3.781; BOYER SK, 1988, NUCLEIC ACIDS RES, V16, P8184, DOI 10.1093/nar/16.16.8184; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHEN SCG, 1995, PHYSIOL PLANTARUM, V93, P617, DOI 10.1111/j.1399-3054.1995.tb05108.x; CHRISTOPHER DA, 1994, PLANT PHYSIOL, V104, P1119, DOI 10.1104/pp.104.4.1119; Christopher DA, 1997, PLANT PHYSIOL, V113, P1273, DOI 10.1104/pp.113.4.1273; CHRISTOPHER DA, 1992, PLANT CELL, V4, P785, DOI 10.1105/tpc.4.7.785; Christopher DA, 1996, PHOTOSYNTH RES, V47, P239, DOI 10.1007/BF02184285; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DEPAMPHILIS CW, 1990, NATURE, V348, P337, DOI 10.1038/348337a0; EISERMANN A, 1990, EMBO J, V9, P3981, DOI 10.1002/j.1460-2075.1990.tb07619.x; GAMBLE PE, 1989, EMBO J, V8, P2785, DOI 10.1002/j.1460-2075.1989.tb08424.x; GAMBLE PE, 1988, EMBO J, V7, P1289, DOI 10.1002/j.1460-2075.1988.tb02943.x; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GRUISSEM W, 1986, NUCLEIC ACIDS RES, V14, P7541, DOI 10.1093/nar/14.19.7541; GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355; Hajdukiewicz PTJ, 1997, EMBO J, V16, P4041, DOI 10.1093/emboj/16.13.4041; HANLEYBOWDOIN L, 1987, TRENDS BIOCHEM SCI, V12, P67, DOI 10.1016/0968-0004(87)90033-8; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hubschmann T, 1998, PLANT MOL BIOL, V36, P493, DOI 10.1023/A:1005924502336; IGLOI GL, 1992, CRIT REV PLANT SCI, V10, P525, DOI 10.1080/07352689209382326; IRATNI R, 1994, GENE DEV, V8, P29228; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; Isono K, 1997, P NATL ACAD SCI USA, V94, P14948, DOI 10.1073/pnas.94.26.14948; Kapoor S, 1997, PLANT J, V11, P327, DOI 10.1046/j.1365-313X.1997.11020327.x; KIM MY, 1993, PLANT MOL BIOL, V22, P447, DOI 10.1007/BF00015975; KIM MY, 1995, PLANT CELL, V7, P1445, DOI 10.1105/tpc.7.9.1445; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KLEIN RR, 1986, J BIOL CHEM, V261, P1138; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; LANDINI P, 1995, EMBO J, V14, P4329, DOI 10.1002/j.1460-2075.1995.tb00107.x; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; LINK G, 1994, PLANT PROMOTERS TRAN, P63; Liu B, 1996, P NATL ACAD SCI USA, V93, P3313, DOI 10.1073/pnas.93.8.3313; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1993, PLANT PHYSIOL, V103, P309, DOI 10.1104/pp.103.2.309; NEUHAUS H, 1989, CURR GENET, V15, P63, DOI 10.1007/BF00445753; OHAD I, 1985, EMBO J, V4, P1655, DOI 10.1002/j.1460-2075.1985.tb03833.x; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RAPP JC, 1992, J BIOL CHEM, V267, P21404; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; SEXTON TB, 1990, EMBO J, V9, P4485, DOI 10.1002/j.1460-2075.1990.tb07899.x; SEXTON TB, 1990, CURR GENET, V17, P445, DOI 10.1007/BF00334526; SIMONS RW, 1983, CELL, V34, P673, DOI 10.1016/0092-8674(83)90400-2; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; Tanaka K, 1997, FEBS LETT, V413, P309, DOI 10.1016/S0014-5793(97)00906-X; Tanaka K, 1996, SCIENCE, V272, P1932, DOI 10.1126/science.272.5270.1932; TILLER K, 1993, EMBO J, V12, P1745, DOI 10.1002/j.1460-2075.1993.tb05822.x; TILLER K, 1993, PLANT MOL BIOL, V21, P503, DOI 10.1007/BF00028807; Tozawa Y, 1998, NUCLEIC ACIDS RES, V26, P415, DOI 10.1093/nar/26.2.415; TROXLER RF, 1994, PLANT PHYSIOL, V104, P753, DOI 10.1104/pp.104.2.753; Vera A, 1996, MOL GEN GENET, V251, P518, DOI 10.1007/s004380050197; WADA T, 1994, PLANT PHYSIOL, V104, P1259, DOI 10.1104/pp.104.4.1259; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x; ZURAWSKI G, 1987, ANNU REV PLANT PHYS, V38, P391, DOI 10.1146/annurev.pp.38.060187.002135; ZURAWSKI G, 1984, GENETICS, V106, P735	72	39	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4684	4692		10.1074/jbc.274.8.4684	http://dx.doi.org/10.1074/jbc.274.8.4684			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988705	hybrid			2022-12-25	WOS:000078698200030
J	Perrone, L; Tell, G; Di Lauro, R				Perrone, L; Tell, G; Di Lauro, R			Calreticulin enhances the transcriptional activity of thyroid transcription factor-1 by binding to its homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; PROTEIN-KINASE-A; FACTOR-I TTF-1; GENE-EXPRESSION; DNA-BINDING; GLUCOCORTICOID RECEPTOR; REDOX REGULATION; FRTL-5 CELLS; B GENE; ACTIVATION	Transcription factors are often regulated by associated protein cofactors that are able to modify their activity by several different mechanisms. In this study we show that calreticulin, a Ca2+-binding protein with chaperone activity, binds to thyroid transcription factor-1 (TTF-1), a homeodomain-containing protein implicated in the differentiation of lung and thyroid. The interaction between calreticulin and TTF-1 appears to have functional significance because it results in increased transcriptional stimulation of TTF-1-dependent promoters. Calreticulin binds to the TTF-1 homeodomain and promotes its folding, suggesting that the mechanism involved in stimulation of transcriptional activity is an increase of the steady-state concentration of active TTF-1 protein in the cell. We also demonstrate that calreticulin mRNA levels in thyroid cells are under strict control by the thyroid-stimulating hormone, thus implicating calreticulin in the modulation of thyroid gene expression by thyroid-stimulating hormone.	Staz Zool Anton Dohrn, I-80121 Naples, Italy; Fac Med, Dipartimento Sci & Tecnol Biomed, Udine, Italy	Stazione Zoologica Anton Dohrn di Napoli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Di Lauro, R (corresponding author), Staz Zool Anton Dohrn, Villa Comunale, I-80121 Naples, Italy.	rdilauro@unina.it	Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; Perrone, Lorena/0000-0001-5399-9397; Tell, Gianluca/0000-0001-8845-6448	Telethon [D.067] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; Aurisicchio L, 1998, J BIOL CHEM, V273, P1477, DOI 10.1074/jbc.273.3.1477; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Burns K, 1997, MOL CELL BIOCHEM, V171, P37, DOI 10.1023/A:1006865108833; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, FEBS LETT, V354, P293, DOI 10.1016/0014-5793(94)01145-1; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Desai D, 1996, J BIOL CHEM, V271, P15153, DOI 10.1074/jbc.271.25.15153; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Gruschus JM, 1997, BIOCHEMISTRY-US, V36, P5372, DOI 10.1021/bi9620060; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JEROEN EM, 1996, P NATL ACAD SCI USA, V93, P13997; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KHANNA NC, 1986, BIOCHEMISTRY-US, V25, P1078, DOI 10.1021/bi00353a020; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Lai JS, 1997, MOL CELL BIOL, V17, P3937, DOI 10.1128/MCB.17.7.3937; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Oguchi H, 1998, ENDOCRINOLOGY, V139, P1999, DOI 10.1210/en.139.4.1999; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Saito T, 1997, ENDOCRINOLOGY, V138, P602, DOI 10.1210/en.138.2.602; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shago M, 1997, EXP CELL RES, V230, P50, DOI 10.1006/excr.1996.3408; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHERMAN F, 1986, METHODS YEAST GENETI, P207; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	56	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4640	4645		10.1074/jbc.274.8.4640	http://dx.doi.org/10.1074/jbc.274.8.4640			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988700	hybrid			2022-12-25	WOS:000078698200025
J	Zetser, A; Gredinger, E; Bengal, E				Zetser, A; Gredinger, E; Bengal, E			p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation - Participation of the MEF2C transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR STRESSES; GENE-EXPRESSION; MOUSE MUSCLE; FACTOR MEF-2; MYOD; ENHANCER; GROWTH; DOMAIN; FAMILY; BINDS	Differentiation of muscle cells is regulated by extracellular growth factors that transmit largely unknown signals into the cells. Some of these growth factors induce mitogen-activated protein kinase (MAPK) cascades within muscle cells, In this work we show that the kinase activity of p38 MAPK is induced early during terminal differentiation of L8 cells. Addition of a specific p38 inhibitor SE 203580 to myoblasts blocked their fusion to multinucleated myotubes and prevented the expression of MyoD and MEF2 family members and myosin light chain 2, The expression of MKK6, a direct activator of p38, or of p38 itself enhanced the activity of MyoD in converting 10T1/2 fibroblasts to muscle, whereas treatment with SE 203580 inhibited MyoD, Several lines of evidence suggesting that the involvement of p38 in MyoD activity is mediated via its co-activator MEF2C, a known substrate of p38, are presented. In these experiments we show that MEF2C protein and MEF2-binding sites are necessary for the p38 MAPK pathway to regulate the transcription of muscle creatine kinase reporter gene. Our results indicate that the p38 MAPK pathway promotes skeletal muscle differentiation at least in part via activation of MEF2C.	Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Family Inst Res Med Sci, POB 9649, IL-31096 Haifa, Israel.	Bengal@tx.technion.ac.il						AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; TAHA C, 1997, AM J PHYSIOL, V273, P68; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	44	365	384	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5193	5200		10.1074/jbc.274.8.5193	http://dx.doi.org/10.1074/jbc.274.8.5193			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988769	hybrid			2022-12-25	WOS:000078698200094
J	Chadli, A; Ladjimi, MM; Baulieu, EE; Catelli, MG				Chadli, A; Ladjimi, MM; Baulieu, EE; Catelli, MG			Heat-induced oligomerization of the molecular chaperone Hsp90 - Inhibition by ATP and geldanamycin and activation by transition metal oxyanions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; SHOCK-PROTEIN; MUTATIONAL ANALYSIS; ESTROGEN-RECEPTOR; STEROID-RECEPTOR; BINDING; INVITRO; PURIFICATION; REACTIVATION	It has been previously reported that heat shock protein 90 (Hsp90) oligomerizes at high temperatures and displays concomitantly a novel chaperone activity (Yonehara, M., Minami, Y., Kawata, Y., Nagai, J., and Yahara, I. (1996) J. Biol. Chem., 271, 2641-2645). In order to better define these oligomerization properties at high temperatures and to know whether they are influenced by modulators of Hsp90 function, heat-induced oligomerization of highly purified dimeric Hsp90 has been investigated over a wide range of temperature and protein concentrations by native polyacrylamide gel electrophoresis and size exclusion chromatography. Whereas below 50 degrees C, the dimeric form is maintained over a large range of concentrations, at the critical temperature of 50 degrees C, a sharp transition from dimeric to higher order oligomeric species takes place within minutes, in a highly ordered process, suggesting that a conformational change, leading to the appearance of a new oligomerization site, occurs in Hsp90 dimer. Moreover, at and above the critical temperature, the extent of oligomerization increases with Hsp90 concentration. Formation of high order oligomers at high temperatures is sensitive to modulators of Hsp90 function. ATP and geldanamycin, both known to bind to the same pocket of Hsp90, are inhibitors of this process, whereas molybdate, vanadate, and Nonidet P-40, which are thought to increase surface hydrophobicity of the protein, are activators. Thus, oligomerization of Hsp90 at high temperatures may be mediated through hydrophobic interactions that are hindered by ligands and favored by transition metal oxyanions. The fact that the heat-induced oligomerization of Hsp90 is affected by specific ligands that modulate its properties also suggests that this process may be involved in cell protection during heat shock.	INSERM U488, F-94276 Le Kremlin Bicetre, France; CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, F-75006 Paris, France; CHU Cochin Port Royal, CNRS, Lab Endocrinol Metab & Dev, UPR 1524, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Catelli, MG (corresponding author), INSERM U488, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	Catelli@icgm.cochin.inserm.fr						BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CORNILLOT JD, 1992, INT J BIOCHEM, V24, P1585, DOI 10.1016/0020-711X(92)90174-Y; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ellis RJ, 1996, CELL STRESS CHAPERON, V1, P155, DOI 10.1379/1466-1268(1996)001<0155:DOMC>2.3.CO;2; Freitag DG, 1997, BIOCHEMISTRY-US, V36, P10221, DOI 10.1021/bi963030g; Garnier C, 1998, BIOCHEM BIOPH RES CO, V249, P197, DOI 10.1006/bbrc.1998.9108; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LANKS KW, 1989, J CELL PHYSIOL, V140, P601, DOI 10.1002/jcp.1041400327; LANKS KW, 1992, BIOCHEM BIOPH RES CO, V184, P394, DOI 10.1016/0006-291X(92)91206-6; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; Meng X, 1996, J CELL SCI, V109, P1677; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MORIMOTO R I, 1990, P1; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Nemoto T, 1998, BIOCHEM J, V330, P989, DOI 10.1042/bj3300989; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADANYI C, 1989, J BIOL CHEM, V264, P2568; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Soti C, 1998, EUR J BIOCHEM, V255, P611, DOI 10.1046/j.1432-1327.1998.2550611.x; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X	45	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4133	4139		10.1074/jbc.274.7.4133	http://dx.doi.org/10.1074/jbc.274.7.4133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933607	hybrid			2022-12-25	WOS:000078575500031
J	Mahon, MG; Lindstedt, KA; Hermann, M; Nimpf, J; Schneider, WJ				Mahon, MG; Lindstedt, KA; Hermann, M; Nimpf, J; Schneider, WJ			Multiple involvement of clusterin in chicken ovarian follicle development - Binding to two oocyte-specific members of the low density lipoprotein receptor gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS AMYLOID-BETA; APOLIPOPROTEIN-J; SULFATED GLYCOPROTEIN-2; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; GRANULOSA-CELLS; TESTIS FLUID; HUMAN PLASMA; LAYING HEN; EXPRESSION	The interaction of the female germ cell with somatic cells during the development of the ovarian follicle in the chicken provides a prime system to study gene expression. Here, we have uncovered the involvement of clusterin, the function(s) of which is still poorly understood, in this complex process. As revealed by molecular cloning, chicken clusterin is a 428-residue protein that migrates at 70 kDa on SDS-polyacrylamide gel electrophoresis and possesses most of the structural features of its mammalian successors. However, in contrast to mammalian clusterin, the chicken protein appears not to be cleaved intracellularly into a disulfide-linked heterodimer; possibly as a consequence thereof, it is not secreted constitutively and is absent from the circulation, where most of clusterin is found in mammals. In the ovary, clusterin is a major product of the somatic granulosa cells, in a pattern correlating with the developmental phases of individual follicles. In that, transcript levels are high not only at onset of vitellogenesis, but also in atretic follicles and in the postovulatory follicle sac, ie. in situations characterized by apoptotic events. Yolk of growing oocytes contains a 43-kDa truncated form of clusterin that does not appear to be synthesized within the oocyte, Rather, we here show for the first time that 70-kDa clusterin interacts not only with megalin, but also with two chicken oocyte-specific members of the low density lipoprotein receptor (LDLR) gene family. These receptors, termed LDLR-related protein with eight ligand binding repeats (LR8) and LDLR-related protein (380 kDa), likely internalize granulosa cell-derived 70-kDa clusterin, which may subsequently be processed to the 43-kDa product. Thus, chicken clusterin could serve as a marker for follicular atresia and resorption, and, based on its ability to bind several other proteins, it may serve as carrier for the receptor-mediated endocytosis into oocytes of components important for embryonic development, two hitherto unknown functions of this intriguing protein.	Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Schneider, WJ (corresponding author), Univ Vienna, Dept Mol Genet, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wjs@mol.univie.ac.at		Hermann, Marcela/0000-0003-2298-4269; Nimpf, Johannes/0000-0002-9273-3492				ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; BURKEY BF, 1991, J LIPID RES, V32, P1039; BUTTERWORTH GE, 1989, REV INT PSYCHOL SOC, V2, P9; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DESILVA HV, 1990, J BIOL CHEM, V265, P14292; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GILBERT AB, 1978, J REPROD FERTIL, V52, P227, DOI 10.1530/jrf.0.0520227; GILBERT AB, 1983, J REPROD FERTIL, V69, P221, DOI 10.1530/jrf.0.0690221; GILBERT AB, 1980, BRIT POULTRY SCI, V21, P257, DOI 10.1080/00071668008416667; Harlow E., 1988, ANTIBODIES LAB MANUA; Hermann M, 1998, FASEB J, V12, P897, DOI 10.1096/fasebj.12.10.897; HSUEH AJW, 1994, ENDOCR REV, V15, P707, DOI 10.1210/er.15.6.707; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; Johnson AL, 1996, ENDOCRINOLOGY, V137, P2059, DOI 10.1210/en.137.5.2059; JORDANSTARCK TC, 1994, J LIPID RES, V35, P194; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; Lindstedt KA, 1997, J BIOL CHEM, V272, P30221, DOI 10.1074/jbc.272.48.30221; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MICHEL D, 1989, ONCOGENE RES, V4, P127; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1994, J BIOL CHEM, V269, P212; PALUMBO A, 1995, J SOC GYNECOL INVEST, V2, P565, DOI 10.1016/1071-5576(94)00062-6; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; STIFANI S, 1991, J BIOL CHEM, V266, P19079; SYLVESTER SR, 1991, BIOL REPROD, V45, P195, DOI 10.1095/biolreprod45.1.195; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; TILLY JL, 1991, ENDOCRINOLOGY, V129, P2799, DOI 10.1210/endo-129-5-2799; TILLY JL, 1991, BIOL REPROD, V44, P305, DOI 10.1095/biolreprod44.2.305; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Waclawek M, 1998, BIOL REPROD, V59, P1230, DOI 10.1095/biolreprod59.5.1230; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825; [No title captured]	57	51	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4036	4044		10.1074/jbc.274.7.4036	http://dx.doi.org/10.1074/jbc.274.7.4036			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933595	hybrid			2022-12-25	WOS:000078575500019
J	Toth, I; Yuan, LP; Rogers, JT; Boyce, H; Bridges, KR				Toth, I; Yuan, LP; Rogers, JT; Boyce, H; Bridges, KR			Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; RESPONSIVE ELEMENT; NITRIC-OXIDE; OXIDATIVE STRESS; METABOLISM; TRANSLATION; ACTIVATION; ACONITASE; ERYTHROPOIETIN	Ferritin and transferrin receptor expression is posttranscriptionally regulated by a conserved mRNA sequence termed the iron-responsive element (IRE), to which a transacting protein called the iron-regulatory protein (IRP) is bound. Our data demonstrate that hypoxia powerfully enhances IRE/IRP-1 binding in human cell lines. Using the human hepatoma cell line Hep3B as a model, we found that 16 h in a 1% oxygen atmosphere markedly increases IRE/IRP-1 binding as assessed by electromobility shift assay. Hypoxia also decreased cytosolic aconitase activity. The hypoxia-enhanced IRE/IRP-1 binding stabilized the transferrin receptor message, increased the cellular mRNA content by over 10-fold, and doubled surface receptor expression. Simultaneously, hypoxia suppressed ferritin message translation. Hypoxia's effect was most strikingly depicted by the absence of ferritin synthesis in cells challenged with inorganic iron. Our results contrast with previously reported data (Hanson, E. S., and Leibold, E. A. (1998) J. Biol. Chem, 273, 7588-7593) in which a 3% oxygen atmosphere reduced IRE/IRP-1 binding in rat hepatoma cells. We discuss some possible reasons for the differences. In aggregate with other investigations involving responses to hypoxia, iron, or nitric oxide, our data indicate that cellular iron metabolic responses are complex and that IRE/IRP-1 interactions vary between cell lines and perhaps between species.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Hematol Div,Joint Ctr Sickle Cell & Thal, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bridges, KR (corresponding author), Joint Ctr Sickle Cell & Thalassem Disorders, BLI 327,221 Longwood Ave, Boston, MA 02115 USA.	bridges@calvin.bwh.harvard.edu		Rogers, Jack/0000-0003-1262-8578	NHLBI NIH HHS [HL 457940] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Constanzo F, 1986, NUCLEIC ACIDS RES, V14, P721; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; GOLBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; Kuriyama-Matsumura K, 1998, BIOCHEM BIOPH RES CO, V249, P241, DOI 10.1006/bbrc.1998.9046; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Menotti E, 1998, J BIOL CHEM, V273, P1821, DOI 10.1074/jbc.273.3.1821; MORRIS CJ, 1995, INT J BIOCHEM CELL B, V27, P109, DOI 10.1016/1357-2725(94)00084-O; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; QI Y, 1994, J NEUROCHEM, V63, P1485; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TOTH I, 1995, J BIOL CHEM, V270, P2846, DOI 10.1074/jbc.270.6.2846; TOTH I, 1995, J BIOL CHEM, V270, P19540, DOI 10.1074/jbc.270.33.19540; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Weiss G, 1997, BLOOD, V89, P680, DOI 10.1182/blood.V89.2.680; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	43	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4467	4473		10.1074/jbc.274.7.4467	http://dx.doi.org/10.1074/jbc.274.7.4467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933651	hybrid			2022-12-25	WOS:000078575500075
J	Giordano, R; Fouts, DL; Tewari, D; Colli, W; Manning, JE; Alves, MJM				Giordano, R; Fouts, DL; Tewari, D; Colli, W; Manning, JE; Alves, MJM			Cloning of a surface membrane glycoprotein specific for the infective form of Trypanosoma cruzi having adhesive properties to laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPOMASTIGOTE STAGE; BASEMENT-MEMBRANES; MAMMALIAN-CELLS; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; MONOCLONAL-ANTIBODIES; PROTEIN; BINDING; INVASION; FAMILY; ENTRY	Trypomastigotes of Trypanosoma cruzi express a set of surface glycoproteins known, collectively, as Tc-85. A monoclonal antibody to these proteins, named H1A10, inhibits (50-90%) in vitro parasite interiorization into host cells, thus implicating these glycoproteins in the infection process. Two DNA inserts, a genomic DNA fragment and a full-length cDNA encoding the H1A10 epitope, have now been cloned and characterized. Results show that both have high sequence identity with all reported members of the gp85/trans-sialidase gene family, although the H1A10 epitope exists only in the Tc-85 subset of the family. The epitope has been mapped by competition of antibody binding to a Tc-85 recombinant protein with peptides having sequences predicted by the Tc-85 DNA sequence, which contains also putative N-glycosylation sites and COOH-terminal glycosylphosphatidylinositol anchor insertion sites, as expected, since an N-glycan chain and a glycosylphosphatidylinositol anchor have been characterized previously in the Tc-85 subset. The protein encoded by the full-length cDNA insert binds to cells and in vitro to laminin, but not to gelatin or fibronectin, in a saturable manner. For the first time it was possible to assign a defined ligand to a sequenced glycoprotein belonging to the gp85 family, This fact, together with the reported binding of family members to cell surfaces, reinforces the hypothesis that this family encodes glycoproteins with similar sequences but differing enough as to bind to different ligands and thus forming a family of adhesion glycoproteins enabling the parasite to overcome the barriers interposed by cell membranes, extracellular matrices, and basal laminae.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, SP, Brazil; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	Universidade de Sao Paulo; University of California System; University of California Irvine	Alves, MJM (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05599970 Sao Paulo, SP, Brazil.	mjmalves@quim.iq.usp.br	Colli, Walter/G-1188-2012; Alves, Maria Julia/K-8976-2012; Giordano, Ricardo/A-2074-2010; Colli, Walter/ABA-5440-2021; Colli, Walter/AAW-7649-2021	Alves, Maria Julia/0000-0001-7211-9631; Giordano, Ricardo/0000-0001-8116-6771; Colli, Walter/0000-0001-7305-4673	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018873] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18873] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abuin G, 1996, EXP PARASITOL, V82, P290, DOI 10.1006/expr.1996.0036; ALVES MJM, 1986, MOL BIOCHEM PARASIT, V21, P75, DOI 10.1016/0166-6851(86)90081-2; ANDREWS NW, 1984, EUR J BIOCHEM, V140, P599, DOI 10.1111/j.1432-1033.1984.tb08144.x; ARAGUTH MF, 1988, PARASITE IMMUNOL, V10, P707, DOI 10.1111/j.1365-3024.1988.tb00256.x; AUBIN G, 1989, MOL BIOCHEM PARASIT, V35, P229; BEARD CA, 1985, MOL BIOCHEM PARASIT, V16, P199, DOI 10.1016/0166-6851(85)90087-8; BEARD CA, 1988, MOL BIOCHEM PARASIT, V28, P227, DOI 10.1016/0166-6851(88)90007-2; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOSCHETTI MA, 1987, MOL BIOCHEM PARASIT, V24, P175, DOI 10.1016/0166-6851(87)90104-6; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; CANO MI, 1995, MOL BIOCHEM PARASIT, V71, P273, DOI 10.1016/0166-6851(95)00066-A; Cazzulo JJ, 1997, BIOL CHEM, V378, P1; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; COLLI W, 1993, FASEB J, V7, P1257, DOI 10.1096/fasebj.7.13.8405811; COUTO AS, 1987, MOL BIOCHEM PARASIT, V26, P145, DOI 10.1016/0166-6851(87)90138-1; COUTO AS, 1993, EUR J BIOCHEM, V217, P597, DOI 10.1111/j.1432-1033.1993.tb18282.x; COUTO AS, 1990, MOL BIOCHEM PARASIT, V39, P101, DOI 10.1016/0166-6851(90)90012-B; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; FERNANDEZ MA, 1993, EUR J IMMUNOL, V23, P552, DOI 10.1002/eji.1830230238; Finlay BB, 1990, CURR OPIN CELL BIOL, V2, P815, DOI 10.1016/0955-0674(90)90078-S; FURTADO GC, 1992, INFECT IMMUN, V60, P2337, DOI 10.1128/IAI.60.6.2337-2342.1992; GIORDANO R, 1994, MOL BIOCHEM PARASIT, V65, P85, DOI 10.1016/0166-6851(94)90117-1; GONCALVES MF, 1991, EXP PARASITOL, V72, P43, DOI 10.1016/0014-4894(91)90119-H; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Hall B. Fenton, 1993, Seminars in Cell Biology, V4, P323, DOI 10.1006/scel.1993.1039; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAHN S, 1990, J EXP MED, V172, P589, DOI 10.1084/jem.172.2.589; Kahn SJ, 1997, J IMMUNOL, V159, P4444; KATZIN AM, 1983, BIOCHIM BIOPHYS ACTA, V727, P403, DOI 10.1016/0005-2736(83)90425-X; LEBLOND CP, 1989, AM J ANAT, V185, P367, DOI 10.1002/aja.1001850403; LIMA MF, 1989, MOL BIOCHEM PARASIT, V33, P159, DOI 10.1016/0166-6851(89)90030-3; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; Mercurio AM, 1990, CURR OPIN CELL BIOL, V2, P845, DOI 10.1016/0955-0674(90)90082-P; ORTEGABARRIA E, 1992, INFECT AGENT DIS, V1, P136; RAMIREZ MI, 1993, INFECT IMMUN, V61, P3636, DOI 10.1128/IAI.61.9.3636-3641.1993; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTANA JM, 1997, BIOCHEM J, V324, P129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Williams JA, 1995, DNA CLONING, P15; WRIGHTSMAN RA, 1994, J IMMUNOL, V153, P3148; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; Zhang LH, 1997, MOL BIOCHEM PARASIT, V87, P183, DOI 10.1016/S0166-6851(97)00066-2; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129; ZINGALES B, 1982, MOL BIOCHEM PARASIT, V6, P111, DOI 10.1016/0166-6851(82)90069-X	50	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3461	3468		10.1074/jbc.274.6.3461	http://dx.doi.org/10.1074/jbc.274.6.3461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920891	hybrid, Green Published			2022-12-25	WOS:000078428200031
J	Kuo, SY; Chesrown, SE; Mellott, JK; Rogers, RJ; Hsu, JL; Nick, HS				Kuo, SY; Chesrown, SE; Mellott, JK; Rogers, RJ; Hsu, JL; Nick, HS			In vivo architecture of the manganese superoxide dismutase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-LESS PROMOTER; LIGATION-MEDIATED PCR; TUMOR NECROSIS FACTOR; TNF-ALPHA; MALIGNANT PHENOTYPE; INITIATOR ELEMENT; EPITHELIAL-CELLS; GENE-EXPRESSION; RECEPTOR GENE; DNASE-I	Mitochondrial manganese superoxide dismutase (Mn-SOD) is the primary cellular defense against damaging superoxide radicals generated by aerobic metabolism and as a consequence of inflammatory disease. Elevated expression of Mn-SOD therefore provides a potent cytoprotective advantage during acute inflammation. Mn SOD contains a GC-rich and TATA/CAAT-less promoter characteristic of a housekeeping gene. In contrast, however, Mn-SOD expression is dramatically regulated in a variety of cells by numerous proinflammatory mediators, including lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-1. To understand the underlying regulatory mechanisms controlling Mn-SOD expression, me utilized DNase I-hypersensitive (HS) site analysis, which revealed seven hypersensitive sites throughout the gene. Following high resolution DNase I HS site analysis, the promoter was found to contain five HS subsites, including a subsite that only appears following stimulus treatment. Dimethyl sulfate in vivo footprinting identified 10 putative constitutive protein-DNA binding sites in the proximal Mn-SOD promoter as well as two stimulus-specific enhanced guanine residues possibly due to alterations in chromatin structure. In vitro footprinting data implied that five of the binding sites may be occupied by a combination of Sp1 and gut-enriched Kruppel-like factor. These studies have revealed the complex promoter architecture of a highly regulated cytoprotective gene.	Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Nick, HS (corresponding author), Univ Florida, Coll Med, Dept Neurosci, POB 100244,JHMHC, Gainesville, FL 32610 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL39593] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; BORG LAH, 1992, ENDOCRINOLOGY, V130, P2851, DOI 10.1210/en.130.5.2851; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG737, DOI 10.1152/ajpgi.1994.266.4.G737; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EGGERS B, 1994, AM J HUM GENET, V55, P183; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; JACOBY DB, 1994, FREE RADICAL BIO MED, V16, P821, DOI 10.1016/0891-5849(94)90198-8; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI JJ, 1995, ONCOGENE, V10, P1989; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MADHUSUDHAN KT, 1995, BIOCHEMISTRY-US, V34, P1288, DOI 10.1021/bi00004a023; MCCORD JM, 1982, CAN J PHYSIOL PHARM, V60, P1346, DOI 10.1139/y82-201; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SHAFFER JB, 1990, FREE RADICAL BIO MED, V8, P497, DOI 10.1016/0891-5849(90)90064-P; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Toda H, 1997, J BIOCHEM-TOKYO, V121, P1035; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; VALENTINE JF, 1992, GASTROENTEROLOGY, V103, P905, DOI 10.1016/0016-5085(92)90024-S; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WARD PA, 1988, FREE RADICAL BIO MED, V5, P403, DOI 10.1016/0891-5849(88)90114-1; WERNER H, 1993, ADV EXP MED BIOL, V343, P91; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YAHARA O, 1991, RES COMMUN CHEM PATH, V72, P315; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	52	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3345	3354		10.1074/jbc.274.6.3345	http://dx.doi.org/10.1074/jbc.274.6.3345			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920876	hybrid			2022-12-25	WOS:000078428200016
J	Tomitori, H; Kashiwagi, K; Sakata, K; Kakinuma, Y; Igarashi, K				Tomitori, H; Kashiwagi, K; Sakata, K; Kakinuma, Y; Igarashi, K			Identification of a gene for a polyamine transport protein in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES SPERMINE UPTAKE; TISSUE-CULTURE CELLS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ORNITHINE DECARBOXYLASE; ANTIZYME; KINASE; GROWTH	Properties of a membrane protein encoded by YLL028w were examined using yeast cells transformed with the gene. The transformed cells became resistant to polyamine toxicity, and the resistance was overcome by bafilomycin A(1), an inhibitor of vacuolar H+-ATPase. Although spermine uptake activity of the transformed cells was almost the same as that of wild type cells, the uptake activity of vacuolar membrane vesicles from the transformed cells was higher than that from wild type cells. The transformed cells became resistant to MGBG (methylglyoxal bis(guanylhydrazone)) and paraquat, but not Ni2+ and Co2+, suggesting that the protein encoded by YLL028w is a transport protein specific for polyamines. When the YLL028w gene was disrupted by inserting the HIS3 gene, the cells became sensitive to polyamines, and spermine uptake activity of the vacuolar membrane vesicles decreased significantly. The accumulated spermine in YLL028w gene-disrupted cells decreased greatly compared with that in wild type cells. The results indicate that a membrane protein encoded by YLL028w (TPO1) is a polyamine transport protein on the vacuolar membrane.	Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	Chiba University	Igarashi, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAISER C, 1994, METHODS YEAST GENETI, P141; KAKINUMA Y, 1995, BIOCHEM BIOPH RES CO, V216, P985, DOI 10.1006/bbrc.1995.2717; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUYAMA T, 1994, BBA-BIOMEMBRANES, V1194, P289, DOI 10.1016/0005-2736(94)90311-5; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Nozaki T, 1996, BIOCHEM BIOPH RES CO, V228, P452, DOI 10.1006/bbrc.1996.1681; PEGG AE, 1988, CANCER RES, V48, P759; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604; Woolridge DP, 1997, J BIOL CHEM, V272, P8864	24	85	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3265	3267		10.1074/jbc.274.6.3265	http://dx.doi.org/10.1074/jbc.274.6.3265			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920864	hybrid			2022-12-25	WOS:000078428200004
J	Benedict, WF; Lerner, SP; Zhou, J; Shen, XH; Tokunaga, H; Czerniak, B				Benedict, WF; Lerner, SP; Zhou, J; Shen, XH; Tokunaga, H; Czerniak, B			Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer	ONCOGENE			English	Article						bladder cancer; RB; p16; prognosis	ALTERED EXPRESSION; RB PROTEIN; PRB ALTERATIONS; CELL-CARCINOMA; HIGH-FREQUENCY; GENE-PRODUCT; LUNG CANCERS; TUMORS; INACTIVATION; MUTATIONS	Recent studies have shown that patients whose bladder cancer exhibit overexpression of RB protein as measured by immunohistochemical analysis do equally poorly as those with loss of RB function. We hypothesized that loss of p16 protein function could be related to RB overexpression, since p16 can induce transcriptional downregulation of RB and its loss may lead to aberrant RB regulation. Conversely, loss of RB function has been associated with high p16 protein expression in several other tumor types, In the present study RB negative bladder tumors also exhibited strong nuclear p16 staining while each tumor with strong, homogeneous RB nuclear staining were p16 negative, supporting our hypothesis. To expand on these immunohistochemical studies additional cases were selected in which the status of the p16 encoding gene had been determined at the molecular level. Absent p16 and high RB protein expression was found in the tumors having loss of heterozygosity within 9p21 and a structural change (mutation or deletion) of the remaining p16 encoding gene allele, confirming the staining results. These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with toss of p16 function and implies that loss of p16 function could be equally deleterious as RB loss in bladder and likely other cancers.	Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Benedict, WF (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Box 13, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA054672, R01CA066723, R29CA066723] Funding Source: NIH RePORTER; NCI NIH HHS [CA66723, CA54672] Funding Source: Medline; NEI NIH HHS [EY06195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; CordonCardo C, 1997, CANCER RES, V57, P1217; Cote RJ, 1998, CANCER RES, V58, P1090; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Grossman HB, 1998, CLIN CANCER RES, V4, P829; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISHIKAWA J, 1991, CANCER RES, V51, P5376; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kratzke RA, 1996, CANCER RES, V56, P3415; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, ONCOGENE, V6, P1139; YEAGER T, 1995, CANCER RES, V55, P493; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	35	105	108	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1197	1203		10.1038/sj.onc.1202452	http://dx.doi.org/10.1038/sj.onc.1202452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022125	Bronze			2022-12-25	WOS:000078510700008
J	Jung, YS; Roberts, VA; Stout, CD; Burgess, BK				Jung, YS; Roberts, VA; Stout, CD; Burgess, BK			Complex formation between Azotobacter vinelandii ferredoxin I and its physiological electron donor NADPH-ferredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; ANABAENA SP PCC-7119; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; 7FE FERREDOXIN; ANGSTROM RESOLUTION; SULFOLOBUS-ACIDOCALDARIUS; ENCODING FLAVODOXIN; SPINACH FERREDOXIN; 3FE-4S CLUSTER	In Azotobacter vinelandii, deletion of the fdxA gene, which encodes ferredoxin I (FdI), leads to activation of the expression of the fpr gene, which encodes NADPH-ferredoxin reductase (FPR), In order to investigate the relationship of these two proteins further, the interactions of the two purified proteins have been examined, AvFdI forms a specific 1:1 cross-linked complex with AvFPR through ionic interactions formed between the Lys residues of FPR and Asp/Glu residues of FdI, The Lys in FPR has been identified as Lys(258), a residue that forms a salt bridge with one of the phosphate oxygens of FAD in the absence of FdI. UV-Vis and circular dichroism data show that on binding FdI, the spectrum of the FPR flavin is hyperchromatic and red-shifted, confirming the interaction region close to the FAD, Cytochrome c reductase assays and electron paramagnetic resonance data show that electron transfer between the two proteins is pH-dependent and that the [3Fe-4S](+) cluster of FdI is specifically reduced by NADPH via FPR, suggesting that the [3Fe-4S] cluster is near FAD in the complex. To further investigate the FPR:FdI interaction, the electrostatic potentials for each protein were calculated. Strongly negative regions around the [3Fe-4S] cluster of FdI are electrostatically complementary with a strongly positive region overlaying the FAD of FPR, centered on Lys(258). These proposed interactions of FdI with FPR are consistent with cross-linking, peptide mapping, spectroscopic, and electron transfer data and strongly support the suggestion that the two proteins are physiological redox partners.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of California System; University of California Irvine; Scripps Research Institute	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu						ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; AONO S, 1994, BIOCHEM BIOPH RES CO, V201, P938, DOI 10.1006/bbrc.1994.1792; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BENEMANN JR, 1971, BIOCHIM BIOPHYS ACTA, V226, P205, DOI 10.1016/0005-2728(71)90087-9; BENNETT LT, 1988, J BIOL CHEM, V263, P1364; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; BOHME H, 1987, BIOCHIM BIOPHYS ACTA, V891, P1, DOI 10.1016/0005-2728(87)90076-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Coligan JE, 1995, CURRENT PROTOCOLS PR; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; DUPORT C, 1990, NUCLEIC ACIDS RES, V18, P4618, DOI 10.1093/nar/18.15.4618; FILLAT MF, 1990, NUCLEIC ACIDS RES, V18, P7161, DOI 10.1093/nar/18.23.7161; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; GomezMoreno C, 1996, BIOCHEM SOC T, V24, P111, DOI 10.1042/bst0240111; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; HARDER J, 1992, J BIOL CHEM, V267, P25548; HOWARD JB, 1983, J BIOL CHEM, V258, P508; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; Macedo AL, 1996, BIOCHEM BIOPH RES CO, V229, P524, DOI 10.1006/bbrc.1996.1837; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MEDINA M, 1992, FEBS LETT, V298, P25, DOI 10.1016/0014-5793(92)80014-8; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; MERRITT EA, 1993, ACTA CRYSTALLOGR D, V49, P272, DOI 10.1107/S0907444992007248; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MOUESCA JM, 1994, J AM CHEM SOC, V116, P11898, DOI 10.1021/ja00105a033; Nishida H, 1996, PROTEINS, V26, P32, DOI 10.1002/(SICI)1097-0134(199609)26:1<32::AID-PROT3>3.0.CO;2-I; OHMORI D, 1976, BIOCHEM BIOPH RES CO, V72, P566, DOI 10.1016/S0006-291X(76)80078-2; Prasad GS, 1998, PROTEIN SCI, V7, P2541, DOI 10.1002/pro.5560071207; PUEYO JJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P367, DOI 10.1016/0003-9861(92)90697-U; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schmitz S, 1998, BBA-BIOENERGETICS, V1363, P85, DOI 10.1016/S0005-2728(97)00085-6; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; TROWER MK, 1990, BIOCHIM BIOPHYS ACTA, V1037, P281, DOI 10.1016/0167-4838(90)90026-C; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; WADSWORTH CL, 1992, TECHNIQUES PROTEIN C, V3, P61; WANG SP, 1995, J BACTERIOL, V177, P2901, DOI 10.1128/jb.177.10.2901-2907.1995; Wang XZ, 1997, APPL ENVIRON MICROB, V63, P1623, DOI 10.1128/AEM.63.4.1623-1626.1997; Yannone SM, 1998, J BIOL INORG CHEM, V3, P253, DOI 10.1007/s007750050229; Yannone SM, 1997, J BIOL CHEM, V272, P14454, DOI 10.1074/jbc.272.22.14454; YOCH DC, 1972, J BIOL CHEM, V247, P4514	63	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2978	2987		10.1074/jbc.274.5.2978	http://dx.doi.org/10.1074/jbc.274.5.2978			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915836	hybrid			2022-12-25	WOS:000078319500054
J	Sexl, V; Diehl, JA; Sherr, CJ; Ashmun, R; Beach, D; Roussel, MF				Sexl, V; Diehl, JA; Sherr, CJ; Ashmun, R; Beach, D; Roussel, MF			A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2	ONCOGENE			English	Article						cdc25; cyclin-dependent kinases; colony-stimulating factor-1 receptor; cell cycle; tyrosine phosphatase; p27(Kip1) inhibitor	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; G1 PHASE; PROTEASOME PATHWAY; ACTIVATING KINASE; DNA-REPLICATION; GROWTH-FACTOR; C-MYC; PHOSPHORYLATION	The cdc25A phosphatase removes inhibitory phosphates from threonine-14 and tyrosine-15 of cyclin dependent kinase-2 (cdk2) in vitro, and it is therefore widely assumed that cdc25A positively regulates cyclin E- and A-associated cdk2 activity at the G1 to S phase transition of the mammalian cell division cycle. Human cdc25A was introduced into mouse NIH3T3 fibroblasts co-expressing a form of the colony-stimulating factor-1 (CSF-1) receptor that is partially defective in transducing mitogenic signals. Cdc25A enabled these cells to form colonies in semisolid medium containing serum plus human recombinant CSF-1 in a manner reminiscent of cells rescued by c-myc. However, cdc25A-rescued cells could not proliferate in chemically defined medium containing CSF-1 and continued to require c-myc function for S phase entry. When contact-inhibited cells overexpressing cdc25A were dispersed and stimulated to synchronously enter the cell division cycle, they entered S phase 2-3 h earlier than their parental untransfected counterparts. Shortening of G1 phase temporally correlated with more rapid degradation of the cdk inhibitor p27(Kip1) and with premature activation of cyclin A-dependent cdk2. Paradoxically, tyrosine phosphorylation of cdk2 increased considerably as cells entered S phase, and cdc25A overexpression potentiated rather than diminished this effect. At face value, these results are inconsistent with the hypothesis that cdc25A acts directly on cdk2 to activate its S phase promoting function.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; Inst Child Hlth, London WC1N 1EH, England	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of London; University College London	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016; Sexl, Veronika/B-8657-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139; Sexl, Veronika/0000-0001-9363-0412	NCI NIH HHS [CA-21765, CA-56819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA056819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P21; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN T, 1993, BONE MARROW TRANSPL, V12, P1; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KARN J, 1989, ONCOGENE, V4, P773; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NAGATA A, 1991, NEW BIOL, V3, P959; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SANDHU K, 1990, P NATL ACAD SCI USA, V87, P5139; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu X, 1996, J BIOL CHEM, V271, P5118	68	87	88	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					573	582		10.1038/sj.onc.1202362	http://dx.doi.org/10.1038/sj.onc.1202362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989807				2022-12-25	WOS:000078394400002
J	Qing, J; Wei, D; Maher, VM; McCormick, JJ				Qing, J; Wei, D; Maher, VM; McCormick, JJ			Cloning and characterization of a novel gene encoding a putative transmembrane protein with altered expression in some human transformed and tumor-derived cell lines	ONCOGENE			English	Article						differential display; cell transformation; gene expression	EUKARYOTIC MESSENGER-RNAS; MALIGNANT TRANSFORMATION; DIFFERENTIAL DISPLAY; HUMAN FIBROBLASTS; CARCINOGENESIS; RECEPTOR; GROWTH; MODEL; STRAIN	Identification and characterization of genes expressed in normal cells and decreased in their malignant counterparts is an important method for detecting candidate tumor suppressors. Using differential display of mRNAs from nontumorigenic infinite life span human fibroblast cell strain MSU-1.1 and an isogenic fibrosarcoma-derived cell line, 6A/SB1, which was derived from chemical carcinogen transformed MSU-1.1 cells, we identified a no, el gene, ST7, showing sixfold lower expression in 6A/SB1 cells compared with parental MSU-1.1 cells. Molecular cloning of a near full-length cDNA revealed that the no, el gene encodes a putative transmembrane protein composed of 859 amino acids: the 492 N-terminal amino acids including a fivefold cysteine-rich repeat of 40 amino acids homologous to the ligand binding repeat of the known low density Lipoprotein receptor, a 24 hydrophobic amino acid stretch spanning the plasma membrane, and a C-terminal domain of 343 residues, ST7 is located on human chromosome 8, band q22.2-23.1, the same locus as the genes involved in acute myeloid leukemia and a locus of high polymorphism in cancer biopsies. The ST7 gene is widely expressed in normal human tissues and is particularly abundant in human heart and skeletal muscle. Northern analysis of 15 tumor cell lines derived from patients and 16 cell lines established from tumors formed in athymic mice by MSU-1.1 cells transformed in culture by various methods showed that 16 of the 31 cell lines ha,le low or undetectable levels of ST7 mRNA. Furthermore, Western blotting analysis using a specific anti-peptide antibody demonstrated that the level of ST7 protein is high in normal fibroblasts and low in 12 sarcoma-derived cell lines tested. Altered expression of ST7 appears to occur at both the transcriptional and post-transcriptional levels. These studies are a first step in characterizing a novel putative receptor protein, whose expression is downregulated in some malignantly transformed cells, and which may play an important role in the transformation process of these cells.	Michigan State Univ, Dept Microbiol, Carcinogenesis Lab, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Canc, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	McCormick, JJ (corresponding author), Michigan State Univ, Dept Microbiol, Carcinogenesis Lab, FST Bldg, E Lansing, MI 48824 USA.				NCI NIH HHS [CA60907] Funding Source: Medline; NIA NIH HHS [AG11026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FARBER E, 1984, CANCER RES, V44, P4217; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUYA T, 1989, CANCER GENET CYTOGEN, V43, P131, DOI 10.1016/0165-4608(89)90136-2; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MCCORMICK JJ, 1994, RISK ANAL, V14, P257, DOI 10.1111/j.1539-6924.1994.tb00240.x; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; PARK NH, 1995, ONCOGENE, V10, P2145; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reinhold DS, 1996, INT J RADIAT BIOL, V69, P707, DOI 10.1080/095530096145454; REZNIKOFF CA, 1993, SEMIN CANCER BIOL, V4, P143; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J., 2002, MOL CLONING LAB MANU; SHABTAI F, 1988, CANCER GENET CYTOGEN, V31, P113, DOI 10.1016/0165-4608(88)90018-0; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STONER GD, 1991, CANCER RES, V51, P365; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237	33	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					335	342		10.1038/sj.onc.1202290	http://dx.doi.org/10.1038/sj.onc.1202290			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927190				2022-12-25	WOS:000078166500006
J	Reichert, M; Eick, D				Reichert, M; Eick, D			Analysis of cell cycle arrest in adipocyte differentiation	ONCOGENE			English	Article						3T3-L1 cells; differentiation; adipocytes; cell cycle; Rb; SV40 large T antigen	LARGE T-ANTIGEN; BINDING-PROTEIN-ALPHA; MYC-INDUCED APOPTOSIS; LARGE TUMOR-ANTIGEN; SV40 LARGE-T; C-MYC; DNA-REPLICATION; C/EBP-ALPHA; DEPENDENT KINASES; TRANSCRIPTIONAL REGULATION	Confluent 3T3-L1 preadipocytes differentiate to adipocytes in the presence of insulin, dexamethasone, and isobutylmethylxanthine (IDI), A transient increase of DNA synthesis is induced in 3T3-L1 cells 18 h after addition of IDI, followed by an arrest in the G1 phase of the cell cycle. Growth arrested cells express the protooncogene oncogene c-myc and gene for the CCAAT/enhancer binding protein (C/EBP alpha) between day 2 and 5, While c-Myc is strongly implicated in cell proliferation, C/EBP alpha is a differentiation-specific transcription factor with antiproliferative, activity. Here we have characterized the cell cycle arrest in differentiating 3T3-L1 cells. Arrested cells express the Cdk inhibitors p21 and p27, but, at the same time, show hyperphosphorylation of Rb and expression of the E2F-regulated thymidine kinase gene. The addition of new serum to arrested cells resulted in cyclin A expression and Cdk2 activity, but not in DNA synthesis, Simian virus 40 large tumor antigen (LTAg) is a potent mitogen, The mutant LTAg-K1, deficient in binding of pocket proteins and unable to induce DNA synthesis in serum-starved 3T3-L1 cells, efficiently induced DNA synthesis in differentiating 3T3-L1 cells. This indicates that pocket proteins are probably not in,ol,ed in the control of the cell cycle arrest during 3T3-L1 cell differentiation. Our data suggest that the differentiation-specific cell cycle block in 3T3-L1 cells is resistant to high levels of c-Myc, inactivation of pocket proteins, upregulation of cyclin A levels, and Cdk2 activation, but can be abolished by a function of LTAg that is independent of binding to pocket proteins.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Eick, D (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.							BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Constance CM, 1996, MOL CELL BIOL, V16, P3878; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GRANA X, 1995, ONCOGENE, V11, P211; GRATZNER HG, 1985, CYTOMETRY, V6, P563, DOI 10.1002/cyto.990060610; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KIESS M, 1995, ONCOGENE, V10, P159; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MEUTH M, 1974, CELL, V3, P367, DOI 10.1016/0092-8674(74)90052-X; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OHKUBO Y, 1994, EXP CELL RES, V214, P270, DOI 10.1006/excr.1994.1258; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WOLF DA, 1995, ONCOGENE, V10, P2067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	51	100	101	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					459	466		10.1038/sj.onc.1202308	http://dx.doi.org/10.1038/sj.onc.1202308			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927202				2022-12-25	WOS:000078166500018
J	Xu, Y; Krishnan, A; Wan, XS; Majima, H; Yeh, CC; Ludewig, G; Kasarskis, EJ; St Clair, DK				Xu, Y; Krishnan, A; Wan, XS; Majima, H; Yeh, CC; Ludewig, G; Kasarskis, EJ; St Clair, DK			Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells	ONCOGENE			English	Article						tumor suppressor gene; mutation; promoter; transcription factors; MnSOD; reactive oxygen species	TRANSCRIPTION FACTOR; MALIGNANT PHENOTYPE; BINDING PROTEINS; TRANSGENIC MICE; DNA-BINDING; ACTIVATION; SP1; SUPPRESSION; OVEREXPRESSION; SITES	Manganese superoxide dismutase (MnSOD) has been shown to play an important role in preventing the development of cancer. MnSOD activity is reduced in many transformed cells and tumor tissues. We previously showed that the reduced level of MnSOD activity in cancer cells was not due to a defect in the primary structure of MnSOD protein, but rather was due to defects in gene expression. To elucidate the cause for the reduced expression of human MnSOD in cancer, we investigated the nucleotide sequence in the regulatory region of the MnSOD gene in a normal human cell line and various human tumor cell lines. A DNA fragment spanning 3.4 kb 5' flanking region of the MnSOD gene isolated from a normal human genomic DNA library was used to determine the DNA sequence of MnSOD promoter. PCR primers were used for amplification of the 3.4 kb 5' flanking region of the human MnSOD gene in cancer cells. Sequence analysis identified three heterozygous mutations in the proximal region of the promoter in five human tumor cell lines; These mutations, clustered around the GC-rich region of the human MnSOD promoter, change the binding pattern of AP-2 and lead to a reduction in transcription activity using a luciferase reporter assay system. These results suggest that the reduced level of MnSOD expression in some tumor cells is, at least in part, due to a defect in the DNA sequence of the promoter region.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.		Majima, Hideyuki J./K-3778-2019; Ludewig, Gabriele/A-2745-2008	Ludewig, Gabriele/0000-0003-2385-7720	NCI NIH HHS [CA 59835, CA 49797] Funding Source: Medline; NHLBI NIH HHS [HL 03544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA059835] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL003544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; IKEDA K, 1993, GENE, V136, P341; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Keller JN, 1998, J NEUROSCI, V18, P687; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LI JJ, 1995, ONCOGENE, V10, P1989; Li M, 1997, ONCOGENE, V15, P1535, DOI 10.1038/sj.onc.1201325; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SAFFORD SE, 1994, CANCER RES, V54, P4261; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; StClair DK, 1997, ONCOL REP, V4, P753; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; StClair DK, 1996, ONCOL REP, V3, P429; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; STCLAIR DK, 1991, CANCER RES, V51, P939; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; URANO M, 1995, CANCER RES, V55, P2490; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; YEN HC, 1997, J BIOMED LAB SCI, V9, P40; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	53	107	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					93	102		10.1038/sj.onc.1202265	http://dx.doi.org/10.1038/sj.onc.1202265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926924				2022-12-25	WOS:000078166000011
J	Shibata, Y; Hayakawa, M; Takiguchi, H; Shiroza, T; Abiko, Y				Shibata, Y; Hayakawa, M; Takiguchi, H; Shiroza, T; Abiko, Y			Determination and characterization of the hemagglutinin-associated short motifs found in Porphyromonas gingivalis multiple gene products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-GINGIVALIS; CYSTEINE PROTEINASE; ARG-GINGIPAIN; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; STRUCTURAL CHARACTERIZATION; PERIODONTAL-DISEASE; MOLECULAR-CLONING; PROTEASE; COLONIZATION; MELANINOGENICUS	Porphyromonas gingivalis is a Gram-negative anaerobic bacterial species implicated as an important pathogen in the development of adult periodontitis, In our studies of P. gingivalis and ways to protect against periodontal disease, we have prepared the monoclonal antibody mAb-Pg-vc and its recombinant antibody, which are capable of inhibiting the hemagglutinating activity of P. gingivalis (Shibata, Y,, Kurihara, K,, Takiguchi, H., and Abiko, Y, (1998) Infect. Immun, 66, 2207-2212), To clarify the antigenically related hemagglutinating do. mains, we attempted to determine the minimum motifs responsible for P, gingivalis hemagglutinin, Initially, the 9-kilobase EcoRI fragment encoding the 130-kDa protein was cloned from the P, gingivalis chromosome using mAb-Pg-vc, Western blot analysis of nested deletion clones, the competition experiments using synthetic peptides, and the binding assay of the phage-displayed peptides using the mAb-Pg-vc allowed us to identify the minimum motifs, PVQNLT, Furthermore, the presence of multi-gene family coding for this epitope was confirmed via Southern blot analysis and PCR using the primers complementary to the domain corresponding to this epitope, It is suggested that the hemagglutinin-associated motif may be PVQNLT and that the gene families specifying this motif found in P, gingivalis chromosome encode many hemagglutinin and/or hemagglutinin-related proteases.	Nihon Univ, Sch Dent Matsudo, Dept Biochem, Chiba 2718587, Japan	Nihon University	Abiko, Y (corresponding author), Nihon Univ, Sch Dent Matsudo, Dept Biochem, 2-870-1 Sakaecho Nishi, Chiba 2718587, Japan.							AduseOpoku J, 1997, J BACTERIOL, V179, P4778, DOI 10.1128/jb.179.15.4778-4788.1997; ADUSEOPOKU J, 1995, INFECT IMMUN, V63, P4744, DOI 10.1128/IAI.63.12.4744-4754.1995; BarkocyGallagher GA, 1996, J BACTERIOL, V178, P2734, DOI 10.1128/jb.178.10.2734-2741.1996; BEDI GS, 1994, J BIOL CHEM, V269, P599; BOYD J, 1984, INFECT IMMUN, V45, P403, DOI 10.1128/IAI.45.2.403-409.1984; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; CHU L, 1991, INFECT IMMUN, V59, P1932, DOI 10.1128/IAI.59.6.1932-1940.1991; Curtis MA, 1996, INFECT IMMUN, V64, P2532, DOI 10.1128/IAI.64.7.2532-2539.1996; DONIS RO, 1989, VIROLOGY, V169, P408, DOI 10.1016/0042-6822(89)90166-9; FLETCHER HM, 1994, INFECT IMMUN, V62, P4279, DOI 10.1128/IAI.62.10.4279-4286.1994; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; Han NM, 1996, INFECT IMMUN, V64, P4000, DOI 10.1128/IAI.64.10.4000-4007.1996; HIRATSUKA K, 1992, ARCH ORAL BIOL, V37, P717, DOI 10.1016/0003-9969(92)90078-M; HOLT S C, 1991, Critical Reviews in Oral Biology and Medicine, V2, P177; ISOGAI H, 1988, ARCH ORAL BIOL, V33, P479, DOI 10.1016/0003-9969(88)90028-3; Kelly CG, 1997, CLIN EXP IMMUNOL, V110, P285; Kiyama M, 1998, BBA-GENE STRUCT EXPR, V1396, P39, DOI 10.1016/S0167-4781(97)00225-X; Kuramitsu H K, 1995, Adv Dent Res, V9, P37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ MS, 1991, J BACTERIOL, V173, P4263, DOI 10.1128/JB.173.14.4263-4270.1991; LANTZ MS, 1991, J BACTERIOL, V173, P495, DOI 10.1128/jb.173.2.495-504.1991; MADDEN TE, 1995, INFECT IMMUN, V63, P238, DOI 10.1128/IAI.63.1.238-247.1995; MALEY J, 1994, FEMS MICROBIOL LETT, V123, P219, DOI 10.1016/0378-1097(94)90298-4; NAITO Y, 1988, J DENT RES, V67, P1075, DOI 10.1177/00220345880670080301; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; NISHIKATA M, 1991, BIOCHEM BIOPH RES CO, V178, P336, DOI 10.1016/0006-291X(91)91819-X; Okamoto K, 1998, J BIOL CHEM, V273, P21225, DOI 10.1074/jbc.273.33.21225; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; OKUDA K, 1974, ARCH ORAL BIOL, V19, P415, DOI 10.1016/0003-9969(74)90184-8; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; PIKE R, 1994, J BIOL CHEM, V269, P406; POTEMPA J, 1995, TRENDS MICROBIOL, V3, P430, DOI 10.1016/S0966-842X(00)88996-9; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; Shibata Y, 1998, INFECT IMMUN, V66, P2207, DOI 10.1128/IAI.66.5.2207-2212.1998; Slakeski N, 1996, BIOCHEM BIOPH RES CO, V224, P605, DOI 10.1006/bbrc.1996.1073; SLOTS J, 1984, J DENT RES, V63, P412, DOI 10.1177/00220345840630031101; SLOTS J, 1978, INFECT IMMUN, V19, P254, DOI 10.1128/IAI.19.1.254-264.1978; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; Yoneda M, 1996, ORAL MICROBIOL IMMUN, V11, P129, DOI 10.1111/j.1399-302X.1996.tb00347.x	42	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5012	5020		10.1074/jbc.274.8.5012	http://dx.doi.org/10.1074/jbc.274.8.5012			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988746	hybrid			2022-12-25	WOS:000078698200071
J	Frohnert, BI; Hui, TY; Bernlohr, DA				Frohnert, BI; Hui, TY; Bernlohr, DA			Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; RETINOID-X RECEPTOR; COA OXIDASE GENE; BINDING-PROTEIN; PPAR-GAMMA; PREADIPOCYTE DIFFERENTIATION; ADIPOCYTE; EXPRESSION; INDUCTION; MEMBRANE	Fatty acid transport protein (FATP), a plasma membrane protein implicated in controlling adipocyte transmembrane fatty acid flux, is up-regulated as a consequence of adipocyte differentiation and down-regulated by insulin, Based upon the sequence of the FATP gene upstream region (Hui, T. Y,, Frohnert, B. I., Smith, A. J., Schaffer, J. A, and Bernlohr, D, A, (1998) J. Biol, Chem. 273, 27420-27429) a putative peroxisome proliferator-activated receptor response element (PPRE) is present from -458 to -474. To determine whether the FATP PPRE was functional, and responded to lipid activators, transient transfection of FATP-luciferase reporter constructs into CV-1 and 3T3-L1 cells was carried out. In CV-1 cells, FATP-luciferase activity was up-regulated 4- and 5.5-fold, respectively, by PPAR alpha and PPAR gamma in the presence of their respective activators in a PPRE-dependent mechanism. PPAR delta, however, was unable to mediate transcriptional activation under any condition. In 3T3-L1 cells, the PPRE conferred a small but significant increase in expression in preadipocytes, as well as a more robust up-regulation of FATP expression in adipocytes. Furthermore, the PPRE conferred the ability for luciferase expression to be up-regulated by activators of both PPAR gamma and retinoid X receptor alpha (RXR alpha) in a synergistic manner. PPAR alpha and PPAR delta activators did not up-regulate FATP expression in 3T3-L1 adipocytes, however, suggesting that these two subtypes do not play a significant role in differentiation-dependent activation in fat cells. Electromobility shift assays showed that all three PPAR subtypes were able to bind specifically to the PPRE as heterodimers with RXR alpha. Nuclear extracts from 3T3-L1 adipocytes also showed a specific gel-shift complex with the FATP PPRE. To correlate the expression of FATP to its physiological function, treatment of 3T3-L1 adipocytes with PPAR gamma and RXR alpha activators resulted in an increased uptake of oleate. Moreover, linoleic acid, a physiological ligand, up-regulated FATP expression 2-fold in a PPRE-dependent manner. These results demonstrate that the FATP gene possesses a functional PPRE and is up-regulated by activators of PPAR alpha and PPAR gamma, thereby linking the activity of the protein to the expression of its gene. Moreover, these results have implications for the mechanism by which certain PPAR gamma activators such as the antidiabetic thiazolidinedione drugs affect adipose lipid metabolism.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA.			Frohnert, Brigitte/0000-0002-6636-4048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049807] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49807] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fitscher BA, 1996, P SOC EXP BIOL MED, V212, P15; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FUJII S, 1987, J BIOCHEM-TOKYO, V101, P679, DOI 10.1093/jb/101.3.679; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Hui TY, 1998, J BIOL CHEM, V273, P27420, DOI 10.1074/jbc.273.42.27420; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Montague CT, 1998, DIABETES, V47, P1384, DOI 10.2337/diabetes.47.9.1384; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, BIOCHIM BIOPHYS ACTA, V877, P191, DOI 10.1016/0005-2760(86)90134-7; STREMMEL W, 1985, J CLIN INVEST, V75, P1068, DOI 10.1172/JCI111769; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; TURCOTTE LP, 1991, FEBS LETT, V279, P327, DOI 10.1016/0014-5793(91)80180-B; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; WAGGONER DW, 1990, J BIOL CHEM, V265, P11417; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	57	203	218	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3970	3977		10.1074/jbc.274.7.3970	http://dx.doi.org/10.1074/jbc.274.7.3970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933587	hybrid			2022-12-25	WOS:000078575500011
J	Kraev, A; Kraev, N; Carafoli, E				Kraev, A; Kraev, N; Carafoli, E			Identification and functional expression of the plasma membrane calcium ATPase gene family from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; CA-2+ PUMP; CA2+ PUMP; LIMITED PROTEOLYSIS; MESSENGER-RNAS; TRANSPORT; HOMOLOG; CA2+-ATPASE	Calcium-pumping ATPases are an essential component of the intracellular calcium homeostasis system and have been characterized in a large variety of species and cell types. In mammalian genomes, these proteins are encoded by gene families whose individual members feature complex: tissue-specific expression and alternative splicing. ale the search for a less complex system that is more amenable to genetic manipulation, we have identified a family of three genes (mca-1, mca-2, rand mca-3) encoding putative calcium ATPases in the Caenorhabditis elegans Genome Project data and completed their transcript structure. In this work, we report the cloning and functional expression of the mca-l gene, which encodes a calcium-stimulated ATPase whose features resemble those of the plasma membrane calcium adenosine triphosphatase family of mammalian cells and appears to be regulated by a multipartite promoter.	ETH Zurich, Lab Biochem 3, Inst Biochem, CH-8092 Zurich, Switzerland; Univ Padua, Dept Biol Chem, I-35121 Padua, Italy	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Padua	Carafoli, E (corresponding author), ETH Zurich, Lab Biochem 3, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	carafoli@bc.biol.ethz.ch	Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				Ahringer J, 1997, CURR OPIN GENET DEV, V7, P410, DOI 10.1016/S0959-437X(97)80157-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BAYLIS H, 1998, EUR WORM M SANG CT T, V7; Carafoli E, 1996, EXPERIENTIA, V52, P1091, DOI 10.1007/BF01952107; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Catty P, 1996, BIOSCIENCE REP, V16, P75, DOI 10.1007/BF01206198; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davis RE, 1996, PARASITOL TODAY, V12, P33, DOI 10.1016/0169-4758(96)80643-0; DAVIS RE, 1994, J BIOL CHEM, V269, P20026; DEMENDONCA RL, 1995, MOL BIOCHEM PARASIT, V72, P129, DOI 10.1016/0166-6851(95)00078-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GUERINI D, 1995, J BIOL CHEM, V270, P14643, DOI 10.1074/jbc.270.24.14643; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HILFIKER H, 1993, J BIOL CHEM, V268, P19717; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Korswagen HC, 1996, P NATL ACAD SCI USA, V93, P14680, DOI 10.1073/pnas.93.25.14680; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maryon EB, 1996, J CELL BIOL, V134, P885, DOI 10.1083/jcb.134.4.885; MONTEITH GR, 1995, CELL CALCIUM, V18, P459, DOI 10.1016/0143-4160(95)90009-8; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PLASTERK RH, 1998, EUR WORM M SANG CT T, V17; Sakube Y, 1997, J MOL BIOL, V267, P849, DOI 10.1006/jmbi.1997.0910; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1991, J BIOL CHEM, V266, P22; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008	43	15	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4254	4258		10.1074/jbc.274.7.4254	http://dx.doi.org/10.1074/jbc.274.7.4254			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933625	hybrid			2022-12-25	WOS:000078575500049
J	Thompson, SJ; Robinson, C; Mant, A				Thompson, SJ; Robinson, C; Mant, A			Dual signal peptides mediate the signal recognition particle Sec-independent insertion of a thylakoid membrane polyprotein, psbY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-TRANSPORT; TRANSIT PEPTIDE; PHOTOSYSTEM-II; INTEGRATION; PATHWAY; REQUIREMENTS; POLYPEPTIDE; COMPONENT; MACHINERY	The nuclear psbY gene (formerly ycf32) encodes two distinct single-spanning chloroplast thylakoid membrane proteins in Arabidopsis thaliana, After import into the chloroplast, the precursor protein is processed to a polyprotein in which each "mature" protein is preceded by an additional hydrophobic region; we show that these regions function as signal peptides that are cleaved after insertion into the thylakoid membrane. Inhibition of the first or second signal cleavage reaction by enlargement of the -1 residues leads in each case to the accumulation of a thylakoid-integrated intermediate containing three hydrophobic regions after import into chloroplasts; a double mutant is converted to a protein containing all four hydrophobic regions. We propose that the overall insertion process involves (i) insertion as a double-loop structure, (ii) two cleavages by the thylakoidal processing peptidase on the lumenal face of the membrane, and (iii) cleavage by an unknown peptidase on the stromal face on the membrane between the first mature protein and the second signal peptide. We also show that this polyprotein can insert into the thylakoid membrane in the absence of stromal factors, nucleoside triphosphates, or a functional Sec apparatus; this effectively shows for the first time that a multispanning protein can insert posttranslationally without the aid of signal recognition particle, SecA, or the membrane-bound Sec machinery.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	CG@dna.bio.warwick.ac.uk		Thompson, Simon/0000-0003-0769-8555; Mant, Alexandra/0000-0001-7169-209X				ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BRASSILANA M, 1996, EMBO J, V15, P5202; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLINE K, 1992, J BIOL CHEM, V267, P2688; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DeGier JWL, 1997, FEBS LETT, V408, P1, DOI 10.1016/S0014-5793(97)00402-X; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Gau AE, 1998, MOL GEN GENET, V260, P56, DOI 10.1007/s004380050870; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENRY R, 1994, J BIOL CHEM, V269, P10189; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; High S, 1997, J BIOL CHEM, V272, P11622; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kim SJ, 1996, FEBS LETT, V390, P175, DOI 10.1016/0014-5793(96)00658-8; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mant A, 1998, FEBS LETT, V423, P183, DOI 10.1016/S0014-5793(98)00089-1; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; Robinson C, 1998, PLANT MOL BIOL, V38, P209, DOI 10.1023/A:1006041917853; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4059	4066		10.1074/jbc.274.7.4059	http://dx.doi.org/10.1074/jbc.274.7.4059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933598	hybrid			2022-12-25	WOS:000078575500022
J	Dan, S; Naito, M; Seimiya, H; Kizaki, A; Mashima, T; Tsuruo, T				Dan, S; Naito, M; Seimiya, H; Kizaki, A; Mashima, T; Tsuruo, T			Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells	ONCOGENE			English	Article						c-Abl; JNK1/SAPK; caspase; apoptosis	DEPENDENT PROTEIN-KINASE; DNA-DAMAGE; IONIZING-RADIATION; CELLULAR-RESPONSE; STRESS-RESPONSE; P53; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; PHOSPHORYLATION; RESISTANCE; SUBSTRATE	Genotoxic stress triggers the activation of several sensor molecules, such as p53, JNK1/SAPK and c-Abl, and occasionally promotes the cells to apoptosis, We previously reported that JNK1/SAPK regulates genotoxic stress-induced apoptosis in p53-negative U937 cells by activating caspases, c-Abl is expected to act upstream of JNK1/SAPK activation upon treatment with genotoxic stressors, but its involvement in apoptosis development is still unclear. We herein investigated the kinase activities of c-Abl and JNK1/SAPK during apoptosis elicited by genotoxic anticancer drugs and tumor necrosis factor (TNF) in U937 cells and their apoptosis-resistant variant UK711 cells. We found that the activation of JNK1/SAPK and c-Abl correlated well with apoptosis development in these cell lines. Unexpectedly, however, the JNK1/SAPK activation preceded the c-Abl activation. Moreover, the caspase inhibitor Z-Asp suppressed c-Abl activation and the onset of apoptosis but not the JNK1/SAPK activation. Interestingly, c-Abl tyrosine kinase inhibition by CGP 57148 reduced apoptosis without interfering with JNK1/SAPK activation. These results indicate that c-Abl acts not upstream of JNK1/SAPK but downstream of caspases during the development of p53-independent apoptosis and is possibly involved in accelerating execution of the cell death pathway.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.			Seimiya, Hiroyuki/0000-0003-3314-9736				Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Buchdunger E, 1996, CANCER RES, V56, P100; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GUNJI H, 1991, CANCER RES, V51, P741; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McConnell KR, 1997, J IMMUNOL, V158, P2083; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	32	26	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1277	1283		10.1038/sj.onc.1202423	http://dx.doi.org/10.1038/sj.onc.1202423			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022809				2022-12-25	WOS:000078510900003
J	Melkonian, KA; Ostermeyer, AG; Chen, JZ; Roth, MG; Brown, DA				Melkonian, KA; Ostermeyer, AG; Chen, JZ; Roth, MG; Brown, DA			Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts - Many raft proteins are acylated, while few are prenylated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; KIDNEY EPITHELIAL-CELLS; GPI-ANCHORED PROTEINS; TYROSINE KINASE; PLASMA-MEMBRANE; TRANSMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION; T-CELLS; CAVEOLAE; CHOLESTEROL	Sphingolipid and cholesterol-rich Triton X-100-insoluble membrane fragments (detergent-resistant membranes, DRMs) containing lipids in a state similar to the liquid-ordered phase can be isolated from mammalian cells, and probably exist as discrete domains or rafts in intact membranes. We postulated that proteins with a high affinity for such an ordered lipid environment might be targeted to rafts. Saturated acyl chains should prefer an extended conformation that would fit well in rafts. In contrast, prenyl groups, which are as hydrophobic as acyl chains but have a branched and bulky structure, should be excluded from rafts. Here, we showed that at least half of the proteins in Madin-Darby canine kidney cell DRMs (other than cytoskeletal contaminants) could be labeled with [H-3]palmitate. Association of influenza hemagglutinin with DRMs required all three of its palmitoylated Cys residues. Prenylated proteins, detected by [H-3]mevalonate labeling or by blotting for Rap1, Rab5, G(beta), or Ras, were excluded from DRMs. Rab5 and H-Ras each contain more than one lipid group, showing that hydrophobicity alone does not target multiply lipid-modified proteins to DRMs. Partitioning of covalently linked saturated acyl chains into liquid-ordered phase domains is likely to be an important mechanism for targeting proteins to DRMs.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	dbrown@mcbsgi.bio.sunysb.edu		Roth, Michael/0000-0002-9056-332X; Chen, Zhe/0000-0002-1668-4051	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897, R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47897, GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DOERING TL, 1990, J BIOL CHEM, V265, P611; Draberova L, 1996, IMMUNOLOGY, V87, P141; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FAUST J, 1987, J BIOL CHEM, V262, P1996; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JONES PP, 1984, METHOD ENZYMOL, V108, P452; JONES PP, 1980, SELECTED METHODS CEL, P398; KIM CM, 1992, J BIOL CHEM, V267, P23113; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NAIM HY, 1992, J VIROL, V66, P7585, DOI 10.1128/JVI.66.12.7585-7588.1992; NEAME SJ, 1995, J CELL SCI, V108, P3127; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PEPPERBERG DR, 1995, METHOD ENZYMOL, V250, P348; PERSCHL A, 1995, J CELL SCI, V108, P1033; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHERNOYSCARIA AM, 1994, J CELL BIOL, V126, P353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SPIEGEL S, 1984, J CELL BIOL, V99, P1575, DOI 10.1083/jcb.99.5.1575; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHAO YH, 1990, ONCOGENE, V5, P1629	77	536	544	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3910	3917		10.1074/jbc.274.6.3910	http://dx.doi.org/10.1074/jbc.274.6.3910			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920947	hybrid			2022-12-25	WOS:000078428200087
J	Schindler, T; Graumann, PL; Perl, D; Ma, SF; Schmid, FX; Marahiel, MA				Schindler, T; Graumann, PL; Perl, D; Ma, SF; Schmid, FX; Marahiel, MA			The family of cold shock proteins of Bacillus subtilis - Stability and dynamics in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-BOX PROTEINS; ESCHERICHIA-COLI; MESSENGER-RNA; CRYSTAL-STRUCTURE; CSPA; BINDING; DOMAIN; EXPRESSION; ACID; DNA	Bacillus subtilis possesses three homologous small cold shock proteins (CSPs; CspB, CspC, CspD, sequence identity >72%). They share a similar beta-sheet structure, as shown by circular dichroism, and have a very low conformational stability, with CspC being the least stable. Similar to CspB, CspC and CspD unfold and refold extremely fast in a N reversible arrow U two-state reaction with average lifetimes of only 100-150 ms for the native state and 1-6 ms for the unfolded states at 25 degrees C. As a consequence of their low stability and low kinetic protection against unfolding, all three cold shock proteins are rapidly degraded by proteases in vitro, Analysis of the CSP stabilities in vivo by pulse-chase experiments revealed that CspB and CspD are stable during logarithmic growth at 37 degrees C as well as after cold shock. The cellular half-life of CspC is shortened at 37 degrees C, but under cold shock conditions CspC becomes stable. The proteolytic susceptibility of the CSPs in vitro was strongly reduced in the presence of a nucleic acid ligand, suggesting that the observed stabilization of CSPs in vivo is mediated by binding to their substrate mRNA at 37 degrees C and, in particular, under cold shock conditions.	Univ Bayreuth, Biochem Lab, D-95440 Bayreuth, Germany; Univ Marburg, Fachbereich Chem, D-35032 Marburg, Germany	University of Bayreuth; Philipps University Marburg	Graumann, PL (corresponding author), Harvard Univ, Biol Labs, Cambridge, MA 02138 USA.	graumann@fas.harvard.edu		Graumann, Peter/0000-0002-8033-5171				Antelmann H, 1997, ELECTROPHORESIS, V18, P1451, DOI 10.1002/elps.1150180820; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandi A, 1996, MOL MICROBIOL, V19, P231, DOI 10.1046/j.1365-2958.1996.362897.x; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Goldenberg D, 1996, MOL MICROBIOL, V19, P241, DOI 10.1046/j.1365-2958.1996.363898.x; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; Graumann P, 1997, MOL GEN GENET, V253, P745, DOI 10.1007/s004380050379; GRAUMANN P, 1994, FEBS LETT, V338, P157, DOI 10.1016/0014-5793(94)80355-2; Graumann P, 1996, J BACTERIOL, V178, P4611, DOI 10.1128/jb.178.15.4611-4619.1996; Graumann P, 1997, MOL MICROBIOL, V25, P741, DOI 10.1046/j.1365-2958.1997.5121878.x; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; JIANG WN, 1993, J BACTERIOL, V175, P5824, DOI 10.1128/JB.175.18.5824-5828.1993; Jiang WN, 1997, J BIOL CHEM, V272, P196; Jones PG, 1996, MOL MICROBIOL, V21, P1207, DOI 10.1111/j.1365-2958.1996.tb02582.x; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; Mayr B, 1996, J BACTERIOL, V178, P2916, DOI 10.1128/jb.178.10.2916-2925.1996; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Reid KL, 1998, PROTEIN SCI, V7, P470; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHINDELIN H, 1992, PROTEINS, V14, P120, DOI 10.1002/prot.340140113; Schindler T, 1996, BIOCHEMISTRY-US, V35, P16833, DOI 10.1021/bi962090j; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x	34	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3407	3413		10.1074/jbc.274.6.3407	http://dx.doi.org/10.1074/jbc.274.6.3407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920884	hybrid			2022-12-25	WOS:000078428200024
J	Cook, J; Krishnan, S; Ananth, S; Sells, SF; Shi, Y; Walther, MM; Linehan, WM; Sukhatme, VP; Weinstein, MH; Rangnekar, VM				Cook, J; Krishnan, S; Ananth, S; Sells, SF; Shi, Y; Walther, MM; Linehan, WM; Sukhatme, VP; Weinstein, MH; Rangnekar, VM			Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma	ONCOGENE			English	Article						Par-4; renal cell carcinoma; apoptosis	TUMOR-SUPPRESSOR GENE; VONHIPPEL-LINDAU DISEASE; KINASE-C; MUTATIONS; CANCER; IDENTIFICATION; PHENOTYPE; ISOFORMS; TISSUES; PRODUCT	Par-4 is a widely expressed leucine zipper protein that confers sensitization to apoptosis induced by exogenous insults. Because the expression of genes that promote apoptosis may be down-regulated during tumorigenesis, we sought to examine the expression of Par-4 in human tumors, We present here evidence that Par-4 protein levels were severely decreased in human renal cell carcinoma specimens relative to normal tubular cells, Replenishment of Par-4 protein levels in renal cell carcinoma cell lines conferred sensitivity to apoptosis, Because apoptosis may serve as a defense mechanism against malignant transformation or progression, decreased expression of Par-4 may contribute to the pathophysiology of renal cell carcinoma.	Univ Kentucky, Dept Surg, Div Urol, Lexington, KY 40536 USA; Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; NCI, Urol Oncol Sect, NIH, Bethesda, MD 20892 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Surg, Div Urol, Combs Res Bldg,Room 303,800 Rose St, Lexington, KY 40536 USA.		Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA068258, R01CA060872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044921] Funding Source: NIH RePORTER; NCI NIH HHS [CA68258, CA60872] Funding Source: Medline; NIDDK NIH HHS [DK44921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GUO Q, 1998, IN PRESS NAT MED; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Pan HC, 1997, CANCER SURV, V29, P305; QIU G, IN PRESS ONCOGENE; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; WALTHER MM, 1995, J UROLOGY, V154, P278, DOI 10.1016/S0022-5347(01)67294-X; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057	20	87	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1205	1208		10.1038/sj.onc.1202416	http://dx.doi.org/10.1038/sj.onc.1202416			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022126				2022-12-25	WOS:000078510700009
J	Buccellato, FR; Miloso, M; Braga, M; Nicolini, G; Morabito, A; Pravettoni, G; Tredici, G; Scalabrino, G				Buccellato, FR; Miloso, M; Braga, M; Nicolini, G; Morabito, A; Pravettoni, G; Tredici, G; Scalabrino, G			Myelinolytic lesions in spinal cord of cobalamin-deficient rats are TNF-alpha-mediated	FASEB JOURNAL			English	Article						myelinolysis; subacute combined degeneration; tumor necrosis factor	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRANSFORMING GROWTH FACTOR-BETA-1; TOTALLY GASTRECTOMIZED RATS; CENTRAL-NERVOUS-SYSTEM; SUBACUTE COMBINED DEGENERATION; SIGNAL-TRANSDUCTION PATHWAYS; MULTIPLE-SCLEROSIS; TRANSGENIC MICE; AUTOIMMUNE ENCEPHALOMYELITIS	Repeated intracerebroventricular (i.c.v.) microinjection of tumor necrosis factor-alpha (TNF-alpha) into normal rats causes intramyelin and interstitial edema in the white matter of the spinal cord (SC). This response is identical to that observed in the SC white matter of rats made cobalamin (Cbl) deficient by total gastrectomy (TG). Immunoblot analysis showed that: 1) the level of the biologically active form of the TNF-alpha protein (17 kDa) is higher in the SC of totally gastrectomized (TGX) rats 2 months after TG, i.e., at the postoperative time when edema is observed; 2) SC levels of TNF-alpha protein (17 kDa) in 2-mo-TGX-, Cbl-treated rats are reduced to control. Repeated i.c.v. microinjections of anti-TNF-alpha antibodies, transforming growth factor-beta(1) (TGF-beta(1)) or interleukin-6 (IL-6) into TGX rats, begun shortly after TG, substantially reduced both intramyelin and interstitial edema in the SC white matter. This study provides the first evidence that the hallmark myelin damage of Cbl-deficient central neuropathy, which is a pure myelinolytic disease, is not caused directly by the withdrawal of the vitamin itself, but reflects enhanced production of the biologically active form of TNF-alpha by SC cells. This study thus supports the view that TGF-beta(1) and IL-6 may act as neuroprotective agents in Cbl deficiency central neuropathy.	Univ Milan, Fac Med, Inst Gen Pathol, I-20133 Milan, Italy; Univ Milan, Fac Med, Inst Human Anat, I-20133 Milan, Italy; Univ Milan, Fac Med, Inst Biometr & Med Stat, I-20133 Milan, Italy; Univ Milan, Fac Med, Dept Neurol 2, I-20133 Milan, Italy; Gife Lab, Lugano, Switzerland	University of Milan; University of Milan; University of Milan; University of Milan	Scalabrino, G (corresponding author), Univ Milan, Fac Med, Inst Gen Pathol, Via Mangiagalli 31, I-20133 Milan, Italy.	scalb@imiucca.csi.unimi.it	NIcolini, Gabriella/AAK-9155-2020; Pravettoni, Gabriella/C-6915-2011; Miloso, Mariarosaria/AAC-7373-2021; Pravettoni, Gabriella/AAC-3500-2022	Pravettoni, Gabriella/0000-0002-4843-4663; NICOLINI, GABRIELLA/0000-0002-6241-4538; BRAGA, Massimiliano/0000-0001-8109-1001				AGAMANOLIS DP, 1978, J NEUROPATH EXP NEUR, V37, P273, DOI 10.1097/00005072-197805000-00006; Akassoglou K, 1997, J IMMUNOL, V158, P438; ALLEN RH, 1993, FASEB J, V7, P1344, DOI 10.1096/fasebj.7.14.7901104; Ariga T, 1998, J LIPID RES, V39, P1; ARMITAGE P, 1994, STAT METHODS MED RES, P394; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BARGER SW, 1998, NEUROPROTECTIVE SIGN, P163; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Benveniste EN, 1997, CHEM IMMUNOL, V69, P31; Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Benveniste Etty N., 1995, P700; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; Bottiglieri T, 1996, NUTR REV, V54, P382, DOI 10.1111/j.1753-4887.1996.tb03851.x; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; Brouwer M, 1996, BLOOD, V88, P1857; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CAMPBELL IL, 1995, INT J DEV NEUROSCI, V13, P275, DOI 10.1016/0736-5748(94)00073-C; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CAMPBELL IL, 1994, J VIROL, V68, P2383, DOI 10.1128/JVI.68.4.2383-2387.1994; DUFFIELD MS, 1990, COMP BIOCHEM PHYS C, V96, P291, DOI 10.1016/0742-8413(90)90010-7; GARRIELI Y, 1992, J CELL BIOL, V119, P493; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; HAMILTON PW, 1995, J PATHOL, V175, P369, DOI 10.1002/path.1711750403; HARTUNG HP, 1995, NEUROLOGY, V45, pS22, DOI 10.1212/WNL.45.6_Suppl_6.S22; HAUSER SL, 1995, ANN NEUROL, V38, P702; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Iwasaki Y, 1997, J NEUROL SCI, V147, P9, DOI 10.1016/S0022-510X(96)05307-5; JOHNS LD, 1991, J IMMUNOL, V147, P1792; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KRIEGLSTEIN K, 1998, NEUROPROTECTIVE SIGN, P119; KURUVILLA AP, 1991, P NATL ACAD SCI USA, V88, P2918, DOI 10.1073/pnas.88.7.2918; LeVine SM, 1997, J NEUROIMMUNOL, V73, P47, DOI 10.1016/S0165-5728(96)00166-X; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; MARTIN D, 1995, EXP NEUROL, V131, P221, DOI 10.1016/0014-4886(95)90044-6; MARTIN D, 1998, NEUROPROTECTIVE SIGN, P185; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MOKHTARIAN F, 1994, J IMMUNOL, V152, P6003; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; OTTEN U, 1994, PROG BRAIN RES, V103, P293; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; POWELL MB, 1992, TUMOR NECROSIS FACTO, P355; Powers J, 1996, MOL CHEM NEUROPATHOL, V27, P31, DOI 10.1007/BF02815031; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Probert L, 1997, J NEUROIMMUNOL, V72, P113, DOI 10.1016/S0165-5728(96)00176-2; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; RACKE MK, 1991, J IMMUNOL, V146, P3012; Rink L, 1996, INT ARCH ALLERGY IMM, V111, P199, DOI 10.1159/000237369; RODRIGUEZ M, 1994, J IMMUNOL, V153, P3811; Rothwell NJ, 1996, NAT MED, V2, P746, DOI 10.1038/nm0796-746; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SCALABRINO G, 1995, LAB INVEST, V72, P114; SCALABRINO G, 1990, LAB INVEST, V62, P297; Scalabrino G, 1997, EXP NEUROL, V144, P258, DOI 10.1006/exnr.1996.6376; SCHINDLER R, 1990, BLOOD, V75, P40; SCOLDING NJ, 1994, PROG NEUROBIOL, V43, P143, DOI 10.1016/0301-0082(94)90011-6; SCOTT JM, 1994, ACTA NEUROL SCAND, V89, P27, DOI 10.1111/j.1600-0404.1994.tb05406.x; SELMAJ K, 1995, J NEUROIMMUNOL, V56, P135, DOI 10.1016/0165-5728(94)00139-F; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SOLIVEN B, 1995, INT J DEV NEUROSCI, V13, P351, DOI 10.1016/0736-5748(95)00019-D; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tredici G, 1998, J SUBMICR CYTOL PATH, V30, P165; Tredici G, 1998, J NEUROL SCI, V156, P18, DOI 10.1016/S0022-510X(98)00005-7; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Walker PR, 1997, CELL DEATH DIFFER, V4, P233, DOI 10.1038/sj.cdd.4400225; WOODROOFE MN, 1995, NEUROLOGY, V45, pS6, DOI 10.1212/WNL.45.6_Suppl_6.S6; WRIGHT JL, 1992, ACTA NEUROPATHOL, V85, P93, DOI 10.1007/BF00304638	82	47	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					297	304		10.1096/fasebj.13.2.297	http://dx.doi.org/10.1096/fasebj.13.2.297			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973317				2022-12-25	WOS:000078615200009
J	Mazzucato, M; Spessotto, P; Masotti, A; De Appollonia, L; Cozzi, MR; Yoshioka, A; Perris, R; Colombatti, A; De Marco, L				Mazzucato, M; Spessotto, P; Masotti, A; De Appollonia, L; Cozzi, MR; Yoshioka, A; Perris, R; Colombatti, A; De Marco, L			Identification of domains responsible for von Willebrand factor type VI collagen interaction mediating platelet adhesion under high flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; HUMAN VASCULAR SUBENDOTHELIUM; MEMBRANE GLYCOPROTEIN-IB; A3 DOMAIN; A1 DOMAIN; EXTRACELLULAR-MATRIX; MULTIPLE FORMS; FIBRINOGEN; DISEASE; LOCALIZATION	We have identified type VI collagen (Col VI) as a primary subendothelial extracellular matrix component responsible for von Willebrand factor (vWF)-dependent platelet adhesion and aggregation under high tensile strength. Intact tetrameric Col VI was the form of the collagen found to be capable of promoting vWF-mediated platelet adhesion/aggregation under this shear condition, whereas removal of the predominant portion of the terminal globules by pepsin treatment abrogated its activity. The inability of the pepsin-digested Col VI to support any platelet interaction at high flow was because of the failure of the A3(vWF) domain to bind to this form of collagen, suggesting a stringent requirement of a tridimensional conformation or of intactness of its macromolecular structure. In contrast, the A1(vWF) domain bound to both intact and pepsin-digested Col VI tetramers but, in accordance with the cooperating function of the two vWF domains, failed to support platelet adhesion/aggregation under high shear onto Col VI by itself. The putative A1(vWF) binding site resided within the A7(VI) module (residues 413-613) of the globular amino-terminal portion of the alpha 3(VI) chain. Soluble recombinant A7(VI) poly-peptide strongly perturbed the vWF-mediated platelet adhesion to Col VI under high shear rates, without affecting the binding of the vWF platelet receptor glycoprotein Ib alpha to its cognate ligand A1(vWF), The findings provide evidence for a concerted action of the A1(vWF) and A3(vWF) domains in inducing platelet arrest on Col VI, This is accomplished via an interaction of the A1(vWF) domain with a site contained in the alpha 3 chain A7(VI) domain and via a conformation-dependent interaction of the A3(vWF) domain with the intact tetrameric collagen, The data further emphasize that Col VI microfilaments linking the subendothelial basement membrane to the interstitial collagenous network may play a pivotal role in the hemostatic process triggered upon damage of the blood vessel wall.	Ctr Riferimento Oncol, Serv Immunotrasfus & Anal Clin, Inst Nazl Tumori Ctr Europeo, I-33081 Aviano, PN, Italy; Ctr Riferimento Oncol, Div Oncol Sperimentale 2, Inst Nazl Tumori Ctr Europeo, I-33081 Aviano, PN, Italy; Nara Med Univ, Dept Pediat, Kashihara, Nara 634, Japan; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Parma, Dept Evolutionary & Funct Biol, I-43100 Parma, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO); Nara Medical University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Parma	De Marco, L (corresponding author), Ctr Riferimento Oncol, Serv Immunotrasfus & Anal Clin, Inst Nazl Tumori Ctr Europeo, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	ldemarco@ets.it	Mazzucato, Mario/ABF-5472-2020; Cozzi, Maria Rita/ABD-7970-2020; Spessotto, Paola/K-5005-2012	Mazzucato, Mario/0000-0001-8319-053X; Cozzi, Maria Rita/0000-0001-6841-2632; Spessotto, Paola/0000-0002-3033-404X; colombatti, alfonso/0000-0002-3676-2379				AGBANYO FR, 1993, J CLIN INVEST, V92, P288, DOI 10.1172/JCI116563; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; BAHNAK BR, 1989, J CELL PHYSIOL, V138, P305, DOI 10.1002/jcp.1041380212; BARUCH D, 1991, BLOOD, V77, P519; BEUMER S, 1995, BLOOD, V86, P3452, DOI 10.1182/blood.V86.9.3452.bloodjournal8693452; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CHRISTOPHE O, 1995, BRIT J HAEMATOL, V90, P195, DOI 10.1111/j.1365-2141.1995.tb03400.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLOMBATTI A, 1989, MATRIX, V9, P177, DOI 10.1016/S0934-8832(89)80048-4; COLOMBATTI A, 1996, SUPERFAMILY VONWILLE; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DEMARCO L, 1987, J CLIN INVEST, V80, P475, DOI 10.1172/JCI113095; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; Doliana R, 1998, MATRIX BIOL, V16, P427, DOI 10.1016/S0945-053X(98)90015-4; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; Galbusera M, 1997, BLOOD, V90, P1558, DOI 10.1182/blood.V90.4.1558.1558_1558_1564; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Godyna S, 1996, BLOOD, V88, P2569, DOI 10.1182/blood.V88.7.2569.bloodjournal8872569; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Gralnick HR, 1996, THROMB RES, V81, P113, DOI 10.1016/0049-3848(95)00219-7; HANDA M, 1986, J BIOL CHEM, V261, P2579; HILBERT L, 1994, BLOOD, V83, P1542; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Keene DR, 1998, J HISTOCHEM CYTOCHEM, V46, P215, DOI 10.1177/002215549804600210; KEHREL B, 1993, BLOOD, V82, P3364; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; KUO HJ, 1989, BIOCHEMISTRY-US, V28, P3757, DOI 10.1021/bi00435a020; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; Lankhof H, 1997, BLOOD, V89, P2766, DOI 10.1182/blood.V89.8.2766; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; MOHRI H, 1989, J BIOL CHEM, V264, P17361; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIJA K, 1987, BLOOD, V70, P475; PARETI FI, 1987, J BIOL CHEM, V262, P13835; Pareti FI, 1996, THROMB HAEMOSTASIS, V76, P460; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; PERRIS R, 1993, DEV DYNAM, V198, P135, DOI 10.1002/aja.1001980207; POLANOWSKAGRABOWSKA R, 1992, P NATL ACAD SCI USA, V89, P5754, DOI 10.1073/pnas.89.13.5754; RAND JH, 1993, AM J PATHOL, V142, P843; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; ROSS JM, 1995, BLOOD, V85, P1826, DOI 10.1182/blood.V85.7.1826.bloodjournal8571826; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SAELMAN EUM, 1994, BLOOD, V83, P1244; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SEGAT D, 1994, BLOOD, V83, P1586; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SINHA D, 1994, BIOCHEM BIOPH RES CO, V203, P881, DOI 10.1006/bbrc.1994.2265; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; Tsuji S, 1996, BLOOD, V88, P3854, DOI 10.1182/blood.V88.10.3854.bloodjournal88103854; VANGENDEREN PJJ, 1994, BLOOD, V84, P3378; vanZanten GH, 1996, BLOOD, V88, P3862, DOI 10.1182/blood.V88.10.3862.bloodjournal88103862; Wu XX, 1996, AM J PATHOL, V149, P283; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967; [No title captured]	65	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3033	3041		10.1074/jbc.274.5.3033	http://dx.doi.org/10.1074/jbc.274.5.3033			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915842	hybrid			2022-12-25	WOS:000078319500060
J	Neptune, ER; Iiri, T; Bourne, HR				Neptune, ER; Iiri, T; Bourne, HR			G alpha(i) is not required for chemotaxis mediated by G(i)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEINS; SPECIFICITY; RESPONSIVENESS; INTERLEUKIN-8; ACTIVATION; LEUKOCYTE; CELLS	Pertussis toxin inhibits chemotaxis of neutrophils by preventing chemoattractant receptors from activating trimeric G proteins in the G(i) subfamily. In HEK293 cells expressing recombinant receptors, directional migration toward appropriate agonist ligands requires release of free G protein beta gamma subunits and can be triggered by agonists for receptors coupled to G(i) but not by agonists for receptors coupled to two other G proteins, G(s) and G(q). Because activation of any G protein presumably releases free G beta gamma, we tested the hypothesis that chemotaxis also requires activated alpha subunits (G alpha(i)) of G(i) proteins. HEK293 cells were stably cotransfected with the G(i)-coupled receptor for interleukin-8, CXCR1, and with a chimeric G alpha G alpha(qz5) which resembles G alpha(i) in susceptibility to activation by G(i)-coupled receptors but cannot regulate the G alpha(i) effector, adenylyl cyclase, These cells, unlike cells expressing CXCR1 alone, migrated toward interleukin-8 even after treatment with pertussis toxin, which prevents activation of endogenous G alpha(i) but not that of G alpha(qz5). We infer that chemotaxis does not require activation of G alpha(i). Because chemotaxis is mediated by G beta gamma subunits released when G(i)-coupled receptors activate G alpha(qz5) but not when G(q)- or G(s)-coupled receptors activate their respective G proteins, we propose that G(i)-coupled receptors transmit a necessary chemotactic signal that is independent of G alpha(i).	Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, S-1212,Box 04500, San Francisco, CA 94143 USA.				NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DAI YL, 1994, J LEUKOCYTE BIOL, V56, P776, DOI 10.1002/jlb.56.6.776; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Elferink JGR, 1996, GEN PHARMACOL-VASC S, V27, P387, DOI 10.1016/0306-3623(95)00070-4; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HARVATH L, 1991, J IMMUNOL, V146, P224; IIRI T, 1995, J BIOL CHEM, V270, P5901, DOI 10.1074/jbc.270.11.5901; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAW SF, 1993, J BIOL CHEM, V268, P10721; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Ueda H, 1997, J CELL SCI, V110, P1503; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197	32	111	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2824	2828		10.1074/jbc.274.5.2824	http://dx.doi.org/10.1074/jbc.274.5.2824			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915816	hybrid			2022-12-25	WOS:000078319500034
J	Pei, L				Pei, L			Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MESSENGER-RNAS; CDNA CLONE; YEAST; EXPRESSION; PHOSPHOPROTEIN; PURIFICATION	Pituitary tumor-transforming gene (PTTG) is a recently characterized proto-oncogene that is expressed specifically in adult testis, In this study, we have used in situ hybridization and developmental Northern blot assays to demonstrate that PTTG mRNA is expressed stage-specifically in spermatocytes and spermatids during rat spermatogenic cycle. We have used the yeast two-hybrid system to identify proteins that interact with PTTG in testicular cells. Two positive clones were characterized. One of the clones is the ribosomal protein S10, the other encodes a novel human DnaJ homologue designated HSJ2. Northern blot analysis showed that testis contains higher levels of HSJ2 mRNA than other tissues examined, and the expression pattern of HSJ2 mRNA in postnatal rat testis is similar to PTTG. S10 mRNA levels do not vary remarkably among different tissues and remains unchanged during testicular germ cell differentiation. In vitro binding assays demonstrated that both S10 and HSJ2 bind to PTTG specifically and that PTTG can be co-immunoprecipitated with S10 and HSJ2 from transfected cells. Moreover, the binding sites for both proteins were located within the C-terminal 75 amino acids of the PTTG protein. These results suggest that PTTG may play a role in spermatogenesis.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, 8700 Beverly Blvd,D-3066, Los Angeles, CA 90048 USA.	pei@cshs.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BARNARD GF, 1992, CANCER RES, V52, P3067; Berruti G, 1998, EXP CELL RES, V239, P430, DOI 10.1006/excr.1997.3879; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; GATEFF E, 1994, INT J DEV BIOL, V38, P565; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLDSTONE SD, 1993, BIOCHEM BIOPH RES CO, V196, P619, DOI 10.1006/bbrc.1993.2294; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KONDOH N, 1992, CANCER RES, V52, P791; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MAHESHWARI Y, 1993, CELL GROWTH DIFFER, V4, P745; Malkov M, 1998, BIOL REPROD, V59, P84, DOI 10.1095/biolreprod59.1.84; MANOVA K, 1990, DEVELOPMENT, V110, P1057; OHKI M, 1986, J BIOL CHEM, V261, P1778; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHARP MGF, 1990, BRIT J CANCER, V61, P83, DOI 10.1038/bjc.1990.19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WESTERMANN P, 1983, BIOCHIM BIOPHYS ACTA, V741, P103, DOI 10.1016/0167-4781(83)90015-5; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	40	37	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3151	3158		10.1074/jbc.274.5.3151	http://dx.doi.org/10.1074/jbc.274.5.3151			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915854	hybrid			2022-12-25	WOS:000078319500072
J	Radisky, DC; Babcock, MC; Kaplan, J				Radisky, DC; Babcock, MC; Kaplan, J			The yeast frataxin homologue mediates mitochondrial iron efflux - Evidence for a mitochondrial, iron cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAA TRIPLET REPEAT; FRIEDREICH-ATAXIA; ABC TRANSPORTER; DESFERRIOXAMINE; ACCUMULATION; DEFICIENCY	Mutations in the nuclear gene encoding the mitochondrial protein frataxin are responsible for the neurological disorder Friedreich ataxia (FA). Yeast strains with a deletion in the frataxin homologue YFH1 accumulate excess iron in mitochondria and demonstrate mitochondrial damage. We show that in the absence of YFH1, mitochondrial damage is proportional to the concentration and duration of exposure to extracellular iron, establishing mitochondrial iron accumulation as causal to mitochondrial damage. Reintroduction of YFH1 results in the rapid export of accumulated mitochondrial iron into the cytosol as free, non-heme bound iron, demonstrating that mitochondrial iron in the yeast FA model can be made bioavailable. These results demonstrate a mitochondrial iron cycle in which Yfh1p regulates mitochondrial iron efflux.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA.	kaplan@bioscience.biology.utah.edu	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784	NCI NIH HHS [CA42014] Funding Source: Medline; NIDDK NIH HHS [DK52380, DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219, R01DK052380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P3018; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972; GIARDINA PJ, 1995, SEMIN HEMATOL, V32, P304; HARDING AE, 1993, ADV NEUROL, V61, P1; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; KUSHNER JP, 1971, MEDICINE, V50, P139, DOI 10.1097/00005792-197105000-00001; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Miyajima H, 1997, ANN NEUROL, V41, P404, DOI 10.1002/ana.410410318; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Ponka P, 1997, BLOOD, V89, P1; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352	19	225	234	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4497	4499		10.1074/jbc.274.8.4497	http://dx.doi.org/10.1074/jbc.274.8.4497			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988680	hybrid			2022-12-25	WOS:000078698200005
J	Sartori, G; Aldegheri, L; Mazzotta, G; Lanfranchi, G; Tournu, H; Brown, AJP; Carignani, G				Sartori, G; Aldegheri, L; Mazzotta, G; Lanfranchi, G; Tournu, H; Brown, AJP; Carignani, G			Characterization of a new hemoprotein in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; GENE-EXPRESSION; STRESS-RESPONSE; FLAVOHEMOGLOBIN GENE; BACTERIAL HEMOGLOBIN; RHIZOBIUM-MELILOTI; RNA-POLYMERASE; OXYGEN SENSOR; PROTEIN; BINDING	The Saccharomyces cerevisiae gene YNL234w encodes a 426-amino acid-long protein that shares significant similarities with the globin family. Compared with known globins from unicellular organisms, the Ynl234wp polypeptide is characterized by an unusual structure. In this protein, a central putative heme-binding domain of about 140 amino acids is flanked by two sequences of about 160 and 120 amino acids, respectively, which share no similarity with known polypeptides. Northern analysis indicates that YNL234w transcription is very low in cells grown under normal aerobic conditions but is induced by oxygen-limited growth conditions and by other stress conditions such as glucose repression, heat shock, osmotic stress, and nitrogen starvation. However the deletion of the gene had no detectable effect on yeast growth. The Ynl234wp polypeptide has been expressed in Escherichia coli, and the hemoprotein nature of the recombinant protein was demonstrated by heme staining after SDS/polyacrylamide gel electrophoresis and spectroscopic analysis. Our data indicate that purified recombinant Ynl234wp possesses a noncovalently bound heme molecule that is predominantly found in a low spin form.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Padua; University of Padua; University of Aberdeen	Carignani, G (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	carigna@civ.bio.unipd.it	Brown, Alistair J.P./B-6627-2014	MAZZOTTA, GABRIELLA MARGHERITA/0000-0001-5461-6837				BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; BROWN AJP, 1995, METHODS YEAST MOL BI, P269; Buisson N, 1998, J BIOL CHEM, V273, P9527, DOI 10.1074/jbc.273.16.9527; Chantrel Y, 1998, GENETICS, V148, P559; Couture M, 1996, EUR J BIOCHEM, V242, P779, DOI 10.1111/j.1432-1033.1996.0779r.x; CRAMM R, 1994, J BIOL CHEM, V269, P7349; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; Drabkin David L., 1942, JOUR BIOL CHEM, V146, P605; Evangelista CC, 1996, GENETICS, V142, P1083; GIETZ RD, 1995, YEAST, V11, P335; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1225, DOI 10.1021/bi00677a021; MARCHLER G, 1998, EMBO J, V14, P1997; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; NISHIMOTO M, 1993, BIOCHEMISTRY-US, V32, P8863, DOI 10.1021/bi00085a018; OHANIANCE L, 1966, BIOCHIM BIOPHYS ACTA, V128, P228, DOI 10.1016/0926-6593(66)90170-6; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pandolfo D, 1996, YEAST, V12, P1071; PILLAR TM, 1991, CURR GENET, V20, P185, DOI 10.1007/BF00326230; PLANTA RJ, 1999, IN PRESS YEAST; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; ROSENBLUMVOS LS, 1991, MOL CELL BIOL, V11, P5639, DOI 10.1128/MCB.11.11.5639; Sambrook J., 2002, MOL CLONING LAB MANU; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAGI T, 1993, CURR OPIN STRUC BIOL, V3, P413, DOI 10.1016/S0959-440X(05)80115-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Thorsteinsson MV, 1996, BBA-PROTEIN STRUCT M, V1292, P133, DOI 10.1016/0167-4838(95)00178-6; TSUBAMOTO Y, 1990, EUR J BIOCHEM, V193, P55, DOI 10.1111/j.1432-1033.1990.tb19303.x; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X; Zhao XJ, 1996, J BIOL CHEM, V271, P25131, DOI 10.1074/jbc.271.41.25131; ZITOMER RS, 1992, MICROBIOL REV, V56, P1; Zitomer RS, 1997, KIDNEY INT, V51, P507, DOI 10.1038/ki.1997.71	46	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5032	5037		10.1074/jbc.274.8.5032	http://dx.doi.org/10.1074/jbc.274.8.5032			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988749	hybrid			2022-12-25	WOS:000078698200074
J	Hoffmeyer, A; Grosse-Wilde, A; Flory, E; Neufeld, B; Kunz, M; Rapp, UR; Ludwig, S				Hoffmeyer, A; Grosse-Wilde, A; Flory, E; Neufeld, B; Kunz, M; Rapp, UR; Ludwig, S			Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor a gene expression in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTIONAL ACTIVATION; TRANSDUCTION PATHWAY; TNF-ALPHA; CELLS; P38; MAP; PROMOTER; PHOSPHORYLATION	Tumor necrosis factor a (TNF-alpha) is a potent proinflammatory cytokine and plays a crucial role in early events of inflammation. TNF-alpha is primarily produced by monocytes and T lymphocytes, In particular, T-cell-derived TNF-alpha plays a critical role in autoimmune inflammation and superantigen-induced septic shock. However, little is known about the intracellular signaling pathways that regulate TNF expression in T cells. Here we show that extracellular signal-regulated kinase (ERK), c-dun N-terminal kinase (JNK), and p38-mitogen-activated protein kinase (MaPK) pathways control the transcription and synthesis of TNF-alpha in A3.01 T cells that produce the cytokine upon T cell activation by costimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA) and ionomycin, Selective activation of each if the distinct MaPK pathways by expression of constitutively active kinases is sufficient for TNF-alpha promoter induction. Furthermore, blockage of all three pathways almost abolishes TPA/ionomycin-induced transcriptional activation of the TNF-alpha promoter. Selective inhibition of one or more MATH pathways impairs TNF-alpha induction by TPA/ionomycin, indicating a cooperation between these signal transduction pathways. Our approach revealed that the MAPK kinase 6 (MKK6)/p38 pathway is involved in both transcriptional and posttranscriptional regulation of TNF expression. Moreover, analysis of the progressive 5' deletion mutants of the TNF-cr promoter indicates that distinct promoter regions are targeted by either ERK-, JNK-, or p38-activating pathways. Thus, unlike what has been reported for other TNF-alpha-producing cells, all three MAPK pathways are critical and cooperate to regulate transcription of the TNF-alpha gene in T lymphocytes, suggesting a T-cell-specific regulation of the cytokine.	Inst Med Strahlenkunde & Zellforsch MSZ, D-97078 Wurzburg, Germany; Univ Wurzburg, Klin & Poliklin Haut & Geschlechtskrankheiten, D-97078 Wurzburg, Germany	University of Wurzburg	Ludwig, S (corresponding author), Inst Med Strahlenkunde & Zellforsch MSZ, Versbacherstr 5, D-97078 Wurzburg, Germany.	IMSD019@rzbox.uni-wuerzburg.de		Ludwig, Stephan/0000-0003-4490-3052				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; DROUET C, 1991, J IMMUNOL, V147, P1694; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GEPPERT TD, 1994, MOL MED, V1, P93; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HAGEMANN D, 1999, IN PRES ONCOGENE; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jongeneel C V, 1994, Prog Clin Biol Res, V388, P367; Korner H, 1997, J EXP MED, V186, P1585, DOI 10.1084/jem.186.9.1585; KRAMER B, 1995, J INFLAMM, V45, P183; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Parry SL, 1997, J IMMUNOL, V158, P3673; PAUL S, 1994, INT J SOFTW ENG KNOW, V4, P325, DOI 10.1142/S0218194094000167; Prieschl EE, 1996, J IMMUNOL, V157, P2645; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Taupin VR, 1997, EUR J IMMUNOL, V27, P905, DOI 10.1002/eji.1830270416; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	56	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4319	4327		10.1074/jbc.274.7.4319	http://dx.doi.org/10.1074/jbc.274.7.4319			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933633	hybrid			2022-12-25	WOS:000078575500057
J	Hurst, ST; Rivier, DH				Hurst, ST; Rivier, DH			Identification of a compound origin of replication at the HMR-E locus in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; DNA-REPLICATION; FISSION YEAST; ARS ELEMENTS; RECOGNITION COMPLEX; CHROMOSOMAL DNA; FUNCTIONAL ELEMENTS; GENE AMPLIFICATION; SEQUENCE-ANALYSIS; DROSOPHILA	Eukaryotic chromosomal origins of replication are best defined in Saccharomyces cerevisiae. Previous analysis of yeast origins suggests that they are relatively simple structures comprised of three or four small DNA sequence elements contained within approximately 100-200-base pair regions (Gilbert, D. M. (1998) Curr. Opin. Genet. Dev. 8, 194-199). In contrast, the sequence elements that may comprise origins in multicellular eukaryotes are largely unknown. The yeast HMR-E region is both a chromosomal origin of replication and a silencer that represses transcription of adjacent genes through a position effect. The analysis presented here indicated that HMR-E had a novel DNA structure that was more complex than defined for other yeast origins, and thus revealed that there is variation in the structural complexity of yeast origins. In contrast to "simple" yeast origins, the origin at HMR-E consisted of at least three independent subregions that had the capacity to initiate replication. We have termed HMR-E a compound origin to reflect its structural complexity. Furthermore, only one origin within the compound origin was a silencer.	Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Rivier, DH (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Chem & Life Sci Lab B107, 601 S Goodwin Ave, Urbana, IL 61801 USA.	rivier@uiuc.edu			NIGMS NIH HHS [5T32-GM07283, GM52103] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283, R01GM052103] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENBOW RM, 1992, BIOESSAYS, V14, P661, DOI 10.1002/bies.950141004; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; Donovan S, 1996, CURR OPIN GENET DEV, V6, P203; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; Gerbi SA, 1997, METHODS, V13, P271, DOI 10.1006/meth.1997.0526; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gilbert DM, 1998, CURR OPIN GENET DEV, V8, P194; HECK MMS, 1990, J CELL BIOL, V110, P903, DOI 10.1083/jcb.110.4.903; Huang RY, 1996, NUCLEIC ACIDS RES, V24, P816, DOI 10.1093/nar/24.5.816; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; JAMES CD, 1986, MOL CELL BIOL, V6, P976, DOI 10.1128/MCB.6.4.976; JOHNSTON LH, 1987, MOL GEN GENET, V207, P161, DOI 10.1007/BF00331504; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; LEWIS EB, 1995, P NATL ACAD SCI USA, V92, P8403, DOI 10.1073/pnas.92.18.8403; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; LIANG C, 1993, GENE DEV, V7, P1072, DOI 10.1101/gad.7.6.1072; Lin S, 1997, MOL CELL BIOL, V17, P5473, DOI 10.1128/MCB.17.9.5473; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; Wang ST, 1998, MOL CELL BIOL, V18, P39, DOI 10.1128/MCB.18.1.39; Zhang Z, 1997, MOL CELL BIOL, V17, P6147, DOI 10.1128/MCB.17.10.6147; ZHU JG, 1994, CHROMOSOMA, V103, P414, DOI 10.1007/s004120050050	58	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4155	4159		10.1074/jbc.274.7.4155	http://dx.doi.org/10.1074/jbc.274.7.4155			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933610	hybrid			2022-12-25	WOS:000078575500034
J	Yu, LX; DeLeo, FR; Biberstine-Kinkade, KJ; Renee, J; Nauseef, WM; Dinauer, MC				Yu, LX; DeLeo, FR; Biberstine-Kinkade, KJ; Renee, J; Nauseef, WM; Dinauer, MC			Biosynthesis of flavocytochrome b(558) - gp91(phox) is synthesized as a 65-kDa precursor (p65) in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; NEUTROPHIL CYTOCHROME-B; PHAGOCYTE NADPH OXIDASE; CYTOSOLIC COMPONENT; PLASMA-MEMBRANE; ACTIVATION; EXPRESSION; MYELOPEROXIDASE; PROTEIN	The redox center of the phagocyte NADPH oxidase is flavocytochrome b(558), a transmembrane protein with two subunits, gp91(phox) and p22(phox). In this study we investigated the identity, subcellular localization, and maturation of a putative 65-kDa gp91(phox) precursor (p65), Expressing the gp91(phox) cDNA in an in vitro transcription and translation system, we found that synthesis of p65 required endoplasmic reticulum (ER) microsomes, Sucrose density gradient centrifugation of postnuclear supernatants obtained from a PLB-985 derived cell line with a constitutively expressed gp91(phox) transgene demonstrated that p65 co-sedimented with the ER marker protein calreticulin and myeloperoxidase precursors, Unexpectedly the majority of p22(phox) was found in subcellular compartments containing the mature 91-kDa form of gp91(phox) and not with p65, suggesting that heterodimer formation may occur in a post-ER compartment, The heme synthesis inhibitor, succinyl acetone, reduced the abundance of mature gp91(phox) and p22(phox) but had little or no impact on p65, These studies demonstrate (a) gp91(phox) is synthesized as a glycosylated 65-kDa precursor in the ER, (b) heterodimer formation is not a co-translational process, and (c) heme insertion is a determinant in the formation of a stable heterodimer but does not appear to affect the stability of p65.	Indiana Univ Sch Med, Riley Hosp Hosp, Wells Ctr Pedit Res, Indianapolis, IN 46202 USA; Vet Adm Med Ctr, Inflammat Program, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA	Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	Dinauer, MC (corresponding author), Indiana Univ Sch Med, Riley Hosp Hosp, Wells Ctr Pedit Res, Canc Res Bldg,Rm 466,1044 W Walnut St, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu		DeLeo, Frank/0000-0003-3150-2516; Nauseef, William/0000-0003-4032-757X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007343] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL45635, P01 HL 35386] Funding Source: Medline; NIAID NIH HHS [5-T32-AI07343-09] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DeLeo FR, 1998, J CLIN INVEST, V101, P2900, DOI 10.1172/JCI2649; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; HARPER AM, 1985, BIOCHEM J, V227, P783, DOI 10.1042/bj2270783; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MIZUNO Y, 1988, J PEDIATR-US, V113, P458, DOI 10.1016/S0022-3476(88)80628-0; NAKAMURA M, 1987, BLOOD, V69, P1404; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1992, BLOOD, V80, P2622; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; PORTER CD, 1994, BLOOD, V84, P2767; Porter CD, 1996, BIOCHEM J, V315, P571, DOI 10.1042/bj3150571; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; Zhen L, 1998, J BIOL CHEM, V273, P6575, DOI 10.1074/jbc.273.11.6575; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	41	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4364	4369		10.1074/jbc.274.7.4364	http://dx.doi.org/10.1074/jbc.274.7.4364			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933639	hybrid			2022-12-25	WOS:000078575500063
J	Brodsky, JL; Werner, ED; Dubas, ME; Goeckeler, JL; Kruse, KB; McCracken, AA				Brodsky, JL; Werner, ED; Dubas, ME; Goeckeler, JL; Kruse, KB; McCracken, AA			The requirement for molecular chaperones during endoplasmic reticulum-associated protein degradation demonstrates that protein export and import are mechanistically distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; ER QUALITY-CONTROL; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; STRESS PROTEINS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; BINDING-SPECIFICITY; SECRETORY PROTEIN; IN-VITRO; BIP	Polypeptide import into the yeast endoplasmic reticulum (ER) requires two hsp70s, Ssa1p in the cytosol and BiP (Kar2p) in the ER lumen. After import, aberrant polypeptides may be exported to the cytoplasm for degradation by the proteasome, and defects in the ER chaperone calnexin (Cne1p) compromise their degradation. Both import and export require BiP and the Sec61p translocation complex, suggesting that import and export may be mechanistically related. We now show that the cne1 Delta and two kar2 mutant alleles exhibit a synthetic interaction and that the export and degradation of pro-alpha factor is defective in kar2 mutant microsomes. Pulse-chase analysis indicates that A1PiZ, another substrate for degradation, is stabilized in the kar2 strains at the restrictive temperature. Because two of the kar2 mutants examined are proficient for polypeptide import, the roles of BiP during ER protein export and import differ, indicating that these processes must be mechanistically distinct. To examine whether Ssa1p drives polypeptides from the ER and is also required for degradation, we assembled reactions using strains either containing a mutation in SSA1 or in which the level of Ssa1p could be regulated. We found that pro-alpha factor and A1PiZ were degraded normally, indicating further that import and export are distinct and that other cytosolic factors may pull polypeptides from the ER.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Nevada, Dept Biol, Reno, NV 89557 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nevada System of Higher Education (NSHE); University of Nevada Reno	Brodsky, JL (corresponding author), Univ Pittsburgh, Dept Biol Sci, 267 Crawford Hall, Pittsburgh, PA 15260 USA.			Goeckeler-Fried, Jennifer/0000-0001-5940-9917				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Becker J, 1996, MOL CELL BIOL, V16, P4378; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BRODSKY JL, 1996, TRENDS BIOCHEM SCI, V21, P121; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHIRICO WJ, 1992, BIOCHEM BIOPH RES CO, V189, P1150, DOI 10.1016/0006-291X(92)92324-Q; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LE AQ, 1994, J BIOL CHEM, V269, P7514; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MCCRACKEN AA, 1993, MOL BIOL CELL, V4, P729, DOI 10.1091/mbc.4.7.729; McCracken AA, 1998, ADV MOL CEL, V27, P165, DOI 10.1016/S1569-2558(08)60461-0; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OH HJ, 1997, J BIOL CHEM, V272, P3636; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; Paunola E, 1998, MOL BIOL CELL, V9, P817, DOI 10.1091/mbc.9.4.817; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P1555, DOI 10.1172/JCI114332; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rose MD., 1990, METHODS YEAST GENETI; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHMITZ A, 1995, EMBO J, V14, P1091, DOI 10.1002/j.1460-2075.1995.tb07092.x; SCHONBERGER O, 1991, MOL MICROBIOL, V5, P2663, DOI 10.1111/j.1365-2958.1991.tb01975.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Simons JF, 1998, EMBO J, V17, P396, DOI 10.1093/emboj/17.2.396; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; VOGEL J, 1993, THESIS PRINCETON U; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	62	214	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3453	3460		10.1074/jbc.274.6.3453	http://dx.doi.org/10.1074/jbc.274.6.3453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920890	hybrid			2022-12-25	WOS:000078428200030
J	Inamori, K; Saito, T; Iwaki, D; Nagira, T; Iwanaga, S; Arisaka, F; Kawabata, S				Inamori, K; Saito, T; Iwaki, D; Nagira, T; Iwanaga, S; Arisaka, F; Kawabata, S			A newly identified horseshoe crab lectin with specificity for blood group A antigen recognizes specific O-antigens of bacterial lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; CDNA CLONING; BIG DEFENSIN; SUBCELLULAR-LOCALIZATION; ANTIBACTERIAL ACTIVITY; PROCLOTTING ENZYME; BINDING-PROTEIN; IMMUNE-SYSTEM; LIMULUS; PURIFICATION	A 14-kDa lectin, named tachylectin-3, was newly identified from hemocytes of the Japanese horseshoe crab, Tachypleus tridentatus. This lectin exhibited hemagglutinating activity against human A-type erythrocytes, but not against the B- and O-types of erythrocytes and animal erythrocytes, including those of sheep, rabbit, horse, and bovine. The hemagglutinating activity of tachylectin-3 was equivalent to that of a previously identified lectin, named tachylectin-2, with affinity for N-acetyl-D-glucosamine or N-acetyl-D-galactosamine. However, the activity of tachylectin-3 was not inhibited by these two N-acetylhexosamines at 100 mM but was inhibited by a blood group A-pentasaccharide at a minimum inhibitory concentration of 0.16 mM. Furthermore, the hemagglutinating activity was strongly inhibited by bacterial S-type lipopolysaccharides (LPSs) from Gramnegative bacteria but not by R-type LPSs lacking O-antigens, One of the most effective S-type LPSs was from Escherichia coli O111:B4, with a minimum inhibitory concentration of 6 ng/ml, These data suggest that tachylectin-3 specifically recognizes Gram-negative bacteria through the unique structural units of O-antigens, Ultracentrifugation analysis revealed that tachylectin-3 is present in dimer in solution. A cDNA coding for tachylectin-3 was isolated from a hemocyte cDNA library. Tachylectin-3 consisted of two repeating sequences, each with a partial sequence similarity to rinderpest virus neuraminidase. Tachylectin-3 and three previously isolated types of tachylectins were all predominantly expressed in hemocytes and released from hemocytes in response to external stimuli. These lectins present at injured sites suggest that they probably serve synergitically to accomplish an effective host defense against invading microbes.	Kyushu Univ, Fac Sci, Dept Biol, Grad SCh Med Sci, Fukuoka 8128581, Japan; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Tokyo Inst Technol, Fac Biosci & Bioengn, Dept Life Sci, Yokohama, Kanagawa 2268501, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan	Kyushu University; Kyushu University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Kawabata, S (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Grad SCh Med Sci, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp		Inamori, Kei-ichiro/0000-0002-5947-3633; Saito, Tetsu/0000-0002-9045-6743				ARMSTRONG PB, 1982, EXP CELL RES, V140, P15, DOI 10.1016/0014-4827(82)90150-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GOLDMAN RC, 1982, J BACTERIOL, V151, P1210, DOI 10.1128/JB.151.3.1210-1221.1982; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; Iwanaga S, 1998, J BIOCHEM, V123, P1; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kawabata S, 1997, BIOL CHEM, V378, P289, DOI 10.1515/bchm.1997.378.3-4.289; Kawabata S, 1997, Methods Mol Biol, V78, P51; Kawabata Shun-ichiro, 1996, P255; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langedijk JPM, 1997, J VIROL, V71, P6155, DOI 10.1128/JVI.71.8.6155-6167.1997; LEFFLER H, 1986, J BIOL CHEM, V261, P119; MANDRELL RE, 1994, METHOD ENZYMOL, V236, P231; Mey A, 1996, J IMMUNOL, V156, P1572; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO S, 1994, J BIOL CHEM, V269, P4424; SENGUPTA P, 1995, CARBOHYD RES, V277, P283, DOI 10.1016/0008-6215(95)00215-F; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SIKDER SK, 1986, CARBOHYD RES, V151, P247, DOI 10.1016/S0008-6215(00)90345-8; SODERHALL K, 1994, ANN NY ACAD SCI, V712, P155, DOI 10.1111/j.1749-6632.1994.tb33570.x; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YAMANAKA M, 1988, VIROLOGY, V166, P251, DOI 10.1016/0042-6822(88)90168-7	40	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3272	3278		10.1074/jbc.274.6.3272	http://dx.doi.org/10.1074/jbc.274.6.3272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920866	hybrid			2022-12-25	WOS:000078428200006
J	Osheroff, WP; Jung, HK; Beard, WA; Wilson, SH; Kunkel, TA				Osheroff, WP; Jung, HK; Beard, WA; Wilson, SH; Kunkel, TA			The fidelity of DNA polymerase beta during distributive and processive DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HIV-1 REVERSE-TRANSCRIPTASE; TEMPLATE-PRIMER; TRANSIENT MISALIGNMENT; MUTATIONAL SPECIFICITY; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; CROSS-LINKING; DNTP BINDING	During base excision repair, DNA polymerase beta fills 1-6-nucleotide gaps processively, reflecting a contribution of both its 8- and 31-kDa domains to DNA binding. Here we report the fidelity of pol beta during synthesis to fill gaps of 1, 5, 6, or >300 nucleotides. Error rates during distributive synthesis by recombinant rat and human polymerase (pol) beta with a 390-base gap are similar to each other and to previous values with pol beta purified from tissues. The base substitution fidelity of human pol beta when processively filling a 5-nucleotide gap is similar to that with a 361-nucleotide gap, but "closely-spaced" substitutions are produced at a rate at least 60-fold higher than for distributive synthesis, Base substitution fidelity when filling a 1-nucleotide gap is higher than when filling a 5-nucleotide gap, suggesting a contribution of the 8-kDa domain to the dNTP binding pocket and/or a difference in base stacking or DNA structure imposed by pol beta. Nonetheless, 1-nucleotide gap filling is inaccurate, even generating complex substitution-addition errors. Finally, the single-base deletion error rate during processive synthesis to fill a 6-nucleotide gap is indistinguishable from that of distributive synthesis to fill a 390-nucleotide gap. Thus the mechanism of processivity by pol beta does not allow the enzyme to suppress template misalignments.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Natl Inst Safety Res, Div Mutagenesis, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KRAEMER KH, 1989, MUTAT RES, V220, P61, DOI 10.1016/0165-1110(89)90011-0; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; Kunkel TA, 1998, NAT STRUCT BIOL, V5, P95, DOI 10.1038/nsb0298-95; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; NOWAK R, 1990, EXP CELL RES, V191, P51, DOI 10.1016/0014-4827(90)90034-8; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PROTICSABLJIC M, 1986, MOL CELL BIOL, V6, P3349, DOI 10.1128/MCB.6.10.3349; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEETHARAM S, 1991, MUTAT RES, V254, P97, DOI 10.1016/0921-8777(91)90045-Q; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1996, BIOCHEMISTRY-US, V35, P3728, DOI 10.1021/bi952632h; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; STALKER DM, 1976, BIOCHEMISTRY-US, V15, P3114, DOI 10.1021/bi00659a027; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Winter DB, 1998, P NATL ACAD SCI USA, V95, P6953, DOI 10.1073/pnas.95.12.6953	63	132	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3642	3650		10.1074/jbc.274.6.3642	http://dx.doi.org/10.1074/jbc.274.6.3642			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920913	hybrid			2022-12-25	WOS:000078428200053
J	Kang, JJ; Schaber, MD; Srinivasula, SM; Alnemri, ES; Litwack, G; Hall, DJ; Bjornsti, MA				Kang, JJ; Schaber, MD; Srinivasula, SM; Alnemri, ES; Litwack, G; Hall, DJ; Bjornsti, MA			Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-I; CELL-DEATH; CAMPTOTHECIN SENSITIVITY; CYSTEINE PROTEASES; SIGNALING COMPLEX; APOPTOSIS; FAMILY; FLICE; RESISTANCE; PATHWAY	Caspases (aspartate-specific cysteine proteases) play a critical role in the execution of the mammalian apoptotic program. To address the regulation of human caspase activation, we used the yeast Saccharomyces cerevisiae, which is devoid of endogenous caspases. The apical procaspases, -8 beta and -10, were efficiently processed and activated in yeast. Although protease activity, per se, was insufficient to drive cell death, caspase-10 activity had little effect on cell viability, whereas expression of caspase-8 beta was cytotoxic. This lethal phenotype was abrogated by co-expression of the pan-caspase inhibitor, baculovirus p35, and by mutation of the active site cysteine of procaspase-8 beta. In contrast, autoactivation of the executioner caspase-3 and -6 zymogens was not detected. Procaspase-3 activation required co-expression of procaspase-8 or -10. Surprisingly, activation of procaspase-6 required proteolytic activities other than caspase-8, -10, or -3. Caspase-8 beta or -10 activity was insufficient to catalyze the maturation of procaspase-6, Moreover, a constitutively active caspase-3, although cytotoxic in its own right, was unable to induce the processing of wild-type procaspase-6 and vice versa, These results distinguish sequential modes of activation for different caspases in vivo and establish a yeast model system to examine the regulation of caspase cascades. Moreover, the distinct terminal phenotypes induced by various caspases attest to differences in the cellular targets of these apoptotic proteases, which may be defined using this system.	Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Bjornsti, MA (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, 233 S 10th St, Philadelphia, PA 19107 USA.	bjornsti@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010		NATIONAL CANCER INSTITUTE [R01CA067032, R01CA070406] Funding Source: NIH RePORTER; NCI NIH HHS [CA67032, CA70406] Funding Source: Medline; NIAID NIH HHS [AI14357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Dixit VM, 1996, ADV EXP MED BIOL, V406, P113; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1993, J BIOL CHEM, V268, P22322; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shaham S, 1998, CELL, V92, P425, DOI 10.1016/S0092-8674(00)80934-4; SHERMAN F, 1986, LAB COURSE MANUAL ME, P61; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; TALANIAN RV, 1997, J BIOL CHEM, V272, P6977; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; [No title captured]	52	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3189	3198		10.1074/jbc.274.5.3189	http://dx.doi.org/10.1074/jbc.274.5.3189			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915859	hybrid			2022-12-25	WOS:000078319500077
J	Liew, CT; Li, HM; Lo, KW; Leow, CK; Chan, JYH; Hin, LY; Lau, WY; Lai, PBS; Lim, BK; Huang, J; Leung, WT; Wu, S; Lee, JCK				Liew, CT; Li, HM; Lo, KW; Leow, CK; Chan, JYH; Hin, LY; Lau, WY; Lai, PBS; Lim, BK; Huang, J; Leung, WT; Wu, S; Lee, JCK			High frequency of p16(INK4A) gene alterations in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; p16; hypermethylation; homozygous deletion; mutation	HOMOZYGOUS DELETIONS; DNA METHYLATION; MUTATIONS; INACTIVATION; INHIBITION; MDM2	The tumor suppressor gene p16 (CDKN2/MTS-1/INK4A) is an important component of the cell cycle and inactivation of the gene has been found in a variety of human cancers. In order to investigate the role of p16 gene in the tumorigenesis of hepatocellular carcinoma (HCC), 48 cases of HCC were analysed for p16 alterations by: methylation-specific PCR (MSP) to determine the methylation status of the p16 promoter region; comparative multiplex PCR to detect homozygous deletion; PCR-SSCP and DNA sequencing analysis to identify mutation of the p16 gene. We found high frequency of hypermethylation of the 5' CpG island of the p16 gene in 30 of 48 cases (62.5%) of HCC tumors. Moreover, homozygous deletion at p16 region were present in five of 48 cases (10.4%); and missense mutation were detected in three of 48 cases (6.3%), The overall frequency of p16 alterations, including homozygous deletion, mutation and hypermethylation, in HCC tumors was 70.8% (34 of 48 cases), These findings suggest that: (a) the inactivation of the p16 is a frequent event in HCC; (b) the p16 gene is inactivated by multiple mechanisms including homozygous deletion, promoter hypermethylation and point mutation; (c) the most common somatic alteration of the p16 gene in HCC is de novo hypermethylation of the 5' CpG island; and (d) in contrast to other studies, high frequency of genomic alterations are not uncommon in the 9p21 of the p16 gene. Our results strongly suggest that the p16 gene plays an important role in the pathogenesis of HCC.	Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Anat & Cellular Pathol, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Surg, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Clin Oncol, Shatin, Peoples R China; Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynecol, Shatin, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Liew, CT (corresponding author), Prince Wales Hosp, Chinese Univ Hong Kong, Fac Med, Dept Anat & Cellular Pathol, Shatin, Peoples R China.		Hin, Lin Yee/B-1204-2009; Lai, Paul BS/K-8556-2015	Hin, Lin Yee/0000-0002-6125-4632; Lai, Paul BS/0000-0002-9469-6728; Lo, Kwok Wai/0000-0002-3488-6124				Baylin SB, 1998, ADV CANCER RES, V72, P141; Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; GERBER MA, 1992, AM J PATHOL, V141, P1271; HERMAN JG, 1995, CANCER RES, V55, P4525; *HONG KONG HOSP AU, 1998, CANC INC MORT HONG K; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1002/hep.510240319; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kita R, 1996, INT J CANCER, V67, P176, DOI 10.1002/(SICI)1097-0215(19960717)67:2<176::AID-IJC4>3.0.CO;2-Q; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MISCHIATI C, 1993, BIOTECHNIQUES, V15, P146; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qin LX, 1996, ONCOL REP, V3, P405; Reed AL, 1996, CANCER RES, V56, P3630; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOMIMATSU M, 1993, CANCER, V72, P683, DOI 10.1002/1097-0142(19930801)72:3<683::AID-CNCR2820720310>3.0.CO;2-C; WEISING K, 1991, ELECTROPHORESIS, V12, P159, DOI 10.1002/elps.1150120211; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	27	156	170	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					789	795		10.1038/sj.onc.1202359	http://dx.doi.org/10.1038/sj.onc.1202359			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989830				2022-12-25	WOS:000078394400025
J	Pupa, SM; Howard, CM; Invernizzi, AM; De Vecchi, R; Giani, C; Claudio, PP; Colnaghi, MI; Giordano, A; Menard, S				Pupa, SM; Howard, CM; Invernizzi, AM; De Vecchi, R; Giani, C; Claudio, PP; Colnaghi, MI; Giordano, A; Menard, S			Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line	ONCOGENE			English	Article						Rb2; oncosuppressor; c-erbB-2; oncogene; ovary carcinoma; tumorigenicity	RETINOBLASTOMA-SUSCEPTIBILITY GENE; TRANSCRIPTIONAL REPRESSION; NEU PROTOONCOGENE; FAMILY MEMBERS; PROTEIN FAMILY; RB2/P130 GENE; CYCLE; PRODUCT; ONCOGENE; E1A	We investigated the in vitro and in vivo effects of the ectopic expression of the pRb2/p130 cell cycle regulator on c-erbB-2-associated tumorigenicity. SKOV3 ovarian cancer cells, which display c-erbB-2 gene amplification and oncoprotein (p185(HER2)) overexpression, were stably transfected with a plasmid containing the coding sequence for human wild-type pRb2/p130 (wtRb2), or with pcDNA3 empty vector. Three wtRb2-transfected clones (cl. 24, cl. 19, cl. 100) and one empty vector-transfected clone (cl, mock) were randomly picked and further analysed, Western blot analysis revealed high levels of pRb2/p130 in the three clones compared to mock cells. Levels of p185(HER2) and the extent of its tyrosine phosphorylation were similar in all transfectant clones, as were levels of pRb1 and p107, In anchorage-independent growth assays, the number of colonies from wtRb2 clone-transfectants was about 90% less than that arising from mock cells (P < 0.001). Tumor take rates of the three wtRb2-transfected clones xenografted in nu/nu mice were much lower than those of mock cells, and tumor volume was decreased by 80% (P < 0.001). A mutant version of pRb2/p130 deleted of the pocket region (mut-Rb2) was also transfected into SKOV3 cells and studied in parallel with the wtRb2-transfected and pcDNA empty vector-transfected bulk populations. mut-Rb2 transfected cells showed no inhibition of in vitro colony formation and were fully tumorigenic. Together, these findings indicate that Rb2 acts as a tumor suppressor gene in vivo and in vitro in SKOV3 cells and that the intact pocket region is required for the suppressor activity.	Ist Nazl Tumori, Div Expt Oncol E, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Sbarro Inst Canc Res & Mol Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Menard, S (corresponding author), Ist Nazl Tumori, Div Expt Oncol E, Via Venezian 1, I-20133 Milan, Italy.		menard, sylvie mm/C-7940-2011; Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021; Pupa, Serenella/K-6388-2016	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; Pupa, Serenella/0000-0002-4592-6830; Howard, Candace/0000-0001-6537-3551	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60999-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BALDI A, 1996, CLIN CANCER RES, V2, P1; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FRISCH SM, 1995, CANCER RES, V55, P5551; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; MATIN A, 1994, ONCOGENE, V9, P1333; MAYOL X, 1993, ONCOGENE, V8, P2561; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; YEUNG RS, 1993, ONCOGENE, V8, P3465; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	31	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					651	656		10.1038/sj.onc.1202363	http://dx.doi.org/10.1038/sj.onc.1202363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989815				2022-12-25	WOS:000078394400010
J	Velasco, JA; Avila, MA; Notario, V				Velasco, JA; Avila, MA; Notario, V			The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress	ONCOGENE			English	Article						chemical carcinogenesis; Syrian hamster embryo cells; oncogenic activation; nucleotide-binding proteins; stress survival	HAMSTER-EMBRYO FIBROBLASTS; MULTISTEP CARCINOGENESIS; RIBONUCLEOTIDE REDUCTASE; SEQUENCE SIMILARITY; SIGNAL-TRANSDUCTION; EXCHANGE ACTIVITY; MAMMALIAN-CELLS; GROWTH-FACTOR; P53 GENE; RAS	Cph was isolated from neoplastic Syrian hamster embryo fibroblasts initiated by 3-methylcholanthrene (MCA), and was shown to be a single copy gene in the hamster genome, conserved from yeast to human cells, expressed in fetal cells and most adult tissues, and acting synergistically with H-ras in the transformation of murine NIH3T3 fibroblasts, We have now isolated Syrian hamster full-length cDNAs for the cph oncogene and proto-oncogene, Nucleotide sequence analysis revealed that cph was activated in MCA-treated cells by a point-mutational deletion at codon 214, which caused a shift in the normal open reading frame (ORF) and brought a translation termination codon 33 amino acids downstream. While proto-cph encodes a protein (pcph) of 469 amino acids, cpk encodes a truncated protein (cph) of 246 amino acids with a new, hydrophobic C-terminus, Similar mechanisms activated cph in other MCA-treated Syrian hamster cells. The cph and proto-cph proteins have partial sequence homology with two protein families: GDP/GTP exchange factors and nucleotide phosphohydrolases. In vitro translated, gel-purified cph proteins did not catalyze nucleotide exchange for H-ras, but were able to bind nucleotide phosphates, in particular ribonucleotide diphosphates such as UDP and GDP, Steady-state levels of cph mRNA increased 6.7-fold in hamster neoplastic cells, relative to a 2.2-fold increase in normal cells, when they were subjected to a nutritional stress such as serum deprivation, Moreover, cph-transformed NIH3T3 cells showed increased survival to various forms of stress (serum starvation, hyperthermia, ionizing radiation), strongly suggesting that cph participates in cellular mechanisms of response to stress.	Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA.		/AFP-0764-2022; /AAB-6461-2022; Avila, Matias A/Y-6342-2019	Avila, Matias A/0000-0001-6570-3557	NCI NIH HHS [CA64472, P30-CA-51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; ALBOR A, 1994, MOL CARCINOGEN, V11, P176, DOI 10.1002/mc.2940110309; ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1995, ONCOGENE, V10, P963; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERWALD Y, 1965, J NATL CANCER I, V35, P641; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOREK C, 1987, P NATL ACAD SCI USA, V84, P794, DOI 10.1073/pnas.84.3.794; BOS JL, 1989, CANCER RES, V49, P4682; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; Broach JR, 1997, CURR OPIN GENET DEV, V7, P1, DOI 10.1016/S0959-437X(97)80102-5; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CHAN AML, 1994, ONCOGENE, V9, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIPAOLO J A, 1986, Toxicologic Pathology, V14, P417; DIPAOLO JA, 1969, SCIENCE, V165, P917, DOI 10.1126/science.165.3896.917; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DIPAOLO JA, 1971, NATURE-NEW BIOL, V230, P240, DOI 10.1038/newbio230240a0; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; FARBER E, 1984, CANCER RES, V44, P4217; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GILMER TM, 1988, MOL CARCINOGEN, V1, P180, DOI 10.1002/mc.2940010306; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARRIS CC, 1991, CANCER RES, V51, pS5023; HART MJ, 1994, J BIOL CHEM, V269, P62; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Leonardsen L, 1996, ONCOGENE, V13, P2177; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOTARIO V, 1990, ONCOGENE, V5, P1425; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SODERMAN K, 1986, ANAL BIOCHEM, V152, P89, DOI 10.1016/0003-2697(86)90124-7; STEVENS CW, 1995, RAD ONCOL INVEST, V2, P212; TOKSOZ D, 1994, ONCOGENE, V9, P621; Velasco JA, 1998, MOL CARCINOGEN, V21, P156, DOI 10.1002/(SICI)1098-2744(199803)21:3<156::AID-MC2>3.0.CO;2-K; Velasco JA, 1996, ONCOGENE, V12, P2713; VELASCO JA, 1993, GENE, V137, P179, DOI 10.1016/0378-1119(93)90004-M; VELASCO JA, 1994, ONCOGENE, V9, P2065; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	69	24	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					689	701		10.1038/sj.onc.1202324	http://dx.doi.org/10.1038/sj.onc.1202324			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989819				2022-12-25	WOS:000078394400014
J	Bird, KJ; Semus, HL; Ruddell, A				Bird, KJ; Semus, HL; Ruddell, A			Resistance to avian leukosis virus lymphomagenesis occurs subsequent to proviral c-myc integration	ONCOGENE			English	Article						c-myc; c-erbB; lymphoma; tumor resistance; avian leukosis virus	REPEAT-ENHANCED TRANSCRIPTION; INDUCED ERYTHROBLASTOSIS; LYMPHOID LEUKOSIS; PROMOTER INSERTION; ERBB ACTIVATION; EGF-RECEPTOR; CELLS; INDUCTION; CHICKENS; MICE	Most chicken strains are highly susceptible to avian leukosis virus (ALV) induction of bursal lymphoma, involving proviral integration within the c-myc protoncogene, while certain strains are genetically resistant to lymphomagenesis, A nested PCR assay was developed to analyse the appearance of proviral c-myc integrations after ALV infection of lymphoma-susceptible birds, and to determine whether these integrations arise in lymphoma-resistant birds. Proviral c-myc integrations are detected in bursa and other tissues from 6 day-old lymphoma-susceptible birds infected as embryos, The abundance of bursal cells carrying these integrations increases roughly 40-fold by 35 days of age, indicating that these cells hyperproliferate within the bursal environment. Bursal cells with proviral c-myc integrations also arise soon after infection of lymphoma-resistant embryos. However, these cells expand much more slowly than cells from lymphoma-susceptible birds. Both strains show the same rate of viral infection, so that resistance to lymphomagenesis occurs at a step subsequent to proviral c-myc integration. Proviral c-erbB gene integrations arise at the same frequency in bursa and other tissues of both strains, and they do not increase in abundance during development. These findings indicate that the mechanism of resistance to lymphomagenesis involves specific inhibition of cells with proviral c-myc integrations within the bursa.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY USA	Fred Hutchinson Cancer Center; University of Rochester	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop C2-023,POB 19024, Seattle, WA 98104 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA TW, 1984, J VIROL, V51, P123, DOI 10.1128/JVI.51.1.123-130.1984; BACON L, 1979, POULTRY SCI, V58, P1033; BACON LD, 1986, IMMUNOGENETICS, V23, P213, DOI 10.1007/BF00373015; BACON LD, 1981, POULTRY SCI, V60, P1132, DOI 10.3382/ps.0601132; BELLI B, 1995, J VIROL, V69, P5138, DOI 10.1128/JVI.69.8.5138-5141.1995; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; BOWERS WJ, 1994, LEUKEMIA, V8, pS211; BURMESTER BR, 1960, J NATL CANCER I, V24, P1423; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; Curristin SM, 1997, J VIROL, V71, P5972, DOI 10.1128/JVI.71.8.5972-5981.1997; ESCOT C, 1993, ONCOGENE, V8, P969; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; FLAMANT F, 1987, VIROLOGY, V160, P301, DOI 10.1016/0042-6822(87)90079-1; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; FUNG YKT, 1982, VIROLOGY, V119, P411; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; HIHARA H, 1980, AVIAN DIS, V24, P971, DOI 10.2307/1589971; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; Neiman P. E., 1980, Viruses in naturally occurring cancers. Book A, P519; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PELICCI PG, 1986, J EXP MED, V164, P2049, DOI 10.1084/jem.164.6.2049; PETERSON RD, 1966, JNCI-J NATL CANCER I, V36, P585, DOI 10.1093/jnci/36.4.585; PINK JRL, 1985, IMMUNOLOGICAL METHOD, V3, P385; PURCHASE HG, 1977, NATURE, V270, P61, DOI 10.1038/270061a0; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; RUDDELL A, 1988, J VIROL, V62, P2728, DOI 10.1128/JVI.62.8.2728-2735.1988; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SMITH CD, 1994, J VIROL, V68, P6232, DOI 10.1128/JVI.68.10.6232-6242.1994; SMITH EJ, 1979, AVIAN DIS, V23, P698, DOI 10.2307/1589746; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414	45	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					201	209		10.1038/sj.onc.1202283	http://dx.doi.org/10.1038/sj.onc.1202283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926935				2022-12-25	WOS:000078166000022
J	Bigey, P; Knox, JD; Croteau, S; Bhattacharya, SK; Theberge, J; Szyf, M				Bigey, P; Knox, JD; Croteau, S; Bhattacharya, SK; Theberge, J; Szyf, M			Modified oligonucleotides as bona fide antagonists of proteins interacting with DNA - Hairpin antagonists of the human DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SIGNALING PATHWAY; IN-VIVO; METHYLATION; CELLS; ANTISENSE; 5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION; TUMORIGENESIS; RECOGNITION	The study of the biological role of DNA methyltransferase (DNA MeTase) has been impeded by the lack of direct and specific inhibitors. This report describes the design of potent DNA based antagonists of DNA MeTase and their utilization to define the interactions of DNA MeTase with its substrate and to study its biological role. We demonstrate that the size, secondary structure, hemimethylation, and phosphorothioate modification strongly affect the antagonists interaction with DNA MeTase whereas base substitutions do not have a significant effect. To study whether DNA MeTase is critical for cellular transformation, human lung non-small carcinoma cells were treated with the DNA MeTase antagonists. Ex vivo, hairpin inhibitors of DNA MeTase are localized to the cell nucleus in lung cancer cells. They inhibit DNA MeTase, cell growth, and anchorage independent growth tan indicator of tumorigenesis in cell culture) in a dose-dependent manner. The inhibitors developed in this study are the first documented example of direct inhibitors of DNA MeTase in living cells and of modified oligonucleotides as bona fide antagonists of critical cellular proteins.	McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Bhattacharya, Sanjoy K/B-2001-2008	bigey, pascal/0000-0002-6795-8569				Akhtar S, 1997, TRENDS PHARMACOL SCI, V18, P12, DOI 10.1016/S0165-6147(96)01002-4; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BOLDEN AH, 1986, MOL CELL BIOL, V6, P1135, DOI 10.1128/MCB.6.4.1135; BOULARD Y, 1991, NUCLEIC ACIDS RES, V19, P5159, DOI 10.1093/nar/19.19.5159; CHIANG PK, 1992, J BIOL CHEM, V267, P4988; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ERIE DA, 1993, BIOCHEMISTRY-US, V32, P436, DOI 10.1021/bi00053a008; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HANCK T, 1993, NUCLEIC ACIDS RES, V21, P303, DOI 10.1093/nar/21.2.303; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESTRE B, 1995, BIOCONJUGATE CHEM, V6, P466, DOI 10.1021/bc00034a017; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Reale A, 1995, BIOCHEM J, V312, P855, DOI 10.1042/bj3120855; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SPROAT BS, 1995, J BIOTECHNOL, V41, P221, DOI 10.1016/0168-1656(95)00012-F; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P233; Tracewell W, 1995, TOXICOL APPL PHARM, V135, P179, DOI 10.1006/taap.1995.1221; Wu J C, 1985, Prog Clin Biol Res, V198, P119; Yang J, 1997, J IMMUNOL, V159, P1303; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	35	28	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4594	4606		10.1074/jbc.274.8.4594	http://dx.doi.org/10.1074/jbc.274.8.4594			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988694	hybrid			2022-12-25	WOS:000078698200019
J	Tcheperegine, SE; Marelli, M; Wozniak, RW				Tcheperegine, SE; Marelli, M; Wozniak, RW			Topology and functional domains of the yeast pore membrane protein Pom152p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; COMPLEX GLYCOPROTEIN; NUCLEAR-ENVELOPE; NUCLEOPORINS; SACCHAROMYCES; POLYPEPTIDE; INTERACTS; NUP188P; GP210	Integral membrane proteins associated with the nuclear pore complex (NPC) are likely to play an important role in the biogenesis of this structure. Here we have examined the functional roles of domains of the yeast pore membrane protein Pom152p in establishing its topology and its interactions with other NPC proteins. The topology of Pom152p was evaluated by alkaline extraction, protease protection, and endoglycosidase H sensitivity assays. The results of these experiments suggest that Pom152p contains a single transmembrane segment with its N terminus (amino acid residues 1-175) extending into the nuclear pore and its C terminus (amino acid residues 196-1337) positioned in the lumen of the nuclear envelope. The functional role of these different domains was investigated in mutants that are dependent on Pom152p for viability. The requirement for Pom152p in strains containing mutations allelic to the NPC protein genes NIC96 and NUP59 could be alleviated by Pom152p's N terminus, independent of its integration into the membrane. However, complementation of a mutation in NUP170 required both the N terminus and the transmembrane segment. Furthermore, mutations in NUP188 were rescued only by full-length Pom152p, suggesting that the lumenal structures play an important role in the function of pore-side NPC structures.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2A7, Canada	University of Alberta	Wozniak, RW (corresponding author), Univ Alberta, Dept Cell Biol, 5-14 Med Sci Bldg, Edmonton, AB T6G 2A7, Canada.		Cheperegin, Sergey/R-6594-2018	Marelli, Marcello/0000-0001-7095-8263				AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BERRIOS M, 1995, EUR J CELL BIOL, V67, P1; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; KILMARTIN JV, 1982, MICROTUBULES MICROOR, P157; KIM H, 1994, MOL MICROBIOL, V11, P819, DOI 10.1111/j.1365-2958.1994.tb00360.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Marelli M, 1998, J CELL BIOL, V143, P1813, DOI 10.1083/jcb.143.7.1813; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; SIKORSKI RS, 1989, GENETICS, V122, P19; Soderqvist H, 1997, EUR J BIOCHEM, V250, P808, DOI 10.1111/j.1432-1033.1997.00808.x; SODERQVIST H, 1994, EUR J CELL BIOL, V64, P186; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; WOZNIAK RW, 1994, J CELL BIOL, V125, P31, DOI 10.1083/jcb.125.1.31; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141	24	30	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5252	5258		10.1074/jbc.274.8.5252	http://dx.doi.org/10.1074/jbc.274.8.5252			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988776	hybrid			2022-12-25	WOS:000078698200101
J	Baird, NR; Orlowski, J; Szabo, EZ; Zaun, HC; Schultheis, PJ; Menon, AG; Shull, GE				Baird, NR; Orlowski, J; Szabo, EZ; Zaun, HC; Schultheis, PJ; Menon, AG; Shull, GE			Molecular cloning, genomic organization, and functional expression of Na+/H+ exchanger isoform 5 (NHE5) from human brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; MAMMALIAN-CELLS; GENE; SEQUENCES	To isolate a cDNA encoding Na+/H+ exchanger isoform 5 (NHE5), we screened a human spleen library using exon sequences of the NHE5 gene. Clones spanning 2.9 kilobase pairs were isolated; however, they contained several introns and were missing coding sequences at both the 5' and 3' ends. The missing 5' sequences were obtained by 5'-rapid amplification of cDNA ends and by analysis of an NHE5 genomic clone, and the missing 3' sequences were obtained by 3'-rapid amplification of cDNA ends. Polymerase chain reaction amplification of brain cDNA yielded products in which each of the introns had been correctly excised, whereas the introns were retained in products from spleen and testis, suggesting that the NHE5 transcripts expressed in these organs do not encode a functional transporter. The intron/exon organization of the NHE5 gene was analyzed and found to be very similar to that of the NHE3 gene. The NHE5 cDNA, which encodes an 896-amino acid protein that is most closely related to NHE3, was expressed in Na+/H+ exchanger-deficient fibroblasts and shown to mediate Na+/H+ exchange activity. Northern blot analysis demonstrated that the mRNA encoding NHE5 is expressed in multiple regions of the brain, including hippocampus, consistent with the possibility that it regulates intracellular pH in hippocampal and other neurons.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; McGill University	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu		Orlowski, John/0000-0001-7371-175X	NIDDK NIH HHS [DK41496, DK50594] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHEARN JM, 1987, J BIOL CHEM, V262, P10695; Attaphitaya S, 1999, J BIOL CHEM, V274, P4383, DOI 10.1074/jbc.274.7.4383; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; Kandasamy RA, 1996, J BIOL CHEM, V271, P10551, DOI 10.1074/jbc.271.18.10551; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MILLER RT, 1991, J BIOL CHEM, V266, P10813; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pathak BG, 1996, GENOMICS, V31, P261, DOI 10.1006/geno.1996.0045; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG Z, 1993, J BIOL CHEM, V268, P11925; YU FH, 1993, J BIOL CHEM, V268, P25536	28	133	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4377	4382		10.1074/jbc.274.7.4377	http://dx.doi.org/10.1074/jbc.274.7.4377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933641	hybrid			2022-12-25	WOS:000078575500065
J	Jans, DA; Sutton, VR; Jans, P; Froelich, CJ; Trapani, JA				Jans, DA; Sutton, VR; Jans, P; Froelich, CJ; Trapani, JA			BCL-2 blocks perforin-induced nuclear translocation of granzymes concomitant with protection against the nuclear events of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MEDIATED CYTOTOXICITY; DEPENDENT PROTEIN-KINASE; DNA BREAKDOWN; TARGET-CELLS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ENDOPLASMIC-RETICULUM; IN-VITRO; C-MYC; LOCALIZATION; MICE	Cytolytic granule-mediated target cell killing is effected in part through the synergistic action of the membrane-acting protein perforin and serine proteases such as granzymes (Gr) A and B, In this study, we examine the subcellular distribution of granzymes in the presence of perforin and the induction of apoptosis in mouse FDC-P1 myeloid and YAC-1 lymphoma cells that express the proto-oncogene bcl2, Using confocal laser scanning microscopy to visualize and quantitate subcellular transport of fluoresceinated granzyme, we find that granzyme entry into the cytoplasm in the absence of perforin is not impaired in the bcl2-expressing lines. However, perforin-dependent enhancement of granzyme cellular uptake and, importantly, granzyme redistribution to the nucleus were strongly inhibited in the bcl2-expressing lines, concomitant with greatly increased resistance to granzyme/perforin-induced cell death, DNA fragmentation induced by granzyme/perforin was severely reduced in the bcl2-expressing lines, implying that prevention of granzyme nuclear translocation blocks the nuclear events of apoptosis, The kinetics of GrB nuclear uptake and induction of apoptosis were faster than for GrA, whereas YAC-1 cells showed greater resistance to granzyme nuclear uptake and apoptosis than FDC-P1 cells. In all cases, granzyme nuclear accumulation in the presence of perforin correlated precisely with ensuing apoptosis. All results supported the idea that GrA and GrB share a common, specific nuclear targeting pathway that contributes significantly to the nuclear changes of apoptosis.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signaling Lab, Canberra, ACT 2601, Australia; Northwestern Univ, Sch Med, Dept Med, Evanston, IL 60201 USA; Austin Res Inst, Cellular Cytotox Lab, Heidelberg, Vic, Australia	Australian National University; John Curtin School of Medical Research; Northwestern University; Austin Research Institute	Jans, DA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signaling Lab, POB 334, Canberra, ACT 2601, Australia.	David.Jans@anu.edu.au		Trapani, Joseph/0000-0003-0983-1532				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU VK, 1995, J IMMUNOL, V154, P2023; DEJONG D, 1994, CANCER RES, V54, P256; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V229, P44, DOI 10.1006/bbrc.1996.1755; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HANNA W, 1996, PROTEIN EXPRES PURIF, V4, P398; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MUNGER WE, 1988, IMMUNOL REV, V103, P99, DOI 10.1111/j.1600-065X.1988.tb00752.x; NAKAJIMA H, 1994, J IMMUNOL, V152, P1057; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; POE M, 1991, J BIOL CHEM, V266, P98; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Schroter M, 1995, EUR J IMMUNOL, V25, P3509, DOI 10.1002/eji.1830251245; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Sutton VR, 1997, J IMMUNOL, V158, P5783; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451	50	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3953	3961		10.1074/jbc.274.7.3953	http://dx.doi.org/10.1074/jbc.274.7.3953			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933585	hybrid			2022-12-25	WOS:000078575500009
J	Liu, CT; Yao, J; de Belle, I; Huang, RP; Adamson, E; Mercola, D				Liu, CT; Yao, J; de Belle, I; Huang, RP; Adamson, E; Mercola, D			The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta(1), fibronectin, and plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WT1 GENE-PRODUCT; FACTOR-BETA; EXTRACELLULAR-MATRIX; CANCER CELLS; DNA-BINDING; EPITHELIAL-CELLS; CARCINOMA CELLS; MESSENGER-RNA; EXPRESSION; ADHESION	Re-expression of EGR-1 in fibrosarcoma HT1080 suppresses transformation including tumorigenicity (Huang, R-P., Liu, C., Fan, Y., Mercola, D., and Adamson, E. (1995) Cancer Res. 55, 5054-5062) owing in part to up-regulation of the transforming growth factor (TGF)-beta 1 promoter by EGR-1 which suppresses growth by an autocrine mechanism (Liu, C., Adamson, E., and Mercola, D. (1996) Proc. Natl. Acad. Sci U. S. A. 93, 11831-11836), Here we show that enhanced cell attachment contributes to the suppression via increased secretion of fibronectin (FN) and also of plasminogen activator inhibitor-1 (PAI-1), The secretion of FN and PAI-1 is strongly correlated with EGR-1 expression (R-PEARSON = 0.971 and 0.985, respectively). Addition of authentic TGF-beta 1 to parental cells greatly stimulated secretion of PAI-1 but not FN, whereas addition of TGF-P antibody or lipofection with specific antisense TGF-PI oligonucleotides to EGR-1-regulated cells completely inhibits the secretion of PAI-1 but not FN, However, in gel mobility shift assays pure EGR-1 or nuclear extracts of EGR-1-regulated cells specifically bind to two GC-rich elements of the human FN promoter at positions -75/-52 and -4/+18, indicating that the increased secretion of FN is likely due to direct up-regulation by EGR-1, Moreover, adhesion was greatly enhanced in EGR-1-regulated cells and was reversed by treatment with Arg-Gly-Asp (RGD) or PAI-1 antibody indicating that the secreted proteins are functional, We conclude that EGR-1 regulates the coordinated expression of gene products important for cell attachment ("oikis" factor) and normal growth control.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA; NW Canc Res Ctr, Seattle, WA 98125 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Mercola, D (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	danmercola@skcc.org	mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA63783, CA67888, CA76173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067888, R01CA063783, R01CA076173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Akamatsu H, 1996, CANCER RES, V56, P4541; BROWN DA, 1992, EUR J IMMUNOL, V22, P2419, DOI 10.1002/eji.1830220935; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CHAKRABARTY S, 1989, INT J CANCER, V44, P325, DOI 10.1002/ijc.2910440223; CHAKRABARTY S, 1987, J CELL PHYSIOL, V133, P415, DOI 10.1002/jcp.1041330302; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHAKRABARTY S, 1990, INT J CANCER, V46, P493, DOI 10.1002/ijc.2910460328; CHANDLER LA, 1991, CELL GROWTH DIFFER, V2, P379; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEBELLE I, 1999, IN PRESS ONCOGENE; DEBHAR S, 1990, BIOESSAYS, V12, P583; DER CJ, 1981, J CELL SCI, V52, P151; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GALLIMORE PH, 1977, CELL, V10, P669, DOI 10.1016/0092-8674(77)90100-3; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOGUEL AF, 1995, CANCER GENET CYTOGEN, V80, P47, DOI 10.1016/0165-4608(94)00154-4; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HARRIS H, 1990, J CELL SCI, V97, P5; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; HUANG S, 1994, J CELL PHYSIOL, V161, P470, DOI 10.1002/jcp.1041610310; HUANG S, 1994, INT J CANCER, V57, P742, DOI 10.1002/ijc.2910570522; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Kagami S, 1996, EXP CELL RES, V229, P1, DOI 10.1006/excr.1996.0336; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LAIHO M, 1989, CANCER RES, V49, P2533; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LeRoy C, 1996, J BIOL CHEM, V271, P11027, DOI 10.1074/jbc.271.18.11027; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1998, CANCER GENE THER, V5, P3; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NAGARAJAN L, 1994, BLOOD, V83, P199, DOI 10.1182/blood.V83.1.199.bloodjournal831199; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; OYAMA F, 1989, J BIOL CHEM, V264, P10331; PAULUS W, 1995, J NEUROPATH EXP NEUR, V54, P236, DOI 10.1097/00005072-199503000-00010; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Planus E, 1997, J CELL SCI, V110, P1091; Powell CT, 1996, CANCER RES, V56, P4137; QUAX PHA, 1992, DEV BIOL, V151, P161; RAMSEY WS, 1984, IN VITRO CELL DEV B, V20, P802; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHREINER C, 1991, CANCER RES, V51, P1738; SCOTT DL, 1981, J IMMUNOL METHODS, V43, P29, DOI 10.1016/0022-1759(81)90033-8; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; VARANI J, 1991, MICROCIRCULATION CAN, P2; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WILSON TE, 1992, J BIOL CHEM, V267, P3718; WIRTH PJ, 1992, ELECTROPHORESIS, V13, P305, DOI 10.1002/elps.1150130163; Xue W, 1997, CANCER RES, V57, P1682; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	79	113	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4400	4411		10.1074/jbc.274.7.4400	http://dx.doi.org/10.1074/jbc.274.7.4400			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933644	hybrid			2022-12-25	WOS:000078575500068
J	Matsubara, K; Kishida, S; Matsuura, Y; Kitayama, H; Noda, M; Kikuchi, A				Matsubara, K; Kishida, S; Matsuura, Y; Kitayama, H; Noda, M; Kikuchi, A			Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation	ONCOGENE			English	Article						intracellular localization; post-translational modification; RalGDS; Ras; Rap	NUCLEOTIDE DISSOCIATION STIMULATOR; GTP-BINDING PROTEINS; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; EUKARYOTIC CELLS; EXCHANGE FACTOR; GOLGI-COMPLEX; H-RAS; R-RAS; TRANSFORMATION	In COS cells, Ral GDP dissociation stimulator (RalGDS)-induced Ral activation was stimulated by Ras(G12V) or a Rap1/Ras chimera in which the IV-terminal region of Rap1 was ligated to the C-terminal region of Ras but not by Rap1(G12V) or a Ras/Rap1 chimera in which the IV-terminal region of Ras was ligated to the C-terminal region of Rap1, although RalGDS interacted with these small GTP-binding proteins, When Ras(G12V), Ral and the Rap1/Ras chimera were individually expressed in NIH3T3 cells, they localized to the plasma membrane. Rap1(Q63E) and the Ras/Rap1 chimera were detected in the perinuclear region, When RalGDS was expressed alone, it was abundant in the cytoplasm, When coexpressed with Ras(G12V) or the Rap1/Ras chimera, RalGDS was detected at the plasma membrane, whereas when coexpressed with Rap1(Q63E) or the Ras/Rap1 chimera, RalGDS was observed in the perinuclear region. RalGDS which was targeted to the plasma membrane by the addition of Ras farnesylation site (RaLGDS-CAAX) activated Ral in the absence of Ras(G12V). Although RalGDS did not stimulate the dissociation of GDP from Ral in the absence of the GTP-bound form of Ras in a reconstitution assay using the liposomes, RalGDS-CAAX could stimulate it without Pas, Ras(G12V) activated Raf-1 when they were coexpressed in Sf9 cells, whereas Ras(G12V) did not affect the RalGDS activity, These results indicate that Pas recruits RalGDS to the plasma membrane and that the translocated RalGDS induces the activation of Ral, but that Rap1 does not activate Pal due to distinct subcellular localization.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjyuku Ku, Tokyo 1628640, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Hiroshima University; National Institute of Infectious Diseases (NIID); Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			kishida, shosei/0000-0003-0405-851X				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1990, JPN J CANCER RES, V81, P445, DOI 10.1111/j.1349-7006.1990.tb02589.x; KITAYAMA H, 1993, KREV 1 RELATED GENES; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Murai H, 1997, J BIOL CHEM, V272, P10483; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PIZON V, 1994, J CELL SCI, V107, P1661; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	43	70	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1303	1312		10.1038/sj.onc.1202425	http://dx.doi.org/10.1038/sj.onc.1202425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022812				2022-12-25	WOS:000078510900006
J	Morimoto, AM; Berson, AE; Fujii, GH; Teng, DHF; Tavtigian, SV; Bookstein, R; Steck, PA; Bolen, JB				Morimoto, AM; Berson, AE; Fujii, GH; Teng, DHF; Tavtigian, SV; Bookstein, R; Steck, PA; Bolen, JB			Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase	ONCOGENE			English	Article						MMAC1/PTEN; tumor suppressor; phosphatase	GERMLINE MUTATIONS; GENE; PTEN; PROTEINS; BREAST; CANCER	MMAC1, also known as PTEN or TEP-1, was recently identified as a gene commonly mutated in a variety of human neoplasias, Sequence analysis revealed that MMAC1 harbored sequences similar to those found in several protein phosphatases, Subsequent studies demonstrated that MMAC1 possessed in vitro enzymatic activity similar to that exhibited by dual specificity phosphatases, To characterize the potential cellular functions of MMAC1, we expressed wild-type and several mutant variants of MMAC1 in the human glioma cell line, U373, that lacks endogenous expression. While expression of wild-type MMAC1 in these cells significantly reduced their growth rate and saturation density, expression of enzymatically inactive MMAC1 significantly enhanced growth in soft agar, Our observations indicate that while wild-type MMAC1 exhibits activities compatible with its proposed role as a tumor suppressor, cellular expression of MMAC1 containing mutations in the catalytic domain may yield protein products that enhance transformation characteristics.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA; Myriad Genet Inc, Salt Lake City, UT 84108 USA; Canji Inc, San Diego, CA 92121 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Neurooncol, Houston, TX 77030 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Myriad Genetics, Inc; University of Texas System; UTMD Anderson Cancer Center	Morimoto, AM (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA.							BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Cheney IW, 1998, CANCER RES, V58, P2331; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Onishi M, 1996, EXP HEMATOL, V24, P324; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221	21	31	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1261	1266		10.1038/sj.onc.1202441	http://dx.doi.org/10.1038/sj.onc.1202441			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022807				2022-12-25	WOS:000078510900001
J	Barath, P; Albert-Fournier, B; Luciakova, K; Nelson, BD				Barath, P; Albert-Fournier, B; Luciakova, K; Nelson, BD			Characterization of a silencer element and purification of a silencer protein that negatively regulates the human adenine nucleotide translocator 2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; CYCLE-DEPENDENT GENES; ADP ATP TRANSLOCASE; TRANSFERASE-P GENE; ADP/ATP TRANSLOCASE; CELL-CYCLE; DIFFERENTIAL REGULATION; ERYTHROID PROMOTER; MOLECULAR-CLONING; BINDING-PROTEINS	Expression of adenine nucleotide translocator isoform 2 (ANT2) is growth regulated. In the present study, we report the presence of a silencer region in the human ANTS promoter and the purification of a two-component factor that recognizes a specific hexanucleotide element, GTCCTG, of the silencer. Transfection of deletion constructs shows that ANTS silencer activity extends over a region of at least 310 nts, However, mutating the GTCCTG element completely relieves silencing activity in the context of the human ANTS promoter. The data suggest that the GTCCTG element might be required for maintaining silencer activity of the extended silencer region. The ANTS silencer region cloned in front of the herpes simplex virus thymidine kinase promoter confers nearly complete inhibition to the heterologous promoter, However, unlike the ANTS promoter, mutating the GTCCTG element restores only partial activity to the herpes simplex virus thymidine kinase promoter. A protein complex consisting of two major polypeptides of 37 and 49 kDa was isolated from HeLa nuclear extracts by affinity chromatography using the GTCCTG element as the affinity resin. Cross-linking studies and Southwestern analysis indicate that p37 binds DNA. p49 appears to be loosely associated with the p37/DNA complex but is necessary for strong binding of p37, Our data implicating the GTCCTG element directly in silencing of the ANT2 promoter, together with data from the literature reporting the presence of this element within the silencer region of several additional promoters, suggest a general role of the GTCCTG element in transcriptional silencing.	Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden	Stockholm University	Nelson, BD (corresponding author), Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden.		Barath, Peter/T-7563-2019	Barath, Peter/0000-0001-7330-955X				Ausubel R.B., 1994, CURRENT PROTOCOLS MO; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Dummler K, 1996, BIOCHEM J, V317, P913; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HAUN RS, 1990, J BIOL CHEM, V265, P15455; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JabraneFerrat N, 1996, MOL CELL BIOL, V16, P4683; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KINDY MS, 1991, J CELL BIOCHEM, V46, P345, DOI 10.1002/jcb.240460409; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; KU DH, 1990, J BIOL CHEM, V265, P16060; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; Ogbourne S, 1998, BIOCHEM J, V331, P1; Osada S, 1997, J BIOCHEM, V121, P355; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; *PROM, 1991, PROM PROT APPL GUID; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RITTLING SR, 1985, BIOCHEM BIOPH RES CO, V132, P327, DOI 10.1016/0006-291X(85)91026-5; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; WONG NCW, 1990, J BIOL CHEM, V265, P8775	48	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3378	3384		10.1074/jbc.274.6.3378	http://dx.doi.org/10.1074/jbc.274.6.3378			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920880	hybrid			2022-12-25	WOS:000078428200020
J	Medvedev, A; Saunders, NA; Matsuura, H; Chistokhina, A; Jetten, AM				Medvedev, A; Saunders, NA; Matsuura, H; Chistokhina, A; Jetten, AM			Regulation of the transglutaminase I gene - Identification of DNA elements involved in its transcriptional control in tracheobronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; INVITRO SQUAMOUS DIFFERENTIATION; MOUSE EPIDERMAL-KERATINOCYTES; RETINOIC ACID; TERMINAL DIFFERENTIATION; TISSUE TRANSGLUTAMINASE; PROXIMAL PROMOTER; BINDING PROTEINS; RESPONSE ELEMENT; LINKING ENZYMES	The transglutaminase I (TGase I) gene encodes an enzyme that catalyzes the cross-linking of structural proteins involved in the formation of the cornified envelope during squamous cell differentiation. To identify DNA elements important for the transcriptional control of the TGase I gene, we analyzed the ability of a 2.9-kilobase pair (kb) upstream regulatory region to control the expression of a reporter gene in vivo and in vitro. Transgenic mice bearing the pTG(-2.9kb)CAT construct exhibited the same pattern of tissue-specific expression of CAT as reported for TGase I. Deletion analysis in transiently transfected rabbit tracheal epithelial cells indicated that two sequences from bp -490 to -470 and from -54 to -37 are involved in the activation of TGase I transcription. Point mutation analysis and mobility shift assays showed that the sequence located between -54 and -37 is a functional Spl-like transcription element. Sp1 and Sp3, but not Sp2, are part of nuclear protein complexes from differentiated RbTE cells binding to this site. The element TGATGTCA between bp -490 and -470 is contained in a larger 22-bp palindrome and resembles the consensus cAMP response element-binding protein (CREB)/AP-1 element recognized by dimeric complexes of members of the CREB, ATF, Fos, and Jun families, Mutations in this sequence greatly reduced promoter activity. Supershift analysis identified CREB1; JunB, c-Fos, Fra-1, and c-Jun in protein complexes isolated from differentiated rabbit tracheal epithelial cells binding to this site. Our study shows that the Sp1- and CREB/AP-1-like sites act in concert to stimulate transcription of the TGase I gene. The 2.9-kb promoter region could guide expression of specific genes in the granular layer of the epidermis and could be useful in gene therapy.	NIEHS, Cell Biol Sect, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jetten, AM (corresponding author), NIEHS, Cell Biol Sect, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA.	jetten@niehs.nih.gov	Jetten, Anton/C-3736-2019; McTaggart, Jill/G-4696-2010; saunders, nicholas/AAJ-6101-2020	Jetten, Anton/0000-0003-0954-4445; McTaggart, Jill/0000-0002-9000-8529; saunders, nicholas/0000-0002-2478-3420; Medvedev, Alexander/0000-0001-6983-1687				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; Choate KA, 1997, HUM GENE THER, V8, P1659, DOI 10.1089/hum.1997.8.14-1659; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FISHER DF, 1996, MOL CELL BIOL, V16, P5365; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; HOHL D, 1991, J BIOL CHEM, V266, P6626; HUANG FL, 1986, IN VITRO CELL DEV, V22, P230; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1989, EXP CELL RES, V182, P622, DOI 10.1016/0014-4827(89)90264-4; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; JETTEN AM, 1992, CELL GROWTH DIFFER, V3, P549; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; Jetten Anton M., 1997, Journal of Dermatology (Tokyo), V24, P711; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; Lee JH, 1996, J BIOL CHEM, V271, P4561; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU B, 1994, J BIOL CHEM, V269, P7443; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; MARVIN KW, 1995, J BIOL CHEM, V270, P28910, DOI 10.1074/jbc.270.48.28910; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Matsuura Hironori, 1994, Journal of Dermatological Science, V8, P25, DOI 10.1016/0923-1811(94)90317-4; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Parameswaran KN, 1997, J BIOL CHEM, V272, P10311; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; REARICK JI, 1987, J BIOL CHEM, V262, P13069; REARICK JI, 1986, J BIOL CHEM, V261, P13898; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Reichert Uwe, 1993, P107; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; Rutberg SE, 1996, ONCOGENE, V13, P167; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; SMITS HL, 1987, MOL CELL BIOL, V7, P4017, DOI 10.1128/MCB.7.11.4017; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; TARCSA E, 1992, J BIOL CHEM, V267, P25648; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	73	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3887	3896		10.1074/jbc.274.6.3887	http://dx.doi.org/10.1074/jbc.274.6.3887			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920944	hybrid			2022-12-25	WOS:000078428200084
J	Tamaru, M; Narumi, S				Tamaru, M; Narumi, S			E-selectin gene expression is induced synergistically with the coexistence of activated classic protein kinase C and signals elicited by interleukin-1 beta but not tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MURINE PERITONEAL-MACROPHAGES; ISCHEMIA-REPERFUSION INJURY; TISSUE-SPECIFIC EXPRESSION; CELL-ADHESION MOLECULE-1; LEUKOCYTE ADHESION; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL REGULATION; GROWTH-FACTOR; IFN-GAMMA	We have examined the effect of protein kinase C (PKC) on the expression of the E-selectin and intercellular adhesion molecule-1 (ICAM-1) mRNAs in human umbilical vein endothelial cells. The lower classic PKC activity on pretreatment with phorbol ester (phorbol 12-myristate 13-acetate (PMA)) for 24 h markedly decreased IL-1 beta-induced E-selectin mRNA expression in the presence of fetal calf serum and basic fibroblast growth factor, although the induction of ICAM-1 mRNA expression was only influenced a little by the PKC down-regulation. On the other hand, tumor necrosis factor-alpha (TNF alpha)-induced gene expression of these adhesion molecules was unaffected by such PKC modulation. The intracellular signals generated by interleukin (IL)-1 beta and TNF alpha themselves are not mediated through classic PKC activation, because the response to neither stimulant was inhibited by the PKC down-regulation in the absence of fetal calf serum and basic fibroblast growth factor. Simultaneous treatment with IL-1 beta and PMA synergistically induced E-selectin gene expression but not when TNFa was substituted for IL-1 beta. ICAM-1 mRNA expression was only additively induced on the cotreatment. The synergistic effect on E-selectin mRNA induction was independent of de novo protein synthesis and mediated by elevated transcriptional activity. Promoter analysis of E-selectin indicated that the NF-ELAM1/activating transcription factor element is critical for the synergistic effect of the cotreatment with IL-1 beta and PMA.	Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 1130033, Japan; Japan Tobacco Inc, Cent Pharmaceut Res Inst, Pharmaceut Frontier Res Labs, Kanagawa 2360004, Japan	University of Tokyo; Japan Tobacco Inc.	Narumi, S (corresponding author), Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	snarumi@tka.att.ne.jp						CARLOS TM, 1994, BLOOD, V84, P2068; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUKAS J, 1990, J IMMUNOL, V145, P1727; DREYER WJ, 1991, CIRCULATION, V84, P400, DOI 10.1161/01.CIR.84.1.400; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; GIMOND C, 1992, EXP CELL RES, V203, P365, DOI 10.1016/0014-4827(92)90010-6; GREEN J, 1995, AM J PHYSIOL-CELL PH, V268, pC1090, DOI 10.1152/ajpcell.1995.268.5.C1090; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HA KS, 1993, J BIOL CHEM, V268, P10534; HAMILTON TA, 1986, J CELL PHYSIOL, V128, P9, DOI 10.1002/jcp.1041280103; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORGAN MJ, 1990, AM J PHYSIOL, V259, pL315, DOI 10.1152/ajplung.1990.259.4.L315; INTRONA M, 1987, J CELL PHYSIOL, V131, P36, DOI 10.1002/jcp.1041310107; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; NARUMI S, 1992, J LEUKOCYTE BIOL, V52, P27, DOI 10.1002/jlb.52.1.27; NARUMI S, 1992, J IMMUNOL, V149, P529; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHMORI Y, 1993, AM J PATHOL, V142, P861; Perbal B., 1988, PRACTICAL GUIDE MOL; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REPINE JE, 1987, AM REV RESPIR DIS, V136, P483, DOI 10.1164/ajrccm/136.2.483; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; SWERLICK RA, 1992, J IMMUNOL, V149, P698; Tamaru M, 1998, ARTERIOSCL THROM VAS, V18, P1292, DOI 10.1161/01.ATV.18.8.1292; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VORABERGER G, 1991, J IMMUNOL, V147, P2777; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	52	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3753	3763		10.1074/jbc.274.6.3753	http://dx.doi.org/10.1074/jbc.274.6.3753			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920928	hybrid			2022-12-25	WOS:000078428200068
J	Cursio, R; Gugenheim, J; Ricci, JE; Crenesse, D; Rostagno, P; Maulon, L; Saint-Paul, MC; Ferrua, B; Auberger, P				Cursio, R; Gugenheim, J; Ricci, JE; Crenesse, D; Rostagno, P; Maulon, L; Saint-Paul, MC; Ferrua, B; Auberger, P			A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis	FASEB JOURNAL			English	Article						caspases; tumor necrosis factor; aminotransferases; DNA fragmentation	INTERLEUKIN-1-BETA CONVERTING-ENZYME; NECROSIS-FACTOR RECEPTOR; FAS-MEDIATED APOPTOSIS; ICE/CED-3 PROTEASE; CELL-DEATH; CPP32-LIKE PROTEASES; HEPATOCYTE APOPTOSIS; CD95 FAS/APO-1; TNF RECEPTOR; ICE-LIKE	Apoptosis is activated during the early phase of reperfusion after liver ischemia and after Liver transplantation in animals. However, the molecular basis of ischemia-induced cell death remains poorly understood. In this study we show that hepatocytes from ischemic liver lobes undergo apoptosis after reperfusion. In vivo pretreatment of rats with a specific inhibitor of caspases abrogates the apoptotic response in ischemic liver lobes. Inhibition of apoptosis can be accounted for by total inhibition of caspase activation as assessed in an enzymatic assay and by specific affinity labeling. Treatment with a caspase inhibitor fully protects rats from death induced by ischemia/reperfusion. These findings indicate that liver injury after ischemia/reperfusion can be prevented by inhibition of caspases. Thus, caspase inhibitors may have important therapeutic implications in liver ischemic diseases and after liver transplantation.	Fac Med, INSERM, CJF 96 05, F-06107 Nice, France; Univ Nice Sophia Antipolis, Fac Med, Lab Rech Chirurg, F-06107 Nice 2, France; Univ Nice Sophia Antipolis, Fac Med, Parasitol Lab, F-06107 Nice 2, France; Ctr Antoine Lacassagne, Lab Cytometrie, F-06189 Nice 2, France; Hop Louis Pasteur, Fac Med, Serv Anat Pathol, F-06000 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; CHU Nice	Auberger, P (corresponding author), Fac Med, INSERM, CJF 96 05, Ave Valombrose, F-06107 Nice, France.	auberger@unice.fr	Ricci, Jean Ehrland/I-7117-2016; RICCI, Jean Ehrland/AAS-4379-2020; AUBERGER, Patrick/G-1491-2013	Ricci, Jean Ehrland/0000-0003-1585-8117; RICCI, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BAKER HD, 1956, J PATHOL BACTERIOL, V71, P135, DOI 10.1002/path.1700710118; BISMUTH H, 1989, ANN SURG, V210, P13, DOI 10.1097/00000658-198907000-00002; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BULKLEY GB, 1986, AM J SURG, V151, P87, DOI 10.1016/0002-9610(86)90017-6; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Feldmann G, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80491-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LEIST M, 1995, J IMMUNOL, V154, P1307; Leist M, 1997, GASTROENTEROLOGY, V112, P923, DOI 10.1053/gast.1997.v112.pm9041255; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Sasaki H, 1997, TRANSPL P, V29, P406, DOI 10.1016/S0041-1345(96)00138-8; Sasaki H, 1996, TRANSPLANT P, V28, P1908; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Smith S L, 1992, Crit Care Nurs Clin North Am, V4, P131; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; THURMAN RG, 1988, TRANSPLANTATION, V46, P502, DOI 10.1097/00007890-198810000-00006; Trieb K, 1997, TRANSPL P, V29, P416, DOI 10.1016/S0041-1345(96)00159-5; VANDERMEER C, 1976, CIRC SHOCK, V3, P191; WYLLIE AH, 1987, ARCH TOXICOL, P3	48	204	208	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					253	261		10.1096/fasebj.13.2.253	http://dx.doi.org/10.1096/fasebj.13.2.253			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973313				2022-12-25	WOS:000078615200005
J	Chen, XZ; Zhu, T; Smith, DE; Hediger, MA				Chen, XZ; Zhu, T; Smith, DE; Hediger, MA			Stoichiometry and kinetics of the high-affinity H+-coupled peptide transporter PepT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-GLUCOSE COTRANSPORTER; BETA-LACTAM ANTIBIOTICS; XENOPUS-LAEVIS OOCYTES; RABBIT SMALL-INTESTINE; OLIGOPEPTIDE TRANSPORTER; EXPRESSION CLONING; MEMBRANE; DIPEPTIDES; DEPENDENCE; SYMPORTER	Proton-coupled peptide transporters mediate the absorption of a large variety of di- and tripeptides as well as peptide-like pharmacologically active compounds. We report a kinetic analysis of the rat kidney high-affinity peptide transporter PepT2 expressed in Xenopus oocytes. By use of simultaneous radioactive uptake and current measurements under voltage-clamp condition, the charge to substrate uptake ratio was found to be close to 2 for both D-Phe-L-Ala and D-Phe-L-Glu, indicating that the H+:substrate stoichiometry is 2:1 and 3:1 for neutral and anionic dipeptides, respectively. The higher stoichiometry for anionic peptides suggests that they are transported in the protonated form. For D-Phe-L-Lys, the charge:uptake ratio averaged 2.4 from pooled experiments, suggesting that Phe-Lys crosses the membrane via PepT2 either in its deprotonated (neutral) or its positively charged form, averaging a H+:Phe-Lys stoichiometry of 1.4:1, These findings led to the overall con elusion that PepT2 couples transport of one peptide molecule to two H+; This is in contrast to the low-affinity transporter PepT1 that couples transport of one peptide to one H+. Quinapril inhibited PepT2-mediated currents in presence or in absence of external substrates, Oocytes expressing PepT2 exhibited quinapril-sensitive outward currents. In the absence of external substrate, a quinapril-sensitive proton inward current (proton leak) was also observed which, together with the observed pH-dependent PepT2-specific presteady-state currents (I-pss), indicates that at least one H+ binds to the transporter prior to substrate. PepT2 exhibited I-pss in response to hyperpolarization at pH 6.5-8.0. However, contrary to previous observations on various transporters, 1) no significant currents were observed corresponding to voltage jumps returning from hyperpolarization, and 2) at reduced extracellular pH, no significant I-pss were observed in either direction. Together with observed lower substrate affinities and decreased PepT2-mediated currents at hyperpolarized V-m, our data are consistent with the concept that hyperpolarization exerts inactivation effects on the transporter which are enhanced by low pH, Our studies revealed distinct properties of PepT2, compared with PepT1 and other ion-coupled transporters.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; Univ Michigan, Upjohn Ctr Clin Pharmacol, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Michigan System; University of Michigan	Hediger, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu		Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035498] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43171] Funding Source: Medline; NIGMS NIH HHS [GM35498] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1987, J PHYSIOL-LONDON, V394, P481, DOI 10.1113/jphysiol.1987.sp016882; ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; Amasheh S, 1997, J MEMBRANE BIOL, V155, P247, DOI 10.1007/s002329900177; Amasheh S, 1997, J PHYSIOL-LONDON, V504, P169, DOI 10.1111/j.1469-7793.1997.169bf.x; BOLL M, 1994, PFLUG ARCH EUR J PHY, V429, P146, DOI 10.1007/BF02584043; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1997, BIOPHYS J, V73, P2503, DOI 10.1016/S0006-3495(97)78278-X; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Chen XZ, 1996, BIOPHYS J, V71, P2544, DOI 10.1016/S0006-3495(96)79447-X; DANIEL H, 1991, J BIOL CHEM, V266, P19917; Daniel H, 1996, J MEMBRANE BIOL, V154, P197, DOI 10.1007/s002329900144; Daniel H, 1997, AM J PHYSIOL-RENAL, V273, pF1, DOI 10.1152/ajprenal.1997.273.1.F1; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; Fei YJ, 1998, PROG NUCLEIC ACID RE, V58, P239; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Ganapathy V, 1996, Curr Opin Nephrol Hypertens, V5, P395, DOI 10.1097/00041552-199609000-00003; GANAPATHY V, 1986, AM J PHYSIOL, V251, pF945, DOI 10.1152/ajprenal.1986.251.6.F945; HEDIGER MA, 1995, J PHYSIOL-LONDON, V482P, pS7; KRAMER W, 1992, EUR J BIOCHEM, V204, P923, DOI 10.1111/j.1432-1033.1992.tb16713.x; LISTER N, 1995, J PHYSIOL-LONDON, V484, P173, DOI 10.1113/jphysiol.1995.sp020656; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MIYAMOTO Y, 1988, BIOCHEM J, V249, P247, DOI 10.1042/bj2490247; Nussberger S, 1996, BIOPHYS J, V70, P998, DOI 10.1016/S0006-3495(96)79643-1; NUSSBERGER S, 1995, EXP NEPHROL, V3, P211; Nussberger S, 1997, J BIOL CHEM, V272, P7777, DOI 10.1074/jbc.272.12.7777; Saadi I, 1998, KIDNEY INT, V54, P48, DOI 10.1046/j.1523-1755.1998.00956.x; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Segel I. H., 1975, ENZYME KINETICS, P884; Smith DE, 1998, PHARM RES-DORDR, V15, P1244, DOI 10.1023/A:1011996009332; Steel A, 1997, J PHYSIOL-LONDON, V498, P563, DOI 10.1113/jphysiol.1997.sp021883; TEMPLE CS, 1995, PFLUG ARCH EUR J PHY, V430, P825, DOI 10.1007/BF00386182; Temple CS, 1996, J PHYSIOL-LONDON, V494, P795, DOI 10.1113/jphysiol.1996.sp021533; THWAITES DT, 1993, PFLUG ARCH EUR J PHY, V425, P178, DOI 10.1007/BF00374520; THWAITES DT, 1993, BIOCHEM BIOPH RES CO, V194, P432, DOI 10.1006/bbrc.1993.1838; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	39	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2773	2779		10.1074/jbc.274.5.2773	http://dx.doi.org/10.1074/jbc.274.5.2773			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915809	hybrid			2022-12-25	WOS:000078319500027
J	Or, E; Goldshleger, R; Karlish, SJD				Or, E; Goldshleger, R; Karlish, SJD			Characterization of disulfide cross-links between fragments of proteolyzed Na,K-ATPase - Implications for spatial organization of trans-membrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; SARCOPLASMIC-RETICULUM; BETA-SUBUNIT; CATION OCCLUSION; ADENOSINE-TRIPHOSPHATASE; SENSITIVE INTERACTIONS; TRANSMEMBRANE DOMAIN; MOLECULAR-WEIGHT; PROTEIN-KINASE	This study characterizes disulfide cross-links between fragments of a well defined tryptic preparation of Na,K-ATPase, 19-kDa membranes solubilized with C12E10 in conditions preserving an intact complex of fragments and Rb occlusion (Or, E., Goldshleger, R., Tal, D. M., and Karlish, S. J. D. (1996) Biochemistry 35, 6853-6864). Upon solubilization, cross-links form spontaneously between the beta subunit, 19- and 11.7-kDa fragments of the alpha subunit, containing trans-membrane segments M7-M10 and M1/M2, respectively. Treatment with Cu2+-phenanthroline (CuP) improves efficiency of cross-linking, Sequencing and immunoblot analysis have shown that the crosslinked products consist of a mixture of beta-19 kDa dimers (approximate to 65%) and beta-19 kDa-11.7 kDa trimers (approximate to 35%). The alpha-beta cross-link has been located within the 19-kDa fragment to a 6.5-kDa chymotryptic fragment containing M8, indicating that beta Cys(44) is cross-linked to either Cys(911) or Cys(930). In addition, an internal cross-link between M9 and M10, Cys(964)-Cys(983), has,, been found by sequencing tryptic fragments of the cross-linked product. The M1/M2-M7/M10 cross-link has not been identified directly. However, we propose that Cys(983) in M10 is cross-linked either to Cys(104) in M1 or internally to Cys(964) in M9. Based on this study, cross-linking induced by o-phthal-aldehyde (Or, E., Goldshleger, R., and Karlish, S. J. D. (1998) Biochemistry 37, 8197-8207), and information from the literature, we propose an approximate spatial organization of trans-membrane segments of the alpha and beta subunits.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bckarlis@weizmann.weizmann.ac.il						ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; EFREMOV RG, 1993, J PROTEIN CHEM, V12, P143, DOI 10.1007/BF01026035; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HARLOW E, 1988, ANTIBODIES LAB MANUA, P509; HUANG WH, 1979, BIOCHIM BIOPHYS ACTA, V578, P547, DOI 10.1016/0005-2795(79)90186-7; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRLEY TL, 1989, J BIOL CHEM, V264, P7185; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIANG SM, 1977, J BIOL CHEM, V252, P8278; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NAGAI M, 1986, J BIOL CHEM, V261, P3197; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; OR E, 1993, J BIOL CHEM, V268, P16929; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SARVAYAN NA, 1992, J BIOL CHEM, V270, P26528; Sarvazyan NA, 1997, J BIOL CHEM, V272, P7855, DOI 10.1074/jbc.272.12.7855; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWAPPACH B, 1994, J BIOL CHEM, V269, P21620; Shainskaya A, 1998, J BIOL CHEM, V273, P7311, DOI 10.1074/jbc.273.13.7311; SHIN JM, 1994, J BIOL CHEM, V269, P8642; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	47	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2802	2809		10.1074/jbc.274.5.2802	http://dx.doi.org/10.1074/jbc.274.5.2802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915813	hybrid			2022-12-25	WOS:000078319500031
J	Salvemini, F; Franze, A; Iervolino, A; Filosa, S; Salzano, S; Ursini, MV				Salvemini, F; Franze, A; Iervolino, A; Filosa, S; Salzano, S; Ursini, MV			Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OXIDATIVE STRESS; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; TRANSCRIPTION FACTOR; FLOW-CYTOMETRY; CELLS; ACTIVATION; APOPTOSIS; GENE; INHIBITION	Glucose-6-phosphate dehydrogenase (G6PD) is the key enzyme of the pentose phosphate pathway that is responsible for the generation of NADPH, which is required in many detoxifying reactions. We have recently demonstrated that G6PD expression is induced by a variety of chemical agents acting at different steps in the biochemical pathway controlling the intracellular redox status. Although we obtained evidence that the oxidative stress-mediated enhancement of G6PD expression is a general phenomenon, the functional significance of such G6PD induction after oxidant insult is still poorly understood. In this report, we used a GSH-depleting drug that determines a marked decrease in the intracellular pool of reduced glutathione and a gradual but notable increase in G6PD expression. Both effects are seen soon after drug addition. Once G6PD activity has reached the maximum, the GSH pool is restored. We suggest and also provide the first direct evidence that G6PD induction serves to maintain and regenerate the intracellular GSH pool. We used HeLa cell clones stably transfected with the human G6PD gene that display higher G6PD activity than the parent HeLa cells. Although the activities of glutathione peroxidase, glutathione reductase, and catalase were comparable in all strains, the concentrations of GSH were significantly higher in G6PD-overexpressing clones. A direct consequence of GSH increase in these cells is a decreased reactive oxygen species production, which makes these cells less sensitive to the oxidative burst produced by external stimuli. Indeed, all clones that constitutively overexpress G6PD exhibited strong protection against oxidants-mediated cell killing. We also observe that NF-kappa B activation, in response to tumor necrosis factor-alpha treatment, is strongly reduced in human HeLa cells overexpressing G6PD.	CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy; CNR, Ctr Endocrinol & Expt Oncol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR)	Ursini, MV (corresponding author), CNR, Int Inst Genet & Biophys, Via Guglielmo Marconi 12, I-80125 Naples, Italy.	usini@iigbna.iigb.na.cnr.it	Filosa, Stefania/A-4609-2014; Franze', Annamaria/H-2539-2012; Franzè, Annamaria/V-3837-2019	Franzè, Annamaria/0000-0002-4392-9739; Filosa, Stefania/0000-0003-2896-3362				AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; BATTISTUZZI G, 1985, P NATL ACAD SCI USA, V82, P1465, DOI 10.1073/pnas.82.5.1465; BENATTI U, 1981, FEBS LETT, V128, P225, DOI 10.1016/0014-5793(81)80086-5; BEUTLER E, 1996, HUM GENET, V29, P49; BEUTLER E, 1981, HUM GENET, V29, P225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; COHEN G, 1963, BIOCHEMISTRY-US, V2, P1420, DOI 10.1021/bi00906a038; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; GAETANI GF, 1989, BLOOD, V73, P334; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; KIRKMAN HN, 1978, P NATL ACAD SCI USA, V81, P4343; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; KOSOWER EM, 1969, NATURE, V224, P117, DOI 10.1038/224117a0; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lioi MB, 1998, ENVIRON MOL MUTAGEN, V32, P39; Lioi MB, 1998, MUTAT RES-FUND MOL M, V403, P13, DOI 10.1016/S0027-5107(98)00010-4; LUZZATTO L, 1995, METABOLIC MOL BASES, P3367; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Martini G, 1996, BIOESSAYS, V18, P631, DOI 10.1002/bies.950180806; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NISHIKI K, 1976, BIOCHEM J, V160, P343, DOI 10.1042/bj1600343; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHERWOOD SW, 1995, METHOD CELL BIOL, V46, P77; TIAN WN, 1994, J BIOL CHEM, V269, P14798; TOWN M, 1990, SOMAT CELL MOLEC GEN, V16, P97, DOI 10.1007/BF01233040; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; URSINI MV, 1993, VIROLOGY, V196, P338, DOI 10.1006/viro.1993.1485; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; Wendel A, 1981, Methods Enzymol, V77, P325; ZIEGLER DM, 1991, OXIDATIVE STRESS OXI, P85	48	266	281	1	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2750	2757		10.1074/jbc.274.5.2750	http://dx.doi.org/10.1074/jbc.274.5.2750			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915806	hybrid			2022-12-25	WOS:000078319500024
J	Slavik, JM; Hutchcroft, JE; Bierer, BE				Slavik, JM; Hutchcroft, JE; Bierer, BE			CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; VAV PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; T-LYMPHOCYTES; COSTIMULATORY RECEPTOR; KINASE SUBSTRATE; B7-2 REGULATION; CLONAL ANERGY; ACTIVATION		Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Bierer, BE (corresponding author), NHLBI, Bldg 10,Rm 5D49,10 Ctr Dr, Bethesda, MD 20892 USA.	BiererB@nih.gov		Bierer, Barbara/0000-0001-6448-8170				BOUSSIOTIS VA, 1993, P NATL ACAD SCI USA, V90, P11059, DOI 10.1073/pnas.90.23.11059; Boutin Y, 1997, J IMMUNOL, V159, P5802; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cefai D, 1996, INT IMMUNOL, V8, P1609, DOI 10.1093/intimm/8.10.1609; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Eck SC, 1997, TRANSPLANTATION, V64, P1497, DOI 10.1097/00007890-199711270-00025; Ellis JH, 1996, J IMMUNOL, V156, P2700; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; Gajewski TF, 1996, J IMMUNOL, V156, P465; GhiottoRagueneau M, 1996, EUR J IMMUNOL, V26, P34, DOI 10.1002/eji.1830260106; GILLIS S, 1978, J IMMUNOL, V120, P2027; Greene JAL, 1996, J BIOL CHEM, V271, P26762, DOI 10.1074/jbc.271.43.26762; Hatchcock Karen S., 1994, Journal of Experimental Medicine, V180, P631; Hutchcroft JE, 1996, J BIOL CHEM, V271, P13362, DOI 10.1074/jbc.271.23.13362; JUNE CH, 1994, CHEM IMMUNOL, V59, P62; Kariv I, 1996, J IMMUNOL, V157, P29; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Matulonis U, 1996, J IMMUNOL, V156, P1126; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; Nunes JA, 1996, MOL IMMUNOL, V33, P63, DOI 10.1016/0161-5890(95)00121-2; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RACKE MK, 1995, J CLIN INVEST, V96, P2195, DOI 10.1172/JCI118274; ROONEY JW, 1995, MOL CELL BIOL, V15, P6269; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; UEDA Y, 1995, INT IMMUNOL, V7, P957, DOI 10.1093/intimm/7.6.957; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WEISS M, 1993, BLOOD, V82, P3298; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	54	61	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3116	3124		10.1074/jbc.274.5.3116	http://dx.doi.org/10.1074/jbc.274.5.3116			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915850	hybrid			2022-12-25	WOS:000078319500068
J	van Geest, M; Nilsson, I; von Heijne, G; Lolkema, JS				van Geest, M; Nilsson, I; von Heijne, G; Lolkema, JS			Insertion of a bacterial secondary transport protein in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; IN-VITRO TRANSLATION; ESCHERICHIA-COLI; TRANSMEMBRANE TOPOLOGY; INTERNAL SIGNAL; TRANSLOCATION; SEQUENCE; INTEGRATION; RECEPTOR; COMPLEX	The sodium ion-dependent citrate carrier of Klebsiella pneumoniae (CitS) contains 12 hydrophobic potential transmembrane domains. Surprisingly, an alkaline phosphatase fusion study in Escherichia coli has suggested that only 9 of these domains are embedded in the membrane, and 3 are translocated to the periplasm (van Geest, M., and Lolkema, J. S. (1996) J. Biol. Chem. 271, 25582-25589), To provide independent data on the topology and mode of membrane insertion of CitS, we have investigated its insertion into the endoplasmic reticulum (ER) membrane. By using in vitro translation of model proteins in the presence of dog pancreas microsomes, each of the putative transmembrane segments of CitS was assayed for its potency to insert into the ER membrane, both as an isolated segment as well as in the context of COOH-terminal truncation mutants. All 12 segments were able to insert into the membrane as N-cyt- C-lum signal anchor sequences, In a series of COOH-terminal truncation mutants, the segments inserted in a sequential way except for one segment, segment Vb, which was translocated to the lumen. Hydrophobic segments VIII and M, which, according to the alkaline phosphatase fusion study, are in the periplasm off, coli, form a helical hairpin in the ER membrane. These observations suggest a topology for CitS with 11 transmembrane segments and also demonstrate that the sequence requirements for signal anchor and stop transfer function are different.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden	University of Groningen; Stockholm University	Lolkema, JS (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklann 30, NL-9751 NN Haren, Netherlands.	j.s.lolkema@biol.rug.nl	Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Erickson B. W., 1976, PROTEINS, VII, P255; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILJESTROM P, 1991, J VIROL, V65, P4107; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Saaf A, 1998, EUR J BIOCHEM, V251, P821, DOI 10.1046/j.1432-1327.1998.2510821.x; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; YANNISCHPERRON C, 1985, GENE, V33, P103	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2816	2823		10.1074/jbc.274.5.2816	http://dx.doi.org/10.1074/jbc.274.5.2816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915815	hybrid, Green Published			2022-12-25	WOS:000078319500033
J	Voorhoeve, PM; Watson, RJ; Farlie, PG; Bernards, R; Lam, EWF				Voorhoeve, PM; Watson, RJ; Farlie, PG; Bernards, R; Lam, EWF			Rapid dephosphorylation of p107 following UV irradiation	ONCOGENE			English	Article						E2F; p107; G1 arrest; PP2A; UV response	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; THREONINE PROTEIN PHOSPHATASES; CELL-CYCLE CONTROL; GROWTH SUPPRESSION; IN-VIVO; SUSCEPTIBILITY GENE; CATALYTIC SUBUNIT; CANCER CELL; FAMILY	In response to UV irradiation, mouse NIH3T3 fibroblasts transiently arrest predominantly in the G1 phase of the cell cycle. Here, we investigate the role of the retinoblastoma-related pocket proteins in this biological process. We report here that UV induces an increase in p107/E2F complexes, shown previously to be repressors of E2F-dependent transcriptional activity. Several lines of evidence indicate that the increase of p107/E2F complexes following UV irradiation is a consequence of rapid dephosphorylation of p107. First, UV-mediated p107 dephosphorylation could be abolished by pretreatment of NIH3T3 fibroblasts with the serine/threonine phosphatase inhibitors calyculin A and okadaic acid. Second, alteration of protein phosphatase 2A holoenzyme composition by over-expression of specific B subunits interfered with UV-mediated dephosphorylation of p107, Consistent with this, p107 could be dephosphorylated in vitro with PP2A, Moreover, dephosphorylation of p107 was shown to be independent of the activity of p53 and p21, as it occurred also in UV-treated p53-null as well as p21-null mouse fibroblasts. We observed a close correlation between the UV dosages required for G1 cell cycle arrest and p107 dephosphorylation. Our data suggest a model in which UV radiation-induced cell cycle arrest depends, at least in part, on the induction of a PP2A-like phosphatase that acts on p107.	Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Imperial Coll Sch Med, Dept Med Microbiol, London W2 1PG, England; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Netherlands Cancer Institute	Lam, EWF (corresponding author), Imperial Coll Sch Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Bernards, Rene/0000-0001-8677-3423				BACHRACH U, 1975, P NATL ACAD SCI USA, V72, P3087, DOI 10.1073/pnas.72.8.3087; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CIMENT G, 1978, SCIENCE, V202, P765, DOI 10.1126/science.213832; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATAKEYAMA M, 1994, COLD SPRING HARB SYM, V59, P1; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO J, 1993, GENE DEV, V7, P331; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; van der Eb A J, 1980, Methods Enzymol, V65, P826; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	66	38	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					679	688		10.1038/sj.onc.1202289	http://dx.doi.org/10.1038/sj.onc.1202289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989818	Green Published			2022-12-25	WOS:000078394400013
J	Liu, JH; Wei, S; Burnette, PK; Gamero, AM; Hutton, M; Djeu, JY				Liu, JH; Wei, S; Burnette, PK; Gamero, AM; Hutton, M; Djeu, JY			Functional association of TGF-beta receptor II with cyclin B	ONCOGENE			English	Article						transforming growth factor receptor; cyclin B; cdc-2; cell cycle control	GROWTH-FACTOR-BETA; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; PROTEIN-KINASE; HUMAN WEE1; PHOSPHORYLATION; INHIBITION; G1; ACTIVATION	Utilizing the cytoplasmic tail of Transforming Growth Factor Receptor Type II (TGF beta RII) as bait in a yeast two hybrid system, we have identified human cyclin B2 as a direct physical partner of TGF beta RII. Analysis of deletion mutants of glutathione-S-transferase (GST)-cyclin B2 mapped its binding domain for TGF beta RII to the C-terminal and revealed a negative regulatory region immediately upstream of the cyclin box. Using recombinant proteins, Cdc2 was demonstrated to indirectly interact with TGF beta RII via cyclin B2. This interaction was reproduced in THP-1 monocytic cells, where TGF beta treatment markedly enhanced the ability of cyclin B2 and, correspondingly, Cdc2 from TGF beta-treated THP-1 cells, to bind the GST-TGF beta RII fusion protein. More importantly, TGF beta RII co-precipitated with cyclin B2 in TGF beta-treated THP-1 cells. TGF beta treatment also caused threonine phosphorylation of Cdc2 in the TGF beta RII-cyclin B2-Cdc2 complex in THP1 cells, in parallel with down regulation of Cdc2 function as measured by histone H1 kinase activity. Cyclin B1 had the same capacity to bind TGF beta RII and mediate indirect Cdc2 binding. These results suggest an alternative mechanism that cell cycle arrest in the G1/S phase caused by TGF beta may, in part, be due to inactivation of cyclin B/Cdc2 kinase, which is needed for entry into the G2/M phase.	Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Mayo Clin, Jacksonville, FL 32224 USA	State University System of Florida; University of South Florida; Mayo Clinic	Djeu, JY (corresponding author), Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA.				NCI NIH HHS [R01-CA63724] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063724] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE PR, 1994, CUR BIOL, V5, P40; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; HARPER JW, 1993, CELL, V75, P805; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lock Leslie F., 1994, Trends in Cell Biology, V4, P404, DOI 10.1016/0962-8924(94)90054-X; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; Moore DD, 1995, GLOB MOB SURV; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAVITZ MJ, 1995, CANCER RES, V55, P1413; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	39	37	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					269	275		10.1038/sj.onc.1202263	http://dx.doi.org/10.1038/sj.onc.1202263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926943				2022-12-25	WOS:000078166000030
J	Peters, UR; Hasse, U; Oppliger, E; Tschan, M; Ong, ST; Rassool, FV; Borisch, B; Tobler, A; Fey, MF				Peters, UR; Hasse, U; Oppliger, E; Tschan, M; Ong, ST; Rassool, FV; Borisch, B; Tobler, A; Fey, MF			Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia	ONCOGENE			English	Article						FHIT; FRA3B; leukaemia; lymphoma	TUMOR-SUPPRESSOR LOCUS; RENAL-CELL CARCINOMA; COMMON FRAGILE SITE; LUNG-CANCER; HOMOZYGOUS DELETIONS; BREAST CARCINOMAS; FRA3B REGION; SHORT ARM; GENE; 3P14.2	Alterations of the recently cloned fragile histidine triad (FHIT) gene at chromosome 3p14.2 are frequent in a variety of solid tumours and cancer cell lines. Based on these findings, FHIT has been proposed as a putative tumour-suppressor gene. We evaluated the mRNA expression of the FHIT gene in samples from 55 patients with various haematological malignancies (21 AML, 8 CML, 10 CLL, seven low-grade and nine high-grade Non-Hodgkin's lymphomas), in a panel of 16 leukaemia cell lines, in normal mature haematopoietic cells of both myeloid and lymphoid lineage, as well as in CD34(+) haematopoietic progenitor cells. Aberrant FHIT mRNA transcripts were observed in 14/16 (88%) leukaemia cell lines, 43/55 (78%) primary haematological neoplasms, but also in 17/22 (77%) normal controls. 1/16 (6%) cell lines and 7/55 (13%) neoplasms did not express and FHIT mRNA. cDNA sequencing revealed exonic deletions, small DNA insertions and combinations of both. Analysis of genomic DNA showed gene deletions in two myeloid leukaemia cell lines. In contrast to all normal types of haematopoietic cells, FHIT protein was clearly reduced or absent in 8/18 (44%) neoplastic samples tested. Our data indicate that whilst aberrant FHIT mRNA transcripts are seen both in normal and malignant cells, lack of FHIT protein is restricted to leukaemia. Absent FHIT protein expression might contribute to leukaemogenesis.	Univ Bern, Dept Clin Res, Bern, Switzerland; Univ Bern, Inst Med Oncol, Bern, Switzerland; Univ Bern, Cent Haematol Lab, Bern, Switzerland; Inselspital Bern, CH-3010 Bern, Switzerland; Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland; Univ Chicago, Med Ctr, Sect Haematol Oncol, Chicago, IL 60637 USA	University of Bern; University of Bern; University of Bern; University of Geneva; University of Chicago; University of Chicago Medical Center	Fey, MF (corresponding author), Univ Bern, Dept Clin Res, Bern, Switzerland.		Borisch, Bettina/AAG-8212-2019; Oppliger Leibundgut, Elisabeth/AGG-5030-2022	Borisch, Bettina/0000-0002-9902-324X; Tschan, Mario P./0000-0001-5897-3647; Ong, S. Tiong/0000-0001-9460-3483; Oppliger Leibundgut, Elisabeth/0000-0002-6652-4160				Ahmadian M, 1997, CANCER RES, V57, P3664; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; Carapeti M., 1996, Blood, V88, p578A; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Gemma A, 1997, CANCER RES, V57, P1435; Greenspan DL, 1997, CANCER RES, V57, P4692; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hayashi S, 1997, CANCER RES, V57, P1981; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Kastury K, 1996, CANCER RES, V56, P978; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Lin PM, 1997, BRIT J HAEMATOL, V99, P612, DOI 10.1046/j.1365-2141.1997.4223235.x; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Mao L, 1996, CANCER RES, V56, P5128; Michael D, 1997, ONCOGENE, V15, P1653; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Schwaller J, 1997, BRIT J HAEMATOL, V99, P896, DOI 10.1046/j.1365-2141.1997.4863289.x; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1997, CANCER RES, V57, P5207; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sugimoto K, 1997, STEM CELLS, V15, P223, DOI 10.1002/stem.150223; Thiagalingam S, 1996, CANCER RES, V56, P2936; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Yeung R. S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P422; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; Zimonjic DB, 1997, CANCER RES, V57, P1166	42	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					79	85		10.1038/sj.onc.1202256	http://dx.doi.org/10.1038/sj.onc.1202256			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926922				2022-12-25	WOS:000078166000009
J	Salgia, R; Li, JL; Ewaniuk, DS; Wang, YB; Sattler, M; Chen, WC; Richards, W; Pisick, E; Shapiro, GI; Rollins, BJ; Chen, LB; Griffin, JD; Sugarbaker, DJ				Salgia, R; Li, JL; Ewaniuk, DS; Wang, YB; Sattler, M; Chen, WC; Richards, W; Pisick, E; Shapiro, GI; Rollins, BJ; Chen, LB; Griffin, JD; Sugarbaker, DJ			Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility	ONCOGENE			English	Article						paxillin; lung cancer; cell motility	ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; KINASE; P210(BCR/ABL); CYTOSKELETON; FIBROBLASTS; BINDING; FORMS	Lung cancer can lead to abnormalities of the actin cytoskeleton structure which may be important in transformation. In this study, we have investigated the expression of the cytoskeletal associated protein paxillin in lung cancer, Paxillin is a 68 kDa focal adhesion protein, with four tandem LIM domains at the C-terminus, involved in growth factor receptor, integrin and oncogenic signaling such as v-src, BCR/ABL, and E6 of the papilloma virus. In non-small cell lung cancer (NSCLC) cell lines, paxillin localized to the focal adhesions. The possible role of paxillin in lung cancer cells was assessed by overexpressing green fluorescence protein (GFP)-paxillin construct in two separate NSCLC cell lines (Calu-1 and H661), Over the course of 48 h, GFP-paxillin consistently caused the cells to become round and to decrease cell motility as compared to normal controls, GFP-N-terminus paxillin, or GFP-LIM transfected cells. Because some lung cancers may be quite aggressive and metastasize quickly, which may be related to the cytoskeleton, we determined the expression of paxillin in NSCLC and small cell lung cancer (SCLC) cell lines and patient tumor tissues. Expression of paxillin in NSCLC and SCLC cell lines were determined by Northern blot and Western blot analysis. The expression of paxillin was consistently low in SCLC cell lines, whereas there was paxillin expression in NSCLC cell lines. There was a variability of expression of paxillin in NSCLC tumor tissue as compared to normal lung tissue. In contrast, by immunohistochemistry, we show that there was no detectable expression of paxillin in 5/5 SCLC patients. This data suggests that absence or low level of paxillin protein expression may cause certain lung cancers, such as SCLC, to be more motile and possibly more aggressive.	Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Cellular & Mol Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Thorac Oncol & Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Salgia, R (corresponding author), Dana Farber Canc Inst, Div Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.		Li, Jian-Liang/AAE-9315-2019; Li, J L/E-6100-2018	Li, Jian-Liang/0000-0002-6487-081X; Li, J L/0000-0002-6487-081X	NATIONAL CANCER INSTITUTE [R29CA075348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [CA75348] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BERNAL SD, 1983, CANCER RES, V43, P1798; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARBONE D, 1996, LUNG CANC PRINCIPLES, P107; Charlesworth A, 1996, ONCOGENE, V12, P1337; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; KERN JA, 1993, CLIN CHEST MED, V14, P31; Lauffenburger DA, 1996, NATURE, V383, P390, DOI 10.1038/383390a0; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; PRINS J, 1993, ANTICANCER RES, V13, P1373; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sidransky D, 1996, ANNU REV MED, V47, P285; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; Strauss GM, 1997, HEMATOL ONCOL CLIN N, V11, P409, DOI 10.1016/S0889-8588(05)70441-X; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Weisberg E, 1997, CRIT REV ONCOGENESIS, V8, P343, DOI 10.1615/CritRevOncog.v8.i4.40; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	39	75	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					67	77		10.1038/sj.onc.1202273	http://dx.doi.org/10.1038/sj.onc.1202273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926921				2022-12-25	WOS:000078166000008
J	Aarts, MM; Levy, D; He, B; Stregger, S; Chen, TP; Richard, S; Henderson, JE				Aarts, MM; Levy, D; He, B; Stregger, S; Chen, TP; Richard, S; Henderson, JE			Parathyroid hormone-related protein interacts with RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DSRNA BINDING DOMAIN; KH-DOMAIN; GENE-EXPRESSION; TAT; LOCALIZATION; PEPTIDE; NUCLEAR; KINASE; TRANSACTIVATION	Parathyroid hormone-related protein (PTHrP) is a secreted protein that acts as an autocrine and paracrine mediator of cell proliferation and differentiation. In addition to its biological activity that is mediated through signal transduction cascades, there is evidence for an intracellular role for PTHrP in cell cycle progression and apoptosis. These effects are mediated through a mid-region nuclear targeting sequence (NTS) that localizes PTHrP to the region of the nucleolus where ribonucleoprotein complexes form in vivo. In this work, we show that endogenous, transfected, and in vitro translated PTHrP proteins bind homopolymeric and total cellular RNAs at salt concentrations up to 1 M. A peptide representing the PTHrP NTS was effective in competing with the wild-type protein for RNA binding, whereas a similar peptide representing the nucleolin NTS was not. Bite-directed mutagenesis revealed that the binding of PTHrP to RNA was direct and was dependent on preservation of a core GXKKXXK motif, embedded in the PTHrP NTS, which is shared with other RNA-binding proteins. The current observations are the first to document RNA binding by a secreted cellular protein and predict a role for PTHrP in regulating RNA metabolism that may be related to its localization in the nucleolus of cells in vivo.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Henderson, JE (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Rm 602,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Aarts, Michelle/C-5766-2008	Aarts, Michelle/0000-0002-9171-0571				ASA SL, 1990, J CLIN ENDOCR METAB, V71, P1112, DOI 10.1210/jcem-71-5-1112; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Broadus Arthur E., 1994, P259; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chorev Michael, 1994, P139; DANG CV, 1989, J BIOL CHEM, V264, P18019; EVAN GI, 1985, MOL CELL BIOL, V4, P2843; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; Goltzman David, 1996, P809; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; HENDERSON JE, 1995, J BONE MINER RES  S1, V10, pS286; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.0.CO;2-C; Lazdins IB, 1997, CHROMOSOMA, V105, P481, DOI 10.1007/BF02510485; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	33	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4832	4838		10.1074/jbc.274.8.4832	http://dx.doi.org/10.1074/jbc.274.8.4832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988723	hybrid			2022-12-25	WOS:000078698200048
J	Blum, E; Carpousis, AJ; Higgins, CF				Blum, E; Carpousis, AJ; Higgins, CF			Polyadenylation promotes degradation of 3 '-structured RNA by the Escherichia coli mRNA degradosome in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RPSO MESSENGER-RNA; POLY(A) POLYMERASE; G-QUARTET; DECAY; GENE; IDENTIFICATION; STABILITY; PLASMIDS; PROTEINS; COMPLEX	Polyadenylation contributes to the destabilization of bacterial mRNA We have investigated the role of polyadenylation in the degradation of RNA by the purified Eseherichia coil degradosome in vitro. RNA molecules with 3'-ends incorporated into a stable stem-loop structure could not readily be degraded by purified polynucleotide phosphorylase or by the degradosome, even though the degradosome contains active RhlB helicase which normally facilitates degradation of structured RNA. The exoribonucleolytic activity of the degradosome was due to polynucleotide phosphorylase, rather than the recently reported exonucleolytic activity exhibited by a purified fragment of RNase E (Huang, H,, Liao, J., and Cohen, S, N. (1998) Nature 391, 99-102), Addition of a 3'-poly(A) tail stimulated degradation by the degradosome, As few as 5 adenosine residues were sufficient to achieve this stimulation, and generic sequences were equally effective. The data show that the degradosome requires a single-stranded "toehold" 3' to a secondary structure to recognize and degrade the RNA molecule efficiently; polyadenylation can provide this single-stranded 3'-end. Significantly, oligo(a) and oligo(U) tails were unable to stimulate degradation; for oligo(a), at least, this is probably due to the formation of a G quartet structure which makes the 3'-end inaccessible. The inaccessibility of 3'-oligo(U) sequences is likely to have a role in stabilization of RNA molecules generated by Rho-independent terminators.	Hammersmith Hosp, Imperial Coll, Sch Med, MRC,Clin Sci Ctr, London W12 0NN, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Clin Biochem, Oxford OX3 9DS, England; CNRS, Lab Microbiol & Genet Mol, F-31062 Toulouse, France	Imperial College London; University of Oxford; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Higgins, CF (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, MRC,Clin Sci Ctr, Du Cane Rd, London W12 0NN, England.		Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				Baker EJ, 1993, CONTROL MESSENGER RN, P367; Bishop JS, 1996, J BIOL CHEM, V271, P5698, DOI 10.1074/jbc.271.10.5698; Blum E, 1997, MOL MICROBIOL, V26, P387, DOI 10.1046/j.1365-2958.1997.5901947.x; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; Cao GJ, 1996, P NATL ACAD SCI USA, V93, P11580, DOI 10.1073/pnas.93.21.11580; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; Coburn GA, 1996, J BIOL CHEM, V271, P15776, DOI 10.1074/jbc.271.26.15776; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HaugelNielsen J, 1996, EMBO J, V15, P3144, DOI 10.1002/j.1460-2075.1996.tb00677.x; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; NEWBURY SF, 1987, CELL, V48, P297, DOI 10.1016/0092-8674(87)90433-8; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PIRTLE RM, 1980, J BIOL CHEM, V255, P199; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR N, 1996, MICROBIOLOGY, V142, P3126; Sugimoto N, 1996, NUCLEOS NUCLEOT NUCL, V15, P559, DOI 10.1080/07328319608002405; SUNDQUIST WI, 1993, CURR BIOL, V3, P893, DOI 10.1016/0960-9822(93)90229-H; TALJANIDISZ J, 1987, J MOL BIOL, V193, P507, DOI 10.1016/0022-2836(87)90263-4; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	32	88	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4009	4016		10.1074/jbc.274.7.4009	http://dx.doi.org/10.1074/jbc.274.7.4009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933592	hybrid			2022-12-25	WOS:000078575500016
J	Rodighiero, C; Aman, AT; Kenny, MJ; Moss, J; Lencer, WI; Hirst, TR				Rodighiero, C; Aman, AT; Kenny, MJ; Moss, J; Lencer, WI; Hirst, TR			Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin - Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; VIBRIO-CHOLERAE; ENDOPLASMIC-RETICULUM; B-SUBUNIT; RIBOSYLATION FACTORS; RECEPTOR; PROTEIN; SEQUENCE; BINDING; ACTIVATION	Cholera toxin (Ctx) and E. coli heat-labile enterotoxin (Etx) are structurally and functionally similar AB, toxins with over 80% sequence identity. When their action in polarized human epithelial (T84) cells was monitored by measuring toxin-induced Cl- ion secretion, Ctx was found to be the more potent of the two toxins. Here, we examine the structural basis for this difference in toxicity by engineering a set of mutant and hybrid toxins and testing their activity in T84 cells, This revealed that the differential toxicity of Ctx and Etx was (i) not due to differences in the A-subunit's C-terminal KDEL targeting motif (which is RDEL in Etx), as a RDEL to RDEL substitution had no effect on cholera toxin activity; (ii) not attributable to the enzymatically active AI-fragment, as hybrid toxins in which the Al-fragment in Ctx was substituted for that of Etx (and vice versa) did not alter relative toxicity; and (iii) not due to the B-subunit, as the replacement of the B-subunit in Ctx for that of Etx caused no alteration in toxicity, thus excluding the possibility that the broader receptor specificity of EtxB is responsible for reduced activity. Remarkably, the difference in toxicity could be mapped to a 10-amino acid segment of the A2-fragment that penetrates the central pore of the B-subunit pentamer, A comparison of the in vitro stability of two hybrid toxins, differing only in this 10-amino acid segment, revealed that the Ctx A2-segment conferred a greater stability to the interaction between the A- and B-subunits than the corresponding: segment from Etx A2. This suggests that the reason for the relative potency of Ctx compared with Etx stems from the increased ability of the A2-fragment of Ctx to maintain holotoxin stability during uptake and transport into intestinal epithelia.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; NHLBI, NIH, Bethesda, MD 20892 USA; Childrens Hosp, Combined Program Pediat Gastroenterol & Nutr, Boston, MA 02115 USA	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Boston Children's Hospital	Hirst, TR (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Univ Walk, Bristol BS8 1TD, Avon, England.	t.r.hirst@bristol.ac.uk	Aman, Abu Tholib/GLV-5081-2022	Aman, Abu Tholib/0000-0002-8634-7624; Lencer, Wayne/0000-0001-7346-2730	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000622] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; Backstrom M, 1997, MOL MICROBIOL, V24, P489, DOI 10.1046/j.1365-2958.1997.3541721.x; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; BLACK RE, 1985, DEV VACCINES DRUGS D, P23; BOOTH BA, 1984, INFECT IMMUN, V45, P558, DOI 10.1128/IAI.45.3.558-560.1984; DALLAS WS, 1980, NATURE, V288, P499, DOI 10.1038/288499a0; DHARMSATHAPHORN K, 1988, METHOD ENZYMOL, V192, P354; DOMENIGHINI M, 1995, MOL MICROBIOL, V15, P1165, DOI 10.1111/j.1365-2958.1995.tb02289.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOL WGJ, 1995, HANDB NAT T, V8, P185; HOLMGREN J, 1985, GASTROENTEROLOGY, V89, P27, DOI 10.1016/0016-5085(85)90741-3; HOLMGREN J, 1982, INFECT IMMUN, V38, P424, DOI 10.1128/IAI.38.2.424-433.1982; HOLMGREN J, 1973, INFECT IMMUN, V8, P208, DOI 10.1128/IAI.8.2.208-214.1973; HOLMGREN J, 1983, INFECT IMMUN, V39, P147, DOI 10.1128/IAI.39.1.147-154.1983; HUNT PD, 1991, INFECT IMMUN, V59, P168, DOI 10.1128/IAI.59.1.168-171.1991; KAPER JB, 1984, NATURE, V308, P655, DOI 10.1038/308655a0; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; KREITMAN RJ, 1995, BIOCHEM J, V307, P29, DOI 10.1042/bj3070029; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1997, J BIOL CHEM, V272, P15562, DOI 10.1074/jbc.272.24.15562; Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MARCELLO A, 1994, THESIS U YORK YORK; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1988, METHOD ENZYMOL, V165, P169; MOON HW, 1993, VACCINE, V11, P213, DOI 10.1016/0264-410X(93)90020-X; MOSS J, 1994, METHOD ENZYMOL, V235, P640; MOSS J, 1992, BACTERIAL PROTEINS T, V23, P220; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; ORLANDI PA, 1993, J BIOL CHEM, V268, P17038; ORLANDI PA, 1994, BIOCHEMISTRY-US, V33, P12886, DOI 10.1021/bi00209a021; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RUDDOCK LW, 1995, J BIOL CHEM, V270, P29953; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; Sandvig K, 1996, P NATL ACAD SCI USA, V93, P12339, DOI 10.1073/pnas.93.22.12339; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; TENEBERG S, 1994, GLYCOCONJUGATE J, V11, P533, DOI 10.1007/BF00731304; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456	47	46	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3962	3969		10.1074/jbc.274.7.3962	http://dx.doi.org/10.1074/jbc.274.7.3962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933586	hybrid			2022-12-25	WOS:000078575500010
J	Sung, TC; Zhang, Y; Morris, AJ; Frohman, MA				Sung, TC; Zhang, Y; Morris, AJ; Frohman, MA			Structural analysis of human phospholipase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; D DEFINES; SUPERFAMILY; FAMILY; INHIBITION; EXPRESSION; SYNTHASES; CLONING	Activation of phosphatidylcholine-specific phospholipase D (PLD) has been proposed to play roles in numerous cellular pathways including signal transduction and membrane vesicular trafficking. We previously reported the cloning of two mammalian genes, PLD1 and PLDS, that encode PLD activities. We additionally reported that PLD1 is activated in a synergistic manner by protein kinase c-alpha (PKC-alpha), ADP-ribosylation factor 1 (ARF1), and Rho family members. We describe here molecular analysis of PLD1 using a combination of domain deletion and mutagenesis. We show that the amino-terminal 325 amino acids are required for PKC-alpha activation of PLD1 but not for activation by ARF1 and RhoA This region does not contain the sole PKC-alpha interaction site and additionally functions to inhibit basal PLD activity in vivo. Second, a region of sequence unique to PLD1 las compared with other PLDs) known as the "loop" region had been proposed to serve as an effector regulatory region but is shown here only to mediate inhibition of PLD1. Finally, we show that modification of the amino terminus, but not of the carboxyl terminus, is compatible with PLD enzymatic function and propose a simple model for PLD activation.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Frohman, MA (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	michael@pharm.som.sunysb.edu	Morris, Andrew/B-7869-2010		NIGMS NIH HHS [GM54813, GM50388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050388, R01GM054813] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cao JX, 1997, VIRUS RES, V48, P11, DOI 10.1016/S0168-1702(96)01422-0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; FROHMAN MA, 1999, PHOSPHOLIPASE D BIOC; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Katayama K, 1998, BIOCHEM J, V329, P647, DOI 10.1042/bj3290647; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 1996, PROTEIN SCI, V5, P914; REDINA O, 1998, GENE AMST, V22, P53; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Wakelam M J, 1995, Methods Mol Biol, V41, P271; Wang XM, 1997, TRENDS PLANT SCI, V2, P261, DOI 10.1016/S1360-1385(97)86348-0	29	140	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3659	3666		10.1074/jbc.274.6.3659	http://dx.doi.org/10.1074/jbc.274.6.3659			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920915	hybrid			2022-12-25	WOS:000078428200055
J	Xu, X; Zeng, WH; Popov, S; Berman, DM; Davignon, I; Yu, K; Yowe, D; Offermanns, S; Muallem, S; Wilkie, TM				Xu, X; Zeng, WH; Popov, S; Berman, DM; Davignon, I; Yu, K; Yowe, D; Offermanns, S; Muallem, S; Wilkie, TM			RGS proteins determine signaling specificity of G(q)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNITS; INOSITOL TRISPHOSPHATE; ACINAR-CELLS; CORE DOMAIN; IN-VITRO; GAIP; EXPRESSION; CHANNELS; FAMILY	Regulators of G protein signaling (RGS) proteins accelerate GTP hydrolysis by G alpha subunits, thereby attenuating signaling. RGS4 is a GTPase-activating protein for G(i) and G(q) class alpha subunits. In the present study, we used knockouts of G(q) class genes in mice to evaluate the potency and selectivity of RGS4 in modulating Ca2+ signaling transduced by different G(q)-coupled receptors. RGS4 inhibited phospholipase C activity and Ca2+ signaling in a receptor-selective manner in both permeabilized cells and cells dialyzed with RGS4 through a patch pipette. Receptor-dependent inhibition of Ca2+ signaling by RGS4 was observed in acini prepared from the rat and mouse pancreas. The response of mouse pancreatic acini to carbachol was about 4- and 33-fold more sensitive to RGS4 than that of bombesin and cholecystokinin (CCK), respectively. RGS1 and RGS16 were also potent inhibitors of G(q)-dependent Ca2+ signaling and acted in a receptor-selective manner. RGS1 showed approximately 1000-fold higher potency in inhibiting carbachol than CCK-dependent signaling. RGS16 was as effective as RGS1 in inhibiting carbachol-dependent signaling but only partially inhibited the response to CCK. By contrast, RGS2 inhibited the response to carbachol and CCK with equal potency. The same pattern of receptor-selective inhibition by RGS4 was observed in acinar cells from wild type and several single and double G(q) class knockout mice. Thus, these receptors appear to couple G(q) class alpha subunit isotypes equally. Difference in receptor selectivity of RGS proteins action indicates that regulatory specificity is conferred by interaction of RGS proteins with receptor complexes.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Millenium Pharmaceut Inc, Cambridge, MA 02139 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmacol, D-14159 Berlin, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Gold SJ, 1997, J NEUROSCI, V17, P8024; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ingi T, 1998, J NEUROSCI, V18, P7178; JENSEN R T, 1984, Journal of Pediatric Gastroenterology and Nutrition, V3, pS25, DOI 10.1097/00005176-198400031-00007; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Saugstad JA, 1998, J NEUROSCI, V18, P905; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Williams John A., 1993, P167; Xu X, 1998, J BIOL CHEM, V273, P27275, DOI 10.1074/jbc.273.42.27275; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520	47	228	232	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3549	3556		10.1074/jbc.274.6.3549	http://dx.doi.org/10.1074/jbc.274.6.3549			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920901	hybrid			2022-12-25	WOS:000078428200041
J	Schwartz, T; Lowenhaupt, K; Kim, YG; Li, LY; Brown, BA; Herbert, A; Rich, A				Schwartz, T; Lowenhaupt, K; Kim, YG; Li, LY; Brown, BA; Herbert, A; Rich, A			Proteolytic dissection of Zab, the Z-DNA-binding domain of human ADAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA ADENOSINE-DEAMINASE; RECEPTOR CHANNELS; CONFORMATIONAL CHANGE; SECONDARY STRUCTURE; ESCHERICHIA-COLI; EDITING ENZYME; ION FLOW; Z-FORM; PROTEIN; ACID	Z alpha is a peptide motif that binds to Z-DNA with high affinity. This motif binds to alternating dC-dG sequences stabilized in the Z-conformation by means of bromination or supercoiling, but not to B-DNA. Z alpha is part of the N-terminal region of double-stranded RNA adenosine deaminase (ADAR1) , a candidate enzyme for nuclear pre-mRNA editing in mammals. Z alpha is conserved in ADAR1 from many species; in each case, there is a second similar motif, Z beta, separated from Z alpha by a more divergent linker. To investigate the structure-function relationship of Z alpha, its domain structure was studied by limited proteolysis. Proteolytic profiles indicated that Z alpha is part of a domain, Zab, of 229 amino acids (residues 133-361 in human ADAR1), This domain contains both Z alpha and Z beta as well as a tandem repeat of a 49-amino acid linker module. Prolonged proteolysis revealed a minimal core domain of 77 amino acids (positions 133-209), containing only Z alpha, which is sufficient to bind left-handed Z-DNA; however, the substrate binding is strikingly different from that of Zab. The second motif, Z beta, retains its structural integrity only in the context of Zab and does not bind Z-DNA as a separate entity. These results suggest that Z alpha and Z beta act as a single bipartite domain. In the presence of substrate DNA, Zab becomes more resistant to proteases, suggesting that it adopts a more rigid structure when bound to its substrate, possibly with conformational changes in parts of the protein.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Herbert, Alan/AAY-4286-2020; Schwartz, Thomas/ABA-1770-2021	Schwartz, Thomas/0000-0001-8012-1512; Herbert, Alan/0000-0002-0093-1572; /0000-0002-8187-6498				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JANIN J, 1985, METHOD ENZYMOL, V115, P420; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kim YG, 1997, P NATL ACAD SCI USA, V94, P12875, DOI 10.1073/pnas.94.24.12875; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Lilley D. M. J., 1995, DNA PROTEIN STRUCTUR; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MALFOY B, 1982, BIOCHEMISTRY-US, V21, P5463, DOI 10.1021/bi00265a013; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Nakagawa N, 1997, J BIOL CHEM, V272, P22703, DOI 10.1074/jbc.272.36.22703; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Petschek JP, 1996, J MOL BIOL, V259, P885, DOI 10.1006/jmbi.1996.0365; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; RIAZANCELAWRENCE JH, 1992, BIOPOLYMERS, V32, P271, DOI 10.1002/bip.360320307; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Roy R, 1996, J BIOL CHEM, V271, P23690, DOI 10.1074/jbc.271.39.23690; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHADE M, 1999, IN PRESS EMBO J; Schulz G. E., 1979, PRINCIPLES PROTEIN S; Seeburg PH, 1996, J NEUROCHEM, V66, P1; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TAL M, 1985, J BIOL CHEM, V260, P9976; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443	39	51	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2899	2906		10.1074/jbc.274.5.2899	http://dx.doi.org/10.1074/jbc.274.5.2899			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915827	hybrid			2022-12-25	WOS:000078319500045
J	Zhong, M; Kim, SJ; Wu, C				Zhong, M; Kim, SJ; Wu, C			Sensitivity of Drosophila heat shock transcription factor to low pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; GENE-TRANSCRIPTION; ACTIVATION DOMAIN; INTRACELLULAR PH; INFLUENZA-VIRUS; COILED-COIL; TRANSACTIVATION DOMAIN; NUCLEAR-LOCALIZATION; PROTEIN-SYNTHESIS	The heat shock transcription factor (HSF) mediates the induction of heat shock gene expression. The activation of HSF involves heat shock-induced trimerization, binding to its cognate DNA sites, and the acquisition of transcriptional competence. In this study, the oligomeric properties of Drosophila HSF were analyzed by equilibrium analytical ultracentrifugation and gel filtration chromatography. Previous findings showed that trimerization of purified Drosophila HSF was directly sensitive to heat and oxidation (1). Here we report that low pH, in the physiological range, also directly induces HSF trimerization and DNA binding in vitro. Furthermore, the induction of HSF trimerization by low pH is synergistic with the actions of heat and oxidation, Since heat or chemical stress leads to a moderate decrease of intracellular pH, we suggest that intracellular acidification may contribute to activating the heat shock response in vivo.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, C (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bldg 37,Rm 5E26, Bethesda, MD 20892 USA.							ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; BURDON R H, 1990, P19; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DIXON SJ, 1995, METH NEUROSCI, V27, P196; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOJ A, 1994, EMBO J, V13, P2617; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KIANG JG, 1990, AM J PHYSIOL, V259, pC727, DOI 10.1152/ajpcell.1990.259.5.C727; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1901; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Orosz A, 1996, MOL CELL BIOL, V16, P7018; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RITOSSA FM, 1964, EXP CELL RES, V35, P601, DOI 10.1016/0014-4827(64)90147-8; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHLESINGER MJ, 1993, PROTEIN SCI, V2, P1356, DOI 10.1002/pro.5560020819; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TREUTER E, 1993, MOL GEN GENET, V240, P113, DOI 10.1007/BF00276890; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; WEITZEL G, 1985, EXP CELL RES, V159, P252, DOI 10.1016/S0014-4827(85)80054-9; WESTWOOD JT, 1989, J CELL PHYSL, V139, P106; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Winegarden NA, 1996, J BIOL CHEM, V271, P26971, DOI 10.1074/jbc.271.43.26971; Wisniewski J, 1996, NUCLEIC ACIDS RES, V24, P367, DOI 10.1093/nar/24.2.367; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zhong M, 1996, METHOD ENZYMOL, V274, P113; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	69	27	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3135	3140		10.1074/jbc.274.5.3135	http://dx.doi.org/10.1074/jbc.274.5.3135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915852	hybrid			2022-12-25	WOS:000078319500070
J	de Fromentel, CC; Gruel, N; Venot, C; Debussche, L; Conseiller, E; Dureuil, C; Teillaud, JL; Tocque, B; Bracco, L				de Fromentel, CC; Gruel, N; Venot, C; Debussche, L; Conseiller, E; Dureuil, C; Teillaud, JL; Tocque, B; Bracco, L			Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments	ONCOGENE			English	Article						p53; scFv; intracellular immunization; gene therapy	DNA-BINDING FUNCTION; C-TERMINAL DOMAIN; ACTIVATION FUNCTION; GROWTH SUPPRESSION; INDUCED APOPTOSIS; PROTEIN; INDUCTION; DAMAGE; INVOLVEMENT; SEQUENCE	We report here the production and the properties of single chain Fv fragments (scFvs) derived from the anti-p53 monoclonal antibodies PAb421 and 11D3, 11D3 is a newly generated monoclonal antibody which exhibits properties very comparable to those of PAb421, The scFvs PAb421 and 11D3 are able to stably associate with p53 and to restore the DNA binding activity of some p53 mutants in vitro. When expressed in p53(-/-) human tumour cells, the scFv421 is essentially localized in the cytoplasm in the absence of p53, and in the nucleus when exogenous p53 is present, Thus, p53 is also able to stably associate with an anti-p53 scFv in cells. Cotransfection of p53(-/-) human tumour cells with expression vectors encoding the His273 p53 mutant and either scFv leads to restoration of the p53 mutant deficient transcriptional activity. These data demonstrate that, in human tumour cells, these scFvs are able to restore a function essential for the tumour suppressor activity of p53 and may represent a novel class of molecules for p53-based cancer therapy.	Rhone Poulenc Rorer SA, Gene Med Dept, F-94403 Vitry, France; Inst Curie, Lab Biotechnol Anticorps, F-75005 Paris, France; Inst Curie, U255, INSERM, F-75005 Paris, France	Sanofi-Aventis; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	de Fromentel, CC (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; Teillaud, Jean-Luc/0000-0003-4442-9565				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BYK G, 1995, Patent No. 01865; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cochet O, 1998, CANCER RES, V58, P1170; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Kabat EA, 1991, SEQUENCES PROTEINS I; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEGROS Y, 1994, ONCOGENE, V9, P2071; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; NIEWOLIK D, 1995, ONCOGENE, V10, P881; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SMITH ML, 1995, ONCOGENE, V10, P1053; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	65	71	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					551	557		10.1038/sj.onc.1202338	http://dx.doi.org/10.1038/sj.onc.1202338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927212				2022-12-25	WOS:000078166500028
J	Hosono, S; Luo, X; Hyink, DP; Schnapp, LM; Wilson, PD; Burrow, CR; Reddy, JC; Atweh, GF; Licht, JD				Hosono, S; Luo, X; Hyink, DP; Schnapp, LM; Wilson, PD; Burrow, CR; Reddy, JC; Atweh, GF; Licht, JD			WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts	ONCOGENE			English	Article						WT1; Wilms'; differentiation; epithelium	WILMS-TUMOR GENE; MICE LACKING GDNF; GROWTH-FACTOR-I; KIDNEY DEVELOPMENT; SUPPRESSOR WT1; TRANSCRIPTIONAL ACTIVATION; BASEMENT-MEMBRANE; PROTO-ONCOGENE; CELL-ADHESION; RECEPTOR GENE	The WT1 tumor suppressor gene, implicated in hereditofamilial and sporadic Wilms' tumor, is required for normal renal development and is up-regulated during the mesenchymal-epithelial transition. NIH3T3 fibroblasts overexpressing WT1 were less proliferative, larger in size and more firmly attached to tissue culture plastic, suggesting an alteration of their state of differentiation. These cells were studied in vivo by subcutaneous injection into nude mice, The resulting tumors exhibited epithelioid histopathology and formed desmosome-like structures. Molecular analyses of these WT1 expressing fibroblasts grown in culture and in nude mice revealed significant alterations in the expression of many kidney epithelial markers. These studies indicate that WT1 expression can initiate features of a program of epithelial differentiation consistent with a prominent role for WT1 in the mesenchymal epithelial transition that occurs during renal development. Through this work we identified a number of novel target genes for the WT1 transcription factor, including uvomorulin, integrin alpha 8 and perlecan, and suggest that WT1 may activate the IGF-II gene, also implicated in the development of Wilms' tumor.	CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, Box 1126, New York, NY 10029 USA.		Licht, Jonathan/L-4239-2019; Hyink, Deborah/AAT-6821-2021	Hyink, Deborah/0000-0001-5820-4995; Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054184] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA59936] Funding Source: Medline; NHLBI NIH HHS [R01 HL54184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; ALBELDA SM, 1993, LAB INVEST, V68, P4; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cook DM, 1996, ONCOGENE, V13, P1789; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GABBIANI G, 1972, CANCER-AM CANCER SOC, V30, P486, DOI 10.1002/1097-0142(197208)30:2<486::AID-CNCR2820300229>3.0.CO;2-F; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; Hewitt SM, 1996, ANTICANCER RES, V16, P621; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LUO XN, 1995, ONCOGENE, V11, P743; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MACHINAMI R, 1982, VIRCHOWS ARCH A, V397, P109, DOI 10.1007/BF00430898; MAW MA, 1992, CANCER RES, V52, P3094; Menke AL, 1996, ONCOGENE, V12, P537; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; NICHOLS KE, 1995, CANCER RES, V55, P4540; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROGERS SA, 1991, J CELL BIOL, V113, P1447, DOI 10.1083/jcb.113.6.1447; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUBIN H, 1993, DIFFERENTIATION, V53, P123, DOI 10.1111/j.1432-0436.1993.tb00652.x; RYAN G, 1995, DEVELOPMENT, V121, P867; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; vandenHeuvel LPWJ, 1995, NEPHROL DIAL TRANSPL, V10, P2205, DOI 10.1093/ndt/10.12.2205; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; WAHRMAN MZ, 1985, TUMOUR BIOL, V6, P41; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Ward A, 1995, GENE, V167, P239, DOI 10.1016/0378-1119(95)00645-1; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	73	42	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					417	427		10.1038/sj.onc.1202311	http://dx.doi.org/10.1038/sj.onc.1202311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927198				2022-12-25	WOS:000078166500014
J	Chai, YL; Cui, JQ; Shao, NS; Reddy, ESP; Rao, VN				Chai, YL; Cui, JQ; Shao, NS; Reddy, ESP; Rao, VN			The second BRCT domain of BRCA-1 proteins interacts with p53 and stimulates transcription from the p21(WAF1/CIP1) promoter	ONCOGENE			English	Article						BRCA1; BRCA1a; BRCA1b; p53; p21(WAF1/CIP1); BRCT domain; CBP/p300	OVARIAN-CANCER INCIDENCE; CELL-CYCLE; GENE BRCA1; BREAST; EXPRESSION; GROWTH; ACTIVATION; INDUCTION; TISSUES; REGION	Inherited mutations in the breast and ovarian cancer susceptibility gene BRCA1 are associated with high risk for developing breast and ovarian cancers. Several studies link BRCA1 to transcriptional regulation, DNA repair, apoptosis and growth/tumor suppression. BRCA1 associates with p53 and stimulates transcription in both p53 dependent and p53-independent manners. BRCA1 splice variants BRCA1a (p110) and BRCA1b (p100) associates with CBP/p300 co-activators. Here we show that BRCA1a and BRCA1b proteins stimulate p53-dependent transcription from the p21(WAF1/CIP1) promoter. In addition, the C-terminal second BRCA1 (BRCT) domain is sufficient for p53 mediated transactivation of the p21 promoter. Previous studies emphasized the importance of the BRCT domain, which shows homology with p53 binding protein (53BP1), in transcriptional activation, growth inhibition and tumor suppression. Our findings demonstrate an additional function for this domain in protein-protein interaction and co-activation of p53. We also found that BRCA1a and BRCA1b proteins interact with p53 in vitro and in vivo. The p53 interaction domain of BRCA1a/1b maps, in vitro, to the second BRCT domain (aa 1760-1863). The BRCT domain binds to the central domain of p53 which is required for sequence specific DNA binding. These results demonstrate for the first time the presence of a second p53 interaction domain in BRCA1 proteins and suggests that BRCA1a and BRCA1b proteins, like BRCA1, function as p53 co-activators. This BRCT domain also binds in vitro to CBP. These results suggest that one of the mechanisms by which BRCA1 proteins function is through recruitment of CBP/p300 associated HAT/FAT activity for acetylation of p53 to specific promoters resulting in transcriptional activation.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,New Coll Bldg,Broad & Vine St, Philadelphia, PA 19102 USA.				NCI NIH HHS [CA57322, CA50507, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507, R01CA057322, R01CA058642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORD D, 1995, AM J HUM GENET, V57, P1457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WU CJ, 1996, NAT GENET, V14, P430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	33	154	157	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					263	268		10.1038/sj.onc.1202323	http://dx.doi.org/10.1038/sj.onc.1202323			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926942				2022-12-25	WOS:000078166000029
J	Wimmer, K; Zhu, XX; Lamb, BJ; Kuick, R; Ambros, PF; Kovar, H; Thoraval, D; Motyka, S; Alberts, JR; Hanash, SM				Wimmer, K; Zhu, XX; Lamb, BJ; Kuick, R; Ambros, PF; Kovar, H; Thoraval, D; Motyka, S; Alberts, JR; Hanash, SM			Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma	ONCOGENE			English	Article						gene amplification; neuroblastoma; N-myc amplicon	HUMAN NEURO-BLASTOMA; DEAD BOX GENE; DNA-SEQUENCES; CELL-LINES; ORNITHINE DECARBOXYLASE; SINGLE-COPY; EXPRESSION; COAMPLIFICATION; CHROMOSOMES; FRAGMENTS	Substantial evidence implicates amplification of the N-myc gene with aggressive tumor growth and poor outcome in neuroblastoma. However some evidence suggests that this gene alone is not the sole determinant of outcome in N-myc amplified tumors. We have searched for genes that co-amplify with N-myc in neuroblastoma by means of two-dimensional analysis of genomic restriction digests. Using this approach, we have identified and cloned a novel genomic fragment which is co-amplified with N-myc in neuroblastomas, This fragment was mapped in close vicinity to N-myc on chromosome arm 2p24, It was amplified in 5/8 N-myc amplified neuroblastoma cell lines and in 9/13 N-myc amplified tumors. Using a PCR-based approach we isolated a 4.5 kb c-DNA sequence that is partly contained in the genomic fragment, The open reading frame of the cDNA encodes a predicted protein of 1353 amino acids (aa), The homology of the predicted protein, which we designated NAG (neuroblastoma amplified gene), to a C, elegans protein of as yet unknown function, and its ubiquious expression suggest that NAG may serve an essential function, By Northern blot analysis we showed that amplification of the cloned gene correlates with over-expression in neuroblastoma cell lines. Amplification and consequent over-expression of NAG may, therefore, contribute to the phenotype of a subset of neuroblastomas.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	University of Michigan System; University of Michigan; Saint Anna Children's Hospital	Wimmer, K (corresponding author), Univ Vienna, Dept Med Biol, Wahringerstr 10, A-1090 Vienna, Austria.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Zhu, Charles/0000-0003-2922-0042; Kovar, Heinrich/0000-0001-6873-9109	NCI NIH HHS [CA-26803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AKIYAMA K, 1994, NUCLEIC ACIDS RES, V25, P157; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ambros IM, 1997, EUR J CANCER, V33, P2043, DOI 10.1016/S0959-8049(97)00204-9; AMLER LC, 1995, ONCOGENE, V10, P1095; AMLER LC, 1992, ONCOGENE, V7, P807; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; ASAKAWA J, 1994, P NATL ACAD SCI USA, V91, P9052, DOI 10.1073/pnas.91.19.9052; BIEDLER JL, 1973, CANCER RES, V33, P2643; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHN SL, 1995, CANCER RES, V55, P721; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; George RE, 1996, ONCOGENE, V12, P1583; GIRVITZ SC, 1980, ANAL BIOCHEM, V106, P492, DOI 10.1016/0003-2697(80)90553-9; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; KANDA N, 1983, P NATL ACAD SCI-BIOL, V80, P4069, DOI 10.1073/pnas.80.13.4069; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuick R, 1996, GENETICS, V144, P307; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lutz W, 1997, ONCOGENE, V15, P303, DOI 10.1038/sj.onc.1201195; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Pandita A, 1997, GENE CHROMOSOME CANC, V20, P243, DOI 10.1002/(SICI)1098-2264(199711)20:3<243::AID-GCC4>3.0.CO;2-2; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Schweizer D, 1994, Methods Mol Biol, V29, P97; SHILOH Y, 1986, CANCER RES, V46, P5297; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; SLAVC I, 1990, CANCER RES, V50, P1459; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Thoraval D, 1996, P NATL ACAD SCI USA, V93, P4442, DOI 10.1073/pnas.93.9.4442; TONIN PN, 1989, ONCOGENE, V4, P1117; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262	40	59	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					233	238		10.1038/sj.onc.1202287	http://dx.doi.org/10.1038/sj.onc.1202287			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926938				2022-12-25	WOS:000078166000025
J	Harris, CM; Sanders, SK; Massey, V				Harris, CM; Sanders, SK; Massey, V			Role of the flavin midpoint potential and NAD binding in determining NAD versus oxygen reactivity of xanthine oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-KINETICS; MOLECULAR-OXYGEN; REDOX POTENTIALS; HALF-REACTION; DEHYDROGENASE; OXIDASE; BEHAVIOR; FLAVOPROTEINS; PURIFICATION; MOLYBDENUM	Xanthine oxidoreductase from bovine milk can be prepared in two interconvertible forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH), depending on the number of protein cysteines versus cystines, Enzyme forms differ in respect to their oxidizing substrates; XDH prefers NAD to molecular oxygen, whereas XO only reacts significantly with oxygen. The preference for oxidizing substrate is partially explained by thermodynamics. Unlike XDH, the midpoint potential of the FAD, the center at which oxygen and NAD react, is too high in XO to efficiently reduce NAD (Hunt, J,, Massey, V., Dunham, W.R,, and Sands, R.H. (1993) J, Biol, Chem, 268, 18685-18691), To distinguish between changes in thermodynamics and in substrate binding, samples of both XO and XDH have been prepared in which the native FAD has been replaced with an FAD analog of different redox potential, 1-deaza-FAD or 8-CN-FAD. Reductive titrations indicate that both 1-deaza-XO and 1-deaza-XDH have a flavin midpoint potential similar to native XDH and that 8-CN-XO and 8-CN-XDH each have a flavin potential higher than XO, Both the low potential. 1-deaza-XO and the high potential 8-CN-XDH contain essentially no xanthine/NAD activity. However, 1-deaza-XDH does exhibit xanthine/NAD activity, and 8-CN-XO has normal xanthine/oxygen activity. The binding of NAD to oxidized XO and XDH was investigated by ultrafiltration and isothermal titration calorimetry. The K-d for the binding of NAD to XDH was determined to be 280 +/- 145 mu M by ultrafiltration and 160 +/- 40 mu M by isothermal titration calorimetry. No evidence for the binding of NAD to XO by either method could be obtained. A low flavin midpoint potential is necessary but not sufficient for dehydrogenase activity.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Massey, V (corresponding author), Univ Michigan, Dept Biol Chem, 3441 Med Sci 1, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08270] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA Y, 1990, J BIOL CHEM, V265, P14170; AVIS PG, 1956, J CHEM SOC, P1219, DOI 10.1039/jr9560001219; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; ENTSCH B, 1980, J BIOL CHEM, V255, P1420; Harris CM, 1997, J BIOL CHEM, V272, P28335, DOI 10.1074/jbc.272.45.28335; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; Harris CM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P723; HILLE R, 1991, J BIOL CHEM, V266, P17401; HILLE R, 1985, J BIOL CHEM, V260, P569; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1994, J BIOL CHEM, V269, P18904; HUNT J, 1993, J BIOL CHEM, V268, P18685; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; MASSEY V, 1962, J BIOL CHEM, V237, P2347; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; Murthy YVSN, 1998, J BIOL CHEM, V273, P8975, DOI 10.1074/jbc.273.15.8975; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1991, ADV EXP MED BIOL, V309, P327; NISHINO T, 1989, J BIOL CHEM, V264, P6075; *PABST LAB, 1965, ULTR ABS SPECTR PYR; PALMER G, 1969, J BIOL CHEM, V244, P2614; PARKS DA, 1983, AM J PHYSIOL, V245, pG285, DOI 10.1152/ajpgi.1983.245.2.G285; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; Segel I. H., 1976, BIOCH CALCULATIONS, P414; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3586, DOI 10.1021/bi00635a014; STEVENS CR, 1991, ANN RHEUM DIS, V50, P760, DOI 10.1136/ard.50.11.760; STIRPE F, 1969, J BIOL CHEM, V244, P3855; Tanner SJ, 1978, BIOCHEM SOC T, V6, P1328, DOI 10.1042/bst0061328; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	38	38	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4561	4569		10.1074/jbc.274.8.4561	http://dx.doi.org/10.1074/jbc.274.8.4561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988690	hybrid			2022-12-25	WOS:000078698200015
J	Hu, DD; White, CA; Panzer-Knodle, S; Page, JD; Nicholson, N; Smith, JW				Hu, DD; White, CA; Panzer-Knodle, S; Page, JD; Nicholson, N; Smith, JW			A new model of dual interacting ligand binding sites on integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; GLYCOPROTEIN-IIB/IIIA RECEPTOR; STIMULATED HUMAN-PLATELETS; IIB-IIIA COMPLEX; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; CELL-ADHESION; VONWILLEBRAND-FACTOR; CYTOPLASMIC DOMAINS; FIBRINOGEN BINDING	The platelet integrin alpha(IIIb)beta(3) mediates platelet aggregation and platelet adhesion. This integrin is the key to hemostasis and also to pathologic vascular occlusion. A key domain on alpha(IIIb)beta(3) is the ligand binding site, which can bind to plasma fibrinogen and to a number of Arg-Gly-Asp (RGD)-type ligands. However, the nature and function of the ligand binding pocket on alpha(IIIb)beta(3) remains controversial. Some studies suggest the presence of two ligand binding pockets, whereas other reports indicate a single binding pocket. Here we use surface plasmon resonance to show that alpha(IIb)beta(3) contains two distinct ligand binding pockets. One site binds to fibrinogen, and a separate site binds to RGD-type ligands, More importantly, however, the two ligand binding pockets are interactive. RGD-type ligands are capable of binding to alpha(IIb)beta(3) even when it is already occupied by fibrinogen, Once bound, RGD-type ligands induce the dissociation of fibrinogen from alpha(IIb)beta(3). This allosteric cross-talk has important implications for anti-platelet therapy because it suggests a novel approach for the dissolution of existing platelet thrombi.	La Jolla Canc Res Fdn, Canc Res Ctr, Program Cell Adhes, Burnham Inst, La Jolla, CA 92037 USA; Searle, Dept Cardiovasc Dis Res, Skokie, IL 60077 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), La Jolla Canc Res Fdn, Canc Res Ctr, Program Cell Adhes, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL58925] Funding Source: Medline; NIAMS NIH HHS [AR 45054, AR42750] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045054, R01AR042750] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BEER JH, 1992, BLOOD, V79, P117; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Byzova TV, 1997, J BIOL CHEM, V272, P27183, DOI 10.1074/jbc.272.43.27183; Coller BS, 1997, CIRCULATION, V95, P860; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kato A, 1997, CRIT REV ONCOL HEMAT, V26, P1, DOI 10.1016/S1040-8428(97)00011-5; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAM SCT, 1987, J BIOL CHEM, V262, P947; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; Mesri M, 1998, J BIOL CHEM, V273, P744, DOI 10.1074/jbc.273.2.744; Moliterno DJ, 1997, THROMB HAEMOSTASIS, V78, P214; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PANZERKNODLE SG, 1995, PLATELETS, V6, P288, DOI 10.3109/09537109509023569; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SEGAL IH, 1975, ENZYME KINETICS; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1994, J BIOL CHEM, V269, P960; Tcheng JE, 1997, THROMB HAEMOSTASIS, V78, P205; Wagner CL, 1996, BLOOD, V88, P907; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	48	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4633	4639		10.1074/jbc.274.8.4633	http://dx.doi.org/10.1074/jbc.274.8.4633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988699	hybrid			2022-12-25	WOS:000078698200024
J	Justice, MC; Ku, T; Hsu, MJ; Carniol, K; Schmatz, D; Nielsen, J				Justice, MC; Ku, T; Hsu, MJ; Carniol, K; Schmatz, D; Nielsen, J			Mutations in ribosomal protein L10e confer resistance to the fungal-specific eukaryotic elongation factor 2 inhibitor sordarin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; EF-G; SUBUNIT; ATPASE; LIVER	The natural product sordarin, a tetracyclic diterpene glycoside, selectively inhibits fungal protein synthesis by impairing the function of eukaryotic elongation factor 2 (eEF2). Sordarin and its derivatives bind to the eEF2-ribosome-nucleotide complex in sensitive fungi, stabilizing the post-translocational GDP form. We have previously described a class of Saccharomyces cerevisiae mutants that exhibit resistance to varying levels of sordarin and have identified amino acid substitutions in yeast eEF2 that confer sordarin resistance. We now report on It second class of sordarin-resistant mutants. Biochemical and molecular genetic analysis of these mutants demonstrates that sordarin resistance is dependent on the essential large ribosomal subunit protein L10e in S. cerevisiae. Five unique L10e alleles were characterized and sequenced, and several nucleotide changes that differ from the wild-type sequence were identified. Changes that result in the resistance phenotype map to 4 amino acid substitutions and 1 amino acid deletion clustered in a conserved 10-amino acid region of L10e. Like the previously identified eEF2 mutations, the mutant ribosomes show reduced sordarin conferred stabilization of the eEF2-nucleotide-ribosome complex. To our know ledge, this report provides the first description of ribosomal protein mutations affecting translocation. These results and our previous observations with eEF2 suggest a functional linkage between L10e and eEF2.	Merck Res Labs, Dept Basic Anim Sci Res, Rahway, NJ 07065 USA; Wesleyan Univ, Middletown, CT 06459 USA	Merck & Company; Wesleyan University	Nielsen, J (corresponding author), Merck Res Labs, Dept Basic Anim Sci Res, POB 2000, Rahway, NJ 07065 USA.							ACHARYA AS, 1973, BIOCHEMISTRY-US, V12, P3108, DOI 10.1021/bi00740a026; Agafonov DE, 1997, P NATL ACAD SCI USA, V94, P12892, DOI 10.1073/pnas.94.24.12892; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; BILGIN N, 1988, BIOCHIMIE, V70, P611, DOI 10.1016/0300-9084(88)90244-1; Bocharov EV, 1998, FEBS LETT, V423, P347, DOI 10.1016/S0014-5793(98)00121-5; Capa L, 1998, ANTIMICROB AGENTS CH, V42, P2694, DOI 10.1128/AAC.42.10.2694; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2279, DOI 10.1128/AAC.42.9.2279; Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2274, DOI 10.1128/AAC.42.9.2274; GUDKOV AT, 1984, FEBS LETT, V176, P32, DOI 10.1016/0014-5793(84)80906-0; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; HAUSER D, 1971, HELV CHIM ACTA, V54, P1178, DOI 10.1002/hlca.19710540427; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; Justice MC, 1998, J BIOL CHEM, V273, P3148, DOI 10.1074/jbc.273.6.3148; KOVALCHUKE O, 1994, EUR J BIOCHEM, V226, P133, DOI 10.1111/j.1432-1033.1994.tb20034.x; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; MAASSEN JA, 1974, P NATL ACAD SCI USA, V71, P1277, DOI 10.1073/pnas.71.4.1277; MITSUI K, 1989, J BIOCHEM-TOKYO, V106, P223, DOI 10.1093/oxfordjournals.jbchem.a122836; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; PHAN LD, 1993, J BIOL CHEM, V268, P8665; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; Skogerson L, 1979, Methods Enzymol, V60, P676; Trusca D, 1998, J BACTERIOL, V180, P3946, DOI 10.1128/JB.180.15.3946-3953.1998; Tse B, 1998, BIOORG MED CHEM LETT, V8, P2269, DOI 10.1016/S0960-894X(98)00401-6; UCHIUMI T, 1986, J BIOL CHEM, V261, P9663; URITANI M, 1988, J BIOCHEM-TOKYO, V103, P522, DOI 10.1093/oxfordjournals.jbchem.a122302; Verschoor A, 1998, NUCLEIC ACIDS RES, V26, P655, DOI 10.1093/nar/26.2.655	30	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4869	4875		10.1074/jbc.274.8.4869	http://dx.doi.org/10.1074/jbc.274.8.4869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988728	hybrid			2022-12-25	WOS:000078698200053
J	Lee, J; Spector, D; Godon, C; Labarre, J; Toledano, MB				Lee, J; Spector, D; Godon, C; Labarre, J; Toledano, MB			A new antioxidant with alkyl hydroperoxide defense properties in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YAP-1 TRANSCRIPTIONAL REGULATION; THIOL-SPECIFIC ANTIOXIDANT; OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; GLUTATHIONE-PEROXIDASE; CANDIDA-BOIDINII; TARGET GENE; THIOREDOXIN; PROTEINS; REDUCTASE	To isolate new antioxidant genes, we have searched for activities that would rescue the tert-butyl hydroperoxide (t-BOOH)-hypersensitive phenotype of a Saccharomyces cerevisiae strain deleted for the gene encoding the oxidative stress response regulator Skn7, We report the characterization of AHP1, which encodes a 19-kDa protein similar to the AhpC/TSA protein family within a small region encompassing Cys-62 of Ahp1p and the highly conserved N-terminal catalytic AhpC/TSA cysteine, Ahp1p contains a peroxisomal sorting signal, suggesting a peroxisomal localization. AHP1 exerts strong antioxidant protective functions, as demonstrated both by gene overexpression and deletion analyses, and is inducible by peroxides in an Yap1- and Skn7 dependent manner. Similar to yeast Tsa1p, Ahp1p forms a disulfide-linked homodimer upon oxidation and in, vivo requires the presence of the thioredoxin system but not of glutathione to perform its antioxidant protective function. Furthermore, in contrast to Tsa1p, which is specific for H2O2, Ahp1p is specific for organic peroxides, Therefore, with respect to substrate specificity, Ahp1p differs from Tsa1p and is similar to prokaryotic alkyl hydroperoxide reductase AhpC. These data suggest that Ahp1p is a yeast orthologue of prokaryotic AhpC and justifies its name of yeast alkyl hydroperoxide reductase.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Rutgers State Univ, Coll Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08855 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Rutgers State University New Brunswick	Toledano, MB (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.	toledano@jonas.saclay.cea.fr						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, BIOFACTORS, V4, P177; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GOODMAN JM, 1986, J BIOL CHEM, V261, P3464; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P273; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; Krems B, 1996, CURR GENET, V29, P327, DOI 10.1007/s002940050053; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LIU HP, 1992, GENETICS, V132, P665; Marinho HS, 1997, FREE RADICAL BIO MED, V22, P871, DOI 10.1016/S0891-5849(96)00468-6; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; RANDEZGIL F, 1994, FEMS MICROBIOL LETT, V122, P153, DOI 10.1111/j.1574-6968.1994.tb07158.x; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SIKORSKI RS, 1989, GENETICS, V122, P19; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	49	148	153	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4537	4544		10.1074/jbc.274.8.4537	http://dx.doi.org/10.1074/jbc.274.8.4537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988687	hybrid			2022-12-25	WOS:000078698200012
J	Vilella-Bach, M; Nuzzi, P; Fang, YM; Chen, J				Vilella-Bach, M; Nuzzi, P; Fang, YM; Chen, J			The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G(1) progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; TRANSLATION INITIATION; PHAS-I; MAMMALIAN PROTEIN; MESSENGER-RNA; EARLY G1; RAPAMYCIN; YEAST; PHOSPHORYLATION; TARGET	The immunosuppressant rapamycin, in complex with its cellular receptor FKBP12, targets the cellular protein FKBP12-rapamycin-associated protein/mammalian target of rapamycin/rapamycin and FKBP12 target 1 (FRAP/mTOR/RAFT1) and inhibits/delays G(1) cell cycle progression in mammalian cells. As a member of the novel phosphatidylinositol kinase-related kinase family, FRAP's kinase activity is essential for its signaling function. The FKBP12-rapamycin binding (FIR) domain in FRAP is also speculated to play an important role in FRAP function and signaling. However, the biochemical and physiological functions of FRB, as well as the mechanism for rapamycin inhibition, have been unclear. The present study focuses on investigation of FRB's role and the functional relationship between FEB domain and kinase domain in FRAP. Microinjection of purified FRB protein into human osteosarcoma MG63 cells results in a drastic blockage of the G(1) to S cell cycle progression; such a dominant negative effect is reversed by a point mutation (Trp(2027) --> Phe). The same mutation also abolishes kinase activity of FRAP without affecting ATP binding, and truncation studies suggest that upstream sequences including FRB are required for kinase activity in vitro, Given these data, we propose a model for FRAP function, in which the FEB domain is required for activation of the kinase domain, possibly through the interaction with an upstream activator. In addition, our observations provide direct evidence linking FRAP function to G(1) cell cycle progression.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), Univ Illinois, Dept Cell & Struct Biol, 601 S Goodwin Ave,B107, Urbana, IL 61801 USA.	jchen@life.uiuc.edu		Chen, Jie/0000-0002-7887-3747				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1995, J IMMUNOL, V155, P3418; Withers DJ, 1997, J BIOL CHEM, V272, P2509; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	49	111	124	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4266	4272		10.1074/jbc.274.7.4266	http://dx.doi.org/10.1074/jbc.274.7.4266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933627	hybrid			2022-12-25	WOS:000078575500051
J	Bevans, CG; Harris, AL				Bevans, CG; Harris, AL			Regulation of connexin channels by pH - Direct action of the protonated form of taurine and other aminosulfonates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GAP-JUNCTIONS; INTRACELLULAR PH; GLYCINE RECEPTOR; XENOPUS OOCYTES; CARBON-DIOXIDE; RAT-BRAIN; TRANSPORTER; EXPRESSION; SENSITIVITY; PROTEIN	Protonated aminosulfonate compounds directly inhibit connexin channel activity. This was demonstrated by pH-dependent connexin channel activity in Good's pH buffers (MES (4-morpholineethanesulfonic acid), HEPES, and TAPS (3-{[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]-1-propanesulfonic acid)) that have an aminosulfonate moiety in common and by the absence of pH-dependent channel activity in pH buffers without an aminosulfonate moiety (maleate, Tris, and bicarbonate). The pH-activity relation was shifted according to the pK(a) of each aminosulfonate pH buffer. At constant pH, increased aminosulfonate concentration inhibited channel activity. Taurine, a ubiquitous cytoplasmic aminosulfonic acid, had the same effect at physiological concentrations. These data raise the possibility that effects on connexin channel activity previously attributed to protonation of connexin may be mediated instead by protonation of cytoplasmic regulators, such as taurine, Modulation by aminosulfonates is specific for heteromeric connexin channels containing connexin-26; it does not occur significantly for homomeric connexin-32 channels. The identification of taurine as a cytoplasmic compound that directly interacts with and modulates connexin channel activity is likely to facilitate understanding of cellular modulation of connexin channels and lead to the development of reagents for use in structure-function studies of connexin protein.	Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA	Johns Hopkins University	Harris, AL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.		Bevans, Carville/C-6651-2009	Bevans, Carville/0000-0001-7389-2124; Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAGI H, 1988, NEUROSCI LETT, V95, P262, DOI 10.1016/0304-3940(88)90668-4; BENNETT MVL, 1994, SOC GEN PHY, V49, P223; Bevans C. G., 1997, Molecular Biology of the Cell, V8, p96A; Bevans C. G., 1996, Biophysical Journal, V70, pA32; Bevans C. G., 1995, Biophysical Journal, V68, pA204; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bevans CG, 1999, J BIOL CHEM, V274, P3720, DOI 10.1074/jbc.274.6.3720; CAMPOSDECARVALHO AC, 1988, BRAZ J MED BIOL RES, V21, P177; CHESLER M, 1989, J NEUROSCI, V9, P2011; CHESNEY RW, 1990, PEDIATR NEPHROL, V4, P399, DOI 10.1007/BF00862526; Christensen J.J., 1976, HDB PROTON IONIZATIO; CLEMENS M, 1993, MOL BIOL CELL, V4, pS330; CONNORS BW, 1984, J NEUROSCI, V4, P1324; DELMAR M, 1995, CARDIAC ELECTROPHYSI, P135; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; FALLON MB, 1995, AM J PHYSIOL-CELL PH, V268, pC1186, DOI 10.1152/ajpcell.1995.268.5.C1186; GOLDIN SM, 1978, J BIOL CHEM, V253, P2575; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GREEN TR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P91, DOI 10.1016/0304-4165(91)90187-L; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS AL, 1992, MOL BRAIN RES, V15, P269, DOI 10.1016/0169-328X(92)90118-U; HARRIS AL, 1997, GAP JUNCTIONS, P60; HARRIS AL, 1994, BIOMEMBRANE ELECTROC, P197; HUXTABLE RJ, 1994, TAURINE HLTH DIS; IWATSUKI N, 1979, J PHYSIOL-LONDON, V291, P317, DOI 10.1113/jphysiol.1979.sp012815; Kumar N M, 1992, Semin Cell Biol, V3, P3; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; LIU SG, 1993, BIOPHYS J, V64, P1422, DOI 10.1016/S0006-3495(93)81508-X; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Nagy JI, 1997, NEUROSCIENCE, V78, P533, DOI 10.1016/S0306-4522(96)00584-2; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; OLLIVON M, 1986, ANAL BIOCHEM, V152, P262, DOI 10.1016/0003-2697(86)90408-2; OLSON KS, 1995, J COMP PHYSIOL A, V176, P527; Peracchia C, 1996, PFLUG ARCH EUR J PHY, V431, P379, DOI 10.1007/BF02207275; Peracchia C, 1997, BRAZ J MED BIOL RES, V30, P577, DOI 10.1590/S0100-879X1997000500003; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; *RES ORG INC, 1996, 1996 7 CAT BIOCH; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; RINK TJ, 1980, NATURE, V283, P658, DOI 10.1038/283658a0; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; Schofield PR, 1996, COLD SPRING HARB SYM, V61, P333; SCHUETZE SM, 1982, J CELL BIOL, V92, P694, DOI 10.1083/jcb.92.3.694; SMITH KE, 1992, MOL PHARMACOL, V42, P563; Spray David C., 1994, P195; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; Torok K, 1997, BIOCHEM J, V326, P479; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; Vinnakota S, 1997, J NEUROCHEM, V69, P2238; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; Wang XG, 1997, BIOPHYS J, V73, P798, DOI 10.1016/S0006-3495(97)78112-8; Wang XG, 1996, PFLUG ARCH EUR J PHY, V431, P844; Wang XG, 1996, AM J PHYSIOL-CELL PH, V271, pC1743, DOI 10.1152/ajpcell.1996.271.5.C1743; WERNER R, 1991, P ROY SOC B-BIOL SCI, V243, P5, DOI 10.1098/rspb.1991.0002; YOUNG AB, 1974, MOL PHARMACOL, V10, P790	62	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3711	3719		10.1074/jbc.274.6.3711	http://dx.doi.org/10.1074/jbc.274.6.3711			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920923	hybrid			2022-12-25	WOS:000078428200063
J	Efimova, IS; Salminen, A; Pohjanjoki, P; Lapinniemi, J; Magretova, NN; Cooperman, BS; Goldman, A; Lahti, R; Baykov, AA				Efimova, IS; Salminen, A; Pohjanjoki, P; Lapinniemi, J; Magretova, NN; Cooperman, BS; Goldman, A; Lahti, R; Baykov, AA			Directed mutagenesis studies of the metal binding site at the subunit interface of Escherichia coli inorganic pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CRYSTAL-STRUCTURE; CATALYTIC PROPERTIES; ACTIVE-SITE; SUBSTITUTION; RESOLUTION; HYDROLYSIS; PHOSPHATE; ANGSTROM; CAVITIES	Recent crystallographic studies on Escherichia coli inorganic pyrophosphatase (E-PPase) have identified three Mg2+ ions/enzyme hexamer in water-filled cavities formed by Asn(24), Ala(25), and Asp(26) at the trimer-trimer interface (Kankare, J., Salminen, T., Lahti, R., Cooperman, B., Baykov, A. A., and Goldman, A. (1996) Biochemistry 35, 4670-4677). Here we show that D26S and D26N substitutions decrease the stoichiometry of tight Mg2+ binding to E-PPase by approximately 0.5 mol/mol monomer and increase hexamer stability in acidic medium. Mg2+ markedly decelerates the dissociation of enzyme hexamer into trimers at pH 5.0 and accelerates hexamer formation from trimers at pH 7.2 with wild type E-PPase and the N24D variant, in contrast to the D26S and D26N variants, when little or no effect is seen. The catalytic parameters describing the dependences of enzyme activity on substrate and Mg2+ concentrations are of the same magnitude for wild type E-PPase and the three variants. The affinity of the intertrimer site for Mg2+ at pH 7.2 is intermediate between those of two Mg2+ binding sites found in the E-PPase active site. It is concluded that the metal ion binding site found at the trimer-trimer interface of E-PPase is a high affinity site whose occupancy by Mg2+ greatly stabilizes the enzyme hexamer but has little effect on catalysis.	Moscow MV Lomonosov State Univ, An Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Univ Turku, Dept Biochem, FIN-20014 Turku, Finland; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Abo Akad Univ, FIN-20251 Turku, Finland; Turku Univ, Ctr Biotechnol, FIN-20251 Turku, Finland	Lomonosov Moscow State University; Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku; University of Pennsylvania; Abo Akademi University; University of Turku	Lahti, R (corresponding author), Moscow MV Lomonosov State Univ, An Belozersky Inst Physicochem Biol, Moscow 119899, Russia.		Baykov, Alexander A/C-7981-2012; Salminen, Tiina A/G-7492-2019; Baykov, Alexander/AAH-5301-2021; Salminen, Tiina A./AAM-5443-2021	Salminen, Tiina A/0000-0002-4135-8020; Salminen, Tiina A./0000-0002-4135-8020; Baykov, Alexander/0000-0002-2495-8200	FOGARTY INTERNATIONAL CENTER [R03TW000407] Funding Source: NIH RePORTER; FIC NIH HHS [TW00407] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Avaeva SM, 1995, FEBS LETT, V377, P44, DOI 10.1016/0014-5793(95)01310-5; Baykov AA, 1996, BIOCHEMISTRY-US, V35, P4655, DOI 10.1021/bi952635u; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Baykov AA, 1995, J BIOL CHEM, V270, P30804, DOI 10.1074/jbc.270.51.30804; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; BORSHCHIK I B, 1986, Biokhimiya, V51, P1484; Brinen LS, 1996, BIOCHEMISTRY-US, V35, P5999, DOI 10.1021/bi9530200; CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; HACHIMORI A, 1979, J BIOCHEM, V86, P121; Harutyunyan EG, 1996, KRISTALLOGRAFIYA+, V41, P84; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Harutyunyan EH, 1996, EUR J BIOCHEM, V239, P220, DOI 10.1111/j.1432-1033.1996.0220u.x; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; HILL CP, 1991, BIOCHEMISTRY-US, V30, P917, DOI 10.1021/bi00218a006; HUBBARD SJ, 1994, PROTEIN SCI, V3, P2194, DOI 10.1002/pro.5560031205; ICHIBA T, 1990, J BIOCHEM-TOKYO, V108, P572, DOI 10.1093/oxfordjournals.jbchem.a123244; JOSSE J, 1966, J BIOL CHEM, V241, P1938; Kankare J, 1996, ACTA CRYSTALLOGR D, V52, P551, DOI 10.1107/S0907444996000376; KANKARE J, 1994, PROTEIN ENG, V7, P823, DOI 10.1093/protein/7.7.823; Kankare J, 1996, BIOCHEMISTRY-US, V35, P4670, DOI 10.1021/bi952637e; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; Kornberg A., 1962, HORIZONS BIOCH, P251; LAHTI R, 1990, BIOCHEMISTRY-US, V29, P5761, DOI 10.1021/bi00476a017; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; PARDE HE, 1993, SCIENCE, V262, P387; Petsko GA, 1996, NAT STRUCT BIOL, V3, P565, DOI 10.1038/nsb0796-565; SALMINEN T, 1995, BIOCHEMISTRY-US, V34, P782, DOI 10.1021/bi00003a011; SCHREIER E, 1980, FEBS LETT, V109, P67, DOI 10.1016/0014-5793(80)81313-5; SONNEWALD U, 1992, PLANT J, V2, P571; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; TEPLYAKOV A, 1994, PROTEIN SCI, V3, P1098, DOI 10.1002/pro.5560030713; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Velichko IS, 1998, BIOCHEMISTRY-US, V37, P734, DOI 10.1021/bi9714823; Volk SE, 1996, BIOCHEMISTRY-US, V35, P4662, DOI 10.1021/bi952636m; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; WONG SCK, 1970, J BIOL CHEM, V245, P4335	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3294	3299		10.1074/jbc.274.6.3294	http://dx.doi.org/10.1074/jbc.274.6.3294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920869	hybrid			2022-12-25	WOS:000078428200009
J	Wang, L; Xu, DZ; Dai, W; Lu, L				Wang, L; Xu, DZ; Dai, W; Lu, L			An ultraviolet-activated K+ channel mediates apoptosis of myeloblastic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CEREBELLAR GRANULE NEURONS; C-JUN; TYROSINE KINASE; PROTEIN-KINASE; DIFFERENTIAL ACTIVATION; POTASSIUM CHANNELS; HUMAN-MONOCYTES; GROWTH-FACTOR; UV RESPONSE	Exposure of mammalian cells to UV light causes initial changes in the cell membrane, induces phosphorylation and clustering of growth factor/cytokine receptors, and activates the Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway leading to programmed cell death (apoptosis). In this study, we found that an early event in the cell membrane of myeloblastic leukemia (ML-1) cells was the vigorous activation of the voltage-gated K+ channel by UV irradiation. The strong enhancement by UV irradiation of K+ channel activity in the cell membrane subsequently activated the JNK/SAPK signaling pathway and resulted in myeloblastic leukemia cell apoptosis. Suppression of UV-induced K+ channel activation with specific channel blockers prevented UV-induced apoptosis through inhibition of UV-induced activation of the proteins SEK (SPAK kinase) and JNK. However, suppression of K+ channel activity could not protect cells from etoposide-induced apoptosis, which bypasses the membrane event. Elimination of extracellular Ca2+ had no effect on the UV-induced and K+ channel-mediated JNK/SAPK activation. Thus, we have identified a novel mechanism in which activation of K+ channels by UV-irradiation upstream of SEK and SAPK/JNK mediates UV-induced myeloblastic cell apoptosis.	Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45435 USA; Univ Cincinnati, Coll Med, Dept Med, Div Hematol, Cincinnati, OH 45243 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; University of Cincinnati	Lu, L (corresponding author), Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45435 USA.	LUO.LU@WRIGHT.EDU			NCI NIH HHS [CA59985] Funding Source: Medline; NEI NIH HHS [EY11653] Funding Source: Medline; NIGMS NIH HHS [GM46834] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059985] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRIGHT J, 1994, BIOSCIENCE REP, V14, P67; BUSCHER M, 1988, ONCOGENE, V3, P301; Cahill MA, 1996, ONCOGENE, V13, P2087; COFFER PJ, 1995, ONCOGENE, V11, P561; deLuca A, 1996, J NEUROSCI, V16, P4174; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; DUPRAT F, 1995, P NATL ACAD SCI USA, V92, P11796, DOI 10.1073/pnas.92.25.11796; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holbrook N J, 1996, EXS, V77, P273; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LU L, 1993, J MEMBRANE BIOL, V132, P267; MATSUURA H, 1991, AM J PHYSIOL, V261, pH1358, DOI 10.1152/ajpheart.1991.261.5.H1358; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Rader RK, 1996, J IMMUNOL, V156, P1425; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUZAIREDUBOIS B, 1990, CELL SIGNAL, V2, P387, DOI 10.1016/0898-6568(90)90069-M; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; Schulz JB, 1996, J NEUROSCI, V16, P4696; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; SOLIVEN B, 1991, J MEMBRANE BIOL, V124, P127, DOI 10.1007/BF01870457; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; VALENZENO DP, 1991, PHOTOCHEM PHOTOBIOL, V53, P195, DOI 10.1111/j.1751-1097.1991.tb03923.x; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Wang L, 1997, AM J PHYSIOL-CELL PH, V273, pC1657, DOI 10.1152/ajpcell.1997.273.5.C1657; Xu B, 1996, AM J PHYSIOL-CELL PH, V271, pC2037, DOI 10.1152/ajpcell.1996.271.6.C2037; YAN MH, 1994, NATURE, V372, P798; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114	53	89	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3678	3685		10.1074/jbc.274.6.3678	http://dx.doi.org/10.1074/jbc.274.6.3678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920918	hybrid			2022-12-25	WOS:000078428200058
J	Czerniak, B; Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Luthra, R; Logothetis, C; Von Eschenbach, AC; Grossman, HB; Benedict, WF; Batsakis, JG				Czerniak, B; Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Luthra, R; Logothetis, C; Von Eschenbach, AC; Grossman, HB; Benedict, WF; Batsakis, JG			Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; chromosome 9; MTS; microsatellites; multistep carcinogenesis; superimposed histologic and genetic mapping	TRANSITIONAL-CELL-CARCINOMA; TUMOR-SUPPRESSOR GENE; CRITICAL REGION; HIGH-FREQUENCY; LUNG CANCERS; DELETION; P16; MUTATIONS; LOCI; DEFINES	The evolution of alterations on chromosome 9, including the putative tumor suppressor genes mapped to the 9p21-22 region (the MTS genes), was studied in relation to the progression of human urinary bladder neoplasia by using whole organ superimposed histologic and genetic mapping in cystectomy specimens and was verified in urinary bladder tumors of various pathogenetic subsets with longterm follow-up, The applicability of chromosome 9 allelic losses as non-invasive markers of urothelial neoplasia was tested on voided urine and/or bladder washings of patients with urinary bladder cancer, Although sequential multiple hits in the MTS locus were documented in the development of intraurothelial precursor lesions, the MTS genes do not seem to represent a major target for p21-23 deletions in bladder cancer, Two additional tumor suppressor genes involved in bladder neoplasia located distally and proximally to the MTS locus within p22-23 and p11-13 regions respectively were identified. Several distinct putative tumor suppressor gene loci within the q12-13, q21-22, and q34 regions were identified on the q arm. In particular, the pericentromeric q12-13 area may contain the critical tumor suppressor gene or genes for the development of early urothelial neoplasia, Allelic losses of chromosome 9 were associated with expansion of the abnormal urothelial clone which frequently involved large areas of urinary bladder mucosa, These losses could be found in a high proportion of urothelial tumors and in voided urine or bladder washing samples of nearly all patients with urinary bladder carcinoma.	Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Czerniak, B (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA.				NCI NIH HHS [CA66723-04, CA54672] Funding Source: Medline; NEI NIH HHS [EYO6195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA066723, R01CA054672, R01CA066723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, AJCC CANC STAGING MA; ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; Brownlee K. A, 1965, STAT THEORY METHODOL; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; COLEMAN A, 1994, CANCER RES, V54, P344; DEVLIN J, 1994, ONCOGENE, V9, P2757; GIBAS Z, 1984, CANCER RES, V44, P1257; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hartigan J., 1975, CLUSTERING ALGORITHM; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; KOSS LG, 1995, DIAGNOSTIC CYTOLOGY; Larsen C J, 1997, Prog Cell Cycle Res, V3, P109; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LIU Q, 1995, ONCOGENE, V10, P1061; Maniatis T., 1989, MOL CLONING LAB MANU; MERLO A, 1995, NATURE, V1, P7; MIYAO N, 1993, CANCER RES, V53, P4066; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLUMI AF, 1990, CANCER RES, V50, P7081; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Ott J., 1991, ANAL HUMAN GENETIC L; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; Reed AL, 1996, CANCER RES, V56, P3630; Simoneau AR, 1996, CANCER RES, V56, P5039; SIMONEAU AR, 1994, WORLD J UROL, V12, P89; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SPRUCK CH, 1994, CANCER RES, V54, P784; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TSAI YC, 1990, CANCER RES, V50, P44; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619	42	104	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1185	1196		10.1038/sj.onc.1202385	http://dx.doi.org/10.1038/sj.onc.1202385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022124				2022-12-25	WOS:000078510700007
J	Egan, C; Pang, A; Durda, D; Cheng, HC; Wang, JH; Fujita, DJ				Egan, C; Pang, A; Durda, D; Cheng, HC; Wang, JH; Fujita, DJ			Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530	ONCOGENE			English	Article						Src kinase; phosphotyrosyl phosphatase; breast cancer	EPIDERMAL-GROWTH-FACTOR; PP60C-SRC PROTEIN-KINASE; C-SRC; FACTOR RECEPTOR; MAMMARY-TUMORS; MITOGENIC RESPONSIVENESS; NEU PROTOONCOGENE; SH2 DOMAIN; EXPRESSION; PP60(C-SRC)	Elevated levels of Src kinase activity have been reported in a number of human cancers, including colon and breast cancer, We have analysed four human breast tumor cell lines that exhibit high levels of Src kinase activity, and have determined that these cell lines also exhibit a high level of a phosphotyrosine phosphatase activity that recognizes the Src carboxy-terminal P-Tyr530 negative regulatory site. Total Src kinase activity in these cell lines is elevated as much as 30-fold over activity in normal control cells and specific activity is elevated as much as 5.6-fold. When the breast tumor cells were grown in the presence of the tyrosine phosphatase inhibitor vanadate, Src kinase activity was reduced in all four breast tumor cell lines, suggesting that Src was being activated by a phosphatase which could recognize the Tyr530 negative regulatory site, In fractionated cell extracts from the breast tumor cells, we found elevated levels of a membrane associated tyrosine phosphatase activity that preferentially dephosphorylated a Src family carboxy-terminal phosphopeptide containing the regulatory tyrosine 530 site, Src was hypophosphorylated in vivo at tyrosine 530 in at least two of the tumor cell lines, further suggesting that Src was being activated by a phosphatase in these cells, In preliminary immunoprecipitation and antibody depletion experiments, we were unable to correlate the major portion of this phosphatase activity with several known phosphatases.	Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Med Ctr, Canc Biol Res Grp, Dept Biochem Med, Calgary, AB T2N 4N1, Canada; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Peoples R China	University of Calgary; University of Calgary; University of Calgary; Hong Kong University of Science & Technology	Fujita, DJ (corresponding author), Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada.			Cheng, Heung-Chin/0000-0002-4965-7148				BERGER MS, 1988, CANCER RES, V48, P1238; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JACOBS C, 1983, CANCER RES, V43, P1696; JANES PW, 1994, ONCOGENE, V9, P3601; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OCONNOR TJ, 1995, CELL GROWTH DIFFER, V6, P123; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pallen C J, 1993, Semin Cell Biol, V4, P403, DOI 10.1006/scel.1993.1048; PENG ZY, 1995, ONCOGENE, V11, P1955; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANAKA A, 1990, ONCOGENE RES, V5, P305; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; VARLEY JM, 1987, ONCOGENE, V1, P423; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZHAI YF, 1993, CANCER RES, V53, P2272; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	46	98	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1227	1237		10.1038/sj.onc.1202233	http://dx.doi.org/10.1038/sj.onc.1202233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022129				2022-12-25	WOS:000078510700012
J	Zhang, YK; Fujita, N; Tsuruo, T				Zhang, YK; Fujita, N; Tsuruo, T			Caspase-mediated cleavage of p21(Wafl)/(Cip1) converts cancer cells from growth arrest to undergoing apoptosis	ONCOGENE			English	Article						p21; apoptosis; caspases; DNA damage; p53	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; DNA-REPLICATION; P53-INDUCED APOPTOSIS; PROTEASE ACTIVATION; NUCLEAR ANTIGEN; CYTOCHROME-C; IN-VIVO; INHIBITION; P21	The cyclin-dependent kinase inhibitor p21(Waf1/Cip1) is a downstream effector of the p53-dependent cell growth arrest. We report herein that p21 was cleaved by caspase-3/CPP32 at the site of (DHVDL)-L-112 down arrow during the DNA damage-induced apoptosis of cancer cells. The cleaved p21 fragment could no more arrest the cells in G(1) phase nor suppress the cells undergoing apoptosis because it failed to bind to the proliferating cell nuclear antigen (PCNA) and lost its capability to localize in the nucleus. Thus, caspase-3-mediated cleavage and inactivation of p21 protein may convert cancer cells from growth arrest to undergoing apoptosis, leading to the acceleration of chemotherapy-induced apoptotic process in cancer cells.	Univ Tokyo, Lab Biomed Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1700012, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Lab Biomed Sci, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Lee SH, 1996, ONCOGENE, V13, P2131; LEHMAN TA, 1991, CANCER RES, V51, P4090; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOMIDA A, 1996, ONCOGENE, V13, P299; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	51	213	222	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1131	1138		10.1038/sj.onc.1202426	http://dx.doi.org/10.1038/sj.onc.1202426			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022118				2022-12-25	WOS:000078510700001
J	Choi, BH; Park, GT; Rho, HM				Choi, BH; Park, GT; Rho, HM			Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II pregenomic promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS HBX PROTEIN; NF-KAPPA-B; LIVER NUCLEAR-PROTEIN; TRANSCRIPTION FACTOR; DNA-BINDING; C/EBP-ALPHA; LEUCINE-ZIPPER; TRANSACTIVATOR PROTEIN; GENE; DOMAIN	The hepatitis B viral X protein (HBx) is known to exert its transactivation activity by the interaction with several cellular transcription factors. Here we report the interaction of HBx and CCAAT/enhancer-binding protein cu (C/EBP alpha) and their effects on the enhancer/promoters of hepatitis B virus (HBV), A chloramphenicol acetyltransferase assay showed that the cotransfection of HBx and C/EBP alpha strongly activated the enhancer II/ pregenomic promoter of HBV in a synergistic manner. This effect was also observed in the heterologous expression system with promoters of SV40 and herpes simplex virus thymidine kinase genes. Serial deletion analysis of the enhancer II/pregenomic promoter identified the responsible region (nucleotides 1639-1679), in which two C/EBP-binding sites are located. An in vitro interaction assay and electrophoretic mobility shift assay showed that HBx augmented the DNA binding activity of C/EBP alpha by direct interaction with it, and its basic leucine zipper domain was responsible for the interaction with HBx, Domain analysis of HBx showed that the central region (amino acids 78-103) was necessary for direct interaction with C/EBP alpha. However, the complete form of HBx was necessary for the synergistic activation of the HBV pregenomic promoter, These results suggest that the interaction of HBx and C/EBP alpha enhances the transcription of the HBV pregenomic promoter for the effective life cycle of HBV in hepatocytes.	Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rho, HM (corresponding author), Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea.							Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; Choi CY, 1996, EUR J BIOCHEM, V239, P579, DOI 10.1111/j.1432-1033.1996.0579u.x; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FAKTOR O, 1990, ONCOGENE, V5, P861; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUO WT, 1993, MOL CELL BIOL, V13, P443, DOI 10.1128/MCB.13.1.443; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LOPEZCABRERA M, 1991, VIROLOGY, V183, P825, DOI 10.1016/0042-6822(91)91019-D; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; METZGER S, 1993, J BIOL CHEM, V268, P16831; Mink S, 1996, MOL CELL BIOL, V16, P1316; NAKATAKE H, 1993, VIROLOGY, V195, P305, DOI 10.1006/viro.1993.1381; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NYE JH, 1990, P NATL ACAD SCI USA, V87, P2992; Osada S, 1996, J BIOL CHEM, V271, P3891; Park GT, 1997, DNA CELL BIOL, V16, P1459, DOI 10.1089/dna.1997.16.1459; Park GT, 1996, J GEN VIROL, V77, P2775, DOI 10.1099/0022-1317-77-11-2775; PEI DQ, 1990, J VIROL, V64, P1517, DOI 10.1128/JVI.64.4.1517-1522.1990; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; SHIN HJ, 1995, J BIOL CHEM, V270, P11047, DOI 10.1074/jbc.270.19.11047; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; Vietor I, 1996, J BIOL CHEM, V271, P5595, DOI 10.1074/jbc.271.10.5595; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU KJ, 1994, J BIOL CHEM, V269, P1177; WU X, 1992, VIROLOGY, V191, P490, DOI 10.1016/0042-6822(92)90217-D; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Yu XM, 1997, J VIROL, V71, P9366, DOI 10.1128/JVI.71.12.9366-9374.1997; YUH CH, 1993, J VIROL, V67, P142, DOI 10.1128/JVI.67.1.142-149.1993; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHENG YW, 1994, J BIOL CHEM, V269, P22593; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	66	77	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2858	2865		10.1074/jbc.274.5.2858	http://dx.doi.org/10.1074/jbc.274.5.2858			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915821	hybrid			2022-12-25	WOS:000078319500039
J	Minnick, DT; Bebenek, K; Osheroff, WP; Turner, RM; Astatke, M; Liu, LX; Kunkel, TA; Joyce, CM				Minnick, DT; Bebenek, K; Osheroff, WP; Turner, RM; Astatke, M; Liu, LX; Kunkel, TA; Joyce, CM			Side chains that influence fidelity at the polymerase active site of Escherichia coli DNA polymerase I (Klenow fragment)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; FRAMESHIFT FIDELITY; THUMB SUBDOMAIN; PROCESSIVITY; REPLICATION; PROTEINS; MUTANT	To investigate the interactions that determine DNA polymerase accuracy, we have measured the fidelity of 26 mutants with amino acid substitutions in the polymerase domain of a 3'-5'-exonuclease-deficient Klenow fragment. Most of these mutant polymerases synthesized DNA with an apparent fidelity similar to that of the wild-type control, suggesting that fidelity at the polymerase active site depends on highly specific enzyme-substrate interactions and is not easily perturbed. In addition to the previously studied Y766A mutator, four novel base substitution mutators were identified; they are R668A R682A, E710A, and N845A, Each of these five mutator alleles results from substitution of a highly conserved amino acid side chain located on the exposed surface of the polymerase cleft near the polymerase active site. Analysis of base substitution errors at four template positions indicated that each of the five mutator polymerases has its own characteristic error specificity, suggesting that the Arg-668, Arg-682, Glu-710, Tyr-766, and Asn-845 side chains may contribute to polymerase fidelity in a variety of different ways. We separated the contributions of the nucleotide insertion and mismatch extension steps by using a novel fidelity assay that scores base substitution errors during synthesis to fill a single nucleotide gap land hence does not require mismatch extension) and by measuring the rates of polymerase-catalyzed mismatch extension reactions. The R682A, E710A, Y766A and N845A mutations cause decreased fidelity at the nucleotide insertion step, whereas R668A results in lower fidelity in both nucleotide insertion and mismatch extension. Relative to wild type, several Klenow fragment mutants showed substantially more discrimination against extension of a TG mismatch under the conditions of the fidelity assay, providing one explanation for the anti-mutator phenotypes of mutants such as R754A and Q849A.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Joyce, CM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	catherine.joyce@yale.edu	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NIGMS NIH HHS [5-F31 GM-18508, GM-28550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550, F31GM018508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; BRUSKOV VI, 1974, DOKL AKAD NAUK SSSR+, V219, P231; BRUSKOV VI, 1979, J THEOR BIOL, V78, P29, DOI 10.1016/0022-5193(79)90323-0; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; OSHEROFF WP, 1999, IN PRESS J BIOL CHEM, V274; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2	34	111	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3067	3075		10.1074/jbc.274.5.3067	http://dx.doi.org/10.1074/jbc.274.5.3067			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915846	hybrid			2022-12-25	WOS:000078319500064
J	Visconti, PE; Galantino-Homer, H; Ning, XP; Moore, GD; Valenzuela, JP; Jorgez, CJ; Alvarez, JG; Kopf, GS				Visconti, PE; Galantino-Homer, H; Ning, XP; Moore, GD; Valenzuela, JP; Jorgez, CJ; Alvarez, JG; Kopf, GS			Cholesterol efflux-mediated signal transduction in mammalian sperm - beta-cyclodextrins initiate transmembrane signaling leading to an increase in protein tyrosine phosphorylation and capacitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SPERMATOZOA; ACROSOME REACTION; BOVINE SPERM; MECHANISM; MEMBRANE; PHOSPHOLIPIDS; FERTILIZATION; TRANSPORT; ALBUMIN; INVITRO	Sperm capacitation in vitro is highly correlated with an increase in protein tyrosine phosphorylation that is regulated by cAMP through a unique mode of signal transduction cross-talk. The activation of this signaling pathway, as well as capacitation, requires bovine serum albumin (BSA) in the incubation medium. BSA is hypothesized to modulate capacitation through its ability to remove cholesterol from the sperm plasma membrane. Here we demonstrate that the cholesterol-binding heptasaccharides, methyl-beta-cyclodextrin and OH-propyl-beta-cyclodextrin, promote the release of cholesterol from the mouse sperm plasma membrane in media devoid of BSA Both of these beta-cyclodextrins were also demonstrated to increase protein tyrosine phosphorylation in the absence of BSA in both mouse and bull sperm, and the patterns of phosphorylation were similar to those induced by media containing BSA The potency of the different beta-cyclodextrins to increase protein tyrosine phosphorylation in sperm was correlated with their cholesterol binding efficiencies, and preincubation of the beta-cyclodextrins with cholesterol-SO4- to saturate their cholesterol-binding sites blocked the ability of these compounds to stimulate protein tyrosine phosphorylation, The beta-cyclodextrin effect on protein tyrosine phosphorylation was both NaHCO3 and protein kinase A-dependent. The beta-cyclodextrins were also able to capacitate mouse sperm in the absence of BSA, as measured by the ability of the zona pellucida to induce the acrosome reaction and by successful fertilization in vitro. In summary, beta-cyclodextrins can completely replace BSA in media to support signal transduction leading to capacitation. These data further support the coupling of cholesterol efflux to the activation of membrane and transmembrane signaling events leading to the activation of a unique signaling pathway involving the cross-talk between cAMP and tyrosine kinase second messenger systems, thus defining a new mode of cellular signal transduction initiated by cholesterol release.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Kopf, GS (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Rm 313,John Morgan Bldg, Philadelphia, PA 19104 USA.	kopf@mail.med.upenn.edu	Alvarez, Juan/GSD-7155-2022		NICHD NIH HHS [HD 22732, HD 06274, HD 36146] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD036146] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aitken RJ, 1996, MOL CELL ENDOCRINOL, V117, P83, DOI 10.1016/0303-7207(95)03733-0; ALVAREZ JG, 1995, MOL REPROD DEV, V42, P334, DOI 10.1002/mrd.1080420311; AUSTIN CR, 1951, AUST J SCI RES SER B, V4, P581, DOI 10.1071/BI9510581; AUSTIN CR, 1952, NATURE, V170, P326, DOI 10.1038/170326a0; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; CHANG MC, 1951, NATURE, V168, P697, DOI 10.1038/168697b0; CHANG MC, 1955, NATURE, V175, P1036, DOI 10.1038/1751036a0; DAVIS BK, 1976, P SOC EXP BIOL MED, V152, P257; DAVIS BK, 1979, BIOCHIM BIOPHYS ACTA, V558, P257, DOI 10.1016/0005-2736(79)90260-8; DAVIS BK, 1981, P NATL ACAD SCI-BIOL, V78, P7560, DOI 10.1073/pnas.78.12.7560; Emiliozzi C, 1997, BIOL REPROD, V56, P674, DOI 10.1095/biolreprod56.3.674; FIELDING CJ, 1995, J LIPID RES, V36, P211; GalantinoHomer HL, 1997, BIOL REPROD, V56, P707, DOI 10.1095/biolreprod56.3.707; GLOMSET JA, 1968, J LIPID RES, V9, P155; GO KJ, 1985, BIOL REPROD, V32, P145, DOI 10.1095/biolreprod32.1.145; Harrison RAP, 1996, REPROD FERT DEVELOP, V8, P581, DOI 10.1071/RD9960581; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KALAB P, 1994, J BIOL CHEM, V269, P3810; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAIS J, 1985, GAMETE RES, V12, P183, DOI 10.1002/mrd.1120120209; Leclerc P, 1996, BIOL REPROD, V55, P684, DOI 10.1095/biolreprod55.3.684; LEE MA, 1986, BIOL REPROD, V34, P349, DOI 10.1095/biolreprod34.2.349; Luconi M, 1996, BIOL REPROD, V55, P207, DOI 10.1095/biolreprod55.1.207; MOORE GD, 1993, DEV BIOL, V159, P669, DOI 10.1006/dbio.1993.1273; PARRISH JJ, 1988, BIOL REPROD, V38, P1171, DOI 10.1095/biolreprod38.5.1171; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; SHOUFFANI A, 1990, J BIOL CHEM, V265, P6002; SUZUKI F, 1989, GAMETE RES, V23, P335, DOI 10.1002/mrd.1120230310; THALER CD, 1995, BIOCHEMISTRY-US, V34, P7788, DOI 10.1021/bi00024a002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEMURI R, 1989, J BIOL CHEM, V264, P8680; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Visconti PE, 1998, J ANDROL, V19, P242; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Visconti PE, 1998, BIOL REPROD, V59, P1, DOI 10.1095/biolreprod59.1.1; WARD CR, 1984, DEV BIOL, V104, P287, DOI 10.1016/0012-1606(84)90084-8; YANAGIMACHI R, 1994, PHYSL REPROD, P183; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zar J. H., 1996, BIOSTATISTICAL ANAL	42	254	261	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3235	3242		10.1074/jbc.274.5.3235	http://dx.doi.org/10.1074/jbc.274.5.3235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915865	hybrid			2022-12-25	WOS:000078319500083
J	Magae, J; Illenye, S; Chang, YC; Mitsui, Y; Heintz, NH				Magae, J; Illenye, S; Chang, YC; Mitsui, Y; Heintz, NH			Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1	ONCOGENE			English	Article						E2F; ubiquitination; c-jun; CKI	UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; RETINOBLASTOMA FAMILY PROTEINS; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; IN-VIVO; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; GENE-EXPRESSION	The cell cycle-regulated transcription factor E2F is a family of heterodimers composed of E2F and DP protein subunits, While DP proteins stabilize DNA binding of E2F proteins, and influence the entry of E2F-4 and E2F-5 into the nucleus, the role of DP proteins in E2F-dependent gene expression is not well understood. Using immunolocalization, immunoprecipitation, and cell fractionation experiments, here we show association with E2F subunits governs intracellular trafficking and ubiquitination of DP-1, In transient transfection experiments, DP-1 polypeptides that stably bound E2F-1 entered the nucleus. DP-1 proteins that failed to associate with E2F subunits accumulated in the cell cytoplasm as polyubiquitinated DP-1, A Chinese hamster cell line that conditionally expresses HA-DP-1 was used to examine the effect of DP-1 on cell cycle progression, In serum response experiments, moderate increases in HA-DP-1 led to a threefold increase in E2F DNA binding activity in vitro, a corresponding increase in dhfr gene expression during transition of G1, and higher rates of S phase entry. However, flow cytometry showed cells expressing very high levels of HA-DP-1 failed to enter the S phase. Inhibition of cell cycle progression by high levels of HA-DP-1 was associated with the accumulation of other ubiquitinated cellular proteins, including c-jun and the cyclin-dependent kinase inhibitor p21, indicating that degradation of ubiquitinated proteins is required for progression from G(0) to S phase even in the presence of activated E2F, Under similar conditions, expression of E2F-1 reduced the levels of ubiquitinated cellular proteins and accelerated cell cycle progression. Our studies indicate association with E2F subunits prevents ubiquitin-dependent degradation of DP-1 in the cytoplasm by promoting nuclear entry of E2F/DP heterodimers.	Univ Vermont, Dept Pathol, Coll Med, Burlington, VT 05405 USA; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST)	Heintz, NH (corresponding author), Univ Vermont, Dept Pathol, Coll Med, Soule Med Alumni Bldg, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054726] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54726] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JOOSS K, 1995, ONCOGENE, V10, P1529; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Magae J, 1996, J CELL SCI, V109, P1717; Maki CG, 1996, CANCER RES, V56, P2649; MILBRANDT JD, 1981, P NATL ACAD SCI USA, V78, P6042; Muller H, 1997, MOL CELL BIOL, V17, P5508; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SCHOWB E, 1994, CELL, V79, P233; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; SHULL S, 1991, J BIOL CHEM, V266, P24398; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Warburg O., 1942, BIOCHEM Z, V310, P384; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells J, 1996, MOL CELL BIOL, V16, P634; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	50	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					593	605		10.1038/sj.onc.1202345	http://dx.doi.org/10.1038/sj.onc.1202345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989809				2022-12-25	WOS:000078394400004
J	Sanz, C; Leon, Y; Troppmair, J; Rapp, UR; Varela-Nieto, I				Sanz, C; Leon, Y; Troppmair, J; Rapp, UR; Varela-Nieto, I			Strict regulation of c-Raf kinase levels is required for early organogenesis of the vertebrate inner ear	ONCOGENE			English	Article						insulin-like growth factor-I; mitogen-activated protein kinase; NGF; organotypic otic vesicle cultures; RCAS vectors; retinoic acid	PROGRAMMED CELL-DEATH; GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; MAP KINASE; RETROVIRAL VECTORS; RETINOIC ACID; SIGNAL-TRANSDUCTION; FOS EXPRESSION; CHICK-EMBRYO; GENE	Regulation of organogenesis involves a dynamic balance of the mechanisms regulating cell division, differentiation and death. Here we have investigated the pattern of expression of c-Raf kinase in the inner ear during early developmental stages and the consequences of manipulating c-Raf levels by misexpression of c-raf viral vectors in organotypic cultures of otic vesicle explants. We found that otic vesicles expressed c-Raf and its level remained constant during embryonic days 2 and 3 (E2-E3). c-Raf activity was increased in response to insulin like growth factor-I (IGF-I) and the activation by IGF-I of the c-Raf kinase pathway was a requirement to turn on cell proliferation in the otic vesicle. Overexpression of c-raf in E2.5 explants increased the proliferative response to low serum and ICF-I and blocked differentiation induced by retinoic acid. The increase in c-Raf levels also prevented nerve growth factor (NGF)-dependent induction of programmed cell death. Consistent with these results, the expression of a dominant negative c-Raf mutant potentiated retinoic acid action and decreased the rate of cell proliferation. We conclude that a strict control of c-Raf levels is essential for the co-ordination of the biological processes that operate simultaneously during early inner ear development.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wurzburg, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Wurzburg	Varela-Nieto, I (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Varela-Nieto, Isabel/G-5289-2015; Leon, Yolanda/ABG-6797-2020; SANZ, CARMEN/L-7266-2014	Varela-Nieto, Isabel/0000-0003-3077-0500; SANZ, CARMEN/0000-0001-7025-6667; Leon Alvarez, Yolanda/0000-0002-4536-8373; Troppmair, Jakob/0000-0002-0611-3837				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bergeron L, 1998, CURR OPIN NEUROBIOL, V8, P55, DOI 10.1016/S0959-4388(98)80008-1; BISSONNETTE JP, 1996, J COMP NEUROL, V174, P1; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Cacace AM, 1996, ONCOGENE, V13, P2517; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Federspiel MJ, 1997, METHOD CELL BIOL, V52, P179, DOI 10.1016/S0091-679X(08)60379-9; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Fekete DM, 1997, DEVELOPMENT, V124, P2451; Fekete DM, 1996, CURR OPIN NEUROBIOL, V6, P533, DOI 10.1016/S0959-4388(96)80061-4; Frago LM, 1998, J CELL SCI, V111, P549; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEMOND SG, 1991, ANAT EMBRYOL, V184, P1, DOI 10.1007/BF01744256; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER E, 1979, METHOD ENZYMOL, P379; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; Kiernan AE, 1997, AUDIOL NEURO-OTOL, V2, P12, DOI 10.1159/000259226; KOENEN M, 1988, ONCOGENE, V2, P179; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lee KH, 1996, HEARING RES, V94, P1, DOI 10.1016/0378-5955(95)00220-0; Lein Y, 1998, J COMP NEUROL, V398, P323, DOI 10.1002/(SICI)1096-9861(19980831)398:3<323::AID-CNE2>3.0.CO;2-1; LEON Y, 1995, DEV BIOL, V167, P75, DOI 10.1006/dbio.1995.1008; LEON Y, 1995, ENDOCRINOLOGY, V136, P3494, DOI 10.1210/en.136.8.3494; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINER C, 1988, ROUX ARCH DEV BIOL, V197, P294, DOI 10.1007/BF00380023; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Oesterle EC, 1997, J COMP NEUROL, V380, P262, DOI 10.1002/(SICI)1096-9861(19970407)380:2<262::AID-CNE8>3.0.CO;2-1; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PERRIMON N, 1994, TRENDS BIOCHEM SCI, V19, P509, DOI 10.1016/0968-0004(94)90140-6; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REPRESA J, 1990, DEVELOPMENT, V110, P1081; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SPAGNOLI A, 1997, CURR OPIN ENDOCRINOL, V4, P1; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; STORM SM, 1990, ONCOGENE, V5, P345; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VONBARTHELD CS, 1991, DEVELOPMENT, V113, P455; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Zheng JL, 1997, J NEUROSCI, V17, P216, DOI 10.1523/JNEUROSCI.17-01-00216.1997	59	26	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					429	437		10.1038/sj.onc.1202312	http://dx.doi.org/10.1038/sj.onc.1202312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927199				2022-12-25	WOS:000078166500015
J	Shtil, AA; Mandlekar, S; Yu, R; Walter, RJ; Hagen, K; Tan, TH; Roninson, IB; Kong, ANT				Shtil, AA; Mandlekar, S; Yu, R; Walter, RJ; Hagen, K; Tan, TH; Roninson, IB; Kong, ANT			Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells	ONCOGENE			English	Article						taxol; colchicine; MAP kinases; microtubules; breast cancer	N-TERMINAL KINASE-1; EPIDERMAL GROWTH-FACTOR; C-JUN; KAPPA-B; INDUCED APOPTOSIS; GENE-EXPRESSION; UV IRRADIATION; JNK ACTIVATION; LEUKEMIA-CELLS; STRESS	Drug design targeted at microtubules has led to the advent of some potent anti-cancer drugs. In the present study, we demonstrated that microtubule-binding agents (MBAs) taxol and colchicine induced immediate early gene (c-jun and A TF3) expression, cell cycle arrest, and apoptosis in the human breast cancer cell line MCF-7. To elucidate the signal transduction pathways that mediate such biological activities of MBAs, we studied the involvement of mitogen-activated protein (MAP) kinases, Treatment,vith tah;ol, colchicine, or other MBAs (vincristine, podophyllotoxin, nocodazole) stimulated the activity of c-jun N-terminal kinase 1 (JNK1) in MCF-7 cells. In contrast, p38 was activated only by taxol and none of the MBAs changed the activity of extracellular signal-regulated protein kinase 2 (ERK2), Activation of JNK1 or p38 by MBAs occurred subsequent to the morphological changes in the microtubule cytoskeleton induced by these compounds. furthermore, baccatine III and beta-lumicolchicine, inactive analogs of taxol and colchicine, respectively, did not activate JNK1 or p38, These results suggest that interactions between microtubules and MBAs are essential for the activation of these kinases, Pretreatment with the antioxidants N-acetyl-L-cysteine (NAC), ascorbic acid or vitamin E, blocked H2O2- or doxorubicin-induced JNK1 activity, but had no effect on JNK1 activation by MBAs, excluding a role for oxidative stress. However, BAPTA/AM, a specific intracellular Ca2+ chelator, attenuated JNK1 activation by taxol but not by colchicine, and had no effect on microtubule changes induced by taxol. Thus, stabilization or depolymerization of microtubules may regulate JNK1 activity via distinct downstream signaling pathways. The differential activation of MAP kinases opens up a new avenue for addressing the mechanism of action of anti-microtubule drugs.	Univ Illinois, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, Coll Pharm, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Cook Cty Hosp, Dept Surg, Chicago, IL 60612 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; Baylor College of Medicine	Kong, ANT (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, Coll Pharm, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017; Tan, Tse-Hua/ABD-7080-2021; Kong, Ah-Ng Tony/AAX-2828-2020; Shtil, Alexander A./K-1568-2017; Tan, Tse-Hua/E-3983-2010	Roninson, Igor/0000-0002-9211-1327; Tan, Tse-Hua/0000-0003-4969-3170; Shtil, Alexander A./0000-0001-6469-0221; Tan, Tse-Hua/0000-0003-4969-3170	NCI NIH HHS [R37CA40333] Funding Source: Medline; NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIEHS NIH HHS [R01-ES06887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; BHALLA K, 1993, LEUKEMIA, V7, P563; BUCKLER AJ, 1988, MOL CELL BIOL, V8, P1371, DOI 10.1128/MCB.8.3.1371; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dustin P., 1984, MICROTUBULES; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JORDAN MA, 1991, CANCER RES, V51, P2212; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Komarov PG, 1996, INT J CANCER, V68, P245, DOI 10.1002/(SICI)1097-0215(19961009)68:2<245::AID-IJC18>3.0.CO;2-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANIE S, 1993, J BIOL CHEM, V268, P13675; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; SYMPSON CJ, 1990, EXP CELL RES, V189, P28, DOI 10.1016/0014-4827(90)90252-6; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	42	147	156	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					377	384		10.1038/sj.onc.1202305	http://dx.doi.org/10.1038/sj.onc.1202305			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927194				2022-12-25	WOS:000078166500010
J	Velasco-Miguel, S; Buckbinder, L; Jean, P; Gelbert, L; Talbott, R; Laidlaw, J; Seizinger, B; Kley, N				Velasco-Miguel, S; Buckbinder, L; Jean, P; Gelbert, L; Talbott, R; Laidlaw, J; Seizinger, B; Kley, N			PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes	ONCOGENE			English	Article						p53; GADD genes; 6q21; genotoxic stress; serum regulation	NON-HODGKINS-LYMPHOMA; BREAST-CANCER-CELLS; WILD-TYPE P53; MDM-2 ONCOGENE; CHROMOSOME 6Q; PROTEIN; APOPTOSIS; INDUCTION; REGIONS; HETEROZYGOSITY	Exposure of mammalian cells to hypoxia, radiation and certain chemotherapeutic agents promotes cell cycle arrest and/or apoptosis. Activation of p53 responsive genes is believed to play an important role in mediating such responses. In this study we identified a novel gene, PA26, which maps to chromosome 6q21 and encodes at least three transcript isoforms, of which two are differentially induced by genotoxic stress (UV, gamma-irradiation and cytotoxic drugs) in a p53-dependent manner. A functional p53-responsive element was identified in the second intron of the PA26 gene, in consistence with a mechanism of transcriptional induction of the PA26 gene by p53. No clues to its functions were revealed by sequence analysis, although pronounced negative regulation by serum factors argues fbr a potential role of PA26 in growth regulation. Immunological analysis suggests that PA26 protein(s) is localized to the cell nucleus. Our results suggest that the PA26 gene is a novel p53 target gene with properties common to the GADD family of growth arrest and DNA damage-inducible stress-response genes, and, thus, a potential novel regulator of cellular growth.	Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08543 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08543 USA; Genome Therapeut Corp, Waltham, MA 02154 USA	Bristol-Myers Squibb; Pfizer; Princeton University	Kley, N (corresponding author), Univ Texas, SW Med Ctr, Dept Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BROWN JL, 1994, CANCER GENET CYTOGEN, V72, P116, DOI 10.1016/0165-4608(94)90126-0; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen JD, 1996, MOL CELL BIOL, V16, P2445; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JACKMAN J, 1994, CANCER RES, V54, P5656; JOHANSSON B, 1995, BLOOD, V86, P3905, DOI 10.1182/blood.V86.10.3905.bloodjournal86103905; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Madden SL, 1996, CANCER RES, V56, P5384; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morelli C, 1997, CANCER RES, V57, P4153; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OFFIT K, 1993, BLOOD, V82, P2157; OKAMOTO K, 1994, EMBO J, V13, P4813; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RAO PH, 1994, CANCER GENET CYTOGEN, V77, P60, DOI 10.1016/0165-4608(94)90150-3; ROAULT JP, 1996, NAT GENT, V14, P482; Sambrook J., 2002, MOL CLONING LAB MANU; Sandhu AK, 1996, ONCOGENE, V12, P247; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	51	177	186	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					127	137		10.1038/sj.onc.1202274	http://dx.doi.org/10.1038/sj.onc.1202274			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926927				2022-12-25	WOS:000078166000014
J	Berfield, JL; Wang, LJC; Reith, MEA				Berfield, JL; Wang, LJC; Reith, MEA			Which form of dopamine is the substrate for the human dopamine transporter: The cationic or the uncharged species?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT STRIATAL MEMBRANES; IDENTICAL CONDITIONS; IONIC REQUIREMENTS; COCAINE BINDING; NEURONAL UPTAKE; NA+ CHANNELS; GBR 12783; CATECHOLAMINES; DEPENDENCE; INHIBITION	The question of which is the active form of dopamine for the neuronal dopamine transporter is addressed in HEK-293 cells expressing the human dopamine transporter. The K-m value for [H-3]dopamine uptake fell sharply when the pH was increased from 6.0 to 7.4 and then changed less between pH 7.4 and 8.2. The K-I for dopamine in inhibiting the cocaine analog [H-3]2 beta-carbomethoxy-3 beta- (4-fluorophenyl) tropane binding displayed an identical pH dependence, suggesting that changes in uptake result from changes in dopamine recognition. Dopamine can exist in the anionic, neutral, cationic, or zwitterionic form, and the contribution of each form was calculated. The contribution of the anion is extremely low (less than or equal to 0.1%), and its pH dependence differs radically from that of dopamine binding, The increase in the neutral form upon raising the pH can model the results only when the pK(a1) (equilibrium neutral-charged) is set to a much lower value (6.8) than reported for dopamine in solution (8.86). The sum of cationic and zwitterionic dopamine concentrations remained constant over the entire pH range studied. These forms are the likely transporter substrates with pH-dependent changes occurring in their interaction with the transporter. The binding of dopamine, a hydroxylated phenylethylamine derivative, displays the same pH dependence as guanethidine, a heptamethyleniminoethylguanidine derivative fully protonated under our conditions. An ionizable residue in the transporter could be involved that does not interact with or impact the binding of bretylium, a quaternary ammonium phenylmethylamine derivative that is always positively charged and shows only a minor reduction in K-I upon increasing pH.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria	Reith, MEA (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.		Reith, Maarten E./AAD-2303-2019; Reith, Maarten E/A-4601-2008	Reith, Maarten E./0000-0002-1900-842X; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008379] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 08379] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMEJDKICHAB N, 1992, J NEUROCHEM, V59, P1795, DOI 10.1111/j.1471-4159.1992.tb11012.x; AMEJDKICHAB N, 1992, J NEUROCHEM, V58, P793, DOI 10.1111/j.1471-4159.1992.tb09327.x; ANDERSEN PH, 1987, J NEUROCHEM, V48, P1887, DOI 10.1111/j.1471-4159.1987.tb05752.x; ARMSTRONG J, 1976, BRIT J PHARMACOL, V57, P501, DOI 10.1111/j.1476-5381.1976.tb10377.x; BONNET JJ, 1988, J NEUROCHEM, V50, P759, DOI 10.1111/j.1471-4159.1988.tb02979.x; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLINS GGS, 1968, BRIT J PHARMACOL, V34, P514, DOI 10.1111/j.1476-5381.1968.tb08480.x; COURTNEY KR, 1987, HDB EXPT PHARM, V81, P53; DARCHEN F, 1988, BIOCHEM PHARMACOL, V37, P4381, DOI 10.1016/0006-2952(88)90621-1; EDVARDSEN O, 1994, MOL BRAIN RES, V27, P265, DOI 10.1016/0169-328X(94)90009-4; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; Eshleman AJ, 1997, J NEUROCHEM, V69, P1459; GARRIS PA, 1994, J NEUROSCI, V14, P6084; GU H, 1994, J BIOL CHEM, V269, P7124; Gu H. H., 1996, Society for Neuroscience Abstracts, V22, P370; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; HILLE B, 1984, IONIC CHANNELS EXCIT, P287; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KAMAL LA, 1983, J PHARMACOL EXP THER, V227, P446; KAMMERER RC, 1979, J MED CHEM, V22, P352, DOI 10.1021/jm00190a004; Katzung B. G., 1995, BASIC CLIN PHARM, P1; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KRUEGER BK, 1990, J NEUROCHEM, V55, P260, DOI 10.1111/j.1471-4159.1990.tb08847.x; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; LEWIS GP, 1954, BRIT J PHARM CHEMOTH, V9, P488, DOI 10.1111/j.1476-5381.1954.tb00866.x; MACK F, 1979, N-S ARCH PHARMACOL, V310, P1, DOI 10.1007/BF00499868; Masuda M, 1998, AM J PHYSIOL-GASTR L, V274, pG29, DOI 10.1152/ajpgi.1998.274.1.G29; MAXWELL RA, 1976, MECHANISM NEURONAL E, P95; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; MEIERGERD SM, 1994, J NEUROCHEM, V62, P998; MOLINOFF PB, 1971, BIOCHEM J, V123, pP32, DOI 10.1042/bj1230032P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NETTLETON J, 1990, BIOPHYS J, V58, P95, DOI 10.1016/S0006-3495(90)82356-0; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; Reith MEA, 1996, N-S ARCH PHARMACOL, V354, P295; REITH MEA, 1992, EUR J PHARM-MOLEC PH, V227, P417, DOI 10.1016/0922-4106(92)90160-W; RUDNICK G, 1989, J BIOL CHEM, V264, P14865; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sachs C, 1970, Acta Physiol Scand Suppl, V341, P1; SILINSKY EM, 1974, BRIT J PHARMACOL, V51, P367, DOI 10.1111/j.1476-5381.1974.tb10671.x; Sonders MS, 1997, J NEUROSCI, V17, P960; STEINMETZ PR, 1973, NEW ENGL J MED, V289, P141; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; WALL SC, 1993, MOL PHARMACOL, V43, P264; Wu Q, 1997, J NEUROCHEM, V69, P1106; XU C, 1995, BIOCHEM PHARMACOL, V49, P339, DOI 10.1016/0006-2952(94)00485-5; Xu C, 1996, J PHARMACOL EXP THER, V278, P1340; ZIMANYI I, 1989, N-S ARCH PHARMACOL, V340, P626, DOI 10.1007/BF00717737; [No title captured]	51	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4876	4882		10.1074/jbc.274.8.4876	http://dx.doi.org/10.1074/jbc.274.8.4876			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988729	hybrid			2022-12-25	WOS:000078698200054
J	Fox, BA; Yee, VC; Pedersen, LC; Le Trong, I; Bishop', PD; Stenkamp, RE; Teller, DC				Fox, BA; Yee, VC; Pedersen, LC; Le Trong, I; Bishop', PD; Stenkamp, RE; Teller, DC			Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by X-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-XIII; PROTEIN STRUCTURES; CROSS-LINKING; CRYSTAL-STRUCTURE; HUMAN-PLACENTA; TRANSGLUTAMINASE; FIBRIN; THROMBIN; DEFICIENCY; ACTIVATION	The presence or absence of calcium determines the activation, activity, oligomerization, and stability of blood coagulation factor XIII. To explore these observed effects, we have determined the x-ray crystal structure of recombinant factor XIII A(2) in the presence of calcium, strontium, and ytterbium. The main calcium binding site within each monomer involves the main chain oxygen atom of Ala-457, and also the side chains from residues Asn-436, Asp-438, Glu-485, and Glu-490. Calcium and strontium bind in the same location, while ytterbium binds several angstroms removed. A novel ytterbium binding site is also found at the dimer two-fold axis, near residues Asp-270 and Glu-272, and this site may be related to the reported inhibition by lanthanide metals (Achyuthan, K. E., Mary, A., and Greenberg, C. S. (1989) Biochem. J. 257, 331-338). The overall structure of ion-bound factor XIII is very similar to the previously determined crystal structures of factor XIII zymogen, likely due to the constraints of this monoclinic crystal form. We have merged the three independent sets of water molecules in the structures to determine which water molecules are conserved and possibly structurally significant.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Zymogenet Inc, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Washington; University of Washington Seattle; Zymogenet Inc.	Teller, DC (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	teller@u.washington.edu	Pedersen, Lars/C-6173-2019	Pedersen, Lars/0000-0002-4488-4077; Fox, Brian/0000-0001-6620-3853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050355] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50355] Funding Source: Medline; NIGMS NIH HHS [GM08268] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1989, BIOCHEM J, V257, P331, DOI 10.1042/bj2570331; ANWAR R, 1995, BRIT J HAEMATOL, V91, P728, DOI 10.1111/j.1365-2141.1995.tb05376.x; Aslam S, 1997, BRIT J HAEMATOL, V98, P346, DOI 10.1046/j.1365-2141.1997.2263043.x; Bardos H, 1996, BLOOD COAGUL FIBRIN, V7, P536; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BOARD PG, 1993, BLOOD REV, V7, P229, DOI 10.1016/0268-960X(93)90010-2; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; Carmassi Franco, 1996, Seminars in Thrombosis and Hemostasis, V22, P489, DOI 10.1055/s-2007-999049; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; COOKE RD, 1974, BIOCHEM J, V141, P79, DOI 10.1042/bj1410079; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3774, DOI 10.1021/bi00715a024; DEBACKERROYER C, 1992, INT J BIOCHEM, V24, P637, DOI 10.1016/0020-711X(92)90340-7; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; GREENBERG CS, 1987, BLOOD, V69, P867; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HORNYAK TJ, 1991, BIOCHEMISTRY-US, V30, P6175, DOI 10.1021/bi00239a014; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; IKURA K, 1995, ARCH BIOCHEM BIOPHYS, V318, P307, DOI 10.1006/abbi.1995.1234; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KITCHENS CS, 1979, MEDICINE, V58, P413, DOI 10.1097/00005792-197911000-00002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI TS, 1994, J BIOL CHEM, V269, P24596; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis KB, 1997, BIOCHEMISTRY-US, V36, P995, DOI 10.1021/bi961636z; MARY A, 1988, ARCH BIOCHEM BIOPHYS, V261, P112, DOI 10.1016/0003-9861(88)90110-5; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mikkola Hanna, 1996, Seminars in Thrombosis and Hemostasis, V22, P393, DOI 10.1055/s-2007-999037; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; MUSZBEK L, 1995, THROMB HAEMOSTASIS, V73, P702; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PEDERSEN LC, 1994, XRAY STRUCTURE DETER, V13; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIPPL MJ, 1993, J COMPUT AID MOL DES, V7, P473, DOI 10.1007/BF02337562; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; Takahashi N, 1998, BLOOD, V91, P2830, DOI 10.1182/blood.V91.8.2830.2830_2830_2838; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; Weiss MS, 1998, FEBS LETT, V423, P291, DOI 10.1016/S0014-5793(98)00098-2; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	49	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4917	4923		10.1074/jbc.274.8.4917	http://dx.doi.org/10.1074/jbc.274.8.4917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988734	hybrid			2022-12-25	WOS:000078698200059
J	Peng, Y; Du, KY; Ramirez, S; Diamond, RH; Taub, R				Peng, Y; Du, KY; Ramirez, S; Diamond, RH; Taub, R			Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1 - Egr-1 activation is an early event in liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; RAPID ACTIVATION; PRIMARY RESPONSE; CELL-GROWTH; 3T3 CELLS; KAPPA-B; EXPRESSION; BINDING; DIFFERENTIATION; COMPLEX	The cellular signals that initiate cell growth are incompletely understood. Insight could be provided by understanding the signals regulating the transcriptional induction of immediate-early genes which occurs within minutes of the growth stimulus. The expression of the PRL-1 gene, which encodes a unique nuclear protein-tyrosine phosphatase, is rapidly induced in regenerating liver and mitogen-treated cells. Transcription of the PRL-1 gene increased in the rat liver remnant within a few minutes after partial hepatectomy and largely explained the increase in steady-state PRL-1 mRNA in the first few hours posthepatectomy. Egr-1 (early growth response factor) specifically bound a region of the proximal PRL-1 promoter P1 (-99), Egr-1 binding activity was more rapidly induced in regenerating liver than mitogen-treated H35 and NIH 3T3 cells, remained elevated through 4 h posthepatectomy, and appeared to be dependent not only on new Egr-1 protein synthesis but on post-translational regulation of Egr-1. Egr-1 efficiently transactivated a PRL-1 promoter re porter construct containing an intact not mutant Egr-1 site, and the Egr-1 site largely accounted for PRL-1 gene up-regulation in response to mitogen stimulation. These data predict that Egr-1 activation is an early event in liver regeneration and mitogen-activated cells that provides a regulatory stimulus for a subset of immediate early genes.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Taub, R (corresponding author), Univ Penn, Sch Med, Dept Genet, 705A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK 49629, DK 44237, DK49210] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044237, P01DK049210, R01DK049629] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO X, 1994, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHRISTY BA, 1989, P NATL ACAD SCI USA, V85, P7857; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIAMOND HR, 1996, AM J PHYSIOL, V271, pG121; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Higgins GM, 1931, ARCH PATHOL, V12, P186; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kren BT, 1996, AM J PHYSIOL-GASTR L, V270, pG763, DOI 10.1152/ajpgi.1996.270.5.G763; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V86, P8737; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LIM RW, 1987, ONCOGENE, V1, P263; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Moore DD, 1995, GLOB MOB SURV; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Peng Y, 1998, J BIOL CHEM, V273, P17286, DOI 10.1074/jbc.273.27.17286; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Suh E, 1996, MOL CELL BIOL, V16, P619; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; TAUB R, 1996, PROTEIN PHOSPHORYLAT, P59; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381	39	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4513	4520		10.1074/jbc.274.8.4513	http://dx.doi.org/10.1074/jbc.274.8.4513			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988683	hybrid			2022-12-25	WOS:000078698200008
J	Kanamaru, K; Wang, RC; Su, WP; Crawford, NM				Kanamaru, K; Wang, RC; Su, WP; Crawford, NM			Ser-534 in the hinge 1 region of Arabidopsis nitrate reductase is conditionally required for binding of 14-3-3 proteins and in vitro inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANTS; POSTTRANSLATIONAL REGULATION; FUNCTIONAL DOMAINS; 14-3-3-PROTEIN; LEAVES; LIGHT; PHOSPHORYLATION; PATHWAYS; SEQUENCE; THALIANA	14-3-3 proteins bind to the hinge 1 region of nitrate reductase (NR) and inhibit its activity. To determine which residues of NR are required for 14-3-3-inhibitory interactions, wild-type and mutant forms of Arabidopsis NR were examined in the yeast two-hybrid system and in vitro inhibition assays, NR fragments with or without hinge 1 were introduced into yeast with one of seven Arabidopsis 14-3-3 isoforms (called GF14s), NR fragments (residues 1-562 or 487-562) containing hinge 1 interacted with all GF-14s tested; an NR fragment (residues 1-487) lacking hinge 1 did not. GF14 binding to NR fragments was dependent on Ser-534, since Asp or Ala substitutions at this site blocked the interaction. Revertants with second site substitutions restoring interaction between GF14 omega and the Ala- or Asp-substituted NR fragments were identified. One isolate had a Lys to Glu substitution at position 531, which is in hinge 1, and six isolates had lie to Leu or Phe substitutions at 561 in the heme binding region. Double mutant forms of holo-NR (S534D plus K531E, I561F, or I561L) were constructed and found to be partially inhibited by protein extracts from Arabidopsis containing 14-3-3 proteins. Wild-type NR is phosphorylated and inhibited by these extracts, but S534D single mutant forms are not. These results show that inhibitory NR/14-3-3 interactions are dependent on Ser-534 but only in the context of the wild-type sequence, since substitutions at second sites render 14-3-3 binding and in vitro NR inhibition independent of Ser-534.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Crawford, NM (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ncrawford@ucsd.edu	Kanamaru, Kengo/GNP-8187-2022	Kanamaru, Kengo/0000-0002-6844-0841	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Athwal GS, 1998, PLANT PHYSIOL, V118, P1041, DOI 10.1104/pp.118.3.1041; BACHMANN M, 1995, PLANT PHYSIOL, V108, P1083, DOI 10.1104/pp.108.3.1083; Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; Campbell WH, 1996, PLANT PHYSIOL, V111, P355, DOI 10.1104/pp.111.2.355; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Ferl RJ, 1996, ANNU REV PLANT PHYS, V47, P49, DOI 10.1146/annurev.arplant.47.1.49; HOFF T, 1994, PLANT CELL ENVIRON, V17, P489, DOI 10.1111/j.1365-3040.1994.tb00145.x; Huber SC, 1996, TRENDS PLANT SCI, V1, P432, DOI 10.1016/S1360-1385(96)10046-7; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; KAISER WM, 1994, PLANT PHYSIOL, V106, P817, DOI 10.1104/pp.106.3.817; Kohalmi SE, 1998, PLANT MOL BIOL MAN M, P1; Lillo C, 1997, PLANT PHYSIOL, V114, P1377, DOI 10.1104/pp.114.4.1377; LILLO C, 1994, PHYSIOL PLANTARUM, V90, P616, DOI 10.1111/j.1399-3054.1994.tb08822.x; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NUSSAUME L, 1995, PLANT CELL, V7, P611, DOI 10.1105/tpc.7.5.611; PELSY F, 1992, ADV GENET, V30, P1, DOI 10.1016/S0065-2660(08)60317-X; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SU W, 1997, PLANT PHYSIOL, V155, P1135; Su WP, 1996, PLANT CELL, V8, P519, DOI 10.1105/tpc.8.3.519; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; Wu K, 1997, PLANT PHYSIOL, V114, P1421, DOI 10.1104/pp.114.4.1421; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4160	4165		10.1074/jbc.274.7.4160	http://dx.doi.org/10.1074/jbc.274.7.4160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933611	hybrid			2022-12-25	WOS:000078575500035
J	Milewski, S; Kuszczak, D; Jedrzejczak, R; Smith, RJ; Brown, AJP; Gooday, GW				Milewski, S; Kuszczak, D; Jedrzejczak, R; Smith, RJ; Brown, AJP; Gooday, GW			Oligomeric structure and regulation of Candida albicans glucosamine-6-phosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-TUBE FORMATION; ESCHERICHIA-COLI; BLASTOCLADIELLA-EMERSONII; FRUCTOSE 6-PHOSPHATE; CHITIN SYNTHESIS; YEAST; AMIDOTRANSFERASE; BINDING; GENE; EFFICIENCY	Candida albicans glucosamine-6-phosphate (GlcN-6-P) synthase was purified to apparent homogeneity with 52% yield from recombinant yeast YRSC-65 cells efficiently overexpressing the GFA1 gene. The pure enzyme exhibited K-m(Gln) = 1.56 mM and Km(Fru-6-P) = 1.41 mM and catalyzed GlcN-6-P formation with k(cat) = 1150 min(-1). The isoelectric point of 4.6 +/- 0.05 was estimated from isoelectric chromatofocusing, Gel filtration, native polyacrylamide gel electrophoresis, subunit cross-linking, and SDS-polyacrylamide gel electrophoresis showed that the native enzyme was a homotetramer of 79.5-kDa subunits, with an apparent molecular mass of 330-340 kDa, Results of chemical modification of the enzyme by group-specific reagents established an essential role of a cysteinyl residue at the glutamine-binding site and histidyl, lysyl, arginyl, and tyrosyl moieties at the Flu-6-P-binding site. GlcN-6-P synthase in crude extract was effectively inhibited by UDP-GlcNAc (IC50 = 0.67 mM). Purification of the enzyme markedly decreased the sensitivity to the inhibitor, but this could be restored by addition of another effector, glucose g-phosphate. Binding of UDP-GlcNAc to the pure enzyme in the presence of Glc-6-P showed strong negative cooperativity, with RN = 0.54, whereas in the absence of this sugar phosphate no cooperative effect was observed. Pure enzyme was a substrate for cAMP-dependent protein kinase, the action of which led to the substantial increase of GlcN-6-P synthase activity, correlated with an extent of protein phosphorylation, The maximal level of activity was observed for the enzyme molecules containing 1.21 +/- 0.08 mol of phosphate/mol of GlcN-6-P synthase, Monitoring of GlcN-6-P synthase activity and its sensitivity to UDP-GlcNAc during yeast --> mycelia transformation of C, albicans cells, under in situ conditions, revealed a marked increase of the former and a substantial fall of the latter.	Gdansk Tech Univ, Dept Pharmaceut Technol & Biochem, PL-80952 Gdansk, Poland; Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	Fahrenheit Universities; Gdansk University of Technology; University of Aberdeen	Milewski, S (corresponding author), Gdansk Tech Univ, Dept Pharmaceut Technol & Biochem, 11-12 Narutowicza St, PL-80952 Gdansk, Poland.	milewski@altis.chem.pg.gda.pl	Brown, Alistair J.P./B-6627-2014	Milewski, Slawomir/0000-0003-2616-4495				BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BADETDENISOT MA, 1993, B SOC CHIM FR, V130, P249; BadetDenisot MA, 1997, ARCH BIOCHEM BIOPHYS, V337, P129, DOI 10.1006/abbi.1996.9741; BADETDENISOT MA, 1992, ARCH BIOCHEM BIOPHYS, V292, P475, DOI 10.1016/0003-9861(92)90018-R; Bollag DM, 1992, PROTEIN METHODS, P143; BORGIA PT, 1992, J BACTERIOL, V174, P384, DOI 10.1128/jb.174.2.384-389.1992; BOROWSI E, 1988, 8 INT S FUT TRENDS C, P158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTAWAY FW, 1968, J GEN MICROBIOL, V51, P367, DOI 10.1099/00221287-51-3-367; CHIEW YY, 1980, ARCH MICROBIOL, V125, P97, DOI 10.1007/BF00403204; CIGAN AM, 1987, GENE, V59, P1; DUTKAMALEN S, 1988, BIOCHIMIE, V70, P287, DOI 10.1016/0300-9084(88)90073-9; EGIDY G, 1990, CELL BIOL INT REP, V14, P59, DOI 10.1016/0309-1651(90)90071-6; ELLIS DB, 1972, BIOCHIM BIOPHYS ACTA, V267, P105; ENDO A, 1970, J BACTERIOL, V103, P588, DOI 10.1128/JB.103.3.588-594.1970; ETCHEBEHERE LC, 1989, ARCH BIOCHEM BIOPHYS, V272, P301, DOI 10.1016/0003-9861(89)90223-3; ETCHEBEHERE LC, 1993, J BACTERIOL, V175, P5022, DOI 10.1128/JB.175.16.5022-5027.1993; FRISA PS, 1982, P NATL ACAD SCI-BIOL, V79, P6289, DOI 10.1073/pnas.79.20.6289; Gadd G.M., 1995, GROWING FUNGUS, P183; GOLINELLIPIMPANEAU B, 1989, J AM CHEM SOC, V111, P3029, DOI 10.1021/ja00190a042; GOLINELLIPIMPANEAU B, 1991, EUR J BIOCHEM, V201, P175, DOI 10.1111/j.1432-1033.1991.tb16271.x; GOODAY GW, 1990, BIOCH CELL WALLS MEM, P61; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HOLCENBERG JS, 1985, METHOD ENZYMOL, V113, P257; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; KENIG M, 1976, J GEN MICROBIOL, V94, P46, DOI 10.1099/00221287-94-1-46; KIKUCHI H, 1976, BIOCHIM BIOPHYS ACTA, V422, P241, DOI 10.1016/0005-2744(76)90023-1; KINGSMAN SM, 1990, METHOD ENZYMOL, V185, P329; KITZ R, 1962, J BIOL CHEM, V237, P3245; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUERMANN V, 1991, CURR GENET, V20, P1, DOI 10.1007/BF00312757; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P72; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; MEI B, 1989, J BIOL CHEM, V264, P16613; MILEWSKI S, 1993, CHITIN ENZYMOLOGY, P167; MIYAGI T, 1974, BIOCHIM BIOPHYS ACTA, V358, P144, DOI 10.1016/0005-2744(74)90266-6; MIYAGI T, 1971, BIOCHIM BIOPHYS ACTA, V250, P51, DOI 10.1016/0005-2744(71)90119-7; Niimi M, 1996, FUNGAL GENET BIOL, V20, P79, DOI 10.1006/fgbi.1996.0013; OBMOLOVA G, 1994, J MOL BIOL, V242, P703, DOI 10.1006/jmbi.1994.1619; PAVETO C, 1991, CELL BIOL INT REP, V15, P169, DOI 10.1016/0309-1651(91)90108-U; RIODAN JF, 1977, SCIENCE, V195, P884; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ G, 1976, METHOD ENZYMOL, V56, P40; Smith RJ, 1996, J BACTERIOL, V178, P2320, DOI 10.1128/jb.178.8.2320-2327.1996; SOLL DR, 1987, BIOESSAYS, V5, P5; STEIN MW, 1968, METHOD ENZYMOL, V1, P299; THEVELEIN JM, 1987, J GEN MICROBIOL, V133, P2197; VESSAL U, 1972, PLANT PHYSIOL, V49, P977; Vidotto V, 1996, MYCOPATHOLOGIA, V133, P143, DOI 10.1007/BF02373021; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WINTERBU.PJ, 1971, BIOCHEM J, V121, P701, DOI 10.1042/bj1210701; ZALKIN H, 1985, METHOD ENZYMOL, V113, P278; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; Zelada A, 1998, EUR J BIOCHEM, V252, P245, DOI 10.1046/j.1432-1327.1998.2520245.x	57	50	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4000	4008		10.1074/jbc.274.7.4000	http://dx.doi.org/10.1074/jbc.274.7.4000			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933591	hybrid			2022-12-25	WOS:000078575500015
J	Posey, SC; Bierer, BE				Posey, SC; Bierer, BE			Actin stabilization by jasplakinolide enhances apoptosis induced by cytokine deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTERLEUKIN 1-BETA-CONVERTING ENZYME; CELL ANTIGEN-RECEPTOR; T-LYMPHOCYTES; F-ACTIN; CARCINOMA-CELLS; ZETA-CHAIN; IN-VITRO; DNASE-I; ACTIVATION	Participation of the actin cytoskeleton in the transduction of proliferative signals has been established through the use of compounds that disrupt the cytoskeleton, To address the possibility that actin also participates in the transduction of an apoptotic signal, we have studied the response of the murine interleukin 2 (IL-2)-dependent T cell line CTLL-20 to treatment with the actin-binding compound jasplakinolide upon IL-2 deprivation, Like phalloidin, jasplakinolide stabilizes F-actin and promotes actin polymerization, Treatment of CTLL-20 cells with jasplakinolide, in the presence or absence of recombinant human IL-2, altered actin morphology as assessed by confocal fluorescence microscopy. Jasplakinolide was not toxic to CTLL-20 cells, nor was apoptosis induced in the presence of exogenous recombinant human IL-2, However, actin stabilization at the time of IL-2 deprivation enhanced apoptosis by changing the time at which CTLL-20 cells committed to the apoptotic pathway. This effect of jasplakinolide correlated with its ability to stabilize polymerized actin, as treatment with a synthetic analog of jasplakinolide with a greatly reduced ability to bind actin, jasplakinolide B, did not enhance apoptosis. The enhancement occurred upstream of the induction of caspase-3-like activity and could be inhibited by the overexpression of the anti-apoptotic protein Bcl-x(L), These data suggest that the actin cytoskeleton plays an active role in modulating lymphocyte apoptosis induced by cytokine deprivation.	NHLBI, NIH, Bethesda, MD 20892 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Med Sci, Comm Immunol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Bierer, BE (corresponding author), NHLBI, NIH, Bldg 10,Rm 5D49,10 Ctr Dr, Bethesda, MD 20892 USA.			Bierer, Barbara/0000-0001-6448-8170	NCI NIH HHS [T32 CA09141] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, T32 GM07753-19] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Allen RT, 1997, J PHARMACOL TOX MET, V37, P215, DOI 10.1016/S1056-8719(97)00033-6; Boise LH, 1996, J IMMUNOL METHODS, V191, P143, DOI 10.1016/0022-1759(96)00011-7; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BROCK MA, 1993, J CELL PHYSIOL, V157, P367, DOI 10.1002/jcp.1041570221; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; Chen ZH, 1996, CANCER RES, V56, P5224; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dipietrantonio A, 1996, BIOCHEM BIOPH RES CO, V224, P837, DOI 10.1006/bbrc.1996.1109; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; FABIAN I, 1995, EXP HEMATOL, V23, P583; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FURUKAWA K, 1995, EXP NEUROL, V133, P153, DOI 10.1006/exnr.1995.1018; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Gomez J, 1997, J IMMUNOL, V158, P1516; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; Guenal I, 1997, J CELL SCI, V110, P489; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; Holzinger A, 1997, CELL MOTIL CYTOSKEL, V38, P365, DOI 10.1002/(SICI)1097-0169(1997)38:4<365::AID-CM6>3.0.CO;2-2; Karino A, 1996, FEBS LETT, V398, P317, DOI 10.1016/S0014-5793(96)01266-5; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lee E, 1998, CELL MOTIL CYTOSKEL, V39, P122, DOI 10.1002/(SICI)1097-0169(1998)39:2<122::AID-CM3>3.0.CO;2-8; Levee MG, 1996, AM J PHYSIOL-CELL PH, V271, pC1981, DOI 10.1152/ajpcell.1996.271.6.C1981; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; LU Y, 1994, J IMMUNOL, V153, P1495; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Matthews JB, 1997, AM J PHYSIOL-CELL PH, V272, pC254, DOI 10.1152/ajpcell.1997.272.1.C254; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PHATAK PD, 1994, J CELL PHYSIOL, V159, P365, DOI 10.1002/jcp.1041590220; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SCOTT VR, 1988, ANTIMICROB AGENTS CH, V32, P1154, DOI 10.1128/AAC.32.8.1154; SENDEROWICZ AMJ, 1995, J NATL CANCER I, V87, P46, DOI 10.1093/jnci/87.1.46; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Takeuchi H, 1998, CANCER CHEMOTH PHARM, V42, P491, DOI 10.1007/s002800050850; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WALPOLE RE, 1989, PROBABILITY STAT ENG, P257; Wyllie A H, 1980, Int Rev Cytol, V68, P251	52	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4259	4265		10.1074/jbc.274.7.4259	http://dx.doi.org/10.1074/jbc.274.7.4259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933626	hybrid			2022-12-25	WOS:000078575500050
J	Rausch, O; Marshall, CJ				Rausch, O; Marshall, CJ			Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; RAS-DEPENDENT ACTIVATION; MAP KINASE; C-JUN; FACTOR-RECEPTOR; INTERLEUKIN-3 STIMULATION; TRANSDUCTION PATHWAYS; SUBSTRATE-SPECIFICITY; MAMMALIAN-CELLS; GROWTH-FACTOR	Hemopoietic cytokines such as interleukin-3 and granulocyte colony-stimulating Factor (G-CSF) are po; tent activators of hemopoietic cell growth and strongly induce activation of extracellular signal-regulated kinase (ERR), c-Jun-N-terminal kinase (JNK), and p38 mitogen-activated protein (MAP) kinases, However, the role of these kinases is unclear. Using specific chemical inhibitors for MEK and p38, we demonstrate here that both ERK and p38 pathways are critically involved in the transduction of a proliferative signal and cooperate in Gr-CSF-induced cell proliferation. We show that, like ERK and JNK activation, activation of p38 and its downstream substrate MAP kinase-activated protein kinase 2 by interleukin-3 or G-CSF requires Pas activation, We demonstrate that two distinct cytoplasmic regions of the G-CSF receptor are involved in activation of the p38 pathway: a region within the 100 membrane-proximal amino acids is sufficient to induce low levels of p38 and MAP kinase-activated protein kinase 2 activation, whereas the membrane-distal phosphorylation site Tyr(763) mediates strong activation of these kinases, The levels of p38 activation correlate closely with those of Pas activation by G-CSF, suggesting that the degree of Pas activation is a critical determinant for the extent of p38 activation by hemopoietic cytokines.	Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Rausch, O (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; deKoning JP, 1996, BLOOD, V87, P132; DEMETRI GD, 1991, BLOOD, V78, P2791; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL NH, 1995, LEUKEMIA LYMPHOMA, V16, P223, DOI 10.3109/10428199509049761; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x	65	99	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4096	4105		10.1074/jbc.274.7.4096	http://dx.doi.org/10.1074/jbc.274.7.4096			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933603	hybrid			2022-12-25	WOS:000078575500027
J	Haapasalo, A; Saarelainen, T; Moshnyakov, M; Arumae, U; Kiema, TR; Saarma, M; Wong, G; Castren, E				Haapasalo, A; Saarelainen, T; Moshnyakov, M; Arumae, U; Kiema, TR; Saarma, M; Wong, G; Castren, E			Expression of the naturally occurring truncated trkB neurotrophin receptor induces outgrowth of filopodia and processes in neuroblastoma cells	ONCOGENE			English	Article						trkB; BDNF; NT-4; N2a; neuroblastoma	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; DIFFERENTIAL RESPONSE; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; RETINOIC ACID; BRAIN; ENCODES	We have investigated the effects of the truncated trkB receptor isoform T1 (trkB.T1) by transient transfection into mouse N2a neuroblastoma cells. We observed that expression of trkB.T1 leads to a striking change in cell morphology characterized by outgrowth of filopodia and processes. A similar morphological response was also observed in SH-SY5Y human neuroblastoma cells and NIH3T3 fibroblasts transfected with trkB.T1. N2a cells lack endogenous expression of trkB isoforms, but express barely detectable amounts of its ligands, brainderived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). The morphological change was ligand-independent, since addition of exogenous BDNF or NT-4 or blockade of endogenous trkB ligands did not influence this response. Filopodia and process outgrowth was significantly suppressed when full-length trkB.TK + was cotransfected together with trkS.T1 and this inhibitory effect was blocked by tyrosine kinase inhibitor K252a. Transfection of trkB.T1 deletion mutants showed that the morphological response is dependent on the extracellular, but not the intracellular domain of the receptor. Our results suggest a novel ligand-independent role for truncated trkB in the regulation of cellular morphology.	Univ Kuopio, AI Vir Tanen Inst, Mol Pharmacol Lab, Kuopio 70100, Finland; Univ Kuopio, Dept Psychiat, Kuopio 70100, Finland; Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland	University of Eastern Finland; University of Eastern Finland; University of Helsinki	Castren, E (corresponding author), Univ Kuopio, AI Vir Tanen Inst, Mol Pharmacol Lab, POB 1627, Kuopio 70100, Finland.		Castrén, Eero/A-4618-2010; Arumäe, Urmas/E-8290-2016	Arumäe, Urmas/0000-0003-3658-6464; Haapasalo, Annakaisa/0000-0003-0959-2957; Castren, Eero/0000-0002-1402-2791				ARMANINI MP, 1995, EUR J NEUROSCI, V7, P1403, DOI 10.1111/j.1460-9568.1995.tb01132.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARIK S, 1995, METH NEUROSCI, V26, P309; Baxter GT, 1997, J NEUROSCI, V17, P2683; BECK KD, 1993, J NEUROSCI, V13, P4001; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIFFO S, 1995, DEVELOPMENT, V121, P2461; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Eide FF, 1996, J NEUROSCI, V16, P3123; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P968; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lucarelli E, 1994, Prog Clin Biol Res, V385, P185; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Ninkina N, 1996, EMBO J, V15, P6385, DOI 10.1002/j.1460-2075.1996.tb01029.x; PASTOR R, 1994, ONCOGENE, V9, P1081; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; Rubio N, 1997, EUR J NEUROSCI, V9, P1847, DOI 10.1111/j.1460-9568.1997.tb00751.x; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TANNAHILL L, 1995, EUR J NEUROSCI, V7, P1424, DOI 10.1111/j.1460-9568.1995.tb01136.x; TOMA JG, 1997, NEURAL NOTES, V111, P20; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VAUGHAN VC, 1979, NELSON TXB PEDIAT, P1444; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Zhou H, 1997, J NEUROSCI RES, V49, P281, DOI 10.1002/(SICI)1097-4547(19970801)49:3<281::AID-JNR3>3.0.CO;2-8	54	57	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1285	1296		10.1038/sj.onc.1202401	http://dx.doi.org/10.1038/sj.onc.1202401			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022810				2022-12-25	WOS:000078510900004
J	Ivaska, J; Kapyla, J; Pentikainen, O; Hoffren, AR; Hermonen, J; Huttunen, P; Johnson, MS; Heino, J				Ivaska, J; Kapyla, J; Pentikainen, O; Hoffren, AR; Hermonen, J; Huttunen, P; Johnson, MS; Heino, J			A peptide inhibiting the collagen binding function of integrin alpha I-2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; CRYSTAL-STRUCTURE; PLATELET-AGGREGATION; LIGAND-BINDING; CELL-ADHESION; A-DOMAIN; RECEPTOR; FIBRONECTIN; PROTEIN; VLA-2	Integrin alpha(2) subunit forms in the complex with the beta(1) subunit a cell surface receptor binding extracellular matrix molecules, such as collagens and laminin-1. It is a receptor for echovirus-1, as well. Ligands are recognized by the special "inserted" domain (I domain) in the integrin alpha(2) subunit, Venom from a pit viper, Bothrops jararaca, has been shown to inhibit the interaction of platelet alpha(2)beta(1) integrin with collagen because of the action of a disintegrin/metalloproteinase named jararhagin. The finding that crude B. jararaca venom could prevent the binding of human recombinant r alpha(2)I domain to type I collagen led us to study jararhagin further. Synthetic peptides representing hydrophilic and charged sequences of jararhagin, including the RSECD sequence replacing the well known RGD motif in the disintegrin-like domain, were synthesized. Although the disintegrin-like domain derived peptides failed to inhibit r alpha(2)I domain binding to collagen, a basic peptide from the metalloproteinase domain proved to be functional. In an in vitro assay, the cyclic peptide, CTRKKHDNAQC, was shown to bind strongly to human recombinant alpha(2)I domain and to prevent its binding to type I and IV collagens and to laminin-1, Mutational analysis indicated that a sequence of three amino acids, arginine-lysine-lysine (RKK), is essential for r alpha(2)I domain binding, whereas the mutation of the other amino acids in the peptide had little if any effect on its binding function. Importantly, the peptide was functional only in the cyclic conformation and its affinity was strictly dependent on the size of the cysteine-constrained loop. Furthermore, the peptide could not bind to alpha(2)I domain in the absence of Mg2+, suggesting that the conformation of the I domain was critical, as well. Cells could attach to the peptide only if they expressed alpha(2)beta(1) integrin, and the attachment was inhibited by anti-integrin antibodies.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Virol, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, Turku, Finland; Abo Akad Univ, Dept Biochem, Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland	University of Turku; University of Turku; University of Turku; University of Turku; Abo Akademi University; Finland National Institute for Health & Welfare; University of Jyvaskyla	Heino, J (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.		Pentikäinen, Olli T/E-1980-2012	Pentikäinen, Olli T/0000-0001-7188-4016; Ivaska, Johanna/0000-0002-6295-6556; Kapyla, Jarmo/0000-0003-3036-713X				ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kamiguti AS, 1997, J BIOL CHEM, V272, P32599, DOI 10.1074/jbc.272.51.32599; KERN A, 1994, J BIOL CHEM, V269, P22811; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1990, J BIOL CHEM, V265, P4020; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PISCHEL KD, 1987, J IMMUNOL, V138, P226; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Zhou Q, 1996, BIOCHEM BIOPH RES CO, V219, P720, DOI 10.1006/bbrc.1996.0301	39	80	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3513	3521		10.1074/jbc.274.6.3513	http://dx.doi.org/10.1074/jbc.274.6.3513			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920897	hybrid			2022-12-25	WOS:000078428200037
J	Mitchell, BA; Paulsen, IT; Brown, MH; Skurray, RA				Mitchell, BA; Paulsen, IT; Brown, MH; Skurray, RA			Bioenergetics of the staphylococcal multidrug export protein QacA - Identification of distinct binding sites for monovalent and divalent cations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; P-GLYCOPROTEIN; SUBSTRATE-SPECIFICITY; DISINFECTANT RESISTANCE; PSEUDOMONAS-AERUGINOSA; BACILLUS-SUBTILIS; PLASMA-MEMBRANE; DRUG EXTRUSION; EFFLUX PUMP; TRANSPORTER	The multidrug efflux pump QacA from Staphylococcus aureus confers resistance to an extensive range of structurally dissimilar compounds. Fluorimetric analyses demonstrated that QacA confers resistance to the divalent cation 4',6-diamidino-2-phenylindole, utilizing a proton motive force-dependent efflux mechanism previously demonstrated for QacA-mediated resistance to the monovalent cation ethidium, Both the ionophores nigericin and valinomycin inhibited QacA-mediated export of ethidium, indicating an electrogenic drug/nH(+) (n greater than or equal to 2) antiport mechanism. The kinetic parameters, K-m and V-max, were determined for QacA-mediated export of four fluorescent substrates, 4',6-diamidino-2-phenylindole, 3',3'-dipropyloxacarbocyanine, ethidium, and pyronin Y, Competition studies showed that QacA-mediated ethidium export is competitively inhibited by monovalent cations, e.g. benzalkonium, and non-competitively inhibited by divalent cations, e.g. propamidine, which suggests that monovalent and divalent cations bind at distinct sites on the QacA protein. The quaternary ammonium salt, 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene, was used as a membrane specific fluorescence probe and demonstrated that the amount of substrate entering the inner leaflet was significantly reduced in QacA-containing strains, supporting the notion that the substrate is extruded directly from the membrane.	Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia	University of Sydney	Skurray, RA (corresponding author), Univ Sydney, Sch Biol Sci, Macleay Bldg A12, Sydney, NSW 2006, Australia.		Paulsen, Ian T/K-3832-2012; Brown, Melissa/V-2296-2017	Paulsen, Ian T/0000-0001-9015-9418; Brown, Melissa/0000-0001-6461-7550				AHMED M, 1993, J BIOL CHEM, V268, P11086; Bolhuis H, 1996, J BIOL CHEM, V271, P24123, DOI 10.1074/jbc.271.39.24123; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; CRISSMAN HA, 1985, SCIENCE, V228, P1321, DOI 10.1126/science.2408339; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; Garrigos M, 1997, EUR J BIOCHEM, V244, P664, DOI 10.1111/j.1432-1033.1997.00664.x; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Haughland R.P., 1996, HDB FLUORESCENT PROB; Hohn B, 1979, Methods Enzymol, V68, P299; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KAPUSCINSKI J, 1979, NUCLEIC ACIDS RES, V6, P3519, DOI 10.1093/nar/6.11.3519; LAMBERT B, 1984, BIOCHEMISTRY-US, V23, P166, DOI 10.1021/bi00296a027; LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259; Liu J, 1996, J BACTERIOL, V178, P3791, DOI 10.1128/jb.178.13.3791-3795.1996; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Mitchell BA, 1998, ANTIMICROB AGENTS CH, V42, P475; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; Ocaktan A, 1997, J BIOL CHEM, V272, P21964, DOI 10.1074/jbc.272.35.21964; PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995; Paulsen IT, 1998, J BACTERIOL, V180, P3477, DOI 10.1128/JB.180.13.3477-3479.1998; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; Ritchie RJ, 1996, BIOCHEM EDUC, V24, P196, DOI 10.1016/S0307-4412(96)00089-1; ROEPE PD, 1994, TRENDS PHARMACOL SCI, V15, P445, DOI 10.1016/0165-6147(94)90056-6; Schuldiner S, 1997, J EXP BIOL, V200, P335; Shapiro AB, 1998, EUR J BIOCHEM, V254, P181, DOI 10.1046/j.1432-1327.1998.2540181.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; TENNENT JM, 1989, J GEN MICROBIOL, V135, P1; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; WIGLER PW, 1993, BIOCHIM BIOPHYS ACTA, V1154, P173, DOI 10.1016/0304-4157(93)90010-L; Yelin R, 1995, FEBS LETT, V377, P201, DOI 10.1016/0014-5793(95)01346-6; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	41	94	98	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3541	3548		10.1074/jbc.274.6.3541	http://dx.doi.org/10.1074/jbc.274.6.3541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920900	hybrid			2022-12-25	WOS:000078428200040
J	Petit, MC; Benkirane, N; Guichard, G; Du, APC; Marraud, M; Cung, MT; Briand, JP; Muller, S				Petit, MC; Benkirane, N; Guichard, G; Du, APC; Marraud, M; Cung, MT; Briand, JP; Muller, S			Solution structure of a retro-inverso peptide analogue mimicking the foot-and-mouth disease virus major antigenic site - Structural basis for its antigenic cross-reactivity with the parent peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SYNTHETIC PEPTIDES; PEPTIDOMIMETICS; ANTIBODIES; CONFORMATIONS; SPECTROSCOPY; IMMUNOGENICITY; RECOGNIZE; PROTEIN; PROGRAM	The antigenic activity of a 19-mer peptide corresponding to the major antigenic region of foot-and-mouth disease virus and its retro-enantiomeric analogue was found to be completely abolished when they were tested in a biosensor system in trifluoroethanol, This suggests that the folding pattern, which is alpha-helix in trifluoroethanol (confirmed by CD measurement), does not correspond to the biologically relevant conformation(s) recognized by antibodies. The NMR structures of both peptides were thus determined in aqueous solution. These studies showed that the two peptides exhibit similar folding features, particularly in their C termini, This may explain in part the cross-reactive properties of the two peptides in aqueous solution. However, the retro-inverso analogue appears to be more rigid than the parent peptide and contains five atypical beta-turns. This feature may explain why retro-inverso foot-and-mouth disease virus peptides are often better recognized than the parent peptide by anti-virion antibodies.	Inst Biol Mol & Cellulaire, CNRS, UPR 9021, F-67000 Strasbourg, France; INPL, ENSIC, Lab Chim Phys Macromol, CNRS,UMR 7568, F-54000 Nancy, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Muller, S (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9021, 15 Rue Descartes, F-67000 Strasbourg, France.		Muller, Sylviane/J-5319-2014; Benkirane-Jessel, Nadia/H-6438-2016; GUICHARD, Gilles/I-3858-2016	GUICHARD, Gilles/0000-0002-2584-7502; Averlant-Petit, Marie-Christine/0000-0001-8956-1231; Benkirane-Jessel, Nadia/0000-0003-3059-3559				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ALDER AJ, 1973, METHOD ENZYMOL, V27, P675; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; Billeter M, 1995, J BIOMOL NMR, V5, P1; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; Briand JP, 1997, P NATL ACAD SCI USA, V94, P12545, DOI 10.1073/pnas.94.23.12545; BROWN F, 1995, SEMIN VIROL, V6, P243, DOI 10.1006/smvy.1995.0029; Carver JA, 1997, BIOPOLYMERS, V41, P569, DOI 10.1002/(SICI)1097-0282(19970415)41:5<569::AID-BIP8>3.0.CO;2-K; dePratGay G, 1997, ARCH BIOCHEM BIOPHYS, V341, P360, DOI 10.1006/abbi.1997.9982; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Higgins KA, 1997, J PEPT RES, V50, P421; HUTCHINSON GE, 1996, PROTEIN SCI, V5, P212; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANG E, 1994, J IMMUNOL METHODS, V170, P103, DOI 10.1016/0022-1759(94)90250-X; McDonnell JM, 1997, J AM CHEM SOC, V119, P5321, DOI 10.1021/ja963884o; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MULLER S, 1995, PEPTIDE RES, V8, P138; MUTTER M, 1992, J AM CHEM SOC, V114, P1463, DOI 10.1021/ja00030a049; Pegna M, 1996, J PEPT SCI, V2, P91, DOI 10.1002/psc.50; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SILIGARDI G, 1991, EUR J BIOCHEM, V199, P545, DOI 10.1111/j.1432-1033.1991.tb16153.x; SILIGARDI G, 1991, INT J PEPT PROT RES, V38, P519; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	27	38	42	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3686	3692		10.1074/jbc.274.6.3686	http://dx.doi.org/10.1074/jbc.274.6.3686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920919	hybrid			2022-12-25	WOS:000078428200059
J	Suzuki, A; Tsutomi, Y; Miura, M; Akahane, K				Suzuki, A; Tsutomi, Y; Miura, M; Akahane, K			Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21	ONCOGENE			English	Article						Fas; caspase 3; p21; ILP; serineproteinase	CELL-DEATH; ICE/CED-3 PROTEASE; INVOLVEMENT; INHIBITION; ACTIVATION; RECEPTOR; COMPLEX; KINASE; PCNA; CDK	The death mediator caspase acts as the dominant regulator during cell death induction. The CPP32 subfamily, including caspase 3 (CPP32/Yama/Apopain), is essential for the cell death signaling, We recently reported that activation of caspase 3 is regulated by complex formation with p21 or ILP, In the present study, we investigated the binding domain with p21 and ILP to further characterize the caspase 3 inactivation machinery, Our results show that caspase 3 contains p21 binding domain in the N-terminus and ILP binding domain in the active site, Further, the caspase 3 binding domain in p21 was independent of the Cdk- or PCNA-binding domain. We also found caspase 3 protection by p21 from the p3-site cleavage serineproteinase contributes to the suppression machinery. Here, we propose the caspase 3 inactivation system by p21 and ILP as new essential system in the regulation of cell death.	Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan; Osaka Univ, Sch Med, Dept Neuroanat, Ctr Biomed Res, Suita, Osaka 565, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Lab 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan	Daiichi Sankyo Company Limited; Osaka University; Daiichi Sankyo Company Limited	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, 16-13 Kitakasai 1 Chome, Tokyo 134, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hasegawa J, 1996, CANCER RES, V56, P1713; LI Y, 1994, ONCOGENE, V9, P2261; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MIYAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P852, DOI 10.1016/0006-291X(92)91705-U; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; SUZUKI A, 1998, IN PRESS ONCOGENE; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	23	133	137	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1239	1244		10.1038/sj.onc.1202409	http://dx.doi.org/10.1038/sj.onc.1202409			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022130				2022-12-25	WOS:000078510700013
J	Yin, XY; Grove, L; Datta, NS; Long, MW; Prochownik, EV				Yin, XY; Grove, L; Datta, NS; Long, MW; Prochownik, EV			C-myc overexpression and p53 loss cooperate to promote genomic instability	ONCOGENE			English	Article						c-myc; p53; tetraploidy; genomic instability	HUMAN-PAPILLOMAVIRUS TYPE-16; LYMPHOMA CELL-LINES; WILD-TYPE P53; NORMAL HUMAN FIBROBLASTS; DNA-DAMAGE; S-PHASE; GROWTH-FACTOR; CYCLE CONTROL; EMBRYO FIBROBLASTS; EPITHELIAL-CELLS	p53 monitors genomic integrity at the G1 and G2/M cell cycle checkpoints. Cells lacking p53 may show gene amplification as well as the polyploidy or aneuploidy typical of many tumors. The pathways through which this develops, however, are not well defined. We demonstrate here that the combination of p53 inactivation and c-myc overexpression in diploid cells markedly accelerates the spontaneous development of tetraploidy. This is not seen with either N-myc or L-myc. Tetraploidy is accompanied by significantly higher levels of cyclin B and its associated cdc2 kinase activity, Mitotic spindle poisons accelerate the appearance of tetraploidy in cells either lacking functional p53 or overexpressing c-myc whereas the combination is additive. Restoration of p53 function in cells overexpressing c-myc causing rapid apoptosis, indicating that cells yet to become tetraploid have nonetheless suffered irreversible genomic and/or mitotic spindle damage. In the face of normal p53 function, such damage would either be repaired or trigger apoptotis. We propose that loss of p53 and overexpression of c-myc permits the emergence and survival of cells with increasingly severe damage and the eventual development of tetraploidy.	Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Michigan, Med Ctr, Dept Pediat, Hematol Oncol Sect, Ann Arbor, MI 48109 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA.				NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BALLERINI P, 1993, BLOOD, V81, P166; BANKS L, 1990, ONCOGENE, V5, P833; Barbosa MS, 1996, CRIT REV ONCOGENESIS, V7, P1; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; Berns EMJJ, 1996, GENE CHROMOSOME CANC, V16, P170, DOI 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLANDINO G, 1995, ONCOGENE, V10, P731; BLOUNT PL, 1994, CANCER RES, V54, P2292; CARDER P, 1993, ONCOGENE, V8, P1397; Coursen JD, 1997, EXP CELL RES, V235, P245, DOI 10.1006/excr.1997.3670; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1991, CANCER RES, V51, P6304; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA A, 1993, ONCOGENE, V8, P1093; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nesbit CE, 1998, BLOOD, V92, P1003; NESBIT CE, 1998, IN PRESS CELL GROWTH; OCONNOR PM, 1993, CANCER RES, V53, P4776; Oda D, 1996, CARCINOGENESIS, V17, P2003, DOI 10.1093/carcin/17.9.2003; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; PURDIE CA, 1994, ONCOGENE, V9, P603; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WIMAN KG, 1991, ONCOGENE, V6, P1633; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	66	115	121	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1177	1184		10.1038/sj.onc.1202410	http://dx.doi.org/10.1038/sj.onc.1202410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022123				2022-12-25	WOS:000078510700006
J	Saito, Y; Hayashi, T; Tanaka, A; Watanabe, Y; Suzuki, M; Saito, E; Takahashi, K				Saito, Y; Hayashi, T; Tanaka, A; Watanabe, Y; Suzuki, M; Saito, E; Takahashi, K			Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase - Isolation and enzymatic characterization of human selenoprotein P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; SELENIUM-DEFICIENT RATS; IODOTHYRONINE DEIODINASE; MONOCLONAL-ANTIBODIES; LIPID-PEROXIDATION; MESSENGER-RNA; PURIFICATION; CDNA; CLONING; SELENOCYSTEINE	Selenoprotein P is an extracellular protein containing presumably 10 selenocysteines that are encoded by the UGA stop codon in the open reading frame of the mRNA. The function of selenoprotein P is currently unknown, although several indirect lines of evidence suggest that selenoprotein P is a free radical scavenger. We first developed a conventional procedure to isolate selenoprotein P from human plasma. Next, we investigated the reactivities of selenoprotein P against various hydroperoxides in the presence of glutathione, Although selenoprotein P reduces neither hydrogen peroxide nor tertiary butyl hydroperoxide, it does reduce phospholipid hydroperoxide such as 1-palmitoyl-2-(13-hydroperoxy-cis-9,trans-11-octadecadienoyl)-3-phosphatidylcholine hydroperoxide. Kinetic analysis demonstrated a tert-uni ping-pong mechanism, similar to those described for classical glutathione peroxidase and phospholipid hydroperoxide glutathione peroxidase. Not only glutathione, but also dithiothreitol, mercaptoethanol, cysteine, and homocysteine, were effective as reducing substances, as in the case of phospholipid hydroperoxide glutathione peroxidase. These results show that selenoprotein P functions as a phospholipid hydroperoxide glutathione peroxidase in extracellular fluids.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Hyg Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Inst Publ Hlth, Kita Ku, Sapporo, Hokkaido 060, Japan; Nihon Univ, Sch Med, Dept Internal Med 2, Itabashi Ku, Tokyo 173, Japan	Hokkaido University; Nihon University	Takahashi, K (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Hyg Chem, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	kazu@pharm.hokudai.ac.jp	Saito, Yoshiro/H-4597-2019	Saito, Yoshiro/0000-0002-0559-5889				AKASAKA M, 1990, NUCLEIC ACIDS RES, V18, P4619, DOI 10.1093/nar/18.15.4619; AKESSON B, 1994, BBA-PROTEIN STRUCT M, V1204, P243, DOI 10.1016/0167-4838(94)90014-0; BAO YP, 1995, ANAL BIOCHEM, V224, P395, DOI 10.1006/abio.1995.1056; BAYFIELD RF, 1985, ANAL BIOCHEM, V144, P569, DOI 10.1016/0003-2697(85)90155-1; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BURK RF, 1995, LAB INVEST, V72, P723; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; BURK RF, 1995, HEPATOLOGY, V21, P561; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; EBERLE B, 1993, J TRACE ELEM ELECT H, V7, P217; Esworthy RS, 1998, BBA-GEN SUBJECTS, V1381, P213, DOI 10.1016/S0304-4165(98)00032-4; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; GIROTTI AW, 1985, ARCH BIOCHEM BIOPHYS, V236, P238, DOI 10.1016/0003-9861(85)90623-X; HATFIELD D, 1993, TRENDS GENET, V9, P69, DOI 10.1016/0168-9525(93)90215-4; HICKS M, 1979, ANAL BIOCHEM, V99, P249, DOI 10.1016/S0003-2697(79)80003-2; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; KISHIRO Y, 1995, CELL STRUCT FUNCT, V20, P151, DOI 10.1247/csf.20.151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MOTCHNIK PA, 1989, BIOCHIM BIOPHYS ACTA, V993, P27, DOI 10.1016/0304-4165(89)90138-4; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; READ R, 1990, J BIOL CHEM, V265, P17899; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1994, BBA-PROTEIN STRUCT M, V1208, P211, DOI 10.1016/0167-4838(94)90106-6; Sado Y, 1996, CELL BIOL INT, V20, P7, DOI 10.1006/cbir.1996.0003; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; TAKAHASHI K, 1986, BLOOD, V68, P640; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1983, J CHROMATOGR, V270, P301, DOI 10.1016/S0021-9673(01)96376-9; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; YAMAMOTO Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P541, DOI 10.1006/abbi.1993.1458; YANG JG, 1987, J BIOL CHEM, V262, P13372	42	212	219	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2866	2871		10.1074/jbc.274.5.2866	http://dx.doi.org/10.1074/jbc.274.5.2866			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915822	hybrid			2022-12-25	WOS:000078319500040
J	Yan, DH; Wen, Y; Spohn, B; Choubey, D; Gutterman, JU; Hung, MC				Yan, DH; Wen, Y; Spohn, B; Choubey, D; Gutterman, JU; Hung, MC			Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202	ONCOGENE			English	Article						p202; interferon-inducible protein; prostate cancer; PC-3; growth retardation; anchorage-independent growth	TUMOR-NECROSIS-FACTOR; CARCINOMA; TRANSCRIPTION; INHIBITION; EXPRESSION; ALPHA; LINES; GENE; DIFFERENTIATION; INTERLEUKIN-2	Interferons (IFNs) can exert cytostatic and immunomodulatory effects on carcinoma cells. In particular, growth inhibition of human prostate carcinoma by IFNs has been demonstrated both in vitro and in vivo. p202 is a 52 kd nuclear phosphoprotein known to be induced by IFNs. In this report, we showed that the expression of p202 was associated with an anti-proliferative effect on human prostate cancer cells. More importantly, cells that expressed p202 showed reduced ability to grow in soft-agar, indicating a loss of transformation phenotype. Our data suggest that p202 is a growth inhibitor gene in prostate cancer cells and its expression may also suppress transformation phenotype of prostate cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Choubey, Divaker/A-4771-2008	Hung, Mien-Chie/0000-0003-4317-4740; 	NATIONAL CANCER INSTITUTE [R29CA069031, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58880, CA69031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALKWILL FR, 1989, LANCET, V1, P1060; CARRENO V, 1987, LANCET, V2, P1086; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 1996, BIOCHEM BIOPH RES CO, V221, P396, DOI 10.1006/bbrc.1996.0607; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; FIDLER IJ, 1987, CANCER RES, V47, P2020; FIGLIN RA, 1993, SEMIN ONCOL, V20, P11; FRAKER DL, 1994, MELANOMA RES, V4, P27; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KAIGHN ME, 1979, INVEST UROL, V17, P16; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Min W, 1996, MOL CELL BIOL, V16, P359; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SEN GC, 1992, J BIOL CHEM, V267, P5017; SICA G, 1989, UROL RES, V17, P111; Sokoloff MH, 1996, CANCER-AM CANCER SOC, V77, P1862; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; VANMOORSELAAR RJA, 1991, PROSTATE, V18, P331, DOI 10.1002/pros.2990180407; vonEschenbach A, 1997, CA-CANCER J CLIN, V47, P261, DOI 10.3322/canjclin.47.5.261; YU DH, 1993, CANCER RES, V53, P891	30	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					807	811		10.1038/sj.onc.1202369	http://dx.doi.org/10.1038/sj.onc.1202369			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989832				2022-12-25	WOS:000078394400027
J	Adnane, J; Shao, ZH; Robbins, PD				Adnane, J; Shao, ZH; Robbins, PD			Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription	ONCOGENE			English	Article						cyclin D1; Sp1; Rb; TAF(II)250	CDK-ACTIVATING KINASE; RETINOBLASTOMA PROTEIN; G1 CYCLINS; DIFFERENTIAL REGULATION; GROWTH SUPPRESSION; ESTROGEN-RECEPTOR; CELL-LINE; GENE; BINDING; E2F	We have previously shown that Sp1-mediated transcription is stimulated by Rb and repressed by cyclin D1. The stimulation of Sp1 transcriptional activity by Rb iis conferred, in part, through a direct interaction with the TBP-associated factor TAF(II)250. Here we investigated the mechanism(s) through which cyclin D1 represses Sp1. We examined the ability of cyclin D1 to regulate transcription mediated by Gal4-Sp1 fusion proteins, which contain the Gal4 DNA-binding domain and Spl trans-activation domain(s). The domain of Spl sufficient to confer repression by cyclin D1 was mapped to a region important for interaction with TAF(II)110. We further demonstrate that TAF(II)250-cyclin D1 complexes can be immunoprecipitated from mammalian and baculovirus-infected insect cells and that recombinant GST-TAF(II)250 (amino acids 1-434) associates with cyclin D1 in vitro. Moreover, the overexpression of Rb or CDK4 reduced the level of TAF(II)250-cyclin D1 complex. The amino terminus of cyclin D1 (amino acids 1-100) was sufficient for association with TAF(II)250 and for repressing Spl-mediated transcription. Taken together, the results suggest that cyclin D1 may regulate transcription by interacting directly or indirectly with TAF(II)250.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Robbins, PD (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CROSS F, 1995, TRENDS GENET, V11, P209, DOI 10.1016/S0168-9525(00)89047-2; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAYASHIDA T, 1994, GENE, V141, P267; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SIEGERT J, 1998, UNPUB MOL CELL BIOL; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					239	247		10.1038/sj.onc.1202297	http://dx.doi.org/10.1038/sj.onc.1202297			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926939	Bronze			2022-12-25	WOS:000078166000026
J	Chen, YC; Freund, R; Listerud, M; Wang, Z; Talmage, DA				Chen, YC; Freund, R; Listerud, M; Wang, Z; Talmage, DA			Retinoic acid inhibits transformation by preventing phosphatidylinositol 3-kinase dependent activation of the c-fos promoter	ONCOGENE			English	Article						vitamin A; retinoic acid; Jun kinase; polyoma virus	MIDDLE-T-ANTIGEN; JUN TRANSCRIPTIONAL ACTIVITY; JNK/SAPK SIGNALING PATHWAY; SERUM RESPONSE ELEMENT; POLYOMA-VIRUS MUTANT; SIZED TUMOR-ANTIGEN; PROTEIN-KINASE-C; PP70 S6 KINASE; TYROSINE PHOSPHORYLATION; RAT FIBROBLASTS	Retinoic acid inhibits transformation of cells by polyoma virus middle T oncoprotein. Inhibition of transformation results from a retinoic acid-dependent failure of cells to fully express the c-fos proto-oncogene. Retinoic acid prevents transactivation of the c-fos promoter by disrupting signaling between tyrosine kinases at the plasma membrane and trans-acting factors at the c-fos promoter. We used complementary genetic, biochemical and molecular approaches to demonstrate that: (1) phosphatidylinositol 3-kinase signaling is the principle mechanism of polyoma virus middle T oncoprotein activation of c-fos expression; (2) middle T/phosphatidylinositol 3-kinase transactivation of the c-fos promoter and transformation of cells requires activation of both the small GTP-binding protein Rac and Jun N-terminal kinase; (3) retinoic acid inhibits activation of Jun N- terminal kinase, thereby preventing c-fos transactivation and transformation; and (4) middle T activation of c-fos transcription requires both the serum response element and the promoter proximal cyclic AMP response element. These studies identify a novel target through which retinoids prevent oncogenic transformation.	Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Columbia University; University System of Maryland; University of Maryland Baltimore	Talmage, DA (corresponding author), Columbia Univ, Inst Human Nutr, New York, NY 10032 USA.			Talmage, David/0000-0003-4627-3007	NCI NIH HHS [CA63111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTO AS, 1908, CELL, V92, P475; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Crespo P, 1996, ONCOGENE, V13, P455; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franklin CC, 1995, ONCOGENE, V11, P2365; FREUND R, 1992, AM J PATHOL, V141, P1409; FREUND R, 1992, VIROLOGY, V191, P716, DOI 10.1016/0042-6822(92)90247-M; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Khuri FR, 1996, CELL GROWTH DIFFER, V7, P595; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; Mangelsdorf David J., 1994, P319; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Soprano DR, 1996, ONCOGENE, V12, P577; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1994, ONCOGENE, V9, P3557; TALMAGE DA, 1992, ONCOGENE, V7, P1837; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Xu X, 1996, ONCOGENE, V13, P135; Yi XD, 1997, J VIROL, V71, P6279, DOI 10.1128/JVI.71.9.6279-6286.1997; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	68	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					139	148		10.1038/sj.onc.1202272	http://dx.doi.org/10.1038/sj.onc.1202272			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926928				2022-12-25	WOS:000078166000015
J	Chen, JK; Wang, DW; Falck, JR; Capdevila, J; Harris, RC				Chen, JK; Wang, DW; Falck, JR; Capdevila, J; Harris, RC			Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatrienoic acid functions as an intracellular second messenger in response to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EPOXYEICOSATRIENOIC ACIDS; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; SMOOTH-MUSCLE; RAT-KIDNEY; CELLS; METABOLITES; CASCADE	A common feature of most isolated cell systems is low or undetectable levels of bioactive cytochrome P450. We therefore developed stable transfectants of the renal epithelial cell line, LLCPKc14, that expressed an active regio- and enantioselective arachidonic acid (AA) epoxygenase, Site-specific mutagenesis was used to convert bacterial P450 BM-3 into an active regio- and stereoselective 14S,15R-epoxygenase (F87V BM-3). In clones expressing F87V BM-3 (F87V BM-3 cells), exogenous AA induced significant 14S,15R-epoxyeicosatrienoic acid (EET) production (241.82 ng/10(8) cells, >97% of total EETs), whereas no detectable EETs were seen in cells transfected with vector alone. In F87V BM-3 cells, AA stimulated [H-3]thymidine incorporation and increased cell proliferation, which was blocked by the tyrosine kinase inhibitor, genistein, by the phosphatidylinositol 3 (PI-3) kinase inhibitors, wortmannin and LY294002, and by the mitogen-activated protein kinase kinase inhibitor, PD98059. AA also induced tyrosine phosphorylation of extracellular signal-regulated kinase (ERK) and PI-3 kinase that was inhibited by the cytochrome P450 BM-3 inhibitor, 17-ODYA. Epidermal growth factor (EGF) increased EET production in F87V BM-3 cells, which was completely abolished by pretreatment with either 17-ODYA or the phospholipase A(2) (PLA(2)) inhibitor, quinacrine, Compared with vector-transfected cells, F87 BM-3 transfected cells demonstrated marked increases in both the extent and sensitivity of DNA synthesis in response to EGF. These changes occurred in the absence of significant differences in EGF receptor expression. As seen with exogenous AA, EGF increased ERK tyrosine phosphorylation to a significantly greater extent in F87V BM-3 cells than in vector-transfected cells. Furthermore, in these control cells, neither 17-ODYA nor quinacrine inhibited EGF-induced ERK tyrosine phosphorylation. On the other hand, in F87V BM-3 cells, both inhibitors reduced ERK tyrosine phosphorylation to levels indistinguishable from that seen in cells transfected with vector alone. These studies provide the first unequivocal evidence for a role for the AA epoxygenase pathway and endogenous EET synthesis in EGF-mediated signaling and mitogenesis and provide compelling evidence for the PL2-AA-EET pathway as an important intracellular-signaling pathway in cells expressing high levels of cytochrome P450 epoxygenase.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Univ Texas SW, Dept Biochem, Dallas, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, S 3322,MCN, Nashville, TN 37232 USA.	Ray.Harris@mcmail.vanderbilt.edu		Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; BAKER RR, 1990, CLIN BIOCHEM, V23, P455; BURNS KD, 1995, AM J PHYSIOL-CELL PH, V269, pC831, DOI 10.1152/ajpcell.1995.269.4.C831; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DIMARZO V, 1995, PROSTAG LEUKOTR ESS, V53, P239, DOI 10.1016/0952-3278(95)90123-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; Li PL, 1997, CIRC RES, V80, P877; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; Makita K, 1996, FASEB J, V10, P1456, DOI 10.1096/fasebj.10.13.8940291; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Needleman P, 1997, J RHEUMATOL, V24, P6; Quilley J, 1997, BIOCHEM PHARMACOL, V54, P1059, DOI 10.1016/S0006-2952(97)00039-7; RIBEIRO CMP, 1994, AM J PHYSIOL, V266, pF497, DOI 10.1152/ajprenal.1994.266.3.F497; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Straub SG, 1996, J BIOL CHEM, V271, P1660, DOI 10.1074/jbc.271.3.1660; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; Vane JR, 1997, SEMIN ARTHRITIS RHEU, V26, P2, DOI 10.1016/S0049-0172(97)80046-7; VANROLLINS M, 1995, BBA-LIPID LIPID MET, V1256, P263, DOI 10.1016/0005-2760(95)00029-C; WONG PYK, 1993, J LIPID MEDIATOR, V6, P199; Wong PYK, 1997, J LIPID MEDIAT CELL, V16, P155, DOI 10.1016/S0929-7855(97)00005-9	36	97	105	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4764	4769		10.1074/jbc.274.8.4764	http://dx.doi.org/10.1074/jbc.274.8.4764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988714	hybrid			2022-12-25	WOS:000078698200039
J	Choi, JY; Martin, CE				Choi, JY; Martin, CE			The Saccharomyces cerevisiae FAT1 gene encodes an acyl-CoA synthetase that is required for maintenance of very long chain fatty acid levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ADRENOLEUKODYSTROPHY GENE; TRANSPORT PROTEIN; OLE1 GENE; RAT-LIVER; ACTIVATION; ELONGATION; EXPRESSION; BINDING; CLONING; IDENTIFICATION	The Saccharomyces cerevisiae FAT1 gene appears to encode an acyl-CoA synthetase that is involved in the regulation of very long chain (C-20-C-26) fatty acids. Fat1p, has homology to a rat peroxisomal very long chain fatty acyl-CoA synthetase, Very long chain acyl-CoA synthetase activity is reduced in strains containing a disrupted FAT1 gene and is increased when FAT1 is expressed in insect cells under control of a baculovirus promoter. Fat1p accounts for approximately 90% of the C-24-specific acyl-CoA synthetase activity in glucose-grown cells and approximately 66% of the total activity in cells grown under peroxisomal induction conditions. Localization of functional Fat1p:green fluorescent protein gene fusions and subcellular fractionation of C-24 acyl-CoA synthetase activities indicate that the majority of Fat1p is located in internal cellular locations. Disruption of the FAT1 gene results in the accumulation of very long chain fatty acids in the sphingolipid and phospholipid fractions. This includes a 10-fold increase in C-24 acids and a 6-fold increase in C-22 acids. These abnormal accumulations are further increased by perturbation of very long chain fatty acid synthesis. Overexpression of Elo2p, a component of the fatty acid elongation system, in fat1 Delta cells causes C-20-C-26 levels to rise to approximately 20% of the total fatty acids. These data suggest that Fat1p is involved in the maintenance of cellular very long chain fatty acid levels, apparently by facilitating beta-oxidation of excess intermediate length (C-20-C-24) species. Although fat1 Delta cells were reported to grow poorly in oleic acid-supplemented medium when fatty acid synthase activity is inactivated by cerulenin, fatty acid import is not significantly affected in cells containing disrupted alleles of FAT1 and FAS2 (a subunit of fatty acid synthase). These results suggest that the primary cause of the growth-defective phenotype is a failure to metabolize the incorporated fatty acid rather than a defect in fatty acid transport. Certain fatty acyl-CoA synthetase activities, however, do appear to be essential for bulk fatty acid transport in Saccharomyces, Simultaneous disruption of FAA1 and FAA4, which encode long chain (C-14-C-18) fatty acyl-CoA synthetases, effectively blocks the import of long chain saturated and unsaturated fatty acids.	Rutgers State Univ, Nelson Biol Labs, Bur Biol Res, Dept Cell Biol & Neurosci,Div Life Sci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Martin, CE (corresponding author), Rutgers State Univ, Nelson Biol Labs, Bur Biol Res, Dept Cell Biol & Neurosci,Div Life Sci, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi JY, 1996, J BIOL CHEM, V271, P3581; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; DOUAR AM, 1994, BIOMED PHARMACOTHER, V48, P215, DOI 10.1016/0753-3322(94)90135-X; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KALISH JE, 1995, BIOCHEM BIOPH RES CO, V206, P335, DOI 10.1006/bbrc.1995.1046; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KOS W, 1995, BBA-GENE STRUCT EXPR, V1264, P79, DOI 10.1016/0167-4781(95)00127-3; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NUNN WD, 1986, J BIOL CHEM, V261, P167; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V254, P526, DOI 10.1016/0003-9861(87)90133-0; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Swartzman EE, 1996, J CELL BIOL, V132, P549, DOI 10.1083/jcb.132.4.549; THIERINGER R, 1991, MOL CELL BIOL, V11, P510, DOI 10.1128/MCB.11.1.510; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Uchida Y, 1996, J BIOCHEM, V119, P565; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WANDERS RJA, 1987, BIOCHIM BIOPHYS ACTA, V919, P21, DOI 10.1016/0005-2760(87)90213-X	32	68	76	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4671	4683		10.1074/jbc.274.8.4671	http://dx.doi.org/10.1074/jbc.274.8.4671			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988704	hybrid			2022-12-25	WOS:000078698200029
J	Herrington, J; Rui, LY; Luo, GY; Yu-Lee, LY; Carter-Su, C				Herrington, J; Rui, LY; Luo, GY; Yu-Lee, LY; Carter-Su, C			A functional DNA binding domain is required for growth hormone-induced nuclear accumulation of Stat5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; GLUCOCORTICOID RECEPTOR; GENE ACTIVATION; MAMMARY TISSUE; SH3 DOMAINS; RAT-LIVER; FACTOR-I	The mechanisms regulating the cellular distribution of STAT family transcription factors remain poorly understood. To identify regions of Stat5B required for ligand-induced nuclear accumulation, we constructed a cDNA encoding green fluorescent protein (GFP) fused to the N terminus of Stat5B and performed site-directed mutagenesis. When co-expressed with growth hormone (GH) receptor in COS-7 cells, GFP-Stat5B is tyrosylphosphorylated, forms dimers, and binds DNA in response to GH in a manner indistinguishable from untagged Stat5B. In multiple cell types, laser scanning confocal imaging of GFP-Stat5B co-expressed with GH receptor shows that GFP-Stat5B undergoes a rapid, dramatic accumulation in the nucleus upon GH stimulation. We introduced alanine substitutions in several regions of Stat5B and assayed for GH-dependent nuclear localization. Only the mutation that prevented binding to DNA ((VVVI469)-V-466) abrogated GH-stimulated nuclear localization. This mutant fusion protein is tyrosyl-phosphorylated and dimerizes in response to GH. These results suggest that either high affinity binding to DNA contributes to nuclear accumulation of Stat5B or that this region is crucial for two functions, namely accumulation of Stat5B in the nucleus and DNA binding. Thus, we have identified a mutant Stat5 defective in nuclear localization despite its ability to be tyrosyl-phosphorylated and to dimerize.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Michigan System; University of Michigan; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 6804 Med Sci 2,1301 Catherine St, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK044625, F32DK009756] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK034171, R01-DK-34171, R01-DK-44625, F32-DK-09756] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stout LE, 1997, ENDOCRINOLOGY, V138, P1592, DOI 10.1210/en.138.4.1592; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang YF, 1996, MOL CELL ENDOCRINOL, V121, P19, DOI 10.1016/0303-7207(96)03840-3; WATERS MJ, 1994, P SOC EXP BIOL MED, V206, P216; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	49	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5138	5145		10.1074/jbc.274.8.5138	http://dx.doi.org/10.1074/jbc.274.8.5138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988763	hybrid			2022-12-25	WOS:000078698200088
J	Oran, AE; Isenman, DE				Oran, AE; Isenman, DE			Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; GROWTH-HORMONE RECEPTOR; 3RD COMPONENT; BINDING-SITES; FACTOR-B; FACTOR-I; REGULATORY DOMAINS; ABOLISH BINDING; LIGAND-BINDING; CR-1	Mapping approaches employing blocking antibodies and synthetic peptides have implicated the 727-767 segment at the NH2 terminus of C3b alpha'-chain as contributing to the interactions with factor B, factor H, and CR1. Our previous mutagenesis study on the NH2-terminal acidic cluster of this segment identified residues Glu-736 and Glu-737 as contributing to the binding of C3b to factor B and CR1 but not factor H, We have now extended the charged residue mutagenic scan to cover the remainder of the segment (738-767) and have assessed the ability of the C3b-like C3(H2O) form of the mutant molecules to interact with factor H, CR1, and membrane cofactor protein (MCP) using a cofactor-dependent factor I cleavage assay as a surrogate binding assay. We have found that the negatively charged side chains of Glu-744 and Glu-747 are important for the interaction between C3(H2O) and factor H, a result in general agreement with an earlier synthetic peptide study (Fishelson, Z. (1991) Mol. Immunol. 28, 545-552) which implicated residues within the 744-754 segment in H binding. The interactions of the mutants with soluble CR1 (sCR1) revealed two classes of residues. The first are residues required for sCR1 to be an I cofactor for the first two cleavages of alpha-chain, These are all acidic residues and include the Glu-736/Glu-737 pair, Glu-747, and the Glu-754/Asp-755 pairing, The second class affects only the ability of sCR1 to be a cofactor for the third factor I cleavage and include Glu-744 and the Lys-757/Glu-758 pairing, The dominance of acidic residues in the loss-of-function mutants is striking and suggests that H and CR1 contribute basic residues to the interface. Additionally, although there is partial overlap, the contacts required for CR1 binding appear to extend over a wider portion of the 727-767 segment than is the case for factor H, Finally, none of the mutations had any effect on the interaction between soluble MCP and C3(H2O), indicating that despite its functional homology to H and CR1, MCP differs in its mode of binding to C3b/C3(H2O).	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Isenman, DE (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.	d.isenman@utoronto.ca						ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1992, DEV COMP IMMUNOL, V16, P63, DOI 10.1016/0145-305X(92)90052-E; ALSENZ J, 1990, CURR TOP MICROBIOL, V153, P235; ARNAOUT MA, 1983, IMMUNOLOGY, V48, P229; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BECHERER JD, 1992, BIOCHEMISTRY-US, V31, P1787, DOI 10.1021/bi00121a029; BECHERER JD, 1988, J BIOL CHEM, V263, P14586; BOLOTIN C, 1977, BIOCHEMISTRY-US, V16, P2008, DOI 10.1021/bi00628a039; COLE FS, 1985, J IMMUNOL, V134, P2610; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; COOPER NR, 1968, IMMUNOCHEMISTRY, V5, P155, DOI 10.1016/0019-2791(68)90100-6; COYNE KE, 1992, J IMMUNOL, V149, P2906; DIEFENBACH RJ, 1995, J IMMUNOL, V154, P2303; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; EBANKS RO, 1992, J IMMUNOL, V148, P2803; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FARRIES TC, 1990, COMPLEMENT INFLAMMAT, V7, P30, DOI 10.1159/000463124; FARRIES TC, 1996, MOL IMMUNOL S1, V33, P58; FISHELSON Z, 1991, MOL IMMUNOL, V28, P545, DOI 10.1016/0161-5890(91)90169-K; GAITHER TA, 1987, IMMUNOLOGY, V62, P405; GANU V S, 1985, Complement, V2, P27; GARRED P, 1989, COMPLEMENT INFLAMMAT, V6, P205, DOI 10.1159/000463094; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GOTZE O, 1971, J EXP MED, V134, pS90; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KOISTINEN V, 1989, COMPLEMENT INFLAMMAT, V6, P270, DOI 10.1159/000463102; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; KUHN S, 1995, J IMMUNOL, V155, P5663; LAMBRIS JD, 1988, IMMUNOL TODAY, V9, P387, DOI 10.1016/0167-5699(88)91240-6; LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147; Lambris JD, 1996, J IMMUNOL, V156, P4821; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; MATHIAS P, 1992, P NATL ACAD SCI USA, V89, P8125, DOI 10.1073/pnas.89.17.8125; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; NAGASAWA S, 1980, J IMMUNOL, V125, P578; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; RAPP HJ, 1970, MOL BASIS COMPLEMENT, P9; ROSS GD, 1982, J IMMUNOL, V129, P2051; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; TANIGUCHISIDLE A, 1992, J BIOL CHEM, V267, P635; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; YOUNG L, 1994, PROTEIN SCI, V3, P717	57	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5120	5130		10.1074/jbc.274.8.5120	http://dx.doi.org/10.1074/jbc.274.8.5120			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988761	hybrid			2022-12-25	WOS:000078698200086
J	Van Brocklyn, JR; Tu, ZX; Edsall, LC; Schmidt, RR; Spiegel, S				Van Brocklyn, JR; Tu, ZX; Edsall, LC; Schmidt, RR; Spiegel, S			Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; SURFACE-RECEPTOR; EXTRACELLULAR ACTION; SIGNAL-TRANSDUCTION; MEMBRANE-RECEPTOR; 3T3 FIBROBLASTS; SMOOTH-MUSCLE; HIGH-AFFINITY; SPHINGOSINE-1-PHOSPHATE	Sphingosine 1-phosphate (SPP) is a lipid second messenger that also acts as a first messenger through the G protein-coupled receptor Edg-1. Here we show that SPP also binds to the related receptors H218 and Edg-3 with high affinity and specificity. SPP and sphinganine 1-phosphate bind to these receptors, whereas neither sphingosylphosphorylcholine nor lysophosphatidic acid compete with SPP for binding to either receptor. Transfection of HER293 cells with H218 or edg-3, but not edg-1, induces rounded cell morphology in the presence of serum, which contains high levels of SPP. SPP treatment of cells overexpressing H218 cultured in delipidated serum causes cell rounding. A similar but less dramatic effect was observed in cells overexpressing Edg-3 but not with Edg-1. Cell rounding was correlated with apoptotic cell death, probably as a result of loss of attachment. Nerve growth factor-induced neuritogenesis in PC12 cells was inhibited by overexpression of H218 and to a lesser extent Edg-3. SPP treatment rapidly enhanced neurite retraction in PC12 cells overexpressing Edg-1, Edg-3, or H218. Thus, H218, and possibly Edg-3, may be the cell surface receptors responsible for cell rounding and neurite retraction induced by SPP. Moreover, the identification of these two additional SPP receptors indicates that a family of highly specific receptors exists that mediate different responses to SPP.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Konstanz, Fak Chem, D-78457 Constance, Germany	Georgetown University; University of Konstanz	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 357 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.		Van Brocklyn, Jim/A-9733-2010		NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019209] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM19209-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; Edsall LC, 1997, J NEUROSCI, V17, P6952; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; Kleuser B, 1998, CANCER RES, V58, P1817; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; MacLennan AJ, 1997, NEUROSCIENCE, V79, P217, DOI 10.1016/S0306-4522(96)00601-X; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P329, DOI 10.1006/bbrc.1997.7666; Spiegel S, 1998, BIOCHEMISTRY-MOSCOW+, V63, P69; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; SPIEGEL S, 1998, ANN NY ACAD SCI, V845, P1; Tarnowski A, 1997, BIOORG MED CHEM LETT, V7, P573, DOI 10.1016/S0960-894X(97)00047-4; Tas PWL, 1998, J NEUROSCI RES, V52, P427, DOI 10.1002/(SICI)1097-4547(19980515)52:4<427::AID-JNR6>3.0.CO;2-B; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yamamura S, 1997, BIOCHEMISTRY-US, V36, P10751, DOI 10.1021/bi970926s; Yamamura S, 1996, FEBS LETT, V382, P193, DOI 10.1016/0014-5793(96)00175-5; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	51	165	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4626	4632		10.1074/jbc.274.8.4626	http://dx.doi.org/10.1074/jbc.274.8.4626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988698	hybrid			2022-12-25	WOS:000078698200023
J	Yamamoto, K; Takeshima, H; Hamada, K; Nakao, M; Kino, T; Nishi, T; Kochi, M; Kuratsu, J; Yoshimura, T; Ushio, Y				Yamamoto, K; Takeshima, H; Hamada, K; Nakao, M; Kino, T; Nishi, T; Kochi, M; Kuratsu, J; Yoshimura, T; Ushio, Y			Cloning and functional characterization of the 5 '-flanking region of the human monocyte chemoattractant protein-1 receptor (CCR2) gene - Essential role of 5 '-untranslated region in tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; GLIOMA; HIV-1; ORGANIZATION; INFILTRATION; SEQUENCE; CELLS	The human monocyte chemoattractant protein-1 receptor designated hCCR2 is an essential co-receptor in cell entry by the human immunodeficiency virus as well as a receptor for monocyte chemoattractant protein-1, a member of the family of C-C chemokines that mediate monocyte chemotaxis, To elucidate the molecular mechanisms underlying the transcriptional regulation of hCCR2, we cloned and sequenced the hCCR2 gene; it was approximately 8 kilobase pairs in length and consisted of three exons divided by two introns, In the 5'-flanking region, there were the typical mammalian promoter consensus elements, a CAAT box and a TATA box, resulting in a single transcription initiation site. In addition, we found clustered tissue-specific cis-regulatory elements such as GATA consensus sequences, Oct-1 binding sequences, and CAAT/enhancer-binding protein binding sequences, Luciferase assays with various promoter deletions and gel mobility shift assays indicated that three cis-regulatory elements located within the region from -89 to +118 are required for basal activity in THP-1 cells. One element is an octamer sequence 36-base pair upstream from the TATA box; it binds mainly to Oct-1 and is capable of increasing transcriptional activity. The other two elements, which are tandem recognition sites of the CAAT/enhancer-binding protein family, are located in the 5'-untranslated region and account for the transcriptional activation as well as the tissue specificity of hCCR2.	Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8608556, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kagoshima Univ, Sch Med, Dept Neurosurg, Kagoshima 8908520, Japan; NCI, Immunopathol Sect, Immunol Lab, NIH, Frederick, MD 21702 USA	Kumamoto University; Kumamoto University; Kagoshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Takeshima, H (corresponding author), Kumamoto Univ, Sch Med, Dept Neurosurg, 1-1-1 Honjo, Kumamoto 8608556, Japan.	m2040@kaiju.medic.kumamoto-u.ac.jp		Yoshimura, Teizo/0000-0002-3853-2075				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; AMROLIA PJ, 1995, J BIOL CHEM, V270, P12892, DOI 10.1074/jbc.270.21.12892; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIEDERICH M, 1993, FEBS LETT, V332, P88, DOI 10.1016/0014-5793(93)80490-L; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; KASHIWAGI K, 1991, BIOCHEM BIOPH RES CO, V178, P815, DOI 10.1016/0006-291X(91)90964-9; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; KURATA H, 1992, FEBS LETT, V312, P10, DOI 10.1016/0014-5793(92)81400-G; KURATSU J, 1989, J NATL CANCER I, V81, P347, DOI 10.1093/jnci/81.5.347; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Meroni G, 1996, EUR J BIOCHEM, V236, P373, DOI 10.1111/j.1432-1033.1996.00373.x; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NISHI T, 1991, ONCOGENE, V6, P1555; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; TAKESHIMA H, 1994, J NEUROSURG, V80, P1056, DOI 10.3171/jns.1994.80.6.1056; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; UEDA A, 1994, J IMMUNOL, V153, P2052; WALTER S, 1991, INT J CANCER, V49, P431, DOI 10.1002/ijc.2910490321; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; YAMASHIRO S, 1994, AM J PATHOL, V145, P856; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; Yoshimura T, 1992, Cytokines, V4, P131	33	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4646	4654		10.1074/jbc.274.8.4646	http://dx.doi.org/10.1074/jbc.274.8.4646			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988701	hybrid			2022-12-25	WOS:000078698200026
J	Alemany, R; Heringdorf, DMZ; van Koppen, CJ; Jakobs, KH				Alemany, R; Heringdorf, DMZ; van Koppen, CJ; Jakobs, KH			Formyl peptide receptor signaling in HL-60 cells through sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; 2ND MESSENGER; CALCIUM MOBILIZATION; HUMAN NEUTROPHILS; SPHINGOSINE-1-PHOSPHATE; TRANSDUCTION; PROLIFERATION; DERIVATIVES; INHIBITION; PLATELETS	Sphingosine-1-phosphate (SPP) produced from sphingosine by sphingosine kinase has recently been reported to act as intracellular second messenger for a number of plasma membrane receptors. In the present study, we investigated whether the sphingosine kinase/SPP pathway is involved in cellular signaling of the G(i) protein-coupled formyl peptide receptor in myeloid differentiated human leukemia (HL-60) cells. Receptor activation resulted in rapid and transient production of SPP by sphingosine kinase, which was abolished after pertussis toxin treatment. Direct activation of heterotrimeric G proteins by AlF4-, also rapidly increased SPP formation in intact HL-60 cells. In cytosolic preparations of HL-60 cells, sphingosine kinase activity was stimulated by the stable GTP analog, guanosine 5'-O-(3-thiotriphosphate). Inhibition of sphingosine kinase by DL-threo-dihydrosphingosine and N,N-dimethylsphingosine did not affect phospholipase C stimulation and superoxide production but markedly inhibited receptor-stimulated Ca2+ mobilization and enzyme release. We conclude that the formyl peptide receptor stimulates through G(i)-type G proteins SPP production by sphingosine kinase, that the enzyme is also stimulated by direct G protein activation, and that the sphingosine kinase/SPP pathway apparently plays an important role in chemoattractant signaling in myeloid differentiated HL-60 cells.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	Jakobs, KH (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.	karl.jakobs@uni-essen.de	Alemany, Regina/A-2314-2011; Heringdorf, Dagmar Meyer zu/A-7705-2018	Heringdorf, Dagmar Meyer zu/0000-0003-1246-9677; Alemany, Regina/0000-0003-2180-1213				Absolom D R, 1986, Methods Enzymol, V132, P95; BHAKDI S, 1991, INFECT IMMUN, V59, P2955, DOI 10.1128/IAI.59.9.2955-2962.1991; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Heringdorf DMZ, 1998, EUR J PHARMACOL, V354, P113, DOI 10.1016/S0014-2999(98)00436-1; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Mathias RS, 1998, AM J PHYSIOL-CELL PH, V274, pC1456, DOI 10.1152/ajpcell.1998.274.6.C1456; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NUBE O, 1997, J BIOL CHEM, V272, P28360; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; Qiao LX, 1998, BIOORG MED CHEM LETT, V8, P711, DOI 10.1016/S0960-894X(98)00112-7; RIDLEY AJ, 1995, CURR BIOL, V5, P710, DOI 10.1016/S0960-9822(95)00140-0; SCHMIDT M, 1995, N-S ARCH PHARMACOL, V352, P469, DOI 10.1007/BF00169379; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P164; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; vanKoppen CJ, 1996, MOL PHARMACOL, V49, P956; WENZELSEIFERT K, 1990, IMMUNOBIOLOGY, V181, P298, DOI 10.1016/S0171-2985(11)80499-7; WIELAND T, 1995, N-S ARCH PHARMACOL, V351, P329, DOI 10.1007/BF00169072; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3	34	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3994	3999		10.1074/jbc.274.7.3994	http://dx.doi.org/10.1074/jbc.274.7.3994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933590	hybrid			2022-12-25	WOS:000078575500014
J	Jamieson, L; Carpenter, L; Biden, TJ; Fields, AP				Jamieson, L; Carpenter, L; Biden, TJ; Fields, AP			Protein kinase C iota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PHOSPHATIDYLINOSITOL 3-KINASE; PHILADELPHIA-CHROMOSOME; CELL-PROLIFERATION; K562 CELLS; DIFFERENTIATION; IDENTIFICATION; P210(BCR/ABL); INHIBITION; TRANSITION	K562 chronic myelogenous leukemia cells are highly resistant to chemotherapeutic drugs, such as taxol, that induce cell death by apoptosis. This resistance is mediated by the chimeric tyrosine kinase oncogene Bcr-Abl. However, little is known about the mechanism by which Bcr-Abl protects K562 cells from apoptosis. We recently demonstrated that expression of PKC iota is necessary for the resistance of K562 cells to taxol-induced apoptosis (Murray, N. R., and Fields, A. P. (1997) J. Biol. Chem. 272, 27521-27524). We now demonstrate that treatment of K562 cells with taxol leads to sustained activation of PKC iota. In contrast, Bcr-Abl-negative HL60 myeloid leukemia cells, which are sensitive to taxol-induced apoptosis, do not exhibit sustained PKC iota activation in response to taxol, Treatment of K562 cells with tyrphostin AG957, a selective Bcr-Abl inhibitor, blocks taxol-induced PKC iota activation and sensitizes these cells to taxol-induced apoptosis, indicating that PKC iota is a relevant downstream target of Bcr-Abl-mediated resistance. Furthermore, expression of constitutively active PKC iota by adenovirus-mediated gene transfer rescues AG957-treated K562 cells from taxol-induced apoptosis. Taken together, these results demonstrate that both Bcr-Abl and PKC iota activity are necessary for apoptotic resistance in K562 cells, Furthermore, they identify PKC iota as a critical downstream target of Bcr-Abl that is sufficient to mediate the anti-apoptotic effects of Bcr-Abl.	Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Garvan Institute of Medical Research	Jamieson, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, 301 Univ Blvd, Galveston, TX 77555 USA.		Biden, Trevor/AAW-2829-2021	Biden, Trevor/0000-0001-5211-0234	NCI NIH HHS [CA56869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ANAFI M, 1993, BLOOD, V82, P3524; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Beran M, 1998, CLIN CANCER RES, V4, P1661; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Deora AB, 1997, TUMORI, V83, P756, DOI 10.1177/030089169708300409; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GOTOH A, 1994, LEUKEMIA, V8, P115; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Green D R, 1994, Important Adv Oncol, P37; HIDDEMANN W, 1993, CURR OPIN ONCOL, V5, P3; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; Kaur G, 1996, ANTI-CANCER DRUG, V7, P815, DOI 10.1097/00001813-199611000-00001; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McGahon AJ, 1997, CELL DEATH DIFFER, V4, P95, DOI 10.1038/sj.cdd.4400213; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; MURRAY NR, 1997, PROTEIN KINASE C, P97; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; OKADA T, 1994, J BIOL CHEM, V269, P3563; Riordan FA, 1998, ONCOGENE, V16, P1533, DOI 10.1038/sj.onc.1201680; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Sattler M, 1996, ONCOGENE, V12, P839; SPESSOT R, 1989, VIROLOGY, V168, P378, DOI 10.1016/0042-6822(89)90279-1; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	33	102	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3927	3930		10.1074/jbc.274.7.3927	http://dx.doi.org/10.1074/jbc.274.7.3927			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933579	hybrid			2022-12-25	WOS:000078575500003
J	Puglielli, L; Mandon, EC; Rancour, DM; Menon, AK; Hirschberg, CB				Puglielli, L; Mandon, EC; Rancour, DM; Menon, AK; Hirschberg, CB			Identification and purification of the rat liver Golgi membrane UDP-N-acetylgalactosamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CMP-SIALIC ACID; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; GALACTOSE TRANSPORTER; HEPARAN-SULFATE; PROTEIN; RECONSTITUTION; APPARATUS; PROTEOLIPOSOMES	Glycosylation of glycoproteins, proteoglycans, and glycosphingolipids occurs mainly in the lumen of the endoplasmic reticulum and the Golgi apparatus. Nucleotide sugars, donors of all the sugars involved in Golgis glycosylation reactions, are synthesized in the cytoplasm and require specialized transporters to be translocated into the lumen of the Golgi apparatus. By controlling the supply of sugar nucleotides in the lumen of the Golgi apparatus, these transporters directly regulate the glycosylation of macromolecules transiting the Golgi. We have identified and purified the rat liver Golgi membrane UDP-N-acetylgalactosamine transporter. The transporter was purified to apparent homogeneity by a combination of conventional and dye color chromatography. An similar to 63,000-fold purification (6% yield) was achieved starting from crude rat liver Golgi membranes and resulting in a protein with an apparent molecular mass of 43 kDa. The transporter was active when reconstituted into phosphatidylcholine vesicles and could be specifically photolabeled with P-3-(4-azidoanilido)-uridine-5'-[p(1)-P-32]triphosphate, an analog of UDP-N-acetylgalactosamine. Native functional size determination on a glycerol gradient suggested that the transporter exists as a homodimer within the Golgi membrane.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01655 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Boston University; University of Massachusetts System; University of Massachusetts Worcester; University of Wisconsin System; University of Wisconsin Madison	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 715 Albany St,W200, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721; Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM34396, GM55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CAREY DJ, 1981, J BIOL CHEM, V256, P989; Delves PJ, 1998, AUTOIMMUNITY, V27, P239, DOI 10.3109/08916939808993836; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Fredman P, 1997, NEUROCHEM RES, V22, P1071, DOI 10.1023/A:1022495430583; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; Ishida N, 1996, J BIOCHEM, V120, P1074; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KOEPSELL H, 1986, REV PHYSIOL BIOCH P, V104, P65, DOI 10.1007/BFb0031013; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MILLA ME, 1992, J BIOL CHEM, V267, P103; MINTON AP, 1989, ANAL BIOCHEM, V176, P209, DOI 10.1016/0003-2697(89)90297-2; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; Rancour DM, 1998, BIOCHEM J, V333, P661, DOI 10.1042/bj3330661; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; Toma L, 1996, J BIOL CHEM, V271, P3897; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZELLER BR, 1992, AM J PHYSIOL, V262, pC1341	33	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4474	4479		10.1074/jbc.274.7.4474	http://dx.doi.org/10.1074/jbc.274.7.4474			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933652	hybrid			2022-12-25	WOS:000078575500076
J	Samejima, K; Svingen, PA; Basi, GS; Kottke, T; Mesner, PW; Stewart, L; Durrieu, F; Poirier, GG; Alnemri, ES; Champoux, JJ; Kaufmann, SH; Earnshaw, WC				Samejima, K; Svingen, PA; Basi, GS; Kottke, T; Mesner, PW; Stewart, L; Durrieu, F; Poirier, GG; Alnemri, ES; Champoux, JJ; Kaufmann, SH; Earnshaw, WC			Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTHERAPY-INDUCED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; SCLERODERMA PATIENTS; PROTEASE ACTIVATION; CATALYTIC ACTIVITY; DRUG CAMPTOTHECIN; LEUKEMIA-CELLS; NUCLEAR EVENTS	Previous studies have demonstrated that topoisomerase I is cleaved late during apoptosis, but have not identified the proteases responsible or examined the functional consequences of this cleavage. Here, we have shown that treatment of purified topoisomerase I with caspase-3 resulted in cleavage at DDVD(146)down arrow Y and EEED(170)down arrow G, whereas treatment with caspase-6 resulted in cleavage at pEDD(123)down arrow G and EEED(170)down arrow G. After treatment of Jurkat T lymphocytic leukemia cells with anti-Fas antibody or A549 lung cancer cells with topotecan, etoposide, or paclitaxel, the topoisomerase I fragment comigrated with the product that resulted from caspase-3 cleavage at DDVD(146)down arrow Y. In contrast, two discrete topoisomerase I fragments that appeared to result from cleavage at DDVD(146)down arrow Y and EEED(170)down arrow G; were observed after treatment of MDA-MB-468 breast cancer cells with paclitaxel. Topoisomerase I cleavage did not occur in apoptotic MCF-7 cells, which lack caspase-3. Cell fractionation and band depletion studies with the topoisomerase I poison topotecan revealed that the topoisomerase I fragment remains in proximity to the chromatin and retains the ability to bind to and cleave DNA. These observations indicate that topoisomerase I is a substrate of caspase-3 and possibly caspase-6, but is cleaved at sequences that differ from those ordinarily preferred by these enzymes, thereby providing a potential explanation why topoisomerase I cleavage lags behind that of classical caspase substrates such as poly(ADP-ribose) polymerase and lamin B-1.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; Athena Neurosci Inc, San Francisco, CA 94080 USA; Thomas Jefferson Univ, Jefferson Canc Inst, Philadelphia, PA 19107 USA; CHU Laval, Res Ctr, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Ste Foy, PQ G1V 4G2, Canada; Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Edinburgh; Mayo Clinic; Jefferson University; Laval University; Laval University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Michael Swann Bldg,Kings Bldgs,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	bill.earnshaw@ed.ac.uk	Alnemri, Emad S/B-4526-2010; Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621; Poirier, Guy/0000-0002-4869-1424; Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA069008, CA69008] Funding Source: Medline; NIA NIH HHS [AG13487] Funding Source: Medline; NIGMS NIH HHS [GM49156] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ARMSTRONG DK, 1992, CANCER RES, V52, P3418; BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; BOCCHIERI MH, 1991, ARTHRITIS RHEUM, V34, P599, DOI 10.1002/art.1780340512; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BONA C, 1994, CURR OPIN IMMUNOL, V6, P931, DOI 10.1016/0952-7915(94)90016-7; Buckwalter CA, 1996, CANCER RES, V56, P1674; CasciolaRosen L, 1997, LUPUS, V6, P175, DOI 10.1177/096120339700600213; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1998, CELL DEATH DIFFER, V5, P183, DOI 10.1038/sj.cdd.4400336; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Costin Dan, 1994, V29B, P51; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; DOUVAS AS, 1979, J BIOL CHEM, V254, P10514; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; FAUBION WA, 1999, IN PRESS J CLIN INVE, V103; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; HSIANG YH, 1988, CANCER RES, V48, P1722; Ibrado AM, 1996, CANCER RES, V56, P4743; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; MAUL GG, 1986, P NATL ACAD SCI USA, V83, P5145, DOI 10.1073/pnas.83.14.5145; McCloskey DE, 1996, CLIN CANCER RES, V2, P847; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Sugimoto K, 1998, BLOOD, V91, P1407, DOI 10.1182/blood.V91.4.1407; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry N A, 1997, Adv Pharmacol, V41, P155, DOI 10.1016/S1054-3589(08)61058-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1997, MOL CELL BIOL, V17, P6502, DOI 10.1128/MCB.17.11.6502; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wright SC, 1998, BIOCHEM BIOPH RES CO, V245, P797, DOI 10.1006/bbrc.1998.8508; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391	72	87	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4335	4340		10.1074/jbc.274.7.4335	http://dx.doi.org/10.1074/jbc.274.7.4335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933635	hybrid			2022-12-25	WOS:000078575500059
J	Wilson, KF; Fortes, P; Singh, US; Ohno, M; Mattaj, IW; Cerione, RA				Wilson, KF; Fortes, P; Singh, US; Ohno, M; Mattaj, IW; Cerione, RA			The nuclear cap-binding complex is a novel target of growth factor receptor-coupled signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IDENTIFICATION; EXPORT; CDC42; CELLS; PHOSPHORYLATION; PATHWAY; ERBB3; RAC1	In an attempt to further understand how nuclear events (such as gene expression, nuclear import/export, and cell cycle checkpoint control) might be subject to regulation by extracellular stimuli, we sought to identify nuclear activities under growth factor control. Using a sensitive photoaffinity labeling assay that measured [alpha-P-32]GTP incorporation into nuclear proteins, we identified the 20-kDa subunit of the nuclear cap-binding complex (CBC) as a protein whose binding activity is greatly enhanced by the extracellular stimulation of serum-arrested cells. The CBC represents a 20- and 80-kDa heterodimer (the subunits independently referred to as CBP20 and CBP80, respectively) that binds the 7-methylguanosine cap on RNAs transcribed by RNA polymerase II. This binding facilitates precursor messenger RNA splicing and export. We have demonstrated that the [alpha-P-32]GTP incorporation into CBP20 was correlated with an increased ability of the CBC to bind capped RNA and have used the [alpha-P-32]GTP photoaffinity assay to characterize the activation of the CBC in response to growth factors. We show that the CBC is activated by heregulin in HeLa cells and by nerve growth factor in PC12 cells as well as during the G(1)/S phase of the cell cycle and when cells are stressed with UV irradiation. Additionally, we show that cap-dependent splicing of precursor mRNA, a functional outcome of CBC activation, can be catalyzed by growth factor addition to serum-arrested cells. Taken together, these data identify the CBC as a nuclear target for growth factor-coupled signal transduction and suggest novel mechanisms by which growth factors can influence gene expression and cell growth.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Biochem Mol & Cellular Biol, Ithaca, NY 14853 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Cornell University; Cornell University; European Molecular Biology Laboratory (EMBL)	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.		Fortes, Puri/J-7872-2016	Fortes, Puri/0000-0001-7571-6220; Mattaj, Iain/0000-0002-5537-8284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZEN F, 1987, NUCLEIC ACIDS RES, V15, P6489, DOI 10.1093/nar/15.16.6489; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	31	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4166	4173		10.1074/jbc.274.7.4166	http://dx.doi.org/10.1074/jbc.274.7.4166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933612	hybrid			2022-12-25	WOS:000078575500036
J	Hudak, KA; Dinman, JD; Tumer, NE				Hudak, KA; Dinman, JD; Tumer, NE			Pokeweed antiviral protein accesses ribosomes by binding to L3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; N-GLYCOSIDASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; INACTIVATING PROTEINS; RNA; INHIBITION; COMPONENTS; IDENTIFICATION; REPLICATION; MUTATIONS	Pokeweed antiviral protein (PAP), a 29-kDa ribosome-inactivating protein, catalytically removes an adenine residue from the conserved alpha-sarcin loop of the large rRNA, thereby preventing the binding of eEF-2.GTP complex during protein elongation, Because the alpha-sarcin loop has been placed near the peptidyltransferase center in Escherichia coli ribosomes, we investigated the effects of alterations at the peptidyltransferase center on the activity of PAP, We demonstrate here that a chromosomal mutant of yeast, harboring the mak8-1 allele of peptidyltransferase-linked ribosomal protein L3 (RPL3), is resistant to the cytostatic effects of PAP. Unlike wild-type yeast, ribosomes from mak8-1 cells are not depurinated when PAP expression is induced in vivo, indicating that wild-type L3 is required for ribosome depurination, Co-immunoprecipitation studies show that PAP binds directly to L3 or Mak8-1p in vitro but does not physically interact with ribosome-associated Mak8-1p. L3 is required for PAP to bind to ribosomes and depurinate the 25 S rRNA, suggesting that it is located in close proximity to the alpha-sarcin loop. These results demonstrate for the first time that a ribosomal protein provides a receptor site for an ribosome-inactivating protein and allows depurination of the target adenine.	Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Plant Pathol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Program Mol Biosci, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Tumer, NE (corresponding author), Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA.	tumer@aesop.rutgers.edu		Dinman, Jonathan/0000-0002-2402-9698				ALEXANDER RW, 1994, BIOCHEMISTRY-US, V33, P12109, DOI 10.1021/bi00206a014; ARON GM, 1980, ANTIMICROB AGENTS CH, V17, P1032, DOI 10.1128/AAC.17.6.1032; Cui Y, 1996, EMBO J, V15, P5726, DOI 10.1002/j.1460-2075.1996.tb00956.x; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1988, J BIOL CHEM, V263, P8735; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HARLEY SM, 1982, P NATL ACAD SCI-BIOL, V79, P5935, DOI 10.1073/pnas.79.19.5935; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; IPPOLITI R, 1992, FEBS LETT, V298, P145, DOI 10.1016/0014-5793(92)80042-F; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; LINDSTROM JT, 1994, PLANT PHYSIOL, V106, P7, DOI 10.1104/pp.106.1.7; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; Muralikrishna P, 1997, NUCLEIC ACIDS RES, V25, P4562, DOI 10.1093/nar/25.22.4562; MURALIKRISHNA P, 1991, BIOCHEMISTRY-US, V30, P5421, DOI 10.1021/bi00236a014; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; OTTO JJ, 1993, METHOD CELL BIOL, V37, P119, DOI 10.1016/S0091-679X(08)60247-2; Peltz SW, 1999, MOL CELL BIOL, V19, P384; STOCKLEIN W, 1980, CURR GENET, V1, P177, DOI 10.1007/BF00390941; TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225; TRECO DA, 1993, CURRENT PROTOCOLS MO; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; VATER CA, 1995, J BIOL CHEM, V270, P12933, DOI 10.1074/jbc.270.21.12933; WICKNER RB, 1974, GENETICS, V76, P423; WICKNER RB, 1982, P NATL ACAD SCI-BIOL, V79, P4706, DOI 10.1073/pnas.79.15.4706; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0	32	94	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3859	3864		10.1074/jbc.274.6.3859	http://dx.doi.org/10.1074/jbc.274.6.3859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920941	hybrid			2022-12-25	WOS:000078428200081
J	Wehland, M; Kiecker, C; Coplin, DL; Kelm, O; Saenger, W; Bernhard, F				Wehland, M; Kiecker, C; Coplin, DL; Kelm, O; Saenger, W; Bernhard, F			Identification of an RcsA/RcsB recognition motif in the promoters of exopolysaccharide biosynthetic operons from Erwinia amylovora and Pantoea stewartii subspecies stewartii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; CAPSULAR POLYSACCHARIDE SYNTHESIS; NITROGEN REGULATOR-I; COLANIC ACID; RCSA GENE; POSITIVE REGULATOR; DNA-BINDING; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION; ACTIVATOR PROTEIN	The regulation of capsule synthesis (Rcs) regulatory network is responsible for the induction of exopolysaccharide biosynthesis in many enterobacterial species. We have previously shown that two transcriptional regulators, RcsA and RcsB, do bind as a heterodimer to the promoter of amsG, the first reading frame in the operon for amylovoran biosynthesis in the plant pathogenic bacterium Erwinia amylovora. We now identified a 23-base pair fragment from position -555 to -533 upstream of the translational start site of amsG as sufficient for the specific binding of the Res proteins. In addition, we could detect an RcsA/RcsB-binding site in a corresponding region of the promoter of cpsA, the homologous counterpart to the E. amylovora amsG gene in the operon for stewartan biosynthesis of Pantoea stewartii. The specificity and characteristic parameters of the protein-DNA interaction were analyzed by DNA retardation, protein-DNA cross-linking, and directed mutagenesis, The central core motif TRVGAAWAWTSYG of the amsG promoter was found to be most important for the specific interaction with RcsA/RcsB, as evaluated by mutational analysis and an in vitro selection approach. The wild type P. stewartii Rcs binding motif is degenerated in two positions and an up-mutation according to our consensus motif resulted in about a 5-fold increased affinity of the RcsA/RcsB proteins.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Ohio State Univ, Dept Plant Pathol, Columbus, OH 43210 USA	Free University of Berlin; University System of Ohio; Ohio State University	Bernhard, F (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	fbern@fu-berlin.chemie.de	Kiecker, Clemens/C-7170-2009	Bernhard, Frank/0000-0002-4860-1783; Wehland, Markus/0000-0002-8160-859X				AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; ALLEN P, 1987, J GEN MICROBIOL, V133, P331; Bereswill S, 1997, J BACTERIOL, V179, P1354, DOI 10.1128/jb.179.4.1354-1361.1997; BERNHARD F, 1990, MOL PLANT MICROBE IN, V3, P429, DOI 10.1094/MPMI-3-429; BEVERIDGE TJ, 1991, MICROBIOL REV, V55, P684, DOI 10.1128/MMBR.55.4.684-705.1991; BRILL JA, 1988, J BACTERIOL, V170, P2599, DOI 10.1128/jb.170.6.2599-2611.1988; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHATTERJEE A, 1990, MOL PLANT MICROBE IN, V3, P144, DOI 10.1094/MPMI-3-144; COLEMAN M, 1990, J GEN MICROBIOL, V136, P1799, DOI 10.1099/00221287-136-9-1799; COPLIN DL, 1986, J BACTERIOL, V168, P619, DOI 10.1128/jb.168.2.619-623.1986; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; GERVAIS FG, 1992, J BACTERIOL, V174, P3964, DOI 10.1128/jb.174.12.3964-3971.1992; GOTTESMAN S, 1995, REGULATION CAPSULE S, P253; Gupte G, 1997, J BACTERIOL, V179, P4328, DOI 10.1128/jb.179.13.4328-4335.1997; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; HOOPES BC, 1987, ESCHERICHIA COLI SAL, P1231; HSU ST, 1978, PHYTOPATHOLOGY, V68, P351, DOI 10.1094/Phyto-68-351; JAYARATNE P, 1993, J BACTERIOL, V175, P5384, DOI 10.1128/JB.175.17.5384-5394.1993; KEENLEYSIDE WJ, 1992, J BACTERIOL, V174, P8, DOI 10.1128/jb.174.1.8-16.1992; Kelm O, 1997, MOL GEN GENET, V256, P72, DOI 10.1007/s004380050547; LANE D, 1992, MICROBIOL REV, V3, P455; LEIGH JA, 1992, ANNU REV MICROBIOL, V46, P307, DOI 10.1146/annurev.mi.46.100192.001515; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MCCALLUM KL, 1991, INFECT IMMUN, V59, P494, DOI 10.1128/IAI.59.2.494-502.1991; MERGAERT J, 1993, INT J SYST BACTERIOL, V43, P162, DOI 10.1099/00207713-43-1-162; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; POETTER K, 1991, MOL GEN GENET, V229, P155, DOI 10.1007/BF00264225; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; ROITSCH T, 1990, J BACTERIOL, V172, P6054, DOI 10.1128/jb.172.10.6054-6060.1990; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; Stout V, 1996, J BACTERIOL, V178, P4273, DOI 10.1128/jb.178.14.4273-4280.1996; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; TRISLER P, 1984, J BACTERIOL, V160, P184, DOI 10.1128/JB.160.1.184-191.1984; Virlogeux I, 1996, J BACTERIOL, V178, P1691, DOI 10.1128/jb.178.6.1691-1698.1996; WACHAROTAYANKUN R, 1992, J BACTERIOL, V174, P1063, DOI 10.1128/jb.174.3.1063-1067.1992; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	44	51	53	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3300	3307		10.1074/jbc.274.6.3300	http://dx.doi.org/10.1074/jbc.274.6.3300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920870	hybrid			2022-12-25	WOS:000078428200010
J	Perletti, GP; Marras, E; Concari, P; Piccinini, F; Tashjian, AH				Perletti, GP; Marras, E; Concari, P; Piccinini, F; Tashjian, AH			PKC delta acts as a growth and tumor suppressor in rat colonic epithelial cells	ONCOGENE			English	Article						PKC isoforms; colon cancer; src oncogene	PROTEIN-KINASE-C; PHORBOL ESTER; EPSILON; OVEREXPRESSION; FIBROBLASTS; ACTIVATION; ONCOGENE	We have analysed the expression of three calcium-independent isoforms of protein kinase C (PKC), PKC delta, PKC epsilon and PKC zeta, in an in vitro model of colon carcinogenesis consisting of the nontumorigenic rat colonic epithelial cell line D/WT, and a derivative src-transformed line D/src. While PKC zeta and PKC epsilon showed similar protein levels, PKC delta was markedly decreased in D/src cells when compared to the D/WT line. To assess whether down-regulation of PKC delta was causally involved in the neoplastic phenotype in D/src cells, we prepared a kinase-defective mutant of PKC delta, Stable transfection of this sequence caused morphological and growth changes characteristic of partial transformation in D/WT cells. Moreover, to test whether PKC delta was involved in growth control and transformation in this model, we over-expressed PKC delta in D/src cells. Transfected cells underwent marked growth and morphological modifications toward the D/WT phenotype, In a late stage in culture, transfected cells ceased to proliferate, rounded up and degenerated into multinucleated, giant-like cells, We conclude that PKC delta can reverse the transformed phenotype and act as a suppressor of cell growth in D/src cells, Moreover, our data show that downregulation of this isoenzyme of PKC may cooperate in the neoplastic transformation induced by the src oncogene in D/WT cells.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Univ Milan, Ist Farmacol, I-20129 Milan, Italy; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Milan; Harvard University; Harvard Medical School	Tashjian, AH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.				NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Blobe GC, 1996, CANCER SURV, V27, P213; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; JIANG YH, 1997, CARCINOGENESIS, V18, P31; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Perletti GP, 1996, INT J ONCOL, V9, P171; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Perletti GP, 1996, ONCOGENE, V12, P847; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Wang QJ, 1998, ONCOGENE, V16, P53, DOI 10.1038/sj.onc.1201507; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	20	75	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1251	1256		10.1038/sj.onc.1202408	http://dx.doi.org/10.1038/sj.onc.1202408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022132				2022-12-25	WOS:000078510700015
J	Ji, GJ; Fleischmann, BK; Bloch, W; Feelisch, M; Andressen, C; Addicks, K; Hescheler, J				Ji, GJ; Fleischmann, BK; Bloch, W; Feelisch, M; Andressen, C; Addicks, K; Hescheler, J			Regulation of the L-type Ca2+ channel during cardiomyogenesis: switch from NO to adenylyl cyclase-mediated inhibition	FASEB JOURNAL			English	Article						ES cell-derived cardiomyocytes; patch-clamp; nitric oxide; switch in the regulation of I-Ca during development	NITRIC-OXIDE SYNTHASE; DEPENDENT PROTEIN-KINASE; EMBRYONIC STEM-CELLS; CHICK HEART-CELLS; CARDIAC MYOCYTES; VENTRICULAR MYOCYTES; CALCIUM CURRENT; CYCLIC-AMP; SELECTIVE-INHIBITION; GUANYLATE-CYCLASE	In adult mammalian cardiomyocytes, stimulation of muscarinic receptors counterbalances the beta-adrenoceptor-mediated increase in myocardial contractility and heart rate by decreasing the L-type Ca2+ current (I-Ca) (1, 2). This effect is mediated via inhibition of adenylyl cyclase and subsequent reduction of cAMP-dependent phosphorylation of voltage-dependent L-type Ca2+ channels (3). Little is known, however, about the nature and origin of this pivotal inhibitory pathway. Using embryonic stem cells as an in vitro model of cardiomyogenesis, we found that muscarinic agonists depress I-Ca by 58 +/- 3% (n=34) in early stage cardiomyocytes lacking functional beta-adrenoceptors. The cholinergic inhibition is mediated by the nitric oxide (NO)/cGMP system since it was abolished by application of NOS inhibitors (L-NMA, L-NAME), an inhibitor of the soluble guanylyl cyclase (ODQ), and a selective phosphodiesterase type II antagonist (EHNA). The NO/cGMP-mediated I-Ca depression was dependent on a reduction of cAMP/ protein kinase A (PKA) levels since application of the catalytic subunit of PKA or of the PKA inhibitor PK) prevented the carbachol effect. In late development stage cells, as reported for ventricular cardiomyocytes (2, 4), muscarinic agonists had no effect on basal I-Ca but antagonized beta-adrenoceptor-stimulated I-Ca by 43 +/- 4% (n=16). This switch in signaling pathways during development is associated with distinct changes in expression of the two NO-producing isoenzymes, eNOS and iNOS, respectively. These findings indicate a fundamental role for NO as a signaling molecule during early embryonic development and demonstrate a switch in the signaling cascades governing I-Ca regulation.	Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Univ Cologne, Inst Anat 1, D-5000 Cologne, Germany; UCL, Wolfson Inst Biomed Res, London, England	University of Cologne; University of Cologne; University of London; University College London	Hescheler, J (corresponding author), Univ Cologne, Inst Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	jh@physiologie.uni-koeln.de	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158				An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; Arnhold S, 1997, NEUROSCI LETT, V229, P165, DOI 10.1016/S0304-3940(97)00457-6; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FABIATO A, 1979, ANNU REV PHYSIOL, V41, P473, DOI 10.1146/annurev.ph.41.030179.002353; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Gouge RC, 1998, BIOL REPROD, V58, P875, DOI 10.1095/biolreprod58.4.875; HADDAD GE, 1995, MOL CELL BIOCHEM, V148, P89, DOI 10.1007/BF00929507; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Han X, 1998, J PHYSIOL-LONDON, V509, P741, DOI 10.1111/j.1469-7793.1998.741bm.x; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Hare JM, 1998, J CLIN INVEST, V101, P1424, DOI 10.1172/JCI1012; HARE JM, 1995, CIRCULATION, V92, P2198, DOI 10.1161/01.CIR.92.8.2198; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; HESCHELER J, 1986, PFLUG ARCH EUR J PHY, V407, P182, DOI 10.1007/BF00580674; Hu H, 1997, CIRC RES, V81, P742; IIJIMA T, 1985, J PHYSIOL-LONDON, V359, P485, DOI 10.1113/jphysiol.1985.sp015598; ISENBERG G, 1982, PFLUG ARCH EUR J PHY, V395, P6, DOI 10.1007/BF00584963; KUMAR R, 1994, J MOL CELL CARDIOL, V26, P1537, DOI 10.1006/jmcc.1994.1174; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MERY PF, 1993, J BIOL CHEM, V268, P26286; MERY PF, 1995, MOL PHARMACOL, V48, P121; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MONCADA S, 1991, PHARMACOL REV, V43, P109; OSTERRIEDER W, 1982, NATURE, V298, P576, DOI 10.1038/298576a0; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SLOTKIN TA, 1994, TOXICOL APPL PHARM, V129, P223, DOI 10.1006/taap.1994.1247; SUMII K, 1995, CIRC RES, V77, P803, DOI 10.1161/01.RES.77.4.803; TOHSE N, 1991, CIRC RES, V69, P325, DOI 10.1161/01.RES.69.2.325; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TRIPATHI O, 1991, J DEV PHYSIOL, V16, P309; UNGUREANULONGROIS D, 1995, J MOL CELL CARDIOL, V27, P155, DOI 10.1016/S0022-2828(08)80015-6; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	48	84	88	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					313	324		10.1096/fasebj.13.2.313	http://dx.doi.org/10.1096/fasebj.13.2.313			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973319				2022-12-25	WOS:000078615200011
J	Parente, JA; Chen, XS; Zhou, CJ; Petropoulos, AC; Chew, CS				Parente, JA; Chen, XS; Zhou, CJ; Petropoulos, AC; Chew, CS			Isolation, cloning, and characterization of a new mammalian coronin family member, coronin(se), which is regulated within the protein kinase C signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-ACID SECRETION; ACTIN-BINDING-PROTEIN; WD-REPEAT; PARIETAL-CELLS; DICTYOSTELIUM; MEMBRANE; TRANSDUCTION; COMPARTMENT	In order to understand the regulatory role of protein kinase C (PKC) in secretory epithelia, it is necessary to identify and characterize specific downstream targets. We previously identified one such protein in studies of gastric parietal cells. This protein was referred to as pp66 because it migrated with an apparent molecular mass of 66 kDa on SDS-polyacrylamide gels. The phosphorylation of pp66 is increased by the cholinergic agonist, carbachol, and by the PKC activator, phorbol-12-myristate-13-acetate, in a calcium-independent manner. In this study, we have purified pp66 to homogeneity and cloned the complete open reading frame. GenBank(Tm) searches revealed a 45% homology with the Dictyostelium actin-binding protein, coronin, and similar to 67% homology with the previously cloned human and bovine coronin-like homologue, p57. pp66 appears to be most highly expressed in the gastrointestinal mucosa and in kidney and lung. Confocal microscopic studies of an enhanced green fluorescent protein fusion construct of pp66 in cultured parietal cells and in Madin-Darby canine kidney cells indicate that pp66 preferentially localizes in F-actin-rich regions. On the basis of our findings, we propose that pp66 may play an important, PKC-dependent role in regulating membrane/cytoskeletal rearrangements in epithelial cells. We have tentatively named this protein coronin(se), because it appears to be highly expressed in secretory epithelia.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chew, CS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Sanders R&E Bldg,Rm CB 2803, Augusta, GA 30912 USA.	cchew@mailer.mcg.edu			NIDDK NIH HHS [R37 DK31900, F32 DK 09447] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009447, R37DK031900] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BROWN MR, 1989, AM J PHYSIOL, V257, pG99, DOI 10.1152/ajpgi.1989.257.1.G99; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Calhoun BC, 1997, BIOCHEM J, V325, P559, DOI 10.1042/bj3250559; CHEW CS, 1989, AM J PHYSIOL, V256, pG254, DOI 10.1152/ajpgi.1989.256.1.G254; Chew CS, 1998, AM J PHYSIOL-CELL PH, V275, pC56, DOI 10.1152/ajpcell.1998.275.1.C56; CHEW CS, 1990, METHOD ENZYMOL, V191, P640; Chew CS, 1997, AM J PHYSIOL-GASTR L, V272, pG246, DOI 10.1152/ajpgi.1997.272.2.G246; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; GLUCK SL, 1996, ANNU REV PHYSIOL, V58, P27; Grogan A, 1997, J CELL SCI, V110, P3071; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; Holt MR, 1998, INT J BIOCHEM CELL B, V30, P307, DOI 10.1016/S1357-2725(97)00101-5; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Maniatis T., 1989, MOL CLONING LAB MANU, Vsecond; MORRIS AP, 1994, ANNU REV PHYSIOL, V56, P371; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Okamoto CT, 1998, AM J PHYSIOL-CELL PH, V274, pC1017, DOI 10.1152/ajpcell.1998.274.4.C1017; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; PEARSON RB, 1991, METHOD ENZYMOL, V200, P63; Rauchenberger R, 1997, CURR BIOL, V7, P215, DOI 10.1016/S0960-9822(97)70093-9; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Urushidani T, 1997, J MEMBRANE BIOL, V159, P99, DOI 10.1007/s002329900274; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049	38	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3017	3025		10.1074/jbc.274.5.3017	http://dx.doi.org/10.1074/jbc.274.5.3017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915840	hybrid			2022-12-25	WOS:000078319500058
J	Zaitseva, EM; Zaitsev, EN; Kowalczykowski, SC				Zaitseva, EM; Zaitsev, EN; Kowalczykowski, SC			The DNA binding properties of Saccharomyces cerevisiae Rad51 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI RECA PROTEIN; DEPENDENT ATPASE ACTIVITY; ESCHERICHIA-COLI; SSB PROTEIN; DUPLEX DNA; IN-VITRO; GAMMA-S; EXCHANGE; RECOMBINATION	Saccharomyces cerevisiae Rad51 protein is the paradigm for eukaryotic ATP-dependent DNA strand exchange proteins. To explain some of the unique characteristics of DNA strand exchange promoted by Rad51 protein, when compared with its prokaryotic homologue the Escherichia coli RecA protein, we analyzed the DNA binding properties of the Rad51 protein. Rad51 protein binds both single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) in an ATP- and Mg2+-dependent manner, over a wide range of pH, with an apparent binding stoichiometry of approximately 1 protein monomer per 4 (+/-1) nucleotides or base pairs, respectively. Only dATP and adenosine 5'-gamma-(thiotriphosphate) (ATP gamma S) can substitute for ATP, but binding in the presence of ATP gamma S requires more than a 5-fold stoichiometric excess of protein. Without nucleotide co-factor, Rad51 protein binds both ssDNA and dsDNA but only at pH values lower than 6.8; in this case, the apparent binding stoichiometry covers the range of 1 protein monomer per 6-9 nucleotides or base pairs. Therefore, Rad51 protein displays two distinct modes of DNA binding. These binding modes are not inter-convertible; however, their initial selection is governed by ATP binding, On the basis of these DNA binding properties, we conclude that the main reason for the low efficiency of the DNA strand exchange promoted by Rad51 protein in vitro is its enhanced dsDNA-binding ability, which inhibits both the presynaptic and synaptic phases of the DNA strand exchange reaction as follows: during pre-synapsis, Rad51 protein interacts with and stabilizes secondary structures in ssDNA thereby inhibiting formation of a contiguous nucleoprotein filament; during synapsis, Rad51 protein inactivates the homologous dsDNA partner by directly binding to it.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Div Biol Sci, Sect Mol & Cell Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NIAID NIH HHS [AI-18987] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bianco P R, 1998, Front Biosci, V3, pD570; de Bongioanni L C, 1988, Rev Argent Microbiol, V20, P1; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Eggleston AK, 1996, NUCLEIC ACIDS RES, V24, P1179, DOI 10.1093/nar/24.7.1179; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAWORTH RS, 1993, MOL CELL BIOCHEM, V124, P131, DOI 10.1007/BF00929205; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1990, LANDOLTBORNSTEIN D, V1, P244; LAUDER SD, 1993, J MOL BIOL, V234, P72, DOI 10.1006/jmbi.1993.1564; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; PUGH BF, 1987, J BIOL CHEM, V262, P1326; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; TROTTA E, 1993, J BIOL CHEM, V268, P3944; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; Zaitsev EN, 1998, NUCLEIC ACIDS RES, V26, P650, DOI 10.1093/nar/26.2.650	45	103	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2907	2915		10.1074/jbc.274.5.2907	http://dx.doi.org/10.1074/jbc.274.5.2907			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915828	Green Submitted, hybrid			2022-12-25	WOS:000078319500046
J	Atienza, JM; Susanto, D; Huang, C; McCarty, AS; Colicelli, J				Atienza, JM; Susanto, D; Huang, C; McCarty, AS; Colicelli, J			Identification of inhibitor specificity determinants in a mammalian phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CATALYTIC ACTIVITY; ROLIPRAM BINDING; AMP PHOSPHODIESTERASES; TYPE-4 INHIBITOR; MESSENGER-RNA; GUINEA-PIG; EXPRESSION; DOMAIN	Mammalian phosphodiesterase types 3 and 4 (PDE3 and PDE4) hydrolyze cAMP and are essential for the regulation of this intracellular second messenger in many cell types. Whereas these enzymes share structural and biochemical similarities, each can be distinguished by its sensitivity to isozyme-specific inhibitors. By using a series of chimeric enzymes, we have localized the region of PDE4 that confers sensitivity to selective inhibitors. This inhibitor specificity domain lies within a short sequence at the carboxyl terminus of the catalytic domain of the protein, consistent with the competitive nature of inhibition by these compounds, Surprisingly, the identified region also includes some of the most highly conserved residues among PDE isoforms, A yeast-based expression system was used for the isolation and characterization of mutations within this area that confer resistance to the PDE4-specific inhibitor rolipram. Analysis of these mutants indicated that both conserved and unique residues are required for isoform-specific inhibitor sensitivity. In some cases, combined point mutations contribute synergistically to the reduction of sensitivity (suppression of IC50). We also report that several mutations display differential sensitivity changes with respect to distinct structural classes of inhibitors.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Colicelli, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.				NINDS NIH HHS [NS31911] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031911] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atienza JM, 1998, METHODS, V14, P35, DOI 10.1006/meth.1997.0563; Barnette MS, 1996, BIOCHEM PHARMACOL, V51, P949; Bolger GB, 1997, BIOCHEM J, V328, P539; Boolell M, 1996, Int J Impot Res, V8, P47; Burns F, 1996, Adv Pharmacol, V36, P29, DOI 10.1016/S1054-3589(08)60575-X; BUSNIK T, 1996, BIOCHEM SOC T, V24, P1014; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; Cheung PP, 1996, BLOOD, V88, P1321, DOI 10.1182/blood.V88.4.1321.bloodjournal8841321; Cohan VL, 1996, J PHARMACOL EXP THER, V278, P1356; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; DAGERMAN E, 1997, J BIOL CHEM, V272, P6823; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; HALL IP, 1993, BRIT J CLIN PHARMACO, V35, P1; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; He Rui, 1998, Cell Biochemistry and Biophysics, V29, P89, DOI 10.1007/BF02737830; HENKELTIGGES J, 1990, MOL PHARMACOL, V37, P7; Holbrook M, 1996, BRIT J PHARMACOL, V118, P1192, DOI 10.1111/j.1476-5381.1996.tb15523.x; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Jacobitz S, 1996, MOL PHARMACOL, V50, P891; Jacobitz S, 1997, MOL PHARMACOL, V51, P999, DOI 10.1124/mol.51.6.999; JIN SLC, 1992, J BIOL CHEM, V267, P18929; Kleinman EF, 1998, J MED CHEM, V41, P266, DOI 10.1021/jm970685m; Leroy MJ, 1996, BIOCHEMISTRY-US, V35, P10194, DOI 10.1021/bi952711t; Loughney K, 1996, J BIOL CHEM, V271, P796, DOI 10.1074/jbc.271.2.796; MONACO L, 1994, J BIOL CHEM, V269, P347; Omburo GA, 1997, BLOOD, V89, P1019, DOI 10.1182/blood.V89.3.1019; Owens RJ, 1997, BIOCHEM J, V326, P53, DOI 10.1042/bj3260053; PILLAI R, 1994, J BIOL CHEM, V269, P30676; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; RAEBURN D, 1994, BRIT J PHARMACOL, V113, P1423, DOI 10.1111/j.1476-5381.1994.tb17156.x; Rocque WJ, 1997, BIOCHEMISTRY-US, V36, P14250, DOI 10.1021/bi971112e; Rybalkin SD, 1996, BIOCHEM SOC T, V24, P1005, DOI 10.1042/bst0241005; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SCHUDT C, 1991, BIOCHEM PHARMACOL, V42, P153, DOI 10.1016/0006-2952(91)90694-Z; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Spina D, 1998, ADV PHARMACOL, V44, P33, DOI 10.1016/S1054-3589(08)60125-8; Teixeira MM, 1997, TRENDS PHARMACOL SCI, V18, P164, DOI 10.1016/S0165-6147(97)90613-1; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; Turko IV, 1998, BIOCHEMISTRY-US, V37, P4200, DOI 10.1021/bi972448r; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; UNDERWOOD DC, 1993, J PHARMACOL EXP THER, V266, P306; Wang P, 1997, BIOCHEM BIOPH RES CO, V234, P320, DOI 10.1006/bbrc.1997.6636	47	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4839	4847		10.1074/jbc.274.8.4839	http://dx.doi.org/10.1074/jbc.274.8.4839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988724	hybrid			2022-12-25	WOS:000078698200049
J	Liu, XF; Culotta, VC				Liu, XF; Culotta, VC			Post-translation control of Nramp metal transport in yeast - Role of metal ions and the BSD2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NATURAL-RESISTANCE; IRON UPTAKE; PROTEIN; COPPER; MEMBRANE; INFECTION; HOMEOSTASIS; ENDOCYTOSIS; REPRESSION	The Saccharomyces cerevisiae SMF1 gene encodes a member of the well conserved family of Nramp metal transport proteins. Previously, we determined that heavy metal uptake by Smf1p was down-regulated by the product of the S. cerevisiae BSD2 gene. We now demonstrate that this regulation occurs at the level of protein stability. In wild type strains, the bulk of Smf1p is normally directed to the vacuole and is rapidly degraded by vacuolar proteases in a PEP4-dependent manner. In bsd2 Delta mutants, Smf1p fails to enter the vacuole, and the Nramp protein is stabilized. Metal ions themselves play an important role in the post-translational regulation of Smf1p. The depletion of heavy metals from the growth medium effects stabilization of Smf1p and additionally results in accumulation of this transporter at the cell surface. Supplementation of manganese alone is sufficient to trigger rapid degradation of Smf1p in a Bsd2p-dependent manner. Together the action of Bsd2p and metal ions provide a rapid and effective means for controlling Nramp metal transport in response to environmental changes.	Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Culotta, VC (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	vculotta@jhsph.edu			NIEHS NIH HHS [ES 07141, ES 08996] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Brachmann CB, 1998, YEAST, V14, P115; Cellier M, 1996, TRENDS GENET, V12, P201, DOI 10.1016/0168-9525(96)30042-5; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; GRUNHEID S, 1995, GENOMICS, V25, P514; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; JONES EW, 1991, J BIOL CHEM, V266, P7963; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEST AH, 1992, J BIOL CHEM, V267, P24625; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	37	122	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4863	4868		10.1074/jbc.274.8.4863	http://dx.doi.org/10.1074/jbc.274.8.4863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988727	hybrid			2022-12-25	WOS:000078698200052
J	Probst, C; Jecht, M; Gauss-Muller, V				Probst, C; Jecht, M; Gauss-Muller, V			Intrinsic signals for the assembly of hepatitis a virus particles - Role of structural proteins VP4 and 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A VIRUS; CAPSID PROTEIN; MONOCLONAL-ANTIBODIES; SUBVIRAL PARTICLES; IDENTIFICATION; CELLS; RNA; MYRISTOYLATION; CLEAVAGE; VIRIONS	Capsid assembly is the final event of virus replication, and its understanding is pivotal for the design of empty capsid-based recombinant vaccines and drug delivery systems. Although the capsid structure of several members of the picornavirus family has been elucidated, little is known about the structural elements governing the assembly process that is tightly associated with proteolytic processing of the viral polyprotein. Among the picornaviruses, hepatitis A virus (HAV) is unique in that it contains VP1-2A as a structural component and the small structural protein VP4, which argues for an assembly pathway different from that proposed for other picornaviruses. Using a recombinant system we show here that proteolytic processing of the HAV capsid proteins' precursor P1-2A is independent of the terminal domains 2A and VP4 of the substrate. However, both terminal domains play distinct roles in the assembly of viral particles. 2A as part of P1-2A is a primary signal for the assembly of pentameric structures which only further aggregate to empty viral capsids when VP4 is present as the N terminus of the precursor. Particle formation in the hepatovirus genus is thus regulated by two intrinsic signals that are distinct from those described for other picornaviruses.	Univ Lubeck, Inst Med Microbiol & Hyg, D-23538 Lubeck, Germany	University of Lubeck	Gauss-Muller, V (corresponding author), Univ Lubeck, Inst Med Mol Biol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.							ANDERSON DA, 1990, J VIROL, V64, P5284, DOI 10.1128/JVI.64.11.5284-5289.1990; ANSARDI DC, 1992, J VIROL, V66, P4556, DOI 10.1128/JVI.66.7.4556-4563.1992; BISHOP NE, 1993, VIROLOGY, V197, P616, DOI 10.1006/viro.1993.1636; BOROVEC SV, 1993, J VIROL, V67, P3095, DOI 10.1128/JVI.67.6.3095-3102.1993; DOTZAUER A, 1995, VIROLOGY, V213, P671; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUSSMULLER V, 1986, VIROLOGY, V155, P732, DOI 10.1016/0042-6822(86)90234-5; HARMON SA, 1991, J VIROL, V65, P2757, DOI 10.1128/JVI.65.5.2757-2760.1991; HARMON SA, 1995, J VIROL, V69, P5576, DOI 10.1128/JVI.69.9.5576-5581.1995; Hellen Christopher U. T., 1995, P155; KUSOV YY, 1992, J MED VIROL, V37, P220, DOI 10.1002/jmv.1890370313; MACGREGOR A, 1983, J CLIN MICROBIOL, V18, P1237, DOI 10.1128/JCM.18.5.1237-1243.1983; MARC D, 1990, J VIROL, V64, P4099, DOI 10.1128/JVI.64.9.4099-4107.1990; MUSCUFO N, 1992, J VIROL, V67, P6849; PING LH, 1988, P NATL ACAD SCI USA, V85, P8281, DOI 10.1073/pnas.85.21.8281; PING LH, 1992, J VIROL, V66, P2208, DOI 10.1128/JVI.66.4.2208-2216.1992; Probst C, 1998, J VIROL, V72, P8013, DOI 10.1128/JVI.72.10.8013-8020.1998; Probst C, 1997, J VIROL, V71, P3288, DOI 10.1128/JVI.71.4.3288-3292.1997; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; RUCHTI F, 1991, J GEN VIROL, V72, P2159, DOI 10.1099/0022-1317-72-9-2159; Rueckert R., 1996, FIELDS VIROLOGY, P609; SCHULTHEISS T, 1994, VIROLOGY, V198, P275, DOI 10.1006/viro.1994.1030; TESAR M, 1992, VIROLOGY, V186, P609, DOI 10.1016/0042-6822(92)90027-M; TESAR M, 1993, VIROLOGY, V194, P616, DOI 10.1006/viro.1993.1301	24	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4527	4531		10.1074/jbc.274.8.4527	http://dx.doi.org/10.1074/jbc.274.8.4527			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988685	hybrid			2022-12-25	WOS:000078698200010
J	Wiersma, EJ; Ronai, D; Berru, M; Tsui, FWL; Shulman, MJ				Wiersma, EJ; Ronai, D; Berru, M; Tsui, FWL; Shulman, MJ			Role of the intronic elements in the endogenous immunoglobulin heavy chain locus - Either the matrix attachment regions or the core enhancer is sufficient to maintain expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX; GENE-EXPRESSION; SWITCH REGION; HYBRIDOMA CELLS; HIGH-LEVEL; IGH LOCUS; MU GENE; TRANSCRIPTION; DELETION; MOUSE	High level expression in mice of transgenes derived from the immunoglobulin heavy chain (IgH) locus requires both the core enhancer (E mu) and the matrix attachment regions (MARs) that flank E mu. The need for both elements implies that they each perform a different function in transcription. While it is generally assumed that expression of the endogenous IgH locus has similar requirements, it has been difficult to assess the role of these elements in expression of the endogenous heavy chain gene, because B cell development and IgH expression are strongly interdependent and also because the locus contains other redundant activating elements. We have previously described a gene-targeting approach in hybridoma cells that overcomes the redundancy problem to yield a stable cell line in which expression of the IgH locus depends strongly on elements in the MAR-E mu-MAR segment. Using this system, we have found that expression of the endogenous mu gene persists at substantially (similar to 50%) normal levels in recombinants which retain either the MARs or E mu. That is, despite the dissimilar biochemical activities of these two elements, either one is sufficient to maintain high level expression of the endogenous locus. These findings suggest new models for how the enhancer and MARs might collaborate in the initiation or maintenance of transcription.	Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Toronto Hosp, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Shulman, MJ (corresponding author), Univ Toronto, Dept Immunol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							AGUILERA RJ, 1985, EMBO J, V4, P3689, DOI 10.1002/j.1460-2075.1985.tb04136.x; BAAR J, 1995, J IMMUNOL, V155, P1911; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; Bode J, 1996, CRIT REV EUKAR GENE, V6, P115, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.20; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; Boulikas T, 1995, INT REV CYTOL, V162A, P279; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; CONNOR A, 1993, SOMAT CELL MOLEC GEN, V19, P313, DOI 10.1007/BF01232744; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GRAM H, 1992, EUR J IMMUNOL, V22, P1185, DOI 10.1002/eji.1830220512; GROSSCHEDL R, 1988, CELL, V55, P645, DOI 10.1016/0092-8674(88)90223-1; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KLEIN S, 1984, EMBO J, V3, P2473, DOI 10.1002/j.1460-2075.1984.tb02158.x; KOHLER G, 1982, EMBO J, V1, P555, DOI 10.1002/j.1460-2075.1982.tb01208.x; Lieberson R, 1995, EMBO J, V14, P6229, DOI 10.1002/j.1460-2075.1995.tb00313.x; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; OANCEA AE, 1995, J IMMUNOL, V155, P5678; OANCEA AE, 1994, INT IMMUNOL, V6, P1161, DOI 10.1093/intimm/6.8.1161; Oancea AE, 1997, MOL CELL BIOL, V17, P2658, DOI 10.1128/MCB.17.5.2658; OCHI A, 1983, P NATL ACAD SCI-BIOL, V80, P6351, DOI 10.1073/pnas.80.20.6351; PORTON B, 1990, MOL CELL BIOL, V10, P1076, DOI 10.1128/MCB.10.3.1076; Saleque S, 1997, J IMMUNOL, V158, P4780; Schubeler D, 1996, BIOCHEMISTRY-US, V35, P11160, DOI 10.1021/bi960930o; SIGURDARDOTTIR D, 1995, J IMMUNOL, V154, P2217; WABL MR, 1984, P NATL ACAD SCI-BIOL, V81, P2452, DOI 10.1073/pnas.81.8.2452; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; ZALLER DM, 1985, P NATL ACAD SCI USA, V82, P5088, DOI 10.1073/pnas.82.15.5088	32	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4858	4862		10.1074/jbc.274.8.4858	http://dx.doi.org/10.1074/jbc.274.8.4858			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988726	hybrid			2022-12-25	WOS:000078698200051
J	Yu, LG; Fernig, DG; White, MRH; Spiller, DG; Appleton, P; Evans, RC; Grierson, I; Smith, JA; Davies, H; Gerasimenko, OV; Petersen, OH; Milton, JD; Rhodes, JM				Yu, LG; Fernig, DG; White, MRH; Spiller, DG; Appleton, P; Evans, RC; Grierson, I; Smith, JA; Davies, H; Gerasimenko, OV; Petersen, OH; Milton, JD; Rhodes, JM			Edible mushroom (Agaricus bisporus) lectin, which reversibly inhibits epithelial cell proliferation, blocks nuclear localization sequence-dependent nuclear protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER CELLS; HEAT-SHOCK PROTEIN-70; HUMAN-COLON-CANCER; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; CYTOSOLIC FACTORS; PEANUT LECTIN; TF ANTIGEN; IDENTIFICATION; EXPRESSION	The Gal beta 1-3GalNAc alpha (TF antigen)-binding lectin (ABL) from the common edible mushroom (Agaricus bisporus) has a potent anti-proliferative effect without any apparent cytotoxicity, This unusual combination of properties prompted investigation of its mechanism of action. In contrast to soluble lectin, agarose-immobilized, and hence noninternalizable ABL had no effect on proliferation of HT29 colon cancer cells. Electron microscopy of HT29 cells incubated with fluorescein- and gold-conjugated ABL showed internalization of the lectin into endocytotic vesicles and multivesicular bodies. Confocal microscopy showed perinuclear accumulation of fluorescein isothiocyanate-conjugated lectin, which also inhibits HT29 cell proliferation, raising the possibility that the lectin might interfere with nuclear pore function. Transport of heat shock protein 70 into the nucleus in response to heat shock was blocked by preincubation of HT29 cells for 6 h with 40 mu g/ml ABL, In digitonin-permeabilized cells, nuclear uptake of bovine albumin conjugated to a nuclear localization sequence (NLS)-containing peptide was also inhibited by a 15-min preincubation with 40-100 mu g/ml ABL, In contrast, serum-stimulated nuclear translocation of mitogen-activated protein kinase, which is NLS-independent, was not affected by pretreatment of cells with the lectin, These results suggest that the anti-proliferative effect of ABL is Likely to be a consequence of the lectin trafficking to the nuclear periphery, where it blocks NLS-dependent protein uptake into the nucleus.	Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England; Univ Liverpool, Dept Physiol, Liverpool L69 3GA, Merseyside, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 3GA, Merseyside, England	University of Liverpool; University of Liverpool; University of Liverpool	Rhodes, JM (corresponding author), Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England.	rhodesjm@liv.ac.uk	Spiller, David G/I-3645-2012; Rhodes, Jonathan M/C-2496-2009; Gerasimenko, Oleg/A-6622-2010; Fernig, David G/A-3590-2008; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Fernig, David G/0000-0003-4875-4293; Spiller, David Geoffrey/0000-0003-2502-6787; White, Michael/0000-0002-3617-3232				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BADACHE A, 1995, GLYCOBIOLOGY, V5, P371, DOI 10.1093/glycob/5.4.371; BUSS F, 1994, J CELL SCI, V107, P631; CAMPBELL BJ, 1995, J CLIN INVEST, V95, P571, DOI 10.1172/JCI117700; DINWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1, DOI 10.1007/s004240050098; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HIRABAYASHI J, 1998, TRENDS GLYCOSCI GLYC, V9, P1; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWEYER DD, 1988, CELL, V51, P641; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NOVOGRODSKY A, 1977, P NATL ACAD SCI USA, V74, P676, DOI 10.1073/pnas.74.2.676; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; PRESANT CA, 1972, J BIOL CHEM, V247, P6937; PUSZTAI A, 1991, PLANT LECTINS, P78; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Rhodes JM, 1996, LANCET, V347, P40, DOI 10.1016/S0140-6736(96)91563-9; RYDER SD, 1994, GASTROENTEROLOGY, V106, P85, DOI 10.1016/S0016-5085(94)94527-6; Ryder SD, 1998, GASTROENTEROLOGY, V114, P44, DOI 10.1016/S0016-5085(98)70631-6; RYDER SD, 1994, GASTROENTEROLOGY, V106, P117, DOI 10.1016/S0016-5085(94)94775-9; RYDER SD, 1992, JNCI-J NATL CANCER I, V84, P1410, DOI 10.1093/jnci/84.18.1410; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; SHAMSUDDIN AM, 1995, CANCER RES, V55, P149; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SPRINGER GF, 1982, J BIOL CHEM, V257, P2744; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; YU LG, 1993, CANCER RES, V53, P4627; Yu LG, 1997, INT J CANCER, V73, P424, DOI 10.1002/(SICI)1097-0215(19971104)73:3<424::AID-IJC18>3.3.CO;2-C; ZANETTA JP, 1994, HISTOL HISTOPATHOL, V9, P385	58	104	109	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4890	4899		10.1074/jbc.274.8.4890	http://dx.doi.org/10.1074/jbc.274.8.4890			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988731	hybrid			2022-12-25	WOS:000078698200056
J	Zhang, ZH; Elly, C; Altman, A; Liu, YC				Zhang, ZH; Elly, C; Altman, A; Liu, YC			Dual regulation of T cell receptor-mediated signaling by oncogenic Cbl mutant 70Z	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-CBL; PHOSPHOTYROSINE-BINDING DOMAIN; OF-FUNCTION MUTATION; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; V-CBL; PHOSPHOINOSITIDE 3-KINASE; ADAPTER PROTEINS	We previously showed that an oncogenic Cbl mutant (70Z) is constitutively active in transcriptional activation of nuclear factor at activated T cells (NFAT), However, the mechanism underlying this effect remains unclear. Here we analyzed the effects of 70Z mutations at an amino-terminal loss of function site (Gly-306) and at carboxyl-terminal potential tyrosine or serine phosphorylation sites on association with signaling proteins and on NFAT activation. Mutation at Gly-306 of 70Z disrupted its association with Zap-70 and almost completely abolished its ability to induce NFAT activation under basal and ionomycin-stimulated conditions. However, mutations at potential tyrosine or serine phosphorylation sites had little effect. In fact, expression of 70Z with Tyr-700, Tyr-731, or Tyr-774 mutated to Phe increased NFAT activity in comparison with unmutated 70Z. These findings suggest that an amino terminus-mediated interaction of 70Z with Zap-70 plays a positive role and that a carboxyl terminus-mediated, phosphotyrosine-dependent interaction with their binding proteins plays a negative role in 70Z-mediated NFAT activation. In support of this notion are the observations that 70Z reduced T cell receptor-induced NFAT activation and that wild-type Cbl further inhibited this event, suggesting that both 70Z and wild-type Cbl employ a similar mechanism by which Cbl proteins dually regulate T cell receptor-mediated signaling.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.			LIU, YUN-CAI/0000-0002-0996-7109	NCI NIH HHS [CA35299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Crabtree GR, 1996, TRENDS BIOCHEM SCI, V21, P418, DOI 10.1016/S0968-0004(96)20027-1; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kong GH, 1996, MOL CELL BIOL, V16, P5026; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	48	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4883	4889		10.1074/jbc.274.8.4883	http://dx.doi.org/10.1074/jbc.274.8.4883			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988730	hybrid			2022-12-25	WOS:000078698200055
J	Kochs, G; Haller, O				Kochs, G; Haller, O			GTP-bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS; ANTIVIRAL ACTIVITY; TICK-BORNE; LEUCINE ZIPPER; RESISTANT MICE; MESSENGER-RNA; DHORI-VIRUS; MURINE MX1; INTERFERON; INHIBITION	Human MxA protein is an interferon-induced member of the dynamin superfamily of large GTPases. MxA inhibits the multiplication of several RNA viruses, including Thogoto virus, an influenza virus-like orthomyxovirus transmitted by ticks. Previous studies have indicated that GTP binding is required for antiviral activity, but the mechanism of action is still unknown. Here, we have used an in vitro cosedimentation assay to demonstrate, for the first time, a GTP-dependent interaction between MxA GTPase and a viral target structure. The assay is based on highly active MxA GTPase as effector molecules, Thogoto virus nucleocapsids as viral targets, and guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) as a stabilizing factor. We show that MxA tightly interacts with viral nucleocapsids by binding to the nucleoprotein component. This interaction requires the presence of GTP gamma S and is mediated by domains in the carboxyl-terminal moiety of MxA. We propose that GTP-bound MxA adopts an antivirally active conformation that allows interaction with viral nucleocapsids, thereby impairing their normal function.	Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, D-79008 Freiburg, Germany	University of Freiburg	Kochs, G (corresponding author), Univ Freiburg, Abt Virol, Inst Med Mikrobiol & Hyg, Hugstetter Str 55, D-79008 Freiburg, Germany.							AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ALBANESE M, 1972, ACTA VIROL, V16, P267; ARNHEITER H, 1988, EMBO J, V7, P1315, DOI 10.1002/j.1460-2075.1988.tb02946.x; BAUDIN F, 1994, EMBO J, V13, P3158, DOI 10.1002/j.1460-2075.1994.tb06614.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOPPIN PW, 1975, INFLUENZA VIRUSES IN; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Frese M, 1996, J VIROL, V70, P915, DOI 10.1128/JVI.70.2.915-923.1996; FULLER FJ, 1987, VIROLOGY, V160, P81, DOI 10.1016/0042-6822(87)90047-X; GARBER EA, 1993, VIROLOGY, V194, P715, DOI 10.1006/viro.1993.1312; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; HUANG T, 1992, J VIROL, V66, P4154, DOI 10.1128/JVI.66.7.4154-4160.1992; Johannes L, 1997, J VIROL, V71, P9792, DOI 10.1128/JVI.71.12.9792-9795.1997; JOHANNES L, 1991, J INTERFERON RES S, V11, P50; JONES LD, 1989, VIRUS RES, V14, P129, DOI 10.1016/0168-1702(89)90034-8; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; PAVLOVIC J, 1995, J VIROL, V69, P4506, DOI 10.1128/JVI.69.7.4506-4510.1995; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; PORTELA A, 1992, J GEN VIROL, V73, P2823, DOI 10.1099/0022-1317-73-11-2823; Pringle CR, 1996, ARCH VIROL, V141, P2251, DOI 10.1007/BF01718231; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; ROERS A, 1994, J INFECT DIS, V169, P807, DOI 10.1093/infdis/169.4.807; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCHNEIDERSCHAULIES S, 1994, J VIROL, V68, P6910, DOI 10.1128/JVI.68.11.6910-6917.1994; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; Siebler J, 1996, ARCH VIROL, V141, P1587, DOI 10.1007/BF01718257; SIMON A, 1991, J VIROL, V65, P968, DOI 10.1128/JVI.65.2.968-971.1991; STAEHELI P, 1985, MOL CELL BIOL, V5, P2150, DOI 10.1128/MCB.5.8.2150; STAEHELI P, 1991, J VIROL, V65, P4498, DOI 10.1128/JVI.65.8.4498-4501.1991; Staeheli P, 1987, Interferon, V8, P1; STAEHELI P, 1985, J BIOL CHEM, V260, P1821; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; STRANDEN AM, 1993, VIROLOGY, V197, P642, DOI 10.1006/viro.1993.1639; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VONWUSSOW P, 1990, AIDS, V4, P119, DOI 10.1097/00002030-199002000-00004; Weber F, 1996, J VIROL, V70, P8361, DOI 10.1128/JVI.70.12.8361-8367.1996; ZURCHER T, 1992, EMBO J, V11, P1657, DOI 10.1002/j.1460-2075.1992.tb05212.x; ZURCHER T, 1992, J VIROL, V66, P5059	52	86	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4370	4376		10.1074/jbc.274.7.4370	http://dx.doi.org/10.1074/jbc.274.7.4370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933640	hybrid			2022-12-25	WOS:000078575500064
J	Tanabe, K; Tucker, SJ; Matsuo, M; Proks, P; Ashcroft, FM; Seino, S; Amachi, T; Ueda, K				Tanabe, K; Tucker, SJ; Matsuo, M; Proks, P; Ashcroft, FM; Seino, S; Amachi, T; Ueda, K			Direct photoaffinity labeling of the Kir6.2 subunit of the ATP-sensitive K+ channel by 8-azido-ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; STOICHIOMETRY; CLONING	ATP-sensitive potassium channels are under complex regulation by intracellular ATP and ADP. The potentiating effect of MgADP is conferred by the sulfonylurea receptor subunit of the channel, SUR, whereas the inhibitory effect of ATP appears to be mediated via the pore-forming subunit, Kir6.2. We determined whether ATP directly interacts with a binding site on the Kir6.2 subunit to mediate channel inhibition by analyzing binding of a photoaffinity analog of ATP (8-azido-[gamma-P-32]ATP) to membranes from COS-7 cells transiently expressing Kir6.2. We demonstrate that Kir6.2 can be directly labeled by 8-azido-[gamma-P-32]ATP but that the related subunit Kir 4.1, which is not inhibited by ATP, is not labeled. Photoaffinity labeling of Kir6.2 is reduced by approximately 50% with 100 mu M ATP. In addition, mutations in the NH, terminus (R50G) and the COOH terminus (K185Q) of Kir6.2, which have both been shown to reduce the inhibitory effect of ATP upon Kir6.2 channel activity, reduced photoaffinity labeling by >50%, These results demonstrate that ATP binds directly to Kir6.2 and that both the NH2- and COOH-terminal intracellular domains may influence ATP binding.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, Chiba 2608670, Japan	Kyoto University; University of Oxford; Chiba University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan.		Tucker, Stephen J./ABE-7468-2020; Tucker, Stephen J./ABE-6741-2020	Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000; Proks, Peter/0000-0001-6097-3646; Ueda, Kazumitsu/0000-0003-2980-6078				Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SEINO S, 1996, DIABETES REV, V4, P177; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983	17	86	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3931	3933		10.1074/jbc.274.7.3931	http://dx.doi.org/10.1074/jbc.274.7.3931			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933580	hybrid			2022-12-25	WOS:000078575500004
J	Balasubramanian, S; Kim, KH; Ahmad, N; Mukhtar, H				Balasubramanian, S; Kim, KH; Ahmad, N; Mukhtar, H			Activation of telomerase and its association with G1-phase of the cell cycle during UVB-induced skin tumorigenesis in SKH-1 hairless mouse	ONCOGENE			English	Article						telomerase; cell cycle; cyclin; cyclin dependent kinase; cyclin dependent kinase inhibitor; skin carcinogenesis	HUMAN BREAST-CANCER; HEMATOPOIETIC-CELLS; IMMORTAL CELLS; CDK INHIBITOR; OVEREXPRESSION; DIFFERENTIATION; CARCINOGENESIS; AMPLIFICATION; PROGRESSION; P15(INK4B)	Telomerase is a ribonucleoprotein enzyme that adds hexanucleotide repeats TTAGGG to the ends of chromosomes, Telomerase activation is known to play a crucial role in cell-immortalization and carcinogenesis. Telomerase is shown to have a correlation with cell cycle progression, which is controlled by the regulation of cyclins, cyclin dependent kinases (cdks) and cyclin dependent kinase inhibitors (cdkis), Abnormal expression of these regulatory molecules may cause alterations in cell cycle with uncontrolled cell growth, a universal feature of neoplasia, Skin cancer is the most prevalent form of cancer in humans and the solar UV radiation is its major cause. Here, we investigated modulation in telomerase activity and protein expression of cell cycle regulatory molecules during the development of UVB-induced tumors in SKH-1 hairless mice, The mice were exposed to 180 mjoules/cm(2) UVB radiation, thrice weekly for 24 weeks. The animals were sacrificed at 4 week intervals and the studies were performed in epidermis, Telomerase activity was barely detectable in the epidermis of non-irradiated mouse. UVB exposure resulted in a progressive increase in telomerase activity starting from the 4th week of exposure. The increased telomerase activity either persisted or further increased with the increased exposure, In papillomas and carcinomas the enzyme activity was comparable and was 45-fold higher than in the epidermis of control mice. Western blot analysis showed an upregulation in the protein expression of cyclin D1 and cyclin E and their regulatory subunits cdk4 and cdk2 during the course of UVB exposure and in papillomas and carcinomas. The protein expression of cdk6 and ckis viz, p16/Ink4A, p21/Waf1 and p27/Kip1 did not show any significant change in WE exposed skin, but significant upregulation was observed both in papillomas and carcinomas. The results suggest that telomerase activation may be involved in UVB-induced tumorigenesis in mouse skin and that increased telomerase activity may be associated with G1 phase of the cell cycle.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA043703, R01CA051802, P01CA048735] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 43703, R01 CA 51802, P01 CA 48735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasubramanian S, 1998, BIOCHEM BIOPH RES CO, V243, P744, DOI 10.1006/bbrc.1998.8172; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bednarek AK, 1997, MOL CARCINOGEN, V20, P329, DOI 10.1002/(SICI)1098-2744(199712)20:4<329::AID-MC1>3.0.CO;2-E; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHADENEAU C, 1995, ONCOGENE, V11, P893; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAS M, 1987, CANCER RES, V47, P760; Engelhardt M, 1997, BLOOD, V90, P182; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Landberg G, 1997, CANCER RES, V57, P549; LEACH FS, 1993, CANCER RES, V53, P1986; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Pandita TK, 1996, ONCOGENE, V13, P1423; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Tron VA, 1996, AM J PATHOL, V149, P1139; Ueda M, 1997, CANCER RES, V57, P370; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Yashima K, 1998, CLIN CANCER RES, V4, P229; Yasumoto S, 1996, ONCOGENE, V13, P433; Yoshimi N, 1996, MOL CARCINOGEN, V16, P1, DOI 10.1002/(SICI)1098-2744(199605)16:1<1::AID-MC1>3.0.CO;2-N; Zhang T, 1997, CANCER RES, V57, P169; ZHOU P, 1995, ONCOGENE, V11, P571	39	25	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1297	1302		10.1038/sj.onc.1202417	http://dx.doi.org/10.1038/sj.onc.1202417			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022811				2022-12-25	WOS:000078510900005
J	Bardelli, A; Basile, ML; Audero, E; Giordano, S; Wennstrom, S; Menard, S; Comoglio, PM; Ponzetto, C				Bardelli, A; Basile, ML; Audero, E; Giordano, S; Wennstrom, S; Menard, S; Comoglio, PM; Ponzetto, C			Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis	ONCOGENE			English	Article						Met-mediated metastasis; met signaling; PI 3-kinase; Grb2; Ras	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; DOCKING PROTEIN; TPR-MET; TRANSFORMATION; ONCOGENE; MOTILITY	The Met tyrosine kinase - the HGF receptor - induces cell transformation and metastasis when constitutively activated. Met signaling is mediated by phosphorylation of two carboxy-terminal tyrosines which act as docking sites for a number of SH2-containing molecules. These include Grb2 and p85 which couple the receptor, respectively, with Ras and PI 3-kinase, We previously showed that a Met mutant designed to obtain preferential coupling with Grb2 (Met(2xGrb2)) is permissive for motility, increases transformation, but - surprisingly - is impaired in causing invasion and metastasis. In this work, we used Met mutants optimized for binding either p85 alone (Met(2xPI3K)) Or p85 and Grb2 (Met(P13/Grb2)) to evaluate the relative importance of Pas and PI 3-kinase as downstream effecters of Met. Met(2xPI3K) was competent in eliciting motility, but not transformation, invasion, or metastasis. Conversely, Met(PI3K/Grb2) induced motility, transformation, invasion and metastasis as efficiently as wild type Met. Furthermore, the expression of constitutively active PI 3-kinase in cells transformed by the Met(2xGrb2) mutant, fully rescued their ability to invade and metastasize. These data point to a central role for PI 3-kinase in Met-mediated invasiveness, and indicate that simultaneous activation of Ras and PI 3-kinase is required to unleash the Met metastatic potential.	Univ Turin, Sch Med, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10126 Turin, Italy; Imperial Canc Res Fund, London WC2A 3PX, England; Ist Nazl Tumori, I-20133 Milan, Italy	University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Cancer Research UK; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ponzetto, C (corresponding author), Univ Turin, Sch Med, Dept Biomed Sci & Oncol, Cso Massimo dAzeglio 52, I-10126 Turin, Italy.		Giordano, Silvia/J-9858-2018; menard, sylvie mm/C-7940-2011; BARDELLI, Alberto/J-9721-2018	Giordano, Silvia/0000-0003-1854-1086; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Audero, Enrica/0000-0002-6138-244X				Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DERMAN MP, 1996, AM J PHYSIOL, V268, pF1211; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SHAW LM, 1972, CELL, V9194, P97; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Sporken R, 1997, MRS INTERNET J N S R, V2, part. no.; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	44	59	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1139	1146		10.1038/sj.onc.1202607	http://dx.doi.org/10.1038/sj.onc.1202607			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022119				2022-12-25	WOS:000078510700002
J	Biden, KG; Simms, LA; Cummings, M; Buttenshaw, R; Schoch, E; Searle, J; Gobe, G; Jass, JR; Meltzer, SJ; Leggett, BA; Young, J				Biden, KG; Simms, LA; Cummings, M; Buttenshaw, R; Schoch, E; Searle, J; Gobe, G; Jass, JR; Meltzer, SJ; Leggett, BA; Young, J			Expression of bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability	ONCOGENE			English	Article						bcl-2; apoptosis; microsatellite instability; colorectal adenocarcinoma	PROGRAMMED CELL-DEATH; C-MYB; CANCER; P53; APOPTOSIS; GENE; SURVIVAL; COLON; POLYMORPHISM; INHIBITION	Bcl-2 is known to inhibit apoptosis and is thought to play a role in colorectal tumour development. Studies of the promoter region of bcl-2 have indicated the presence of a p53 responsive element which downregulates bcl-2 expression, Since p53 is commonly mutated in colorectal cancers, but rarely in those tumours showing microsatellite instability (MSI), the aim of this study was to examine the relationship of bcl-2 protein expression to MSI, as well as to other clinicopathological and molecular variables, in colorectal adenocarcinomas. Expression of bcl-2 was analysed by immunohistochemistry in 71 colorectal cancers which had been previously assigned to three classes depending upon their levels of MSI. MSI-high tumours demonstrated instability in three or more of six microsatellite markers tested, MSI-low tumours in one or two of six, and MSI-null in none of six, Bcl-2 expression in tumours was quantified independently by two pathologists and assigned to one of five categories, with respect to the number of cells which showed positive staining: 0, up to 5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, greater than or equal to 76%, Bcl-2 negative tumours were defined as those with a score of 0. Bcl-2 protein expression was tested for association with clinicopathological stage, differentiation level, tumour site, age, sex, survival, evidence of p53 inactivation and MSI level, A significant association was found between bcl-2 expression and patient survival (P = 0.012, Gehan Wilcoxon test). Further, a significant reciprocal relationship was found between bcl-2 expression and the presence of MSI (P = 0.012, Wilcoxon rank sum test). We conclude that bcl-2 expressing colorectal cancers are more likely to be MSI-null, and to be associated with improved patient survival.	Royal Brisbane Hosp Fdn Clin Res Ctr, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; Royal Brisbane Hosp, Dept Pathol, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Pathol, Brisbane, Qld, Australia; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Grad Program Mol & Cell Biol, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Royal Brisbane & Women's Hospital; University of Queensland; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Biden, KG (corresponding author), RBHRF, Clin Res Ctr, Conjoint Gastroenterol Lab, Bancroft Ctr, 300 Herston Rd, Brisbane, Qld 4029, Australia.		Gobe, Glenda C/G-2315-2010; Cummings, Margaret/B-5747-2011; Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011; Leggett, Barbara A/D-3579-2011	Cummings, Margaret/0000-0002-7657-0240; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397	NATIONAL CANCER INSTITUTE [R01CA067497, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDI A, 1995, CANCER RES, V55, P1811; BJERKESET T, 1987, DIS COLON RECTUM, V30, P934, DOI 10.1007/BF02554279; BRONNER MP, 1995, AM J PATHOL, V146, P20; Cottu PH, 1996, ONCOGENE, V13, P2727; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HAGUE A, 1994, ONCOGENE, V9, P3367; HENRIKSEN R, 1995, BRIT J CANCER, V72, P1324, DOI 10.1038/bjc.1995.509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Kaklamanis L, 1996, J PATHOL, V179, P10; KASTAN MB, 1991, CANCER RES, V51, P6304; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYASHITA T, 1994, CANCER RES, V54, P3131; OFNER D, 1995, BRIT J CANCER, V72, P981, DOI 10.1038/bjc.1995.446; OLSCHWANG S, 1991, HUM GENET, V86, P369; PIETENPOL JA, 1994, CANCER RES, V54, P3714; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Simms LA, 1997, ONCOGENE, V14, P2613, DOI 10.1038/sj.onc.1201094; SINICROPE FA, 1995, CANCER RES, V55, P237; Sun XF, 1996, APMIS, V104, P35, DOI 10.1111/j.1699-0463.1996.tb00683.x; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	35	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1245	1249		10.1038/sj.onc.1202413	http://dx.doi.org/10.1038/sj.onc.1202413			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022131				2022-12-25	WOS:000078510700014
J	Das, TK; Boffi, A; Chiancone, E; Rousseau, DL				Das, TK; Boffi, A; Chiancone, E; Rousseau, DL			Hydroxide rather than histidine is coordinated to the heme in five-coordinate ferric Scapharca inaequivalvis hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; COOPERATIVE DIMERIC HEMOGLOBIN; CYTOCHROME-C PEROXIDASE; SPIN-STATE EQUILIBRIA; RAMAN-SCATTERING; STRUCTURAL CHARACTERIZATION; HOMODIMERIC HEMOGLOBIN; INOSITOL HEXAPHOSPHATE; TETRAMERIC HEMOGLOBINS; ALLOSTERIC TRANSITIONS	The ferric form of the homodimeric Scapharca hemoglobin undergoes a pH-dependent spin transition of the heme iron. The transition can also be modulated by the presence of salt. From our earlier studies it was shown that three distinct species are populated in the pH range 6-9, At acidic pH, a low-spin six-coordinate structure predominates. At neutral and at alkaline pHs, in addition to a small population of a hexacoordinate high-spin species, a pentacoordinate species is significantly populated. Isotope difference spectra clearly show that the heme group in the latter species has a hydroxide ligand and thereby is not coordinated by the proximal histidine, The stretching frequency of the Fe-OH moiety is 578 cm(-1) and shifts to 553 cm(-1) in (H2O)-O-18, as would be expected for a Fe OH unit. On the other hand, the ferrous form of the protein shows substantial stability over a wide pH range. These observations suggest that Scapharca hemoglobin has a unique heme structure that undergoes substantial redox-dependent rearrangements that stabilize the Fe-proximal histidine bond in the functional deoxy form of the protein but not in the ferric form.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ La Sapienza, Dept Biochem Sci, CNR, Ctr Biol Mol, I-00185 Rome, Italy	Yeshiva University; Albert Einstein College of Medicine; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Das, Tapan/0000-0002-3641-3988	NIGMS NIH HHS [GM54812, GM54806] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054812, R01GM054806] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1984, J BIOL CHEM, V259, P6730; ANTONINI E, 1982, ADV EXP MED BIOL, V148, P67; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; ASCENZI P, 1981, J BIOL CHEM, V256, P5383; ASHER SA, 1977, BIOCHEMISTRY-US, V16, P5849, DOI 10.1021/bi00645a032; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; Boffi A, 1997, BIOCHEMISTRY-US, V36, P4505, DOI 10.1021/bi9618880; BOFFI A, 1991, J BIOL CHEM, V266, P17898; BOFFI A, 1994, J BIOL CHEM, V269, P20437; BOFFI A, 1994, BIOPHYS J, V67, P1713, DOI 10.1016/S0006-3495(94)80645-9; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CHIANCONE E, 1990, BIOPHYS CHEM, V37, P287, DOI 10.1016/0301-4622(90)88028-Q; COLETTA M, 1990, J BIOL CHEM, V265, P4828; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DESIDERI A, 1984, FEBS LETT, V166, P378, DOI 10.1016/0014-5793(84)80116-7; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Guarrera L, 1998, BIOCHEMISTRY-US, V37, P5608, DOI 10.1021/bi972380f; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HENRY ER, 1985, BIOCHEMISTRY-US, V24, P5907, DOI 10.1021/bi00342a033; INUBUSHI T, 1988, FEBS LETT, V235, P87, DOI 10.1016/0014-5793(88)81239-0; MONCADA S, 1991, PHARMACOL REV, V43, P109; Mozzarelli A, 1996, J BIOL CHEM, V271, P3627; NAGAI K, 1980, BIOCHIM BIOPHYS ACTA, V624, P304, DOI 10.1016/0005-2795(80)90249-4; NOBLE RW, 1989, BIOCHEMISTRY-US, V28, P5293, DOI 10.1021/bi00438a056; Paoli M, 1997, J MOL BIOL, V271, P161, DOI 10.1006/jmbi.1997.1180; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2187, DOI 10.1021/bi00707a028; PERUTZ MF, 1978, BIOCHEMISTRY-US, V17, P3640, DOI 10.1021/bi00610a034; PERUTZ MF, 1974, BIOCHEMISTRY-US, V13, P2174, DOI 10.1021/bi00707a027; ROUSSEAU DL, 1993, J BIOL CHEM, V268, P5719; ROUSSEAU DL, 1989, J BIOL CHEM, V264, P7878; ROUSSEAU DL, 1980, NATURE, V285, P49, DOI 10.1038/285049a0; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPAGNUOLO C, 1983, J MOL BIOL, V164, P627, DOI 10.1016/0022-2836(83)90054-2; SPAGNUOLO C, 1994, J BIOL CHEM, V269, P20441; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; Sun J, 1997, J AM CHEM SOC, V119, P2064, DOI 10.1021/ja963461m; TAKAHASHI S, 1980, BIOCHEMISTRY-US, V19, P5196, DOI 10.1021/bi00564a007; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; VERZILI D, 1982, BIOCHIM BIOPHYS ACTA, V704, P215, DOI 10.1016/0167-4838(82)90148-0; WANG J, 1996, RESONANCE RAMAN SCAT, P427; YONETANI T, 1974, J BIOL CHEM, V249, P2168	51	29	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2916	2919		10.1074/jbc.274.5.2916	http://dx.doi.org/10.1074/jbc.274.5.2916			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915829	hybrid			2022-12-25	WOS:000078319500047
J	Jouanneau, J; Moens, G; Thiery, JP				Jouanneau, J; Moens, G; Thiery, JP			The community effect in FGF-1 mediated tumor progression of a rat bladder carcinoma does not involve a direct paracrine signaling	ONCOGENE			English	Article						dominant-negative FGFR mutant; community effect; tumor heterogeneity; tumor cell interactions	FIBROBLAST GROWTH-FACTOR; TISSUE-CULTURE; ATHYMIC MICE; CELL-LINE; IN-VIVO; EXPRESSION; RECEPTORS; TUMORIGENICITY; TRANSFORMATION; ORGANIZATION	A community effect was found to occur between heterogeneous tumor cell populations leading to an overall increased tumorigenicity without a clonal dominance of the more tumorigenic clone. In the rat bladder carcinoma cell line NET-II, this effect appears mediated by the Fibroblast Growth Factor-1 (FGF-1) through either a direct or an indirect signaling pathway. Neovascularization induced by FGF-1 was found not to be responsible for the community effect. The present study shows that the community effect does not involve a direct FGF-1 signaling since tumor cells expressing a dominant-negative FGF receptor mutant were still responding to the highly tumorigenic FGF-1 expressing cells. Tumors arising from inoculates of the FGF-1 producing NET-II cells mixed with non tumorigenic epithelial MDCK cells contain only the tumorigenic cells indicating that MDCK cells may exerce a helper effect for the growth of the tumor not dependant on their own growth. Therefore the helper function of MDCK cells must be distinguished from a community effect where the contribution of low tumorigenic cells not only provides an in vivo growth advantage to few highly tumorigenic cells but become themselves highly tumorigenic indicating that the community effect may require cell-cell specific cooperativity independent from an helper effect.	UMR 144 CNRS, F-75248 Paris 05, France; Inst Curie, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jouanneau, J (corresponding author), UMR 144 CNRS, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				AABO K, 1995, EUR J CANCER, V31A, P222, DOI 10.1016/0959-8049(94)00434-7; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; COLBEREGARAPIN F, 1981, J MOL BIOL, V105, P1; DeBoth NJ, 1997, INT J CANCER, V72, P1137, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1137::AID-IJC32>3.0.CO;2-Z; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; GARTNER MFRM, 1992, INT J CANCER, V51, P788, DOI 10.1002/ijc.2910510520; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; GURDON JB, 1993, CELL, V75, P831, DOI 10.1016/0092-8674(93)90526-V; HENNIGAN TW, 1994, SURG ONCOL, V3, P275, DOI 10.1016/0960-7404(94)90029-9; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; Loizidou MC, 1996, BRIT J SURG, V83, P24, DOI 10.1002/bjs.1800830107; MEHTA RR, 1993, BREAST CANCER RES TR, V25, P65, DOI 10.1007/BF00662402; Nakajima M, 1993, Hum Cell, V6, P7; PAWELETZ N, 1994, CRIT REV ONCOGENESIS, V5, P69, DOI 10.1615/CritRevOncog.v5.i1.40; RAK JW, 1993, IN VITRO CELL DEV-AN, V29A, P742; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schor S L, 1995, EXS, V74, P273; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; ULRICH A, 1990, CELL, V61, P203; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4	33	12	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					327	333		10.1038/sj.onc.1202285	http://dx.doi.org/10.1038/sj.onc.1202285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927189				2022-12-25	WOS:000078166500005
J	Ioannidis, P; Courtis, N; Havredaki, M; Michailakis, E; Tsiapalis, CM; Trangas, T				Ioannidis, P; Courtis, N; Havredaki, M; Michailakis, E; Tsiapalis, CM; Trangas, T			The polyadenylation inhibitor cordycepin (3 ' dA) causes a decline in c-MYC mRNA levels without affecting c-MYC protein levels	ONCOGENE			English	Article						c-myc mRNA; translation; poly(A) tail; cordycepin	MESSENGER-RNA DEGRADATION; AU-RICH ELEMENTS; TUMOR NECROSIS FACTOR; POLY(A) TAIL; 3'-UNTRANSLATED REGION; UNTRANSLATED REGION; CELL-CYCLE; TRANSLATIONAL EFFICIENCY; INITIATION; SEQUENCE	Study of the distribution of the poly(A) tail length of c-myc mRNA in several cell lines revealed a distinct, prevailing population with short poly(A) tails, derived through sequential deadenylation, To elucidate the possible in vivo function of this distinct short failed c-myc mRNA population, the polyadenylation inhibitor cordycepin was used, This resulted in a decline in steady state c-myc mRNA levels with the remaining messenger mostly oligoadenylated, However, c-MYC proteins did not follow the reduction of the c-myc mRNA, On the other hand, in cells exposed to physiological agents known to downregulate c-myc expression, the reduction of mRNA steady state levels, was reflected upon c-MYC protein levels, The dissociation between c-myc mRNA and protein levels caused by cordycepin was not dare to the stabilization of the c-MYC proteins and was not an indiscriminate effect since in the presence of cordycepin, c-fos mRNA and protein levels concomitantly declined, Our data indicate that under these conditions, a long poly(A) tail is not instrumental for c-myc mRNA translation and furthermore, the discrepancy in the steady state of c-myc mRNA level: c-MYC protein ratio between control cells and cells treated with cordycepin indicates that c-myc mRNA is subjected to translational control.	St Savvas Hosp, Papanikolaou Res Ctr Oncol, Athens 11522, Greece; NCSR Democritos, Athens, Greece; Athens Gen Hosp, Oncol Unit, Athens, Greece	National Centre of Scientific Research "Demokritos"	Trangas, T (corresponding author), St Savvas Hosp, Papanikolaou Res Ctr Oncol, 171 Alexandras Ave, Athens 11522, Greece.							BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BALLANTINE JEM, 1985, FEBS LETT, V180, P224, DOI 10.1016/0014-5793(85)81075-9; BEACH LR, 1978, J BIOL CHEM, V253, P2628; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BREWER G, 1990, METHOD ENZYMOL, V181, P202; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Dehlin E, 1996, MOL CELL BIOL, V16, P468; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Ioannidis P, 1996, NUCLEIC ACIDS RES, V24, P4969, DOI 10.1093/nar/24.24.4969; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KLEENE KC, 1989, DEVELOPMENT, V106, P367; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LIN JX, 1987, J BIOL CHEM, V262, P11908; Lorenzini EC, 1997, BIOCHEM J, V326, P361, DOI 10.1042/bj3260361; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MACIEJEWSKILENOIR D, 1993, P NATL ACAD SCI USA, V90, P1435, DOI 10.1073/pnas.90.4.1435; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; NABRU C, 1997, J BIOL CHEM, V272, P32061; Paulin FEM, 1996, ONCOGENE, V13, P505; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STOECKLE MY, 1993, BIOTECHNIQUES, V15, P227; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	60	23	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					117	125		10.1038/sj.onc.1202255	http://dx.doi.org/10.1038/sj.onc.1202255			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926926				2022-12-25	WOS:000078166000013
J	Ezaki, S; Maeda, N; Kishimoto, T; Atomi, H; Imanaka, T				Ezaki, S; Maeda, N; Kishimoto, T; Atomi, H; Imanaka, T			Presence of a structurally novel type ribulose-bisphosphate carboxylase/oxygenase in the hyperthermophilic archaeon, Pyrococcus kodakaraensis KOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; CO2 FIXATION OPERON; RHODOBACTER-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM; NUCLEOTIDE-SEQUENCE; STRAIN KOD1; FORM-I; EXPRESSION; GENE; PURIFICATION	We have characterized the gene encoding ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) of the hyperthermophilic archaeon, Pyrococcus kodakaraensis KOD1, The gene encoded a protein consisting of 444 amino acid residues, corresponding in size to the large subunit of previously reported Rubiscos, Rubisco of P. kodakaraensis KOD1 (Pk-Rubisco) showed only 51.4% similarity with the large subunit of type I Rubisco from spinach and 47.3% with that of type II Rubisco from Rhodospirillum rubrum, suggesting that the enzyme was not a member of either type. Active site residues identified from type I and type II Rubiscos were conserved. We expressed the gene in Escherichia coli, and we obtained a soluble protein with the expected molecular mass and N-terminal amino acid sequence. Purification of the recombinant protein revealed that Pk-Rubisco was an L-8 type homo-octamer. Pk-Rubisco showed highest specific activity of 19.8 x 10(3) nmol of CO2 fixed per min/mg, and a tau value of 310 at 90 degrees C, both higher than any previously characterized Rubisco, The optimum pH was 8.3, and the enzyme possessed extreme thermostability, with a half-life of 15 h at 80 degrees C, Northern blot analysis demonstrated that the gene was transcribed in P. kodakaraensis KOD1. Furthermore, Western blot analysis with cell-free extract of P. kodakaraensis KOD1 clearly indicated the presence of Pk-Rubisco in the native host cells.	Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.			Atomi, Haruyuki/0000-0001-9687-6426				Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN JH, 1991, J BIOL CHEM, V266, P20447; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; HARTMAN FC, 1984, ARCH BIOCHEM BIOPHYS, V232, P280, DOI 10.1016/0003-9861(84)90544-7; Hernandez JM, 1996, J BACTERIOL, V178, P347, DOI 10.1128/jb.178.2.347-356.1996; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Maniatis T., 1989, MOL CLONING LAB MANU; MORIKAWA M, 1994, APPL ENVIRON MICROB, V60, P4559, DOI 10.1128/AEM.60.12.4559-4566.1994; NARGANG F, 1984, MOL GEN GENET, V193, P220, DOI 10.1007/BF00330671; RAJAGOPALAN R, 1994, EUR J BIOCHEM, V221, P863, DOI 10.1111/j.1432-1033.1994.tb18801.x; Rashid N, 1997, J FERMENT BIOENG, V83, P412, DOI 10.1016/S0922-338X(97)82993-5; Rashid N, 1997, NUCLEIC ACIDS RES, V25, P719, DOI 10.1093/nar/25.4.719; Siddiqui MA, 1997, MOL GEN GENET, V254, P433, DOI 10.1007/s004380050436; TABITA FR, 1995, ADV PHOTOSYNTH, V2, P885; Takagi M, 1997, APPL ENVIRON MICROB, V63, P4504, DOI 10.1128/AEM.63.11.4504-4510.1997; Uemura K, 1996, PLANT CELL PHYSIOL, V37, P325, DOI 10.1093/oxfordjournals.pcp.a028949; Uemura K, 1997, BIOCHEM BIOPH RES CO, V233, P568, DOI 10.1006/bbrc.1997.6497; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Yan Z, 1997, APPL ENVIRON MICROB, V63, P785, DOI 10.1128/AEM.63.2.785-789.1997; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	22	76	78	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5078	5082		10.1074/jbc.274.8.5078	http://dx.doi.org/10.1074/jbc.274.8.5078			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988755	hybrid			2022-12-25	WOS:000078698200080
J	Wlassoff, WA; Kimura, M; Ishihama, A				Wlassoff, WA; Kimura, M; Ishihama, A			Functional organization of two large subunits of the fission yeast Schizosaccharomyces pombe RNA polymerase II - Location of the catalytic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-BOUND P-32; ESCHERICHIA-COLI; ACTIVE-SITE; WHEAT-GERM; TRANSCRIPTION COMPLEXES; ALPHA-AMANITIN; DNA; GENE; RESIDUES; DOMAIN	The catalytically competent transcription complex of RNA polymerase II from the fission yeast Schizosaccharomyces pombe was affinity labeled with photoreactive nucleotide analogues incorporated at 3' termini of nascent RNA chains. To locate the catalytic site for RNA polymerization, the labeled subunits were separated by SDS-polyacrylamide gel electrophoresis and subjected to partial proteolysis, After microsequencing of proteolytic fragments, a complex multidomain organization was indicated for both of the two large subunits, Rpb1 and Rpb2, with the most available sites of proteolysis in junctions between the conserved sequences among RNA polymerase from both prokaryotes and eukaryotes. The cross-linking studies indicate the following: (i) the 3' termini of growing RNA chains are most extensively cross-linked to the second largest subunit Rpb2 between amino acids 825 and 994; (ii) the regions 298-535 of Rpb2 and 614-917 of Rpb1 are cross-linked to less extents, suggesting that these regions are situated in the vicinity of the catalytic site. All these regions include the conserved sequences of RNA polymerases, and the catalytic site of Rpb2 belongs to an NH2-terminal part of its conserved sequence H.	Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Ishihama, A (corresponding author), Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan.	aishiham@lab.nig.ac.jp		Kimura, Makoto/0000-0003-0868-5334				ACKER J, 1992, J MOL BIOL, V226, P1295, DOI 10.1016/0022-2836(92)91071-V; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; ASANO Y, 1995, J BIOCHEM-TOKYO, V117, P677, DOI 10.1093/oxfordjournals.jbchem.a124762; AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; BARTHOLOMEW B, 1990, J BIOL CHEM, V265, P3731; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; CHEN Y, 1993, MOL CELL BIOL, V13, P4214, DOI 10.1128/MCB.13.7.4214; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; FREUND E, 1986, BIOCHEMISTRY-US, V25, P276, DOI 10.1021/bi00349a038; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P112; Ishiguro A, 1998, J MOL BIOL, V279, P703, DOI 10.1006/jmbi.1998.1823; Ishihama A, 1981, Adv Biophys, V14, P1; JOB C, 1992, BIOCHEM J, V285, P85, DOI 10.1042/bj2850085; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAENA JFW, 1990, J ORG CHEM, V55, P3640; KawagishiKobayashi M, 1996, MOL GEN GENET, V250, P1; KELLY S, 1990, J BIOL CHEM, V265, P7787; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; Miyao T, 1998, MOL GEN GENET, V259, P123, DOI 10.1007/s004380050796; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1987, J BIOL CHEM, V262, P14377; SAFRONOV IV, 1997, RUSSIAN J BIOORGAN C, V23, P531; Sakurai H, 1998, GENE, V221, P11, DOI 10.1016/S0378-1119(98)00449-1; Sakurai H, 1997, GENE, V196, P165, DOI 10.1016/S0378-1119(97)00222-9; Sambrook J., 2002, MOL CLONING LAB MANU; SHENG NJ, 1993, BIOCHEMISTRY-US, V32, P2248, DOI 10.1021/bi00060a017; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003; WOODY AYM, 1984, BIOCHEMISTRY-US, V23, P2843, DOI 10.1021/bi00308a001; WOYCHIK NA, 1994, TRANSCRIPTION MECH R, P227; Yasui K, 1998, BIOCHEMISTRY-US, V37, P5542, DOI 10.1021/bi972939b; Yasui K, 1996, GENES CELLS, V1, P843, DOI 10.1046/j.1365-2443.1996.730274.x	43	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5104	5113		10.1074/jbc.274.8.5104	http://dx.doi.org/10.1074/jbc.274.8.5104			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988759	hybrid			2022-12-25	WOS:000078698200084
J	Auxilien, S; Keith, G; Le Grice, SFJ; Darlix, JL				Auxilien, S; Keith, G; Le Grice, SFJ; Darlix, JL			Role of post-transcriptional modifications of primer tRNA(Lys,3) in the fidelity and efficacy of plus strand DNA transfer during HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCAPSID PROTEIN; IN-VITRO; RIBONUCLEASE-H; TRANSFER-RNA; VIRAL-DNA; SPECIFICITY; DOMAIN; REPLICATION; MUTATIONS; MECHANISM	During HIV reverse transcription, (+) strand DNA synthesis is primed by an RNase H-resistant sequence, the polypurine tract, and continues as far as a 18-nt double-stranded RNA region corresponding to the 3' end of tRNA(Lys,3) hybridized to the viral primer binding site (PBS). Before (+) strand DNA transfer, reverse transcriptase (RT) needs to unwind the double-stranded tRNA-PBS RNA in order to reverse-transcribe the 3' end of primer tRNA(Lys,3). Since the detailed mechanism of (+) strand DNA transfer remains incompletely understood, we developed an in vitro system to closely examine this mechanism, composed of HIV 5' RNA, natural modified tRNA(Lys,3), synthetic unmodified tRNALys,3 Or oligonucleotides (RNA or DNA) complementary to the PBS, as well as the viral proteins RT and nucleocapsid protein (NCp7), Prior to (+) strand DNA transfer, RT stalls at the double-stranded tRNA-PBS RNA complex and is able to reverse-transcribe modified nucleosides of natural tRNA(Lys,3). Modified nucleoside m(1)A-58 of natural tRNA(Lys,3) is only partially effective as a stop signal, as RT can transcribe as far as the hyper-modified adenosine (ms(2)t(6)A-37) in the anticodon loop. m(1)A-58 is almost always transcribed into A, whereas other modified nucleosides are transcribed correctly, except for m(7)G-46, which is sometimes transcribed into T. In contrast, synthetic tRNA(Lys,3), an RNA PBS primer, and a DNA PBS primer are completely reverse-transcribed, In the presence of an acceptor template, (+) strand DNA transfer is efficient only with templates containing natural tRNA(Lys,)3 or the RNA PBS primer, Sequence analysis of transfer products revealed frequent errors at the transfer site with synthetic tRNA(Lys,3), not observed with natural tRNA(Lys,3). Thus, modified nucleoside m(1)A-58, present in all retroviral tRNA primers, appears to be important for both efficacy and fidelity of (+) strand DNA transfer. We show that other factors such as the nature of the (-) PBS of the acceptor template and the RNase PP activity of RT also influence the efficacy of (+) strand DNA transfer.	INSERM, LaboRetro ENS, U412, F-69364 Lyon 07, France; CNRS, Inst Biol Mol & Cellulaire, UPR 9002, F-67084 Strasbourg, France; Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Case Western Reserve University	Darlix, JL (corresponding author), INSERM, LaboRetro ENS, U412, 46 Allee Ditalie, F-69364 Lyon 07, France.		LUC, DARLIX JEAN/AAE-9268-2020					AGRIS PF, 1986, BIOCHEMISTRY-US, V25, P5126, DOI 10.1021/bi00366a022; Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BenArtzi H, 1996, BIOCHEMISTRY-US, V35, P10549, DOI 10.1021/bi960439x; BLAIN SW, 1995, J VIROL, V69, P4440, DOI 10.1128/JVI.69.7.4440-4452.1995; Burnett BP, 1997, P NATL ACAD SCI USA, V94, P7210, DOI 10.1073/pnas.94.14.7210; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUBER HE, 1990, J BIOL CHEM, V265, P10565; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KARAGEORGOS L, 1995, J GEN VIROL, V76, P1675, DOI 10.1099/0022-1317-76-7-1675; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KEITH G, 1983, BIOCHIMIE, V65, P661; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Liang C, 1997, J VIROL, V71, P9075, DOI 10.1128/JVI.71.12.9075-9086.1997; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SMITH JS, 1992, J BIOL CHEM, V267, P15071; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; Telesnitsky A., 1997, P121; WITTIG B, 1978, NUCLEIC ACIDS RES, V5, P1165, DOI 10.1093/nar/5.4.1165; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YU H, 1992, J BIOL CHEM, V267, P10888; Yusupova G, 1996, J MOL BIOL, V261, P315, DOI 10.1006/jmbi.1996.0463	43	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4412	4420		10.1074/jbc.274.7.4412	http://dx.doi.org/10.1074/jbc.274.7.4412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933645	hybrid			2022-12-25	WOS:000078575500069
J	Johnson, JL; Brooker, RJ				Johnson, JL; Brooker, RJ			A K319N/E325Q double mutant of the lactose permease cotransports H+ with lactose - Implications for a proposed mechanism of H+ lactose symport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR SPECIFICITY MUTATIONS; ESCHERICHIA-COLI; CARRIER PROTEIN; LAC PERMEASE; 2 HALVES; TRANSPORT; PROTON; SITE; SUPERFAMILY; SEQUENCE	In this study, we have examined the transport characteristics of the wild-type lactose permease, single mutants in which Lys-319 was changed to asparagine or alanine or Glu-325 was changed to glutamine or alanine, and the corresponding double mutant strains. The wildtype and Asn-319 mutant showed high levels of lactose uptake, with K-m values of 0.42 and 1.30 mM and V-max values of 102.6 and 48.3 nmol of lactose/min/mg of protein, respectively. The Asn-319/Gln-325 strain had a normal K-m of 0.36 mM and a moderate V-max of 18.5 nmol of lactose/min/mg of protein, By comparison, the single E325Q strain had a normal K-m of 0.27 mM but a very defective V-max of 1.3 nmol of lactose/min/mg of protein, A similar trend was observed among the alanine substitutions at these positions, although the V-max values were lower for the Ala-319 mutations. When comparing the V-max values between the single position 325 mutants with those of the double mutants, these results indicate that neutral 319 mutations substantially alleviate a defect in V-max caused by neutral 325 mutations, With regard to H+/lactose coupling, the wild-type permease is normally coupled and can transport lactose against a gradient, The position 325 single mutants showed no evidence of H+ transport with lactose or thiodigalactoside (TDG) and were unable to facilitate uphill lactose transport. The single Asn-319 mutant and double Asn-319/Gln-325 mutant were able to transport H+ upon the addition of lactose or TDG. In addition, both of these strains catalyzed a sugar-dependent Hf leak that inhibited cell growth in the presence of TDG, These two strains were also defective in uphill transport, which may be related to their sugar-dependent leak pathway. Based on these and other results in the literature, a model is presented that describes how the interactions among several ionizable residues within the lactose permease act in a concerted manner to control H+/lactose coupling. In this model, Lys-319 and Glu-325 play a central role in governing the ability of the lactose permease to couple the transport of H+ and lactose.	Univ Minnesota, Dept Genet & Cell Biol, St Paul, MN 55108 USA; Univ Minnesota, Inst Adv Studies Biol Proc Technol, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Brooker, RJ (corresponding author), Bioproc Tech Inst, Gortner Labs 240, 1479 Gortner Ave, St Paul, MN 55108 USA.				NIGMS NIH HHS [GM53259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1213; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; EELKEMA JA, 1991, J BIOL CHEM, V266, P4139; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LEE JI, 1993, J BIOL CHEM, V268, P20007; LEE JI, 1992, J BIOL CHEM, V267, P20758; Lee JI, 1996, BBA-BIOMEMBRANES, V1278, P111, DOI 10.1016/0005-2736(95)00209-X; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mandel M, 1970, J MOL BIOL, V53, P154; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; Pazdernik NJ, 1997, J BIOL CHEM, V272, P26110, DOI 10.1074/jbc.272.42.26110; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; UJWAL ML, 1994, MOL MEMBR BIOL, V11, P9, DOI 10.3109/09687689409161024; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8	38	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4074	4081		10.1074/jbc.274.7.4074	http://dx.doi.org/10.1074/jbc.274.7.4074			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933600	hybrid			2022-12-25	WOS:000078575500024
J	Rivkees, SA; Barbhaiya, H; IJzerman, AP				Rivkees, SA; Barbhaiya, H; IJzerman, AP			Identification of the adenine binding site of the human A(1) adenosine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; DIRECTED MUTAGENESIS; EXPRESSION; ANTAGONIST; DOMAINS; ARRANGEMENT; RECOGNITION; HELICES; AGONIST; SYSTEM	To provide new insights into ligand-A(1) adenosine receptor (A(1)AR) interactions, site-directed mutagenesis was used to test the role of several residues in the first four transmembrane domains of the human A(1)AR. First, we replaced eight unique A(1)AR residues with amino acids present at corresponding transmembrane (TM) positions of A(2A)ARs. We also tested the role of carboxamide amino acids in TMs 1-4, and the roles of Val-87, Leu-88, and Thr-91 in TM3, Following conversion of Gly-14 in TM1 to Thr-14, the affinity for adenosine agonists increased 100-fold, and after Pro-25 in TM1 was converted to Leu-25, the affinity for agonists fell. After conversion of TM3 sites Thr-91 to Ala-91, and Gln-92 to Ala-92, the affinity for N-6-substituted agonists was reduced, and binding of ligands without N-6 substituents was eliminated. When Leu-88 was converted to Ala-88, the binding of ligands with N-6 substituents was reduced to a greater extent than ligands without N-6 substituents. Following conversion of Pro-86 to Phe-86, the affinity for N-6-substituted agonists was lost, and the affinity for ligands without N-6 substitution was reduced. These observations strongly suggest that Thr-91 and Gln-92 in TM3 interact with the adenosine adenine moiety, and Leu-88 and Pro-86 play roles in conferring specificity for A(1)AR selective compounds. Using computer modeling based on the structure of rhodopsin, a revised model of adenosine-A,AR interactions is proposed with the N-6-adenine position oriented toward the top of TM3 and the ribose group interacting with the bottom half of TMs 3 and 7.	Yale Univ, Sch Med, Div Pediat Endocrinol, New Haven, CT 06520 USA; Leiden Amsterdam Ctr Drug Res, Div Med Chem, NL-2300 RA Leiden, Netherlands	Yale University; Leiden University; Leiden University - Excl LUMC	Rivkees, SA (corresponding author), Yale Univ, Sch Med, Div Pediat Endocrinol, POB 208081, New Haven, CT 06520 USA.		IJzerman, Ad/ABG-1353-2020	IJzerman, Ad/0000-0002-1182-2259	NINDS NIH HHS [R01 NS326224] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Barbhaiya H, 1996, MOL PHARMACOL, V50, P1635; Brundege J M, 1997, Adv Pharmacol, V39, P353, DOI 10.1016/S1054-3589(08)60076-9; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IJzerman A P, 1992, Drug Des Discov, V9, P49; IJZERMAN AP, 1994, EUR J PHARM-MOLEC PH, V268, P95, DOI 10.1016/0922-4106(94)90124-4; Ijzerman AP, 1996, EUR J PHARMACOL, V310, P269, DOI 10.1016/0014-2999(96)00495-5; Jiang QL, 1996, MOL PHARMACOL, V50, P512; Kennedy AP, 1996, MOL PHARMACOL, V50, P789; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; OLAH ME, 1994, J BIOL CHEM, V269, P24692; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; RIVKEES SA, 1995, ENDOCRINE, V3, P623, DOI 10.1007/BF02746338; RIVKEES SA, 1995, J BIOL CHEM, V270, P20485, DOI 10.1074/jbc.270.35.20485; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; SHRYOCK JC, 1992, J PHARMACOL EXP THER, V260, P1292; TIVEDI BK, 1990, ADENOSINE ADENOSINE, P57; TOWNSENDNICHOLSON A, 1994, J BIOL CHEM, V269, P2373; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; UKENA D, 1987, FEBS LETT, V215, P203, DOI 10.1016/0014-5793(87)80146-1; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANGALEN PJM, 1994, MOL PHARMACOL, V45, P1101	25	75	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3617	3621		10.1074/jbc.274.6.3617	http://dx.doi.org/10.1074/jbc.274.6.3617			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920910	Green Published, hybrid			2022-12-25	WOS:000078428200050
J	Jabrane-Ferrat, N; Bloom, D; Wu, A; Li, L; Lo, D; Sreedharan, SP; Turck, CW; Goetzl, EJ				Jabrane-Ferrat, N; Bloom, D; Wu, A; Li, L; Lo, D; Sreedharan, SP; Turck, CW; Goetzl, EJ			Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells	FASEB JOURNAL			English	Article						neuropeptide; receptors; G-proteins; cytokines; lymphocytes	MODEL BASEMENT-MEMBRANE; MESSENGER-RNA; EXPRESSION; NEUROPEPTIDES; RECEPTOR; LYMPHOCYTES; CHEMOTAXIS; NEUROIMMUNOMODULATION; SPECIFICITY; MOLECULES	Vasoactive intestinal peptide (VIP) is a neuroendocrine mediator in immune tissues that affects many T cell functions through two homologous high-affinity G-protein-coupled receptors, termed VIPR1 and VIPR2. Antigen-stimulated secretion of gamma-interferon (IFN-gamma) by sperm whale myoglobin-specific Th1 cells of DBA/2 mouse I-E(d)-restricted clones, which express VIPR1 and VIPR2, was enhanced by 10(-10) M to 10(-7) M VIP. Enhancement of IFN-gamma secretion reached a mean maximum of fourfold for VIP and threefold for a VIPR2-selective agonist, without any effect of a VIPR1-selective agonist. Secretion of IFN-gamma by PMA and ionomycin-stimulated clones of Th1 cells was not altered by VIP. Antigen-stimulated secretion of IFN-gamma by T cell receptor-transgenic, influenza hemagglutinin-specific, and cytokine-differentiated mouse lymph node Th1 cells, which also express VIPR1 and VIPR2, was enhanced by 10(-10) M to 10(-8) M VIP. Enhancement of IFN-gamma secretion increased to a maximum of 14-fold for VIP, 14-fold for the VIPR2-selective agonist, and 20-fold for the VIPR1-selective agonist. In contrast to VIP suppression of interleukin production and lack of effect on IFN-gamma production by T cells stimulated with anti-CD3 antibody or a mitogenic lectin, generation of IFN-gamma by antigen-stimulated T cells is enhanced significantly by physiological concentrations of VIP.	Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Microbiol Immunol, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Scripps Research Institute	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, UB8B,Box 0711,533 Parnassus, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Jabrane-Ferrat, Nabila/K-1224-2014	Jabrane-Ferrat, Nabila/0000-0003-4809-7836; Li, Li/0000-0001-9844-7692	NIAID NIH HHS [AI29912] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APNKHANIYA R, 1998, FASEB J, V12, P119; BARNES D, 1991, QUAL ASSUR GOOD PRAC, V1, P1; BOIRIVANT M, 1994, GASTROENTEROLOGY, V106, P576, DOI 10.1016/0016-5085(94)90688-2; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DEGERMANN S, 1994, EUR J IMMUNOL, V24, P3155, DOI 10.1002/eji.1830241236; Delgado M, 1996, J NEUROIMMUNOL, V68, P27, DOI 10.1016/0165-5728(96)00063-X; FINK T, 1988, NEUROSCI LETT, V90, P39, DOI 10.1016/0304-3940(88)90783-5; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; GANEA D, 1993, J NEUROIMMUNOL, V47, P147, DOI 10.1016/0165-5728(93)90025-T; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; GERMAIN RN, 1986, NATURE, V320, P72, DOI 10.1038/320072a0; GOETZL EJ, 1992, FASEB J, V6, P2646, DOI 10.1096/fasebj.6.9.1612288; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; HASSNER A, 1993, J ALLERGY CLIN IMMUN, V92, P891, DOI 10.1016/0091-6749(93)90067-P; ICHIKAWA S, 1994, REGUL PEPTIDES, V54, P385, DOI 10.1016/0167-0115(94)90536-3; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; LITWIN DK, 1992, REGUL PEPTIDES, V40, P63, DOI 10.1016/0167-0115(92)90084-8; MATTHEW RC, 1992, J IMMUNOL, V148, P3572; Metwali A, 1996, J IMMUNOL, V157, P265; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; NIO DA, 1993, J IMMUNOL, V150, P5281; OTTAWAY CA, 1991, GASTROENTEROL CLIN N, V20, P511; RUBERTI G, 1992, J EXP MED, V175, P157, DOI 10.1084/jem.175.1.157; SAID SI, 1994, CL ALLER IM, V4, P143; SMITH CH, 1993, J IMMUNOL, V151, P3274; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; TANG H, 1995, J INTERF CYTOK RES, V15, P993, DOI 10.1089/jir.1995.15.993; Wang HY, 1996, J IMMUNOL, V156, P3243; WEINSTOCK JV, 1992, CLIN IMMUNOL IMMUNOP, V64, P17, DOI 10.1016/0090-1229(92)90053-Q; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J CLIN IMMUNOL, V16, P21, DOI 10.1007/BF01540969; Xia MH, 1996, J CELL BIOCHEM, V61, P452, DOI 10.1002/(SICI)1097-4644(19960601)61:3<452::AID-JCB12>3.3.CO;2-9; Xia MH, 1996, J IMMUNOL, V157, P1132; Xia MH, 1996, J IMMUNOL, V156, P160; YU YL, 1991, J CLIN LAB ANAL, V5, P262	37	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					347	353		10.1096/fasebj.13.2.347	http://dx.doi.org/10.1096/fasebj.13.2.347			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973323				2022-12-25	WOS:000078615200015
J	Gross, M; Hessefort, S; Olin, A				Gross, M; Hessefort, S; Olin, A			Purification of a 38-kDa protein from rabbit reticulocyte lysate which promotes protein renaturation by heat shock protein 70 and its identification as delta-aminolevulinic acid dehydratase and as a putative DnaJ protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; CONTROLLED TRANSLATIONAL REPRESSOR; ATPASE ACTIVITY; ERYTHROID-DIFFERENTIATION; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; 66-KDA PROTEIN; HUMAN HOMOLOG; BOVINE LIVER; HSP70	We reported recently that a rabbit reticulocyte 66-kDa protein (termed RF-hsp 70 by our laboratory and p60 and hop by others) functions as a hsp 70 recycling protein and markedly enhances the renaturation of luciferase by hsp 70 (Gross, M., and Hessefort, S. (1996) J. Biol. Chem. 271, 16833-16841). In this report, we confirm that the ability of RF-hsp 70 to promote the conversion of hsp 70 ADP to hsp 70 ATP, thus enhancing the protein folding activity of hsp 70, is caused by the purified 66-kDa protein and not by a trace DnaJ/hsp 40 protein contaminant. To determine the relationship between RF-hsp 70 and the DnaJ/hsp 40 heat shock protein family, which also enhances protein renaturation by hsp 70, we purified a 38-kDa protein from rabbit reticulocyte lysate based upon its ability to stimulate renaturation of luciferase by hsp 70. Partial amino acid sequencing of this 38-kDa protein has indicated, unexpectedly, that it is the enzyme delta-aminolevulinic acid dehydratase (ALA-D) and that it does not contain detectable sequences corresponding to the DnaJ/hsp 40 protein family. In addition, immunoblot analysis with a polyclonal antibody made to HeLa cell hsp 40 (from Stress-Gen) confirms that our purified ALA-D contains no hsp 40, although hsp 40 is present in relatively crude rabbit reticulocyte protein fractions. Rabbit reticulocyte ALA-D is about as active in converting delta-aminolevulinic acid to porphobilinogen and as Zn2+-dependent as ALA-D purified from other sources. Rabbit reticulocyte ALA-D stimulates the renaturation of luciferase by hsp 70 up to 10-fold at concentrations that are the same as or less than that of hsp 70, and it has no renaturation activity in the absence of hsp 70. The renaturation effect of ALA-D is additive with that of RF-hsp 70 at limiting or saturating concentrations of each, and, unlike RF-hsp 70, ALA-D does not promote the dissociation of hsp 70 ADP in the presence of ATP. The renaturation-enhancing effect of ALA-D may be caused by a region near its carboxyl terminus which has sequence homology to the highly conserved domain of the DnaJ protein family, which is similar to the sequence homology between this domain and a carboxyl-terminal region in auxilin, a DnaJ-like protein that requires this region for its hsp 70-dependent function.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago	Gross, M (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mgross@midway.uchicago.edu			NHLBI NIH HHS [HL-30121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; BERU N, 1985, J BIOL CHEM, V260, P9251; BEVAN DR, 1980, J BIOL CHEM, V255, P2030; BISHOP TR, 1986, NUCLEIC ACIDS RES, V14, P10115, DOI 10.1093/nar/14.24.10115; BISHOP TR, 1989, NUCLEIC ACIDS RES, V17, P1775, DOI 10.1093/nar/17.4.1775; Blatch G. L., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P68; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHEETHAM ME, 1996, BIOCHEM J, V319, P13; CHEH A, 1973, BIOCHEM BIOPH RES CO, V55, P1060, DOI 10.1016/S0006-291X(73)80002-6; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GIBSON KD, 1955, BIOCHEM J, V61, P618, DOI 10.1042/bj0610618; GROSS M, 1987, J BIOL CHEM, V262, P6899; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; Gross M, 1996, J BIOL CHEM, V271, P16842, DOI 10.1074/jbc.271.28.16842; GROSS M, 1978, BIOCHIM BIOPHYS ACTA, V520, P650, DOI 10.1016/0005-2787(78)90150-8; GROSS M, 1994, J BIOL CHEM, V269, P22738; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HONORE B, 1992, J BIOL CHEM, V267, P8485; ISHIDA N, 1992, J CLIN INVEST, V89, P1431, DOI 10.1172/JCI115732; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; NAKAO K, 1968, ANN NY ACAD SCI, V149, P224, DOI 10.1111/j.1749-6632.1968.tb15155.x; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; SASSA A, 1981, ADV HUM GENET, P121; SASSA S, 1982, ENZYME, V28, P133, DOI 10.1159/000459097; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHEMIN D, 1970, METHODS ENZYMOLOGY A, V17, P205; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; TSUKAMOTO I, 1980, INT J BIOCHEM, V12, P751; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WALL D, 1994, J BIOL CHEM, V269, P5446; WU WH, 1974, P NATL ACAD SCI USA, V71, P1767, DOI 10.1073/pnas.71.5.1767; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	49	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3125	3134		10.1074/jbc.274.5.3125	http://dx.doi.org/10.1074/jbc.274.5.3125			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915851	hybrid			2022-12-25	WOS:000078319500069
J	Dkhissi, F; Raynal, SP; Jullien, P; Lawrence, DA				Dkhissi, F; Raynal, SP; Jullien, P; Lawrence, DA			Growth stimulation of murine fibroblasts by TGF-beta 1 depends on the expression of a functional p53 protein	ONCOGENE			English	Article						TGF-beta 1; P53; pRB; SV40; p21Waf; growth stimulation; growth inhibition	LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE PROGRESSION; FACTOR-BETA; TGF-BETA; MOUSE FIBROBLASTS; TRANSFORMING GROWTH-FACTOR-BETA-1; DOWN-REGULATION; INDUCTION; INHIBITION	Transforming Growth Factor-beta 1 (TGF-beta 1) inhibits the proliferation of most cells, but stimulates some mesenchymal cell types, including murine NIH3T3 fibroblasts, We show here that TGF-beta 1 growth stimulation of NIH3T3 fibroblasts is reversed when these cells are transformed by SV40 or are transfected with a plasmid encoding the SV40 Large T antigen. Inversion of the TGF-beta 1 growth stimulation of NIH3T3 cells is not observed when these cells are transfected with plasmids expressing either a mutant Large T, unable to bind P53, or the E1A adenovirus oncoprotein which binds the retinoblastoma protein pRB but not P53, But when the TGF-beta 1-growth stimulated cells are transfected with a plasmid expressing a mutant form of Large T capable of binding to P53, but not to pRB, or with one expressing the E1B-55 kD adenovirus oncoprotein, which also binds to P53 but not to pRB, the cells are growth-inhibited by TGF-beta 1. The cdk inhibitor p21Waf is decreased in TGF-beta 1-stimulated NIH3T3 fibroblasts and increased in TGF-beta 1-inhibited SV40-transformed cells. Finally, we show that T12 fibroblasts, from a P53 knockout mouse, are growth inhibited by TGF-beta 1 and that they remain so upon transfection with a P53 which is mutant at restrictive temperature, but become growth-stimulated by this factor at permissive temperature when P53 is functional. These data strongly suggest that growth-stimulation of fibroblasts by TGF-beta 1 depends on the presence of a functional P53 protein and that inversion of this response occurs if P53 is absent or inactivated.	CNRS, UPR 9079, F-94801 Villejuif, France; CNRS, Inst Curie, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lawrence, DA (corresponding author), CNRS, UPR 9079, BP 8, F-94801 Villejuif, France.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; Benzakour O, 1992, GROWTH FACTORS, V6, P265, DOI [10.3109/08977199209021539, 10.3109/08977199209026933]; BLAYDES JP, 1995, ONCOGENE, V10, P307; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evangelisti R, 1997, CELL BIOCHEM FUNCT, V15, P47; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GREGOIRE M, 1984, EXP CELL RES, V152, P38, DOI 10.1016/0014-4827(84)90228-3; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL DJ, 1986, J CELL PHYSIOL, V128, P322, DOI 10.1002/jcp.1041280226; HUANG F, 1994, ONCOGENE, V9, P3701; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIM TA, 1993, CANCER LETT, V71, P125, DOI 10.1016/0304-3835(93)90107-K; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAWRENCE DA, 1995, KIDNEY INT, V47, P19; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; OKADOME T, 1994, J BIOL CHEM, V269, P30753; ONG G, 1991, ONCOGENE, V6, P761; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; RAVITZ MJ, 1995, CANCER RES, V55, P1413; RAYNAL S, 1994, GROWTH FACTORS, V11, P197, DOI 10.3109/08977199409046917; RAYNAL S, 1995, INT J ONCOL, V7, P337; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, HDB EXPT PHARM, V95; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WATABE K, 1994, J NEUROSCI RES, V39, P525, DOI 10.1002/jnr.490390504; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	49	20	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					703	711		10.1038/sj.onc.1202341	http://dx.doi.org/10.1038/sj.onc.1202341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989820				2022-12-25	WOS:000078394400015
J	Giamarchi, C; Solanas, M; Chailleux, C; Augereau, P; Vignon, F; Rochefort, H; Richard-Foy, H				Giamarchi, C; Solanas, M; Chailleux, C; Augereau, P; Vignon, F; Rochefort, H; Richard-Foy, H			Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormone-dependent and -independent breast cancer cell lines	ONCOGENE			English	Article						breast cancer; chromatin; pS2; cathepsin D; estrogens; IGFI	ESTROGEN-RESPONSIVE ELEMENT; GROWTH-FACTORS; RECEPTOR; PROMOTER; BINDING; ANTIESTROGENS; EXPRESSION; PROTEIN; CBP; TRANSFECTION	We have compared the DNase I hypersensitivity of the regulatory region of two estrogen-regulated genes, pS2 and cathepsin D in hormone-dependent and -independent breast carcinoma cell lines. This strategy allowed the identification of two important control regions, one in pS2 and the other in cathepsin D genes, In the hormone-dependent MCF7 cell line within the pS2 gene 5'-flanking region, we detected two major DNase I hypersensitive sites, induced by estrogens and/or IGFI: pS2-HS1, located in the proximal promoter and pS2-HS4, located -10.5 Kb from the CAP site, within a region that has not been cloned. The presence of these two DNase I hypersensitive sites correlates with pS2 expression. Interestingly in MCF7 cells, estrogens and IGFI induced indistinguishable chromatin structural changes over the pS2 regulatory region, suggesting that the two transduction-pathways converge to a unique chromatin target, In two cell lines that do not express pS2, MDA MB 231, a hormone-independent cell line that lacks the estrogen receptor alpha, and HE5, a cell line derived from MDA MB 231 by transfection that expresses estrogen receptor alpha, there was only one hormone-independent DNase I hypersensitive site. This site, pS2-HS2, was located immediately upstream of pS2-HS1, In MCF7 cells, two major DNase I hypersensitive sites were present in the 5'-flanking sequences of the cathepsin D gene, which is regulated by estrogens in these cells. These sites, catD-HS2 and catD-HS3, located at positions -2.3 Kb and -3.45 Kb, respectively, were both hormone-independent. A much weaker site, catD-HS1, covered the proximal promoter. In MDA MB 231 cells, that express cathepsin D constitutively we detected an additional strong hormone-independent DNase I hypersensitive site, catD-HS4, located at position -4.3 Kb, This region might control the constitutive over-expression of cathepsin D in hormone-independent breast cancer cells, All together, these data demonstrate that a local reorganization of the chromatin structure over pS2 and cathepsin D promoters accompanies the establishment of the hormone-independent phenotype of the cells.	CNRS, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Univ Autonoma Barcelona, Fac Med, Dept Biol Cellular & Fisiol, E-08193 Barcelona, Spain; INSERM, U148, Unite Hormones & Canc, F-34090 Montpellier, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Autonomous University of Barcelona; University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Richard-Foy, H (corresponding author), CNRS, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.		Solanas Garcia, Montserrat/O-4684-2016; Medale Giamarchi, Claire/M-3263-2014	Solanas Garcia, Montserrat/0000-0003-2949-1344; 				AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHALBOS D, 1992, J STEROID BIOCHEM, V43, P223, DOI 10.1016/0960-0760(92)90211-Z; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; FOEKENS JA, 1993, J CLIN ONCOL, V11, P899, DOI 10.1200/JCO.1993.11.5.899; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROCHEFORT H, 1990, BREAST CANCER RES TR, V16, P3, DOI 10.1007/BF01806570; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; Vladusic EA, 1998, CANCER RES, V58, P210	32	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					533	541		10.1038/sj.onc.1202317	http://dx.doi.org/10.1038/sj.onc.1202317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927210				2022-12-25	WOS:000078166500026
J	Spencer, W; Kwon, H; Crepieux, P; Leclerc, N; Lin, RT; Hiscott, J				Spencer, W; Kwon, H; Crepieux, P; Leclerc, N; Lin, RT; Hiscott, J			Taxol selectively blocks microtubule dependent NF-kappa B activation by phorbol ester via inhibition of I kappa-B alpha phosphorylation and degradation	ONCOGENE			English	Article						NF-kappa B; taxol; I kappa B; microtubules; gene regulation	PROTEIN-KINASE-C; SIGNAL-INDUCED PHOSPHORYLATION; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSDUCTION PATHWAY; ARACHIDONIC-ACID; CANCER CELLS; MAP KINASE; TNF-ALPHA	Activation of the NF-kappa B transcription factors has been shown to be directly influenced by changes in the microtubule cytoskeleton network, To better understand cytoskeletal regulation of NF-kappa B, experiments were performed to determine whether the microtubule (MT) stabilizing agent taxol could modulate NF-kappa B activation in the presence of different NF-kappa B inducers. Pretreatment of murine NIH3T3 and human 293 cells with 5 mu M taxol resulted in complete inhibition of phorbol, 12-myristate, 13-acetate (PMA) mediated NF-kappa B activation, detected as the loss of DNA binding and reduced NF-kappa B dependent reporter gene activity. Furthermore, in COS-7 and NIH3T3 cells, PMA-induced I kappa B alpha turnover was dramatically reduced in taxol treated cells, mediated via the inhibition of I kappa-B alpha phosphorylation, However, taxol did not prevent TNF-alpha induced I kappa B alpha phosphorylation, degradation, or NF-kappa B activation, indicating that TNF-alpha acts through a microtubule-independent pathway. In vitro kinase assays with PMA stimulated cell extracts demonstrated that taxol reduced protein kinase C activity by 30%, thus implicating the loss of PKC activity as a possible regulatory target of taxol-mediated suppression of NF-kappa B, Since PMA causes modulation of cytoarchitecture through PKC activation, microtubule integrity and cell morphology was analysed by indirect immunofluorescence. Both PMA and nocodazole, a MT depolymerizing agent, caused microtubule depolymerization, whereas TNF-alpha did not alter MT integrity; concomitant taxol treatment blocked both nocodazole and PMA induced depolymerization of MTs, as well as NF-kappa B induction, thus demonstrating a link between microtubule depolymerization and NF-kappa B activation, These observations illustrate a novel biological activity of taxol as a selective inhibitor of NF-kappa B activity, suggesting a link between the state of microtubule integrity and gene regulation.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Univ Montreal, Dept Pathol, Montreal, PQ H3C 3J7, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; Universite de Montreal	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada.		Crepieux, Pascale/X-3217-2019; Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503; Spencer, Will/0000-0003-0633-1575				ALEXANDROVA AY, 1993, CELL MOTIL CYTOSKEL, V25, P254, DOI 10.1002/cm.970250306; ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Basu A, 1996, CELL GROWTH DIFFER, V7, P1507; BASU A, 1990, J BIOL CHEM, V265, P8451; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BITAR R, 1995, CELL GROWTH DIFFER, V6, P965; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Bouron A, 1997, FEBS LETT, V404, P221, DOI 10.1016/S0014-5793(97)00135-X; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Debal V, 1997, ANTICANCER RES, V17, P1147; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FOGUEIRA L, 1996, J VIROL, V70, P223; Forgacs G, 1995, BIOCHEM CELL BIOL, V73, P317, DOI 10.1139/o95-040; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Haldar S, 1996, CANCER RES, V56, P1253; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JUN CD, 1995, J IMMUNOL, V154, P6541; KAWASUGI K, 1995, CELL MOTIL CYTOSKEL, V31, P215, DOI 10.1002/cm.970310305; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liu DC, 1996, CELL IMMUNOL, V174, P73, DOI 10.1006/cimm.1996.0295; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; MANGOURA D, 1995, DEV BRAIN RES, V87, P1, DOI 10.1016/0165-3806(95)00046-G; MANIE S, 1993, J BIOL CHEM, V268, P13675; McGowan K, 1996, J CELL PHYSIOL, V167, P113, DOI 10.1002/(SICI)1097-4652(199604)167:1<113::AID-JCP13>3.0.CO;2-C; MELAMED I, 1995, BIOCHEM BIOPH RES CO, V209, P1102, DOI 10.1006/bbrc.1995.1611; MOORE GD, 1995, DEV BIOL, V170, P519, DOI 10.1006/dbio.1995.1233; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NIU MY, 1994, CELL MOTIL CYTOSKEL, V27, P327, DOI 10.1002/cm.970270405; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Seufferlein T, 1996, CANCER RES, V56, P5758; Shibata Y, 1996, J IMMUNOL, V156, P772; Simms H, 1996, J LAB CLIN MED, V127, P364, DOI 10.1016/S0022-2143(96)90185-7; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sun SC, 1996, MOL CELL BIOL, V16, P1058; SWEET MJ, 1995, J INFLAMM, V45, P126; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Vani K, 1997, BBA-MOL CELL RES, V1358, P67, DOI 10.1016/S0167-4889(97)00079-7; Veis N, 1996, J INFLAMM, V46, P106; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Young SW, 1996, FEBS LETT, V384, P181, DOI 10.1016/0014-5793(96)00287-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	78	42	42	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					495	505		10.1038/sj.onc.1202335	http://dx.doi.org/10.1038/sj.onc.1202335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927206				2022-12-25	WOS:000078166500022
J	Moorman, JP; Luu, D; Wickham, J; Bobak, DA; Hahn, CS				Moorman, JP; Luu, D; Wickham, J; Bobak, DA; Hahn, CS			A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival	ONCOGENE			English	Article						Rho family; apoptosis; cytoskeleton; C3 exoenzyme	BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; FOCAL COMPLEXES; T-LYMPHOCYTES; TOXIN-A; RAS; TRANSDUCTION; APOPTOSIS; EXPRESSION; ACTIVATION	Rho family GTPases are known to be involved in cytoskeletal reorganization. We examined the possibility that these functions may be dictated by a balance of Rho family GTPase signaling. Using transient viral expression of RhoA, Rac1, Cdc42 and their mutants, as well as C3 exoenzyme, we altered cytoskeletal organization under normal growth conditions. Overexpression of wild-type or constitutively active forms of the Rho family GTPases led to their respective activation phenotypes, Overexpression of dominant negative forms of given Rho family GTPases led to a phenotype consistent with activation of the other Rho family GTPase, Treatment with C, difficile toxin A, that inactivates all Rho family GTPases, led to the transient appearance of a variety of activation phenotypes, Previously, we reported that inactivation of Rho led to induction of apoptosis, implying that Rho may play an important role in cell survival signaling. This signaling, however, is not affected by expression of tiny forms of Rad or Cdc42, and only inactivation of Rho led to induction of apoptosis, Rho family GTPases appear to coordinate cytoskeletal organization by a balance of signaling, while cell survival is regulated by :I distinct Rho-mediated signaling pathway.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001478, R01AI033434] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01478, AI33434] Funding Source: Medline; NIGMS NIH HHS [GM54572] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hall A, 1995, GUIDEBOOK SMALL GTPA, P3; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Li GP, 1997, J BIOL CHEM, V272, P10337; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Moorman JP, 1996, J IMMUNOL, V156, P4146; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; THELESTAM M, 1984, J TOXICOL-TOXIN REV, V3, P139, DOI 10.3109/15569548409097924; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	33	81	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					47	57		10.1038/sj.onc.1202262	http://dx.doi.org/10.1038/sj.onc.1202262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926919				2022-12-25	WOS:000078166000006
J	Simoneau, M; Aboulkassim, TO; LaRue, H; Rousseau, F; Fradet, Y				Simoneau, M; Aboulkassim, TO; LaRue, H; Rousseau, F; Fradet, Y			Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31	ONCOGENE			English	Article						chromosome 9; microsatellites; bladder cancer; tumor suppressor gene	TRANSITIONAL-CELL CARCINOMA; INTERNATIONAL WORKSHOP; HOMOZYGOUS DELETIONS; GENE; YAC; UK; HETEROZYGOSITY; LOCALIZATION; CAMBRIDGE; COLLEGE	The most common genetic alteration identified in transitional cell carcinoma (TCC) of the bladder is loss of heterozygosity (LOH) on chromosome 9, However, localization of tumor suppressor genes on 9q has been hampered by the low frequency of subchromosomal deletions. We have analysed 139 primary, initial low stage TCC of the bladder using a panel of 28 microsatellite markers spanning chromosome 9 at an average distance of 5 Mb, following a primer-extension preamplification (PEP) technique. Sixty-seven (48%) tumors showed LOH at one or more loci and partial deletions were detected in 62 (45%) tumors; apparent monosomy 9 was detected in only five (4%) tumors. Deletions were more frequent on 9q (44%) than on 9p (23%), the latter being mostly associated with 9q deletion, suggesting that alteration of genes on 9q may be an early event associated with superficial papillary tumors. Combined data from the cases with partial 9q deletions displayed four candidate regions for tumor suppressor loci, based on the frequency of deletion observed and tumors with unique deletions at these sites. In two tumors, the unique partial deletion comprised D9S12 at 9q22.3, a region encompassing loci for the Gorlin syndrome and multiple self-healing squamous epithelioma gene. In two other tumors, the single LOH was identified at the D9S172 locus at 9q31-32 where the dysautonia and Fukuyama-type congenital muscular dystrophy genes have been Located. One tumor showed unique LOH at the GSN locus at 9q33, a region frequently deleted in other sporadic tumors while the fourth region of deletion was observed at 9q34 between ASS and ABL-I, in two tumors. This region is frequently deleted in tumors and encompasses the locus for the hereditary hemorrhagic telangiectasia gene. These findings suggest four target regions on 9q within which suppressor genes for TCC may reside.	Pavillon Hotel Dieu Quebec, Ctr Rech Cancerol, Lab Urooncol Expt, Quebec City, PQ, Canada; CHU Quebec, Unite Rech Genet Humaine & Mol, Quebec City, PQ, Canada	Laval University; Laval University	Fradet, Y (corresponding author), Pavillon Hotel Dieu Quebec, Ctr Rech Cancerol, Lab Urooncol Expt, Quebec City, PQ, Canada.			Fradet, Yves/0000-0002-7581-2500	NCI NIH HHS [CA47526] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA047526, R01CA047526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard P, 1995, CLIN CANCER RES, V1, P1195; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, CANCER RES, V53, P1230; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DEVLIN J, 1994, ONCOGENE, V9, P2757; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; KAMB A, 1994, SCIENCE, V264, P440; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; LARUE H, 1995, CLIN CANCER RES, V1, P435; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MARCHUK DA, 1994, ANN HUM GENET, V58, P224; MCDONALD MT, 1994, NAT GENET, V6, P197, DOI 10.1038/ng0294-197; MELDGAARD P, 1995, INT J CANCER, V63, P341, DOI 10.1002/ijc.2910630306; MERLO A, 1994, CANCER RES, V54, P2322; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NORTHRUP H, 1994, ANN HUM GENET, V58, P229; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1994, CANCER RES, V54, P2848; Ozelius LJ, 1997, GENOME RES, V7, P483, DOI 10.1101/gr.7.5.483; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P347, DOI 10.1111/j.1469-1809.1995.tb00756.x; Povey S, 1997, ANN HUM GENET, V61, P183, DOI 10.1017/S0003480097006106; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; POVEY S, 1992, ANN HUM GENET, V56, P167, DOI 10.1111/j.1469-1809.1992.tb01145.x; ROUSSEAU F, 1994, HUM MUTAT, V4, P51, DOI 10.1002/humu.1380040107; RUPPERT JM, 1993, CANCER RES, V53, P5093; Shapiro GI, 1996, BBA-REV CANCER, V1242, P165, DOI 10.1016/0304-419X(95)00011-4; Simoneau AR, 1996, CANCER RES, V56, P5039; STADLER WM, 1994, CANCER RES, V54, P2060; TANAKA M, 1995, CANCER RES, V55, P3228; Van Tilborg AAG, 1998, INT J CANCER, V75, P9, DOI 10.1002/(SICI)1097-0215(19980105)75:1<9::AID-IJC2>3.3.CO;2-I; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	39	90	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					157	163		10.1038/sj.onc.1202277	http://dx.doi.org/10.1038/sj.onc.1202277			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926930	Bronze			2022-12-25	WOS:000078166000017
J	Allgayer, H; Wang, H; Wang, Y; Heiss, MM; Bauer, R; Nyormoi, O; Boyd, D				Allgayer, H; Wang, H; Wang, Y; Heiss, MM; Bauer, R; Nyormoi, O; Boyd, D			Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2 alpha-related factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINES; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; CANCER-CELLS; POSTTRANSCRIPTIONAL REGULATION; COLON ADENOCARCINOMAS; EXPRESSION; INVASION; AP-2; PROTEIN	The urokinase receptor overexpressed in invasive cancers promotes laminin degradation. The current study was undertaken to identify cis elements and trans-acting factors activating urokinase receptor expression through a footprinted (-148/-124) region of the promoter containing putative activator protein-2- and Sp1-binding motifs, Mobility shifting experiments using nuclear extract from a high urokinase receptor-expressing cell line (RKO) indicated that Sp1, Sp3, and a factor similar to, but distinct from, activator protein-2 alpha bound to this region, Mutations preventing the binding of the activator protein 2 alpha-related factor diminished urokinase receptor promoter activity. In RKO cells, the expression of a negative regulator of activator protein-2 function diminished urokinase receptor promoter activity, protein, and laminin degradation. Conversely, urokinase receptor promoter activity in low urokinase receptor-expressing GEO cells was increased by activator protein-2 alpha A expression. Although using GEO nuclear extract, little activator protein-2 alpha-related factor bound to the footprinted region, phorbol 12-myristate 13-acetate treatment, which induces urokinase receptor expression, increased complex formation. Mutations preventing the activator protein-2 alpha-related factor and Sp1/Sp8 binding reduced urokinase receptor promoter stimulation by this agent. Thus, the constitutive and phorbol 12-myristate 13-acetate-inducible expression of the urokinase receptor is mediated partly through trans-activation of the promoter via a sequence (-152/-135) bound with an activator protein-2 alpha-related factor.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem, Houston, TX 77030 USA; Univ Sydney, Westmead Hosp, Dept Renal Med, Westmead, NSW 2145, Australia; Univ Munich, Klinikum Grosshadern, Dept Surg, D-81377 Munich, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Sydney; University of Munich	Boyd, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845, P50DE011906] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [P01 DE11906, R01 DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSSON G, 1994, CELL GROWTH DIFFER, V5, P27; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRUCKNER A, 1992, CANCER RES, V52, P3043; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; CASEY JR, 1994, BLOOD, V84, P1151; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CONESE M, 1994, J BIOL CHEM, V269, P17886; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; ELLIS V, 1991, J BIOL CHEM, V266, P12752; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KARIKO K, 1993, CANCER RES, V53, P3109; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Lee BS, 1997, J BIOL CHEM, V272, P174; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Long FX, 1998, J BIOL CHEM, V273, P6542, DOI 10.1074/jbc.273.11.6542; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Min HY, 1996, CANCER RES, V56, P2428; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1991, AM J PATHOL, V138, P1059; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SCHLECHTE W, 1989, CANCER RES, V49, P6064; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Sillaber C, 1997, J BIOL CHEM, V272, P7824, DOI 10.1074/jbc.272.12.7824; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xing RH, 1997, CANCER RES, V57, P3585; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	58	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4702	4714		10.1074/jbc.274.8.4702	http://dx.doi.org/10.1074/jbc.274.8.4702			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988707	hybrid			2022-12-25	WOS:000078698200032
J	Bridges, EG; Jiang, ZL; Cheng, YC				Bridges, EG; Jiang, ZL; Cheng, YC			Characterization of a dCTP transport activity reconstituted from human mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BEEF-HEART MITOCHONDRIA; HUMAN LEUKEMIA-CELLS; DNA-SYNTHESIS; TRICARBOXYLATE CARRIER; PHOSPHATE-TRANSPORT; PURIFICATION; PROTEIN; ZIDOVUDINE; HYDROXYLAPATITE	A protein fraction of mitochondria from human acute lymphocytic leukemia cells, which could be reconstituted into proteoliposomes to have dCTP transport activity, has been partially purified by hydroxyapatite and blue Sepharose chromatography. The dCTP transport activity in proteoliposomes was time-dependent and could be activated by Ca2+ and to a lesser extent by Mg2+. None of the other divalent cations tested could activate the transport activity. The K-m value of dCTP in the presence of Ca2+ was shown to be 3 mu M. dCDP but not dCMP or dCyd could inhibit the transport activity. Other deoxynucleoside triphosphates could also inhibit the uptake of dCTP with the potency dGTP = dATP > TTP. Although ATP could competitively inhibit dCTP uptake with a K-i value of 8 mu M, the reconstituted dCTP uptake activity was not sensitive to the ATP/ADP carrier inhibitor atractyloside or the sulfhydryl reagent N-ethylmaleimide. This suggests that the dCTP transport system studied is not the same as the ATP/ADP carrier. In conclusion, these studies describe the first functionally reconstituted mitochondrial carrier that displays an efficient transport activity for dCTP.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, POB 802066, New Haven, CT 06520 USA.				NIAID NIH HHS [AI-38204] Funding Source: Medline; NIGMS NIH HHS [F32GM17474] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017474] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; BANERJEE RK, 1983, MOL CELL BIOCHEM, V50, P3; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; Casademont J, 1996, BRAIN, V119, P1357, DOI 10.1093/brain/119.4.1357; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P143; ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861; FRILAND A, 1990, MOL PHARMACOL, V37, P665; GANDHI V, 1995, SEMIN ONCOL, V22, P61; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; HEINEMANN V, 1989, BIOCHEM PHARMACOL, V38, P4115, DOI 10.1016/0006-2952(89)90693-X; Iwasaki H, 1997, BLOOD, V90, P270; JOYAL JL, 1992, J BIOL CHEM, V267, P19198; KAPLAN RS, 1985, J BIOL CHEM, V260, P293; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KLINGENBERG M, 1978, BIOCHIM BIOPHYS ACTA, V503, P193, DOI 10.1016/0005-2728(78)90182-2; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209; KRAMER R, 1994, BIOCHIM BIOPHYS ACTA, V974, P1; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344; PARKER WB, 1994, J NIH RES, V6, P57; PARSONS P, 1973, J BIOL CHEM, V248, P1912; PICK U, 1981, ARCH BIOCHEM BIOPHYS, V212, P186, DOI 10.1016/0003-9861(81)90358-1; ROJO M, 1994, BBA-BIOENERGETICS, V1187, P360, DOI 10.1016/0005-2728(94)90010-8; SCHAFER JA, 1994, METHODS MEMBRANE TRA, P325; STAPPEN R, 1994, J BIOL CHEM, V269, P11240; STIPANI I, 1983, FEBS LETT, V161, P269, DOI 10.1016/0014-5793(83)81023-0; WEHRLE JP, 1983, ARCH BIOCHEM BIOPHYS, V223, P477, DOI 10.1016/0003-9861(83)90612-4; Xie KC, 1996, CANCER RES, V56, P3030	35	60	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4620	4625		10.1074/jbc.274.8.4620	http://dx.doi.org/10.1074/jbc.274.8.4620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988697	hybrid			2022-12-25	WOS:000078698200022
J	Della Rocca, GJ; Mukhin, YV; Garnovskaya, MN; Daaka, Y; Clark, GJ; Luttrell, LM; Lefkowitz, RJ; Raymond, JR				Della Rocca, GJ; Mukhin, YV; Garnovskaya, MN; Daaka, Y; Clark, GJ; Luttrell, LM; Lefkowitz, RJ; Raymond, JR			Serotonin 5-HT1A receptor-mediated Erk activation requires calcium/calmodulin-dependent receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CALMODULIN-BINDING DOMAIN; TYROSINE-KINASE; COATED VESICLES; PHOSPHORYLATION; CELLS; DESENSITIZATION; LOCALIZATION; PP60C-SRC; IDENTIFICATION	Many receptors that couple to heterotrimeric guanine nucleotide-binding (G) proteins mediate rapid activation of the mitogen-activated protein kinases, Erk1 and Erk2. The G(i)-coupled serotonin (5-hydroxytryptamine (5-HT)) 5-HT1A receptor, heterologously expressed in Chinese hamster ovary or human embryonic kidney 293 cells, mediated rapid activation of Erk1/2 via a mechanism dependent upon both Ras activation and clathrin-mediated endocytosis. This activation was attenuated by chelation of intracellular Ca2+ and Ca2+/calmodulin (CAM) inhibitors or the CAM sequestrant protein calspermin, The CAM-dependent step in the Erk1/2 activation cascade is downstream of Ras activation, because inhibitors of CAM antagonize Erk1/2 activation induced by constitutively activated mutants of Ras and c-Src but not by constitutively activated mutants of Raf and MEK (mitogen and extracellular signal-regulated kinase). Inhibitors of the classical CAM effecters myosin light chain kinase, CAM-dependent protein kinases II and IV, PP2B, and CAM-sensitive phosphodiesterase had no effect upon 5-HT1A receptor-mediated Erk1/2 activation. Because clathrin-mediated endocytosis was required for 5-HT1A receptor-mediated Erk1/2 activation, we pos tulated a role for CAM in receptor endocytosis. Inhibition of receptor endocytosis by use of sequestration-defective mutants of beta-arrestin, and dynamin attenuated 5-HT1A receptor-stimulated Erk1/2 activation. Inhibition of CAM prevented agonist dependent endocytosis of epitope-tagged 5-HT1A receptors. We conclude that CAM-dependent activation of Erk1/2 through the 5-HT1A receptor reflects its role in endocytosis of the receptor, which is a required step in the activation of MEK and subsequently Erk1/2.	Med Univ S Carolina, Dept Med Nephrol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; NCI, NIH, Rockville, MD 20857 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Raymond, JR (corresponding author), Med Univ S Carolina, Dept Med Nephrol, 829 Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA.	raymondj@musc.edu	Della Rocca, Gregory/AAM-5281-2021; Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949; Garnovskaya, Maria/0000-0002-6216-038X	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK02352, DK52448] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002352, R56DK052448, R01DK052448] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEFIGUEIREDO P, 1995, MOL BIOL CELL, V6, P871, DOI 10.1091/mbc.6.7.871; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; GEISOW MJ, 1983, NATURE, V301, P432, DOI 10.1038/301432a0; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Llorente A, 1996, EXP CELL RES, V227, P298, DOI 10.1006/excr.1996.0279; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MERISKO EM, 1985, EUR J CELL BIOL, V39, P167; Moroi K, 1998, BRAIN RES, V794, P291, DOI 10.1016/S0006-8993(98)00245-5; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEY UM, 1995, J BIOL CHEM, V270, P2395, DOI 10.1074/jbc.270.5.2395; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SALISBURY JL, 1981, NATURE, V294, P163, DOI 10.1038/294163a0; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WIDADA JS, 1990, BIOCHIMIE, V72, P19, DOI 10.1016/0300-9084(90)90168-G; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	44	127	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4749	4753		10.1074/jbc.274.8.4749	http://dx.doi.org/10.1074/jbc.274.8.4749			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988712	hybrid			2022-12-25	WOS:000078698200037
J	Freebern, WJ; Osman, A; Niles, EG; Christen, L; LoVerde, PT				Freebern, WJ; Osman, A; Niles, EG; Christen, L; LoVerde, PT			Identification of a cDNA encoding a retinoid X receptor homologue from Schistosoma mansoni - Evidence for a role in female-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACID RECEPTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; ECDYSONE RECEPTOR; DNA-BINDING; TRANSACTIVATION DOMAIN; TRANSCRIPTION FACTOR; LIGAND-BINDING; PROTEIN	Schistosoma mansoni, a multicelluar eukaryotic blood fluke, is a major cause of morbidity worldwide in humans. The study of female parasite growth, development, and gene regulation is important because the eggs produced are responsible for the pathogenesis observed in schistosomiasis, p14, an eggshell precursor gene expressed only in sexually mature females in response to a male stimulus, is a model for female-specific gene regulation. The upstream region of the p14 gene shares sequences present in insect genes known to be regulated in a sex-, temporal-, and tissue-specific manner by members of the steroid receptor superfamily, Herein, we report the identification and characterization of a cDNA that encodes the S, mansoni (Sm) RXR homologue, Sequence analysis predicts and Western blot analysis confirms the synthesis of a 74-kDa protein, the largest member of the RXR family reported to date. We show by electrophoretic mobility shift assay analysis that SmRXR binds to cis-elements of the p14 gene including a direct repeat that follows the "3-4-5" rule of binding elements recognized by members of the steroid receptor superfamily, Furthermore, we demonstrate that SmRXR can act as a transcription activator in the yeast one-hybrid system. Through quantitative reverse transcriptase-polymerase chain reaction, we show that the SmRXR gene is constitutively expressed and thus must play multiple roles throughout the schistosome life cycle.	SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Ctr Microbial Pathogenesis, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	LoVerde, PT (corresponding author), SUNY Buffalo, Dept Microbiol, 138 Farber Hall, Buffalo, NY 14214 USA.	loverde@buffalo.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027219, R22AI027219] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27219] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BOBEK L, 1986, P NATL ACAD SCI USA, V83, P5544, DOI 10.1073/pnas.83.15.5544; BOBEK L, 1987, MOL CELL BIOL, V42, P133; BOBEK LA, 1988, MOL CELL BIOL, V8, P3008, DOI 10.1128/MCB.8.8.3008; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHEN LL, 1992, MOL BIOCHEM PARASIT, V52, P39, DOI 10.1016/0166-6851(92)90034-H; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Engers HD, 1996, DEV BIOL STAND, V87, P73; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLYNN TR, 1994, J BIOL CHEM, V269, P32713; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; Grevelding CG, 1997, PARASITOLOGY, V115, P635, DOI 10.1017/S0031182097001728; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KOSTER B, 1988, MOL BIOCHEM PARASIT, V31, P183, DOI 10.1016/0166-6851(88)90169-7; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LENG XH, 1994, J BIOL CHEM, V269, P31436; LOVERDE PT, 1991, PARASITOL TODAY, V7, P303, DOI 10.1016/0169-4758(91)90263-N; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCDONNELL DP, 1988, J STEROID BIOCHEM, V30, P41, DOI 10.1016/0022-4731(88)90074-X; Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150; MENRATH M, 1995, PARASITOLOGY, V111, P477, DOI 10.1017/S0031182000065987; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ORO AE, 1992, DEVELOPMENT, V115, P449; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Schussler P, 1997, PARASITOLOGY, V115, P629, DOI 10.1017/S003118209700173X; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4577	4585		10.1074/jbc.274.8.4577	http://dx.doi.org/10.1074/jbc.274.8.4577			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988692	hybrid			2022-12-25	WOS:000078698200017
J	Hanson, ES; Foot, LM; Leibold, EA				Hanson, ES; Foot, LM; Leibold, EA			Hypoxia post-translationally activates iron-regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HYDROXYLASE MESSENGER-RNA; INDUCIBLE FACTOR 1-ALPHA; ELEMENT-BINDING PROTEIN; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; ERYTHROPOIETIN GENE; CYTOPLASMIC PROTEIN; ACONITASE ACTIVITY; OXIDATIVE STRESS	Iron-regulatory proteins 1 and 2 (IRP1 and IRP2) are RNA-binding proteins that post-transcriptionally regulate the expression of mRNAs that code for proteins involved in the maintenance of iron and energy homeostasis, Here we show that hypoxia differentially regulates the RNA binding activities of IRP1 and IRP2 in human 293 and in mouse Hepa-1 cells, In contrast to IRP1, where hypoxic exposure decreases IRP1 RNA binding activity, hypoxia increases IRP2 RNA binding activity. The hypoxic increase in IRP2 RNA binding activity results from increased IRP2 protein levels. Cobalt, which mimics hypoxia by activation of hypoxia-inducible factor 1 (HIF-1), also increases IRP2 protein levels; however, cobalt-induced IRP2 lacks RNA binding activity. Addition of a reductant to cobalt-treated extracts restored IRP2 RNA binding activity. Hypoxic activation of IRP2 is not because of an increase in transcriptional activation by HIF-1, because IRP2 accumulates in Hepa-1 cells lacking a functional HIF-1 beta subunit, nor is it because of an increase in IRP2 mRNA stability. Rather, our data indicate that hypoxia increases IRP2 levels by a post-translational mechanism involving pro tein stability. Differential regulation of IRP1 and IRP2 during hypoxia may regulate specific IRP target mRNAs whose expression is required for hypoxic adaptation. Furthermore, these data imply mechanistic parallels between the hypoxia-induced post-transcriptional regulation of IRP2 and HIF-1 alpha.	Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Div Hematol Oncol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Leibold, EA (corresponding author), Univ Utah, Eccles Program Human Mol Biol & Genet, 15 N 2030 E,Bldg 533,Rm 4220, Salt Lake City, UT 84112 USA.	betty.leibold@hci.utah.edu			NIDDK NIH HHS [T32 DK07115] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CzyzykKrzeska MF, 1997, KIDNEY INT, V51, P585, DOI 10.1038/ki.1997.84; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; ECKARDT KU, 1993, PFLUG ARCH EUR J PHY, V423, P356, DOI 10.1007/BF00374928; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; Henderson ER, 1996, J BIOL CHEM, V271, P4900; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HUANG EL, 1997, J BIOL CHEM, V271, P32253; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1997, BBA-GENE STRUCT EXPR, V1352, P167, DOI 10.1016/S0167-4781(97)00052-3; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LEWIS CPL, 1992, BIOCHEM PHARMACOL, V43, P519, DOI 10.1016/0006-2952(92)90573-2; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	40	122	125	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5047	5052		10.1074/jbc.274.8.5047	http://dx.doi.org/10.1074/jbc.274.8.5047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988751	hybrid			2022-12-25	WOS:000078698200076
J	Tokitou, F; Nomura, T; Khan, MM; Kaul, SC; Wadhwa, R; Yasukawa, T; Kohno I; Ishii, S				Tokitou, F; Nomura, T; Khan, MM; Kaul, SC; Wadhwa, R; Yasukawa, T; Kohno, I; Ishii, S			Viral ski inhibits retinoblastoma protein (Rb)-mediated transcriptional repression in a dominant negative fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; CO-REPRESSOR; N-COR; ONCOGENE; COMPLEX; GENE; MAD; MYC; SEQUENCE; MSIN3A	The mechanism by which the viral oncogene ski (v-ski) transforms chicken embryo fibroblasts is currently unknown. Recently, the c-ski gene product (c-Ski) was found to bind to N-CoR (nuclear hormone receptor corepressor), an element implicated in transcriptional repression mediated by multiple transcriptional repressors including the nuclear hormone receptors and Mad. c-Ski is required for transcriptional repression mediated by Mad involved in negative regulation of cellular proliferation, v-Ski abrogates Mad-induced transcriptional repression in a dominant negative fashion. Here we report that v-Ski also inhibits transcriptional repression mediated by Rb, another tumor suppressor gene product. Rb forms a complex with c-Ski, Sin3A, and histone deacetylase (HDAC) via direct binding to c-Ski and HDAC. c-Ski is required for the transcriptional repression mediated by Rb. These results suggest that inhibition of Rb activity contributes, at least partly, to transformation by v-Ski.	RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Inst Med Sci, Tsukuba, Ibaraki 3050006, Japan; Natl Inst Biosci & Human Technol, Agcy Ind Sci & Technol, Tsukuba, Ibaraki 3050046, Japan; Chugai Res Inst Mol Med, Niihari, Ibaraki 3004101, Japan; Iatron Labs Inc, Chiba 2892247, Japan; JST, CREST, Tokyo, Japan	RIKEN; University of Tsukuba; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016; Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Ishii, Shunsuke/0000-0002-6530-2478; Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEVINS JR, 1992, SCIENCE, V258, P424; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; NOMURA T, 1999, IN PRESS GENES DEV; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	28	77	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4485	4488		10.1074/jbc.274.8.4485	http://dx.doi.org/10.1074/jbc.274.8.4485			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988677	hybrid			2022-12-25	WOS:000078698200002
J	Fouts, ET; Yu, X; Egelman, EH; Botchan, MR				Fouts, ET; Yu, X; Egelman, EH; Botchan, MR			Biochemical and electron microscopic image analysis of the hexameric E1 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS TYPE-1 ORIGIN; SINGLE-STRANDED-DNA; LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; BOVINE PAPILLOMAVIRUS; ESCHERICHIA-COLI; REPLICATION PROTEIN; BRANCH MIGRATION; VIRAL ORIGIN; E2 PROTEINS	DNA replication initiator proteins bind site specifically to origin sites and in most cases participate in the early steps of unwinding the duplex. The papillomavirus preinitiation complex that assembles on the origin of replication is composed of proteins E1 and the activator protein E2, E2 is an ancillary factor that increases the affinity of E1 for the ori site through cooperative binding. Here we show that duplex DNA affects E1 (in the absence of E2) to assemble into an active hexameric structure. As a 10-base oligonucleotide can also induce this oligomerization, it seems likely that DNA binding allosterically induces a conformation that enhances hexamers, E1 assembles as a bi-lobed, presumably double hexameric structure on duplex DNA and can initiate bi-directional unwinding from an ori site. The DNA takes an apparent straight path through the double hexamers. Image analysis of E1 hexameric rings shows that the structures are heterogeneous and have either a 6- or 3-fold symmetry. The rings are about 40-50 Angstrom thick and 125 Angstrom in diameter. The density of the central cavity appears to be a variable and we speculate that a plugged center may represent a conformational flexibility of a subdomain of the monomer, to date unreported for other hexameric helicases.	Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Minnesota System; University of Minnesota Twin Cities	Botchan, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	mbotchan@uclink4.berkeley.edu	Egelman, Edward H/A-2488-2009	Egelman, Edward/0000-0003-4844-5212	NCI NIH HHS [CA42414, CA30490] Funding Source: Medline; NIGMS NIH HHS [GM35269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042414, R01CA030490, R37CA030490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISWAS EE, 1986, BIOCHEMISTRY-US, V25, P7368, DOI 10.1021/bi00371a019; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; Chen G, 1998, J VIROL, V72, P2567, DOI 10.1128/JVI.72.4.2567-2576.1998; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FRANK J, 1988, METHOD ENZYMOL, V164, P3; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; Ito K, 1996, EMBO J, V15, P5636, DOI 10.1002/j.1460-2075.1996.tb00948.x; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; MACPHERSON P, 1994, VIROLOGY, V204, P403, DOI 10.1006/viro.1994.1544; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; Martin Carmen San, 1998, Structure (London), V6, P501, DOI 10.1016/S0969-2126(98)00051-3; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MENDOZA R, 1995, J VIROL, V69, P3789, DOI 10.1128/JVI.69.6.3789-3798.1995; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MULLER F, 1994, J BIOL CHEM, V269, P17086; NILSSON M, 1991, NUCLEIC ACIDS RES, V19, P7061, DOI 10.1093/nar/19.25.7061; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SanMartin MC, 1997, J MOL BIOL, V268, P15, DOI 10.1006/jmbi.1997.0952; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SENGUPTA DJ, 1994, EMBO J, V13, P982, DOI 10.1002/j.1460-2075.1994.tb06343.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STITT BL, 1988, J BIOL CHEM, V263, P11130; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	65	103	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4447	4458		10.1074/jbc.274.7.4447	http://dx.doi.org/10.1074/jbc.274.7.4447			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933649	hybrid			2022-12-25	WOS:000078575500073
J	Molloy, DP; Smith, KJ; Milner, AE; Gallimore, PH; Grand, RJA				Molloy, DP; Smith, KJ; Milner, AE; Gallimore, PH; Grand, RJA			The structure of the site on adenovirus early region 1A responsible for binding to TATA-binding protein determined by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; E1A PROTEINS; CELL-GROWTH; ZINC-FINGER; FUNCTIONAL DOMAINS; PEPTIDE; GENE; ACTIVATION; TRANSFORMATION; IDENTIFICATION	Previous detailed mutational analysis has shown that the binding site on adenovirus (Ad) early region 1A (E1A) for TATA-binding protein (TBP) is located toward the N terminus of conserved region 3 (CR3), Here we demonstrate that synthetic peptides of between 15 and 22 amino acids, identical to amino acid sequences of CR3 present in the larger Ad5 E1A (13 S product) and in both the Ad12 E1A (13 and 12 S products) proteins that lie N-terminal to the zinc finger motif, can disrupt binding of E1A to TBP, These findings suggest that the peptides are biologically active in terms of interacting with TBP and must therefore comprise some, if not all, of the TBP binding site on E1A, The interaction between Ad12 E1A and TBP was confirmed by direct co precipitation experiments, In H-1 NMR studies of CR3 peptides, regular patterns of NOEs were observed from which their conformational preferences in aqueous solution were determined. Both Ad5 and Ad12 peptides were shown to contain regions of helical backbone structure in 50% trifluoroethanol. In each case, the type and intensities of NOE cross-peaks observed correlated best to alpha-helical turns. These helices are more extensive in larger peptides and extend from Glu(141) to Val(147) and from Arg(144) to Pro(152) in the full-length Ad5 and Ad12 13S E1A proteins, respectively. The structure of a 19-residue Ad5 CR3 peptide carrying the V147L mutation in the full-length protein that abolishes TBP binding was examined. No significant differences between the substituted and wild type peptides were observed, suggesting that this substitution in the intact protein may cause disruption of global rather than local structures.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	R.J.A.Grand@bham.ac.uk						BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CRISMA M, 1995, PEPTIDE RES, V8, P187; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GALLIMORE PH, 1988, CANCER RES, V45, P2670; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; LUI F, 1990, CELL, V61, P1217; LUI F, 1994, NATURE, V368, P520; MIICK SM, 1992, NATURE, V359, P653, DOI 10.1038/359653a0; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SEGAWA S, 1991, BIOPOLYMERS, V31, P497, DOI 10.1002/bip.360310505; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SHENK T, 1991, ADV CANCER RES, V57, P47; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; SMITH KJ, 1994, BIOCHEMISTRY-US, V33, P6063, DOI 10.1021/bi00186a005; SMITH LJ, 1994, STRUCTURE, V2, P703, DOI 10.1016/S0969-2126(00)00071-X; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILLIAMS J, 1994, CURR TOP MICROBIOL, V199, P149	50	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3503	3512		10.1074/jbc.274.6.3503	http://dx.doi.org/10.1074/jbc.274.6.3503			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920896	hybrid			2022-12-25	WOS:000078428200036
J	Zhu, CC; Furuichi, T; Mikoshiba, R; Wojcikiewicz, RJH				Zhu, CC; Furuichi, T; Mikoshiba, R; Wojcikiewicz, RJH			Inositol 1,4,5-trisphosphate receptor down-regulation is activated directly by inositol 1,4,5-trisphosphate binding - Studies with binding-defective mutant receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH-SY5Y NEUROBLASTOMA-CELLS; TRISPHOSPHATE RECEPTOR; PHOSPHOINOSITIDASE-C; CA2+ MOBILIZATION; DESENSITIZATION; FIBROBLASTS; DEGRADATION; EXPRESSION; INVOLVEMENT; STIMULATION	Activation of certain phosphoinositidase C-linked cell surface receptors is known to cause an acceleration of the proteolysis of inositol 1,4,5-trisphosphate (InsP(3)) receptors and, thus, lead to InsP(3) receptor down-regulation. To gain insight into this process, we examined whether or not InsP(3) receptor degradation is a direct consequence of InsP(3) binding by analyzing the downregulation of exogenous wild-type and binding-defective mutant InsP(3) receptors expressed in SH-SY5Y human neuroblastoma cells. Stimulation of these cells with carbachol showed that wild-type exogenous receptors could be down-regulated but that the binding-defective mutant exogenous receptors were not. Thus, InsP(3) binding appears to mediate down-regulation. To validate this conclusion, a comprehensive analysis of the effects of the exogenous receptors was undertaken. This showed that exogenous receptors (i) are localized appropriately within the cell, (ii) enhance InsP(3)-induced Ca2+ release in permeabilized cells, presumably by increasing the number of InsP(3)-sensitive Ca2+ channels, (iii) have minimal effects on Ca2+ mobilization and InsP(3) formation in intact cells, (iv) form heteromers with endogenous receptors, and (v) do not alter the down-regulation of endogenous receptors, In total, these data show that the introduction of exogenous receptors into SH-SY5Y cells does not compromise intracellular signaling or the down-regulatory process. We can thus conclude that InsP(3) binding directly activates InsP(3) receptor degradation. Because InsP(3) binding induces a conformational change in the InsP(3) receptor, these data suggest that this change provides the signal for accelerated proteolysis.	SUNY Hlth Sci Ctr, Coll Med, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 108, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Tokyo	Wojcikiewicz, RJH (corresponding author), SUNY Hlth Sci Ctr, Coll Med, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	wojcikir@vax.cs.hscsyr.edu	Furuichi, Teiichi/B-5086-2014	Furuichi, Teiichi/0000-0002-9676-1888	NIDDK NIH HHS [DK49194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049194, R29DK049194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1994, J BIOL CHEM, V269, P27167; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DeSmedt H, 1997, BIOCHEM J, V322, P575; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Lievremont JP, 1996, BIOCHEM J, V317, P755, DOI 10.1042/bj3170755; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Quick MW, 1996, J BIOL CHEM, V271, P32021, DOI 10.1074/jbc.271.50.32021; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; WATRAS J, 1991, J NEUROSCI, V11, P3239; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, MOL PHARMACOL, V53, P656, DOI 10.1124/mol.53.4.656; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; Yoshida Y, 1997, JPN J PHARMACOL, V74, P125, DOI 10.1254/jjp.74.125	43	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3476	3484		10.1074/jbc.274.6.3476	http://dx.doi.org/10.1074/jbc.274.6.3476			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920893	hybrid			2022-12-25	WOS:000078428200033
J	Piredda, L; Farrace, MG; Lo Bello, M; Malorni, W; Melino, G; Petruzzelli, R; Piacentini, M				Piredda, L; Farrace, MG; Lo Bello, M; Malorni, W; Melino, G; Petruzzelli, R; Piacentini, M			Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis	FASEB JOURNAL			English	Article						cell death; human neuroblastoma cells; staurosporine; histone H2B; microtubules; chromatin; glutathione	PLACENTAL GLUTATHIONE TRANSFERASE; HUMAN NEUROBLASTOMA-CELLS; CROSS-LINKING; S-TRANSFERASES; RAT-LIVER; DEATH; LOCALIZATION; STIMULATION; EXPRESSION; ANTIBODIES	Overexpression of 'tissue' transglutaminase (tTG) in the human neuroblastoma cells increases spontaneous apoptosis and renders these cells highly susceptible to death induced by various stimuli, We used immunoprecipitation to identify cellular proteins that interact specifically with tTG in SK-N-BE(2)-derived stable transfectants, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis showed that tTG binding proteins have molecular masses of 110, 50, 22, 14, and 12 kDa. Microsequencing and computer search analyses allowed us to identify these polypeptides as the beta-tubulin (50 kDa), the histone H2B (14 kDa), and two GST P1-l-truncated forms (22 and 12 kDa), The specificity of the interaction between tTG and these proteins was confirmed by competing tTG binding with purified enzyme and by detecting tTG in immunoprecipitates obtained using beta-tubulin or GST P1-l mAb's, Here we demonstrate that the GST P1-1 acts as an efficient acyl donor as well as acceptor tTG substrate both in cells and in vitro. The tTG-catalyzed polymerization of GST P1-l leads to its functional inactivation and is competitively inhibited by GSH, By contrast, the tTG-beta-tubulin interaction does not result in the cross-linking of this cytoskeletal protein, which suggests that microtubules act as the anchorage site for tTG and GST P1-1 interaction.	Univ Rome Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Super Sanita, Ultrastrutture Lab, I-00161 Rome, Italy; IRCCS, IDI, Biochem Lab, Rome, Italy; Univ GD Annunsio, Dept Biomed Sci, Chieti, Italy; IRCCS, Cell Biol Lab L Spallanzani, Rome, Italy	University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Piacentini, M (corresponding author), Univ Rome Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	mauro.piacentini@UniRoma2.it	Malorni, Walter/G-5874-2016; Piacentini, Mauro/I-2411-2016	Piacentini, Mauro/0000-0003-2919-1296; malorni, walter/0000-0002-1223-7000				Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; BATTISTONI A, 1995, PROTEIN EXPRES PURIF, V6, P579, DOI 10.1006/prep.1995.1076; ELBARBARY A, 1993, HEARING RES, V71, P80; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; Gorza L, 1997, AM J PATHOL, V150, P2087; GREEN F, 1992, NEW STATESMAN SOC, V5, P30; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; KIM H, 1979, J CELL BIOL, V80, P226; Kletsas D, 1998, BIOCHEM BIOPH RES CO, V243, P416, DOI 10.1006/bbrc.1997.7975; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; MASSOUD R, 1991, HYBRIDOMA, V10, P89, DOI 10.1089/hyb.1991.10.89; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; MITHIEUX G, 1986, BIOCHIM BIOPHYS ACTA, V888, P49, DOI 10.1016/0167-4889(86)90070-4; Nagy L, 1997, CELL DEATH DIFFER, V4, P534, DOI 10.1038/sj.cdd.4400290; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PIACENTINI M, 1986, BIOCHEM J, V234, P435, DOI 10.1042/bj2340435; Piacentini M, 1996, J PATHOL, V180, P415, DOI 10.1002/(SICI)1096-9896(199612)180:4<415::AID-PATH684>3.0.CO;2-A; PIACENTINI M, 1994, APOPTOSIS MOL BASIS, P143; Piredda L, 1997, CELL DEATH DIFFER, V4, P463, DOI 10.1038/sj.cdd.4400267; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Shimizu T, 1996, NATURE, V380, P32, DOI 10.1038/380032a0; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; TIMMS BG, 1986, AM J ANAT, V175, P267, DOI 10.1002/aja.1001750211; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471	48	93	95	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					355	364		10.1096/fasebj.13.2.355	http://dx.doi.org/10.1096/fasebj.13.2.355			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973324	Bronze			2022-12-25	WOS:000078615200016
J	Liu, N; Cigola, E; Tinti, C; Jin, BK; Conti, B; Volpe, BT; Baker, H				Liu, N; Cigola, E; Tinti, C; Jin, BK; Conti, B; Volpe, BT; Baker, H			Unique regulation of immediate early gene and tyrosine hydroxylase expression in the odor-deprived mouse olfactory bulb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DECARBOXYLASE; ELEMENT-BINDING PROTEIN; CENTRAL-NERVOUS-SYSTEM; CAMP RESPONSE ELEMENT; CYCLIC-AMP; MESSENGER-RNA; C-FOS; TRANSCRIPTION FACTORS; ADRENAL-MEDULLA; TRANSGENIC MICE	Tyrosine hydroxylase (TH), expressed in a population of periglomerular neurons intrinsic to the olfactory bulb, displays dramatic down-regulation in response to odor deprivation. To begin to elucidate the importance of immediate early genes (IEG) in TH gene regulation, the present study examined expression of IEGs in the olfactory bulb in response to odor deprivation. In addition, the composition of TH AP-1 and CRE binding complexes was investigated in control and odor-deprived mice. Immunocytochemical studies showed that c-Fos, Fos-B, Jun-D, CRE-binding protein (CREB), and phosphorylated CREB (pCREB) are colocalized with TH in the dopaminergic periglomerular neurons. Unilateral naris closure resulted in down-regulation of c-Fos and Fos-B, but not Jun-D, CREB, or pCREB, in the glomerular layer of the ipsilateral olfactory bulb. Gel shift assays demonstrated a significant decrease (32%) in TH AP-I, but not CRE, binding activity in the odor-deprived bulb. Fos-B was found to be the exclusive member of the Fos family present in the TH BP-l complex. CREB, CRE modulator protein (CREM), Fos-B, and Jun-D, but not c-Fos, all contributed to the CRE: DNA-protein complex. These results indicated that Fos-B, acting through both AP-1 and CRE motifs, may be implicated in the regulation of TH expression in the olfactory bulb dopaminergic neurons.	Cornell Univ, Coll Med, Burke Med Res Inst, Mol Neurobiol Lab, White Plains, NY 10605 USA	Cornell University	Baker, H (corresponding author), Cornell Univ, Coll Med, Burke Med Res Inst, Mol Neurobiol Lab, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	habaker@med.cornell.edu	volpe, b/U-8409-2019	Conti, Bruno/0000-0002-9185-5201; Volpe, Bruce/0000-0002-1098-1848	PHS HHS [NIA09686] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER H, 1984, NEUROSCIENCE, V11, P605, DOI 10.1016/0306-4522(84)90047-2; BAKER H, 1983, J NEUROSCI, V3, P69; BAKER H, 1990, NEUROSCIENCE, V36, P761, DOI 10.1016/0306-4522(90)90018-Y; BAKER H, 1993, NEUROSCIENCE, V52, P115, DOI 10.1016/0306-4522(93)90187-K; BAKER H, 1993, BRAIN RES, V614, P109, DOI 10.1016/0006-8993(93)91023-L; BRUNJES PC, 1985, DEV BRAIN RES, V22, P1, DOI 10.1016/0165-3806(85)90063-X; CHEN JS, 1995, MOL PHARMACOL, V48, P880; Cho JY, 1996, J COMP NEUROL, V369, P264; CUBELLS JF, 1995, J NEUROCHEM, V65, P502; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS BJ, 1983, J COMP NEUROL, V214, P427, DOI 10.1002/cne.902140407; DEMMER J, 1993, MOL BRAIN RES, V17, P279, DOI 10.1016/0169-328X(93)90012-E; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Ghee M, 1998, MOL BRAIN RES, V55, P101, DOI 10.1016/S0169-328X(97)00370-7; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN R, 1980, J CELL BIOL, V84, P495, DOI 10.1083/jcb.84.3.495; GUTHRIE KM, 1990, J NEUROSCI, V10, P3402; GUTHRIE KM, 1995, NEUROREPORT, V6, P2145, DOI 10.1097/00001756-199511000-00012; HABENER JF, 1990, METABOLISM, V39, P13, DOI 10.1016/0026-0495(90)90199-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRINGTON CA, 1987, NUCLEIC ACIDS RES, V15, P2363, DOI 10.1093/nar/15.5.2363; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; HUGHES P, 1995, PHARMACOL REV, V47, P133; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Jin BK, 1996, INT J DEV NEUROSCI, V14, P971, DOI 10.1016/S0736-5748(96)00044-5; JOH TH, 1973, J NEUROCHEM, V39, P342; KIM KS, 1993, J BIOL CHEM, V268, P15689; Kumer SC, 1996, J NEUROCHEM, V67, P443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MCLEAN JH, 1988, J NEUROSCI, V8, P3658; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PENNYPACKER KR, 1995, DEV BRAIN RES, V86, P242, DOI 10.1016/0165-3806(95)00033-A; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RYSECK RP, 1991, ONCOGENE, V6, P533; Sabban EL, 1997, SEMIN CELL DEV BIOL, V8, P101, DOI 10.1006/scdb.1996.0129; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, V3rd Edn, P133; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; STONE DM, 1991, J COMP NEUROL, V311, P223, DOI 10.1002/cne.903110205; STONE DM, 1990, MOL BRAIN RES, V8, P291, DOI 10.1016/0169-328X(90)90042-C; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trocme C, 1997, J NEUROSCI RES, V48, P489, DOI 10.1002/(SICI)1097-4547(19970615)48:6<489::AID-JNR1>3.0.CO;2-6; WEISER M, 1993, MOL BRAIN RES, V17, P319, DOI 10.1016/0169-328X(93)90017-J; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	60	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3042	3047		10.1074/jbc.274.5.3042	http://dx.doi.org/10.1074/jbc.274.5.3042			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915843	Green Published, hybrid			2022-12-25	WOS:000078319500061
J	Kanoe, H; Nakayama, T; Hosaka, T; Murakami, H; Yamamoto, H; Nakashima, Y; Tsuboyama, T; Nakamura, T; Ron, D; Sasaki, MS; Toguchida, J				Kanoe, H; Nakayama, T; Hosaka, T; Murakami, H; Yamamoto, H; Nakashima, Y; Tsuboyama, T; Nakamura, T; Ron, D; Sasaki, MS; Toguchida, J			Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation	ONCOGENE			English	Article						TLS; CHOP; liposarcoma; topoisomerase II; Translin	ROUND-CELL LIPOSARCOMA; ACUTE MYELOID-LEUKEMIA; RNA-BINDING PROTEIN; MYXOID LIPOSARCOMA; CHROMOSOMAL TRANSLOCATIONS; DNA-SEQUENCE; BCR GENE; ONCOGENIC TRANSFORMATION; CLUSTER REGION; RECOMBINATION	Fusion of TLS/FUS and CHOP gene by reciprocal translocation t(12;16)(q32;q16) is a common genetic event found in myxoid and round-cell liposarcomas, Characterization of this genetic event was performed by three methods, Southern blot, RT-PCR, and genomic long-distance PCR in nine myxoid and three round-cell liposarcomas. All but one tumors showed genetic alternations indicating the fusion of TLS/FUS and CHOP gene, Two novel types of fusion transcripts were found, of which one lacked exon 2 sequence of CHOP gene, and the other lacked 3' half of exon 5 of TLS gene, The latter case was caused by a cryptic splicing site which,vas created by the genomic fusion, Detailed analyses genomic fusion points revealed several sequence characteristics surrounding the fusion points, Homology analyses of breakpoint sequences with known sequence motifs possibly involve in the process of translocation uncovered Translin binding sequences at both of TLS/ FUS and CHOP breakpoints in two cases. Translocations were always associated with other genetic alterations, such as deletions, duplications, or insertions. Short direct repeats were almost always found at both ends of deleted or duplicated fragments some of which had apparently been created by joining of sequences that flank the rearrangement. Finally, consensus topoisomerase II cleavage sites were found at breakpoints in all cases analysed, suggesting a role of this enzyme in creating staggered ends at the breakpoint, These data suggested that sequence characteristics may play an important role to recruit several factors such as Translin and topoisomerase II in the process of chromosomal translation in liposarcomas.	Kyoto Univ, Dept Orthopaed Surg, Kyoto 606, Japan; Kyoto Univ, Dept Pathol, Kyoto 606, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 606, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 606, Japan; NYU Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA	Kyoto University; Kyoto University; Kyoto University; Kyoto University; New York University	Toguchida, J (corresponding author), Kyoto Univ, Dept Orthopaed Surg, Kyoto 606, Japan.			Ron, David/0000-0002-3014-5636	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI K, 1994, ONCOGENE, V9, P1109; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CHEN SJ, 1989, ONCOGENE, V4, P195; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CROWTHER PJ, 1991, NUCLEIC ACIDS RES, V19, P2395, DOI 10.1093/nar/19.9.2395; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KASAI M, 1994, INT IMMUNOL, V6, P1017, DOI 10.1093/intimm/6.7.1017; KNIGHT JC, 1995, CANCER RES, V55, P24; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; KURODA M, 1995, AM J PATHOL, V147, P1221; Kuroda M, 1997, AM J PATHOL, V151, P735; NILBERT M, 1994, CANCER GENET CYTOGEN, V72, P155, DOI 10.1016/0165-4608(94)90133-3; Panagopoulos I, 1996, GENE CHROMOSOME CANC, V17, P102, DOI 10.1002/(SICI)1098-2264(199610)17:2<102::AID-GCC5>3.0.CO;2-9; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPTIZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	40	53	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					721	729		10.1038/sj.onc.1202364	http://dx.doi.org/10.1038/sj.onc.1202364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989822	Green Submitted			2022-12-25	WOS:000078394400017
J	Soulie, P; Poupon, MF; Remvikos, Y; Dutrillaux, B; Muleris, M				Soulie, P; Poupon, MF; Remvikos, Y; Dutrillaux, B; Muleris, M			Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers	ONCOGENE			English	Article						gene amplification; human colon cancer; p53; drug resistance; chromosome; PALA	WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE GENE; CHINESE-HAMSTER CELLS; MUTANT P53; MULTIPLE MECHANISMS; HUMAN FIBROBLASTS; CYCLE REGULATION; AMPLIFICATION; DNA; LINES	This study investigates the chromosomal alterations involved in the acquisition of PALA resistance of LoVo colorectal cancer cells homozygous for wild-type TP53 before and after transfection with a 143Ala-mutated TP53 gene. PALA resistance was always associated with an increased number of CAD gene copies, but gene amplification sensu stricto was rarely observed, Interestingly, distinct chromosome patterns were found in relation to the TP53 status of the cells. In parental LoVo cells, the CAD copy number was increased through gains of normal chromosome 2 whereas in transfectant clones, resistance mostly occurred through chromosome rearrangements. The relationship with the two different cytogenetic patterns described in colorectal tumors is discussed.	Inst Curie, CNRS, UMR 147, Lab Cytogenet Mol & Oncol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Muleris, M (corresponding author), Inst Curie, CNRS, UMR 147, Lab Cytogenet Mol & Oncol, 26 Rue dUlm, F-75248 Paris 05, France.							Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1; Chen CYM, 1996, CANCER RES, V56, P3659; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Cottu PH, 1996, ONCOGENE, V13, P2727; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FREBOURG T, 1994, CANCER RES, V54, P878; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Lesec G, 1997, INT J ONCOL, V10, P747; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Muleris M, 1996, CANCER GENET CYTOGEN, V92, P11, DOI 10.1016/S0165-4608(96)00116-1; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; PARK DJ, 1994, ONCOGENE, V9, P1899; Pocard M, 1996, ONCOGENE, V12, P875; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; Remvikos Y, 1997, CANCER GENET CYTOGEN, V93, P63, DOI 10.1016/S0165-4608(96)00305-6; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SHARMA RC, 1994, MUTAT RES, V304, P243, DOI 10.1016/0027-5107(94)90217-8; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Smith KA, 1997, P NATL ACAD SCI USA, V94, P1816, DOI 10.1073/pnas.94.5.1816; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1986, CANCER SURV, V5, P1; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; UMAR A, 1994, J BIOL CHEM, V269, P14367; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	44	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					775	781		10.1038/sj.onc.1202336	http://dx.doi.org/10.1038/sj.onc.1202336			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989828				2022-12-25	WOS:000078394400023
J	Martinez, LA; Chen, Y; Fischer, SM; Conti, CJ				Martinez, LA; Chen, Y; Fischer, SM; Conti, CJ			Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation	ONCOGENE			English	Article						cell cycle; cyclins; CDK; epidermis; terminal differentiation; keratinocytes	RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; IN-VITRO; G1 PHASE; EXPRESSION; GENE; P21; INHIBITOR; GROWTH; PROGRESSION	Differentiation of cells is typically marked by a cessation of proliferation with a concurrent entrance into a distinct metabolic state marked by tissue specific gene expression, The mechanism by which the cell exits the cell cycle in this process is poorly understood. To determine the potential roles of the cell cycle machinery in the regulation of the terminal differentiation process of epidermal cells, we selected a well characterized in vitro model in which primary mouse keratinocytes are induced to differentiate in response to a raised calcium ion concentration in the medium. The withdrawal from the cell cycle correlates very well with a number of changes in the cell cycle machinery. Changes in the phosphorylation status of the Rb family of proteins occurs coordinately with an increased association of p21, p27 and p57 with cdk2, Furthermore, we find that inhibition of cdk2 activity is not sufficient to elicit changes that occur during keratinocyte differentiation. Finally, the previously described v-Ha-ras block of keratinocyte differentiation correlates with altered regulation of both cyclin D1 and cdk2 suggesting that these genes may play a role in the Ha-ras transformation of a keratinocyte.	Univ Texas, MD Anderson Cancer Ctr, Sci Pk Res Div, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Conti, CJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.				NCI NIH HHS [CA 57596, CA 42157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA057596, R01CA042157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Botz J, 1996, MOL CELL BIOL, V16, P3401; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; Gotz C, 1996, ONCOGENE, V13, P391; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, FEBS LETT, V367, P103, DOI 10.1016/0014-5793(95)00587-Y; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG WC, 1995, ONCOGENE, V10, P2271; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	48	59	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					397	406		10.1038/sj.onc.1202300	http://dx.doi.org/10.1038/sj.onc.1202300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927196				2022-12-25	WOS:000078166500012
J	Denny, MF; Kaufman, HC; Chan, AC; Straus, DB				Denny, MF; Kaufman, HC; Chan, AC; Straus, DB			The Lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PROTOONCOGENE C-CBL; TYROSINE KINASE; SRC-FAMILY; CROSS-LINKING; ZETA-CHAIN; NEGATIVE SELECTION; BINDING PROTEIN; ZAP-70 KINASE; TRANSDUCTION	Initiation of T-cell antigen receptor (TCR) signaling is dependent upon the activity of protein tyrosine kinases, The Src family kinase Lck is required for the initial events in TCR signaling, such as the phosphorylation of the TCR complex and the activation of ZAP-70, but little is known of its role in downstream signaling. Expression of a mutated form of Lck lacking SH3 domain function (LckW97A) in the Lck-deficient T-cell line JCaM1 revealed a requirement for Lck beyond the initiation of TCR signaling. In cells expressing LckW97A, stimulation of the TCR failed to activate the mitogen-activated protein kinase (MAPK) pathway, despite normal TCR zeta chain phosphorylation, ZAP-70 recruitment, and ZAP-70 activation. Activation of extracellular signal-regulated kinase (ERK) and MAPK kinase (MEK), as well as the induction of CD69 expression, was greatly impaired in JCaM1/LckW97A cells. In contrast, the phosphorylation of phospholipase C gamma 1 (PLC gamma 1) and corresponding elevations in intracellular calcium concentration ([Ca2+](i)) were intact. Thus, cells expressing LckW97A exhibit selective defect in the activation of the MAPK pathway. These results demonstrate that Lck has a role in the activation of signaling pathways beyond the initiation of TCR signaling and suggest that the MAPK pathway may be selectively controlled by regulating the function of Lck.	Univ Chicago, Dept Med & Pathol, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	University of Chicago; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Straus, DB (corresponding author), Univ Chicago, Dept Med MC6084, 5841 S Maryland Ave, Chicago, IL 60637 USA.	dstraus@midway.uchicago.edu		Denny, Michael/0000-0002-7874-1744	NCI NIH HHS [CA71516-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; August A, 1996, J BIOL CHEM, V271, P10054; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; LeeFruman KK, 1996, J BIOL CHEM, V271, P25003, DOI 10.1074/jbc.271.40.25003; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Popik W, 1996, MOL CELL BIOL, V16, P6532; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; TESTI R, 1989, J IMMUNOL, V142, P1854; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wong J, 1998, MOL CELL BIOL, V18, P2855, DOI 10.1128/MCB.18.5.2855; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	58	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5146	5152		10.1074/jbc.274.8.5146	http://dx.doi.org/10.1074/jbc.274.8.5146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988764	hybrid			2022-12-25	WOS:000078698200089
J	Xiao, H; Tao, Y; Roeder, RG				Xiao, H; Tao, Y; Roeder, RG			The human homologue of Drosophila TRF-proximal protein is associated with an RNA polymerase II SRB complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; REPEAT DOMAIN; HOLOENZYME; MEDIATOR; COMPONENTS; INITIATION; YEAST; CTD	Mammalian RNA polymerase II holoenzymes are large complexes that have been reported to contain, in addition to RNA polymerase II, homologues of several yeast SRBs, various general transcription factors, and other polypeptides. On the basis of its copurification with an SRB-containing RNA polymerase II complex by conventional chromatography procedures, we have identified a human homologue of Drosophila TRF-proximal protein, designated hTRFP, and isolated its cognate cDNA Antibody specific for SRB7 can immunoprecipitate hTRFP and RNA polymerase II and, reciprocally, antibody specific for hTRFP can immunoprecipitate RNA polymerase II and SRB7. These data indicate that hTRFP is an integral component of an RNA polymerase II-SRB complex. Whereas the precise function of hTRFP remains to be determined, the hTRFP-containing RNA polymerase II-SRB complex supports basal level transcription and, relative to RNA polymerase II alone, enhances transcriptional activation by Ga14-VP16 in the presence of cofactor PC4. Thus, hTRFP may regulate transcription of class II genes through association with the RNA polymerase II-SRB complex.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Roeder, RG (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA.	roeder@rockvax.rockefeller.edu			NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037327] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI37327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GU W, 1998, IN PRESS MOL CELL; Gustafsson CM, 1997, J BIOL CHEM, V272, P48; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LEE YC, 1997, MOL CELL BIOL, V9, P5364; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NONET ML, 1989, GENETICS, V123, P715; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Song WJ, 1996, MOL CELL BIOL, V16, P115; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146	33	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3937	3940		10.1074/jbc.274.7.3937	http://dx.doi.org/10.1074/jbc.274.7.3937			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933582	hybrid			2022-12-25	WOS:000078575500006
J	Szak, ST; Pietenpol, JA				Szak, ST; Pietenpol, JA			High affinity insertion/deletion lesion binding by p53 - Evidence for a role of the p53 central domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; SEQUENCE-SPECIFIC DNA; DAMAGE-RECOGNITION; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; CRYSTAL-STRUCTURE; UV IRRADIATION; STRAND BREAKS; IN-VIVO	In addition to binding DNA in a sequence-specific manner, p53 can interact with nucleic acids in a sequence-independent manner. p53 can bind short single-stranded DNA and double-stranded DNA containing nucleotide loops; these diverse associations may be critical for p53 signal transduction, In this study, we analyzed p53 binding to DNA fragments containing insertion/deletion mismatches (IDLs). p53 required an intact central domain and dimerization domain for high affinity complex formation with IDLs. In fact, the C terminus of p53 (amino acids 293-393) was functionally replaceable with a foreign dimerization domain in IDL binding assays. From saturation binding studies we determined that the K-D of p53 binding to IDLs was 45 pM as compared with a K-D of 31 pM for p53 binding to DNA fragments containing a consensus binding site. Consistent with these dissociation constants, p53-IDL complexes were dissociated with relatively low concentrations of competitor consensus site-containing DNA. Although p53 has a higher affinity for DNA with a consensus site as compared with IDLs, the relative number and availability of each form of DNA in a cell immediately after DNA damage may promote p53 interaction with DNA lesions. Understanding how the sequence-specific and nonspecific DNA binding activities of p53 are integrated will contribute to our knowledge of how signaling cascades are initiated after DNA damage.	Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, 652 Med Res Bldg 2, Nashville, TN 37232 USA.	pietenpol@toxicology.mc.vanderbilt.edu			NCI NIH HHS [CA68485, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070856, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1997, BIOCHEM J, V328, P1, DOI 10.1042/bj3280001; COATES PJ, 1995, J PATHOL, V176, P19, DOI 10.1002/path.1711760105; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P806; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Ji C, 1998, CARCINOGENESIS, V19, P1275, DOI 10.1093/carcin/19.7.1275; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Sutherland BM, 1996, ANAL BIOCHEM, V239, P53, DOI 10.1006/abio.1996.0290; WAKAGUCHI K, 1998, GENE DEV, V12, P2831; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	56	33	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3904	3909		10.1074/jbc.274.6.3904	http://dx.doi.org/10.1074/jbc.274.6.3904			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920946	hybrid			2022-12-25	WOS:000078428200086
J	Bobanovic, F; Bootman, MD; Berridge, MJ; Parkinson, NA; Lipp, P				Bobanovic, F; Bootman, MD; Berridge, MJ; Parkinson, NA; Lipp, P			Elementary [Ca2+](i) signals generated by electroporation functionally mimic those evoked by hormonal stimulation	FASEB JOURNAL			English	Article						Ca2+ puffs; Ca2+ waves; HeLa cells; confocal microscopy; InsP(3) receptors	1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; CYTOSOLIC CA2+; CELL-MEMBRANES; CALCIUM; EVENTS; MUSCLE	The generation of oscillations and global Ca2+ waves relies on the spatio-temporal recruitment of elementary Ca2+ signals, such as 'Ca2+ puffs', Each elementary signal contributes a small amount of Ca2+ into the cytoplasm, progressively promoting neighboring Ca2+ release sites into an excitable state, Previous studies have indicated that increases in frequency or amplitude of such hormone-evoked elementary Ca2+ signals: are necessary to initiate Ca2+ wave propagation. In the present study, an electroporation device was used to rapidly and reversibly permeabilize the plasma membrane of HeLa cells and to allow a limited influx of Ca2+, With low held intensities (100-500 V/cm), brief (50-100 mu s) electroporation triggered localized Ca2+ signals that resembled hormone-evoked Ca2+ puffs, but not global signals. With such low intensity electroporative pulses, the Ca2+ influx component was usually undetectable, confirming that the electroporation-induced local signals represented Ca2+ puffs arising from the opening of intracellular Ca2+ release channels. Increasing either the frequency at which low-intensity electroporative pulses were applied, or the intensity of a single electroporative pulse (>500 V/cm), resulted in caffeine-sensitive regenerative Ca2+ waves. We suggest that Ca2+ puffs caused by electroporation functionally mimic hormone-evoked elementary events and can activate global Ca2+ signals if they provide a sufficient trigger.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Ljubljana, Fac Elect Engn, Lab Biocybernet, Ljubljana 61000, Slovenia; Univ Cambridge, Dept Zool, Cambridge, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Ljubljana; University of Cambridge	Bootman, MD (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	martin.bootman@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOBANOVIC F, 1998, FLUORESCENT LUMINESC; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBINO M, 1993, BIOPHYS J, V64, P1789, DOI 10.1016/S0006-3495(93)81550-9; Huser J, 1996, PFLUG ARCH EUR J PHY, V433, P194, DOI 10.1007/s004240050267; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KINOSITA K, 1988, BIOPHYS J, V53, P1015, DOI 10.1016/S0006-3495(88)83181-3; Kotnik T, 1997, BIOELECTROCH BIOENER, V43, P285, DOI 10.1016/S0302-4598(97)00023-8; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; Park JT, 1996, MICROB DRUG RESIST, V2, P105, DOI 10.1089/mdr.1996.2.105; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; SUN FZ, 1992, DEVELOPMENT, V115, P947; TEKLE E, 1994, P NATL ACAD SCI USA, V91, P11512, DOI 10.1073/pnas.91.24.11512; Teruel MN, 1997, BIOPHYS J, V73, P1785, DOI 10.1016/S0006-3495(97)78209-2; TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9; Weaver JC, 1996, BIOELECTROCH BIOENER, V41, P135, DOI 10.1016/S0302-4598(96)05062-3; WEAVER JC, 1993, J CELL BIOCHEM, V51, P426, DOI 10.1002/jcb.2400510407; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	36	21	21	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					365	376		10.1096/fasebj.13.2.365	http://dx.doi.org/10.1096/fasebj.13.2.365			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973325				2022-12-25	WOS:000078615200017
J	Gao, JH; Li, Y; Yan, HG				Gao, JH; Li, Y; Yan, HG			NMR solution structure of domain 1 of human annexin I shows an autonomous folding unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CORRELATION SPECTROSCOPY; IMPROVED SENSITIVITY; LARGER PROTEINS; H-1-NMR SPECTRA; CAPPING BOX; PROTON; H-1; IDENTIFICATION; ASSOCIATION	Annexins are excellent models for studying the folding mechanisms of multidomain proteins because they have four-eight homologous helical domains with low identity in sequence but high similarity in folding. The structure of an isolated domain 1 of human annexin I has been determined by NMR spectroscopy, The sequential assignments of the H-1, C-13, and N-15 resonances of the isolated domain 1 were established by multinuclear, multidimensional NMR spectroscopy. The solution structure of the isolated domain 1 was derived from 1,099 experimental NMR restraints using a hybrid distance geometry-simulated annealing protocol. The root mean square deviation of the ensemble of 20 refined conformers that represent the structure from the mean coordinate set derived from them was 0.57 +/- 0.14 Angstrom and 1.11 +/- 0.19 ? for the backbone atoms and all heavy atoms, respectively. The NMR structure of the isolated domain 1 could be superimposed with a root mean square deviation of 1.36 Angstrom for all backbone atoms with the corresponding part of the crystal structure of a truncated human annexin I containing all four domains, indicating that the structure of the isolated domain 1 is highly similar to that when it folded together with the other three domains. The result suggests that in contrast to isolated domain 2, which is largely unfolded in solution, isolated domain 1 constitutes an autonomous folding unit and interdomain interactions may play critical roles in the folding of annexin I.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Yan, HG (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	yanh@pilot.msu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051901] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08299] Funding Source: Medline; NIGMS NIH HHS [GM51901] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cordier-Ochsenbein F, 1998, J MOL BIOL, V279, P1177, DOI 10.1006/jmbi.1998.1828; Cordier-Ochsenbein F, 1998, J MOL BIOL, V279, P1163, DOI 10.1006/jmbi.1998.1829; CordierOchsenbein F, 1996, BIOCHEMISTRY-US, V35, P10347, DOI 10.1021/bi960747v; CREIGHTON TE, 1992, PROTEIN FOLDING; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; Jaenicke R, 1996, CURR TOP CELL REGUL, V34, P209, DOI 10.1016/S0070-2137(96)80008-2; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; MACQUAIRE F, 1993, BIOCHEMISTRY-US, V32, P7244, DOI 10.1021/bi00079a022; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MORGAN RO, 1995, MOL BIOL EVOL, V12, P967; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ODAERT B, 1995, BIOCHEMISTRY-US, V34, P12820, DOI 10.1021/bi00039a043; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; SRERE PA, 1984, TRENDS BIOCHEM SCI, V9, P387, DOI 10.1016/0968-0004(84)90221-4; Voges D, 1995, ADV ENZYMOL RAMB, V71, P209; WENG XW, 1993, PROTEIN SCI, V2, P448; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; ZHU G, 1992, J MAGN RESON, V100, P202, DOI 10.1016/0022-2364(92)90379-L	48	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2971	2977		10.1074/jbc.274.5.2971	http://dx.doi.org/10.1074/jbc.274.5.2971			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915835	hybrid			2022-12-25	WOS:000078319500053
J	Nakashima, N; Rose, DW; Xiao, S; Egawa, K; Martin, SS; Haruta, T; Saltiel, AR; Olefsky, JM				Nakashima, N; Rose, DW; Xiao, S; Egawa, K; Martin, SS; Haruta, T; Saltiel, AR; Olefsky, JM			The functional role of CrkII in actin cytoskeleton organization and mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; PHOSPHORYLATION-DEPENDENT MANNER; COMPLEXES IN-VIVO; TYROSINE PHOSPHORYLATION; C-CRK; V-CRK; SIGNALING PATHWAYS; INSULIN-RECEPTOR; BINDING PROTEIN	Crk is a member of a family of adapter proteins predominantly composed of Src homology 2 and 3 domains, whose role in signaling pathways is presently unclear. Using an in situ electroporation system which permits the introduction of glutathione S-transferase (GST) fusion proteins into cells, we found that c-CrkII bound to p130(cas), but not to paxillin in serum-starved rat-1 fibro-blasts overexpressing the human insulin receptor (HIRc cells) in vivo, 17 nM insulin stimulation dissociated the binding of c-CrkII to p130(cas), whereas 13 nM insulin-like growth factor-I, 16 nM epidermal growth factor (EGF), and 10% serum each showed little or no effect. We found that stress fiber formation is consistent with a change in the p130(cas.)c-CrkII interactions before and after growth factor stimulation. Microinjection of either GST-Crk-SH2 or -Crk-(N)SH3 domains, or anti-Crk antibody each inhibited stress fiber formation before and after insulin-like growth factor-I, EGF, and serum stimulation. Insulin stimulation by itself caused stress fiber breakdown and there was no additive effect of microinjection. Microinjection of anti-p130(cas) antibody also blocked stress fiber formation in quiescent cells. Microinjection of the Crk-inhibitory reagents also inhibited DNA synthesis after insulin-like growth factor-I, EGF, and serum stimulation, but not after insulin. These data suggest that the complex containing p130(cas) .c-CrkII may play a crucial role in actin cytoskeleton organization and in anchorage-dependent DNA synthesis.	Univ Calif San Diego, Dept Med 9111-G, Div Endocrinol & Metab, Whittier Diabetes Program, La Jolla, CA 92093 USA; Vet Adm Med Ctr, Med Res Serv, La Jolla, CA 92161 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Signal Transduct, Ann Arbor, MI 48105 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pfizer	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 9111-G, Div Endocrinol & Metab, Whittier Diabetes Program, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [R01 DK36651] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Flinn HM, 1996, J CELL SCI, V109, P1133; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ishiki M, 1997, ENDOCRINOLOGY, V138, P4950, DOI 10.1210/en.138.11.4950; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nievers MG, 1997, J CELL SCI, V110, P389; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Tobe K, 1996, MOL CELL BIOL, V16, P4765; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3001	3008		10.1074/jbc.274.5.3001	http://dx.doi.org/10.1074/jbc.274.5.3001			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915838	hybrid			2022-12-25	WOS:000078319500056
J	Pugazhenthi, S; Boras, T; O'Connor, D; Meintzer, MK; Heidenreich, KA; Reusch, JEB				Pugazhenthi, S; Boras, T; O'Connor, D; Meintzer, MK; Heidenreich, KA; Reusch, JEB			Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells - Involvement of p38 mitogen-activated protein kinase-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS TRANSCRIPTION; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; PHOSPHORYLATED CREB; APOPTOSIS; DIFFERENTIATION; RECEPTOR; MEMORY; CONSOLIDATION; REQUIREMENT	IGF-I is known to support growth and to prevent apoptosis in neuronal cells. Activation of the nuclear transcription factor cAMP response element-binding protein (CREB) has emerged as a central determinant in neuronal functions. In the present investigation, we examined the IGF-I-mediated phosphorylation and transcriptional activation of CREB in rat pheochromocytoma (PC12) cells, a cellular model for neuronal differentiation, and defined three distinct postreceptor signaling pathways important for this effect including the p38 mitogen-activated protein kinase (MAPK) pathway. CREB phosphorylation at serine 133 and its transcriptional activation as measured by a CREB-specific Gal4-CREB reporter and the neuroendocrine-specific gene chromogranin A was induced 2-3.3-fold by insulinlike growth factor (IGF)-I. This activation was significantly blocked (p < 0.001) by the dominant negative K-CREB or by mutation of the CRE site. IGF-I stimulated chromogranin A gene expression by Northern blot analysis 3.7-fold. Inhibition of MAPK kinase with PD98059, PI 3-kinase with wortmannin, and p38 MAPK with SB203580 blocked IGF-I-mediated phosphorylation and transcriptional activation of CREB by 30-50% (p < 0.001), Constitutively active and dominant negative regulators of the Ras and PI 3-kinase pathways confirmed the contribution of these pathways for CREB regulation by IGF-I, Cotransfection of PC12 cells with p38 beta and constitutively active MAPK kinase 6 resulted in enhanced basal as well. as IGF-I-stimulated chromogranin A promoter. IGF-I activated p38 MAPK, which was blocked by the inhibitor SB203580, This is the first description of a p38 MAPK-mediated nuclear signaling pathway for IGF-I leading to CREB-dependent neuronal specific gene expression.	Vet Affairs Med Ctr, Sect Endocrinol 111H, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Dept Vet Affairs Med Ctr, San Diego, CA 92161 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Diego; University of California System; University of California San Diego	Pugazhenthi, S (corresponding author), Vet Affairs Med Ctr, Sect Endocrinol 111H, 1055 Clermont St, Denver, CO 80220 USA.	jreusch@sembilan.uchsc.edu		Reusch, Jane/0000-0001-8620-1003	NIDDK NIH HHS [KO8 DK02351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002351] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bevilaqua L, 1997, BRAZ J MED BIOL RES, V30, P967, DOI 10.1590/S0100-879X1997000800009; Canaff L, 1998, ENDOCRINOLOGY, V139, P1184, DOI 10.1210/en.139.3.1184; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Das S, 1997, SYNAPSE, V25, P227; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; ISHII DN, 1994, PHARMACOL THERAPEUT, V62, P125, DOI 10.1016/0163-7258(94)90007-8; ISHII DN, 1995, BRAIN RES REV, V20, P47, DOI 10.1016/0165-0173(94)00005-A; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONNIER D, 1994, MOL CELL ENDOCRINOL, V104, P139, DOI 10.1016/0303-7207(94)90116-3; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parrizas M, 1997, J BIOL CHEM, V272, P154; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shimomura A, 1998, J NEUROCHEM, V70, P1029; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tang KC, 1996, J BIOL CHEM, V271, P28382, DOI 10.1074/jbc.271.45.28382; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; VINIK AI, 1995, DIABETES REV, V3, P139; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1	53	104	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2829	2837		10.1074/jbc.274.5.2829	http://dx.doi.org/10.1074/jbc.274.5.2829			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915817	hybrid			2022-12-25	WOS:000078319500035
J	Hoshino, R; Chatani, Y; Yamori, T; Tsuruo, T; Oka, H; Yoshida, O; Shimada, Y; Ari-i, S; Wada, H; Fujimoto, J; Kohno, M				Hoshino, R; Chatani, Y; Yamori, T; Tsuruo, T; Oka, H; Yoshida, O; Shimada, Y; Ari-i, S; Wada, H; Fujimoto, J; Kohno, M			Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors	ONCOGENE			English	Article						41-/43-kDa MAP kinases (ERKs); MEK; aberrant activation; human tumor; carcinogenesis	CANCER CELL-LINES; BONE MORPHOGENETIC PROTEIN-2; MAMMALIAN-CELLS; AGENTS INDUCE; MAP KINASES; TYROSINE; TRANSFORMATION; GROWTH; GENES; PHOSPHORYLATION	The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-l, As aberrant activation of signal transducing molecules such as Pas and Raf-l has been linked with cancer, we examined whether constitutive activation of the 41-/43-kDa MAP kinases is associated with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs. Constitutive activation of the MAP kinases was observed in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed especially high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation. We also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large number of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue. Many tumor cells, in which point mutations of vas genes mere detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation. In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-l in the majority of tumor cells and was completely associated with the activation of MEK and p90(rsk) in all the tumor cells examined, These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-l, Pas, or some other signaling molecules upstream of Ras.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; Gifu Pharmaceut Univ, Gifu 5028585, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1138657, Japan; Kyoto Univ, Fac Med, Grad Sch Med, Dept Surg & Surg Basic Sci, Kyoto 6068507, Japan; Kyoto Univ, Dept Thorac Surg, Chest Dis Res Inst, Kyoto 6068507, Japan; Hyogo Coll Med, Dept Surg 1, Nishinomiya, Hyogo 6638501, Japan	Nagasaki University; Gifu Pharmaceutical University; Japanese Foundation for Cancer Research; University of Tokyo; Kyoto University; Kyoto University; Hyogo College of Medicine	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P273; Bansal A, 1997, ONCOGENE, V14, P1231, DOI 10.1038/sj.onc.1200947; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNET A, 1994, ONCOGENE, V9, P3379; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P409; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; Kawada M, 1998, JPN J CANCER RES, V89, P110, DOI 10.1111/j.1349-7006.1998.tb00537.x; Kawaguchi Y, 1997, CANCER LETT, V116, P53, DOI 10.1016/S0304-3835(97)04751-4; KOHNO M, 1985, J BIOL CHEM, V260, P1771; LI PM, 1993, ONCOGENE, V8, P1731; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; NAKATSU Y, 1985, COLD SPRING HARB SYM, V51, P1001; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKA H, 1995, CANCER RES, V55, P4182; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1902; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YAO M, 1988, CANCER RES, V48, P6753	41	594	658	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					813	822		10.1038/sj.onc.1202367	http://dx.doi.org/10.1038/sj.onc.1202367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989833				2022-12-25	WOS:000078394400028
J	Kato, M; Liu, W; Akhand, AA; Dai, Y; Ohbayashi, M; Tuzuki, T; Suzuki, H; Isobe, K; Takahashi, M; Nakashima, I				Kato, M; Liu, W; Akhand, AA; Dai, Y; Ohbayashi, M; Tuzuki, T; Suzuki, H; Isobe, K; Takahashi, M; Nakashima, I			Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I ret transgenic mouse lines	ONCOGENE			English	Article						metallothionein-I ret transgenic mouse lines; melanocytic tumor; Ret protein expression; immune surveillance; oncogene product-specific-tolerance	SV40 T-ANTIGEN; PROTOONCOGENE PRODUCTS; SAIKOSAPONIN-D; LYMPHOCYTES-T; CELLS; MICE; MECHANISM; RESPONSES; ONCOGENE; PEPTIDE	We examined the basis of the all or none difference in inducing melanocytic tumor development among three transgenic mouse lines (304, 192 and 242) to which the same promoter-enhancer (metallothionein-I) and oncogene (ret) were introduced. We initially demonstrated that both skin melanosis and Ret protein expression in skin, thymus and brain first became detectable before or immediately after birth in the mice of the tumor developing lines (304 and 192), whereas they became detectable a few days after birth in the mice of the nontumor developing line (242) by Western blotting and immunohistochemical analysis. Interestingly, the Ret protein expression in skin developed rapidly after birth as a burst with peak levels on 0.5-1.5 day newborns of lines 304 and 192 and on 7.0-7.5 day-old mice of line 242, The levels of autophosphorylation of Ret kinase in skin were, however, invariable among these three transgenic mouse lines. The mice of line 242, but not those of lines 192 and 304, responded to Ret protein immunization by increased antigen-dependent lymphocyte proliferation and T-cell-mediated tumor growth suppression in vitro. Furthermore, ret-transgenic mice of line 242, but not line 304, rejected the subcutaneously transplanted tumors that had originally developed in a mouse of line 304, These results suggest that whether oncogene product-specific-tolerance is established or not to antitumor immunity may be decided by the dynamics of rer oncogene expression before and after delivery and this is the primary factor determining development or non-development of melanoma.	Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Chubu Natl Hosp, Inst Longev Sci, Dept Basic Gerontol, Aichi 4748511, Japan	Nagoya University; Nagoya University	Nakashima, I (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		isobe, ken-ichi/A-6685-2011; KATO, Masashi/I-7250-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	isobe, ken-ichi/0000-0002-8150-2496; Takahashi, Masahide/0000-0002-2803-2683; 				ASAI N, 1995, MOL CELL BIOL, V15, P1613; CAMPBELL AE, 1983, J IMMUNOL, V130, P490; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CORRADIN G, 1977, J IMMUNOL, V119, P1048; DAI Y, 1994, INT J ONCOL, V5, P661; FAAS SJ, 1987, J EXP MED, V165, P417, DOI 10.1084/jem.165.2.417; ICHIHARA M, 1995, BRIT J CANCER, V71, P808, DOI 10.1038/bjc.1995.156; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JUNG S, 1991, J EXP MED, V173, P273, DOI 10.1084/jem.173.1.273; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KATO M, 1994, CELL IMMUNOL, V159, P15, DOI 10.1006/cimm.1994.1291; KATO M, 1995, IMMUNOPHARMACOLOGY, V29, P207, DOI 10.1016/0162-3109(95)00059-3; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; NAKASHIMA I, 1982, EUR J IMMUNOL, V12, P713, DOI 10.1002/eji.1830120904; SCHRIMBECK R, 1992, EUR J IMMUNOL, V22, P759; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TANIGUCHI M, 1992, ONCOGENE, V7, P1491; TEVETHIA SS, 1980, VIROLOGY, V107, P13, DOI 10.1016/0042-6822(80)90268-8; TSUZUKI T, 1995, ONCOGENE, V10, P191; YANUCK M, 1993, CANCER RES, V53, P3257	21	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					837	842		10.1038/sj.onc.1202329	http://dx.doi.org/10.1038/sj.onc.1202329			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989837				2022-12-25	WOS:000078394400032
J	Rapp, L; Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ				Rapp, L; Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ			The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis	ONCOGENE			English	Article						BPV-1 E6; TNF; cytolysis; apoptosis; p53; arachidonic acid	CYTOSOLIC PHOSPHOLIPASE A(2); CALCIUM-BINDING PROTEIN; OPEN READING FRAME; P53 FUNCTION; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GENE; ARACHIDONIC-ACID; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; VIRUS DNA	Expression of viral proteins may result in susceptibility of cells to the cytotoxic effect of Tumor Necrosis Factor Alpha (TNF), While murine C127 cells containing the bovine papillomavirus type 1 (BPV-1) genome were reported to exhibit increased TNF sensitivity, the gene(s) responsible was not identified. The BPV-1 E6 oncoprotein induces tumorigenic transformation of murine C127 cells and stimulates transcription when targeted to a promoter. BPV-1 E6 was introduced into C127 cells (PBE6) by retroviral infection and stable clones were isolated. These cells showed increased apoptosis in response to TNF, as measured by several criteria. TNF-induced apoptosis in PBE6 cells was accompanied by increased release of arachidonic acid, indicating that phospholipase A, was activated. We also provide evidence that BPV-1 E6 mediated-sensitization of cells to TNF-induced apoptosis can ocur in the absence of p53.	New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Chen, JJ (corresponding author), New England Med Ctr, Dept Dermatol, 750 Washington St,Box 166, Boston, MA 02111 USA.			Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA073558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007562] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73558] Funding Source: Medline; NIAMS NIH HHS [T32 AR 07562] Funding Source: Medline; PHS HHS [F32] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chen JJ, 1997, VIROLOGY, V236, P30, DOI 10.1006/viro.1997.8725; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEURKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DODDS D, 1995, J NEUROCHEM, V64, P2339; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; FAN SJ, 1995, CANCER RES, V55, P1649; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; Hawkins DS, 1996, CANCER RES, V56, P892; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KERR JFR, 1992, APOPTOSIS MOL BASIS, P5; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; KULL FC, 1981, CANCER RES, V41, P4885; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LASTER SM, 1988, J IMMUNOL, V141, P2629; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ned R, 1997, J VIROL, V71, P4866, DOI 10.1128/JVI.71.6.4866-4870.1997; OSTROVE JM, 1979, P SOC EXP BIOL MED, V160, P354; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; QUI ZH, 1998, J BIOL CHEM, V273, P8203; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Steller MA, 1996, CANCER RES, V56, P5087; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomas M, 1996, ONCOGENE, V13, P265; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TSANG NM, 1995, ONCOGENE, V10, P2403; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WEIS K, 1994, J BIOL CHEM, V269, P19142; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; ZURHAUSEN H, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF55; [No title captured]	70	13	13	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					607	615		10.1038/sj.onc.1202373	http://dx.doi.org/10.1038/sj.onc.1202373			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989810				2022-12-25	WOS:000078394400005
J	Yamochi, T; Kaneita, Y; Akiyama, T; Mori, S; Moriyama, M				Yamochi, T; Kaneita, Y; Akiyama, T; Mori, S; Moriyama, M			Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X-L	ONCOGENE			English	Article						BCL-6; apoptosis; cell cycle; BCL-2; recombinant adenovirus	GERMINAL-CENTER FORMATION; CENTER B-CELLS; PROTEIN INTERACTION MOTIF; FINGER ENCODING GENE; IN-VIVO; BTB/POZ DOMAIN; TRANSCRIPTIONAL REPRESSION; RECOMBINANT ADENOVIRUS; DNA-BINDING; LYMPHOMA	The BCL-6 proto-oncogene encodes a 92- to 98-kDa transcriptional repressor containing the BTB/POZ domain at its N-terminal region and the zinc finger domain at its C-terminal region, respectively. In the present study, we examined the function of BCL-6 by using a recombinant adenovirus expressing BCL-6 (Ax1CA-BCL-6) and the lacZ reporter gene (Ax1CA-lacZ), Viability of CV-1 and HeLa cells infected, with Ax1CA-BCL-6 was markedly reduced due to apoptosis, suggesting that BCL-6-overexpression induces apoptosis in CV-1 and HeLa cells. FAGS analysis revealed that BCL-6-overexpressing cells are accumulated not only at the sub-G1 but also at G2/M phase. Induction of apoptosis by BCL-6 was preceded by down-regulation of apoptosis repressors BCL-2 and BCL-X-L. These results suggest that BCL-6 induces apoptosis by regulating the expression of these apoptosis-regulating genes.	Univ Tokyo, Inst Med Sci, Dept Pathol, Minato Ku, Tokyo 108, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Suita, Osaka 565, Japan	University of Tokyo; Osaka University	Moriyama, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.							Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FAN SJ, 1995, CANCER RES, V55, P1649; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; ISHIDA T, 1995, J IMMUNOL, V155, P5527; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LO CF, 1994, BLOOD, V83, P1757; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Seyfert VL, 1996, ONCOGENE, V12, P2331; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	41	56	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					487	494		10.1038/sj.onc.1202334	http://dx.doi.org/10.1038/sj.onc.1202334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927205				2022-12-25	WOS:000078166500021
J	He, XH; Rezaie, AR				He, XH; Rezaie, AR			Identification and characterization of the sodium-binding site of activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; FACTOR-LIKE DOMAIN; BLOOD-COAGULATION; CRYSTAL-STRUCTURE; BIOLOGICAL-ACTIVITY; ENZYME COMPLEXES; MOLECULAR-BASIS; FACTOR-V; FACTOR-X; SPECIFICITY	Activated protein C (APC) requires both Ca2+ and Na+ for its optimal catalytic function. In contrast to the Ca2+-binding sites, the Na+-binding site(s) of APC has not been identified. Based on a recent study with thrombin, the 221-225 loop is predicted to be a potential Na+-binding site in APC. The sequence of this loop is not conserved in trypsin. We engineered a Gla domainless form of protein C (GDPC) in which the 221-225 loop was replaced with the corresponding loop of trypsin. We found that activated GDPC (aGDPC) required Na+ (or other alkali cations) for its amidolytic activity with dissociation constant (K-d(app)) = 44.1 +/- 8.6 mM. In the presence of Ca2+, however, the requirement for Na+ by aGDPC was eliminated, and Na+ stimulated the cleavage rate 5-6-fold with K-d(app) = 2.3 +/- 0.3 mm. Both cations were required for efficient factor Va inactivation by aGDPC. In the presence of Ca2+, the catalytic function of the mutant was independent of Na+. Unlike aGDPC, the mutant did not discriminate among monovalent cations. We conclude that the 221-225 loop is a Na+-binding site in APC and that an allosteric link, between the Na+ and Ca2+ binding loops modulates the structure and function of this anticoagulant enzyme.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Rezaie, AR (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	alireza-rezaie@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1981, BIOCHEMISTRY-US, V20, P2156, DOI 10.1021/bi00511a013; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREENQUIST AC, 1975, BLOOD, V45, P769; GRINNELL BW, 1991, ADV APPL BIOTECHNOL, V11, P29; GUINTO ER, 1982, J BIOL CHEM, V257, P38; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL KAW, 1986, J BIOL CHEM, V261, P4991; HILL KAW, 1987, J BIOL CHEM, V262, P7105; HILL KAW, 1987, J BIOL CHEM, V262, P9581; HILL KAW, 1987, J BIOL CHEM, V262, P7098; HILL KAW, 1987, ARCH BIOCHEM BIOPHYS, V254, P196, DOI 10.1016/0003-9861(87)90095-6; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P8701, DOI 10.1021/bi00027a020; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; OWEN WG, 1974, J BIOL CHEM, V249, P594; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; REZAIE AR, 1995, BIOCHEMISTRY-US, V34, P12221, DOI 10.1021/bi00038a016; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; STEINER SA, 1982, BIOCHEMISTRY-US, V21, P4609, DOI 10.1021/bi00262a015; STEINER SA, 1998, BIOCHEMISTRY-US, V24, P609; STENFLO J, 1991, BLOOD, V78, P1637; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	52	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4970	4976		10.1074/jbc.274.8.4970	http://dx.doi.org/10.1074/jbc.274.8.4970			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988741	hybrid			2022-12-25	WOS:000078698200066
J	Ishida, H; Makino, A; Mae, T				Ishida, H; Makino, A; Mae, T			Fragmentation of the large subunit of ribulose-1,5-bisphosphate carboxylase by reactive oxygen species occurs near Gly-329	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; OXIDATIVE STRESS; RICE LEAVES; PROTEOLYTIC ACTIVITY; HYDROXYL RADICALS; OAT CHLOROPLASTS; WHEAT SEEDLINGS; DEGRADATION; LIGHT; SENESCENCE	The large subunit (LSU) of ribulose-1,5-bisphosphate carboxylase/oxygenase (rubisco) in the illuminated lysates of wheat (Triticum aestivum L.) chloroplasts is broken down by reactive oxygen radicals into 37- and 16-kDa polypeptides, Analysis of the terminal amino acid residues of both fragments revealed that the C terminus of the 37-kDa fragment was Ser-328 and the N terminus of the 16-kDa fragment was Thr-330. Gly-329, which links the two fragments, was missing, suggesting that the fragmentation of the LSU in the lysates driven by oxygen-free radicals occurs at Gly-329. Purified rubisco, exposed to a hydroxyl radical-generating system, was also cleaved at the same site of the LSU, The cleavage site was positioned at the N-terminal end of the flexible loop (loop 6) within the beta/alpha-barrel domain, constituting the catalytic site of rubisco. The binding of a reaction intermediate analogue, 2-carboxyarabinitol 1,5-bisphosphate, to the active form of rubisco completely protected the enzyme from the fragmentation. The fragmentation was differentially affected by CO2, Mg2+, ribulose 1,5-bisphosphate, or 2-carboxyarabinitol 1,5-bisphosphate, All these results indicate that the conformation of the catalytic site of the enzyme is involved as an important factor determining the breakdown of rubisco by reactive oxygen species. Reactive oxygen species generated at its catalytic site by a Fenton-type reaction may trigger the site-specific degradation of the LSU in the lysates of chloroplasts in the light.	Tohoku Univ, Fac Agr, Dept Appl Biol Chem, Aoba Ku, Sendai, Miyagi 9818555, Japan	Tohoku University	Mae, T (corresponding author), Tohoku Univ, Fac Agr, Dept Appl Biol Chem, Aoba Ku, 1-1 Tsutsumidori Amamiyamachi, Sendai, Miyagi 9818555, Japan.			Ishida, Hiroyuki/0000-0002-8682-4566				Asada K., 1987, PHOTOINHIBITION, P227; BADGER MR, 1980, J BIOL CHEM, V255, P7870; Barlow JN, 1997, BIOCHEMISTRY-US, V36, P3563, DOI 10.1021/bi962521y; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BHALLA PL, 1986, J PLANT PHYSIOL, V122, P289, DOI 10.1016/S0176-1617(86)80162-6; CASANO LM, 1990, PLANT CELL PHYSIOL, V31, P377; CASANO LM, 1994, PLANT CELL PHYSIOL, V35, P145; CHRISTELLER JT, 1981, BIOCHEM J, V193, P839, DOI 10.1042/bj1930839; Desimone M, 1996, PLANT PHYSIOL, V111, P789, DOI 10.1104/pp.111.3.789; Desimone M, 1998, PLANTA, V205, P459, DOI 10.1007/s004250050344; Evans J.R., 1989, PHOTOSYNTHESIS, P183; HOUTZ RL, 1989, P NATL ACAD SCI USA, V86, P1855, DOI 10.1073/pnas.86.6.1855; HUFFAKER RC, 1990, NEW PHYTOL, V116, P199, DOI 10.1111/j.1469-8137.1990.tb04710.x; Ishida H, 1997, PLANT CELL PHYSIOL, V38, P471, DOI 10.1093/oxfordjournals.pcp.a029191; Ishida H, 1998, PLANTA, V204, P305, DOI 10.1007/s004250050260; Jakob B, 1996, PLANT CELL PHYSIOL, V37, P629, DOI 10.1093/oxfordjournals.pcp.a028991; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY LG, 1993, PLANT PHYSIOL, V101, P1355, DOI 10.1104/pp.101.4.1355; MAKINO A, 1985, PLANTA, V166, P414, DOI 10.1007/BF00401181; MAKINO A, 1984, PLANT CELL PHYSIOL, V25, P429; MAKINO A, 1985, PLANT PHYSIOL, V79, P57, DOI 10.1104/pp.79.1.57; MEHTA RA, 1992, J BIOL CHEM, V267, P2810; MITSUHASHI W, 1992, J PLANT PHYSIOL, V139, P653, DOI 10.1016/S0176-1617(11)81706-2; MIZIORKO HM, 1979, J BIOL CHEM, V254, P270; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PERCHOROWICZ JT, 1981, P NATL ACAD SCI-BIOL, V78, P2985, DOI 10.1073/pnas.78.5.2985; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; SCHNEIDER G, 1992, ANNU REV BIOPH BIOM, V21, P119, DOI 10.1146/annurev.bb.21.060192.001003; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; SUGIYAMA T, 1967, J BIOCHEM, V62, P474; Taylor TC, 1997, BIOCHEMISTRY-US, V36, P4041, DOI 10.1021/bi962818w; TERACHI T, 1987, JPN J GENET, V62, P375, DOI 10.1266/jjg.62.375; TERRY N, 1982, J PLANT NUTR, V5, P301, DOI 10.1080/01904168209362959; Vierstra RD, 1996, PLANT MOL BIOL, V32, P275, DOI 10.1007/BF00039386; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; YOKOTA S, 1990, SOIL SCI PLANT NUTR, V36, P91, DOI 10.1080/00380768.1990.10415713	38	92	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5222	5226		10.1074/jbc.274.8.5222	http://dx.doi.org/10.1074/jbc.274.8.5222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988772	hybrid			2022-12-25	WOS:000078698200097
J	Zachos, G; Clements, B; Conner, J				Zachos, G; Clements, B; Conner, J			Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE LARGE SUBUNIT; RNA-POLYMERASE-II; C-JUN; GENE-EXPRESSION; CELLS; MUTANT; GROWTH; STRESS; DOMAIN; RAS	Cells respond to environmental stress and proinflammatory cytokines by stimulating the Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and the p38 mitogen-activated protein kinase cascades. Infection of eukaryotic cells with herpes simplex virus type 1 (HSV-1) resulted in stimulation of both JNK/SAPK and p38 mitogen-activated protein kinase after 3 h of infection, and activation reached a maximum of 4-fold by 9 h post-infection. By using a series of mutant viruses, we showed that the virion transactivator protein VP16 stimulates p38/JNK, whereas no immediate-early, early, or late viral expressed gene is involved. We identified the stress-activated protein kinase kinase 1 as an upstream activator of p38/JNK, and we demonstrated that activation of AP-1 binding proceeded p38/JNK stimulation. During infection, the activated AP-1 consisted mainly of JunB and JunD with a simultaneous decrease in the cellular levels of Jun protein. We suggest that activation of the stress pathways by HSV-1 infection either represents a cascade triggered by the virus to facilitate the lytic cycle or a defense mechanism of the host cell against virus invasion.	Glasgow Caledonian Univ, Sch Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Inst Virol, Glasgow G11 5JR, Lanark, Scotland	Glasgow Caledonian University; University of Glasgow	Conner, J (corresponding author), Glasgow Caledonian Univ, Sch Biol & Biomed Sci, Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.	J.Conner@gcal.ac.uk	Li, Chia Cheng/D-9906-2015					ACE CI, 1989, J VIROL, V63, P2260, DOI 10.1128/JVI.63.5.2260-2269.1989; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CONNER J, 1992, J VIROL, V66, P7511, DOI 10.1128/JVI.66.12.7511-7516.1992; CONNER J, 1995, VIROLOGY, V213, P615, DOI 10.1006/viro.1995.0033; CONNER J, 1993, BIOCHEMISTRY-US, V32, P13673, DOI 10.1021/bi00212a036; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVERETT R, 1993, J GEN VIROL, V74, P1955, DOI 10.1099/0022-1317-74-9-1955; EVERETT RD, 1993, VIROLOGY, V197, P751, DOI 10.1006/viro.1993.1651; EVERETT RD, 1989, J GEN VIROL, V70, P1185, DOI 10.1099/0022-1317-70-5-1185; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Ingram A, 1996, J GEN VIROL, V77, P1847, DOI 10.1099/0022-1317-77-8-1847; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; MARTI A, 1994, ONCOGENE, V9, P1213; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; PATERSON T, 1988, VIROLOGY, V166, P186, DOI 10.1016/0042-6822(88)90160-2; PRESTON CM, 1979, J VIROL, V29, P275, DOI 10.1128/JVI.29.1.275-284.1979; RICE SA, 1995, J VIROL, V69, P5550, DOI 10.1128/JVI.69.9.5550-5559.1995; ROIZMAN B, 1996, FIELDS VIROLOGY, P2281; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SEARS AE, 1985, J VIROL, V55, P338, DOI 10.1128/JVI.55.2.338-346.1985; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shackelford DA, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P466; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	51	142	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5097	5103		10.1074/jbc.274.8.5097	http://dx.doi.org/10.1074/jbc.274.8.5097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988758	hybrid			2022-12-25	WOS:000078698200083
J	Hippler, M; Drepper, F; Rochaix, JD; Muhlenhoff, U				Hippler, M; Drepper, F; Rochaix, JD; Muhlenhoff, U			Insertion of the N-terminal part of PsaF from Chlamydomonas reinhardtii into photosystem I from Synechococcus elongatus enables efficient binding of algal plastocyanin and cytochrome c(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION CENTER COMPLEXES; FAST-ELECTRON TRANSFER; GREEN-ALGA; NUCLEOTIDE-SEQUENCE; FLASH-PHOTOLYSIS; SUBUNIT; COPPER; GENE; MUTAGENESIS; EXPRESSION	A strain of the cyanobacterium Synechococcus elongatus was generated that expresses a hybrid version of the photosystem I subunit PsaF consisting of the first 83 amino acids of PsaF from the green alga Chlamydomonas reinhardtii fused to the C-terminal portion of PsaF from S, elongatus, The corresponding modified gene was introduced into the genome of the psaF-deletion strain FK2 by cointegration with an antibiotic resistance gene. The transformants express a new PsaF subunit similar in size to PsaF from C, reinhardtii that is assembled into photosystem I (PSI). Hybrid PSI complexes isolated from these strains show an increase by 2 or 3 orders of magnitude in the rate of P700(+) reduction by C, reinhardtii cytochrome c(6) or plastocyanin in 30% of the complexes as compared with wild type cyanobacterial PSI. The corresponding optimum second-order rate constants (k(2) = 4.0 and 1.7 x 10(7) M-1 S-1 for cytochrome c(6) and plastocyanin) are similar to those of PSI from C, reinhardtii. The remaining complexes are reduced at a slow rate similar to that observed with wild type PSI from S. elongatus and the algal donors, At high concentrations of C, reinhardtii cytochrome c(6), a fast first-order kinetic component (t(1/2) = 4 mu s) is revealed, indicative of intramolecular electron transfer within a complex between the hybrid PSI and cytochrome c(6). This first-order phase is characteristic for P700(+) reduction by cytochrome c(6) or plastocyanin in algae and higher plants. However, a similar fast phase is not detected for plastocyanin, Crosslinking studies show that, in contrast to PSI from wild type S, elongatus, the chimeric PsaF of PSI from the transformed strain cross-links to cytochrome c(6) or plastocyanin with a similar efficiency as PsaF from C. reinhardtii PSI. Our data indicate that development of a eukaryotic type of reaction mechanism for binding and electron transfer between PSI and its electron donors required structural changes in both PSI and cytochrome c(6) or plastocyanin.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Geneva, Dept Mol Biol & Plant Biol, CH-1211 Geneva, Switzerland	University of Freiburg; University of Geneva	Muhlenhoff, U (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.		Rochaix, Jean-David/ABC-5243-2020	Michael, Hippler/0000-0001-9670-6101; Drepper, Friedel/0000-0002-2043-5795				BENGIS C, 1977, J BIOL CHEM, V252, P4564; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; DELOSME R, 1991, PHOTOSYNTH RES, V29, P45, DOI 10.1007/BF00035205; DIAZ A, 1994, EUR J BIOCHEM, V222, P1001, DOI 10.1111/j.1432-1033.1994.tb18951.x; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FRANZEN LG, 1989, PLANT MOL BIOL, V12, P463, DOI 10.1007/BF00017585; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HAEHNEL W, 1989, J CELL BIOL, V108, P1397, DOI 10.1083/jcb.108.4.1397; Harlow E., 1988, ANTIBODIES LAB MANUA; HATANAKA H, 1993, BIOCHIM BIOPHYS ACTA, V1141, P45, DOI 10.1016/0005-2728(93)90187-K; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; KOIKE H, 1979, PLANT CELL PHYSIOL, V20, P1157; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LEE BH, 1995, J BIOCHEM, V117, P1209; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Morand L.Z., 1994, MOL BIOL CYANOBACTER, P381; Muhlenhoff U, 1996, MOL GEN GENET, V252, P93, DOI 10.1007/s004389670011; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; NAKAMURA M, 1992, J BIOCHEM, V111, P219, DOI 10.1093/oxfordjournals.jbchem.a123740; NECHUSHTAI R, 1996, ADV PHOTOSYNTHESIS O, P289; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; Reith M, 1996, OXYGENIC PHOTOSYNTHE, P643; ROGNER M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P415, DOI 10.1016/0005-2728(90)90074-E; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sambrook J., 2002, MOL CLONING LAB MANU; SANDMANN G, 1980, PLANT SCI LETT, V17, P417, DOI 10.1016/0304-4211(80)90128-5; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; Stirewalt VL, 1995, PLANT MOL BIOL REP, V13, P327, DOI 10.1007/BF02669186; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; XU QA, 1994, J BIOL CHEM, V269, P3205	43	53	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4180	4188		10.1074/jbc.274.7.4180	http://dx.doi.org/10.1074/jbc.274.7.4180			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933614	Green Published, hybrid			2022-12-25	WOS:000078575500038
J	Kriegler, S; Sudweeks, S; Yakel, JL				Kriegler, S; Sudweeks, S; Yakel, JL			The nicotinic alpha 4 receptor subunit contributes to the lining of the ion channel pore when expressed with the 5-HT3 receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SUBSTITUTION; M2 SEGMENT; RESIDUES; IDENTIFICATION; MUTANTS	To understand the wide variation of calcium permeability seen in native and recombinant 5-HT3, receptor (5-HT3R) channels, we reported previously the novel hypothesis that the serotonin 5-HT3R subunit can co-assemble with the alpha 4 subunit of the nicotinic acetylcholine receptor (van Hooft, J. A., Spier, A. D., Yakel, J. L., Lummis, S. C. R. & Vijverberg, H. P. M. (1998) Proc. Natl. Acad, Sci. U. S. A. 95, 11456-11461), To test the hypothesis that the alpha 4 subunit contributes to the lining of the pore of the resulting 5-HT3R channel, a mutant nicotinic alpha 4 subunit with a reactive cysteine residue engineered into the putative pore region was constructed by substituting the leucine at position 285 (alpha 4-L285C), The sulfhydryl-modifying reagent [2-(trimethylammonium) ethyl]methanethiosulfonate (MTSET) reduced the acetylcholine-induced current in oocytes expressing this mutant nicotinic (alpha 4-L285C subunit along with the nicotinic beta 2 subunit by similar to 60%. When the alpha 4-L285C subunit was co-expressed with the 5-HT3R subunit, both MTSET and silver nitrate (AgNO3), another cysteine-modifying reagent, significantly reduced the serotonin-induced current, No reduction was seen when the 5-HT3R was expressed alone or with the wild-type alpha 4 subunit, These data provide direct molecular evidence that the nicotinic alpha 4 subunit co-assembles with the 5-HT3R subunit and forms an integral part of the ion channel pore.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yakel, JL (corresponding author), NIEHS, Lab Signal Transduct, NIH, F2-08,POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	yakel@niehs.nih.gov		Yakel, Jerrel/0000-0001-5463-674X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090089, Z01ES090089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Egan TM, 1998, J NEUROSCI, V18, P2350; Fletcher S, 1998, NEUROPHARMACOLOGY, V37, P397, DOI 10.1016/S0028-3908(98)00052-5; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Nayak S. V., 1998, Society for Neuroscience Abstracts, V24, P1819; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; Ronde P, 1997, CELL CALCIUM, V22, P357, DOI 10.1016/S0143-4160(97)90020-8; Ronde P, 1998, J NEUROCHEM, V70, P1094; van Hooft JA, 1998, P NATL ACAD SCI USA, V95, P11456, DOI 10.1073/pnas.95.19.11456; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177	17	21	23	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3934	3936		10.1074/jbc.274.7.3934	http://dx.doi.org/10.1074/jbc.274.7.3934			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933581	hybrid			2022-12-25	WOS:000078575500005
J	Ward, C; Chilvers, ER; Lawson, MF; Pryde, JG; Fujihara, S; Farrow, SN; Haslett, C; Rossi, AG				Ward, C; Chilvers, ER; Lawson, MF; Pryde, JG; Fujihara, S; Farrow, SN; Haslett, C; Rossi, AG			NF-kappa B activation is a critical regulator of human granulocyte apoptosis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ZINC-FINGER PROTEIN; NECROSIS-FACTOR-ALPHA; IN-VITRO; NEUTROPHIL APOPTOSIS; BACTERIAL LIPOPOLYSACCHARIDE; MACROPHAGE PHAGOCYTOSIS; SYNTHESIS INHIBITORS; DNA FRAGMENTATION; AGING NEUTROPHILS	During beneficial inflammation, potentially tissue-damaging granulocytes undergo apoptosis before being cleared by phagocytes in a non-phlogistic manner. Here we show that the rate of constitutive apoptosis in human neutrophils and eosinophils is greatly accelerated in both a rapid and concentration-dependent manner by the fungal metabolite gliotoxin, but not by its inactive analog methylthiogliotoxin, This induction of apoptosis was abolished by the caspase inhibitor zVAD-fmk, correlated with the inhibition of nuclear factor-kappa B (NF-kappa B), and was mimicked by a cell permeable inhibitory peptide of NF-kappa B, SN-50; other NF-kappa B inhibitors, curcumin and pyrrolidine dithiocarbamate; and the proteasome inhibitor, MG-132, Gliotoxin also augmented dramatically the early (2-6 h) pro-apoptotic effects of tumor necrosis factor-alpha (TNF-alpha) in neutrophils and unmasked the ability of TNF-alpha to induce eosinophil apoptosis, In neutrophils, TNF-alpha caused a gliotoxin-inhibitable activation of an inducible form of NF-kappa B, a response that may underlie the ability of TNF-alpha to delay apoptosis at later times (12-24 h) and limit its early killing effect. Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappa B may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha, These data shed light on the biochemical and molecular mechanisms regulating human granulocyte apoptosis and, in particular, indicate that the transcription factor NF-kappa B plays a crucial role in regulating the physiological cell death pathway in granulocytes.	Univ Edinburgh, Sch Med, Rayne Lab, Dept Med,Resp Med Unit, Edinburgh EH8 9AG, Midlothian, Scotland; Glaxo Wellcome Res & Dev Ltd, Cell Biol Unit, Stevenage SG1 2NY, Herts, England	University of Edinburgh; GlaxoSmithKline	Rossi, AG (corresponding author), Univ Edinburgh, Sch Med, Rayne Lab, Dept Med,Resp Med Unit, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	a.g.rossi@ed.ac.uk		Chilvers, Edwin/0000-0002-4230-9677; Lawson, Mark/0000-0001-5361-2842				Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; BAEUERLE PA, 1994, ADV IMMUNOL, V62, P1192; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BRAITHWAITE AW, 1987, MOL IMMUNOL, V24, P47, DOI 10.1016/0161-5890(87)90110-6; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; COLOTTA F, 1992, BLOOD, V80, P2012; Cousin JM, 1997, BIOCHEM SOC T, V25, pS243, DOI 10.1042/bst025243s; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; Faggioli L, 1997, BIOCHEM BIOPH RES CO, V233, P507, DOI 10.1006/bbrc.1997.6489; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HACHIYA O, 1995, MICROBIOL IMMUNOL, V39, P715, DOI 10.1111/j.1348-0421.1995.tb03247.x; Hallsworth MP, 1996, BRIT J PHARMACOL, V117, P79, DOI 10.1111/j.1476-5381.1996.tb15157.x; HANNAH S, 1995, FEBS LETT, V372, P233, DOI 10.1016/0014-5793(95)00986-J; HASLETT C, 1985, AM J PATHOL, V119, P101; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LUI ZG, 1996, CELL, V87, P565; MACDONALD PP, 1997, FEBS LETT, V412, P583; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Meagher LC, 1996, J IMMUNOL, V156, P4422; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ozaki K, 1997, FEBS LETT, V410, P297, DOI 10.1016/S0014-5793(97)00653-4; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stern M, 1996, AM J PATHOL, V149, P911; STERN M, 1992, J IMMUNOL, V148, P3543; Sutton P, 1995, BIOCHEM PHARMACOL, V50, P2009, DOI 10.1016/0006-2952(95)02101-9; SUTTON P, 1994, INFECT IMMUN, V62, P1192, DOI 10.1128/IAI.62.4.1192-1198.1994; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vollebregt M, 1998, FEBS LETT, V432, P40, DOI 10.1016/S0014-5793(98)00821-7; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Ward C, 1997, BIOCHEM SOC T, V25, pS245, DOI 10.1042/bst025245s; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WARING P, 1988, J BIOL CHEM, V263, P18493; WARING P, 1990, J BIOL CHEM, V265, P14476; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Whyte MKB, 1997, J LEUKOCYTE BIOL, V62, P195, DOI 10.1002/jlb.62.2.195; WONG T, 1997, J CLIN SCI, V92, P7; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	59	307	330	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4309	4318		10.1074/jbc.274.7.4309	http://dx.doi.org/10.1074/jbc.274.7.4309			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933632	hybrid			2022-12-25	WOS:000078575500056
J	Zhao, H; Wiederkehr, MR; Fan, LZ; Collazo, RL; Crowder, LA; Moe, OW				Zhao, H; Wiederkehr, MR; Fan, LZ; Collazo, RL; Crowder, LA; Moe, OW			Acute inhibition of Na/H exchanger NHE-3 by cAMP - Role of protein kinase A and NHE-3 phosphoserines 552 and 605	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; RENAL EPITHELIAL-CELLS; PARATHYROID-HORMONE; MEDIATED INHIBITION; MEMBRANE; ISOFORM; ANTIPORTER; COFACTOR; ACID; IDENTIFICATION	Regulation of the renal Na/H exchanger NHE-3 by protein kinase A (PKA) is a key intermediate step in the hormonal regulation of acid-base and salt balance. We studied the role of NHE-3 phosphorylation in this process in NHE-deficient AP-1 cells transfected with NHE-3 and in OKP cells expressing native NHE-8. A dominant-negative PRA-regulatory subunit completely abolished the effect of cAMP on NHE-5 activity demonstrating a role of PEA in the functional regulation of NHE-3 by cAMP, NHE-3 isolated from cAMP-treated cells showed lower phosphorylation by purified PKA in vitro suggesting that NHE-5 is a PKA substrate in vivo. Although changes in NHE-3 whole protein phosphorylation is difficult to detect in response to cAMP addition, the tryptic phosphopeptide map of in vivo phosphorylated NHE-3 showed a complex pattern of constitutive and cAMP-induced phosphopeptides. To test the causal relationship between phosphorylation and activity, we mutated eight serines in the cytoplasmic domain to glycine or alanine, Single or multiple mutants harboring S552A or S605G showed no PEA activation or reduced regulation by PKA activation. Ser-552 and Ser-605 were phosphorylated in vivo. However, multiple mutations of serines other than Ser-552 or Ser-605 also reduced the functional PKA regulation. We conclude that regulation of NHE-3 by PKA in vivo involves complex mechanisms, which include phosphorylation of Ser-552 and Ser-605.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Vet Affairs Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	omoe@mednet.swmed.edu			NIDDK NIH HHS [DK48482, T32 DK07257-17] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048482, R01DK048482, T32DK007257] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CANO A, 1993, J CLIN INVEST, V92, P1632, DOI 10.1172/JCI116748; CASAVOLA V, 1989, BIOCHEM BIOPH RES CO, V165, P833, DOI 10.1016/S0006-291X(89)80041-5; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KAUPP UB, 1995, CURR OPIN NEUROBIOL, V5, P434, DOI 10.1016/0959-4388(95)80002-6; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MOE OW, 1998, STRUCTURE FUNCTION M; MORELL G, 1990, AM J PHYSIOL, V259, pF867, DOI 10.1152/ajprenal.1990.259.6.F867; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; TSE CM, 1992, J BIOL CHEM, V267, P9340; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; WEINMAN EJ, 1998, AM J PHYSIOL, V258, pF1254; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; ZHANG J, STRUCTURE, V3, P299	33	125	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3978	3987		10.1074/jbc.274.7.3978	http://dx.doi.org/10.1074/jbc.274.7.3978			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933588	hybrid			2022-12-25	WOS:000078575500012
J	Daniele, N; Rajas, F; Payrastre, B; Mauco, G; Zitoun, C; Mithieux, G				Daniele, N; Rajas, F; Payrastre, B; Mauco, G; Zitoun, C; Mithieux, G			Phosphatidylinositol 3-kinase translocates onto liver endoplasmic reticulum and may account for the inhibition glucose-6-phosphatase during refeeding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; PHOSPHATASE-ACTIVITY; INSULIN-RESISTANT; PROTEIN-KINASE; MESSENGER-RNA; IN-VITRO; RATS; MUSCLE; CELLS; GENE	By using a rapid procedure of isolation of microsomes, we have shown that the liver glucose-6-phosphatase activity was lowered by about 30% (p < 0.001) after refeeding for 360 min rats previously unfed for 48 h, whereas the amount of glucose-6-phosphatase protein was not lowered during the same time. The amount of the regulatory subunit (p85) and the catalytic activity of phosphatidylinositol 3-kinase (PI3K) were higher by a factor of 2.6 and 2.4, respectively (p < 0.01), in microsomes from refed as compared with fasted rats. This resulted from a translocation process because the total amount of p85 was the same in the whole liver homogenates from fasted and refed rats. The amount of insulin receptor substrate 1 (IRS1) was also higher by a factor of 2.6 in microsomes from refed rats (p < 0.01). Microsome-bound IRS1 was only detected in p85 immunoprecipitates. These results strongly suggest that an insulin-triggered mechanism of translocation of PI3K onto microsomes occurs in the liver of rats during refeeding. This process, via the lipid products of PI3K, which are potent inhibitors of glucose-6-phosphatase (Mithieux, G., Daniele, N., Payrastre, B., and Zitoun, C. (1998) J. Biol. Chem. 273, 17-19), may account for the inhibition of the enzyme and participate to the inhibition of hepatic glucose production occurring in this situation.	Fac Med RTH Laennec, INSERM, F-69372 Lyon 08, France; Fac Med RTH Laennec, U449, F-69372 Lyon, France; Hop Purpan, U326, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Mithieux, G (corresponding author), Fac Med RTH Laennec, INSERM, Rue G Paradin, F-69372 Lyon 08, France.		Danièle, Nathalie/J-7432-2013; Mauco, Gerard/A-3164-2016; RAJAS, Fabienne/P-4091-2016	Mauco, Gerard/0000-0003-2998-2397; RAJAS, Fabienne/0000-0002-9233-7633; , Bernard/0000-0002-8693-0190; Gilles, Mithieux/0000-0003-3579-8529; Daniele, Nathalie/0000-0002-7985-2788				AJZANNAY A, 1994, J BIOCHEM-TOKYO, V116, P1336, DOI 10.1093/oxfordjournals.jbchem.a124684; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BODE AM, 1992, J BIOL CHEM, V267, P2860; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG PY, 1995, J BIOL CHEM, V270, P29928; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; GUIGNOT L, 1994, DIABETOLOGIA S1, V39, P13; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Harlow E., 1988, ANTIBODIES LAB MANUA; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KELLY KL, 1992, J BIOL CHEM, V267, P3423; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAITRA SR, 1994, BIOCHEM BIOPH RES CO, V204, P716, DOI 10.1006/bbrc.1994.2518; MASSILLON D, 1996, DIABETES S2, V45, P35; Mevorach M, 1998, J CLIN INVEST, V102, P744, DOI 10.1172/JCI2720; Minassian C, 1996, MOL CELL BIOCHEM, V155, P37, DOI 10.1007/BF00714331; Minassian C, 1998, BIOCHEM PHARMACOL, V55, P1213, DOI 10.1016/S0006-2952(97)00576-5; MINASSIAN C, 1994, J BIOL CHEM, V269, P16585; MINASSIAN C, 1995, J NUTR, V125, P2727; Mithieux G, 1998, J BIOL CHEM, V273, P17, DOI 10.1074/jbc.273.1.17; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NEWGARD CB, 1984, DIABETES, V33, P192, DOI 10.2337/diabetes.33.2.192; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P53; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SCHULTZ RM, 1995, ANTICANCER RES, V15, P1135; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Thomson FJ, 1996, BIOCHEM J, V316, P161, DOI 10.1042/bj3160161; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	39	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3597	3601		10.1074/jbc.274.6.3597	http://dx.doi.org/10.1074/jbc.274.6.3597			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920907	hybrid			2022-12-25	WOS:000078428200047
J	Lupold, DS; Caoile, AGFS; Stern, DB				Lupold, DS; Caoile, AGFS; Stern, DB			The maize mitochondrial cox2 gene has five promoters in two genomic regions, including a complex promoter consisting of seven overlapping units	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; PERENNIAL TEOSINTES; CYTOCHROME-OXIDASE; IN-VITRO; RNA; SEQUENCE; CONTAINS; CHLOROPLASTS; ARABIDOPSIS; EXPRESSION	Plant mitochondrial genes are often transcribed into complex sets of RNAs, resulting from multiple initiation sites and processing steps. To elucidate the role of initiation in generating the more than 10 cox2 transcripts found in maize mitochondria, we surveyed sequences upstream of cox2 for active promoters. Because the cox2 coding region is immediately downstream of a 0.7-kb recombination repeat, cox2 is under the control of two different sets of potential expression signals. Using an in vitro transcription assay, we localized four promoters upstream of the coding region in the so-called master chromosome, and two promoters upstream of the coding region in the recombinant subgenome, Ribonuclease protection analysis of labeled primary transcripts confirmed that all but one of these promoters is active in vivo. Primer extension was used to identify the promoter sequences and initiation sites, which agree with the consensus established earlier for maize mitochondria. This study identified two unusual promoters, the core sequences of which were composed entirely of adenines and thymines, and one of which was a complex promoter consisting of seven overlapping units. Deletion mutagenesis of the complex promoter suggested that each of its units was recognized independently by RNA polymerase, While each active promoter fit the maize core consensus sequence YRTAT, not all such sequences surveyed supported initiation. We conclude that in vitro transcription is a powerful tool for locating mitochondrial promoters and that, in the case of cox2, promoter multiplicity contributes strongly to transcript complexity.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Cornell Univ, Genet & Dev Sect, Ithaca, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research; Cornell University	Stern, DB (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.		Stern, David B/H-7852-2012		NIGMS NIH HHS [R01GM52560] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052560] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bendich AJ, 1996, J MOL BIOL, V255, P564, DOI 10.1006/jmbi.1996.0048; BINDER S, 1995, J BIOL CHEM, V270, P22182, DOI 10.1074/jbc.270.38.22182; Biswas TK, 1998, GENE, V212, P305, DOI 10.1016/S0378-1119(98)00133-4; Caoile AGFS, 1997, NUCLEIC ACIDS RES, V25, P4055, DOI 10.1093/nar/25.20.4055; Chang TL, 1996, CURR GENET, V30, P522, DOI 10.1007/s002940050165; COOPER P, 1990, GENETICS, V126, P461; Dombrowski S, 1997, EMBO J, V16, P5069, DOI 10.1093/emboj/16.16.5069; FANGMAN WL, 1984, P NATL ACAD SCI-BIOL, V81, P7156, DOI 10.1073/pnas.81.22.7156; FAURON C, 1995, TRENDS GENET, V11, P228, DOI 10.1016/S0168-9525(00)89056-3; FINNEGAN PM, 1990, PLANT CELL, V2, P71, DOI 10.1105/tpc.2.1.71; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; Giese A, 1996, MOL GEN GENET, V252, P429, DOI 10.1007/BF02173008; HANICJOYCE PJ, 1991, MOL CELL BIOL, V11, P2035, DOI 10.1128/MCB.11.4.2035; HECK JD, 1988, J BIOL CHEM, V263, P857; IRATNI R, 1994, GENE DEV, V8, P2928, DOI 10.1101/gad.8.23.2928; Li XQ, 1996, PLANT CELL, V8, P1961, DOI 10.1105/tpc.8.11.1961; LONSDALE DM, 1984, NUCLEIC ACIDS RES, V12, P9249, DOI 10.1093/nar/12.24.9249; MULLIGAN RM, 1988, MOL GEN GENET, V211, P373, DOI 10.1007/BF00425688; MULLIGAN RM, 1991, MOL CELL BIOL, V11, P533, DOI 10.1128/MCB.11.1.533; MULLIGAN RM, 1988, P NATL ACAD SCI USA, V85, P7998, DOI 10.1073/pnas.85.21.7998; NEWTON KJ, 1985, P NATL ACAD SCI USA, V82, P6879, DOI 10.1073/pnas.82.20.6879; NEWTON KJ, 1995, EMBO J, V14, P585, DOI 10.1002/j.1460-2075.1995.tb07034.x; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; RAPP WD, 1993, MOL CELL BIOL, V13, P7232, DOI 10.1128/MCB.13.12.7232; RAPP WD, 1992, EMBO J, V11, P1065, DOI 10.1002/j.1460-2075.1992.tb05145.x; SCHINKEL AH, 1988, NUCLEIC ACIDS RES, V16, P9147, DOI 10.1093/nar/16.19.9147; STOHL LL, 1992, MOL CELL BIOL, V12, P2561, DOI 10.1128/MCB.12.6.2561; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; TRACY RL, 1995, CURR GENET, V28, P205, DOI 10.1007/BF00309779; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57	31	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3897	3903		10.1074/jbc.274.6.3897	http://dx.doi.org/10.1074/jbc.274.6.3897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920945	hybrid			2022-12-25	WOS:000078428200085
J	Matsunaga, J; Sinha, D; Pannell, L; Santis, C; Solano, F; Wistow, GJ; Hearing, VJ				Matsunaga, J; Sinha, D; Pannell, L; Santis, C; Solano, F; Wistow, GJ; Hearing, VJ			Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE INDUCES APOPTOSIS; FACTOR MIF; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; DOPACHROME TAUTOMERASE; MOLECULAR-CLONING; SUBSTANTIA-NIGRA; BOVINE BRAIN; CELL-DEATH; NEUROMELANIN	Macrophage migration inhibitory factor (MIF) is a relatively small, 12.5-kDa protein that is structurally related to some isomerases and for which multiple immune and catalytic roles have been proposed. MIF is widely expressed in tissues with particularly high levels in neural tissues. Here we show that MIF is able to catalyze the conversion of 3,4-dihydroxyphenylaminechrome and norepinephrinechrome, toxic quinone products of the neurotransmitter catecholamines 3,4-dihydroxyphenylamine and norepinephrine, to indoledihydroxy derivatives that may serve as precursors to neuromelanin. This raises the possibility that MIF participates in a detoxification pathway for catecholamine products and could therefore have a protective role in neural tissues, which as in Parkinson's disease, may be subject to catecholamine-related cell death.	NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NEI, Sect Mol Struct & Funct, NIH, Bethesda, MD 20892 USA; Univ Murcia, Dept Biochem, E-30100 Murcia, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University of Murcia	Hearing, VJ (corresponding author), NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov	Solano, Francisco/G-5001-2013	Solano, Francisco/0000-0001-9612-761X	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [Z01EY000320, ZIAEY000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032102] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apte RS, 1998, J IMMUNOL, V160, P5693; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; dIschia M, 1997, PIGM CELL RES, V10, P370, DOI 10.1111/j.1600-0749.1997.tb00694.x; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; ENOCHS WS, 1993, J NEUROCHEM, V61, P68, DOI 10.1111/j.1471-4159.1993.tb03538.x; Esumi N, 1998, MAMM GENOME, V9, P753, DOI 10.1007/s003359900858; GALAT A, 1994, EUR J BIOCHEM, V224, P417, DOI 10.1111/j.1432-1033.1994.00417.x; GALAT A, 1993, FEBS LETT, V319, P233, DOI 10.1016/0014-5793(93)80553-7; Hastings TG, 1997, J NEURAL TRANSM-SUPP, P103; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LINDQUIST NG, 1987, PIGM CELL RES, V1, P133, DOI 10.1111/j.1600-0749.1987.tb00403.x; Magi B, 1998, ELECTROPHORESIS, V19, P2010, DOI 10.1002/elps.1150191120; Mena MA, 1996, NEUROREPORT, V7, P441, DOI 10.1097/00001756-199601310-00016; MIKAYAMA T, 1993, P NATL ACAD SCI USA, V90, P10056, DOI 10.1073/pnas.90.21.10056; Mischke R, 1997, FEBS LETT, V414, P226, DOI 10.1016/S0014-5793(97)01039-9; Mischke R, 1998, FEBS LETT, V427, P85, DOI 10.1016/S0014-5793(98)00400-1; MozeticFrancky B, 1997, PROTEIN EXPRES PURIF, V9, P115, DOI 10.1006/prep.1996.0641; Nishibori M, 1996, NEUROSCI LETT, V213, P193; Nishibori M, 1997, BRAIN RES, V758, P259, DOI 10.1016/S0006-8993(97)00342-9; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Offen D, 1997, NEUROCHEM INT, V31, P207, DOI 10.1016/S0197-0186(96)00150-7; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PARALKAR V, 1994, GENOMICS, V19, P48, DOI 10.1006/geno.1994.1011; PAWELEK J, 1980, NATURE, V286, P617, DOI 10.1038/286617a0; PAWELEK JM, 1978, NATURE, V276, P627, DOI 10.1038/276627a0; PROTA G, 1993, PIGM CELL RES, V6, P333, DOI 10.1111/j.1600-0749.1993.tb00610.x; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; SeguraAguilar J, 1997, J BIOL CHEM, V272, P5727, DOI 10.1074/jbc.272.9.5727; Shinkai T, 1997, J NEUROSCI RES, V47, P393; Smythies J, 1996, P ROY SOC B-BIOL SCI, V263, P487, DOI 10.1098/rspb.1996.0073; STEEL KP, 1992, DEVELOPMENT, V115, P1111; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Sugimoto H, 1996, FEBS LETT, V389, P145, DOI 10.1016/0014-5793(96)00553-4; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Sun HW, 1996, PROTEIN ENG, V9, P631, DOI 10.1093/protein/9.8.631; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Suzuki M, 1997, J BIOCHEM-TOKYO, V122, P1040; Temlett JA, 1996, CURR OPIN NEUROL, V9, P303, DOI 10.1097/00019052-199608000-00011; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Wilhelmsen K, 1997, ANN NEUROL, V41, P813, DOI 10.1002/ana.410410619; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272; WISTOW GJ, 1998, ENCY IMMUNOLOGY, P1658; ZECCA L, 1992, BIOCHIM BIOPHYS ACTA, V1138, P6, DOI 10.1016/0925-4439(92)90144-C; ZHANG M, 1995, FEBS LETT, V373, P203, DOI 10.1016/0014-5793(95)01041-C; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	53	73	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3268	3271		10.1074/jbc.274.6.3268	http://dx.doi.org/10.1074/jbc.274.6.3268			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920865	hybrid			2022-12-25	WOS:000078428200005
J	Pham, PT; Olson, MW; McHenry, CS; Schaaper, RM				Pham, PT; Olson, MW; McHenry, CS; Schaaper, RM			Mismatch extension by Escherichia coli DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE MISINCORPORATION; FIDELITY; REPLICATION; BACTERIOPHAGE-T4; EXONUCLEASE; FREQUENCIES; MUTATIONS; COMPLEX; ERRORS; GENE	The in vitro fidelity of Escherichia coli DNA polymerase III holoenzyme (HE) is characterized by an unusual propensity for generating (-1)-frameshift mutations, Here we have examined the capability of HE isolated from both a wild-type and a proofreading-impaired mutD5 strain to polymerize from M13mp2 DNA primer-templates containing a terminal T(template).C mismatch, These substrates contained either an A or a G as the next (5') template base. The assay allows distinction between: (i) direct extension of the terminal C (producing a base substitution), (ii) exonucleolytic removal of the C, or (iii), for the G-containing template, extension after misalignment of the C on the next template G (producing a (-1)-frameshift), On the A-containing substrate, both HEs did not extend the terminal C (<1%); instead, they exonucleolytically removed it (>99%), In contrast, on the G-containing substrate, the MutD5 HE yielded 61% (-1)-frameshifts and 6% base substitutions, The wild-type HE mostly excised the mispaired C from this substrate before extension (98%), but among the 2% mutants, (-1)-frameshifts exceeded base substitutions by 20 to 1, The preference of polymerase III HE for misalignment extension over direct mismatch extension provides a basis for explaining the in vitro (-1)-frameshift specificity of polymerase III HE.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Schaaper, RM (corresponding author), NIEHS, Mol Genet Lab, NIH, E3-01,POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	schaaper@niehs.nih.gov	Schaaper, Roel M/E-6680-2019	Schaaper, Roel M/0000-0003-1344-3196				BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; FARABAUGH PJ, 1978, J MOL BIOL, V126, P847, DOI 10.1016/0022-2836(78)90023-2; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kornberg A., 1992, DNA REPLICATION, P165; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; PRIBNOW D, 1981, J MOL BIOL, V149, P337, DOI 10.1016/0022-2836(81)90477-0; RIPLEY LS, 1986, J MOL BIOL, V191, P601, DOI 10.1016/0022-2836(86)90448-1; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	24	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3705	3710		10.1074/jbc.274.6.3705	http://dx.doi.org/10.1074/jbc.274.6.3705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920922	hybrid			2022-12-25	WOS:000078428200062
J	Prince, LS; Peter, K; Hatton, SR; Zaliauskiene, L; Cotlin, LF; Clancy, JP; Marchase, RB; Collawn, JF				Prince, LS; Peter, K; Hatton, SR; Zaliauskiene, L; Cotlin, LF; Clancy, JP; Marchase, RB; Collawn, JF			Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR INTERNALIZATION; CFTR CHLORIDE CHANNELS; CYTOPLASMIC DOMAIN; SORTING SIGNALS; SEQUENCE; MOTIF; DNA; PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION	We previously demonstrated that the cystic fibrosis transmembrane conductance regulator (CFTR) is rapidly endocytosed in epithelial cells (Prince, L. S., Workman, R. B., Jr., and Marchase, R. B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5192-5196), To determine the structural features of CFTR required for endocytosis, we prepared chimeric molecules consisting of the amino-terminal (residues 2-78) and carboxyl-terminal tail regions (residues 1391-1476) of CFTR, each fused to the transmembrane and extracellular domains of the transferrin receptor. Functional analysis of the CFTR-(2-78) and CFTR-(1391-1476) indicated that both chimeras were rapidly internalized. Deletion of residues 1440-1476 had no effect on chimera internalization. Mutations of potential internalization signals in both cytoplasmic domains reveal that only one mutation inhibits internalization, Y1424A. Using a surface biotinylation reaction, we also examined internalization rates of wild type and mutant CFTRs expressed in COS-7 cells, We found that both wild type and A1440X CFTR were rapidly internalized, whereas the Y1424A CFTR mutant, like the chimeric protein, had similar to 40% reduced internalization activity. Deletions in the amino-terminal tail region of CFTR resulted in defective trafficking of CFTR out of the endoplasmic reticulum to the cell surface, suggesting that an intact amino terminus is critical for biosynthesis, In summary, our results suggest that both tail regions of CFTR are sufficient to promote rapid internalization of a reporter molecule and that tyrosine 1424 is required for efficient CFTR endocytosis.	Univ Alabama Birmingham, Dept Cell Biol, UAB Stn, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, UAB Stn, Gregory Fleming James Cyst Fibrosis Res Ctr, BHSB 392, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Collawn, James/0000-0002-2528-2759	NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; George AL, 1998, P NATL ACAD SCI USA, V95, P7843, DOI 10.1073/pnas.95.14.7843; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HUGHES SH, 1990, J REPROD FERTIL, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOGAN JJ, 1995, GENE THER, V2, P38; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILEY HS, 1982, J BIOL CHEM, V257, P4222	45	79	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3602	3609		10.1074/jbc.274.6.3602	http://dx.doi.org/10.1074/jbc.274.6.3602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920908	hybrid			2022-12-25	WOS:000078428200048
J	Schierau, A; Dietz, F; Lange, H; Schestag, F; Parastar, A; Gieselmann, V				Schierau, A; Dietz, F; Lange, H; Schestag, F; Parastar, A; Gieselmann, V			Interaction of arylsulfatase A with UDP-N-acetylglucosamine : lysosomal enzyme-N-acetylglucosamine-1-phosphotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN RECOGNITION DETERMINANTS; ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; PROCATHEPSIN-D; TARGETING SIGNAL; ACTIVE-SITE; PHOSPHORYLATION; OLIGOSACCHARIDES; PHOSPHOTRANSFERASE; GLYCOSYLATION; MUTAGENESIS	The critical step in lysosomal targeting of soluble lysosomal enzymes is the recognition by an UDP-N-acetyl-glucosamine:lysosomal enzyme-N-acetylglucosamine-1-phosphotransferase. The structure of the determinant common to all lysosomal enzymes for proper recognition by the phosphotransferase is not completely understood. Our current knowledge is largely based on the introduction of targeted amino acid substitutions into lysosomal enzymes and analysis of their effects on phosphotransferase recognition. We have investigated the effect of eight anti-arylsulfatase A monoclonal antibodies on the interaction of arylsulfatase A with the lysosomal enzyme phosphotransferase in vitro, We also show that a lysine-rich surface area of arylsulfatases A and B is essential for proper recognition by the phosphotransferase, Monoclonal antibodies bind to at least six different epitopes at different locations on the surface of arylsulfatase A. All antibodies bind outside the lysine-rich recognition area, but nevertheless Fab fragments of these antibodies prevent interaction of arylsulfatase A with the phosphotransferase, Our data support a model in which binding of arylsulfatase A to the phosphotransferase is not restricted to a limited surface area but involves the simultaneous recognition of large parts of arylsulfatase A.	Univ Kiel, Inst Biochem, D-24098 Kiel, Germany	University of Kiel	Gieselmann, V (corresponding author), Univ Kiel, Inst Biochem, Olshausenstr 40, D-24098 Kiel, Germany.							AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; KAARTINEN M, 1983, J IMMUNOL, V130, P937; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LANG L, 1984, J BIOL CHEM, V259, P4663; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Peters J, 1992, MONOCLONAL ANTIBODIE; SCHULZEGARG C, 1993, J CELL BIOL, V122, P541, DOI 10.1083/jcb.122.3.541; SOMMERLADE HJ, 1994, J BIOL CHEM, V269, P20977; SOMMERLADE HJ, 1994, BIOCHEM J, V297, P123, DOI 10.1042/bj2970123; STEIN C, 1989, J BIOL CHEM, V264, P1252; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; VONFIGURA K, 1990, NATURWISSENSCHAFTEN, V77, P116, DOI 10.1007/BF01134471	27	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3651	3658		10.1074/jbc.274.6.3651	http://dx.doi.org/10.1074/jbc.274.6.3651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920914	hybrid			2022-12-25	WOS:000078428200054
J	Xia, M; Dempski, R; Hille, R				Xia, M; Dempski, R; Hille, R			The reductive half-reaction of xanthine oxidase - Reaction with aldehyde substrates and identification of the catalytically labile oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOM TRANSFER-REACTIONS; ANALOG REACTION SYSTEM; MOLYBDENUM OXOTRANSFERASES; ACTIVE-SITES; COMPLEXES; KINETICS; O-17; MOLYBDOENZYMES; MECHANISM; DEHYDROGENASE	The kinetics of xanthine oxidase has been investigated with the aim of addressing several outstanding questions concerning the reaction mechanism of the enzyme. Steady-state and rapid kinetic studies with the substrate 2,5-dihydroxybenzaldehyde demonstrated that (k(cat)/K-m)(app) and k(red)/K-d exhibit comparable bell-shaped pH dependence with pK(a) values of 6.4 +/- 0.2 and 8.4 +/- 0.2, with the lower pK(a) assigned to an active-site residue of xanthine oxidase (possibly Glu-1261, by analogy to Glu-869 in the crystallographically known aldehyde oxidase from Desulfovibrio gigas) and the higher pK(a) to substrate. Early steps in the catalytic sequence have been investigated by following the reaction of the oxidized enzyme with a second aldehyde substrate, 2-aminopteridine-6-aldehyde. The absence of a well defined acid limb in this pH profile and other data indicate that this complex represents an E-ox.S rather than E-red.P complex (i.e. no chemistry requiring the active-site base has taken place in forming the long wavelength-absorbing complex seen with this substrate). It appears that xanthine oxidase (and by inference, the closely related aldehyde oxidases) hydroxylates both aromatic heterocycles and aldehydes by a mechanism involving base-assisted catalysis, Single-turnover experiments following incorporation of O-17 into the molybdenum center of the enzyme demonstrated that a single oxygen atom is incorporated at a site that gives rise to strong hyperfine coupling to the unpaired electron spin of the metal in the Mo-V oxidation state. By analogy to the hyperfine interactions seen in a homologous series of molybdenum model compounds, we conclude that this strongly coupled, catalytically labile site represents a metal-coordinated hydroxide rather than the Mo=O group and that this Mo-OH represents the oxygen that is incorporated into product in the course of catalysis.	Ohio State Univ, Dept Biochem Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Hille, R (corresponding author), Ohio State Univ, Dept Biochem Med, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	Hille.1@osu.edu			NIAMS NIH HHS [AR38917] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038917] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1993, ADV INORGANIC CHEM, DOI DOI 10.1016/S0898-8838(08)60181-6; BERG JM, 1985, J AM CHEM SOC, V107, P917, DOI 10.1021/ja00290a029; BERG JM, 1984, J AM CHEM SOC, V106, P3035, DOI 10.1021/ja00322a050; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1982, BIOCHEMISTRY-US, V21, P5992, DOI 10.1021/bi00266a041; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; GEORGE GN, 1988, BIOCHEMISTRY-US, V27, P3603, DOI 10.1021/bi00410a011; GHELLER SF, 1992, J AM CHEM SOC, V114, P6934, DOI 10.1021/ja00043a059; GREENWOOD RJ, 1993, J AM CHEM SOC, V115, P5385, DOI 10.1021/ja00066a005; GUTTERIDGE S, 1980, BIOCHEM J, V189, P615, DOI 10.1042/bj1890615; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1981, PHARMACOL THERAPEUT, V14, P249, DOI 10.1016/0163-7258(81)90063-2; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM RH, 1987, CHEM REV, V87, P1401, DOI 10.1021/cr00082a005; HOLM RH, 1993, POLYHEDRON, V12, P571, DOI 10.1016/S0277-5387(00)84972-4; Howes BD, 1996, BIOCHEMISTRY-US, V35, P1432, DOI 10.1021/bi9520500; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUNT J, 1994, J BIOL CHEM, V269, P18904; JOHNSON KA, 1992, ENZYMES, V20, P2; KIM JH, 1993, J BIOL CHEM, V268, P44; Kim JH, 1996, J BIOL CHEM, V271, P6771, DOI 10.1074/jbc.271.12.6771; KOMAI H, 1969, J BIOL CHEM, V244, P1692; LISTER JH, 1971, CHEM HETEROCYCLIC 2, P203; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MORPETH FF, 1983, BIOCHIM BIOPHYS ACTA, V744, P328, DOI 10.1016/0167-4838(83)90207-8; OLSON JS, 1974, J BIOL CHEM, V249, P4350; PARSONS SM, 1972, BIOCHEMISTRY-US, V11, P1633, DOI 10.1021/bi00759a015; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; ROBERTS SA, 1990, INORG CHEM, V29, P3650, DOI 10.1021/ic00344a007; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; Schindelin H, 1997, J BIOL INORG CHEM, V2, P773, DOI 10.1007/s007750050194; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; SCHULTZ BE, 1993, INORG CHEM, V32, P4244, DOI 10.1021/ic00072a016; SCHULTZ BE, 1993, J AM CHEM SOC, V115, P2714, DOI 10.1021/ja00060a021; SKIBO EB, 1987, BIOCHEMISTRY-US, V26, P3032, DOI 10.1021/bi00385a013; Stiefel E.I, 1977, PROG INORG CHEM, P1, DOI 10.1002/9780470166239.ch1; Voityuk AA, 1997, J AM CHEM SOC, V119, P3159, DOI 10.1021/ja963901+; XIAO ZG, 1992, J AM CHEM SOC, V114, P9194, DOI 10.1021/ja00049a065	41	84	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3323	3330		10.1074/jbc.274.6.3323	http://dx.doi.org/10.1074/jbc.274.6.3323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920873	hybrid			2022-12-25	WOS:000078428200013
J	Bichet, S; Wenger, RH; Camenisch, G; Rolfs, A; Ehleben, W; Porwol, T; Acker, H; Fandrey, J; Bauer, C; Gassmann, M				Bichet, S; Wenger, RH; Camenisch, G; Rolfs, A; Ehleben, W; Porwol, T; Acker, H; Fandrey, J; Bauer, C; Gassmann, M			Oxygen tension modulates beta-globin switching in embryoid bodies	FASEB JOURNAL			English	Article						embryonic stem cells; hemoglobin; hypoxia-inducible factor; erythropoietin	INDUCIBLE FACTOR-I; STEM-CELLS; GENE-EXPRESSION; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC DEVELOPMENT; VITRO DIFFERENTIATION; INVITRO DEVELOPMENT; ENDOTHELIAL-CELLS; HEPATOMA-CELLS; MESSENGER-RNA	Little is known about the factors influencing the hemoglobin switch in vertebrates during develop ment. Inasmuch as the mammalian conceptus is exposed to changing oxygen tensions in utero, we examined the effect of different oxygen concentrations on beta-globin switching. We used an in vitro model of mouse embryogenesis based on the differentiation of blastocyst-derived embryonic stem cells to embryoid bodies (EBs). Cultivation of EBs at increasing oxygen concentrations (starting at 1% O-2) did not influence the temporal expression pattern of embryonic (beta H1) globin compared to the normoxic controls (20% O-2). In contrast, when compared to normoxically grown EBs, expression of fetal/adult (beta(maj)) globin in EBs cultured at varying oxygen concentrations was delayed by about 2 days and persisted throughout differentiation. Quantitation of hemoglobin in EBs using a 2,7-diaminofluorene-based colorimetric assay revealed the appearence of hemoglobin in two waves, an early and a late one. This observation was verified by spectrophotometric analysis of hemoglobin within single EBs. These two waves might reflect the switch of erythropoiesis from yolk sac to fetal liver. Reduced oxygenation is known to activate the hypoxia-inducible factor-1 (HIF-1), which in turn specifically induces expression of a variety of genes among them erythropoietin (EPO). Although EBs increased EPO expression upon hypoxic exposure, the altered beta-globin appearance was not related to EPO levels as determined in EBs overexpressing EPO. Since mRNA from both mouse HIF-1 alpha isoforms was detected in all EBs tested at different differentiation stages, we propose that HIV-1 modulates beta-globin expression during development.	Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland; Max Planck Inst Mol Physiol, D-44026 Dortmund, Germany; Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Zurich; Max Planck Society; University of Lubeck	Gassmann, M (corresponding author), Univ Zurich Irchel, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	labbauer@physiol.unizh.ch	Acker, Helmut Anton Josef/AAS-6841-2020; Wenger, Roland H./B-7953-2009; Acker, Helmut/AAJ-8332-2020	Acker, Helmut Anton Josef/0000-0001-5589-5508; Wenger, Roland H./0000-0001-7592-4839; Fandrey, Joachim/0000-0001-9585-0531				ALLEN DW, 1960, J CLIN INVEST, V39, P1107, DOI 10.1172/JCI104125; ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CALLUS BA, 1995, HEMOGLOBIN, V19, P7; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; CHANCE B, 1975, ANAL BIOCHEM, V66, P498, DOI 10.1016/0003-2697(75)90617-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESIMONE J, 1978, P NATL ACAD SCI USA, V75, P2937, DOI 10.1073/pnas.75.6.2937; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V93, P2867; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; Ehleben W, 1997, KIDNEY INT, V51, P483, DOI 10.1038/ki.1997.67; FISCHER B, 1993, J REPROD FERTIL, V99, P673, DOI 10.1530/jrf.0.0990673; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; GASSMANN M, 1995, TOXICOL IN VITRO, V9, P429, DOI 10.1016/0887-2333(95)00036-8; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; GORLACH A, 1993, BIOCHEM J, V290, P771; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JAHN CL, 1980, CELL, V21, P159, DOI 10.1016/0092-8674(80)90123-3; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOVACH JS, 1967, J MOL BIOL, V25, P131, DOI 10.1016/0022-2836(67)90284-7; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LEDER P, 1980, SCIENCE, V209, P1336, DOI 10.1126/science.7414319; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MCCLANAHAN T, 1993, BLOOD, V81, P2903; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; PENNATHURDAS R, 1987, BLOOD, V69, P899; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; TAN CC, 1992, AM J PHYSIOL, V263, pF474, DOI 10.1152/ajprenal.1992.263.3.F474; THOMAS ED, 1960, NATURE, V185, P396, DOI 10.1038/185396a0; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Weiss MJ, 1996, J CLIN INVEST, V97, P591, DOI 10.1172/JCI118454; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432-1033.1997.t01-1-00155.x; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; WENGER RH, 1994, ANAL BIOCHEM, V221, P416, DOI 10.1006/abio.1994.1436; Wenger RH, 1997, BIOL CHEM, V378, P609; WHITELAW E, 1989, HEMOGLOBIN SWITCHI A, P323; WILES MV, 1991, DEVELOPMENT, V111, P259; Wood WG, 1996, TRENDS GENET, V12, P204, DOI 10.1016/0168-9525(96)30043-7; WORTHINGTON RE, 1987, EXP HEMATOL, V15, P85; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZON LI, 1995, BLOOD, V86, P2876	65	26	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					285	295		10.1096/fasebj.13.2.285	http://dx.doi.org/10.1096/fasebj.13.2.285			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973316	Green Accepted			2022-12-25	WOS:000078615200008
J	Mittelstadt, PR; Ashwell, JD				Mittelstadt, PR; Ashwell, JD			Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; TRANSCRIPTION FACTORS; CYCLOSPORINE-A; LYMPHOPROLIFERATIVE DISORDERS; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; GENE-MUTATIONS; LPR/LPR MICE; FAMILY GENE; NGFI-A	We previously identified a Fas ligand regulatory element (FLRE) in the Fas ligand (fasL) promoter that binds Egr family proteins and demonstrated that Egr-3 (PILOT) but not Egr-1 (NGFI-A, Krox-24, Tis-8, and Zif-268) induces transcription of fast. The aberrant CD4(-)CD8(-) T cells from lpr/lpr and gld/gld mice, which have mutations in the genes encoding Fas and Fast, respectively, have an activated phenotype and constitutively express high levels of fasL mRNA, prompting us to ask what role if any the FLRE and Egr family proteins have in this aberrant expression of fast. Unstimulated MRL-lpr/lpr and C3H-gld/gld CD4(-)CD8(-) T cells constitutively contained high levels of two proteins that bound to the FLRE, Supershift analysis revealed these proteins to be Egr-1 and Egr-2 (Krox-20); Egr-3 was not detected. Activation of normal lymph node cells resulted in increased expression of Egr-1, -2, and -3, As with egr-3, expression of egr-2 was blocked by cyclosporin A. Although overexpressed Egr-1 was ineffective, overexpressed Egr-2 was as potent as Egr-3 in inducing fast promoter-dependent reporter constructs in T cell hybridomas and HeLa cells, and both up-regulated endogenous fast mRNA in HeLa cells. FasL- dependent reporter constructs in MRL-lpr/lpr and C3H-gld/gld CD4(-)CD8(-) T cells were constitutively active, and this activity was largely prevented by mutation of the critical Egr family binding element. Thus, Egr-2, in addition to Egr-3, regulates Fast expression in activated normal T cells, and Egr-2 is likely to play a direct role in aberrant fast up-regulation in lpr/lpr and gld/gld CD4(-)CD8(-) T cells.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA.	jda@Box-j.nih.gov						AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V9; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHU JL, 1995, J EXP MED, V181, P393, DOI 10.1084/jem.181.1.393; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEMENTS JL, 1995, J IMMUNOL, V154, P6372; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DAVIGNON JL, 1985, J IMMUNOL, V135, P2423; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GIESE T, 1993, J IMMUNOL, V151, P597; GIESE T, 1992, J IMMUNOL, V149, P3097; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; IWATA M, 1992, J IMMUNOL, V149, P3302; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; Matsui K, 1997, EUR J IMMUNOL, V27, P2269, DOI 10.1002/eji.1830270922; Mimura T, 1997, J IMMUNOL, V158, P2977; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; Nittenberg R, 1997, DEVELOPMENT, V124, P2297; Nonchev S, 1996, DEVELOPMENT, V122, P543; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; Skerka C, 1997, IMMUNOBIOLOGY, V198, P179, DOI 10.1016/S0171-2985(97)80039-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Theil T, 1998, DEVELOPMENT, V125, P443; TOMITAYAMAGUCHI M, 1990, J IMMUNOL, V144, P3946; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; WATANABE D, 1995, EMBO J, V14, P12, DOI 10.1002/j.1460-2075.1995.tb06970.x; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Williams MS, 1996, J IMMUNOL, V157, P2395; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	59	72	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3222	3227		10.1074/jbc.274.5.3222	http://dx.doi.org/10.1074/jbc.274.5.3222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915863	hybrid			2022-12-25	WOS:000078319500081
J	Nakamura, E; Sato, M; Yang, HL; Miyagawa, F; Harasaki, M; Tomita, K; Matsuoka, S; Noma, A; Iwai, K; Minato, N				Nakamura, E; Sato, M; Yang, HL; Miyagawa, F; Harasaki, M; Tomita, K; Matsuoka, S; Noma, A; Iwai, K; Minato, N			4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE ANTIGEN; EXPRESSION CLONING; SYSTEM; ACTIVATION; CYSTINURIA; INHIBITION; OOCYTES; SUBUNIT; FUSION; CDNA	4F2, also termed CD98, is an integral membrane protein consisting of a heavy chain linked to a light chain by disulfide bond. We have generated a monoclonal antibody to the mouse 4F2 light chain and cloned the cDNA It encodes a mouse counterpart of rat L-type amino acid transporter-1, and induces system L amino acid transport in Xenopus oocytes in the presence of 4F2 heavy chain. Transfection studies in mammalian cells have indicated that the 4F2 heavy chain is expressed on the plasma membrane on its own, whereas the 4F2 light chain can be transported to the surface only in the presence of 4F2 heavy chain. 4F2 heavy chain is expressed diffusely on the surface of fibroblastic L cells, whereas it is localized selectively to the cell-cell adhesion sites in L cells expressing cadherins, These results indicate that the 4F2 heavy chain is associated covalently with an amino acid transporter and controls the cell surface expression as well as the membrane topology of the 4F2 heterodimer. Although 4F2 heavy and light chains are expressed coordinately in most tissues, the light chain is barely detected by the antibody in kidney and intestine, despite the presence of heavy chain in a complex form. The results predict the presence of multiple 4F2 light chains.	Kyoto Univ, Fac Med, Dept Immunol & Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Physiol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Minato, N (corresponding author), Kyoto Univ, Fac Med, Dept Immunol & Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.	minato@med.kyoto-u.ac.jp	IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Broer A, 1998, BIOCHEM J, V333, P549, DOI 10.1042/bj3330549; Chillaron J, 1997, J BIOL CHEM, V272, P9543; CHOW DC, 1995, J EXP BIOL, V198, P1; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; HAYNES BF, 1981, J IMMUNOL, V127, P347; HEMLER ME, 1982, J IMMUNOL, V129, P623; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KUBOTA H, 1994, INT IMMUNOL, V6, P1323, DOI 10.1093/intimm/6.9.1323; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; LUMADUE JA, 1987, P NATL ACAD SCI USA, V84, P9204, DOI 10.1073/pnas.84.24.9204; MICHALAK M, 1986, J BIOL CHEM, V261, P92; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; Palacin M, 1998, CURR OPIN CELL BIOL, V10, P455, DOI 10.1016/S0955-0674(98)80058-6; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YAGITA H, 1986, CANCER RES, V46, P1478	29	232	241	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3009	3016		10.1074/jbc.274.5.3009	http://dx.doi.org/10.1074/jbc.274.5.3009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915839	hybrid			2022-12-25	WOS:000078319500057
J	Malumbres, M; Perez de Castro, I; Santos, J; Piqueras, JF; Pellicer, A				Malumbres, M; Perez de Castro, I; Santos, J; Piqueras, JF; Pellicer, A			Hypermethylation of the cell cycle inhibitor p15(INK4b) 3 '-untranslated region interferes with its transcriptional regulation in primary lymphomas	ONCOGENE			English	Article						DNA methylation; p15(INK4b) CDK inhibitor; 3'-UTR; T-cell; lymphoma	DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR; DNA METHYLATION; TGF-BETA; P16(INK4) GENE; HUMAN CANCERS; EXPRESSION; INACTIVATION; MOUSE; P15	The cyclin-dependent kinase inhibitor p15(INK4h) has been shown to he involved in human and rodent tumors and seems to act as a tumor suppressor gene in hematological malignancies, Alterations of this gene in tumors include mainly homozygous deletions and hypermethylation of the CpG island in the promoter region. In this work, we describe a new area sensitive to methylation in the 3' untranslated region (UTR) of the murine p15(INK4b) gene, This region shows different levels of methylation depending on the tissues, being relatively highly methylated in brain and gut, and weakly methylated in liver, spleen or thymus, DNA methylation and expression is similar in both maternal and paternal alleles indicating no imprinting effect. Although methylation of the p15(INK4h) 3'-UTR is low in normal thymus, increased levels (up to 100%) of specific methylation in this region are found in up to 30% of radiation- or carcinogen-induced thymic Lymphomas, correlating with decreased gene expression. Hypermethylation of the p15(INK4b) 3'-UTR frequently occurs in tumors with loss of heterozygosity (LOH) but without methylation of the promoter CpG island or intragenic mutations. Furthermore, in vitro CpG methylation of the 3'-UTR produces reduced levels of a luciferase reporter in cultured cells, Methylation of two CpG sites in a 120 bp region is sufficient to interfere with transcription of the reporter gene. These data suggest that although the levels of p15(INK4h) in normal tissues can be mainly determined by promoter regulatory elements, strong hypermethylation of the 3'-UTR can interfere with transcription, Thus, hypermethylation of the 3'-UTR may explain the lack of p15(INK4b) gene expression in a subset of tumors with no promoter methylation and could be a new alternative mechanism for tumor suppressor gene inactivation in tumorigenesis.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	New York University; New York University; Autonomous University of Madrid	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		Holt, Janet E/B-2415-2013; Malumbres, Marcos/E-8834-2011; de Castro, Ignacio Pérez/A-6260-2012; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Santos, Javier/ABF-5755-2021	Malumbres, Marcos/0000-0002-0829-6315; de Castro, Ignacio Pérez/0000-0002-8822-8274; Santos, Javier/0000-0002-4168-6251; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA050434, R01CA036327, R37CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50434, CA 36327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschmied J, 1997, BIOTECHNIQUES, V23, P436, DOI 10.2144/97233bm19; Batova A, 1997, CANCER RES, V57, P832; BATTISTUZZI G, 1985, P NATL ACAD SCI USA, V82, P1465, DOI 10.1073/pnas.82.5.1465; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORRELLO MG, 1992, ONCOGENE, V7, P269; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cost GJ, 1997, CANCER RES, V57, P926; GLENDENING JM, 1995, CANCER RES, V55, P5531; GRANA X, 1995, ONCOGENE, V11, P211; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; HIRAMA T, 1995, BLOOD, V86, P841; Iavarone A, 1997, NATURE, V387, P417; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kay PH, 1997, GENE, V184, P45, DOI 10.1016/S0378-1119(96)00572-0; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li XS, 1996, CANCER RES, V56, P5055; LOIS AF, 1995, CANCER RES, V55, P4010; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Malumbres M, 1998, MAMM GENOME, V9, P183, DOI 10.1007/s003359900722; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MULLINS LJ, 1987, MOL CELL BIOL, V7, P3916, DOI 10.1128/MCB.7.11.3916; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, ONCOGENE, V11, P635; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RIGGS AD, 1983, ADV CANCER RES, V40, P1, DOI 10.1016/S0065-230X(08)60678-8; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Rishi AK, 1997, CANCER RES, V57, P5129; Santos J, 1996, ONCOGENE, V12, P669; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SHANDU C, 1997, MOL CELL BIOL, V17, P2458; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tsubari M, 1997, CANCER RES, V57, P2966; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	52	43	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					385	396		10.1038/sj.onc.1202299	http://dx.doi.org/10.1038/sj.onc.1202299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927195				2022-12-25	WOS:000078166500011
J	Burden, DA; Osheroff, N				Burden, DA; Osheroff, N			In vitro evolution of preferred topoisomerase II DNA cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP ATTACHMENT SITES; EUKARYOTIC TOPOISOMERASE; DROSOPHILA-MELANOGASTER; RELIGATION REACTION; SEQUENCE; BINDING; ENZYMES; MECHANISM; REGIONS; PROTEIN	Topoisomerase II is an essential enzyme that is the target for several clinically important anticancer drugs. Although this enzyme must create transient double-stranded breaks in the genetic material in order to carry out its indispensable DNA strand passage reaction, the factors that underlie its nucleotide cleavage specificity remain an enigma. Therefore, to address the critical issue of enzyme specificity, a modified systematic evolution of ligands by exponential enrichment (SELEX) protocol was employed to select/evolve DNA sequences that were preferentially cleaved by Drosophila melanogaster topoisomerase II. Levels of DNA scission rose substantially (from 3 to 20%) over 20 rounds of SELEX, In vitro selection/evolution converged on an alternating purine/pyrmidine sequence that was highly AT-rich (TATATATACATATATATA). The preference for this sequence was more pronounced for Drosophila topoisomerase II over other species and was increased in the presence of DNA cleavage-enhancing anticancer drugs. Enhanced cleavage appeared to be based on higher rates of DNA scission rather than increased binding affinity or decreased religation rates. The preferred sequence for topoisomerase II-mediated DNA cleavage is dramatically overrepresented (similar to 10,000-fold) in the euchromatic genome of D. melanogaster, implying that it may be a site for the physiological action of this enzyme.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; ANDERSON HJ, 1992, CELL BIOL INT REP, V16, P717, DOI 10.1016/S0309-1651(05)80016-5; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BLASQUEZ VC, 1989, GENOME, V31, P503, DOI 10.1139/g89-098; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Capranico G, 1996, Cancer Chemother Biol Response Modif, V16, P68; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cornarotti M, 1996, MOL PHARMACOL, V50, P1463; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEE MP, 1989, J BIOL CHEM, V264, P21779; LINDSLEY JE, 1995, FASEB J, V9, pA1392; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1983, J BIOL CHEM, V258, P5365; LUND K, 1990, J BIOL CHEM, V265, P13856; Malonne H, 1997, ANTI-CANCER DRUG, V8, P811, DOI 10.1097/00001813-199710000-00001; Miassod R, 1997, NUCLEIC ACIDS RES, V25, P2041, DOI 10.1093/nar/25.11.2041; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; RAZIN SV, 1991, BIOCHEM BIOPH RES CO, V177, P265, DOI 10.1016/0006-291X(91)91977-K; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SPITZNER JR, 1990, NUCLEIC ACIDS RES, V18, P1, DOI 10.1093/nar/18.1.1; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Yarovaya OV, 1998, MOL BIOL+, V32, P36; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	58	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5227	5235		10.1074/jbc.274.8.5227	http://dx.doi.org/10.1074/jbc.274.8.5227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988773	hybrid			2022-12-25	WOS:000078698200098
J	Campos-Caro, A; Carrasco-Serrano, C; Valor, LM; Viniegra, S; Ballesta, JJ; Criado, M				Campos-Caro, A; Carrasco-Serrano, C; Valor, LM; Viniegra, S; Ballesta, JJ; Criado, M			Multiple functional Sp1 domains in the minimal promoter region of the neuronal nicotinic receptor alpha 5 subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; BOVINE CHROMAFFIN CELLS; ACETYLCHOLINE-RECEPTOR; TRANSCRIPTIONAL REGULATION; REPRESSES TRANSCRIPTION; POU DOMAIN; EXPRESSION; BETA-4; DNA; ACTIVATION	The alpha 5 subunit is a component of the neuronal nicotinic acetylcholine receptors, which are probably involved in the activation step of the catecholamine secretion process in bovine adrenomedullary chromaffin cells. The promoter of the gene coding for this subunit was isolated, and its proximal region was characterized, revealing several GC boxes located close to the site of transcription initiation (from -111 to -40). Deletion analysis and transient transfections showed that a 266-base pair region (-111 to +155) gave rise to similar to 77 and 100% of the maximal transcriptional activity observed in chromaffin and SHSY-5Y neuroblastoma cells, respectively. Site-directed mutagenesis of five different GC motifs indicated that all of them contribute to the activity of the alpha 5 gene, but in a different way, depending on the type of transfected cell. Thus, in SHSY-5Y cells, alteration of the most promoter-proximal of the GC boxes decreased alpha 5 promoter activity by similar to 50%, whereas single mutations of the other GC boxes had no effect. In chromaffin cells, by contrast, modification of any of the GC boxes produced a similar decrease in promoter activity (50-69%). In both cell types, however, activity was almost abolished when four GC boxes were suppressed simultaneously. Electrophoretic mobility shift assays using nuclear extracts from either chromaffin or SHSY-5Y cells showed the specific binding of Sp1 protein to fragment -111 to -27, Binding of Sp1 to the GC boxes was also demonstrated by DNase I footprint analysis. This study suggests that the general transcription factor Sp1 plays a dominant role in alpha 5 subunit expression, as has also been demonstrated previously for alpha 3 and beta 4 subunits, Since these three subunits have their genes tightly clustered and are expressed in chromaffin cells, probably as components of the same receptor subtype, we propose that Sp1 constitutes the key factor of a regulatory mechanism common to the three subunits.	Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain; Univ Miguel Hernandez, Dept Pharmacol, Alicante 03550, Spain; Univ Miguel Hernandez, Inst Neurosci, Alicante 03550, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche	Criado, M (corresponding author), Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain.	Manuel.Criado@umh.es	Criado, Manuel/K-5109-2014; Viniegra, Salvador/K-5063-2014; Campos-Caro, Antonio/T-2807-2019; Valor, Luis/ABG-1754-2020	Criado, Manuel/0000-0002-3953-0346; Viniegra, Salvador/0000-0002-3892-8563; Campos-Caro, Antonio/0000-0001-8532-2153; Valor, Luis M./0000-0002-1229-0565				BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOULTER J, 1990, J BIOL CHEM, V265, P4472; CamposCaro A, 1997, J NEUROCHEM, V68, P488; Carrasco-Serrano C, 1998, J BIOL CHEM, V273, P20021, DOI 10.1074/jbc.273.32.20021; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; GANDIA L, 1991, BRIT J PHARMACOL, V103, P1073, DOI 10.1111/j.1476-5381.1991.tb12302.x; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOWARD MJ, 1995, DEV BIOL, V170, P479, DOI 10.1006/dbio.1995.1231; IKEDA K, 1993, GENE, V136, P341; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; McDonough J, 1997, J NEUROSCI, V17, P2273; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SIF S, 1993, ONCOGENE, V8, P2501; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Yang XD, 1997, J NEUROBIOL, V32, P311, DOI 10.1002/(SICI)1097-4695(199703)32:3<311::AID-NEU5>3.0.CO;2-A	48	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4693	4701		10.1074/jbc.274.8.4693	http://dx.doi.org/10.1074/jbc.274.8.4693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988706	hybrid			2022-12-25	WOS:000078698200031
J	Haas, H; Zadra, I; Stoffler, G; Angermayr, K				Haas, H; Zadra, I; Stoffler, G; Angermayr, K			The Aspergillus nidulans GATA factor SREA is involved in regulation of siderophore biosynthesis and control of iron uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ENCODING GENE; USTILAGO-MAYDIS; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; ZINC-FINGER; PENICILLIUM-CHRYSOGENUM; EXPRESSION SIGNALS; MOLECULAR ANALYSIS; DNA-BINDING; URBS1	A gene encoding a new GATA factor from Aspergillus nidulans, sreA, was isolated and characterized. SREA displays homology to two fungal regulators of siderophore biosynthesis: about 30% overall identity to SRE from Neurospora crassa and about 50% identity to URBS1 from Ustilago maydis over a stretch of 200 amino acid residues containing two GATA-type zinc finger motifs and a cysteine-rich region. This putative DNA binding domain, expressed as a fusion protein in Escherichia coli, specifically binds to GATA sequence motifs, Deletion of sreA results in derepression of L-ornithine-N(5)-oxygenase activity and consequently in derepression of the biosynthesis of the hydroxamate siderophore N,N',N "-triacetyl fusarinine under sufficient iron supply in A. nidulans, Transcription of sreA is confined to high iron conditions, underscoring the function of SREA as a repressor of siderophore biosynthesis under sufficient iron supply. Nevertheless, overexpression of sreA does not result in repression of siderophore synthesis under low iron conditions, suggesting additional mechanisms involved in this regulatory circuit. Consistent with increased sensitivity to the iron-activated antibiotics phleomycin and streptonigrin, the sreA deletion mutant displays increased accumulation of (59)Fe. These results demonstrate that SREA plays a central role in iron uptake in addition to siderophore biosynthesis.	Univ Innsbruck, Sch Med, Dept Microbiol, A-6020 Innsbruck, Austria	University of Innsbruck	Haas, H (corresponding author), Univ Innsbruck, Sch Med, Dept Microbiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	hubertus.haas@uibk.ac.at						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; An ZQ, 1997, P NATL ACAD SCI USA, V94, P5882, DOI 10.1073/pnas.94.11.5882; An ZQ, 1997, EMBO J, V16, P1742, DOI 10.1093/emboj/16.7.1742; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; CHARLANG G, 1982, J BACTERIOL, V150, P785, DOI 10.1128/JB.150.2.785-787.1982; de Souza CC, 1998, CURR GENET, V33, P60, DOI 10.1007/s002940050309; Feng B, 1998, MOL CELL BIOL, V18, P3983, DOI 10.1128/MCB.18.7.3983; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; Haas H, 1997, J BIOL CHEM, V272, P22576, DOI 10.1074/jbc.272.36.22576; Hoe KL, 1996, BIOCHEM MOL BIOL INT, V39, P127; Huschka H G, 1989, Biol Met, V2, P108, DOI 10.1007/BF01129209; Konetschny-Rapp S, 1988, Biol Met, V1, P9, DOI 10.1007/BF01128012; Leong SA, 1998, MET IONS BIOL SYST, V35, P147; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MOORE CW, 1994, ANTIMICROB AGENTS CH, V38, P1615, DOI 10.1128/AAC.38.7.1615; MOORE CW, 1989, CANCER RES, V49, P6935; NILIUS AM, 1997, FUNGAL DIS, P401; PAYNE SM, 1994, METHOD ENZYMOL, V235, P329; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PUNT PJ, 1991, J BIOTECHNOL, V17, P19, DOI 10.1016/0168-1656(91)90024-P; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Sambrook J., 2002, MOL CLONING LAB MANU; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; UPSHALL A, 1986, MOL GEN GENET, V204, P349, DOI 10.1007/BF00425521; VANGORCOM RFM, 1986, GENE, V48, P211, DOI 10.1016/0378-1119(86)90079-X; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; WHITE JR, 1982, BIOCHEM BIOPH RES CO, V106, P407, DOI 10.1016/0006-291X(82)91125-1; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470; ZHOU L, 1997, MOL GEN GENET, V259, P532	39	133	141	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4613	4619		10.1074/jbc.274.8.4613	http://dx.doi.org/10.1074/jbc.274.8.4613			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988696	hybrid			2022-12-25	WOS:000078698200021
J	Iozzo, RV; Moscatello, DK; McQuillan, DJ; Eichstetter, I				Iozzo, RV; Moscatello, DK; McQuillan, DJ; Eichstetter, I			Decorin is a biological ligand for the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; SQUAMOUS CARCINOMA-CELLS; MONOCLONAL-ANTIBODIES; COLLAGEN FIBRILLOGENESIS; GENE-EXPRESSION; PURIFICATION; INHIBITION; P21; SUPPRESSION; ACTIVATION	Ectopic expression of decorin induces profound cytostatic effects in transformed cells with diverse histogenetic backgrounds. The mechanism of action has only recently begun to be elucidated. Exogenous decorin activates the epidermal growth factor (EGF) receptor, thereby triggering a signaling cascade that leads to phosphorylation of mitogen-activated protein (MAP) kinase, induction of p21, and growth suppression. In this study we demonstrate a direct interaction of decorin with the EGF receptor. Binding of decorin induces dimerization of the EGF receptor and rapid and sustained phosphorylation of MAP kinase in squamous carcinoma cells. In a cell-free system, decorin induces autophosphorylation of purified EGF receptor by activating the receptor tyrosine kinase and can also act as a substrate for the EGF receptor kinase itself. Using radioligand binding assays we show that both immobilized and soluble decorin bind to the EGF receptor ectodomain or to purified EGF receptor. The binding is mediated by the protein core and has relatively low affinity (K-d similar to 87 nM). Thus, decorin should be considered as a novel biological ligand for the EGF receptor, an interaction that could regulate cell growth during remodeling and cancer growth.	Thomas Jefferson Univ, JAH, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	Jefferson University; Jefferson University; Texas A&M University System	Iozzo, RV (corresponding author), Thomas Jefferson Univ, JAH, Dept Pathol Anat & Cell Biol, Rm 249,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NIAMS NIH HHS [R01 AR42826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; FAN Z, 1993, J BIOL CHEM, V268, P21073; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jakus J, 1996, ONCOGENE, V12, P2369; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WEBER W, 1984, J BIOL CHEM, V259, P4631; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; YARDEN Y, 1985, J BIOL CHEM, V260, P315	30	308	318	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4489	4492		10.1074/jbc.274.8.4489	http://dx.doi.org/10.1074/jbc.274.8.4489			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988678	hybrid			2022-12-25	WOS:000078698200003
J	Krieger, J; Schmitt, A; Lobell, D; Gudermann, T; Schultz, G; Breer, H; Boekhoff, I				Krieger, J; Schmitt, A; Lobell, D; Gudermann, T; Schultz, G; Breer, H; Boekhoff, I			Selective activation of G protein subtypes in the vomeronasal organ upon stimulation with urine-derived compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; ADENYLYL-CYCLASE; GLUTAMATE RECEPTORS; MULTIGENE FAMILY; BINDING-PROTEINS; FEMALE MICE; RAT; MAMMALS; SYSTEM; ORGANIZATION	Chemosensory neurons in the vomeronasal organ (VNO) detect pheromones related to social and reproductive behavior in most terrestrial vertebrates. Current evidence indicate that the chemoelectrical transduction process is mediated by G protein-coupled second messenger cascades. In the present study, attempts were made to identify the G protein subtypes which are activated upon stimulation with urinary pheromonal components. G protein-specific antibodies were employed to interfere specifically with inositol 1,3,4-trisphosphate formation induced by urinary stimuli and to immunoprecipitate G alpha-subunits, activation dependently labeled with [alpha-P-32]GTP azidoanilide. The results of both experimental approaches indicate that stimulation of female VNO membrane preparations with male urine samples induces activation of G(i) as well as G(o) subtypes, Experiments using different fractions of urine revealed that upon stimulation with lipophilic volatile odorants, only G(i) proteins were activated, whereas G(o) activation was elicited by alpha(2u)-globulin, a major urinary protein, which is a member of the lipocalin superfamily, Since each G protein subtype is stereotypically coexpressed with one of the two structurally different candidate pheromone receptors (V1R and V2R), the results provide the first experimental evidence that V1Rs coexpressed with G(i) may be activated by lipophilic probably volatile odorants, whereas V2Rs coexpressed with G(o) seem to be specialized to interact with pheromonal components of proteinaceous nature.	Univ Stuttgart Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	University Hohenheim; Free University of Berlin	Boekhoff, I (corresponding author), Univ Stuttgart Hohenheim, Inst Physiol, Garbenstr 30, D-70593 Stuttgart, Germany.	boekhoff@uni-hohenheim.de						BACCHINI A, 1992, EXPERIENTIA, V48, P419, DOI 10.1007/BF01923448; Bargmann CI, 1997, CELL, V90, P585, DOI 10.1016/S0092-8674(00)80518-8; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berghard A, 1996, J NEUROSCI, V16, P909; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CLARK AJ, 1985, EMBO J, V4, P3159, DOI 10.1002/j.1460-2075.1985.tb04059.x; CLISSOLD PM, 1984, BIOCHEM GENET, V22, P379, DOI 10.1007/BF00484236; DIHN BL, 1965, J IMMUNOL, V95, P774; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Flower DR, 1996, BIOCHEM J, V318, P1; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOLMQUIST L, 1990, J BIOCHEM BIOPH METH, V20, P303, DOI 10.1016/0165-022X(90)90092-Q; Inamura K, 1997, CHEM SENSES, V22, P93, DOI 10.1093/chemse/22.1.93; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kroner C, 1996, NEUROREPORT, V7, P2989, DOI 10.1097/00001756-199611250-00038; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Lobel D, 1998, EUR J BIOCHEM, V254, P318, DOI 10.1046/j.1432-1327.1998.2540318.x; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; MENZIES RA, 1992, PHYSIOL BEHAV, V52, P741, DOI 10.1016/0031-9384(92)90408-T; MUCIGNATCARETTA C, 1995, J PHYSIOL-LONDON, V486, P517, DOI 10.1113/jphysiol.1995.sp020830; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NOVOTNY M, 1985, P NATL ACAD SCI USA, V82, P2059, DOI 10.1073/pnas.82.7.2059; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P268; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PELOSI P, 1994, CRIT REV BIOCHEM MOL, V29, P199, DOI 10.3109/10409239409086801; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schandar M, 1998, J BIOL CHEM, V273, P16669, DOI 10.1074/jbc.273.27.16669; SHOJI T, 1991, J GEN PHYSIOL, V98, P909, DOI 10.1085/jgp.98.5.909; SINGER AG, 1990, CHEM SENSES, V15, P199, DOI 10.1093/chemse/15.2.199; VANDENBERGH JG, 1975, J REPROD FERTIL, V43, P515, DOI 10.1530/jrf.0.0430515; Wekesa KS, 1997, ENDOCRINOLOGY, V138, P3497, DOI 10.1210/en.138.8.3497; WYSOCKI CJ, 1991, NEUROBIOLOGY TASTE S, P125; Zhou AW, 1997, NEUROREPORT, V8, P2173, DOI 10.1097/00001756-199707070-00017	45	134	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4655	4662		10.1074/jbc.274.8.4655	http://dx.doi.org/10.1074/jbc.274.8.4655			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988702	hybrid			2022-12-25	WOS:000078698200027
J	Wagstaff, MJD; Collaco-Moraes, Y; Smith, J; de Belleroche, JS; Coffin, RS; Latchman, DS				Wagstaff, MJD; Collaco-Moraes, Y; Smith, J; de Belleroche, JS; Coffin, RS; Latchman, DS			Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SYSTEMIC LUPUS-ERYTHEMATOSUS; THERMAL-STRESS; CULTURED NEURONS; HYPERTHERMIA PROTECTS; ACTIN POLYMERIZATION; GANGLION NEURONS; MAMMALIAN-CELLS; MESSENGER-RNAS; EXPRESSION	Overexpression of the gene encoding the 70-kDa heat shock protein (hsp70) has previously been shown to protect neuronal cells against subsequent thermal or ischemic stress. It has no protective effect, however, against stimuli that induce apoptosis, although a mild heat shock (sufficient to induce hsp synthesis) does have a protective effect against apoptosis. We have prepared disabled herpes simplex virus-based vectors that are able to produce high level expression of individual hsps in infected neuronal cells without damaging effects. We have used these vectors to show that hsp27 and hsp56 (which have never previously been overexpressed in neuronal cells) as well as hsp70 can protect dorsal root ganglion neurons from thermal or ischemic stress. In contrast, only hsp27 can protect dorsal root ganglion neurons from apoptosis induced by nerve growth factor withdrawal, and hsp27 also protects the ND7 neuronal cell line from retinoic acid-induced apoptosis. However, hsp70 showed no protective effect against apoptosis in contrast to its anti-apoptotic effect in non-neuronal cell types. These results thus identify hsp27 as a novel neuroprotective factor and show that it can mediate this effect when delivered via a high efficiency viral vector.	UCL, Sch Med, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Neuromuscular Dis, London W6 8RF, England	University of London; University College London; UCL Medical School; Imperial College London	Latchman, DS (corresponding author), UCL, Sch Med, Windeyer Inst Med Sci, Dept Mol Pathol, Windeyer Bldg,Cleveland St, London W1P 6DB, England.	d.latchman@ucl.ac.uk						Amin V, 1996, NEUROSCI LETT, V206, P45, DOI 10.1016/0304-3940(96)12421-6; AMIN V, 1995, NEUROSCI LETT, V200, P85, DOI 10.1016/0304-3940(95)12074-E; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; BANSAL GS, 1991, EXP CELL RES, V195, P303, DOI 10.1016/0014-4827(91)90377-7; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Coffin RS, 1996, GENE THER, V3, P886; COFFIN RS, 1995, GENETIC MANIPULATION, P99; Davies A. M., 1995, NEURAL CELL CULTURE, P153; DHILLON VB, 1993, ANN RHEUM DIS, V52, P436, DOI 10.1136/ard.52.6.436; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; FERRINI U, 1984, INT J CANCER, V34, P651, DOI 10.1002/ijc.2910340511; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; Fink SL, 1997, J NEUROCHEM, V68, P961; Fraefel C, 1996, J VIROL, V70, P7190, DOI 10.1128/JVI.70.10.7190-7197.1996; GAMSTROP I, 1984, PROGR SPINAL MUSCULA; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; HEADS RJ, 1994, J MOL CELL CARDIOL, V26, P695, DOI 10.1006/jmcc.1994.1084; Howard MK, 1998, GENE THER, V5, P1137, DOI 10.1038/sj.gt.3300700; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; Howard MK, 1997, J MOL NEUROSCI, V9, P65; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LATCHMAN DS, 1991, J ROY COLL PHYS LOND, V25, P295; LAVOIE J, 1990, NUCLEIC ACIDS RES, V18, P1637, DOI 10.1093/nar/18.6.1637; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MILLER EK, 1991, J NEUROCHEM, V56, P2060, DOI 10.1111/j.1471-4159.1991.tb03467.x; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; SACKS WR, 1985, J VIROL, V55, P796, DOI 10.1128/JVI.55.3.796-805.1985; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; TWOMEY BM, 1993, CLIN EXP IMMUNOL, V93, P178; TWOMEY BM, 1993, J AUTOIMMUN, V6, P495, DOI 10.1006/jaut.1993.1041; UNEY JB, 1993, FEBS LETT, V334, P313, DOI 10.1016/0014-5793(93)80701-U; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; WATSON K, 1984, FEBS LETT, V169, P267; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; WIEDLITZ RB, 1986, MOL CELL BIOL, V6, P1088; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wyatt S, 1996, MOL BRAIN RES, V39, P52, DOI 10.1016/0169-328X(95)00352-S	54	189	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5061	5069		10.1074/jbc.274.8.5061	http://dx.doi.org/10.1074/jbc.274.8.5061			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988753	hybrid			2022-12-25	WOS:000078698200078
J	Millar, DS; Ow, KK; Paul, CL; Russell, PJ; Molloy, PL; Clark, SJ				Millar, DS; Ow, KK; Paul, CL; Russell, PJ; Molloy, PL; Clark, SJ			Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer	ONCOGENE			English	Article						DNA methylation; bisulphite genomic sequencing; GSTP1; prostate cancer	DNA METHYLATION; EXPRESSION; CELLS; PATTERNS; PROMOTER; TUMORS; OVEREXPRESSION; CARCINOGENESIS; CARCINOMAS; SEQUENCES	Glutathione-S-Transferases (GSTs) comprise a family of isoenzymes that provide protection to mammalian cells against electrophilic metabolites of carcinogens and reactive oxygen species. Previous studies have shown that the CpG-rich promoter region of the pi-class gene GSTP1 is methylated at single restriction sites in the majority of prostate cancers, In order to understand the nature of abnormal methylation of the GSTP1 gene in prostate cancer we undertook a detailed analysis of methylation at 131 CpG sites spanning the promoter and body of the gene. Our results show that DNA methylation is not confined to specific CpG sites in the promoter region of the GSTP1 gene but is extensive throughout the CpG island in prostate cancer cells. Furthermore we found that both alleles are abnormally methylated in this region. In normal prostate tissue, the entire CpG island was unmethylated, but extensive methylation was found outside the island in the body of the gene. Loss of GSTP1 expression correlated with DNA methylation of the CpG island in both prostate cancer cell lines and cancer tissues whereas methylation outside the CpG island in normal prostate tissue appeared to have no effect on gene expression.	CSIRO, Div Mol Sci, Sydney Lab, N Ryde, NSW 1670, Australia; Royal Prince Alfred Hosp, Kanematsu Labs, Camperdown, NSW 2050, Australia; Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney	Clark, SJ (corresponding author), CSIRO, Div Mol Sci, Sydney Lab, POB 184, N Ryde, NSW 1670, Australia.		Clark, Susan J/B-2272-2008; Molloy, Peter L/H-7931-2013; Russell, Pamela J/G-1685-2010; Russell, Pamela/O-8504-2019; Clark, Susan J/U-7365-2019	Clark, Susan J/0000-0001-5925-5030; Molloy, Peter L/0000-0002-7788-3417; Russell, Pamela J/0000-0002-3995-1239; Clark, Susan J/0000-0001-5925-5030				BATIST G, 1986, J BIOL CHEM, V261, P5544; Baylin SB, 1998, ADV CANCER RES, V72, P141; Clark S. J., 1997, P151; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARK SJ, 1995, DNA NUCLEOPROTEIN ST, P103; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; ISAACS WB, 1995, CANCER SURV, V23, P19; ISHIOKA C, 1991, CANCER, V67, P2560, DOI 10.1002/1097-0142(19910515)67:10<2560::AID-CNCR2820671028>3.0.CO;2-M; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; MULDER TPJ, 1995, CANCER RES, V55, P2696; Paul CL, 1996, BIOTECHNIQUES, V21, P126; PETERS WHM, 1990, CARCINOGENESIS, V11, P1593, DOI 10.1093/carcin/11.9.1593; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Schmutte C, 1996, CANCER RES, V56, P2375; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stirzaker C, 1997, CANCER RES, V57, P2229; Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Wang X, 1997, CLIN CANCER RES, V3, P111; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Warnecke PM, 1998, DEV GENET, V22, P111, DOI 10.1002/(SICI)1520-6408(1998)22:2&lt;111::AID-DVG1&gt;3.0.CO;2-9	38	177	196	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1313	1324		10.1038/sj.onc.1202415	http://dx.doi.org/10.1038/sj.onc.1202415			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022813				2022-12-25	WOS:000078510900007
J	Chen, YG; Massague, J				Chen, YG; Massague, J			Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; I RECEPTORS; MAD PROTEINS; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; MEDIATOR SMAD1; ACTIVIN; KINASE; DROSOPHILA; IDENTIFICATION	Two structural elements, the L45 loop on the kinase domain of the transforming growth factor-beta (TGF-beta) family type I receptors and the L3 loop on the MH2 domain of Smad proteins, determine the specificity of the interactions between these receptors and Smad proteins. The L45 sequence of the TGF-beta type I receptor (T beta R-I) specifies Smad2 interaction, whereas the related L45 sequence of the bone morphogenetic protein (BMP) type I receptor (BMPR-I) specifies Smad1 interactions. Here we report that members of a third receptor group, which includes ALK1 and ALK2 from vertebrates and Saxophone from Drosophila, specifically phosphorylate and activate Smad1 even though the L45 sequence of this group is very divergent from that of BMPR-I. We investigated the structural elements that determine the specific recognition of Smad1 by ALK1 and ALK2, In addition to the receptor L45 loop and the Smad1 L3 loop, the specificity of this recognition requires the alpha-helix 1 of Smad1, The alpha-helix 1 is a conserved structural element located in the vicinity of the L3 loop on the surface of the Smad MH2 domain. Thus, Smad1 recognizes two distinct groups of receptors, the BMPR-I group and the ALK1 group, through different L45 sequences on the receptor kinase domain and a differential use of two surface structures on the Smad1 MH2 domain.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, 1275 York Ave,Box 116, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armes NA, 1997, DEVELOPMENT, V124, P3797; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Candia AF, 1997, DEVELOPMENT, V124, P4467; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Das P, 1998, DEVELOPMENT, V125, P1519; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hudson JB, 1998, DEVELOPMENT, V125, P1407; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	41	163	180	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3672	3677		10.1074/jbc.274.6.3672	http://dx.doi.org/10.1074/jbc.274.6.3672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920917	hybrid			2022-12-25	WOS:000078428200057
J	Hsu, W; Zeng, L; Costantini, F				Hsu, W; Zeng, L; Costantini, F			Identification of a domain of axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE FUSED LOCUS; BETA-CATENIN; XENOPUS EMBRYOS; SIGNAL-TRANSDUCTION; CELL-GROWTH; MAP KINASE; PATHWAY; ACTIVATION; DROSOPHILA; GENE	Axin is a negative regulator of embryonic axis formation in vertebrates, which acts through a Wnt signal transduction pathway involving the serine/threonine kinase GSK-3 and beta-catenin. Axin has been shown to have distinct binding sites for GSK-3 and beta-catenin and to promote the phosphorylation of beta-catenin and its consequent degradation. This provides an explanation for the ability of Axin to inhibit signaling through beta-catenin, In addition, a more N-terminal region of Axin binds to adenomatous polyposis coli (APC), a tumor suppressor protein that also regulates levels of beta-catenin. Here, we report the results of a yeast two-hybrid screen for proteins that interact with the C-terminal third of Axin, a region in which no binding sites for other proteins have previously been identified, We found that Axin can bind to the catalytic subunit of the serine/threonine protein phosphatase 2A through a domain between amino acids 632 and 836. This interaction was confirmed by in vitro binding studies as well as by co-immunoprecipitation of epitope-tagged proteins expressed in cultured cells. Our results suggest that protein phosphatase 2A might interact with the Axin.APC.GSK-3.beta-catenin complex, where it could modulate the effect of GSK-3 on beta-catenin or other proteins in the complex. We also identified a region of Axin that may allow it to form dimers or multimers, Through two-hybrid and co-immunoprecipitation studies, we demonstrated that the C-terminal 100 amino acids of Axin could bind to the same region as other Axin molecules.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Costantini, F (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.	fdc3@columbia.edu	Hsu, Wei/ABG-6856-2021	Hsu, Wei/0000-0001-6738-6030				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carnac G, 1996, DEVELOPMENT, V122, P3055; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fagotto F, 1997, DEVELOPMENT, V124, P453; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; GREENSPAN RJ, 1986, P NATL ACAD SCI USA, V83, P4413, DOI 10.1073/pnas.83.12.4413; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; James P, 1996, GENETICS, V144, P1425; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; MAYERJAEKEL RE, 1995, SEMIN CANCER BIOL, V6, P249, DOI 10.1006/scbi.1995.0032; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; PERRY WL, 1995, GENETICS, V141, P321; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Reed SC, 1937, GENETICS, V22, P1; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tilghman SM, 1996, GENOME RES, V6, P773, DOI 10.1101/gr.6.9.773; Vasicek TJ, 1997, GENETICS, V147, P777; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	61	209	217	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3439	3445		10.1074/jbc.274.6.3439	http://dx.doi.org/10.1074/jbc.274.6.3439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920888	hybrid			2022-12-25	WOS:000078428200028
J	Hughes, JMX; Ptushkina, M; Karim, MM; Koloteva, N; von der Haar, T; McCarthy, JEG				Hughes, JMX; Ptushkina, M; Karim, MM; Koloteva, N; von der Haar, T; McCarthy, JEG			Translational repression by human 4E-BP1 in yeast specifically requires human eIF4E as target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4E; CAP-DEPENDENT TRANSLATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; BINDING; SYSTEM; CELL; PHOSPHORYLATION; RIBOSOMES; PROTEINS	4E-binding proteins (4E-BPs) are believed to have important regulatory functions in controlling the rate of translation initiation in mammalian cells. They do so by binding to the mRNA cap-binding protein, eIF4E, thereby inhibiting formation of the cap-binding complex, a process essential for cap-dependent translation initiation. We have reproduced the translation-repressive function of human 4E-BP1 in yeast and find its activity to be dependent on substitution of human eIF4E for its yeast counterpart. Translation initiation and growth are inhibited when human 4E-BP1 is expressed in a strain with the human eIF4E substitution, but not in an unmodified strain. We have compared the relative affinities of human 4E-BP1 for human and yeast eIF4E, both in vitro using an m(7)GTP cap-binding assay and in vivo using a yeast two-hybrid assay, and find that the affinity of human 4E-BP1 for human eIF4E is markedly greater than for yeast eIF4E. Thus yeast eIF4E lacks structural features required for binding to human 4E-BP1. These results therefore demonstrate that the features of eIF4E required for binding to 4E-BP1 are distinct from those required for cap-complex assembly.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, Manchester M60 1QD, Lancs, England	University of Manchester	Hughes, JMX (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Posttranscript Control Grp, POB 88, Manchester M60 1QD, Lancs, England.		Karim, Muhammad Manjurul/ABC-6229-2020	Karim, Muhammad Manjurul/0000-0003-0476-8239				Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; EDERY I, 1987, TRANSLATIONAL REGULA, P335; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; LANG V, 1994, J BIOL CHEM, V269, P6117; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SCHNEPPE B, 1994, GENE, V143, P201, DOI 10.1016/0378-1119(94)90097-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	27	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3261	3264		10.1074/jbc.274.6.3261	http://dx.doi.org/10.1074/jbc.274.6.3261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920863	hybrid			2022-12-25	WOS:000078428200003
J	Kisselev, AF; Akopian, TN; Woo, KM; Goldberg, AL				Kisselev, AF; Akopian, TN; Woo, KM; Goldberg, AL			The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes - Implications for understanding the degradative mechanism and antigen presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR-HISTOCOMPATIBILITY-COMPLEX; ACTIVE-SITE FORMATION; THERMOPLASMA-ACIDOPHILUM; PROCESSIVE DEGRADATION; ESCHERICHIA-COLI; ENCODED SUBUNITS; ATP HYDROLYSIS; UBIQUITIN; REQUIREMENT; RESOLUTION	Knowledge about the sizes of peptides generated by proteasomes during protein degradation is essential to fully understand their degradative mechanisms and the subsequent steps in protein turnover and generation of major histocompatibility complex class I antigenic peptides. We demonstrate here that 26 S and activated 20 S proteasomes from rabbit muscle degrade denatured, nonubiquitinated proteins in a highly processive fashion but generate different patterns of peptides (despite their containing identical proteolytic sites). With both enzymes, products range in length from 3 to 22 residues, and their abundance decreases with increasing length according to a log-normal distribution. Less than 15% of the products are the length of class I presented peptides (8 or 9 residues), and two-thirds are too short to function in antigen presentation, Surprisingly, these mammalian proteasomes, which contain two "chymotryptic," two "tryptic," and two "post-acidic" active sites, generate peptides with a similar size distribution as do archaeal 20 S proteasomes, which have 14 identical sites. Furthermore, inactivation of the "tryptic" sites altered the peptides produced without significantly affecting their size distribution. Therefore, this distribution is not determined by the number, specificity, or arrangement of the active sites (as proposed by the "molecular ruler" model); instead, we propose that proteolysis continues until products are small enough to diffuse out of the proteasomes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	agoldber@bcmp.med.harvard.edu						Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; EDMUNDS T, 1986, J CELL BIOCHEM, V32, P187, DOI 10.1002/jcb.240320304; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Goldberg AL, 1995, COLD SPRING HARB SYM, V60, P479, DOI 10.1101/SQB.1995.060.01.052; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG HC, 1997, THESIS HARVARD U; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LEIBOVITZ D, 1995, J BIOL CHEM, V270, P11029, DOI 10.1074/jbc.270.19.11029; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; Maupin-Furlow JA, 1998, J BACTERIOL, V180, P1480, DOI 10.1128/JB.180.6.1480-1487.1998; McCormack TA, 1998, BIOCHEMISTRY-US, V37, P7792, DOI 10.1021/bi980097q; Michalek MT, 1996, J IMMUNOL, V157, P617; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Stock D, 1995, COLD SPRING HARB SYM, V60, P525, DOI 10.1101/SQB.1995.060.01.056; Stuart DI, 1997, NATURE, V386, P437, DOI 10.1038/386437a0; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	55	420	431	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3363	3371		10.1074/jbc.274.6.3363	http://dx.doi.org/10.1074/jbc.274.6.3363			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920878	hybrid			2022-12-25	WOS:000078428200018
J	Pallaoro, M; Fejzo, MS; Shayesteh, L; Blount, JL; Caughey, GH				Pallaoro, M; Fejzo, MS; Shayesteh, L; Blount, JL; Caughey, GH			Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG TRYPTASE; COMPLEMENTARY-DNA; PHYSICAL MAP; CLONING; TRANSCRIPTION; EXPRESSION; PROTEASES; AIRWAY; AMPLIFICATION; PURIFICATION	Tryptases are serine proteases implicated in asthma and are very highly expressed in human mast cells. They fall into two groups, alpha and beta. Although several related tryptase mRNAs are known, it is unclear which if any are transcripts of separate haploid genes. The studies described here investigated the nature and number of human tryptases and sought possibly novel members of the family. To this end, two human bacterial artificial chromosome (BAC) clones containing tryptase genes were identified and mapped to chromosome 16p13.3, of which similar to 2.2 megabases are syntenic with the part of mouse chromosome 17 containing tryptase genes mouse mast cell protease (mMCP)-6 and -7, Sequencing and restriction mapping suggest that the BACs may partially overlap. Sequenced BAC genes correspond to three known beta-tryptases (beta I, beta II, and beta III), an alpha-like gene, and a pair of novel hybrid genes related partly to alpha/beta-tryptases and partly to orthologs of mMCP-7. beta II and beta III, beta I and alpha II, as well as the two mMCP-7-like genes, may be alleles at single loci; in total, there are at least three nonallelic tryptase genes in the isolated BAC clones. DNA blotting and restriction analysis suggest that the BACs include most members of the immediate tryptase family. Thus, chromosome 16p13.3 harbors a cluster of known and previously undescribed members of the tryptase gene family.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Caughey, GH (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.		Pallaoro, Michele/AAU-7429-2020	Fejzo, Marlena/0000-0001-6800-687X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, R01HL054774] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136, HL-54774] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLOM T, 1993, SCAND J IMMUNOL, V37, P203, DOI 10.1111/j.1365-3083.1993.tb01757.x; Caughey GH, 1997, AM J RESP CELL MOL, V16, P621, DOI 10.1165/ajrcmb.16.6.9191463; Caughey GH, 1995, MAST CELL PROTEASES, P305; CHAN H, 1995, FASEB J, V9, pA1343; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DOGGETT NA, 1995, NATURE, V377, P335; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; HARVIMA IT, 1989, ARCH DERMATOL RES, V281, P231, DOI 10.1007/BF00431056; HUANG R, 1993, SCAND J IMMUNOL, V38, P359, DOI 10.1111/j.1365-3083.1993.tb01738.x; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KOURILSKY P, 1986, TRENDS GENET, V2, P60, DOI 10.1016/0168-9525(86)90179-4; KRISHNA MT, 1998, AM J RESP CRIT CARE, V157, P456; LITTLE SS, 1995, BIOCHEM J, V307, P341, DOI 10.1042/bj3070341; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SANCTIS GTD, 1995, NAT GENET, V11, P150; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1985, BIOCHEM BIOPH RES CO, V129, P76, DOI 10.1016/0006-291X(85)91405-6; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; STACK MS, 1994, J BIOL CHEM, V269, P9416; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; XIA HZ, 1995, J IMMUNOL, V154, P5472; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747	40	112	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3355	3362		10.1074/jbc.274.6.3355	http://dx.doi.org/10.1074/jbc.274.6.3355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920877	hybrid			2022-12-25	WOS:000078428200017
J	Roghani, M; Becherer, JD; Moss, ML; Atherton, RE; Erdjument-Bromage, H; Arribas, J; Blackburn, RK; Weskamp, G; Tempst, P; Blobel, CP				Roghani, M; Becherer, JD; Moss, ML; Atherton, RE; Erdjument-Bromage, H; Arribas, J; Blackburn, RK; Weskamp, G; Tempst, P; Blobel, CP			Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SPERM-EGG FUSION; ANGIOTENSIN-CONVERTING ENZYME; FACTOR-ALPHA; TNF RECEPTOR; SURFACE PROTEIN; CYSTEINE SWITCH; POTENTIAL ROLE; CELL-ADHESION; IL-6 RECEPTOR	Metalloprotease disintegrins are a family of membrane-anchored glycoproteins that are known to function in fertilization, myoblast fusion, neurogenesis, and ectodomain shedding of tumor necrosis factor (TNF)-alpha. Here we report the analysis of the intracellular maturation and catalytic activity of the widely expressed metalloprotease disintegrin MDC9, Our results suggest that the pro-domain of MDC9 is removed by a furin-type pro-protein convertase in the secretory pathway before the protein emerges on the cell surface. The soluble metalloprotease domain of MDC9 cleaves the insulin B-chain, a generic protease substrate, providing the first evidence that MDC9 is catalytically active. Soluble MDC9 appears to have distinct specificities for cleaving candidate substrate peptides compared with the TNF-cu convertase (TACE/ADAM17). The catalytic activity of MDC9 can be inhibited by hydroxamic acid-type metalloprotease inhibitors in the low nanomolar range, in one case with up to 50-fold selectivity for MDC9 versus TACE, Peptides mimicking the predicted cysteine-switch region of MDC9 or TACE inhibit both enzymes in the low micromolar range, providing experimental evidence for regulation of metalloprotease disintegrins via a cysteine-switch mechanism. Finally, MDC9 is shown to become phosphorylated when cells are treated with the phorbol ester phorbol la-myristate 13-acetate, a known inducer of protein ectodomain shedding. This work implies that removal of the inhibitory pro-domain of MDC9 by a fur-in-type pro-protein convertase in the secretory pathway is a prerequisite for protease activity, After pro-domain removal, additional steps, such as protein kinase C-dependent phosphorylation, may be involved in regulating the catalytic activity of MDC9, which is likely to target different substrates than the related TNF-alpha-convertase.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ Med Coll, Grad Sch, Program Mol Biol, New York, NY 10021 USA; Glaxo Wellcome Res & Dev Inc, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Inc, Dept Analyt Chem, Res Triangle Pk, NC 27709 USA; Hosp Gen Psg Vall Hebron, Lab Rec Oncol, Barcelona 08035, Spain	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; GlaxoSmithKline; GlaxoSmithKline; Hospital Universitari Vall d'Hebron	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.	c-blobel@ski.mskcc.org	Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051988] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [R55GM51988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BECHERER JD, 1991, J CELL BIOCH G S, V15, P139; BEYNON RJ, 1989, PROTEOLYTIC ENZYMES, P76; BICKETT DM, 1993, ANAL BIOCHEM, V212, P58, DOI 10.1006/abio.1993.1291; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FOX JW, 1995, METHOD ENZYMOL, V248, P368; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; MCGEEHAN GM, 1995, METHOD ENZYMOL, V248, P35; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Wen CH, 1997, DEVELOPMENT, V124, P4759; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Williams J W, 1979, Methods Enzymol, V63, P437; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	66	267	278	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3531	3540		10.1074/jbc.274.6.3531	http://dx.doi.org/10.1074/jbc.274.6.3531			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920899	hybrid			2022-12-25	WOS:000078428200039
J	Tang, XB; Kovacs, R; Sterling, D; Casey, JR				Tang, XB; Kovacs, R; Sterling, D; Casey, JR			Identification of residues lining the translocation pore of human AE1, plasma membrane anion exchange protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTEINE-SCANNING MUTAGENESIS; SITE-DIRECTED MUTAGENESIS; CELL BAND-3 PROTEIN; LACTOSE PERMEASE; ESCHERICHIA-COLI; CHLORIDE CHANNEL; INTRACELLULAR PH; SUBSTITUTION; LOCALIZATION	AE1 is the chloride/bicarbonate anion exchanger of the erythrocyte plasma membrane. We have used scanning cysteine mutagenesis and sulfhydryl-specific chemistry to identify pore-lining residues in the Ser(643)-Ser(690) region of the protein. The Ser(643)-Ser(690) region spans transmembrane segment 8 of AE1 and surrounds Glu(681), which may reside at the transmembrane permeability barrier. Glu(681) also directly interacts with some anions during anion transport. The introduced cysteine mutants were expressed by transient transfection of HEK293 cells. Anion exchange activity was assessed by measurement of changes of intracellular pH, which follow transmembrane bicarbonate movement mediated by AE1, To identify residues that might form part of an aqueous transmembrane pore, we measured anion exchange activity of each introduced cysteine mutant before and after incubation with the sulfhydryl reagents para-chloromercuribenzene sulfonate and 2-(aminoethyl)methanethiosulfonate hydrobromide, Our data identified transmembrane mutants A666C, S667C, L669C, L673C, L677C, and L680C and intracellular mutants I684C and I688C that could be inhibited by sulfhydryl reagents and may therefore form a part of a transmembrane pore. These residues map to one face of a helical wheel plot. The ability to inhibit two intracellular mutants suggests that transmembrane helix 8 extends at least two helical turns beyond the intracellular membrane surface. The identified hydrophobic pore-lining residues (leucine, isoleucine, and alanine) may limit interactions with substrate anions.	Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1988, J GEN PHYSIOL, V92, P161, DOI 10.1085/jgp.92.2.161; JENNINGS ML, 1992, J BIOL CHEM, V267, P13964; JENNINGS ML, 1989, ANION TRANSPORT PROT, P59; JONS T, 1994, HISTOCHEMISTRY, V102, P255, DOI 10.1007/BF00269161; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOPITO RR, 1985, J CELL BIOCHEM, V29, P1, DOI 10.1002/jcb.240290102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LINN SC, 1992, J BIOL CHEM, V267, P7927; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; MULLERBERGER S, 1995, BIOCHEMISTRY-US, V34, P9315; Reithmeier R.A.F., 1996, HDB BIOL PHYS, V2, P281; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEKLER I, 1995, J BIOL CHEM, V270, P28751, DOI 10.1074/jbc.270.48.28751; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XU M, 1993, J BIOL CHEM, V268, P21505; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; ZHANG ZH, 1992, BIOCHIM BIOPHYS ACTA, V1106, P31, DOI 10.1016/0005-2736(92)90218-B	47	49	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3557	3564		10.1074/jbc.274.6.3557	http://dx.doi.org/10.1074/jbc.274.6.3557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920902	hybrid			2022-12-25	WOS:000078428200042
J	Abbott, DW; Holt, JT				Abbott, DW; Holt, JT			Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G(2)/M checkpoint arrest in cells exposed to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ATAXIA-TELANGIECTASIA CELLS; ABL TYROSINE KINASE; NIH 3T3 CELLS; MAP KINASE; DNA-DAMAGE; C-ABL; CYCLE PROGRESSION; NIH-3T3 CELLS; PHOSPHORYLATION	An increasing body of evidence suggests that mitogen-induced activation of the RAF/ERK signaling pathway is functionally separate from the stress-induced activation of the SEK/JNK/p38 signaling pathway. In general, stress stimuli strongly activate the p38s and the JNKs while only weakly activating ERK1 and ERK2. However, a number of independent groups have now shown that the RAF/ERK signaling pathway is strongly activated by ionizing radiation. In this work, we examine this paradox. We show that both mitogen-activated protein (MAP) kinase kinase 1 (MEK1) and MAP kinase kinase 2 (MEK2) are activated by ionizing radiation. Blockage of this activation through the use of dominant negative MEK2 increases sensitivity of the cell to ionizing radiation and decreases the ability of a cell to recover from the G(2)/M cell cycle checkpoint arrest. Blocking MEK2 activation does not affect double-strand DNA break repair, however, Although MEK1 is activated to a lesser extent by ionizing radiation, expression of a dominant negative MEK1 does not affect radiation sensitivity of the cell, the G(2)/M checkpoint of the cell, or double-strand break repair. Because ionizing radiation leads to a different cell cycle arrest (G(2)/M arrest) than that typically seen with other stress stimuli, and because we have shown that MEK2 can affect G(2)/M checkpoint kinetics, these results provide an explanation for the observation that the MEKs can be strongly activated by ionizing radiation and only weakly activated by other stressful stimuli.	Vanderbilt Univ, Ctr Canc, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Holt, JT (corresponding author), Vanderbilt Univ, Ctr Canc, 2220 Pierce Ave S,Rm 659 MRB 2, Nashville, TN 37232 USA.			Abbott, Derek/0000-0003-4387-8094	NATIONAL CANCER INSTITUTE [R01CA051735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51735] Funding Source: Medline; NIGMS NIH HHS [5T32GM07347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1997, J BIOL CHEM, V272, P32454, DOI 10.1074/jbc.272.51.32454; Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Abbott DW, 1997, J BIOL CHEM, V272, P14005, DOI 10.1074/jbc.272.22.14005; Abrieu A, 1997, MOL BIOL CELL, V8, P249, DOI 10.1091/mbc.8.2.249; Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLESSI DR, 1994, EMBO J, V13, P1610; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; BERNHARD EJ, 1994, RADIAT RES, V140, P193; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Friedman LS, 1998, CANCER RES, V58, P1338; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GOTOH Y, 1995, MOL REPROD DEV, V42, P486, DOI 10.1002/mrd.1080420417; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HAIN J, 1994, CELL SIGNAL, V6, P539, DOI 10.1016/0898-6568(94)90008-6; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Jackson SP, 1996, CANCER SURV, V28, P261; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lohrer HD, 1996, EXPERIENTIA, V52, P316, DOI 10.1007/BF01919534; Maity A, 1997, INT J RADIAT ONCOL, V37, P639, DOI 10.1016/S0360-3016(96)00598-6; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STEVENSON MA, 1994, CANCER RES, V54, P12; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; YAN MH, 1994, NATURE, V372, P798; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	72	119	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2732	2742		10.1074/jbc.274.5.2732	http://dx.doi.org/10.1074/jbc.274.5.2732			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915804	hybrid			2022-12-25	WOS:000078319500022
J	Tait, JF; Smith, C				Tait, JF; Smith, C			Phosphatidylserine receptors: Role of CD36 in binding of anionic phospholipid vesicles to monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MEMBRANE PHOSPHATIDYLSERINE; PHAGOCYTE RECOGNITION; APOPTOTIC CELLS; HUMAN CD68; SR-BI; EXPOSURE; MACROPHAGES; PROTEIN; IDENTIFICATION	Exposure of phosphatidylserine (PtdSer) has been implicated in the recognition and phagocytosis of senescent and apoptotic cells, and CD36 has been proposed as one receptor protein that recognizes PtdSer and other anionic phospholipids. We investigated the binding of phospholipid vesicles to the monocytic leukemia cell lines THP-1 and J774A.1 with a flow cytometric assay; vesicles contained 50 mol% PtdSer, phosphatidylinositol (PtdIns), or phosphatidylglycerol (PtdGro), with the balance being phosphatidylcholine. Specific, high affinity binding was observed for vesicles containing PtdSer, PtdIns, or PtdGro, Specificity of the assay was confirmed by control experiments with erythrocytes, which showed minimal vesicle binding, and with annexin V, which blocked the binding of PtdSer, PtdGro, and PtdIns vesicles to the THP-1 cells. However, O-phospho-L-serine (to 1 mM) had no effect on the binding of PtdSer vesicles, indicating that high affinity binding requires a surface containing multiple phosphoserine groups rather than a single molecule. A monoclonal antibody to CD36 blocked up to 60% of the specific binding of PtdSer vesicles but had minimal to no effect on the binding of PtdGro or PtdIns vesicles. This antibody also selectively inhibited the phagocytosis of PtdSer-containing vesicles as measured by fluorescence microscopy, indicating that CD36 is functionally significant for phagocytosis of this vesicle type. In addition, collagen and thrombospondin, two other putative ligands of CD36, were unable to inhibit the binding of PtdSer vesicles. We conclude that CD36 is the primary protein responsible for the high affinity binding of PtdSer vesicles to these monocyte like cells. In addition, CD36 appears to be specific for PtdSer among anionic phospholipids, and non-phospholipid ligands of CD36 do not share binding sites with PtdSer on CD36.	Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tait, JF (corresponding author), Univ Washington, Dept Lab Med, Room NW-120,Box 357110, Seattle, WA 98195 USA.	tait@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47151] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASTION ML, 1993, LAB MED, V24, P341, DOI 10.1093/labmed/24.6.341; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1993, J IMMUNOL, V151, P4274; FADOK VA, 1992, J IMMUNOL, V148, P2207; GABRIEL NE, 1984, BIOCHEMISTRY-US, V23, P4011, DOI 10.1021/bi00313a001; LEE KD, 1993, BIOCHEMISTRY-US, V32, P889, DOI 10.1021/bi00054a021; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; RALPH P, 1975, J IMMUNOL, V114, P898; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Wood BL, 1996, BLOOD, V88, P1873; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	32	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3048	3054		10.1074/jbc.274.5.3048	http://dx.doi.org/10.1074/jbc.274.5.3048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915844	hybrid			2022-12-25	WOS:000078319500062
J	Kuhn, C; Muller, F; Melle, C; Nasheuer, HP; Janus, F; Deppert, W; Grosse, F				Kuhn, C; Muller, F; Melle, C; Nasheuer, HP; Janus, F; Deppert, W; Grosse, F			Surface plasmon resonance measurements reveal stable complex formation between p53 and DNA polymerase alpha	ONCOGENE			English	Article						DNA replication; DNA repair; protein-protein interactions; biomolecular interaction analysis (BIA); BIAcore	REPLICATION PROTEIN-A; SV40 T-ANTIGEN; SV40-TRANSFORMED CELLS; IN-VITRO; BINDING; DOMAINS; SUBUNIT; PRIMASE; EXPRESSION; ACTIVATION	Surface plasmon resonance measurements were used for detecting and quantifying protein-protein interactions detecting and quantifying protein-protein interactions between the tumorsuppressor protein p53, the SV40 large T antigen (T-ag), the cellular DNA polymerase alpha-primase complex (pol-prim), and the cellular single-strand DNA binding protein RPA, Highly purified p53 protein bound to immobilized T-ag with an apparent binding constant of 2 x 10(8) M-1. Binding of p53 to RPA was in the same order of magnitude with a binding constant of 4 x 10(8) M-1, when RPA was coupled to the sensor chip via its smallest subunit, and 1 x 10(8) M-1, when RPA,vas coupled via its p70 subunit, Furthermore, p53 bound human DNA polymerase a-primase complex (pol-prim) with a K-A value of 1 x 10(10) M-1. Both the p68 subunit and the p180 subunit of pol-prim could interact with p53 displaying binding constants of 2 x 10(10) M-1 and 5 x 10(9) M-1, respectively, Complex formation was also observed with a p180/p68 heterodimer, and again with a binding constant similar. Hence, there was no synergistic effect when p53 bound to higher order complexes of pol-prim. A truncated form of p53, consisting of amino acids 1-320, bound pol-prim by four orders of magnitude less efficiently, Therefore, an intact C-terminus of p53 seems to be important for efficient binding to pol-prim. It was also tried to measure complex formation between p53, pol-prim, and T-ag. However there was no evidence for the existence of a ternary complex consisting of T-ag, pol-prim, and p53.	Inst Mol Biotechnol, Abt Biochem, D-07745 Jena, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Abt Tumorvirol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Grosse, F (corresponding author), Inst Mol Biotechnol, Abt Biochem, Beutenbergstr 11, D-07745 Jena, Germany.			Melle, Christian/0000-0002-1870-9419; Nasheuer, Heinz Peter/0000-0002-9218-9079				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Boulikas T, 1996, ANTICANCER RES, V16, P693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOCHULI E, 1987, J CHROMATOGR, V411, P371, DOI 10.1016/S0021-9673(00)93988-8; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Warbrick E, 1996, CURR BIOL, V6, P1057, DOI 10.1016/S0960-9822(02)70663-5; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0	37	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					769	774		10.1038/sj.onc.1202327	http://dx.doi.org/10.1038/sj.onc.1202327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989827				2022-12-25	WOS:000078394400022
J	Blandino, G; Levine, AJ; Oren, M				Blandino, G; Levine, AJ; Oren, M			Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy	ONCOGENE			English	Article						apoptosis; mutant p53; etoposide; chemoresistance	CISPLATIN-BASED CHEMOTHERAPY; BREAST-CANCER PATIENTS; DNA-DAMAGING AGENTS; FUNCTION MUTATIONS; DRUG-RESISTANCE; GROWTH ARREST; APOPTOSIS; GENE; EXPRESSION; PROTEIN	Many tumors overexpress mutant forms of p53, A growing number of studies suggest that the nature of a p53 mutation in a cell can impact upon cellular properties, clinical responses to therapy and prognosis of a tumor. To explore the cellular basis of these observations, experiments were designed to compare the properties of cells with and without p53 mutations within the same cell population. To that end, various tumor-derived human p53 mutants,were introduced into p53-null H1299 lung adenocarcinoma cells. Clonogenic survival assays revealed that cells overexpressing the p53His175 mutant, but not the p53His273 mutant, recover preferentially from etoposide treatment, Moreover, p53His175 as well as p53His179 reduced substantially the rate of etoposide-induced apoptosis, whereas p53His273 and p53Trp248 had a much milder protective effect. In contrast, p53His175 and p53His273 exerted, very similar effects on the cellular response to cisplatin; both conferred increased resistance to low concentrations of the drug (2.5 mu g/ml), but did not protect at all against high concentrations (10 mu g/ml). Hence particular p53 mutants may confer upon tumor cells a selective survival advantage during chemotherapy, These findings define a new type of mutant p53 selective gain of function which may compromise the efficacy of cancer chemotherapy.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Weizmann Institute of Science; Princeton University	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELROUBY S, 1993, BLOOD, V82, P3452; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOH HS, 1995, CANCER RES, V55, P5217; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HSIAO M, 1994, AM J PATHOL, V145, P702; KASTAN MB, 1991, CANCER RES, V51, P6304; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MATHIEU MC, 1995, LANCET, V345, P1182; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Peled A, 1996, CANCER RES, V56, P2148; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Ribeiro JCC, 1997, INT J RADIAT BIOL, V72, P11, DOI 10.1080/095530097143491; Righetti SC, 1996, CANCER RES, V56, P689; RUSCH V, 1995, CANCER RES, V55, P5038; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; TRAUBERT H, 1996, CANCER RES, V56, P4134; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	48	363	371	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					477	485		10.1038/sj.onc.1202314	http://dx.doi.org/10.1038/sj.onc.1202314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927204				2022-12-25	WOS:000078166500020
J	Jenkins, TD; Mueller, A; Odze, R; Shahsafaei, A; Zukerberg, LR; Kent, R; Stoner, GD; Rustgi, AK				Jenkins, TD; Mueller, A; Odze, R; Shahsafaei, A; Zukerberg, LR; Kent, R; Stoner, GD; Rustgi, AK			Cyclin D1 overexpression combined with N-nitrosomethylbenzylamine increases dysplasia and cellular proliferation in murine esophageal squamous epithelium	ONCOGENE			English	Article						cyclin D1; N-nitrosomethylbenzylamine; esophageal squamous dysplasia; transgenic mice	MOUSE SKIN CARCINOGENESIS; RAT ESOPHAGUS; HA-RAS; GENE; EXPRESSION; ONCOGENE; CANCER; MICE; P53; METHYLBENZYLNITROSAMINE	We previously described the oral-esophageal tissue-specific expression of cyclin D1 with the Epstein-Barr virus ED-L2 promoter in transgenic mice, and resulting dysplasia, Given the evidence for an interplay between environmental and genetic factors in esophageal squamous carcinogenesis, the aim of this study was tot determine the potential cooperation of the nitrosamine compound N-nitrosomethylbenzylamine (NMBA), an esophageal specific carcinogen, in the cyclin D1 transgenic mice, NMBA was first demonstrated to induce dysplasia in two strains of inbred mice, C57BL/6 and FVB/N, Subcutaneous NMBA was then administrated to wild type and transgenic mice beginning at 4 weeks of age. Mice were monitered for the duration of the study for general appearance, activity and weight, and were euthanized at 12 and 15 months. Histopathologic analysis revealed increased severity of dysplasia in cyclin D1 mice treated with NMBA compared with treated age-matched wild-type mice and untreated mice. There was also increased proliferating cell nuclear antigen (PCNA) expression in the esophagi of NMBA treated cyclin D1 mice. Taken together, these findings suggest that a genetic alteration, specifically cyclin D1 overexpression and a chemical carinogen, NMBA, may cooperate to increase the severity of esophageal squamous dysplasia, a prominent precursor to carcinoma.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Hematol Oncol Unit, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; Forsyth Dent Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA; Ohio State Univ, Dept Prevent Med, Canc Etiol & Chemoprevent Lab, Columbus, OH 43210 USA; Ohio State Univ, Arthur James Canc Hosp & Res Inst, Columbus, OH 43210 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Forsyth Institute; Harvard University; Harvard School of Dental Medicine; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 6CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01 DE12467-01A1] Funding Source: Medline; NIDDK NIH HHS [NIDDK K08, DK53377] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT JM, 1994, J VIROL, V68, P4358; ANTRUP H, 1982, CANCER RES, V42, P1307; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARCH DH, 1986, J NATL CANCER I, V77, P1145; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CRADDOCK VM, 1987, CARCINOGENESIS, V8, P1129, DOI 10.1093/carcin/8.8.1129; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONIGER J, 1985, P NATL ACAD SCI USA, V82, P421, DOI 10.1073/pnas.82.2.421; DRUCKREY H, 1963, NATURWISSENSCHAFTEN, V50, P100, DOI 10.1007/BF00590822; FONG LYY, 1979, INT J CANCER, V23, P679, DOI 10.1002/ijc.2910230514; Garber SA, 1997, CARCINOGENESIS, V18, P1149, DOI 10.1093/carcin/18.6.1149; HARRIS CC, 1979, CANCER RES, V39, P4401; HODGSON RM, 1982, CANCER RES, V42, P2836; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LABUC GE, 1982, CANCER RES, V42, P3181; Li M H, 1986, Nutr Cancer, V8, P63, DOI 10.1080/01635588609513877; LIJINSKY W, 1982, J NATL CANCER I, V68, P681; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Mueller A, 1997, CANCER RES, V57, P5542; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; ODELEYE OE, 1992, CARCINOGENESIS, V13, P1811, DOI 10.1093/carcin/13.10.1811; ODELEYE OE, 1992, ANN NY ACAD SCI, V669, P368; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Sheyn I, 1997, HUM PATHOL, V28, P270, DOI 10.1016/S0046-8177(97)90123-4; Siglin JC, 1996, CARCINOGENESIS, V17, P1135, DOI 10.1093/carcin/17.5.1135; STERN MC, 1995, CARCINOGENESIS, V16, P1947, DOI 10.1093/carcin/16.8.1947; STINSON SF, 1978, JNCI-J NATL CANCER I, V61, P1471; VANBENTHEM J, 1992, CARCINOGENESIS, V13, P2101; WALKER EA, 1979, J NATL CANCER I, V63, P947; Wang D, 1996, CARCINOGENESIS, V17, P625, DOI 10.1093/carcin/17.4.625; Wang QS, 1996, MOL CARCINOGEN, V15, P144, DOI 10.1002/(SICI)1098-2744(199602)15:2<144::AID-MC7>3.0.CO;2-J; Wang QS, 1996, CARCINOGENESIS, V17, P1583, DOI 10.1093/carcin/17.8.1583; WANG Y, 1990, CANCER RES, V50, P1591; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; Youssef EM, 1997, JPN J CANCER RES, V88, P18, DOI 10.1111/j.1349-7006.1997.tb00296.x	41	24	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					59	66		10.1038/sj.onc.1202296	http://dx.doi.org/10.1038/sj.onc.1202296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926920				2022-12-25	WOS:000078166000007
J	Behre, G; Whitmarsh, AJ; Coghlan, MP; Hoang, T; Carpenter, CL; Zhang, DE; Davis, RJ; Tenen, DG				Behre, G; Whitmarsh, AJ; Coghlan, MP; Hoang, T; Carpenter, CL; Zhang, DE; Davis, RJ; Tenen, DG			c-Jun is a JNK-independent coactivator of the PU.1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; ACTIVATED PROTEIN-KINASE; FACTOR-I RECEPTOR; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; HA-RAS; MACROPHAGE DIFFERENTIATION; MONOCYTIC DIFFERENTIATION; REGULATES EXPRESSION; TARGETED DISRUPTION	The ETS domain transcription factor PU.1 is necessary for the development of monocytes and regulates, in particular, the expression of the monocyte-specific macrophage colony-stimulating factor (M-CSF) receptor, which is critical for monocytic cell survival, proliferation, and differentiation. The bZIP transcription factor c-Jun, which is part of the AP-1 transcription factor complex, is also important for monocytic differentiation, but the monocyte-specific M-CSF receptor promoter has no AP-1 consensus binding sites. We asked the question of whether c-Jun could promote the induction of the M-CSF receptor by collaborating with PU.1. We demonstrate that c-Jun enhances the ability of PU.1 to transactivate the M-CSF receptor promoter as well as a minimal thymidine kinase promoter containing only PU.1 DNA binding sites. c-Jun does not directly bind to the M-CSF receptor promoter but associates via its basic domain with the ETS domain of PU.1, Consistent with our observation that AP-1 binding does not contribute to c-Jun coactivation is the observation that the activation of PU.1 by c-Jun is blocked by overexpression of c-Fos. Phosphorylation of c-Jun by c-Jun NH2-terminal kinase on Ser-63 and -73 does not alter the ability of c-Jun to enhance PU.1 transactivation. Activated Ras enhances the transcriptional activity of PU.1 by up-regulating c-Jun expression without changing the phosphorylation pattern of PU.1. The activation of PU.1 by Ras is blocked by a mutant c-Jun protein lacking the basic domain. The expression of this mutant form of c-Jun also completely blocks 12-O-tetradecanoylphorbol-13-acetate-induced M-CSF receptor promoter activity during monocytic differentiation. We propose therefore that c-Jun acts as a c-Jun NH2-terminal kinase-independent coactivator of PU.1, resulting in M-CSF receptor expression and development of the monocytic lineage.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Tenen, DG (corresponding author), Harvard Inst Med, Room 954,77 Ave Louis Pasteur, Boston, MA 02115 USA.	dtenen@bidmc.harvard.edu		Whitmarsh, Alan/0000-0003-1184-6610; Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456, P01CA072009] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA72009, CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Bannister AJ, 1995, ONCOGENE, V11, P2509; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; GAYNOR R, 1991, BLOOD, V77, P2618; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hass R, 1997, LEUKEMIA RES, V21, P589, DOI 10.1016/S0145-2126(97)00010-6; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; HIBI S, 1993, BLOOD, V81, P1841; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Hume DA, 1997, MOL REPROD DEV, V46, P46; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JIN DI, 1995, MOL CELL BIOL, V15, P693; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lodie TA, 1997, J IMMUNOL, V158, P1848; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Maher J, 1996, LEUKEMIA, V10, P83; Mao C, 1996, ONCOGENE, V12, P863; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Olweus J, 1996, BLOOD, V88, P3741, DOI 10.1182/blood.V88.10.3741.bloodjournal88103741; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHERR CJ, 1990, BLOOD, V75, P1; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WASYLYK C, 1994, ONCOGENE, V9, P3665; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YAN MH, 1994, NATURE, V372, P798; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	68	151	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4939	4946		10.1074/jbc.274.8.4939	http://dx.doi.org/10.1074/jbc.274.8.4939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988737	hybrid			2022-12-25	WOS:000078698200062
J	Perez-Juste, G; Aranda, A				Perez-Juste, G; Aranda, A			The cyclin-dependent kinase inhibitor p27(Kip1) is involved in thyroid hormone-mediated neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST CELL-CYCLE; RETINOBLASTOMA PROTEIN; NEUROBLASTOMA-CELLS; RESTRICTION POINT; NEURO-2A CELLS; MESSENGER-RNA; RECEPTOR; GROWTH; ARREST; PHASE	The thyroid hormone (triiodothyronine, T3) is essential for normal brain maturation. To determine the mechanisms by which T3 controls neuronal proliferation and differentiation, we have analyzed the effect of this hormone on the expression and activity of cell cycle-regulating molecules in neuroblastoma N2a-beta cells that overexpress the beta 1 isoform of the T3 receptor. Our results show that incubation of N2a-beta cells with T3 leads to a rapid down-regulation of the c-myc gene and to a decrease of cyclin D1 levels. T3 also causes a strong and sustained increase of the levels of the cyclin kinase inhibitor p27(Kip1). This increase is secondary, to the augmented levels of p27(Kip1) transcripts as well as to stabilization of the p27(Kip1) protein. The increased levels of p27(Kip1) lead to a significant increase in the amount of p27(Kip1) associated with cyclin-dependent kinase 2 (CDK2), and to a marked inhibition of the kinase activity of the cyclin . CDK2 complexes. As a consequence, the retinoblastoma protein (pRb) and the retinoblastoma protein-related protein p130 are hypophosphorylated in T3-treated N2a-beta cells. This study shows for the first time that T3-mediated growth arrest and neuronal differentiation are associated with an increase in the levels of a cyclin kinase inhibitor, which does not allow the inactivation of retinoblastoma proteins required for progression through the restriction point in the cell cycle.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@iib.uam.es	Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589				BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LAZAR MA, 1993, ENDOCR REV, V14, P194; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLIAK K, 1994, CELL, V78, P59; POLIAK K, 1994, GENE DEV, V8, P9; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Puymirat J, 1995, J BIOL CHEM, V270, P30651, DOI 10.1074/jbc.270.51.30651; PUYMIRAT J, 1992, PROG NEUROBIOL, V39, P281, DOI 10.1016/0301-0082(92)90019-B; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang QM, 1997, CANCER RES, V57, P2851; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUSTA B, 1990, J NEUROSCI RES, V27, P1, DOI 10.1002/jnr.490270102	39	78	79	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5026	5031		10.1074/jbc.274.8.5026	http://dx.doi.org/10.1074/jbc.274.8.5026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988748	Green Published, hybrid			2022-12-25	WOS:000078698200073
J	Angerer, ND; Du, Y; Nalbant, D; Williams, SC				Angerer, ND; Du, Y; Nalbant, D; Williams, SC			A short conserved motif is required for repressor domain function in the myeloid-specific transcription factor CCAAT enhancer-binding protein epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C/EBP-BETA; ACTIVATION DOMAINS; EXPRESSION NF-IL6; INHIBITOR DOMAIN; LEUCINE-ZIPPER; DEFICIENT MICE; NUCLEAR FACTOR; DIFFERENTIATION; CELLS	CCAAT/enhancer-binding protein epsilon (C/EBP epsilon) is expressed almost exclusively in the myeloid lineage of the hematopoietic system and functions during terminal differentiation of neutrophils and macrophages, and in the regulation of cytokine gene expression in macrophages and T cells. We have undertaken a series of structure/function studies on the murine C/EBP epsilon polypeptide to investigate the mechanism by which C/EBP epsilon activates transcription. Studies with deletion mutants and fusion proteins consisting of C/EBP epsilon sequences joined to the Gal4 DNA-binding protein identified two transcriptional activation domains in C/EBP epsilon, Removal of sequences between the two activation domains or sequences between the second activation domain and the C-terminal DNA binding domain significantly increased the activity of C/EBP epsilon, suggesting the presence of two separate regulatory domains (designated RD-1 epsilon and RD-2 epsilon), RD-1 epsilon behaved as a classic active repressor domain being capable of inhibiting adjacent activation domains irrespective of their origin and when linked to a heterologous DNA binding domain. Mutagenesis studies revealed a short motif in RD-1 epsilon that appears to be a target site for protein-protein interactions and is conserved in repressor domains from C/EBP beta, Sp3, c-Fos, and FosB, The juxtaposition of activation and repressor domains may permit C/EBP epsilon to function as a transcriptional activator or repressor at different stages of myeloid differentiation or as an inducible transcriptional activator of cytokine genes.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA; Texas Tech Univ, Med Ctr, SW Canc Ctr, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University	Williams, SC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St, Lubbock, TX 79430 USA.	cbbscw@ttuhsc.edu						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hu HM, 1998, J IMMUNOL, V160, P2334; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; POLI V, 1994, LIVER GENE EXPRESSIO, P131; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sterneck E, 1998, J NEUROCHEM, V70, P2424; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Williams SC, 1997, GENE EXPRESSION, V6, P371; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4147	4154		10.1074/jbc.274.7.4147	http://dx.doi.org/10.1074/jbc.274.7.4147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933609	hybrid			2022-12-25	WOS:000078575500033
J	Harth, G; Horwitz, MA				Harth, G; Horwitz, MA			Export of recombinant Mycobacterium tuberculosis superoxide dismutase is dependent upon both information in the protein and mycobacterial export machinery - A model for studying export of leaderless proteins by pathogenic mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GLUTAMINE-SYNTHETASE; EXPRESSION; GENE; IDENTIFICATION; PHAGOCYTOSIS; RECEPTORS; SEQUENCE; ANTIGEN; RELEASE	We have investigated the expression and extracellular release of enzymatically active superoxide dismutase, one of the 10 major extracellular proteins of Mycobacterium tuberculosis, both in its native host and in the heterologous host Mycobacterium smegmatis, We found that the M, tuberculosis superoxide dismutase gene, encoding a leaderless polypeptide of M-r similar to 23,000 representing one of the four identical subunits of the enzyme, is expressed constitutively under normal growth conditions and at a B-fold increased level under conditions of hydrogen peroxide stress. The highly pathogenic mycobacterium M. tuberculosis expresses 93-fold more superoxide dismutase than the nonpathogenic mycobacterium M. smegmatis, and it exports a much higher proportion of expressed enzyme (76 versus 21%); taking both expression and export into consideration, IM, tuberculosis exports similar to 350-fold more enzyme than M, smegmatis, In M. smegmatis, recombinant M. tuberculosis superoxide dismutase is expressed at 8.4 times the level of the endogenous enzyme and the proportion exported (66%) approaches that in the homologous host; hence M. smegmatis exports up to 26-fold more of the recombinant than endogenous enzyme. Interestingly, subunits of the M. tuberculosis and M. smegmatis enzymes readily and stoichiometrically exchange with each other, forming five different complexes of four subunits, both when the enzymes are expressed in the recombinant host and when the purified enzymes are incubated together; however, each subunit retains its characteristic metal ion, iron for IM. tuberculosis and manganese for M.. smegmatis, Compared with the cell-associated enzyme, the supernatant enzyme of recombinant IM, smegmatis is enriched for M, tuberculosis enzyme subunits, consistent with preferential export of the M. tuberculosis enzyme. Recombinant M. tuberculosis superoxide dismutase transcomplements a superoxide dismutase-deficient Escherichia coli, resulting in a reduction of sensitivity of the strain to oxidative stress, but the enzyme is not exported from this nonmycobacterial host. Our findings indicate that the information for export of the M, tuberculosis superoxide dismutase is contained within the protein but that export additionally requires export machinery specific to mycobacteria.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Horwitz, MA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042925, R01AI031338] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR05554] Funding Source: Medline; NIAID NIH HHS [AI 31338, AI 42925] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BULL TJ, 1995, J CLIN PATHOL-CL MOL, V48, pM124; Bunting K, 1998, EUR J BIOCHEM, V251, P795, DOI 10.1046/j.1432-1327.1998.2510795.x; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; EIDUS I, 1964, AM REV RESPIR DIS, V90, P258; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harth G, 1997, INFECT IMMUN, V65, P2321, DOI 10.1128/IAI.65.6.2321-2328.1997; Harth G, 1997, J BIOL CHEM, V272, P22728, DOI 10.1074/jbc.272.36.22728; HARTH G, 1994, P NATL ACAD SCI USA, V91, P9342, DOI 10.1073/pnas.91.20.9342; Horwitz LD, 1998, P NATL ACAD SCI USA, V95, P5263, DOI 10.1073/pnas.95.9.5263; HOWARD NS, 1995, GENE, V166, P181, DOI 10.1016/0378-1119(95)00597-X; KEELE BB, 1970, J BIOL CHEM, V245, P6176; MAYER BK, 1986, INFECT IMMUN, V53, P631, DOI 10.1128/IAI.53.3.631-635.1986; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; MUNO D, 1981, BIOCHEM INT, V2, P33; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; STEINMAN HM, 1973, P NATL ACAD SCI USA, V70, P3725, DOI 10.1073/pnas.70.12.3725; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; ZHANG Y, 1991, MOL MICROBIOL, V5, P381, DOI 10.1111/j.1365-2958.1991.tb02120.x; ZOLG JW, 1994, J CLIN MICROBIOL, V32, P2801, DOI 10.1128/JCM.32.11.2801-2812.1994	28	68	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4281	4292		10.1074/jbc.274.7.4281	http://dx.doi.org/10.1074/jbc.274.7.4281			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933629	hybrid			2022-12-25	WOS:000078575500053
J	Kose, S; Imamoto, N; Tachibana, T; Yoshida, M; Yoneda, Y				Kose, S; Imamoto, N; Tachibana, T; Yoshida, M; Yoneda, Y			beta-subunit of nuclear pore-targeting complex (importin-beta) can be exported from the nucleus in a Ran-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; PROTEIN IMPORT; BINDING PROTEIN; GTPASE ACTIVITY; MESSENGER-RNA; LEPTOMYCIN-B; LIVING CELLS; RCC1; TRANSPORT; SIGNAL	The nuclear export of importin-alpha is mediated by GAS, which is related to importin-beta, whereas the mechanism for the export of importin-beta remains unclear. In this study, we demonstrate that the nuclear export of importin-beta is mediated by the nuclear pore complex-binding domain of this molecule, Insensitivity to leptomycin B indicates that its export is not mediated by a leucine-rich nuclear export signal-specific receptor, CRM1. Furthermore, the nuclear export of importin-a was not inhibited by co-injection with a GTPase-deficient Ran mutant (G19V), The cell line tsBN2 contains a temperature-sensitive point mutation in the RCC1 gene, which encodes a guanine nucleotide exchange factor of Ran. At the nonpermissive temperature, importin-beta was exported from the nucleus of these cells, even when Ran-GAP1, a GTPase-activating protein for Ran, was co-injected. These results not only provide support for the view that Ran-dependent GTP hydrolysis is not required for the nuclear export of importin-beta but also indicate that nuclear RanGTP is not essential for its export. As a result, we propose: that importin-beta can be recycled from the nucleus alone in a Ran-independent manner.	Osaka Univ, Sch Med, Dept Anat & Cell Biol, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1130033, Japan	Osaka University; University of Tokyo	Yoneda, Y (corresponding author), Osaka Univ, Sch Med, Dept Anat & Cell Biol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	yyoneda@anat3.med.osaka-u.ac.jp	Yoshida, Minoru/C-8049-2014; Imamoto, Naoko/A-7458-2015	Yoshida, Minoru/0000-0002-4376-5674; Imamoto, Naoko/0000-0002-2886-3022				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NISHI K, 1994, J BIOL CHEM, V269, P6320; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	46	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3946	3952		10.1074/jbc.274.7.3946	http://dx.doi.org/10.1074/jbc.274.7.3946			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933584	hybrid			2022-12-25	WOS:000078575500008
J	Melville, MW; Tan, SL; Wambach, M; Song, J; Morimoto, RI; Katze, MG				Melville, MW; Tan, SL; Wambach, M; Song, J; Morimoto, RI; Katze, MG			The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; MOLECULAR CHAPERONE; STRESS-RESPONSE; J-DOMAIN; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION; SUBSTRATE-BINDING; ESCHERICHIA-COLI; T ANTIGENS; DNAJ	p58(IPK), a member of the tetratricopeptide repeat and J-domain protein families, was first recognized for its ability to inhibit the double-stranded RNA-activated protein kinase, PKR. PKR is part of the interferon-induced host defense against viral infection, and down-regulates translation initiation via phosphorylation of eukaryotic initiation factor 2 on the alpha-subunit. P58(IPK) is activated in response to infection by influenza virus, and inhibits PKR through direct protein-protein interaction. Previously, we demonstrated that the molecular chaperone heat shock protein 40 (hsp40) was a negative regulator of p58(IPK). We could now report that influenza virus activates the p58(IPK) pathway by promoting the dissociation of hsp40 from p58(IPK) during infection. We also found that the P58(IPK)-hsp40 association was disrupted during recovery from heat shock, which suggested a regulatory role for P58(IPK) in the absence of virus infection. The PKR pathway is even more complex as we show in this report that the molecular chaperone, hsp/Hsc70, was a component of a trimeric complex with hsp40 and p58(IPK). Moreover, like other J-domain proteins, p58(IPK) stimulated the ATPase activity of Hsc70, Taken together, our data suggest that p58(IPK) is a co-chaperone, possibly directing hsp/Hsc70 to refold, and thus inhibit kinase function.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98185 USA	University of Washington; University of Washington Seattle; Northwestern University; University of Washington; University of Washington Seattle	Katze, MG (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	honey@u.washington.edu	Tan, Seang Lin/I-7710-2012	Song, Jaewhan/0000-0001-8152-9210	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041629, R01AI022646] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00166] Funding Source: Medline; NIAID NIH HHS [AI-41629, AI-22646] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; ETKIND PR, 1975, J VIROL, V16, P1464, DOI 10.1128/JVI.16.6.1464-1475.1975; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Gale M, 1996, MOL CELL BIOL, V16, P4172; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOHFELD J, 1995, CELL, V83, P589; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Irmer H, 1997, J BIOL CHEM, V272, P2230; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; JINDAL S, 1992, J VIROL, V66, P5357, DOI 10.1128/JVI.66.9.5357-5362.1992; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; King C, 1997, BIOCHEMISTRY-US, V36, P4067, DOI 10.1021/bi9625307; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MACEJAK DG, 1991, VIROLOGY, V180, P120, DOI 10.1016/0042-6822(91)90015-4; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Mayer MP, 1998, BIOL CHEM, V379, P261; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; SAGARA J, 1992, VIROLOGY, V190, P845, DOI 10.1016/0042-6822(92)90923-D; SAITO S, 1990, MICROBIOL IMMUNOL, V34, P859, DOI 10.1111/j.1348-0421.1990.tb01064.x; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; Smith DF, 1998, BIOL CHEM, V379, P283; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tang NM, 1996, J BIOL CHEM, V271, P28660, DOI 10.1074/jbc.271.45.28660; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trgovcich J, 1997, VIROLOGY, V227, P234, DOI 10.1006/viro.1996.8289; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	62	110	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3797	3803		10.1074/jbc.274.6.3797	http://dx.doi.org/10.1074/jbc.274.6.3797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920933	hybrid			2022-12-25	WOS:000078428200073
J	Stockand, JD; Al-Baldawi, NF; Al-Khalili, OK; Worrell, RT; Eaton, DC				Stockand, JD; Al-Baldawi, NF; Al-Khalili, OK; Worrell, RT; Eaton, DC			S-adenosyl-L-homocysteine hydrolase regulates aldosterone-induced Na+ transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLHOMOCYSTEINE-HYDROLASE; SODIUM-TRANSPORT; APICAL MEMBRANE; METHYLATION; CHANNELS; PURIFICATION; METABOLISM; EXPRESSION; EPITHELIA	Aldosterone-induced Na+ reabsorption, in part, is regulated by a critical methyl esterification; however, the signal transduction pathway regulating this methylation remains unclear. The A6 cell line was used as a model epithelia to investigate regulation of aldosterone-induced Na+ transport by S-adenosyl-L-homocysteine hydrolase (SAHHase), the only enzyme in vertebrates known to catabolize S-adenosyl-L-homocysteine (SAH), an end product inhibitor of methyl esterification, Sodium reabsorption was decreased within 2 h by 3-deazaadenosine, a competitive inhibitor of SAHHase, with a half inhibitory concentration between 40 and 50 mu M. Aldosterone increased SAH catabolism by activating SAHHase. Increased SAH catabolism was associated with a concomitant increase in S-adenosylmethionine catabolism, Moreover, SAH decreased substrate methylation. Antisense oligonucleotide complementary to SAHHase mRNA decreased SAHHase activity and Na+ current by approximately 50%. Overexpression of SAHHase increased SAHHase activity and dependent substrate methyl esterification, Whereas basal Na+ current was not affected by overexpression of SAHHase, aldosterone-induced current in SAHHase-overexpressing cells was significantly potentiated. These results demonstrate that aldosterone induction of SAHHase activity is necessary for a concomitant relief of the methylation reaction from end product inhibition by SAH and the subsequent increase in Na+ reabsorption. Thus, regulation of SAHHase activity is a control point for aldosterone signal transduction, but SAHHase is not an aldosterone-induced protein.	Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA	Emory University	Stockand, JD (corresponding author), Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signaling, 1648 Pierce Dr, Atlanta, GA 30322 USA.	jstocka@emory.edu		Stockand, James/0000-0002-3817-4319; Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037963, R37DK037963, F32DK009729] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37963, DK09729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBALDAWI NF, 1998, FASEB J, V21, P2447; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC1928, DOI 10.1152/ajpcell.1997.272.6.C1928; CHEN S, 1998, J AM SOC NEPHROL, V9, P398; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; FINKELSTEIN JD, 1973, ARCH BIOCHEM BIOPHYS, V159, P160, DOI 10.1016/0003-9861(73)90440-2; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HERSHFIELD MS, 1985, BIOCHEM J, V230, P43, DOI 10.1042/bj2300043; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; KIM IK, 1983, ARCH BIOCHEM BIOPHYS, V226, P65, DOI 10.1016/0003-9861(83)90271-0; Kloor D, 1996, KIDNEY BLOOD PRESS R, V19, P100, DOI 10.1159/000174051; Ling BN, 1997, J BIOL CHEM, V272, P594; PALMER JL, 1979, J BIOL CHEM, V254, P1217; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SCHRADER J, 1981, BIOCHEM J, V196, P65, DOI 10.1042/bj1960065; SEERY LT, 1994, BIOCHEM BIOPH RES CO, V205, P1539, DOI 10.1006/bbrc.1994.2842; TREWYN RW, 1981, J BIOCHEM BIOPH METH, V4, P299, DOI 10.1016/0165-022X(81)90070-1; UELAND PM, 1982, PHARMACOL REV, V34, P223; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43	23	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3842	3850		10.1074/jbc.274.6.3842	http://dx.doi.org/10.1074/jbc.274.6.3842			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920939	hybrid			2022-12-25	WOS:000078428200079
J	Koreth, J; Bakkenist, CJ; Larin, Z; Hunt, NCA; James, MR; McGee, JO				Koreth, J; Bakkenist, CJ; Larin, Z; Hunt, NCA; James, MR; McGee, JO			11q23.1 and 11q25-qter YACs suppress tumour growth in vivo	ONCOGENE			English	Article						tumour suppressor gene; YAC functional complementation; chromosome 11q; cancer; A9 cells	BREAST-CANCER; OVARIAN-CANCER; ATAXIA-TELANGIECTASIA; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; CHROMOSOME 11Q23; HUMAN GENE; HETEROZYGOSITY; REGION; CELLS	Frequent allelic deletion at chromosome 11q22-q23.1 has been described in breast cancer and a number of other malignancies, suggesting putative tumour suppressor gene(s) within the similar to 8 Mb deleted region. In addition, we recently described another locus, at the 11q25-qter region, frequently deleted in breast cancer, suggesting additional tumour suppressor gene(s) in this similar to 2 Mb deleted region. An 11q YAC contig was accessed and three YACs, one containing the candidate gene A TM at 11q23.1, and two contiguous YACs (overlapping for similar to 400-600kb) overlying most of the 11q25 deleted region, were retrofitted with a G418 resistance marker and transfected into murine A9 fibrosarcoma cells, Selected A9 transfectant clones (and control untransfected and 'irrelevant' alphoid YAC transfectant A9 clones) were assayed for in vivo tumorigenicity in athymic female Balb c-nu/nu mice. All the 11q YAC transfectant clones demonstrated significant tumour suppression compared to the control untransfected and 'irrelevant' YAC transfected A9 cells. These results define two discrete tumour suppressor loci on chromosome 11q by functional complementation, one to a similar to 1.2 Mb region on 11q23.1 (containing the ATM locus) and another to a similar to 400-600 kb subterminal region on 11q25-qter.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Wellcome Trust Ctr Human Genet, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	McGee, JO (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England.		Monaco, Zoia L/C-5762-2011					Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Baffa R, 1996, CANCER RES, V56, P268; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; CARTER SL, 1994, CANCER RES, V54, P6270; Davis M, 1996, CANCER RES, V56, P741; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; EASTON DF, 1994, INT J RADIAT BIOL, V66, P6270; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Gioeli D, 1997, CANCER RES, V57, P1157; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; HIRST MC, 1991, NUCLEIC ACIDS RES, V19, P3283, DOI 10.1093/nar/19.12.3283; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; IIZUKA M, GENES CHROMOSOMES CA, V13, P40; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; KORETH J, 1998, IN PRESS J PATHOL; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; LARIN Z, 1995, PULSED FIELD GEL ELE, P139; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; Phillips KK, 1996, CANCER RES, V56, P1222; RASIO D, 1995, CANCER RES, V55, P3988; Robertson G, 1996, CANCER RES, V56, P4487; Savitsky K, 1996, GENOMICS, V33, P199, DOI 10.1006/geno.1996.0184; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Todd MC, 1996, ONCOGENE, V13, P2387; Tomlinson IPM, 1996, J CLIN PATHOL, V49, P386, DOI 10.1136/jcp.49.5.386; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; Vorechovsky I, 1996, CANCER RES, V56, P2726; WINQVIST R, 1995, CANCER RES, V55, P2660; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	46	13	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1157	1164		10.1038/sj.onc.1202372	http://dx.doi.org/10.1038/sj.onc.1202372			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022121				2022-12-25	WOS:000078510700004
J	Yeh, JC; Ong, E; Fukuda, M				Yeh, JC; Ong, E; Fukuda, M			Molecular cloning and expression of a novel beta-1,6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; HAMSTER OVARY CELLS; BLOOD GROUP-I; L-SELECTIN; CARBOHYDRATE STRUCTURE; GLYCAN BIOSYNTHESIS; GASTRIC-MUCOSA; GENE FAMILY; ANTIGEN; MUCIN	Mucin-type O-glycans are classified according to their core structures. Among them, cores 2 and 4 are important for having N-acetyllactosamine side chains, which can be further modified to express various functional oligosaccharides. Previously, we discovered by cloning cDNAs that the core 2 branching enzyme, termed core 2 beta-1,6-N-acetylglucosaminyltransferase-leukocyte type (C2GnT-L), is highly homologous to the I branching beta-1,6-N-acetylglucosaminyltransferase (IGnT) (Bierhuizen, M. F. A., Mattei, M.-G., and Fukuda, M. (1993) Genes Dev. 7, 468-478). Using these homologous sequences as probes, we identified an expressed sequence tag in dbEST, which has significant homology to C2GnT-L and IGnT, This approach, together with 5' and 3' rapid amplification of cDNA ends, yielded a human cDNA that encompasses a whole coding region of an enzyme, termed C2GnT-mucin type (C2GnT-M), C2GnT-M has 48.2 and 33.8% identity with C2GnT-L and IGnT at the amino acid levels. The expression of C2GnT-M cDNA directed the expression of core 2 branched oligosaccharides and I antigen on the cell surface. Moreover, a soluble chimeric C2GnT-M had core 4 branching activity in addition to core 2 and I branching activities. A soluble chimeric C2GnT-L, in contrast, almost exclusively contains core 2 branching activity. Northern blot analysis demonstrated that the C2GnT-M transcripts are heavily expressed in colon, small intestine, trachea, and stomach, where mucin is produced. In contrast, the transcripts of C2GnT-L were more widely detected, including the lymph node and bone marrow. These results indicate that the newly cloned C2GnT-M plays a critical role in O-glycan synthesis in mucins and might have distinctly different roles in oligosaccharide ligand formation compared with C2GnT-L.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham-inst.org			NATIONAL CANCER INSTITUTE [R37CA033000, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R37 CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Edge ASB, 1997, ARCH BIOCHEM BIOPHYS, V343, P73, DOI 10.1006/abbi.1997.0143; ELLIES LG, 1998, IN PRESS IMMUNITY; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; Gebe JA, 1997, J BIOL CHEM, V272, P6151, DOI 10.1074/jbc.272.10.6151; GU J, 1992, J BIOL CHEM, V267, P2994; HANISCH FG, 1989, J BIOL CHEM, V264, P261; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOUNSELL EF, 1980, BIOCHEM BIOPH RES CO, V92, P1143, DOI 10.1016/0006-291X(80)90406-4; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LOWE JB, 1994, MOL GLYCOBIOLOGY, P163; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Mattila P, 1998, J BIOL CHEM, V273, P27633, DOI 10.1074/jbc.273.42.27633; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PILLER F, 1984, J BIOL CHEM, V259, P3385; PILLER F, 1988, J BIOL CHEM, V263, P15146; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Shimodaira K, 1997, CANCER RES, V57, P5201; SMITH DF, 1990, J BIOL CHEM, V265, P6225; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; VAVASSEUR F, 1995, GLYCOBIOLOGY, V5, P351, DOI 10.1093/glycob/5.3.351; WEN DX, 1992, J BIOL CHEM, V267, P21011; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	41	169	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3215	3221		10.1074/jbc.274.5.3215	http://dx.doi.org/10.1074/jbc.274.5.3215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915862	hybrid			2022-12-25	WOS:000078319500080
J	Kumagai, T; Miki, T; Kikuchi, M; Fukuda, T; Miyasaka, N; Kamiyama, R; Hirosawa, S				Kumagai, T; Miki, T; Kikuchi, M; Fukuda, T; Miyasaka, N; Kamiyama, R; Hirosawa, S			The proto-oncogene Bc16 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells	ONCOGENE			English	Article						Bc16; apoptosis; muscle cell	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; CENTER B-CELLS; GROWTH-FACTOR; DNA-BINDING; MYOCYTE DIFFERENTIATION; 3Q27 TRANSLOCATION; BCL-6 GENE; EXPRESSION	The Bc16 gent is located at chromosomal band 3q27, a breakpoint for translocation that frequently occurs in B cell lymphomas. Bc16 has been found to be preferentially expressed in germinal center B cells, and expression of this gene has been shown to be essential for germinal center formation in vivo. The physiological function of Bc16 and its role in lymphomagenesis, however, are not yet known, Since significant expression of Bc16 has been demonstrated in skeletal muscle, we have utilized a differentiation-inducible mouse myogenic cell line, C2C12, to elucidate the function of the Bc16 gene product. Expression of Bc16 mRNA was very low in growing myocytes, but was increased in differentiating myocytes cultured in serum-started medium, Incubation of these cells with cytokines or chemicals that are known to block differentiation suppressed this increased Bc16 message abundance, indicating that Bc16 induction is related to the process of terminal differentiation in muscle cells. While a fraction of myocytes is known to undergo apoptosis after serum-starvation to induce differentiation, adenovirus-mediated overexpression of Bc16 enhanced the viability of the differentiating cells by preventing the apoptosis, High levels of Bc16 antisense mRNA expression induced substantial apoptosis during the differentiation of C2C12 cells, but this,vas effectively prevented by infection with adenovirus that expressed Bc16 sense mRNA, These results indicate that Bc16 acts to prevent apoptotic cell death in differentiating myocytes. The deregulation of expression of this anti-apoptotic gene may also contribute to the development of B cell lymphomas.	Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Sch Allied Hlth Sci, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hirosawa, S (corresponding author), Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Tokyo 1138519, Japan.							Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DIBELLO PR, 1991, GENETICS, V129, P385; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KIM SJ, 1992, J BIOL CHEM, V267, P15140; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MIKI T, 1994, BLOOD, V83, P217; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OFFIT K, 1989, BLOOD, V74, P1876; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Okada S, 1998, J IMMUNOL, V160, P2590; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	45	54	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					467	475		10.1038/sj.onc.1202306	http://dx.doi.org/10.1038/sj.onc.1202306			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927203				2022-12-25	WOS:000078166500019
J	Griner, RD; Qin, F; Jung, EM; Sue-Ling, CK; Crawford, KB; Mann-Blakeney, R; Bollag, RJ; Bollag, WB				Griner, RD; Qin, F; Jung, EM; Sue-Ling, CK; Crawford, KB; Mann-Blakeney, R; Bollag, RJ; Bollag, WB			1,25-dihydroxyvitamin D-3 induces phospholipase D-1 expression in primary mouse epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; RAT-BRAIN; VITAMIN-D; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PHOSPHOINOSITIDE TURNOVER; TERMINAL DIFFERENTIATION; CELLS; CALCIUM; CLONING	The hormone 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) elicits the programmed pattern of differentiation in epidermal keratinocytes. Based on data indicating a potential role of phospholipase D (PLD) in mediating keratinocyte differentiation, we investigated the effect of 1,25(OH),D, on PLD expression, A 24-h exposure to 1,25(OH)(2)D-3 stimulated PLD-1, but not PLD-2, mRNA expression. This 1,25(OH)(2)D-3-enhanced expression was accompanied by increased total PLD and PLD-1 activity. Time course studies indicated that 1,25(OH)(2)D-3 induced PLD-1 expression by 8 h, with a maximal increase at 20-24 h. Exposure to 1,25(OH)(2)D-3 inhibited proliferation over the same time period with similar kinetics. Expression of the early (spinous) differentiation marker keratin 1 decreased in response to 1,25(OH)(2)D-3 over 12-24 h, Treatment with 1,25(OH)(2)D-3 enhanced the activity of transglutaminase, a late (granular) differentiation marker, by 12 h with a maximal increase after 24 h. In situ hybridization studies demonstrated that the highest levels of PLD-1 expression are in the more differentiated (spinous and granular) layers of the epidermis, with little expression in basal keratinocytes. Our results suggest a role for PLD expression/activity during keratinocyte differentiation.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med Dermatol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Bollag, WB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Dept Med & Cellular Biol & Anat, 1120 15th St, Augusta, GA 30912 USA.			Bollag, Wendy/0000-0003-3146-162X	NIAMS NIH HHS [AR45212] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR045212, R01AR045212] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERTHJONES J, 1992, BRIT J DERMATOL, V127, P71, DOI 10.1111/j.1365-2133.1992.tb08035.x; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BIKLE DD, 1995, J NUTR, V125, pS1709; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; Bollag W B, 1998, Methods Mol Biol, V105, P151; BOLLAG WB, 1991, ENDOCRINOLOGY, V128, P231, DOI 10.1210/endo-128-1-231; BOLLAG WB, 1995, J CELL PHYSIOL, V163, P248, DOI 10.1002/jcp.1041630205; CHANG PL, 1994, ENDOCRINOLOGY, V135, P863, DOI 10.1210/en.135.3.863; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; Geilen GC, 1997, J BIOL CHEM, V272, P8997, DOI 10.1074/jbc.272.14.8997; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HANAFIN NM, 1995, J CELL BIOCHEM, V57, P362, DOI 10.1002/jcb.240570220; Inohara S, 1992, Exp Dermatol, V1, P207, DOI 10.1111/j.1600-0625.1992.tb00079.x; Iwasaki-Bessho Y, 1998, J INVEST DERMATOL, V110, P376; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; JOHNSON RM, 1992, SEC MESS PHOSPHOPROT, V14, P21; Jung EM, 1998, J INVEST DERMATOL, V110, P318, DOI 10.1046/j.1523-1747.1998.00137.x; KIM HJ, 1992, J CELL PHYSIOL, V151, P579, DOI 10.1002/jcp.1041510318; Kodaki T, 1997, J BIOL CHEM, V272, P11408; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LU B, 1994, J BIOL CHEM, V269, P7443; MATKOVITS T, 1995, ENDOCRINOLOGY, V136, P3971, DOI 10.1210/en.136.9.3971; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohguchi K, 1997, J BIOL CHEM, V272, P1990, DOI 10.1074/jbc.272.3.1990; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; SEISHIMA M, 1995, J INVEST DERMATOL, V104, P835, DOI 10.1111/1523-1747.ep12607015; SREEKUMAR P, 1995, J CLIN INVEST, V96, P602, DOI 10.1172/JCI118075; SU MJ, 1994, J BIOL CHEM, V269, P14723; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TALWAR HS, 1990, J INVEST DERMATOL, V95, P705, DOI 10.1111/1523-1747.ep12514507; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2; YADA Y, 1991, BIOCHEM J, V279, P665, DOI 10.1042/bj2790665; Yoshimura S, 1996, BIOCHEM BIOPH RES CO, V225, P494, DOI 10.1006/bbrc.1996.1201; YUSPA SH, 1990, UCLA SYM BI, V124, P211; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	46	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4663	4670		10.1074/jbc.274.8.4663	http://dx.doi.org/10.1074/jbc.274.8.4663			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988703	hybrid			2022-12-25	WOS:000078698200028
J	Hirabayashi, T; Kume, K; Hirose, K; Yokomizo, T; Iino, M; Itoh, H; Shimizu, T				Hirabayashi, T; Kume, K; Hirose, K; Yokomizo, T; Iino, M; Itoh, H; Shimizu, T			Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; NUCLEAR-ENVELOPE; FACTOR RECEPTOR; SUBCELLULAR-LOCALIZATION; PROTEIN-KINASE; MAP KINASE; CALCIUM; PHOSPHORYLATION; CELLS; EXPRESSION	When cells are exposed to certain external stimuli, arachidonic acid (AA) is released from the membrane and serves as a precursor of various types of eicosanoids. A Ca2+-regulated cytosolic phospholipase A(2) (cPLA(2)) plays a dominant role in the release of AA. To closely examine the relation between Ca2+ response and AA release by stimulation of G protein-coupled receptors, we established several lines of Chinese hamster ovary cells expressing platelet-activating factor receptor or leukotriene B-4 receptor. Measurement of intracellular Ca2+ concentration ([Ca2+](i)) demonstrated that cell lines capable of releasing AA. elicited a sustained [Ca2+](i) increase when stimulated by agonists. The prolonged [Ca2+](i) elevation is the result of Ca2+ entry, because this elevation was blocked by EGTA treatment or in the presence of Ca2+ channel blockers (SKF 96365 and methoxyverapamil). cPLA(2) fused with a green fluorescent protein (cPLA(2)-GFP) translocated from the cytosol to the perinuclear region in response to increases in [Ca2+](i). When EGTA was added shortly after [Ca2+](i) increase, the cPLA(2)-GFP returned to the cytosol, without liberating AA. After a prolonged [Ca2+](i) increase, even by EGTA treatment, the enzyme was not readily redistributed to the cytosol. Thus, we propose that a critical time length of [Ca2+](i) elevation is required for continuous membrane localization and full activation of cPLA(2).	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	University of Tokyo; University of Tokyo; Tokyo Institute of Technology	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		; Yokomizo, Takehiko/P-5673-2016	Hirabayashi, Tetsuya/0000-0001-8099-5367; Kume, Kazuhiko/0000-0003-4232-1657; Yokomizo, Takehiko/0000-0002-5219-1553				Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KLEY N, 1987, J BIOL CHEM, V262, P4083; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Miyakawa T, 1998, BIOCHEM J, V329, P107, DOI 10.1042/bj3290107; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NarayFejesToth A, 1996, J BIOL CHEM, V271, P15436, DOI 10.1074/jbc.271.26.15436; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; TAKANO T, 1994, J BIOL CHEM, V269, P22453; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VIAL D, 1995, J NEUROCHEM, V64, P2765; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; XU XX, 1994, J BIOL CHEM, V269, P31693; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	44	147	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5163	5169		10.1074/jbc.274.8.5163	http://dx.doi.org/10.1074/jbc.274.8.5163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988766	hybrid			2022-12-25	WOS:000078698200091
J	Picard, V; Marque, PE; Paolucci, F; Aiach, M; Le Bonniec, BF				Picard, V; Marque, PE; Paolucci, F; Aiach, M; Le Bonniec, BF			Topology of the stable serpin-protease complexes revealed by an autoantibody that fails to react with the monomeric conformers of antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CENTER LOOP; CRYSTAL-STRUCTURE; BETA-SHEET; BOND LOOP; CONFORMATIONAL-CHANGES; HEPARIN-BINDING; C1 INHIBITOR; SITE LOOP; ALPHA-1-PROTEINASE INHIBITOR	Solving the structure of the stable complex between a serine protease inhibitor (serpin) and its target has been a long standing goal. We describe herein the characterization of a monoclonal antibody that selectively recognizes antithrombin in complex with either thrombin, factor Xa, or a synthetic peptide corresponding to residues P-14 to P-9 of the serpin's reactive center loop (RCL, ultimately cleaved between the P-1 and P'(1) residues), Accordingly, this antibody reacts with none of the monomeric conformers of antithrombin (native, latent, and RCL-cleaved) and does not recognize heparin-activated antithrombin or antithrombin bound to a non-catalytic mutant of thrombin (S195A, in which the serine of the charge stabilizing system has been swapped for alanine). The neoepitope encompasses the motif DAFHX, located in native antithrombin on strand 4 of beta-sheet A, which becomes strand 5 of beta-sheet A in the RCL-cleaved and latent conformers. The inferences on the structure of the antithrombin-protease stable complex are that either a major remodeling of antithrombin accompanies the final elaboration of the complex or that, within the complex, at the most residues P-14 to P-9 of the RCL are inserted into beta-sheet A. These conclusions limit drastically the possible locations of the defeated protease within the complex.	Univ Paris 05, Fac Pharm, INSERM, U428, F-75270 Paris 06, France; Sanofi Res, F-34000 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis	Le Bonniec, BF (corresponding author), Univ Paris 05, Fac Pharm, INSERM, U428, 4 Av Observ, F-75270 Paris 06, France.		Le Bonniec, Bernard/S-5756-2016; Le Bonniec, Bernard/ABA-1366-2020	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363				ASAKURA S, 1990, J BIOL CHEM, V265, P5135; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1992, J BIOL CHEM, V267, P19047; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Fitton HL, 1997, BIOL CHEM, V378, P1059; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kjoller L, 1996, EUR J BIOCHEM, V241, P38, DOI 10.1111/j.1432-1033.1996.0038t.x; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; Nordling K, 1996, BIOCHEMISTRY-US, V35, P10436, DOI 10.1021/bi9603579; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; Song HK, 1995, FEBS LETT, V377, P150; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Zahedi R, 1996, J BIOL CHEM, V271, P24307, DOI 10.1074/jbc.271.39.24307	63	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4586	4593		10.1074/jbc.274.8.4586	http://dx.doi.org/10.1074/jbc.274.8.4586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988693	hybrid			2022-12-25	WOS:000078698200018
J	Sun, XM; MacFarlane, M; Zhuang, JG; Wolf, BB; Green, DR; Cohen, GM				Sun, XM; MacFarlane, M; Zhuang, JG; Wolf, BB; Green, DR; Cohen, GM			Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-LIKE PROTEASES; INDUCED CELL-DEATH; CYTOCHROME-C; SIGNALING COMPLEX; BCL-2; MITOCHONDRIA; INVOLVEMENT; ACTIVATION; PATHWAY; RELEASE	Release of cytochrome c is important in many forms of apoptosis. Recent studies of CD95 (Fas/APO-1)-induced apoptosis have implicated caspase-8 cleavage of Bid, a BH3 domain-containing proapoptotic member of the Bcl-2 family, in this release. We now demonstrate that both receptor-induced (CD95 and tumor necrosis factor) and chemical-induced apoptosis result in a similar time-dependent activation of caspases-3, -7, -8, and -9 in Jurkat T cells and human leukemic U937 cells. In receptor-mediated apoptosis, the caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone (Z-VAD.FMK), inhibits apoptosis prior to commitment to cell, death by inhibiting the upstream activator caspase-8, cleavage of Bid, release of mitochondrial cytochrome c, processing of effector caspases, loss of mitochondrial membrane potential, and externalization of phosphatidylserine, However, Z-VAD.FMK inhibits chemical-induced apoptosis at a stage after commitment to cell death by inhibiting the initiator caspase-9 and the resultant postmitochondrial activation of effector caspases. Cleavage of Bid but not release of cytochrome c is blocked by Z-VAD.FMK demonstrating that in chemical-induced apoptosis cytochrome c release is caspase-independent and is not mediated by activation of Bid. We propose that caspases form an integral part of the cell death-inducing mechanism in receptor-mediated apoptosis, whereas in chemical-induced apoptosis they act solely as executioners of apoptosis.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	University of Leicester; La Jolla Institute for Immunology	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Green, Douglas R/N-8083-2018; Cohen, Gerald M/A-1687-2008	Green, Douglas R/0000-0002-7332-1417; Zhuang, Jianguo/0000-0003-3245-0789				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	770	787	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5053	5060		10.1074/jbc.274.8.5053	http://dx.doi.org/10.1074/jbc.274.8.5053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988752	hybrid			2022-12-25	WOS:000078698200077
J	Benov, L; Fridovich, I				Benov, L; Fridovich, I			Why superoxide imposes an aromatic amino acid auxotrophy on Escherichia coli - The transketolase connection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDRATASE; ENZYME; INACTIVATION; DISMUTASE; MUTANTS; 7-PHOSPHATE; CLUSTER; STRESS	The lack of superoxide dismutase and the consequent elevation of [O-2(-)] imposes, on Escherichia coli, auxotrophies far branched chain, sulfur-containing, and aromatic amino acids. The former two classes of auxotrophies have already been explained, whereas the third is explained herein. Thus O-2(-) is shown to interfere with the production of erythrose-4-phosphate, which is essential for the first step of the aromatic biosynthetic pathway. It does so by oxidizing the 1,2-dihydroxyethyl thiamine pyrophosphate; intermediate of transketolase and inactivating this enzyme.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146				ASAMI S, 1977, BIOCHEMISTRY-US, V16, P2202, DOI 10.1021/bi00629a025; Benov L, 1998, J BIOL CHEM, V273, P25741, DOI 10.1074/jbc.273.40.25741; Benov L, 1998, J BIOL CHEM, V273, P10313, DOI 10.1074/jbc.273.17.10313; Benov L, 1996, J BIOL CHEM, V271, P21037, DOI 10.1074/jbc.271.35.21037; Benov L, 1997, ARCH BIOCHEM BIOPHYS, V347, P271, DOI 10.1006/abbi.1997.0343; BLACKMORE PF, 1976, FEBS LETT, V64, P222, DOI 10.1016/0014-5793(76)80288-8; BROWN OR, 1995, ARCH BIOCHEM BIOPHYS, V319, P10, DOI 10.1006/abbi.1995.1262; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P315; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P320; CREWE R, 1966, BIOCH PREP, V11, P21; DATTA AG, 1961, J BIOL CHEM, V236, P617; DRATHS KM, 1992, J AM CHEM SOC, V114, P3956, DOI 10.1021/ja00036a050; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; FROST JW, 1984, BIOCHEMISTRY-US, V23, P4465, DOI 10.1021/bi00314a035; HASLAN E, 1987, METHOD ENZYMOL, V142, P498; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; JOSEPHSON BL, 1974, J BACTERIOL, V118, P1082, DOI 10.1128/JB.118.3.1082-1089.1974; KUO CF, 1987, J BIOL CHEM, V262, P4724; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; Maniatis T, 1982, MOL CLONING LABORATO, P68; MEHDI S, 1987, METHOD ENZYMOL, V142, P306; PAOLETTI F, 1979, ANAL BIOCHEM, V95, P250, DOI 10.1016/0003-2697(79)90213-6; SCHONER R, 1976, J BIOL CHEM, V251, P5440; SMYKRANDALL E, 1993, FREE RADICAL BIO MED, V14, P609, DOI 10.1016/0891-5849(93)90142-H; TAKABE T, 1980, BIOCHEMISTRY-US, V19, P3985, DOI 10.1021/bi00558a015; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; TRIBE DE, 1976, J BACTERIOL, V127, P1085, DOI 10.1128/JB.127.3.1085-1097.1976; WILLIAMS JF, 1980, INT J BIOCHEM, V12, P339, DOI 10.1016/0020-711X(80)90112-3	31	55	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4202	4206		10.1074/jbc.274.7.4202	http://dx.doi.org/10.1074/jbc.274.7.4202			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933617	hybrid			2022-12-25	WOS:000078575500041
J	Bozue, JA; Tullius, MV; Wang, J; Gibson, BW; Munson, RS				Bozue, JA; Tullius, MV; Wang, J; Gibson, BW; Munson, RS			Haemophilus ducreyi produces a novel sialyltransferase - Identification of the sialyltransferase gene and construction of mutants deficient in the production of the sialic acid-containing glycoform of the lipooligosaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FORESKIN FIBROBLASTS; GENITAL ULCER DISEASE; NEISSERIA-GONORRHOEAE; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE BIOSYNTHESIS; MONOCLONAL-ANTIBODIES; HEMOPHILUS-INFLUENZAE; MUCOSAL PATHOGENS; MASS-SPECTROMETRY; HUMAN NEUTROPHILS	Haemophilus ducreyi, the cause of the sexually transmitted disease chancroid produces a lipooligosaccharide (LOS) containing a terminal sialyl N-acetyllactosamine trisaccharide, Previously, we reported the identification and characterization of the N-acetylneuraminic acid cytidylsynthetase gene (neuA), Forty-nine base pairs downstream of the synthetase gene is an open reading frame (ORF) encoding a protein with a predicted molecular weight of 34,646, This protein has weak homology to the polysialyltransferase of Escherichia colt K92, Downstream of this ORF is the gene encoding the H, ducreyi homologue of the Salmonella typhimurium rmlB gene. Mutations were constructed in the neuA gene and the gene encoding the second ORF by insertion of an Omega kanamycin cassette, and isogenic strains were constructed. LOS was isolated from each strain and characterized by SDS-polyacrylamide gel electrophoresis, carbohydrate, and mass spectrometric analysis, LOS isolated from strains containing a mutation in neuA or in the second ORF, designated Ist, lacked the sialic acid-containing glycoform, Complementation studies were performed, The neuA gene and the ist gene were each cloned into the shuttle vector pLS88 after polymerase chain reaction amplification. Complementation of the mutation in the ist gene was observed, but we were unable to complement the neuA mutation, Since it is possible that transcription of the neuA gene and the Ist gene were coupled, we constructed a nonpolar mutation in the neuA gene, in this construct, the neuA mutation was complemented, suggesting transcriptional coupling of the neuA gene and the ist gene, Sialyltransferase activity was detected by incorporation of C-14-labeled NeuAc from CMP-NeuAc into trichloroacetic acid-precipitable material when the Ist gene was overexpressed in the nonpolar neuA mutant. We conclude that the Ist gene encodes the H, ducreyi sialyltransferase, Since the Ist gene product has little, if any, structural relationship to other sialyltransferases, this protein represents a new class of sialyltransferase.	Childrens Hosp Res Fdn, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; Ohio State Univ, Dept Med Microbiol, Columbus, OH 43205 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California San Francisco	Munson, RS (corresponding author), Childrens Hosp Res Fdn, 700 Childrens Dr,Room W402, Columbus, OH 43205 USA.	munsonr@pediatrics.ohio-state.edu	Bozue, Joel/AAE-4363-2022; Munson, Jr, Robert/E-3710-2011; Bozue, Joel/AAE-4357-2022	Bozue, Joel/0000-0001-6959-8176; Munson, Jr, Robert/0000-0002-3204-3019; Bozue, Joel/0000-0001-6959-8176	NIAID NIH HHS [AI31254, AI34967, AI38444] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038444, R01AI031254, R01AI034967] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABECK D, 1992, INT J STD AIDS, V3, P319, DOI 10.1177/095646249200300503; Ahmed HJ, 1997, INFECT IMMUN, V65, P3151, DOI 10.1128/IAI.65.8.3151-3158.1997; Alfa MJ, 1997, MICROB PATHOGENESIS, V22, P39, DOI 10.1006/mpat.1996.0089; Alfa MJ, 1996, INFECT IMMUN, V64, P2349, DOI 10.1128/IAI.64.6.2349-2352.1996; APICELLA MA, 1994, METHOD ENZYMOL, V235, P242; APICELLA MA, 1990, J INFECT DIS, V162, P506, DOI 10.1093/infdis/162.2.506; BARCAK GJ, 1991, METHOD ENZYMOL, V204, P321; BITTERSUERMANN D, 1993, POLYSIALIC ACID MICR, P11; Bozue JA, 1998, FEMS MICROBIOL LETT, V164, P269, DOI 10.1111/j.1574-6968.1998.tb13097.x; CAMPAGNARI AA, 1994, INFECT IMMUN, V62, P2379, DOI 10.1128/IAI.62.6.2379-2386.1994; CAMPAGNARI AA, 1990, MICROB PATHOGENESIS, V8, P353, DOI 10.1016/0882-4010(90)90094-7; CAMPAGNARI AA, 1991, INFECT IMMUN, V59, P2601, DOI 10.1128/IAI.59.8.2601-2608.1991; Cope LD, 1997, P NATL ACAD SCI USA, V94, P4056, DOI 10.1073/pnas.94.8.4056; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON LG, 1994, PLASMID, V32, P228, DOI 10.1006/plas.1994.1060; FLOOD JM, 1993, J INFECT DIS, V167, P1106, DOI 10.1093/infdis/167.5.1106; FOX AJ, 1989, MICROB PATHOGENESIS, V7, P317, DOI 10.1016/0882-4010(89)90050-8; Gibson BW, 1997, J BACTERIOL, V179, P5062, DOI 10.1128/jb.179.16.5062-5071.1997; Gibson BW, 1997, J AM SOC MASS SPECTR, V8, P645, DOI 10.1016/S1044-0305(97)00042-1; GIBSON BW, 1993, J BACTERIOL, V175, P2702, DOI 10.1128/JB.175.9.2702-2712.1993; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; HAMMERSCHMIDT S, 1994, MOL MICROBIOL, V11, P885, DOI 10.1111/j.1365-2958.1994.tb00367.x; HAMMOND GW, 1978, ANTIMICROB AGENTS CH, V13, P608, DOI 10.1128/AAC.13.4.608; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; INZANA TJ, 1983, J INFECT DIS, V148, P492, DOI 10.1093/infdis/148.3.492; Jann K., 1985, The virulence of Escherichia coli, P157; JENNINGS HJ, 1984, PURE APPL CHEM, V56, P893, DOI 10.1351/pac198456070893; JESSAMINE PG, 1990, MED CLIN N AM, V74, P1417, DOI 10.1016/S0025-7125(16)30488-6; JOHNSON KG, 1976, CAN J MICROBIOL, V22, P29, DOI 10.1139/m76-004; KIM JJ, 1992, INFECT IMMUN, V60, P4439, DOI 10.1128/IAI.60.10.4439-4442.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGERGARD T, 1992, MICROB PATHOGENESIS, V13, P203, DOI 10.1016/0882-4010(92)90021-F; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; Maniatis T., 1982, MOL CLONING LAB MANU; McGee DJ, 1996, INFECT IMMUN, V64, P4129, DOI 10.1128/IAI.64.10.4129-4136.1996; Melaugh W, 1996, J BACTERIOL, V178, P564, DOI 10.1128/jb.178.2.564-570.1996; MELAUGH W, 1994, BIOCHEMISTRY-US, V33, P13070, DOI 10.1021/bi00248a016; MENARD R, 1993, J BACTERIOL, V175, P5899; MORSE SA, 1989, CLIN MICROBIOL REV, V2, P137, DOI 10.1128/CMR.2.2.137-157.1989; Munoz P, 1997, ARCH INTERN MED, V157, P213, DOI 10.1001/archinte.157.2.213; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; PARSONS NJ, 1988, MICROB PATHOGENESIS, V5, P303, DOI 10.1016/0882-4010(88)90103-9; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; REST RF, 1992, INFECT IMMUN, V60, P989, DOI 10.1128/IAI.60.3.989-997.1992; REUTER G, 1994, METHOD ENZYMOL, V230, P168; RICE PA, 1987, A VAN LEEUW J MICROB, V53, P565, DOI 10.1007/BF00415518; RICE PA, 1977, J CLIN INVEST, V60, P1149, DOI 10.1172/JCI108867; ROBERTSON BD, 1994, J BACTERIOL, V176, P6915, DOI 10.1128/JB.176.22.6915-6920.1994; ROMANA LK, 1991, BIOCHEM BIOPH RES CO, V174, P846, DOI 10.1016/0006-291X(91)91495-X; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; SCHOOLNIK GK, 1976, J CLIN INVEST, V58, P1163, DOI 10.1172/JCI108569; SCHULTE J M, 1992, Morbidity and Mortality Weekly Report, V41, P57; SCHWEDA EKH, 1995, J BACTERIOL, V177, P5316, DOI 10.1128/jb.177.18.5316-5321.1995; SCHWEDA EKH, 1994, J BIOL CHEM, V269, P12040; SHAW DJ, 1982, J BACTERIOL, V152, P1132; SMITH H, 1992, FEMS MICROBIOL LETT, V100, P287, DOI 10.1016/0378-1097(92)90223-B; Smith H, 1995, MICROB PATHOGENESIS, V19, P365, DOI 10.1006/mpat.1995.0071; Spinola SM, 1996, J INFECT DIS, V173, P394, DOI 10.1093/infdis/173.2.394; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; SWANSON J, 1991, NEISSERIAE 1990, P391; TELZAK EE, 1993, ANN INTERN MED, V119, P1181, DOI 10.7326/0003-4819-119-12-199312150-00005; TIMMIS KN, 1985, CURR TOP MICROBIOL, V118, P197; TREES DL, 1995, CLIN MICROBIOL REV, V8, P357, DOI 10.1128/CMR.8.3.357; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TUFFREY M, 1990, J EXP PATHOL, V71, P233; Tullius MV, 1996, J BIOL CHEM, V271, P15373, DOI 10.1074/jbc.271.26.15373; VANPUTTEN JPM, 1995, MOL MICROBIOL, V16, P847; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; Vogel U, 1997, MED MICROBIOL IMMUN, V186, P159, DOI 10.1007/s004300050059; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030	76	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4106	4114		10.1074/jbc.274.7.4106	http://dx.doi.org/10.1074/jbc.274.7.4106			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933604	hybrid			2022-12-25	WOS:000078575500028
J	Chrisman, TD; Garbers, DL				Chrisman, TD; Garbers, DL			Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; NITRIC-OXIDE; CLEARANCE RECEPTOR; MESANGIAL CELLS; CYCLIC-GMP; INHIBITION; MECHANISM; CYCLASE	The fibroblast, a cell central to effective wound remodeling, not only contains various growth factor receptors but also high activities of a guanylyl cyclase receptor (GC-B), Here we demonstrate that marked elevations of cyclic GMP induced by C-type natriuretic peptide (CNP), the ligand of GC-B, blocks activation of the mitogen-activated protein kinase cascade in fibroblasts. We also show that platelet-derived growth factor, fibroblast growth factor, serum, or Na3VO4 rapidly (within 5 min) and extensively (up to 85% inhibition) disrupt CNP-dependent elevations of cyclic GMP. In addition, the mitogens also lower cyclic GMP concentrations (50% decrease) in cells not treated with CNP. Cytoplasmic forms of guanylyl cyclase, in contrast to the CNP-stimulated pathway, are not antagonized by the various mitogens, The effects of the mitogens on cellular cyclic GMP are fully explained by a direct and stable inactivation of GC-B. Homogenates obtained from fibroblasts treated with or without the various mitogens contain equivalent amounts of GC-B protein, but both ligand-dependent and ligand-independent activity are markedly (up to 90% inhibition of CNP-dependent activity) decreased after mitogen addition. The stable inactivation is correlated with the dephosphorylation of phosphoserine and phosphothreonine residues of the cyclase receptor. These results not only establish a specific and reciprocal antagonistic relationship between mitogen-activated and GC-B-regulated signaling pathways in the fibroblast but also suggest that one of the earliest events following mitogen activation of a fibroblast is an interruption of cyclic GMP production from this receptor.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75325 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chrisman, TD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75325 USA.	Ted.Chrisman@email.swmed.edu						APPEL RG, 1990, AM J PHYSIOL, V259, pE312, DOI 10.1152/ajpendo.1990.259.3.E312; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAHILL PA, 1991, BIOCHEM BIOPH RES CO, V179, P1606, DOI 10.1016/0006-291X(91)91758-5; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; Clark RA., 1995, MOL CELLULAR BIOL WO, P3; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; Diegelmann RF, 1997, J UROLOGY, V157, P298, DOI 10.1016/S0022-5347(01)65364-3; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FETHIERE J, 1989, MOL PHARMACOL, V35, P584; GARG UC, 1991, J BIOL CHEM, V266, P9; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; GRAINGER DJ, 1995, CLIN CHIM ACTA, V235, P11, DOI 10.1016/0009-8981(94)05995-4; Haneda M, 1996, KIDNEY INT, V50, P384, DOI 10.1038/ki.1996.327; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hutchinson HG, 1997, CARDIOVASC RES, V35, P158, DOI 10.1016/S0008-6363(97)00086-2; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; Kohno M, 1997, CIRC RES, V81, P585, DOI 10.1161/01.RES.81.4.585; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MEYERINGOLD W, 1995, CELL BIOL INT, V19, P389, DOI 10.1006/cbir.1995.1084; NESBITT JA, 1976, J BIOL CHEM, V251, P2344; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; SUGIMOTO T, 1993, BIOCHEM BIOPH RES CO, V195, P72, DOI 10.1006/bbrc.1993.2011; SUZUKI R, 1992, J ENDOCRINOL, V135, P317, DOI 10.1677/joe.0.1350317; Takizawa T, 1997, HYPERTENSION, V30, P1035, DOI 10.1161/01.HYP.30.5.1035; TAWARAGI Y, 1991, BIOCHEM BIOPH RES CO, V175, P645, DOI 10.1016/0006-291X(91)91614-I; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; YU SM, 1997, CIRCULATION, V95, P1296; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	39	79	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4293	4299		10.1074/jbc.274.7.4293	http://dx.doi.org/10.1074/jbc.274.7.4293			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933630	hybrid			2022-12-25	WOS:000078575500054
J	Shriver, Z; Liu, DF; Hu, Y; Sasisekharan, R				Shriver, Z; Liu, DF; Hu, Y; Sasisekharan, R			Biochemical investigations and mapping of the calcium-binding sites of heparinase I from Flavobacterium heparinum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOODWARDS-REAGENT-K; CHEMICAL MODIFICATION; DIRECTED MUTAGENESIS; HISTIDINE RESIDUE; ESCHERICHIA-COLI; GLYCOSAMINOGLYCANS; PROTEINS; PURIFICATION; LANTHANIDES; CATALYSIS	The heparinases from Flavobacterium heparinum are lyases that specifically cleave heparin-like glycosaminoglycans, Previously, amino acids located in the active site of heparinase I have been identified and mapped. In an effort to further understand the mechanism by which heparinase I cleaves its polymer substrate, we sought to understand the role of calcium, as a necessary cofactor, in the enzymatic activity of heparinase I, Specifically, we undertook a series of biochemical and biophysical experiments to answer the question of whether heparinase I binds to calcium and, if so, which regions of the protein are involved in calcium binding. Using the fluorescent calcium analog terbium, we found that heparinase I tightly bound divalent and trivalent cations, Furthermore, we established that this interaction was specific for ions that closely approximate the ionic radius of calcium. Through the use of the modification reagents N-ethyl-5-phenylisoxazolium-3'-sulfonate (Woodward's reagent K) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, we showed that the interaction between heparinase I and calcium was essential for proper functioning of the enzyme. Preincubation with either calcium alone or calcium in the presence of heparin was able to protect the enzyme from inactivation by these modifying reagents. In addition, through mapping studies of Woodward's reagent K-modified heparinase I, we identified two putative calcium-binding sites, CB-1 (Glu(207)-Ala(219)) and CB-2 (Thr(373)-Arg(384)), in heparinase I that not only are specifically modified by Woodward's reagent K, leading to loss of enzymatic activity, but also conform to the calcium-coordinating consensus motif.	MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Bioengn & Environm Hlth, 16-561,77 Massachusetts Ave, Cambridge, MA 02139 USA.	ramnat@mit.edu			NIGMS NIH HHS [GM 57073] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073, R37GM057073] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515; Binari RC, 1997, DEVELOPMENT, V124, P2623; BRAUD C, 1988, INT J BIOL MACROMOL, V10, P2, DOI 10.1016/0141-8130(88)90059-1; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; Bustos P, 1996, J PROTEIN CHEM, V15, P467, DOI 10.1007/BF01886854; CHAUTHAIWALE J, 1994, BBA-PROTEIN STRUCT M, V1204, P164, DOI 10.1016/0167-4838(94)90004-3; DEJERSEY J, 1980, ARCH BIOCHEM BIOPHYS, V205, P536, DOI 10.1016/0003-9861(80)90136-8; EPSTEIN M, 1974, BIOCHEMISTRY-US, V13, P1777, DOI 10.1021/bi00705a034; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Evans C.H, 2013, BIOCH LANTHANIDES, V8; GABRIEL DA, 1989, AM J MED SCI, V298, P8, DOI 10.1097/00000441-198907000-00002; Godavarti R, 1998, J BIOL CHEM, V273, P248, DOI 10.1074/jbc.273.1.248; Godavarti R, 1996, BIOCHEMISTRY-US, V35, P6846, DOI 10.1021/bi960356g; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KERESZTESSY Z, 1994, ARCH BIOCHEM BIOPHYS, V314, P142, DOI 10.1006/abbi.1994.1422; KOMISSAROV AA, 1995, J BIOL CHEM, V270, P10050, DOI 10.1074/jbc.270.17.10050; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KUIMOV AN, 1988, ANAL BIOCHEM, V172, P56, DOI 10.1016/0003-2697(88)90411-3; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Liu DF, 1999, J BIOL CHEM, V274, P4089, DOI 10.1074/jbc.274.7.4089; LLAMAS K, 1986, J AM CHEM SOC, V108, P5543, DOI 10.1021/ja00278a030; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; Lyle S.J., 1963, TALANTA, V10, P1177, DOI [DOI 10.1016/0039-9140(63)80170-8, 10.1016/0039-9140(63)80170-8]; MARALIHALLI GB, 1993, J PROTEIN CHEM, V12, P451, DOI 10.1007/BF01025045; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Raser KJ, 1996, BBA-PROTEIN STRUCT M, V1292, P9, DOI 10.1016/0167-4838(95)00170-0; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sasisekharan R, 1996, J BIOL CHEM, V271, P3124, DOI 10.1074/jbc.271.6.3124; SASISEKHARAN R, 1995, BIOCHEMISTRY-US, V34, P14441, DOI 10.1021/bi00044a022; SASISEKHARAN R, 1993, P NATL ACAD SCI USA, V90, P3660, DOI 10.1073/pnas.90.8.3660; YANG VC, 1985, J BIOL CHEM, V260, P1849	33	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4082	4088		10.1074/jbc.274.7.4082	http://dx.doi.org/10.1074/jbc.274.7.4082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933601	hybrid			2022-12-25	WOS:000078575500025
J	Faure, S; Vigneron, S; Galas, S; Brassac, T; Delsert, C; Morin, N				Faure, S; Vigneron, S; Galas, S; Brassac, T; Delsert, C; Morin, N			Control of G(2)/M transition in Xenopus by a member of the p21-activated kinase (PAK) family: A link between protein kinase a and PAK signaling pathways?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; OOCYTE MATURATION; MAP KINASE; MEIOTIC MATURATION; CYCLIN-B; ONCOGENE PRODUCT; EGG EXTRACTS; ACTIVATION; MOS; INITIATION	X-PAKs are involved in negative control of the process of oocyte maturation in Xenopus (1), In the present study, we define more precisely the events targetted by the kinase in the inhibition of the G(2)/M transition. We show that microinjection of recombinant X-PAK1-Cter active kinase into progesterone-treated oocytes prevents c-Mos accumulation and activation of both MAPK and maturation-promoting factor (MPF), In conditions permissive for MAPK activation, MPF activation still fails. We demonstrate that a constitutive truncated version of X-PAK1 (X-PAK1-Cter) does not prevent the association of cyclin B with p34(cdc2) but rather prevents the activation of the inactive complexes present in the oocyte. Proteins participating in the MPF amplification loop, including the Cdc25-activating Polo-like kinase are all blocked. Indeed, using active MPF, the amplification loop is not turned on in the presence of X-PAK1. Our results indicate that X-PAK and protein kinase A targets in the control of oocyte maturation are similar and furthermore that this negative regulation is not restricted to meiosis, because we demonstrate that G(2)/M progression is also prevented in Xenopus cycling extracts in the presence of active X-PAK1.	Ctr Rech Biochim Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France; IFREMER, F-17390 La Tremblade, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Ifremer	Morin, N (corresponding author), Ctr Rech Biochim Macromol, CNRS, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.	morin@crbm.cnrs-mop.fr	Galas, Simon/X-1312-2019; FAURE, Sandrine/N-6506-2018	Galas, Simon/0000-0002-1717-1266; FAURE, Sandrine/0000-0002-8902-8274; Morin, Nathalie/0000-0001-8677-1401				Abrieu A, 1998, J CELL SCI, V111, P1751; Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Faure S, 1998, ONCOGENE, V17, P1215, DOI 10.1038/sj.onc.1202056; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; Keryer G, 1998, J BIOL CHEM, V273, P34594, DOI 10.1074/jbc.273.51.34594; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V201, P291; LEBERER E, 1997, CURR OPIN GENE DEV, V7, P162; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MACKNIGHT GS, 1991, CURR OPIN CELL BIOL, V3, P213; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MALLER JL, 1977, J BIOL CHEM, V252, P1712; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murakami MS, 1998, DEVELOPMENT, V125, P237; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	49	31	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3573	3579		10.1074/jbc.274.6.3573	http://dx.doi.org/10.1074/jbc.274.6.3573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920904	hybrid			2022-12-25	WOS:000078428200044
J	Hu, WM; Bellone, CJ; Baldassare, JJ				Hu, WM; Bellone, CJ; Baldassare, JJ			RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; FIBROBLAST CELL-CYCLE; CDK INHIBITOR; RAS TRANSFORMATION; GROWTH-FACTOR; GENE-PRODUCT; G(1) PHASE; 3T3 CELLS; TGF-BETA; PROTEIN	RhoA has been identified as an important regulator of cell proliferation. We recently showed that the Ras/RhoA pathway regulates the degradation of p27(Kip) and the progression of Chinese hamster embryo fibroblasts (IIC9 cells) through G(1) into S phase (Weber, J. D., Hu, W., Jefcoat, S. C., Raben, D. M., and Baldassare, J. J. (1997) J. Biol. Chem, 272, 32966-32971). In this report, we have demonstrated that, in IIC9 cells, RhoA regulates cyclin E/CDK2 activity, which is required for p27(Kip) degradation. As previously shown in several fibroblasts cell lines, expression of dominant-negative CDK2 in IIC9 cells blocked serum-induced cyclin E/CDK2 activity and p27(Kip) degradation. In the absence of serum, expression of constitutively active RhoA(63) resulted in significant stimulation of cyclin E/CDK2 activity and degradation of p27(Kip). Cotransfection of dominant-negative CDK2 and RhoA(63) inhibited RhoA(63)-induced cyclin E/CDK2 activity and p27(Kip) degradation. In addition, expression of dominant-negative RhoA blocked serum-induced cyclin E/CDK2 activity and p27(Kip) degradation. Finally, expression of catalytically active cyclin E/CDK2 rescued the effect of expression of dominant-negative RhoA, Taken together, these data show that RhoA regulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63110 USA.				NIDDK NIH HHS [R01 DK46814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Geng Y, 1996, ONCOGENE, V12, P1173; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirai A, 1997, J BIOL CHEM, V272, P13; KATO J, 1993, GENE DEV, V7, P331; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	36	105	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3396	3401		10.1074/jbc.274.6.3396	http://dx.doi.org/10.1074/jbc.274.6.3396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920882	hybrid			2022-12-25	WOS:000078428200022
J	Moilanen, AM; Karvonen, U; Poukka, H; Yan, W; Toppari, J; Janne, OA; Palvimo, JJ				Moilanen, AM; Karvonen, U; Poukka, H; Yan, W; Toppari, J; Janne, OA; Palvimo, JJ			A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; COACTIVATORS; BINDING; SEARCH; DNA	We have characterized a novel partner for androgen receptor (AR), termed ARIP3, that interacts with the DNA-binding domain/zinc finger region of AR and is predominantly expressed in the testis. Rat ARIP3 is a nuclear protein comprising 572 amino acids, It modulates AR-dependent but not basal transcription, suggesting that ARIP3 acts as an AR transcriptional coregulator. Except for the C-terminal AR-interacting domain, ARIP3 contains distinct regions that are also present in two recently described proteins, a protein inhibitor of activated Stat3 and an RNA helicase II-interacting protein (Gu/RH-II binding protein). Conserved structural features of these proteins indicate the existence of a gene family involved in the regulation of various transcription factors. Collectively, ARIP3 belongs to a novel nuclear protein family and is perhaps the first tissue-specific coregulator of androgen receptor.	Univ Helsinki, Inst Biomed, Dept Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland; Univ Turku, Dept Physiol & Pediat, FIN-20520 Turku, Finland	University of Helsinki; University of Helsinki; University of Turku	Palvimo, JJ (corresponding author), Univ Helsinki, Inst Biomed, Dept Physiol, POB 9,Siltavuorenpenger 20J, FIN-00014 Helsinki, Finland.	jorma.palvimo@helsinki.fi	Yan, Wei/G-1618-2011	Palvimo, Jorma/0000-0003-2373-0578				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; ZHANG FP, 1995, ENDOCRINOLOGY, V136, P2904, DOI 10.1210/en.136.7.2904	27	128	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3700	3704		10.1074/jbc.274.6.3700	http://dx.doi.org/10.1074/jbc.274.6.3700			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920921	hybrid			2022-12-25	WOS:000078428200061
J	Elly, C; Witte, S; Zhang, ZH; Rosnet, O; Lipkowitz, S; Altman, A; Liu, YC				Elly, C; Witte, S; Zhang, ZH; Rosnet, O; Lipkowitz, S; Altman, A; Liu, YC			Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation	ONCOGENE			English	Article						protein tyrosine kinase; Cbl; proto-oncogene; Crk-L	EXCHANGE PROTEIN C3G; C-CBL; ANTIGEN RECEPTOR; V-CBL; ASSOCIATION; ACTIVATION; ZAP-70; PROTOONCOGENE; KINASE; 14-3-3-PROTEINS	Cbl-b, a mammalian homolog of Cbl, consists of an N-terminal region (Cbl-b-N) highly homologous to oncogenic v-Cbl, a Ring finger, and a C-terminal region containing multiple proline-rich stretches and potential tyrosine phosphorylation sites. In the present study, we demonstrate that upon engagement of the T cell receptor (TCR), endogenous Cbl-b becomes rapidly tyrosine-phosphorylated, In heterogeneous COS-1 cells, Cbl-b was phosphorylated on tyrosine residues by both Syk(Syk/Zap-70) and Src- (Fyn/Lck) family kinases, with Syk kinase inducing the most prominent effect. Syk associates and phosphorylates Cbl-b in Jurkat T cells, A Tyr-316 Chi-binding site in Syk was required for the association with and for the maximal tyrosine phosphorylation of Cbl-b, Mutation at a loss-of-function site (Gly-298) in Cbl-b-N disrupts its interaction with Syk, Cbl-b constitutively binds Grb2 and becomes associated with Crk-L upon TCR stimulation. The Grb2- and the Crk-L-binding regions were mapped to the C-terminus of Cbl-b, The Crk-L-binding sites were further determined to be (YDVP)-D-655 and (YKIP)-K-709, With th, latter being the primary binding site. Taken together, these results implicate that Cbl-b is involved in TCR-mediated intracellular signaling pathways.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; INSERM U119, Mol Oncol Lab, F-13009 Marseille, France; NCI, Navy Med Oncol Branch, Gaithersburg, MD 20899 USA	La Jolla Institute for Immunology; Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Rosnet, Olivier/G-3536-2013	LIU, YUN-CAI/0000-0002-0996-7109; Rosnet, Olivier/0000-0002-3020-910X	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; BLAKE TJ, 1991, ONCOGENE, V6, P653; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; KEANE MM, 1995, ONCOGENE, V10, P2367; Kong GH, 1996, MOL CELL BIOL, V16, P5026; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; ZHANG Z, 1998, UNPUB; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	33	56	61	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1147	1156		10.1038/sj.onc.1202411	http://dx.doi.org/10.1038/sj.onc.1202411			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022120				2022-12-25	WOS:000078510700003
J	Cousin, B; Munoz, O; Andre, M; Fontanilles, AM; Dani, C; Cousin, JL; Laharrague, P; Casteilla, L; Penicaud, L				Cousin, B; Munoz, O; Andre, M; Fontanilles, AM; Dani, C; Cousin, JL; Laharrague, P; Casteilla, L; Penicaud, L			A role for preadipocytes as macrophage-like cells	FASEB JOURNAL			English	Article						tumor necrosis factor; cell culture; ROS; stromal cells; antigens; SOD	TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE; MONOCLONAL-ANTIBODIES; DIFFERENTIATION; ADIPOCYTES; EXPRESSION; COMPLEMENT; RAT; HETEROGENEITY; FIBROBLAST	Several lines of evidence have supported a link betweeen adipose tissue and immunocompetent cells. This link is illustrated in obesity, where excess adiposity and impaired immune function have been described in both humans and genetically obese rodents. In addition, numerous factors involved in inflammatory response are secreted by both preadipocytes and macrophages. Here we show that proliferating preadipocytes in cell lines and primary cultures, develop phagocytic activity toward microorganisms. This is demonstrated by phagocytosis assays and confocal microscopy. This function disappears when preadipocytes stop proliferating and differentiate into adipocytes. After phagocytosis, preadipocytes show microbicide activity via an oxygen-dependent mechanism. In addition, preadipocytes as well as adipocytes are stained with MOMA-2, a marker of monocyte-macrophage lineage, but are negative for specific mature macrophage markers (F4/80 and Mac-1). These results suggest that preadipocytes could function as macrophage-like cells and raise the possibility of a potential direct involvement of adipose tissue in inflammatory processes.	CHU Rangueil, CNRS, UPRESA 5018, IFR 31,ESA 5018 UPS, F-31403 Toulouse, France; Hop Archet, INSERM, U343, F-06202 Nice 3, France; Univ Nice Sophia Antipolis, CNRS, UMR 6543, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Cousin, B (corresponding author), CHU Rangueil, CNRS, UPRESA 5018, IFR 31,ESA 5018 UPS, 1 Av J Poulhes, F-31403 Toulouse, France.	cousinb@rangueil.inserm.fr	DANI, Christian/G-3639-2014	DANI, Christian/0000-0003-3228-0230; Casteilla, Louis/0000-0001-9647-3248; Cousin, Beatrice/0000-0003-2952-4601				BEUTLER B, 1988, ENDOCR REV, V9, P57, DOI 10.1210/edrv-9-1-57; BJORNTORP P, 1978, J LIPID RES, V19, P316; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY PJ, 1987, AM J PATHOL, V128, P505; BURYSEK L, 1993, FEBS LETT, V334, P229, DOI 10.1016/0014-5793(93)81717-E; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY LN, 1992, J BIOL CHEM, V267, P12736; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DIJKSTRA CD, 1994, J IMMUNOL METHODS, V174, P21, DOI 10.1016/0022-1759(94)90006-X; HOFMAN FM, 1984, CELL IMMUNOL, V88, P61, DOI 10.1016/0008-8749(84)90052-2; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; KRAWISZ BR, 1981, CANCER RES, V41, P2891; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRISHNAN EC, 1982, J SURG RES, V33, P89, DOI 10.1016/0022-4804(82)90012-9; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; NAITO M, 1993, ARCH HISTOL CYTOL, V56, P331, DOI 10.1679/aohc.56.331; NISHIKAWA M, 1993, BLOOD, V81, P1184; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Peake PW, 1997, EUR J CLIN INVEST, V27, P922, DOI 10.1046/j.1365-2362.1997.2090759.x; Plotkin BJ, 1996, J MED MICROBIOL, V44, P277, DOI 10.1099/00222615-44-4-277; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SHAW DR, 1981, METHODS STUDYING MON, P511; SPEERT DP, 1992, NATURAL IMMUNE SYSTE, P215; STALLONE DD, 1994, NUTR REV, V52, P37; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Takao S, 1996, AM J PHYSIOL-CELL PH, V271, pC1278, DOI 10.1152/ajpcell.1996.271.4.C1278; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776	35	245	258	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					305	312		10.1096/fasebj.13.2.305	http://dx.doi.org/10.1096/fasebj.13.2.305			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973318	Bronze			2022-12-25	WOS:000078615200010
J	Schmidt, PH; Dransfield, DT; Claudio, JO; Hawley, RG; Trotter, KW; Milgram, SL; Goldenring, JR				Schmidt, PH; Dransfield, DT; Claudio, JO; Hawley, RG; Trotter, KW; Milgram, SL; Goldenring, JR			AKAP350, a multiply spliced protein kinase A-anchoring protein associated with centrosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC PARIETAL-CELLS; REGULATORY SUBUNIT; GOLGI-COMPLEX; GAMMA-TUBULIN; IDENTIFICATION; SYSTEM; SCAFFOLD; CLONING; NEURONS; LOCALIZATION	Protein kinase A-anchoring proteins (AKAPs) localize the second messenger response to particular subcellular domains by sequestration of the type II protein kinase A. Previously, AKAP120 was identified from a rabbit gastric parietal cell cDNA library; however, a monoclonal antibody raised against AKAP120 labeled a 350-kDa band in Western blots of parietal cell cytosol, Recloning has now revealed that AKAP120 is a segment of a larger protein, AKAP350, We have now obtained a complete sequence of human gastric AKAP350 as well as partial cDNA sequences from human lung and rabbit parietal cells. The genomic region containing AKAP350 is found on chromosome 7q21 and is multiply spliced, producing at least three distinct AKAP350 isoforms as well as yotiao, a protein associated with the N-methyl-D-aspartate receptor, Rabbit parietal cell AKAP350 is missing a sequence corresponding to a single exon in the middle of the molecule located just after the yotiao homology region. Two carboxyl-terminal splice variants were also identified. Both of the major splice variants showed tissue- and cell-specific expression patterns. Immunofluorescence microscopy demonstrated that AKAP350 was associated with centrosomes in many cell types. In polarized Madin-Darby canine kidney cells, AKAP350 localized asymmetrically to one pole of the centrosome, and nocodazole did not alter its localization. During the cell cycle, AKAP350 was associated with the centrosomes as well as with the cleavage furrow during anaphase and telophase, Several epithelial cell types also demonstrated noncentrosomal pools of AKAP350, especially parietal cells, which contained multiple cytosolic immunoreactive foci throughout the cells. The localization of AKAP350 suggests that it may regulate centrosomal and noncentrosomal cytoskeletal systems in many different cell types.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Dept Anat & Cellular Biol, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ Toronto, Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M1, Canada	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Goldenring, JR (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Dept Med, 1120 15th St, Augusta, GA 30912 USA.	jgolden@mail.mcg.edu		Hawley, Robert/0000-0003-3512-5818	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048370, R29DK050744, R01DK043405, R29DK043405] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48370, DK50744, DK43405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BERGLINDH T, 1979, ACTA PHYSL SCAND, V96, P150; Breer H, 1996, BEHAV GENET, V26, P209, DOI 10.1007/BF02359381; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Goldenring JR, 1996, AM J PHYSIOL-GASTR L, V270, pG515, DOI 10.1152/ajpgi.1996.270.3.G515; GOSTITESTU F, 1986, EMBO J, V5, P2545, DOI 10.1002/j.1460-2075.1986.tb04533.x; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLOTZ C, 1990, J CELL BIOL, V110, P405, DOI 10.1083/jcb.110.2.405; KOMESLI S, 1989, J CELL BIOL, V109, P2869, DOI 10.1083/jcb.109.6.2869; LEWIS JJ, 1990, AM J PHYSIOL, V258, pG476, DOI 10.1152/ajpgi.1990.258.3.G476; Lin JW, 1998, J NEUROSCI, V18, P2017; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MILLER P, 1982, P NATL ACAD SCI-BIOL, V79, P5562, DOI 10.1073/pnas.79.18.5562; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SOROKA CJ, 1993, EUR J CELL BIOL, V60, P76; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SZOLLOSI D, 1964, J CELL BIOL, V21, P465, DOI 10.1083/jcb.21.3.465; TANG LH, 1992, BIOCHEM J, V285, P715, DOI 10.1042/bj2850715; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104	40	114	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3055	3066		10.1074/jbc.274.5.3055	http://dx.doi.org/10.1074/jbc.274.5.3055			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915845	hybrid, Green Published			2022-12-25	WOS:000078319500063
J	Thottassery, JV; Sun, DX; Zambetti, GP; Troutman, A; Sukhatme, VP; Schuetz, EG; Schuetz, JD				Thottassery, JV; Sun, DX; Zambetti, GP; Troutman, A; Sukhatme, VP; Schuetz, EG; Schuetz, JD			Sp1 and Egr-1 have opposing effects on the regulation of the rat pgp2/mdr1b gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; MDR1 PROMOTER; MESSENGER-RNA; EXPRESSION; CELLS; LIVER; ACTIVATION; HEPATOCYTES	The promoter of the rat pgp2/mdr1b gene has a GC-rich region (pgp2GC) that is highly conserved in mdr genes and contains an consensus Sp1 site. Sp1's role in transactivation of the pgp2/mdr1b promoter was tested in Drosophila Schneider cells. The pgp2/mdr1b promoter was strongly activated by co-transfected wild type Sp1 but not mutant Sp1 and mutation of the Sp1 site abrogated Sp1-dependent transactivation, In gel shift assays, the same mutations abolished Sp1-DNA complex formation. Moreover, basal activity of the pgp2/mdr1b Sp1 mutant promoter was dramatically lower. Enforced ectopic overexpression of Sp1 in H35 rat hepatoma cells revealed that cell lines overexpressing Sp1 had increased endogenous pgp2/mdr1b mRNA, demonstrating that Spl activates the endogenous pgp2/mdr1b gene. Pgp2GC oligonucleotide also bound Egr-1 in gel shift assays and Egr-1 competitively displaced bound Sp1. In transient transfections of H35 cells land human LS180 and HepG2 cells) Egr-1 potently and specifically suppressed pgp2/mdr1b promoter activity and mutations in the Egr-1 site decreased Egr-1 binding and correlated with pgp2/mdr1b up-regulation. Ectopic overexpression of Egr-1 in H35 cells decreased Pgp expression and selectively increased vinblastine sensitivity. In conclusion, Sp1 positively regulates while Egr-1 negatively regulates the rat pgp2/mdr1b gene, Moreover, competitive interactions between Sp1 and Egr-1 in all likelihood determine the constitutive expression of the pgp2/mdr1b gene in H35 cells.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Beth Israel Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.		Schuetz, Erin/N-8087-2018; Zambetti, Gerard/N-8093-2018; Schuetz, John D/N-2692-2018; Sukhatme, Vikas/W-2776-2019	Zambetti, Gerard/0000-0002-0929-5007; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005851, R01ES008658, R29ES005851] Funding Source: NIH RePORTER; NCI NIH HHS [CA63203] Funding Source: Medline; NIEHS NIH HHS [ES05851, ES08658] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; BHUSHAN A, 1992, MOL PHARMACOL, V42, P69; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; COHEN D, 1991, J BIOL CHEM, V266, P2239; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DENT CL, 1994, TRANSCRIPTION FACTOR, P1; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; Furuya KN, 1997, J BIOL CHEM, V272, P11518; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HUS JM, 1996, P NATL ACAD SCI USA, V93, P4666; Ince TA, 1996, CANCER RES, V56, P2021; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; MOHN KL, 1990, J BIOL CHEM, V265, P21914; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; SCHUETZ EG, 1995, MOL CARCINOGEN, V12, P61, DOI 10.1002/mc.2940120202; SCHUETZ JD, 1993, CELL GROWTH DIFFER, V4, P31; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SCHUETZ JD, 1995, CELL GROWTH DIFFER, V6, P1321; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, DNA CELL BIOL, V10, P433, DOI 10.1089/dna.1991.10.433; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; YANG CPH, 1990, J BIOL CHEM, V265, P10282; YU LJ, 1993, J BIOL CHEM, V268, P7520	38	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3199	3206		10.1074/jbc.274.5.3199	http://dx.doi.org/10.1074/jbc.274.5.3199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915860	hybrid			2022-12-25	WOS:000078319500078
J	Cambier, N; Zhang, Y; Vairo, G; Kosmopoulos, K; Metcalf, D; Nicola, NA; Elefanty, AG				Cambier, N; Zhang, Y; Vairo, G; Kosmopoulos, K; Metcalf, D; Nicola, NA; Elefanty, AG			Expression of BCR-ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation	ONCOGENE			English	Article						BCR-ABL oncogene; M1 cell differentiation	CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE C-MYC; INHIBITORY FACTOR; TYROSINE KINASE; MONOCLONAL-ANTIBODY; SCAVENGER RECEPTOR; CYCLIN D1; V-ABL; ERYTHROLEUKEMIA-CELLS; ONCOGENE EXPRESSION	The mechanism leading to the expanding population of maturing myeloid cells which characterises chronic myeloid leukemia (CML) remains obscure. Because of its ability to mimic the proliferative and cell survival functions of hematopoietic growth factors, me hypothesized that the oncogene activated in CML, BCR-ABL, might also influence differentiation. To test this hypothesis, nle examined the effects of expressing BCR-ABL on the myeloid differentiation of murine M1 leukemic cells, which cease dividing and differentiate into macrophages in the presence of the cytokines leukemia inhibitory factor (LIF) or interleukin (IL)-6, We found that BCR-ABL induced macrophage differentiation in M1 cells, accompanied by increased expression of macrophage cell surface markers and the acquisition of phagocytic ability. Interestingly, clones of M1 cells which expressed BCR-ABL remained in cell cycle and were refractory to the growth inhibition and apoptosis induced by IL-6 or LIF in parental M1 cells. These cells also expressed inappropriately high levels of c-MYC mRNA for their degree of differentiation, which may have been important in maintaining cellular proliferation. These data suggest that BCR-ABL can stimulate both differentiation and proliferation and that these characterisitics may contribute to the phenotype observed in CML.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; PO Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Elefanty, AG (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Elefanty, Andrew G/A-6066-2008; Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889; Elefanty, Andrew/0000-0001-6448-8314	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BRUCE AG, 1992, J IMMUNOL, V149, P1271; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1992, BLOOD, V79, P1271; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELEFANTY AG, 1997, MOL HAEMOPOIESIS, P589; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GROFFEN J, 1987, CHRONIC MYELOID LEUK, P983; Hariharan I K, 1988, Oncogene Res, V3, P387; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; METCALF D, 1988, LEUKEMIA, V2, P216; Metcalf D, 1984, CLONAL CULTURE HEMOP; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P239; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHABO Y, 1988, BLOOD, V72, P2070; SIRARD C, 1994, BLOOD, V83, P1575; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Smith D, 1997, BRIT TELECOMMUN ENG, V16, P1; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TANIGAWA T, 1995, BLOOD, V85, P379; TAUCHI T, 1995, INT J HEMATOL, V61, P105; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Vairo G, 1996, ONCOGENE, V13, P1511; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAFRIRI D, 1993, P NATL ACAD SCI USA, V90, P477, DOI 10.1073/pnas.90.2.477	58	16	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					343	352		10.1038/sj.onc.1202302	http://dx.doi.org/10.1038/sj.onc.1202302			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927191				2022-12-25	WOS:000078166500007
J	Davies, JM; Hawe, N; Kabarowski, J; Huang, QH; Zhu, J; Brand, NJ; Leprince, D; Dhordain, P; Cook, M; Morriss-Kay, G; Zelent, A				Davies, JM; Hawe, N; Kabarowski, J; Huang, QH; Zhu, J; Brand, NJ; Leprince, D; Dhordain, P; Cook, M; Morriss-Kay, G; Zelent, A			Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene	ONCOGENE			English	Article						transcription factor; development; limb; lymphoma; dimerization	ACUTE PROMYELOCYTIC LEUKEMIA; ACID RECEPTOR-ALPHA; B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; TRANSCRIPTIONAL REPRESSION; LAZ3/BCL6 ONCOPROTEIN; MYELOGENOUS LEUKEMIA; 3Q27 TRANSLOCATION; INTERACTION MOTIF; GENE-EXPRESSION	BTB/POZ-domain C2H2 zinc(Zn)-finger proteins are encoded by a subfamily of genes related to the Drosophila gap gene kruppel. To date, two such proteins, PLZF and LAZ-3/BCL-6, have been implicated in oncogenesis. We have now identified a new member of this gent subfamily which encodes a 62 kDa Zn-finger protein, termed LRF, with a BTB/POZ domain highly similar to that of PLZF, Both human and mouse LRF genes, which localized to syntenic chromosomal regions (19p13.3 and 10B5.3, respectively), were widely expressed in adult tissues and cell lines. At approximately 9.5-10.0 days of embryonic development, the mouse LRF gene was expressed in the limb buds, pharyngeal arches, tail bud, placenta and neural tube. The LRF protein associated in vivo with LAZ-3/BCL-6, but not with PLZF to which it was more related. Although the LRF, or LAZ-3/BCL-6, BTB/POZ domain could readily homodimerize, no heterodimerization was detected in vivo between the LRF and LAZ-3/BCL-6 BTB/POZ domains and interaction between full length LRF and LAZ-3/BCL-6 required the presence of both the BTB/POZ domain and Zn-fingers in each partner protein. As expected from the above results, LRF and LAZ-3/BCL-6 also colocalized with each other in the nucleus. Taken together, our findings suggest that BTB/POZ-domain Zn-finger proteins may function as homo and heterodimeric complexes whose formation, and hence the resultant effect on transcription of their downstream target genes, is determined by the levels and expression domains of a given partner protein.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Natl Heart & Lung Inst, Imperial Coll, Sch Med, London SW3 6LY, England; Inst Rech Canc Lille, U124 INSERM, F-59045 Lille, France; Univ Oxford, Dept Human Anat, Oxford OX1 3QX, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oxford	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.		Zelent, Arthur/B-3532-2009	Leprince, Dominique/0000-0002-1999-0775; O'Connor, Nicola/0000-0003-1981-3055; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN SJ, 1992, ONCOGENE, V7, P1223; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN W, 1995, MOL CELL BIOL, V15, P3424; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5299; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CONSTANTINOUDELTAS CD, 1992, GENOMICS, V12, P581, DOI 10.1016/0888-7543(92)90451-W; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; FRIEND C, 1965, NATL CANC I MONO, V22, P505; FUKUDA T, 1995, ONCOGENE, V11, P1657; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODT D, 1993, DEVELOPMENT, V119, P799; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBERGER JS, 1983, CELL BIOL, V60, P2931; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; HARPER JW, 1993, CELL, V75, P805; Hawe N, 1996, BLOOD, V88, P1151; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEIM S, 1987, CANC CYTOGNETICS; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Johnston J.R., 1994, MOL GENETICS YEAST P; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Karin M, 1990, CURR OPIN CELL BIOL, V2, P996, DOI 10.1016/0955-0674(90)90148-8; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLEIN E, 1968, CANCER RES, V28, P1300; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MINOWADA J, 1978, J NATL CANCER I, V60, P1269, DOI 10.1093/jnci/60.6.1269; MITELMAN F, 1991, CATALOG CHROMOSOME A; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; ONIZUKA T, 1995, BLOOD, V86, P25; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; RALPH P, 1977, CANCER RES, V37, P546; RALPH P, 1973, J NATL CANCER I, V31, P883; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Sambrook J., 2002, MOL CLONING LAB MANU; Seyfert VL, 1996, ONCOGENE, V12, P2331; SHAKNOVICH R, 1998, IN PRESS MOL CELL BI; Shi YP, 1997, GENOMICS, V45, P42, DOI 10.1006/geno.1997.4904; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEIMA SM, 1988, DIFFERENTIATION, V38, P203, DOI 10.1111/j.1432-0436.1988.tb00214.x; WEISS A, 1984, J IMMUNOL, V133, P1; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZELENT A, 1997, METHOD MOL BIOL, V89, P307; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	92	116	132	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					365	375		10.1038/sj.onc.1202332	http://dx.doi.org/10.1038/sj.onc.1202332			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927193				2022-12-25	WOS:000078166500009
J	Mishra, L; Cai, T; Yu, P; Monga, SPS; Mishra, B				Mishra, L; Cai, T; Yu, P; Monga, SPS; Mishra, B			Elf3 encodes a novel 200-kD beta-spectrin: role in liver development	ONCOGENE			English	Article						spectrin; cloning; chromosome 11; mouse; liver; embryonic development; immunohistochemistry	PLASMA-MEMBRANE DOMAINS; POLARIZED EPITHELIAL-CELLS; BRAIN SPECTRIN; HEPATOCYTE DIFFERENTIATION; ERYTHROCYTE SPECTRIN; SELF-ASSOCIATION; CDNA LIBRARIES; MESSENGER-RNAS; MECHANISM; SEQUENCES	beta-spectrins are crucial for the maintenance of cell shape, the establishment of cell polarity, and the formation of distinct membrane domains. Our strategy for identifying genes important for hepatocyte polarity has been to utilize subtractive hybridization of early embryonic mouse cDNA liver libraries. As a result,,ve have cloned three isoforms of a novel beta-spectrin elf (embryonic liver beta-fodrin), and here we report the analysis of elf3, the longest isoform (8172 nt), ELF3 comprises 2154 residues with an overall similarity of 89.0% and 95.3% to mouse beta-spectrin (beta SpII Sigma 1) at the nucleotide and amino acid level, respectively. ELF3 is characterized by an actin-binding domain, a long repeat domain, and a short regulatory domain remarkable for the absence of a PH domain, Linkage analysis reveals that elf3 maps to mouse chromosome 11 between D11Bir6 and D11Xrf477, a different chromosomal locus from that of the other four spectrin genes, Northern blot analysis utilizing an elf3 3'-UTR probe demonstrates an abundant 9.0-kb transcript in brain, liver, and heart tissues. Western blot with a polyclonal antibody against ELF identifies a 200 kD protein in mouse liver, brain, kidney, and heart tissues. Immunohistochemical studies demonstrate ELF labeling of the basolateral or sinusoidal membranes surface as well as a granular cytoplasmic pattern in hepatocytes, Antisense studies utilizing cultured liver explants show a vital role of elf3 in hepatocyte differentiation and intrahepatic bile duct formation, The differential expression, tissue localization, and functional studies demonstrate the importance of elf3 in modulating interactions between various components of the cytoskeleton proteins controlling liver and bile duct development.	Dept Vet Affairs, Lab Dev Mol Biol, Washington, DC 20422 USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Natl Human Genome Res Inst, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Mishra, L (corresponding author), Dept Vet Affairs, Lab Dev Mol Biol, Washington, DC 20422 USA.			Mishra, Lopa/0000-0002-6850-0808; Monga, Satdarshan/0000-0002-8437-3378; Cai, Tao/0000-0002-2877-8637	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050458] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK50458-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BLAKESLEE D, 1977, J IMMUNOL METHODS, V17, P361, DOI 10.1016/0022-1759(77)90118-1; BOUWENS L, 1992, ENZYME, V46, P155, DOI 10.1159/000468782; CAI T, 1998, IN PRESS BIOCH BIOPH, V1390; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CASCIO S, 1991, DEVELOPMENT, V113, P217; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; COOK J, 1983, J CELL BIOL, V97, P1823, DOI 10.1083/jcb.97.6.1823; Engvall E, 1980, Methods Enzymol, V70, P419; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GOODMAN SR, 1981, P NATL ACAD SCI-BIOL, V78, P7570, DOI 10.1073/pnas.78.12.7570; GOODMAN SR, 1984, BRAIN RES BULL, V13, P813, DOI 10.1016/0361-9230(84)90239-9; GOODMAN SR, 1984, AM J PHYSIOL, V247, pC61, DOI 10.1152/ajpcell.1984.247.1.C61; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS HW, 1980, J BIOL CHEM, V255, P1512; HARRISON P, 1995, J NEUROSURG ANESTH, V7, P121, DOI 10.1097/00008506-199504000-00008; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; HU RJ, 1992, J BIOL CHEM, V267, P18715; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kwon Y, 1997, PHARMACEUT RES, V14, P780, DOI 10.1023/A:1012158607766; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1975, MED BIOL, V53, P427; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MAURICE M, 1988, J CELL SCI, V90, P79; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; MISHRA L, 1998, INT J DEV BIOL, V41, P747; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; NELSON WJ, 1991, BIOCHEM SOC T, V19, P1055, DOI 10.1042/bst0191055; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; WINKELMANN JC, 1993, BLOOD, V81, P3173; ZIMMER WE, 1992, BRAIN RES, V594, P75, DOI 10.1016/0006-8993(92)91030-I	48	57	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					353	364		10.1038/sj.onc.1202313	http://dx.doi.org/10.1038/sj.onc.1202313			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927192				2022-12-25	WOS:000078166500008
J	Liu, JA; Shworak, NW; Sinay, P; Schwartz, JJ; Zhang, LJ; Fritze, LMS; Rosenberg, RD				Liu, JA; Shworak, NW; Sinay, P; Schwartz, JJ; Zhang, LJ; Fritze, LMS; Rosenberg, RD			Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE N-SULFOTRANSFERASE; GLOMERULAR-BASEMENT-MEMBRANE; MOLECULAR-CLONING; ANTITHROMBIN-III; HIGH-AFFINITY; BIOSYNTHESIS; MOUSE; PURIFICATION; PROTEOGLYCAN; CELLS	The 3-O-sulfation of glucosamine residues is an important modification during the biosynthesis of heparan sulfate (HS), Our previous studies have led us to purify and molecularly clone the heparan sulfate D-glucosaminyl 5-O-sulfotransferase (5-OST-1), which is the key enzyme converting nonanticoagulant heparan sulfate (HSinact) to anticoagulant heparan sulfate (HSact). In this study, we expressed and characterized the full-length cDNAs of 3-OST-1 homologous genes, designated as 3-OST-2, 3-OST-3(A), and 3-OST-3(B) as described in the accompanying paper (Shworak, N. W., Liu, J., Petros, L. M., Zhang, L., Kobayashi, M., Copeland, N. G., Jenkins, N. A., and Rosenberg, R. D. (1999) J. Biol. Chem, 274, 5170-5184), All these cDNAs were successfully expressed in COS-7 cells, and heparan sulfate sulfotransferase activities were found in the cell extracts, We demonstrated that 3-OST-2, 3-OST-3(A), and 3-OST-3(B) are heparan sulfate D-glucosaminyl 3-O-sulfotransferases because the enzymes transfer sulfate from adenosine 3'-phosphophate 5'-phospho-[S-35]sulfate ([S-35]PAPS) to the 5-OH position of glucosamine, 3-OST-3(A) and 3-OST-3(B) sulfate an identical disaccharide. HSact conversion activity in the cell extract transfected by 3-OST-1 was shown to be 300-fold greater than that in the cell extracts transfected by 5-OST-2 and 3-OST-3(A), suggesting that 3-OST-2 and 3-OST-3(A) do not make HSact. The results of the disaccharide analysis of the nitrous acid-degraded [35S]HS suggested that 3-OST-2 transfers sulfate to GlcA2S-GlcNS and IdoA2S-GlcNS; 3-OST-3(A) transfers sulfate to IdoA2S-GlcNS. Our results demonstrate that the 3-O-sulfation of glucosamine is generated by different isoforms depending on the saccharide structures around the modified glucosamine residue. This discovery has provided evidence for a new cellular mechanism for generating a defined saccharide sequence in structurally complex HS polysaccharide.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Hosp, Sch Med, Dept Med, Boston, MA 02215 USA; Ecole Normale Super, Dept Chim, F-75231 Paris, France	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [5-P01-HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAME KJ, 1991, J BIOL CHEM, V266, P10287; BIELICKI J, 1990, BIOCHEM J, V271, P75, DOI 10.1042/bj2710075; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DELANEY SR, 1980, ANAL BIOCHEM, V100, P253; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHEN GQ, 1995, ARCH BIOCHEM BIOPHYS, V321, P83, DOI 10.1006/abbi.1995.1371; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VERNIER RL, 1992, KIDNEY INT, V41, P1070, DOI 10.1038/ki.1992.163; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	40	143	155	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5185	5192		10.1074/jbc.274.8.5185	http://dx.doi.org/10.1074/jbc.274.8.5185			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988768	hybrid			2022-12-25	WOS:000078698200093
J	Reddy, GB; Srinivas, VR; Ahmad, N; Surolia, A				Reddy, GB; Srinivas, VR; Ahmad, N; Surolia, A			Molten globule-like state of peanut lectin monomer retains its carbohydrate specificity - Implications in protein folding and legume lectin oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LACTALBUMIN; CONCANAVALIN-A; 3-STATE DENATURATION; CRYSTAL-STRUCTURE; BINDING; APOMYOGLOBIN; AGGLUTININ; INTERMEDIATE; RESOLUTION; STABILITY	A central question in biological chemistry is the minimal structural requirement of a protein that would determine its specificity and activity, the underlying basis being the importance of the entire structural element of a protein with regards to its activity vis a vis the overall integrity and stability of the protein. Although there are many reports on the characterization of protein folding/ unfolding intermediates, with considerable secondary structural elements but substantial loss of tertiary structure, none of them have been reported to show any activity toward their respective ligands. This may be a result of the conditions under which such intermediates have been isolated or due to the importance of specific structural elements for the activity. In this paper we report such an intermediate in the unfolding of peanut agglutinin that seems to retain, to a considerable degree, its carbohydrate binding specificity and activity. This result has significant implications on the molten globule state during the folding pathway(s) of proteins in general and the quaternary association in legume lectins in particular, where precise subunit topology is required for their biologic activities.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		Reddy, G Bhanuprakash/AAJ-3494-2020; SUROLIA, AVADESHA/C-5442-2009	Reddy, G Bhanuprakash/0000-0003-4787-3944; 				Ahmad N, 1998, BIOCHEMISTRY-US, V37, P16765, DOI 10.1021/bi9811720; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; Banerjee R, 1996, J MOL BIOL, V259, P281, DOI 10.1006/jmbi.1996.0319; BARRICK D, 1994, J MOL BIOL, V237, P588, DOI 10.1006/jmbi.1994.1257; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BREWER CF, 1996, CHEMTRACTS BIOCH MOL, V6, P165; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; FISH WW, 1978, ARCH BIOCHEM BIOPHYS, V190, P693, DOI 10.1016/0003-9861(78)90328-4; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; KIEFHABER T, 1995, J MOL BIOL, V252, P122, DOI 10.1006/jmbi.1995.0479; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1976, J MOL BIOL, V106, P359, DOI 10.1016/0022-2836(76)90091-7; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; Lis H, 1991, CURR OPIN STRUC BIOL, V1, P741, DOI 10.1016/0959-440X(91)90173-Q; LOTAN R, 1975, J BIOL CHEM, V250, P8518; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; NEUROHR KJ, 1980, J BIOL CHEM, V255, P9205; NOZAKA M, 1978, BIOCHEMISTRY-US, V17, P3753, DOI 10.1021/bi00611a013; Nozaki Y, 1972, Methods Enzymol, V26, P43; Prabu MM, 1998, J MOL BIOL, V276, P787, DOI 10.1006/jmbi.1997.1568; SAANAN B, 1991, SCIENCE, V234, P862; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SUROLIA A, 1996, J BIOL CHEM, V271, P17696; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YOUNG NM, 1991, EUR J BIOCHEM, V196, P693	30	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4500	4503		10.1074/jbc.274.8.4500	http://dx.doi.org/10.1074/jbc.274.8.4500			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988681	hybrid			2022-12-25	WOS:000078698200006
J	Ziady, AG; Ferkol, T; Dawson, DV; Perlmutter, DH; Davis, PB				Ziady, AG; Ferkol, T; Dawson, DV; Perlmutter, DH; Davis, PB			Chain length of the polylysine in receptor-targeted gene transfer complexes affects duration of reporter gene expression both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SEC RECEPTOR; HEPATOMA-CELLS; DNA COMPLEXES; DELIVERY; IDENTIFICATION; ENDOCYTOSIS; EFFICIENCY; PROTEIN; ALPHA	Complexes composed of peptide ligand for the serpin enzyme complex receptor covalently coupled to poly-L-lysine condensed by charge interaction with plasmid DNA direct gene transfer into receptor bearing cells, We compared intensity and duration of reporter gene expression in vitro and in vivo from serpin-enzyme receptor-directed gene transfer complexes prepared with poly-L-lysine of different chain lengths. When substituted with linker and ligand to comparable extents, DNA complexes containing short chain poly-L-lysine were larger and gave higher peak expression but significantly shorter duration of expression than those containing long chain poly-L-lysine. Both peak expression and duration of expression exceeded that observed with Lipofectin, Neither naked DNA nor DNA complexed with unsubstituted polylysine was effective in gene transfer. For in vivo experiments, complexes containing optimal ligand and degree of substitution (based on in vitro data, peptide C105Y, 11 ligands/plasmid DNA molecule) were prepared with either short chain or long chain polylysine and a beta-galactosidase expression plasmid. Following injection into the tail veins of mice, longer chain complexes gave significantly higher expression of reporter gene in lung and spleen that lasted for a significantly longer period of time than the shorter chain complexes. The short chain poly-L-lysine-DNA complexes were larger in diameter, as assessed by electron microscopy or atomic force microscopy, and gave less protection against DNase digestion in, vitro than longer chain complexes. Thus, for gene transfer complexes directed at the serpin enzyme complex receptor, longer chain poly-L-lysine gave a much longer duration of expression both in vitro and in vivo, We speculate that this may be due to protection against degradation afforded the plasmid DNA by the tighter compaction produced by long chain poly-L-lysine.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Washington Univ, Sch Med, Dept Pediat Cell Biol & Physiol, St Louis, MO 63110 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Washington University (WUSTL)	Davis, PB (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	pbd@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043999, P30DK027651, R01DK049138] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43999, P30 DK27651, DK 49138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Brubaker JO, 1996, J IMMUNOL, V157, P1598; BU GJ, 1992, J BIOL CHEM, V267, P15595; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; ERBACHER P, 1995, BIOCONJUGATE CHEM, V6, P401, DOI 10.1021/bc00034a010; FERKOL T, 1993, J CLIN INVEST, V92, P2394, DOI 10.1172/JCI116845; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; FERKOL T, 1993, FASEB J, V7, P1081, DOI 10.1096/fasebj.7.11.8370479; Ferkol T, 1996, P NATL ACAD SCI USA, V93, P101, DOI 10.1073/pnas.93.1.101; GLANTZ SA, 1987, BIOSTATISTICS, P287; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JUNG G, 1981, BIOCHEM BIOPH RES CO, V101, P599, DOI 10.1016/0006-291X(81)91301-2; Kleinbaum D, 1988, APPL REGRESSION ANAL; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LIN WC, 1991, BIOTECHNIQUES, V11, P344; Maniatis T., 1989, MOL CLONING LAB MANU; MAURER PH, 1962, J IMMUNOL, V88, P330; MICHAEL SI, 1994, GENE THER, V1, P223; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1994, PEDIATR RES, V36, P271, DOI 10.1203/00006450-199409000-00001; Scidmore MA, 1996, J CELL BIOL, V134, P363, DOI 10.1083/jcb.134.2.363; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WILSON DL, 1995, LANGMUIR, V11, P265, DOI 10.1021/la00001a045; Wolfert MA, 1996, GENE THER, V3, P269; WU GY, 1987, J BIOL CHEM, V262, P4299; Ziady AG, 1997, AM J PHYSIOL-GASTR L, V273, pG545, DOI 10.1152/ajpgi.1997.273.2.G545	31	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4908	4916		10.1074/jbc.274.8.4908	http://dx.doi.org/10.1074/jbc.274.8.4908			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988733	hybrid			2022-12-25	WOS:000078698200058
J	Das, TK; Lee, HC; Duff, SMG; Hill, RD; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB				Das, TK; Lee, HC; Duff, SMG; Hill, RD; Peisach, J; Rousseau, DL; Wittenberg, BA; Wittenberg, JB			The heme environment in barley hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; RESONANCE RAMAN; DISTAL HISTIDINE; CARBON-MONOXIDE; HORSERADISH-PEROXIDASE; FECO UNIT; MYOGLOBIN; PROTEINS; PLANTS; GENE	To elucidate the environment and ligand structure of the heme in barley hemoglobin (Hb), resonance Raman and electron paramagnetic resonance spectroscopic studies have been carried out. The heme is shown to have bis-imidazole coordination, and neither of the histidines has imidazolate character. Barley Hb has a unique heme environment as judged from the Fe-CO and C-O stretching frequencies in the CO complex. Two Fe-CO stretching modes are observed with frequencies at 534 and 493 cm(-1), with relative intensities that are pH sensitive. The 534 cm(-1) conformer shows a deuterium shift, indicating that the iron-bound CO is hydrogen-bonded, presumably to the distal histidine, A C-O stretching mode at 1924 cm(-1) is assigned as being associated with the 534 cm(-1) conformer. Evidence is presented that the high Fe-CO and low C-O stretching frequencies (534 and 1924 cm(-1), respectively) arise from a short hydrogen bond between the distal histidine and the CO. The 493 cm(-1) conformer arises from an open conformation of the heme pocket and becomes the dominant population under acidic conditions when the distal histidine moves away from the CO. Strong hydrogen bonding between the bound ligand and the distal histidine in the CO complex of barley Hb implies that a similar structure may occur in the oxy derivative, imparting a high stability to the bound oxygen. This stabilization is confirmed by the dramatic decrease in the oxygen dissociation rate compared with sperm whale myoglobin.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada	Yeshiva University; Albert Einstein College of Medicine; University of Manitoba	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.			Das, Tapan/0000-0002-3641-3988	NIGMS NIH HHS [GM40168, GM54806, GM54812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM054812, R37GM040168, R01GM040168] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; APPLEBY CA, 1992, SCI PROG, V76, P365; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BELL RL, 1994, J CHEM PHYS, V101, P10442, DOI 10.1063/1.467862; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BOGUSZ D, 1988, NATURE, V331, P178, DOI 10.1038/331178a0; BOGUSZ D, 1990, PLANT CELL, V2, P633, DOI 10.1105/tpc.2.7.633; BOISPOLTORATSKY R, 1967, EUR J BIOCHEM, V2, P361, DOI 10.1111/j.1432-1033.1967.tb00146.x; CAUGHEY WS, 1978, BIOCH CLIN ASPECTS H, P29; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DEROPP JS, 1985, J AM CHEM SOC, V107, P8268, DOI 10.1021/ja00312a080; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; DURLEY RCE, 1994, PROTEIN DATA BANK BR; EVANGELISTAKIRKUP R, 1986, BIOCHEMISTRY-US, V25, P4420, DOI 10.1021/bi00363a037; Hill RD, 1998, CAN J BOT, V76, P707, DOI 10.1139/cjb-76-5-707; HIROTA S, 1995, J AM CHEM SOC, V117, P821, DOI 10.1021/ja00107a028; HORI H, 1971, BIOCHIM BIOPHYS ACTA, V251, P227, DOI 10.1016/0005-2795(71)90106-1; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KITAGAWA T, 1982, NATURE, V298, P869, DOI 10.1038/298869a0; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kushkuley B, 1996, BIOPHYS J, V70, P1214, DOI 10.1016/S0006-3495(96)79680-7; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LING JH, 1994, BBA-BIOENERGETICS, V1188, P417, DOI 10.1016/0005-2728(94)90063-9; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; MOURANT JR, 1993, BIOPHYS J, V65, P1496, DOI 10.1016/S0006-3495(93)81218-9; Muskett FW, 1996, J MOL BIOL, V258, P172, DOI 10.1006/jmbi.1996.0241; MYLRAJAN M, 1990, BIOCHEMISTRY-US, V29, P9617, DOI 10.1021/bi00493a016; Nie XZ, 1997, PLANT PHYSIOL, V114, P835, DOI 10.1104/pp.114.3.835; NIE XZ, 1997, REGULATION FUNCTION; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; PEISACH J, 1968, J BIOL CHEM, V243, P1871; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; Scheiner S, 1996, J AM CHEM SOC, V118, P1511, DOI 10.1021/ja9530376; SMULEVICH G, 1986, BIOCHEMISTRY-US, V25, P4426, DOI 10.1021/bi00363a038; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; SPRINGER BA, 1989, J BIOL CHEM, V264, P3087; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Unno M, 1998, J AM CHEM SOC, V120, P2670, DOI 10.1021/ja973293d; UNO T, 1987, J BIOL CHEM, V262, P4549; Wang J., 1996, METHODS NITRIC OXIDE, P427; WANG JL, 1993, J AM CHEM SOC, V115, P3390, DOI 10.1021/ja00061a072; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	51	56	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4207	4212		10.1074/jbc.274.7.4207	http://dx.doi.org/10.1074/jbc.274.7.4207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933618	hybrid			2022-12-25	WOS:000078575500042
J	Liu, DF; Shriver, Z; Godavarti, R; Venkataraman, G; Sasisekharan, R				Liu, DF; Shriver, Z; Godavarti, R; Venkataraman, G; Sasisekharan, R			The calcium-binding sites of heparinase I from Flavobacterium heparinum are essential for enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL MODIFICATION; DIRECTED MUTAGENESIS; GLYCOSAMINOGLYCANS; EXPRESSION; CATALYSIS; RESIDUE; CLONING	In the accompanying paper (Shriver, Z,, Liu, D., Hu, Y., and Sasisekharan, R, (1999) J. Biol. Chem. 274, 4082-4088), we have shown that calcium binds specifically to heparinase I and have identified two major calcium-binding sites (CB-1 and CB-2) that partly conform to the EF-hand calcium-binding motif. In this study, through systematic site-directed mutagenesis, we have confirmed the accompanying biochemical studies and have shown that both CB-1 and CB-2 are involved in calcium binding and enzymatic activity. More specifically, we identified critical residues (viz, Asp(210), Asp(212), Gly(213), and Thr(216) in CB-1 and Asn(375), Tyr(379), and Glu(381) in CB-2) that are important for calcium binding and heparinase I enzymatic activity. Mutations in CB-1 resulted in a lower k(cat), but did not change the product profile of heparinase I action on heparin; conversely, mutations in CB-2 not only altered the k(cat) for heparinase I, but also resulted in incomplete degradation, leading to longer saccharides. Fluorescence competition experiments along with heparin affinity chromatography suggested that mutations in CB-1 alter heparinase I activity primarily through decreasing the enzyme's affinity for its calcium cofactor without altering heparin binding to heparinase I. Compared with CB-1 mutations, mutations in CB-2 affected calcium binding to a lesser extent, but they had a more pronounced effect on heparinase I activity, suggesting a different role for CB-2 in the enzymatic action of heparinase I. These results, taken together with our accompanying study, led us to propose a model for calcium binding to heparinase I that includes both CB-1 and CB-2 providing critical interactions, albeit via a different mechanism. Through binding to CB-1 and/or CB-2, we propose that calcium may play a role in the catalytic mechanism and/or in the exolytic processive mechanism of heparin-like glycosaminoglycan depolymerization by heparinase I.	MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; Genet Inst, Andover, MA 01810 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Bioengn & Environm Hlth, 16-561,77 Massachusetts Ave, Cambridge, MA 02139 USA.	ramnat@mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073, R37GM057073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1996, BIOCHEM J, V315, P589, DOI 10.1042/bj3150589; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; Godavarti R, 1998, J BIOL CHEM, V273, P248, DOI 10.1074/jbc.273.1.248; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V225, P751, DOI 10.1006/bbrc.1996.1246; Godavarti R, 1996, BIOCHEMISTRY-US, V35, P6846, DOI 10.1021/bi960356g; Higuchi R., 1990, PCR PROTOCOLS GUIDE; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sasisekharan R, 1996, J BIOL CHEM, V271, P3124, DOI 10.1074/jbc.271.6.3124; SASISEKHARAN R, 1995, BIOCHEMISTRY-US, V34, P14441, DOI 10.1021/bi00044a022; SASISEKHARAN R, 1993, P NATL ACAD SCI USA, V90, P3660, DOI 10.1073/pnas.90.8.3660; Shriver Z, 1999, J BIOL CHEM, V274, P4082, DOI 10.1074/jbc.274.7.4082; TEJIDOR L, 1993, THROMB HAEMOSTASIS, V69, P866	19	27	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4089	4095		10.1074/jbc.274.7.4089	http://dx.doi.org/10.1074/jbc.274.7.4089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933602	hybrid			2022-12-25	WOS:000078575500026
J	Kessler, B; Michielin, O; Blanchard, CL; Apostolou, I; Delarbre, C; Gachelin, G; Gregoire, C; Malissen, B; Cerottini, JC; Wurm, F; Karplus, M; Luescher, IF				Kessler, B; Michielin, O; Blanchard, CL; Apostolou, I; Delarbre, C; Gachelin, G; Gregoire, C; Malissen, B; Cerottini, JC; Wurm, F; Karplus, M; Luescher, IF			T cell recognition of hapten - Anatomy of T cell receptor binding of a H-2K(d)-associated photoreactive peptide derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LIGAND INTERACTIONS; ANTIGEN RECEPTOR; MHC RESTRICTION; ALPHA; COMPLEX; CHAIN; SITE; DETERMINANTS; SPECIFICITY	To elucidate the structural basis of T cell recognition of hapten-modified antigenic peptides, we studied the interaction of the T1 T cell antigen receptor (TCR) with its ligand, the H-2K(d)-bound Plasmodium berghei circumsporozoite peptide 252-260 (SYIPSAEKI) containing photoreactive 4-azidobenzoic acid (ABA) on P. berghei circumsporozoite Lys(259). The photoaffinity-labeled TCR residue(s) were mapped as Tyr(48) and/or Tyr(50) of complementary determining region 2 beta (CDR2 beta). Other TCR-ligand contacts were identified by mutational analysis. Molecular modeling, based on crystallographic coordinates of closely related TCR and major histocompatibility complex I molecules, indicated that ABA binds strongly and specifically in a cavity between CDR3 alpha and CDR2 beta. We conclude that TCR expressing selective V beta and CDR3 alpha sequences form a binding domain between CDR3 alpha and CDR2 beta that can accommodate nonpeptidic moieties conjugated at the C-terminal portion of peptides binding to major histocompatibility complex (MHC) encoded proteins.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Inst Pasteur, INSERM, Dept Immunol, U277, F-75015 Paris, France; CNRS, INSERM, Ctr Immunol, F-13288 Marseille, France; Univ Strasbourg 1, Inst Le Bel, F-67404 Strasbourg, France; Ecole Polytech Fed Lausanne, Dept Chem, Ctr Biotechnol, CH-1015 Lausanne, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Luescher, IF (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.		Kessler, Benedikt/AAY-8614-2021; Michielin, Olivier/ABE-7924-2020; Wurm, Florian M./D-7224-2013; Blanchard, Christopher L/P-5124-2016; Malissen, Bernard/AAK-4659-2020	Kessler, Benedikt/0000-0002-8160-2446; Blanchard, Christopher L/0000-0001-5800-4678; Malissen, Bernard/0000-0003-1340-9342				Anjuere F, 1997, J BIOL CHEM, V272, P8505, DOI 10.1074/jbc.272.13.8505; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Bjorkman PJ, 1997, CELL, V89, P167, DOI 10.1016/S0092-8674(00)80195-6; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; DUNBRACK RL, 1994, NAT STRUCT BIOL, V1, P334, DOI 10.1038/nsb0594-334; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GANJU RK, 1992, P NATL ACAD SCI USA, V89, P11552, DOI 10.1073/pnas.89.23.11552; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GODEAU F, 1991, RES IMMUNOL, V142, P409, DOI 10.1016/0923-2494(91)90039-L; Gregoire C, 1996, P NATL ACAD SCI USA, V93, P7184, DOI 10.1073/pnas.93.14.7184; HARDING CV, 1993, J IMMUNOL, V151, P2419; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; Jensen T, 1997, J IMMUNOL, V158, P3769; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KEESEY J, 1987, BIOCH PROTEIN RES, P87; Kohler J, 1997, J IMMUNOL, V158, P591; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; LUESCHER IF, 1994, J BIOL CHEM, V269, P5574; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN S, 1993, J IMMUNOL, V151, P678; MARTIN S, 1992, J IMMUNOL, V149, P2569; MATIS LA, 1990, ANNU REV IMMUNOL, V8, P65; NALEFSKI EA, 1992, J EXP MED, V175, P1553, DOI 10.1084/jem.175.6.1553; NALEFSKI EA, 1993, J IMMUNOL, V150, P3806; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; ROMERO P, 1993, J EXP MED, V177, P1245; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHRAGGER H, 1987, ANAL BIOCHEM, V166, P368; SILICIANO RF, 1986, CELL, V47, P161, DOI 10.1016/0092-8674(86)90439-3; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5	40	18	18	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3622	3631		10.1074/jbc.274.6.3622	http://dx.doi.org/10.1074/jbc.274.6.3622			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920911	hybrid			2022-12-25	WOS:000078428200051
J	Krishnamoorthy, RR; Crawford, MJ; Chaturvedi, MM; Jain, SK; Aggarwal, BB; Al-Ubaidi, MR; Agarwal, N				Krishnamoorthy, RR; Crawford, MJ; Chaturvedi, MM; Jain, SK; Aggarwal, BB; Al-Ubaidi, MR; Agarwal, N			Photo-oxidative stress down-modulates the activity of nuclear factor-kappa B via involvement of caspase-1, leading to apoptosis of photoreceptor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; LIPID-PEROXIDATION; T-ANTIGEN; ACTIVATION; ALPHA; DEATH; DEGENERATION; EXPRESSION; PROTEINS	The mechanisms of photoreceptor cell death via apoptosis, in retinal dystrophies, are largely not understood. In the present report we show that visible light exposure of mouse cultured 661W photoreceptor cells at 4.5 milliwatt/cm(2) caused a significant increase in oxidative damage of 661W cells, leading to apoptosis of these cells. These cells show constitutive expression of nuclear factor-kappa B (NF-kappa B), and light exposure of photoreceptor cells results in lowering of NF-kappa B levels in both the nuclear and cytosolic fractions in a time-dependent manner. Immunoblot analysis of I kappa B alpha and p50, and p65 (RelA) subunits of NF-kappa B, suggested that photo-oxidative stress results in their depletion. Immunocytochemical studies using antibody to RelA subunit of NF-kappa B further revealed the presence of this subunit constitutively both in the nucleus and cytoplasm of the 661W cells. Upon exposure to photo-oxidative stress, a depletion of the cytoplasmic and nuclear RelA subunit was observed. The depletion of NF-kappa B appears to be mediated through involvement of caspase-1, Furthermore, transfection of these cells with a dominant negative mutant I kappa B alpha greatly enhanced the kinetics of down modulation of NF-kappa B, resulting in a faster photo-oxidative stress-induced apoptosis. Taken together, these studies show that the presence of NF-kappa B RelA subunit in the nucleus is essential for protection of photoreceptor cells against apoptosis mediated by an oxidative pathway.	Univ N Texas, Hlth Sci Ctr, Dept Anat & Cell Biol, N Texas Eye Res Inst, Ft Worth, TX 76107 USA; Louisiana State Univ, Med Ctr, Dept Pediat, Shreveport, LA 71130 USA; Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Mol Oncol, Houston, TX 77030 USA; Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA	University of North Texas System; University of North Texas Health Science Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Texas System; UTMD Anderson Cancer Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Agarwal, N (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Anat & Cell Biol, N Texas Eye Res Inst, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	nagarwal@hsc.unt.edu	Aggarwal, Bharat B/G-3388-2013	Jain, Sushil/0000-0002-9574-0436				ABLER AS, 1994, INVEST OPHTH VIS SCI, V35, P1517; AGARWAL N, 1990, J NEUROSCI, V10, P3275; Agarwal N, 1996, BIOCHEM BIOPH RES CO, V225, P84, DOI 10.1006/bbrc.1996.1134; AlUbaidi MR, 1997, EXP EYE RES, V64, P573, DOI 10.1006/exer.1996.0240; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; ANDERSON RE, 1994, ADV EXP MED BIOL, V366, P73; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HALL MO, 1975, BIOCHEM BIOPH RES CO, V67, P1199, DOI 10.1016/0006-291X(75)90800-1; HEATH H, 1962, VISION RES, V2, P333, DOI 10.1016/0042-6989(62)90001-9; Hecker M, 1996, FEBS LETT, V380, P224, DOI 10.1016/0014-5793(96)00046-4; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JAIN SK, 1989, J BIOL CHEM, V264, P21340; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KAGAN VE, 1973, BIOCHIM BIOPHYS ACTA, V330, P76, DOI 10.1016/0005-2736(73)90285-X; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Li SH, 1995, DEGENERATIVE DISEASES OF THE RETINA, P27; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MEYER M, 1994, MCBU, P217; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Naash ML, 1996, INVEST OPHTH VIS SCI, V37, P775; Noell W K, 1966, Invest Ophthalmol, V5, P450; Organisciak DT, 1995, DEGENERATIVE DISEASES OF THE RETINA, P9; ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; PAPERMASTER DS, 1995, INVEST OPHTH VIS SCI, V36, P977; Penn J.S., 1985, RETINAL DEGENERATION, P439; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Rapp L, 1985, RETINAL DEGENERATION, P421; RAPP LM, 1990, INVEST OPHTH VIS SCI, V31, P1186; Ravi R, 1998, CANCER RES, V58, P882; Reme CE, 1995, DEGENERATIVE DISEASES OF THE RETINA, P19; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SEN J, 1995, J IMMUNOL, V154, P3213; Shen YM, 1996, AM J PHYSIOL-HEART C, V270, pH1624, DOI 10.1152/ajpheart.1996.270.5.H1624; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSO MOM, 1994, INVEST OPHTH VIS SCI, V35, P2693; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	68	131	143	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3734	3743		10.1074/jbc.274.6.3734	http://dx.doi.org/10.1074/jbc.274.6.3734			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920926	hybrid			2022-12-25	WOS:000078428200066
J	Liu, XD; Prabhu, A; Van Ness, B				Liu, XD; Prabhu, A; Van Ness, B			Developmental regulation of the kappa locus involves both positive and negative sequence elements in the 3 ' enhancer that affect synergy with the intron enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE-TRANSCRIPTION; LIGHT-CHAIN ENHANCERS; PRE-B CELLS; IG-KAPPA; 3'-ENHANCER REGION; NUCLEAR FACTOR; EXPRESSION; ACTIVATION; BINDING; SITE	Expression of the mouse immunoglobulin kappa locus is regulated by the intron and 3' enhancers. Previously, we have reported that these enhancers can synergize at mature B cell stages. Here we present our recent studies on the identification and characterization of the 3' enhancer sequences that play important roles in this synergy. By performing mutational analyses with novel reporter constructs, we find that the 5' region of the cAMP response element (CRE), the PU.1/PIP, and the E2A motifs of the 3' enhancer are critical for the synergy. These motifs are known to contribute to the enhancer activity. However, we also show that mutating other functionally important sequences has no significant effect on the synergy. Those sequences include the 3' region of the CRE motif, the BSAP motif, and the region 3' of the E2A motif. We have further demonstrated that either the 5'-CRE, the PU.1/PIP, or the E2A motif alone is sufficient to synergize with the intron enhancer. Moreover, the PU.1 motif appears to act as a negative element at pre-B cell stages but as a positive element at mature B cell stages. We have also identified a novel negative regulatory sequence within the 3' enhancer that contributes to the regulation of synergy, as well as developmental stage and tissue specificity of expression. While the levels of many of the 3' enhancer binding factors change very little in cell lines representing different B cell stages, the intron enhancer binding factors significantly increase at more mature B cell stages.	Univ Minnesota, Inst Human Genet, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Univ Minnesota, Inst Human Genet, Dept Biochem, Canc Ctr Res Bldg,Box 806 UMHC,425 E River Rd SE, Minneapolis, MN 55455 USA.							BLASQUEZ VC, 1992, J BIOL CHEM, V267, P23888; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EMORINE L, 1983, NATURE, V304, P447, DOI 10.1038/304447a0; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; FULTON R, 1994, NUCLEIC ACIDS RES, V22, P4216, DOI 10.1093/nar/22.20.4216; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; Hayashi R, 1997, J IMMUNOL, V159, P4145; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hiramatsu R, 1995, CELL, V83, P1113, DOI 10.1016/0092-8674(95)90138-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Meyer KB, 1996, INT IMMUNOL, V8, P1561, DOI 10.1093/intimm/8.10.1561; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; MEYER KB, 1994, NUCLEIC ACIDS RES, V22, P1576, DOI 10.1093/nar/22.9.1576; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NELMS K, 1990, NUCLEIC ACIDS RES, V18, P1037; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARSLOW TG, 1982, NATURE, V299, P449, DOI 10.1038/299449a0; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Sambrook J., 2002, MOL CLONING LAB MANU; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shaffer AL, 1997, IMMUNITY, V6, P131, DOI 10.1016/S1074-7613(00)80420-3; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4	37	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3285	3293		10.1074/jbc.274.6.3285	http://dx.doi.org/10.1074/jbc.274.6.3285			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920868	hybrid			2022-12-25	WOS:000078428200008
J	Ruiz, A; Winston, A; Lim, YH; Gilbert, BA; Rando, RR; Bok, D				Ruiz, A; Winston, A; Lim, YH; Gilbert, BA; Rando, RR; Bok, D			Molecular and biochemical characterization of lecithin retinol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL ACYLTRANSFERASE; PIGMENT-EPITHELIUM; VITAMIN-A; BINDING-PROTEIN; ENERGY-SOURCE; RAT-LIVER; 11-CIS-RETINOIDS; DEHYDROGENASE; BIOSYNTHESIS; EXPRESSION	The enzyme responsible for conversion of all-trans-retinol into retinyl esters, the lecithin retinol acyltransferase (LRAT) has been characterized at the molecular level, The cDNA coding for this protein was cloned and its amino acid sequence deduced. LRAT is composed of a polypeptide of 230 amino acid residues with a calculated mass of 25.3 kDa. Tissue distribution analysis by Northern blot showed expression of a 5.0-kilobase transcript in the human retinal pigment epithelium as well as in other tissues that are known for their high LRAT activity and vitamin A processing. Affinity labeling experiments using specific compounds with high affinity for LRAT and monospecific polyclonal antibodies raised in rabbits against two peptide sequences for LRAT confirmed the molecular mass of LRAT as a 25-kDa protein. High performance liquid chromatography analysis of the reaction product formed by HEK-293 cells transfected with LRAT cDNA confirmed the ability of the transfected cells to convert [H-3]all-trans-retinol into authentic [H-3]all-trans-retinyl palmitate as chemically determined.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA	Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rando, RR (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	rando@warren.med.harvard.edu			NEI NIH HHS [EY00331, EY00444, EY04096] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000444, R37EY000444, P30EY000331, R01EY004096, R37EY004096] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARON L, 1978, J BIOL CHEM, V253, P7220; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BOK D, 1993, J CELL SCI, P189; BOK D, 1992, EXP EYE RES, V55, P853, DOI 10.1016/0014-4835(92)90011-G; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; FULTON BS, 1987, BIOCHEMISTRY-US, V26, P7938, DOI 10.1021/bi00398a059; Goodman DS, 1984, RETINOIDS, V2, P2; Goodman DS, 1984, RETINOIDS, V2, P42; HELLER J, 1976, AM J OPHTHALMOL, V81, P93, DOI 10.1016/0002-9394(76)90198-7; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JANIN J, 1985, METHOD ENZYMOL, V115, P420; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEAN J, 1986, P NATL ACAD SCI USA, V83, P2335; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; Napoli JL, 1996, CLIN IMMUNOL IMMUNOP, V80, pS52, DOI 10.1006/clin.1996.0142; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; RANDO RR, 1983, J AM CHEM SOC, V105, P2879, DOI 10.1021/ja00347a058; Ross A. Catharine, 1994, P521; ROSS AC, 1993, J LIPID RES, V34, P1201; SAARI JC, 1989, J BIOL CHEM, V264, P8636; Saari John C., 1994, P351; SCHMITT MC, 1993, BIOL REPROD, V49, P972, DOI 10.1095/biolreprod49.5.972; SGOUTAS DS, 1972, BIOCHEMISTRY-US, V11, P293, DOI 10.1021/bi00752a022; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P1257, DOI 10.1021/bi00056a009; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P3077, DOI 10.1021/bi00063a019; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4	35	211	220	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3834	3841		10.1074/jbc.274.6.3834	http://dx.doi.org/10.1074/jbc.274.6.3834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920938	hybrid			2022-12-25	WOS:000078428200078
J	Wang, XL; Uzawa, K; Imai, FL; Tanzawa, H				Wang, XL; Uzawa, K; Imai, FL; Tanzawa, H			Localization of a novel tumor suppressor gene associated with human oral cancer on chromosome 4q25	ONCOGENE			English	Article						chromosome 4; loss of heterozygosity (LOH); oral carcinoma; tumor suppressor gene (TSG)	SQUAMOUS-CELL CARCINOMA; LONG ARM; ALLELOTYPE ANALYSIS; CERVICAL-CARCINOMA; BLADDER-CARCINOMA; HEAD; HETEROZYGOSITY; DELETION; REGIONS	Recent cytogenetic and molecular studies with highly polymorphic microsatellite markers have implicated allele loss involving chromosome 4 in several human cancers, which suggests the presence of multiple tumor suppressor gene (TSG) loci, However, there has been no detailed analysis of loss of heterozygosity (LOH) on chromosome 4 in oral squamous cell carcinoma (OSCC). To determine the location of a putative TSG associated with OSCC on chromosome 4, polymerase chain reaction (PCR) analysis of microsatellite polymorphisms corresponding to 17 loci was performed to screen 32 patients with OSCC. LOH was observed in the majority of the tumors (75%) in at least one of the loci. The loci on the long arm exhibited a significantly higher frequency of deletions (66%) than those of the short arm (25%). Among the loci tested, frequent LOH was centered at D4S1573 on 4q25, which represents a region of about 4 centimorgans (cM), However, no commonly deleted regions were found on the short arm of the chromosome, We detected microsatellite instability (MI) in 31% of the cases. MI was also observed more frequently on the long arm (28%) than the short arm (6%), Thus, our data indicate that alterations of chromosome 4 regions, especially the long arm, are associated with OSCC tumorigenesis and that the 4q25 region may harbor at least one putative TSG.	Chiba Univ, Sch Med, Dept Oral Surg, Chuo Ku, Chiba 2608670, Japan	Chiba University	Tanzawa, H (corresponding author), Chiba Univ, Sch Med, Dept Oral Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.			Uzawa, Katsuhiro/0000-0002-7036-0859				AHSEE KW, 1994, CANCER RES, V54, P1617; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; ELDER PA, 1994, ONCOGENE, V9, P3433; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hammoud ZT, 1996, CANCER RES, V56, P4499; Hampton GM, 1996, P NATL ACAD SCI USA, V93, P6704, DOI 10.1073/pnas.93.13.6704; Larson AA, 1996, CANCER RES, V56, P1426; Leon M, 1996, ANTICANCER RES, V16, P349; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MITRA AB, 1994, CANCER RES, V54, P4481; NAWROZ H, 1994, CANCER RES, V54, P1152; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; POLASCIK TJ, 1995, CANCER RES, V55, P5396; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Uzawa K, 1996, INT J CANCER, V67, P510, DOI 10.1002/(SICI)1097-0215(19960807)67:4<510::AID-IJC8>3.3.CO;2-R; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Wang XL, 1998, INT J CANCER, V75, P671, DOI 10.1002/(SICI)1097-0215(19980302)75:5<671::AID-IJC2>3.3.CO;2-6; Wang XL, 1997, INT J ONCOL, V10, P535; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	22	31	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					823	825		10.1038/sj.onc.1202318	http://dx.doi.org/10.1038/sj.onc.1202318			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989834				2022-12-25	WOS:000078394400029
J	Fournier, E; Blaikie, P; Rosnet, O; Margolis, B; Birnbaum, D; Borg, JP				Fournier, E; Blaikie, P; Rosnet, O; Margolis, B; Birnbaum, D; Borg, JP			Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF Receptor 3 signaling	ONCOGENE			English	Article						angiogenesis; FLT4; SHC; signal transduction; tyrosine kinase; VEGF receptor	PHOSPHOTYROSINE BINDING-DOMAIN; ENDOTHELIAL GROWTH-FACTOR; MIDDLE T-ANTIGEN; FLT4 RECEPTOR; PHOSPHORYLATION SITES; TRANSFORMING ACTIVITY; MULTIPLE CYTOKINES; KINASE ACTIVATION; V-SRC; LIGAND	The VEGFR3/FLT4 receptor, which is involved in vasculogenesis and angiogenesis, binds and phosphorylates SHC proteins on tyrosine residues. SHC contains two phosphotyrosine interaction domains: a PTB (Phosphotyrosine Binding) and a SH2 (Src Homology 2) domain. Previous studies have shown that SHC proteins are phosphorylated on Y239/Y240 and Y313 (Y317 in humans) by tyrosine kinases such as the EGF and IL3 receptors, We have investigated which of the SHC tyrosine residues are targeted by the VEGFR3/FLT4 kinase and the role of the SHC PTB and SH2 domains in this process. Our results show that Y239/Y240 and Y313 are simultaneously phosphorylated by the kinase, creating GRB2 binding sites. Mutation of SHC PTB, but not SH2, domain interferes with the SHC phosphorylation by VEGFR3/FLT4, Soft agar assay experiments revealed that the VEGFR3/FLT4 transforming capacity is increased by the mutation of Y239/Y240 to phenylalanines in SHC, suggesting that these two residues mediate an inhibitory signal for cell growth. Mutation of the two phosphorylation sites increases this effect, suggesting that they have a synergistic role.	INSERM, U119, Mol Oncol Lab, F-13258 Marseille, France; Dept Internal Med & Biol Chem, Ann Arbor, MI USA; Howard Hughes Med Inst, Ann Arbor, MI USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Howard Hughes Medical Institute	Birnbaum, D (corresponding author), INSERM, U119, Mol Oncol Lab, F-13258 Marseille, France.		Rosnet, Olivier/G-3536-2013; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Rosnet, Olivier/0000-0002-3020-910X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORG JP, 1995, ONCOGENE, V10, P973; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; FOURNIER E, 1995, ONCOGENE, V11, P921; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Joukov V, 1996, EMBO J, V15, P290; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOEPELAINEN E, 1998, CURR OPIN CELL BIOL, V10, P159; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wang JF, 1997, BLOOD, V90, P3507, DOI 10.1182/blood.V90.9.3507; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU S, 1995, J BIOL CHEM, V270, P14863	45	26	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					507	514		10.1038/sj.onc.1202315	http://dx.doi.org/10.1038/sj.onc.1202315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927207				2022-12-25	WOS:000078166500023
J	Fogerty, FJ; Juang, JL; Petersen, J; Clark, MJ; Hoffmann, FM; Mosher, DF				Fogerty, FJ; Juang, JL; Petersen, J; Clark, MJ; Hoffmann, FM; Mosher, DF			Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis	ONCOGENE			English	Article						Bcr-Abl; oncogene; Drosophila; tyrosine kinase	TYROSINE KINASE-ACTIVITY; CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; ADAPTER PROTEIN; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; ECTOPIC EXPRESSION; TRANSGENIC MICE; CELL FATES; SH2 DOMAIN	We targeted expression of human/fly chimeric Bcr-Abl proteins to the developing central nervous system (CNS) and eye imaginal disc of Drosophila melanogaster, Neural expression of human/fly chimeric P210 Bcr-Abl or P185 Bcr-Abl rescued abl mutant flies from pupal lethality, indicating that P210 and P185 Bcr-Abl can substitute functionally for Drosophila Abl during axonogenesis, However, increased levels of neurally expressed P210 or P185 Bcr-Abl but not Drosophila Abl produced CNS defects and lethality. Expression of P210 or P185 in the eye imaginal disc produced a dominant rough eye phenotype that was dependent on dosage of the transgene. Drosophila Enabled, previously identified as a suppressor of the abl mutant phenotype and substrate for Drosophila Abl kinase, had markedly increased phosphotyrosine levels in Bcr-Abl expressing Drosophila, indicating that it is a substrate for Bcr-Abl as well, Drosophila, therefore, is a suitable model system to identify Bcr-Abl interactions important for signal transduction and oncogenesis.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fogerty, FJ (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.		Juang, Jyh-Lyh/E-3944-2010	Hoffmann, F. Michael/0000-0002-2770-9656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644, P50HL056396] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56396-01, HL21644] Funding Source: Medline; NICHD NIH HHS [N01-HD-7-3263] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHERNDJAMALI SM, 1998, IN PRESS MOL BIOL CE; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BENNETT RL, 1992, DEVELOPMENT, V116, P953; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NL, 1991, DEVELOPMENT, V113, P1245; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HILL KK, 1995, GENETICS, V141, P595; HOLLAND GD, 1990, J VIROL, V64, P2226, DOI 10.1128/JVI.64.5.2226-2235.1990; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; JUANG JL, 1994, CELL TISSUE RES, V277, P87, DOI 10.1007/BF00303084; KANTARJIAN HM, 1993, BLOOD, V82, P691; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; ODA T, 1995, LEUKEMIA, V9, P295; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Santamaria P., 1986, DROSOPHILA PRACTICAL, P159; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG KK, 1995, ONCOGENE, V10, P705; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	68	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					219	232		10.1038/sj.onc.1202239	http://dx.doi.org/10.1038/sj.onc.1202239			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926937				2022-12-25	WOS:000078166000024
J	Wieser, RJ; Faust, D; Dietrich, C; Oesch, F				Wieser, RJ; Faust, D; Dietrich, C; Oesch, F			p16(INK4) mediates contact-inhibition of growth	ONCOGENE			English	Article						contact-inhibition; cdk4; p16(INK4)	PLASMA-MEMBRANE GLYCOPROTEINS; DENSITY-DEPENDENT REGULATION; CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; HUMAN-FIBROBLASTS; KINASE; PHOSPHORYLATION; P27(KIP1); PROGRESSION; CANCER	Growth of non-transformed cells in vitro is regulated by density-dependent mechanisms via cell-cell contacts, leading to arrest in late G1-phase at confluency (contact-inhibition of growth). In the present study it is shown that this results from p16(INK4)-mediated dissociation of the complex cdk4-cyclin D1, which is responsible for the inactivation of the gate keeper of G1-S transition, the retinoblastoma protein pRb, As consequence of the inactivation of cdk4, downstream the activation of cdk2 and hyperphosphorylation and thus inactivation of pRb was impaired, Direct evidence for the central role of p16(INK4) in growth control comes from the observation that a competitive inhibitor of p16(INK4) repressed contact inhibition of growth, These findings provide an explanation for the high incidence of mutation or loss of INK4 in human tumours.	Inst Toxikol, D-55131 Mainz, Germany		Wieser, RJ (corresponding author), Inst Toxikol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.		Oesch, Franz/AAA-8746-2020					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Botz J, 1996, MOL CELL BIOL, V16, P3401; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Higashi H, 1997, BIOCHEM BIOPH RES CO, V231, P743, DOI 10.1006/bbrc.1997.6181; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OESCH F, 1987, EUR J CELL BIOL, V43, P403; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RINDERKNECHT SB, 1983, J IMMUNOL METHODS, V65, P293, DOI 10.1016/0022-1759(83)90124-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; Yasaka T, 1996, CELL STRUCT FUNCT, V21, P483, DOI 10.1247/csf.21.483	33	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					277	281		10.1038/sj.onc.1202270	http://dx.doi.org/10.1038/sj.onc.1202270			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926944				2022-12-25	WOS:000078166000031
J	Dowd, CJ; Cooney, CL; Nugent, MA				Dowd, CJ; Cooney, CL; Nugent, MA			Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; BOVINE DESCEMETS MEMBRANE; PLASMINOGEN-ACTIVATOR PRODUCTION; ENDOTHELIAL-CELLS; PROTEOLYTIC DEGRADATION; CORNEAL ENDOTHELIUM; MAGNETIC-RESONANCE; ANGIOGENIC PROTEIN; BALB/C3T3 CELLS	Basic fibroblast growth factor (bFGF) is a pluripotent cytokine with a wide range of target cells. Heparan sulfate binds bFGF, and this interaction has been demonstrated to protect bFGF against physical denaturation and protease degradation. The high concentrations of heparan sulfate in basement membranes have implicated these matrices as storage sites for bFGF in vivo. However, the mechanisms by which basement membranes modulate bFGF storage and release is unknown. To gain insight into these mechanisms, we have developed experimental and mathematical models of extracellular growth factor transport through basement membrane. Intact Descemet's membranes isolated from bovine corneas were mounted within customized diffusion cells and growth factor transport was measured under a variety of conditions that decoupled the diffusion process from the heparan sulfate binding phenomenon. Transport experiments were conducted with bFGF and interleukin 1 beta. In addition, bFGF-heparan sulfate binding was disrupted in diffusion studies with high ionic strength buffer and buffers containing protamine sulfate. Transport of bFGF was enhanced dramatically when heparan sulfate binding was inhibited. This process was modeled as a problem of diffusion with fast reversible binding. Experimental parameters were incorporated into a mathematical model and independent simulations were run that showed that the experimental data were accurately predicted by the mathematical model. Thus, this study indicated that basement membranes function as dynamic regulators of growth factor transport, allowing for rapid response to changing environmental conditions. The fundamental principles controlling bFGF transport through basement membrane that have been identified here might have applications in understanding how growth factor distribution is regulated throughout an organism during development and in the adult state.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Boston University; Boston University; Massachusetts Institute of Technology (MIT)	Nugent, MA (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			Nugent, Matthew/0000-0002-8630-4712	NATIONAL EYE INSTITUTE [R01EY011004] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902] Funding Source: NIH RePORTER; NEI NIH HHS [EY11004] Funding Source: Medline; NHLBI NIH HHS [HL46902] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BENNETT NT, 1993, AM J SURG, V166, P74, DOI 10.1016/S0002-9610(05)80589-6; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; CLORE GM, 1991, J MOL BIOL, V221, P47, DOI 10.1016/0022-2836(91)90802-D; COOKE J, 1995, BIOESSAYS, V17, P93, DOI 10.1002/bies.950170202; DABIN I, 1991, J CELL PHYSIOL, V147, P396, DOI 10.1002/jcp.1041470303; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; EDELMAN ER, 1993, P NATL ACAD SCI USA, V90, P1513, DOI 10.1073/pnas.90.4.1513; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; Hata R, 1996, CELL BIOL INT, V20, P59, DOI 10.1006/cbir.1996.0009; JEANNY JC, 1987, EXP CELL RES, V171, P63, DOI 10.1016/0014-4827(87)90251-5; Johnston TP, 1998, PHARMACEUT RES, V15, P246, DOI 10.1023/A:1011966602179; KAPOOR R, 1986, BIOCHEMISTRY-US, V25, P3930, DOI 10.1021/bi00361a029; KIM JH, 1971, EXP EYE RES, V12, P231, DOI 10.1016/0014-4835(71)90143-6; LABERMEIER U, 1983, EXP EYE RES, V37, P225, DOI 10.1016/0014-4835(83)90157-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUBIMOV AV, 1995, LAB INVEST, V72, P461; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; MCMANUS JFA, 1946, NATURE, V158, P202, DOI 10.1038/158202a0; Miao HQ, 1996, J BIOL CHEM, V271, P4879; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Moy FJ, 1996, BIOCHEMISTRY-US, V35, P13552, DOI 10.1021/bi961260p; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Papageorgiou S, 1996, DEV DYNAM, V207, P461; PHILLIPS RJ, 1989, AICHE J, V35, P1761, DOI 10.1002/aic.690351102; Press W., 1986, NUMERICAL RECIPES; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; REGNIER FE, 1976, J CHROMATOGR SCI, V14, P316, DOI 10.1093/chromsci/14.7.316; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; Rich CB, 1996, J BIOL CHEM, V271, P23043, DOI 10.1074/jbc.271.38.23043; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SAWADA H, 1982, CELL TISSUE RES, V226, P241, DOI 10.1007/BF00218356; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SYMES K, 1994, DEVELOPMENT, V120, P2339; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Trinkaus-Randall V, 1998, J CONTROL RELEASE, V53, P205, DOI 10.1016/S0168-3659(97)00254-X; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	53	133	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5236	5244		10.1074/jbc.274.8.5236	http://dx.doi.org/10.1074/jbc.274.8.5236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988774	hybrid			2022-12-25	WOS:000078698200099
J	Klussmann, E; Maric, K; Wiesner, B; Beyermann, M; Rosenthal, W				Klussmann, E; Maric, K; Wiesner, B; Beyermann, M; Rosenthal, W			Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED WATER CHANNEL; ANTIDIURETIC-HORMONE; PHOSPHORYLATION; EXPRESSION; VESICLES; CLONING; IDENTIFICATION; PERMEABILITY; TRAFFICKING; SCAFFOLD	The antidiuretic hormone arginine-vasopressin (AVP) regulates water reabsorption in renal collecting duct principal cells by inducing a cAMP-dependent translocation of water channels (aquaporin-2, AQP-2) from intracellular vesicles into the apical cell membranes. In subcellular fractions from primary cultured rat inner medullary collecting duct (IMCD) cells, enriched for intracellular AQP-2-bearing vesicles, catalytic protein kinase A (PKA) subunits and several protein kinase A anchoring proteins (AKAPs) were detected. In nonstimulated IMCD cells the majority of AQP-2 staining was detected intracellularly but became mainly localized within the cell membrane after stimulation with AVP or forskolin, Quantitative analysis revealed that preincubation of the cells with the synthetic peptide S-Ht31, which prevents the binding between AKAPs and regulatory subunits of PKA, strongly inhibited AQP-2 translocation in response to forskolin, Preincubation of the cells with the PRA inhibitor H89 prior to forskolin stimulation abolished AQP-2 translocation. In contrast to H89, S-Ht31 did not affect the catalytic activity of PKA. These data demonstrate that not only the activity of PRA, but also its tethering to subcellular compartments, are prerequisites for cAMP-dependent AQP-2 translocation.	Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Klussmann, E (corresponding author), Forschungsinst Mol Pharmakol, Alfred Kowalke Str 4, D-10315 Berlin, Germany.							AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Bretscher A, 1997, J CELL SCI, V110, P3011; CARR DW, 1992, J BIOL CHEM, V267, P13376; Deen PMT, 1998, CURR OPIN NEPHROL HY, V7, P37; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; Klussmann E., 1998, Journal of Molecular Medicine (Berlin), V76, pB58; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LIEBENHOFF U, 1995, FEBS LETT, V365, P209, DOI 10.1016/0014-5793(95)00476-P; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; Maric K, 1998, AM J PHYSIOL-RENAL, V275, pF796, DOI 10.1152/ajprenal.1998.275.5.F796; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; ROSENTHAL W, 1998, ADV MOL CELL ENDOCR, V2, P143; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Sasaki S, 1998, ANNU REV PHYSIOL, V60, P199, DOI 10.1146/annurev.physiol.60.1.199; SCHWOCH G, 1980, BIOCHEM J, V192, P223, DOI 10.1042/bj1920223; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747	37	134	138	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4934	4938		10.1074/jbc.274.8.4934	http://dx.doi.org/10.1074/jbc.274.8.4934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988736	hybrid			2022-12-25	WOS:000078698200061
J	Kodym, R; Calkins, P; Story, M				Kodym, R; Calkins, P; Story, M			The cloning and characterization of a new stress response protein a mammalian member of - A family of theta class glutathione S-transferase-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RADIATION-INDUCED APOPTOSIS; INDUCED CELL-DEATH; ESCHERICHIA-COLI; TRYPANOSOMA-CRUZI; HUMAN HSP27; RESISTANCE; GENE; EXPRESSION; STARVATION	Using differential display, a cDNA fragment was identified as being overexpressed in a mouse lymphoma cell line that had gained resistance to cell death after exposure to a variety of agents used in cancer therapy. The fall-length cDNA of 1.1 kb that was cloned contained an open reading frame coding for a previously unidentified 28-kDa mammalian protein, p28, p28 showed significant homologies to a large family of stress response proteins that contain a glutathione S-transferase (GST) domain. In correspondence with the sequence homology, p28 was found to bind glutathione; however, GST or glutathione peroxidase activity could not be demonstrated. Northern analysis of the mRNA of this protein showed abundant expression in mouse heart and liver tissues, whereas anti-p28 antibody binding identified p28 expression in mouse 3T3 cells and early passage mouse embryo fibroblasts. Subcellular protein fractionation revealed p28 localization in the cytoplasm, but with thermal stress p28 relocated to the nuclear fraction of cellular proteins. Based on sequence homology and protein activity we conclude that p28 acts as a small stress response protein, likely involved in cellular redox homeostasis, and belongs to a family of GST-like proteins related to class theta GSTs.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Story, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	mstory@odin.mdacc.tmc.edu	Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NCI NIH HHS [CA62209, CA77050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA077050, R29CA062209] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Ban N, 1996, CANCER RES, V56, P3577; BOMPART GJ, 1990, CLIN BIOCHEM, V23, P501, DOI 10.1016/0009-9120(90)80039-L; BUREL C, 1992, EXPERIENTIA, V48, P629, DOI 10.1007/BF02118307; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; CZARNECKA E, 1984, PLANT MOL BIOL, V3, P45, DOI 10.1007/BF00023415; DREWINKO B, 1972, P SOC EXP BIOL MED, V140, P339; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Elliott MJ, 1998, CANCER CHEMOTH PHARM, V41, P457, DOI 10.1007/s002800050767; Habig W H, 1981, Methods Enzymol, V77, P398; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HUOT J, 1991, CANCER RES, V51, P5245; JAKOBY WB, 1985, METHOD ENZYMOL, V113, P495; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppa S, 1997, ANN MED, V29, P73, DOI 10.3109/07853899708998745; Lock RB, 1996, CANCER RES, V56, P4006; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; MOUTIEZ M, 1995, BIOCHEM J, V310, P433, DOI 10.1042/bj3100433; NOEL F, 1994, P NATL ACAD SCI USA, V91, P4150, DOI 10.1073/pnas.91.10.4150; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; REEH S, 1976, MOL GEN GENET, V149, P279, DOI 10.1007/BF00268529; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHLESINGER MJ, 1994, PEDIATR RES, V36, P1; SCHONECK R, 1994, BIOL CELL, V80, P1, DOI 10.1016/0248-4900(94)90011-6; SERIZAWA H, 1987, NUCLEIC ACIDS RES, V15, P1153, DOI 10.1093/nar/15.3.1153; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; TAYLOR JL, 1990, MOL PLANT MICROBE IN, V3, P72; Trautinger F, 1996, J PHOTOCH PHOTOBIO B, V35, P141, DOI 10.1016/S1011-1344(96)07344-7; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; vanderKop DAM, 1996, PLANT MOL BIOL, V30, P839, DOI 10.1007/BF00019016; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; WILLIAMS MD, 1994, MOL MICROBIOL, V11, P1029, DOI 10.1111/j.1365-2958.1994.tb00381.x	41	88	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5131	5137		10.1074/jbc.274.8.5131	http://dx.doi.org/10.1074/jbc.274.8.5131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988762	hybrid			2022-12-25	WOS:000078698200087
J	Rahman, I; Antonicelli, F; MacNee, W				Rahman, I; Antonicelli, F; MacNee, W			Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; HUMAN-IMMUNODEFICIENCY-VIRUS; HEAVY SUBUNIT GENE; CIGARETTE-SMOKE; TRANSCRIPTIONAL REGULATION; SUPEROXIDE-DISMUTASE; ENDOTHELIAL-CELLS; LINING FLUID; LUNG-CANCER; IN-VITRO	Glutathione (GSH) is an important physiological antioxidant in lung epithelial cells and lung lining fluid. We studied the regulation of GSH synthesis in response to the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the anti-inflammatory agent dexamethasone in human alveolar epithelial cells (A549). TNF-alpha (10 ng/ml) exposure increased GSH levels, concomitant with a significant increase in gamma-glutamylcysteine synthetase (gamma-GCS) activity and the expression of gamma-GCS heavy subunit (gamma-GCS-HS) mRNA at 24 h, Treatment with TNF-alpha also increased chloramphenicol acetyltransferase (CAT) activity of a gamma-GCS-HS 5'-flanking region reporter construct, transfected into alveolar epithelial cells. Mutation of the putative proximal AP-1-binding site (-269 to -263 base pairs), abolished TNF-alpha-mediated activation of the promoter. Gel shift and supershift analysis showed that TNF-alpha increased AP-1 DNA binding which was predominantly formed by dimers of c-Jun. Dexamethasone (3 mu M) produced a significant decrease in the levels of GSH, decreased gamma-GCS activity and gamma-GCS-HS mRNA expression at 24 h. The increase in GSH levels, gamma-GCS-HS mRNA, gamma-GCS-HS promoter activity, and AP-1 DNA binding produced by TNF-alpha were abrogated by co-treating the cells with dexamethasone. Thus these data demonstrate that TNF-alpha and dexamethasone modulate GSH levels and gamma-GCS-HS mRNA expression by their effects on AP-1 (c-Jun homodimer). These data have implications for the oxidant/antioxidant balance in inflammatory lung diseases.	Univ Edinburgh, Sch Med, Resp Med Unit, Rayne Lab, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Rahman, I (corresponding author), Univ Edinburgh, Sch Med, Resp Med Unit, Rayne Lab, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	IR@srv1.med.ed.ac.uk		MacNee, William/0000-0002-3692-1448				AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174, DOI 10.1164/ajrccm/148.5.1174; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Imanishi H, 1997, BIOCHEM BIOPH RES CO, V230, P120, DOI 10.1006/bbrc.1996.5901; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KONDO T, 1993, J BIOL CHEM, V268, P20366; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; LI XY, 1994, AM J RESP CRIT CARE, V149, P1518, DOI 10.1164/ajrccm.149.6.8004308; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; MADHU C, 1992, TOXICOL APPL PHARM, V115, P191, DOI 10.1016/0041-008X(92)90323-K; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; McIntosh LJ, 1998, BRAIN RES, V791, P209, DOI 10.1016/S0006-8993(98)00115-2; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Melloni B, 1996, AM J RESP CRIT CARE, V154, P1706, DOI 10.1164/ajrccm.154.6.8970359; Morales A, 1998, FEBS LETT, V427, P15, DOI 10.1016/S0014-5793(98)00381-0; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; MORRIS PE, 1994, AM J MED SCI, V307, P119, DOI 10.1097/00000441-199402000-00010; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Rahman I, 1998, AM J PHYSIOL-LUNG C, V275, pL80, DOI 10.1152/ajplung.1998.275.1.L80; Rahman I, 1998, FEBS LETT, V427, P129, DOI 10.1016/S0014-5793(98)00410-4; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; RAHMAN I, 1995, AM J PHYSIOL-LUNG C, V269, pL285, DOI 10.1152/ajplung.1995.269.3.L285; Rahman I, 1997, FEBS LETT, V411, P393; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; SEKHAR KR, 1997, BIOCHEM BIOPH RES CO, V234, P488; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHI MM, 1994, J BIOL CHEM, V269, P26512; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tomonari A, 1997, BIOCHEM BIOPH RES CO, V236, P616, DOI 10.1006/bbrc.1997.7020; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Tu ZH, 1998, BIOCHEM BIOPH RES CO, V244, P801, DOI 10.1006/bbrc.1998.8345; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YAO KS, 1995, CANCER RES, V55, P4367; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405	53	113	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5088	5096		10.1074/jbc.274.8.5088	http://dx.doi.org/10.1074/jbc.274.8.5088			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988757	hybrid			2022-12-25	WOS:000078698200082
J	Yan, Q; Prestwich, GD; Lennarz, WJ				Yan, Q; Prestwich, GD; Lennarz, WJ			The Ost1p subunit of yeast oligosaccharyl transferase recognizes the peptide glycosylation site sequence, -Asn-X-Ser/Thr-	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; ASPARAGINE-LINKED GLYCOSYLATION; PROTEIN DISULFIDE-ISOMERASE; ACTIVE-SITE; N-GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; STRUCTURAL REQUIREMENTS; SUBSTRATE RECOGNITION; ENZYMATIC CONVERSION; BINDING	Other laboratories have established that oligosaccharyl transferase (OST) from Saccharomyces cerevisiae can be purified as a protein complex containing eight different subunits. To identify the OST subunit that recognizes the peptide sites that can be glycosylated, we developed photoaffinity probes containing a photoreactive benzophenone derivative, p-benzoylphenylalanine (Bpa), as part of an I-125-labeled peptide that could be expected to be glycosylated. We found that Asn-Bpa-Thr peptides served as substrates for OST and that photoactivation of these probes in the presence of microsomes abolished the OST activity. Photoactivation of 125I-labeled Asn-Epa-Thr in the presence of microsomes resulted in specific covalent labeling of a protein doublet of molecular mass 62 and 64 kDa. By carrying out the photoactivation of the probe using microsomes containing epitope-tagged Ost1p, we demonstrated that the I-125-labeled protein was Ost1p. Radiolabeling of this protein was dependent on irradiation at 350 nm. No labeling was detected using a probe containing Ala instead of Thr as the third amino acid residue. We conclude that Ost1p is the subunit of the OST complex that recognizes the peptide sites in the nascent chains that are destined to be glycosylated.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Utah System of Higher Education; University of Utah	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, R37GM033185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; Bause E, 1997, BIOCHEM J, V322, P95, DOI 10.1042/bj3220095; BAUSE E, 1983, BIOCHEM J, V209, P323, DOI 10.1042/bj2090323; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HART GW, 1979, J BIOL CHEM, V254, P9747; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HORTIN G, 1983, J BIOL CHEM, V258, P4047; HORTIN G, 1980, J BIOL CHEM, V255, P8007; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRONQUIST KE, 1978, J SUPRAMOL STR CELL, V8, P51, DOI 10.1002/jss.400080105; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAU JTY, 1983, J BIOL CHEM, V258, P5255; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NOIVA R, 1993, J BIOL CHEM, V268, P19210; PATHAK R, 1995, BIOCHEMISTRY-US, V34, P4179, DOI 10.1021/bi00013a005; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; RONIN C, 1981, EUR J BIOCHEM, V118, P159, DOI 10.1111/j.1432-1033.1981.tb05499.x; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; Xu T, 1998, BIOORGAN MED CHEM, V6, P1821, DOI 10.1016/S0968-0896(98)00135-7	32	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5021	5025		10.1074/jbc.274.8.5021	http://dx.doi.org/10.1074/jbc.274.8.5021			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988747	hybrid			2022-12-25	WOS:000078698200072
J	McCawley, LJ; Li, SN; Wattenberg, EV; Hudson, LG				McCawley, LJ; Li, SN; Wattenberg, EV; Hudson, LG			Sustained activation of the mitogen-activated protein kinase pathway - A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAP KINASE; INFLAMMATORY CYTOKINES; MAMMALIAN-CELLS; EGF RECEPTOR; PC12 CELLS; EXPRESSION; COLLAGENASE; SIGNAL; RAS	Activation of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway is required for ligand-dependent regulation of numerous cellular functions by receptor tyrosine kinases. We have shown previously that although many receptor tyrosine kinase ligands are mitogens for keratinocytes, cell migration and induction of the 92-kilodalton gelatinase/matrix metalloproteinase (MMP)-9 are selectively regulated by the epidermal growth factor and scatter factor/hepatocyte growth factor receptors. In this report we present evidence of an underlying mechanism to account for these observed differences in receptor tyrosine kinase-mediated response. Ligands that are mitogenic, but do not induce MMP-9 or colony dispersion, transiently activate the p42/p44 ERK/MAP kinases. In contrast, ligands that stimulate MMP-9 induction and colony dispersion induced sustained activation of these kinases. The functional significance of sustained MAPK activation was demonstrated by inhibition of the MAP kinase kinase MEK1. Disruption of the prolonged signal by addition of the MEK1 inhibitor PD 98059 up to 4 h after growth factor stimulation substantially impaired ligand-dependent colony dispersion and MMP-9 induction. These findings support the conclusion that duration of MAPK activation is an important determinant for certain growth factor-mediated functions in keratinocytes.	Univ New Mexico, Ctr Hearing Sci, Program Pharmacol & Toxicol, Coll Pharm, Albuquerque, NM 87131 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Div Environm & Occupat Hlth, Minneapolis, MN 55455 USA	University of New Mexico; Northwestern University; University of Minnesota System; University of Minnesota Twin Cities	Hudson, LG (corresponding author), Univ New Mexico, Ctr Hearing Sci, Program Pharmacol & Toxicol, Coll Pharm, 2502 Marble NE, Albuquerque, NM 87131 USA.	lghudson@unm.edu			NCI NIH HHS [CA72498] Funding Source: Medline; NIAMS NIH HHS [R01AR42989] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Boyd D, 1996, CANCER METAST REV, V15, P77, DOI 10.1007/BF00049488; Chen RH, 1996, ONCOGENE, V12, P1493; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Heldin CH, 1996, CANCER SURV, V27, P7; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; JENSEN PJ, 1993, J CELL PHYSIOL, V155, P333, DOI 10.1002/jcp.1041550214; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kuroki DW, 1996, CANCER RES, V56, P637; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SALO T, 1994, LAB INVEST, V70, P176; SATO H, 1993, J BIOL CHEM, V268, P23460; Simon C, 1998, CANCER RES, V58, P1135; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; Vu TH, 1998, BIOL EXTRAC, P115	37	189	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4347	4353		10.1074/jbc.274.7.4347	http://dx.doi.org/10.1074/jbc.274.7.4347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933637	hybrid			2022-12-25	WOS:000078575500061
J	Proost, P; Struyf, S; Schols, D; Opdenakker, G; Sozzani, S; Allavena, P; Mantovani, A; Augustyns, K; Bal, G; Haemers, A; Lambeir, AM; Scharpe, S; Van Damme, J; De Meester, I				Proost, P; Struyf, S; Schols, D; Opdenakker, G; Sozzani, S; Allavena, P; Mantovani, A; Augustyns, K; Bal, G; Haemers, A; Lambeir, AM; Scharpe, S; Van Damme, J; De Meester, I			Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-IV; IN-VIVO; INHIBITION; CD26; MDC	The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) and chemokines are known key players in immunological processes; Surprisingly, CD26/DPP IV not only removed the expected Gly(1)-Pro(2) dipeptide from the NH(2) terminus of macrophage-derived chemokine (MDC) but subsequently also the Tyr(3)-Gly(4) dipeptide, generating MDC(5-69). This second cleavage after a Gly residue demonstrated that the substrate specificity of this protease is less restricted than anticipated. The unusual processing of MDC by CD26/DPP TV was confirmed on the synthetic peptides GPYGANMED (MDC(1-9)) and YGANMED (MDC(3-9)). Compared with intact MDC(1-69), CD26/DPP IV-processed MDC(5-69) had reduced chemotactic activity on lymphocytes and monocyte-derived dendritic cells, showed impaired mobilization of intracellular Ca(2+) through CC chemokine receptor 4 (CCR4), and was unable to desensitize for MDC-induced Ca(2+)-responses in CCR4 transfectants. However, MDC(5-69) remained equally chemotactic as intact MDC(1-69) on monocytes. In contrast to the reduced binding to lymphocytes and CCR4 transfectants, MDC(5-69) retained its binding properties to monocytes and its anti-HIV-l activity. Thus, NH(2)-terminal truncation of MDC by CD26/DPP TV has profound biological consequences and may be an important regulatory mechanism during the migration of Th2 lymphocytes and dendritic cells to germinal centers and to sites of inflammation.	Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Expt Chemotherapy, B-3000 Louvain, Belgium; Mario Negri Inst Pharmacol Res, Immunol Lab, I-20157 Milan, Italy; Univ Instelling Antwerp, Lab Clin Biochem, B-2610 Antwerp, Belgium	KU Leuven; KU Leuven; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Antwerp	Proost, P (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.	Paul.Proost@rega.kuleuven.ac.be	Proost, Paul/V-3052-2017; Opdenakker, Ghislain/Q-3130-2017; Augustyns, Koen/C-1102-2008; Augustyns, Koen/ABG-2306-2020; Schols, Dominique/S-9057-2017; Opdenakker, Ghislain/V-8562-2019; De Meester, Ingrid/A-6881-2017; Lambeir, Anne-Marie/B-2477-2017; Sozzani, Silvano/C-1447-2009; Mantovani, Alberto/HCI-7449-2022; Schols, Dominique/AAC-1309-2021; Struyf, Sofie/U-2455-2017; Allavena, Paola/HHM-5218-2022	Proost, Paul/0000-0002-0133-5545; Opdenakker, Ghislain/0000-0003-1714-2294; Augustyns, Koen/0000-0002-5203-4339; Augustyns, Koen/0000-0002-5203-4339; Schols, Dominique/0000-0003-3256-5850; Opdenakker, Ghislain/0000-0003-1714-2294; De Meester, Ingrid/0000-0002-3421-0124; Lambeir, Anne-Marie/0000-0001-9386-3777; Sozzani, Silvano/0000-0002-3144-8743; Mantovani, Alberto/0000-0001-5578-236X; Schols, Dominique/0000-0003-3256-5850; Struyf, Sofie/0000-0003-4558-0769; Allavena, Paola/0000-0002-6697-6028				Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BONGERS J, 1992, BIOCHIM BIOPHYS ACTA, V1122, P147, DOI 10.1016/0167-4838(92)90317-7; Chang MS, 1997, J BIOL CHEM, V272, P25229, DOI 10.1074/jbc.272.40.25229; Chantry D, 1998, J LEUKOCYTE BIOL, V64, P49, DOI 10.1002/jlb.64.1.49; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DeMeester I, 1997, BIOCHEM PHARMACOL, V54, P173, DOI 10.1016/S0006-2952(97)00149-4; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Drucker DJ, 1997, NAT BIOTECHNOL, V15, P673, DOI 10.1038/nbt0797-673; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOFFMANN T, 1993, FEBS LETT, V336, P61, DOI 10.1016/0014-5793(93)81609-4; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; KEIL B, 1992, SPECIFICITY PROTEOLY, P19; Korom S, 1997, TRANSPLANTATION, V63, P1495, DOI 10.1097/00007890-199705270-00021; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Proost Paul, 1996, Methods (Orlando), V10, P82, DOI 10.1006/meth.1996.0082; Schmitz T, 1996, J CLIN INVEST, V97, P1545, DOI 10.1172/JCI118577; Schols D, 1998, ANTIVIR RES, V39, P175, DOI 10.1016/S0166-3542(98)00039-4; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3082, DOI 10.1073/pnas.91.8.3082; Van Coillie E, 1998, BIOCHEMISTRY-US, V37, P12672, DOI 10.1021/bi980497d; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; von Bonin A, 1998, IMMUNOL REV, V161, P43; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	32	127	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3988	3993		10.1074/jbc.274.7.3988	http://dx.doi.org/10.1074/jbc.274.7.3988			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933589	hybrid			2022-12-25	WOS:000078575500013
J	Bei, R; Masuelli, L; Moriconi, E; Visco, V; Moretti, A; Kraus, MH; Muraro, R				Bei, R; Masuelli, L; Moriconi, E; Visco, V; Moretti, A; Kraus, MH; Muraro, R			Immune responses to all ErbB family receptors detectable in serum of cancer patients	ONCOGENE			English	Article						ErbB receptors; cancer; serum antibody	EPIDERMAL GROWTH-FACTOR; NIH 3T3 CELLS; CARCINOMA PATIENTS; PROTO-ONCOGENE; OVARIAN-CANCER; BREAST-CANCER; SELF-PROTEIN; HER-2/NEU; ANTIBODY; TRANSFORMATION	Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4, Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4, Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3, Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates, Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in Light of immunotherapeutic approaches targeting these receptors.	Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy; Univ La Sapienza, Dept Expt Med & Pathol, Rome, Italy	G d'Annunzio University of Chieti-Pescara; IRCCS European Institute of Oncology (IEO); Sapienza University Rome	Muraro, R (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy.		Masuelli, Laura/AGW-4259-2022; Bei, Roberto/W-8023-2019	MASUELLI, Laura/0000-0001-8174-8034				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baulida J, 1996, J BIOL CHEM, V271, P5251; BRICE EC, 1993, DEV GENET, V14, P174, DOI 10.1002/dvg.1020140304; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CEBRA JJ, 1984, ANNU REV IMMUNOL, V2, P493, DOI 10.1146/annurev.immunol.2.1.493; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; Clark MA, 1997, CLIN EXP IMMUNOL, V109, P166, DOI 10.1046/j.1365-2249.1997.4161316.x; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1991, ADV CELLULAR MOL BIO, P139; Disis ML, 1996, J IMMUNOL, V156, P3151; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; DISIS ML, 1994, CANCER RES, V54, P16; DISIS ML, 1994, CANCER RES, V54, P1071; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Glushkov AN, 1996, EXP ONCOL, V18, P81; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUBIN R, 1995, NAT MED, V1, P701, DOI 10.1038/nm0795-701; MARIANICOSTANTINI R, 1991, CANCER-AM CANCER SOC, V67, P2880, DOI 10.1002/1097-0142(19910601)67:11<2880::AID-CNCR2820671129>3.0.CO;2-A; Nagata Y, 1997, J IMMUNOL, V159, P1336; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PUPA SM, 1993, CANCER RES, V53, P5864; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tuttle TM, 1996, CANCER IMMUNOL IMMUN, V43, P135, DOI 10.1007/s002620050314; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Zafiropoulos A, 1997, J IMMUNOL METHODS, V200, P181, DOI 10.1016/S0022-1759(96)00207-4; Zhang K, 1996, J BIOL CHEM, V271, P3884	41	61	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1267	1275		10.1038/sj.onc.1202442	http://dx.doi.org/10.1038/sj.onc.1202442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022808				2022-12-25	WOS:000078510900002
J	Feng, JH; Ito, M; Kureishi, Y; Ichikawa, K; Amano, M; Isaka, N; Okawa, K; Iwamatsu, A; Kaibuchi, K; Hartshorne, DJ; Nakano, T				Feng, JH; Ito, M; Kureishi, Y; Ichikawa, K; Amano, M; Isaka, N; Okawa, K; Iwamatsu, A; Kaibuchi, K; Hartshorne, DJ; Nakano, T			Rho-associated kinase of chicken gizzard smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; SERINE-THREONINE KINASE; LIGHT-CHAIN PHOSPHATASE; ACTIN STRESS FIBERS; MYOSIN PHOSPHATASE; SERINE/THREONINE KINASE; ARACHIDONIC-ACID; PUTATIVE TARGET; CA2+ SENSITIZATION; FOCAL ADHESIONS	Rho-associated kinase (Rho-kinase) from chicken gizzard smooth muscle was purified to apparent homogeneity (160 kDa on SDS-polyacrylamide gel electrophoresis) and identified as the ROK alpha isoform, Several substrates were phosphorylated. Rates with myosin phosphatase target subunit 1 (MYPT1), myosin, and the 20-kDa myosin light chain were higher than other substrates, Thiophosphorylation of MYPT1 inhibited myosin phosphatase activity. Phosphorylation of myosin at serine 19 increased actin-activated Mg+-ATPase activity, i.e, similar to myosin light chain kinase. Myosin phosphorylation was increased at higher ionic strengths, possibly by formation of 6 S myosin, Phosphorylation of the isolated light chain and myosin phosphatase was decreased by increasing ionic strength. Rhokinase was stimulated 1.5-2-fold by guanosine 5'-O-3-(thio)triphosphate.RhoA whereas limited tryptic hydrolysis caused a 5-6-fold activation, independent of RhoA. Several kinase inhibitors were screened and most effective were Y-27632, staurosporine, and H-89, Several lipids caused slight activation of Rho-kinase, but arachidonic acid (30-50 mu M) induced a 5-6-fold activation, independent of RhoA. These results suggest that Rho-kinase of smooth muscle may be involved in the contractile process via phosphorylation of MYPT1 and myosin, Activation by arachidonic acid presents a possible regulatory mechanism for Rho-kinase.	Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 236, Japan; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Mie University; Nara Institute of Science & Technology; Kirin Brewery Company Limited; University of Arizona	Ito, M (corresponding author), Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan.	m-ito@clin.medic.mie-u.ac.jp	Bando, Yasuko K./M-4831-2014; Amano, Mutsuki/M-4820-2014	Bando, Yasuko K./0000-0003-4166-6784; Amano, Mutsuki/0000-0002-0662-1524	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984, R01HL023615] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23615, HL20984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GONG MC, 1995, J PHYSIOL-LONDON, V486, P113, DOI 10.1113/jphysiol.1995.sp020795; GONG MC, 1992, J BIOL CHEM, V267, P21492; Gong MC, 1997, J BIOL CHEM, V272, P10704; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HIDAKA H, 1979, MOL PHARMACOL, V15, P49; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1984, BIOCHEMISTRY-US, V23, P5062, DOI 10.1021/bi00316a036; IKEBE M, 1986, J BIOL CHEM, V261, P36; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MERKEL L, 1989, BIOCHEMISTRY-US, V28, P2215, DOI 10.1021/bi00431a037; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	54	214	220	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3744	3752		10.1074/jbc.274.6.3744	http://dx.doi.org/10.1074/jbc.274.6.3744			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920927	hybrid			2022-12-25	WOS:000078428200067
J	Igarashi, K; Verhagen, MFJM; Samejima, M; Schulein, M; Eriksson, KEL; Nishino, T				Igarashi, K; Verhagen, MFJM; Samejima, M; Schulein, M; Eriksson, KEL; Nishino, T			Cellobiose dehydrogenase from the fungi Phanerochaete chrysosporium and Humicola insolens - A flavohemoprotein from Humicola insolens contains 6-hydroxy-FAD as the dominant active cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPOROTRICHUM-PULVERULENTUM; QUINONE OXIDOREDUCTASE; OXIDIZING ENZYMES; OXIDASE; CELLULOSE; PURIFICATION; DEGRADATION; OXIDATION; BREAKDOWN; CULTURES	Cellobiose dehydrogenases (CDH) were purified from cellulose-grown cultures of the fungi Phanerochaete chrysosporium and Humicola insolens, The pH optimum of the cellobiose cytochrome c oxidoreductase activity of P, chrysosporium CDH was acidic, whereas that of H, insolens CDH was neutral. The absorption spectra of the two CDHs showed them to be typical hemoproteins, but there was a small. difference in the visible region. Limited proteolysis between the heme and flavin domains was performed to investigate the cofactors, There was no difference in absorption spectrum between the heme domains of P, chrysosporium and H, insolens CDHs. The midpoint potentials of heme at pH 7.0 were almost identical, and no difference in pH dependence was observed over the range of pH 3-9, The pH dependence of cellobiose oxidation by the flavin domains was similar to that of the native CDHs, indicating that the difference in the pH dependence of the catalytic activity between the two CDHs is because of the flavin domains. The absorption spectrum of the flavin domain from H, insolens CDH has absorbance maxima at 343 and 426 and a broad absorption peak at 660 nm, whereas that of P, chrysosporium CDH showed a normal flavoprotein spectrum. Flavin cofactors were extracted from the flavin domains and analyzed by high-performance liquid chromatography. The flavin cofactor from H. insolens was found to be a mixture of 60% 6-hydroxy-FAD and 40% FAD, whereas that from P, chrysosporium CDH was normal FAD, After reconstitution of the deflavo-proteins it was found that flavin domains containing B-hydroxy-FAD were clearly active but their cellobiose oxidation rates were lower than those of flavin domains containing normal FAD, Reconstitution of flavin cofactor had no effect on the optimum pH, From these results, it is concluded that the pH dependence is not because of the flavin cofactor but is because of the protein molecule.	Univ Tokyo, Sch Agr & Life Sci, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138657, Japan; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan	University of Tokyo; University System of Georgia; University of Georgia; Novo Nordisk; Nippon Medical School	Samejima, M (corresponding author), Univ Tokyo, Sch Agr & Life Sci, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138657, Japan.	amsam@hongo.ecc.u-tokyo.ac.jp	Igarashi, Kiyohiko/E-6799-2016	Igarashi, Kiyohiko/0000-0001-5152-7177				ANDER P, 1994, FEMS MICROBIOL REV, V13, P297, DOI 10.1016/0168-6445(94)90087-6; AYERS AR, 1978, EUR J BIOCHEM, V90, P171, DOI 10.1111/j.1432-1033.1978.tb12588.x; BAO WJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P705, DOI 10.1006/abbi.1993.1098; ERIKSSON KE, 1975, EUR J BIOCHEM, V51, P213, DOI 10.1111/j.1432-1033.1975.tb03921.x; ERIKSSON KE, 1974, FEBS LETT, V49, P282, DOI 10.1016/0014-5793(74)80531-4; ERIKSSON KEL, 1993, ENZYME MICROB TECH, V15, P1002, DOI 10.1016/0141-0229(93)90046-5; HABU N, 1993, FEBS LETT, V327, P161, DOI 10.1016/0014-5793(93)80162-N; HAGEN WR, 1989, EUR J BIOCHEM, V182, P523, DOI 10.1111/j.1432-1033.1989.tb14859.x; HENRIKSSON G, 1991, EUR J BIOCHEM, V196, P101, DOI 10.1111/j.1432-1033.1991.tb15791.x; HENRIKSSON G, 1995, COMPREHENSIVE SUMMAR, V112, P35; Igarashi K, 1997, FUNGAL GENET BIOL, V21, P214, DOI 10.1006/fgbi.1996.0954; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KREMER SM, 1992, FEMS MICROBIOL LETT, V92, P187, DOI 10.1111/j.1574-6968.1992.tb05257.x; KREMER SM, 1992, EUR J BIOCHEM, V205, P133, DOI 10.1111/j.1432-1033.1992.tb16760.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE HJ, 1956, J BIOL CHEM, V221, P983; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MORPETH FF, 1986, BIOCHEM J, V236, P221, DOI 10.1042/bj2360221; Radola BJ, 1980, ELECTROPHORESIS, V1, P43, DOI DOI 10.1002/ELPS.1150010109; RENGANATHAN V, 1990, APPL MICROBIOL BIOT, V32, P609, DOI 10.1007/BF00173735; SAMEJIMA M, 1992, EUR J BIOCHEM, V207, P103, DOI 10.1111/j.1432-1033.1992.tb17026.x; Samejima M, 1997, BIOTECHNOL APPL BIOC, V25, P135; SAMEJIMA M, 1992, FEBS LETT, V306, P165, DOI 10.1016/0014-5793(92)80991-O; Schou C, 1998, BIOCHEM J, V330, P565, DOI 10.1042/bj3300565; Schulein M, 1993, FDN BIOTECH IND FERM, V8, P109; WESTERMARK U, 1974, ACTA CHEM SCAND B, VB 28, P209, DOI 10.3891/acta.chem.scand.28b-0209; WESTERMARK U, 1975, ACTA CHEM SCAND B, V29, P419, DOI 10.3891/acta.chem.scand.29b-0419; WOOD JD, 1992, BIOCHIM BIOPHYS ACTA, V1119, P90, DOI 10.1016/0167-4838(92)90239-A; WOOD TM, 1972, BIOCHEM J, V128, P1183, DOI 10.1042/bj1281183	30	66	66	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3338	3344		10.1074/jbc.274.6.3338	http://dx.doi.org/10.1074/jbc.274.6.3338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920875	hybrid			2022-12-25	WOS:000078428200015
J	Kosa, JL; Sweasy, JB				Kosa, JL; Sweasy, JB			3 '-azido-3 '-deoxythymidine-resistant mutants of DNA polymerase beta identified by in vivo selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HIV-1 REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MECHANISM; ALPHA; MUTAGENESIS; RESOLUTION; RESISTANCE; FRAGMENT	We developed an in vivo selection to identify 3-'azido-3'-deoxythymidine (AZT)-resistant mutants of rat DNA polymerase beta (pol beta). The selection utilizes pol beta's ability to substitute for Escherichia coli DNA polymerase I (pol I) in the SC18-12 strain, which lacks active pol I. pol beta allows SC18-12 cells to grow, but they depend on pol beta activity, so inhibition of pol beta by AZT kills them. We screened a library of randomly mutated pol beta cDNA for complementation of the pol I defect in the presence of AZT, and identified AZT-resistant mutants. We purified two enzymes with nonconservative mutations in the palm domain of the polymerase, The substitutions D246V and R253M result in reductions in the steady-state catalytic efficiency (K-cat/K-m) of AZT-TP incorporation. The efficiency of dTTP incorporation was unchanged for the D246V enzyme, indicating that the substantial decrease in AZT-TP incorporation is responsible for its drug resistance, The R253M enzyme exhibits significantly higher K-m(dTTP) and K-cat(dTTP) values, implying that the incorporation reaction is altered. These are the first pol beta mutants demonstrated to exhibit AZT resistance in vitro. The locations of the Asp-246 and Arg-253 side chains indicate that substrate specificity is influenced by residues distant from the nucleotide-binding pocket.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University	Sweasy, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA.	joann.sweasy@yale.edu						Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bouayadi K, 1997, CANCER RES, V57, P110; CASASFINET JR, 1992, BIOCHEMISTRY-US, V31, P10272, DOI 10.1021/bi00157a014; Clairmont CA, 1996, J BACTERIOL, V178, P656, DOI 10.1128/jb.178.3.656-661.1996; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; Falcieri E, 1996, CELL STRUCT FUNCT, V21, P213, DOI 10.1247/csf.21.213; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LACEY SF, 1992, J BIOL CHEM, V267, P15789; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Miscia S, 1997, CELL PROLIFERAT, V30, P325; Opresko PL, 1998, BIOCHEMISTRY-US, V37, P2111, DOI 10.1021/bi9722711; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Reichenberger S, 1998, EUR J BIOCHEM, V251, P81, DOI 10.1046/j.1432-1327.1998.2510081.x; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STEIN CA, 1994, J MED VIROL, V44, P115, DOI 10.1002/jmv.1890440203; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; WITKIN EM, 1982, MOL GEN GENET, V185, P43, DOI 10.1007/BF00333788; WITKIN EM, 1992, J BACTERIOL, V174, P4166, DOI 10.1128/jb.174.12.4166-4168.1992; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	32	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3851	3858		10.1074/jbc.274.6.3851	http://dx.doi.org/10.1074/jbc.274.6.3851			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920940	hybrid			2022-12-25	WOS:000078428200080
J	Minard, KI; McAlister-Henn, L				Minard, KI; McAlister-Henn, L			Dependence of peroxisomal beta-oxidation on cytosolic sources of NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTOSE-PHOSPHATE PATHWAY; SACCHAROMYCES-CEREVISIAE; ISOCITRATE DEHYDROGENASE; HYDROGEN-PEROXIDE; FATTY-ACIDS; YEAST; GENE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; EXPRESSION; DISRUPTION	Growth of Saccharomyces cerevisiae with a fatty acid as carbon source was shown previously to require function of either glucose-6-phosphate dehydrogenase (ZWF1) or cytosolic NADP(+)-specific isocitrate dehydrogenase (IDP2), suggesting dependence of beta-oxidation on a cytosolic source of NADPH. In this study, we find that Delta IDP2 Delta ZWF1 strains containing disruptions in genes encoding both enzymes exhibit a rapid loss of viability when transferred to medium containing oleate as the carbon source. This loss of viability is not observed following transfer of a Delta IDP3 strain lacking peroxisomal isocitrate dehydrogenase to medium with docosahexaenoate, a nonpermissive carbon source that requires function of IDP3 for beta-oxidation. This suggests that the fatty acid(-) phenotype of Delta IDP2 Delta ZWF1 strains is not a simple defect in utilization. Instead, we propose that the common function shared by IDP2 and ZWF1 is maintenance of significant levels of NADPH for enzymatic removal of the hydrogen peroxide generated in the first step of peroxisomal beta-oxidation in yeast and that inadequate levels of the reduced form of the cofactor can produce lethality. This proposal is supported by the finding that the sensitivity to exogenous hydrogen peroxide previously reported for Delta ZWF1 mutant strains is less pronounced when analyses are conducted with a nonfermentable carbon source, a condition associated with elevated expression of IDP2. Under those conditions, similar slow growth phenotypes are observed for Delta ZWF1 and hIDP2 strains, and co-disruption of both genes dramatically exacerbates the H2O2s phenotype, Collectively, these results suggest that IDP2, when expressed, and ZWF1 have critical overlapping functions in provision of reducing equivalents for defense against endogenous or exogenous sources of H2O2.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.	henn@uthscsa.edu						BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V403, P65, DOI 10.1016/S0027-5107(98)00050-5; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HALLIWELL B, 1994, NUTR REV, V52, P253; HARDER W, 1989, YEASTS, V3, P261; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LAZAROW PB, 1997, MOL CELLULAR BIOL YE, V3, P547; Lee SM, 1998, BBA-PROTEIN STRUCT M, V1382, P167, DOI 10.1016/S0167-4838(97)00172-6; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; Minard KI, 1998, J BIOL CHEM, V273, P31486, DOI 10.1074/jbc.273.47.31486; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; STRYER L, 1988, BIOCHEMISTRY-US, P431; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149	28	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3402	3406		10.1074/jbc.274.6.3402	http://dx.doi.org/10.1074/jbc.274.6.3402			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920883	hybrid			2022-12-25	WOS:000078428200023
J	Wright, RM; Clayton, DK; Riley, MG; McManaman, JL; Repine, JE				Wright, RM; Clayton, DK; Riley, MG; McManaman, JL; Repine, JE			cDNA cloning, sequencing, and characterization of male and female rat liver aldehyde oxidase (rAOX1) - Differences in redox status may distinguish male and female forms of hepatic AOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHINE DEHYDROGENASE; MOLYBDENUM-COFACTOR; MOLECULAR CHARACTERIZATION; DROSOPHILA-PSEUDOOBSCURA; SUBSTRATE-SPECIFICITY; ALS2 GENE; PURIFICATION; CONVERSION; CANDIDATE; ENZYMES	Molecular characterization of male and female rat liver aldehyde oxidase is reported. As described for the mouse liver, male and female rat liver expressed kinetically distinct forms of aldehyde oxidase, Our data suggest that the two forms arise as a result of differences in redox state and are most simply explained by expression of a single gene encoding aldehyde oxidase in rats, In support of this argument we have sequenced cDNAs from male and female rat liver, We examined mRNA expression by Northern blot analysis with RNA from males and females, from several tissues, and following androgen induction. Purified rat liver enzyme from males or females revealed a single 150-kDa species consistent with cDNA sequence analysis. Both male and female forms were reactive to the same carboxyl-terminal directed antisera. K-m(app) values obtained in crude extracts of male or female rat liver and post-benzamidine-purified aldehyde oxidase differed substantially from each other but could be interconverted by chemical reduction with dithiothreitol or oxidation with 4,4'-dithiodipyridine, Our data indicate that a single gene is most likely expressed in male or female rat liver and that the kinetic differences between male and female rat liver aldehyde oxidases are sensitive to redox manipulation.	Univ Colorado, Hlth Sci Ctr, Webb Waring Antioxidant Res Inst, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem Biophys & Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wright, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Webb Waring Antioxidant Res Inst, 4200 E 9th Ave, Denver, CO 80262 USA.				NHLBI NIH HHS [HL45582, HL52509] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052509, R01HL045582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEEDHAM C, 1987, EUR J DRUG METAB PH, V12, P307, DOI 10.1007/BF03189919; BEEDHAM C, 1995, ARCH BIOCHEM BIOPHYS, V319, P481, DOI 10.1006/abbi.1995.1320; Bendotti C, 1997, NEUROREPORT, V8, P2343, DOI 10.1097/00001756-199707070-00048; BERGER R, 1995, SOMAT CELL MOLEC GEN, V21, P121, DOI 10.1007/BF02255787; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cai S, 1997, J MEMBRANE BIOL, V158, P147, DOI 10.1007/s002329900252; Comeron JM, 1996, GENETICS, V144, P1053; DICKINSON WJ, 1970, GENETICS, V66, P487; Eager KR, 1998, J MEMBRANE BIOL, V163, P9, DOI 10.1007/s002329900365; FELSTED RL, 1967, J BIOL CHEM, V242, P1274; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; GLUECKSO.S, 1967, J BIOL CHEM, V242, P1271; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Hille R., 1985, Metal Ions in Biology, V7, P443; Hoff T, 1998, BBA-GENE STRUCT EXPR, V1398, P397, DOI 10.1016/S0167-4781(98)00085-2; HOLMES RS, 1979, BIOCHEM GENET, V17, P517, DOI 10.1007/BF00498887; HUFF SD, 1967, J BIOL CHEM, V242, P1265; KEITH TP, 1985, MOL BIOL EVOL, V2, P206; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; Li Calzi Marco, 1995, Journal of Biological Chemistry, V270, P31037; Nishino T, 1997, J BIOL CHEM, V272, P29859, DOI 10.1074/jbc.272.47.29859; NISHINO T, 1994, J BIOCHEM, V116, P1; OHKUBO M, 1982, BIOCHEM INT, V4, P353; OHKUBO M, 1983, ARCH BIOCHEM BIOPHYS, V221, P534, DOI 10.1016/0003-9861(83)90172-8; Ori N, 1997, J BIOL CHEM, V272, P1019, DOI 10.1074/jbc.272.2.1019; RILEY MA, 1992, MOL BIOL EVOL, V9, P56; SAITO T, 1989, J BIOL CHEM, V264, P10015; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Sekimoto H, 1997, J BIOL CHEM, V272, P15280, DOI 10.1074/jbc.272.24.15280; Sugihara K, 1995, BIOCHEM MOL BIOL INT, V37, P861; TAYLOR SM, 1984, BIOCHEM J, V220, P67, DOI 10.1042/bj2200067; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TYNES RE, 1985, ARCH BIOCHEM BIOPHYS, V240, P77, DOI 10.1016/0003-9861(85)90010-4; WARNER CK, 1981, MOL GEN GENET, V184, P92, DOI 10.1007/BF00271201; WARNER CK, 1980, MOL GEN GENET, V180, P449, DOI 10.1007/BF00425861; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; Wright RM, 1997, REDOX REP, V3, P135, DOI 10.1080/13510002.1997.11747101; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; Wright RM, 1995, REDOX REP, V1, P313, DOI 10.1080/13510002.1995.11747005; Yoshihara S, 1997, ARCH BIOCHEM BIOPHYS, V338, P29, DOI 10.1006/abbi.1996.9774; Yoshihara S, 1997, BIOCHEM PHARMACOL, V53, P1099, DOI 10.1016/S0006-2952(97)00088-9; Zheng SY, 1997, INT J BIOL MACROMOL, V20, P307, DOI 10.1016/S0141-8130(97)00030-5; ZIEGLER DM, 1980, CIBA FDN S, V72, P191	47	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3878	3886		10.1074/jbc.274.6.3878	http://dx.doi.org/10.1074/jbc.274.6.3878			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920943	hybrid			2022-12-25	WOS:000078428200083
J	Shin, HW; Takatsu, H; Mukai, H; Munekata, E; Murakami, K; Nakayama, K				Shin, HW; Takatsu, H; Mukai, H; Munekata, E; Murakami, K; Nakayama, K			Intermolecular and interdomain interactions of a dynamin-related GTP-binding protein, Dnm1p/Vps1p-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; ENDOCYTOSIS; MUTANT; YEAST; ASSEMBLES; RINGS	Dnm1p/Vps1p-like protein (DVLP) is a mammalian member of the dynamin GTPase family, which is classified into subfamilies on the basis of the structural similarity. Mammalian dynamins constitute the dynamin subfamily. DVLP belongs to the Vps1 subfamily, which also includes yeast Vps1p and Dnm1p, Typical structural features that discriminate between members of the Vps1 and dynamin subfamilies are that the former lacks the pleckstrin homology and Pro-rich domains. Dynamin exists as tetramers under physiological salt conditions, whereas under low salt conditions, it can polymerize into spirals that resemble the collar structures seen at the necks of constricted coated pits. In this study, we found that DVLP is also oligomeric, probably tetrameric, under physiological salt conditions and forms sedimentable large aggregates under low salt conditions. The data indicate that neither the pleckstrin homology nor Pro-rich domain is required for the self-assembly. Analyses using the two-hybrid system and coimmunoprecipitation show that the N-terminal region containing the GTPase domain and a domain (DVH1) conserved across members of the dynamin and Vps1 subfamilies, can interact with the C-terminal region containing another conserved domain (DVH2), The data on the interdomain interaction of DVLP is compatible with the previous reports on the interdomain interaction of dynamin, Thus, the self-assembly mechanism of DVLP appears to resemble that of dynamin, suggesting that DVLP may also be involved in the formation of transport vesicles.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba	Nakayama, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.		Shin, Hye-Won/P-5398-2018; Nakayama, Kazuhisa/ABF-2924-2020	Shin, Hye-Won/0000-0002-9138-9554; Nakayama, Kazuhisa/0000-0001-7701-7183				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; GAMMIE AE, 1995, J CELL BIOL, V130, P553, DOI 10.1083/jcb.130.3.553; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Imoto M, 1998, J CELL SCI, V111, P1341; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779	24	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2780	2785		10.1074/jbc.274.5.2780	http://dx.doi.org/10.1074/jbc.274.5.2780			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915810	hybrid			2022-12-25	WOS:000078319500028
J	Hengstschlager, M; Holzl, G; Hengstschlager-Ottnad, E				Hengstschlager, M; Holzl, G; Hengstschlager-Ottnad, E			Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle	ONCOGENE			English	Article						apoptosis; cell cycle; c-Myc; E2F-1; centrifugal elutriation	UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; DEREGULATED EXPRESSION; DNA-SYNTHESIS; E2F-1; INDUCTION; FIBROBLASTS; LEADS; PROLIFERATION; DEGRADATION	The transcription factors c-Myc and E2F-1 have been shown to harbour both mitogenic and apoptotic properties. Both factors have been implicated in the regulation of the transition from the G1 phase to the S phase in the mammalian cell cycle, However, whether cell death triggered by these molecules is dependent on the cell's position in the ongoing cell cycle remained elusive. Using centrifugal elutriation we here show for the first time that c-Myc induces apoptosis in G1 and in G2 phase, whereas E2F-l-induced apoptosis specifically occurs in G1, S phase cells are resistant to cell death triggered by these factors. We demonstrate that this is not a general phenomenon, since S phase cells are susceptible to apoptosis induced by treatment with actinomycin D and to the anti-apoptotic activity of Bcl-2, Our data indicate that S phase cells harbour specific protective activities against c-Myc- and E2F-l-induced apoptosis, Our results demonstrate that these transcription factors, although probably sharing specific apoptotic pathways, also take distinct routes to induce cell death and that apoptosis can occur at different phases of the cell cycle depending on the apoptotic stimulus. In this report we present the usefulness of a new approach to determine the regulation of apoptosis in the ongoing unperturbated cell cycle. This approach has clear implications for the identification of target genes involved in the regulation of cell death.	Univ Vienna, Dept Prenatal Diagnosis & Therapy, A-1090 Vienna, Austria; Univ Vienna, Inst Genet Mol, A-1030 Vienna, Austria	University of Vienna; University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Dept Prenatal Diagnosis & Therapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							ASKEW DS, 1991, ONCOGENE, V6, P1915; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Dao T, 1997, J IMMUNOL, V159, P4261; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hengstschlager M, 1997, BIOTECHNIQUES, V23, P232, DOI 10.2144/97232bm12; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Packham G, 1996, ONCOGENE, V13, P461; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reed J C, 1996, Behring Inst Mitt, P72; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; STRASSER A, 1996, BEHRING I MITT, V97, P101; Vairo G, 1996, ONCOGENE, V13, P1511; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	30	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					843	848		10.1038/sj.onc.1202342	http://dx.doi.org/10.1038/sj.onc.1202342			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989838				2022-12-25	WOS:000078394400033
J	Yokouchi, M; Wakioka, T; Sakamoto, H; Yasukawa, H; Ohtsuka, S; Sasaki, A; Ohtsubo, M; Valius, M; Inoue, A; Komiya, S; Yoshimura, A				Yokouchi, M; Wakioka, T; Sakamoto, H; Yasukawa, H; Ohtsuka, S; Sasaki, A; Ohtsubo, M; Valius, M; Inoue, A; Komiya, S; Yoshimura, A			APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-indnced mitogenesis	ONCOGENE			English	Article						adaptor molecules containing PH and SH2 domains (APS); platelet derived growth factor receptor (PDGFR); signal transduction; molecular biology	FACTOR-BETA-RECEPTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; NEGATIVE REGULATOR; ACTIVATION; PROTOONCOGENE; RAS; CLONING; STIMULATION	Previously we cloned a novel adaptor protein, APS (adaptor molecules containing PH and SH2 domains) which was tyrosine phosphorylated in response to c-kit or B cell receptor stimulation. Here we report that APS was expressed in some human osteosarcoma cell lines, markedly so in SaOS-2 cells, and was tyrosine-phosphorylated in response to several growth factors, including platelet derived growth factor (PDGF), insulinlike growth factor (IGF), and granulocyte-macrophage colony stimulating factor (GM-CSF), Ectopic expression of the wild type APS, but not C-terminal truncated APS, in NIH3T3 fibroblasts suppressed PDGF-induced MAP kinase (Erk2) activation, c-fos and c-myc induction as well as cell proliferation. In vitro binding experiments suggest that APS bound to the beta type PDGF receptor, mainly via phosphotyrosine 1021 (pY1021), Indeed, tyrosine phosphorylation of PLC-gamma, which has been demonstrated to bind to pY1021, but not that of PI3 kinase and associated proteins, was reduced in APS transformants, PDGF induced phosphorylation of the tyrosine residue of APS close to the C-terminal end. in vitro and in vivo binding experiments indicate that the tyrosine phosphorylated C-terminal region of APS bound to c-Cbl, which has been shown to be a negative regulator of tyrosine kinases, Since coexpression of c-Cbl with wild type APS, but not C-terminal truncated APS, synergistically inhibited PDGF-induced c-fos promoter activation, c-Cbl could be a mechanism of inhibitory action of APS on PDGF receptor signaling.	Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Orthopaed Surg, Kurume, Fukuoka 8300011, Japan; Lithuania Acad Sci, Inst Biochem, LT-2600 Vilnius, Lithuania	Kurume University; Vilnius University	Yoshimura, A (corresponding author), Inst Life Sci, Aikawamachi 2432-3, Kurume, Fukuoka 8390861, Japan.		Valius, Mindaugas/N-1220-2019; Yoshimura, Akihiko/K-5515-2013; Valius, Mindaugas/F-2734-2012	Valius, Mindaugas/0000-0001-8478-8517; Sasaki, Atsuo/0000-0003-2963-4501; ohtsubo, motoaki/0000-0002-2479-3178				Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KEANE MM, 1995, ONCOGENE, V10, P2367; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAWSON T, 1992, CELL, V56, P5; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; RODAN SB, 1987, CANCER RES, V47, P4961; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	38	68	71	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					759	767		10.1038/sj.onc.1202326	http://dx.doi.org/10.1038/sj.onc.1202326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989826				2022-12-25	WOS:000078394400021
J	Houston, M; Estevez, A; Chumley, P; Aslan, M; Marklund, S; Parks, DA; Freeman, BA				Houston, M; Estevez, A; Chumley, P; Aslan, M; Marklund, S; Parks, DA; Freeman, BA			Binding of xanthine oxidase to vascular endothelium - Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-SUPEROXIDE DISMUTASE; REPERFUSION INJURY; ISCHEMIA-REPERFUSION; OXYGEN METABOLITES; LIPOPROTEIN-LIPASE; RABBIT MYOCARDIUM; GENE-EXPRESSION; CELL-SURFACE; LUNG INJURY; DEHYDROGENASE	Concentrations of up to 1.5 milliunits/ml xanthine oxidase (XO) (1.1 mu g/ml) are found circulating in plasma during diverse inflammatory events. The saturable, high affinity binding of extracellular XO to vascular endothelium and the effects of cell binding on both XO catalytic activity and differentiated vascular cell function are reported herein. Xanthine oxidase purified from bovine cream bound specifically and with high affinity (K-d = 6 nM) at 4 degrees C to bovine aortic endothelial cells, increasing cell XO specific activity up to 10-fold, Xanthine oxidase-cell binding was not inhibited by serum or albumin and was partially inhibited by the addition of heparin. Pretreatment of endothelial cells with chondroitinase, but not heparinase or heparitinase, diminished endothelial binding by similar to 50%, suggesting association with chondroitin sulfate proteoglycans. Analysis of rates of superoxide production by soluble and cell-bound XO revealed that endothelial binding did not alter the percentage of univalent reduction of oxygen to superoxide. Com parison of the extent of CuZn-SOD inhibition of native and succinoylated cytochrome c reduction by cell-bound XO indicated that XO-dependent superoxide production was occurring in a cell compartment inaccessible to CuZn-SOD, This was further supported by the observation of a shift of exogenously added XO from extracellular binding sites to intracellular compartments, as indicated by both protease-reversible cell. binding and immunocytochemical localization studies. Endothelium-bound XO also inhibited nitric oxide-dependent cGMP production by smooth muscle cell co-cultures in an SOD-resistant manner. This data supports the concept that circulating XO can bind to vascular cells, impairing cell function via oxidative mechanisms, and explains how vascular XO activity diminishes vasodilatory responses to acetylcholine in hypercholesterolemic rabbits and atherosclerotic humans, The ubiquity of cell-XO binding and endocytosis as a fundamental mechanism of oxidative tissue injury is also affirmed by the significant extent of XO binding to human vascular endothelial cells, rat lung type 2 alveolar epthelial cells, and fibroblasts.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Umea Univ Hosp, Dept Clin Chem, S-90185 Umea, Sweden	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Umea University	Freeman, BA (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 946 Tinsley Harrison Tower,619 S 19th St, Birmingham, AL 35233 USA.	bruce.freeman@ccc.uab.edu	Freeman, Bruce A/H-9342-2012; Aslan, Mutay/C-7566-2016	Aslan, Mutay/0000-0002-0660-971X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051245, R01HL058115] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL51245, P01 HL40456, R01 HL58115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1993, BIOCHEM J, V289, P523, DOI 10.1042/bj2890523; BARLOW GH, 1966, J BIOL CHEM, V241, P1473; BECKMAN JS, 1989, FREE RADICAL BIO MED, V6, P607, DOI 10.1016/0891-5849(89)90068-3; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Benboubetra M, 1997, EUR J CLIN INVEST, V27, P611, DOI 10.1046/j.1365-2362.1997.1550704.x; BOISSINOT M, 1993, BIOCHEM BIOPH RES CO, V190, P250, DOI 10.1006/bbrc.1993.1038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Cardillo C, 1997, HYPERTENSION, V30, P57, DOI 10.1161/01.HYP.30.1.57; CLARE DA, 1991, ARCH BIOCHEM BIOPHYS, V286, P233, DOI 10.1016/0003-9861(91)90034-G; CRUZ FS, 1983, J PARASITOL, V69, P237, DOI 10.2307/3281307; DUPONT GP, 1992, J CLIN INVEST, V89, P197, DOI 10.1172/JCI115563; FUKUSHIMA T, 1995, BIOL PHARM BULL, V18, P156; GARDNER TJ, 1983, SURGERY, V94, P423; GILER S, 1975, CLIN CHIM ACTA, V63, P37, DOI 10.1016/0009-8981(75)90375-7; GRACE PA, 1994, BRIT J SURG, V81, P637, DOI 10.1002/bjs.1800810504; Grum C.M., 1987, J CRIT CARE, V2, P22; GRUM CM, 1986, BIOCHEM BIOPH RES CO, V141, P1104, DOI 10.1016/S0006-291X(86)80157-7; Gutierrez HH, 1996, FREE RADICAL BIO MED, V21, P43, DOI 10.1016/0891-5849(95)02226-0; Hassoun PM, 1998, AM J RESP CRIT CARE, V158, P299, DOI 10.1164/ajrccm.158.1.9709116; HIEBERT LM, 1990, ATHEROSCLEROSIS, V83, P47, DOI 10.1016/0021-9150(90)90129-7; INOUE M, 1991, J BIOL CHEM, V266, P16409; JEROUDI MO, 1994, AM J CARDIOL, V73, pB2, DOI 10.1016/0002-9149(94)90257-7; KARLSSON K, 1989, LAB INVEST, V60, P659; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOIKE K, 1993, J SURG RES, V54, P469, DOI 10.1006/jsre.1993.1072; KOOIJ A, 1994, HEPATOLOGY, V19, P1488, DOI 10.1002/hep.1840190626; KOPACZ M, 1993, J MOL CELL CARDIOL, V25, P859, DOI 10.1006/jmcc.1993.1095; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; LAPENNA D, 1992, BIOCHEM PHARMACOL, V44, P188, DOI 10.1016/0006-2952(92)90057-P; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; MARZI I, 1989, TRANSPLANT P, V21, P1319; MIYAMOTO Y, 1995, SOC EXP BIOL MED, V211, P366; Mohacsi A, 1996, BBA-MOL BASIS DIS, V1316, P210, DOI 10.1016/0925-4439(96)00027-0; MUGGE A, 1991, AM J PHYSIOL, V260, pC219, DOI 10.1152/ajpcell.1991.260.2.C219; Murad F, 1996, JAMA-J AM MED ASSOC, V276, P1189, DOI 10.1001/jama.276.14.1189; NIELSEN VG, 1994, J THORAC CARDIOV SUR, V107, P1222, DOI 10.1016/S0022-5223(94)70041-9; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OHTA H, 1994, FREE RADICAL BIO MED, V16, P501, DOI 10.1016/0891-5849(94)90128-7; PALERMARTINEZ A, 1994, ARCH BIOCHEM BIOPHYS, V311, P79, DOI 10.1006/abbi.1994.1211; PANUS PC, 1992, ARCH BIOCHEM BIOPHYS, V294, P695, DOI 10.1016/0003-9861(92)90743-G; PARKS D, 1998, REACTIVE OXYGEN SPEC, P397; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; PARTRIDGE CA, 1992, ARCH BIOCHEM BIOPHYS, V294, P184, DOI 10.1016/0003-9861(92)90155-P; Pasquet JPEE, 1996, BIOCHIMIE, V78, P785, DOI 10.1016/S0300-9084(97)82537-0; Patetsios P, 1996, ANN NY ACAD SCI, V800, P243, DOI 10.1111/j.1749-6632.1996.tb33318.x; PFEFFER KD, 1994, J IMMUNOL, V153, P1789; Poss WB, 1996, AM J PHYSIOL-LUNG C, V270, pL941, DOI 10.1152/ajplung.1996.270.6.L941; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 1997, ARCH BIOCHEM BIOPHYS, V339, P125, DOI 10.1006/abbi.1996.9844; ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROSS R, 1992, INFLAMMATION BASIC P, P1057; RYAN US, 1986, J TISSUE CULT METHOD, V10, P7; Sanders SA, 1997, EUR J BIOCHEM, V245, P541, DOI 10.1111/j.1432-1033.1997.00541.x; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; Sarnesto A, 1996, LAB INVEST, V74, P48; SCHON P, 1992, EUR J CELL BIOL, V59, P329; SCHWARTZ CJ, 1993, AM J CARDIOL, V71, pB9, DOI 10.1016/0002-9149(93)90139-4; SELLAK H, 1994, BLOOD, V83, P2669; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; Suzuki H, 1998, P NATL ACAD SCI USA, V95, P4754, DOI 10.1073/pnas.95.8.4754; TAN S, 1995, SOUTHERN MED J, V88, P479, DOI 10.1097/00007611-199504000-00021; TAN S, 1993, FREE RADICAL BIO MED, V15, P407, DOI 10.1016/0891-5849(93)90040-2; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; TERADA LS, 1992, P NATL ACAD SCI USA, V89, P3362, DOI 10.1073/pnas.89.8.3362; TERADA LS, 1991, AM J PHYSIOL, V260, pH805, DOI 10.1152/ajpheart.1991.260.3.H805; TERADA LS, 1992, AM J PHYSIOL, V263, pL394, DOI 10.1152/ajplung.1992.263.3.L394; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; WEINBROUM A, 1995, AM J PHYSIOL-GASTR L, V268, pG988, DOI 10.1152/ajpgi.1995.268.6.G988; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; YAMANAKA H, 1992, METABOLISM, V41, P364, DOI 10.1016/0026-0495(92)90069-M; ZIMMERMAN BJ, 1988, AM J PHYSIOL, V255, pH202, DOI 10.1152/ajpheart.1988.255.1.H202	76	198	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4985	4994		10.1074/jbc.274.8.4985	http://dx.doi.org/10.1074/jbc.274.8.4985			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988743	hybrid			2022-12-25	WOS:000078698200068
J	Kim, E; Arnould, T; Sellin, LK; Benzing, T; Fan, MJ; Gruning, W; Sokol, SY; Drummond, I; Walz, G				Kim, E; Arnould, T; Sellin, LK; Benzing, T; Fan, MJ; Gruning, W; Sokol, SY; Drummond, I; Walz, G			The polycystic kidney disease 1 gene product modulates Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; BETA-CATENIN; C-JUN; MOLECULAR MECHANISM; XENOPUS EMBRYOS; AXIS INDUCTION; PROTEIN; EXPRESSION; PATHWAY; LITHIUM	Two distinct signaling pathways, involving Wnt signaling and polycystin, have been found to be critical for normal kidney development. Renal tubulogenesis requires the presence of certain Wnt proteins, whereas mutations in polycystin impede the terminal differentiation of renal tubular epithelial cells, causing the development of large cystic kidneys that characterize autosomal dominant polycystic kidney disease. Polycystin is an integral membrane protein, consisting of several extracellular motifs indicative of cell-cell and cell-matrix interactions, coupled through multiple transmembrane domains to a functionally active cytoplasmic domain. We report here that expression of the C-terminal cytoplasmic domain of polycystin stabilizes soluble endogenous beta-catenin and stimulates TCF-dependent gene transcription in human embryonic kidney cells. Microinjection of the polycystin C-terminal cytoplasmic do main induces dorsalization in zebrafish, Our findings suggest that polycystin has the capacity to modulate Wnt signaling during renal development.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Mol & Dev Neurosci, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Renal Unit, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Walz, G (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA.	gwalz@bidmc.harvard.edu	Benzing, Thomas/X-5476-2019	Sokol, Sergei/0000-0002-3963-9202	NIMH NIH HHS [MH-01147] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH001147] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BURROW CR, 1997, J AM SOC NEPHROL, V8, P370; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, pS498; Fan MJ, 1998, P NATL ACAD SCI USA, V95, P5626, DOI 10.1073/pnas.95.10.5626; Geng L, 1997, AM J PHYSIOL-RENAL, V272, pF451, DOI 10.1152/ajprenal.1997.272.4.F451; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Griffin MD, 1997, KIDNEY INT, V52, P1196, DOI 10.1038/ki.1997.444; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Hatta K, 1996, DEV DYNAM, V205, P183, DOI 10.1002/(SICI)1097-0177(199602)205:2<183::AID-AJA9>3.0.CO;2-E; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KELLY GM, 1995, MECH DEVELOP, V53, P261, DOI 10.1016/0925-4773(95)00442-4; Kispert A, 1996, DEVELOPMENT, V122, P3627; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; Peters DJM, 1996, LAB INVEST, V75, P221; Pierce SB, 1996, DEV BIOL, V175, P256, DOI 10.1006/dbio.1996.0113; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602	46	227	236	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4947	4953		10.1074/jbc.274.8.4947	http://dx.doi.org/10.1074/jbc.274.8.4947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988738	hybrid			2022-12-25	WOS:000078698200063
J	Law, BK; Norgaard, P; Gnudi, L; Kahn, BB; Poulson, HS; Moses, HL				Law, BK; Norgaard, P; Gnudi, L; Kahn, BB; Poulson, HS; Moses, HL			Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; IN-VIVO; GROWTH; RECEPTOR; INSULIN; PHOSPHORYLATION	Previously, the protein farnesyltransferase inhibitor (FTI), L-744,832, has been shown to inhibit the proliferation of a number of tumor cell lines in vitro in a manner that correlated with the inhibition of the mitogen-activated protein kinase cascade. Here we show that FTI inhibits p70(s6k) phosphorylation in mammary tumors in vivo in transgenic mice. Furthermore, in a mouse keratinocyte cell line, FTI inhibits p70(s6k) phosphorylation and activity and inhibits PHAS-1 phosphorylation in vitro in both rapidly growing cells and in growth factor-stimulated quiescent cells, Dominant-negative Ras expression inhibits p70(s6k) stimulation by epidermal growth factor, demonstrating a requirement for Pas activity during p70(s6k) activation. FTI does not inhibit protein kinase B phosphorylation on Ser(473), indicating that FTI does not act by inhibiting phosphatidylinositol 3-kinase, FTI also inhibits DNA synthesis in keratinocytes, and inhibition of DNA synthesis correlates closely with p70(S6k) inhibition. Rapamycin, an inhibitor of p70(s6k) and PHAS-1 phosphorylation, causes a 30-45% reduction in DNA synthesis in keratinocytes, while FTI induces an 80-90% reduction in DNA synthesis. These observations suggest that alteration of p70(s6k) and PHAS-1 function by FTI are responsible for a substantial portion of the growth-inhibitory properties of FTI. Together, these data demonstrate that p70S6k and PHAS-1 are novel downstream targets of FTI and suggest that the antitumor properties of FTI are probably due to the inhibition of multiple mitogenic pathways.	Vanderbilt Univ, Ctr Canc, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Rigshosp, Finsen Ctr, Sect Radiat Biol, DK-2100 Copenhagen, Denmark; Beth Israel Deaconess Med Ctr, Dept Med, Diabet Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Vanderbilt University; Vanderbilt University; Rigshospitalet; University of Copenhagen; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Moses, HL (corresponding author), Vanderbilt Univ, Ctr Canc, 649 Med Res Bldg II, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu	Law, Brian/L-6043-2019	gnudi, luigi/0000-0002-6353-630X	NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043051, R01DK043051] Funding Source: NIH RePORTER; NCI NIH HHS [CA09582] Funding Source: Medline; NIDDK NIH HHS [R01 DK043051, DK43051] Funding Source: Medline; PHS HHS [A42572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; MANGUES R, 1998, CANCER RES, V58, P153; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SUN JZ, 1995, CANCER RES, V55, P4243; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	50	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4743	4748		10.1074/jbc.274.8.4743	http://dx.doi.org/10.1074/jbc.274.8.4743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988711	hybrid			2022-12-25	WOS:000078698200036
J	Chiorini, JA; Miyamoto, S; Harkin, SJ; Safer, B				Chiorini, JA; Miyamoto, S; Harkin, SJ; Safer, B			Genomic cloning and characterization of the human eukaryotic initiation factor-2 beta promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; GENE; FACTOR-EIF-2; EXPRESSION	The translation initiation factor eIF2 consists of three subunits that are present in equal molar amounts. The genomic DNA containing the gene for eIF2 beta and its promoter were cloned and sequenced to characterize further the mechanism of their regulated synthesis. Whereas Southern blot analysis indicated that a number of copies of the gene may exist, only one full-length intron-containing copy was identified. Similar to the eIF2 alpha promoter, the eIF2 beta promoter is TATA-less, CAAT-less, and CC-rich and contains an alpha-Pal binding motif, Mutation of the alpha-Pal binding sequence resulted in an 8-fold decrease in activity when assayed by the luciferase reporter gene constructs. The data suggest a common mechanism of transcriptional control for the two cloned subunits of eIF2.	NHLBI, DIR, Mol Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Safer, B (corresponding author), NHLBI, DIR, Mol Hematol Branch, NIH, Bldg 10,Rm 7D18,MSC 1654, Bethesda, MD 20892 USA.							CHIORINI JA, 1993, J BIOL CHEM, V268, P13748; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; SELDEN RF, 1987, CURRENT PROTOCOLS MO	14	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4195	4201		10.1074/jbc.274.7.4195	http://dx.doi.org/10.1074/jbc.274.7.4195			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933616	hybrid			2022-12-25	WOS:000078575500040
J	Nadeau, OW; Domanski, P; Usacheva, A; Uddin, S; Platanias, LC; Pitha, P; Raz, R; Levy, D; Majchrzak, B; Fish, E; Colamonici, OR				Nadeau, OW; Domanski, P; Usacheva, A; Uddin, S; Platanias, LC; Pitha, P; Raz, R; Levy, D; Majchrzak, B; Fish, E; Colamonici, OR			The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation - Evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOKINE RECEPTORS; ANTIVIRAL STATE; IFN-ALPHA; SUBUNIT; KINASE; PATHWAY; EXPRESSION; PROTEIN	The precise role of the different subunits (alpha/IFNAR1 and beta(L)/IFNAR2) of the type I interferon receptor (IFN-R) in the activation of signal transducer and activator of transcription (Stat) 1, Stat2, and Stat3 has not yet been established. In this report we demonstrate that there are functionally redundant phosphotyrosine-dependent and -independent binding sites for Stat2 in the alpha and beta subunits of the type I IFN-R, Expression of a type I IFN-R containing only the constitutive Stat2 site or the proximal tyrosines of beta(L), but not the docking site on the a chain (Tyr(466) and Tyr(481)), supported low levels of Stat2 activation. However, the presence of only one intact Stat2 site did not lead to induction of interferon-stimulated gene factor 3 (ISGF3) or an antiviral state. Normal levels of Stat2 tyrosine phosphorylation, induction of ISGF3, and an antiviral effect always required the proximal tyrosines of beta(L) and at least one of the other Stat2 sites (Tyr(alpha 466,481) or beta(L404-462)). These data suggest that a threshold of Stat2 tyrosine phosphorylation is required for complete activation of ISGF3. Interestingly, a receptor in which all tyrosines were mutated to phenylalanine shows normal Stat3 phosphorylation and low levels of activation of Stat1.	Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Moscow Region, Russia; Univ Illinois, Hematol Oncol Sect, Chicago, IL 60606 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E2, Canada; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	University of Tennessee System; University of Tennessee Health Science Center; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; New York University; Johns Hopkins University; Johns Hopkins Medicine	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott,Rm E403 M-C 868, Chicago, IL 60612 USA.	ocolamon@uic.edu	Usacheva, Anna/J-7543-2018	Usacheva, Anna/0000-0001-7508-6513; Levy, David/0000-0002-7320-7788; Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R29CA073381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NCI NIH HHS [CA73381] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; CHEUNG SC, 1991, J IMMUNOL, V146, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; GHISLAIN J, 1995, J BIOL CHEM, V270, P21785, DOI 10.1074/jbc.270.37.21785; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4045	4052		10.1074/jbc.274.7.4045	http://dx.doi.org/10.1074/jbc.274.7.4045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933596	hybrid			2022-12-25	WOS:000078575500020
J	Overall, CM; King, AE; Sam, DK; Ong, AD; Lau, TTY; Wallon, UM; DeClerck, YA; Atherstone, J				Overall, CM; King, AE; Sam, DK; Ong, AD; Lau, TTY; Wallon, UM; DeClerck, YA; Atherstone, J			Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase a by site-directed mutagenesis - The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HUMAN 72-KDA GELATINASE; HIGH-AFFINITY BINDING; MATRIX METALLOPROTEINASE; PROGELATINASE-A; CRYSTAL-STRUCTURE; AUTOPROTEOLYTIC ACTIVATION; EXTRACELLULAR-MATRIX; HUMAN-FIBROBLASTS; KINETIC-ANALYSIS	Cell surface activation of progelatinase A occurs in a quaternary complex with the tissue inhibitor of metalloproteinases-2 (TIMP-2) and two membrane-type matrix metalloproteinases. We have mutated the unique cationic clusters found in hemopexin modules III and TV of the carboxyl domain (C domain) of human gelatinase A to determine their role in binding TIMP-2. Twelve single, double, and triple site-directed mutations were produced that exhibited different TIMP-2 binding properties. Notably, single alanine substitutions at Lys(547) and Lys(617) reduced TIMP-2 binding by an order of magnitude from that of the recombinant wild-type C domain. Mutations that completely disrupted the C domain TIMP-2 interaction were K558A/R561A, K610T/K617A, and K566A/K568A/K617A. A triple mutation, K566A/K568A/K575A, having TIMP-2 binding indistinguishable from the wild-type C domain (K-d 3.0 X 10-2 M), showed that simple reduction of net positive charge does not reduce TIMP-2 affinity. Because the double mutation R566A/K568A also did not alter TIMP-2 binding, these data do not confirm previously reported chimera studies that indicated the importance of the triple lysine cluster at positions 566/567/568 in TIMP-2 binding. Nonetheless, a subtle role in TIMP-2 interaction for the 566/567/568-lysine triad is indicated from the enhanced reduction in TIMP-2 binding that occurs when mutations here were combined with K617A. Thus, these analyses indicate that the TIMP-2 binding surface lies at the junction of hemopexin modules III and IV on the peripheral rim of the gelatinase A C domain. This location implies that considerable molecular movement of the TIMP-2 C domain complex would be needed for the bound TIMP-2 to inhibit in cis the gelatinase A active site.	Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Los Angeles, CA 90027 USA	University of British Columbia; University of British Columbia; Children's Hospital Los Angeles; University of Southern California	Overall, CM (corresponding author), Univ British Columbia, Fac Dent, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	overall@interchange.ubc.ca		Lau, Tim/0000-0001-6447-7797; DeClerck, Yves/0000-0002-3688-0113				Assmann V, 1998, J CELL SCI, V111, P1685; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; CUNNINGHAM BG, SCIENCE, V244, P1081; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRIEDMAN R, 1992, J BIOL CHEM, V267, P15398; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Hewitt RE, 1996, TRENDS GLYCOSCI GLYC, V8, P23, DOI 10.4052/tigg.8.23; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Maurus R, 1997, BBA-PROTEIN STRUCT M, V1341, P1, DOI 10.1016/S0167-4838(97)00064-2; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; OVERALL CM, 1999, IN PRESS ANN NY ACAD; OVERALL CM, 1991, TRENDS GLYCOSCI GLYC, V3, P384; OVERALL CM, 1999, IN PRESS INHIBITORS; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	48	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4421	4429		10.1074/jbc.274.7.4421	http://dx.doi.org/10.1074/jbc.274.7.4421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933646	hybrid			2022-12-25	WOS:000078575500070
J	Tian, XQ; Holick, MF				Tian, XQ; Holick, MF			A liposomal model that mimics the cutaneous production of vitamin D-3 - Studies of the mechanism of the membrane-enhanced thermal isomerization of previtamin D-3 to vitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOTROPIC PHASE-BEHAVIOR; CHOLESTEROL SIDE-CHAIN; HUMAN-SKIN; LIPID-PEROXIDATION; PHOTOSYNTHESIS; ORGANIZATION; ERGOSTEROL; TAMOXIFEN; BILAYERS; NMR	We reported previously that the rate of previtamin D-3 (preD(3)) half right arrow over half left arrow vitamin D-3 isomerization was enhanced by about 10 times in the skin compared with that in organic solvents, To elucidate the mechanism by which the rate of this reaction is enhanced in the skin, we developed a liposomal model that mimicked the enhanced isomerization of preD(3) to vitamin D-3 that was described in human skin. Using this model we studied the effect of changing the polarity of preD(3) as well as changing the chain length and the degree of saturation of liposomal phospholipids on the kinetics of preD(3) half right arrow over half left arrow vitamin D-3 isomerization, We found that a decrease in the hydrophilic interaction of the preD(3) with liposomal phospholipids by an esterification of the 3 beta-hydroxy of preD(3) (previtamin D-3-3 beta-acetate) reduced the rate of the isomerization by 67%. The addition of a hydroxyl on C-25 of the hydrophobic side chain (25-hydroxyprevitamin D-3), which decreased the hydrophobic interaction of preD(3) with the phospholipids, reduced the rate by 87%, In contrast, in an isotropic n-hexane solution, there was little difference among the rates of the conversion of preD(3), its BP-acetate, and 25-hydroxy derivatives to their corresponding vitamin D-3 compounds, We also determined rate constants (k) of preD(3) half right arrow over half left arrow vitamin D-3 isomerization in liposomes containing phosphatidylcholines with different carbon chain lengths, The rates of the reaction were found to be enhanced as the number of carbons (C-n) in the hydrocarbon chain of the phospholipids increased from 10 to 18, In conclusion, these results support our hypothesis that amphipathic interactions between preD(3) and membrane phospholipids stabilize preD(3) in its "cholesterol like" cZc-conformer, the only conformer of preD(3) that can convert to vitamin D-3. The stronger these interactions were, the more preD(3) was likely in its cZc conformation at any moment and the faster was the rate of its conversion to vitamin D-3.	Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Physiol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Vitamin D Skin & Bone Res Lab, Endocrinol Nutr & Diabet Sect, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Holick, MF (corresponding author), Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA.	mfholick@bu.edu		Holick, Michael/0000-0001-6023-9062	NIAMS NIH HHS [R0-AR-36963] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bittman R, 1997, Subcell Biochem, V28, P145; CASSIS EG, 1982, PHOTOCHEM PHOTOBIOL, V35, P439; DAUBEN WG, 1988, J ORG CHEM, V53, P5376, DOI 10.1021/jo00257a039; DAUBEN WG, 1987, J ORG CHEM, V53, P5070; HAVINGA E, 1973, EXPERIENTIA, V29, P1181, DOI 10.1007/BF01935064; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; HOLICK MF, 1995, P NATL ACAD SCI USA, V92, P3124, DOI 10.1073/pnas.92.8.3124; HOLICK MF, 1994, AM J CLIN NUTR, V60, P619, DOI 10.1093/ajcn/60.4.619; HOLICK MF, 1989, VERTEBRATE ENDOCRINO, V3, P7; LANCEEHERMKENS AMW, 1977, BIOCHIM BIOPHYS ACTA, V470, P141, DOI 10.1016/0005-2736(77)90095-5; MACLAUGHLIN JA, 1982, SCIENCE, V216, P1001, DOI 10.1126/science.6281884; MCMULLEN TPW, 1994, BIOPHYS J, V66, P741, DOI 10.1016/S0006-3495(94)80850-1; MCMULLEN TPW, 1993, BIOCHEMISTRY-US, V32, P516, DOI 10.1021/bi00053a016; MORIARTY RM, 1980, J AM CHEM SOC, V102, P4257, DOI 10.1021/ja00532a047; OKAMURA WH, 1995, J STEROID BIOCHEM, V53, P603, DOI 10.1016/0960-0760(95)00107-B; SCHLATMANN JLM, 1964, RECL TRAV CHIM PAY B, V83, P1173; THEUNISSEN JJH, 1986, BIOCHIM BIOPHYS ACTA, V860, P66, DOI 10.1016/0005-2736(86)90499-2; TIAN XQ, 1993, J BIOL CHEM, V268, P14888; TIAN XQ, 1995, J BIOL CHEM, V270, P8706, DOI 10.1074/jbc.270.15.8706; TIAN XQ, 1994, ENDOCRINOLOGY, V135, P655, DOI 10.1210/en.135.2.655; Tian XQ, 1995, BIOL EFFECTS LIGHT 1, P39; VERMA SP, 1983, BIOCHEMISTRY-US, V22, P4587, DOI 10.1021/bi00288a037; Villalain J, 1996, EUR J BIOCHEM, V241, P586, DOI 10.1111/j.1432-1033.1996.00586.x; WISEMAN H, 1993, FEBS LETT, V326, P285, DOI 10.1016/0014-5793(93)81809-E; WISEMAN H, 1990, FEBS LETT, V274, P107, DOI 10.1016/0014-5793(90)81341-K; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; WOODWARD RB, 1965, J AM CHEM SOC, V87, P2511, DOI 10.1021/ja01089a050; WU WG, 1991, J AM CHEM SOC, V113, P4683, DOI 10.1021/ja00012a049	28	39	41	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4174	4179		10.1074/jbc.274.7.4174	http://dx.doi.org/10.1074/jbc.274.7.4174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933613	hybrid			2022-12-25	WOS:000078575500037
J	Beltman, J; Erickson, JR; Martin, GA; Lyons, JF; Cook, SJ				Beltman, J; Erickson, JR; Martin, GA; Lyons, JF; Cook, SJ			C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in rat-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; PROTEIN-TYROSINE PHOSPHORYLATION; MULTIPLE SEQUENCE ELEMENTS; N-TERMINAL KINASE; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION	Lysophosphatidic acid (LPA) stimulates the c-Fos serum response element (SRE) by activating two distinct signal pathways regulated by the small GTPases, Pas and RhoA. has activates the ERK cascade leading to phosphorylation of the transcription factors Elk-1 and Sap1a at the Ets/TCF site, RhoA regulates an undefined pathway required for the activation of the SRF/CArG site. Here we have examined the role of the Ras and RhoA pathways in activation of the SRF: and c-Fos expression in Rat-1 cells. Pertussis toxin and PD98059 strongly inhibited LPA-stimulated c-Fos expression and activation of a SRE:Luc reporter. C3 toxin completely inhibited RhoA function, partially inhibited SRE:Luc activity, but had no effect on LPA-stimulated c-Fos expression, Thus, in a physiological context the Ras-Raf-MEK-ERK pathway, but not RhoA, is required for LPA-stimulated c-Fos expression in Rat-1 cells. C3 toxin stimulated the stress-activated protein kinases JNK and p38 and potentiated c-Jun expression and phosphorylation; these properties were shared by another cellular stress agonist the protein kinase C inhibitor Ro-31-8220, However, C3 toxin alone or in combination with growth factors did not stimulate AP-1:Luc activity and actually antagonized the synergistic activation of AP-1:Luc observed in response to co-stimulation with growth factors and Ro-31-8220, These data indicate that C3 toxin is a cellular stress which antagonizes activation of AP-1 at a point downstream of stress-activated kinase activation or immediate-early gene induction.	Onyx Pharmaceut, Richmond, CA 94806 USA		Cook, SJ (corresponding author), Babraham Inst, Dept Signaling, Babraham Hall, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk			NIGMS NIH HHS [GM 16575] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL S, 1995, ONCOGENE, V11, P427; AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen RH, 1996, ONCOGENE, V12, P1493; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; DECESARE D, 1995, ONCOGENE, V11, P365; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Johnson CM, 1997, J NEUROSCI, V17, P6189; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORII N, 1995, METHOD ENZYMOL, V256, P196; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SASSONECORSI P, 1988, NATURE, V334, P310; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	61	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3772	3780		10.1074/jbc.274.6.3772	http://dx.doi.org/10.1074/jbc.274.6.3772			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920930	hybrid			2022-12-25	WOS:000078428200070
J	Dzantiev, L; Romano, LJ				Dzantiev, L; Romano, LJ			Interaction of Escherichia coli DNA polymerase I (Klenow fragment) with primer-templates containing N-acetyl-2-aminofluorene or N-2-aminofluorene adducts in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; FIDELITY; AMINOFLUORENE; IDENTIFICATION; TRIPHOSPHATE; JUNCTION	DNA adducts formed by aromatic amines such as N-acetyl-2-aminofluorene (AAF) and N-2-aminofluorene (AF) are known to cause mutations by interfering with the process of DNA replication. To understand this phenomenon better, a gel retardation assay was used to measure the equilibrium dissociation constants for the binding of an exonuclease-deficient Escherichia coli DNA polymerase I (Klenow fragment) to DNA primer-templates modified with an AAF or AF adduct. The results indicate that the nature of the adduct as well as the presence and nature of an added dNTP have a significant influence on the strength of the binding of the polymerase to the DNA. More specifically, it was found that the binding is 5-10-fold stronger when an AAF adduct, but not an AF adduct, is positioned in the enzyme active site. In addition, the polymerase was found to bind the unmodified primer-template less strongly in the presence of a noncomplementary dNTP than in the presence of the correct nucleotide. The same trend holds true for the primer-template having an AF adduct, although the magnitude of this difference was lower. In the case of the AAF adduct, the interaction of the polymerase with the primer-template was stronger and almost independent of the nucleotide present.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Romano, LJ (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.				NATIONAL CANCER INSTITUTE [R01CA040605] Funding Source: NIH RePORTER; NCI NIH HHS [CA40605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BELGUISEVALLADIER P, 1995, J MOL BIOL, V249, P903, DOI 10.1006/jmbi.1995.0347; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Burnouf DY, 1998, MUTAT RES-DNA REPAIR, V407, P35, DOI 10.1016/S0921-8777(97)00058-X; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DOISY R, 1995, BIOCHEMISTRY-US, V34, P4358, DOI 10.1021/bi00013a027; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; HEFLICH RH, 1994, MUTAT RES-REV GENET, V318, P73, DOI 10.1016/0165-1110(94)90025-6; Hoffmann GR, 1997, CHEM RES TOXICOL, V10, P347, DOI 10.1021/tx960128n; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8470; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018; Liu DY, 1997, CHEM BIOL, V4, P919, DOI 10.1016/S1074-5521(97)90300-8; Mao B, 1997, BIOCHEMISTRY-US, V36, P14491, DOI 10.1021/bi972206r; Mao B, 1998, BIOCHEMISTRY-US, V37, P95, DOI 10.1021/bi972258g; MICHAELS ML, 1991, CARCINOGENESIS, V12, P1641, DOI 10.1093/carcin/12.9.1641; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; Patel DJ, 1998, CHEM RES TOXICOL, V11, P391, DOI 10.1021/tx9702143; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; Singh SB, 1998, BIOCHEMISTRY-US, V37, P878, DOI 10.1021/bi9720639; VONHIPPEL PH, 1994, ANN NY ACAD SCI, V726, P118; ZHOU YZ, 1993, BIOCHEMISTRY-US, V32, P14043, DOI 10.1021/bi00213a038	37	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3279	3284		10.1074/jbc.274.6.3279	http://dx.doi.org/10.1074/jbc.274.6.3279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920867	hybrid			2022-12-25	WOS:000078428200007
J	Jiang, YQ; Roberts, SC; Jardim, A; Carter, NS; Shih, S; Ariyanayagam, M; Fairlamb, AH; Ullman, B				Jiang, YQ; Roberts, SC; Jardim, A; Carter, NS; Shih, S; Ariyanayagam, M; Fairlamb, AH; Ullman, B			Ornithine decarboxylase gene deletion mutants of Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DL-ALPHA-DIFLUOROMETHYLORNITHINE; TRYPANOSOMA-BRUCEI; CRITHIDIA-FASCICULATA; MOLECULAR-CLONING; CRUZI; TRYPANOTHIONE; BIOSYNTHESIS; REPLACEMENT; INHIBITORS; SPERMIDINE	A knockout strain of Leishmania donovani lacking both ornithine decarboxylase (ODC) alleles has been created by targeted gene replacement. Growth of Delta odc cells in polyamine-deficient medium resulted in a rapid and profound depletion of cellular putrescine pools, although levels of spermidine were relatively unaffected. Concentrations of trypanothione, a spermidine conjugate, were also reduced, whereas glutathione concentrations were augmented. The Delta odc L, donovani exhibited an auxotrophy for polyamines that could be circumvented by the addition of the naturally occurring polyamines, putrescine or spermidine, to the culture medium. Whereas putrescine supplementation restored intracellular pools of both putrescine and spermidine, exogenous spermidine was not converted back to putrescine, indicating that spermidine alone is sufficient to meet the polyamine requirement, and that L, donovani does not express the enzymatic machinery for polyamine degradation. The lack of a polyamine catabolic pathway in intact parasites was confirmed radiometrically, In addition, the Delta odc strain could grow in medium supplemented with either 1,3-diaminopropane or 1,5-diaminopentane (cadaverine), but polyamine auxotrophy could not be overcome by other aliphatic diamines or spermine. These data establish genetically that ODC is an essential gene in L, donovani, define the polyamine requirements of the parasite, and reveal the absence of a polyamine-degradative pathway.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	Oregon Health & Science University; University of Dundee	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	ullmanb@ohsu.edu	Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041622, R56AI041622] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41622] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; Ariyanayagam MR, 1997, MOL BIOCHEM PARASIT, V84, P111, DOI 10.1016/S0166-6851(96)02788-0; Bacchi C.J., 1987, P317; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COHN MS, 1980, J BACTERIOL, V142, P791, DOI 10.1128/JB.142.3.791-799.1980; COWARD JK, 1987, ADV ENZYME REGUL, V26, P107, DOI 10.1016/0065-2571(87)90008-2; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; GIFFIN BF, 1986, J PROTOZOOL, V33, P238, DOI 10.1111/j.1550-7408.1986.tb05599.x; GILLIN FD, 1984, J PROTOZOOL, V31, P161, DOI 10.1111/j.1550-7408.1984.tb04308.x; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HANSON S, 1992, J BIOL CHEM, V267, P2350; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; HUNTER KJ, 1994, EUR J BIOCHEM, V226, P1019, DOI 10.1111/j.1432-1033.1994.t01-1-01019.x; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; KAUR K, 1986, J PROTOZOOL, V33, P518, DOI 10.1111/j.1550-7408.1986.tb05654.x; KIERSZENBAUM F, 1987, P NATL ACAD SCI USA, V84, P4278, DOI 10.1073/pnas.84.12.4278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Li F, 1996, MOL BIOCHEM PARASIT, V78, P227, DOI 10.1016/S0166-6851(96)02630-8; MAJUMDER S, 1992, J PARASITOL, V78, P371, DOI 10.2307/3283493; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; PAULUS TJ, 1982, J BACTERIOL, V152, P291; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; RojasChaves M, 1996, MOL BIOCHEM PARASIT, V75, P261, DOI 10.1016/0166-6851(95)02520-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIM H, 1988, J GEN MICROBIOL, V134, P807; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; TABOR CW, 1968, BIOCHEM BIOPH RES CO, V30, P339, DOI 10.1016/0006-291X(68)90747-X; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; WILSON K, 1991, J BIOL CHEM, V266, P1665; WITTICH RM, 1990, MOL BIOCHEM PARASIT, V38, P13, DOI 10.1016/0166-6851(90)90199-V; Zappia V, 1988, PROGR POLYAMINE RES, V250	41	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3781	3788		10.1074/jbc.274.6.3781	http://dx.doi.org/10.1074/jbc.274.6.3781			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920931	hybrid			2022-12-25	WOS:000078428200071
J	Marks, DS; Gregory, CA; Wallis, GA; Brass, A; Kadler, RE; Boot-Handford, RP				Marks, DS; Gregory, CA; Wallis, GA; Brass, A; Kadler, RE; Boot-Handford, RP			Metaphyseal chondrodysplasia type Schmid mutations are predicted to occur in two distinct three-dimensional clusters within type X collagen NC1 domains that retain the ability to trimerize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBULAR DOMAIN; SEQUENCE; PROTEIN; CHAIN; GENE; CARTILAGE; MICE; C1Q; PRECEREBELLIN; LOCALIZATION	Metaphyseal chondrodysplasia type Schmid (MCDS) is caused by mutations in COL10A1 that are clustered in the carboxyl-terminal non-collagenous (NC1) encoding domain. This domain is responsible for initiating trimerization of type X collagen during biosynthesis, We have built a molecular model of the NC1 domain trimer based on the crystal structure coordinates of the highly homologous trimeric domain of ACRP30 (adipocyte complement-related protein of 30 kDa or AdipoQ), Mapping of the MCDS mutations onto the structure reveals two specific clusters of residues as follows: one on the surface of the monomer which forms a tunnel through the center of the assembled trimer and the other on a patch exposed to solvent on the exterior surface of each monomeric unit within the assembled trimer. Biochemical studies on recombinant trimeric NC1 domain show that the trimer has an unusually high stability not exhibited by the closely related ACRP30, The high thermal stability of the trimeric NC1 domain, in comparison with ACRP30, appears to be the result of a number of factors including the 17% greater total buried solvent-accessible surface and the increased numbers of hydrophobic contacts formed upon trimerization. The 27 amino acid sequence present at the amino terminus of the NC1 domain, which has no counterpart in ACRP30, also contributes to the stability of the trimer. We have also shown that NC1 domains containing the MCDS mutations Y598D and S600P retain the ability to homotrimerize and heterotrimerize with wild type NC1 domain, although the trimeric complexes formed are less stable than those of the wild type molecule. These studies suggest strongly that the predominant mechanism causing MCDS involves a dominant interference of mutant chains on wild type chain assembly.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Boot-Handford, RP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ray.boot-handford@man.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Gregory, Carl/0000-0001-6444-5541; Brass, Andrew/0000-0002-0389-7058; Boot-Handford, Raymond/0000-0002-6167-8419				BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Girkontaite I, 1996, MATRIX BIOL, V15, P231, DOI 10.1016/S0945-053X(96)90114-6; GRANT WT, 1987, J BIOL CHEM, V262, P9844; GREGORY CA, 1998, THESIS U MANCHESTER; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Ikegawa S, 1997, HUM MUTAT, V9, P131, DOI 10.1002/(SICI)1098-1004(1997)9:2<131::AID-HUMU5>3.3.CO;2-U; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PETRY F, 1992, EUR J BIOCHEM, V209, P129, DOI 10.1111/j.1432-1033.1992.tb17269.x; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; THOMAS JT, 1991, BIOCHEM SOC T, V19, P804, DOI 10.1042/bst0190804; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; WADA C, 1991, MOL BRAIN RES, V9, P71, DOI 10.1016/0169-328X(91)90131-G; WALLIS GA, 1994, AM J HUM GENET, V54, P169; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	34	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3632	3641		10.1074/jbc.274.6.3632	http://dx.doi.org/10.1074/jbc.274.6.3632			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920912	hybrid			2022-12-25	WOS:000078428200052
J	Toraya, T; Mori, K				Toraya, T; Mori, K			A reactivating factor for coenzyme B-12-dependent diol dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; GLYCEROL; ENTEROBACTERIACEAE; 1,2-PROPANEDIOL; FERMENTATION; EXPRESSION; OXYTOCA; ENZYME; GENERA	Adenosylcobalamin-dependent diol dehydratase of Klebsiella oxytoca undergoes suicide inactivation by glycerol, a physiological substrate. The coenzyme is modified through irreversible cleavage of its cobalt-carbon bond, resulting in inactivation of the enzyme by tight binding of the modified coenzyme to the active site. Recombinant DdrA and DdrB proteins of K. oxytoca were co-purified to homogeneity from cell-free extracts of Escherichia coli overexpressing the ddrAB genes. They existed as a tight complex, i.e. a putative reactivating factor, with an apparent molecular weight of 150,000, The factor consists of equimolar amounts of the two subunits with M-r of 64,000 (A) and 14,000 (B), encoded by the ddrA and ddrB genes, respectively. Therefore, its subunit structure is most likely A(2)B(2). The factor not only reactivated glycerol-inactivated and O-2-inactivated holoenzymes but also activated enzyme-cyanocobalamin complex in the presence of free adenosylcobalamin, ATP, and Mg2+. The reactivating factor mediated ATP-dependent exchange of the enzyme-bound cyanocobalamin for free 5-adeninylpentylcobalamin in the presence of ATP and Mg2+, but the reverse was not the case. Thus, it can be concluded that the inactivated holoenzyme becomes reactivated by exchange of the enzyme-bound, adenine-lacking cobalamins for free adenosylcobalamin, an adenine-containing cobalamin.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan	Okayama University	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Tsushima Naka, Okayama 7008530, Japan.		Mori, Koichi/ABC-7268-2021; MORI, Koichi/B-2567-2011	Mori, Koichi/0000-0001-8865-2107; 				Babior B. M., 1982, B12, V2, P263; BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V16, P1082, DOI 10.1021/bi00625a009; BACHOVCHIN WW, 1978, BIOCHEMISTRY-US, V17, P2218, DOI 10.1021/bi00604a031; Blakley R.L., 1982, B12, V2, P381; Buckel W, 1996, CHEM SOC REV, V25, P329, DOI 10.1039/cs9962500329; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; FORAGE RG, 1982, J BACTERIOL, V149, P413, DOI 10.1128/JB.149.2.413-419.1982; FORAGE RG, 1979, BIOCHIM BIOPHYS ACTA, V569, P249, DOI 10.1016/0005-2744(79)90060-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HONDA S, 1980, J BACTERIOL, V143, P1458, DOI 10.1128/JB.143.3.1458-1465.1980; HOSOI N, 1978, J FERMENT TECHNOL, V56, P566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mori K, 1997, BIOSCI BIOTECH BIOCH, V61, P1729, DOI 10.1271/bbb.61.1729; Mori K, 1997, J BIOL CHEM, V272, P32034, DOI 10.1074/jbc.272.51.32034; POZNANSKAYA AA, 1977, BIOCHIM BIOPHYS ACTA, V484, P236, DOI 10.1016/0005-2744(77)90128-0; Retey J., 1982, B12, VII, P357; Sambrook J., 1989, MOL CLONING, pA1; SANDO GN, 1976, BIOCHIM BIOPHYS ACTA, V428, P228; SCHNEIDER Z, 1966, ACTA BIOCHIM POL, V13, P311; SWITZER RL, 1982, B12, V2, P289; Tobimatsu T, 1997, ARCH BIOCHEM BIOPHYS, V347, P132, DOI 10.1006/abbi.1997.0325; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1980, J BACTERIOL, V141, P1439, DOI 10.1128/JB.141.3.1439-1442.1980; TORAYA T, 1978, J BACTERIOL, V135, P726, DOI 10.1128/JB.135.2.726-729.1978; TORAYA T, 1979, J BACTERIOL, V139, P39, DOI 10.1128/JB.139.1.39-47.1979; TORAYA T, 1979, BIOCHEMISTRY-US, V18, P417, DOI 10.1021/bi00570a005; Toraya T., 1982, B12, P233; USHIO K, 1982, J NUTR SCI VITAMINOL, V28, P225; WAGNER OW, 1966, J BIOL CHEM, V241, P1751	36	67	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3372	3377		10.1074/jbc.274.6.3372	http://dx.doi.org/10.1074/jbc.274.6.3372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920879	hybrid			2022-12-25	WOS:000078428200019
J	Botchkarev, VA; Botchkareva, NV; Welker, P; Metz, M; Lewin, GR; Subramaniam, A; Bulfone-Paus, S; Hagen, E; Braun, A; Lommatzsch, M; Renz, H; Paus, R				Botchkarev, VA; Botchkareva, NV; Welker, P; Metz, M; Lewin, GR; Subramaniam, A; Bulfone-Paus, S; Hagen, E; Braun, A; Lommatzsch, M; Renz, H; Paus, R			A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control	FASEB JOURNAL			English	Article						BDNF; NT-4; TrkB; p75NTR; catagen	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; FOLLICLE REGRESSION CATAGEN; MURINE SKIN; MESSENGER-RNA; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; DEPENDENT CHANGES; TRANSGENIC MICE; GENE-EXPRESSION	Neurotrophins exert many biological effects not directly targeted at neurons, including modulation of keratinocyte proliferation and apoptosis in vitro. Here we exploit the cyclic growth and regression activity of the murine hair follicle to explore potential nonneuronal functions of neurotrophins in the skin, and analyze the follicular expression and hair growth-modulatory function of BDNF, NT-4, and their high-affinity receptor, TrkB. The cutaneous expression of BDNF and NT-4 mRNA was strikingly hair cycle dependent and peaked during the spontaneous, apoptosis-driven hair follicle regression (catagen). During catagen, BDNF mRNA and immunoreactivity, as well as NT-4-immunoreactivity, were expressed in the regressing hair follicle compartments, whereas TrkB mRNA and immunoreactivity were seen in dermal papilla fibroblasts, epithelial strand, and hair perm. BDNF or NT-4 knockout mice showed significant catagen retardation, whereas BDNF-overexpressing: mice dis played acceleration of catagen and significant shortening of hair length. Finally, BDNF and NT-4 accelerated catagen development in murine skin organ culture. Together, our data suggest that BDNF and NT-4 play a previously unrecognized role in skin physiology as agents of hair growth control. Thus, TrkB agonists and antagonists deserve exploration as novel hair growth-modulatory drugs for the management of common hair growth disorders.	Humboldt Univ, Charite, Dept Dermatol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Inst Lab Med, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, Growth Factor & Regenerat Grp, D-13122 Berlin, Germany; Free Univ Berlin, Inst Immunol, D-12203 Berlin, Germany; Hoechst Marion Roussel Inc, Bridgewater, NJ 08807 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin	Paus, R (corresponding author), Humboldt Univ, Charite, Dept Dermatol, Campus Virchow Clin,Schumannstr 20-21, D-10117 Berlin, Germany.	ralf.paus@charite.de	Metz, Martin/M-5237-2013; Lewin, Gary R/B-8028-2011; Metz, Martin/B-8799-2009; Braun, Armin/B-8750-2009	Metz, Martin/0000-0002-4070-9976; Metz, Martin/0000-0002-4070-9976; Braun, Armin/0000-0002-1142-1463; Lewin, Gary/0000-0002-2890-6352; Botchkarev, Vladimir/0000-0002-5212-5353				ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; ALBERS KM, 1994, J NEUROSCI, V14, P1422, DOI 10.1523/JNEUROSCI.14-03-01422.1994; Albers KM, 1996, J CELL BIOL, V134, P487, DOI 10.1083/jcb.134.2.487; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Botchkarev VA, 1997, ARCH DERMATOL RES, V289, P292, DOI 10.1007/s004030050195; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; Botchkarev VA, 1998, EUR J NEUROSCI, V10, P3276, DOI 10.1046/j.1460-9568.1998.00365.x; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Bothwell M, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P27, DOI 10.1038/jidsymp.1997.7; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; BREDMAN JJ, 1992, J ANAT, V180, P263; BRONZETTI E, 1996, ITAL J ANAT EMBRY S1, V100, P565; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Carroll P, 1998, NAT NEUROSCI, V1, P42, DOI 10.1038/242; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Chou TT, 1997, J NEUROSCI RES, V49, P522, DOI 10.1002/(SICI)1097-4547(19970901)49:5<522::AID-JNR2>3.3.CO;2-M; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Davies AM, 1997, CURR BIOL, V7, pR38, DOI 10.1016/S0960-9822(06)00016-9; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; Donohoe TJ, 1996, CONTEMP ORG SYNTH, V3, P1, DOI 10.1039/co9960300001; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; Frade JM, 1996, NATURE, V383, P166; Fundin BT, 1997, DEV BIOL, V190, P94, DOI 10.1006/dbio.1997.8658; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HECKERS S, 1994, J NEUROSCI, V14, P1271, DOI 10.1523/JNEUROSCI.14-03-01271.1994; Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Huber LJ, 1996, DEV BIOL, V179, P369, DOI 10.1006/dbio.1996.0268; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; Ibanez CF, 1996, NEUROCHEM RES, V21, P787, DOI 10.1007/BF02532301; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lewin GR, 1996, PHILOS T ROY SOC B, V351, P405, DOI 10.1098/rstb.1996.0035; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; Luukko K, 1997, DEV DYNAM, V210, P117, DOI 10.1002/(SICI)1097-0177(199710)210:2<117::AID-AJA5>3.0.CO;2-J; Luukko K, 1996, DEV DYNAM, V206, P87, DOI 10.1002/(SICI)1097-0177(199605)206:1<87::AID-AJA8>3.0.CO;2-X; Ma YT, 1998, J NEUROSCI, V18, P2097; Maurer M, 1997, AM J PATHOL, V150, P1433; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Muragaki Y, 1997, J NEUROSCI, V17, P530; NAKANISHI T, 1994, BIOCHEM BIOPH RES CO, V198, P891, DOI 10.1006/bbrc.1994.1127; Nosrat CA, 1997, CELL TISSUE RES, V290, P569, DOI 10.1007/s004410050962; Panteleyev AA, 1997, J INVEST DERMATOL, V108, P324, DOI 10.1111/1523-1747.ep12286476; Paus R, 1996, CANCER RES, V56, P4438; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; PAUS R, 1999, IN PRESS J DERMATOL; PERSSON H, 1993, NEUROMETHODS, V25, P57; PethoSchramm A, 1996, ARCH DERMATOL RES, V288, P264, DOI 10.1007/BF02530098; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; PINCELLI C, 1997, J INVEST DERMATOL S, V2, P61; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Rice FL, 1998, DEV BIOL, V198, P57, DOI 10.1006/dbio.1998.8861; Roloff B, 1998, FASEB J, V12, P287, DOI 10.1096/fasebj.12.3.287; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; Schilli MB, 1997, J INVEST DERMATOL, V108, P928, DOI 10.1111/1523-1747.ep12294690; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; Shibayama E, 1996, AM J PATHOL, V148, P1807; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; Stucky CL, 1998, J NEUROSCI, V18, P7040; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SuterCrazzolara C, 1996, MOL BRAIN RES, V43, P351, DOI 10.1016/S0169-328X(96)00243-4; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VICKLAND H, 1995, NEURAL NOTES, V1, P8; Welker P, 1997, ARCH DERMATOL RES, V289, P554, DOI 10.1007/s004030050239	98	88	92	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					395	410		10.1096/fasebj.13.2.395	http://dx.doi.org/10.1096/fasebj.13.2.395			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973328	Bronze			2022-12-25	WOS:000078615200020
J	Iljin, K; Dube, A; Kontusaari, S; Korhonen, J; Lahtinen, I; Oettgen, P; Alitalo, K				Iljin, K; Dube, A; Kontusaari, S; Korhonen, J; Lahtinen, I; Oettgen, P; Alitalo, K			Role of Ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter	FASEB JOURNAL			English	Article						gene therapy; receptor tyrosine kinase; vascular endothelium	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; ENHANCED EXPRESSION; TRANSGENIC MICE; IN-VIVO; ANGIOGENESIS; BINDING; PROTOONCOGENE; KDR/FLK-1; LINE	The Tie gene encodes an endothelial cell receptor tyrosine kinase necessary for normal vascular development, The Tie gene promoter targets expression of heterologous genes specifically to endothelial cells in transgenic mice. Here we have characterized the promoter sequences critical for endothelial cell-specific activity in cultured cells and transgenic mice. Progressive deletions and site-directed mutations of the promoter showed that the critical endothelial cell-specific elements are an octamer transcription factor binding site and several Ets binding sites located in two clusters within 300 bp upstream of the major transcription initiation site, Among members of the Ets transcription factor family tested, NERF-2 (a novel transcription factor related to the ets factor ELF-1), which is expressed in endothelial cells, and ETS2 showed the strongest transactivation of the Tie promoter; ETS1 gave lower levels of stimulation and the other Ets factors gave little or no transactivation, Furthermore, the Tie promoter directed the production of high amounts of human growth hormone into the circulation of transgenic mice, The secreted amounts correlated with transgene copy number, being relatively insensitive to the effects of the transgene integration site, These properties suggest that Tie promoter activity is controlled by endothelial cell Ets factors and that it has potential for use in vectors for endothelial cell-specific gene expression.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, SF-00014 Helsinki, Finland; Univ Helsinki, Dept Biomed, SF-00014 Helsinki, Finland; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, NEB Bone & Joint Inst, Boston, MA 02115 USA; Bioctr Oulu, Oulu 90570, Finland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland	University of Helsinki; University of Helsinki; Harvard University; Beth Israel Deaconess Medical Center; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, SF-00014 Helsinki, Finland.		Oettgen, Peter/AAF-5026-2021; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Iljin, Kristiina/0000-0002-5161-0584	NCI NIH HHS [CA71429-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA071429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almendro N, 1996, J IMMUNOL, V157, P5411; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; HATVA E, 1995, AM J PATHOL, V146, P368; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; KAIPAINEN A, 1994, CANCER RES, V54, P6571; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KORHONEN J, 1994, ONCOGENE, V9, P395; KORHONEN J, 1992, BLOOD, V80, P2548; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; TAKAHASHI K, 1991, IN VITRO CELL DEV B, V27, P766; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WERNERT N, 1992, AM J PATHOL, V140, P119	34	75	78	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					377	386		10.1096/fasebj.13.2.377	http://dx.doi.org/10.1096/fasebj.13.2.377			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973326				2022-12-25	WOS:000078615200018
J	Lucas, T; Krugluger, W; Samorapoompichit, P; Gamperl, R; Beug, H; Forster, O; Boltz-Nitulescu, G				Lucas, T; Krugluger, W; Samorapoompichit, P; Gamperl, R; Beug, H; Forster, O; Boltz-Nitulescu, G			Self-renewal, maturation, and differentiation of the rat myelomonocytic hematopoietic stem cell	FASEB JOURNAL			English	Article						lectins; stem cell factor; cell proliferation; cell differentiation; dexamethasone; calcitriol	COLONY-STIMULATING FACTORS; BONE-MARROW-CELLS; MACROPHAGE PROGENITOR CELLS; TYROSINE KINASE RECEPTOR; PROTOONCOGENE C-KIT; GROWTH-FACTOR; PERIPHERAL-BLOOD; SI-LOCUS; W-LOCUS; LIGAND	Hematopoiesis is viewed as a differentiating system emanating from a pluripotent hematopoietic stem cell capable of both self-renewal and differentiation. By identifying and characterizing a novel and highly specific in vitro mitogenic response to the N-acetyl glucosamyl/sialic acid specific, stem ceh-binding lectin wheat perm agglutinin (WGA), we demonstrate the existance of a rare (0.1%), plastic adherent precursor in rat bone marrow capable of proliferation (two to seven divisions) in response to WGA. Stimulated cells possess a lineage (lin)(low/-) immunophenotype and immature blastoid morphology (WGA blasts). A subsequent proliferative response-to stem cell factor (SCF), the ligand for the proto-oncogene receptor tyrosine kinase c-kit, is characterized by an initial maturation in immunophenotype and subsequent self-renewal of cells (SCF blasts) without differentiation for at least 50 generations. Although granulocyte colony-stimulating factor (G-CSF), interleukin (IL) -6, IL-7, and IL-11 synergize with SCF to increase blast colony formation, cytokines such as granulocyte-macrophage CSF or IL-3 are without significant effect. At all time points in culture, however, cells rapidly differentiate to mature neutrophils with dexamethasone or to mainly monocytes/macrophages in the presence of 1 alpha,25-dihydroxyvitamin D-3, characterized by cell morphology and cytochemistry. Removal of SCF during blast maturation, self-renewal, or induction of differentiation phases results in apoptotic cell. death. Data indicate a pivotal role for SCF/c-kit interaction during antigenic maturation, self-renewal, and apoptotic protection of these lineage-restricted progenitors during non-CSF-mediated induction of differentiation. This approach provides a source of many normal, proliferating myelomonocytic precursor cells, and introduces possible clinical applications of ex vivo expanded myeloid stem cells.	Univ Vienna, Inst Gen & Expt Pathol, AKH 3Q, A-1090 Vienna, Austria; Univ Vienna, Inst Histol & Embryol, A-1090 Vienna, Austria; Inst Med Biol & Human Genet, A-8010 Graz, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Vienna; University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Boltz-Nitulescu, G (corresponding author), Univ Vienna, Inst Gen & Expt Pathol, AKH 3Q, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	georg.boltz@akh-wien.ac.at		Lucas, Trevor/0000-0002-5114-8035				AIZAWA S, 1987, P NATL ACAD SCI USA, V84, P4485, DOI 10.1073/pnas.84.13.4485; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BASCH RS, 1977, NATURE, V270, P520, DOI 10.1038/270520a0; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1995, ONCOGENE, V11, P59; BEVERLEY PCL, 1980, NATURE, V287, P332, DOI 10.1038/287332a0; BOL S, 1981, EXP HEMATOL, V9, P431; BOLTZNITULESCU G, 1987, J LEUKOCYTE BIOL, V41, P83, DOI 10.1002/jlb.41.1.83; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DEXTER TM, 1984, LONG TERM BONE MARRO, P57; FALKENBURG JHF, 1984, BLOOD, V63, P1125; FERRERO D, 1983, P NATL ACAD SCI-BIOL, V80, P4114, DOI 10.1073/pnas.80.13.4114; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GOLDSCHNEIDER I, 1980, J EXP MED, V152, P419, DOI 10.1084/jem.152.2.419; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KELLER G, 1992, CURR OPIN IMMUNOL, V4, P133, DOI 10.1016/0952-7915(92)90002-V; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KOEFFLER HP, 1984, CANCER RES, V44, P5624; KREUTZ M, 1990, BLOOD, V76, P2449; Krugluger W, 1996, IMMUNOL LETT, V52, P53, DOI 10.1016/0165-2478(96)02581-3; LOWRY PA, 1991, EXP HEMATOL, V19, P994; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MCCARTHY KF, 1987, CYTOMETRY, V8, P296, DOI 10.1002/cyto.990080310; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1995, BIOL CLINB APPL; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MULDER AH, 1984, CELL IMMUNOL, V88, P401, DOI 10.1016/0008-8749(84)90173-4; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NAKAHATA T, 1982, J CELL PHYSIOL, V111, P239, DOI 10.1002/jcp.1041110304; NELSON DA, 1990, HEMATOLOGY, P1751; OKADA S, 1991, BLOOD, V78, P1706; PAQUETTE RL, 1992, HEMATOL ONCOL CLIN N, V6, P687, DOI 10.1016/S0889-8588(18)30336-8; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHEZEN E, 1985, J CELL PHYSIOL, V124, P545, DOI 10.1002/jcp.1041240326; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; SPOONCER E, 1985, NATURE, V316, P62, DOI 10.1038/316062a0; SZILVASSY SJ, 1989, BLOOD, V74, P930; TSUJI K, 1992, BLOOD, V79, P2855; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; ULICH TR, 1991, EXP HEMATOL, V19, P639; VISSER JWM, 1984, J EXP MED, V159, P1576, DOI 10.1084/jem.159.6.1576; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YU H, 1993, BLOOD, V81, P373; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	10	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					263	272		10.1096/fasebj.13.2.263	http://dx.doi.org/10.1096/fasebj.13.2.263			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973314				2022-12-25	WOS:000078615200006
J	Galiegue, S; Jbilo, O; Combes, T; Bribes, E; Carayon, P; Le Fur, G; Casellas, P				Galiegue, S; Jbilo, O; Combes, T; Bribes, E; Carayon, P; Le Fur, G; Casellas, P			Cloning and characterization of PRAX-1 - A new protein that specifically interacts with the peripheral benzodiazepine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION; MOLECULAR-CLONING; SH3 DOMAINS; LOCALIZATION; CELLS; BINDING; STEROIDOGENESIS; EXPRESSION; MEMBRANE; INVITRO	Using a cytoplasmic domain of the peripheral benzodiazepine receptor (PBR) as a bait in the yeast two-hybrid system, we have isolated a cDNA encoding a new protein that specifically interacts with PER. We named it PRAX-1, for peripheral benzodiazepine receptor-associated protein 1. PRAX-1 is a 1857-amino acid protein, the sequence of which was structurally unrelated to any known proteins. The gene encoding PRAX-1 is located in the q22-q23 region of the long arm of the human chromosome 17. The PRAX-1 mRNA is 7.5 kilobase pairs, predominantly expressed in the central nervous system, pituitary gland, and thymus, At the protein level, we found the PRAX-1 as a single 220-250-kDa protein in the brain and in many different human cell lines tested using specific antibody raised against PRAX-1, Parallel analysis of the PRAX-1 mRNA and protein expression performed in mouse and rat gave similar results. Immunocytochemistry analysis carried out to define the distribution of the PRAX-1 protein in the rat brain showed that PRAX-1 was prevalent in the mesolimbic system, specially abundant in the CA1 subfield of the hippocampus. Exhibiting several domains involved in protein-protein interaction (three proline-rich domains, three leucine-zipper motifs, and an Src homology region 3-like domain), the PRAX-1 may be looked upon as a new adaptator protein. We show that both the Src homology region 3-like domain and a proline-rich domain in PRAX-1 are required for the interaction with PER, PRAX-1 is a cytoplasmic protein that also partially colocalizes with PER in the mitochondria, as determined by confocal microscopy and Western blotting. Altogether our observations support a model of interaction implicating PER and this newly described protein, PRAX-1, As being the first cytoplasmic protein associated with PER, PRAX-1 is a new tool that opens new fields for exploring PER biological roles.	Sanofi Rech, Dept Immunol, F-34184 Montpellier 04, France; Sanofi Rech, F-75013 Paris, France	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), Sanofi Rech, Dept Immunol, 371 Rue Prof Joseph Blayac, F-34184 Montpellier 04, France.	pierre.casellas@sanofi.com						ANHOLT RRH, 1984, J NEUROSCI, V4, P593; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; BAKER ME, 1991, CELL, V65, P721, DOI 10.1016/0092-8674(91)90379-D; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; Bessler H, 1997, INT J IMMUNOPHARMACO, V19, P249, DOI 10.1016/S0192-0561(97)00013-1; Bird TD, 1997, NEUROLOGY, V48, P949, DOI 10.1212/WNL.48.4.949; BRAESTRUP C, 1977, P NATL ACAD SCI USA, V74, P3805, DOI 10.1073/pnas.74.9.3805; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAHARD D, 1994, LAB INVEST, V70, P23; CANAT X, 1993, LIFE SCI, V52, P107, DOI 10.1016/0024-3205(93)90293-C; Carayon P, 1996, BLOOD, V87, P3170, DOI 10.1182/blood.V87.8.3170.bloodjournal8783170; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dussossoy D, 1996, CYTOMETRY, V24, P39; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATTHEW E, 1981, P NATL ACAD SCI-BIOL, V78, P3935, DOI 10.1073/pnas.78.6.3935; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1994, MOL CELL ENDOCRINOL, V104, pR5, DOI 10.1016/0303-7207(94)90061-2; PAROLA AL, 1993, LIFE SCI, V52, P1329, DOI 10.1016/0024-3205(93)90168-3; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RUFF MR, 1985, SCIENCE, V229, P1281, DOI 10.1126/science.2994216; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P753, DOI 10.1073/pnas.81.3.753; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P3770, DOI 10.1073/pnas.81.12.3770; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101	45	79	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2938	2952		10.1074/jbc.274.5.2938	http://dx.doi.org/10.1074/jbc.274.5.2938			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915832	hybrid			2022-12-25	WOS:000078319500050
J	Murakami, M; Kambe, T; Shimbara, S; Kudo, I				Murakami, M; Kambe, T; Shimbara, S; Kudo, I			Functional coupling between various phospholipase A(2)s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; ARACHIDONIC-ACID MOBILIZATION; MAST-CELLS; II PHOSPHOLIPASE-A(2); H SYNTHASE-1; P388D(1) MACROPHAGES; GENE DISRUPTION; GENERATION; MOUSE; INHIBITION	Several distinct phospholipase A(2)s (PLA(2)s) and two cyclooxygenases (COXs) were transfected, alone or in combination, into human embryonic kidney 293 cells, and their functional coupling during immediate and delayed prostaglandin (PG)-biosynthetic responses was reconstituted, Signaling PLA(2)s, i.e. cytosolic PLA(2) (cPLA(2)) (type IV) and two secretory PLA(2)s (sPLA(2)), types IIA (sPLA(2)-IIA) and V (sPLA(2)-V), promoted arachidonic acid (AA) release from their respective transfectants after stimulation with calcium ionophore or, when bradykinin receptor was cotransfected, with bradykinin, which evoked the immediate response, and interleukin-l plus serum, which induced the delayed response. Experiments on cells transfected with either COX alone revealed subtle differences between the PG-biosynthetic properties of the two isozymes in that COX-1 and COX-2 were favored over the other in the presence of high and low exogenous AA concentrations, respectively. Moreover, COX-2, but not COX-1, could turn on endogenous AA release, which was inhibited by a cPLA(2) inhibitor. When PLA(2) and COX were coexpressed, AA released by cPLA(2), sPLA(2)-IIA and sPLA(2)-V was converted to PGE(2) by both COX-1 and COX-2 during the immediate response and predominantly by COX-2 during the delayed response. Ca2+-independent PLA(2) (iPLA(2)) (type VI), which plays a crucial role in phospholipid remodeling, failed to couple with COX-2 during the delayed response, whereas it was linked to ionophore-induced immediate PGE(2) generation via COX-1 in marked preference to COX-2. Finally, coculture of PLA(2) and COX transfectants revealed that extracellular sPLA(2)s-IIA and -V, but neither intracellular cPLA(2) nor iPLA(2), augmented PGE, generation by neighboring COX-expressing cells, implying that the heparin-binding sPLA(2)s play a particular role as paracrine amplifiers of the PG-biosynthetic response signal from one cell to another.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.	kudo@pharm.showa-u.ac.jp						ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; CAPDEVILA JH, 1996, J BIOL CHEM, V271, P22263; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; KIRIKARA K, 1998, J EXP MED, V187, P517; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1043, P34; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; Naraba H, 1998, J IMMUNOL, V160, P2974; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Polgar J, 1997, BIOCHEM J, V327, P259, DOI 10.1042/bj3270259; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; SUGA H, 1995, J BIOCHEM-TOKYO, V118, P939, DOI 10.1093/jb/118.5.939; Swinney DC, 1997, J BIOL CHEM, V272, P12393, DOI 10.1074/jbc.272.19.12393; Tada K, 1998, J IMMUNOL, V161, P5008; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522	62	319	325	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3103	3115		10.1074/jbc.274.5.3103	http://dx.doi.org/10.1074/jbc.274.5.3103			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915849	hybrid			2022-12-25	WOS:000078319500067
J	Chughtai, SA; Crundwell, MC; Cruickshank, NRJ; Affie, E; Armstrong, S; Knowles, MA; Takle, LA; Kuo, M; Khan, N; Phillips, SMA; Neoptolemos, JP; Morton, DG				Chughtai, SA; Crundwell, MC; Cruickshank, NRJ; Affie, E; Armstrong, S; Knowles, MA; Takle, LA; Kuo, M; Khan, N; Phillips, SMA; Neoptolemos, JP; Morton, DG			Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer	ONCOGENE			English	Article						colorectal cancer; human; chromosome 8p; loss of heterozygosity; tumour behaviour; putative TSGs	TUMOR-SUPPRESSOR GENE; HUMAN PROSTATE-CANCER; BETA-GENE; BREAST-CARCINOMA; COPY NUMBER; DNA; CLONING; HETEROZYGOSITY; MUTATION; LOCI	We have investigated interstitial deletions of chromosome 8 in 70 colorectal carcinomas and 11 colonic adenomas using 11 microsatellite markers, including eight spanning the centromeric region of chromosome 8p (p11.2-p12). Allelic loss or imbalance was observed in 38 (54%) cancers and four (36%) adenomas, Twenty-eight (40%) of the cancers had deletions of 8p11.2-p12. Two distinct and independent regions of interstitial loss were found within this region. Fluorescent in situ hybridization, using an alpha! satellite repeat probe to the centromere of 8p and two probes to the P1 region, was performed in four tumours that demonstrated allelic imbalance. Localized heterozygous deletions were confirmed in all four tumours, Eleven (16%) cancers had localized deletion in the region ANK-1 to D8S255 (P1) and a further eleven (16%) cancers had a less well localized deletion in the region defined by the markers D8S87 to D8S259 (P2), Loss of both centromeric loci was identified in a further six (9%) tumours, A functional significance for these two deletion regions was sought by correlation with primary and secondary tumour characteristics. Isolated P2 deletion was associated with 'early' T1 cancers (2p = 0.0002), and were also identified in 3/11 adenomas, Conversely, interstitial deletions of the P1 locus were more frequently seen in 'locally invasive' T3/4 cancers (2p = 0.015), and isolated P1 deletions were also associated with the presence of liver metastases (2p = 0.016). Our data provide evidence of at least two genes within the 8p11.2-p12 region, mutations in which may confer different and independent roles in the pathogenesis of colorectal cancer.	Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Urol, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Pathol, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Biol, Birmingham B15 2TT, W Midlands, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Marie Curie Res Inst, Surrey RH8 0TL, England; Royal Liverpool Univ Hosp, Dept Surg, Liverpool L69 3GA, Merseyside, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Saint James's University Hospital; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Morton, DG (corresponding author), Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England.		Neoptolemos, John/HGU-7742-2022; Neoptolemos, John P/G-4488-2010	Knowles, Margaret/0000-0002-9363-8657; Neoptolemos, John/0000-0002-6201-7399				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; *ACS, 1990, CANC FACTS FIG, P4; Afify A, 1997, CANCER GENET CYTOGEN, V97, P101, DOI 10.1016/S0165-4608(96)00361-5; Afify A, 1996, BREAST CANCER RES TR, V38, P201, DOI 10.1007/BF01806674; BERKNER KL, 1977, J BIOL CHEM, V252, P3176; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CANNIZZARO LA, 1987, CYTOGENET CELL GENET, V46, P589; CHYAN YJ, 1994, NUCLEIC ACIDS RES, V22, P2719, DOI 10.1093/nar/22.14.2719; Crundwell MC, 1996, INT J CANCER, V69, P295, DOI 10.1002/(SICI)1097-0215(19960822)69:4<295::AID-IJC10>3.3.CO;2-#; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; DIB A, 1995, ONCOGENE, V10, P995; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOBASHI Y, 1994, CANCER RES, V54, P2827; EMI M, 1992, CANCER RES, V52, P5368; Eydmann ME, 1997, CANCER GENET CYTOGEN, V93, P167, DOI 10.1016/S0165-4608(96)00200-2; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Gustafson CE, 1996, CANCER RES, V56, P5238; Hermanek P, 1987, UICC TNM CLASSIFICAT; Ichikawa K, 1997, GENE, V189, P277, DOI 10.1016/S0378-1119(96)00863-3; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; JONES TA, 1993, CYTOGENET CELL GENET, V63, P35, DOI 10.1159/000133497; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LIPPINCOTT JB, 1992, AM JOINT COMMITTEE C; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MACOSKA JA, 1995, CANCER RES, V55, P5390; ROHEN C, 1995, CANCER GENET CYTOGEN, V80, P33, DOI 10.1016/0165-4608(94)00164-7; SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377; Shimamoto A, 1996, P NATL ACAD SCI USA, V93, P10913, DOI 10.1073/pnas.93.20.10913; Visscher DW, 1997, GENE CHROMOSOME CANC, V18, P1; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG LM, 1992, CANCER RES, V52, P4824; WASYLYSHYN ML, 1991, SURGERY, V110, P265; Yamabe Y, 1997, GENOMICS, V39, P198, DOI 10.1006/geno.1996.4480; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; [No title captured]	43	29	30	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					657	665		10.1038/sj.onc.1202340	http://dx.doi.org/10.1038/sj.onc.1202340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989816				2022-12-25	WOS:000078394400011
J	Dumont, A; Hehner, SP; Hofmann, TG; Ueffing, M; Droge, W; Schmitz, ML				Dumont, A; Hehner, SP; Hofmann, TG; Ueffing, M; Droge, W; Schmitz, ML			Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappa B	ONCOGENE			English	Article						apoptosis; hydrogen peroxide; reactive oxygen species; mitochondria; NF-kappa B	TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GLUTATHIONE DISULFIDE; THYMOCYTE APOPTOSIS; FOREBRAIN NEURONS; CELL-DEATH; E1B 19K; PROTEIN; BCL-2; EXPRESSION	Reactive oxygen species (ROS) play an important role in cell death induced by many different stimuli. This study shows that hydrogen peroxide-induced apoptosis in T-cells did not require tyrosine kinase p56(lck), phosphatase CD45, the CD95 receptor and its associated Caspase-8, H2O2-triggered cell death led to the induced cleavage and activation of Caspase-3, Hydrogen peroxide-treatment of T-cells resulted in the formation of mitochondrial permeability transition pores, a rapid decrease of the mitochondrial transmembrane potential Delta Psi(m) and the release of Cytochrome C, Inhibition of the mitochondrial permeability transition by bongkrekic acid (BA), or interference with the mitochondrial electron transport system by rotenone or menadione prevented the cytotoxic effect of H2O2, Antimycin A, a mitochondrial inhibitor that increases the release of mitochondrial ROS (MiROS), enhanced apoptosis. Overexpression of Bcl-2 and the viral anti-apoptotic proteins BHRF-1 and E1B 19K counteracted H2O2-induced apoptosis, Pharmacological and genetic inhibition of transcription factor NF-kappa B protected cells from hydrogen peroxide-elicited cell death. This detrimental effect of NF-kappa B mediating hydrogen peroxide-induced cell death presumably relies on the induced expression of death effector genes such as p53, which was NF-kappa B-dependently upregulated in the presence of H2O2.	German Canc Res Ctr, DKFZ, Dept Immunochem, D-69120 Heidelberg, Germany; Univ Munich, Mol Eye Genet Grp, Munich, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich	Schmitz, ML (corresponding author), German Canc Res Ctr, DKFZ, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; DELCARMEN RRM, 1997, EUR J IMMUNOL, V27, P1442; Droge W, 1997, FASEB J, V11, P1077, DOI 10.1096/fasebj.11.13.9367343; DROGE W, 1994, FASEB J, V8, P1131; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han J, 1996, MOL CELL BIOL, V16, P5857; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hoyt KR, 1997, NEUROCHEM RES, V22, P333, DOI 10.1023/A:1022403224901; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Khanim F, 1997, J GEN VIROL, V78, P2987, DOI 10.1099/0022-1317-78-11-2987; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Limbourg FP, 1996, J BIOL CHEM, V271, P20392, DOI 10.1074/jbc.271.34.20392; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Mollereau B, 1997, J IMMUNOL, V159, P2668; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WU HY, 1994, J BIOL CHEM, V269, P20067; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	63	286	298	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					747	757		10.1038/sj.onc.1202325	http://dx.doi.org/10.1038/sj.onc.1202325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989825				2022-12-25	WOS:000078394400020
J	Rey, O; Baluda, MA; Park, NH				Rey, O; Baluda, MA; Park, NH			Differential gene expression in neoplastic and human papillomavirus-immortalized oral keratinocytes	ONCOGENE			English	Article						HPV; human oral keratinocytes; tumor development	PROMOTER-BINDING PROTEIN; HERPES-SIMPLEX VIRUS; SPLICING FACTOR; ADENOVIRUS E1A; CERVICAL-CARCINOMA; COMPLEMENTARY-DNA; NUCLEAR-BODIES; PML; ONCOPROTEIN; INFECTION	We have previously demonstrated that normal human oral keratinocytes immortalized by transfection with human papillomavirus type-16 Dna became tumorigenic after exposure to a chemical carcinogen, In an effort to detect differentially regulated genes associated with this transition from the immortal to the malignant phenotype, we employed representational differences analysis (a PCR-coupled subtractive hybridization technique). After analysing 50 colonies, 12 putative messages were identified. Northern analysis comparison using the identified cDNAs as probes was made between normal human oral keratinocyte, papillomavirus-immortalized human oral keratinocytes (HOK-16B), a neoplastic cell line derived from HOK-16B (HOK-16B-BaP-T) and the human oral cancer cell lines Hep-2, SCC-9 and Tu-177, We found that mRNAs encoding for cyclophilin A, c-myc binding protein 1, the heat shock protein 90 alpha and one unknown transcript were up-regulated in the oral cancer cell lines analysed as well as in HOK-16B cells. We also detected a downregulation of the mRNAs encoding the skin-derived antileukoproteinase SKALP/elafin, the translationally regulated p23 protein and one unknown transcript. Whether these messages are associated to the neoplastic conversion of human keratinocytes remains to be determined.	Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Dent Res, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Park, NH (corresponding author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010598, R03DE011728, P20DE010598] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10598, DE11728] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; ALKEMADE HAC, 1993, AM J PATHOL, V143, P1679; ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOHM H, 1989, BIOCHEM INT, V19, P277; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CHANG FJ, 1990, ARCH DERMATOL RES, V282, P493, DOI 10.1007/BF00371942; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DILUCA D, 1990, J DENT RES, V69, P51; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GISSMANN L, 1984, J INVEST DERMATOL, V86, pS26; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; LI WZ, 1994, J BIOL CHEM, V269, P18616; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LISITYSN N, 1993, SCIENCE, V259, P949; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEANWELL CA, 1988, CANCER SURV, V7, P481; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOROZOV A, 1995, FEBS LETT, V371, P214, DOI 10.1016/0014-5793(95)00884-C; MULLEN MA, 1995, J VIROL, V69, P476, DOI 10.1128/JVI.69.1.476-491.1995; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; PARK NH, 1995, ONCOGENE, V10, P2145; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RADICE P, 1995, GENOMICS, V26, P101, DOI 10.1016/0888-7543(95)80087-3; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAFFER EL, 1980, J ORAL PATHOL MED, V9, P163, DOI 10.1111/j.1600-0714.1980.tb00373.x; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SPITZ MR, 1988, CANCER, V61, P203, DOI 10.1002/1097-0142(19880101)61:1<203::AID-CNCR2820610134>3.0.CO;2-6; SUMMERS L, 1977, ORAL SURG, V38, P273; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; SYRJANEN KJ, 1983, BR J ORAL SURG, V21, P143; SYRJANEN S, 1992, SCAND J DENT RES, V100, P17; SYRJANEN SM, 1986, ORAL SURG ORAL MED O, V62, P660, DOI 10.1016/0030-4220(86)90262-8; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; YEUDALL WA, 1992, ORAL ONCOL, V28B, P61, DOI 10.1016/0964-1955(92)90015-S; ZURHAUSEN H, 1977, CURR TOP MICROBIOL I, V778, P1	49	33	36	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					827	831		10.1038/sj.onc.1202328	http://dx.doi.org/10.1038/sj.onc.1202328			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989835				2022-12-25	WOS:000078394400030
J	van der Reijden, BA; Dauwerse, HG; Giles, RH; Jagmohan-Changur, S; Wijmenga, C; Liu, PP; Smit, B; Wessels, HW; Beverstock, GC; Jotterand-Bellomo, M; Martinet, D; Muhlematter, D; Lafage-Pochitaloff, M; Gabert, J; Reiffers, J; Bilhou-Nabera, C; van Ommen, GJB; Hagemeijer, A; Breuning, MH				van der Reijden, BA; Dauwerse, HG; Giles, RH; Jagmohan-Changur, S; Wijmenga, C; Liu, PP; Smit, B; Wessels, HW; Beverstock, GC; Jotterand-Bellomo, M; Martinet, D; Muhlematter, D; Lafage-Pochitaloff, M; Gabert, J; Reiffers, J; Bilhou-Nabera, C; van Ommen, GJB; Hagemeijer, A; Breuning, MH			Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered	ONCOGENE			English	Article						inv(16)(p13q22); CBFB; MYH11; AML; genomic; breakpoints	ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ABNORMAL MARROW EOSINOPHILS; ACUTE MYELOGENOUS LEUKEMIA; MYOSIN HEAVY-CHAIN; MOLECULAR CHARACTERIZATION; FUSION; GENE; TRANSLOCATION; CHROMOSOME-16	The inv(16) and related t(16;16) are found in 10% of all cases with ne novo acute myeloid leukemia. In these rearrangements the core binding factor beta (CBFB) gene on 16q22 is fused to the smooth muscle myosin heavy chain gene (MYH11) on 16p13, To gain insight into the mechanisms causing the inv(16) ne have analysed 24 genomic CBFB-MYH11 breakpoints. All breakpoints in CBFB are located in a 15-Kb intron, More than 50% of the sequenced 6.2 Kb of this intron consists of human repetitive elements. Twenty-one of the 24 breakpoints in MYH11 are located in a 370-hp intron, The remaining three breakpoints in MYH11 ape located more upstream, The localization of three breakpoints adjacent to a V(D)J recombinase signal sequence in MYH11 suggests a V(D)J recombinase-mediated rearrangement in these cases, V(D)J recombinase-associated characteristics (small nucleotide deletions and insertions of random nucleotides) were detected in six other cases. CBFB and MYH11 duplications were detected in four of six cases tested.	Erasmus Univ, Inst Hematol, Dept Cell Biol & Genet, Rotterdam, Netherlands; Leiden Univ, Dept Human Genet, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Natl Ctr Human Genome Res, Lab Gene Transfer, NIH, Bethesda, MD USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; CHU Vaudois, Div Autonome Genet Med, CH-1011 Lausanne, Switzerland; Inst J Paoli I Calmettes, Hematol Lab, F-13009 Marseille, France; Univ Bordeaux, Lab Univ Hematol, Bordeaux, France	Erasmus University Rotterdam; Leiden University; Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Erasmus University Rotterdam; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Universite de Bordeaux	van der Reijden, BA (corresponding author), Erasmus Univ, Inst Hematol, Dept Cell Biol & Genet, Rotterdam, Netherlands.		Liu, Paul/A-7976-2012; Breuning, Martijn H/E-3429-2010; van der Reijden, Bert A/A-3543-2014; Wijmenga, Cisca/D-2173-2009; Wijmenga, Cisca/AAE-7719-2019	Liu, Paul/0000-0002-6779-025X; Wijmenga, Cisca/0000-0002-5635-1614; Giles, Rachel/0000-0001-9133-2008				ADRIAANSEN HJ, 1993, BLOOD, V81, P3043; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CLAXTON DF, 1994, BLOOD, V83, P1750; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; DONG WF, 1995, LEUKEMIA, V9, P1812; GELLERT M, 1992, TRENDS GENET, V8, P408, DOI 10.1016/0168-9525(92)90322-U; HEBERT J, 1994, BLOOD, V84, P2291, DOI 10.1182/blood.V84.7.2291.bloodjournal8472291; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KUSS BJ, 1994, LANCET, V343, P1531, DOI 10.1016/S0140-6736(94)92938-6; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OHNO H, 1993, LEUKEMIA, V7, P2057; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; POIREL H, 1995, BLOOD, V85, P1313, DOI 10.1182/blood.V85.5.1313.bloodjournal8551313; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SMIT AFA, 1995, NUCLEIC ACIDS RES, V23, P98, DOI 10.1093/nar/23.1.98; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; VANDERREIJDEN BA, 1993, BLOOD, V82, P2948; VANDERREIJDEN BA, 1995, BLOOD, V86, P277, DOI 10.1182/blood.V86.1.277.bloodjournal861277; vanderReijden BA, 1996, LEUKEMIA, V10, P1459; VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WIJMENGA C, 1993, HUM GENET, V92, P198; YANAGISAWA K, 1991, BLOOD, V78, P451	33	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					543	550		10.1038/sj.onc.1202321	http://dx.doi.org/10.1038/sj.onc.1202321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927211				2022-12-25	WOS:000078166500027
J	Julius, MA; Rai, SD; Kitajewski, J				Julius, MA; Rai, SD; Kitajewski, J			Chimeric Wnt proteins define the amino-terminus of Wnt-1 as a transformation-specific determinant	ONCOGENE			English	Article						Wnt; chimera; transformation; beta-catenin	MAMMARY EPITHELIAL-CELLS; POLARITY GENE ARMADILLO; PROTO-ONCOGENE INT-1; XENOPUS EMBRYOS; BETA-CATENIN; WINGLESS GENE; DROSOPHILA; FAMILY; EXPRESSION; LINE	Wnt-1 induces morphological transformation of C57MG mammary epithelial cells and accumulation of cytosolic beta-catenin whereas Wnt-5a has no effect. To identify regions within the 370 amino acid Wnt-1 protein required for these functions we tested eleven chimeric genes that contained variable amounts of Wnt-1;Ind Wnt-5a sequence. Transformation and beta-catenin regulation in C57MG cells is controlled by amino acids that lie within 186 residues of the amino terminus of Wnt-1. Small substitutions between residues 186 and 292 reduced Wnt-1 activity. Replacement of the carboxy terminal 79 amino acids of Wnt-1 by Wnt-5a did not affect function. These results were supported by transient expression assays in 293 cells wherein beta-catenin accumulated in the cytoplasm in response to ectopic Wnt-1 expression. Un 293 cells, a larger region of the amino-terminus of Wnt-1 was found to be required for beta-catenin regulation. Nonfunctional chimeras that contained at least 99 amino terminal Wnt-1 residues inhibited Wnt-1 stimulation of 293 cells. One of these chimeras inhibited both Wnt-1 and Wnt-3 activity suggesting that Wnt-1 and Wnt-3 interact with a common signaling component.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	Columbia University; Columbia University	Kitajewski, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.							BEJSOVEC A, 1995, GENETICS, V139, P309; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Binari RC, 1997, DEVELOPMENT, V124, P2623; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BROWN AMC, 1995, RETROVIRAL VECTORS, V4, P113; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; Dale TC, 1998, BIOCHEM J, V329, P209; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Fagotto F, 1997, DEVELOPMENT, V124, P453; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Haerry TE, 1997, DEVELOPMENT, V124, P3055; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JASIN M, 1992, P NATL ACAD SCI USA, V89, P10681, DOI 10.1073/pnas.89.22.10681; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Klymkowsky MW, 1997, BIOESSAYS, V19, P537, DOI 10.1002/bies.950190702; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOON RT, 1993, DEVELOPMENT, V119, P97; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; Schryver B, 1996, ONCOGENE, V13, P333; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	61	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					149	156		10.1038/sj.onc.1202268	http://dx.doi.org/10.1038/sj.onc.1202268			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926929				2022-12-25	WOS:000078166000016
J	Burns, CM; Nowatzke, WL; Richardson, JP				Burns, CM; Nowatzke, WL; Richardson, JP			Activation of rho dependent transcription termination by NusG - Dependence on terminator location and acceleration of RNA release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MICROCOCCUS-LUTEUS; PROTEIN; POLYMERASE; ELONGATION; SEQUENCE; ANTITERMINATION; EFFICIENCY; LAMBDA; GENE	There is a kinetic limitation to Rho function at the first intragenic terminator in the lacZ gene (tiZ1) which can be overcome by NusG:Rho can terminate transcription with slowly moving, but not rapidly moving, RNA polymerase unless NusG is also present. Here we report further studies with two other Rho dependent terminators that are not kinetically limited (tiZ2 and lambda tR1) which show that the requirement for NusG depends on the properties of the terminator and its location in the transcription unit. NusG is also shown to increase the rate of Rho-mediated dissociation of transcription complexes arrested at a specific termination stop point in the tiZ1 region and the rates of dissociation with three different Rho factors and two different terminators correlated with their sensitivity to RNA polymerase elongation kinetics. These results suggest a model of NusG function which involves an alteration in the susceptibility of the transcription complex to Rho action which allows termination to occur within the short kinetic window when RNA polymerase is traversing the termination region.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	jrichard@bio.indiana.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI010142, R01AI010142] Funding Source: NIH RePORTER; NIAID NIH HHS [AI10142] Funding Source: Medline; NIGMS NIH HHS [GM07227] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS C, 1985, J BIOL CHEM, V260, P5826; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burns CM, 1998, J MOL BIOL, V278, P307, DOI 10.1006/jmbi.1998.1691; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; BURNS CM, 1996, THESIS INDIANA U, P109; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; LI J, 1992, J BIOL CHEM, V267, P6012; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LINN T, 1990, J BACTERIOL, V172, P1077, DOI 10.1128/jb.172.2.1077-1084.1990; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Nehrke Keith W., 1993, Gene Expression, V3, P119; NEHRKE KW, 1994, J MOL BIOL, V243, P830, DOI 10.1006/jmbi.1994.1685; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nowatzke WL, 1997, J BIOL CHEM, V272, P2207; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; OLINS PO, 1983, GENE, V26, P11, DOI 10.1016/0378-1119(83)90031-8; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; RUTESHOUSER EC, 1989, J MOL BIOL, V208, P23, DOI 10.1016/0022-2836(89)90085-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGESADA K, 1980, NUCLEIC ACIDS RES, V8, P3355, DOI 10.1093/nar/8.15.3355; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; Washburn RS, 1996, J MOL BIOL, V260, P347, DOI 10.1006/jmbi.1996.0405; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	35	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5245	5251		10.1074/jbc.274.8.5245	http://dx.doi.org/10.1074/jbc.274.8.5245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988775	hybrid			2022-12-25	WOS:000078698200100
J	Aridor, M; Bannykh, SI; Rowe, T; Balch, WE				Aridor, M; Bannykh, SI; Rowe, T; Balch, WE			Cargo can modulate COPII vesicle formation from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; MANNOSE 6-PHOSPHATE RECEPTORS; VIRAL MEMBRANE GLYCOPROTEIN; CLATHRIN-COATED VESICLES; PROTEIN-TRANSPORT; SECRETORY PATHWAY; GOLGI-COMPLEX; QUALITY-CONTROL; SELECTIVE TRANSPORT; CYTOPLASMIC DOMAIN	The COPII coat complex found on endoplasmic reticulum (ER)-derived vesicles plays a critical role in cargo selection. We now address the potential role of biosynthetic cargo in modulating COPII coat assembly and vesicle budding. The ER accumulation of vesicular stomatitis glycoprotein (VSV-G), a transmembrane protein, or the soluble PiZ variant of alpha 1-antitrypsin, reduced levels of general COPII vesicle formation in vivo. Consistent with this result, conditions that prevent the export of VSV-G; from the ER led to a significant inhibition of general COPII vesicle budding from ER microsomes and the export of an endogenous recycling protein p58 in vitro. In contrast, synchronized export of VSV-G stimulated COPII vesicle budding both in vivo and in vitro. Under conditions where VSV-G is retained in the ER, we find that it can to be recovered in pre-budding complexes containing COPII components. These results suggest that the export of biosynthetic cargo is integrated with ER functions involved in protein folding and oligomerization. The ability of biosynthetic cargo to prevent or enhance ER export suggests that interactions of cargo with the COPII machinery contribute to the formation of vesicles budding from the ER.	Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell & Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58689] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Brooks DA, 1997, FEBS LETT, V409, P115, DOI 10.1016/S0014-5793(97)00423-7; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNIGAN DD, 1983, J VIROL, V45, P618, DOI 10.1128/JVI.45.2.618-626.1983; FABBRI M, 1994, J BIOL CHEM, V269, P26848; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KELLER GA, 1986, J HISTOCHEM CYTOCHEM, V34, P12223; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Melancon P, 1989, Soc Gen Physiol Ser, V44, P175; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Pryde JG, 1998, MOL CELL BIOL, V18, P1125, DOI 10.1128/MCB.18.2.1125; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHMAN JE, 1996, SCIENCE, V272, P272; ROWE T, 1995, METHOD ENZYMOL, V257, P49; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SIFERS RN, 1989, J BIOL CHEM, V264, P15696; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SIFERS RN, 1992, SEMIN LIVER DIS, V12, P301, DOI 10.1055/s-2008-1040399; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stone S, 1997, MOL BIOL CELL, V8, P1175, DOI 10.1091/mbc.8.7.1175; STORRIE B, 1994, J CELL SCI, V107, P1309; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU Y, 1994, P NATL ACAD SCI USA, V267, P1072; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; ZAGOURAS P, 1991, J VIROL, V65, P1976, DOI 10.1128/JVI.65.4.1976-1984.1991	84	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4389	4399		10.1074/jbc.274.7.4389	http://dx.doi.org/10.1074/jbc.274.7.4389			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933643	hybrid			2022-12-25	WOS:000078575500067
J	Laird, AD; Morrison, DK; Shalloway, D				Laird, AD; Morrison, DK; Shalloway, D			Characterization of Raf-1 activation in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-CYCLE; PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; INDEPENDENT MANNER; RAS BINDING; REQUIREMENT; PATHWAY; DOMAIN	We have used site-directed mutagenesis to explore the mechanisms underlying Raf-1 activation in mitosis, and we have excluded most previously characterized activating interactions. Our results indicate that the primary locus of activation lies in the carboxyl-half of the molecule, although the extent of activation can be influenced by the amino-proximal region, particularly by the Raf-1 zinc finger, We also found that Raf-1 is hyperphosphorylated in mitosis at multiple sites within residues 283-302 and that these hyperphosphorylations are not required for activation, In addition, neither Mek1 nor Mek2 are stably activated in coordination with Raf-1 in nocodazole-arrested cells. Overall, the data suggest that the mechanism(s) responsible for activating Raf-1 during mitosis, and the subsequent downstream effects, are distinct from those involved in growth factor stimulation.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA; NCI, Frederick Canc Res & Dev Ctr, ABL, Mol Basis Carcinogenesis Lab,Basic Res Program, Frederick, MD 21702 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shalloway, D (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA.	dis2@cornell.edu			NCI NIH HHS [CA 68743, CA32317] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068743, R01CA032317] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HAGAG N, 1990, ONCOGENE, V5, P1481; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huby RDJ, 1998, J BIOL CHEM, V273, P12024, DOI 10.1074/jbc.273.20.12024; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lovric J, 1996, ONCOGENE, V12, P1109; Lovric J, 1998, J BIOL CHEM, V273, P22848; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MCGREW BR, 1992, ONCOGENE, V7, P33; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; Popik W, 1996, MOL CELL BIOL, V16, P6532; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TAYLOR SJ, 1993, CURR OPIN CELL BIOL, V3, P36; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Torres K, 1998, CANCER RES, V58, P3620; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	82	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4430	4439		10.1074/jbc.274.7.4430	http://dx.doi.org/10.1074/jbc.274.7.4430			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933647	hybrid			2022-12-25	WOS:000078575500071
J	Li, J; Foitzik, K; Calautti, E; Baden, H; Doetschman, T; Dotto, GP				Li, J; Foitzik, K; Calautti, E; Baden, H; Doetschman, T; Dotto, GP			TGF-beta 3, but not TGF-beta 1, protects keratinocytes against 12-O-tetradecanoylphorbol-13-acetate-induced cell death in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; MOUSE EPIDERMIS; APOPTOSIS; DIFFERENTIATION; MICE; IDENTIFICATION; EXPRESSION; DISRUPTION; RECEPTORS	We have examined the role that individual TGF-beta isoforms, and in particular TGF-beta 3, play in control of epidermal homeostasis, Mice with a knockout mutation of the TGF-beta 3 gene die a few hours after birth. A full-thickness skin grafting approach was used to investigate the postnatal development and homeostatic control of the skin of these mice. Grafted skin of mice with a disruption of the TGF-beta 3 gene developed similarly to grafts of wild type and TGF-beta 1 knockout animals. However, a strikingly different response was observed after acute treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), When exposed to TPA, the grafted skin of wild type and TGF-beta 1 knockout mice underwent a hyperplastic response similar to that of normal mouse skin. In marked contrast, TPA treatment of TGF-beta 3 knockout grafts induced widespread areas of keratinocyte cell death. Analysis of cultured keratinocytes treated with purified TGF-beta isoforms revealed that TGF-beta 3 plays a direct and specific function in protecting keratinocytes against TPA-induced cell death. The protective function of TGF-beta 3 on TPA-induced cell death was not because of general suppression of the signaling pathways triggered by this agent, as ERK1/2 activation occurred to a similar if not greater extent in TGF-beta 3-treated versus control keratinocytes. Instead, TGF-beta 3 treatment led to a significant reduction in TPA-induced c-Jun N-terminal kinase activity, which was associated and possibly explained by specific counteracting effects of TGF-beta 3 on TPA-induced disruption of keratinocyte focal adhesions.	MGH E, CBRC, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Harvard University; University System of Ohio; University of Cincinnati	Dotto, GP (corresponding author), MGH E, CBRC, 13th St, Charlestown, MA 02129 USA.	Paolo.Dotto@cbrc2.mgh.harvard.edu	Calautti, Enzo/M-8283-2018	Calautti, Enzo/0000-0002-4439-9709	NCI NIH HHS [CA73796, CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073796, P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; Benassi L, 1997, J INVEST DERMATOL, V109, P276, DOI 10.1111/1523-1747.ep12335756; Brissette JL, 1996, GENE DEV, V10, P2212, DOI 10.1101/gad.10.17.2212; Budunova IV, 1996, MOL CARCINOGEN, V15, P202; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; COLLINS RJ, 1992, INT J RADIAT BIOL, V61, P451, DOI 10.1080/09553009214551201; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Escherick J S, 1993, Cancer Res, V53, P5517; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MASSAGUE J, 1992, CANCER SURV, V12, P81; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SHAH M, 1995, J CELL SCI, V108, P985; Shimizu S, 1996, ONCOGENE, V12, P2045; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu JS, 1996, CANCER RES, V56, P5423	40	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4213	4219		10.1074/jbc.274.7.4213	http://dx.doi.org/10.1074/jbc.274.7.4213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933619	hybrid			2022-12-25	WOS:000078575500043
J	Tandai-Hiruma, M; Endo, T; Kobata, A				Tandai-Hiruma, M; Endo, T; Kobata, A			Detection of novel carbohydrate binding activity of interleukin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; HUMAN-PREGNANCY URINE; SUGAR CHAINS; N-ACETYLGALACTOSAMINE; MONOCLONAL-ANTIBODY; STRUCTURAL-ANALYSIS; UROMODULIN; LECTIN; PROTEIN	Tamm-Horsfall glycoprotein (THGP) and the oligosaccharide fraction liberated from THGP by hydrazinolysis inhibited tetanus toroid-induced T cell proliferation. Intact THGP showed approximately 100-fold more inhibitory activity than the free oligosaccharides. After fractionating the oligosaccharides by anion-exchange column chromatography, the inhibitory activity could be detected in a sialidase-resistant acidic oligosaccharide fraction (fraction AR). The inhibitory activity of fraction AR was not observed when the fraction was added to the T cell culture medium 24 h after the addition of tetanus toroid. Increased concentration of interleukin (IL) 1 beta and decreased concentration of IL-2 were observed in the T cell culture medium after the addition of fraction AR. The oligosaccharides in fraction AR also inhibited the growth of an IL-1-dependent cell line, D10-G4. These results strongly suggested that the oligosaccharides in fraction AR bind to IL-1 beta and suppress its cytokine activity. IL-1 beta actually bound to the fraction AR immobilized on an amino-bonded thin layer plate. Fractionation of the oligosaccharides indicated that only oligosaccharides containing an N-acetylgalactosamine residue and a sulfate residue bound specifically to IL-1 beta. Removal of either the sulfate residue or the N-acetylgalactosamine residue from the oligosaccharides abolished both the proliferation-inhibition and IL-1 beta binding activities. Since IL-1 beta did not bind to thyroid-stimulating hormone, which has the sulfate group at C-4 of the N-acetylgalactosamine residue in its N-linked sugar chains, the binding of IL-1 beta toward oligosaccharides in fraction AR was considered to be highly specific.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1080071, Japan	University of Tokyo	Endo, T (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Glycobiol, Itabashi Ku, Tokyo 1730015, Japan.	endo@tmig.or.jp						ABBONDANZA A, 1980, BIOCHEM J, V187, P525, DOI 10.1042/bj1870525; ADLER W H, 1970, Journal of Experimental Medicine, V131, P1049, DOI 10.1084/jem.131.6.1049; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN KM, 1986, P NATL ACAD SCI USA, V83, P9119, DOI 10.1073/pnas.83.23.9119; DALLOLIO F, 1988, CARBOHYD RES, V178, P327, DOI 10.1016/0008-6215(88)80123-X; DALLOLIO F, 1991, CELL IMMUNOL, V137, P303, DOI 10.1016/0008-8749(91)90081-L; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Fukushima K, 1997, J BIOL CHEM, V272, P10579; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; KAYE J, 1984, J IMMUNOL, V133, P1339; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MAKITA A, 1963, JPN J EXP MED, V33, P361; MOONEN P, 1988, FEBS LETT, V226, P314, DOI 10.1016/0014-5793(88)81446-7; MUCHMORE AV, 1987, J IMMUNOL, V138, P2547; MUCHMORE AV, 1985, SCIENCE, V229, P479, DOI 10.1126/science.2409603; MUCHMORE AV, 1990, J LEUKOCYTE BIOL, V48, P457, DOI 10.1002/jlb.48.5.457; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; MUCHMORE AV, 1986, J BIOL CHEM, V261, P3404; OHBAYASHI H, 1989, ANAL BIOCHEM, V182, P200, DOI 10.1016/0003-2697(89)90579-4; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SERAFINICESSI F, 1979, BIOCHEM J, V183, P381, DOI 10.1042/bj1830381; SMAGULA RM, 1990, GLYCOCONJUGATE J, V7, P609, DOI 10.1007/BF01189081; TADANO K, 1982, J BIOL CHEM, V257, P1482; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6; YAMAKAWA T, 1962, J BIOCHEM-TOKYO, V52, P226, DOI 10.1093/oxfordjournals.jbchem.a127602; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144	36	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4459	4466		10.1074/jbc.274.7.4459	http://dx.doi.org/10.1074/jbc.274.7.4459			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933650	hybrid			2022-12-25	WOS:000078575500074
J	Watababe, A; Kurokawa, Y; Yoshimura, T; Kurihara, T; Soda, K; Esaki, N				Watababe, A; Kurokawa, Y; Yoshimura, T; Kurihara, T; Soda, K; Esaki, N			Role of lysine 39 of alanine racemase from Bacillus stearothermophilus that binds pyridoxal 5 '-phosphate - Chemical rescue studies of Lys(39)-> Ala mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; PROTEIN-SEQUENCE DETERMINATION; SITE-DIRECTED MUTANT; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; ENZYME-PURIFICATION; BRONSTED ANALYSIS; EXOGENOUS AMINES; LYSYL RESIDUE; DNA	The lysine residue binding with the cofactor pyridoxal 5'-phosphate (PLP) plays an important role in catalysis, such as in the transaldimination and abstraction of alpha-hydrogen from a substrate amino acid in PLP-dependent enzymes. We studied the role of Lys(39) Of alanine racemase (EC 5.1.1.1) from Bacillus stearothermophilus, the PLP-binding residue of the enzyme, by replacing it site-specifically with alanine and characterizing the resultant K39A mutant enzyme. The mutant enzyme turned out to be inherently inactive, but gained an activity as high as about 0.1% of that of the wild-type enzyme upon addition of 0.2 M methylamine. The amine-assisted activity of the mutant enzyme depended on the pK(a), values and molecular volumes of the alkylamines used. A strong kinetic isotope effect was observed when alpha-deuterated D-alanine was used as a substrate in the methylamine-assisted reaction, but little effect was observed using its antipode, In marked contrast, only L-enantiomer of alanine showed a solvent isotope effect in deuterium oxide in the methylamine-assisted reaction. These results suggest that methylamine serves as a base not only to abstract the alpha-hydrogen from D-alanine but also to transfer a proton from water to the alpha-position of the deprotonated (achiral) intermediate to form D-alanine. Therefore, the exogenous amine can be regarded as a functional group fully representing Lys(39) of the wild-type enzyme. Lys(39) Of the wild-type enzyme probably acts as the base catalyst specific to the D-enantiomer of alanine. Another residue specific to the L-enantiomer in the wild-type enzyme is kept intact in the K39A mutant.	Kyoto Univ, Inst Chem Res, Lab Biofunct Mol, Uji, Kyoto 6110011, Japan; Kansai Univ, Fac Engn, Dept Biotechnol, Suita, Osaka 5648680, Japan	Kyoto University; Kansai University	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Lab Biofunct Mol, Uji, Kyoto 6110011, Japan.	esaki@scl.kyoto-u.ac.jp						BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; Boehlein SK, 1997, J BIOL CHEM, V272, P12384, DOI 10.1074/jbc.272.19.12384; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS B, 1992, BIOCHEM BIOPH RES CO, V184, P1386, DOI 10.1016/S0006-291X(05)80036-1; ESAKI N, 1985, BIOCHEMISTRY-US, V24, P3857, DOI 10.1021/bi00336a007; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; Fersht A., 1985, ENZYME STRUCTURE MEC; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P13363, DOI 10.1021/bi961453c; GALAKATOS NG, 1986, BIOCHEMISTRY-US, V25, P3255, DOI 10.1021/bi00359a026; HARPEL MR, 1994, BIOCHEMISTRY-US, V33, P5553, DOI 10.1021/bi00184a026; Huang SQ, 1997, BIOCHEMISTRY-US, V36, P14609, DOI 10.1021/bi9722554; INAGAKI K, 1986, BIOCHEMISTRY-US, V25, P3268, DOI 10.1021/bi00359a028; KIRSCH JF, 1990, ANN NY ACAD SCI, V585, P48, DOI 10.1111/j.1749-6632.1990.tb28040.x; Kurokawa Y, 1998, J BIOCHEM-TOKYO, V124, P1163, DOI 10.1093/oxfordjournals.jbchem.a022234; LU ZC, 1993, J BIOL CHEM, V268, P8727; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; Nishino J, 1997, J BIOCHEM-TOKYO, V121, P604; Rynkiewicz MJ, 1996, BIOCHEMISTRY-US, V35, P16174, DOI 10.1021/bi961311i; SAWADA S, 1994, BIOSCI BIOTECH BIOCH, V58, P807, DOI 10.1271/bbb.58.807; SEKIMOTO T, 1993, J BIOL CHEM, V268, P27039; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; TANIZAWA K, 1989, J BIOL CHEM, V264, P2445; TANIZAWA K, 1988, BIOCHEMISTRY-US, V27, P1311, DOI 10.1021/bi00404a033; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TOYAMA H, 1991, J BIOL CHEM, V266, P13634; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; YOSHIMURA T, 1992, BIOCHEMISTRY-US, V31, P11748, DOI 10.1021/bi00162a011	31	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4189	4194		10.1074/jbc.274.7.4189	http://dx.doi.org/10.1074/jbc.274.7.4189			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933615	hybrid			2022-12-25	WOS:000078575500039
J	Bourdon, E; Loreau, N; Blache, D				Bourdon, E; Loreau, N; Blache, D			Glucose and free radicals impair the antioxidant properties of serum albumin	FASEB JOURNAL			English	Article						oxidation; LDL oxidation; red blood cell hemolysis; atherosclerosis; diabetes	LOW-DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; NEPHROTIC SYNDROME; PROTEIN GLYCATION; DIABETES-MELLITUS; BLOOD-PLASMA; ATHEROSCLEROSIS; DISEASE; GLYCOSYLATION; CHOLESTEROL	Epidemiological data consistently show that reduced levels of serum albumin, which is the most abundant protein in plasma, are associated with an increased mortality risk. Various biological properties evidenced by direct effects of the albumin molecule may explain its beneficial effects. The present work aimed to investigate in vitro whether glycation or free radicals or both factors would affect the antioxidant properties of bovine serum albumin (BSA), Glycation was performed by long-term incubations (60 days) of BSA with increasing concentrations of glucose (up to 500 mmol/l) at 37 degrees C, Minimally oxidized BSA was obtained after controlled incubations of dialyzed BSA samples with a water-soluble free radical generator [2,2' azo-bis(2-amidinopropane) HCl], The glycation-mediated modifications and the free radical-induced conformational changes of BSA were monitored using intrinsic fluorescence measurements of the tryptophan residues and acrylamide as a quenching agent. Thiol groups, Amadori glycophore contents, and boronate binding were also measured. We found that the changes observed in the conformation of the BSA molecule were associated with modifications of its antioxidant properties. The latter were studied by the copper-mediated oxidation of human low density lipoproteins and the free radical-induced blood hemolysis test. Our data support the concept that oxidative-induced BSA modifications are important determinants in the antioxidant properties of BSA, Glycated BSA still behaved as an antioxidant but became pro-oxidant in the presence of copper, probably by generating oxygenated species. These data confirm the key role of metals ions in this process. Although these results warrant further in vivo investigations, we propose that, considering the poor glucose control found in diabetics as well as the key role of oxidative stress in vascular complications, glycation-mediated and free radical-induced impairment of the antioxidant properties of albumin might be important parameters in vascular complications encountered in diabetes.	Univ Bourgogne, INSERM, U498, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Blache, D (corresponding author), Univ Bourgogne, INSERM, U498, 7 Bd Jeanne Arc, F-21033 Dijon, France.	dblache@u-bourgogne.fr	Bourdon, Emmanuel/P-8455-2019	Bourdon, Emmanuel/0000-0003-3731-150X				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AVIRAM M, 1993, ATHEROSCLEROSIS, V98, P1, DOI 10.1016/0021-9150(93)90217-I; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; Blache D, 1998, J AM OIL CHEM SOC, V75, P107, DOI 10.1007/s11746-998-0019-6; BLACHE D, 1995, FEBS LETT, V357, P135, DOI 10.1016/0014-5793(94)01348-5; BLACHE D, 1995, AM J PHYSIOL-HEART C, V268, pH679, DOI 10.1152/ajpheart.1995.268.2.H679; BLACHE D, 1992, P 9 COLL PARK C CHEM, P82; BROWNLEE M, 1995, CLIN INVEST MED, V18, P275; Cha MK, 1996, BIOCHEM BIOPH RES CO, V222, P619, DOI 10.1006/bbrc.1996.0793; Coussons PJ, 1997, FREE RADICAL BIO MED, V22, P1217, DOI 10.1016/S0891-5849(96)00557-6; DAMMACCO F, 1980, VOX SANG, V39, P153, DOI 10.1111/j.1423-0410.1980.tb01851.x; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; Dean RT, 1997, BIOCHEM J, V324, P1; DEAN RT, 1991, FREE RADICAL BIO MED, V11, P161, DOI 10.1016/0891-5849(91)90167-2; Durand P, 1997, ARTERIOSCL THROM VAS, V17, P1939, DOI 10.1161/01.ATV.17.10.1939; Durand P, 1997, FASEB J, V11, P1157, DOI 10.1096/fasebj.11.13.9367351; Durand P, 1996, ATHEROSCLEROSIS, V121, P205, DOI 10.1016/0021-9150(95)05720-X; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FAURE P, 1994, BBA-PROTEIN STRUCT M, V1209, P260, DOI 10.1016/0167-4838(94)90194-5; Girodon F, 1997, J AM COLL NUTR, V16, P357, DOI 10.1080/07315724.1997.10718698; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; GRANT AJ, 1992, BIOCHIM BIOPHYS ACTA, V1134, P203, DOI 10.1016/0167-4889(92)90177-D; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Halliwell B, 1996, FREE RADICAL RES, V25, P57, DOI 10.3109/10715769609145656; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HARRIS RC, 1994, AM J KIDNEY DIS, V23, P477, DOI 10.1016/S0272-6386(12)80369-6; HUNT JV, 1994, BIOCHEM J, V300, P243, DOI 10.1042/bj3000243; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; LUOMA PV, 1995, J INTERN MED, V237, P49, DOI 10.1111/j.1365-2796.1995.tb01139.x; MONTGOMERY DA, 1962, CLIN SCI, V22, P141; Mooradian AD, 1996, FREE RADICAL BIO MED, V21, P699, DOI 10.1016/0891-5849(96)00127-X; Moriyama Y, 1996, J PROTEIN CHEM, V15, P265, DOI 10.1007/BF01887115; NAGANO Y, 1992, ATHEROSCLEROSIS, V92, P131, DOI 10.1016/0021-9150(92)90272-I; Ogino T, 1995, BBA-GEN SUBJECTS, V1245, P359, DOI 10.1016/0304-4165(95)00101-8; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PHILLIPS A, 1989, LANCET, V2, P1434; PROST M, 1992, Patent No. 5135850; QUINTANILHA AT, 1982, ANN NY ACAD SCI, V393, P32, DOI 10.1111/j.1749-6632.1982.tb31230.x; REAVEN PD, 1992, ARTERIOSCLER THROMB, V12, P318, DOI 10.1161/01.ATV.12.3.318; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schnitzer E, 1997, BBA-LIPID LIPID MET, V1344, P300, DOI 10.1016/S0005-2760(96)00154-3; SHAKLAI N, 1984, J BIOL CHEM, V259, P3812; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORIANI M, 1994, ARCH BIOCHEM BIOPHYS, V312, P180, DOI 10.1006/abbi.1994.1297; STAMPFER MJ, 1995, AM J CLIN NUTR, V62, P1365, DOI 10.1093/ajcn/62.6.1365S; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; WAYNER DDM, 1985, FEBS LETT, V187, P33, DOI 10.1016/0014-5793(85)81208-4; WHEELER DC, 1994, AM J KIDNEY DIS, V23, P331, DOI 10.1016/S0272-6386(12)80994-2; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Woodside JV, 1998, AM J CLIN NUTR, V67, P858, DOI 10.1093/ajcn/67.5.858; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZAWADZKI Z, 1991, J LIPID RES, V32, P243	60	240	246	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					233	244		10.1096/fasebj.13.2.233	http://dx.doi.org/10.1096/fasebj.13.2.233			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973311				2022-12-25	WOS:000078615200003
J	Bascom, RA; Srinivasan, S; Nussbaum, RL				Bascom, RA; Srinivasan, S; Nussbaum, RL			Identification and characterization of Golgin-84, a novel Golgi integral membrane protein with a cytoplasmic coiled-coil domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET-II ONCOGENE; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAINS; VESICLE DOCKING; SEQUENCES; COMPLEX; RECOGNITION; APPARATUS; RECEPTORS; RETENTION	The cytoplasmic face of the Golgi contains a variety of proteins with coiled-coil domains. We identified one such protein in a yeast two hybrid screen, using as bait the peripheral Golgi phosphatidylinositol(4,5)P-2 8-phosphatase OCRL1 that is implicated in a human disease, the oculocerebrorenal syndrome. The similar to 2.8-kilobase mRNA is ubiquitously expressed and abundant in testis; it encodes a 731-amino acid protein with a predicted mass of 83 kDa. Antibodies against the sequence detect a novel similar to 84-kDa Golgi protein we termed golgin-84. Golgin-84 is an integral membrane protein with a single transmembrane domain close to its C terminus. In vitro, the protein inserts post-translationally into microsomal membranes with an N-cytoplasmic and C-lumen orientation. Cross-linking indicates that golgin-84 forms dimers, consistent with the prediction of an similar to 400-residue dimerizing coiled coil domain in its N terminus. The dimerization potential is supported by a data base search that showed that the N-terminal 497 residues of golgin-84 contain a coiled-coil domain that when fused to the RET tyrosine kinase domain had the ability to activate it, forming the RET-II oncogene. Data base searching also indicates golgin-84 is similar in structure and sequence to giantin, a membrane protein that tethers coatamer complex I vesicles to the Golgi.	NHGRI, GDRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Nussbaum, RL (corresponding author), NHGRI, GDRB, NIH, 49 Convent Dr, Bethesda, MD 20892 USA.	rlnuss@nhgri.nih.gov		Bascom, Roger/0000-0002-9106-8224				ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Desjardins C, 1993, CELL MOL BIOL TESTIS; DOHLMAN JG, 1993, BIOCHEM BIOPH RES CO, V195, P686, DOI 10.1006/bbrc.1993.2100; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; Riezman H, 1997, SCIENCE, V278, P1728, DOI 10.1126/science.278.5344.1728; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Tong Q, 1997, J BIOL CHEM, V272, P9043; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	46	84	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2953	2962		10.1074/jbc.274.5.2953	http://dx.doi.org/10.1074/jbc.274.5.2953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915833	hybrid			2022-12-25	WOS:000078319500051
J	Makino, Y; Yoshikawa, N; Okamoto, K; Hirota, K; Yodoi, J; Makino, I; Tanaka, H				Makino, Y; Yoshikawa, N; Okamoto, K; Hirota, K; Yodoi, J; Makino, I; Tanaka, H			Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NF-KAPPA-B; STEROID-HORMONE RECEPTORS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CONFORMATIONAL-CHANGES; NUCLEAR TRANSLOCATION; ACTIVATING FACTOR; ACTIVITY INVITRO; PROTEIN-KINASE	The glucocorticoid receptor (GR) is considered to belong to a class of transcription factors, the functions of which are exposed to redox regulation. We have recently demonstrated that thioredoxin (TRX), a cellular reducing catalyst, plays an important role in restoration of GR function in vivo under oxidative conditions. Although both the ligand binding domain and other domains of the GR have been suggested to be modulated by TRX, the molecular mechanism of the interaction is largely unknown. In the present study, we hypothesized that the DNA binding domain (DBD) of the GR, which is highly conserved among the nuclear receptors, is also responsible for communication with TRX in vivo, Mammalian two-hybrid assay and glutathione S-transferase pull-down assay revealed the direct association between TRX and the GR DBD. Moreover, analysis of subcellular localization of TRX and the chimeric protein harboring herpes simplex viral protein 16 transactivation domain and the GR DBD indicated that the interaction might take place in the nucleus under oxidative conditions. Together these observations indicate that TRX, via a direct association with the conserved DBD motif, may represent a key mediator operating in interplay between cellular redox signaling and nuclear receptor-mediated signal transduction.	Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Kyoto 6068507, Japan	Asahikawa Medical College; Kyoto University; Kyoto University	Tanaka, H (corresponding author), Asahikawa Med Coll, Dept Internal Med 2, 4-5-3 Nishikagura, Asahikawa, Hokkaido 0788510, Japan.	hirotnk@asahikawa-med.ac.jp	Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BODWELL JE, 1984, BIOCHEMISTRY-US, V23, P1392, DOI 10.1021/bi00302a009; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GRIPPO JF, 1983, J BIOL CHEM, V258, P3658; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JEWELL CM, 1995, J STEROID BIOCHEM, V55, P135, DOI 10.1016/0960-0760(95)00174-X; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Makino Y, 1996, MOL PHARMACOL, V49, P612; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sanchez Edwin R., 1996, Methods (Orlando), V9, P188, DOI 10.1006/meth.1996.0025; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; TAGAYA Y, 1990, MOL IMMUNOL, V27, P1279; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TANAKA H, 1995, MOL PHARMACOL, V48, P938; Tanaka H, 1996, J IMMUNOL, V156, P1601; Tanaka T, 1997, LAB INVEST, V77, P145; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; Wu XS, 1996, MOL CELL BIOL, V16, P1035; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YOKOMIZO A, 1995, CANCER RES, V55, P4293	64	161	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3182	3188		10.1074/jbc.274.5.3182	http://dx.doi.org/10.1074/jbc.274.5.3182			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915858	hybrid			2022-12-25	WOS:000078319500076
J	Matroule, JY; Bonizzi, G; Morliere, P; Paillous, N; Santus, R; Bours, V; Piette, J				Matroule, JY; Bonizzi, G; Morliere, P; Paillous, N; Santus, R; Bours, V; Piette, J			Pyropheophorbide-a methyl ester-mediated photosensitization activates transcription factor NF-kappa B through the interleukin-1 receptor-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTODYNAMIC THERAPY; SINGLET OXYGEN; CERAMIDE GENERATION; INDUCED EXPRESSION; IN-VIVO; CELLS; TUMOR; PROTEINS; KINASE; ALPHA	Pyropheophorbide-a methyl ester (PPME) is a second generation of photosensitizers used in photodynamic therapy. We demonstrated that PPME photosensitization activated NF-kappa B transcription Factor in colon cancer cells. Unexpectedly, this activation occurred in two separate waves, i.e. a rapid and transient one and a second slower but sustained phase. The former was due to photosensitization by PPME localized in the cytoplasmic membrane which triggered interleukin-l receptor internalization and the transduction pathways controlled by the interleukin-l type I receptor. Indeed, TRAF6 dominant negative mutant abolished NF-kappa B activation by PPME photosensitization, and TRAF2 dominant negative mutant was without any effect, and overexpression of I kappa B kinases increased gene transcription controlled by NF-kappa B, Oxidative stress was not likely involved in the activation. On the other hand, the slower and sustained wave could be the product of the release of ceramide through activation of the acidic sphingomyelinase, PPME localization within the lysosomal membrane could explain why ceramide acted as second messenger in NF-kappa B activation by PPME photosensitization. These data will allow a better understanding of the molecular basis of tumor eradication by photodynamic therapy, in particular the importance of the host cell response in the treatment.	Univ Liege, Inst Pathol B23, Virol Lab, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Med Chem Lab, B-4000 Liege, Belgium; Museum Natl Hist Nat, F-75231 Paris 05, France; Univ Toulouse, IMRCP Lab, CNRS URA 470, F-31062 Toulouse, France	University of Liege; University of Liege; Museum National d'Histoire Naturelle (MNHN); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Virol Lab, B-4000 Liege, Belgium.	jpiette@ulg.ac.be	Bonizzi, Giuseppina/AAD-9042-2022					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATHAR M, 1988, J INVEST DERMATOL, V90, P652, DOI 10.1111/1523-1747.ep12560814; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bonizzi G, 1997, J IMMUNOL, V159, P5264; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Daziano JP, 1996, PHOTOCHEM PHOTOBIOL, V64, P712, DOI 10.1111/j.1751-1097.1996.tb03129.x; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY TJ, 1993, PHOTOCHEM PHOTOBIOL, V58, P895, DOI 10.1111/j.1751-1097.1993.tb04990.x; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FISHER AMR, 1995, LASER SURG MED, V17, P2, DOI 10.1002/lsm.1900170103; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAULLIER JM, 1995, PHOTOCHEM PHOTOBIOL, V62, P114, DOI 10.1111/j.1751-1097.1995.tb05247.x; GEZE M, 1993, J PHOTOCH PHOTOBIO B, V20, P23, DOI 10.1016/1011-1344(93)80128-V; GLINSKI JA, 1995, PHOTOCHEM PHOTOBIOL, V62, P144, DOI 10.1111/j.1751-1097.1995.tb05250.x; Gollnick SO, 1997, CANCER RES, V57, P3904; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Henderson BW, 1997, CANCER RES, V57, P4000; ITO T, 1978, PHOTOCHEM PHOTOBIOL, V28, P493, DOI 10.1111/j.1751-1097.1978.tb06957.x; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KESSEL D, 1984, BIOCHEM PHARMACOL, V33, P1389, DOI 10.1016/0006-2952(84)90403-9; KIK G, 1996, BRIT J CANCER, V74, P30; Kim MJ, 1998, BLOOD, V91, P4106, DOI 10.1182/blood.V91.11.4106.411k40_4106_4117; Korbelik M, 1997, BRIT J CANCER, V75, P202, DOI 10.1038/bjc.1997.34; KRUTMANN J, 1989, J BIOL CHEM, V264, P11407; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Morliere P, 1998, CANCER RES, V58, P3571; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pandey RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P194, DOI 10.1111/j.1751-1097.1996.tb02442.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; PIETTE J, 1986, PHOTOCHEM PHOTOBIOL, V44, P793, DOI 10.1111/j.1751-1097.1986.tb05539.x; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIEMAN DJ, 1992, ONCOL RES, V4, P193; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Separovic D, 1997, CANCER RES, V57, P1717; SERET A, 1990, PHOTOCHEM PHOTOBIOL, V52, P601, DOI 10.1111/j.1751-1097.1990.tb01805.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLARI R, 1994, BIOCHEM PHARMACOL, V47, P93, DOI 10.1016/0006-2952(94)90441-3; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sousa C, 1996, PHOTOCHEM PHOTOBIOL, V63, P601, DOI 10.1111/j.1751-1097.1996.tb05662.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TYRRELL RM, 1989, PHOTOCHEM PHOTOBIOL, V49, P407, DOI 10.1111/j.1751-1097.1989.tb09187.x; VALENZENO DP, 1987, PHOTOCHEM PHOTOBIOL, V46, P147, DOI 10.1111/j.1751-1097.1987.tb04749.x; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; VILE GF, 1995, FREE RADICAL BIO MED, V18, P721, DOI 10.1016/0891-5849(94)00192-M; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	71	74	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2988	3000		10.1074/jbc.274.5.2988	http://dx.doi.org/10.1074/jbc.274.5.2988			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915837	hybrid			2022-12-25	WOS:000078319500055
J	McCormack, FX; Damodarasamy, M; Elhalwagi, BM				McCormack, FX; Damodarasamy, M; Elhalwagi, BM			Deletion mapping of N-terminal domains of surfactant protein A - The N-terminal segment is required for phospholipid aggregation and specific inhibition of surfactant secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; MANNOSE-BINDING PROTEIN; PULMONARY SURFACTANT; II CELLS; HIGH-AFFINITY; HELIX FORMATION; LUNG; APOPROTEIN; LIPIDS; GENE	The objective of the current study was to examine the functional importance of the N-terminal domains of surfactant protein A (SP-A) including the N-terminal segment from Asn(1) to Ala(7) (denoted domain 1), the N-terminal portion of the collagen domain from Gly(8) to Gly(44) (domain 2), and the C-terminal portion of the collagenlike domain from Gly(45) to Pro(80) (domain 3), Wild type recombinant SP-A (Sp-A(hyp); where hyp indicates hydroxyproline-deficient) and truncated mutant (TM) SP-As containing deletions of domain(s) 1 (TM1), 2 (TM2), 1 and 2 (TM1-2), and 1, 2, and 3 (TM1-2-3) were synthesized in insect cells and purified by mannose-Sepharose affinity chromatography, N-terminal disulfide-dependent dimerization was preserved at near wild type levels in the TM1-2 (at Cys(-1)) and TM2 proteins (at Cys(-1) and Cys(6)), and to a lesser extent in TM1 (at Cys(-1)), but not in TM1-2-3, Cross-linking analyses demonstrated that the neck + CRD was sufficient for assembly of monomers into noncovalent trimers and that the N-terminal segment was required for the association of trimers to form higher oligomers, All TM proteins except TM1-2-3 bound to phospholipid, but only the N-terminal segment containing TM proteins aggregated phospholipid vesicles. The TM1, TM1-2, and TM2 but not the TM1-2-3 inhibited the secretion of surfactant from type II cells as effectively as Sp-A(hyp), but the inhibitory activity of each mutant was blocked by excess alpha-methylmannoside and therefore nonspecific, TM1 and TM1-2-3 did not enhance the uptake of phospholipids by isolated type II cells, but the TM1-2 and TM2 had activities that were 72 and 83% of Sp-A(hyp), respectively. We conclude the following for SP-A: 1) trimerization does not require the collagen-like region or interchain disulfide linkage; 2) the N-terminal portion of the collagen-like domain is required for specific inhibition of surfactant secretion but not for binding to liposomes or for enhanced uptake of phospholipids into type II cells; 3) N-terminal interchain disulfide linkage can functionally replace the N-terminal segment for lipid binding, receptor binding, and enhancement of lipid uptake; 4) the N-terminal segment is required for the association of trimeric subunits into higher oligomers, for phospholipid aggregation, and for specific inhibition of surfactant secretion and cannot be functionally replaced by disulfide linkage alone for these activities.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Pulm Crit Care Med, Cincinnati, OH 45267 USA	University of Cincinnati	McCormack, FX (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Pulm Crit Care Med, Cincinnati, OH 45267 USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NIEHS NIH HHS [P30ES-0609606] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL42; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LeVine AM, 1997, J IMMUNOL, V158, P4336; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MCCORMACK FX, 1996, COLLECTINS INNATE IM, P9; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Veldhuizen RAW, 1996, BIOCHEM J, V313, P835, DOI 10.1042/bj3130835; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; Zhang M, 1998, BIOCHEMISTRY-US, V37, P16481, DOI 10.1021/bi9817966	44	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3173	3181		10.1074/jbc.274.5.3173	http://dx.doi.org/10.1074/jbc.274.5.3173			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915857	hybrid			2022-12-25	WOS:000078319500075
J	Sugiura, T; Kodaka, T; Nakane, S; Miyashita, T; Kondo, S; Suhara, Y; Takayama, H; Waku, K; Seki, C; Baba, N; Ishima, Y				Sugiura, T; Kodaka, T; Nakane, S; Miyashita, T; Kondo, S; Suhara, Y; Takayama, H; Waku, K; Seki, C; Baba, N; Ishima, Y			Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor - Structure-activity relationship of 2-arachidonoylglycerol ether-linked analogues, and related compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYBRID NG108-15 CELLS; ENZYMATIC-SYNTHESIS; ENDOGENOUS LIGAND; RAT-BRAIN; ARACHIDONIC-ACID; ANANDAMIDE; BIOSYNTHESIS; TRANSACYLASE; HYDROLYSIS; TRANSIENT	An endogenous cannabimimetic molecule, 2-arachidonoylglycerol, induces a rapid, transient increase in intracellular free Ca2+ concentrations in NG108-15 cells through a cannabinoid CB1 receptor-dependent mechanism. We examined the activities of 24 relevant compounds (2-arachidonoylglycerol, its structural analogues, and several synthetic cannabinoids). We found that 2-arachidonoylglycerol is the most potent compound examined so far: its activity was detectable from as low as 0.3 nM, and the maximal response induced by 2-arachidonoylglycerol exceeded the responses by others. Activities of HU-210 and CP55940, potent cannabinoid receptor agonists, were also detectable from as low as 0.3 nM, whereas the maximal responses induced by these compounds were low compared with 2-arachidonoylglycerol, Anandamide was also found to act as a partial agonist in this assay system. We confirmed that free arachidonic acid failed to elicit a response. Furthermore, we found that a metabolically stable ether-linked analogue of 2-arachidonoylglycerol possesses appreciable agonistic activity, although its activity was apparently lower than that of 2-arachidonoylglycerol. We also confirmed that pretreating cells with various cannabinoid receptor agonists nullified the response induced by 2-arachidonoylglycerol, whereas pretreating cells with other neurotransmitters or neuromodulators did not affect the response. These results strongly suggested that the cannabinoid CB1 receptor is originally a 2-arachidonoylglycerol receptor, and 2-arachidonoylglycerol is the intrinsic physiological ligand for the cannabinoid CB1 receptor.	Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan; Okayama Univ, Fac Agr, Tsushima, Okayama 7008530, Japan; Ishima Inst Neurosci, Tokyo 1860002, Japan	Teikyo University; Okayama University	Sugiura, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan.			Suhara, Yoshitomo/0000-0002-4770-2910				Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; Cadas H, 1997, J NEUROSCI, V17, P1226; DEADWYLER SA, 1995, CANNABINOID RECEPTOR, P205; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; Di Marzo V, 1998, BIOCHEMISTRY-MOSCOW+, V63, P13; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; Di Marzo V, 1998, BIOCHEM J, V331, P15; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; GAMMON CM, 1989, J NEUROCHEM, V53, P95, DOI 10.1111/j.1471-4159.1989.tb07299.x; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Hansen HS, 1998, BIOCHEM PHARMACOL, V55, P719, DOI 10.1016/S0006-2952(97)00396-1; HANSEN HS, BIOCH BIOPHYS ACTA, V1258, P303; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HERKENHAM M, 1995, CANNABINOID RECEPTOR, P145; HOWLETT AC, 1995, CANNABINOID RECEPTOR, P167; Kempe K, 1996, J BIOL CHEM, V271, P17287, DOI 10.1074/jbc.271.29.17287; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; MARTIN JB, 1953, J AM CHEM SOC, V75, P5482, DOI 10.1021/ja01118a004; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MECHOULAM R, 1995, CANNABINOID RECEPTOR, P233; Murphy L, 1992, MARIJUANA CANNABINOI; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; SCHMID PC, 1996, FEBS LETT, V385, P124; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 1997, BIOCHEM BIOPH RES CO, V233, P207, DOI 10.1006/bbrc.1997.6425; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V229, P58, DOI 10.1006/bbrc.1996.1757; Sugiura T, 1997, J BIOCHEM-TOKYO, V122, P890; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; SUGIURA T, 1994, P JPN C BIOCH LIPIDS, V36, P71; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	43	250	258	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2794	2801		10.1074/jbc.274.5.2794	http://dx.doi.org/10.1074/jbc.274.5.2794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915812	hybrid			2022-12-25	WOS:000078319500030
J	Wu, YX; Patterson, C				Wu, YX; Patterson, C			The human KDR/flk-1 gene contains a functional initiator element that is bound and transactivated by TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; RNA-POLYMERASE-II; TATA-LESS PROMOTER; MAMMALIAN-CELLS; BINDING PROTEIN; DNA-SEQUENCE; TRANSCRIPTION; EXPRESSION; ANGIOGENESIS	KDR/flk-1, the receptor for vascular endothelial growth factor, is required for normal vascular development. KDR/flk-1 is a TATA-less gene, containing four upstream Spl sites and a single transcription start site, although analysis of the start site sequence discloses only weak similarities with the consensus initiator element (Inr) sequence. In vitro transcription assays, however, demonstrate that the region from -10 to +10 relative to the start site contains Inr activity that is orientation- and position-dependent, and mutagenesis of the KDR/flk-1 Inr reduces promoter activity to 28% of the wild-type promoter in transient transfection assays. Gel shift assays confirm that nuclear proteins specifically bind the Inr, and competition experiments demonstrate that TFII-I, a multifunctional Inr-binding nuclear protein, is a component of these DNA-protein complexes. TFII-I transactivates the wild-type KDR/flk-1 promoter, but not a promoter containing a mutated Inr, in transient transfection assays. Immunodepletion of TFII-I from nuclear extracts prior to in vitro transcription assays abolishes transcription from the KDR/flk-1 Inr, an effect that can be rescued by adding back purified TFII-I, reflecting the importance of TFII-I in KDR/flk-1 Inr activity. These experiments demonstrate that the KDR/flk-1 gene contains a functional Inr that is bound by TFII-I and that both the functional Inr and TFII-I activity are essential for transcription.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Cardiol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Patterson, C (corresponding author), Univ Texas, Med Branch, Div Cardiol, 9-138 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	cpatters@utmb.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003658, R01HL061656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61656, HL03658] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Goetz TL, 1996, J BIOL CHEM, V271, P33317, DOI 10.1074/jbc.271.52.33317; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEWIS BA, 1995, J BIOL CHEM, V270, P28139; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Montano MA, 1996, P NATL ACAD SCI USA, V93, P12376, DOI 10.1073/pnas.93.22.12376; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; Parks CL, 1996, J BIOL CHEM, V271, P4417; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu YX, 1998, BIOCHEM J, V330, P1469, DOI 10.1042/bj3301469; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Yin LY, 1998, MAMM GENOME, V9, P408, DOI 10.1007/s003359900783; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	47	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3207	3214		10.1074/jbc.274.5.3207	http://dx.doi.org/10.1074/jbc.274.5.3207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915861	hybrid			2022-12-25	WOS:000078319500079
J	Taylor, WR; Agarwal, ML; Agarwal, A; Stacey, DW; Stark, GR				Taylor, WR; Agarwal, ML; Agarwal, A; Stacey, DW; Stark, GR			p53 inhibits entry into mitosis when DNA synthesis is blocked	ONCOGENE			English	Article						cell cycle; checkpoint; hydroxyurea; PALA	CELL-CYCLE ARREST; WILD-TYPE P53; S-PHASE; GENE AMPLIFICATION; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; BUDDING YEAST	Human and mouse fibroblasts with normal p53 fail to enter mitosis when DNA synthesis is blocked by aphidicolin or hydroxyurea, Isogenic p53-null fibroblasts do enter mitosis with incompletely replicated DNA, revealing that p53 contributes to a checkpoint that ensures that mitosis does not occur until DNA synthesis is complete, When treated with N-(phosphonacetyl)-L-aspartate (PALA), which inhibits pyrimidine nucleotide synthesis, leading to synthesis of damaged DNA from highly unbalanced dNTP pools, p53-null cells enter mitosis after they have completed DNA replication, but cells with wild-type p53 do not, revealing that p53 also mediates a checkpoint that monitors the quality of newly replicated DNA.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGARWAL ML, 1998, IN PRESS P NATL ACAD; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Anderson GR, 1995, J SURG RES, V59, P666, DOI 10.1006/jsre.1995.1221; ATTARDI LD, 1996, EMBO J, V15, P3696; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chen GQ, 1996, BLOOD, V88, P1052; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HAIN J, 1993, CANCER RES, V53, P1507; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1993, ONCOGENE, V8, P2457; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERZINGER T, 1995, ONCOGENE, V11, P2151; Hughes TA, 1996, EXP CELL RES, V222, P275, DOI 10.1006/excr.1996.0035; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JACOBBERGER J W, 1991, Methods (Orlando), V2, P207, DOI 10.1016/S1046-2023(05)80063-5; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU MJ, 1994, CHROMOSOMA, V103, P111; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MIYASHITA T, 1995, CELL, V80, P293; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1996, J BIOL CHEM, V271, P13282; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STEWART N, 1995, ONCOGENE, V10, P109; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	82	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					283	295		10.1038/sj.onc.1202516	http://dx.doi.org/10.1038/sj.onc.1202516			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927185				2022-12-25	WOS:000078166500001
J	Vadlamudi, R; Mandal, M; Adam, L; Steinbach, G; Mendelsohn, J; Kumar, R				Vadlamudi, R; Mandal, M; Adam, L; Steinbach, G; Mendelsohn, J; Kumar, R			Regulation of cyclooxygenase-2 pathway by HER2 receptor	ONCOGENE			English	Article						NDF; COX-2; colon cancer	NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR-ALPHA; HUMAN-COLON-CANCER; PROSTAGLANDIN-H SYNTHASE-2; TYROSINE KINASE-ACTIVITY; EPITHELIAL-CELLS; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; ERBB RECEPTORS; GENE-PRODUCT	Emerging lines of evidence suggest that in addition to growth factors, the process of colorectal tumorigenesis map also be driven by the upregulation of the inducible form of cyclooxygenase-2 (COX-2), an enzyme responsible for the conversion of arachidonic acid to PGEs, The present study was undertaken to investigate the expression and activation of the HER family members, and to explore the regulation of COS-2 expression by the HER2 pathway in human colorectal cancer cells. Here, rye report that human colorectal cancer cell lines express abundant levels of HER2, and HER3 receptors, and are growth-stimulated by recombinant neu-differentiation factor-beta 1 (NDF), NDF-treatment of colorectal cancer cells was accompanied by increased tyrosine phosphorylation and heterodimerization of HER3 with HER2, In addition, we demonstrated that HER2 and HER3 receptors in colorectal cancer cells are constitutively phosphorylated on tyrosine residues and form heterodimeric complexes in the absence of exogenous NDF, Inhibition of HER2/HER3 signaling by an anti-HER3 mAb against the ligand binding site resulted in a decrease in the levels of constitutively activated HER2/HER3 heterodimers, and the unexpected reduction of COS-2 expression, Activation of the HER2/HER3 pathway by NDF induced the activation of COX-2 promoter, expression of COX-2 mRNA, COX-2 protein and accumulation of prostaglandin E2 in the culture medium. Finally, we demonstrated that NDF promotes the ability of colorectal cancer cells to sur,ive in an extracellular matrix milieu, such as Matrigel, and also to invade through a 8 mu m porous membrane. These biological activities of NDF and its stimulation of cell proliferation are blocked by a specific inhibitor of COX-2, Taken together, our findings provide the first biochemical evidence of a possible role of the COS-2 pathway in the mitogenic action of NDF in colorectal cancer cells where it may be constitutively upregulated due to the autocrine/paracrine activation of HER2/HER3 heterodimers.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Gastrointestinal Oncol & Digest Dis, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323; Steinbach, Gideon/0000-0001-7597-0544	NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANZANO MA, 1989, CANCER RES, V49, P2898; Boolbol SK, 1996, CANCER RES, V56, P2556; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chiu CH, 1997, CANCER RES, V57, P4267; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COFFEY RJ, 1987, CANCER RES, V47, P4590; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; Granstrom E, 1978, Adv Prostaglandin Thromboxane Res, V5, P119; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1996, J CELL BIOCHEM, V239, P914; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MANDAL M, 1998, IN PRESS ONCOGENE; Mandel C, 1997, AM BOOK REV, V18, P29; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; REIDEL H, 1988, P NATL ACAD SCI USA, V85, P1477; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1990, CELL, V61, P212; UNTAWALE S, 1993, CANCER RES, V53, P1630; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yang JL, 1997, ANTICANCER RES, V17, P1023; Zhang K, 1996, J BIOL CHEM, V271, P3884	49	187	202	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					305	314		10.1038/sj.onc.1202307	http://dx.doi.org/10.1038/sj.onc.1202307			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927187				2022-12-25	WOS:000078166500003
J	Khanna, M; Park, P; Zirvi, M; Cao, WG; Picon, A; Day, J; Paty, P; Barany, F				Khanna, M; Park, P; Zirvi, M; Cao, WG; Picon, A; Day, J; Paty, P; Barany, F			Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors	ONCOGENE			English	Article						colorectal cancer; K-ras mutations; polymerase chain reaction; ligase detection reaction; thermostable ligase; microdissection	POLYMERASE CHAIN-REACTION; OLIGONUCLEOTIDE LIGATION ASSAY; SEQUENCE-CODED SEPARATION; THERMOPHILUS DNA-LIGASE; COLORECTAL-CANCER; GENE-MUTATIONS; POINT MUTATIONS; PANCREATIC ADENOCARCINOMA; MOLECULAR DIAGNOSIS; CODON-12 MUTATIONS	Point mutations in codons 12, 13, and 61 of the K-ras gene occur early in the development of colorectal cancer and are preserved throughout the course of tumor progression. These mutations can serve as biomarkers for shed or circulating tumor cells and may be useful for diagnosis of early, curable tumors and for staging of advanced cancers. We have developed a multiplex polymerase chain reaction/ligase detection reaction (PCR/LDR) method which identifies all 19 possible single-base mutations in K-ras codons 12, 13, and 61, with a sensitivity of 1 in 500 wild-type sequences. In a blinded study, 144 paraffin-embedded archival colon carcinomas were microdissected and K-ras mutations determined by both dideoxy-sequencing and multiplex PCR/LDR. Results were concordant for 134 samples. The ten discordant samples were re-evaluated using higher sensitivity uniplex PCR/LDR, and the original multiplex PCR/LDR result was confirmed in nine of these ten cases. Multiplex PCR/LDR was able to identify mutations in solid tumors or paraffin-embedded tissues containing a majority of wild-type stromal cells, with or without microdissection. The technique is well suited for large scale studies and for analysis of clinical samples containing a minority population of mutated cells.	Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Barany, F (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, Box 62,1300 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA65930-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA065930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BARANY F, 1991, GENE, V109, P1, DOI 10.1016/0378-1119(91)90582-V; Barany F, 1991, PCR Methods Appl, V1, P5, DOI 10.1101/gr.1.1.5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Belgrader P, 1996, GENOME SCI TECHNOLOG, V1, P77, DOI [DOI 10.1089/GST.1996.1.77, 10.1089/gst.1996.1.77]; BENHATTAR J, 1993, GASTROENTEROLOGY, V104, P1044, DOI 10.1016/0016-5085(93)90272-E; BERTHELEMY P, 1995, ANN INTERN MED, V123, P188, DOI 10.7326/0003-4819-123-3-199508010-00005; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CALDAS C, 1994, CANCER RES, V54, P3568; CAPELLA G, 1991, ENVIRON HEALTH PERSP, V93, P125, DOI 10.2307/3431180; Cha R S, 1992, PCR Methods Appl, V2, P14; CHEHAB FF, 1989, P NATL ACAD SCI USA, V86, P9178, DOI 10.1073/pnas.86.23.9178; CHEN J, 1991, ANAL BIOCHEM, V195, P51, DOI 10.1016/0003-2697(91)90293-3; CHEN J, 1994, ENV HLTH PERSPECT, V3, P227; Day DJ, 1996, HUM MOL GENET, V5, P2039, DOI 10.1093/hmg/5.12.2039; DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226; DIGIUSEPPE JA, 1994, AM J PATHOL, V144, P889; EGGERDING FA, 1995, HUM MUTAT, V5, P153, DOI 10.1002/humu.1380050209; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEERO WG, 1993, NEUROLOGY, V43, P668, DOI 10.1212/WNL.43.4.668; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GROSSMAN PD, 1994, NUCLEIC ACIDS RES, V22, P4527, DOI 10.1093/nar/22.21.4527; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HASEGAWA H, 1995, ONCOGENE, V10, P1413; HAYASHI N, 1994, CANCER RES, V54, P3853; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; HORN T, 1986, TETRAHEDRON LETT, V27, P4705, DOI 10.1016/S0040-4039(00)85043-1; Jacobson D R, 1992, PCR Methods Appl, V1, P299; JEN J, 1994, CANCER RES, V54, P5523; KAHN SM, 1991, ONCOGENE, V6, P1079; KHRAPKO K, 1994, NUCLEIC ACIDS RES, V22, P364, DOI 10.1093/nar/22.3.364; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KORN SH, 1993, J CLIN PATHOL, V46, P621, DOI 10.1136/jcp.46.7.621; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVI S, 1991, CANCER RES, V51, P3497; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; LO YMD, 1991, NUCLEIC ACIDS RES, V19, P3561, DOI 10.1093/nar/19.13.3561; LOSI L, 1992, EUR J CANCER, V28A, P1115, DOI 10.1016/0959-8049(92)90468-H; LU ZB, 1993, PCR METH APPL, V3, P176; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071; MANSFIELD V, 1992, PCR METH APPL, V1, P211; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MAO L, 1994, CANCER RES, V54, P1634; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MOERKERK P, 1994, CANCER RES, V54, P3376; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK P, 1998, UNPUB; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravin J S, 1995, GUT, V36, P81; REDSTON MS, 1995, GASTROENTEROLOGY, V108, P383, DOI 10.1016/0016-5085(95)90064-0; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P8392, DOI 10.1093/nar/17.20.8392; RUST S, 1993, NUCLEIC ACIDS RES, V21, P3623, DOI 10.1093/nar/21.16.3623; SATO Y, 1990, AM J PATHOL, V136, P267; SEYAMA T, 1992, NUCLEIC ACIDS RES, V20, P2493, DOI 10.1093/nar/20.10.2493; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMITH AJ, 1994, CANCER RES, V54, P5527; TADA M, 1993, CANCER RES, V53, P2472; TORIBARA NW, 1995, NEW ENGL J MED, V332, P861, DOI 10.1056/NEJM199503303321306; TRUMPER LH, 1994, BRIT J CANCER, V70, P278, DOI 10.1038/bjc.1994.292; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; WINNDEEN E, 1993, AM J HUM GENET, V53, P1512; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757; WU S, 1994, EARLY DETECTION CANC, P237; Zhu D, 1997, CANCER RES, V57, P2485	80	137	161	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					27	38		10.1038/sj.onc.1202291	http://dx.doi.org/10.1038/sj.onc.1202291			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926917				2022-12-25	WOS:000078166000004
J	Korpelainen, EI; Karkkainen, M; Gunji, Y; Vikkula, M; Alitalo, K				Korpelainen, EI; Karkkainen, M; Gunji, Y; Vikkula, M; Alitalo, K			Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response	ONCOGENE			English	Article						STAT; VEGF; VEGF receptors; Tek; Tie; p21; signal transduction	EPIDERMAL GROWTH-FACTOR; CELL-GROWTH; CYTOKINE RECEPTORS; GENE-EXPRESSION; PLC-GAMMA; VEGF-C; TRANSCRIPTION; PROTEIN; BMX; PHOSPHORYLATION	Endothelial receptor tyrosine kinases (RTKs) and their signaling mechanisms are of interest because they may control tumor angiogenesis and thereby tumor growth, In this report we have examined activation of the signal transducers and activators of transcription (STATs) by the three known vascular endothelial growth factor receptors (VEGFR1-3), as well as by the endothelial Tie-1 and -2 receptors, We also studied signaling by the R849W mutant of Tie-2 (MTie-2), which has been shown to cause venous malformations. When overexpressed in 293T cells, MTie-2 activated STAT1 while the other endothelial RTKs failed to do so, In contrast, the three VEGFRs were strong activators of STAT3 and STAT5, suggesting that they activate only a specific subset of these signal transducers. STAT3 and STAT5 were also activated by Tie-2 and, more so, by MTie-2, Tyrosine phosphorylation and DNA binding of STAXs correlated with their ability to activate transcription as judged by luciferase assays. When co-expressed with STAT5, VEGFR-1 as well as both the Tie-2 receptor forms increased expression of the cell cycle inhibitor p21, Interestingly, co-expression of the Tie-2 receptors with STAT1 resulted in appearance of a novel, p21 related transcript. Taken together, these findings identify STAT proteins as novel targets for signal transduction by the endothelial RTKs, suggesting that they may be involved in the regulation of endothelial function.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Catholic Univ Louvain, Lab Human Mol Genet, Brussels, Belgium; Christian Duve Inst, Brussels, Belgium	University of Helsinki; Universite Catholique Louvain	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014; Vikkula, Miikka/Q-1038-2018	Alitalo, Kari K/0000-0002-7331-0902; Vikkula, Miikka/0000-0002-6236-338X; Korpelainen, Eija/0000-0002-4406-5602				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HUANG LW, 1995, ONCOGENE, V11, P2097; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Saharinen P, 1997, BLOOD, V90, P4341; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; ZIEGLER SF, 1993, ONCOGENE, V8, P663	63	100	110	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					1	8		10.1038/sj.onc.1202288	http://dx.doi.org/10.1038/sj.onc.1202288			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926914				2022-12-25	WOS:000078166000001
J	Arai, M; Imai, H; Koumura, T; Yoshida, M; Emoto, K; Umeda, M; Chiba, N; Nakagawa, Y				Arai, M; Imai, H; Koumura, T; Yoshida, M; Emoto, K; Umeda, M; Chiba, N; Nakagawa, Y			Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; HEART-MITOCHONDRIA; KAPPA-B; ACTIVATION; STRESS; BCL-2	Phospholipid hydroperoxide glutathione peroxidase (PHGPx) is synthesized as a long form (L-form; 23 kDa) and a short form (S-form; 20 kDa). The L-form contains a leader sequence that is required for transport to mitochondria, whereas the S-form lacks the leader sequence. A construct encoding the leader sequence of PHGPx tagged with green fluorescent protein was used to transfect RBL-2H3 cells, and the fusion protein was transported to mitochondria. The L-form of PHGPx was identified as the mitochondrial form of PHGPx and the S-form as the non-mitochondrial form of PHGPx since preferential enrichment of mitochondria for PHGPx was detected in M15 cells that overexpressed the L-form of PHGPx, whereas no similar enrichment was detected in L9 cells that overexpressed the S-form. Cell death caused by mitochondrial injury due to potassium cyanide (KCN) or rotenone (chemical hypoxia) was considerably suppressed in the M15 cells, whereas the L9 cells and control RBL-2H3 cells (S1 cells, transfected with the vector alone) succumbed to the cytotoxic effects of KCN, Flow cytometric analysis showed that mitochondrial PHGPx suppressed the generation of hydroperoxide, the loss of mitochondrial membrane potential, and the loss of plasma membrane integrity that are induced by KCN. Mitochondrial PHGPx might prevent changes in mitochondrial functions and cell death by reducing intracellular hydroperoxides. Mitochondrial PHGPx failed to protect M15 cells from mitochondrial injury by carbonyl cyanide m-chlorophenylhydrazone, which directly reduces membrane potential without the generation of hydroperoxides. M15 cells were more resistant than L9 cells to cell death caused by direct damage to mitochondria and to extracellular oxidative stress. L9 cells were more resistant to tert-butylhydroperoxide than S1 cells, whereas resistance to t-butylhydroperoxide was even more pronounced in M15 cells than in L9 cells. These results suggest that mitochondria might be a target for intracellular and extracellular oxidative stress and that mitochondrial PHGPx, as distinct form non-mitochondrial PHGPx, might play a primary role in protecting cells from oxidative stress.	Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 108, Japan; Tokyo Metropolitan Inst Med Sci, Dept Inflamat Res, Bunkyo Ku, Tokyo 113, Japan; Japan Energy Corp, Toda, Saitama 335, Japan	Kitasato University; Tokyo Metropolitan Institute of Medical Science; Japan Energy Corporation	Nakagawa, Y (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 108, Japan.	nakagaway@pharm.kitasato-u.ac.jp	EMOTO, KAZUO/G-4992-2014					Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRIGELIUSFLOHE R, 1997, BIOCHEM J, V15, P199; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHU FF, 1994, CYTOGENET CELL GENET, V66, P96, DOI 10.1159/000133675; Crapo J D, 1978, Methods Enzymol, V53, P382; de Duve C, 1995, BIOCHEM J, V60, P604; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; EDWARD MM, 1996, J NEUROCHEM, V67, P1039; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GODEAS C, 1994, BBA-BIOMEMBRANES, V1191, P147, DOI 10.1016/0005-2736(94)90242-9; GUARNIERI C, 1992, FREE RADICALS AGING, P73; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; IMAI K, 1983, ANAL BIOCHEM, V128, P471, DOI 10.1016/0003-2697(83)90404-9; Imanaka T, 1996, J BIOL CHEM, V271, P3706; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LAWRENCE JJ, 1976, BIOCHEMISTRY-US, V15, P3301, DOI 10.1021/bi00660a021; LESTIENNE P, 1994, BIOMED PHARMACOTHER, V48, P199, DOI 10.1016/0753-3322(94)90134-1; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McGuire SO, 1997, LIPIDS, V32, P219, DOI 10.1007/s11745-997-0028-x; MYERS KM, 1995, J NEUROCHEM, V65, P2432; NADERI S, 1990, ANAL BIOCHEM, V190, P304, DOI 10.1016/0003-2697(90)90198-I; NOHL H, 1987, FEBS LETT, V214, P269, DOI 10.1016/0014-5793(87)80068-6; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Piette J, 1997, BIOL CHEM, V378, P1237; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; RODERICK AC, 1995, METHOD ENZYMOL, V260, P117; SCHONHEIT K, 1995, BBA-MOL BASIS DIS, V1271, P335, DOI 10.1016/0925-4439(95)00052-6; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMAS JP, 1990, J BIOL CHEM, V265, P454; TRITSCHLER HJ, 1994, BIOCHEM MOL BIOL INT, V34, P169; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	53	235	248	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4924	4933		10.1074/jbc.274.8.4924	http://dx.doi.org/10.1074/jbc.274.8.4924			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988735	hybrid			2022-12-25	WOS:000078698200060
J	Faure, V; Hecquet, C; Courtois, Y; Goureau, O				Faure, V; Hecquet, C; Courtois, Y; Goureau, O			Role of interferon regulatory factor-1 and mitogen-activated protein kinase pathways in the induction of nitric oxide synthase-2 in retinal pigmented epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; GLIAL-CELLS; EXPRESSION; GAMMA; IRF-1; GENE; PROLIFERATION; MACROPHAGES; CYTOKINES; ENDOTOXIN	Bovine retinal pigmented epithelial cells express an inducible nitric oxide synthase (NOS-2) after activation with interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS). Experiments were performed to investigate the involvement of interferon regulatory factor-1 (IRF-1) on NOS-2 induction and its regulation by NOS-2 inhibitors such as pyrrolidine dithiocarbamate (PDTC), an antioxidant, or protein kinase inhibitors. Analysis by transitory transfections showed that LPS, alone or with IFN-gamma, stimulated activity of the murine NOS-2 promoter fragment linked upstream of luciferase and its suppression by PDTC and by the different protein kinase inhibitors, genistein (tyrosine kinase inhibitor), PD98059 (mitogen-actived protein (MAP) kinase kinase inhibitor), and SE 203580 (p38 MAP inhibitor). Using specific antibodies, we have confirmed that extracellular signal-regulated kinases and p38 MAP kinase were activated by LPS and IFN-gamma in retinal pigmented epithelial cells. Analysis by reverse transcriptase-polymerase chain reaction, Western blot, and electrophoretic mobility shift assay demonstrated that IFN-gamma alone or combined with LPS induced an accumulation of IRF-1 mRNA and protein and IRF-1 DNA binding. Transfections assays with the IRF-1 promoter showed an induction of this promoter with IFN-gamma, potentiated by LPS. The decrease of LPS/IFN-gamma-induced IRF-1 promoter activity, IRF-1 synthesis, and IRF-1 activation, by PDTC, genistein, PD98059, and SE 203580, could explained in part the inhibition of the NOS-2 induction by these compounds. Our results demonstrate that IRF-1 is necessary for NOS-2 induction by LPS and IFN-gamma and that its synthesis requires the involvement of a redox-sensitive step, the activation of tyrosine kinases, and extracellular signal-regulated kinases 1/2 and p38 MAP kinases.	INSERM, U450, Dev Vieillissement & Pathol Reinte, F-75016 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Goureau, O (corresponding author), INSERM, U450, Dev Vieillissement & Pathol Reinte, 29 Rue Wilhelm, F-75016 Paris, France.	ogoureau@infobiogen.fr	GOUREAU, Olivier/F-2752-2017; GOUREAU, Olivier/ABH-9547-2020	GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU, Olivier/0000-0001-7730-9143				BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157; Bhat NR, 1998, J NEUROSCI, V18, P1633; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Faure V, 1997, J BIOL CHEM, V272, P32169, DOI 10.1074/jbc.272.51.32169; Faure V, 1998, AM J PHYSIOL-CELL PH, V275, pC208, DOI 10.1152/ajpcell.1998.275.1.C208; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Fujimura M, 1997, BRAIN RES, V759, P247, DOI 10.1016/S0006-8993(97)00264-3; GOUREAU O, 1995, J IMMUNOL, V154, P6518; GOUREAU O, 1994, BIOCHEM BIOPH RES CO, V198, P120, DOI 10.1006/bbrc.1994.1017; Goureau O, 1995, DEGENERATIVE DISEASES OF THE RETINA, P61; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GOUREAU O, 1994, J NEUROCHEM, V63, P310; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hecker M, 1996, BRIT J PHARMACOL, V118, P2178, DOI 10.1111/j.1476-5381.1996.tb15660.x; HICKS D, 1990, EXP EYE RES, V51, P119, DOI 10.1016/0014-4835(90)90063-Z; Hinton DR, 1998, EXP CELL RES, V239, P11, DOI 10.1006/excr.1997.3873; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kleinert H, 1998, BRIT J PHARMACOL, V123, P1716, DOI 10.1038/sj.bjp.0701782; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LIVERSIDGE J, 1994, IMMUNOLOGY, V83, P404; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Murphy WJ, 1996, J ENDOTOXIN RES, V3, P381, DOI 10.1177/096805199600300502; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; SPARROW JR, 1994, EXP EYE RES, V59, P129, DOI 10.1006/exer.1994.1091; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; XIE QW, 1994, J BIOL CHEM, V269, P4705	39	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4794	4800		10.1074/jbc.274.8.4794	http://dx.doi.org/10.1074/jbc.274.8.4794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988718	hybrid			2022-12-25	WOS:000078698200043
J	Lakkakorpi, PT; Nakamura, I; Nagy, RM; Parsons, JT; Rodan, GA; Duong, LT				Lakkakorpi, PT; Nakamura, I; Nagy, RM; Parsons, JT; Rodan, GA; Duong, LT			Stable association of PYK2 and p(130)Cas in their co-localization in the sealing zone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; MEDIATED CELL-ADHESION; EXPRESS HIGH-LEVELS; BONE-RESORPTION; VITRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; BETA-3 INTEGRIN; V-SRC; P130(CAS)	Bone resorption is initiated by osteoclast attachment to the mineralized matrix, cytoskeletal reorganization, cellular polarization, and the formation of the sealing zone. The present study examines the interaction between PYK2 and p130(Cas) ((C) under bar rk-(a) under bar ssociated (s) under bar ubstrate), suggested to be part of the signaling pathway initiated by osteoclast adhesion. Using murine osteoclast-like cells (OCLs) and their mononuclear precursors (pOCs), generated in a co-culture of bone marrow and osteoblastic MB1.8 cells, we show that: 1) p130(Cas) is tyrosine-phosphorylated upon adhesion of pOCs to vitronectin or ligation of beta(3) integrins; 2) p130(Cas) colocalizes with PYK2 and the cytoskeletal proteins F-actin, vinculin, and paxillin in the podosomal-rich ring-like structures of OCLs plated on glass and in the sealing zone in actively resorbing OCLs on bone; 3) p130(Cas) and PYK2 form a stable complex in pOCs, independent of tyrosine phosphorylation of either molecule, and this complex is present in Src (-/-) OCLs, in which neither protein is phosphorylated or associated with the osteoclast adhesion structure; 4) the association of p130(Cas) and PYK2 is mediated by the SH3 domain of p130(Cas) and the C-terminal domain of PYK2. These findings suggest that p130(Cas) and its association with PYK2 may play an important role in the adhesion-dependent signaling that leads to cytoskeletal reorganization and formation of the sealing zone during osteoclast activation.	Merck Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA; Univ Turku, Inst Biomed, Dept Anat, FIN-20014 Turku, Finland; Univ Turku, Med Res Labs, FIN-20014 Turku, Finland; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	Merck & Company; University of Turku; University of Turku; University of Virginia; University of Virginia	Duong, LT (corresponding author), Merck Res Labs, Dept Bone Biol & Osteoporosis Res, WP26A-1000, West Point, PA 19486 USA.	le_duong@merck.com						Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; Helfrich MH, 1996, BONE, V19, P317, DOI 10.1016/S8756-3282(96)00223-2; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1996, CELL TISSUE RES, V286, P507, DOI 10.1007/s004410050720; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Raja S, 1997, J BIOL CHEM, V272, P10941; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	45	95	97	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4900	4907		10.1074/jbc.274.8.4900	http://dx.doi.org/10.1074/jbc.274.8.4900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988732	hybrid			2022-12-25	WOS:000078698200057
J	Zhao, WC; Schorey, JS; Groger, R; Allen, PM; Brown, EJ; Ratliff, TL				Zhao, WC; Schorey, JS; Groger, R; Allen, PM; Brown, EJ; Ratliff, TL			Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; BLADDER-TUMOR CELLS; BOVIS BCG; INTERNALIZATION; TUBERCULOSIS; ANTIGEN; LEPRAE	Studies were performed to define the fibronectin binding motif of the previously identified Mycobacterium avium fibronectin attachment protein (FAP-A). Using synthetic peptides of a previously identified fibronectin binding region (amino acids 269-292), the minimal binding sequence was determined to be 12 amino acids, 269-280 (FAP-A-(269-280)), Synthetic peptides were prepared in which each amino acid in the 269-280 sequence was substituted with Ala, Assessment of the effect of Ala substitution on fibronectin binding showed that the presence of Ala at amino acids 273-276 (RWFV) completely abrogated fibronectin binding activity. Furthermore, the ability to inhibit the attachment of viable Mycobacterium bovis BCG to fibronectin was abrogated by Ala substitution at the RWFV sites. To validate the function of RWFV, further studies were performed with recombinant FAP-A in which single Ala mutations were generated for the RWFV sites and as controls at amino acids 269 and 280. Mutant FAP-A containing single Ala substitutions at the RWFV sites (amino acids 273, 274, 275, or 276) showed significant abrogation of fibronectin binding function. Recombinant FAP-A with Ala substitutions at either 269 or 280 showed wild type activity. When the four essential amino acids (RWFV) were either substituted en bloc with Ala or were all deleted, complete loss of fibronectin binding function was observed. Control recombinant proteins with en bloc Ala substitutions or deletions at four positions outside the fibronectin binding region (amino acids 255-257) retained functional activity. These data show that the RWFV sequence is necessary for fibronectin binding function of FAP-A, Furthermore, the data suggest that mycobacterial FAP proteins, all of which share the RWFV binding motif, constitute a family of highly homologous proteins that bind fibronectin in a unique manner.	Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of Iowa; Washington University (WUSTL); Washington University (WUSTL)	Ratliff, TL (corresponding author), Univ Iowa, Dept Urol, 200 Hawkins Dr,3 RCP, Iowa City, IA 52242 USA.	tim-ratliff@uiowa.edu			NATIONAL CANCER INSTITUTE [R55CA044426, R01CA044426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033348] Funding Source: NIH RePORTER; NCI NIH HHS [CA44426] Funding Source: Medline; NIAID NIH HHS [AI33348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; BECICH MJ, 1991, J UROLOGY, V145, P1316, DOI 10.1016/S0022-5347(17)38622-6; GOLDSTEIN DS, 1993, J ENDOUROL, V7, P237, DOI 10.1089/end.1993.7.237; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; KAVOUSSI LR, 1989, J UROLOGY, V142, P875, DOI 10.1016/S0022-5347(17)38934-6; KURODA K, 1993, J CLIN INVEST, V91, P69, DOI 10.1172/JCI116202; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; Naito M, 1998, J BIOL CHEM, V273, P2905, DOI 10.1074/jbc.273.5.2905; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; RATLIFF TL, 1987, CANCER RES, V47, P1762; RATLIFF TL, 1988, J GEN MICROBIOL, V134, P1307; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOREY JS, 1995, INFECT IMMUN, V63, P2652, DOI 10.1128/IAI.63.7.2652-2657.1995; Schorey JS, 1996, MOL MICROBIOL, V21, P321, DOI 10.1046/j.1365-2958.1996.6381353.x; THOLE JER, 1992, MOL MICROBIOL, V6, P153, DOI 10.1111/j.1365-2958.1992.tb01996.x; WIKER HG, 1990, AM REV RESPIR DIS, V141, P830, DOI 10.1164/ajrccm/141.4_Pt_1.830	17	49	50	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4521	4526		10.1074/jbc.274.8.4521	http://dx.doi.org/10.1074/jbc.274.8.4521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988684	hybrid			2022-12-25	WOS:000078698200009
J	Attaphitaya, S; Park, K; Melvin, JE				Attaphitaya, S; Park, K; Melvin, JE			Molecular cloning and functional expression of a rat Na+/H+ exchanger (NHE5) highly expressed in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA/H EXCHANGER; INTRACELLULAR PH; MAMMALIAN-CELLS; ANTIPORTER; GROWTH; ISOFORMS; SEQUENCE; PROTEIN	We report here the cloning, primary structure, heterologous expression, tissue distribution, and localization of a cDNA encoding rat NHE5, a fifth member of the mammalian plasma membrane Na+/H+ exchanger (NHE) gene family. The full-length open reading frame as well as 34 nucleotides of 5'-untranslated and 1443 nucleotides of 3'-untranslated sequences were obtained using a polymerase chain reaction strategy involving reverse transcription-polymerase chain reaction and 5'/3'-rapid amplification of cDNA ends. The NHE5 cDNA encodes a protein of 898 amino acids with a calculated M-r of 99,044 and is predicted to contain 11-13 transmembrane domains. An amino acid comparison of the coding region of rat NHE5 reveals 95% identity with human NHE5. Northern hybridization analysis showed that high level expression of NHE5 mRNA is restricted to brain. Transfection of the coding region of rat NHE5 into NHE-deficient PS120 cells resulted in Na+/H+ exchange activity that was relatively insensitive to the amiloride analogue, 5-(N-ethyl-N-isopropyl) amiloride, with a half-maximal inhibitory concentration (IC50) of 1.53 +/- 0.25 mu M. In situ hybridization of rat brain sections revealed significant NHE5 mRNA levels in the dentate gyrus with lower levels observed in the hippocampus and cerebral cortex. These results suggest a specialized role for this fifth NHE isoform in neuronal tissues.	Univ Rochester, Sch Med & Dent, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurobiol & Anat, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Melvin, JE (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Oral Biol, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.	james_melvin@nrmc.rochester.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE00159, DE08921] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; BASSNETT S, 1990, AM J PHYSIOL, V258, pC171, DOI 10.1152/ajpcell.1990.258.1.C171; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V272, pC90, DOI 10.1152/ajpcell.1997.272.1.C90; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin CW, 1996, BRAIN RES, V731, P108, DOI 10.1016/S0006-8993(96)00512-4; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SAUVAIGO S, 1984, BRAIN RES, V301, P371, DOI 10.1016/0006-8993(84)91106-5; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; TOLKOVSKY AM, 1987, NEUROSCIENCE, V22, P1093, DOI 10.1016/0306-4522(87)92984-8; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG Z, 1993, J BIOL CHEM, V268, P11925; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHANG GH, 1992, J MEMBRANE BIOL, V129, P311	28	111	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4383	4388		10.1074/jbc.274.7.4383	http://dx.doi.org/10.1074/jbc.274.7.4383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933642	hybrid			2022-12-25	WOS:000078575500066
J	Hall, KU; Collins, SP; Gamm, DM; Massa, E; DePaoli-Roach, AA; Uhler, MD				Hall, KU; Collins, SP; Gamm, DM; Massa, E; DePaoli-Roach, AA; Uhler, MD			Phosphorylation-dependent inhibition of protein phosphatase-1 by G-substrate - A Purkinje cell substrate of the cyclic GMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; 3'-5'-MONOPHOSPHATE-REGULATED NEURONAL PHOSPHOPROTEIN; CAMP-REGULATED PHOSPHOPROTEIN; SYNTHETIC PEPTIDE ANALOGS; CATALYTIC SUBUNIT; MAMMALIAN BRAIN; 2 ISOFORMS; DIFFERENTIAL EXPRESSION; GLYCOGEN-METABOLISM; MESSENGER-RNA	G-substrate, a specific substrate of the cGMP-dependent protein kinase, has previously been localized to the Purkinje cells of the cerebellum. We report here the isolation from mouse brain of a cDNA encoding G-substrate. This cDNA was used to localize G-substrate mRNA expression, as well as to produce recombinant protein for the characterization of G-substrate phosphatase inhibitory activity. Brain and eye were the only tissues in which a G-substrate transcript was detected. Within the brain, G-substrate transcripts were restricted almost entirely to the Purkinje cells of the cerebellum, although transcripts were also detected at low levels in the paraventricular region of the hypothalamus and the pons/medulla, Like the native protein, the recombinant protein was preferentially phosphorylated by cGMP-dependent protein kinase (K-m = 0.2 mu M) over cAMP-dependent protein kinase (K-m = 2.0 mu M). Phospho-G-substrate inhibited the catalytic subunit of native protein phosphatase-1 with an IC50 of 131 +/- 27 nM. Dephospho-G-substrate was not found to be inhibitory. Both dephospho and phospho-G-substrate were weak inhibitors of native protein phosphatase-2A(1), which dephosphorylated G-substrate 20 times faster than the catalytic subunit of protein phosphatase-1. G-substrate potentiated the action of cAMP-dependent protein kinase on a cAMP-regulated luciferase reporter construct, consistent with an inhibition of cellular phosphatases in vivo. These results provide the first demonstration that G-substrate inhibits protein phosphatase-1 and suggest a novel mechanism by which cGMP-dependent protein kinase I can regulate the activity of the type 1 protein phosphatases.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Neurosci Program, Ann Arbor, MI 48109 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis	Uhler, MD (corresponding author), Univ Michigan, Mental Hlth Res Inst, Neurosci Lab Bldg,1103 E Huron St, Ann Arbor, MI 48109 USA.	muhler@umich.edu			NIDDK NIH HHS [DK36569] Funding Source: Medline; NIGMS NIH HHS [GM50791] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050791] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; AITKEN A, 1981, J BIOL CHEM, V256, P3501; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASWAD DW, 1981, J BIOL CHEM, V256, P3494; ASWAD DW, 1981, J BIOL CHEM, V256, P3487; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1977, FEBS LETT, V76, P182, DOI 10.1016/0014-5793(77)80147-6; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; DETRE JA, 1984, J NEUROSCI, V4, P2843; Eadie GS, 1942, J BIOL CHEM, V146, P85; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Ferrendelli J A, 1978, Adv Cyclic Nucleotide Res, V9, P453; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; FOULKES JG, 1983, J BIOL CHEM, V258, P431; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1990, PEPTIDES PROTEIN PHO; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4486; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; KING MM, 1984, J BIOL CHEM, V259, P8080; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; NIMMO GA, 1978, EUR J BIOCHEM, V87, P353, DOI 10.1111/j.1432-1033.1978.tb12384.x; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; SAITOH Y, 1989, BRAIN RES, V489, P291, DOI 10.1016/0006-8993(89)90862-7; SCHLICHTER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P5537, DOI 10.1073/pnas.77.9.5537; SCHLICHTER DJ, 1978, NATURE, V273, P61, DOI 10.1038/273061a0; SEASHOLTZ AF, 1995, P NATL ACAD SCI USA, V92, P1734, DOI 10.1073/pnas.92.5.1734; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TAKAISHI T, 1991, BIOCHEM BIOPH RES CO, V174, P393, DOI 10.1016/0006-291X(91)90533-D; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Wang X, 1997, J NEUROCHEM, V68, P443; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890	54	62	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3485	3495		10.1074/jbc.274.6.3485	http://dx.doi.org/10.1074/jbc.274.6.3485			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920894	hybrid			2022-12-25	WOS:000078428200034
J	Giese, H; Dolle, MET; Hezel, A; van Steeg, H; Vijg, J				Giese, H; Dolle, MET; Hezel, A; van Steeg, H; Vijg, J			Accelerated accumulation of somatic mutations in mice deficient in the nucleotide excision repair gene XPA	ONCOGENE			English	Article						nucleotide excision repair; XPA; mutation accumulation; lacZ reporter gene; ageing	ULTRAVIOLET-B; LACKING; TUMORS; LIVER	Inheritable mutations in nucleotide excision repair (NER) genes cause cancer-prone human disorders, such as xeroderma pigmentosum, which are also characterized by symptoms of accelerated ageing. To study the impact of NER deficiency on mutation accumulation iN vivo, mutant frequencies have been determined in liver and brain of 2-16 month old NER deficient XPA(-/-), lacZ hybrid mice. While mutant frequencies in liver of 2-month old XPA(-/-), lacZ mice were comparable to XPA (+/-), lacZ and the lacZ parental strain animals, by 4 months of age mutant frequencies in the XPA-deficient mice were significantly increased by a factor of two and increased further until the age of 16 months. In brain, mutant frequencies were not found to increase with age, These results show that a deficiency in the NER gene XPA causes an accelerated accumulation of somatic mutations in Liver but not in brain. This is in keeping with a higher incidence of spontaneous liver tumors reported earlier for XPA(-/-) mice after about 15 months of age.	Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Natl Inst Publ Hlth & Environm, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Netherlands National Institute for Public Health & the Environment	Vijg, J (corresponding author), Beth Israel Deaconess Med Ctr, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE ON AGING [P30AG013314] Funding Source: NIH RePORTER; NIA NIH HHS [P01 1801 AG10829-01, 1 P30 AG13314-01] Funding Source: Medline; NIEHS NIH HHS [1 RO1 ES/CA 08797-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bootsma D., 1998, GENETIC BASIS HUMAN, P245; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; de Vries A, 1997, CARCINOGENESIS, V18, P2327, DOI 10.1093/carcin/18.12.2327; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; deVries A, 1997, MOL CARCINOGEN, V19, P46, DOI 10.1002/(SICI)1098-2744(199705)19:1<46::AID-MC7>3.3.CO;2-O; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HART RW, 1979, MECH AGEING DEV, V9, P203, DOI 10.1016/0047-6374(79)90100-3; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; STREHLER BL, 1980, MECH AGEING DEV, V14, P15, DOI 10.1016/0047-6374(80)90103-7; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X	13	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1257	1260		10.1038/sj.onc.1202404	http://dx.doi.org/10.1038/sj.onc.1202404			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022133				2022-12-25	WOS:000078510700016
J	Kil, SJ; Hobert, M; Carlin, C				Kil, SJ; Hobert, M; Carlin, C			A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED PIT ADAPTINS; POSTENDOCYTIC TRAFFICKING; INDUCED INTERNALIZATION; ENHANCED DEGRADATION; PROTEIN-DEGRADATION; MEMBRANE-TRANSPORT; ENDOCYTIC PATHWAY; EGF RECEPTORS; CELLS; MOTIF	Ligand binding causes the epidermal growth factor (EGF) receptor to undergo accelerated internalization with eventual degradation in lysosomes. The goal of this study was to investigate the molecular basis of endocytic sorting, focussing on post-internalization events. We have identified a sequence located between amino acid residues 675 and 697, encompassing a dileucine motif at residues 679 and 680, that enhances endosome-to-lysosome transport when conformational restraints in the EGF receptor carboxyl terminus are removed by truncation. The same dileucine motif is also necessary for efficient lysosomal transport of ligand-occupied full-length EGF receptors, A L679A,L680A substitution diminished the degradation of occupied full-length EGF receptors without affecting internalization but had a significant effect on recycling. Rapid recycling of mutant receptors resulted in reduced intracellular retention of occupied EGF receptors and delayed down-regulation of cell surface receptors, We propose that the L679A,L680A substitution acts primarily to impair transport of ligand-receptor complexes through an early endosomal compartment, diverting occupied receptors to a recycling compartment at the expense of incorporation into lysosome transport vesicles. We also found that mutant receptors with truncations at the distal half of tyrosine kinase domain (residues 809-957) were not efficiently delivered to the cell surface but were destroyed in an endoplasmic reticulum-associated degradative pathway.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Carlin, C (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 1900 Euclid Ave, Cleveland, OH 44106 USA.	cxc39@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA049540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045669] Funding Source: NIH RePORTER; NCI NIH HHS [CA49540] Funding Source: Medline; NHLBI NIH HHS [T 32-HL07717] Funding Source: Medline; NIDDK NIH HHS [DK45669] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HOFFMAN P, 1994, MOL CELL BIOL, V14, P3695, DOI 10.1128/MCB.14.6.3695; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; MATSUI H, 1991, CANCER RES, V22, P6170; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083	52	63	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3141	3150		10.1074/jbc.274.5.3141	http://dx.doi.org/10.1074/jbc.274.5.3141			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915853	hybrid			2022-12-25	WOS:000078319500071
J	Smith, JA; Poteet-Smith, CE; Malarkey, K; Sturgill, TW				Smith, JA; Poteet-Smith, CE; Malarkey, K; Sturgill, TW			Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; IN-VIVO; C-FOS; PHOSPHORYLATION; DOMAIN; CELLS; CASCADE; INSULIN; PATHWAY	Glutathione S-transferase (GST)-fusion proteins containing the carboxyl-terminal tails of three p90 ribosomal S6 kinase (RSK) isozymes (RSK1, RSK2, and RSK3) interacted with extracellular signal-regulated kinase (ERK) but not c-Jun-NH2-kinase (JNK) or p38 mitogen-activated protein kinase (MAPK). Within the carboxyl-terminal residues of the RSK isozymes is a region of high conservation corresponding to residues (722)LAQRRVRKLPSTTL(735) in RSK1, Truncation of the carboxyl-terminal 9 residues, (VRKLPSTTL735)-V-727, completely eliminated the interaction of the GST-RSK1 fusion protein with purified recombinant ERK2, whereas the truncation of residues (PSTTL735)-P-731 had no effect on the interaction with purified ERK2. ERK1 and ERK2 co-immunoprecipitated with hemagglutinin-tagged wild type RSK2 (HA-RSK2) in BHK cell cytosol, However, ERK did not coimmunoprecipitate with HA-RSK2((1-729)), a mutant missing the carboxyl-terminal 11 amino acids, similar to the minimal truncation that eliminated in vitro interaction of ERK with the GST-RSK1 fusion protein. Kinase activity of HA-RSK2 increased B-fold in response to insulin. HA-RSK2((1-729)) had similar basal kinase activity to that of HA-RSK2 but was not affected by insulin treatment. Immunoprecipitated HA-RSK2 and HA-RSK2((1-729)) could be activated to the same extent in vitro by active ERK2, demonstrating that HA-RSK2((1-729)) was properly folded. These data suggest that the conserved region of the RSK isozymes ((722)LAQRRVRKL(730) Of RSK1) provides for a specific ERK docking site approximately 150 amino acids carboxyl-terminal to the nearest identified ERK phosphorylation site (Thr(573)). Complex formation between RSK and ERK is essential for the activation of RSK by ERK in vivo, Comparison of the docking site of RSK with the carboxyl-terminal tails of other MAPK-activated kinases reveals putative docking sites within each of these MAPK-targeted kinases, The number and placement of lysine and arginine residues within the conserved region correlate with specificity for activation by ERK and p38 MAPKs in vivo.	Univ Virginia, Ctr Hlth Sci, Howard Hughes Med Inst, Charlottesville, VA 22908 USA; Univ Virginia, Markey Ctr Cell Signaling, Dept Med & Pharmacol, Charlottesville, VA 22908 USA	Howard Hughes Medical Institute; University of Virginia; University of Virginia	Sturgill, TW (corresponding author), Univ Virginia, Ctr Hlth Sci, Howard Hughes Med Inst, Box 577, Charlottesville, VA 22908 USA.				NIDDK NIH HHS [DK41077] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; DAI TN, 1995, ONCOGENE, V10, P849; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Pende M, 1997, J NEUROSCI, V17, P1291; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	35	235	239	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2893	2898		10.1074/jbc.274.5.2893	http://dx.doi.org/10.1074/jbc.274.5.2893			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915826	hybrid			2022-12-25	WOS:000078319500044
J	Wunder, JS; Eppert, K; Burrow, SR; Gogkoz, N; Bell, RS; Andrulis, IL				Wunder, JS; Eppert, K; Burrow, SR; Gogkoz, N; Bell, RS; Andrulis, IL			Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas	ONCOGENE			English	Article						gene amplification; CDK4; SAS; osteosarcoma	SOFT-TISSUE SARCOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-MALIGNANT GLIOMAS; METASTASIS SUPPRESSOR GENE; CELL-CYCLE ARREST; RING CHROMOSOMES; RETINOBLASTOMA PROTEIN; QUANTITATIVE-ANALYSIS; MAMMALIAN-CELLS; DNA-SEQUENCES	Amplification of genes in the 12q13-15 region occurs frequently in several malignancies including osteosarcoma. The products of these amplified genes are thought to provide cancer cells with a selective growth advantage; however, the specific gene(s) driving this amplicon is unknown. We have previously shown that the SAS gene is amplified in most parosteal osteosarcomas. In this study we analysed additional putative growth regulatory genes in this chromosomal region in 24 primary osteosarcoma specimens. CDK4 and SAS were coamplified in 6/6 parosteal tumors, and MDM2 was also amplified in 4/5 parosteal cases, In comparison, amplification occurred in only 2/16 classical intramedullary osteosarcomas and involved the SAS gene. Each amplified gene had a correspondingly elevated mRNA level. Four high grade intramedullary tumors had elevated mRNA expression of SAS, but did not exhibit gene amplification, Gene amplification/overexpression was not associated with metastatic disease and did not change markedly with tumor progression, as evidenced by analysis of sequential tumor specimens from eight patients. Three other genes in the 12q13-15 region (CDK2, WNT1 and WNT10b) were not amplified in any of the tumors. The different patterns of gene amplification and overexpression of CDK4, SAS and MDM2 in parosteal and intramedullary osteosarcomas may help explain the disparity in the biological behaviour of these two types of osteosarcoma.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Univ Musculoskeletal Oncol Unit, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Andrulis, IL (corresponding author), Univ Toronto, Dept Surg, Toronto, ON, Canada.		Andrulis, Irene L./E-7267-2013	Eppert, Kolja/0000-0001-9061-8856				Adachi M, 1996, CANCER RES, V56, P1751; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ARHEDEN K, 1988, CYTOGENET CELL GENET, V47, P86, DOI 10.1159/000132513; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Guo XZ, 1996, CANCER RES, V56, P4876; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; LADANYI M, 1993, CANCER RES, V53, P16; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LEACH FS, 1993, CANCER RES, V53, P2231; Lee PD, 1996, BRIT J CANCER, V74, P1046, DOI 10.1038/bjc.1996.487; LI Y, 1994, ONCOGENE, V9, P2261; Lonardo F, 1997, CANCER, V79, P1541, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mousses S, 1996, MODERN PATHOL, V9, P1; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; NobleTopham SE, 1996, J ORTHOPAED RES, V14, P700, DOI 10.1002/jor.1100140504; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORNDAL C, 1992, CANCER GENET CYTOGEN, V60, P170, DOI 10.1016/0165-4608(92)90011-V; RAYMOND AK, 1991, CLIN ORTHOP RELAT R, P140; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Sambrook J., 2002, MOL CLONING LAB MANU; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH SH, 1992, CANCER RES, V52, P3746; Souhami RL, 1997, LANCET, V350, P911, DOI 10.1016/S0140-6736(97)02307-6; SU YA, 1994, P NATL ACAD SCI USA, V91, P9121, DOI 10.1073/pnas.91.19.9121; SUIJKERBUIJK RF, 1994, GENE CHROMOSOME CANC, V9, P292, DOI 10.1002/gcc.2870090410; Szymanska J, 1996, GENE CHROMOSOME CANC, V16, P31; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; TARKKANEN M, 1995, CANCER RES, V55, P1334; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TSAI LH, 1993, ONCOGENE, V8, P1593; UNNI KK, 1976, CANCER, V37, P2466, DOI 10.1002/1097-0142(197605)37:5<2466::AID-CNCR2820370540>3.0.CO;2-G; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; Wolf M, 1997, GENE CHROMOSOME CANC, V18, P66, DOI 10.1002/(SICI)1098-2264(199701)18:1<66::AID-GCC8>3.0.CO;2-#; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	65	122	125	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					783	788		10.1038/sj.onc.1202346	http://dx.doi.org/10.1038/sj.onc.1202346			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989829				2022-12-25	WOS:000078394400024
J	Mary, MN; Venot, C; de Fromentel, CC; Debussche, L; Conseiller, E; Cochet, O; Gruel, N; Teillaud, JL; Schweighoffer, F; Tocque, B; Bracco, L				Mary, MN; Venot, C; de Fromentel, CC; Debussche, L; Conseiller, E; Cochet, O; Gruel, N; Teillaud, JL; Schweighoffer, F; Tocque, B; Bracco, L			A tumor specific single chain antibody dependent gene expression system	ONCOGENE			English	Article						gene expression; gene therapy; scFv; p53	PHAGE DISPLAY LIBRARY; INTRACELLULAR IMMUNIZATION; HIV-1 INFECTION; 2-HYBRID SYSTEM; FV-FRAGMENTS; EGF RECEPTOR; P53; CELLS; PROMOTERS; DOMAIN	The design of conditional gene expression systems restricted to given tissues or cellular types is an important issue of gene therapy. Systems based on the targeting of molecules characteristic of the pathological state of tissues would be of interest. We have developed a synthetic transcription factor by fusing a single chain antibody (scFv) directed against p53 with the bacterial tetracycline repressor as a DNA binding domain. This hybrid protein binds to p53 and can interact with a synthetic promoter containing tetracycline-operator sequences. Gene expression can now be specifically achieved in tumor cells harboring an endogenous mutant p53 but not in a wild-type p53 containing tumor cell line or in a non-transformed cell line, Thus, a functional transactivator centered on single chain antibodies can be expressed intracellularly and induce gene expression in a scFv-mediated specific manner. This novel class of transcriptional transactivators could be referred as 'trabodies' for transcription-activating-antibodies. The trabodies technology could be useful to any cell type in which a disease related protein could be the target of specific antibodies.	Rhone Poulenc Rorer SA, Gene Med Dept, F-94403 Vitry, France; INSERM, U255, Lab Biotechnol Anticorps, F-75005 Paris, France; INSERM, U255, Inst Curie, F-75005 Paris, France	Sanofi-Aventis; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bracco, L (corresponding author), ExonHit Therapeut SA, 65 Blvd Massena, F-75013 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; Teillaud, Jean-Luc/0000-0003-4442-9565				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BYK G, Patent No. 9625508; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; CHEN X, 1995, NAT STRUCT BIOL, V2, P2; COCHET O, 1998, IN PRESS CANC RES; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hu SZ, 1996, CANCER RES, V56, P3055; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Jannot CB, 1996, ONCOGENE, V13, P275; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Luo Y, 1997, BIOTECHNIQUES, V22, P350, DOI 10.2144/97222pf02; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; MORITZ D, 1995, GENE THER, V2, P539; Nilson BHK, 1996, GENE THER, V3, P280; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; Persic L, 1997, GENE, V187, P9, DOI 10.1016/S0378-1119(96)00628-2; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Pilkington GR, 1996, MOL IMMUNOL, V33, P439, DOI 10.1016/0161-5890(95)00153-0; REIHSAUS E, 1990, ONCOGENE, V5, P137; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; Schmidt M, 1996, INT J CANCER, V65, P538, DOI 10.1002/(SICI)1097-0215(19960208)65:4<538::AID-IJC24>3.0.CO;2-4; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120	36	5	7	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					559	564		10.1038/sj.onc.1202377	http://dx.doi.org/10.1038/sj.onc.1202377			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927213				2022-12-25	WOS:000078166500029
J	Zamanian-Daryoush, M; Der, SD; Williams, BRG				Zamanian-Daryoush, M; Der, SD; Williams, BRG			Cell cycle regulation of the double stranded RNA activated protein kinase, PKR	ONCOGENE			English	Article						interferon; PKR; cell cycle	NF-KAPPA-B; SENSITIVE HEMATOPOIETIC-CELLS; C-MYC SUPPRESSION; RETINOBLASTOMA PROTEIN; ALPHA-INTERFERON; MALIGNANT TRANSFORMATION; INTERLEUKIN-6 SUPPRESS; GROWTH SUPPRESSION; INDUCED APOPTOSIS; BINDING PROTEIN	The interferon (IFN)-induced, double stranded RNA (dsRNA)-activated serine/threonine kinase, PKR, is a potent negative regulator of cell growth when overexpressed in yeast or mammalian cells. To determine whether endogenous PKR plays a role in cell growth control, we have investigated the regulation of PKR levels and activity during the cell cycle in human glioblastoma T98G cells. The steady-state level of PKR mRNA in T98G cells was highest in growth arrested cells, dropped sharply within 3h of serum stimulation then gradually increased as cells progressed through G1, reaching a plateau in early S phase. PKR protein level increased following serum stimulation reaching a peak at the G2 + M boundary and declining thereafter, In contrast, PKR kinase activity exhibited two peaks, in early G1 and at the G1/S boundary, declining sharply in early S phase. Thus, the activity profile did not follow the protein profile indicating a tight regulation of PKR at the level of activity. In T98G cells expressing the catalytically inactive PKRK296R the dsRNA-induced activation of NF-kappa B and IRF-1 was suppressed and the mutant cells exhibited resistance to stress induced apoptosis, Cell cycle distribution analysis shared that the mutant expressing cells exhibited longer G1 phase and fewer cells engaged in S phase, Furthermore, early passage mouse embryo fibroblasts derived from PKR knockout mice grew more slowly compared with the control cells. Taken together these results suggest that PKR may play a role in cell cycle progression.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034039, R01AI034039] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34039] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BURKE LC, 1992, ONCOGENE, V7, P783; BYBEE A, 1992, BIOCHIM BIOPHYS ACTA, V1137, P73, DOI 10.1016/0167-4889(92)90102-H; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; IWASE S, 1997, J BIOL CHEM, V272, P12414; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KERR IM, 1977, NATURE, V268, P540, DOI 10.1038/268540a0; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MAYOL X, 1995, ONCOGENE, V11, P801; MCMILLAN NAG, 1996, CELL GROWTH REGULATI; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SAITO S, 1991, MICROBIOL IMMUNOL, V35, P1105, DOI 10.1111/j.1348-0421.1991.tb01632.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	65	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					315	326		10.1038/sj.onc.1202293	http://dx.doi.org/10.1038/sj.onc.1202293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927188				2022-12-25	WOS:000078166500004
J	Iwata, S; Sato, Y; Asada, M; Takagi, M; Tsujimoto, A; Inaba, T; Yamada, T; Sakamoto, S; Yata, J; Shimogori, T; Igarashi, K; Mizutani, S				Iwata, S; Sato, Y; Asada, M; Takagi, M; Tsujimoto, A; Inaba, T; Yamada, T; Sakamoto, S; Yata, J; Shimogori, T; Igarashi, K; Mizutani, S			Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation	ONCOGENE			English	Article						polyamine; anti-tumor activity; cancer	TISSUE-CULTURE CELLS; POLYAMINE TRANSPORT; GENE; EXPRESSION; PROTEIN; INHIBITION; APOPTOSIS; HETEROZYGOSITY; DEGRADATION; LEUKEMIAS	Cell proliferation and transformation induced by growth factor stimulation or by carcinogens, viruses, or oncogenes are characterized by an associated increase in polyamine levels, which is mediated by increased polyamine biosynthesis and enhanced uptake of polyamines, Polyamine biosynthesis is catalyzed particularly, in the level of ornithine decarboxylase (ODC), The elevation of cellular polyamine levels on the other hand accelerates the induction of ornithine decarboxylase antizyme (antizyme), which is involved not only in ODC-degradation, but in the negative regulation of polyamine transport. Taking advantage of these characteristics of antizyme, the potential of antizyme as a factor having anti-cell growth and anti-tumor activity was investigated. We show that antizyme can induce cell death associated with a rapid decline of intracellular polyamine contents. The possible anti-tumor activities of ectopically expressed antizyme were tested in p21H-ras (Val 12)-transformed NIH3T3 cells and several human malignant cell lines including a line with loss of p53 expression, and they were shown to be as sensitive as nontransformed NIH3T3 cells in vitro. The in vivo antitumor activity was also tested using nude mice inoculated with H-vas transformed NIH3T3 cells that had been transfected with inducible antizyme expression vector and the results showed that antizyme expression in vivo blocks tumor formation in these mice. These results suggest that ectopic antizyme expression is of possible therapeutic benefit in the treatment of cancer, which is mediated by ODC inactivation and intracellular polyamine depletion.	Natl Childrens Med Res Ctr, Dept Virol, Setagaya Ku, Tokyo 154, Japan; Jichi Med Sch, Dept Mol Biol, Minami Kawachi, Tochigi, Japan; Kyoto Inst Technol, Dept Polymer Sci & Engn, Kyoto 606, Japan; Tokyo Med & Dent Univ, Dept Pediat, Tokyo 113, Japan; Chiba Univ, Fac Pharmaceut Sci, Chiba, Japan	National Center for Child Health & Development - Japan; Jichi Medical University; Kyoto Institute of Technology; Tokyo Medical & Dental University (TMDU); Chiba University	Mizutani, S (corresponding author), Natl Childrens Med Res Ctr, Dept Virol, Setagaya Ku, 3-35-31 Taishido, Tokyo 154, Japan.		Takagi, Masatoshi/F-3713-2011; Shimogori, Tomomi/L-2893-2013	Takagi, Masatoshi/0000-0002-7580-9184; Shimogori, Tomomi/0000-0002-6931-5401; Igarashi, Kazuei/0000-0003-3751-3187				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; EVANS BD, 1982, BRIT J CANCER, V45, P466, DOI 10.1038/bjc.1982.75; FUKUCHI J, 1992, EUR J BIOCHEM, V209, P689, DOI 10.1111/j.1432-1033.1992.tb17337.x; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HADDOX MK, 1980, CANCER RES, V40, P604; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Ichimiya A., 1994, Surface Review and Letters, V1, P1, DOI 10.1142/S0218625X94000023; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kankare K, 1997, BIOCHEM J, V324, P807, DOI 10.1042/bj3240807; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDBLOM A, 1993, CANCER RES, V53, P4356; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MANDAHL N, 1989, GENE CHROMOSOME CANC, V1, P9, DOI 10.1002/gcc.2870010104; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Matsufuji S, 1996, GENOMICS, V38, P102, DOI 10.1006/geno.1996.0601; Matsufuji S, 1996, EMBO J, V15, P1360, DOI 10.1002/j.1460-2075.1996.tb00478.x; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; OCHI H, 1986, CANCER GENET CYTOGEN, V22, P295, DOI 10.1016/0165-4608(86)90022-1; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Parchment R E, 1991, In Vivo, V5, P493; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; SATO T, 1991, CANCER RES, V51, P5118; SCALABRINO G, 1982, ADV CANCER RES, V36, P1, DOI 10.1016/S0065-230X(08)60422-4; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TEWARI DS, 1994, BBA-PROTEIN STRUCT M, V1209, P293, DOI 10.1016/0167-4838(94)90199-6; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Yang D, 1997, J BIOL CHEM, V272, P3376, DOI 10.1074/jbc.272.6.3376	47	72	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					165	172		10.1038/sj.onc.1202275	http://dx.doi.org/10.1038/sj.onc.1202275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926931				2022-12-25	WOS:000078166000018
J	Aragay, AM; Quick, MW				Aragay, AM; Quick, MW			Functional regulation of G alpha(16) by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; HETEROTRIMERIC G-PROTEINS; COUPLED RECEPTOR KINASES; GTP-BINDING-PROTEIN; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; XENOPUS-OOCYTES; INOSITOL TRISPHOSPHATE; TRANSMEMBRANE SIGNALS; ACTIVATION	Recent evidence demonstrates that the a subunits of some heterotrimeric GTP-binding proteins (G proteins) are subject to modification by protein kinase C (PKC). For the family of G proteins that activate the phospholipase C/inositol trisphosphate/calcium/PKC pathway, such modification could result in G protein autoregulation. To examine the potential regulation of members of the G alpha(q) family by PKC phosphorylation, we expressed the thyrotropin-releasing hormone (TRH) receptor in combination with G alpha(q), G alpha(11), G alpha(14), G alpha(15), or G alpha(16) in Xenopus oocytes and examined the regulation of signaling by PKC activators and inhibitors, For G alpha(16) and G alpha(15), the two family members of hematopoietic lineage, PKC activators reduce both the magnitude and the time course of TRH-mediated responses; PKC inhibitors have the opposite effect. The PKC-mediated effects are evident in measurements of GTPase activity, suggesting that the regulation is occurring early in the signaling pathway. In vivo phosphorylation experiments demonstrate that G alpha(16) is a substrate for PHC modification. By comparison, G alpha(q) is not phosphorylated by PHC in vivo and oocytes expressing G alpha(q) are not functionally modulated by PKC. Repeated TRH stimulation of oocytes expressing G alpha(16) mimics the effects of PKC activators, and this functional regulation is correlated with an increase in G alpha(16) phosphorylation. A mutant G alpha(16) with four consensus PKC phosphorylation sites removed is not phosphorylated in vivo, and TRH responses mediated through the mutant are not regulated by PKC. These results demonstrate that signaling involving hematopoietic G proteins is subject to PKC-mediated autoregulation, at least in part, by phosphorylation of the G protein a subunit.	Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol, E-28049 Madrid, Spain	University of Alabama System; University of Alabama Birmingham; Autonomous University of Madrid	Quick, MW (corresponding author), Univ Alabama, Dept Neurobiol, CIRC 446,1719 6th Ave S, Birmingham, AL 35294 USA.	quick@nrc.uab.edu	Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bohm SK, 1997, BIOCHEM J, V322, P1; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COREY JL, 1994, J BIOL CHEM, V269, P14759; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DenisHenriot D, 1996, BIOCHEM BIOPH RES CO, V220, P443, DOI 10.1006/bbrc.1996.0392; Fenster CP, 1997, J NEUROSCI, V17, P5747; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; GIERSCHIK P, 1992, HDB EXPT PHARM, V102, P807; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HO BY, 1992, FEBS LETT, V301, P303, DOI 10.1016/0014-5793(92)80262-F; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KESSELRING F, 1994, BLOOD, V84, P4088, DOI 10.1182/blood.V84.12.4088.bloodjournal84124088; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOSAZA T, 1996, J BIOL CHEM, V271, P12562; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lippert E, 1997, FEBS LETT, V417, P292, DOI 10.1016/S0014-5793(97)01308-2; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MAPARA MY, 1995, BLOOD, V85, P1836, DOI 10.1182/blood.V85.7.1836.bloodjournal8571836; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; NEER EJ, 1994, PROTEIN SCI, V3, P3; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PARK DG, 1993, J BIOL CHEM, V268, P4573; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Quick Michael W., 1994, V19, P261; QUICK MW, 1994, J BIOL CHEM, V269, P30164; Quick MW, 1996, J BIOL CHEM, V271, P32021, DOI 10.1074/jbc.271.50.32021; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UI M, 1990, ADP RIBOSYLATING TOX, P45; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297	51	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4807	4815		10.1074/jbc.274.8.4807	http://dx.doi.org/10.1074/jbc.274.8.4807			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988720	hybrid			2022-12-25	WOS:000078698200045
J	Machaca, K; Hartzell, HC				Machaca, K; Hartzell, HC			Adenophostin A and inositol 1,4,5-trisphosphate differentially activate Cl- currents in Xenopus oocytes because of disparate Ca2+ release kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; PANCREATIC ACINAR-CELLS; BETA-GAMMA-SUBUNITS; LAEVIS OOCYTES; PENICILLIUM-BREVICOMPACTUM; INTRACELLULAR CALCIUM; POTENT AGONISTS; RECEPTOR; INFLUX; STORES	Depletion of endoplasmic reticulum Ca2+ stores induces Ca2+ entry from the extracellular space by a process termed "store-operated Ca2+ entry" (SOCE), It has been suggested that the novel fungal metabolite adenophostin-A may be able to stimulate Ca2+ entry without stimulating Ca2+ release from stores. To test this idea further, we compared Ca2+ release, SOCE, and the stimulation of Ca2+-activated Cl- currents in Xenopus oocytes in response to inositol 1,4,5-trisphosphate (IP3) and adenophostin-A injection. IP3 stimulated an outward Cl- current, ICIl-S, in response to Ca2+ release from stores followed by an inward current, I-Cl2, in response to SOCE. In contrast, low concentrations of adenophostins (AdAs) activated I-Cl2 without activating ICl1-S, consistent with the suggestion that AdA can activate Ca2+ entry without stimulating Ca2+ release. However, when Ca2+ entry has been stimulated by AdA, Ca2+ stores are largely depleted of Ca2+, as assessed by the inability of ionomycin to release additional Ca2+. The Ca2+ release stimulated by AdA, however, was 7 times slower than the release stimulated by IP3, which could explain the minimal activation of ICl1-S; when Ca2+ is released slowly, the threshold level required for ICl1-S, activation is not attained.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Hartzell, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.	Criss@cellbio.emory.edu	Machaca, Khaled/AAF-3579-2019	Machaca, Khaled/0000-0001-6215-2411	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021195, R37HL021195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055276] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21195] Funding Source: Medline; NIGMS NIH HHS [GM55276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARISH ME, 1984, J PHYSIOL-LONDON, V352, P243, DOI 10.1113/jphysiol.1984.sp015289; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DeLisle S, 1997, J BIOL CHEM, V272, P9956; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; GILON P, 1995, J BIOL CHEM, V270, P8050, DOI 10.1074/jbc.270.14.8050; Grygorczyk R, 1996, J NEUROSCI METH, V67, P19; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kobrinsky E, 1995, DEV BIOL, V172, P531, DOI 10.1006/dbio.1995.8058; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Kuruma A, 1999, AM J PHYSIOL-CELL PH, V276, pC161, DOI 10.1152/ajpcell.1999.276.1.C161; Machaca K, 1998, BIOPHYS J, V74, P1286, DOI 10.1016/S0006-3495(98)77842-7; MACHACA K, 1999, IN PRESS J GEN PHYSL; Marchant JS, 1998, BIOCHEM J, V334, P505, DOI 10.1042/bj3340505; Marchant JS, 1997, BIOCHEMISTRY-US, V36, P12780, DOI 10.1021/bi971397v; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; PARKER I, 1994, CELL CALCIUM, V15, P276, DOI 10.1016/0143-4160(94)90067-1; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAKAHASHI M, 1993, J ANTIBIOT, V46, P1643, DOI 10.7164/antibiotics.46.1643; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684	36	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4824	4831		10.1074/jbc.274.8.4824	http://dx.doi.org/10.1074/jbc.274.8.4824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988722	hybrid			2022-12-25	WOS:000078698200047
J	Reuter, M; Schneider-Mergener, D; Kupper, D; Meisel, A; Mackeldanz, P; Kruger, DH; Schroeder, C				Reuter, M; Schneider-Mergener, D; Kupper, D; Meisel, A; Mackeldanz, P; Kruger, DH; Schroeder, C			Regions of endonuclease EcoRII involved in DNA target recognition identified by membrane-bound peptide repertoires	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RESTRICTION ENDONUCLEASES; CRYSTAL-STRUCTURE; REFRACTORY DNA; SEQUENCE; SITES; BINDING; CLEAVAGE; COMPLEX; DNA-(CYTOSINE-C5)-METHYLTRANSFERASES; SPECIFICITY	Target sequence-specific DNA binding regions of the restriction endonuclease EcoRII were identified by screening a membrane-bound EcoRII-derived peptide scan with an EcoRII recognition site (CCWGG) oligonucleotide duplex, Dodecapeptides overlapping by nine amino acids and representing the complete protein were prepared by spot synthesis. Two separate DNA binding regions, amino acids 88-102 and amino acids 256-273, which share the consensus motif KXRXXK, emerged. Screening 570 single substitution analogues obtained by exchanging every residue of both binding sites for all other amino acids demonstrated that replacing basic residues in the consensus motifs significantly reduced DNA binding. EcoRII mutant enzymes generated by substituting alanine or glutamic acid for the consensus lysine residues in DNA binding site I expressed attenuated DNA binding, whereas corresponding substitutions in DNA binding site II caused impaired cleavage, but enzyme secondary structure was unaffected. Furthermore, Glu(96), which is part of a potential catalytic motif and also locates to DNA binding site I, was demonstrated to be critical for DNA cleavage and binding. Homology studies of DNA binding site II revealed strong local homology to SsoII (recognition sequence, CCNGG) and patterns of sequence conservation, suggesting the existence of functionally related DNA binding sites in diverse restriction endonucleases with recognition sequences containing terminal C:G or G:C pairs.	Humboldt Univ, Med Sch Charite, Inst Virol, D-10098 Berlin, Germany; Humboldt Univ, Med Sch Charite, Inst Med Immunol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reuter, M (corresponding author), Humboldt Univ, Med Sch Charite, Inst Virol, D-10098 Berlin, Germany.			Meisel, Andreas/0000-0001-7233-5342				Aggarwal AK, 1998, CURR OPIN STRUC BIOL, V8, P19, DOI 10.1016/S0959-440X(98)80005-5; BHAGWAT AS, 1990, J BIOL CHEM, V265, P767; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Colandene JD, 1998, P NATL ACAD SCI USA, V95, P3531, DOI 10.1073/pnas.95.7.3531; FRANK R, 1992, TETRAHEDRON, V48, P9211; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GOPAL J, 1994, NUCLEIC ACIDS RES, V22, P4482, DOI 10.1093/nar/22.21.4482; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6051, DOI 10.1093/nar/20.22.6051; JANULAITIS A, 1996, BIOLOGIJA, V2, P28; JELTSCH A, 1995, GENE, V160, P7, DOI 10.1016/0378-1119(95)00181-5; JELTSCH A, 1995, J BIOL CHEM, V270, P5122, DOI 10.1074/jbc.270.10.5122; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KOSSYKH V, 1989, BIOCHIM BIOPHYS ACTA, V1009, P290, DOI 10.1016/0167-4781(89)90117-6; KOSSYKH VG, 1993, GENE, V125, P65, DOI 10.1016/0378-1119(93)90746-P; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer A, 1998, METH MOL B, V87, P25; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; KUPPER D, 1995, PROTEIN EXPRES PURIF, V6, P1, DOI 10.1006/prep.1995.1001; Lange C, 1996, EMBO J, V15, P1443, DOI 10.1002/j.1460-2075.1996.tb00486.x; MALIN R, 1995, J AM CHEM SOC, V117, P11821, DOI 10.1021/ja00152a031; MCLANE KE, 1995, P NATL ACAD SCI USA, V92, P5214, DOI 10.1073/pnas.92.11.5214; Morgenstern B, 1996, P NATL ACAD SCI USA, V93, P12098, DOI 10.1073/pnas.93.22.12098; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; OSULLIVAN DJ, 1995, J BACTERIOL, V177, P134, DOI 10.1128/jb.177.1.134-143.1995; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PEIN CD, 1989, FEBS LETT, V245, P141, DOI 10.1016/0014-5793(89)80208-X; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; PETRAUSKENE OV, 1994, BIOCHEM BIOPH RES CO, V198, P885, DOI 10.1006/bbrc.1994.1126; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Reineke U, 1998, PROTEIN SCI, V7, P951; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Roberts RJ, 1998, NUCLEIC ACIDS RES, V26, P338, DOI 10.1093/nar/26.1.338; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SAMBROOK J, 1989, MOL CLONING, V1, P7; SIKSNYS V, 1995, GENE, V157, P311, DOI 10.1016/0378-1119(94)00632-3; STANOJEVIC D, 1995, NAT STRUCT BIOL, V2, P450, DOI 10.1038/nsb0695-450; Swaminathan N, 1996, NUCLEIC ACIDS RES, V24, P2463, DOI 10.1093/nar/24.13.2463; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; Trautner TA, 1996, EMBO J, V15, P1434, DOI 10.1002/j.1460-2075.1996.tb00485.x; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; Wenz C, 1996, J BIOL CHEM, V271, P5565, DOI 10.1074/jbc.271.10.5565	53	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5213	5221		10.1074/jbc.274.8.5213	http://dx.doi.org/10.1074/jbc.274.8.5213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988771	hybrid			2022-12-25	WOS:000078698200096
J	Shworak, NW; Liu, JA; Petros, LM; Zhang, LJ; Kobayashi, M; Copeland, NG; Jenkins, NA; Rosenberg, RD				Shworak, NW; Liu, JA; Petros, LM; Zhang, LJ; Kobayashi, M; Copeland, NG; Jenkins, NA; Rosenberg, RD			Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase - Isolation, characterization, and expression of human cDNAs and identification of distinct genomic loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; INTEGRATED MOLECULAR ANALYSIS; GENE CONVERSION; MESSENGER-RNA; CELL-LINE; CLONING; MOUSE; SEQUENCE; PROTEIN; BINDING	3-O-Sulfated glucosaminyl residues are rare constituents of heparan sulfate and are essential for the activity of anticoagulant heparan sulfate. Cellular production of the critical active structure is controlled by the rate-limiting enzyme, heparan sulfate D-glucosaminyl 3-O-sulfotransferase-1 (3-OST-1) (EC 2.8.2.23). We have probed the expressed sequence tag data base with the carboxyl-terminal sulfotransferase domain of 3-OST-1 to reveal three novel, incomplete human cDNAs. These were utilized in library screens to isolate full-length cDNAs. Clones corresponding to predominant transcripts were obtained for the 367-, 406-, and 390-amino acid enzymes 3-OST-2, 3-OST-3(A), and 3-OST-3(B), respectively. These type II integral membrane proteins are comprised of a divergent amino-terminal region and a very homologous carboxyl-terminal sulfotransferase domain of similar to 260 residues. Also recovered were partial length clones for 3-OST-4. Expression of the full-length enzymes confirms the 3-O-sulfation of specific glucosaminyl residues within heparan sulfate (Liu, J., Shworak, N. W., Sinay, P., Schwartz, J. J. Zhang, L., Fritze, L. M. S., and Rosenberg, R. D. (1999) J. Biol. Chem. 274, 5185-5192). Southern analyses suggest the human 3OST1, 3OST2, and 3OST4 genes, and the corresponding mouse isologs, are single copy. However, 3OST3A and 3OST3B genes are each duplicated in humans and show at least one copy each in mice. Intriguingly, the entire sulfotransferase domain sequence of the 3-OST-3(B) cDNA (774 base pairs) was 99.2% identical to the same region of 3-OST-3(A). Together, these data argue that the structure of this functionally important region is actively maintained by gene conversion between 3OST3A and 3OST3B loci. Interspecific mouse back-cross analysis identified the loci for mouse 3Ost genes and syntenic assignments of corresponding human isologs were confirmed by the identification of mapped sequence-tagged site markers, Northern blot analyses indicate brain exclusive and brain predominant expression of 3-OST-4 and 3-OST-2 transcripts, respectively; whereas, 3-OST-3(A) and 3-OST-3(B) isoforms show widespread expression of multiple transcripts. The reiteration and conservation of the 3-OST sulfotransferase domain suggest that this structure is a self-contained functional unit. Moreover, the extensive number of 3OST genes with diverse expression patterns of multiple transcripts suggests that the novel 3-OST enzymes, like 3-OST-1, regulate important biologic properties of heparan sulfate proteoglycans.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shworak, NW (corresponding author), Beth Israel Deaconess Med Ctr, Angiogenesis Res Ctr, SL-418,330 Brookline Ave, Boston, MA 02215 USA.	nshworak@caregroup.harvard.edu	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [5-PO1-HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1995, NATURE, V377, P3; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; AVRAHAM KB, 1994, GENOMICS, V21, P656, DOI 10.1006/geno.1994.1330; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BUCHBERG AM, 1989, GENETICS, V122, P153; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carey DJ, 1997, BIOCHEM J, V327, P1; CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Chopra R, 1996, EXP HEMATOL, V24, P755; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Pathak BG, 1996, GENOMICS, V33, P124, DOI 10.1006/geno.1996.0168; POWERS PA, 1991, GENETICS, V129, P133; RAU C, 1995, PHYSIOL CHEM PHYS M, V27, P55; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1995, PROTEIN SCI, V4, P521; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SCHIMENTI JC, 1994, SOC GEN PHY, V49, P85; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; SHWORAK NW, 1995, ENDOTHELIAL CELL HLT, P119; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHL GM, 1987, METHOD ENZYMOL, V152, P399; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	64	191	201	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5170	5184		10.1074/jbc.274.8.5170	http://dx.doi.org/10.1074/jbc.274.8.5170			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988767	hybrid			2022-12-25	WOS:000078698200092
J	Ray, A; Schatten, H; Ray, BK				Ray, A; Schatten, H; Ray, BK			Activation of Sp1 and its functional co-operation with serum amyloid a-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR; REACTIVE PROTEIN; POSTTRANSCRIPTIONAL MECHANISMS; RHEUMATOID-ARTHRITIS; FAMILY PROTEINS; NUCLEAR FACTOR; MESSENGER-RNA; C/EBP-BETA	The serum amyloid A (SAA) protein has been implicated in the progression and pathogenesis of rheumatoid arthritis through induction of collagenase activity in synovial fibroblast cells that line the joint tissues. We demonstrate that SAA is synergistically induced in synovial cells by interleukin (IL)-1 and IES that are present at significantly high level in the synovial fluid of arthritis patients. These cytokines induced phenotypic changes in synovial cells, promoting protrusion and increased cellular contact. Induction of SAA under this condition is mediated by promoter elements located between -254 and -226, which contains binding sites for transcription factors Sp1 and SAA activating sequence binding factor (SAF). Mutation of these sequences abolishes SAA promoter response to IL-1 and IL-6. The role of Spl in SAA induction was demonstrated by increased DNA binding activity, phosphorylation, and increased protein content of Spl during cytokine treatment. Spl interacts with the SAA promoter in association with SAF as an SAF Spl heteromeric complex. Furthermore, using a phosphatase inhibitor, we demonstrated increased transactivation potential of both Spl and SAF as a consequence of a phosphorylation event. These results provide first evidence for cytokine-mediated activation of Spl in synovial fibroblast cells and its participation in regulating SAA expression by acting in conjunction with SAF.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205, R56DK049205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BENSON MD, 1979, ARTHRITIS RHEUM, V22, P36, DOI 10.1002/art.1780220106; BETTS JC, 1993, J BIOL CHEM, V268, P25624; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; CLINE CA, 1983, CELL MOTIL CYTOSKEL, V3, P513, DOI 10.1002/cm.970030518; CONTI P, 1995, IMMUNOL INVEST, V24, P523, DOI 10.3109/08820139509066848; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; Horackova M, 1997, EXP CELL RES, V237, P158, DOI 10.1006/excr.1997.3775; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jensen LE, 1997, J IMMUNOL, V158, P384; JIANG SL, 1995, J CLIN INVEST, V95, P1253, DOI 10.1172/JCI117775; JIANG SL, 1995, J IMMUNOL, V154, P825; Koj A, 1985, ACUTE PHASE RESPONSE, P139; Kumon Y, 1997, SCAND J IMMUNOL, V46, P284, DOI 10.1046/j.1365-3083.1997.d01-128.x; Kumon Y, 1997, J RHEUMATOL, V24, P14; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray A, 1997, DNA CELL BIOL, V16, P1, DOI 10.1089/dna.1997.16.1; Ray Alpana, 1993, Gene Expression, V3, P151; Ray BK, 1997, J BIOL CHEM, V272, P28948, DOI 10.1074/jbc.272.46.28948; RAY BK, 1993, BIOCHEM BIOPH RES CO, V193, P1159, DOI 10.1006/bbrc.1993.1747; RIENHOFF HY, 1988, MOL CELL BIOL, V8, P3710, DOI 10.1128/MCB.8.9.3710; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; Strissel KJ, 1997, EXP CELL RES, V237, P275, DOI 10.1006/excr.1997.3783; SUKENIK S, 1988, J RHEUMATOL, V15, P942; URIELISHOVAL S, 1994, AM J PATHOL, V145, P650; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; YANNI G, 1994, ANN RHEUM DIS, V53, P39, DOI 10.1136/ard.53.1.39; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	55	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4300	4308		10.1074/jbc.274.7.4300	http://dx.doi.org/10.1074/jbc.274.7.4300			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933631	hybrid			2022-12-25	WOS:000078575500055
J	Huang, CF; Buu, LM; Yu, WL; Lee, FJS				Huang, CF; Buu, LM; Yu, WL; Lee, FJS			Characterization of a novel ADP-ribosylation factor-like protein (yARL3) in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; STIMULATORY REGULATORY COMPONENT; PHOSPHOLIPASE-D ACTIVITY; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; CHOLERA-TOXIN; ARF PROTEINS; ADENYLATE-CYCLASE; ESCHERICHIA-COLI; GENE DISRUPTION	ADP-ribosylation factors (ARFs) are highly conserved, similar to 20-kDa guanine nucleotide-binding proteins that enhance the ADP-ribosyltransferase activity of cholera toxin and have an important role in vesicular transport. Several cDNAs for ARF-like proteins (ARLs) have been cloned from human, Drosophila, rat, and yeast, although the biological function(s) of ARLs is unknown. We have identified a yeast gene (yARL3) encoding a protein that is structurally related (>43% identical) to the mammalian ARF-like protein ARP. Biochemical studies of purified recombinant yARL3 protein revealed properties similar to those of ARF and ARL proteins, including the ability to bind and hydrolyze GTP. Like other ARLs, recombinant yARL3 did not stimulate cholera toxin-catalyzed auto-ADP-ribosylation. Anti-yARL3 antibodies did not cross-react with yARFs or yARL1. yARL3 was not essential for cell viability, but disruption of yARL3 resulted in cold-sensitive cell growth. At the nonpermissive temperature, processing of alkaline phosphatase and carboxypeptidase Y in arl3 mutant was slowed. yARL3 might be required for protein transport from endoplasmic reticulum to Golgi or from Golgis to vacuole at nonpermissive temperatures. On subcellular fractionation, unlike its mammalian homologue ARP, yARL3 was detected in the soluble fraction but not in the plasma membrane. Indirect immunofluorescence analysis revealed that yARL3 when overexpressed was associated in part with the endoplasmic reticulum-nuclear envelope. Thus, the structural and functional characteristics of yARL3 indicate that it may have a unique role(s) in vesicular trafficking.	Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei, Taiwan	National Taiwan University	Lee, FJS (corresponding author), Natl Taiwan Univ, Sch Med, Inst Mol Med, 7 Chang Shan S Rd, Taipei, Taiwan.	fangjen@ha.mc.ntu.edu.tw		LEE, FANG-JEN/0000-0002-2167-2426				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUKIC V, 1991, METHOD ENZYMOL, V194, P697; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Gaynor EC, 1998, MOL BIOL CELL, V9, P653, DOI 10.1091/mbc.9.3.653; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Lowe SL, 1996, J CELL SCI, V109, P209; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Schurmann A, 1995, J BIOL CHEM, V270, P30657, DOI 10.1074/jbc.270.51.30657; SEGEV N, 1987, MOL CELL BIOL, V7, P2367, DOI 10.1128/MCB.7.7.2367; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wang XM, 1996, MOL CELL BIOL, V16, P5375; WHITNEY JA, 1995, CELL, V83, P703; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	60	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3819	3827		10.1074/jbc.274.6.3819	http://dx.doi.org/10.1074/jbc.274.6.3819			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920936	hybrid			2022-12-25	WOS:000078428200076
J	Monnet, C; Laune, D; Laroche-Traineau, J; Biard-Piechaczyk, M; Briant, L; Bes, C; Pugniere, M; Mani, JC; Pau, B; Cerutti, R; Devauchelle, G; Devaux, C; Granier, C; Chardes, T				Monnet, C; Laune, D; Laroche-Traineau, J; Biard-Piechaczyk, M; Briant, L; Bes, C; Pugniere, M; Mani, JC; Pau, B; Cerutti, R; Devauchelle, G; Devaux, C; Granier, C; Chardes, T			Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARITY-DETERMINING REGION; IMMUNOGLOBULIN CDR3-LIKE REGION; CLASS-II MHC; SYNCYTIUM FORMATION; GP120 BINDING; LYMPHOCYTES-T; ANTIGEN; TYPE-1; ENVELOPE; RECEPTOR	The monoclonal antibody (mAb) ST40, specific for the immunoglobulin complementarity-determining region (CDR) 3-like loop in domain 1 of the CD4 molecule, inhibits human immunodeficiency virus type 1 (HIV-1) promoter activity and viral transcription in HIV-infected cells. To design synthetic peptides from the ST40 paratope that could mimic these biological properties, a set of 220 overlapping 12-mer peptides frameshifted by one residue, corresponding to the deduced ST40 amino acid sequence, was synthesized by the Spot method and tested for binding to recombinant soluble CD4 antigen. Several peptides that included in their sequences amino acids from the CDRs of the antibody and framework residues flanking the CDRs were found to bind soluble CD4, Eleven paratope-derived peptides (termed CM1-CM11) were synthesized in a cyclic and soluble form. All the synthetic peptides showed CD4 binding capacity with affinities ranging from 1.6 to 86.4 nM. Moreover, peptides CM2, CM6, CM7, CM9, and CM11 were able to bind a cyclic peptide corresponding to the CDR3-like loop in domain 1 of CD4 (amino acids 81-92 of CD4), Peptide CM9 from the light chain variable region of mAb ST40 and, to a lesser extent, peptides CM2 and CM11 were able to inhibit HIV-1 promoter long terminal repeat-driven beta-galactosidase gene expression in the HeLa P4 HIV-1 long terminal repeat beta-galactosidase indicator cell line infected with HIV-1, The binding of mAb ST40 to CD4 was also efficiently displaced by peptides CM2, CM9, and CM11, Our results indicate that the information gained from a systematic exploration of the antigen binding capacity of synthetic peptides from immunoglobulin variable sequences can lead to the identification of bioactive paratope-derived peptides of potential pharmacological interest.	INRA, CNRS, URA 2209, Lab Pathol Comparee, F-30380 St Christol Les Ales, France; Fac Pharm Montpellier, CNRS, UMR 9921, F-34060 Montpellier, France; CRBM, CNRS, UPR 1086, Lab Infect Retrovirales & Signalisation Cellulair, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Chardes, T (corresponding author), INRA, CNRS, URA 2209, Lab Pathol Comparee, F-30380 St Christol Les Ales, France.		Chardès, Thierry/B-5420-2019; PUGNIERE, Martine/AAD-4315-2020; GRANIER, Claude/A-8841-2008; Pugniere, Martine/T-1355-2017; Briant, Laurence/AAB-9281-2021	Chardès, Thierry/0000-0002-1836-7439; PUGNIERE, Martine/0000-0002-2049-2909; Pugniere, Martine/0000-0002-2049-2909; MONNET, Celine/0000-0003-0492-5062; Briant, Laurence/0000-0002-1995-3501				ALANEN A, 1989, EUR J IMMUNOL, V19, P1961, DOI 10.1002/eji.1830191031; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BATINIC D, 1992, J BIOL CHEM, V267, P6664; BENKIRANE M, 1995, J VIROL, V69, P6898, DOI 10.1128/JVI.69.11.6898-6903.1995; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Briant L, 1997, J BIOL CHEM, V272, P19441, DOI 10.1074/jbc.272.31.19441; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CARRIERE D, 1994, CLIN CHEM, V40, P30; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DOUGALL WC, 1994, TRENDS BIOTECHNOL, V12, P372, DOI 10.1016/0167-7799(94)90038-8; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; IDZIOREK T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P39, DOI 10.1016/0005-2736(91)90332-3; IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JARRIN A, 1994, FEBS LETT, V354, P169, DOI 10.1016/0014-5793(94)01113-3; Kabat EA, 1991, SEQUENCES PROTEINS I; KALYANARAMAN VS, 1990, J IMMUNOL, V145, P4072; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; Koch U, 1997, BLOOD, V89, P2880, DOI 10.1182/blood.V89.8.2880; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; LASARTE JJ, 1994, J ACQ IMMUN DEF SYND, V7, P129; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; LEAHY DJ, 1995, FASEB J, V9, P17, DOI 10.1096/fasebj.9.1.7821755; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOHMAN KL, 1992, J IMMUNOL, V149, P3247; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MCDONNELL JM, 1992, IMMUNOMETHODS, V1, P33; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; Molina F, 1996, PEPTIDE RES, V9, P151; NARA PL, 1989, P NATL ACAD SCI USA, V86, P7139, DOI 10.1073/pnas.86.18.7139; PRESS JL, 1993, J IMMUNOL, V151, P1998; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SMITH JW, 1994, J BIOL CHEM, V269, P32788; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAUB R, 1989, J BIOL CHEM, V264, P259; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WELLING GW, 1991, J CHROMATOGR, V548, P235, DOI 10.1016/S0021-9673(01)88605-2; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	57	52	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3789	3796		10.1074/jbc.274.6.3789	http://dx.doi.org/10.1074/jbc.274.6.3789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920932	hybrid, Green Published			2022-12-25	WOS:000078428200072
J	Wallis, R; Drickamer, K				Wallis, R; Drickamer, K			Molecular determinants of oligomer formation and complement fixation in mannose-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; ENDOPLASMIC-RETICULUM; ACTIVATES COMPLEMENT; BACTERICIDAL FACTOR; CLASSICAL PATHWAY; MANNAN; SERUM; COLLAGEN; LECTIN; HYDROXYLYSINE	Rat serum mannose-binding protein (MBP-A) functions as part of the innate immune system by targetting complement toward potentially pathogenic microorganisms. In order to examine the molecular basis for complement activation, rat MBP-A has been overproduced in Chinese hamster ovary cells, Recombinant protein is post-translationally modified in the same way as the native lectin, Hydrodynamic studies indicate that MBP-A consists predominantly of covalent oligomers containing one to four copies of a subunit that comprises a trimer of polypeptides. These oligomers are non-interconverting and do not assemble into higher order structures at concentrations in excess of those normally found in serum. Disulfide bonds formed between cysteine residues at the N-terminal end of the collagen-like domain link polypeptides to form covalent oligomers, Analysis of wild-type MBP-A and MBP-A containing the substitution Cys(6) --> Ser suggests that polypeptides within each trimeric structural unit are mostly linked by disulfide bonds between cysteine residues at positions 13 and 18 arranged in an asymmetrical configuration. Disulfide bonds involving Cys(6) connect polypeptides within separate trimers. Analysis of chimeras between MBP-A and rat liver MBP (MBP-C) indicates that residues within the N-terminal region of the collagenous domain and the cysteine-rich domain of MBP-A enable assembly of trimers into higher order oligomers. The activity of MBP-A in a hemolytic complement fixation assay using mannan-coated sheep erythrocytes was approximately 20-fold greater than the activity of MBP-C. Analysis of the MBP chimeras and isolated oligomers of MBP-A reveals that the larger oligomers are more efficient at complement activation. These data indicate that the overall complement fixing activity of MBP-A is a function of the individual molecular activities of oligomers and their relative abundance within the serum.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.			Wallis, Russell/0000-0002-8705-5295				BUTLER WT, 1982, METHOD ENZYMOL, V82, P339; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1986, J BIOL CHEM, V261, P6578; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HULMES DJS, 1973, J MOL BIOL, V79, P137, DOI 10.1016/0022-2836(73)90275-1; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JI YH, 1993, J IMMUNOL, V150, P571; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; KOZUTSUMI Y, 1980, BIOCHEM BIOPH RES CO, V95, P658, DOI 10.1016/0006-291X(80)90836-0; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ST, 1975, J MOL BIOL, V98, P835, DOI 10.1016/S0022-2836(75)80015-5; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; LU J, 1990, J IMMUNOL, V144, P2287; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; OKA S, 1988, ARCH BIOCHEM BIOPHYS, V260, P257, DOI 10.1016/0003-9861(88)90448-1; PERUCCA PJ, 1969, J IMMUNOL, V102, P812; Quesenberry MS, 1997, BIOCHEMISTRY-US, V36, P2724, DOI 10.1021/bi9622635; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUPER M, 1989, LANCET, V2, P1236; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TAKAHASHI A, 1993, BIOCHEM BIOPH RES CO, V190, P681, DOI 10.1006/bbrc.1993.1103; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; WALLACE DG, 1990, BIOPOLYMERS, V29, P1015, DOI 10.1002/bip.360290613; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414	35	90	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3580	3589		10.1074/jbc.274.6.3580	http://dx.doi.org/10.1074/jbc.274.6.3580			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920905	hybrid			2022-12-25	WOS:000078428200045
J	Goalstone, ML; Leitner, JW; Golovchenko, I; Stjernholm, MR; Cormont, M; Le Marchand-Brustel, Y; Draznin, B				Goalstone, ML; Leitner, JW; Golovchenko, I; Stjernholm, MR; Cormont, M; Le Marchand-Brustel, Y; Draznin, B			Insulin promotes phosphorylation and activation of geranylgeranyltransferase II - Studies with geranylgeranylation of Rab-3 and Rab-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; 3T3-L1 ADIPOCYTES; ALPHA-SUBUNIT; FARNESYLTRANSFERASE; TRANSFERASE; MEMBRANE; REDISTRIBUTION; LOCALIZATION; PRENYLATION	Rab proteins play a crucial role in the trafficking of intracellular vesicles, Rab proteins are GTPases that cycle between an inactive GDP-bound form and an active GTP-bound conformation. A prerequisite to Rab activation by GTP loading is its post-translational modification by the addition of geranylgeranyl moieties to highly conserved C-terminal cysteine residues. We examined the effect of insulin on the activity of geranylgeranyltransferase II (GGTase II) in 3T3-L1 fibroblasts and adipocytes. In fibroblasts, insulin increased the enzymatic activity of GGTase II 2.5-fold after 1 h of incubation, an effect that is blocked by perillyl alcohol, an inhibitor of prenyltransferases, but not by the geranylgeranyltransferase I inhibitor, GGTI-298, or the farnesyltransferase inhibitor, alpha-hydroxyfarnesylphosphonic acid. Concomitantly, insulin stimulated the phosphorylation of the GGTase II alpha-subunit without any effect on the GGTase II beta-subunit, At the same time, insulin also increased the amounts of geranylgeranylated Rab-3 in 3T3-L1 fibroblasts from 44 +/- 1.2% in control cells to 63 +/- 3.8 and 64 +/- 6.1% after 1 and 24 h of incubation, respectively. In adipocytes, insulin increased the amounts of geranylgeranylated Rab-4 from 38 +/- 0.6% in control cells to 56 +/- 1.7 and 60 +/- 2.6% after 1 and 24 h of incubation, respectively. In both fibroblasts and adipocytes, the presence of perillyl alcohol blocked the ability of insulin to increase geranylgeranylation of Rab-4, whereas GGTI-298 and alpha-hydroxyfarnesylphosphonic acid were without effect, indicating that insulin activates GGTase II. In summary, insulin promotes phosphorylation and activation of GGTase II in both 3T3 L1 fibroblasts and adipocytes and increases the amounts of geranylgeranylated Rab-S and Rab-4 proteins.	Vet Affairs Med Ctr, Res Serv 151, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA; Fac Med, INSERM U145, F-06107 Nice, France	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Draznin, B (corresponding author), Vet Affairs Med Ctr, Res Serv 151, 1055 Clermont St, Denver, CO 80220 USA.	DRAZNINB@den-res.org		CORMONT, Mireille/0000-0001-6918-2410				ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bortoluzzi MN, 1996, DIABETOLOGIA, V39, P899, DOI 10.1007/BF00403908; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; Chinni SR, 1998, EXP CELL RES, V242, P373, DOI 10.1006/excr.1998.4105; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CORMONT M, 1994, EUR J BIOCHEM, V219, P1081, DOI 10.1111/j.1432-1033.1994.tb18591.x; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Goud B, 1992, Semin Cell Biol, V3, P301; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; MOORES SL, 1991, J BIOL CHEM, V266, P14603; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2880	2884		10.1074/jbc.274.5.2880	http://dx.doi.org/10.1074/jbc.274.5.2880			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915824	hybrid			2022-12-25	WOS:000078319500042
J	Hong, SH; Privalsky, ML				Hong, SH; Privalsky, ML			Retinoid isomers differ in the ability to induce release of SMRT corepressor from retinoic acid receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; X-RECEPTOR; CRYSTAL-STRUCTURE; ONCOGENE PRODUCT; RAR-ALPHA; N-COR	Nuclear hormone receptors are ligand-regulated transcription factors that modulate the expression of specific target genes in response to the binding of small, hydrophobic hormone ligands. Many nuclear hormone receptors, such as the retinoic acid receptors, can both repress and activate target gene expression; these bimodal transcription properties are mediated by the ability of these receptors to tether auxiliary factors, denoted corepressors and coactivators. Corepressors are typically bound by receptors in the absence of cognate hormone, whereas binding of an appropriate hormone agonist induces an allosteric alteration in the receptor resulting in release of the corepressor and recruitment of coactivator, Structural analysis indicates that there is a close induced fit between the hormone ligand and the receptor polypeptide chain. This observation suggests that different ligands, once bound, may confer distinct conformations on the receptor that may invoke, in turn, distinct functional consequences. We report here that different retinoids do differ in the ability to release corepressor once bound to retinoic acid receptor and suggest that these differences in corepressor release may manifest as differences in transcriptional regulation.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu		Hong, Suk-Hyun/0000-0001-7541-4847	NCI NIH HHS [R37 CA053394, R37 CA053394-06S1, R37 CA-53394] Funding Source: Medline; NIDDK NIH HHS [R01 DK053528, R01 DK-53528, R01 DK053528-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; Chen H, 1998, DRUG METAB DISPOS, V26, P222; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Claret FX, 1996, MOL CELL BIOL, V16, P219; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hong SH, 1998, MOL ENDOCRINOL, V12, P1161, DOI 10.1210/me.12.8.1161; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RIBEIRO RC, 1993, ANN NY ACAD SCI, V758, P366; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shih TW, 1997, DRUG METAB DISPOS, V25, P27; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	60	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2885	2892		10.1074/jbc.274.5.2885	http://dx.doi.org/10.1074/jbc.274.5.2885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915825	hybrid, Green Accepted			2022-12-25	WOS:000078319500043
J	Karantzoulis-Fegaras, F; Antoniou, H; Lai, SLM; Kulkarni, G; D'Abreo, C; Wong, GKT; Miller, TL; Chan, Y; Atkins, J; Wang, Y; Marsden, PA				Karantzoulis-Fegaras, F; Antoniou, H; Lai, SLM; Kulkarni, G; D'Abreo, C; Wong, GKT; Miller, TL; Chan, Y; Atkins, J; Wang, Y; Marsden, PA			Characterization of the human endothelial nitric-oxide synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ZINC-FINGER PROTEIN; TATA-LESS PROMOTER; T-CELL LEUKEMIA; VIRUS TYPE-I; NF-KAPPA-B; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ETS-DOMAIN; POTENTIAL ROLE	Understanding transcription initiation of the endothelial nitric-oxide synthase (eNOS) gene appears pivotal to gaining a comprehensive view of NO biology in the blood vessel wall. The present study therefore focused upon a detailed dissection of the functionally important cis-DNA elements and the multiprotein complexes implicated in the cooperative control of constitutive expression of the human eNOS gene in vascular endothelium, Two tightly clustered cis-regulatory regions were identified in the proximal enhancer of the TATA-less eNOS promoter using deletion analysis and linker-scanning mutagenesis: positive regulatory domains I (-104/-95 relative to transcription initiation) and II (-144/-115), Analysis of trans-factor binding and functional expression studies revealed a surprising degree of cooperativity and complexity. The nucleoprotein complexes that form upon these regions in endothelial cells contained Ets family members, Spl, variants of Sp3, MAZ, and YY1. Functional domain studies in Drosophila Schneider cells and endothelial cells revealed examples of positive and negative protein-protein cooperativity involving Sp1, variants of Sp3, Ets-1, Elf-1, and MAZ, Therefore, multiprotein complexes are formed on the activator recognition sites within this 50-base pair region of the human eNOS promoter in vascular endothelium.	Univ Toronto, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Rm 7358,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Marsden, Philip A/B-1441-2012					Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; Ernst P, 1996, MOL CELL BIOL, V16, P6121; Fadel BM, 1998, BIOCHEM J, V330, P335; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; Fuks F, 1996, J VIROL, V70, P1331, DOI 10.1128/JVI.70.3.1331-1339.1996; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; Graef IA, 1997, SCIENCE, V277, P193, DOI 10.1126/science.277.5323.193; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; Parks CL, 1996, J BIOL CHEM, V271, P4417; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; SCHRODER FH, 1989, PROSTATE, P17; Seelan RS, 1997, J BIOL CHEM, V272, P10175, DOI 10.1074/jbc.272.15.10175; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Vassias I, 1998, J BIOL CHEM, V273, P8287, DOI 10.1074/jbc.273.14.8287; VENEMA RC, 1994, BBA-GENE STRUCT EXPR, V1218, P413, DOI 10.1016/0167-4781(94)90195-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WARIISHI S, 1995, BIOCHEM BIOPH RES CO, V216, P729, DOI 10.1006/bbrc.1995.2682; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNERT N, 1992, AM J PATHOL, V140, P119; WERNERT N, 1994, CANCER RES, V54, P5638; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Wilkinson DA, 1997, LEUKEMIA, V11, P86, DOI 10.1038/sj.leu.2400516; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	90	175	182	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3076	3093		10.1074/jbc.274.5.3076	http://dx.doi.org/10.1074/jbc.274.5.3076			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915847	hybrid			2022-12-25	WOS:000078319500065
J	Shao, R; Yan, W; Rockey, DC				Shao, R; Yan, W; Rockey, DC			Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC-FIBROSIS; RAT-LIVER; POSSIBLE INVOLVEMENT; CELL LINES; ITO CELLS; EXPRESSION; LIPOCYTES; GENE; RECEPTORS; CIRRHOSIS	Endothelin-1 (ET-1) is involved in the pathogenesis of a number of diseases, including wound healing. In cirrhosis, the wounding response of the liver, circulating ET-1 levels are elevated; moreover, ET-1 has potent effects on hepatic stellate cells, the key effecters of cirrhosis. In this study, we have examined the regulatory role of ECE-1, a critical enzyme involved in ET-1 synthesis, in the two major cellular sources of hepatic ET-1, ET-1 release from normal hepatic endothelial cells was 25-fold higher than that from normal stellate cells. However, after liver injury, ET-1 release was increased in stellate cells but markedly decreased in endothelial cells. The two major isoforms of ECE-1, ECE-1 alpha/1 beta, made up 80% and 20%, respectively, of total ECE-1 in both stellate and endothelial cells. Following liver injury, ECE-1 alpha mRNA was decreased by 44.2% in stellate cells, and by 16.1% in endothelial cells. ECE-1 beta mRNA expression remained unchanged after injury. In contrast to ECE-1 mRNA, ECE-1 protein expression was increased by 43.9% in stellate cells but decreased in endothelial cells, while relative ECE-1 enzymatic activity was unchanged. In mRNA stability experiments, the half-life of ECE-alpha mRNA in normal stellate cells was 13 h compared with 38 h in cells from injured livers. Thus, during hepatic wound healing, differential regulation of ECE-1 mRNA and protein appears to be critical in controlling ET-1 production.	Duke Univ, Med Ctr, Ctr Liver, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Ctr Liver, Sands Bldg,Box 3083,Rm 334, Durham, NC 27710 USA.	dcrockey@acpub.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002124, R01DK050574] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02124, DK 50574] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARDINI G, 1988, VIRCHOWS ARCH B, V56, P45, DOI 10.1007/BF02890000; Barnes K, 1997, J NEUROCHEM, V68, P570; BAUER M, 1994, AM J PHYSIOL, V267, pG143, DOI 10.1152/ajpgi.1994.267.1.G143; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; GANDHI CR, 1995, LIFE SCI, V58, P55, DOI 10.1016/0024-3205(95)02255-4; GUI GJ, 1993, J CARDIOVASC PHARM, V22, pS53, DOI 10.1097/00005344-199322008-00016; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; KAWADA N, 1993, EUR J BIOCHEM, V213, P815, DOI 10.1111/j.1432-1033.1993.tb17824.x; KENT G, 1976, P NATL ACAD SCI USA, V73, P3719, DOI 10.1073/pnas.73.10.3719; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; Matsuura A, 1997, BIOCHEM BIOPH RES CO, V235, P713, DOI 10.1006/bbrc.1997.6885; Minamino T, 1997, CIRCULATION, V95, P221, DOI 10.1161/01.CIR.95.1.221; MOLLER S, 1995, J HEPATOL, V23, P135, DOI 10.1016/0168-8278(95)80327-0; MOORE K, 1992, NEW ENGL J MED, V327, P1774, DOI 10.1056/NEJM199212173272502; OKUMURA S, 1994, HEPATOLOGY, V19, P155, DOI 10.1002/hep.1840190125; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Rockey DC, 1998, HEPATOLOGY, V27, P472, DOI 10.1002/hep.510270222; Rockey DC, 1996, J CLIN INVEST, V98, P1381, DOI 10.1172/JCI118925; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; Saleh D, 1997, AM J RESP CELL MOL, V16, P187, DOI 10.1165/ajrcmb.16.2.9032126; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; STEWART DJ, 1991, J AM COLL CARDIOL, V18, P38, DOI 10.1016/S0735-1097(10)80214-1; TAKADA J, 1992, BIOCHEM BIOPH RES CO, V182, P1383, DOI 10.1016/0006-291X(92)91886-U; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YORIMITSU K, 1995, BIOCHEM BIOPH RES CO, V208, P721, DOI 10.1006/bbrc.1995.1397; Yoshimura H, 1997, AM J RESP CELL MOL, V17, P471, DOI 10.1165/ajrcmb.17.4.2832; ZHANG JX, 1995, AM J PHYSIOL-GASTR L, V269, pG269, DOI 10.1152/ajpgi.1995.269.2.G269; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624, DOI 10.1152/ajpgi.1994.266.4.G624	44	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3228	3234		10.1074/jbc.274.5.3228	http://dx.doi.org/10.1074/jbc.274.5.3228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915864	hybrid			2022-12-25	WOS:000078319500082
J	Jinno, S; Hung, SC; Okayama, H				Jinno, S; Hung, SC; Okayama, H			Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4	ONCOGENE			English	Article						Cdk4; G(0)-G(1) transition; quiescence; tyrosine phosphorylation; UV	DEPENDENT KINASES; PROTEIN-KINASE; G1 ARREST; TGF-BETA; ACTIVATION; INHIBITION; CDC25A; GROWTH; SITES; PHASE	In mammals Cdk4 (or Cdk6 in some cell types) is required for starting the cell cycle. Recently we showed that Cdk4 is regulated by tyrosine phosphorylation and dephosphorylation, and that this regulation is required for a DNA damage-induced G(1) arrest. We report here that a generic anti-phosphotyrosine antibody can detect tyrosine-phosphorylated Cdk4 and that as revealed by immunoblot detection and kinase assay, this regulation is employed for DIVA damage-responsive checkpoint control during cell cycle start from quiescence. In rat fibroblasts traversing G(1) or arrested in G(1) by deprivation of anchorage, Cdk4 does not undergo tyrosine phosphorylation, Tyrosine phosphorylation occurs only during cell's arrest in quiescence and dephosphorylation during their cell cycle start. Ultraviolet irradiation blocks dephosphorylation and concomitant activation of Cdk4, thereby preventing the start of cell cycling, Thus, unlike tyrosine phosphorylation of Cdc2, which controls phase transition in the regular cell cycle, tyrosine phosphorylation of Cdk4 is employed for controlling cell cycle start from quiescence in a rat fibroblast.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan.							BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V5, P2981; HAN A, 1978, RADIAT RES, V74, P88, DOI 10.2307/3574759; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jung E G, 1986, Curr Probl Dermatol, V15, P117; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUME K, 1992, NEW BIOL, V4, P504; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILLER JB, 1992, CELL, V63, P407; NAGATA A, 1991, NEW BIOL, V3, P959; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Okada S., 1970, RAD BIOCH, VI; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SEFTON BM, 1995, CURRENT PROTOCOL PRO; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; THOMPSON LH, 1970, RADIAT RES, V41, P183, DOI 10.2307/3572905; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	31	41	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					565	571		10.1038/sj.onc.1202347	http://dx.doi.org/10.1038/sj.onc.1202347			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989806				2022-12-25	WOS:000078394400001
J	Donzelli, M; Bernardi, R; Negri, C; Prosperi, E; Padovan, L; Lavialle, C; Brison, O; Scovassi, AI				Donzelli, M; Bernardi, R; Negri, C; Prosperi, E; Padovan, L; Lavialle, C; Brison, O; Scovassi, AI			Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene	ONCOGENE			English	Article						apoptosis; human colon carcinoma cells; serum starvation; c-myc; amplification; PARP proteolysis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR GENES; POLY(ADP-RIBOSE) POLYMERASE; MEDIATED APOPTOSIS; EPITHELIAL-CELLS; CYCLE ARREST; HELA-CELLS; IN-VIVO; DEATH	Although apoptosis can be induced by the enforced expression of exogenously introduced c-myc genes, it is not clear whether overexpression resulting from the amplification of the resident c-myc gene in tumor cells is sufficient to induce apoptosis, We have investigated the relationship between c-myc gene amplification and the propensity of tumor cells to undergo apoptosis, using the SW613-12A1 and SW613-B3 cell lines, which are representatives, respectively, of tumorigenic and nontumorigenic clones isolated from the SW613-S human colon carcinoma cell line. Tumorigenic clones are characterized by a high level of amplification and expression of the c-myc gene, whereas cells of nontumorigenic clones have a small number of copies and a lower level of expression of this gene. Analysis of c-myc mRNA level in cells cultured under low serum conditions indicated that the expression of the gene is tightly regulated by serum growth factors in non-tumorigenic B3 cells, whereas it is poorly regulated in tumorigenic 12A1 cells, the level of mRNAs remaining relatively high in serum-started 12A1 cells, Under these conditions, 12A1 cells showed clear evidence of apoptosis, whereas B3 cells were completely refractory to the induction of apoptosis, Moreover, the study of cell lines derived from nontumorigenic apoptosis-resistant clones following the introduction by transfection of exogenous c-myc gene copies showed that they have acquired an apapoptosis-prone phenotype. Altogether, our results strongly suggest that deregulated c-myc expression due to high-level amplification confers an apoptosis-prone phenotype to tumor cells. The possible consequences of these observations for cancer therapy are discussed.	CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Genet, I-27100 Pavia, Italy; Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, Villejuif, France	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Pavia; UNICANCER; Gustave Roussy	Scovassi, AI (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.		bernardi, rosa/B-1650-2013; Scovassi, Anna Ivana/F-2458-2010; Donzelli, Maddalena/ABD-3774-2020; Prosperi, Ennio/A-3439-2014; Lavialle, Christian/O-2329-2019	bernardi, rosa/0000-0002-3607-6336; Scovassi, Anna Ivana/0000-0003-3484-9881; Prosperi, Ennio/0000-0001-5391-5157; DONZELLI, MADDALENA/0000-0002-4045-0802				Alarcon RM, 1996, CANCER RES, V56, P4315; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ASKEW DS, 1991, ONCOGENE, V6, P1915; Augenlicht LH, 1997, CANCER RES, V57, P1769; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BRACEY TS, 1995, ONCOGENE, V10, P2391; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GALDEMARD C, 1995, ONCOGENE, V10, P2331; Guano F, 1994, Cell Death Differ, V1, P101; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1997, BRIT J CANCER, V75, P960, DOI 10.1038/bjc.1997.167; Han JW, 1997, CANCER RES, V57, P176; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LAVIALLE C, 1988, ONCOGENE, V3, P335; LAVIALLE C, 1990, ONCOGENE, V5, P245; LAVIALLE C, 1989, ANTICANCER RES, V9, P1265; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; Negri C, 1995, BIOCHIMIE, V77, P893, DOI 10.1016/0300-9084(95)90009-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RENAULT B, 1993, CANCER RES, V53, P2614; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Sakamuro D, 1995, ONCOGENE, V11, P2411; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	62	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					439	448		10.1038/sj.onc.1202309	http://dx.doi.org/10.1038/sj.onc.1202309			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927200				2022-12-25	WOS:000078166500016
J	Iyengar, TD; Ng, SW; Lau, CC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Iyengar, TD; Ng, SW; Lau, CC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; cancer; NF1; retinoic acid	GTPASE-ACTIVATING PROTEIN; RETINOIC ACID; CELL-LINES; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; ALKALINE-PHOSPHATASE; GENE TRANSCRIPTS; CANCER; GROWTH; RAS; GAP	The NF1 gene, a putative tumor suppresser gene, contains a GAP related domain (GRD) which accelerates hydrolysis of ras-bound GTP to GDP, thereby converting the ras oncogene from its active to inactive form, Two forms of the NF1 GRD transcript (Type I and Type II) are differentially expressed in neuroectodermal tumor tissue relative to differentiated neural cells, and in gastric cancer cell lines relative to normal stomach mucosa, We measured relative expression of NF1 Type II and Type I isoforms in cultured normal and malignant human ovarian surface epithelial cells(HOSE) and in invasive and borderline ovarian tumor tissue. We demonstrated an Ii-fold increase in Type II: Type I ratio in 7 HOSE cultures relative to eight ovarian cancer cell lines, Our findings indicate a significant decrease in Type II isoform expression and increase in Type I expression in ovarian cancer cells and tumor tissue relative to HOSE cells. We also demonstrate an increase in Type II: Type I ratio, and a decrease in cell proliferation rate in three ovarian cancer cell lines on treatment with retinoic acid. We propose that differential expression of the NF1 Type I and Type II isoforms is related to cellular differentiation in ovarian epithelial cancer and strategies based on alteration in NF1 isoform expression may have therapeutic potential in ovarian malignancies.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Texas Childrens Hosp, Div Hematol Oncol, Houston, TX 77030 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Pennsylvania; Baylor College of Medicine	Mok, SC (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA069453, R01CA063381, R29CA070216] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381, R29CA70216, R01CA69453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALALAWI N, 1993, MOL CELL BIOL, V13, P2497, DOI 10.1128/MCB.13.4.2497; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; Auersperg N, 1998, SEMIN ONCOL, V25, P281; AZUMA M, 1988, CANCER RES, V48, P7219; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BROOKS SE, 1991, GYNECOL ONCOL, V42, P265, DOI 10.1016/0090-8258(91)90356-A; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CLIBY W, 1993, CANCER RES, V53, P2393; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; GOLDGAR DE, 1987, AM J HUM GENET, V44, P6; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; International Federation of Gynecology and Obstetrics, 1987, AM J OBSTET GYNECOL, V156, P263; IYENGAR TD, 1996, GYNECOL ONCOL, V60, P114; Jing YK, 1997, CANCER RES, V57, P1668; LANGDON SP, 1988, CANCER RES, V48, P6161; Lu KH, 1997, CANCER RES, V57, P387; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P643; MAZARS R, 1991, ONCOGENE, V6, P1685; MCCORMICK F, 1988, COLD SPRING HARB SYM, V53, P849, DOI 10.1101/SQB.1988.053.01.097; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; Phillips NJ, 1996, CANCER RES, V56, P606; REESE DH, 1983, CANCER RES, V43, P5443; RICCARDI VM, 1981, ADV NEUROLOGY, V29; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SATO T, 1991, CANCER RES, V51, P5118; SEIZINGER BR, 1987, CELL, V49, P589, DOI 10.1016/0092-8674(87)90534-4; SIDELL N, 1988, CANCER RES, V48, P2226; SKUSE GR, 1995, LANCET, V345, P902, DOI 10.1016/S0140-6736(95)90015-2; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tangir J, 1996, CANCER RES, V56, P2501; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wertheim I, 1996, ONCOGENE, V12, P2147; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	40	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					257	262		10.1038/sj.onc.1202294	http://dx.doi.org/10.1038/sj.onc.1202294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926941				2022-12-25	WOS:000078166000028
J	Dong, MQ; Dings, XQ; Pinon, DI; Hadac, EM; Oda, RP; Landers, JP; Miller, LJ				Dong, MQ; Dings, XQ; Pinon, DI; Hadac, EM; Oda, RP; Landers, JP; Miller, LJ			Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor - Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER-INDUCED FLUORESCENCE; GEL-ELECTROPHORESIS; PROTEIN; SITE; IDENTIFICATION; GLYCOPROTEIN; MOLECULES; ENZYME	The molecular basis of ligand binding to receptors provides important insights for drug development. Here, we explore domains of the cholecystokinin (CCK) receptor that are critical for ligand binding, using a novel series of fluorescent photolabile probes, receptor proteolysis, and rapid high resolution separation of peptide fragments by capillary electrophoresis, Each probe incorporated the same fluorophore and a photolabile p-benzoylphenylalanine at the amino terminus of the pharmacophoric domain (residue 24 of CCK-33) of CCK analogues representing full agonist, partial agonist, and antagonist of this receptor. Each was used to label the CCK receptor expressed on Chinese hamster ovary-CCKR cells, with the labeled domain then released by cyanogen bromide cleavage. Capillary electrophoresis with laser-induced fluorescence detection achieved an on-capillary mass sensitivity of 1.6 attomoles (10(-18) mol), with an excellent signal to-noise ratio, Each of the biologically divergent, but structurally similar probes saturably and specifically labeled the same receptor domain, consistent with conservation of "docking" determinants. This had an apparent mass of 2.9 kDa, most consistent with the first extracellular loop domain. An additional probe having its site of covalent attachment in a different region of the probe (residue 29 of CCK-33) labeled a distinct receptor fragment with differential migration on capillary electrophoresis (third extracellular loop). Identification of the specific receptor residue(s) covalently linked to the amino-terminal probes must await further fragmentation and sequence analysis.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Prot Core Facil, Rochester, MN 55905 USA; Univ Pittsburgh, Dept Chem, Analyt Div, Pittsburgh, PA 15260 USA	Mayo Clinic; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dong, MQ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032878, R37DK032878] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32878] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARRIAGA E, 1993, J CHROMATOGR A, V652, P347, DOI 10.1016/0021-9673(93)83252-N; CHEN DY, 1994, J CHROMATOGR B, V657, P265; CHEN DY, 1994, ANALYST, V119, P349, DOI 10.1039/an9941900349; CHENG YF, 1988, SCIENCE, V242, P562, DOI 10.1126/science.3140381; Dong MQ, 1996, J BIOL CHEM, V271, P28875, DOI 10.1074/jbc.271.46.28875; Dong MQ, 1997, ELECTROPHORESIS, V18, P1767, DOI 10.1002/elps.1150181010; FADDEN P, 1995, ANAL BIOCHEM, V225, P81, DOI 10.1006/abio.1995.1111; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GALARDY RE, 1977, MOL PHARMACOL, V13, P852; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JORGENSON JW, 1981, J CHROMATOGR, V218, P209, DOI 10.1016/S0021-9673(00)82057-9; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KLUEPPELBERG UG, 1989, BIOCHEMISTRY-US, V28, P3463, DOI 10.1021/bi00434a047; LANDERS JP, 1997, CAPILLARY ELECTROPHO; MONNIG CA, 1994, ANAL CHEM, V66, pR280, DOI 10.1021/ac00084a013; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON RK, 1987, J BIOL CHEM, V262, P869; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; POWERS SP, 1988, J BIOL CHEM, V263, P5295; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SWERDLOW H, 1991, ANAL CHEM, V63, P2835, DOI 10.1021/ac00024a006; WILLIAMS DC, 1995, ANAL CHEM, V67, P3427, DOI 10.1021/ac00115a010; XUE QF, 1994, ANAL CHEM, V66, P1175, DOI 10.1021/ac00079a036; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	31	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4778	4785		10.1074/jbc.274.8.4778	http://dx.doi.org/10.1074/jbc.274.8.4778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988716	hybrid			2022-12-25	WOS:000078698200041
J	Hanson, SRA; Chen, AA; Smith, JB; Lou, MF				Hanson, SRA; Chen, AA; Smith, JB; Lou, MF			Thiolation of the gamma B-crystallins in intact bovine lens exposed to hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE MIXED DISULFIDE; MASS-SPECTROMETRY; ALPHA-CRYSTALLINS; POSTTRANSLATIONAL MODIFICATIONS; BETA-CRYSTALLINS; FREE CYSTEINE; EYE-LENS; PROTEIN; STABILITY; CATARACT	Oxidative damage of the lens causes disulfide bonds between cysteinyl residues of lens proteins and thiols such as glutathione and cysteine, which may lead to cataract. The effect of H2O2 oxidation was determined by comparing bovine lenses incubated with and without 30 mM H2O2. The H2O2 treatment decreased the glutathione and increased the protein-glutathione and proteincysteine disulfides in the lens. The molecular mass of the gamma B-crystallin isolated from lenses, not treated with H2O2, agreed with the published sequence (M-r 20,966). Some lenses also had a less abundant gamma B-crystallin component 305 Da higher (M-r 21,270), suggesting the presence of a glutathione adduct. The gamma B-crystallins from H2O2 treated lenses had three components, the major one with one GSH adduct, another one with the mass of unmodified gamma B-crystallin, and a third with a mass consistent with addition of two GSH adducts. Mass spectrometric analysis of tryptic peptides of gamma B-crystallins from different lenses indicated that the +305 Da modifications were not at a specific cysteine, For the lenses incubated without H2O2, there was evidence of adducts at Cys-41 and in peptide 10-31, which includes 3 cysteines. Analysis of modified peptide 10-31 by tandem mass spectrometry showed GSH adducts at Cys-15, Cys-18, and Cys-22, In addition, gamma B-crystallins from H2O2-treated lenses had an adduct at Cys-109, partial oxidation at all 7 Met residues, and evidence for two disulfide bonds.	Univ Nebraska, Dept Vet & Biomed Sci, Ctr Biotechnol, Lincoln, NE 68583 USA; Univ Nebraska, Dept Chem, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Lou, MF (corresponding author), Univ Nebraska, Dept Vet & Biomed Sci, Ctr Biotechnol, 134 VBS, Lincoln, NE 68583 USA.				NEI NIH HHS [EY RO1 07609] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY U, IN PRESS PRINCIPLES; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; Blundell T.L., 1983, LENS RES, V1, P109; CU XL, 1993, EXP EYE RES, V57, P157, DOI 10.1006/exer.1993.1111; Dickerson JE, 1997, EXP EYE RES, V65, P451, DOI 10.1006/exer.1997.0343; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; EMMONS T, 1992, EXP EYE RES, V55, P551, DOI 10.1016/S0014-4835(05)80167-8; GIBLIN FJ, 1995, EXP EYE RES, V60, P219, DOI 10.1016/S0014-4835(05)80105-8; HAY RE, 1987, BIOCHEM BIOPH RES CO, V146, P332, DOI 10.1016/0006-291X(87)90729-7; Jiang XY, 1996, J MASS SPECTROM, V31, P1309, DOI 10.1002/(SICI)1096-9888(199611)31:11<1309::AID-JMS423>3.0.CO;2-R; KILBY GW, 1995, EXP EYE RES, V60, P465, DOI 10.1016/S0014-4835(05)80061-2; KILBY GW, 1995, EUR MASS SPECTROM, V1, P203, DOI 10.1255/ejms.126; KONO M, 1990, BIOCHEMISTRY-US, V29, P464, DOI 10.1021/bi00454a022; LIANG JN, 1988, EXP EYE RES, V47, P17, DOI 10.1016/0014-4835(88)90020-6; LOU MF, 1989, CURR EYE RES, V8, P883; Lou MF, 1997, ADVANCES IN OCULAR TOXICOLOGY, P27; LOU MF, 1990, EXP EYE RES, V50, P819, DOI 10.1016/0014-4835(90)90133-F; LOU MF, 1986, EXP EYE RES, V42, P607, DOI 10.1016/0014-4835(86)90050-3; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; LOU MF, 1993, INVEST OPHTH VIS SCI, V34, P987; LOU MF, 1986, P INT SOC EYE RES, V4, P87; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; MILBERG R M, 1990, P305; PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634; Qin CA, 1996, CURR EYE RES, V15, P719, DOI 10.3109/02713689609003454; SIEZEN RJ, 1989, EXP EYE RES, V48, P225, DOI 10.1016/S0014-4835(89)80072-7; SLINGSBY C, 1985, BIOCHEM J, V230, P143, DOI 10.1042/bj2300143; SMITH JB, 1991, INT J MASS SPECTROM, V111, P229, DOI 10.1016/0168-1176(91)85057-S; SMITH JB, 1991, ANAL BIOCHEM, V193, P118, DOI 10.1016/0003-2697(91)90050-4; SMITH JB, 1995, J PROTEIN CHEM, V14, P179, DOI 10.1007/BF01980330; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; Smith JB, 1997, FREE RADICAL RES, V26, P103, DOI 10.3109/10715769709097789; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Takemoto L, 1996, EXP EYE RES, V63, P585, DOI 10.1006/exer.1996.0149; Takemoto LJ, 1997, CURR EYE RES, V16, P719, DOI 10.1076/ceyr.16.7.719.5055; Takemoto LJ, 1997, EXP EYE RES, V64, P609, DOI 10.1006/exer.1996.0247; VELTMAN J, 1993, INVEST OPHTH VIS SCI, V34, P758; Wang GM, 1997, EXP EYE RES, V64, P693, DOI 10.1006/exer.1996.0251; WEN Q, 1992, EXP EYE RES, V54, P23, DOI 10.1016/0014-4835(92)90065-Z; XU GT, 1992, EXP EYE RES, V54, P63, DOI 10.1016/0014-4835(92)90070-9; ZIGLER JS, 1985, EXP EYE RES, V41, P67, DOI 10.1016/0014-4835(85)90095-8; ZIGMAN S, 1991, INVEST OPHTH VIS SCI, V32, P1723	45	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4735	4742		10.1074/jbc.274.8.4735	http://dx.doi.org/10.1074/jbc.274.8.4735			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988710	hybrid			2022-12-25	WOS:000078698200035
J	Kim, SJ; Jansson, S; Hoffman, NE; Robinson, C; Mant, A				Kim, SJ; Jansson, S; Hoffman, NE; Robinson, C; Mant, A			Distinct "assisted" and "spontaneous" mechanisms for the insertion of polytopic chlorophyll-binding proteins into the thylakoid membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; CHLOROPLAST HOMOLOG; PRECURSOR PROTEIN; INNER MEMBRANE; PHOTOSYSTEM-II; INTEGRATION; TRANSPORT; POLYPEPTIDE; MACHINERY	The biogenesis of several bacterial polytopic membrane proteins has been shown to require signal recognition particle (SRP) and protein transport machinery, and one such protein, the major light-harvesting chlorophyll-binding protein (LHCP) exhibits these requirements in chloroplasts. In this report we have used in vitro insertion assays to analyze four additional members of the chlorophyll-alb-binding protein family. We show that two members, Lhca1 and Lhcb5, display an absolute requirement for stroma, nucleoside triphosphates, and protein transport apparatus, indicating an "assisted" pathway that probably resembles that of LHCP. Two other members, however, namely an early light-inducible protein 2 (Elip2) and photosystem II subunit S (PsbS), can insert efficiently in the complete absence of SRP, SecA activity, nucleoside triphosphates, or a functional Sec system. The data suggest a possibly spontaneous insertion mechanism that, to date, has been characterized only for simple single-span proteins. Of the membrane proteins whose insertion into thylakoids has been analyzed, five have now been shown to insert by a SRP/Sec-independent mechanism, suggesting that this is a mainstream form of targeting pathway. We also show that PsbS and Elip2 molecules are capable of following either "unassisted" or assisted pathways, and we discuss the implications for the mechanism and role of SRP in chloroplasts.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Umea Univ, Dept Plant Physiol, S-90187 Umea, Sweden; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	University of Warwick; Umea University; Carnegie Institution for Science	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	CG@dna.bio.warwick.ac.uk	Jansson, Stefan/A-1119-2009	Jansson, Stefan/0000-0002-7906-6891; Hoffman, Neil/0000-0002-4057-555X; Mant, Alexandra/0000-0001-7169-209X				BREYTON C, 1994, J BIOL CHEM, V269, P7597; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLINE K, 1992, J BIOL CHEM, V267, P2688; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DeGier JWL, 1997, FEBS LETT, V408, P1, DOI 10.1016/S0014-5793(97)00402-X; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; High S, 1997, J BIOL CHEM, V272, P11622; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HOFFMAN NE, IN PRESS RES PHOTOSY; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mant A, 1998, FEBS LETT, V423, P183, DOI 10.1016/S0014-5793(98)00089-1; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; NAKAI M, 1994, J BIOL CHEM, V269, P31338; Robinson C, 1998, PLANT MOL BIOL, V38, P209, DOI 10.1023/A:1006041917853; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	38	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4715	4721		10.1074/jbc.274.8.4715	http://dx.doi.org/10.1074/jbc.274.8.4715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988708	hybrid			2022-12-25	WOS:000078698200033
J	Le Beyec, J; Chauffeton, V; Kan, HY; Janvier, PL; Cywiner-Golenzer, C; Chatelet, FP; Kalopissis, AD; Zannis, V; Chambaz, J; Pincon-Raymond, M; Cardot, P				Le Beyec, J; Chauffeton, V; Kan, HY; Janvier, PL; Cywiner-Golenzer, C; Chatelet, FP; Kalopissis, AD; Zannis, V; Chambaz, J; Pincon-Raymond, M; Cardot, P			The -700/-310 fragment of the apolipoprotein A-IV gene combined with the -890/-500 apolipoprotein C-III enhancer is sufficient to direct a pattern of gene expression similar to that for the endogenous apolipoprotein A-IV gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN GENE; CIS-ACTING ELEMENTS; HUMAN APOCIII GENE; TRANSGENIC MICE; GUT EPITHELIUM; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; INTESTINAL EPITHELIUM; PROXIMAL PROMOTER; DIFFERENTIATION	Spatial gene expression in the intestine is mediated by specific regulatory sequences. The three genes of the apoA-I/C-III/A-IV cluster are expressed in the intestine following cephalocaudal and crypt-to-villus axes. Previous studies have shown that the -780/-520 enhancer region of the apoC-III gene directs the expression of the apoA-I gene in both small intestinal villi and crypts, implying that other unidentified elements are necessary for a normal intestinal pattern of apoA-I gene expression. In this study, we have characterized transgenic mice expressing the chloramphenicol acetyltransferase gene under the control of different regions of the apoC-III and apoA-IV promoters. We found that the -890/+24 apoC-III promoter directed the expression of the reporter gene in crypts and villi and did not follow a cephalocaudal gradient of expression. In contrast, the -700/+10 apoA-IV promoter linked to the -500/-890 apoC-III enhancer directed the expression of the reporter gene in enterocytes with a pattern of expression similar to that of the endogenous apoA-IV gene. Furthermore, linkage of the -700/-310 apoA-IV distal promoter region to the -890/+24 apoC-III promoter was sufficient to restore the appropriate pattern of intestinal expression of the reporter gene. These findings demonstrate that the -700/-310 distal region of the apoA-IV promoter contains regulatory elements that, in combination with proximal promoter elements and the -500/-890 enhancer, are necessary and sufficient to restrict apoC-III and apoA-IV gene expression to villus enterocytes of the small intestine along the cephalocaudal axis.	INSERM, U505, F-75006 Paris, France; CNRS, UPRESA 7079, F-75006 Paris, France; Boston Univ, Med Ctr, Cardiovasc Inst, Mol Genet Sect, Boston, MA 02118 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Boston University	Le Beyec, J (corresponding author), INSERM, U505, 15 Rue Ecole med, F-75006 Paris, France.			Le Beyec - Le Bihan, johanne/0000-0002-5647-2002				BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTIERREZ ED, 1995, AM J PHYSIOL-GASTR L, V269, pG500, DOI 10.1152/ajpgi.1995.269.4.G500; Henning Susan J., 1994, P571; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, AM J PHYSIOL-GASTR L, V268, pG813, DOI 10.1152/ajpgi.1995.268.5.G813; JANUZZI JL, 1992, GENOMICS, V14, P1081, DOI 10.1016/S0888-7543(05)80133-8; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUER SJ, 1991, CIRCULATION, V84, P1390; Le Beyec J, 1998, TRANSGENICS, V2, P211; LI Z, 1993, DEVELOPMENT, V117, P947; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; OGAMI K, 1990, J BIOL CHEM, V265, P9808; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; REUE K, 1991, J BIOL CHEM, V266, P12715; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; RUBIN DC, 1992, AM J PHYSIOL, V263, pG853, DOI 10.1152/ajpgi.1992.263.6.G853; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; Steinmetz A, 1998, J BIOL CHEM, V273, P10543, DOI 10.1074/jbc.273.17.10543; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; Vergnes L, 1997, BBA-LIPID LIPID MET, V1348, P299, DOI 10.1016/S0005-2760(97)00071-4; WALSH A, 1989, J BIOL CHEM, V264, P6488; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	38	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4954	4961		10.1074/jbc.274.8.4954	http://dx.doi.org/10.1074/jbc.274.8.4954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988739	hybrid			2022-12-25	WOS:000078698200064
J	Evans, TC; Benner, J; Xu, MQ				Evans, TC; Benner, J; Xu, MQ			The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; SPLICING ELEMENT	The smallest known intein, found in the ribonucleoside diphosphate reductase gene of Methanobacterium thermoautotrophicum (Mth RIR1 intein), was found to splice poorly in Escherichia coli with the naturally occurring proline residue adjacent to the N-terminal cysteine of the intein. Splicing proficiency increased when this proline was replaced with an alanine residue, However, constructs that displayed efficient N- and C-terminal cleavage were created by replacing either the C-terminal asparagine or N-terminal cysteine of the intein, respectively, with an alanine. Furthermore, these constructs were used to specifically generate complementary reactive groups on protein sequences for use in ligation reactions. Reaction between an intein-generated C-terminal thioester on E. coli maltose-binding protein (43 kDa) and an intein-generated cysteine at the N terminus of either T4 DNA ligase (56 kDa) or thioredoxin (12 kDa) resulted in the ligation of the proteins through a native peptide bond. Thus the smallest of the known inteins is capable of splicing and its unique properties extend the utility of intein-mediated protein ligation to include the in vitro fusion of large, bacterially expressed proteins.	New England Biolabs Inc, Beverly, MA 01915 USA		Evans, TC (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	xum@neb.com	Wood, David W/B-2992-2012					Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DUPLAY P, 1984, J BIOL CHEM, V259, P606; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Gimble FS, 1998, CHEM BIOL, V5, pR251, DOI 10.1016/S1074-5521(98)90109-0; Holford M, 1998, STRUCTURE, V6, P951, DOI 10.1016/S0969-2126(98)00097-5; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; PERLER FB, 1999, IN PRESS NUCL ACIDS, V27; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Telenti A, 1997, J BACTERIOL, V179, P6378, DOI 10.1128/jb.179.20.6378-6382.1997; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	22	128	147	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					3923	3926		10.1074/jbc.274.7.3923	http://dx.doi.org/10.1074/jbc.274.7.3923			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933578	hybrid			2022-12-25	WOS:000078575500002
J	Bodeau-Pean, S; Ravassard, P; Neuner-Jehle, M; Faucheux, B; Mallet, J; Dumas, S				Bodeau-Pean, S; Ravassard, P; Neuner-Jehle, M; Faucheux, B; Mallet, J; Dumas, S			A human tyrosine hydroxylase isoform associated with progressive supranuclear palsy shows altered enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PROTEASE CALPAIN; DOPA-RESPONSIVE DYSTONIA; MESSENGER-RNA; LIMITED PROTEOLYSIS; ADRENAL-MEDULLA; GENE; PHOSPHORYLATION; ACTIVATION; BINDING; REGION	A novel human tyrosine hydroxylase (HTH) messenger RNA subgroup generated by alternative splicing and characterized by the absence of the third exon was recently identified. The corresponding putative protein lacks 74 amino acids including Ser(31) and Ser(40), two major phosphorylation sites implicated in the regulation of HTH activity. These mRNA species are detected in adrenal medulla and are overexpressed in patients suffering from progressive supranuclear palsy, a neurodegenerative disease mostly affecting catecholaminergic neurons of the basal ganglia. In the present work, an HTH protein isoform lacking exon 3 was identified in human adrenal medulla. For this purpose, an antibody was raised against the HTH exon 3, The effect of the removal of exon 3 on the enzymatic activity of HTH was studied in vitro by comparing a purified recombinant fusion protein without exon 3 (glutathione S-transferase (GST)-HTH Delta 3) to the equivalent protein containing exon 3 (GST-HTH3). In initial velocity conditions, GST-HTH Delta 3 has 30% of the maximal velocity of GST-HTH3. Moreover, the skipping of exon 3 results in the absence of activation of GST-HTH by heparin and increases by 10-fold the retroinhibition constant for dopamine, demonstrating the involvement of exon 3 in the regulation of HTH enzymatic activity. The identification of a variably expressed HTH isoform that lacks an exon implicated in activity regulation supports the view that HTH alternative splicing contributes to the functional diversity within the catecholaminergic system and may be implicated in some neurological diseases.	Hop La Pitie Salpetriere, CNRS, UMR 9923, Lab Genet Mol Neurotransmiss & Proc Neurodigenera, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Dumas, S (corresponding author), Hop La Pitie Salpetriere, LGN, Batiment CERVI Etage 5,83 Bd Hop, F-75013 Paris, France.			ravassard, philippe/0000-0002-0393-9262				ABATE C, 1991, J MOL NEUROSCI, V2, P203; ALMAS B, 1992, EUR J BIOCHEM, V209, P249, DOI 10.1111/j.1432-1033.1992.tb17283.x; Alterio J, 1998, J BIOL CHEM, V273, P10196, DOI 10.1074/jbc.273.17.10196; ANDERSSON KK, 1992, BIOCHEM J, V284, P687, DOI 10.1042/bj2840687; BIRMAN S, 1994, J BIOL CHEM, V269, P26559; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; COKER GT, 1990, MOL BRAIN RES, V8, P93, DOI 10.1016/0169-328X(90)90052-F; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DANIEL SE, 1995, BRAIN, V118, P759, DOI 10.1093/brain/118.3.759; DAUBNER SC, 1995, PROTEIN SCI, V4, P538; DEYEBENES JG, 1995, BRAIN, V118, P1095, DOI 10.1093/brain/118.5.1095; DIXON M, 1964, ENZYMES, P81; Dumas S, 1996, J NEUROCHEM, V67, P19; GAHN LG, 1993, BIOCHEM J, V295, P189, DOI 10.1042/bj2950189; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Haavik J, 1997, J NEUROCHEM, V68, P328; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HAYCOCK JW, 1993, J NEUROCHEM, V60, P493, DOI 10.1111/j.1471-4159.1993.tb03177.x; HAYCOCK JW, 1991, J NEUROCHEM, V56, P2139, DOI 10.1111/j.1471-4159.1991.tb03477.x; HAYKALCOATES N, 1991, BRAIN RES, V556, P353, DOI 10.1016/0006-8993(91)90330-X; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V213, P645, DOI 10.1006/bbrc.1995.2180; Joh T H, 1998, Adv Pharmacol, V42, P33; KATZ IR, 1976, BIOCHIM BIOPHYS ACTA, V429, P84, DOI 10.1016/0005-2744(76)90032-2; KIUCHI K, 1991, BIOCHEMISTRY-US, V30, P10416, DOI 10.1021/bi00107a008; KNAPPSKOG PM, 1995, HUM MOL GENET, V4, P1209, DOI 10.1093/hmg/4.7.1209; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kumer SC, 1996, J NEUROCHEM, V67, P443; Laniece P, 1996, J NEUROCHEM, V66, P1819; LEBOURDELLES B, 1988, J NEUROCHEM, V50, P988; LEWIS DA, 1993, NEUROSCIENCE, V54, P477, DOI 10.1016/0306-4522(93)90267-J; LIU X, 1991, NEUROCHEM INT, V18, P27, DOI 10.1016/0197-0186(91)90031-8; Ludecke B, 1996, HUM MOL GENET, V5, P1023, DOI 10.1093/hmg/5.7.1023; Nagatsu T, 1995, ESSAYS BIOCHEM, V30, P15; OKUNO S, 1991, J NEUROCHEM, V57, P53, DOI 10.1111/j.1471-4159.1991.tb02098.x; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P2910; OTA A, 1995, BIOCHEM BIOPH RES CO, V213, P1099, DOI 10.1006/bbrc.1995.2240; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; TOGARI A, 1986, BIOCHEM BIOPH RES CO, V134, P749, DOI 10.1016/S0006-291X(86)80484-3; VRANA KE, 1994, J NEUROCHEM, V63, P2014; WU J, 1992, J BIOL CHEM, V267, P25754	43	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3469	3475		10.1074/jbc.274.6.3469	http://dx.doi.org/10.1074/jbc.274.6.3469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920892	hybrid			2022-12-25	WOS:000078428200032
J	Chen, H; Slepnev, VI; Di Fiore, PP; De Camilli, P				Chen, H; Slepnev, VI; Di Fiore, PP; De Camilli, P			The interaction of epsin and Eps15 with the clathrin adaptor AP-2 is inhibited by mitotic phosphorylation and enhanced by stimulation-dependent dephosphorylation in nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; COATED PITS; VESICLE FORMATION; PROTEIN; DOMAIN; DYNAMIN; EH; PHOSPHOPROTEINS; ENDOCYTOSIS; CELLS	Clathrin-mediated endocytosis was shown to be arrested in mitosis due to a block in the invagination of clathrin-coated pits. A Xenopus mitotic phosphoprotein, MP90, is very similar to an abundant mammalian nerve terminal protein, epsin, which binds the Eps15 homology (EH) domain of Eps15 and the alpha-adaptin subunit of the clathrin adaptor AP-2, We show here that both rat epsin and Eps15 are mitotic phosphoproteins and that their mitotic phosphorylation inhibits binding to the appendage domain of alpha-adaptin. Both epsin and Eps15, like other cytosolic components of the synaptic vesicle endocytic machinery, undergo constitutive phosphorylation and depolarization-dependent dephosphorylation in nerve terminals. Furthermore, their binding to AP-2 in brain extracts is enhanced by dephosphorylation, Epsin together with Eps15 was proposed to assist the clathrin coat in its dynamic rearrangements during the invagination/fission reactions. Their mitotic phosphorylation may be one of the mechanisms by which the invagination of clathrin-coated pits is blocked in mitosis and their stimulation-dependent dephosphorylation at synapses may contribute to the compensatory burst of endocytosis after a secretory stimulus.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Bari, Ist Microbiol, I-70124 Bari, Italy	Howard Hughes Medical Institute; Yale University; IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu	Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Gad H, 1998, NEURON, V21, P607, DOI 10.1016/S0896-6273(00)80570-X; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Iannolo G, 1997, CANCER RES, V57, P240; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Nigg E A, 1991, Semin Cell Biol, V2, P261; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	34	110	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3257	3260		10.1074/jbc.274.6.3257	http://dx.doi.org/10.1074/jbc.274.6.3257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920862	hybrid			2022-12-25	WOS:000078428200002
J	Heyduk, E; Heyduk, T				Heyduk, E; Heyduk, T			Architecture of a complex between the sigma(70) subunit of Escherichia coli RNA polymerase and the nontemplate strand oligonucleotide - Luminescence resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER RECOGNITION; BACILLUS-SUBTILIS; TRANSCRIPTION INITIATION; SIGMA-70 SUBUNIT; FACTOR MUTATIONS; MISMATCH BUBBLE; AMINO-ACIDS; DNA; BINDING; SPECIFICITY	We used luminescence energy transfer measurements to determine the localization of 5'- and 3'-ends of a 12-nucleotide nontemplate strand oligonucleotide bound to sigma(70) holoenzyme, Five single reactive cysteine mutants of sigma(70) (cysteine residues at positions 1, 59, 366, 442, and 596) were labeled with a europium chelate fluorochrome (donor). The oligonucleotide was modified at the 5'- or at the S'-end with Cy5 fluorochrome (acceptor). The energy transfer was observed upon complex formation between the donor-labeled sigma(70) holoenzyme and the acceptor-labeled nontemplate strand oligonucleotide, whereas no interaction was observed with the template strand oligonucleotide. The oligonucleotide was bound in one preferred orientation. This observation together with the sequence specificity of single-stranded oligonucleotide interaction suggests that two mechanisms of discrimination between the template and nontemplate strand are used by sigma(70): sequence specificity and strand polarity specificity. The bound oligonucleotide was found to be close to residue 442, confirming that the single-stranded DNA binding site of sigma(70) is located in an cu-helix containing residue 442. The 5'-end of the oligonucleotide was oriented toward the COOH terminus of the helix.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@wpogate.slu.edu			NIGMS NIH HHS [GM50514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; AIYAR SE, 1994, J BIOL CHEM, V269, P13179; BURGESS RR, 1970, FED PROC, V29, P1164; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HEYDUK E, 1992, BIOCHEMISTRY-US, V31, P3682, DOI 10.1021/bi00129a017; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; Ishihama A, 1990, Adv Biophys, V26, P19, DOI 10.1016/0065-227X(90)90005-E; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; LEIRMO S, 1990, NUCLEIC ACIDS MOL BI, P123; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Savinkova L. K., 1996, Molekulyarnaya Biologiya (Moscow), V30, P188; SAVINKOVA LK, 1983, DOKL AKAD NAUK SSSR+, V270, P1501; SAVINKOVA LK, 1993, MOL BIOL+, V27, P33; SAVINKOVA LK, 1988, MOL BIOL+, V22, P651; Selvin PR, 1996, IEEE J SEL TOP QUANT, V2, P1077, DOI 10.1109/2944.577339; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; TRIPATARA A, 1993, J MOL BIOL, V233, P349, DOI 10.1006/jmbi.1993.1516; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	45	31	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3315	3322		10.1074/jbc.274.6.3315	http://dx.doi.org/10.1074/jbc.274.6.3315			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920872	hybrid			2022-12-25	WOS:000078428200012
J	Krasnoperov, V; Bittner, MA; Holz, RW; Chepurny, O; Petrenko, AG				Krasnoperov, V; Bittner, MA; Holz, RW; Chepurny, O; Petrenko, AG			Structural requirements for alpha-latrotoxin binding and alpha-latrotoxin-stimulated secretion - A study with calcium-independent receptor of alpha-latrotoxin (CIRL) deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; CATIONS; FAMILY	Stimulation of neurotransmitter release by alpha-latrotoxin requires its binding to the calcium-independent receptor of alpha-latrotoxin (CIRL), an orphan neuronal G protein-coupled receptor. CIRL consists of two noncovalently bound subunits, p85, a heptahelical integral membrane protein, and p120, a large extracellular polypeptide with domains homologous to lectin, olfactomedin, mucin, the secretin receptor family, and a novel structural motif common for large orphan G protein-coupled receptors, The analysis of CIRL deletion mutants indicates that the high affinity alpha-latrotoxin-binding site is located within residues 467-891, which comprise the first transmembrane segment of p85 and the C-terminal half of p120, The N-terminal lectin, olfactomedin, and mucin domains of p120 are not required for the interaction with alpha-latrotoxin. Soluble p120 and all its fragments, which include the 467-770 residues, bind alpha-latrotoxin with low affinity suggesting the importance of membrane-embedded p85 for the stabilization of the complex of the toxin with p120, Two COOH-terminal deletion mutants of CIRL, one with the truncated cytoplasmic domain and the other with only one transmembrane segment left of seven, supported both alpha-latrotoxin-induced calcium uptake in HEK293 cells and alpha-latrotoxin-stimulated secretion when expressed in chromaffin cells, although with a different dose dependence than wild-type CIRL and its N-terminal deletion mutant, Thus the signaling domains of CIRL are not critically important for the stimulation of exocytosis in intact chromaffin cells by alpha-latrotoxin.	NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU Med Ctr, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU Med Ctr, Dept Environm Med, New York, NY 10016 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	New York University; New York University; New York University; University of Michigan System; University of Michigan	Petrenko, AG (corresponding author), NYU Med Ctr, Dept Pharmacol, 550 1st Ave,MSB 202, New York, NY 10016 USA.			Petrenko, Alexander/0000-0002-6689-6546	NIDDK NIH HHS [R01DK27959] Funding Source: Medline; NINDS NIH HHS [R01NS34937, R01NS35098] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035098, R01NS034937] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; ICHTCHENKO K, 1999, IN PRESS J BIOL CHEM; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; MISLER S, 1987, AM J PHYSIOL, V253, pC469, DOI 10.1152/ajpcell.1987.253.3.C469; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1998, CELLULAR MOL MECH TO, P185; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094	20	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3590	3596		10.1074/jbc.274.6.3590	http://dx.doi.org/10.1074/jbc.274.6.3590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920906	hybrid			2022-12-25	WOS:000078428200046
J	Davidson, JM; Aquino, AM; Woodward, SC; Wilfinger, WW				Davidson, JM; Aquino, AM; Woodward, SC; Wilfinger, WW			Sustained microgravity reduces intrinsic wound healing and growth factor responses in the rat	FASEB JOURNAL			English	Article						space medicine; granulation tissue; PDGF; bFGF	PERIPHERAL-BLOOD LEUKOCYTES; SPACEFLIGHT; REPAIR; SPACE; BONE	Spaceflight is known to diminish bone mass and reduce immune function, suggesting that repair of connective tissue might be impaired in a microgravity environment. Fisher 344 rats were used to test wound healing responses in the orbiting Space Shuttle Endeavour by preflight implantation of polyvinyl acetal sponge disks in which pellets were placed to release either platelet-derived growth factor (PDGF-EB), basic fibroblast growth factor (bFGF), or placebo. Control groups on the ground included a matched environment group in similar housing modules and temperature control groups in cages at 22 degrees C and 28 degrees C, After 12 days of implantation and 10 days in orbit, the removed sponges were analyzed for histological and biochemical responses. Growth factor responses were histologically evident after release of PDGF-BB and bFGF in ground controls, whereas only immediate-release bFGF and delayed-release PDGF-BB showed significant responses in microgravity, Biochemical data confirmed that cellularity was increased by both factors in ground sponges; however, this response was significantly blunted in flight sponges (P<0.005, ANOVA), irrespective timing of factor release, Collagen content was 62% lower in sponges from animals with 10 days of microgravity exposure (P<0.01, ANOVA) and further reduced by bFGF, These data suggest that orbital exposure retards the capacity of wounds to heal and respond to exogenous stimuli.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA; Penn State Univ, Ctr Cell Res, University Pk, PA 16802 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Davidson, JM (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, MCN C-3321,21st & Garland St, Nashville, TN 37232 USA.			Wilfinger, William/0000-0002-7891-2232				Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; ALLEBBAN Z, 1994, J LEUKOCYTE BIOL, V55, P209, DOI 10.1002/jlb.55.2.209; Bolton L, 1997, WOUNDS, V9, P127; BORKOWSKI GL, 1995, AWIC NEWSLETTER, V6, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROADLEY KN, 1989, LAB INVEST, V61, P571; BROADLEY KN, 1989, LAB INVEST, V61, P511; BUCKLEY A, 1985, P NATL ACAD SCI USA, V82, P7340, DOI 10.1073/pnas.82.21.7340; CLARK RAF, 1996, MOL CELLULAR BIOL WO, P611; COHEN IK, 1991, WOUND REPAIR BIOMEDI; DAVIDSON JM, 1996, CELLULAR MOL PATHOGE, P79; DAVIDSON JM, 1998, ANIMAL MODELS WOUND; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; GROTENDORST GR, 1985, J CLIN INVEST, V76, P2323, DOI 10.1172/JCI112243; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; Ichiki AT, 1996, J LEUKOCYTE BIOL, V60, P37, DOI 10.1002/jlb.60.1.37; Ilyina-Kakueva E I, 1991, Physiologist, V34, pS141; Kaplansky A S, 1991, Physiologist, V34, pS196; MCGEE GS, 1988, J SURG RES, V45, P145, DOI 10.1016/0022-4804(88)90034-0; Meehan R, 1987, Adv Exp Med Biol, V225, P273; POSPISILOVA I, 1989, KOSM BIOL AVIAK MED+, V23, P44; Riches DWH, 1996, MOL CELLULAR BIOL WO, P95; SONNENFELD G, 1992, J APPL PHYSIOL, V73, pS191, DOI 10.1152/jappl.1992.73.2.S191; TAYLOR GR, 1986, AVIAT SPACE ENVIR MD, V57, P213; VAILAS AC, 1990, FASEB J, V4, P47, DOI 10.1096/fasebj.4.1.2295378; WOODWARD SC, 1968, ARCH SURG-CHICAGO, V96, P189	26	66	68	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					325	329		10.1096/fasebj.13.2.325	http://dx.doi.org/10.1096/fasebj.13.2.325			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973320	Bronze			2022-12-25	WOS:000078615200012
J	Bradbury, P; Mann, CJ; Kochl, S; Anderson, TA; Chester, SA; Hancock, JM; Ritchie, PJ; Amey, J; Harrison, GB; Levitt, DG; Banaszak, LJ; Scott, J; Shoulders, CC				Bradbury, P; Mann, CJ; Kochl, S; Anderson, TA; Chester, SA; Hancock, JM; Ritchie, PJ; Amey, J; Harrison, GB; Levitt, DG; Banaszak, LJ; Scott, J; Shoulders, CC			A common binding site on the microsomal triglyceride transfer protein for apolipoprotein B and protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CONTAINING LIPOPROTEINS; ABETALIPOPROTEINEMIA GENE; HEPG2 CELLS; VITELLOGENIN; DEGRADATION; EXPRESSION; SECRETION; SEQUENCE; PRODUCT	The assembly of triglyceride-rich lipoproteins requires the formation in the endoplasmic reticulum of a complex between apolipoprotein B (apoB), a microsomal triglyceride transfer protein (MTP), and protein disulfide isomerase (PDI). In the MTP complex, the aminoterminal region of MTP (residues 22-303) interacts with the amino-terminal region of apoB (residues 1-264). Here, we report the identification and characterization of a site on apoB between residues 512 and 721, which interacts with residues 517-603 of MTP. PDI binds in close proximity to this apoB binding site on MTP. The proximity of these binding sites on MTP for PDI and amino acids 512-721 of apoB was evident from studies carried out in a yeast two-hybrid system and by coimmunoprecipitation. The expression of PDI with MTP and apoB16 (residues 1-721) in the baculovirus expression system reduced the amount of MTP co-immunoprecipitated with apoB by 73%. The interaction of residues 512-721 of apoB with MTP facilitates lipoprotein production. Mutations of apoB that markedly reduced this interaction also reduced the level of apoB-containing lipoprotein secretion.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, MRC Mol Med Grp, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, Gene Genome Evolut Grp, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Natl Heart & Lung Inst, London W12 0NN, England; Inst Gerichtliche Med, A-6020 Innsbruck, Austria; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA	Imperial College London; Imperial College London; Imperial College London; University of Minnesota System; University of Minnesota Twin Cities	Shoulders, CC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, MRC Mol Med Grp, Du Cane Rd, London W12 0NN, England.		Hancock, John/A-2442-2009	Hancock, John/0000-0003-2991-2217				Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GERBERHUBER S, 1987, NUCLEIC ACIDS RES, V15, P4737, DOI 10.1093/nar/15.12.4737; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; REYNOLDS A, 1992, SHORT PROTOCOLS MOL; ROST B, 1992, NATURE, V360, P540, DOI 10.1038/360540b0; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, NAT STRUCT BIOL, V1, P285, DOI 10.1038/nsb0594-285; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1997, ARTERIOSCL THROM VAS, V17, P3347, DOI 10.1161/01.ATV.17.11.3347; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	26	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3159	3164		10.1074/jbc.274.5.3159	http://dx.doi.org/10.1074/jbc.274.5.3159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915855	hybrid			2022-12-25	WOS:000078319500073
J	Lam, CW; Xie, JW; To, KF; Ng, HK; Lee, KC; Yuen, NWF; Lim, PL; Chan, LYS; Tong, SF; McCormick, F				Lam, CW; Xie, JW; To, KF; Ng, HK; Lee, KC; Yuen, NWF; Lim, PL; Chan, LYS; Tong, SF; McCormick, F			A frequent activated smoothened mutation in sporadic basal cell carcinomas	ONCOGENE			English	Article						hedgehog; patched; smoothened; basal cell carcinoma; mutation	HUMAN HOMOLOG; RECEPTOR; GENE	Basal-cell carcinomas (BCCs) are the most common cancer in Caucasians, It has been reported that the patched gene is inactivated in 30-40% sporadic BCCs and 20% sporadic medulloblastomas via loss of heterozygosity and nonsense mutations. Recently, two activating smoothened mutations have been found in the sporadic basal cell carcinomas. One, at base pair 1604 (G-to-T transversion) of exon 9, changes codon 535 from tryptophan to leucine, and the other, at base pair 1685 (G-to-A transition) of exon 10, changes codon 562 from arginine to glutamine (Xie et al,, 1998), In our study, 1604G-->T was found in 20 out of 97 (20.6%) sporadic BCCs, The high prevalence indicates that 1604G is the mutation hot spot in our tumor samples. This mutation was detected in all three histological subtypes of BCCs, suggesting that smoothened mutation is an early event during the development of the tumor. Our finding of a high smoothened mutation rate, together with high frequent patched gene mutations reported recently, indicates that activation of the hedgehog signal transduction pathway is the most common and early event in the development of sporadic BCCs, Additionally, to determine whether smoothened, like patched, is also involved in the carcinogenesis of medulloblastomas, we screened medulloblastoma samples for these two mutations by restriction analysis. We have found the 1604G-->T mutation in 1 out of 21 medulloblastomas. This result confirmed smoothened gene involvement in the carcinogenesis of medulloblastoma.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Clin Immunol Unit, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Pathol, Hong Kong, Peoples R China; United Christian Hosp, Dept Pathol, Hong Kong, Peoples R China; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; United Christian Hospital; University of California System; University of California San Francisco	Lam, CW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China.		Ng, Ho Keung/I-3952-2015					BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; MAK ASY, 1995, SCAND J PLAST RECONS, V29, P149, DOI 10.3109/02844319509034331; Raffel C, 1997, CANCER RES, V57, P842; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Wicking C, 1997, AM J HUM GENET, V60, P21; Wong SS, 1998, J AM ACAD DERMATOL, V38, P179, DOI 10.1016/S0190-9622(98)70596-1; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	14	140	152	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					833	836		10.1038/sj.onc.1202360	http://dx.doi.org/10.1038/sj.onc.1202360			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989836				2022-12-25	WOS:000078394400031
J	Wistuba, II; Behrens, C; Milchgrub, S; Bryant, D; Hung, J; Minna, JD; Gazdar, AF				Wistuba, II; Behrens, C; Milchgrub, S; Bryant, D; Hung, J; Minna, JD; Gazdar, AF			Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma	ONCOGENE			English	Article						lung carcinoma; preneoplastic lesions; loss of heterozygosity; chromosome 3p; chromosome 9p; TP53 gene	MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; CLONAL EVOLUTION; FORMER SMOKERS; CHROMOSOME 3P; ALLELE LOSS; FHIT GENE; CANCER; LESIONS; P53	To understand the molecular pathways involved in the pathogenesis of squamous cell lung carcinoma, we obtained DNA from 94 microdissected foci from 12 archival surgically resected tumors including histologically normal epithelium (n = 13), preneoplastic lesions (n = 54), carcinoma is situ (CIS) (n = 15) and invasive tumors (n = 12). We determined loss of heterozygosity (LOH) at 10 chromosomal regions (3p12, 3p14.2, 3p14.1-21.3, 3p21, 3p22-24, 3p25, 5q22, 9p21, 13q14 RE, and 17p13 TP53) frequently deleted in lung cancer, using 31 polymorphic microsatellite markers, including 24 that spanned the entire 3p arm. Our major findings are as follows: (1) Thirty one percent of histologically normal epithelium and 42% of mildly abnormal (hyperplasia/metaplasia) specimens had clones of cells with allelic loss at one or more regions; (2) There was a progressive increase of the overall LOH frequency within clones with increasing severity of histopathological changes; (3) The earliest and most frequent regions of allelic loss occurred at 3p21, 3p22-24, 3p25 and 9p21; (4) The size of the 3p deletions increased with progressive histologic changes; (5) TP53 allelic loss was present in many histologically advanced lesions (dysplasia and CIS); (6) Analyses of 58 normal and non-invasive foci having any molecular abnormality, indicated that 30 probably arose as independent clonal events, while 28 were potentially of the same clonal origin as the corresponding tumor; (7) Nevertheless, when the allelic losses in the 30 clonally independent lesions and their clonally unrelated tumors were compared the same parental allele was lost in 113 of 125 (90%) of comparisons. The mechanism by which this phenomenon (known as allele specific mutations) occurs is unknown; (8) Four patterns of allelic loss in clones were found. Histologically normal or mildly abnormal foci had a negative pattern (no allelic loss) or early pattern of loss while all foci of CIS and invasive tumor had an advanced pattern. However dysplasias demonstrated the entire spectrum of allelic loss patterns, and were the only histologic category having the intermediate pattern. Our findings indicate that multiple, sequentially occurring allele specific molecular changes commence in widely dispersed, apparently clonally independent foci, early in the multistage pathogenesis of squamous cell carcinomas of the lung.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Pontificia Univ Catolica Chile, Dept Pathol, Santiago, Chile	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pontificia Universidad Catolica de Chile	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd,NB8-106, Dallas, TX 75235 USA.				NCI NIH HHS [P50-CA70907, N01CN45580-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI J, 1995, GENE CHROMOSOME CANC, V14, P301, DOI 10.1002/gcc.2870140409; BAND PR, 1986, CANCER DETECT PREV, V9, P157; Birch DE, 1996, NATURE, V381, P445, DOI 10.1038/381445a0; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; Chung GTY, 1995, ONCOGENE, V11, P2591; Chung GTY, 1996, CANCER RES, V56, P1609; COLBY TV, 1995, TUMORS LOWER RESP TR; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Fishel R, 1996, J NATL CANCER I, V88, P1608, DOI 10.1093/jnci/88.22.1608; FISHER JC, 1958, NATURE, V181, P651, DOI 10.1038/181651b0; FONG KM, 1995, CANCER RES, V55, P28; Fong KM, 1997, CANCER RES, V57, P2256; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; FROST JK, 1986, J OCCUP ENVIRON MED, V28, P692, DOI 10.1097/00043764-198608000-00031; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MERLO A, 1994, CANCER RES, V54, P2098; Minna John D., 1997, P849; Miozzo M, 1996, CANCER RES, V56, P2285; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; RISSE EKJ, 1988, ACTA CYTOL, V32, P629; SACCOMANNO G, 1974, CANCER-AM CANCER SOC, V33, P256, DOI 10.1002/1097-0142(197401)33:1<256::AID-CNCR2820330139>3.0.CO;2-G; SIEGEL S., 1956, NONPARAMETRIC STAT B; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; STRONG MS, 1984, J OTOLARYNGOL, V13, P1; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; THIBERVILLE L, 1995, CANCER RES, V55, P5133; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WISTUBA II, 1995, CANCER RES, V55, P2511; Wistuba II, 1998, JAMA-J AM MED ASSOC, V279, P1554, DOI 10.1001/jama.279.19.1554; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	42	261	273	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					643	650		10.1038/sj.onc.1202349	http://dx.doi.org/10.1038/sj.onc.1202349			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989814				2022-12-25	WOS:000078394400009
J	Walker, DR; Bond, JP; Tarone, RE; Harris, CC; Makalowski, W; Boguski, MS; Greenblatt, MS				Walker, DR; Bond, JP; Tarone, RE; Harris, CC; Makalowski, W; Boguski, MS; Greenblatt, MS			Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features	ONCOGENE			English	Article						molecular evolution; missense mutation; crystal structure; DNA binding; domain	TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; CELL-LINES; GENE; DOMAIN; SUBSTITUTIONS; APOPTOSIS; CANCER	Missense mutations in p53 frequently occur at 'hotspot' amino acids which are highly conserved and represent regions of structural or functional importance. Using the p53 mutation database and the p53 DNA sequences for 11 species, we more precisely defined the relationships among conservation, mutation frequency and protein structure. We aligned the p53 sequences codon-by-codon and determined the degree of substitution among them. As a whole, p53 is evolving at an average rate for a mammalian protein-coding gene. As expected, the DNA binding domain is evolving more slowly than the carboxy and amino termini, A detailed map of evolutionary conservation shows that within the DNA binding domain there are repeating peaks and valleys of higher and lower evolutionary constraint, Mutation hotspots were identified by comparing the observed distribution of mutations to the pattern expected from a random multinomial distribution, Seventy-three hotspots were identified; these 19% of codons account for 88% of all reported p53 mutations. Both high evolutionary constraint and mutation hotspots are noted at amino acids close to the protein-DNA interface and at others more distant from DNA, often buried within the core of the folded protein but sometimes on its surface. The results indicate that targeting highly conserved regions for mutational and functional analysis may be efficient strategies for the study of cancer-related genes.	NCI, Natl Ctr Biotechnol Informat, Natl Lib Med, NIH, Bethesda, MD 20894 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Greenblatt, MS (corresponding author), Univ Vermont, Coll Med, Dept Med, Hematol Oncol Unit, Patrick 534,MCHV Campus, Burlington, VT 05401 USA.		Makalowski, Wojciech/I-2843-2016	Makalowski, Wojciech/0000-0003-2303-9541	DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010130] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; INA Y, 1995, J MOL EVOL, V40, P190, DOI 10.1007/BF00167113; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KYTE J, 1995, MECH PROTEIN CHEM; Li W. H, 1997, MOL EVOLUTION; LI WH, 1991, FUNDAMENTALS MOL EVO, P69; MAKALOWSKI W, 1998, IN PRESS P NATL ACAD; Miller R. G., 1981, SIMULTANEOUS STAT IN, P6; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rodin SN, 1998, INT J MOL MED, V1, P191; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOUSSI T, 1990, ONCOGENE, V5, P945; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TICHER A, 1989, J MOL EVOL, V28, P286, DOI 10.1007/BF02103424; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219	27	164	169	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					211	218		10.1038/sj.onc.1202298	http://dx.doi.org/10.1038/sj.onc.1202298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926936				2022-12-25	WOS:000078166000023
J	Zwicker, J; Brusselbach, S; Jooss, KU; Sewing, A; Behn, M; Lucibello, FC; Muller, R				Zwicker, J; Brusselbach, S; Jooss, KU; Sewing, A; Behn, M; Lucibello, FC; Muller, R			Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation	ONCOGENE			English	Article						cyclin D1; transformation; retinoblastoma protein (Rb); Ras, cooperation with cyclin D1; CDK4	RETINOBLASTOMA PROTEIN; TRANSGENIC MICE; EXPRESSION; ONCOGENE; YEAST; GENE; DNA; PHOSPHORYLATION; PHASE; CDK4	Although cyclin D1 plays a major role during cell cycle progression and is involved in human tumourigenesis, its domain structure is still poorly understood. In the present study, we have generated a series of cyclin D1 N- and C1-terminal deletion constructs. These mutants were used to define the domains required for transformation of rat embryonal fibroblasts (REF) in cooperation with activated Ha-ras and and to establish correlations with defined biochemical properties of cyclin D1, Protein binding and REF assays showed that the region of the cyclin box required for the interaction with CDK4 as well as C-terminal sequences determining protein stability were crucial for transformation. Surprisingly, however, the N-terminal deletion of 20 amino acids which impaired pRb kinase activity did not affect the transforming ability of cyclin D1, Likewise, no effect on transformation was observed with mutants defective in p21(CIP) interaction. These observations argue against a crucial role of pRb inactivation or p21(CIP) squelching in cyclin D1-mediated transformation.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Maeda K, 1998, ONCOLOGY-BASEL, V55, P145, DOI 10.1159/000011849; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SEWING A, 1994, ONCOGENE, V9, P2733; SEWING A, 1993, J CELL SCI, V104, P545; SIKORSKI RS, 1989, GENETICS, V122, P19; TAM SW, 1994, ONCOGENE, V9, P2663; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	40	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					19	25		10.1038/sj.onc.1202286	http://dx.doi.org/10.1038/sj.onc.1202286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926916				2022-12-25	WOS:000078166000003
J	Lee, SR; Kim, JR; Kwon, KS; Yoon, HW; Levine, RL; Ginsburg, A; Rhee, SG				Lee, SR; Kim, JR; Kwon, KS; Yoon, HW; Levine, RL; Ginsburg, A; Rhee, SG			Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG ADENOCARCINOMA CELLS; GLUTATHIONE-REDUCTASE; DISULFIDE OXIDOREDUCTASES; LIPOAMIDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; REDOX REGULATION; SELENOPROTEIN-W; SECIS ELEMENTS; C-ELEGANS	A thioredoxin reductase (TrxR), named here TrxR2, that did not react with antibodies to the previously identified TrxR (now named TrxR1) was purified from rat liver. Like TrxR1, TrxR2 was a dimeric enzyme containing selenocysteine (Secys) as the COOH-terminal penultimate residue. A cDNA encoding TrxRa was cloned from rat liver; the open reading frame predicts a polypeptide of 526 amino acids with a COOH-terminal Gly-Cys-Secys-Gly motif provided that an in-frame TGA codon encodes Secys. The 3'-untranslated region of the cDNA contains a canonical Secys insertion sequence element, The deduced amino acid sequence of TrxR1 shows 54% identity to that of TrxR1 and contained 36 additional residues upstream of the experimentally determined NH2-terminal sequence. The sequence of this 36-residue region is typical of that of a mitochondrial leader peptide. Immunoblot analysis confirmed that TrxR2 is localized almost exclusively in mitochondria, whereas TrxR1 is a cytosolic protein. Unlike TrxR1, which was expressed at a level of 0.6 to 1.6 mu g/mill/gram of total soluble protein in all rat tissues examined, TrxRa was relatively abundant (0.3 to 0.6 mu g/mg) only in liver, kidney, adrenal gland, and heart. The specific localization of TrxR2 in mitochondria, together with the previous identification of mitochondria-specific thioredoxin and thioredoxin-dependent peroxidase, suggest that these three proteins provide a primary line of defense against H2O2 produced by the mitochondrial respiratory chain.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122, Bethesda, MD 20892 USA.	sgrhee@nih.gov	Levine, Rodney L/D-9885-2011					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BROWN NL, 1983, BIOCHEMISTRY-US, V22, P4089, DOI 10.1021/bi00286a015; Candas M, 1997, ARCH BIOCHEM BIOPHYS, V339, P323, DOI 10.1006/abbi.1996.9872; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; DAHER R, 1994, CLIN CHEM, V40, P62; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu QP, 1997, GENE, V193, P187, DOI 10.1016/S0378-1119(97)00113-3; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KLUK RM, 1997, SCIENCE, V275, P1132; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; KROEMER G, 1997, CELL DEATH DIFFER, V4, P449; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu SY, 1997, P NATL ACAD SCI USA, V94, P6138, DOI 10.1073/pnas.94.12.6138; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schachman H.K., 1959, ULTRACENTRIFUGATION; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stafford Walter F., 1996, Biophysical Journal, V70, pA231; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Tamura T, 1995, BIOFACTORS, V5, P99; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO T, 1989, GENE, V80, P337; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; [No title captured]	63	233	240	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4722	4734		10.1074/jbc.274.8.4722	http://dx.doi.org/10.1074/jbc.274.8.4722			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988709	hybrid			2022-12-25	WOS:000078698200034
J	Levine, J; Etter, J; Apostol, I				Levine, J; Etter, J; Apostol, I			Nickel-catalyzed N-terminal oxidative deamination in peptides containing histidine at position 2 coupled with sulfite oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; CROSS-LINKING; PROTEIN OXIDATION; HYDROXYL RADICALS; DECARBOXYLATION; PEROXIDATION; AUTOXIDATION; (BI)SULFITE; METHIONINE; COMPLEX	Peptides containing histidine at position 2 were observed to undergo spontaneous N-terminal oxidative deamination in aqueous solution in the presence of Ni(II), sulfite, and ambient oxygen. The reaction resulted in the formation of a free carbonyl on the N-terminal alpha-carbon (alpha-ketoamide) and was catalytic with respect to nickel. This oxidative deamination was confirmed by C-13 NMR, H-1 MMR, mass spectrometry, and chemical tests. No evidence of modification of histidine was found. It was demonstrated that the nickel-dependent N-terminal oxidative deamination also occurred in His-2 peptides using potassium peroxymonosulfate (oxone) as an oxidant. When oxone was used, oxygen was not required for the deamination to proceed. The results suggest that both nickel-catalyzed reactions (sulfite and oxygen, and oxone) produce an imine intermediate that spontaneously hydrolyzes to form the free carbonyl, These findings may provide a physiologically relevant model for oxidative carbonyl formation in vivo, as well as a useful method for producing a site-specific carbonyl on peptides and proteins.	Baxter Hemoglobin Therapeut Inc, Boulder, CO 80301 USA		Apostol, I (corresponding author), Baxter Hemoglobin Therapeut Inc, 2545 Cent Ave, Boulder, CO 80301 USA.							AMICI A, 1989, J BIOL CHEM, V264, P3341; Apostol I, 1997, J BIOL CHEM, V272, P28980, DOI 10.1074/jbc.272.46.28980; ATHAR M, 1987, BIOCHEM BIOPH RES CO, V147, P1276, DOI 10.1016/S0006-291X(87)80208-5; BAL W, 1994, J CHEM SOC CHEM COMM, P1889, DOI 10.1039/c39940001889; BRANDT C, 1995, CHEM REV, V95, P119, DOI 10.1021/cr00033a006; BROWN KC, 1995, BIOCHEMISTRY-US, V34, P4733, DOI 10.1021/bi00014a030; Brown KC, 1998, BIOCHEMISTRY-US, V37, P4397, DOI 10.1021/bi9728046; CHEN K, 1991, J AM CHEM SOC, V113, P5884; Cornish VW, 1996, J AM CHEM SOC, V118, P8150, DOI 10.1021/ja961216x; Davies MJ, 1996, ARCH BIOCHEM BIOPHYS, V336, P163, DOI 10.1006/abbi.1996.0545; Dean RT, 1997, BIOCHEM J, V324, P1; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; Gaertner HF, 1996, BIOCONJUGATE CHEM, V7, P38, DOI 10.1021/bc950074d; Gill G, 1997, CHEM RES TOXICOL, V10, P302, DOI 10.1021/tx960170i; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; INOUE S, 1989, BIOCHEM BIOPH RES CO, V159, P445, DOI 10.1016/0006-291X(89)90012-0; Levine J, 1998, J BIOL CHEM, V273, P13037, DOI 10.1074/jbc.273.21.13037; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Liang Q, 1998, J AM CHEM SOC, V120, P248, DOI 10.1021/ja9720218; March J., 1992, REACTIONS MECH STRUC, V4th; MERKLER DJ, 1995, FEBS LETT, V366, P165, DOI 10.1016/0014-5793(95)00516-C; MOTTLEY C, 1988, ARCH BIOCHEM BIOPHYS, V267, P681, DOI 10.1016/0003-9861(88)90077-X; Muller JG, 1997, J AM CHEM SOC, V119, P1501, DOI 10.1021/ja963701y; NETA P, 1985, ENVIRON HEALTH PERSP, V64, P209, DOI 10.2307/3430011; REED GA, 1986, P NATL ACAD SCI USA, V83, P7499, DOI 10.1073/pnas.83.19.7499; SAKURAI T, 1979, INORG CHIM ACTA, V34, pL243, DOI 10.1016/S0020-1693(00)94648-6; SCHONEICH C, 1993, BIOCHIM BIOPHYS ACTA, V1158, P307, DOI 10.1016/0304-4165(93)90030-C; SHIEMKE AK, 1989, J BIOL CHEM, V264, P7276; SHULLENBERGER DF, 1993, J AM CHEM SOC, V115, P11038, DOI 10.1021/ja00076a091; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; THORNE GC, 1990, J AM SOC MASS SPECTR, V1, P249, DOI 10.1016/1044-0305(90)85042-K; TORREILLES J, 1990, FREE RADICAL RES COM, V11, P159, DOI 10.3109/10715769009109679; ZHUANG ZX, 1994, TOXICOL APPL PHARM, V126, P319, DOI 10.1006/taap.1994.1122	34	10	10	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					4848	4857		10.1074/jbc.274.8.4848	http://dx.doi.org/10.1074/jbc.274.8.4848			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988725	hybrid			2022-12-25	WOS:000078698200050
J	Liu, Y; Samuel, CE				Liu, Y; Samuel, CE			Editing of glutamate receptor subunit B pre-mRNA by splice-site variants of interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; GLUR-B; UNWINDING ACTIVITY; MOLECULAR-CLONING; HUMAN-CELLS; ION FLOW; 2 FORMS; Z-DNA; CHANNELS; BINDING	The interferon-inducible RNA-specific adenosine deaminase (ADAR1) is an RNA-editing enzyme that catalyzes the deamination of adenosine in double-stranded RNA structures. Three alternative splice-site variants of ADAR1 (ADAR1-a, -b, and -c) occur that possess functionally distinct double-stranded RNA-binding motifs as measured with synthetic double-stranded RNA substrates, The pre-mRNA transcript encoding the B subunit of glutamate receptor (GluR-B) has two functionally important editing sites (Q/R and R/G sites) that undergo selective A-to-I conversions. We have examined the ability of the three ADAR1 splice-site variants to catalyze the editing of GluR-B pre-mRNA at the Q/R and R/G sites as well as an intron hotspot (+60) of unknown function. Measurement of GluR-B pre-mRNA editing in vitro revealed different site-specific deamination catalyzed by the three ADAR1 variants. The ADAR1-a, -b, and -c splice variants all efficiently edited the R/G site and the intron +60 hotspot but exhibited little editing activity at the Q/R site, ADAR1-b and -c showed higher editing activity than ADAR1-a for the R/G site, whereas the intron +60 site was edited with comparable efficiency by all three ADAR1 splice variants. Mutational analysis revealed that the functional importance of each of the three RNA-binding motifs of ADAR1 varied with the specific target editing site in GluR-B RNA. Quantitative reverse transcription-polymerase chain reaction analyses of GluR-B RNA from dissected regions of rat brain showed significant expression and editing at the R/G site in all brain regions examined except the choroid plexus. The relative levels of the alternatively spliced flip and flop isoforms of GluR-B RNA varied among the choroid plexus, cortex, hippocampus, olfactory bulb, and striatum, but in all regions of rat brain the editing of the flip isoform was greater than that of the flop isoform.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Grad Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI012520] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; Belcher SM, 1997, MOL BRAIN RES, V52, P130, DOI 10.1016/S0169-328X(97)00252-0; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Brooks R, 1998, FEBS LETT, V434, P121, DOI 10.1016/S0014-5793(98)00963-6; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CATTANEO R, 1994, CURR OPIN GENET DEV, V4, P895, DOI 10.1016/0959-437X(94)90076-0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; Gerber A, 1997, RNA, V3, P453; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1994, J BIOL CHEM, V269, P17367; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; Lai F, 1997, J NEUROCHEM, V69, P43; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; Lei M, 1998, VIROLOGY, V245, P188, DOI 10.1006/viro.1998.9162; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; Liu Y, 1998, METHODS, V15, P199, DOI 10.1006/meth.1998.0624; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Mittaz L, 1997, GENOMICS, V41, P210, DOI 10.1006/geno.1997.4655; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Polson AG, 1996, NATURE, V380, P454; Rueter S.M., 1998, MODIFICATION EDITING, P343; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Villard L, 1997, SOMAT CELL MOLEC GEN, V23, P135, DOI 10.1007/BF02679972; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WATHELET MG, 1988, SOMAT CELL MOLEC GEN, V14, P415, DOI 10.1007/BF01534709; WEIER HUG, 1995, GENOMICS, V30, P372, DOI 10.1006/geno.1995.0034; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	51	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5070	5077		10.1074/jbc.274.8.5070	http://dx.doi.org/10.1074/jbc.274.8.5070			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988754	hybrid			2022-12-25	WOS:000078698200079
J	Nakaar, V; Samuel, BU; Ngo, EO; Joiner, KA				Nakaar, V; Samuel, BU; Ngo, EO; Joiner, KA			Targeted reduction of nucleoside triphosphate hydrolase by antisense RNA inhibits Toxoplasma gondii proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOPHOROUS VACUOLE MEMBRANE; ANTI-SENSE RNA; GENE-EXPRESSION; SELECTABLE MARKER; SYNTHASE GENE; PROTEIN; CELLS; RIBOZYMES; NUCLEAR; TRANSFORMATION	Nucleoside triphosphate hydrolase (NTPase) is a very abundant protein secreted by the obligate intracellular parasite Toxoplasma gondii shortly after invasion of the host cell, When activated by dithiols, NTPase is one of the most potent apyrases known to date, but its physiological function remains unknown. The genes encoding NTPase have been cloned (Bermudes, D., Peck, K. R., Afifi-Afifi, M., Beckers, C. J. M., and Joiner, K. A. (1994) J. Biol. Chem. 269, 29252-29260), We have recently shown that the enzyme is tightly controlled within the vacuolar space and may influence parasite exit from the host cell (Silverman, J. A., Qi, H., Riehl, A., Beckers, C., Nakaar, V., and Joiner, K. A (1998) J. Biol. Chem. 273, 12352-12359). In the present study, we have generated an antisense NTP RNA construct in which the 3'-untranslated region is replaced by a hammerhead ribozyme, The constitutive synthesis of the chimeric antisense RNA-ribozyme construct in parasites that were stably transfected with this construct resulted in a dramatic reduction in the steady-state levels of NTPase, This inhibition was accompanied by a decrease in the capacity of the parasites to replicate. The reduction in parasite proliferation was due to a specific effect of antisense NTP RNA, since a drastic inhibition of hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT) expression by a chimeric antisense HXGPRT RNA-ribozyme construct did not alter NTPase expression nor compromise parasite replication. These data implicate NTPase in an essential parasite function and suggest that NTPase may have more than one function in vivo, These results also establish that it is possible to study gene function in apicomplexan parasites using antisense RNA coupled to ribozymes.	Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA	Yale University	Joiner, KA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, 333 Cedar St,808 LCI, New Haven, CT 06520 USA.		Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X				ASAI T, 1983, J BIOL CHEM, V258, P6816; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; ASAI T, 1996, 4 INT BIENN TOX C JU; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BEVILACQUA A, 1988, P NATL ACAD SCI USA, V85, P831, DOI 10.1073/pnas.85.3.831; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CORNELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P7203, DOI 10.1093/nar/17.18.7203; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; ECKER JR, 1986, P NATL ACAD SCI USA, V83, P5372, DOI 10.1073/pnas.83.15.5372; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GU JL, 1995, CIRC RES, V77, P14, DOI 10.1161/01.RES.77.1.14; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUIPERS AGJ, 1995, MOL GEN GENET, V246, P745, DOI 10.1007/BF00290722; LIU Z, 1994, P NATL ACAD SCI USA, V91, P4258, DOI 10.1073/pnas.91.10.4258; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; Nakaar V, 1998, MOL BIOCHEM PARASIT, V92, P229, DOI 10.1016/S0166-6851(97)00220-X; OSSORIO PN, 1994, J BIOL CHEM, V269, P15350; PFEFFERKORN ER, 1992, ANTIMICROB AGENTS CH, V36, P1091, DOI 10.1128/AAC.36.5.1091; RODERMEL SR, 1988, CELL, V55, P673, DOI 10.1016/0092-8674(88)90226-7; ROTHSTEIN SJ, 1987, P NATL ACAD SCI USA, V84, P8439, DOI 10.1073/pnas.84.23.8439; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SIBLEY LD, 1994, EXP PARASITOL, V79, P301, DOI 10.1006/expr.1994.1093; Silverman JA, 1998, J BIOL CHEM, V273, P12352, DOI 10.1074/jbc.273.20.12352; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; Tilley M, 1997, INFECT IMMUN, V65, P4598, DOI 10.1128/IAI.65.11.4598-4605.1997; VANDERKROL AR, 1988, NATURE, V333, P866, DOI 10.1038/333866a0; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807	42	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 19	1999	274	8					5083	5087		10.1074/jbc.274.8.5083	http://dx.doi.org/10.1074/jbc.274.8.5083			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	168NB	9988756	hybrid			2022-12-25	WOS:000078698200081
J	Mock, HP; Heller, W; Molina, A; Neubohn, B; Sandermann, H; Grimm, B				Mock, HP; Heller, W; Molina, A; Neubohn, B; Sandermann, H; Grimm, B			Expression of uroporphyrinogen decarboxylase or coproporphyrinogen oxidase antisense RNA in tobacco induces pathogen defense responses conferring increased resistance to tobacco mosaic virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; PROGRAMMED CELL-DEATH; SALICYLIC-ACID; DISEASE RESISTANCE; GENE-EXPRESSION; TRANSGENIC TOBACCO; ACCUMULATION; SCOPOLETIN; PROTEINS; NECROSIS	Transgenic tobacco plants with reduced activity of either uroporphyrinogen decarboxylase or coproporphyrinogen oxidase, two enzymes of the tetrapyrrole biosynthetic pathway, are characterized by the accumulation of photosensitizing tetrapyrrole intermediates, antioxidative responses, and necrotic leaf lesions, In this study we report on cellular responses in uroporphyrinogen decarboxylase and coproporphyrinogen oxidase antisense plants, normally associated with pathogen defense. These plants accumulate the highly fluorescent coumarin scopolin in their leaves. They also display increased pathogenesis-related protein expression and higher levels of free and conjugated salicylic acid. Upon tobacco mosaic virus inoculation, the plants with leaf lesions and high levels of PR-I mRNA expression show reduced accumulation of virus RNA relative to wild-type controls. This result is indicative of an increased resistance to tobacco mosaic virus. We conclude that porphyrinogenesis as a result of deregulated tetrapyrrole synthesis induces a set of defense responses that resemble the hypersensitive reaction observed after pathogen attack.	Inst Pflanzengenet & Kulturpflanzenforsch, D-06466 Gatersleben, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Biochem Pflanzenpathol, D-85764 Oberschleissheim, Germany; Novartis Crop Protect Inc, Biotechnol & Genomics Ctr, Res Triangle Pk, NC 27709 USA	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mock, HP (corresponding author), Inst Pflanzengenet & Kulturpflanzenforsch, Corrensstr 3, D-06466 Gatersleben, Germany.	mock@ipk-gatersleben.de	Molina, Antonio/G-9789-2015; Mock, Hans-Peter/C-8202-2019	Molina, Antonio/0000-0003-3137-7938; Mock, Hans-Peter/0000-0002-3983-3099				Abad MS, 1997, MOL PLANT MICROBE IN, V10, P635, DOI 10.1094/MPMI.1997.10.5.635; ALVAREZ ME, 1997, OXIDATIVE STRESS MOL, P815; ANTONIW JF, 1986, PLANT MOL BIOL, V6, P145, DOI 10.1007/BF00021483; Arakane K, 1996, BIOCHEM BIOPH RES CO, V223, P578, DOI 10.1006/bbrc.1996.0937; Asada K, 1996, PHOTOSYNTHESIS ENV, P123, DOI DOI 10.1007/0-306-48135-9_5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEFFA R, 1995, EMBO J, V14, P5753, DOI 10.1002/j.1460-2075.1995.tb00264.x; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; BORS W, 1990, METHOD ENZYMOL, V186, P343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; Chamnongpol S, 1996, PLANT J, V10, P491, DOI 10.1046/j.1365-313X.1996.10030491.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; Dellinger M, 1996, PHOTOCHEM PHOTOBIOL, V64, P182, DOI 10.1111/j.1751-1097.1996.tb02440.x; DIETERMAN LJ, 1964, ARCH BIOCHEM BIOPHYS, V106, P275, DOI 10.1016/0003-9861(64)90188-2; DIETERMAN LJ, 1964, ANAL BIOCHEM, V9, P139, DOI 10.1016/0003-2697(64)90095-8; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; DOKE N, 1997, OXIDATIVE STRESS MOL, P815; Durner J, 1997, TRENDS PLANT SCI, V2, P266, DOI 10.1016/S1360-1385(97)86349-2; ELMODAFAR C, 1995, EUR J PLANT PATHOL, V101, P503, DOI 10.1007/BF01874474; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; Foyer C. H., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P1; Friedrich L, 1996, PLANT J, V10, P61, DOI 10.1046/j.1365-313X.1996.10010061.x; FRITIG B, 1971, Acta Phytopathologica Academiae Scientiarum Hungaricae, V6, P21; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GOY PA, 1993, PLANTA, V191, P200; HASELOFF RF, 1989, J PHOTOCH PHOTOBIO B, V3, P593, DOI 10.1016/1011-1344(89)80082-X; HEITZ T, 1994, MOL PLANT MICROBE IN, V7, P776, DOI 10.1094/MPMI-7-0776; HELLER W, 1990, ENVIRON POLLUT, V64, P353, DOI 10.1016/0269-7491(90)90057-J; Herbers K, 1996, PLANT CELL, V8, P793, DOI 10.1105/tpc.8.5.793; HOSEL W, 1987, ARCH BIOCHEM BIOPHYS, V252, P152, DOI 10.1016/0003-9861(87)90019-1; HUGHES JC, 1960, PHYTOPATHOLOGY, V50, P398; JURD L, 1971, PHYTOCHEMISTRY, V10, P2971, DOI 10.1016/S0031-9422(00)97334-5; KRUSE E, 1995, EMBO J, V14, P3712, DOI 10.1002/j.1460-2075.1995.tb00041.x; LAGRIMINI LM, 1987, P NATL ACAD SCI USA, V84, P7542, DOI 10.1073/pnas.84.21.7542; LUMMERZHEIM M, 1995, PLANT CELL ENVIRON, V18, P499, DOI 10.1111/j.1365-3040.1995.tb00550.x; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MCINTYRE JL, 1981, PHYTOPATHOLOGY, V71, P297, DOI 10.1094/Phyto-71-297; MCMURCHY RA, 1984, PHYSIOL PLANT PATHOL, V25, P229, DOI 10.1016/0048-4059(84)90061-4; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MEUWLY P, 1993, ANAL BIOCHEM, V214, P500, DOI 10.1006/abio.1993.1529; Mittler R, 1996, PLANT CELL, V8, P1991, DOI 10.1105/tpc.8.11.1991; Mittler R, 1997, J CELL SCI, V110, P1333; Mock HP, 1998, PLANT PHYSIOL, V116, P107, DOI 10.1104/pp.116.1.107; Mock HP, 1997, PLANT PHYSIOL, V113, P1101, DOI 10.1104/pp.113.4.1101; OKAZAKI M, 1982, AGR BIOL CHEM TOKYO, V46, P601, DOI 10.1080/00021369.1982.10865137; Peng Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235, DOI 10.1111/j.1751-1097.1997.tb08549.x; REBEIZ CA, 1984, ENZYME MICROB TECH, V6, P390, DOI 10.1016/0141-0229(84)90012-7; RiceEvans CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SCHUSTER B, 1986, Z NATURFORSCH C, V41, P511; SPIKES JD, 1991, CHLOROPHYLLS, P1181; STEIN A, 1985, PHYTOPATHOL Z, V114, P295; Takahashi H, 1997, PLANT J, V11, P993, DOI 10.1046/j.1365-313X.1997.11050993.x; TAL B, 1986, PLANT PHYSIOL, V82, P167, DOI 10.1104/pp.82.1.167; TAL B, 1986, PHYTOCHEMISTRY, V25, P2913, DOI 10.1016/S0031-9422(00)94505-9; TANGUY J, 1972, PHYTOCHEMISTRY, V11, P19, DOI 10.1016/S0031-9422(00)89962-8; Thalmair M, 1996, J PLANT PHYSIOL, V148, P222, DOI 10.1016/S0176-1617(96)80318-X; Valle T, 1997, PLANT SCI, V125, P97, DOI 10.1016/S0168-9452(97)00057-5; VANETTEN HD, 1994, PLANT CELL, V6, P1191; Vereecke D, 1997, PLANTA, V201, P342, DOI 10.1007/s004250050076; VERNOOIJ B, 1995, MOL PLANT MICROBE IN, V8, P228, DOI 10.1094/MPMI-8-0228; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WERNER C, 1985, J PLANT PHYSIOL, V118, P237, DOI 10.1016/S0176-1617(85)80225-X; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621	69	70	77	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4231	4238		10.1074/jbc.274.7.4231	http://dx.doi.org/10.1074/jbc.274.7.4231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933622	hybrid			2022-12-25	WOS:000078575500046
J	Silver, DL; Jiang, XC; Tall, AR				Silver, DL; Jiang, XC; Tall, AR			Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice - Possible role of leptin in stimulation of HDL turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; GENETICALLY-OBESE MICE; TRANSGENIC MICE; INCREASED PLASMA; SR-BI; RECEPTOR; GENE; CHOLESTEROL; PROTEIN; ATHEROSCLEROSIS	Abnormalities of plasma high density lipoprotein (HDL) levels commonly reflect altered metabolism of the major HDL apolipoproteins, apoA-I and apoA-II, but the regulation of apolipoprotein metabolism is poorly understood. Two mouse models of obesity, ob/ob and db/db, have markedly increased plasma HDL cholesterol levels. The purpose of this study was to evaluate mechanisms responsible for increased HDL in ob/ob mice and to assess potential reversibility by leptin administration. ob/ob mice were found to have increased HDL cholesterol (2-fold), apoA-I (1.3-fold), and apoA-II (4-fold). ApoA-I mRNA was markedly decreased (to 25% of wildtype) and apoA-II mRNA was unchanged, suggesting a defect in HDL catabolism, HDL apoprotein turnover studies using nondegradable radiolabels confirmed a decrease in catabolism of apoA-I and apoA-II and a 4-fold decrease in hepatic uptake in ob/ob mice compared with wild-type, but similar renal uptake, Low dose leptin treatment markedly lowered HDL cholesterol and apoA-II levels in both ob/ob mice and in lean wild-type mice, and it restored apoA-I mRNA to normal levels in ob/ob mice. These changes occurred without significant alteration in body weight, Moreover, ob/ob neuropeptide Y-/- mice, despite marked attenuation of diabetes and obesity phenotypes, showed no change in HDL cholesterol levels relative to ob/ob mice. Thus, increased HDL levels in ob/ob mice reflect a marked hepatic catabolic defect for apoA-I and apoA-II, In the case of apoA-I, this is offset by decreased apoA-I mRNA, resulting in apoA-II-rich HDL particles. The studies reveal a specific HDL particle catabolic pathway that is downregulated in ob/ob mice and suggest that HDL apolipoprotein turnover may be regulated by obesity and/or leptin signaling.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 622 W 168th St, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682, F32HL009928] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22682, HL09928-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AZROLAN N, 1995, J BIOL CHEM, V270, P19833, DOI 10.1074/jbc.270.34.19833; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Breslow Jan L., 1994, Current Opinion in Lipidology, V5, P175, DOI 10.1097/00041433-199405030-00004; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHENG CF, 1985, J BIOL CHEM, V260, P720; Cohen SM, 1998, P NATL ACAD SCI USA, V95, P7385, DOI 10.1073/pnas.95.13.7385; Cooper AD, 1997, J LIPID RES, V38, P2173; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; FIDGE N, 1980, METABOLISM, V29, P643, DOI 10.1016/0026-0495(80)90109-2; GLASS C, 1985, J BIOL CHEM, V260, P744; GLASS CK, 1983, J BIOL CHEM, V258, P7161; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Hamann A, 1998, Z ERNAHRUNGSWISS, V37, P1; HILDENBRANDT GR, 1979, BIOCHIM BIOPHYS ACTA, V587, P373, DOI 10.1016/0304-4165(79)90441-0; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; Huang QL, 1998, ENDOCRINOLOGY, V139, P1524, DOI 10.1210/en.139.4.1524; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; JOOSTEN HFP, 1974, METABOLISM, V23, P59, DOI 10.1016/0026-0495(74)90104-8; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Le N A, 1986, Methods Enzymol, V129, P384; LE NA, 1988, METABOLISM, V37, P614, DOI 10.1016/0026-0495(88)90077-7; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LIU AC, 1994, J LIPID RES, V35, P2263; LIU MS, 1994, J BIOL CHEM, V269, P11417; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; Miller N. E., 1980, Atherosclerosis 5. Proceedings of the Fifth International Symposium, P500; Mooradian AD, 1996, AM J PHYSIOL-REG I, V271, pR1602, DOI 10.1152/ajpregu.1996.271.6.R1602; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RATH EA, 1974, DIABETOLOGIA, V10, P261; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Sarmiento U, 1997, LAB INVEST, V77, P243; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1996, ATHEROSCLEROSIS CORO, P105; Taylor AH, 1996, BIOCHEMISTRY-US, V35, P8281, DOI 10.1021/bi960269o; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WALSH A, 1989, J BIOL CHEM, V264, P6488; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Zaiou M, 1998, J CLIN INVEST, V101, P1699, DOI 10.1172/JCI2166; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	106	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4140	4146		10.1074/jbc.274.7.4140	http://dx.doi.org/10.1074/jbc.274.7.4140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933608	hybrid			2022-12-25	WOS:000078575500032
J	Simpson, PJ; Nighorn, A; Morton, DB				Simpson, PJ; Nighorn, A; Morton, DB			Identification of a novel guanylyl cyclase that is related to receptor guanylyl cyclases, but lacks extracellular and transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; MANDUCA-SEXTA; EXPRESSION; NEURONS; CONTAINS; FORM	We have identified a novel guanylyl cyclase, named MsGC-I, that is expressed in the nervous system of Manduca sexta. MsGC-I shows highest sequence identity with receptor guanylyl cyclases throughout its catalytic and dimerization domains but does not contain the ligand-binding, transmembrane, or kinase-like domains characteristic of receptor guanylyl cyclases. In addition, MsGC-I contains a C-terminal extension of 149 amino acids that is not present in other receptor guanylyl cyclases; The sequence of MsGC-I contains no regions that show similarity to the regulatory domain of soluble guanylyl cyclases, Thus, MsGC-I appears to represent a member of a new class of guanylyl cyclases, We show that both a transcript and a protein of the sizes predicted from the MsGC-I cDNA are present in the nervous system of Manduca and that MsGC-I is expressed in a small population of neurons within the abdominal ganglia, When expressed in COS-7 cells, MsGC-I appears to exist as a soluble homodimer with high levels of basal guanylyl cyclase activity that is insensitive to stimulation by nitric oxide. Western blot analysis, however, shows that MsGC-I is localized to the particulate fraction of nervous system homogenates, suggesting that it may be membrane-associated in vivo.	Oregon Hlth & Sci Univ, Sch Dent, Dept Biol Struct & Funct, Portland, OR 97201 USA; Univ Arizona, Arizona Res Labs, Div Neurobiol, Tucson, AZ 85721 USA	Oregon Health & Science University; University of Arizona	Morton, DB (corresponding author), Oregon Hlth & Sci Univ, Sch Dent, Dept Biol Struct & Funct, 611 SW Campus Dr,SD, Portland, OR 97201 USA.	mortonda@ohsu.edu			NINDS NIH HHS [NS29740] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029740, R29NS029740] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; Bhatt TR, 1997, BIOTECHNIQUES, V23, P1000, DOI 10.2144/97236bm06; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; DAVIS NT, 1993, J COMP NEUROL, V338, P612, DOI 10.1002/cne.903380410; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Kojima M, 1995, BIOCHEM BIOPH RES CO, V217, P993, DOI 10.1006/bbrc.1995.2868; Komminoth P., 1996, NONRADIOACTIVE IN SI, P126; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Moon C, 1998, J NEUROSCI, V18, P3195; Nighorn A, 1998, J NEUROSCI, V18, P7244; NIGHORN AJ, 1999, IN PRESS J BIOL CHEM; Prabhakar S, 1997, J NEUROCHEM, V69, P1650; Schulz S, 1998, J BIOL CHEM, V273, P1032, DOI 10.1074/jbc.273.2.1032; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; THORPE DS, 1990, J BIOL CHEM, V265, P14717; TREMBLAY J, 1988, ADV SEC MESS PHOSPH, V22, P319; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	26	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	1999	274	7					4440	4446		10.1074/jbc.274.7.4440	http://dx.doi.org/10.1074/jbc.274.7.4440			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	166KQ	9933648	hybrid			2022-12-25	WOS:000078575500072
J	Li, Q; Subbulakshmi, V; Fields, AP; Murray, NR; Cathcart, MK				Li, Q; Subbulakshmi, V; Fields, AP; Murray, NR; Cathcart, MK			Protein kinase C alpha regulates human monocyte O-2(center dot-) production and low density lipoprotein lipid oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; ACTIVATED HUMAN MONOCYTES; ADENINE-DINUCLEOTIDE PHOSPHATE; SUPEROXIDE ANION PRODUCTION; HUMAN-NEUTROPHILS; NADPH-OXIDASE; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; PHOSPHORYLATION	Our previous studies have shown that human native low density lipoprotein (LDL) can be oxidized by activated human monocytes, In this process, both activation of protein kinase C (PKC) and induction of superoxide anion (O-2(radical anion)) production are required. PKC is a family of isoenzymes, and the functional roles of individual PKC isoenzymes are believed to differ based on subcellular location and distinct responses to regulatory signals. We have shown that the PKC isoenzyme that is required for both monocyte O-2(radical anion) production and oxidation of LDL is a member of the conventional PKC group of PKC isoenzymes (Li, Q., and Cathcart, M.K. (1994) J. Biol. Chem, 269, 17508-17515), The conventional PKC group includes PKC alpha, PKC beta I, PKC beta II, and PKC gamma. With the exception of PKC gamma, each of these isoenzymes was detected in human monocytes, in these studies, we investigated the requirement for select PKC isoenzymes in the process of monocyte-mediated LDL lipid oxidation, Our data indicate that PKC activity was rapidly induced upon monocyte activation with the majority of the activity residing in the membrane/particulate fraction. This enhanced PRC activity was sustained for up to 24 h after activation. PKC alpha, PKC beta I, and PKC beta II protein levels were induced upon monocyte activation, and PKC alpha and PKC beta II substantially shifted their location from the cytosol to the particulate/ membrane fraction. To distinguish between these isoenzymes for regulating monocyte O-2(radical anion) production and LDL oxidation, PKC alpha or PKC beta isoenzyme-specific antisense oligonucleotides were used to selectively suppress isoenzyme expression. We found that suppression of PKC alpha expression inhibited both monocyte-mediated O-2(radical anion) production and LDL lipid oxidation by activated human monocytes, In contrast, inhibition of PKC beta expression (including both PKC beta I and PKC beta II) did not affect O-2(radical anion) production or LDL lipid oxidation, Further studies demonstrated that the respiratory burst oxidase responsible for O-2(radical anion) production remained functionally intact in monocytes with depressed levels of PKC alpha because O-2(radical anion) production could be restored by treating the monocytes with arachidonic acid. Taken together, our data reveal that PKC alpha, and not PKC beta I or PKC beta II, is the predominant isoenzyme required for O-2(radical anion) production and maximal oxidation of LDL by activated human monocytes.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA	Cleveland Clinic Foundation; University of Texas System; University of Texas Medical Branch Galveston	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	cathcam@esmtp.ccf.org			NCI NIH HHS [CA56869] Funding Source: Medline; NHLBI NIH HHS [HL51068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHISOLM GM, 1996, ATHEROSCLEROSIS CORO, P129; COSTACASNELLIE MR, 1986, J CELL PHYSIOL, V129, P336, DOI 10.1002/jcp.1041290311; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Hatch F T, 1968, Adv Lipid Res, V6, P1; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; HOCEVAR BA, 1992, J CELL SCI, V101, P671; JACOB T, 1994, J LEUKOCYTE BIOL, V55, P310, DOI 10.1002/jlb.55.3.310; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; KADRIHASSANI N, 1995, J BIOL CHEM, V270, P15111, DOI 10.1074/jbc.270.25.15111; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAKE DS, 1990, BIOCHEM J, V270, P741, DOI 10.1042/bj2700741; LI Q, 1993, J CLIN INVEST, V91, P1499, DOI 10.1172/JCI116355; Li Q, 1997, J LIPID MEDIAT CELL, V17, P175, DOI 10.1016/S0929-7855(97)00030-8; LI Q, 1994, J BIOL CHEM, V269, P17508; Li Q, 1997, J BIOL CHEM, V272, P2404, DOI 10.1074/jbc.272.4.2404; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MYERS MA, 1985, J IMMUNOL, V135, P3411; Park JW, 1998, EXP HEMATOL, V26, P37; Park JW, 1997, J BIOL CHEM, V272, P11035; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PRABHAKAR U, 1993, EUR CYTOKINE NETW, V4, P31; Roy B, 1998, J BIOL CHEM, V273, P32023, DOI 10.1074/jbc.273.48.32023; SAKATA A, 1987, J IMMUNOL, V138, P4353; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; STEINMAN RM, 1972, J CELL BIOL, V55, P186, DOI 10.1083/jcb.55.1.186; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; ZHENG L, 1995, J IMMUNOL, V155, P776	47	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3764	3771		10.1074/jbc.274.6.3764	http://dx.doi.org/10.1074/jbc.274.6.3764			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920929	hybrid			2022-12-25	WOS:000078428200069
J	Morris, SNK; Harkins, TT; Tennyson, RB; Lindsley, JE				Morris, SNK; Harkins, TT; Tennyson, RB; Lindsley, JE			Kinetic and thermodynamic analysis of mutant type II DNA topoisomerases that cannot covalently cleave DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; BINDING; MECHANISM; PURIFICATION; RELAXATION; TRANSPORT; CLAMP	DNA topoisomerase II catalyzes two different chemical reactions as part of its DNA transport cycle: ATP hydrolysis and DNA breakage/religation, The coordination between these reactions was studied using mutants of yeast topoisomerase II that are unable to covalently cleave DNA. In the absence of DNA, the ATPase activities of these mutant enzymes are identical to the wild type activity. DNA binding stimulates the ATPase activity of the mutant enzymes, but with steady-state parameters different from those of the wild type enzyme. These differences were examined through DNA binding experiments and pre-steady-state ATPase assays. One mutant protein, Y782F, binds DNA with the same affinity as wild type protein. This mutant topologically traps one DNA circle in the presence of a nonhydrolyzable ATP analog under the same conditions that the wild type protein catenates two circles. Rapid chemical quench and pulse-chase ATPase experiments reveal that the mutant proteins bound to DNA have the same sequential hydrolysis reaction cycle as the wild type enzyme. Binding of ATP to the mutants is not notably impaired, but hydrolysis of the first ATP is slower than for the wild type enzyme. Models to explain these results in the context of the entire DNA topoisomerase II reaction cycle are discussed.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.	Janet.Lindsley@hsc.utah.edu			NCI NIH HHS [CA09602-06] Funding Source: Medline; NIGMS NIH HHS [GM51194, 5T32GM08753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051194, T32GM008753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Alsner J, 1996, J MOL BIOL, V259, P317, DOI 10.1006/jmbi.1996.0321; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; FIERKE CA, 1995, METHOD ENZYMOL, V249, P3; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; FREIFELDER D, 1982, PHYSICAL BIOCH APPL, P430; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1994, ADV PHARM B, V29; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; Tennyson RB, 1997, BIOCHEMISTRY-US, V36, P6107, DOI 10.1021/bi970152f; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3446	3452		10.1074/jbc.274.6.3446	http://dx.doi.org/10.1074/jbc.274.6.3446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920889	hybrid			2022-12-25	WOS:000078428200029
J	Seol, DW; Chen, QY; Smith, ML; Zarnegar, R				Seol, DW; Chen, QY; Smith, ML; Zarnegar, R			Regulation of the c-met proto-oncogene promoter by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; TYROSINE KINASE; TUMOR-SUPPRESSOR; FACTOR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; EPITHELIAL-CELLS; GENE PROMOTER; BINDING-SITE; FACTOR-ALPHA	In the present study, we have investigated the possible involvement of p53 in the transcriptional regulation of the c-met gene. Cotransfection of various c-met promoter reporter vectors with p53 expression plasmids demonstrated that only wild-type p53 but not tumor-derived mutant forms of p53 resulted in a significant enhancement of c-met promoter activity. Functional assays revealed that the p53 responsive element in the c-met promoter region is located at position -278 to -216 and confers p53 responsiveness not only in the context of the c-met promoter but also in the context of a heterologous promoter. Electrophoretic mobility shift assays using purified recombinant p53 protein showed that the p53 binding element identified within the c-met promoter specifically binds to p53 protein. Induction of p53 by UV irradiation in RKO cells that express wildtype p53 increased the level of the endogenous c-met gene product and p21(WAF1/CIP1), a known target of p53 regulation. On the other hand, in RKO cells in which the function of p53 is impaired either by stable transfection of a dominant negative form of p53 or by HPV-E6 viral protein, no induction of the endogenous c-met gene or p21(WAF1/CIP1) was noted by UV irradiation. These results suggest that the c-met gene is also a target of p53 gene regulation.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Indiana University System; Indiana University-Purdue University Indianapolis	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, BST S 419, Pittsburgh, PA 15261 USA.	rezazar+@pitt.edu						Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BELL A, 1989, IN PRESS ONCOGENE; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen QY, 1996, CELL GROWTH DIFFER, V7, P821; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU YH, 1994, J BIOL CHEM, V269, P4152; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; MIYASHITA T, 1995, CELL, V80, P293; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, ONCOGENE, V6, P501; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PONZETTO C, 1991, ONCOGENE, V6, P553; RONG S, 1993, CANCER RES, V53, P5355; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SAXENA A, 1992, ONCOGENE, V7, P243; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Thorgeirsson SS, 1997, MUTAT RES-FUND MOL M, V376, P221, DOI 10.1016/S0027-5107(97)00047-X; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	50	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1999	274	6					3565	3572		10.1074/jbc.274.6.3565	http://dx.doi.org/10.1074/jbc.274.6.3565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	163VZ	9920903	hybrid			2022-12-25	WOS:000078428200043
J	Hagen, TM; Ingersoll, RT; Lykkesfeldt, J; Liu, JK; Wehr, CM; Vinarsky, V; Bartholomew, JC; Ames, BN				Hagen, TM; Ingersoll, RT; Lykkesfeldt, J; Liu, JK; Wehr, CM; Vinarsky, V; Bartholomew, JC; Ames, BN			(R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate	FASEB JOURNAL			English	Article						aging; ambulatory activity; MDA; antioxidants; liver	ACETYL-L-CARNITINE; ALPHA-LIPOIC ACID; CHROMATOGRAPHY MASS-SPECTROMETRY; THIOCTIC ACID; LIQUID-CHROMATOGRAPHY; DEHYDROASCORBIC ACID; LIPID-PEROXIDATION; HEART MITOCHONDRIA; DIHYDROLIPOIC ACID; ASCORBIC-ACID	A diet supplemented with (R)-lipoic acid, a mitochondrial coenzyme, was fed to old rats to determine its efficacy in reversing the decline in metabolism seen with age. Young (3 to 5 months) and old (24 to 26 months) rats were fed an AlN-93M diet with or without (R)-lipoic acid (0.5% w/w) for 2 wk, killed and their liver parenchymal cells were isolated. Hepatocytes from untreated old rats vs. young controls had significantly lower oxygen consumption (P<0.03) and mitochondrial membrane potential. (R)-Lipoic acid supplementation reversed the age-related decline in O-2 consumption and increased (P<0.03) mitochondrial membrane potential. Ambulatory activity, a measure of general metabolic activity, was almost threefold lower in untreated old rats vs. controls, but this decline was reversed (P<0.005) in old rats fed (R)-lipoic acid. The increase of oxidants with age, as measured by the fluorescence produced on oxidizing 2',7'-dichlorofluorescin, was significantly lowered in (R)-lipoic acid supplemented old rats (P<0.01). Malondialdehyde (MDA) levels, an indicator of lipid peroxidation, were increased fivefold with age in cells from unsupplemented rats. Feeding rats, the (R)-lipoic acid diet reduced MDA levels markedly (P<0.01). Both glutathione and ascorbic acid levels declined in hepatocytes with age, but their loss was completely reversed with (R)-lipoic acid supplementation. Thus, (R)-lipoic acid supplementation improves indices of metabolic activity as well. as lowers oxidative stress and damage evident in aging.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Ames, BN (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	bnames@uclink4.berkeley.edu	Lykkesfeldt, Jens/A-1072-2011; Liu, Jiankang/A-1610-2011	Lykkesfeldt, Jens/0000-0002-6514-8407; 	NCI NIH HHS [CA39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bustamante J, 1998, FREE RADICAL BIO MED, V24, P1023, DOI 10.1016/S0891-5849(97)00371-7; CARTA A, 1993, ANN NY ACAD SCI, V695, P324, DOI 10.1111/j.1749-6632.1993.tb23077.x; Erdincler DS, 1997, CLIN CHIM ACTA, V265, P77, DOI 10.1016/S0009-8981(97)00106-X; Estrada DE, 1996, DIABETES, V45, P1798, DOI 10.2337/diabetes.45.12.1798; GREGUS Z, 1992, TOXICOL APPL PHARM, V114, P88, DOI 10.1016/0041-008X(92)90100-7; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; HARRISON EH, 1974, ARCH BIOCHEM BIOPHYS, V160, P514, DOI 10.1016/0003-9861(74)90428-7; Jacob S, 1996, EXP CLIN ENDOCR DIAB, V104, P284, DOI 10.1055/s-0029-1211455; JACOB S, 1995, LIPOIC ACID HLT DIS, P373; KAGEN VE, 1992, J LIPID RES, V33, P385; Korkina Ludmila G., 1993, Biochemical Society Transactions, V21, p314S; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liu JK, 1997, ANAL BIOCHEM, V245, P161, DOI 10.1006/abio.1996.9990; Lykkesfeldt J, 1998, FASEB J, V12, P1183, DOI 10.1096/fasebj.12.12.1183; LYKKESFELDT J, 1995, ANAL BIOCHEM, V229, P329, DOI 10.1006/abio.1995.1421; Maitra I, 1996, BIOCHEM BIOPH RES CO, V221, P422, DOI 10.1006/bbrc.1996.0611; Moldeus P, 1978, Methods Enzymol, V52, P60; OU PM, 1995, BIOCHEM PHARMACOL, V50, P123, DOI 10.1016/0006-2952(95)00116-H; PARADIES G, 1990, BIOCHIM BIOPHYS ACTA, V1016, P207, DOI 10.1016/0005-2728(90)90060-H; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; Paradies G, 1995, MECH AGEING DEV, V84, P103, DOI 10.1016/0047-6374(95)01636-8; PEINADO J, 1989, ARCH BIOCHEM BIOPHYS, V273, P389, DOI 10.1016/0003-9861(89)90497-9; PETER G, 1995, ARZNEIMITTELFORSCH, V45-1, P293; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Sachse G, 1980, Horm Metab Res Suppl, V9, P105; SANZ N, 1997, J HEPATOL, V27, P524; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; SCOTT BC, 1994, FREE RADICAL RES, V20, P119, DOI 10.3109/10715769409147509; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STEINKAMP JA, 1973, REV SCI INSTRUM, V44, P1301, DOI [10.1063/1.1686375, 10.1063/1.1686082]; Steyn D G, 1966, S Afr Med J, V40, P405; Streeper RS, 1997, AM J PHYSIOL-ENDOC M, V273, pE185, DOI 10.1152/ajpendo.1997.273.1.E185; SUZUKI YJ, 1991, FREE RADICAL RES COM, V15, P255, DOI 10.3109/10715769109105221; TEICHERT J, 1995, J CHROMATOGR B, V672, P277, DOI 10.1016/0378-4347(95)00225-8; VILLA RF, 1998, NEUROCHEM RES, V10, P909; Xu DP, 1996, J BIOENERG BIOMEMBR, V28, P77; YEO HC, 1994, ANAL BIOCHEM, V220, P391, DOI 10.1006/abio.1994.1355; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603; ZIMMER G, 1991, ARCH BIOCHEM BIOPHYS, V288, P609, DOI 10.1016/0003-9861(91)90243-C; ZIMMER G, 1995, J MOL CELL CARDIOL, V27, P1895, DOI 10.1016/0022-2828(95)90012-8	43	233	258	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					411	418		10.1096/fasebj.13.2.411	http://dx.doi.org/10.1096/fasebj.13.2.411			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973329				2022-12-25	WOS:000078615200021
J	Hamilton, LC; Mitchell, JA; Tomlinson, AM; Warner, TD				Hamilton, LC; Mitchell, JA; Tomlinson, AM; Warner, TD			Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy	FASEB JOURNAL			English	Article						antiinflammatory agents; cyclooxygenase inhibitors; disease models; prostaglandins; prostaglandin endoperoxide synthase	PROSTAGLANDIN-H SYNTHASE-2; NITRIC-OXIDE SYNTHASE; PHOSPHOLIPASE A(2); MESSENGER-RNA; G-PROTEIN; IN-VIVO; EXPRESSION; LIPOPOLYSACCHARIDE; CYCLOOXYGENASE-2; CELLS	Prostanoids produced via the action of cyclo-oxygenase-2 (COX-2) appear central to many inflammatory conditions. Here we show in LPS treated rats, however, that COX-2 induction alone does not greatly increase prostanoid production in vivo. For this, a second, arachidonic acid liberating stimulus is also required. Thus, only after intravenous injection of bradykinin or exogenous arachidonic acid was a marked increase in prostanoid formation seen. There is, therefore, synergy between proinflammatory mediators: both induction of COX-2 protein and an increase in the supply of arachidonic acid are required to greatly enhance prostanoid production, Second, we show that supplying arachidonic acid to increase prostanoid production reduces the effectiveness of both currently used nonsteroidal antiinflammatory drugs (NSAIDs) (diclofenac) and novel COX-2-selective inhibitors (NS-398, celecoxib) as inhibitors of COX-2 activity. Our data lead to two important conclusions. First, increased prostanoid production in inflammation is a two-component response: increased COX-2 expression and increased arachidonic acid supply, Second, the supply of arachidonic acid to COX-2 determines the effectiveness of NSAIDs, NSAIDs and selective COX-2 inhibitors, therefore, will generally be less effective at more inflamed sites, providing a rationale for the very high doses of NSAIDs required in human conditions such as rheumatoid arthritis.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; Royal Brompton Hosp, Unit Crit Care Med, London SW3 6NP, England	University of London; Queen Mary University London; Royal Brompton Hospital	Warner, TD (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	t.d.warner@mds.qmw.ac.uk	Mitchell, Jane A/A-1991-2009; Warner, Timothy D/A-1980-2009	Warner, Timothy D/0000-0003-3988-4408	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brideau C, 1996, INFLAMM RES, V45, P68, DOI 10.1007/BF02265118; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; Chinn KS, 1997, LIPIDS, V32, P979, DOI 10.1007/s11745-997-0128-7; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hulkower KI, 1997, EUR J PHARMACOL, V331, P79, DOI 10.1016/S0014-2999(97)01029-7; LEE SH, 1992, J BIOL CHEM, V267, P25934; Liu SF, 1996, CLIN SCI, V90, P301, DOI 10.1042/cs0900301; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Nakatsugi S, 1996, PROSTAG LEUKOTR ESS, V55, P451, DOI 10.1016/S0952-3278(96)90130-1; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; RICUPERO D, 1993, AGENTS ACTIONS, V40, P110, DOI 10.1007/BF01976759; SALVEMINI D, 1995, BRIT J PHARMACOL, V114, P1171, DOI 10.1111/j.1476-5381.1995.tb13330.x; Seibert K, 1996, BRIT J PHARMACOL, V117, P1016, DOI 10.1111/j.1476-5381.1996.tb16691.x; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SWIERKOSZ TA, 1995, BRIT J PHARMACOL, V114, P1335, DOI 10.1111/j.1476-5381.1995.tb13353.x; Takahashi S, 1995, ARCH INT PHARMACOD T, V330, P102; Vadas P, 1996, EUR J BIOCHEM, V235, P557, DOI 10.1111/j.1432-1033.1996.t01-1-00557.x; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; VANE JR, 1976, ADV PROSTAG THROMB R, V2, P791; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	27	45	45	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					245	251		10.1096/fasebj.13.2.245	http://dx.doi.org/10.1096/fasebj.13.2.245			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973312				2022-12-25	WOS:000078615200004
J	Hook, VYH; Sei, C; Yasothornsrikul, S; Toneff, T; Kang, YH; Efthimiopoulos, S; Robakis, NK; Van Nostrand, W				Hook, VYH; Sei, C; Yasothornsrikul, S; Toneff, T; Kang, YH; Efthimiopoulos, S; Robakis, NK; Van Nostrand, W			The kunitz protease inhibitor form of the amyloid precursor protein (KPI/APP) inhibits the proneuropeptide processing enzyme prohormone thiol protease (PTP) - Colocalization of KPI/APP and PTP in secretory vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-CONTAINING PEPTIDES; ALZHEIMERS-DISEASE; CHROMAFFIN GRANULES; ADRENAL-MEDULLA; NEXIN-II; CYSTEINE PROTEASE; NERVE-TERMINALS; FULL-LENGTH; PURIFICATION; DOMAIN	Proteolytic processing of proenkephalin and proneuropeptides is required for the production of active neurotransmitters and peptide hormones. Variations in the extent of proenkephalin processing in vivo suggest involvement of endogenous protease inhibitors. This study demonstrates that "protease nexin 2 (PN2)," the secreted form of the kunitz protease inhibitor (KPI) of the amyloid precursor protein (APP), potently inhibited the proenkephalin processing enzyme known as prohormone thiol protease (PTP), with a K-i,K-app of 400 nM. Moreover, PTP and PN2 formed SDS-stable complexes that are typical of kunitz protease inhibitor interactions with target proteases, In vivo, KPI/APP (120 kDa), as well as a truncated form of KPI/APP that resembles PN2 in apparent molecular mass (110 kDa), were colocalized with PTP and (Met)enkephalin in secretary vesicles of adrenal medulla (chromaffin granules). KPI/APP (110-120 kDa) was also detected in pituitary secretory vesicles that contain PTP, In chromaffin cells, calcium-dependent secretion of KPI/APP with PTP and (Met)enkephalin demonstrated the colocalization of these components in functional secretory vesicles. These results suggest a role for KPI/APP inhibition of PTP in regulated secretory vesicles. In addition, these results are the first to identify an endogenous protease target of KPI/APP, which is developmentally regulated in aging and Alzheimer's disease.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; USN, Med Res Inst, Bethesda, MD 20892 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Ctr Neurobiol, New York, NY 10029 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Med, Stony Brook, NY 11794 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hook, VYH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr 0822, La Jolla, CA 92093 USA.	vhook@ucsd.edu	Robakis, Nikolaos/AAA-1838-2021; Efthimiopoulos, Spiros/H-3956-2013	Efthimiopoulos, Spiros/0000-0001-9244-4570	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004271] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49566] Funding Source: Medline; NIDA NIH HHS [DA04271] Funding Source: Medline; NINDS NIH HHS [NS24553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON JP, 1989, EMBO J, V8, P3627, DOI 10.1002/j.1460-2075.1989.tb08536.x; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; AZARYAN AV, 1995, J NEUROCHEM, V65, P1771; AZARYAN AV, 1994, ARCH BIOCHEM BIOPHYS, V314, P171, DOI 10.1006/abbi.1994.1426; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; BEESON JG, 1994, J COMP NEUROL, V342, P78, DOI 10.1002/cne.903420109; BJORKLUND A, 1990, HDB CHEM NEUROANAT, V9, P1; BJORKLUND A, 1990, HDB CHEM NEUROANATOM, V9, P287; CARMICHAEL SW, 1990, NEUROSCIENCE, V34, P433, DOI 10.1016/0306-4522(90)90152-T; CARMICHAEL SW, 1985, SCI AM, V253, P40, DOI 10.1038/scientificamerican0885-40; Efthimiopoulos S, 1996, P NATL ACAD SCI USA, V93, P8046, DOI 10.1073/pnas.93.15.8046; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; FLEMINGER G, 1983, P NATL ACAD SCI-BIOL, V80, P6418, DOI 10.1073/pnas.80.20.6418; FURUYA S, 1989, J ELECTRON MICROSC, V38, P143; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gottfries CG, 1995, EUR NEUROPSYCHOPHARM, V5, P491, DOI 10.1016/0924-977X(95)00038-Q; HOOK VYH, 1982, NATURE, V295, P341, DOI 10.1038/295341a0; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1985, J BIOL CHEM, V260, P5991; HOOK VYH, 1998, MOL B INT U, V2, P89; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; LEWIS ME, 1985, PEPTIDES, V6, P37, DOI 10.1016/0196-9781(85)90010-5; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Loh Y. P., 1993, MECHANISMS INTRACELL, P179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MERCHENTHALER I, 1986, NEUROSCIENCE, V17, P325, DOI 10.1016/0306-4522(86)90250-2; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MOYA KL, 1994, J NEUROCHEM, V63, P1971; NORRIS DO, 1997, VERTEBRATE ENDOCRINO, P104; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; Robakis Nikolaos K., 1994, P317; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Roeske LC, 1995, REV NEUROSCIENCE, V6, P317; ROKAEUS A, 1986, P NATL ACAD SCI USA, V83, P6287, DOI 10.1073/pnas.83.17.6287; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; SCHILLER MR, 1995, BIOCHEMISTRY-US, V34, P7988, DOI 10.1021/bi00025a004; SCHULTZBERG M, 1978, ACTA PHYSIOL SCAND, V103, P475, DOI 10.1111/j.1748-1716.1978.tb06243.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SINHA S, 1990, J BIOL CHEM, V265, P8983; SOLA C, 1993, NEUROSCIENCE, V53, P267, DOI 10.1016/0306-4522(93)90304-X; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Tezapsidis N, 1998, BIOCHEMISTRY-US, V37, P1274, DOI 10.1021/bi9714159; TEZAPSIDIS N, 1995, J BIOL CHEM, V270, P13285, DOI 10.1074/jbc.270.22.13285; TOOMIM CS, 1992, BIOCHEM BIOPH RES CO, V183, P449, DOI 10.1016/0006-291X(92)90502-C; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VASSILACOPOULOU D, 1995, J NEUROCHEM, V64, P2140; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yasothornsrikul S, 1998, J NEUROCHEM, V70, P153; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	70	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					3165	3172		10.1074/jbc.274.5.3165	http://dx.doi.org/10.1074/jbc.274.5.3165			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915856	hybrid			2022-12-25	WOS:000078319500074
J	Nagano, K; Fukami, K; Minagawa, T; Watanabe, Y; Ozaki, C; Takenawa, T				Nagano, K; Fukami, K; Minagawa, T; Watanabe, Y; Ozaki, C; Takenawa, T			A novel phospholipase C delta 4 (PLC delta 4) splice variant as a negative regulator of PLC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDE BINDING-SPECIFICITY; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ALPHA-SUBUNIT; EXPRESSION; C-BETA(1)	It has been reported that there are two alternatively spliced variants of phospholipase C-delta 4 (PLC delta 4), termed ALT I and II, that contain an additional 32 and 14 amino acids in their respective sequences in the linker region between the catalytic X and Y domains (Lee, S. B., and Rhee, S. G. (1996) J. Biol. Chem. 271, 25-31). We report here the isolation and characterization of a novel alternative splicing isoform of PLC delta 4, termed ALT III, as a negative regulator of PLC. In ALT III, alternative splicing occurred in the catalytic X domain, i.e. 63 amino acids (residues 424-486) containing the C-terminal of the X domain and linker region were substituted for 32 amino acids corresponding to the insert sequence of ALT I. Although the expression level of ALT III was found to be much lower in most tissues and cells compared with that of PLC delta 4, it was significantly higher in some neural cells, such as NIE-115 cells and p19 cells differentiated to neural cells by retinoic acid. Interestingly, recombinant ALT III protein did not retain enzymatic activity, and the activity of PLC delta 4 overexpressed in COS7 cells was markedly decreased by the co-expression of ALT III but not by ALT I or II. Moreover, N-terminal pleckstrin homology domain (PH domain) of ALT III alone could inhibit the increase of inositol-1,4,5-trisphosphate levels in PLC delta 4-overexpressing NIH3T3 cells, whereas a PH domain deletion mutant could not, indicating that the PH domain is necessary and sufficient for its inhibitory effect. The ALT III PH domain specifically bound to phosphatidylinositol (PtdIns)-4,5-P-2 and PtdIns-3,4,5-P-3 but not PtdIns, PtdIns-4-P, or inositol phosphates, and the mutant R36G, which retained only weak affinity for PtdIns-4,5-P-2, could not inhibit the activity of PLC delta 4. These results indicate that PtdIns-4,5-P-2 binding to PH domain is essential for the inhibitory effect of ALT III. ALT III also inhibited PLC delta 1 activity and partially suppressed PLC gamma 1 activity, but not PLC beta 1 in vitro; it did inhibit all types of isozymes tested in vivo. Taken together, our results indicate that ALT III is a negative regulator of PLC that is most effective against the PLC delta-type isozymes, and its PH domain is essential for its function.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Ehime Univ, Fac Technol, Matsuyama, Ehime 7908577, Japan	University of Tokyo; Ehime University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; BAHK YY, 1994, J BIOL CHEM, V269, P8240; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KENNEDY CRJ, 1995, BBA-LIPID LIPID MET, V1258, P206, DOI 10.1016/0005-2760(95)00049-I; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; KIM S, 1995, J BIOL CHEM, V270, P14376, DOI 10.1074/jbc.270.24.14376; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Lee SB, 1996, J BIOL CHEM, V271, P25, DOI 10.1074/jbc.271.1.25; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; Sims CE, 1998, J BIOL CHEM, V273, P4052, DOI 10.1074/jbc.273.7.4052; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Takeuchi H, 1996, BIOCHEM J, V318, P561, DOI 10.1042/bj3180561; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	41	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 29	1999	274	5					2872	2879		10.1074/jbc.274.5.2872	http://dx.doi.org/10.1074/jbc.274.5.2872			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	161ZB	9915823	hybrid			2022-12-25	WOS:000078319500041
